the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
another . . O
section . . O
of . . O
the . . O
label . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5 . . O
) . . O
] . . O
: . . O

the . . O
safety . . O
of . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
was . . O
evaluated . . O
in . . O
trial . . O
2 . . O
and . . O
other . . O
trials . . O
consisting . . O
of . . O
a . . O
total . . O
of . . O
202 . . O
patients . . O
with . . O
braf . . O
v600 . . O
mutation . . O
- . . O
positive . . O
unresectable . . O
or . . O
metastatic . . O
melanoma . . O
who . . O
received . . O
tafinlar . . O
150 . . O
mg . . O
orally . . O
twice . . O
daily . . O
in . . O
combination . . O
with . . O
trametinib . . O
2 . . O
mg . . O
orally . . O
once . . O
daily . . O
until . . O
disease . . O
progression . . O
or . . O
unacceptable . . O
toxicity . . O
. . . O

5.8 . . O
hypokalemia . . O
and . . O
hyperglycemia . . O

5.10 . . O
immunizations . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
muscle . . B-AdverseReaction
hemorrhage . . I-AdverseReaction

( . . O
4 . . O
, . . O
5.1 . . O
) . . O

such . . O
monitoring . . O
may . . O
increase . . O
the . . O
risk . . O
of . . O
unnecessary . . O
procedures . . O
, . . O
due . . O
to . . O
the . . O
low . . O
specificity . . O
of . . O
serum . . O
calcitonin . . O
testing . . O
for . . O
mtc . . O
and . . O
a . . O
high . . O
background . . O
incidence . . O
of . . O
thyroid . . O
disease . . O
. . . O

( . . O
5.2 . . O
) . . O

excerpt . . O
: . . O
warning . . O
: . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O

complete . . O
blood . . O
counts . . O
( . . O
with . . O
white . . O
blood . . O
cell . . O
differential . . O
counts . . O
) . . O
should . . O
be . . O
obtained . . O
pretreatment . . O
, . . O
and . . O
at . . O
treatment . . O
weeks . . O
2 . . O
, . . O
4 . . O
, . . O
8 . . O
, . . O
and . . O
12 . . O
, . . O
and . . O
should . . O
be . . O
monitored . . O
closely . . O
at . . O
other . . O
time . . O
points . . O
, . . O
as . . O
clinically . . O
appropriate . . O
. . . O

the . . O
safety . . O
data . . O
reflect . . O
exposure . . O
to . . O
zydelig . . O
in . . O
146 . . O
adults . . O
with . . O
indolent . . O
non . . O
- . . O
hodgkin . . O
lymphoma . . O
treated . . O
with . . O
zydelig . . O
150 . . O
mg . . O
twice . . O
daily . . O
in . . O
clinical . . O
trials . . O
. . . O

do . . O
not . . O
administer . . O
granix . . O
to . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
serious . . O
allergic . . O
reactions . . O
to . . O
filgrastim . . O
or . . O
pegfilgrastim . . O
. . . O

( . . O
5.6 . . O
) . . O

5.6 . . O
potential . . O
for . . O
tumor . . O
growth . . O
stimulatory . . O
effects . . O
on . . O
malignant . . O
cells . . O

clevidipine . . O
was . . O
evaluated . . O
in . . O
15 . . O
studies . . O
in . . O
hypertensive . . O
patients . . O
: . . O
1099 . . O
patients . . O
with . . O
perioperative . . O
hypertension . . O
, . . O
126 . . O
with . . O
severe . . O
hypertension . . O
and . . O
82 . . O
patients . . O
with . . O
essential . . O
hypertension . . O
. . . O

consider . . O
as . . O
a . . O
possible . . O
cause . . O
for . . O
severe . . O
joint . . O
pain . . O
and . . O
discontinue . . O
drug . . O
if . . O
appropriate . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
takeda . . O
pharmaceuticals . . O
at . . O
1-877 . . O
- . . O
takeda . . O
- . . O
7 . . O
( . . O
1-877-825-3327 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
acute . . O
rejection . . O
and . . O
graft . . B-AdverseReaction
loss . . I-AdverseReaction
with . . O
corticosteroid . . O
minimization . . O
: . . O
corticosteroid . . O
utilization . . O
should . . O
be . . O
consistent . . O
with . . O
the . . O
nulojix . . O
clinical . . O
trial . . O
experience . . O
. . . O

5.2 . . O
infections . . O

permanently . . O
discontinue . . O
yervoy . . O
in . . O
patients . . O
with . . O
severe . . O
enterocolitis . . O
and . . O
initiate . . O
systemic . . O
corticosteroids . . O
at . . O
a . . O
dose . . O
of . . O
1 . . O
to . . O
2 . . O
mg . . O
/ . . O
kg . . O
/ . . O
day . . O
of . . O
prednisone . . O
or . . O
equivalent . . O
. . . O

approximately . . O
one . . O
third . . O
( . . O
3% . . O
, . . O
39 . . O
of . . O
1,509 . . O
) . . O
of . . O
these . . O
patients . . O
had . . O
antibodies . . O
with . . O
neutralizing . . O
activity . . O
in . . O
vitro . . O
. . . O

in . . O
patients . . O
predisposed . . O
to . . O
hypocalcemia . . O
and . . O
disturbances . . O
of . . O
mineral . . O
metabolism . . O
( . . O
e . . O
. . . O
g . . O
. . . O
history . . O
of . . O
hypoparathyroidism . . O
, . . O
thyroid . . O
surgery . . O
, . . O
parathyroid . . O
surgery . . O
, . . O
malabsorption . . O
syndromes . . O
, . . O
excision . . O
of . . O
small . . O
intestine . . O
, . . O
severe . . O
renal . . O
impairment . . O
[ . . O
creatinine . . O
clearance . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
] . . O
or . . O
receiving . . O
dialysis . . O
) . . O
, . . O
clinical . . O
monitoring . . O
of . . O
calcium . . O
and . . O
mineral . . O
levels . . O
( . . O
phosphorus . . O
and . . O
magnesium . . O
) . . O
is . . O
highly . . O
recommended . . O
within . . O
14 . . O
days . . O
of . . O
prolia . . O
injection . . O
. . . O

eight . . O
of . . O
these . . O
11 . . O
patients . . O
had . . O
received . . O
a . . O
single . . O
dose . . O
of . . O
voraxaze . . O
. . . O

* . . O
neutropenia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

5.4 . . O
pulmonary . . O
toxicity . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
cytokine . . B-AdverseReaction
release . . I-AdverseReaction
syndrome . . I-AdverseReaction
and . . O

overall . . O
, . . O
20.2% . . O
of . . O
patients . . O
seroconverted . . O
to . . O
anti . . O
- . . O
ecallantide . . O
antibodies . . O
. . . O

the . . O
most . . O
frequent . . O
serious . . O
adverse . . O
events . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
xalkori . . O
were . . O
dyspnea . . B-AdverseReaction
( . . O
4.1% . . O
) . . O
and . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
( . . O
2.9% . . O
) . . O
. . . O

as . . O
with . . O
other . . O
antipsychotic . . O
drugs . . O
, . . O
saphris . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
seizures . . O
or . . O
with . . O
conditions . . O
that . . O
potentially . . O
lower . . O
the . . O
seizure . . O
threshold . . O
. . . O

table . . O
2 . . O
shows . . O
the . . O
number . . O
of . . O
adjudicated . . O
major . . B-Severity
bleeding . . B-AdverseReaction
events . . O
during . . O
the . . O
treatment . . O
period . . O
in . . O
the . . O
re . . O
- . . O
ly . . O
study . . O
, . . O
with . . O
the . . O
bleeding . . B-AdverseReaction
rate . . O
per . . O
100 . . O
subject . . O
- . . O
years . . O
( . . O
% . . O
) . . O
. . . O

in . . O
clinical . . O
studies . . O
of . . O
gabapentin . . O
as . . O
adjunctive . . O
therapy . . O
in . . O
epilepsy . . O
comprising . . O
2,085 . . O
patient . . O
- . . O
years . . O
of . . O
exposure . . O
in . . O
patients . . O
> . . O
12 . . O
years . . O
of . . O
age . . O
, . . O
new . . O
tumors . . B-AdverseReaction
were . . O
reported . . O
in . . O
10 . . O
patients . . O
( . . O
2 . . O
breast . . O
, . . O
3 . . O
brain . . O
, . . O
2 . . O
lung . . O
, . . O
1 . . O
adrenal . . O
, . . O
1 . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
hodgkin's . . I-AdverseReaction
lymphoma . . I-AdverseReaction
, . . O
1 . . O
endometrial . . B-AdverseReaction
carcinoma . . I-AdverseReaction
in . . I-AdverseReaction
situ . . I-AdverseReaction
) . . O
, . . O
and . . O
preexisting . . O
tumors . . O
worsened . . O
in . . O
11 . . O
patients . . O
( . . O
9 . . O
brain . . O
, . . O
1 . . O
breast . . O
, . . O
1 . . O
prostate . . O
) . . O
during . . O
or . . O
up . . O
to . . O
2 . . O
years . . O
following . . O
discontinuation . . O
of . . O
gabapentin . . O
. . . O

during . . O
adult . . O
pre . . O
- . . O
marketing . . O
clinical . . O
trials . . O
with . . O
saphris . . O
, . . O
including . . O
long . . O
- . . O
term . . O
trials . . O
without . . O
comparison . . O
to . . O
placebo . . O
, . . O
seizures . . B-AdverseReaction
were . . O
reported . . O
in . . O
0.3% . . O
( . . O
5 . . O
/ . . O
1953 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
. . . O

there . . O
are . . O
no . . O
adequate . . O
and . . O
well . . O
- . . O
controlled . . O
studies . . O
of . . O
adcetris . . O
in . . O
pregnant . . O
women . . O
. . . O

tudorza . . O
pressair . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
urinary . . O
retention . . O
. . . O

weight . . B-AdverseReaction
gain . . I-AdverseReaction
has . . O
been . . O
observed . . O
with . . O
atypical . . B-DrugClass
antipsychotic . . I-DrugClass
use . . O
. . . O

jardiance . . O
increases . . O
the . . O
risk . . B-Factor
for . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
severe . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
or . . O
fatal . . B-AdverseReaction
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
dermatitis . . I-AdverseReaction
( . . O
eg . . O
, . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
, . . O
or . . O
rash . . B-AdverseReaction
complicated . . O
by . . O
full . . O
thickness . . O
dermal . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
or . . O
necrotic . . O
, . . O
bullous . . O
, . . O
or . . O
hemorrhagic . . O
manifestations . . O
; . . O
grade . . B-Severity
3-5 . . I-Severity
) . . O
occurred . . O
in . . O
13 . . O
( . . O
2.5% . . O
) . . O
yervoy . . O
- . . O
treated . . O
patients . . O
. . . O

warning . . O
: . . O
risk . . B-Factor
of . . O
anaphylaxis . . B-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
and . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
and . . O
risk . . B-Factor
of . . O
cardiorespiratory . . B-AdverseReaction
failure . . I-AdverseReaction

6 . . O
adverse . . O
reactions . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

although . . O
a . . O
causal . . O
link . . O
between . . O
the . . O
emergence . . O
of . . O
such . . O
symptoms . . O
and . . O
either . . O
the . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
depression . . I-AdverseReaction
and . . O
/ . . O
or . . O
the . . O
emergence . . O
of . . O
suicidal . . B-AdverseReaction
impulses . . I-AdverseReaction
has . . O
not . . B-Negation
been . . I-Negation
established . . I-Negation
, . . O
there . . O
is . . O
concern . . O
that . . O
such . . O
symptoms . . O
may . . B-Factor
represent . . O
precursors . . O
to . . O
emerging . . O
suicidality . . B-AdverseReaction
. . . O

investigations . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
electrocardiogram . . B-AdverseReaction
qt . . I-AdverseReaction
prolonged . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
creatine . . I-AdverseReaction
phosphokinase . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
creatinine . . I-AdverseReaction

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trial . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

allopurinol . . O
has . . O
also . . O
been . . O
used . . O
during . . O
the . . O
beginning . . O
of . . O
treanda . . O
therapy . . O
. . . O

gadolinium . . B-DrugClass
- . . I-DrugClass
based . . I-DrugClass
contrast . . I-DrugClass
agents . . I-DrugClass
( . . O
gbcas . . O
) . . O
increase . . O
the . . O
risk . . O
for . . O
nsf . . B-AdverseReaction
among . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
the . . O
drugs . . O
. . . O

in . . O
2 . . O
- . . O
year . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
reduction . . O
from . . O
baseline . . O
in . . O
the . . O
percent . . O
of . . O
predicted . . O
values . . O
for . . O
fev1 . . O
at . . O
the . . O
time . . O
of . . O
last . . O
assessment . . O
on . . O
drug . . O
was . . O
2.8% . . B-Severity
for . . O
gilenya . . O
0.5 . . O
mg . . O
and . . O
1.0% . . O
for . . O
placebo . . O
. . . O

* . . O
serious . . B-Severity
dermatologic . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.11 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
were . . O
: . . O

therefore . . O
nulojix . . O
is . . O
recommended . . O
for . . O
use . . O
only . . O
in . . O
patients . . O
who . . O
are . . O
ebv . . O
seropositive . . O
[ . . O
see . . O
boxed . . O
warning . . O
and . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

neurological . . B-AdverseReaction
toxicities . . I-AdverseReaction

a . . O
variety . . O
of . . O
cns . . B-AdverseReaction
anticholinergic . . I-AdverseReaction
effects . . I-AdverseReaction
have . . O
been . . O
reported . . O
, . . O
including . . O
headache . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
and . . O
somnolence . . B-AdverseReaction
. . . O

treanda . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

initiation . . O
of . . O
gilenya . . O
treatment . . O
has . . O
resulted . . O
in . . O
transient . . B-Severity
av . . B-AdverseReaction
conduction . . I-AdverseReaction
delays . . I-AdverseReaction
. . . O

ribavirin . . O
dose . . O
reduction . . O
is . . O
recommended . . O
for . . O
the . . O
initial . . O
management . . O
of . . O
anemia . . O
. . . O

the . . O
median . . O
age . . O
of . . O
these . . O
patients . . O
was . . O
64 . . O
years . . O
( . . O
range . . O
32-87 . . O
) . . O
. . . O

excerpt . . O
: . . O
* . . O
gastrointestinal . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
monitor . . O
and . . O
manage . . O
as . . O
necessary . . O
. . . O

* . . O
carcinogenicity . . O
of . . O
albiglutide . . O
could . . O
not . . O
be . . O
assessed . . O
in . . O
rodents . . O
, . . O
but . . O
other . . O
glucagon . . B-DrugClass
- . . I-DrugClass
like . . I-DrugClass
peptide . . I-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
( . . I-DrugClass
glp . . I-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
) . . I-DrugClass
receptor . . I-DrugClass
agonists . . I-DrugClass
have . . O
caused . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
in . . O
rodents . . B-Animal
at . . O
clinically . . O
relevant . . O
exposures . . O
. . . O

laboratory . . O
, . . O
ecg . . O
and . . O
vital . . O
sign . . O
changes . . O
observed . . O
in . . O
mdd . . O
clinical . . O
studies . . O

5.2 . . O
eye . . O
irritation . . O

of . . O
this . . O
total . . O
, . . O
782 . . O
received . . O
toviaz . . O
4 . . O
mg . . O
/ . . O
day . . O
, . . O
and . . O
785 . . O
received . . O
toviaz . . O
8 . . O
mg . . O
/ . . O
day . . O
in . . O
phase . . O
2 . . O
or . . O
3 . . O
studies . . O
with . . O
treatment . . O
periods . . O
of . . O
8 . . O
or . . O
12 . . O
weeks . . O
. . . O

excerpt . . O
: . . O
* . . O
image . . O
interpretation . . O
errors . . O
( . . O
especially . . O
false . . O
negatives . . O
) . . O
have . . O
been . . O
observed . . O
( . . O
5.1 . . O
) . . O
. . . O

patients . . O
requiring . . O
oral . . O
corticosteroids . . O
should . . O
be . . O
weaned . . O
slowly . . O
from . . O
systemic . . O
corticosteroid . . O
use . . O
after . . O
transferring . . O
to . . O
breo . . O
ellipta . . O
. . . O

5.5 . . O
dizziness . . O
and . . O
somnolence . . O

6 . . O
adverse . . O
reactions . . O

advise . . O
female . . O
patients . . O
of . . O
reproductive . . O
potential . . O
to . . O
avoid . . O
becoming . . O
pregnant . . O
and . . O
to . . O
use . . O
highly . . O
effective . . O
contraception . . O
while . . O
using . . O
afinitor . . O
and . . O
for . . O
up . . O
to . . O
8 . . O
weeks . . O
after . . O
ending . . O
treatment . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

among . . O
401 . . O
patients . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
treated . . O
with . . O
the . . O
recommended . . O
regimen . . O
of . . O
nulojix . . O
and . . O
the . . O
71 . . O
patients . . O
in . . O
study . . O
3 . . O
treated . . O
with . . O
a . . O
very . . O
similar . . O
( . . O
but . . O
non . . O
- . . O
identical . . O
) . . O
nulojix . . O
regimen . . O
, . . O
there . . O
were . . O
5 . . O
cases . . O
of . . O
ptld . . B-AdverseReaction
: . . O
3 . . O
in . . O
ebv . . O
seropositive . . O
patients . . O
and . . O
2 . . O
in . . O
ebv . . O
seronegative . . O
patients . . O
. . . O

5.1 . . O
asthma . . O
- . . O
related . . O
death . . O

effects . . O
of . . O
fluticasone . . O
furoate . . O
on . . O
the . . O
hpa . . O
axis . . O
are . . O
not . . O
observed . . O
with . . O
the . . O
therapeutic . . O
doses . . O
of . . O
breo . . O
ellipta . . O
. . . O

there . . O
is . . O
limited . . O
experience . . O
with . . O
short . . O
- . . O
duration . . O
therapy . . O
with . . O
beta . . O
- . . O
blockers . . O
as . . O
a . . O
treatment . . O
for . . O
cleviprex . . O
- . . O
induced . . O
tachycardia . . O
. . . O

investigations . . O
: . . O
alanine . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
aspartate . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
neutrophil . . B-AdverseReaction
count . . I-AdverseReaction
decreased . . I-AdverseReaction

in . . O
controlled . . O
clinical . . O
trials . . O
, . . O
adverse . . O
reactions . . O
of . . O
symptomatic . . B-AdverseReaction
bradycardia . . I-AdverseReaction
following . . O
the . . O
first . . O
dose . . O
were . . O
reported . . O
in . . O
0.6% . . O
of . . O
patients . . O
receiving . . O
gilenya . . O
0.5 . . O
mg . . O
and . . O
in . . O
0.1% . . O
of . . O
patients . . O
on . . O
placebo . . O
. . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
1% . . O
and . . O
more . . O
common . . O
than . . O
with . . O
placebo . . O
) . . O
: . . O
ocular . . B-AdverseReaction
irritation . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
irritation . . I-AdverseReaction
, . . O
and . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
anesthesia . . I-AdverseReaction
and . . O
hypoesthesia . . O
. . . O

monitor . . O
alanine . . O
aminotransferase . . O
( . . O
alt . . O
) . . O
, . . O
aspartate . . O
aminotransferase . . O
( . . O
ast . . O
) . . O
, . . O
gamma . . O
- . . O
glutamyl . . O
transferase . . O
( . . O
ggt . . O
) . . O
, . . O
and . . O
total . . O
blood . . O
bilirubin . . O
prior . . O
to . . O
the . . O
start . . O
of . . O
and . . O
during . . O
blincyto . . O
treatment . . O
. . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
presenting . . O
as . . O
proteinuria . . B-AdverseReaction
, . . O
nephrotic . . B-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
and . . O
necrotizing . . B-AdverseReaction
skin . . I-AdverseReaction
lesions . . I-AdverseReaction
have . . O
occurred . . O
in . . O
some . . O
patients . . O
following . . O
alglucosidase . . O
alfa . . O
treatment . . O
. . . O

in . . O
the . . O
placebo . . O
controlled . . O
adjunctive . . O
therapy . . O
trials . . O
in . . O
patients . . O
with . . O
partial . . O
- . . O
onset . . O
seizures . . O
( . . O
study . . O
3 . . O
, . . O
study . . O
4 . . O
and . . O
study . . O
5 . . O
) . . O
, . . O
1021 . . O
patients . . O
received . . O
aptiom . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

testing . . O
for . . O
igg . . O
titers . . O
may . . O
also . . O
be . . O
considered . . O
if . . O
patients . . O
develop . . O
hypersensitivity . . O
reactions . . O
, . . O
other . . O
immune . . O
- . . O
mediated . . O
reactions . . O
, . . O
or . . O
lose . . O
clinical . . O
response . . O
. . . O

the . . O
dosage . . O
of . . O
potiga . . O
should . . O
be . . O
reduced . . O
over . . O
a . . O
period . . O
of . . O
at . . O
least . . O
3 . . O
weeks . . O
, . . O
unless . . O
safety . . O
concerns . . O
require . . O
abrupt . . O
withdrawal . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

table . . O
2 . . O
adjudicated . . O
major . . B-Severity
bleeding . . B-AdverseReaction
events . . O
in . . O
treated . . O
patientsa . . O
apatients . . O
during . . O
treatment . . O
or . . O
within . . O
2 . . O
days . . O
of . . O
stopping . . O
study . . O
treatment . . O
. . . O

postherpetic . . O
neuralgia . . O
: . . O
the . . O
exposure . . O
to . . O
horizant . . O
in . . O
417 . . O
patients . . O
with . . O
phn . . O
included . . O
207 . . O
patients . . O
exposed . . O
for . . O
at . . O
least . . O
3 . . O
months . . O
. . . O

other . . O
adverse . . O
reactions . . O

* . . O
with . . O
congenital . . O
prolongation . . O
of . . O
the . . O
qt . . O
interval . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
long . . O
qt . . O
syndrome . . O
) . . O
or . . O
any . . O
other . . O
clinical . . O
condition . . O
known . . O
to . . O
prolong . . O
the . . O
qtc . . O
interval . . O
such . . O
as . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
symptomatic . . O
cardiac . . O
arrhythmias . . O
, . . O
with . . O
clinically . . O
relevant . . O
bradycardia . . O
or . . O
with . . O
severe . . O
cardiac . . O
disease . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
cases . . O
of . . O
pancytopenia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
and . . O
thrombocytopenia . . B-AdverseReaction
have . . O
also . . O
occurred . . O
in . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

in . . O
vitro . . O
experiments . . O
have . . O
demonstrated . . O
paradoxical . . O
activation . . O
of . . O
map . . O
- . . O
kinase . . O
signaling . . O
and . . O
increased . . B-AdverseReaction
cell . . I-AdverseReaction
proliferation . . I-AdverseReaction
in . . O
braf . . O
wild . . O
- . . O
type . . O
cells . . O
which . . O
are . . O
exposed . . O
to . . O
braf . . B-DrugClass
inhibitors . . I-DrugClass
. . . O

in . . O
patients . . O
with . . O
chronic . . O
renal . . O
impairment . . O
, . . O
acute . . B-AdverseReaction
kidney . . I-AdverseReaction
injury . . I-AdverseReaction
sometimes . . O
requiring . . O
dialysis . . O
has . . O
been . . O
observed . . O
with . . O
the . . O
use . . O
of . . O
some . . O
gbcas . . B-DrugClass
. . . O

these . . O
findings . . O
were . . O
consistent . . O
with . . O
data . . O
from . . O
an . . O
earlier . . O
144 . . O
- . . O
week . . O
trial . . O
of . . O
treatment . . O
- . . O
naive . . O
subjects . . O
receiving . . O
tenofovir . . O
df . . O
+ . . O
lamivudine . . O
+ . . O
efavirenz . . O
. . . O

5.5 . . O
interference . . O
with . . O
laboratory . . O
tests . . O

adverse . . O
reactions . . O
during . . O
exposure . . O
were . . O
obtained . . O
by . . O
general . . O
inquiry . . O
and . . O
recorded . . O
by . . O
clinical . . O
investigators . . O
using . . O
their . . O
own . . O
terminology . . O
. . . O

risk . . O
by . . O
indication . . O
for . . O
antiepileptic . . O
drugs . . O
in . . O
the . . O
pooled . . O
analysis . . O
indication . . O
placebopatients . . O
withevents . . O
per1,000 . . O
patients . . O
drug . . O
patientswith . . O
events . . O
per1,000 . . O
patients . . O
relative . . O
risk . . O
: . . O
incidence . . O
of . . O
eventsin . . O
drugpatients . . O
/ . . O
incidencein . . O
placebo . . O
patients . . O
risk . . O
difference . . O
: . . O
additional . . O
drugpatients . . O
withevents . . O
per . . O
1,000patients . . O
epilepsy . . O
1.0 . . O
3.4 . . O
3.5 . . O
2.4 . . O
psychiatric . . O
5.7 . . O
8.5 . . O
1.5 . . O
2.9 . . O
other . . O
1.0 . . O
1.8 . . O
1.9 . . O
0.9 . . O
total . . O
2.4 . . O
4.3 . . O
1.8 . . O
1.9 . . O
the . . O
relative . . O
risk . . B-Factor
for . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
was . . O
higher . . O
in . . O
clinical . . O
trials . . O
for . . O
epilepsy . . O
than . . O
in . . O
clinical . . O
trials . . O
for . . O
psychiatric . . O
or . . O
other . . O
conditions . . O
, . . O
but . . O
the . . O
absolute . . O
risk . . O
differences . . O
were . . O
similar . . O
for . . O
the . . O
epilepsy . . O
and . . O
psychiatric . . O
indications . . O
. . . O

data . . O
from . . O
a . . O
placebo . . O
- . . O
controlled . . O
, . . O
4 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
dose . . O
study . . O
, . . O
in . . O
which . . O
fasting . . O
blood . . O
samples . . O
were . . O
drawn . . O
, . . O
in . . O
adult . . O
subjects . . O
with . . O
schizophrenia . . O
are . . O
presented . . O
in . . O
table . . O
3 . . O
. . . O

therefore . . O
, . . O
pde5 . . O
inhibitors . . O
, . . O
including . . O
stendra . . O
, . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
these . . O
patients . . O
and . . O
only . . O
when . . O
the . . O
anticipated . . O
benefits . . O
outweigh . . O
the . . O
risks . . O
. . . O

pristiq . . O
was . . O
evaluated . . O
for . . O
safety . . O
in . . O
8,394 . . O
patients . . O
diagnosed . . O
with . . O
major . . O
depressive . . O
disorder . . O
who . . O
participated . . O
in . . O
multiple . . O
- . . O
dose . . O
pre . . O
- . . O
marketing . . O
studies . . O
, . . O
representing . . O
2,784 . . O
patient . . O
- . . O
years . . O
of . . O
exposure . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
seizures . . B-AdverseReaction
: . . O
use . . O
cautiously . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
seizures . . O
or . . O
with . . O
conditions . . O
that . . O
lower . . O
seizure . . O
threshold . . O
. . . O

5.7 . . O
switching . . O
between . . O
biological . . O
disease . . O
modifying . . O
antirheumatic . . O
drugs . . O
( . . O
dmards . . O
) . . O

physicians . . O
should . . O
consider . . O
pml . . O
in . . O
the . . O
differential . . O
diagnosis . . O
in . . O
patients . . O
with . . O
new . . O
or . . O
worsening . . O
neurological . . O
, . . O
cognitive . . O
, . . O
or . . O
behavioral . . O
signs . . O
or . . O
symptoms . . O
. . . O

beleodaq . . O
may . . B-Factor
cause . . O
teratogenicity . . B-AdverseReaction
and . . O
/ . . O
or . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
lethality . . I-AdverseReaction
because . . O
it . . O
is . . O
genotoxic . . B-AdverseReaction
and . . O
targets . . O
actively . . O
dividing . . O
cells . . O
[ . . O
see . . O
nonclinical . . O
toxicology . . O
( . . O
13.1 . . O
) . . O
] . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
dulaglutide . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
of . . O
other . . O
products . . O
. . . O

a . . O
total . . O
of . . O
801 . . O
patients . . O
were . . O
treated . . O
for . . O
at . . O
least . . O
6 . . O
months . . O
, . . O
585 . . O
patients . . O
were . . O
treated . . O
for . . O
1 . . O
year . . O
or . . O
longer . . O
, . . O
and . . O
311 . . O
patients . . O
were . . O
treated . . O
for . . O
at . . O
least . . O
2 . . O
years . . O
. . . O

in . . O
the . . O
xiaflex . . O
controlled . . O
trials . . O
in . . O
peyronie's . . O
disease . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
, . . O
65.5% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
developed . . O
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
, . . O
and . . O
14.5% . . O
developed . . O
penile . . B-AdverseReaction
ecchymosis . . I-AdverseReaction
( . . O
see . . O
table . . O
4 . . O
) . . O
. . . O

healthcare . . O
professionals . . O
should . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
the . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
other . . O
trials . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

patients . . O
treated . . O
with . . O
any . . O
aed . . O
for . . O
any . . O
indication . . O
should . . O
be . . O
monitored . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
depression . . O
, . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
, . . O
and . . O
/ . . O
or . . O
any . . O
unusual . . O
changes . . O
in . . O
mood . . O
or . . O
behavior . . O
. . . O

as . . O
with . . O
other . . O
pde5 . . O
inhibitors . . O
stendra . . O
has . . O
systemic . . O
vasodilatory . . O
properties . . O
and . . O
may . . O
augment . . O
the . . O
blood . . O
pressure . . O
- . . O
lowering . . O
effect . . O
of . . O
other . . O
anti . . O
- . . O
hypertensive . . O
medications . . O
. . . O

doses . . O
of . . O
the . . O
related . . O
beta2 . . B-DrugClass
- . . I-DrugClass
adrenoceptor . . I-DrugClass
agonist . . I-DrugClass
albuterol . . O
, . . O
when . . O
administered . . O
intravenously . . O
, . . O
have . . O
been . . O
reported . . O
to . . O
aggravate . . B-AdverseReaction
preexisting . . I-AdverseReaction
diabetes . . I-AdverseReaction
mellitus . . I-AdverseReaction
and . . O
ketoacidosis . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

advise . . O
patients . . O
of . . O
signs . . O
and . . O
symptoms . . O
of . . O
blood . . O
loss . . O
and . . O
to . . O
report . . O
them . . O
immediately . . O
or . . O
go . . O
to . . O
an . . O
emergency . . O
room . . O
. . . O

eliquis . . O
can . . B-Factor
cause . . O
serious . . B-Severity
, . . O
potentially . . B-Factor
fatal . . B-AdverseReaction
bleeding . . B-AdverseReaction
. . . O

* . . O
immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

risk . . O
may . . O
be . . O
increased . . O
with . . O
neutropenia . . O
, . . O
age . . O
, . . O
steroid . . O
use . . O
, . . O
concomitant . . O
use . . O
of . . O
nsaids . . O
, . . O
anti . . O
- . . O
platelet . . O
therapy . . O
or . . O
anti . . O
- . . O
coagulants . . O
, . . O
and . . O
patients . . O
with . . O
a . . O
prior . . O
history . . O
of . . O
pelvic . . O
radiotherapy . . O
, . . O
adhesions . . O
, . . O
ulceration . . O
and . . O
gi . . O
bleeding . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

withhold . . O
then . . O
dose . . O
reduce . . O
, . . O
or . . O
permanently . . O
discontinue . . O
zykadia . . O
. . . O

the . . O
most . . O
common . . O
key . . O
laboratory . . O
abnormalities . . O
( . . O
incidence . . O
> . . O
= . . O
50% . . O
) . . O
were . . O
hypercholesterolemia . . B-AdverseReaction
and . . O
elevated . . B-AdverseReaction
partial . . I-AdverseReaction
thromboplastin . . I-AdverseReaction
time . . I-AdverseReaction
. . . O

6.1 . . O
clinical . . O
trial . . O
experience . . O

see . . O
contraindications . . O

epidural . . O
or . . O
spinal . . O
punctures . . O
a . . O
history . . O
of . . O
spinal . . O
deformity . . O

re . . O
- . . O
medy . . O
was . . O
an . . O
active . . O
- . . O
controlled . . O
study . . O
( . . O
warfarin . . O
) . . O
in . . O
which . . O
1430 . . O
patients . . O
received . . O
pradaxa . . O
150 . . O
mg . . O
twice . . O
daily . . O
following . . O
3 . . O
to . . O
12 . . O
months . . O
of . . O
oral . . O
anticoagulant . . O
regimen . . O
. . . O

5.2 . . O
renal . . O
impairment . . O

the . . O
occurrence . . O
of . . O
adverse . . O
reactions . . O
was . . O
also . . O
evaluated . . O
in . . O
a . . O
larger . . O
pool . . O
of . . O
patients . . O
with . . O
type . . O
2 . . O
diabetes . . O
participating . . O
in . . O
6 . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
evaluating . . O
the . . O
use . . O
of . . O
trulicity . . O
as . . O
monotherapy . . O
and . . O
add . . O
- . . O
on . . O
therapy . . O
to . . O
oral . . O
medications . . O
or . . O
insulin . . O
. . . O

psychiatric . . O
disorders . . O
: . . O
anxiety . . B-AdverseReaction
, . . O
bipolar . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
and . . O
suicide . . B-AdverseReaction
attempt . . I-AdverseReaction
. . . O

cardiomyopathy . . B-AdverseReaction
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
and . . O
with . . O
trametinib . . O
as . . O
a . . O
single . . O
agent . . O
[ . . O
refer . . O
to . . O
full . . O
prescribing . . O
information . . O
for . . O
trametinib . . O
] . . O
. . . O

adverse . . O
reactions . . O
were . . O
reported . . O
according . . O
to . . O
nci . . O
ctc . . O
v . . O
. . . O
2.0 . . O
. . . O

6 . . O
adverse . . O
reactions . . O

three . . O
of . . O
these . . O
4 . . O
adverse . . O
reactions . . O
were . . O
described . . O
as . . O
a . . O
hypertensive . . B-AdverseReaction
crisis . . I-AdverseReaction
and . . O
were . . O
managed . . O
with . . O
oral . . O
medications . . O
and . . O
resolved . . O
. . . O

table . . O
1 . . O
adverse . . O
reactions . . O
reaction . . O
rate . . O
( . . O
% . . O
) . . O
n . . O
= . . O
1581 . . O
nausea . . B-AdverseReaction
1.1 . . O
headache . . B-AdverseReaction
1.1 . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
0.8 . . O
dizziness . . B-AdverseReaction
0.6 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
0.6 . . O
vomiting . . B-AdverseReaction
0.4 . . O
blood . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
0.4 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
pain . . O
, . . O
burning . . O
, . . O
coldness . . O
, . . O
extravasation . . O
, . . O
irritation . . O
) . . O
0.4 . . O
dysgeusia . . B-AdverseReaction
0.4 . . O
paresthesia . . B-AdverseReaction
0.3 . . O
flushing . . B-AdverseReaction
0.3 . . O
parosmia . . B-AdverseReaction
0.3 . . O
pruritus . . O
( . . O
generalized . . O
, . . O
eye . . O
) . . O
0.3 . . O
rash . . B-AdverseReaction
0.3 . . O
respiratory . . B-AdverseReaction
disorders . . I-AdverseReaction
( . . O
dyspnea . . B-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
distress . . I-AdverseReaction
) . . O
0.2 . . O
fatigue . . B-AdverseReaction
0.2 . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
0.1 . . O
vertigo . . B-AdverseReaction
0.1 . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
0.1 . . O
chills . . B-AdverseReaction
0.1 . . O
feeling . . B-AdverseReaction
abnormal . . I-AdverseReaction
0.1 . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
with . . O
a . . O
frequency . . O
of . . O
< . . O
0.1% . . O
in . . O
subjects . . O
who . . O
received . . O
eovist . . O
include . . O
: . . O
tremor . . B-AdverseReaction
, . . O
akathisia . . B-AdverseReaction
, . . O
bundle . . B-AdverseReaction
branch . . I-AdverseReaction
block . . I-AdverseReaction
, . . O
palpitation . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
salivary . . B-AdverseReaction
hypersecretion . . I-AdverseReaction
, . . O
maculopapular . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
discomfort . . B-AdverseReaction
, . . O
and . . O
malaise . . B-AdverseReaction
. . . O

( . . O
2.2 . . O
, . . O
5.1 . . O
) . . O
* . . O
infection . . B-AdverseReaction
: . . O
serious . . B-Severity
and . . O
fatal . . B-AdverseReaction
infections . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
pneumonia . . B-AdverseReaction
and . . O
sepsis . . B-AdverseReaction
) . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

overall . . O
, . . O
the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reactions . . O
in . . O
patients . . O
receiving . . O
potiga . . O
( . . O
> . . O
= . . O
4% . . O
and . . O
occurring . . O
approximately . . O
twice . . O
the . . O
placebo . . O
rate . . O
) . . O
were . . O
dizziness . . B-AdverseReaction
( . . O
23% . . O
) . . O
, . . O
somnolence . . B-AdverseReaction
( . . O
22% . . O
) . . O
, . . O
fatigue . . B-AdverseReaction
( . . O
15% . . O
) . . O
, . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
vertigo . . B-AdverseReaction
( . . O
8% . . O
) . . O
, . . O
tremor . . B-AdverseReaction
( . . O
8% . . O
) . . O
, . . O
abnormal . . B-AdverseReaction
coordination . . I-AdverseReaction
( . . O
7% . . O
) . . O
, . . O
diplopia . . B-AdverseReaction
( . . O
7% . . O
) . . O
, . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
attention . . I-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
memory . . B-AdverseReaction
impairment . . I-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
asthenia . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
aphasia . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
dysarthria . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
and . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
4% . . O
) . . O
( . . O
see . . O
table . . O
4 . . O
) . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O

in . . O
addition . . O
to . . O
adcetris . . O
therapy . . O
, . . O
other . . O
possible . . O
contributory . . O
factors . . O
include . . O
prior . . O
therapies . . O
and . . O
underlying . . O
disease . . O
that . . O
may . . O
cause . . O
immunosuppression . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
also . . O
discussed . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O
agranulocytosis . . B-AdverseReaction
/ . . O
neutropenia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

dose . . O
reduction . . O
due . . O
to . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
was . . O
required . . O
by . . O
3% . . O
( . . O
14 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
who . . O
received . . O
halaven . . O
. . . O

discontinuations . . O
due . . O
to . . O
adverse . . O
events . . O
were . . O
reported . . O
for . . O
6% . . O
of . . O
xtandi . . O
- . . O
treated . . O
patients . . O
and . . O
6% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

5.2 . . O
arterial . . O
thromboembolic . . O
events . . O

in . . O
short . . O
- . . O
term . . O
placebo . . O
- . . O
controlled . . O
trials . . O
( . . O
4 . . O
- . . O
to . . O
6 . . O
- . . O
weeks . . O
) . . O
, . . O
seizures . . B-AdverseReaction
occurred . . O
in . . O
0.1% . . O
( . . O
1 . . O
/ . . O
1344 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
fanapt . . O
compared . . O
to . . O
0.3% . . O
( . . O
2 . . O
/ . . O
587 . . O
) . . O
on . . O
placebo . . O
. . . O

if . . O
hemoglobin . . O
is . . O
less . . O
than . . O
10 . . O
g . . O
per . . O
dl . . O
, . . O
a . . O
decrease . . O
in . . O
dosage . . O
of . . O
ribavirin . . O
is . . O
recommended . . O
; . . O
and . . O
if . . O
hemoglobin . . O
is . . O
less . . O
than . . O
8.5 . . O
g . . O
per . . O
dl . . O
, . . O
discontinuation . . O
of . . O
ribavirin . . O
is . . O
recommended . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
and . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

permanent . . O
discontinuation . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
occurred . . O
in . . O
34 . . O
/ . . O
359 . . O
patients . . O
( . . O
9% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
46 . . O
/ . . O
355 . . O
patients . . O
( . . O
13% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

these . . O
events . . O
are . . O
notable . . O
because . . O
of . . O
their . . O
seriousness . . O
, . . O
severity . . O
, . . O
or . . O
increased . . O
frequency . . O
in . . O
subjects . . O
who . . O
received . . O
victrelis . . O
in . . O
combination . . O
with . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
compared . . O
with . . O
subjects . . O
who . . O
received . . O
only . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
. . . O

patients . . O
on . . O
the . . O
placebo . . O
arm . . O
could . . O
cross . . O
over . . O
to . . O
open . . O
- . . O
label . . O
afinitor . . O
upon . . O
disease . . O
progression . . O
. . . O

in . . O
premarketing . . O
clinical . . O
trials . . O
, . . O
18 . . O
of . . O
235 . . O
( . . O
7.7% . . O
) . . O
patients . . O
treated . . O
with . . O
vimizim . . O
experienced . . O
signs . . O
and . . O
symptoms . . O
consistent . . O
with . . O
anaphylaxis . . B-AdverseReaction
. . . O

long . . O
- . . O
term . . O
safety . . O
data . . O
is . . O
based . . O
on . . O
two . . O
12 . . O
- . . O
month . . O
trials . . O
( . . O
trials . . O
3 . . O
and . . O
4 . . O
; . . O
n . . O
= . . O
1,633 . . O
and . . O
n . . O
= . . O
1,622 . . O
, . . O
respectively . . O
) . . O
. . . O

in . . O
many . . O
cases . . O
, . . O
this . . O
hyponatremia . . B-AdverseReaction
appears . . O
to . . O
be . . O
the . . O
result . . O
of . . O
the . . O
syndrome . . B-AdverseReaction
of . . I-AdverseReaction
inappropriate . . I-AdverseReaction
antidiuretic . . I-AdverseReaction
hormone . . I-AdverseReaction
secretion . . I-AdverseReaction
( . . O
siadh . . B-AdverseReaction
) . . O
. . . O

aspiration . . B-AdverseReaction
may . . B-Factor
result . . O
from . . O
severe . . B-Severity
dysphagia . . B-AdverseReaction
and . . O
is . . O
a . . O
particular . . O
risk . . O
when . . O
treating . . O
patients . . O
in . . O
whom . . O
swallowing . . O
or . . O
respiratory . . O
function . . O
is . . O
already . . O
compromised . . O
. . . O

for . . O
patients . . O
taking . . O
concomitant . . O
moderate . . O
cyp3a4 . . O
inhibitors . . O
( . . O
including . . O
erythromycin . . O
, . . O
amprenavir . . O
, . . O
aprepitant . . O
, . . O
diltiazem . . O
, . . O
fluconazole . . O
, . . O
fosamprenavir . . O
, . . O
and . . O
verapamil . . O
) . . O
, . . O
the . . O
maximum . . O
recommended . . O
dose . . O
of . . O
stendra . . O
is . . O
50 . . O
mg . . O
, . . O
not . . O
to . . O
exceed . . O
once . . O
every . . O
24 . . O
hours . . O
[ . . O
seedrug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
] . . O
. . . O

5.6 . . O
other . . O
immune . . O
- . . O
mediated . . O
adverse . . O
reactions . . O
, . . O
including . . O
ocular . . O
manifestations . . O

( . . O
6.1 . . O
) . . O

it . . O
is . . O
not . . B-Factor
possible . . I-Factor
to . . I-Factor
determine . . I-Factor
whether . . O
potiga . . O
caused . . O
this . . O
decreased . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
. . . O

the . . O
overall . . O
adverse . . O
reaction . . O
profile . . O
of . . O
potiga . . O
was . . O
similar . . O
for . . O
females . . O
and . . O
males . . O
. . . O

there . . O
has . . O
been . . O
a . . O
long . . O
- . . O
standing . . O
concern . . O
, . . O
however . . O
, . . O
that . . O
antidepressants . . B-DrugClass
may . . O
have . . O
a . . O
role . . O
in . . O
inducing . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
depression . . I-AdverseReaction
and . . O
the . . O
emergence . . O
of . . O
suicidality . . B-AdverseReaction
in . . O
certain . . O
patients . . O
during . . O
the . . O
early . . O
phases . . O
of . . O
treatment . . O
. . . O

do . . O
not . . O
administer . . O
cometriq . . O
to . . O
patients . . O
with . . O
severe . . O
hemorrhage . . O
. . . O

adverse . . O
reactions . . O
are . . O
categorized . . O
by . . O
system . . O
organ . . O
class . . O
. . . O

an . . O
open . . O
- . . O
label . . O
extension . . O
trial . . O
was . . O
conducted . . O
in . . O
173 . . O
patients . . O
who . . O
completed . . O
the . . O
placebo . . O
- . . O
controlled . . O
trial . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
* . . O
serious . . B-Severity
infections . . B-AdverseReaction
- . . O
do . . O
not . . O
start . . O
simponi . . O
aria . . O
during . . O
an . . O
active . . O
infection . . O
. . . O

excerpt . . O
: . . O
* . . O
depression . . B-AdverseReaction
: . . O
advise . . O
patients . . O
, . . O
their . . O
caregivers . . O
, . . O
and . . O
families . . O
to . . O
be . . O
alert . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
depression . . O
, . . O
suicidal . . O
thoughts . . O
or . . O
other . . O
mood . . O
changes . . O
and . . O
if . . O
such . . O
changes . . O
occur . . O
to . . O
contact . . O
their . . O
healthcare . . O
provider . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . O
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
, . . O
have . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
kalbitor . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
valeant . . O
pharmaceuticals . . O
north . . O
america . . O
llc . . O
at . . O
1-800-321-4576 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

5.1 . . O
gout . . O
flare . . O

5 . . O
warnings . . O
and . . O
precautions . . O

clinical . . O
trials . . O
in . . O
late . . O
- . . O
onset . . O
pompe . . O
disease . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
anorexia . . B-AdverseReaction
, . . O
appetite . . B-AdverseReaction
decreased . . I-AdverseReaction
/ . . O
increased . . O
, . . O
dehydration . . B-AdverseReaction
, . . O
diabetes . . B-AdverseReaction
mellitus . . I-AdverseReaction
, . . O
hypercholesterolemia . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
hyperlipidemia . . B-AdverseReaction
, . . O
hypertriglyceridemia . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
/ . . O
increased . . O
. . . O

if . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
no . . O
longer . . O
controls . . O
symptoms . . O
of . . O
bronchoconstriction . . O
; . . O
the . . O
patient's . . O
inhaled . . O
, . . O
short . . O
- . . O
acting . . O
, . . O
beta2 . . O
- . . O
agonist . . O
becomes . . O
less . . O
effective . . O
; . . O
or . . O
the . . O
patient . . O
needs . . O
more . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonist . . O
than . . O
usual . . O
, . . O
these . . O
may . . O
be . . O
markers . . O
of . . O
deterioration . . O
of . . O
disease . . O
. . . O

do . . O
not . . O
take . . O
2 . . O
doses . . O
at . . O
the . . O
same . . O
time . . O
unless . . O
your . . O
healthcare . . O
provider . . O
tells . . O
you . . O
to . . O
. . . O

however . . O
, . . O
relapsing . . O
malaria . . O
caused . . O
by . . O
p . . O
. . . O
vivax . . O
requires . . O
additional . . O
treatment . . O
with . . O
other . . O
antimalarial . . O
agents . . O
to . . O
achieve . . O
radical . . O
cure . . O
i . . O
. . . O
e . . O
. . . O
, . . O
eradicate . . O
any . . O
hypnozoites . . O
forms . . O
that . . O
may . . O
remain . . O
dormant . . O
in . . O
the . . O
liver . . O
. . . O

5.1 . . O
supine . . O
hypertension . . O

forty . . O
- . . O
eight . . O
percent . . O
of . . O
patients . . O
were . . O
white . . O
, . . O
15% . . O
african . . O
/ . . O
african . . O
american . . O
, . . O
9% . . O
asian . . O
, . . O
and . . O
26% . . O
were . . O
hispanic . . O
/ . . O
latino . . O
. . . O

management . . O
of . . O
these . . O
events . . O
may . . O
require . . O
either . . O
temporary . . O
interruption . . O
or . . O
discontinuation . . O
of . . O
blincyto . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
5.0% . . O
of . . O
subjects . . O
who . . O
received . . O
two . . O
concurrent . . O
injections . . O
of . . O
xiaflex . . O
in . . O
study . . O
3 . . O
adverse . . O
reaction . . O
xiaflexn . . O
= . . O
715 . . O
subjects . . O
with . . O
> . . O
= . . O
1 . . O
adverse . . O
reaction . . O
95% . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
77% . . O
contusion . . B-AdverseReaction
59% . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
51% . . O
laceration . . B-AdverseReaction
22% . . O
pruritus . . B-AdverseReaction
15% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
14% . . O
lymphadenopathy . . B-AdverseReaction
13% . . O
blood . . B-AdverseReaction
blister . . I-AdverseReaction
12% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
8% . . O
axillary . . B-AdverseReaction
pain . . I-AdverseReaction
7% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
6% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
swelling . . I-AdverseReaction
5% . . O
ecchymosis . . B-AdverseReaction
5% . . O
safety . . O
of . . O
retreatment . . O
of . . O
recurrent . . O
contractures . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

if . . O
eovist . . O
is . . O
used . . O
in . . O
these . . O
patients . . O
, . . O
complete . . O
mri . . O
no . . O
later . . O
than . . O
60 . . O
minutes . . O
after . . O
eovist . . O
administration . . O
and . . O
use . . O
a . . O
paired . . O
non . . O
- . . O
contrast . . O
and . . O
contrast . . O
mri . . O
set . . O
for . . O
diagnosis . . O
. . . O

5.2 . . O
hypotension . . O
in . . O
volume . . O
- . . O
or . . O
salt . . O
- . . O
depleted . . O
patients . . O

one . . O
percent . . O
( . . O
1% . . O
) . . O
of . . O
patients . . O
discontinued . . O
zykadia . . O
in . . O
study . . O
1 . . O
due . . O
to . . O
ild . . B-AdverseReaction
/ . . O
pneumonitis . . B-AdverseReaction
. . . O

this . . O
information . . O
does . . O
not . . O
take . . O
the . . O
place . . O
of . . O
talking . . O
to . . O
your . . O
healthcare . . O
provider . . O
about . . O
your . . O
medical . . O
condition . . O
or . . O
your . . O
treatment . . O
. . . O

infantile . . O
- . . O
onset . . O
pompe . . O
disease . . O
patients . . O
with . . O
compromised . . O
cardiac . . O
or . . O
respiratory . . O
function . . O
may . . B-Factor
be . . O
at . . O
risk . . O
of . . O
serious . . B-Severity
acute . . O
exacerbation . . O
of . . O
their . . O
cardiac . . O
or . . O
respiratory . . O
compromise . . O
due . . O
to . . O
fluid . . B-AdverseReaction
overload . . I-AdverseReaction
, . . O
and . . O
require . . O
additional . . O
monitoring . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

these . . O
findings . . O
were . . O
generally . . O
observed . . O
within . . O
the . . O
first . . O
12 . . O
weeks . . O
of . . O
treatment . . O
and . . O
were . . O
reversible . . O
with . . O
dose . . O
interruption . . O
. . . O

body . . O
as . . O
a . . O
whole . . O
- . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction

xeomin . . O
- . . O
treated . . O
patients . . O
were . . O
18 . . O
to . . O
79 . . O
years . . O
old . . O
( . . O
mean . . O
53 . . O
years . . O
) . . O
, . . O
and . . O
were . . O
predominantly . . O
female . . O
( . . O
66% . . O
) . . O
and . . O
caucasian . . O
( . . O
91% . . O
) . . O
. . . O

patients . . O
should . . O
be . . O
closely . . O
monitored . . O
during . . O
treatment . . O
for . . O
the . . O
emergence . . O
of . . O
possible . . O
bacterial . . O
, . . O
fungal . . O
, . . O
or . . O
viral . . O
infections . . O
. . . O

( . . O
6.1 . . O
) . . O

no . . O
new . . O
safety . . O
findings . . O
were . . O
reported . . O
compared . . O
to . . O
the . . O
placebo . . O
controlled . . O
trials . . O
. . . O

normal . . O
274 . . O
53 . . O
( . . O
19 . . O
) . . O
174 . . O
( . . O
64 . . O
) . . O
30 . . O
( . . O
11 . . O
) . . O
14 . . O
( . . O
5 . . O
) . . O
1 . . O
( . . O
< . . O
1 . . O
) . . O
1 . . O
( . . O
< . . O
1 . . O
) . . O
mild . . O
438 . . O
10 . . O
( . . O
2 . . O
) . . O
170 . . O
( . . O
39 . . O
) . . O
177 . . O
( . . O
40 . . O
) . . O
63 . . O
( . . O
14 . . O
) . . O
14 . . O
( . . O
3 . . O
) . . O
2 . . O
( . . O
1 . . O
) . . O
mild . . O
to . . O
moderate . . O
79 . . O
0 . . O
4 . . O
( . . O
5 . . O
) . . O
28 . . O
( . . O
35 . . O
) . . O
37 . . O
( . . O
47 . . O
) . . O
10 . . O
( . . O
13 . . O
) . . O
0 . . O
moderate . . O
to . . O
severe . . O
24 . . O
0 . . O
1 . . O
( . . O
4 . . O
) . . O
1 . . O
( . . O
4 . . O
) . . O
6 . . O
( . . O
25 . . O
) . . O
15 . . O
( . . O
63 . . O
) . . O
1 . . O
( . . O
4 . . O
) . . O
severe . . O
1 . . O
0 . . O
0 . . O
0 . . O
0 . . O
0 . . O
1 . . O
( . . O
100 . . O
) . . O
total . . O
816 . . O
63 . . O
( . . O
8 . . O
) . . O
349 . . O
( . . O
43 . . O
) . . O
236 . . O
( . . O
29 . . O
) . . O
120 . . O
( . . O
15 . . O
) . . O
40 . . O
( . . O
5 . . O
) . . O
5 . . O
( . . O
1 . . O
) . . O
monitor . . O
renal . . O
function . . O
at . . O
baseline . . O
and . . O
during . . O
therapy . . O
with . . O
bosulif . . O
, . . O
with . . O
particular . . O
attention . . O
to . . O
those . . O
patients . . O
who . . O
have . . O
preexisting . . O
renal . . O
impairment . . O
or . . O
risk . . O
factors . . O
for . . O
renal . . O
dysfunction . . O
. . . O

patients . . O
with . . O
alanine . . O
aminotransferase . . O
or . . O
aspartate . . O
aminotransferase . . O
> . . O
3 . . O
* . . O
uln . . O
( . . O
upper . . O
limit . . O
of . . O
normal . . O
) . . O
experienced . . O
a . . O
higher . . O
incidence . . O
of . . O
grade . . B-Severity
4 . . I-Severity
neutropenia . . B-AdverseReaction
and . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
than . . O
patients . . O
with . . O
normal . . O
aminotransferase . . O
levels . . O
. . . O

patients . . O
with . . O
low . . O
albumin . . O
levels . . O
( . . O
less . . O
than . . O
3.5 . . O
g . . O
/ . . O
dl . . O
) . . O
or . . O
model . . O
for . . O
end . . O
- . . O
stage . . O
liver . . O
disease . . O
( . . O
meld . . O
) . . O
score . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
10 . . O
at . . O
baseline . . O
had . . O
a . . O
greater . . O
risk . . B-Factor
for . . O
hepatic . . B-AdverseReaction
decompensation . . I-AdverseReaction
on . . O
the . . O
arm . . O
receiving . . O
treatment . . O
with . . O
promacta . . O
plus . . O
antivirals . . O
. . . O

in . . O
trial . . O
2 . . O
, . . O
treatment . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
resulted . . O
in . . O
an . . O
increased . . O
incidence . . O
of . . O
deep . . B-AdverseReaction
venous . . I-AdverseReaction
thrombosis . . I-AdverseReaction
( . . O
dvt . . B-AdverseReaction
) . . O
and . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
( . . O
pe . . B-AdverseReaction
) . . O
: . . O
7% . . O
( . . O
4 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
compared . . O
with . . O
none . . O
of . . O
the . . O
53 . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

5.5 . . O
angle . . O
closure . . O
glaucoma . . O

the . . O
concomitant . . O
use . . O
of . . O
adcetris . . O
with . . O
bleomycin . . O
is . . O
contraindicated . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

* . . O
store . . O
duavee . . O
at . . O
room . . O
temperature . . O
between . . O
68 . . O
degrees . . O
f . . O
to . . O
77 . . O
degrees . . O
f . . O
( . . O
20 . . O
degrees . . O
c . . O
to . . O
25 . . O
degrees . . O
c . . O
) . . O
. . . O

an . . O
elevated . . O
risk . . B-Factor
of . . O
acute . . B-AdverseReaction
dystonia . . I-AdverseReaction
is . . O
observed . . O
in . . O
males . . O
and . . O
younger . . O
age . . O
groups . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
, . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.4 . . O
) . . O
, . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
adrenocortical . . B-AdverseReaction
insufficiency . . I-AdverseReaction
: . . O
monitor . . O
for . . O
symptoms . . O
and . . O
signs . . O
of . . O
adrenocortical . . O
insufficiency . . O
. . . O

this . . O
component . . O
reduces . . O
the . . O
risk . . O
of . . O
endometrial . . O
hyperplasia . . O
that . . O
can . . O
occur . . O
with . . O
the . . O
conjugated . . O
estrogens . . O
component . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
associated . . O
with . . O
discontinuation . . O
in . . O
subjects . . O
treated . . O
with . . O
saphris . . O
( . . O
rates . . O
at . . O
least . . O
1% . . O
and . . O
at . . O
least . . O
twice . . O
the . . O
placebo . . O
rate . . O
) . . O
were . . O
depression . . B-AdverseReaction
( . . O
2.5% . . O
) . . O
, . . O
suicidal . . B-AdverseReaction
ideation . . I-AdverseReaction
( . . O
2.5% . . O
) . . O
, . . O
bipolar . . B-AdverseReaction
i . . I-AdverseReaction
disorder . . I-AdverseReaction
( . . O
1.9% . . O
) . . O
, . . O
insomnia . . B-AdverseReaction
( . . O
1.9% . . O
) . . O
and . . O
depressive . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
1.3% . . O
) . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
dysport . . O
( . . O
r . . O
) . . O
in . . O
357 . . O
cervical . . O
dystonia . . O
patients . . O
in . . O
6 . . O
studies . . O
. . . O

* . . O
corneal . . B-AdverseReaction
exposure . . I-AdverseReaction
and . . O
ulceration . . O
* . . O
injection . . O
of . . O
xeomin . . O
into . . O
the . . O
orbicularis . . O
oculi . . O
muscle . . O
may . . B-Factor
lead . . O
to . . O
reduced . . B-AdverseReaction
blinking . . I-AdverseReaction
and . . O
corneal . . B-AdverseReaction
exposure . . I-AdverseReaction
with . . O
possible . . B-Factor
ulceration . . O
or . . O
perforation . . O
. . . O

at . . O
the . . O
end . . O
of . . O
treatment . . O
, . . O
0.5% . . O
with . . O
placebo . . O
, . . O
0.7% . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
1.4% . . O
with . . O
invokana . . O
300 . . O
mg . . O
had . . O
a . . O
significant . . B-Severity
renal . . B-AdverseReaction
function . . I-AdverseReaction
decline . . I-AdverseReaction
. . . O

no . . O
complications . . O
attributable . . O
to . . O
leukocytosis . . B-AdverseReaction
were . . O
reported . . O
in . . O
clinical . . O
studies . . O
. . . O

laboratory . . O
abnormalities . . O

cardiac . . O
disorders . . O

permanently . . O
discontinue . . O
yervoy . . O
in . . O
patients . . O
with . . O
stevens . . O
- . . O
johnson . . O
syndrome . . O
, . . O
toxic . . O
epidermal . . O
necrolysis . . O
, . . O
or . . O
rash . . O
complicated . . O
by . . O
full . . O
thickness . . O
dermal . . O
ulceration . . O
, . . O
or . . O
necrotic . . O
, . . O
bullous . . O
, . . O
or . . O
hemorrhagic . . O
manifestations . . O
. . . O

the . . O
qt . . O
interval . . O
should . . O
be . . O
monitored . . O
when . . O
potiga . . O
is . . O
prescribed . . O
with . . O
medicines . . O
known . . O
to . . O
increase . . O
qt . . O
interval . . O
and . . O
in . . O
patients . . O
with . . O
known . . O
prolonged . . O
qt . . O
interval . . O
, . . O
congestive . . O
heart . . O
failure . . O
, . . O
ventricular . . O
hypertrophy . . O
, . . O
hypokalemia . . O
, . . O
or . . O
hypomagnesemia . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
121 . . O
patients . . O
who . . O
received . . O
one . . O
( . . O
n . . O
= . . O
99 . . O
) . . O
, . . O
two . . O
( . . O
n . . O
= . . O
21 . . O
) . . O
, . . O
or . . O
three . . O
( . . O
n . . O
= . . O
1 . . O
) . . O
doses . . O
of . . O
voraxaze . . O
were . . O
evaluated . . O
for . . O
anti . . O
- . . O
glucarpidase . . O
antibodies . . O
. . . O

study . . O
1 . . O
excluded . . O
the . . O
use . . O
of . . O
concomitant . . O
medications . . O
that . . O
may . . O
lower . . O
the . . O
seizure . . O
threshold . . O
, . . O
whereas . . O
study . . O
2 . . O
permitted . . O
the . . O
use . . O
of . . O
these . . O
medications . . O
. . . O

women . . O
who . . O
take . . O
medications . . O
that . . O
are . . O
strong . . O
cytochrome . . O
p450 . . O
3a4 . . O
( . . O
cyp3a4 . . O
) . . O
inducers . . O
( . . O
for . . O
example . . O
, . . O
carbamazepine . . O
, . . O
phenytoin . . O
, . . O
rifampicin . . O
, . . O
and . . O
st . . O
. . . O
john's . . O
wort . . O
) . . O
should . . O
not . . O
choose . . O
natazia . . O
as . . O
their . . O
oral . . O
contraceptive . . O
while . . O
using . . O
these . . O
inducers . . O
and . . O
for . . O
at . . O
least . . O
28 . . O
days . . O
after . . O
discontinuation . . O
of . . O
these . . O
inducers . . O
due . . O
to . . O
the . . O
possibility . . O
of . . O
decreased . . O
contraceptive . . O
efficacy . . O
. . . O

tafinlar . . O
results . . O
in . . O
an . . O
increased . . O
incidence . . O
of . . O
cutaneous . . B-AdverseReaction
squamous . . I-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
, . . O
keratoacanthoma . . B-AdverseReaction
, . . O
and . . O
melanoma . . B-AdverseReaction
. . . O

tuberculosis . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

anti . . O
- . . O
tuberculosis . . O
therapy . . O
should . . O
also . . O
be . . O
considered . . O
prior . . O
to . . O
initiation . . O
of . . O
cimzia . . O
in . . O
patients . . O
with . . O
a . . O
past . . O
history . . O
of . . O
latent . . O
or . . O
active . . O
tuberculosis . . O
in . . O
whom . . O
an . . O
adequate . . O
course . . O
of . . O
treatment . . O
cannot . . O
be . . O
confirmed . . O
, . . O
and . . O
for . . O
patients . . O
with . . O
a . . O
negative . . O
test . . O
for . . O
latent . . O
tuberculosis . . O
but . . O
having . . O
risk . . O
factors . . O
for . . O
tuberculosis . . O
infection . . O
. . . O

cometriq . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

schizophrenia . . O
( . . O
6 . . O
- . . O
weeks . . O
) . . O
bipolar . . O
( . . O
3 . . O
- . . O
weeks . . O
) . . O
placebo . . O
saphris . . O
placebo . . O
saphris5 . . O
or . . O
10 . . O
mgtwice . . O
daily . . O
5 . . O
mgtwice . . O
daily . . O
10 . . O
mgtwice . . O
daily . . O
5 . . O
or . . O
10 . . O
mgtwice . . O
daily . . O
s . . O
change . . O
from . . O
baseline . . O
( . . O
kg . . O
) . . O
( . . O
n . . O
* . . O
) . . O
0.0(348 . . O
) . . O
1.0(251 . . O
) . . O
0.9(200 . . O
) . . O
1.1(532 . . O
) . . O
0.2(171 . . O
) . . O
1.3(336 . . O
) . . O
proportion . . O
of . . O
patients . . O
with . . O
a . . O
> . . O
= . . O
7% . . B-Severity
increase . . B-AdverseReaction
in . . I-AdverseReaction
body . . I-AdverseReaction
weight . . I-AdverseReaction
% . . O
with . . O
> . . O
= . . O
7% . . B-Severity
increase . . B-AdverseReaction
in . . I-AdverseReaction
body . . I-AdverseReaction
weight . . I-AdverseReaction
1.6% . . O
4.4% . . O
4.8% . . O
4.9% . . O
0.5% . . O
5.8% . . O
adult . . O
patients . . O
: . . O
in . . O
a . . O
52 . . O
- . . O
week . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
comparator . . O
- . . O
controlled . . O
adult . . O
trial . . O
that . . O
included . . O
primarily . . O
patients . . O
with . . O
schizophrenia . . O
, . . O
the . . O
mean . . O
weight . . B-AdverseReaction
gain . . I-AdverseReaction
from . . O
baseline . . O
was . . O
0.9 . . O
kg . . O
. . . O
the . . O
proportion . . O
of . . O
patients . . O
with . . O
a . . O
> . . O
= . . O
7% . . B-Severity
increase . . B-AdverseReaction
in . . I-AdverseReaction
body . . I-AdverseReaction
weight . . I-AdverseReaction
( . . O
at . . O
endpoint . . O
) . . O
was . . O
14.7% . . O
. . . O
table . . O
5provides . . O
the . . O
mean . . O
weight . . B-AdverseReaction
change . . I-AdverseReaction
from . . O
baseline . . O
and . . O
the . . O
proportion . . O
of . . O
patients . . O
with . . O
a . . O
weight . . B-AdverseReaction
gain . . I-AdverseReaction
of . . O
> . . O
= . . O
7% . . B-Severity
categorized . . O
by . . O
body . . O
mass . . O
index . . O
( . . O
bmi . . O
) . . O
at . . O
baseline . . O
. . . O

the . . O
incidence . . O
of . . O
hypertension . . B-AdverseReaction
increases . . O
with . . O
increasing . . O
concentration . . O
of . . O
progestin . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

at . . O
one . . O
year . . O
after . . O
transplantation . . O
these . . O
values . . O
were . . O
183 . . O
mg . . O
/ . . O
dl . . O
, . . O
50 . . O
mg . . O
/ . . O
dl . . O
, . . O
102 . . O
mg . . O
/ . . O
dl . . O
, . . O
and . . O
151 . . O
mg . . O
/ . . O
dl . . O
, . . O
respectively . . O
, . . O
in . . O
401 . . O
patients . . O
treated . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
and . . O
196 . . O
mg . . O
/ . . O
dl . . O
, . . O
48 . . O
mg . . O
/ . . O
dl . . O
, . . O
108 . . O
mg . . O
/ . . O
dl . . O
, . . O
and . . O
195 . . O
mg . . O
/ . . O
dl . . O
, . . O
respectively . . O
, . . O
in . . O
405 . . O
patients . . O
treated . . O
with . . O
the . . O
cyclosporine . . O
control . . O
regimen . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
laboratory . . O
test . . O
alterations . . O
: . . O
elevations . . B-AdverseReaction
of . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
, . . O
urinary . . O
protein . . O
, . . O
blood . . O
glucose . . O
, . . O
and . . O
lipids . . O
may . . O
occur . . O
. . . O

inlyta . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
evidence . . O
of . . O
untreated . . O
brain . . O
metastasis . . O
or . . O
recent . . O
active . . O
gastrointestinal . . O
bleeding . . O
and . . O
should . . O
not . . O
be . . O
used . . O
in . . O
those . . O
patients . . O
. . . O

laba . . O
, . . O
such . . O
as . . O
vilanterol . . O
, . . O
one . . O
of . . O
the . . O
active . . O
ingredients . . O
in . . O
breo . . O
ellipta . . O
, . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
. . . O

decisions . . O
about . . O
whether . . O
or . . O
not . . O
to . . O
restart . . O
tecfidera . . O
should . . O
be . . O
individualized . . O
based . . O
on . . O
clinical . . O
circumstances . . O
. . . O

if . . O
pancreatitis . . O
is . . O
suspected . . O
, . . O
promptly . . O
discontinue . . O
tanzeum . . O
. . . O

if . . O
this . . O
product . . O
is . . O
used . . O
for . . O
10 . . O
days . . O
or . . O
longer . . O
, . . O
intraocular . . O
pressure . . O
should . . O
be . . O
monitored . . O
. . . O

table . . O
7 . . O
: . . O
key . . O
laboratory . . O
abnormalities . . O
reported . . O
in . . O
patients . . O
with . . O
rcc . . O
at . . O
a . . O
higher . . O
rate . . O
in . . O
the . . O
afinitor . . O
arm . . O
than . . O
the . . O
placebo . . O
arm . . O
grading . . O
according . . O
to . . O
ctcae . . O
version . . O
3.0 . . O
a . . O
reflects . . O
corresponding . . O
adverse . . O
drug . . O
reaction . . O
reports . . O
of . . O
anemia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
and . . O
thrombocytopenia . . B-AdverseReaction
( . . O
collectively . . O
pancytopenia . . B-AdverseReaction
) . . O
, . . O
which . . O
occurred . . O
at . . O
lower . . O
frequency . . O
. . . O

four . . O
patients . . O
( . . O
1% . . O
) . . O
treated . . O
with . . O
promacta . . O
and . . O
three . . O
patients . . O
in . . O
the . . O
placebo . . O
group . . O
( . . O
2% . . O
) . . O
discontinued . . O
treatment . . O
due . . O
to . . O
hepatobiliary . . B-AdverseReaction
laboratory . . I-AdverseReaction
abnormalities . . I-AdverseReaction
. . . O

withhold . . O
kyprolis . . O
for . . O
pulmonary . . O
hypertension . . O
until . . O
resolved . . O
or . . O
returned . . O
to . . O
baseline . . O
and . . O
consider . . O
whether . . O
to . . O
restart . . O
kyprolis . . O
based . . O
on . . O
a . . O
benefit . . O
/ . . O
risk . . O
assessment . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

all . . O
9 . . O
patients . . O
had . . O
hypopituitarism . . B-AdverseReaction
and . . O
some . . O
had . . O
additional . . O
concomitant . . O
endocrinopathies . . B-AdverseReaction
such . . O
as . . O
adrenal . . B-AdverseReaction
insufficiency . . I-AdverseReaction
, . . O
hypogonadism . . B-AdverseReaction
, . . O
and . . O
hypothyroidism . . B-AdverseReaction
. . . O

table . . O
2 . . O
lists . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
0.1% . . O
subjects . . O
who . . O
received . . O
gadavist . . O
. . . O

drugs . . O
that . . O
have . . O
a . . O
mixed . . O
effect . . O
on . . O
cyp3a4 . . O
, . . O
especially . . O
antiretroviral . . O
drugs . . O
such . . O
as . . O
hiv . . O
protease . . O
inhibitors . . O
and . . O
non . . O
- . . O
nucleoside . . O
reverse . . O
transcriptase . . O
inhibitors . . O
, . . O
and . . O
those . . O
that . . O
have . . O
an . . O
effect . . O
on . . O
the . . O
qt . . O
interval . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
taking . . O
coartem . . O
tablets . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.3 . . O
, . . O
7.7 . . O
) . . O
] . . O
. . . O

5.1 . . O
myelosuppression . . O

side . . O
- . . O
by . . O
- . . O
side . . O
tabulation . . O
is . . O
to . . O
simplify . . O
presentation . . O
; . . O
direct . . O
comparisons . . O
across . . O
trials . . O
should . . O
not . . O
be . . O
made . . O
due . . O
to . . O
differing . . O
trial . . O
designs . . O
. . . O

6 . . O
. . . O

spirometric . . O
evaluation . . O
of . . O
respiratory . . O
function . . O
and . . O
evaluation . . O
of . . O
dlco . . O
should . . O
be . . O
performed . . O
during . . O
therapy . . O
with . . O
gilenya . . O
if . . O
clinically . . O
indicated . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
13 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
changes . . O
from . . O
baseline . . O
in . . O
mean . . O
lipid . . O
values . . O
were . . O
reported . . O
in . . O
farxiga . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

increases . . O
in . . O
low . . O
- . . O
density . . O
lipoprotein . . O
cholesterol . . O
( . . O
ldl . . O
- . . O
c . . O
) . . O
and . . O
non . . O
- . . O
high . . O
- . . O
density . . O
lipoprotein . . O
cholesterol . . O
( . . O
non . . O
- . . O
hdl . . O
- . . O
c . . O
) . . O

if . . O
the . . O
diagnosis . . O
is . . O
suspected . . O
, . . O
stop . . O
kyprolis . . O
and . . O
evaluate . . O
. . . O

there . . O
are . . O
insufficient . . O
data . . O
to . . O
support . . O
meaningful . . O
analyses . . O
of . . O
adverse . . O
reactions . . O
by . . O
age . . O
or . . O
race . . O
. . . O

fatal . . B-AdverseReaction
outcomes . . O
have . . O
been . . O
observed . . O
. . . O

5.4 . . O
hypersensitivity . . O
reactions . . O

if . . O
liver . . O
injury . . O
is . . O
found . . O
, . . O
institute . . O
appropriate . . O
treatment . . O
and . . O
investigate . . O
the . . O
probable . . O
cause . . O
. . . O

in . . O
the . . O
re . . O
- . . O
ly . . O
study . . O
, . . O
drug . . O
hypersensitivity . . B-AdverseReaction
( . . O
including . . O
urticaria . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
pruritus . . B-AdverseReaction
) . . O
, . . O
allergic . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
anaphylactic . . B-AdverseReaction
reaction . . I-AdverseReaction
, . . O
and . . O
anaphylactic . . B-AdverseReaction
shock . . I-AdverseReaction
were . . O
reported . . O
in . . O
< . . O
0.1% . . O
of . . O
patients . . O
receiving . . O
pradaxa . . O
. . . O

eliquis . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
bleeding . . B-AdverseReaction
and . . O
can . . B-Factor
cause . . O
serious . . B-Severity
, . . O
potentially . . B-Factor
fatal . . B-AdverseReaction
, . . O
bleeding . . B-AdverseReaction
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
andadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

toviaz . . O
is . . O
associated . . O
with . . O
anticholinergic . . O
central . . O
nervous . . O
sytem . . O
( . . O
cns . . O
) . . O
effects . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

a . . O
causal . . O
association . . O
with . . O
single . . O
- . . O
agent . . O
adcetris . . O
has . . O
not . . O
been . . O
established . . O
. . . O

6.3 . . O
postmarketing . . O
experience . . O

caps . . O
study . . O
1 . . O
investigated . . O
the . . O
safety . . O
of . . O
ilaris . . O
in . . O
an . . O
8 . . O
- . . O
week . . O
, . . O
open . . O
- . . O
label . . O
period . . O
( . . O
part . . O
1 . . O
) . . O
, . . O
followed . . O
by . . O
a . . O
24 . . O
- . . O
week . . O
, . . O
randomized . . O
withdrawal . . O
period . . O
( . . O
part . . O
2 . . O
) . . O
, . . O
followed . . O
by . . O
a . . O
16 . . O
- . . O
week . . O
, . . O
open . . O
- . . O
label . . O
period . . O
( . . O
part . . O
3 . . O
) . . O
. . . O

eight . . O
of . . O
these . . O
13 . . O
fractures . . B-AdverseReaction
were . . O
in . . O
patients . . O
who . . O
had . . O
a . . O
baseline . . O
egfr . . O
of . . O
30 . . O
to . . O
45 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
. . . O

cutaneous . . B-AdverseReaction
squamous . . I-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
( . . O
scc . . B-AdverseReaction
) . . O
, . . O
including . . O
keratoacanthoma . . B-AdverseReaction
, . . O
occurred . . O
in . . O
7% . . O
of . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
and . . O
19% . . O
of . . O
patients . . O
receiving . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

hyperglycemia . . O
, . . O
in . . O
some . . O
cases . . O
extreme . . B-Severity
and . . O
associated . . O
with . . O
ketoacidosis . . B-AdverseReaction
or . . O
hyperosmolar . . B-AdverseReaction
coma . . I-AdverseReaction
or . . O
death . . B-AdverseReaction
, . . O
has . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
atypical . . O
antipsychotics . . O
including . . O
fanapt . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

the . . O
association . . O
with . . O
treanda . . O
therapy . . O
has . . O
not . . O
been . . O
determined . . O
. . . O

patients . . O
with . . O
ra . . O
, . . O
particularly . . O
those . . O
with . . O
highly . . O
active . . O
disease . . O
, . . O
are . . O
at . . O
a . . O
higher . . O
risk . . O
for . . O
the . . O
development . . O
of . . O
lymphoma . . O
. . . O

treat . . O
patients . . O
with . . O
rehydration . . O
, . . O
anti . . O
- . . O
diarrheal . . O
or . . O
anti . . O
- . . O
emetic . . O
medications . . O
as . . O
needed . . O
. . . O

the . . O
mean . . O
age . . O
of . . O
the . . O
population . . O
was . . O
56 . . O
years . . O
and . . O
2% . . O
were . . O
older . . O
than . . O
75 . . O
years . . O
of . . O
age . . O
. . . O

adverse . . O
reactions . . O
in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
reported . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
treated . . O
with . . O
tanzeum . . O
a . . O

hepatobiliary . . O
disorders . . O
: . . O
elevated . . B-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
and . . O
hepatitis . . B-AdverseReaction
. . . O

because . . O
this . . O
adverse . . O
reaction . . O
was . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
possible . . O
to . . O
estimate . . O
its . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

adverse . . O
reactions . . O
for . . O
fulyzaq . . O
that . . O
occurred . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
patients . . O
and . . O
at . . O
a . . O
higher . . O
incidence . . O
than . . O
placebo . . O
are . . O
provided . . O
in . . O
table . . O
1 . . O
. . . O

it . . O
is . . O
not . . B-Factor
possible . . I-Factor
to . . I-Factor
determine . . I-Factor
whether . . O
potiga . . O
caused . . O
this . . O
decreased . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
, . . O
as . . O
baseline . . O
assessments . . O
are . . O
not . . O
available . . O
for . . O
these . . O
patients . . O
. . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
in . . O
clinical . . O
trials . . O
reaction . . O
rate . . O
( . . O
% . . O
) . . O
n . . O
= . . O
2813 . . O
nausea . . B-AdverseReaction
0.6% . . O
headache . . B-AdverseReaction
0.5% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
0.4% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
coldness . . I-AdverseReaction
0.2% . . O
burning . . B-AdverseReaction
sensation . . I-AdverseReaction
0.2% . . O

assessment . . O
of . . O
adverse . . O
reactions . . O
in . . O
patients . . O
with . . O
late . . O
- . . O
onset . . O
pompe . . O
disease . . O
is . . O
based . . O
on . . O
the . . O
exposure . . O
of . . O
90 . . O
patients . . O
( . . O
45 . . O
male . . O
, . . O
45 . . O
female . . O
) . . O
, . . O
aged . . O
10 . . O
to . . O
70 . . O
years . . O
, . . O
to . . O
20 . . O
mg . . O
/ . . O
kg . . O
alglucosidase . . O
alfa . . O
or . . O
placebo . . O
in . . O
a . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trial . . O
. . . O

rash . . B-AdverseReaction
was . . O
self . . O
- . . O
limiting . . O
and . . O
generally . . O
resolved . . O
within . . O
1 . . O
week . . O
on . . O
continued . . O
therapy . . O
. . . O

taper . . O
patients . . O
slowly . . O
from . . O
systemic . . O
corticosteroids . . O
if . . O
transferring . . O
to . . O
breo . . O
ellipta . . O
. . . O

tanzeum . . O
monotherapyb . . O
placebo . . O
30 . . O
mg . . O
weekly . . O
( . . O
52 . . O
weeks . . O
) . . O
n . . O
= . . O
101 . . O
n . . O
= . . O
101 . . O
documented . . O
symptomaticc . . O
2% . . O
2% . . O
severed . . O
- . . O
- . . O
in . . O
combination . . O
with . . O
metformin . . O
trial . . O
placebo . . O
tanzeum . . O
( . . O
104 . . O
weeks . . O
) . . O
e . . O
n . . O
= . . O
101 . . O
n . . O
= . . O
302 . . O
documented . . O
symptomatic . . O
4% . . O
3% . . O
severe . . O
- . . O
- . . O
in . . O
combination . . O
with . . O
pioglitazone . . O
+ . . O
/ . . O
- . . O
placebo . . O
tanzeum . . O
metformin . . O
( . . O
52 . . O
weeks . . O
) . . O
n . . O
= . . O
151 . . O
n . . O
= . . O
150 . . O
documented . . O
symptomatic . . O
1% . . O
3% . . O
severe . . O
- . . O
1% . . O
in . . O
combination . . O
with . . O
metformin . . O
and . . O
placebo . . O
tanzeum . . O
sulfonylurea . . O
( . . O
52 . . O
weeks . . O
) . . O
n . . O
= . . O
115 . . O
n . . O
= . . O
271 . . O
documented . . O
symptomatic . . O
7% . . O
13% . . O
severe . . O
- . . O
0.4% . . O
in . . O
combination . . O
with . . O
insulin . . O
lispro . . O
tanzeum . . O
insulin . . O
glargine . . O
( . . O
26 . . O
weeks . . O
) . . O
n . . O
= . . O
281 . . O
n . . O
= . . O
285 . . O
documented . . O
symptomatic . . O
30% . . O
16% . . O
severe . . O
0.7% . . O
- . . O
in . . O
combination . . O
with . . O
insulin . . O
glargine . . O
tanzeum . . O
metformin . . O
+ . . O
/ . . O
- . . O
sulfonylurea . . O
( . . O
52 . . O
weeks . . O
) . . O
n . . O
= . . O
241 . . O
n . . O
= . . O
504 . . O
documented . . O
symptomatic . . O
27% . . O
17% . . O
severe . . O
0.4% . . O
0.4% . . O
in . . O
combination . . O
with . . O
oads . . O
in . . O
renal . . O
sitagliptin . . O
tanzeum . . O
impairment . . O
( . . O
26 . . O
weeks . . O
) . . O
n . . O
= . . O
246 . . O
n . . O
= . . O
249 . . O
documented . . O
symptomatic . . O
6% . . O
10% . . O
severe . . O
0.8% . . O
- . . O
* . . O
oad . . O
= . . O
oral . . O
antidiabetic . . O
agents . . O
. . . O

hyponatremia . . B-AdverseReaction
was . . O
also . . O
observed . . O
in . . O
monotherapy . . O
trials . . O
. . . O

cimzia . . O
is . . O
not . . O
indicated . . O
for . . O
use . . O
in . . O
pediatric . . O
patients . . O
. . . O

for . . O
patients . . O
at . . O
risk . . O
for . . O
chronically . . O
reduced . . O
renal . . O
function . . O
( . . O
for . . O
example . . O
, . . O
age . . O
> . . O
60 . . O
years . . O
, . . O
hypertension . . O
or . . O
diabetes . . O
) . . O
, . . O
estimate . . O
the . . O
glomerular . . O
filtration . . O
rate . . O
( . . O
gfr . . O
) . . O
through . . O
laboratory . . O
testing . . O
( . . O
5.1 . . O
) . . O
. . . O

fanapt . . O
is . . O
not . . O
approved . . O
for . . O
use . . O
in . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
. . . O

hepatitis . . O
b . . O
virus . . O
reactivation . . O

avoid . . O
use . . O
of . . O
gbcas . . O
in . . O
these . . O
patients . . O
unless . . O
the . . O
diagnostic . . O
information . . O
is . . O
essential . . O
and . . O
not . . O
available . . O
with . . O
non . . O
- . . O
contrasted . . O
mri . . O
or . . O
other . . O
modalities . . O
. . . O

across . . O
four . . O
phase . . O
2 . . O
and . . O
five . . O
phase . . O
3 . . O
clinical . . O
studies . . O
, . . O
64 . . O
( . . O
1.6% . . O
) . . O
trulicity . . O
treated . . O
patients . . O
developed . . O
anti . . O
- . . O
drug . . O
antibodies . . O
( . . O
adas . . O
) . . O
to . . O
the . . O
active . . O
ingredient . . O
in . . O
trulicity . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
dulaglutide . . O
) . . O
. . . O

* . . O
in . . O
other . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
( . . O
9 . . O
of . . O
1044 . . O
; . . O
0.9% . . O
) . . O
, . . O
a . . O
combination . . O
of . . O
penile . . B-AdverseReaction
ecchymoses . . I-AdverseReaction
or . . O
hematoma . . O
, . . O
sudden . . O
penile . . B-AdverseReaction
detumescence . . I-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
a . . O
penile . . B-AdverseReaction
" . . I-AdverseReaction
popping . . I-AdverseReaction
" . . I-AdverseReaction
sound . . I-AdverseReaction
or . . O
sensation . . O
was . . O
reported . . O
, . . O
and . . O
in . . O
these . . O
cases . . O
, . . O
a . . O
diagnosis . . O
of . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
cannot . . B-Factor
be . . I-Factor
excluded . . I-Factor
. . . O

systemic . . O
and . . O
local . . O
corticosteroid . . O
use . . O
may . . O
result . . O
in . . O
the . . O
following . . O
: . . O

routine . . O
monthly . . O
pregnancy . . O
tests . . O
must . . O
be . . O
performed . . O
during . . O
this . . O
time . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
drug . . O
interactions . . O
( . . O
7 . . O
) . . O
] . . O
. . . O

atypical . . B-DrugClass
antipsychotic . . I-DrugClass
drugs . . I-DrugClass
have . . O
been . . O
associated . . O
with . . O
metabolic . . O
changes . . O
that . . O
may . . O
increase . . O
cardiovascular . . O
/ . . O
cerebrovascular . . O
risk . . O
. . . O

patients . . O
with . . O
a . . O
pre . . O
- . . O
existing . . O
low . . O
wbc . . O
or . . O
a . . O
history . . O
of . . O
drug . . O
induced . . O
leukopenia . . O
/ . . O
neutropenia . . O
should . . O
have . . O
their . . O
complete . . O
blood . . O
count . . O
( . . O
cbc . . O
) . . O
monitored . . O
frequently . . O
during . . O
the . . O
first . . O
few . . O
months . . O
of . . O
therapy . . O
and . . O
should . . O
discontinue . . O
fanapt . . O
at . . O
the . . O
first . . O
sign . . O
of . . O
a . . O
decline . . O
in . . O
wbc . . O
in . . O
the . . O
absence . . O
of . . O
other . . O
causative . . O
factors . . O
. . . O

this . . O
product . . O
contains . . O
fd&c . . O
yellow . . O
no . . O
. . . O
5 . . O
( . . O
tartrazine . . O
) . . O
which . . O
may . . B-Factor
cause . . O
allergic . . B-AdverseReaction
- . . I-AdverseReaction
type . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
including . . O
bronchial . . B-AdverseReaction
asthma . . I-AdverseReaction
) . . O
in . . O
certain . . O
susceptible . . O
persons . . O
. . . O

hypersensitivity . . O
reactions . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
generalized . . B-AdverseReaction
urticaria . . I-AdverseReaction
) . . O
, . . O
some . . O
serious . . B-Severity
, . . O
were . . O
reported . . O
with . . O
invokana . . O
treatment . . O
; . . O
these . . O
reactions . . O
generally . . O
occurred . . O
within . . O
hours . . O
to . . O
days . . O
after . . O
initiating . . O
invokana . . O
. . . O

uloric . . O
should . . O
not . . O
be . . O
restarted . . O
in . . O
these . . O
patients . . O
without . . O
another . . O
explanation . . O
for . . O
the . . O
liver . . O
test . . O
abnormalities . . O
. . . O

adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
prolia . . O
- . . O
treated . . O
patients . . O
receiving . . O
adt . . O
for . . O
prostate . . O
cancer . . O
or . . O
adjuvant . . O
ai . . O
therapy . . O
for . . O
breast . . O
cancer . . O
, . . O
and . . O
more . . O
frequently . . O
than . . O
in . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
were . . O
: . . O
arthralgia . . B-AdverseReaction
( . . O
13.0% . . O
placebo . . O
vs . . O
. . . O
14.3% . . O
prolia . . O
) . . O
and . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
10.5% . . O
placebo . . O
vs . . O
. . . O
11.5% . . O
prolia . . O
) . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
not . . O
recommended . . O
in . . O
patients . . O
with . . O
end . . O
- . . O
stage . . O
renal . . O
disease . . O
. . . O

the . . O
median . . O
time . . O
to . . O
first . . O
cuscc . . B-AdverseReaction
was . . O
9 . . O
weeks . . O
( . . O
range . . O
: . . O
1 . . O
to . . O
53 . . O
weeks . . O
) . . O
. . . O

5.6 . . O
macrovascular . . O
outcomes . . O

( . . O
5.2 . . O
) . . O
* . . O
angioedema . . B-AdverseReaction
: . . O
patients . . O
taking . . O
concomitant . . O
ace . . O
inhibitor . . O
therapy . . O
may . . O
be . . O
at . . O
increased . . O
risk . . O
for . . O
angioedema . . O
. . . O

because . . O
these . . O
reactions . . O
may . . O
worsen . . O
renal . . O
function . . O
, . . O
use . . O
caution . . O
when . . O
initiating . . O
or . . O
escalating . . O
doses . . O
of . . O
tanzeum . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
, . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

the . . O
concomitant . . O
use . . O
of . . O
stribild . . O
and . . O
other . . O
drugs . . O
may . . O
result . . O
in . . O
known . . O
or . . O
potentially . . O
significant . . O
drug . . O
interactions . . O
, . . O
some . . O
of . . O
which . . O
may . . O
lead . . O
to . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
, . . O
drug . . O
interactions . . O
( . . O
7.5 . . O
) . . O
] . . O
: . . O

* . . O
supine . . B-AdverseReaction
hypertension . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
hyperpyrexia . . B-AdverseReaction
and . . O
confusion . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
may . . B-Factor
exacerbate . . O
existing . . O
ischemic . . O
heart . . O
disease . . O
, . . O
arrhythmias . . O
, . . O
and . . O
congestive . . O
heart . . O
failure . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
excerpt . . O
: . . O
headache . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
and . . O
fatigue . . B-AdverseReaction
( . . O
greater . . O
than . . O
5% . . O
) . . O
( . . O
6.1 . . O
) . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
label . . O
: . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
potential . . O
for . . O
immunogenicity . . O
. . . O

kalibitorn . . O
= . . O
100 . . O
placebon . . O
= . . O
81 . . O
adverse . . O
reactions . . O
n . . O
( . . O
% . . O
) . . O
a . . O
n . . O
( . . O
% . . O
) . . O
a . . O
headache . . B-AdverseReaction
8 . . O
( . . O
8% . . O
) . . O
6 . . O
( . . O
7% . . O
) . . O
nausea . . B-AdverseReaction
5 . . O
( . . O
5% . . O
) . . O
1 . . O
( . . O
1% . . O
) . . O
diarrhea . . B-AdverseReaction
4 . . O
( . . O
4% . . O
) . . O
3 . . O
( . . O
4% . . O
) . . O
pyrexia . . B-AdverseReaction
4 . . O
( . . O
4% . . O
) . . O
0 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
3 . . O
( . . O
3% . . O
) . . O
1 . . O
( . . O
1% . . O
) . . O
nasopharyngitis . . B-AdverseReaction
3 . . O
( . . O
3% . . O
) . . O
0 . . O
some . . O
patients . . O
in . . O
edema3 . . O
and . . O
edema4 . . O
received . . O
a . . O
second . . O
, . . O
open . . O
- . . O
label . . O
30 . . O
mg . . O
subcutaneous . . O
dose . . O
of . . O
kalbitor . . O
within . . O
24 . . O
hours . . O
following . . O
the . . O
initial . . O
dose . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
vertex . . O
pharmaceuticals . . O
incorporated . . O
at . . O
1-877-634-8789 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

patients . . O
who . . O
develop . . O
symptoms . . O
of . . O
hyperglycemia . . O
during . . O
treatment . . O
with . . O
atypical . . O
antipsychotics . . O
should . . O
undergo . . O
fasting . . O
blood . . O
glucose . . O
testing . . O
. . . O

cough . . B-AdverseReaction
following . . O
inhalation . . O
in . . O
clinical . . O
trials . . O
was . . O
not . . B-Negation
associated . . O
with . . O
bronchospasm . . B-AdverseReaction
, . . O
exacerbations . . O
, . . O
deteriorations . . O
of . . O
disease . . O
or . . O
loss . . B-AdverseReaction
of . . I-AdverseReaction
efficacy . . I-AdverseReaction
. . . O

other . . O
errors . . O
may . . O
be . . O
due . . O
to . . O
extensive . . O
brain . . O
atrophy . . O
that . . O
limits . . O
the . . O
ability . . O
to . . O
distinguish . . O
gray . . O
and . . O
white . . O
matter . . O
on . . O
the . . O
amyvid . . O
scan . . O
as . . O
well . . O
as . . O
motion . . O
artifacts . . O
that . . O
distort . . O
the . . O
image . . O
. . . O

consider . . O
discontinuation . . O
of . . O
duavee . . O
if . . O
pancreatitis . . O
occurs . . O
. . . O

because . . O
clinical . . O
studies . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

clinically . . O
significant . . O
adverse . . O
reactions . . O
that . . O
appear . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
include . . O
the . . O
following . . O
: . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
7% . . O
and . . O
higher . . O
than . . O
placebo . . O
) . . O
: . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
ucb . . O
, . . O
inc . . O
. . . O
at . . O
1-866-822-0068 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

fatal . . B-AdverseReaction
adverse . . O
reactions . . O
in . . O
gilotrif . . O
- . . O
treated . . O
patients . . O
in . . O
study . . O
1 . . O
included . . O
pulmonary . . B-AdverseReaction
toxicity . . I-AdverseReaction
/ . . O
ild . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
1.3% . . O
) . . O
, . . O
sepsis . . B-AdverseReaction
( . . O
0.43% . . O
) . . O
, . . O
and . . O
pneumonia . . B-AdverseReaction
( . . O
0.43% . . O
) . . O
. . . O

common . . O
adverse . . O
reactions . . O

* . . O
fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
intestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
can . . O
occur . . O
in . . O
zydelig . . O
- . . O
treated . . O
patients . . O
across . . O
clinical . . O
trials . . O
. . . O

physicians . . O
should . . O
exercise . . O
caution . . O
when . . O
administering . . O
ilaris . . O
to . . O
patients . . O
with . . O
infections . . O
, . . O
a . . O
history . . O
of . . O
recurring . . O
infections . . O
or . . O
underlying . . O
conditions . . O
which . . O
may . . O
predispose . . O
them . . O
to . . O
infections . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
in . . O
2-5% . . O
of . . O
subjects . . O
included . . O
anterior . . B-AdverseReaction
chamber . . I-AdverseReaction
flare . . I-AdverseReaction
, . . O
corneal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
dry . . B-AdverseReaction
eye . . I-AdverseReaction
, . . O
iridocyclitis . . B-AdverseReaction
, . . O
photophobia . . B-AdverseReaction
, . . O
and . . O
reduced . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
. . . O

( . . O
2.1 . . O
, . . O
5.9 . . O
) . . O
* . . O
thrombocytopenia . . B-AdverseReaction
: . . O
monitor . . O
platelet . . O
counts . . O
; . . O
interrupt . . O
or . . O
reduce . . O
kyprolis . . O
dosing . . O
as . . O
clinically . . O
indicated . . O
. . . O

beleodaq . . O
can . . B-Factor
cause . . O
thrombocytopenia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
( . . O
neutropenia . . B-AdverseReaction
and . . O
lymphopenia . . B-AdverseReaction
) . . O
, . . O
and . . O
/ . . O
or . . O
anemia . . B-AdverseReaction
; . . O
monitor . . O
blood . . O
counts . . O
weekly . . O
during . . O
treatment . . O
, . . O
and . . O
modify . . O
dosage . . O
as . . O
necessary . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

in . . O
the . . O
kalbitor . . O
hae . . O
program . . O
, . . O
patients . . O
developed . . O
antibodies . . O
to . . O
kalbitor . . O
. . . O

laboratory . . O
tests . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
low . . I-AdverseReaction
- . . I-AdverseReaction
density . . I-AdverseReaction
lipoprotein . . I-AdverseReaction
cholesterol . . I-AdverseReaction
( . . O
ldl . . O
- . . O
c . . O
) . . O
dose . . O
- . . O
related . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
low . . I-AdverseReaction
- . . I-AdverseReaction
density . . I-AdverseReaction
lipoprotein . . I-AdverseReaction
cholesterol . . I-AdverseReaction
( . . O
ldl . . O
- . . O
c . . O
) . . O
were . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
jardiance . . O
. . . O

although . . O
breo . . O
ellipta . . O
may . . O
control . . O
copd . . O
or . . O
asthma . . O
symptoms . . O
during . . O
these . . O
episodes . . O
, . . O
in . . O
recommended . . O
doses . . O
it . . O
supplies . . O
less . . O
than . . O
normal . . O
physiological . . O
amounts . . O
of . . O
glucocorticoid . . O
systemically . . O
and . . O
does . . O
not . . O
provide . . O
the . . O
mineralocorticoid . . O
activity . . O
that . . O
is . . O
necessary . . O
for . . O
coping . . O
with . . O
these . . O
emergencies . . O
. . . O

four . . O
patients . . O
out . . O
of . . O
2,367 . . O
patients . . O
treated . . O
with . . O
cimzia . . O
in . . O
ra . . O
clinical . . O
studies . . O
developed . . O
clinical . . O
signs . . O
suggestive . . O
of . . O
a . . O
lupus . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

in . . O
a . . O
limited . . O
number . . O
of . . O
patients . . O
, . . O
hypophysitis . . B-AdverseReaction
was . . O
diagnosed . . O
by . . O
imaging . . O
studies . . O
through . . O
enlargement . . O
of . . O
the . . O
pituitary . . O
gland . . O
. . . O

cervical . . O
dystonia . . O
( . . O
5.4 . . O
) . . O
: . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

the . . O
potency . . O
units . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
are . . O
specific . . O
to . . O
the . . O
preparation . . O
and . . O
assay . . O
method . . O
utilized . . O
. . . O

gadolinium . . B-DrugClass
- . . I-DrugClass
based . . I-DrugClass
contrast . . I-DrugClass
agents . . I-DrugClass
( . . O
gbcas . . O
) . . O
increase . . O
the . . O
risk . . O
for . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O
among . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
the . . O
drugs . . O
. . . O

symptoms . . O
have . . O
included . . O
hypotension . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
throat . . B-AdverseReaction
tightness . . I-AdverseReaction
, . . O
facial . . O
and . . O
upper . . B-AdverseReaction
airway . . I-AdverseReaction
edema . . I-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
and . . O
urticaria . . B-AdverseReaction
. . . O

however . . O
, . . O
the . . O
incidence . . O
of . . O
nonfatal . . O
serious . . B-Severity
infections . . B-AdverseReaction
was . . O
3.3% . . O
in . . O
the . . O
placebo . . O
and . . O
4.0% . . O
in . . O
the . . O
prolia . . O
groups . . O
. . . O

in . . O
controlled . . O
studies . . O
of . . O
cimzia . . O
for . . O
crohn's . . O
disease . . O
and . . O
other . . O
investigational . . O
uses . . O
, . . O
there . . O
was . . O
one . . O
case . . O
of . . O
lymphoma . . B-AdverseReaction
among . . O
2,657 . . O
cimzia . . O
- . . O
treated . . O
patients . . O
and . . O
one . . O
case . . O
of . . O
hodgkin's . . B-AdverseReaction
lymphoma . . I-AdverseReaction
among . . O
1,319 . . O
placebo . . B-Factor
- . . O
treated . . O
patients . . O
. . . O

if . . O
signs . . O
and . . O
symptoms . . O
of . . O
tardive . . O
dyskinesia . . O
appear . . O
in . . O
a . . O
patient . . O
on . . O
fanapt . . O
, . . O
drug . . O
discontinuation . . O
should . . O
be . . O
considered . . O
. . . O

anaphylactic . . O
and . . O
other . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
with . . O
cardiovascular . . O
, . . O
respiratory . . O
or . . O
cutaneous . . O
manifestations . . O
, . . O
ranging . . O
from . . O
mild . . B-Severity
to . . O
severe . . B-Severity
, . . O
including . . O
death . . B-AdverseReaction
, . . O
have . . O
uncommonly . . O
occurred . . O
following . . O
gadavist . . O
administration . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

there . . O
were . . O
no . . O
drug . . O
- . . O
related . . O
adverse . . O
reactions . . O
associated . . O
with . . O
discontinuation . . O
in . . O
patients . . O
treated . . O
with . . O
saphris . . O
at . . O
the . . O
rate . . O
of . . O
at . . O
least . . O
1% . . O
and . . O
at . . O
least . . O
twice . . O
the . . O
placebo . . O
rate . . O
. . . O

in . . O
those . . O
diseases . . O
causing . . O
thinning . . O
of . . O
the . . O
cornea . . O
or . . O
sclera . . O
, . . O
perforations . . B-AdverseReaction
have . . O
been . . O
known . . O
to . . O
occur . . O
with . . O
the . . O
use . . O
of . . O
topical . . O
steroids . . B-DrugClass
. . . O

( . . O
6 . . O
) . . O

because . . O
postmarketing . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

patients . . O
with . . O
diabetes . . O
mellitus . . O
or . . O
a . . O
history . . O
of . . O
uveitis . . O
are . . O
at . . O
increased . . O
risk . . O
. . . O

discontinue . . O
treatment . . O
with . . O
ilaris . . O
if . . O
a . . O
patient . . O
develops . . O
a . . O
serious . . O
infection . . O
. . . O

of . . O
56 . . O
patients . . O
who . . O
tested . . O
negative . . O
for . . O
antibodies . . O
during . . O
treatment . . O
and . . O
reassessed . . O
approximately . . O
7 . . O
half . . O
- . . O
lives . . O
after . . O
discontinuation . . O
of . . O
nulojix . . O
, . . O
1 . . O
tested . . O
antibody . . O
positive . . O
. . . O

transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
generally . . O
occurred . . O
within . . O
the . . O
first . . O
2 . . O
months . . O
of . . O
treatment . . O
. . . O

* . . O
cardiac . . O
disorders . . O
: . . O
tachycardia . . B-AdverseReaction
, . . O
angina . . B-AdverseReaction
pectoris . . I-AdverseReaction
* . . O
gastrointestinal . . O
disorders . . O
: . . O
ileus . . B-AdverseReaction
, . . O
gastritis . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
distension . . I-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
flatulence . . B-AdverseReaction
, . . O
ileus . . B-AdverseReaction
paralytic . . I-AdverseReaction
* . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
infusion . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
* . . O
infections . . O
and . . O
infestations . . O
: . . O
candidiasis . . B-AdverseReaction
, . . O
oropharyngeal . . O
, . . O
fungal . . B-AdverseReaction
urinary . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
* . . O
investigations . . O
: . . O
increased . . B-AdverseReaction
serum . . I-AdverseReaction
gamma . . I-AdverseReaction
- . . I-AdverseReaction
glutamyl . . I-AdverseReaction
transpeptidase . . I-AdverseReaction
( . . O
ggt . . O
) . . O
, . . O
increased . . B-AdverseReaction
serum . . I-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
, . . O
positive . . B-AdverseReaction
coombs . . I-AdverseReaction
test . . I-AdverseReaction
* . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
hyperglycemia . . B-AdverseReaction
, . . O
hypomagnesemia . . B-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
* . . O
nervous . . O
system . . O
disorders . . O
: . . O
ischemic . . B-AdverseReaction
stroke . . I-AdverseReaction
* . . O
renal . . O
and . . O
urinary . . O
system . . O
: . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
* . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
dyspnea . . B-AdverseReaction
* . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
urticaria . . B-AdverseReaction
* . . O
vascular . . O
disorders . . O
: . . O
venous . . B-AdverseReaction
thrombosis . . I-AdverseReaction

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
dermatitis . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
nodosum . . I-AdverseReaction
, . . O
and . . O
urticaria . . B-AdverseReaction
. . . O

osteonecrosis . . O
of . . O
the . . O
jaw . . O
( . . O
onj . . O
) . . O
, . . O
which . . O
can . . O
occur . . O
spontaneously . . O
, . . O
is . . O
generally . . O
associated . . O
with . . O
tooth . . O
extraction . . O
and . . O
/ . . O
or . . O
local . . O
infection . . O
with . . O
delayed . . O
healing . . O
. . . O

* . . O
aminotransferase . . O
elevations . . O
are . . O
accompanied . . O
by . . O
total . . O
bilirubin . . O
elevation . . O
greater . . O
than . . O
two . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
* . . O
aminotransferase . . O
elevations . . O
are . . O
greater . . O
than . . O
eight . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
* . . O
aminotransferase . . O
elevations . . O
are . . O
greater . . O
than . . O
five . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
and . . O
persist . . O
beyond . . O
two . . O
weeks . . O
5.4 . . O
drug . . O
interactions . . O

5.3 . . O
congestive . . O
heart . . O
failure . . O

renal . . O
function . . O

horizant . . O
is . . O
not . . O
interchangeable . . O
with . . O
other . . O
gabapentin . . O
products . . O
because . . O
of . . O
differing . . O
pharmacokinetic . . O
profiles . . O
. . . O

discontinue . . O
tivicay . . O
and . . O
other . . O
suspect . . O
agents . . O
immediately . . O
if . . O
signs . . O
or . . O
symptoms . . O
of . . O
hypersensitivity . . O
reactions . . O
develop . . O
, . . O
as . . O
a . . O
delay . . O
in . . O
stopping . . O
treatment . . O
may . . O
result . . O
in . . O
a . . O
life . . O
- . . O
threatening . . O
reaction . . O
. . . O

( . . O
2.2 . . O
, . . O
5.4 . . O
) . . O
* . . O
depression . . B-AdverseReaction
: . . O
depression . . B-AdverseReaction
and . . O
suicidality . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
trials . . O
with . . O
benlysta . . O
. . . O

the . . O
following . . O
serious . . O
and . . O
otherwise . . O
important . . O
adverse . . O
drug . . O
reactions . . O
( . . O
adrs . . O
) . . O
are . . O
discussed . . O
in . . O
detail . . O
in . . O
another . . O
section . . O
of . . O
the . . O
labeling . . O
: . . O

nms . . B-AdverseReaction
is . . O
an . . O
uncommon . . O
but . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
syndrome . . O
characterized . . O
by . . O
fever . . B-AdverseReaction
or . . O
hyperthermia . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
rigidity . . I-AdverseReaction
, . . O
involuntary . . B-AdverseReaction
movements . . I-AdverseReaction
, . . O
altered . . B-AdverseReaction
consciousness . . I-AdverseReaction
, . . O
and . . O
mental . . B-AdverseReaction
status . . I-AdverseReaction
changes . . I-AdverseReaction
. . . O

the . . O
risk . . O
of . . O
symptoms . . O
is . . O
probably . . O
greatest . . O
in . . O
children . . O
treated . . O
for . . O
spasticity . . O
but . . O
symptoms . . O
can . . O
also . . O
occur . . O
in . . O
adults . . O
, . . O
particularly . . O
in . . O
those . . O
patients . . O
who . . O
have . . O
underlying . . O
conditions . . O
that . . O
would . . O
predispose . . O
them . . O
to . . O
these . . O
symptoms . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
ecchymosis . . B-AdverseReaction
, . . O
skin . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
petechiae . . B-AdverseReaction

gastrointestinal . . O
: . . O
gastritis . . B-AdverseReaction
, . . O
intestinal . . B-AdverseReaction
obstruction . . I-AdverseReaction
. . . O

the . . O
following . . O
coagulation . . O
proteins . . O
were . . O
decreased . . O
in . . O
the . . O
majority . . O
of . . O
patients . . O
after . . O
a . . O
2 . . O
- . . O
week . . O
course . . O
of . . O
erwinaze . . O
by . . O
intramuscular . . O
administration . . O
: . . O
fibrinogen . . O
, . . O
protein . . O
c . . O
activity . . O
, . . O
protein . . O
s . . O
activity . . O
, . . O
and . . O
anti . . O
- . . O
thrombin . . O
iii . . O
. . . O

two . . O
placebo . . O
- . . O
controlled . . O
monotherapy . . O
trials . . O
of . . O
12 . . O
and . . O
26 . . O
weeks . . O
of . . O
duration . . O
were . . O
conducted . . O
in . . O
patients . . O
treated . . O
with . . O
nesina . . O
12.5 . . O
mg . . O
daily . . O
, . . O
nesina . . O
25 . . O
mg . . O
daily . . O
and . . O
placebo . . O
. . . O

these . . O
symptoms . . O
have . . O
been . . O
reported . . O
hours . . O
to . . O
weeks . . O
after . . O
injection . . O
. . . O

* . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

5.6 . . O
immunosuppression . . O

withhold . . O
cometriq . . O
in . . O
patients . . O
with . . O
dehiscence . . O
or . . O
wound . . O
healing . . O
complications . . O
requiring . . O
medical . . O
intervention . . O
. . . O

table . . O
2 . . O
compares . . O
the . . O
incidence . . O
of . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactions . . O
reported . . O
with . . O
an . . O
incidence . . O
of . . O
> . . O
= . . O
10% . . O
for . . O
patients . . O
receiving . . O
afinitor . . O
10 . . O
mg . . O
daily . . O
versus . . O
placebo . . O
. . . O

neutralizing . . O
antibodies . . O
were . . O
detected . . O
in . . O
3 . . O
patients . . O
receiving . . O
benlysta . . O
1 . . O
mg . . O
/ . . O
kg . . O
. . . O
three . . O
patients . . O
with . . O
anti . . O
- . . O
belimumab . . O
antibodies . . O
experienced . . O
mild . . B-Severity
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
of . . O
nausea . . B-AdverseReaction
, . . O
erythematous . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
dyspnea . . B-AdverseReaction
; . . O
none . . O
of . . O
the . . O
reactions . . O
was . . O
life . . O
- . . O
threatening . . O
. . . O

advise . . O
females . . O
of . . O
reproductive . . O
potential . . O
to . . O
use . . O
effective . . O
contraception . . O
during . . O
treatment . . O
with . . O
xalkori . . O
and . . O
for . . O
at . . O
least . . O
45 . . O
days . . O
following . . O
the . . O
final . . O
dose . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
, . . O
8.3 . . O
) . . O
] . . O
. . . O

c . . O
includes . . O
skin . . B-AdverseReaction
papilloma . . I-AdverseReaction
and . . O
papilloma . . B-AdverseReaction
. . . O

onfi . . O
should . . O
be . . O
tapered . . O
by . . O
decreasing . . O
the . . O
dose . . O
every . . O
week . . O
by . . O
5-10 . . O
mg . . O
/ . . O
day . . O
until . . O
discontinuation . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
serious . . B-Severity
dermatological . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
including . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
and . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
) . . O
: . . O
discontinue . . O
onfi . . O
at . . O
first . . O
sign . . O
of . . O
rash . . O
unless . . O
the . . O
rash . . O
is . . O
clearly . . O
not . . O
drug . . O
- . . O
related . . O
. . . O

patients . . O
with . . O
severe . . O
neutropenia . . O
( . . O
absolute . . O
neutrophil . . O
count . . O
< . . O
1000 . . O
/ . . O
mm . . O
3 . . O
) . . O
should . . O
discontinue . . O
fanapt . . O
and . . O
have . . O
their . . O
wbc . . O
followed . . O
until . . O
recovery . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

because . . O
xiaflex . . O
contains . . O
foreign . . O
proteins . . O
, . . O
severe . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
to . . O
xiaflex . . O
can . . B-Factor
occur . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
of . . O
those . . O
exposed . . O
to . . O
durezol . . O
occurring . . O
in . . O
5-10% . . O
of . . O
subjects . . O
included . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
irritation . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
iop . . I-AdverseReaction
, . . O
iritis . . B-AdverseReaction
, . . O
limbal . . O
and . . O
conjunctival . . B-AdverseReaction
hyperemia . . I-AdverseReaction
, . . O
punctate . . B-AdverseReaction
keratitis . . I-AdverseReaction
, . . O
and . . O
uveitis . . B-AdverseReaction
. . . O

in . . O
patients . . O
who . . O
do . . O
require . . O
chronic . . O
treatment . . O
, . . O
the . . O
smallest . . O
dose . . O
and . . O
the . . O
shortest . . O
duration . . O
of . . O
treatment . . O
producing . . O
a . . O
satisfactory . . O
clinical . . O
response . . O
should . . O
be . . O
sought . . O
. . . O

in . . O
the . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
schizophrenia . . O
adult . . O
trials . . O
, . . O
the . . O
incidence . . O
of . . O
reported . . O
eps . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
events . . I-AdverseReaction
, . . O
excluding . . B-Negation
events . . O
related . . O
to . . O
akathisia . . B-AdverseReaction
, . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
was . . O
10% . . O
versus . . O
7% . . O
for . . O
placebo . . O
; . . O
and . . O
the . . O
incidence . . O
of . . O
akathisia . . B-AdverseReaction
- . . O
related . . O
events . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
was . . O
6% . . O
versus . . O
3% . . O
for . . O
placebo . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

the . . O
decision . . O
to . . O
resume . . O
inlyta . . O
therapy . . O
after . . O
surgery . . O
should . . O
be . . O
based . . O
on . . O
clinical . . O
judgment . . O
of . . O
adequate . . O
wound . . O
healing . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
drugs . . B-DrugClass
that . . I-DrugClass
act . . I-DrugClass
directly . . I-DrugClass
on . . I-DrugClass
the . . I-DrugClass
renin . . I-DrugClass
- . . I-DrugClass
angiotensin . . I-DrugClass
system . . I-DrugClass
can . . O
cause . . O
injury . . O
and . . O
death . . B-AdverseReaction
to . . I-AdverseReaction
the . . I-AdverseReaction
developing . . I-AdverseReaction
fetus . . I-AdverseReaction
. . . O

monitor . . O
and . . O
treat . . O
as . . O
appropriate . . O
. . . O

prompt . . O
use . . O
of . . O
all . . O
therapies . . O
necessary . . O
to . . O
reduce . . O
plasma . . O
ammonia . . O
levels . . O
is . . O
essential . . O
. . . O

the . . O
management . . O
of . . O
this . . O
syndrome . . O
should . . O
include . . O
: . . O
( . . O
1 . . O
) . . O
immediate . . O
discontinuation . . O
of . . O
the . . O
antipsychotic . . O
drugs . . O
and . . O
other . . O
drugs . . O
not . . O
essential . . O
to . . O
concurrent . . O
therapy . . O
, . . O
( . . O
2 . . O
) . . O
intensive . . O
symptomatic . . O
treatment . . O
and . . O
medical . . O
monitoring . . O
, . . O
and . . O
( . . O
3 . . O
) . . O
treatment . . O
of . . O
any . . O
concomitant . . O
serious . . O
medical . . O
problems . . O
for . . O
which . . O
specific . . O
treatments . . O
are . . O
available . . O
. . . O

after . . O
administration . . O
of . . O
kalbitor . . O
. . . O

monitor . . O
heart . . O
rate . . O
and . . O
blood . . O
pressure . . O
regularly . . O
. . . O

in . . O
some . . O
cases . . O
of . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
epinephrine . . O
was . . O
administered . . O
. . . O

5.3 . . O
worsening . . O
of . . O
narrow . . O
- . . O
angle . . O
glaucoma . . O

in . . O
the . . O
patients . . O
with . . O
ap . . O
cml . . O
and . . O
bp . . O
cml . . O
, . . O
the . . O
median . . O
duration . . O
of . . O
bosulif . . O
treatment . . O
was . . O
10 . . O
months . . O
and . . O
3 . . O
months . . O
, . . O
respectively . . O
. . . O

if . . O
paradoxical . . O
bronchospasm . . O
occurs . . O
, . . O
arcapta . . O
neohaler . . O
should . . O
be . . O
discontinued . . O
immediately . . O
and . . O
alternative . . O
therapy . . O
instituted . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
eight . . O
clinical . . O
trials . . O
, . . O
the . . O
incidence . . O
rate . . O
of . . O
pancreatitis . . O
( . . O
acute . . O
or . . O
chronic . . O
) . . O
was . . O
0.9 . . O
, . . O
2.7 . . O
, . . O
and . . O
0.9 . . O
per . . O
1000 . . O
patient . . O
- . . O
years . . O
of . . O
exposure . . O
to . . O
comparator . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

during . . O
the . . O
controlled . . O
portion . . O
of . . O
the . . O
phase . . O
3 . . O
trial . . O
in . . O
ra . . O
for . . O
simponi . . O
aria . . O
, . . O
the . . O
incidence . . O
of . . O
malignancies . . B-AdverseReaction
other . . O
than . . O
lymphoma . . O
and . . O
nmsc . . O
per . . O
100 . . O
- . . O
patient . . O
- . . O
years . . O
of . . O
follow . . O
- . . O
up . . O
was . . O
0.56 . . O
( . . O
95% . . O
ci . . O
: . . O
0.01 . . O
, . . O
3.11 . . O
) . . O
in . . O
the . . O
simponi . . O
aria . . O
group . . O
compared . . O
with . . O
an . . O
incidence . . O
of . . O
0 . . O
( . . O
95% . . O
ci . . O
: . . O
0.00 . . O
, . . O
3.79 . . O
) . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

6 . . O
adverse . . O
reactions . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
pfizer . . O
inc . . O
. . . O
at . . O
1-800-438-1985 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

ensure . . O
safe . . O
handling . . O
to . . O
protect . . O
the . . O
patient . . O
and . . O
health . . O
care . . O
worker . . O
( . . O
5.3 . . O
) . . O
. . . O

most . . O
cases . . O
of . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
occurred . . O
early . . O
in . . O
treatment . . O
; . . O
of . . O
patients . . O
who . . O
experienced . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
of . . O
any . . O
grade . . O
, . . O
more . . O
than . . O
80% . . O
experienced . . O
their . . O
first . . O
event . . O
within . . O
the . . O
first . . O
3 . . O
months . . O
. . . O

the . . O
median . . O
daily . . O
dose . . O
of . . O
tafinlar . . O
was . . O
300 . . O
mg . . O
( . . O
range . . O
: . . O
118 . . O
to . . O
300 . . O
mg . . O
) . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
cigarette . . O
smoking . . O
and . . O
serious . . B-Severity
cardiovascular . . B-AdverseReaction
events . . I-AdverseReaction

5 . . O
warnings . . O
and . . O
precautions . . O

6 . . O
adverse . . O
reactions . . O

in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
adverse . . O
event . . O
of . . O
increased . . B-AdverseReaction
ggt . . I-AdverseReaction
occurred . . O
more . . O
frequently . . O
in . . O
the . . O
group . . O
treated . . O
with . . O
tanzeum . . O
( . . O
0.9% . . O
and . . O
1.5% . . O
for . . O
placebo . . O
versus . . O
tanzeum . . O
) . . O
. . . O

a . . O
grade . . O
of . . O
0 . . O
represented . . O
no . . O
reaction . . O
present . . O
in . . O
the . . O
treated . . O
area . . O
, . . O
and . . O
a . . O
grade . . O
of . . O
4 . . O
indicated . . O
a . . O
marked . . O
and . . O
severe . . O
skin . . O
reaction . . O
that . . O
extended . . O
beyond . . O
the . . O
treated . . O
area . . O
. . . O

other . . O
adverse . . O
reactions . . O

excerpt . . O
: . . O
warning . . O
: . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O

in . . O
a . . O
pooled . . O
analysis . . O
of . . O
randomized . . O
double . . O
- . . O
blind . . O
oncology . . O
clinical . . O
trials . . O
, . . O
the . . O
incidence . . O
of . . O
angioedema . . B-AdverseReaction
in . . O
patients . . O
taking . . O
everolimus . . O
with . . O
an . . O
ace . . O
inhibitor . . O
was . . O
6.8% . . O
compared . . O
to . . O
1.3% . . O
in . . O
the . . O
control . . O
arm . . O
with . . O
an . . O
ace . . O
inhibitor . . O
. . . O

hematuria . . O
: . . O

the . . O
following . . O
adverse . . O
drug . . O
reactions . . O
( . . O
adverse . . O
events . . O
assessed . . O
as . . O
causally . . O
related . . O
by . . O
the . . O
investigator . . O
or . . O
adrs . . O
) . . O
are . . O
discussed . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

reported . . O
cases . . O
of . . O
post . . B-AdverseReaction
- . . I-AdverseReaction
transplant . . I-AdverseReaction
lymphoproliferative . . I-AdverseReaction
disorder . . I-AdverseReaction
( . . O
ptld . . B-AdverseReaction
) . . O
up . . O
to . . O
36 . . O
months . . O
post . . O
transplant . . O
were . . O
obtained . . O
for . . O
nulojix . . O
by . . O
pooling . . O
both . . O
dosage . . O
regimens . . O
of . . O
nulojix . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
( . . O
804 . . O
patients . . O
) . . O
with . . O
data . . O
from . . O
a . . O
third . . O
study . . O
in . . O
kidney . . O
transplantation . . O
( . . O
study . . O
3 . . O
, . . O
145 . . O
patients . . O
) . . O
which . . O
evaluated . . O
two . . O
nulojix . . O
dosage . . O
regimens . . O
similar . . O
, . . O
but . . O
slightly . . O
different . . O
, . . O
from . . O
those . . O
of . . O
studies . . O
1 . . O
and . . O
2 . . O
( . . O
see . . O
table . . O
2 . . O
) . . O
. . . O

gamma . . O
glutamyltransferase . . O
( . . O
ggt . . O
) . . O
increase . . O

reduced . . B-AdverseReaction
fetal . . I-AdverseReaction
weights . . I-AdverseReaction
were . . O
observed . . O
at . . O
lower . . O
exposures . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
the . . O
overall . . O
incidence . . O
of . . O
cutaneous . . B-AdverseReaction
reactions . . I-AdverseReaction
consisting . . O
of . . O
rash . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
and . . O
acneiform . . B-AdverseReaction
rash . . I-AdverseReaction
was . . O
90% . . O
, . . O
and . . O
the . . O
incidence . . O
of . . O
grade . . B-Severity
3 . . I-Severity
cutaneous . . B-AdverseReaction
reactions . . I-AdverseReaction
was . . O
16% . . O
. . . O

stop . . O
natazia . . O
if . . O
an . . O
arterial . . O
or . . O
venous . . O
thrombotic . . O
event . . O
( . . O
vte . . O
) . . O
occurs . . O
. . . O

withhold . . O
yervoy . . O
dosing . . O
in . . O
patients . . O
with . . O
moderate . . O
to . . O
severe . . O
signs . . O
and . . O
symptoms . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
qt . . B-AdverseReaction
interval . . I-AdverseReaction
prolongation . . I-AdverseReaction
: . . O
occurred . . O
in . . O
2.1% . . O
of . . O
patients . . O
. . . O

* . . O
have . . O
any . . O
other . . O
medical . . O
conditions . . O
. . . O

hematologic . . B-AdverseReaction
toxicities . . I-AdverseReaction
, . . O
based . . O
on . . O
laboratory . . O
values . . O
and . . O
ctc . . O
grade . . O
, . . O
in . . O
nhl . . O
patients . . O
treated . . O
in . . O
both . . O
single . . O
arm . . O
studies . . O
combined . . O
are . . O
described . . O
in . . O
table . . O
4 . . O
. . . O

falls . . O
and . . O
fall . . O
- . . O
related . . O
injuries . . O
in . . O
the . . O
two . . O
randomized . . O
clinical . . O
trials . . O
, . . O
falls . . B-AdverseReaction
including . . O
fall . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
injuries . . I-AdverseReaction
, . . O
occurred . . O
in . . O
9% . . O
of . . O
patients . . O
treated . . O
with . . O
xtandi . . O
compared . . O
to . . O
4% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

5.1 . . O
effects . . O
on . . O
driving . . O

concurrent . . O
administration . . O
with . . O
vemurafenib . . O

data . . O
in . . O
table . . O
1 . . O
are . . O
for . . O
all . . O
aes . . O
for . . O
all . . O
caps . . O
patients . . O
receiving . . O
canakinumab . . O
. . . O

no . . O
formal . . O
studies . . O
of . . O
the . . O
effect . . O
of . . O
inlyta . . O
on . . O
wound . . O
healing . . O
have . . O
been . . O
conducted . . O
. . . O

in . . O
case . . O
of . . O
recurrent . . O
events . . O
of . . O
the . . O
same . . O
category . . O
, . . O
the . . O
first . . O
event . . O
was . . O
considered . . O
. . . O
cdefined . . O
as . . O
bleeding . . B-AdverseReaction
accompanied . . O
by . . O
one . . O
or . . O
more . . O
of . . O
the . . O
following . . O
: . . O
a . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
of . . O
> . . O
= . . O
2 . . B-Severity
g . . I-Severity
/ . . I-Severity
dl . . I-Severity
, . . O
a . . O
transfusion . . O
of . . O
2 . . O
or . . O
more . . O
units . . O
of . . O
packed . . O
red . . O
blood . . O
cells . . O
, . . O
bleeding . . B-AdverseReaction
at . . I-AdverseReaction
a . . I-AdverseReaction
critical . . I-AdverseReaction
site . . I-AdverseReaction
or . . O
with . . O
fatal . . B-AdverseReaction
outcome . . O
. . . O
dintracranial . . O
bleed . . B-AdverseReaction
included . . O
intracerebral . . O
( . . O
hemorrhagic . . B-AdverseReaction
stroke . . I-AdverseReaction
) . . O
, . . O
subarachnoid . . O
, . . O
and . . O
subdural . . B-AdverseReaction
bleeds . . I-AdverseReaction
. . . O
eon . . O
- . . O
treatment . . O
analysis . . O
based . . O
on . . O
the . . O
safety . . O
population . . O
, . . O
compared . . O
to . . O
itt . . O
analysis . . O
presented . . O
in . . O
section . . O
14 . . O
clinical . . O
studies . . O
. . . O
ffatal . . O
bleed . . B-AdverseReaction
: . . O
adjudicated . . O
major . . B-Severity
bleed . . B-AdverseReaction
as . . O
defined . . O
above . . O
with . . O
investigator . . O
reported . . O
fatal . . B-AdverseReaction
outcome . . O
and . . O
adjudicated . . O
death . . B-AdverseReaction
with . . O
primary . . O
cause . . O
from . . O
bleeding . . B-AdverseReaction
. . . O
gnon . . O
- . . O
intracranial . . O
fatal . . B-AdverseReaction
bleed . . O
: . . O
adjudicated . . O
major . . B-Severity
bleed . . B-AdverseReaction
as . . O
defined . . O
above . . O
and . . O
adjudicated . . O
death . . B-AdverseReaction
with . . O
primary . . O
cause . . O
from . . O
bleeding . . B-AdverseReaction
but . . O
without . . B-Negation
symptomatic . . B-AdverseReaction
intracranial . . I-AdverseReaction
bleed . . I-AdverseReaction
based . . O
on . . O
investigator's . . O
clinical . . O
assessment . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
gilead . . O
sciences . . O
, . . O
inc . . O
. . . O
at . . O
1-800 . . O
- . . O
gilead . . O
- . . O
5 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

5.2 . . O
severe . . O
diarrhea . . O
or . . O
colitis . . O

these . . O
patients . . O
received . . O
treanda . . O
at . . O
a . . O
dose . . O
of . . O
120 . . O
mg . . O
/ . . O
m . . O
2 . . O
intravenously . . O
on . . O
days . . O
1 . . O
and . . O
2 . . O
for . . O
up . . O
to . . O
eight . . O
21 . . O
- . . O
day . . O
cycles . . O
. . . O

one . . O
case . . O
of . . O
malignancy . . B-AdverseReaction
other . . O
than . . O
lymphoma . . B-AdverseReaction
and . . O
nmsc . . B-AdverseReaction
with . . O
simponi . . O
aria . . O
was . . O
reported . . O
through . . O
week . . O
24 . . O
during . . O
the . . O
controlled . . O
phase . . O
of . . O
trial . . O
1 . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O
in . . O
chronic . . O
obstructive . . O
pulmonary . . O
disease . . O

avoid . . O
using . . O
xalkori . . O
in . . O
combination . . O
with . . O
other . . O
agents . . O
known . . O
to . . O
cause . . O
bradycardia . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
beta . . O
- . . O
blockers . . O
, . . O
non . . O
- . . O
dihydropyridine . . O
calcium . . O
channel . . O
blockers . . O
, . . O
clonidine . . O
and . . O
digoxin . . O
) . . O
to . . O
the . . O
extent . . O
possible . . O
. . . O

there . . O
have . . O
been . . O
reports . . O
of . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
in . . O
patients . . O
with . . O
severe . . O
milk . . O
protein . . O
allergy . . O
after . . O
inhalation . . O
of . . O
other . . O
powder . . B-DrugClass
medications . . I-DrugClass
containing . . I-DrugClass
lactose . . I-DrugClass
; . . O
therefore . . O
, . . O
patients . . O
with . . O
severe . . O
milk . . O
protein . . O
allergy . . O
should . . O
not . . O
use . . O
breo . . O
ellipta . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

in . . O
both . . O
indications . . O
, . . O
about . . O
25% . . O
of . . O
the . . O
subjects . . O
were . . O
65 . . O
years . . O
of . . O
age . . O
or . . O
older . . O
. . . O

this . . O
is . . O
approximately . . O
2 . . O
- . . O
fold . . O
higher . . O
than . . O
expected . . O
in . . O
the . . O
general . . O
population . . O
. . . O

in . . O
these . . O
patients . . O
, . . O
a . . O
comprehensive . . O
evaluation . . O
of . . O
urologic . . O
symptoms . . O
prior . . O
to . . O
and . . O
during . . O
treatment . . O
with . . O
potiga . . O
may . . O
be . . O
appropriate . . B-Factor
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
in . . O
patients . . O
who . . O
received . . O
yervoy . . O
at . . O
3 . . O
mg . . O
/ . . O
kg . . O
were . . O
fatigue . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
colitis . . B-AdverseReaction
. . . O

discontinue . . O
erwinaze . . O
for . . O
severe . . O
or . . O
hemorrhagic . . O
pancreatitis . . O
manifested . . O
by . . O
abdominal . . O
pain . . O
> . . O
72 . . O
hours . . O
and . . O
amylase . . O
elevation . . O
> . . O
= . . O
2.0 . . O
x . . O
uln . . O
. . . O

rupture . . B-AdverseReaction
of . . I-AdverseReaction
hepatic . . I-AdverseReaction
adenomas . . I-AdverseReaction
may . . B-Factor
cause . . O
death . . B-AdverseReaction
through . . O
intra . . B-AdverseReaction
- . . I-AdverseReaction
abdominal . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
. . . O

postmarketing . . O
experience . . O

tissue . . O
culture . . O
experiments . . O
indicate . . O
that . . O
approximately . . O
one . . O
- . . O
third . . O
of . . O
human . . O
breast . . O
cancers . . O
are . . O
prolactin . . O
- . . O
dependent . . O
in . . O
vitro . . O
, . . O
a . . O
factor . . O
of . . O
potential . . O
importance . . O
if . . O
the . . O
prescription . . O
of . . O
these . . O
drugs . . O
is . . O
considered . . O
in . . O
a . . O
patient . . O
with . . O
previously . . O
- . . O
detected . . O
breast . . O
cancer . . O
. . . O

of . . O
the . . O
28 . . O
patients . . O
with . . O
moderate . . B-Severity
enterocolitis . . B-AdverseReaction
, . . O
46% . . O
were . . O
not . . O
treated . . O
with . . O
systemic . . O
corticosteroids . . O
, . . O
29% . . O
were . . O
treated . . O
with . . O
< . . O
40 . . O
mg . . O
prednisone . . O
or . . O
equivalent . . O
per . . O
day . . O
for . . O
a . . O
median . . O
duration . . O
of . . O
5.1 . . O
weeks . . O
, . . O
and . . O
25% . . O
were . . O
treated . . O
with . . O
high . . O
- . . O
dose . . O
corticosteroids . . O
for . . O
a . . O
median . . O
duration . . O
of . . O
10 . . O
days . . O
prior . . O
to . . O
corticosteroid . . O
taper . . O
. . . O

in . . O
patients . . O
receiving . . O
blincyto . . O
in . . O
clinical . . O
trials . . O
, . . O
grade . . B-Severity
3 . . I-Severity
or . . O
greater . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
occurred . . O
in . . O
approximately . . O
6% . . O
of . . O
patients . . O
outside . . B-Negation
the . . O
setting . . O
of . . O
crs . . B-AdverseReaction
and . . O
resulted . . O
in . . O
treatment . . O
discontinuation . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
patients . . O
. . . O

table . . O
1 . . O
presents . . O
selected . . O
adverse . . O
reactions . . O
from . . O
study . . O
1 . . O
, . . O
which . . O
occurred . . O
in . . O
at . . O
least . . O
5% . . O
of . . O
patients . . O
in . . O
the . . O
yervoy . . O
- . . O
containing . . O
arms . . O
and . . O
with . . O
at . . O
least . . O
5% . . O
increased . . O
incidence . . O
over . . O
the . . O
control . . O
gp100 . . O
arm . . O
for . . O
all . . O
- . . O
grade . . O
events . . O
and . . O
at . . O
least . . O
1% . . O
incidence . . O
over . . O
the . . O
control . . O
group . . O
for . . O
grade . . O
3-5 . . O
events . . O
. . . O

* . . O
? . . O

if . . O
mefloquine . . O
is . . O
administered . . O
immediately . . O
prior . . O
to . . O
coartem . . O
tablets . . O
there . . O
may . . O
be . . O
a . . O
decreased . . O
exposure . . O
to . . O
lumefantrine . . O
, . . O
possibly . . O
due . . O
to . . O
a . . O
mefloquine . . O
- . . O
induced . . O
decrease . . O
in . . O
bile . . O
production . . O
. . . O

adverse . . O
drug . . O
reactions . . O
that . . O
do . . O
not . . O
appear . . O
in . . O
table . . O
1 . . O
or . . O
that . . O
occurred . . O
< . . O
1% . . O
in . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
during . . O
trial . . O
1 . . O
through . . O
week . . O
24 . . O
that . . O
do . . O
not . . O
appear . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O
included . . O
the . . O
following . . O
events . . O
listed . . O
by . . O
system . . O
organ . . O
class . . O
: . . O

the . . O
95% . . O
confidence . . O
limits . . O
that . . O
are . . O
shown . . O
do . . O
not . . O
take . . O
into . . O
account . . O
how . . O
many . . O
comparisons . . O
were . . O
made . . O
, . . O
nor . . O
do . . O
they . . O
reflect . . O
the . . O
effect . . O
of . . O
a . . O
particular . . O
factor . . O
after . . O
adjustment . . O
for . . O
all . . O
other . . O
factors . . O
. . . O

5.1 . . O
ophthalmic . . O
adverse . . O
reactions . . O

granix . . O
clinical . . O
trials . . O
safety . . O
data . . O
are . . O
based . . O
upon . . O
the . . O
results . . O
of . . O
three . . O
randomized . . O
clinical . . O
trials . . O
in . . O
patients . . O
receiving . . O
myeloablative . . O
chemotherapy . . O
for . . O
breast . . O
cancer . . O
( . . O
n . . O
= . . O
348 . . O
) . . O
, . . O
lung . . O
cancer . . O
( . . O
n . . O
= . . O
240 . . O
) . . O
and . . O
non . . O
- . . O
hodgkin's . . O
lymphoma . . O
( . . O
n . . O
= . . O
92 . . O
) . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
postapproval . . O
use . . O
of . . O
benlysta . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
guerbet . . O
llc . . O
at . . O
1-877-729-6679 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

the . . O
rate . . O
of . . O
progression . . O
of . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
and . . O
their . . O
reversibility . . O
are . . O
unknown . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
somnolence . . B-AdverseReaction
/ . . O
sedation . . B-AdverseReaction
and . . O
dizziness . . B-AdverseReaction
: . . O
may . . B-Factor
impair . . O
the . . O
patient's . . O
ability . . O
to . . O
operate . . O
complex . . O
machinery . . O
. . . O

consider . . O
the . . O
diagnosis . . O
of . . O
pml . . O
in . . O
any . . O
patient . . O
presenting . . O
with . . O
new . . O
- . . O
onset . . O
or . . O
deteriorating . . O
neurological . . O
signs . . O
and . . O
symptoms . . O
and . . O
consult . . O
with . . O
a . . O
neurologist . . O
or . . O
other . . O
appropriate . . O
specialist . . O
as . . O
clinically . . O
indicated . . O
. . . O

because . . O
these . . O
studies . . O
did . . O
not . . O
include . . O
a . . O
placebo . . O
control . . O
group . . O
, . . O
causality . . O
could . . O
not . . O
be . . O
established . . O
. . . O

if . . O
pneumonitis . . O
is . . O
suspected . . O
, . . O
interrupt . . O
zydelig . . O
until . . O
the . . O
etiology . . O
of . . O
the . . O
pulmonary . . O
symptoms . . O
has . . O
been . . O
determined . . O
. . . O

in . . O
the . . O
amplify . . O
study . . O
, . . O
eliquis . . O
was . . O
statistically . . O
superior . . O
to . . O
enoxaparin . . O
/ . . O
warfarin . . O
in . . O
the . . O
primary . . O
safety . . O
endpoint . . O
of . . O
major . . B-Severity
bleeding . . B-AdverseReaction
( . . O
relative . . O
risk . . O
0.31 . . O
, . . O
95% . . O
ci . . O
[ . . O
0.17 . . O
, . . O
0.55 . . O
] . . O
, . . O
p . . O
- . . O
value . . O
< . . O
0.0001 . . O
) . . O
. . . O

worsening . . B-AdverseReaction
hypertension . . I-AdverseReaction
was . . O
reported . . O
in . . O
4 . . O
patients . . O
treated . . O
with . . O
treanda . . O
in . . O
the . . O
cll . . O
trial . . O
and . . O
in . . O
none . . O
treated . . O
with . . O
chlorambucil . . O
. . . O

adverse . . O
reaction . . O
placebo . . O
( . . O
n . . O
= . . O
468 . . O
) . . O
% . . O
tanzeum . . O
( . . O
n . . O
= . . O
923 . . O
) . . O
% . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
13.0 . . O
14.2 . . O
diarrhea . . B-AdverseReaction
10.5 . . O
13.1 . . O
nausea . . B-AdverseReaction
9.6 . . O
11.1 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactionb . . O
2.1 . . O
10.5 . . O
cough . . B-AdverseReaction
6.2 . . O
6.9 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
5.8 . . O
6.7 . . O
arthralgia . . B-AdverseReaction
6.4 . . O
6.6 . . O
sinusitis . . B-AdverseReaction
5.8 . . O
6.2 . . O
influenza . . B-AdverseReaction
3.2 . . O
5.2 . . O
* . . O
a . . O
adverse . . O
reactions . . O
reported . . O
includes . . O
adverse . . O
reactions . . O
occurring . . O
with . . O
the . . O
use . . O
of . . O
glycemic . . O
rescue . . O
medications . . O
which . . O
included . . O
metformin . . O
( . . O
17% . . O
for . . O
placebo . . O
and . . O
10% . . O
for . . O
tanzeum . . O
) . . O
and . . O
insulin . . O
( . . O
24% . . O
for . . O
placebo . . O
and . . O
14% . . O
for . . O
tanzeum . . O
) . . O
. . . O

in . . O
the . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
a . . O
total . . O
of . . O
485 . . O
patients . . O
with . . O
parkinson's . . O
disease . . O
, . . O
multiple . . O
system . . O
atrophy . . O
, . . O
pure . . O
autonomic . . O
failure . . O
, . . O
dopamine . . O
beta . . O
- . . O
hydroxylase . . O
deficiency . . O
, . . O
or . . O
non . . O
- . . O
diabetic . . O
autonomic . . O
neuropathy . . O
were . . O
randomized . . O
and . . O
treated . . O
, . . O
245 . . O
with . . O
northera . . O
and . . O
240 . . O
with . . O
placebo . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
were . . O
neutropenia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
and . . O
vomiting . . B-AdverseReaction
. . . O

monitor . . O
supine . . O
blood . . O
pressure . . O
prior . . O
to . . O
and . . O
during . . O
treatment . . O
and . . O
more . . O
frequently . . O
when . . O
increasing . . O
doses . . O
. . . O

it . . O
is . . O
not . . O
known . . O
if . . O
duavee . . O
is . . O
safe . . O
and . . O
effective . . O
in . . O
people . . O
with . . O
kidney . . O
problems . . O
. . . O

at . . O
the . . O
time . . O
of . . O
perforation . . O
, . . O
some . . O
patients . . O
had . . O
moderate . . B-Severity
to . . O
severe . . B-Severity
diarrhea . . B-AdverseReaction
. . . O

cataracts . . B-AdverseReaction
were . . O
observed . . O
in . . O
toxicology . . O
studies . . O
of . . O
eltrombopag . . O
in . . O
rodents . . B-Animal
[ . . O
see . . O
nonclinical . . O
toxicology . . O
( . . O
13.2 . . O
) . . O
] . . O
. . . O

* . . O
c . . O
plasma . . B-AdverseReaction
glucose . . I-AdverseReaction
concentration . . I-AdverseReaction
< . . I-AdverseReaction
= . . I-AdverseReaction
70 . . I-AdverseReaction
mg . . I-AdverseReaction
/ . . I-AdverseReaction
dl . . I-AdverseReaction
and . . O
presence . . O
of . . O
hypoglycemic . . B-AdverseReaction
symptoms . . I-AdverseReaction
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
cytokine . . B-AdverseReaction
release . . I-AdverseReaction
syndrome . . I-AdverseReaction
and . . O
neurological . . B-AdverseReaction
toxicities . . I-AdverseReaction
see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

5.4 . . O
qt . . O
interval . . O
prolongation . . O

in . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
four . . O
cases . . O
of . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
cutaneous . . I-AdverseReaction
malignancies . . I-AdverseReaction
were . . O
identified . . O
: . . O
kras . . B-AdverseReaction
mutation . . I-AdverseReaction
- . . I-AdverseReaction
positive . . I-AdverseReaction
pancreatic . . I-AdverseReaction
adenocarcinoma . . I-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
, . . O
recurrent . . B-AdverseReaction
nras . . I-AdverseReaction
mutation . . I-AdverseReaction
- . . I-AdverseReaction
positive . . I-AdverseReaction
colorectal . . I-AdverseReaction
carcinoma . . I-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
, . . O
head . . B-AdverseReaction
and . . I-AdverseReaction
neck . . I-AdverseReaction
carcinoma . . I-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
, . . O
and . . O
glioblastoma . . B-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
. . . O

there . . O
were . . O
many . . O
adverse . . O
events . . O
associated . . O
with . . O
the . . O
operative . . O
procedure . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
cleviprex . . O
and . . O
relatively . . O
few . . O
plausibly . . O
related . . O
to . . O
the . . O
drugs . . O
used . . O
to . . O
lower . . O
blood . . O
pressure . . O
. . . O

forty . . O
- . . O
four . . O
( . . O
70% . . O
) . . O
patients . . O
with . . O
moderate . . B-Severity
dermatitis . . B-AdverseReaction
were . . O
reported . . O
to . . O
have . . O
complete . . O
resolution . . O
, . . O
7 . . O
( . . O
11% . . O
) . . O
improved . . O
to . . O
mild . . O
( . . O
grade . . O
1 . . O
) . . O
severity . . O
, . . O
and . . O
12 . . O
( . . O
19% . . O
) . . O
had . . O
no . . O
reported . . O
improvement . . O
. . . O

these . . O
patients . . O
may . . B-Factor
have . . O
an . . O
increased . . O
risk . . O
for . . O
a . . O
hypersensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
to . . O
dotarem . . O
. . . O

monitor . . O
blood . . O
counts . . O
at . . O
least . . O
every . . O
two . . O
weeks . . O
for . . O
the . . O
first . . O
3 . . O
months . . O
of . . O
therapy . . O
, . . O
and . . O
at . . O
least . . O
weekly . . O
in . . O
patients . . O
while . . O
neutrophil . . O
counts . . O
are . . O
less . . O
than . . O
1.0 . . O
gi . . O
/ . . O
l . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

the . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
was . . O
generally . . O
consistent . . O
among . . O
drugs . . O
in . . O
the . . O
data . . O
analyzed . . O
. . . O

if . . O
the . . O
patient . . O
is . . O
known . . O
or . . O
strongly . . O
suspected . . O
to . . O
have . . O
hypersensitivity . . O
to . . O
iodine . . O
, . . O
an . . O
iodine . . O
- . . O
containing . . O
contrast . . O
agent . . O
or . . O
other . . O
products . . O
containing . . O
iodine . . O
, . . O
the . . O
decision . . O
to . . O
administer . . O
adreview . . O
should . . O
be . . O
based . . O
upon . . O
an . . O
assessment . . O
of . . O
the . . O
expected . . O
benefits . . O
compared . . O
to . . O
the . . O
potential . . O
hypersensitivity . . O
risks . . O
. . . O

5.2 . . O
cerebrovascular . . O
adverse . . O
events . . O
, . . O
including . . O
stroke . . O
, . . O
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

the . . O
impact . . O
of . . O
treatment . . O
with . . O
cimzia . . O
on . . O
the . . O
development . . O
and . . O
course . . O
of . . O
malignancies . . O
, . . O
as . . O
well . . O
as . . O
active . . O
and . . O
/ . . O
or . . O
chronic . . O
infections . . O
, . . O
is . . O
not . . O
fully . . O
understood . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
, . . O
5.2 . . O
, . . O
5.5 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

withhold . . O
if . . O
not . . O
responsive . . O
to . . O
anti . . O
- . . O
emetics . . O
or . . O
anti . . O
- . . O
diarrheals . . O
, . . O
then . . O
dose . . O
reduce . . O
zykadia . . O
. . . O

it . . O
is . . O
unknown . . B-Factor
whether . . O
tanzeum . . O
causes . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
, . . O
including . . O
medullary . . B-AdverseReaction
thyroid . . I-AdverseReaction
carcinoma . . I-AdverseReaction
( . . O
mtc . . B-AdverseReaction
) . . O
, . . O
in . . O
humans . . O
. . . O

all . . O
cases . . O
of . . O
ptld . . B-AdverseReaction
reported . . O
up . . O
to . . O
36 . . O
months . . O
post . . O
transplant . . O
in . . O
nulojix . . O
- . . O
or . . O
cyclosporine . . O
- . . O
treated . . O
patients . . O
presented . . O
within . . O
18 . . O
months . . O
of . . O
transplantation . . O
. . . O

mean . . O
percentage . . O
decreases . . B-AdverseReaction
in . . I-AdverseReaction
bmd . . I-AdverseReaction
from . . O
baseline . . O
to . . O
week . . O
144 . . O
in . . O
the . . O
stribild . . O
group . . O
were . . O
comparable . . O
to . . O
the . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
group . . O
at . . O
the . . O
lumbar . . O
spine . . O
( . . O
- . . O
1.43% . . O
versus . . O
- . . O
3.68% . . O
, . . O
respectively . . O
) . . O
and . . O
at . . O
the . . O
hip . . O
( . . O
- . . O
2.83% . . O
versus . . O
- . . O
3.77% . . O
, . . O
respectively . . O
) . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

presence . . O
of . . O
antibody . . O
did . . O
not . . O
correlate . . O
with . . O
reduced . . O
efficacy . . O
as . . O
measured . . O
by . . O
hba1c . . O
and . . O
fasting . . O
plasma . . O
glucose . . O
or . . O
specific . . O
adverse . . O
reactions . . O
. . . O

for . . O
patients . . O
at . . O
risk . . O
for . . O
chronically . . O
reduced . . O
renal . . O
function . . O
( . . O
for . . O
example . . O
, . . O
age . . O
> . . O
60 . . O
years . . O
, . . O
hypertension . . O
or . . O
diabetes . . O
) . . O
, . . O
estimate . . O
the . . O
glomerular . . O
filtration . . O
rate . . O
( . . O
gfr . . O
) . . O
through . . O
laboratory . . O
testing . . O
. . . O

a . . O
causal . . O
relationship . . O
to . . O
stendra . . O
is . . O
uncertain . . O
. . . O

the . . O
incidence . . O
of . . O
all . . O
- . . O
cause . . O
mortality . . B-AdverseReaction
was . . O
0.0% . . B-Negation
in . . O
the . . O
duavee . . O
group . . O
and . . O
0.2% . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

rare . . O
cases . . O
of . . O
neurological . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
including . . O
seizure . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
optic . . B-AdverseReaction
neuritis . . I-AdverseReaction
, . . O
and . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
cimzia . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

cardiac . . O
disorders . . O
- . . O
bradycardia . . B-AdverseReaction
, . . O
palpitations . . B-AdverseReaction

the . . O
most . . O
frequently . . O
reported . . O
adr . . O
at . . O
least . . O
grade . . B-Severity
2 . . I-Severity
in . . O
severity . . O
was . . O
rash . . B-AdverseReaction
( . . O
10.0% . . O
) . . O
. . . O

available . . O
data . . O
from . . O
controlled . . O
clinical . . O
trials . . O
suggest . . O
that . . O
laba . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
hospitalization . . O
in . . O
pediatric . . O
and . . O
adolescent . . O
patients . . O
. . . O

if . . O
pradaxa . . O
is . . O
discontinued . . O
for . . O
a . . O
reason . . O
other . . O
than . . O
pathological . . O
bleeding . . O
or . . O
completion . . O
of . . O
a . . O
course . . O
of . . O
therapy . . O
, . . O
consider . . O
coverage . . O
with . . O
another . . O
anticoagulant . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
, . . O
2.5 . . O
, . . O
2.6 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
* . . O
cerebrovascular . . B-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
: . . O
an . . O
increased . . O
incidence . . O
of . . O
cerebrovascular . . B-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
stroke . . B-AdverseReaction
, . . O
transient . . B-AdverseReaction
ischemic . . I-AdverseReaction
attack . . I-AdverseReaction
) . . O
has . . O
been . . O
seen . . O
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychoses . . O
treated . . O
with . . O
atypical . . B-DrugClass
antipsychotic . . I-DrugClass
drugs . . I-DrugClass
. . . O

the . . O
frequency . . O
, . . O
type . . O
and . . O
severity . . O
of . . O
adverse . . O
drug . . O
reactions . . O
in . . O
pediatric . . O
subjects . . O
were . . O
comparable . . O
to . . O
those . . O
observed . . O
in . . O
adult . . O
subjects . . O
, . . O
except . . O
for . . O
rash . . B-AdverseReaction
which . . O
was . . O
observed . . O
more . . O
frequently . . O
in . . O
pediatric . . O
subjects . . O
. . . O

( . . O
6.2 . . O
) . . O

neutrophils . . O
and . . O
platelets . . O

( . . O
5.6 . . O
) . . O
* . . O
immunization . . O
: . . O
live . . O
vaccines . . O
should . . O
not . . O
be . . O
given . . O
concurrently . . O
with . . O
benlysta . . O
. . . O

6 . . O
adverse . . O
reactions . . O

baseline . . O
renal . . O
function . . O
was . . O
normal . . O
or . . O
mildly . . O
impaired . . O
( . . O
mean . . O
egfr . . O
88 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
. . . O

the . . O
following . . O
events . . O
have . . O
been . . O
identified . . O
during . . O
postmarketing . . O
use . . O
of . . O
intelence . . O
( . . O
r . . O
) . . O
. . . O

* . . O
are . . O
going . . O
to . . O
have . . O
surgery . . O
or . . O
will . . O
be . . O
on . . O
bed . . O
rest . . O
. . . O

other . . O
adverse . . O
reactions . . O

5.4 . . O
hypoglycemia . . O
with . . O
concomitant . . O
use . . O
with . . O
insulin . . O
and . . O
insulin . . O
secretagogues . . O

multaq . . O
is . . O
contraindicated . . O
in . . O
patients . . O
in . . O
atrial . . O
fibrillation . . O
( . . O
af . . O
) . . O
who . . O
will . . O
not . . O
or . . O
cannot . . O
be . . O
cardioverted . . O
into . . O
normal . . O
sinus . . O
rhythm . . O
. . . O

6 . . O
adverse . . O
reactions . . O

if . . O
not . . O
treated . . O
immediately . . O
, . . O
penile . . O
tissue . . O
damage . . O
and . . O
permanent . . O
loss . . O
of . . O
potency . . O
could . . O
result . . O
. . . O

jevtana . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
neutrophil . . O
counts . . O
of . . O
< . . O
= . . O
1,500 . . O
cells . . O
/ . . O
mm . . O
3 . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

in . . O
some . . O
postmarketing . . O
cases . . O
, . . O
hypocalcemia . . B-AdverseReaction
persisted . . O
for . . O
weeks . . O
or . . O
months . . O
and . . O
required . . O
frequent . . O
monitoring . . O
and . . O
intravenous . . O
and . . O
/ . . O
or . . O
oral . . O
calcium . . O
replacement . . O
, . . O
with . . O
or . . O
without . . O
vitamin . . O
d . . O
. . . O

prior . . O
to . . O
the . . O
initiation . . O
of . . O
the . . O
next . . O
cycle . . O
of . . O
therapy . . O
, . . O
the . . O
anc . . O
should . . O
be . . O
> . . O
= . . O
1 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
and . . O
the . . O
platelet . . O
count . . O
should . . O
be . . O
> . . O
= . . O
75 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
. . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
( . . O
2.3 . . O
) . . O
] . . O

6.1 . . O
clinical . . O
trial . . O
experience . . O

5.6 . . O
hypersensitivity . . O
reactions . . O

1915 . . O
05 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rashrash . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
erythema . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
erythematous . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
generalized . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
macular . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
maculo . . B-AdverseReaction
- . . I-AdverseReaction
papular . . I-AdverseReaction
rash . . I-AdverseReaction
, . . O
papular . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
and . . O
vesicular . . B-AdverseReaction
rash . . I-AdverseReaction
. . . O

evaluate . . O
patients . . O
with . . O
thigh . . O
or . . O
groin . . O
pain . . O
to . . O
rule . . O
out . . O
a . . O
femoral . . O
fracture . . O
( . . O
5.5 . . O
) . . O
* . . O
serious . . B-Severity
infections . . B-AdverseReaction
including . . O
skin . . B-AdverseReaction
infections . . I-AdverseReaction
: . . O
may . . O
occur . . O
, . . O
including . . O
those . . O
leading . . O
to . . O
hospitalization . . O
. . . O

in . . O
several . . O
cases . . O
, . . O
these . . O
reactions . . O
occurred . . O
after . . O
the . . O
first . . O
dose . . O
. . . O

cerdelga . . O
( . . O
n . . O
= . . O
106 . . O
) . . O
imiglucerase . . O
( . . O
n . . O
= . . O
53 . . O
) . . O
adverse . . O
reaction . . O
patientsn . . O
( . . O
% . . O
) . . O
patientsn . . O
( . . O
% . . O
) . . O
fatigue . . B-AdverseReaction
15 . . O
( . . O
14 . . O
) . . O
1 . . O
( . . O
2 . . O
) . . O
headache . . B-AdverseReaction
14 . . O
( . . O
13 . . O
) . . O
1 . . O
( . . O
2 . . O
) . . O
nausea . . B-AdverseReaction
13 . . O
( . . O
12 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
diarrhea . . B-AdverseReaction
13 . . O
( . . O
12 . . O
) . . O
2 . . O
( . . O
4 . . O
) . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
13 . . O
( . . O
12 . . O
) . . O
3 . . O
( . . O
6 . . O
) . . O
pain . . O
in . . O
extremity . . O
12 . . O
( . . O
11 . . O
) . . O
1 . . O
( . . O
2 . . O
) . . O
upper . . B-AdverseReaction
abdominal . . I-AdverseReaction
pain . . I-AdverseReaction
11 . . O
( . . O
10 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
dizziness . . B-AdverseReaction
9 . . O
( . . O
8 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
asthenia . . B-AdverseReaction
9 . . O
( . . O
8 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
cough . . B-AdverseReaction
7 . . O
( . . O
7 . . O
) . . O
2 . . O
( . . O
4 . . O
) . . O
dyspepsia . . B-AdverseReaction
7 . . O
( . . O
7 . . O
) . . O
1 . . O
( . . O
2 . . O
) . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
7 . . O
( . . O
7 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
constipation . . B-AdverseReaction
5 . . O
( . . O
5 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
palpitations . . B-AdverseReaction
5 . . O
( . . O
5 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
rash . . B-AdverseReaction
5 . . O
( . . O
5 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
in . . O
an . . O
uncontrolled . . O
study . . O
, . . O
with . . O
up . . O
to . . O
4 . . O
years . . O
of . . O
treatment . . O
, . . O
in . . O
26 . . O
patients . . O
, . . O
the . . O
types . . O
and . . O
incidences . . O
of . . O
adverse . . O
reactions . . O
were . . O
similar . . O
to . . O
trials . . O
1 . . O
and . . O
2 . . O
. . . O

* . . O
perforations . . B-AdverseReaction
and . . O
fistulas . . B-AdverseReaction
: . . O
gastrointestinal . . B-AdverseReaction
perforations . . I-AdverseReaction
occurred . . O
in . . O
3% . . O
and . . O
fistula . . B-AdverseReaction
formation . . I-AdverseReaction
in . . O
1% . . O
of . . O
cometriq . . O
- . . O
treated . . O
patients . . O
. . . O

endocarditis . . B-AdverseReaction
was . . O
reported . . O
in . . O
no . . O
placebo . . O
patients . . O
and . . O
3 . . O
patients . . O
receiving . . O
prolia . . O
. . . O

hypertension . . B-AdverseReaction
was . . O
managed . . O
with . . O
standard . . O
antihypertensive . . O
therapy . . O
. . . O

neutralizing . . O
antibody . . O
titers . . O
were . . O
not . . O
determined . . O
in . . O
the . . O
patients . . O
. . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
a . . O
potential . . O
for . . O
immunogenicity . . O
. . . O

the . . O
safety . . O
of . . O
cometriq . . O
was . . O
evaluated . . O
in . . O
330 . . O
patients . . O
with . . O
progressive . . O
metastatic . . O
medullary . . O
thyroid . . O
cancer . . O
randomized . . O
to . . O
receive . . O
140 . . O
mg . . O
cometriq . . O
( . . O
n . . O
= . . O
214 . . O
) . . O
or . . O
placebo . . O
( . . O
n . . O
= . . O
109 . . O
) . . O
administered . . O
daily . . O
until . . O
disease . . O
progression . . O
or . . O
intolerable . . O
toxicity . . O
in . . O
a . . O
randomized . . O
, . . O
doubleblind . . O
, . . O
controlled . . O
trial . . O
. . . O

bleeding . . B-AdverseReaction
results . . O
from . . O
the . . O
amplify . . O
study . . O
are . . O
summarized . . O
in . . O
table . . O
5 . . O
. . . O

5.5 . . O
sudden . . O
hearing . . O
loss . . O

the . . O
conduction . . B-AdverseReaction
abnormalities . . I-AdverseReaction
were . . O
usually . . O
transient . . B-Severity
and . . O
asymptomatic . . O
, . . O
and . . O
resolved . . O
within . . O
the . . O
first . . O
24 . . O
hours . . O
on . . O
treatment . . O
, . . O
but . . O
they . . O
occasionally . . O
required . . O
treatment . . O
with . . O
atropine . . O
or . . O
isoproterenol . . O
. . . O

the . . O
majority . . O
of . . O
these . . O
events . . O
were . . O
infections . . B-AdverseReaction
. . . O

risk . . O
factors . . O
for . . O
development . . O
of . . O
serious . . B-Severity
dermatologic . . B-AdverseReaction
reactions . . I-AdverseReaction
with . . O
aptiom . . O
use . . O
have . . O
not . . B-Negation
been . . O
identified . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
across . . O
products . . O
in . . O
this . . O
class . . O
may . . O
be . . O
misleading . . O
. . . O

* . . O
? . . O
use . . O
of . . O
indwelling . . O
epidural . . O
catheters . . O
* . . O
? . . O
concomitant . . O
use . . O
of . . O
other . . O
drugs . . O
that . . O
affect . . O
hemostasis . . O
, . . O
such . . O
as . . O
nonsteroidal . . O
anti . . O
- . . O
inflammatory . . O
drugs . . O
( . . O
nsaids . . O
) . . O
, . . O
platelet . . O
inhibitors . . O
, . . O
other . . O
anticoagulants . . O
* . . O
? . . O
a . . O
history . . O
of . . O
traumatic . . O
or . . O
repeated . . O
epidural . . O
or . . O
spinal . . O
punctures . . O
* . . O
? . . O
a . . O
history . . O
of . . O
spinal . . O
deformity . . O
or . . O
spinal . . O
surgery . . O
* . . O
? . . O
optimal . . O
timing . . O
between . . O
the . . O
administration . . O
of . . O
eliquis . . O
and . . O
neuraxial . . O
procedures . . O
is . . O
not . . O
known . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O

interrupt . . O
or . . O
discontinue . . O
blincyto . . O
as . . O
recommended . . O
. . . O

adverse . . O
reactions . . O
that . . O
occurred . . O
with . . O
a . . O
frequency . . O
< . . O
0.2% . . O
in . . O
patients . . O
who . . O
received . . O
dotarem . . O
include . . O
: . . O
feeling . . B-AdverseReaction
cold . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
paresthesia . . B-AdverseReaction
, . . O
dysgeusia . . B-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
, . . O
anxiety . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
palpitations . . B-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
serum . . B-AdverseReaction
creatinine . . I-AdverseReaction
increased . . I-AdverseReaction
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
site . . O
inflammation . . O
, . . O
extravasation . . O
, . . O
pruritus . . O
, . . O
and . . O
warmth . . O
. . . O

all . . O
were . . O
serious . . B-Severity
and . . O
one . . O
gi . . B-AdverseReaction
fistula . . I-AdverseReaction
was . . O
fatal . . B-AdverseReaction
( . . O
< . . O
1% . . O
) . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
acute . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
angioedema . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
) . . O
have . . O
been . . O
reported . . O
. . . O

ibrutinib . . O
caused . . O
malformations . . B-AdverseReaction
in . . O
rats . . B-Animal
at . . O
exposures . . O
14 . . O
times . . O
those . . O
reported . . O
in . . O
patients . . O
with . . O
mcl . . O
and . . O
20 . . O
times . . O
those . . O
reported . . O
in . . O
patients . . O
with . . O
cll . . O
or . . O
wm . . O
, . . O
receiving . . O
the . . O
ibrutinib . . O
dose . . O
of . . O
560 . . O
mg . . O
per . . O
day . . O
and . . O
420 . . O
mg . . O
per . . O
day . . O
, . . O
respectively . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
were . . O
vulvovaginal . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
in . . O
females . . O
and . . O
balanitis . . B-AdverseReaction
in . . O
males . . O
. . . O

the . . O
time . . O
to . . O
onset . . O
of . . O
symptoms . . O
following . . O
initiation . . O
of . . O
drug . . O
therapy . . O
varied . . O
from . . O
one . . O
day . . O
to . . O
years . . O
. . . O

* . . O
limiting . . O
the . . O
dose . . O
injected . . O
into . . O
the . . O
sternocleidomastoid . . O
muscle . . O
may . . O
decrease . . O
the . . O
occurrence . . O
of . . O
dysphagia . . O
. . . O

5.4 . . O
venous . . O
thromboembolism . . O

if . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
, . . O
no . . O
dose . . O
modification . . O
of . . O
trametinib . . O
is . . O
required . . O
for . . O
patients . . O
who . . O
develop . . O
non . . O
- . . O
cutaneous . . O
malignancies . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
activation . . B-AdverseReaction
of . . I-AdverseReaction
mania . . I-AdverseReaction
/ . . O
hypomania . . O
: . . O
use . . O
cautiously . . O
in . . O
patients . . O
with . . O
bipolar . . O
disorder . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
ferriprox . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

elevations . . B-AdverseReaction
of . . I-AdverseReaction
transaminases . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
ilaris . . O
. . . O

discontinue . . O
gilotrif . . O
in . . O
patients . . O
who . . O
develop . . O
life . . O
- . . O
threatening . . O
bullous . . O
, . . O
blistering . . O
, . . O
or . . O
exfoliating . . O
lesions . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

only . . O
study . . O
1 . . O
included . . O
a . . O
placebo . . O
group . . O
, . . O
allowing . . O
comparison . . O
of . . O
adverse . . O
reaction . . O
rates . . O
on . . O
onfi . . O
at . . O
several . . O
doses . . O
to . . O
placebo . . O
. . . O

if . . O
a . . O
serious . . O
hypersensitivity . . O
reaction . . O
is . . O
suspected . . O
, . . O
discontinue . . O
nesina . . O
, . . O
assess . . O
for . . O
other . . O
potential . . O
causes . . O
for . . O
the . . O
event . . O
and . . O
institute . . O
alternative . . O
treatment . . O
for . . O
diabetes . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

patients . . O
were . . O
permitted . . O
to . . O
participate . . O
sequentially . . O
in . . O
both . . O
placebo . . O
- . . O
controlled . . O
trials . . O
; . . O
safety . . O
data . . O
collected . . O
during . . O
exposure . . O
to . . O
kalbitor . . O
was . . O
attributed . . O
to . . O
treatment . . O
with . . O
kalbitor . . O
, . . O
and . . O
safety . . O
data . . O
collected . . O
during . . O
exposure . . O
to . . O
placebo . . O
was . . O
attributed . . O
to . . O
treatment . . O
with . . O
placebo . . O
. . . O

the . . O
adverse . . O
reaction . . O
profile . . O
was . . O
similar . . O
to . . O
that . . O
for . . O
adults . . O
. . . O

the . . O
cough . . B-AdverseReaction
usually . . O
occurred . . O
within . . O
15 . . O
seconds . . O
following . . O
inhalation . . O
and . . O
lasted . . O
for . . O
no . . O
more . . O
than . . O
15 . . O
seconds . . O
. . . O

injection . . O
- . . O
site . . O
reactions . . O

6 . . O
adverse . . O
reactions . . O

no . . B-Negation
cases . . O
of . . O
pml . . B-AdverseReaction
were . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
recommended . . O
nulojix . . O
regimen . . O
or . . O
the . . O
control . . O
regimen . . O
in . . O
these . . O
trials . . O
. . . O

stribild . . O
should . . O
be . . O
avoided . . O
with . . O
concurrent . . O
or . . O
recent . . O
use . . O
of . . O
a . . O
nephrotoxic . . O
agent . . O
. . . O

interrupt . . O
ferriprox . . O
if . . O
infection . . O
develops . . O
, . . O
and . . O
monitor . . O
the . . O
anc . . O
more . . O
frequently . . O
. . . O

grade . . O
3-4 . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
44% . . O
of . . O
xtandi . . O
- . . O
treated . . O
patients . . O
and . . O
37% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

in . . O
these . . O
trials . . O
, . . O
449 . . O
patients . . O
were . . O
exposed . . O
to . . O
the . . O
recommended . . O
dose . . O
of . . O
75 . . O
mcg . . O
for . . O
up . . O
to . . O
3 . . O
months . . O
, . . O
and . . O
144 . . O
, . . O
583 . . O
and . . O
425 . . O
copd . . O
patients . . O
were . . O
exposed . . O
to . . O
a . . O
dose . . O
of . . O
150 . . O
, . . O
300 . . O
or . . O
600 . . O
mcg . . O
for . . O
one . . O
year . . O
, . . O
respectively . . O
. . . O

* . . O
before . . O
dotarem . . O
administration . . O
, . . O
assess . . O
all . . O
patients . . O
for . . O
any . . O
history . . O
of . . O
a . . O
reaction . . O
to . . O
contrast . . O
media . . O
, . . O
bronchial . . O
asthma . . O
and . . O
/ . . O
or . . O
allergic . . O
disorders . . O
. . . O

* . . O
serious . . O
asthma . . O
- . . O
related . . O
events . . O
, . . O
including . . O
death . . B-AdverseReaction
, . . O
were . . O
reported . . O
in . . O
clinical . . O
studies . . O
with . . O
arcapta . . O
neohaler . . O
. . . O

factors . . O
that . . O
can . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
developing . . O
epidural . . O
or . . O
spinal . . B-AdverseReaction
hematomas . . I-AdverseReaction
in . . O
these . . O
patients . . O
include . . O
: . . O

in . . O
trial . . O
2 . . O
, . . O
the . . O
incidence . . O
of . . O
any . . O
skin . . B-AdverseReaction
toxicity . . I-AdverseReaction
was . . O
similar . . O
for . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
( . . O
65% . . O
[ . . O
36 . . O
/ . . O
55 . . O
] . . O
) . . O
compared . . O
with . . O
patients . . O
receiving . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
( . . O
68% . . O
[ . . O
36 . . O
/ . . O
53 . . O
] . . O
) . . O
. . . O

an . . O
additional . . O
13 . . O
( . . O
2.5% . . O
) . . O
patients . . O
experienced . . O
moderate . . B-Severity
hepatotoxicity . . B-AdverseReaction
manifested . . O
by . . O
liver . . B-AdverseReaction
function . . I-AdverseReaction
test . . I-AdverseReaction
abnormalities . . I-AdverseReaction
( . . O
ast . . O
or . . O
alt . . B-AdverseReaction
elevations . . I-AdverseReaction
of . . O
more . . O
than . . O
2.5 . . B-Severity
times . . I-Severity
but . . I-Severity
not . . I-Severity
more . . I-Severity
than . . I-Severity
5 . . I-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
or . . O
total . . B-AdverseReaction
bilirubin . . I-AdverseReaction
elevation . . I-AdverseReaction
of . . O
more . . O
than . . O
1.5 . . B-Severity
times . . I-Severity
but . . I-Severity
not . . I-Severity
more . . I-Severity
than . . I-Severity
3 . . I-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
; . . O
grade . . B-Severity
2 . . I-Severity
) . . O
. . . O

the . . O
safety . . O
of . . O
prolia . . O
in . . O
the . . O
treatment . . O
of . . O
postmenopausal . . O
osteoporosis . . O
was . . O
assessed . . O
in . . O
a . . O
3 . . O
- . . O
year . . O
, . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
multinational . . O
study . . O
of . . O
7808 . . O
postmenopausal . . O
women . . O
aged . . O
60 . . O
to . . O
91 . . O
years . . O
. . . O

in . . O
trial . . O
2 . . O
, . . O
the . . O
incidence . . O
of . . O
fever . . O
( . . O
serious . . B-Severity
and . . O
non . . O
- . . O
serious . . O
) . . O
was . . O
71% . . O
( . . O
39 . . O
/ . . O
55 . . O
) . . O
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
and . . O
26% . . O
( . . O
14 . . O
/ . . O
53 . . O
) . . O
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

individuals . . O
with . . O
conditions . . O
that . . O
affect . . O
the . . O
sympathetic . . O
nervous . . O
system . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
parkinsonian . . O
syndromes . . O
such . . O
as . . O
parkinson's . . O
disease . . O
or . . O
multiple . . O
system . . O
atrophy . . O
, . . O
may . . O
show . . O
decreased . . O
cardiac . . O
uptake . . O
of . . O
adreview . . O
independent . . O
of . . O
heart . . O
disease . . O
. . . O

laboratory . . O
tests . . O

increases . . O
in . . O
serum . . O
potassium . . O

farxiga . . O
increases . . B-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
decreases . . B-AdverseReaction
egfr . . I-AdverseReaction
. . . O

5.8 . . O
use . . O
with . . O
biological . . O
disease . . O
- . . O
modifying . . O
antirheumatic . . O
drugs . . O
( . . O
biological . . O
dmards . . O
) . . O

cerebrovascular . . O
adverse . . O
events . . O
, . . O
including . . O
stroke . . O

the . . O
most . . O
serious . . O
adverse . . O
reactions . . O
were . . O
: . . O

injection . . O
into . . O
these . . O
structures . . O
may . . O
result . . O
in . . O
possible . . O
permanent . . O
injury . . O
, . . O
such . . O
as . . O
tendon . . O
rupture . . O
or . . O
ligament . . O
damage . . O
, . . O
or . . O
skin . . O
laceration . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

in . . O
a . . O
52 . . O
- . . O
week . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
comparator . . O
- . . O
controlled . . O
trial . . O
that . . O
included . . O
primarily . . O
adult . . O
patients . . O
with . . O
schizophrenia . . O
, . . O
the . . O
mean . . O
increase . . O
from . . O
baseline . . O
of . . O
alt . . O
was . . O
1.7 . . B-Severity
units . . I-Severity
/ . . I-Severity
l . . I-Severity
. . . O

in . . O
phase . . O
2 . . O
and . . O
3 . . O
placebo . . O
- . . O
controlled . . O
trials . . O
combined . . O
, . . O
the . . O
incidences . . O
of . . O
serious . . O
adverse . . O
events . . O
in . . O
patients . . O
receiving . . O
placebo . . O
, . . O
toviaz . . O
4 . . O
mg . . O
, . . O
and . . O
toviaz . . O
8 . . O
mg . . O
were . . O
1.9% . . O
, . . O
3.5% . . O
, . . O
and . . O
2.9% . . O
, . . O
respectively . . O
. . . O

patients . . O
with . . O
a . . O
pre . . O
- . . O
existing . . O
low . . O
white . . O
blood . . O
cell . . O
count . . O
( . . O
wbc . . O
) . . O
or . . O
a . . O
history . . O
of . . O
leukopenia . . O
/ . . O
neutropenia . . O
should . . O
have . . O
their . . O
complete . . O
blood . . O
count . . O
( . . O
cbc . . O
) . . O
monitored . . O
frequently . . O
during . . O
the . . O
first . . O
few . . O
months . . O
of . . O
therapy . . O
and . . O
should . . O
discontinue . . O
fanapt . . O
at . . O
the . . O
first . . O
sign . . O
of . . O
a . . O
decline . . O
in . . O
wbc . . O
in . . O
the . . O
absence . . O
of . . O
other . . O
causative . . O
factors . . O
. . . O

chromaturia . . B-AdverseReaction
( . . O
reddish . . O
/ . . O
brown . . O
discoloration . . O
of . . O
the . . O
urine . . O
) . . O
is . . O
a . . O
result . . O
of . . O
the . . O
excretion . . O
of . . O
the . . O
iron . . O
in . . O
the . . O
urine . . O
. . . O

excerpt . . O
: . . O
hyperammonemia . . B-AdverseReaction
: . . O
monitor . . O
plasma . . O
ammonia . . O
levels . . O
during . . O
treatment . . O
. . . O

other . . O
risk . . O
factors . . O

across . . O
the . . O
347 . . O
patients . . O
who . . O
were . . O
randomized . . O
to . . O
study . . O
treatment . . O
( . . O
343 . . O
received . . O
at . . O
least . . O
one . . O
dose . . O
of . . O
study . . O
treatment . . O
) . . O
, . . O
the . . O
median . . O
age . . O
was . . O
50 . . O
years . . O
; . . O
14% . . O
of . . O
patients . . O
were . . O
older . . O
than . . O
65 . . O
years . . O
. . . O

other . . O
malignancies . . B-AdverseReaction
( . . O
range . . O
, . . O
5 . . O
to . . O
14% . . O
) . . O
including . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
skin . . I-AdverseReaction
carcinomas . . I-AdverseReaction
( . . O
range . . O
, . . O
1 . . O
to . . O
3% . . O
) . . O
have . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
imbruvica . . O
. . . O

the . . O
median . . O
onset . . O
time . . O
for . . O
hypertension . . B-AdverseReaction
( . . O
systolic . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
> . . I-AdverseReaction
150 . . I-AdverseReaction
mmhg . . I-AdverseReaction
or . . O
diastolic . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
> . . I-AdverseReaction
100 . . I-AdverseReaction
mmhg . . I-AdverseReaction
) . . O
was . . O
within . . O
the . . O
first . . O
month . . O
of . . O
the . . O
start . . O
of . . O
inlyta . . O
treatment . . O
and . . O
blood . . B-AdverseReaction
pressure . . I-AdverseReaction
increases . . I-AdverseReaction
have . . O
been . . O
observed . . O
as . . O
early . . O
as . . O
4 . . O
days . . O
after . . O
starting . . O
inlyta . . O
. . . O

in . . O
clinical . . O
trials . . O
where . . O
ethnicity . . O
was . . O
recorded . . O
the . . O
ethnic . . O
distribution . . O
was . . O
74% . . O
caucasian . . O
, . . O
12% . . O
asian . . O
, . . O
4% . . O
black . . O
, . . O
and . . O
10% . . O
others . . O
. . . O

adjunctive . . O
therapy . . O
in . . O
adult . . O
patients . . O
with . . O
bipolar . . O
mania . . O
: . . O
the . . O
following . . O
findings . . O
are . . O
based . . O
on . . O
a . . O
12 . . O
week . . O
placebo . . O
- . . O
controlled . . O
trial . . O
( . . O
with . . O
a . . O
3 . . O
week . . O
efficacy . . O
endpoint . . O
) . . O
in . . O
adult . . O
patients . . O
with . . O
bipolar . . O
mania . . O
in . . O
which . . O
sublingual . . O
saphris . . O
was . . O
administered . . O
in . . O
doses . . O
of . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
as . . O
adjunctive . . O
therapy . . O
with . . O
lithium . . O
or . . O
valproate . . O
. . . O

oral . . B-DrugClass
contraceptive . . I-DrugClass
- . . O
related . . O
cholestasis . . B-AdverseReaction
may . . O
occur . . O
in . . O
women . . O
with . . O
a . . O
history . . O
of . . O
pregnancy . . O
- . . O
related . . O
cholestasis . . O
. . . O

5.4 . . O
avoid . . O
use . . O
with . . O
other . . O
antiretroviral . . O
products . . O

6.1 . . O
clinical . . O
trial . . O
experience . . O

there . . O
are . . O
currently . . O
no . . O
marketed . . O
tests . . O
for . . O
antibodies . . O
against . . O
alglucosidase . . O
alfa . . O
; . . O
however . . O
, . . O
a . . O
testing . . O
service . . O
is . . O
provided . . O
by . . O
genzyme . . O
. . . O

most . . O
subjects . . O
( . . O
530 . . O
, . . O
70% . . O
) . . O
received . . O
a . . O
dose . . O
of . . O
185 . . O
mbq . . O
( . . O
5 . . O
mci . . O
) . . O
. . . O

( . . O
2.6 . . O
, . . O
5.7 . . O
) . . O
* . . O
drug . . B-AdverseReaction
induced . . I-AdverseReaction
liver . . I-AdverseReaction
injury . . I-AdverseReaction
: . . O
discontinue . . O
aptiom . . O
in . . O
patients . . O
with . . O
jaundice . . O
or . . O
evidence . . O
of . . O
significant . . O
liver . . O
injury . . O
. . . O

aspiration . . O
pneumonia . . O
is . . O
a . . O
common . . O
cause . . O
of . . O
morbidity . . O
and . . O
mortality . . O
in . . O
elderly . . O
patients . . O
, . . O
in . . O
particular . . O
those . . O
with . . O
advanced . . O
alzheimer's . . O
dementia . . O
. . . O

intracranial . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
was . . O
fatal . . B-AdverseReaction
in . . O
4% . . O
( . . O
2 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

table . . O
2 . . O
: . . O
shift . . O
from . . O
baseline . . O
to . . O
lowest . . O
observed . . O
egfr . . O
group . . O
during . . O
treatment . . O
safety . . O
population . . O
in . . O
clinical . . O
studies . . O
( . . O
n . . O
= . . O
818 . . O
) . . O
among . . O
the . . O
818 . . O
patients . . O
, . . O
egfr . . O
was . . O
missing . . O
in . . O
5 . . O
patients . . O
at . . O
baseline . . O
or . . O
on . . O
- . . O
therapy . . O
. . . O

* . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
- . . O
worsening . . O
, . . O
or . . O
new . . O
onset . . O
, . . O
may . . B-Factor
occur . . O
. . . O

approximately . . O
five . . O
percent . . O
of . . O
patients . . O
receiving . . O
imbruvica . . O
in . . O
study . . O
1 . . O
and . . O
study . . O
2 . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
events . . O
. . . O

a . . O
causal . . O
relationship . . O
of . . O
ilaris . . O
to . . O
these . . O
events . . O
cannot . . O
be . . O
excluded . . O
. . . O

galactorrhea . . B-AdverseReaction
, . . O
amenorrhea . . B-AdverseReaction
, . . O
gynecomastia . . B-AdverseReaction
, . . O
and . . O
impotence . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
prolactin . . B-DrugClass
- . . I-DrugClass
elevating . . I-DrugClass
compounds . . I-DrugClass
. . . O

use . . O
cautiously . . O
in . . O
patients . . O
with . . O
seizure . . O
disorder . . O
( . . O
5.8 . . O
) . . O
. . . O

systemic . . O
and . . O
cutaneous . . B-AdverseReaction
immune . . I-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
proteinuria . . B-AdverseReaction
and . . O
nephrotic . . B-AdverseReaction
syndrome . . I-AdverseReaction
secondary . . O
to . . O
membranous . . B-AdverseReaction
glomerulonephritis . . I-AdverseReaction
, . . O
and . . O
necrotizing . . B-AdverseReaction
skin . . I-AdverseReaction
lesions . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
postmarketing . . O
safety . . O
experience . . O
with . . O
alglucosidase . . O
alfa . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

consider . . O
interruption . . O
of . . O
tecfidera . . O
if . . O
lymphocyte . . O
counts . . O
< . . O
0.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
persist . . O
for . . O
more . . O
than . . O
six . . O
months . . O
. . . O

5.5 . . O
genital . . O
mycotic . . O
infections . . O

5.12 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

persons . . O
who . . O
are . . O
using . . O
drugs . . B-DrugClass
that . . I-DrugClass
suppress . . I-DrugClass
the . . I-DrugClass
immune . . I-DrugClass
system . . I-DrugClass
are . . O
more . . O
susceptible . . O
to . . O
infections . . B-AdverseReaction
than . . O
healthy . . O
individuals . . O
. . . O

table . . O
3 . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
crohn's . . O
disease . . O
who . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
reactions . . O
in . . O
the . . O
controlled . . O
clinical . . O
studies . . O
was . . O
8% . . O
for . . O
cimzia . . O
and . . O
7% . . O
for . . O
placebo . . O
. . . O

across . . O
the . . O
clinical . . O
development . . O
program . . O
for . . O
yervoy . . O
, . . O
mycophenolate . . O
treatment . . O
has . . O
been . . O
administered . . O
in . . O
patients . . O
who . . O
have . . O
persistent . . O
severe . . O
hepatitis . . O
despite . . O
high . . O
- . . O
dose . . O
corticosteroids . . O
. . . O

however . . O
, . . O
prescribers . . O
and . . O
patients . . O
should . . O
be . . O
aware . . O
that . . O
patients . . O
' . . O
ability . . O
to . . O
assess . . O
their . . O
own . . O
driving . . O
competence . . O
, . . O
as . . O
well . . O
as . . O
their . . O
ability . . O
to . . O
assess . . O
the . . O
degree . . O
of . . O
somnolence . . O
caused . . O
by . . O
horizant . . O
, . . O
can . . O
be . . O
imperfect . . O
. . . O

blepharospasm . . O
( . . O
5.6 . . O
) . . O
: . . O

in . . O
the . . O
controlled . . O
clinical . . O
trials . . O
, . . O
adverse . . B-AdverseReaction
events . . I-AdverseReaction
associated . . I-AdverseReaction
with . . I-AdverseReaction
the . . I-AdverseReaction
infusion . . I-AdverseReaction
( . . O
occurring . . O
on . . O
the . . O
same . . O
day . . O
of . . O
the . . O
infusion . . O
) . . O
were . . O
reported . . O
in . . O
17% . . O
( . . O
251 . . O
/ . . O
1,458 . . O
) . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
and . . O
15% . . O
( . . O
99 . . O
/ . . O
675 . . O
) . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

out . . O
of . . O
2,133 . . O
patients . . O
in . . O
3 . . O
clinical . . O
trials . . O
, . . O
a . . O
total . . O
of . . O
14 . . O
deaths . . B-AdverseReaction
occurred . . O
during . . O
the . . O
placebo . . O
- . . O
controlled . . O
, . . O
double . . O
- . . O
blind . . O
treatment . . O
periods . . O
: . . O
3 . . O
/ . . O
675 . . O
( . . O
0.4% . . O
) . . O
, . . O
5 . . O
/ . . O
673 . . O
( . . O
0.7% . . O
) . . O
, . . O
0 . . O
/ . . O
111 . . O
( . . O
0% . . O
) . . O
, . . O
and . . O
6 . . O
/ . . O
674 . . O
( . . O
0.9% . . O
) . . O
deaths . . B-AdverseReaction
in . . O
the . . O
groups . . O
receiving . . O
placebo . . O
, . . O
benlysta . . O
1 . . O
mg . . O
/ . . O
kg . . O
, . . O
benlysta . . O
4 . . O
mg . . O
/ . . O
kg . . O
, . . O
and . . O
benlysta . . O
10 . . O
mg . . O
/ . . O
kg . . O
, . . O
respectively . . O
. . . O

if . . O
the . . O
diagnosis . . O
of . . O
ttp . . O
/ . . O
hus . . O
is . . O
excluded . . O
, . . O
kyprolis . . O
may . . O
be . . O
restarted . . O
. . . O

withhold . . O
halaven . . O
in . . O
patients . . O
who . . O
experience . . O
grade . . O
3 . . O
or . . O
4 . . O
peripheral . . O
neuropathy . . O
until . . O
resolution . . O
to . . O
grade . . O
2 . . O
or . . O
less . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

* . . O
demyelinating . . B-AdverseReaction
disease . . I-AdverseReaction
, . . O
exacerbation . . O
or . . O
new . . O
onset . . O
, . . O
may . . B-Factor
occur . . O
( . . O
5.4 . . O
) . . O
. . . O

patients . . O
who . . O
are . . O
suspected . . O
of . . O
having . . O
or . . O
who . . O
develop . . O
onj . . O
while . . O
on . . O
prolia . . O
should . . O
receive . . O
care . . O
by . . O
a . . O
dentist . . O
or . . O
an . . O
oral . . O
surgeon . . O
. . . O

adequately . . O
supplement . . O
patients . . O
with . . O
calcium . . O
and . . O
vitamin . . O
d . . O
( . . O
5.3 . . O
) . . O
* . . O
osteonecrosis . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
jaw . . I-AdverseReaction
: . . O
has . . O
been . . O
reported . . O
with . . O
prolia . . O
. . . O

the . . O
increase . . O
in . . O
vte . . B-AdverseReaction
risk . . B-Factor
was . . O
demonstrated . . O
during . . O
the . . O
first . . O
2 . . O
years . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.5 . . O
) . . O
] . . O
. . . O

a . . O
recent . . O
cbc . . O
should . . O
be . . O
available . . O
before . . O
initiating . . O
treatment . . O
. . . O

a . . O
rcapta . . O
neohaler . . O
is . . O
not . . O
indicated . . O
for . . O
the . . O
treatment . . O
of . . O
asthma . . O
. . . O

reduction . . O
of . . O
risk . . O
of . . O
stroke . . O
and . . O
systemic . . O
embolism . . O
in . . O
non . . O
- . . O
valvular . . O
atrial . . O
fibrillation . . O

patients . . O
with . . O
osteosarcoma . . O
were . . O
eligible . . O
for . . O
these . . O
studies . . O
if . . O
the . . O
plasma . . O
methotrexate . . O
concentration . . O
was . . O
greater . . O
than . . O
50 . . O
mumol . . O
/ . . O
l . . O
at . . O
24 . . O
hours . . O
, . . O
greater . . O
that . . O
5 . . O
mumol . . O
/ . . O
l . . O
at . . O
48 . . O
hours . . O
, . . O
or . . O
greater . . O
than . . O
2 . . O
standard . . O
deviations . . O
above . . O
the . . O
mean . . O
methotrexate . . O
elimination . . O
curve . . O
at . . O
least . . O
12 . . O
hours . . O
after . . O
methotrexate . . O
administration . . O
and . . O
there . . O
was . . O
a . . O
2 . . O
- . . O
fold . . O
or . . O
greater . . O
increase . . O
in . . O
serum . . O
creatinine . . O
above . . O
baseline . . O
. . . O

in . . O
this . . O
study . . O
, . . O
76% . . O
( . . O
44 . . O
of . . O
58 . . O
) . . O
completed . . O
all . . O
planned . . O
therapy . . O
. . . O

( . . O
2.2 . . O
) . . O
complications . . O
of . . O
myelosuppression . . B-AdverseReaction
may . . B-Factor
lead . . O
to . . O
death . . B-AdverseReaction
. . . O

5.4 . . O
immediate . . O
hypersensitivity . . O
reactions . . O

the . . O
increase . . O
may . . O
be . . O
larger . . O
when . . O
coadministered . . O
with . . O
chlorthalidone . . O
or . . O
hydrochlorothiazide . . O
. . . O

xiaflex . . O
was . . O
not . . B-Negation
associated . . O
with . . O
shortening . . B-AdverseReaction
of . . I-AdverseReaction
penile . . I-AdverseReaction
length . . I-AdverseReaction
in . . O
clinical . . O
trials . . O
in . . O
the . . O
treatment . . O
of . . O
peyronie's . . O
disease . . O
. . . O

re . . O
- . . O
sonate . . O
was . . O
a . . O
placebo . . O
- . . O
controlled . . O
study . . O
in . . O
which . . O
684 . . O
patients . . O
received . . O
pradaxa . . O
150 . . O
mg . . O
twice . . O
daily . . O
following . . O
6 . . O
to . . O
18 . . O
months . . O
of . . O
oral . . O
anticoagulant . . O
regimen . . O
. . . O

increase . . O
in . . O
hematocrit . . O

the . . O
following . . O
additional . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
less . . O
than . . O
10% . . O
of . . O
afinitor . . O
- . . O
treated . . O
patients . . O
: . . O
nausea . . B-AdverseReaction
( . . O
8% . . O
) . . O
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
( . . O
8% . . O
) . . O
, . . O
insomnia . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
pneumonia . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
epistaxis . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
hypersensitivity . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
increased . . O
blood . . O
luteinizing . . O
hormone . . O
( . . O
lh . . O
) . . O
levels . . O
( . . O
1% . . O
) . . O
and . . O
pneumonitis . . B-AdverseReaction
( . . O
1% . . O
) . . O
. . . O

long . . B-AdverseReaction
- . . I-AdverseReaction
standing . . I-AdverseReaction
hyperprolactinemia . . I-AdverseReaction
when . . O
associated . . O
with . . O
hypogonadism . . B-AdverseReaction
may . . B-Factor
lead . . O
to . . O
decreased . . B-AdverseReaction
bone . . I-AdverseReaction
density . . I-AdverseReaction
in . . O
both . . O
female . . O
and . . O
male . . O
patients . . O
. . . O

patients . . O
should . . O
be . . O
made . . O
aware . . O
that . . O
both . . O
alcohol . . O
and . . O
pde5 . . O
inhibitors . . O
including . . O
stendra . . O
act . . O
as . . O
vasodilators . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
asthma . . B-AdverseReaction
, . . O
pharyngo . . B-AdverseReaction
- . . I-AdverseReaction
laryngeal . . I-AdverseReaction
pain . . I-AdverseReaction

the . . O
data . . O
described . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
reflect . . O
exposure . . O
to . . O
inlyta . . O
in . . O
359 . . O
patients . . O
with . . O
advanced . . O
rcc . . O
who . . O
participated . . O
in . . O
a . . O
randomized . . O
clinical . . O
study . . O
versus . . O
sorafenib . . O
[ . . O
seeclinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

the . . O
other . . O
cases . . O
represented . . O
a . . O
variety . . O
of . . O
malignancies . . B-AdverseReaction
, . . O
including . . O
rare . . B-AdverseReaction
malignancies . . I-AdverseReaction
that . . O
are . . O
usually . . O
associated . . O
with . . O
immunosuppression . . B-AdverseReaction
, . . O
and . . O
malignancies . . O
that . . O
are . . O
not . . O
usually . . O
observed . . O
in . . O
children . . O
and . . O
adolescents . . O
. . . O

immune . . O
system . . O
disorders . . O
: . . O
hypersensitivity . . B-AdverseReaction
manifesting . . O
as . . O
bullous . . B-AdverseReaction
rash . . I-AdverseReaction
. . . O

somnolence . . B-AdverseReaction
includes . . O
the . . O
following . . O
events . . O
: . . O
somnolence . . B-AdverseReaction
and . . O
sedation . . B-AdverseReaction
. . . O

patients . . O
with . . O
abnormal . . O
coagulation . . O
( . . O
except . . O
for . . O
patients . . O
taking . . O
low . . O
- . . O
dose . . O
aspirin . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
up . . O
to . . O
150 . . O
mg . . O
per . . O
day . . O
) . . O
were . . O
excluded . . O
from . . O
participating . . O
in . . O
these . . O
studies . . O
. . . O

5 . . O
. . . O

elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
treated . . O
with . . O
antipsychotic . . B-DrugClass
drugs . . I-DrugClass
are . . O
at . . O
an . . O
increased . . O
risk . . O
of . . O
death . . B-AdverseReaction
. . . O

table . . O
2 . . O
: . . O
summary . . O
of . . O
ptld . . B-AdverseReaction
reported . . O
in . . O
studies . . O
1 . . O
, . . O
2 . . O
, . . O
and . . O
3 . . O
through . . O
three . . O
years . . O
of . . O
treatment . . O
nulojix . . O
non . . O
- . . O
recommended . . O
regimen . . O
* . . O
( . . O
n . . O
= . . O
477 . . O
) . . O
nulojix . . O
recommended . . O
regimen . . O
( . . O
n . . O
= . . O
472 . . O
) . . O
cyclosporine . . O
( . . O
n . . O
= . . O
476 . . O
) . . O
trial . . O
ebv . . O
positive . . O
( . . O
n . . O
= . . O
406 . . O
) . . O
ebv . . O
negative . . O
( . . O
n . . O
= . . O
43 . . O
) . . O
ebv . . O
unknown . . O
( . . O
n . . O
= . . O
28 . . O
) . . O
ebv . . O
positive . . O
( . . O
n . . O
= . . O
404 . . O
) . . O
ebv . . O
negative . . O
( . . O
n . . O
= . . O
48 . . O
) . . O
ebv . . O
unknown . . O
( . . O
n . . O
= . . O
20 . . O
) . . O
ebv . . O
positive . . O
( . . O
n . . O
= . . O
399 . . O
) . . O
ebv . . O
negative . . O
( . . O
n . . O
= . . O
57 . . O
) . . O
ebv . . O
unknown . . O
( . . O
n . . O
= . . O
20 . . O
) . . O
* . . O
regimen . . O
with . . O
higher . . O
cumulative . . O
dose . . O
and . . O
more . . O
frequent . . O
dosing . . O
than . . O
the . . O
recommended . . O
nulojix . . O
regimen . . O
. . . O

adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
4% . . O
patients . . O
treated . . O
with . . O
nesina . . O
25 . . O
mg . . O
and . . O
more . . O
frequently . . O
than . . O
in . . O
patients . . O
given . . O
placebo . . O
in . . O
pooled . . O
studies . . O
number . . O
of . . O
patients . . O
( . . O
% . . O
) . . O
nesina25 . . O
mg . . O
placebo . . O
active . . O
comparator . . O
n . . O
= . . O
5902 . . O
n . . O
= . . O
2926 . . O
n . . O
= . . O
2257 . . O
nasopharyngitis . . B-AdverseReaction
257 . . O
( . . O
4.4 . . O
) . . O
89 . . O
( . . O
3.0 . . O
) . . O
113 . . O
( . . O
5.0 . . O
) . . O
headache . . B-AdverseReaction
247 . . O
( . . O
4.2 . . O
) . . O
72 . . O
( . . O
2.5 . . O
) . . O
121 . . O
( . . O
5.4 . . O
) . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
247 . . O
( . . O
4.2 . . O
) . . O
61 . . O
( . . O
2.1 . . O
) . . O
113 . . O
( . . O
5.0 . . O
) . . O
pancreatitis . . O

in . . O
averroes . . O
, . . O
the . . O
mean . . O
duration . . O
of . . O
exposure . . O
was . . O
approximately . . O
59 . . O
weeks . . O
( . . O
> . . O
3000 . . O
patient . . O
- . . O
years . . O
) . . O
. . . O

co . . O
- . . O
administration . . O
of . . O
sirturo . . O
with . . O
strong . . O
cyp3a4 . . O
inhibitors . . O
may . . O
increase . . O
the . . O
systemic . . O
exposure . . O
to . . O
bedaquiline . . O
, . . O
which . . O
could . . O
potentially . . O
increase . . O
the . . O
risk . . O
of . . O
adverse . . O
reactions . . O
. . . O

5.4 . . O
hypersensitivity . . O
reactions . . O

saphris . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
[ . . O
seeboxed . . O
warningand . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

based . . O
on . . O
the . . O
mechanism . . O
of . . O
action . . O
, . . O
afinitor . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O

the . . O
overall . . O
exposure . . O
in . . O
the . . O
controlled . . O
trials . . O
was . . O
equivalent . . O
to . . O
1716 . . O
person . . O
- . . O
years . . O
. . . O

* . . O
bradyarrhythmia . . B-AdverseReaction
and . . O
atrioventricular . . B-AdverseReaction
blocks . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
infections . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
posterior . . B-AdverseReaction
reversible . . I-AdverseReaction
encephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
respiratory . . B-AdverseReaction
effects . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
liver . . B-AdverseReaction
injury . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
10% . . O
and . . O
> . . O
placebo . . O
) . . O
: . . O
headache . . B-AdverseReaction
, . . O
liver . . B-AdverseReaction
transaminase . . I-AdverseReaction
elevation . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
( . . O
6.1 . . O
) . . O

( . . O
5.1,5.2,7.7,12.3 . . O
) . . O
* . . O
substrates . . O
, . . O
inhibitors . . O
, . . O
or . . O
inducers . . O
of . . O
cyp3a4 . . O
, . . O
including . . O
antiretroviral . . O
medications . . O
, . . O
should . . O
be . . O
used . . O
cautiously . . O
with . . O
coartem . . O
tablets . . O
, . . O
due . . O
to . . O
a . . O
potential . . O
loss . . O
of . . O
efficacy . . O
of . . O
the . . O
concomitant . . O
drug . . O
or . . O
additive . . O
qt . . O
prolongation . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
at . . O
an . . O
incidence . . O
of . . O
2% . . O
or . . O
more . . O
among . . O
fanapt . . O
- . . O
treated . . O
patients . . O
and . . O
more . . O
frequent . . O
than . . O
placebo . . O

warfarinhr . . O
( . . O
95% . . O
ci . . O
) . . O
major . . B-Severity
bleeding . . B-AdverseReaction
c . . O
350 . . O
( . . O
3.47 . . O
) . . O
374 . . O
( . . O
3.58 . . O
) . . O
0.97 . . O
( . . O
0.84 . . O
, . . O
1.12 . . O
) . . O
intracranial . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
( . . O
ich . . B-AdverseReaction
) . . O
d . . O
23 . . O
( . . O
0.22 . . O
) . . O
82 . . O
( . . O
0.77 . . O
) . . O
0.29 . . O
( . . O
0.18 . . O
, . . O
0.46 . . O
) . . O
hemorrhagic . . B-AdverseReaction
stroke . . I-AdverseReaction
e . . O
6 . . O
( . . O
0.06 . . O
) . . O
40 . . O
( . . O
0.37 . . O
) . . O
0.16 . . O
( . . O
0.07 . . O
, . . O
0.37 . . O
) . . O
other . . O
ich . . B-AdverseReaction
17 . . O
( . . O
0.17 . . O
) . . O
46 . . O
( . . O
0.43 . . O
) . . O
0.38 . . O
( . . O
0.22 . . O
, . . O
0.67 . . O
) . . O
gastrointestinal . . O
162 . . O
( . . O
1.59 . . O
) . . O
111 . . O
( . . O
1.05 . . O
) . . O
1.51 . . O
( . . O
1.19 . . O
, . . O
1.92 . . O
) . . O
fatal . . B-AdverseReaction
bleeding . . B-AdverseReaction
f . . O
7 . . O
( . . O
0.07 . . O
) . . O
16 . . O
( . . O
0.15 . . O
) . . O
0.45 . . O
( . . O
0.19 . . O
, . . O
1.10 . . O
) . . O
ich . . B-AdverseReaction
3 . . O
( . . O
0.03 . . O
) . . O
9 . . O
( . . O
0.08 . . O
) . . O
0.35 . . O
( . . O
0.09 . . O
, . . O
1.28 . . O
) . . O
non . . O
- . . O
intracranial . . O
g . . O
4 . . O
( . . O
0.04 . . O
) . . O
7 . . O
( . . O
0.07 . . O
) . . O
0.59 . . O
( . . O
0.17 . . O
, . . O
2.02 . . O
) . . O
there . . O
was . . O
a . . O
higher . . O
rate . . O
of . . O
any . . O
gastrointestinal . . B-AdverseReaction
bleeds . . I-AdverseReaction
in . . O
patients . . O
receiving . . O
pradaxa . . O
150 . . O
mg . . O
than . . O
in . . O
patients . . O
receiving . . O
warfarin . . O
( . . O
6.6% . . O
vs . . O
. . . O
4.2% . . O
, . . O
respectively . . O
) . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

table . . O
5 . . O
: . . O
bleeding . . B-AdverseReaction
results . . O
in . . O
the . . O
amplify . . O
study . . O
eliquisn . . O
= . . O
2676n . . O
( . . O
% . . O
) . . O
enoxaparin . . O
/ . . O
warfarinn . . O
= . . O
2689n . . O
( . . O
% . . O
) . . O
relative . . O
risk . . O
( . . O
95% . . O
ci . . O
) . . O
* . . O
crnm . . B-AdverseReaction
= . . O
clinically . . B-AdverseReaction
relevant . . I-AdverseReaction
nonmajor . . I-AdverseReaction
bleeding . . I-AdverseReaction
. . . O
events . . O
associated . . O
with . . O
each . . O
endpoint . . O
were . . O
counted . . O
once . . O
per . . O
subject . . O
, . . O
but . . O
subjects . . O
may . . O
have . . O
contributed . . O
events . . O
to . . O
multiple . . O
endpoints . . O
. . . O

patients . . O
who . . O
tested . . O
positive . . O
for . . O
uptake . . O
inhibition . . O
tended . . O
to . . O
have . . O
higher . . O
igg . . O
titers . . O
than . . O
patients . . O
who . . O
tested . . O
negative . . O
for . . O
uptake . . O
inhibition . . O
. . . O

during . . O
adult . . O
pre . . O
- . . O
marketing . . O
clinical . . O
trials . . O
with . . O
saphris . . O
, . . O
including . . O
long . . O
- . . O
term . . O
trials . . O
without . . O
comparison . . O
to . . O
placebo . . O
, . . O
somnolence . . B-AdverseReaction
was . . O
reported . . O
in . . O
18% . . O
( . . O
358 . . O
/ . . O
1953 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
. . . O

there . . O
have . . O
been . . O
postmarketing . . O
reports . . O
of . . O
serious . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
nesina . . O
. . . O

the . . O
median . . O
time . . O
to . . O
onset . . O
of . . O
tb . . B-AdverseReaction
for . . O
all . . O
patients . . O
exposed . . O
to . . O
cimzia . . O
across . . O
all . . O
indications . . O
was . . O
345 . . O
days . . O
. . . O

jevtana . . O
treatment . . O
delay . . O
or . . O
discontinuation . . O
may . . O
be . . O
necessary . . O
. . . O

families . . O
and . . O
caregivers . . O
of . . O
patients . . O
being . . O
treated . . O
with . . O
antidepressants . . O
for . . O
major . . O
depressive . . O
disorder . . O
or . . O
other . . O
indications . . O
, . . O
both . . O
psychiatric . . O
and . . O
nonpsychiatric . . O
, . . O
should . . O
be . . O
alerted . . O
about . . O
the . . O
need . . O
to . . O
monitor . . O
patients . . O
for . . O
the . . O
emergence . . O
of . . O
agitation . . O
, . . O
irritability . . O
, . . O
unusual . . O
changes . . O
in . . O
behavior . . O
, . . O
and . . O
the . . O
other . . O
symptoms . . O
described . . O
above . . O
, . . O
as . . O
well . . O
as . . O
the . . O
emergence . . O
of . . O
suicidality . . O
, . . O
and . . O
to . . O
report . . O
such . . O
symptoms . . O
immediately . . O
to . . O
healthcare . . O
providers . . O
. . . O

percentages . . O
calculated . . O
with . . O
the . . O
number . . O
of . . O
male . . O
subjects . . O
in . . O
each . . O
group . . O
as . . O
denominator . . O
: . . O
placebo . . O
( . . O
n . . O
= . . O
514 . . O
) . . O
, . . O
jardiance . . O
10 . . O
mg . . O
( . . O
n . . O
= . . O
556 . . O
) . . O
, . . O
jardiance . . O
25 . . O
mg . . O
( . . O
n . . O
= . . O
557 . . O
) . . O
. . . O

ovarian . . O
cancer . . O

of . . O
these . . O
1368 . . O
patients . . O
, . . O
safety . . O
data . . O
were . . O
received . . O
for . . O
940 . . O
patients . . O
with . . O
a . . O
median . . O
age . . O
of . . O
9 . . O
years . . O
( . . O
0 . . O
to . . O
76 . . O
years . . O
) . . O
, . . O
63% . . O
were . . O
male . . O
, . . O
91% . . O
with . . O
leukemia . . O
, . . O
3% . . O
with . . O
lymphoma . . O
, . . O
and . . O
6% . . O
with . . O
unknown . . O
disease . . O
information . . O
. . . O

table . . O
4 . . O
lists . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
with . . O
rls . . O
treated . . O
with . . O
horizant . . O
and . . O
numerically . . O
greater . . O
than . . O
placebo . . O
. . . O

activated . . O
prothrombin . . O
complex . . O
concentrates . . O
( . . O
apccs . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
feiba . . O
) . . O
, . . O
or . . O
recombinant . . O
factor . . O
viia . . O
, . . O
or . . O
concentrates . . O
of . . O
coagulation . . O
factors . . O
ii . . O
, . . O
ix . . O
or . . O
x . . O
may . . O
be . . O
considered . . O
but . . O
their . . O
use . . O
has . . O
not . . O
been . . O
evaluated . . O
in . . O
clinical . . O
trials . . O
. . . O

excerpt . . O
: . . O
* . . O
hypotension . . B-AdverseReaction
: . . O
before . . O
initiating . . O
farxiga . . O
, . . O
assess . . O
volume . . O
status . . O
and . . O
correct . . O
hypovolemia . . O
in . . O
the . . O
elderly . . O
, . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
or . . O
low . . O
systolic . . O
blood . . O
pressure . . O
, . . O
and . . O
in . . O
patients . . O
on . . O
diuretics . . O
. . . O

permanently . . O
discontinue . . O
tafinlar . . O
and . . O
trametinib . . O
for . . O
life . . O
- . . O
threatening . . O
pe . . O
. . . O

( . . O
5.4 . . O
) . . O

impaact . . O
p1093 . . O
is . . O
an . . O
ongoing . . O
multicenter . . O
, . . O
open . . O
- . . O
label . . O
, . . O
non . . O
- . . O
comparative . . O
trial . . O
of . . O
approximately . . O
160 . . O
hiv . . O
- . . O
1 . . O
- . . O
infected . . O
pediatric . . O
subjects . . O
aged . . O
6 . . O
weeks . . O
to . . O
less . . O
than . . O
18 . . O
years . . O
, . . O
of . . O
which . . O
23 . . O
treatment . . O
- . . O
experienced . . O
, . . O
insti . . O
- . . O
naive . . O
subjects . . O
aged . . O
12 . . O
to . . O
less . . O
than . . O
18 . . O
years . . O
were . . O
enrolled . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.4 . . O
) . . O
, . . O
clinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
] . . O
. . . O

5.4 . . O
abnormal . . O
bleeding . . O

* . . O
dulaglutide . . O
causes . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
in . . O
rats . . B-Animal
. . . O

* . . O
ptld . . B-AdverseReaction
, . . O
predominantly . . O
cns . . B-AdverseReaction
ptld . . I-AdverseReaction
, . . O
and . . O
other . . O
malignancies . . B-AdverseReaction
[ . . O
see . . O
boxed . . O
warning . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
, . . O
5.3 . . O
) . . O
] . . O
* . . O
serious . . B-Severity
infections . . B-AdverseReaction
, . . O
including . . O
jc . . B-AdverseReaction
virus . . I-AdverseReaction
- . . O
associated . . O
pml . . B-AdverseReaction
and . . O
polyoma . . B-AdverseReaction
virus . . I-AdverseReaction
nephropathy . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
, . . O
5.5 . . O
, . . O
5.6 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
on . . O
nulojix . . O
treatment . . O
) . . O
are . . O
anemia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
graft . . B-AdverseReaction
dysfunction . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
hyperkalemia . . B-AdverseReaction
, . . O
and . . O
leukopenia . . B-AdverseReaction
. . . O

the . . O
population . . O
exposed . . O
to . . O
cometriq . . O
was . . O
70% . . O
male . . O
, . . O
90% . . O
white . . O
, . . O
and . . O
had . . O
a . . O
median . . O
age . . O
of . . O
55 . . O
years . . O
. . . O

additionally . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

ecg . . O
monitoring . . O
is . . O
recommended . . O
if . . O
therapy . . O
is . . O
initiated . . O
in . . O
patients . . O
with . . O
congestive . . O
heart . . O
failure . . O
, . . O
bradyarrhythmias . . O
, . . O
drugs . . O
known . . O
to . . O
prolong . . O
the . . O
qt . . O
interval . . O
, . . O
including . . O
class . . O
ia . . O
and . . O
iii . . O
antiarrhythmics . . O
, . . O
and . . O
electrolyte . . O
abnormalities . . O
. . . O

warnings . . O
: . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
; . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction

* . . O
elevated . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
: . . O
control . . O
hypertension . . O
before . . O
initiating . . O
treatment . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

active . . O
ingredients . . O
: . . O
conjugated . . O
estrogens . . O
and . . O
bazedoxifene . . O
. . . O

in . . O
such . . O
cases . . O
, . . O
promptly . . O
discontinue . . O
nesina . . O
, . . O
assess . . O
for . . O
other . . O
potential . . O
causes . . O
, . . O
institute . . O
appropriate . . O
monitoring . . O
and . . O
treatment . . O
and . . O
initiate . . O
alternative . . O
treatment . . O
for . . O
diabetes . . O
. . . O

( . . O
6 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
janssen . . O
biotech . . O
, . . O
inc . . O
. . . O
at . . O
1-800-526-7736 . . O
( . . O
1-800 . . O
- . . O
janssen . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

for . . O
patients . . O
at . . O
highest . . O
risk . . O
for . . O
nsf . . O
, . . O
do . . O
not . . O
exceed . . O
the . . O
recommended . . O
eovist . . O
dose . . O
and . . O
allow . . O
a . . O
sufficient . . O
period . . O
of . . O
time . . O
for . . O
elimination . . O
of . . O
the . . O
drug . . O
prior . . O
to . . O
any . . O
re . . O
- . . O
administration . . O
. . . O

nsf . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
fatal . . B-AdverseReaction
or . . O
debilitating . . B-Severity
fibrosis . . B-AdverseReaction
affecting . . O
the . . O
skin . . O
, . . O
muscle . . O
and . . O
internal . . O
organs . . O
. . . O

acute . . O
symptoms . . O
should . . O
be . . O
treated . . O
with . . O
an . . O
inhaled . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonist . . O
. . . O

these . . O
include . . O
cases . . O
of . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
and . . O
erythema . . B-AdverseReaction
multiforme . . I-AdverseReaction
. . . O

in . . O
those . . O
diseases . . O
causing . . O
thinning . . O
of . . O
the . . O
cornea . . O
or . . O
sclera . . O
, . . O
perforations . . B-AdverseReaction
have . . O
been . . O
known . . O
to . . O
occur . . O
with . . O
the . . O
use . . O
of . . O
topical . . O
steroids . . B-DrugClass
. . . O

* . . O
the . . O
potency . . O
units . . O
of . . O
xeomin . . O
are . . O
not . . O
interchangeable . . O
with . . O
other . . O
preparations . . O
of . . O
botulinum . . O
toxin . . O
products . . O
. . . O

[ . . O
see . . O
boxed . . O
warning . . O
. . . O
] . . O

if . . O
concomitant . . O
use . . O
of . . O
pristiq . . O
with . . O
other . . O
serotonergic . . O
drugs . . O
is . . O
clinically . . O
warranted . . O
, . . O
patients . . O
should . . O
be . . O
made . . O
aware . . O
of . . O
a . . O
potential . . O
increased . . O
risk . . O
for . . O
serotonin . . O
syndrome . . O
, . . O
particularly . . O
during . . O
treatment . . O
initiation . . O
and . . O
dose . . O
increases . . O
( . . O
5.2 . . O
) . . O
. . . O

t3 . . O
resin . . O
uptake . . O
is . . O
decreased . . O
, . . O
reflecting . . O
the . . O
elevated . . B-AdverseReaction
tbg . . I-AdverseReaction
. . . O

it . . O
is . . O
unknown . . B-Factor
whether . . O
trulicity . . O
will . . O
cause . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
, . . O
including . . O
medullary . . B-AdverseReaction
thyroid . . I-AdverseReaction
carcinoma . . I-AdverseReaction
( . . O
mtc . . B-AdverseReaction
) . . O
, . . O
in . . O
humans . . O
, . . O
as . . O
the . . O
human . . O
relevance . . O
of . . O
dulaglutide . . O
- . . O
induced . . O
rodent . . B-Animal
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
has . . O
not . . O
been . . O
determined . . O
. . . O

the . . O
types . . O
of . . O
adverse . . O
events . . O
that . . O
led . . O
to . . O
discontinuation . . O
were . . O
similar . . O
for . . O
the . . O
fanapt . . O
- . . O
and . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
anemia . . B-AdverseReaction
, . . O
hemorrhagic . . B-AdverseReaction
anemia . . I-AdverseReaction
, . . O
leucopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
petechiae . . B-AdverseReaction
, . . O
eosinophilia . . B-AdverseReaction
, . . O
thrombocytosis . . B-AdverseReaction

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

cases . . O
of . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
including . . O
pneumonitis . . B-AdverseReaction
and . . O
pulmonary . . B-AdverseReaction
fibrosis . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
multaq . . O
in . . O
the . . O
post . . O
- . . O
marketing . . O
setting . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
triglycerides . . I-AdverseReaction
> . . O
= . . O
200 . . B-Severity
mg . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
at . . O
endpoint . . O
) . . O
was . . O
15.2% . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
versus . . O
11.4% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

for . . O
patients . . O
receiving . . O
hemodialysis . . O
, . . O
physicians . . O
may . . O
consider . . O
the . . O
prompt . . O
initiation . . O
of . . O
hemodialysis . . O
following . . O
the . . O
administration . . O
of . . O
a . . O
gbca . . O
in . . O
order . . O
to . . O
enhance . . O
the . . O
contrast . . O
agent's . . O
elimination . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

a . . O
pharmacokinetic . . O
analysis . . O
suggested . . B-Factor
that . . O
zykadia . . O
causes . . O
concentration . . O
- . . O
dependent . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
the . . I-AdverseReaction
qtc . . I-AdverseReaction
interval . . I-AdverseReaction
. . . O

monitor . . O
serum . . O
glucose . . O
levels . . O
as . . O
clinically . . O
appropriate . . O
when . . O
tafinlar . . O
is . . O
administered . . O
as . . O
a . . O
single . . O
agent . . O
or . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
in . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
diabetes . . O
or . . O
hyperglycemia . . O
. . . O

no . . B-Negation
deaths . . B-AdverseReaction
clearly . . O
related . . O
to . . O
zytiga . . O
were . . O
reported . . O
due . . O
to . . O
hepatotoxicity . . B-AdverseReaction
events . . O
. . . O

take . . O
the . . O
next . . O
dose . . O
at . . O
your . . O
regular . . O
time . . O
. . . O

6 . . O
adverse . . O
reactions . . O

spinal . . O
/ . . O
epidural . . O
anesthesia . . O
or . . O
puncture . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
1% . . O
) . . O
are . . O
related . . O
to . . O
bleeding . . B-AdverseReaction
. . . O
( . . O
6.1 . . O
) . . O

of . . O
the . . O
1,834 . . O
patients . . O
, . . O
12% . . O
discontinued . . O
treatment . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
, . . O
compared . . O
with . . O
3% . . O
of . . O
the . . O
1,116 . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

* . . O
impaired . . B-AdverseReaction
wound . . I-AdverseReaction
healing . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
. . . O

* . . O
keep . . O
duavee . . O
in . . O
the . . O
blister . . O
until . . O
you . . O
are . . O
ready . . O
to . . O
take . . O
it . . O
to . . O
protect . . O
the . . O
tablet . . O
from . . O
moisture . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
, . . O
and . . O
treat . . O
promptly . . O
. . . O

all . . O
had . . O
grade . . B-Severity
4 . . I-Severity
neutropenia . . B-AdverseReaction
and . . O
one . . O
had . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
. . . O

excerpt . . O
: . . O
* . . O
correct . . O
volume . . O
or . . O
salt . . O
depletion . . O
prior . . O
to . . O
administration . . O
of . . O
edarbi . . O
. . . O

increases . . B-AdverseReaction
in . . I-AdverseReaction
ast . . I-AdverseReaction
and . . O
alt . . O
of . . O
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
were . . O
limited . . O
to . . O
1% . . O
and . . O
3% . . O
of . . O
patients . . O
, . . O
respectively . . O
. . . O

analysis . . O
of . . O
seventeen . . O
placebo . . O
- . . O
controlled . . O
trials . . O
( . . O
modal . . O
duration . . O
10 . . O
weeks . . O
) . . O
, . . O
largely . . O
in . . O
patients . . O
taking . . O
atypical . . O
antipsychotic . . O
drugs . . O
, . . O
revealed . . O
a . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
in . . O
the . . O
drug . . O
- . . O
treated . . O
patients . . O
of . . O
between . . O
1.6 . . O
to . . O
1.7 . . O
times . . O
the . . O
risk . . O
of . . O
death . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

patients . . O
may . . O
require . . O
a . . O
lower . . O
dose . . O
of . . O
sulfonylurea . . O
or . . O
insulin . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
in . . O
this . . O
setting . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

the . . O
increased . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
is . . O
considered . . O
a . . O
class . . O
effect . . O
of . . O
laba . . B-DrugClass
, . . O
including . . O
vilanterol . . O
, . . O
one . . O
of . . O
the . . O
active . . O
ingredients . . O
in . . O
breo . . O
ellipta . . O
. . . O

the . . O
median . . O
time . . O
to . . O
onset . . O
from . . O
last . . O
dose . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
was . . O
approximately . . O
one . . O
week . . O
, . . O
and . . O
the . . O
median . . O
duration . . O
was . . O
approximately . . O
three . . O
weeks . . O
. . . O

in . . O
the . . O
randomized . . O
clinical . . O
trial . . O
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
of . . O
any . . O
grade . . O
occurred . . O
in . . O
4% . . O
of . . O
the . . O
patients . . O
being . . O
treated . . O
with . . O
jevtana . . O
, . . O
including . . O
four . . O
cases . . O
with . . O
fatal . . B-AdverseReaction
outcome . . O
. . . O

table . . O
4 . . O
: . . O
number . . O
( . . O
% . . O
) . . O
of . . O
patients . . O
with . . O
clinically . . O
relevant . . O
or . . O
severe . . O
grade . . O
3 . . O
/ . . O
4 . . O
laboratory . . O
test . . O
abnormalities . . O
in . . O
patients . . O
with . . O
cml . . O
in . . O
study . . O
1 . . O
, . . O
safety . . O
population . . O
chronic . . O
phase . . O
cml . . O
advanced . . O
phase . . O
cml . . O
all . . O
cp . . O
and . . O
advp . . O
cml . . O
n . . O
= . . O
406 . . O
n . . O
= . . O
140 . . O
n . . O
= . . O
546 . . O
n . . O
( . . O
% . . O
) . . O
n . . O
( . . O
% . . O
) . . O
n . . O
( . . O
% . . O
) . . O
hematology . . O
parameters . . O
platelet . . O
count . . O
( . . O
low . . O
) . . O
less . . O
than . . O
50*10 . . B-Severity
9 . . I-Severity
/ . . I-Severity
l . . I-Severity
102 . . O
( . . O
25 . . O
) . . O
80 . . O
( . . O
57 . . O
) . . O
182 . . O
( . . O
33 . . O
) . . O
absolute . . B-AdverseReaction
neutrophil . . I-AdverseReaction
count . . I-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
1*10 . . I-AdverseReaction
9 . . I-AdverseReaction
/ . . I-AdverseReaction
l . . I-AdverseReaction
74 . . O
( . . O
18 . . O
) . . O
52 . . O
( . . O
37 . . O
) . . O
126 . . O
( . . O
23 . . O
) . . O
hemoglobin . . O
( . . O
low . . O
) . . O
less . . O
than . . O
80 . . B-Severity
g . . I-Severity
/ . . I-Severity
l . . I-Severity
53 . . O
( . . O
13 . . O
) . . O
49 . . O
( . . O
35 . . O
) . . O
102 . . O
( . . O
19 . . O
) . . O
biochemistry . . O
parameters . . O
sgpt . . O
/ . . O
alt . . B-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
5.0 . . I-AdverseReaction
* . . I-AdverseReaction
uln . . I-AdverseReaction
39 . . O
( . . O
10 . . O
) . . O
8 . . O
( . . O
6 . . O
) . . O
47 . . O
( . . O
9 . . O
) . . O
sgot . . O
/ . . O
ast . . B-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
5.0 . . I-AdverseReaction
* . . I-AdverseReaction
uln . . I-AdverseReaction
17 . . O
( . . O
4 . . O
) . . O
4 . . O
( . . O
3 . . O
) . . O
21 . . O
( . . O
4 . . O
) . . O
lipase . . B-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
2 . . I-AdverseReaction
* . . I-AdverseReaction
uln . . I-AdverseReaction
33 . . O
( . . O
8 . . O
) . . O
4 . . O
( . . O
3 . . O
) . . O
37 . . O
( . . O
7 . . O
) . . O
phosphorus . . O
( . . O
low . . O
) . . O
less . . O
than . . O
0.6 . . B-Severity
mmol . . I-Severity
/ . . I-Severity
l . . I-Severity
30 . . O
( . . O
7 . . O
) . . O
10 . . O
( . . O
7 . . O
) . . O
40 . . O
( . . O
7 . . O
) . . O
total . . B-AdverseReaction
bilirubin . . I-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
3.0 . . I-AdverseReaction
* . . I-AdverseReaction
uln . . I-AdverseReaction
3 . . O
( . . O
1 . . O
) . . O
2 . . O
( . . O
1 . . O
) . . O
5 . . O
( . . O
1 . . O
) . . O
additional . . O
adverse . . O
reactions . . O
from . . O
multiple . . O
clinical . . O
trials . . O

consider . . O
periodic . . O
monitoring . . O
with . . O
electrocardiograms . . O
( . . O
ecgs . . O
) . . O
and . . O
electrolytes . . O
in . . O
patients . . O
with . . O
congestive . . O
heart . . O
failure . . O
, . . O
bradyarrhythmias . . O
, . . O
electrolyte . . O
abnormalities . . O
, . . O
or . . O
who . . O
are . . O
taking . . O
medications . . O
that . . O
are . . O
known . . O
to . . O
prolong . . O
the . . O
qt . . O
interval . . O
. . . O

avoid . . O
the . . O
use . . O
of . . O
adcetris . . O
in . . O
patients . . O
with . . O
moderate . . O
( . . O
child . . O
- . . O
pugh . . O
b . . O
) . . O
or . . O
severe . . O
( . . O
child . . O
- . . O
pugh . . O
c . . O
) . . O
hepatic . . O
impairment . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.7 . . O
) . . O
] . . O
. . . O

( . . O
6 . . O
) . . O

should . . O
any . . O
of . . O
these . . O
occur . . O
or . . O
be . . O
suspected . . O
, . . O
duavee . . O
should . . O
be . . O
discontinued . . O
immediately . . O
. . . O

an . . O
estimate . . O
of . . O
the . . O
attributable . . O
risk . . O
is . . O
3.3 . . O
cases . . O
/ . . O
100,000 . . O
coc . . O
users . . O
. . . O

the . . O
effect . . O
of . . O
antibody . . O
development . . O
on . . O
the . . O
long . . O
term . . O
efficacy . . O
of . . O
alglucosidase . . O
alfa . . O
is . . O
not . . O
fully . . O
understood . . O
. . . O

continuation . . O
of . . O
gilenya . . O
in . . O
patients . . O
who . . O
develop . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
has . . O
not . . O
been . . O
evaluated . . O
. . . O

adcetris . . O
was . . O
studied . . O
in . . O
329 . . O
patients . . O
with . . O
classical . . O
hl . . O
at . . O
high . . O
risk . . O
of . . O
relapse . . O
or . . O
progression . . O
post . . O
- . . O
auto . . O
- . . O
hsct . . O
in . . O
a . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trial . . O
in . . O
which . . O
the . . O
recommended . . O
starting . . O
dose . . O
and . . O
schedule . . O
was . . O
1.8 . . O
mg . . O
/ . . O
kg . . O
of . . O
adcetris . . O
administered . . O
intravenously . . O
over . . O
30 . . O
minutes . . O
every . . O
3 . . O
weeks . . O
or . . O
placebo . . O
for . . O
up . . O
to . . O
16 . . O
cycles . . O
. . . O

5.4 . . O
probable . . O
dementia . . O

the . . O
risk . . O
appears . . O
lower . . O
for . . O
patients . . O
with . . O
chronic . . O
, . . O
moderate . . O
kidney . . O
disease . . O
( . . O
gfr . . O
30 . . O
to . . O
59 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m . . O
2 . . O
) . . O
and . . O
little . . O
, . . O
if . . O
any . . O
, . . O
for . . O
patients . . O
with . . O
chronic . . O
, . . O
mild . . O
kidney . . O
disease . . O
( . . O
gfr . . O
60 . . O
to . . O
89 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m . . O
2 . . O
) . . O
. . . O

one . . O
of . . O
the . . O
1,564 . . O
crohn's . . O
disease . . O
patients . . O
treated . . O
with . . O
cimzia . . O
developed . . O
symptoms . . O
of . . O
a . . O
lupus . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

use . . O
of . . O
a . . O
sensitive . . O
real . . O
- . . O
time . . O
reverse . . O
- . . O
transcription . . O
polymerase . . O
chain . . O
reaction . . O
( . . O
rt . . O
- . . O
pcr . . O
) . . O
assay . . O
for . . O
monitoring . . O
hcv . . O
- . . O
rna . . O
levels . . O
during . . O
treatment . . O
is . . O
recommended . . O
. . . O

in . . O
a . . O
3 . . O
- . . O
week . . O
, . . O
bipolar . . O
mania . . O
pediatric . . O
trial . . O
, . . O
syncope . . B-AdverseReaction
was . . O
reported . . O
in . . O
1% . . O
( . . O
1 . . O
/ . . O
104 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
, . . O
1% . . O
( . . O
1 . . O
/ . . O
99 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
5 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
0% . . O
( . . O
0 . . O
/ . . O
99 . . O
) . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
10 . . O
mg . . O
twice . . O
daily . . O
compared . . O
to . . O
0% . . O
( . . O
0 . . O
/ . . O
101 . . O
) . . O
for . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

( . . O
4 . . O
) . . O

5.6 . . O
alpha . . O
- . . O
blockers . . O
and . . O
other . . O
antihypertensives . . O

hypoglycemia . . B-AdverseReaction
was . . O
more . . O
frequent . . O
when . . O
farxiga . . O
was . . O
added . . O
to . . O
sulfonylurea . . O
or . . O
insulin . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

a . . O
gradual . . O
reduction . . O
in . . O
the . . O
dose . . O
rather . . O
than . . O
abrupt . . O
cessation . . O
is . . O
recommended . . O
whenever . . O
possible . . O
. . . O

may . . O
worsen . . O
, . . O
especially . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
. . . O

congenital . . O
, . . O
familial . . O
and . . O
genetic . . O
disorders . . O
: . . O
hypospadias . . B-AdverseReaction
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
the . . O
postmarketing . . O
use . . O
of . . O
nesina . . O
. . . O

hypertension . . B-AdverseReaction
was . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
in . . O
32% . . O
of . . O
nulojix . . O
- . . O
treated . . O
patients . . O
and . . O
37% . . O
of . . O
cyclosporine . . O
- . . O
treated . . O
patients . . O
( . . O
see . . O
table . . O
4 . . O
) . . O
. . . O

therefore . . O
, . . O
the . . O
efficacy . . O
and . . O
safety . . O
of . . O
xiaflex . . O
in . . O
patients . . O
receiving . . O
anticoagulant . . O
medications . . O
( . . O
other . . O
than . . O
low . . O
- . . O
dose . . O
aspirin . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
up . . O
to . . O
150 . . O
mg . . O
per . . O
day . . O
) . . O
within . . O
7 . . O
days . . O
prior . . O
to . . O
xiaflex . . O
administration . . O
is . . O
not . . O
known . . O
. . . O

5.6 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

premature . . O
discontinuation . . O
of . . O
any . . O
oral . . O
anticoagulant . . O
, . . O
including . . O
eliquis . . O
, . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
. . . O

5.1 . . O
post . . O
- . . O
transplant . . O
lymphoproliferative . . O
disorder . . O

a . . O
total . . O
of . . O
111 . . O
patients . . O
were . . O
treated . . O
with . . O
pemetrexed . . O
/ . . O
cisplatin . . O
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
neutropenia . . B-AdverseReaction

do . . O
not . . O
give . . O
duavee . . O
to . . O
other . . O
people . . O
, . . O
even . . O
if . . O
they . . O
have . . O
the . . O
same . . O
symptoms . . O
you . . O
have . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

lactic . . B-AdverseReaction
acidosis . . I-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
observed . . O
with . . O
multaq . . O
400 . . O
mg . . O
twice . . O
daily . . O
in . . O
the . . O
5 . . O
studies . . O
were . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
and . . O
asthenia . . B-AdverseReaction
. . . O

digestive . . O
- . . O
gastritis . . B-AdverseReaction
, . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
hypoglycemia . . B-AdverseReaction
, . . O
blood . . B-AdverseReaction
glucose . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
alanine . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
stomach . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
epistaxis . . B-AdverseReaction

adverse . . O
reactions . . O
related . . O
to . . O
toxic . . O
methotrexate . . O
levels . . O
due . . O
to . . O
prolonged . . O
methotrexate . . O
clearance . . O
include . . O
myelosuppression . . O
, . . O
mucositis . . O
, . . O
acute . . O
hepatitis . . O
, . . O
and . . O
renal . . O
dysfunction . . O
and . . O
failure . . O
. . . O

serious . . O
drug . . O
- . . O
related . . O
adverse . . O
reactions . . O
reported . . O
in . . O
clinical . . O
trials . . O
included . . O
myelosuppression . . B-AdverseReaction
, . . O
infection . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
and . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5 . . O
) . . O
] . . O
. . . O

[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
. . . O
] . . O

withhold . . O
then . . O
dose . . O
reduce . . O
, . . O
or . . O
permanently . . O
discontinue . . O
zykadia . . O
. . . O

these . . O
reactions . . O
may . . O
occur . . O
in . . O
patients . . O
with . . O
no . . O
history . . O
of . . O
prior . . O
exposure . . O
to . . O
vizamyl . . O
. . . O

in . . O
the . . O
controlled . . O
adjunctive . . O
epilepsy . . O
trials . . O
, . . O
these . . O
events . . O
were . . O
reported . . O
in . . O
13% . . O
of . . O
placebo . . O
patients . . O
, . . O
16% . . O
of . . O
patients . . O
randomized . . O
to . . O
receive . . O
800 . . O
mg . . O
/ . . O
day . . O
aptiom . . O
, . . O
and . . O
28% . . O
of . . O
patients . . O
randomized . . O
to . . O
receive . . O
1200 . . O
mg . . O
/ . . O
day . . O
aptiom . . O
. . . O

the . . O
development . . O
of . . O
pneumonitis . . B-AdverseReaction
has . . O
been . . O
reported . . O
even . . O
at . . O
a . . O
reduced . . O
dose . . O
. . . O

because . . O
of . . O
the . . O
possibility . . O
of . . O
significant . . O
systemic . . O
absorption . . O
of . . O
inhaled . . O
corticosteroids . . O
in . . O
sensitive . . O
patients . . O
, . . O
patients . . O
treated . . O
with . . O
breo . . O
ellipta . . O
should . . O
be . . O
observed . . O
carefully . . O
for . . O
any . . O
evidence . . O
of . . O
systemic . . O
corticosteroid . . O
effects . . O
. . . O

inform . . O
patients . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
anaphylaxis . . O
and . . O
have . . O
them . . O
seek . . O
immediate . . O
medical . . O
care . . O
should . . O
symptoms . . O
occur . . O
. . . O

in . . O
the . . O
placebo . . O
- . . O
controlled . . O
phase . . O
3 . . O
trial . . O
in . . O
patients . . O
with . . O
blepharospasm . . B-AdverseReaction
previously . . O
treated . . O
with . . O
onabotulinumtoxina . . O
( . . O
botox . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
] . . O
, . . O
74 . . O
patients . . O
received . . O
xeomin . . O
at . . O
a . . O
mean . . O
dose . . O
of . . O
approximately . . O
33 . . O
units . . O
per . . O
eye . . O
( . . O
minimum . . O
10 . . O
units . . O
, . . O
maximum . . O
50 . . O
units . . O
) . . O
. . . O

infections . . B-AdverseReaction
were . . O
more . . O
frequently . . O
reported . . O
in . . O
females . . O
than . . O
in . . O
males . . O
( . . O
see . . O
table . . O
1 . . O
) . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
1% . . O
) . . O
were . . O
ingrown . . B-AdverseReaction
toenails . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
dermatitis . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
vesicles . . I-AdverseReaction
, . . O
and . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
. . . O

5.5 . . O
hypersensitivity . . O

two . . O
patients . . O
( . . O
2% . . O
) . . O
on . . O
placebo . . O
and . . O
1 . . O
patient . . O
( . . O
0.5% . . O
) . . O
on . . O
kalydeco . . O
permanently . . O
discontinued . . O
treatment . . O
for . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
, . . O
all . . O
> . . B-Severity
8 . . I-Severity
* . . I-Severity
uln . . I-Severity
. . . O

all . . O
adverse . . O
reactions . . O
were . . O
mild . . O
to . . O
moderate . . O
in . . O
severity . . O
and . . O
of . . O
short . . O
duration . . O
. . . O

the . . O
safety . . O
data . . O
reflect . . O
subject . . O
exposure . . O
to . . O
zydelig . . O
from . . O
study . . O
1 . . O
, . . O
in . . O
which . . O
218 . . O
subjects . . O
with . . O
relapsed . . O
cll . . O
received . . O
up . . O
to . . O
8 . . O
doses . . O
of . . O
rituximab . . O
with . . O
or . . O
without . . O
zydelig . . O
150 . . O
mg . . O
twice . . O
daily . . O
. . . O

( . . O
5.9 . . O
) . . O

qtc . . B-AdverseReaction
prolongation . . I-AdverseReaction
can . . B-Factor
occur . . O
in . . O
patients . . O
treated . . O
with . . O
xalkori . . O
. . . O

some . . O
of . . O
these . . O
events . . O
have . . O
been . . O
fatal . . B-AdverseReaction
or . . O
life . . O
- . . O
threatening . . O
. . . O

when . . O
discontinuing . . O
horizant . . O
, . . O
patients . . O
with . . O
rls . . O
receiving . . O
600 . . O
mg . . O
or . . O
less . . O
once . . O
daily . . O
can . . O
discontinue . . O
the . . O
drug . . O
without . . O
tapering . . O
. . . O

5.9 . . O
progressive . . O
multifocal . . O
leukoencephalopathy . . O

tanzeum . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
pancreatitis . . O
to . . O
determine . . O
whether . . O
these . . O
patients . . O
are . . O
at . . O
increased . . O
risk . . O
for . . O
pancreatitis . . O
. . . O

in . . O
one . . O
case . . O
, . . O
insufficient . . O
information . . O
was . . O
obtained . . O
to . . O
establish . . O
or . . O
refute . . O
a . . O
drug . . O
- . . O
related . . O
causality . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
postapproval . . O
use . . O
of . . O
yervoy . . O
. . . O

among . . O
the . . O
404 . . O
ebv . . O
seropositive . . O
recipients . . O
treated . . O
with . . O
the . . O
recommended . . O
dosage . . O
regimen . . O
of . . O
nulojix . . O
, . . O
three . . O
ptld . . B-AdverseReaction
cases . . O
were . . O
detected . . O
among . . O
99 . . O
cmv . . O
seronegative . . O
patients . . O
( . . O
3% . . O
) . . O
and . . O
there . . O
was . . O
no . . O
case . . O
detected . . O
among . . O
303 . . O
cmv . . O
seropositive . . O
patients . . O
. . . O

adreview . . O
safety . . O
and . . O
efficacy . . O
have . . O
not . . O
been . . O
established . . O
in . . O
these . . O
patients . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

approximately . . O
55% . . O
of . . O
subjects . . O
were . . O
female . . O
, . . O
45% . . O
were . . O
male . . O
, . . O
and . . O
94% . . O
were . . O
caucasian . . O
. . . O

( . . O
5.8 . . O
) . . O
* . . O
reversible . . B-AdverseReaction
posterior . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
rpls . . B-AdverseReaction
) . . O
: . . O
discontinue . . O
cometriq . . O
. . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
diabetes . . B-AdverseReaction
mellitus . . I-AdverseReaction
, . . O
anorexia . . B-AdverseReaction
, . . O
dyslipidemia . . B-AdverseReaction

patients . . O
received . . O
benlysta . . O
at . . O
doses . . O
of . . O
1 . . O
mg . . O
/ . . O
kg . . O
( . . O
n . . O
= . . O
673 . . O
) . . O
, . . O
4 . . O
mg . . O
/ . . O
kg . . O
( . . O
n . . O
= . . O
111 . . O
; . . O
trial . . O
1 . . O
only . . O
) . . O
, . . O
or . . O
10 . . O
mg . . O
/ . . O
kg . . O
( . . O
n . . O
= . . O
674 . . O
) . . O
or . . O
placebo . . O
( . . O
n . . O
= . . O
675 . . O
) . . O
intravenously . . O
over . . O
a . . O
1 . . O
- . . O
hour . . O
period . . O
on . . O
days . . O
0 . . O
, . . O
14 . . O
, . . O
28 . . O
, . . O
and . . O
then . . O
every . . O
28 . . O
days . . O
. . . O

if . . O
infectious . . O
etiologies . . O
are . . O
not . . O
considered . . O
, . . O
and . . O
fulyzaq . . O
is . . O
initiated . . O
based . . O
on . . O
a . . O
presumptive . . O
diagnosis . . O
of . . O
non . . O
- . . O
infectious . . O
diarrhea . . O
, . . O
then . . O
there . . O
is . . O
a . . O
risk . . O
that . . O
patients . . O
with . . O
infectious . . O
etiologies . . O
will . . O
not . . O
receive . . O
the . . O
appropriate . . O
treatments . . O
, . . O
and . . O
their . . O
disease . . O
may . . O
worsen . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
supine . . B-AdverseReaction
hypertension . . I-AdverseReaction
see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

skin . . O
: . . O
case . . O
of . . O
severe . . B-Severity
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
, . . O
erythema . . B-AdverseReaction
multiforme . . I-AdverseReaction
, . . O
and . . O
new . . O
or . . O
worsening . . O
psoriasis . . B-AdverseReaction
( . . O
all . . O
sub . . O
- . . O
types . . O
including . . O
pustular . . O
and . . O
palmoplantar . . O
) . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
. . . O

if . . O
a . . O
patient . . O
develops . . O
skin . . O
discoloration . . O
, . . O
serious . . O
consideration . . O
should . . O
be . . O
given . . O
to . . O
an . . O
alternative . . O
treatment . . O
. . . O

for . . O
patients . . O
who . . O
develop . . O
prolonged . . O
grade . . O
2 . . O
cutaneous . . O
adverse . . O
reactions . . O
lasting . . O
more . . O
than . . O
7 . . O
days . . O
, . . O
intolerable . . O
grade . . O
2 . . O
, . . O
or . . O
grade . . O
3 . . O
cutaneous . . O
reactions . . O
, . . O
withhold . . O
gilotrif . . O
until . . O
the . . O
adverse . . O
reaction . . O
resolves . . O
to . . O
grade . . O
1 . . O
or . . O
less . . O
, . . O
and . . O
resume . . O
gilotrif . . O
with . . O
appropriate . . O
dose . . O
reduction . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

aeds . . B-DrugClass
increase . . O
the . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
in . . O
patients . . O
taking . . O
these . . O
drugs . . O
for . . O
any . . O
indication . . O
. . . O

table . . O
3 . . O
: . . O
overall . . O
infections . . B-AdverseReaction
and . . O
select . . O
infections . . B-AdverseReaction
with . . O
identified . . O
etiology . . O
by . . O
treatment . . O
group . . O
following . . O
one . . O
and . . O
three . . O
years . . O
of . . O
treatment . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
* . . O
up . . O
to . . O
year . . O
1 . . O
up . . O
to . . O
year . . O
3 . . O
nulojix . . O
recommended . . O
regimen . . O
n . . O
= . . O
401 . . O
n . . O
( . . O
% . . O
) . . O
cyclosporine . . O
n . . O
= . . O
405 . . O
n . . O
( . . O
% . . O
) . . O
nulojix . . O
recommended . . O
regimen . . O
n . . O
= . . O
401 . . O
n . . O
( . . O
% . . O
) . . O
cyclosporine . . O
n . . O
= . . O
405 . . O
n . . O
( . . O
% . . O
) . . O
* . . O
studies . . O
1 . . O
and . . O
2 . . O
were . . O
not . . O
designed . . O
to . . O
support . . O
comparative . . O
claims . . O
for . . O
nulojix . . O
for . . O
the . . O
adverse . . O
reactions . . O
reported . . O
in . . O
this . . O
table . . O
. . . O

patients . . O
on . . O
concomitant . . O
immunosuppressant . . O
agents . . O
or . . O
with . . O
impaired . . O
immune . . O
systems . . O
may . . B-Factor
be . . O
at . . O
increased . . O
risk . . O
for . . O
serious . . B-Severity
infections . . B-AdverseReaction
. . . O

do . . O
not . . O
use . . O
nulojix . . O
in . . O
transplant . . O
recipients . . O
who . . O
are . . O
ebv . . O
seronegative . . O
or . . O
with . . O
unknown . . O
serostatus . . O
. . . O

stop . . O
treatment . . O
with . . O
cometriq . . O
at . . O
least . . O
28 . . O
days . . O
prior . . O
to . . O
scheduled . . O
surgery . . O
. . . O

baseline . . O
estimated . . O
renal . . O
function . . O
was . . O
normal . . O
or . . O
mildly . . O
impaired . . O
( . . O
egfr . . O
> . . O
= . . O
60ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
in . . O
96.0% . . O
of . . O
the . . O
pooled . . O
study . . O
populations . . O
. . . O

amyvid . . O
, . . O
similar . . O
to . . O
other . . O
radiopharmaceuticals . . O
, . . O
contributes . . O
to . . O
a . . O
patient's . . O
overall . . O
long . . B-AdverseReaction
- . . I-AdverseReaction
term . . I-AdverseReaction
cumulative . . I-AdverseReaction
radiation . . I-AdverseReaction
exposure . . I-AdverseReaction
. . . O

in . . O
study . . O
1 . . O
, . . O
the . . O
incidence . . O
of . . O
grade . . O
> . . O
= . . O
3 . . O
ild . . B-AdverseReaction
was . . O
1.3% . . O
and . . O
resulted . . O
in . . O
death . . B-AdverseReaction
in . . O
1% . . O
of . . O
gilotrif . . O
- . . O
treated . . O
patients . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
malignancy . . B-AdverseReaction

5.2 . . O
risk . . O
for . . O
image . . O
misinterpretation . . O
and . . O
other . . O
errors . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
patients . . O
in . . O
the . . O
125 . . O
mg . . O
twice . . O
daily . . O
group . . O

if . . O
either . . O
occurs . . O
, . . O
decrease . . O
the . . O
dose . . O
of . . O
cleviprex . . O
. . . O

in . . O
the . . O
randomized . . O
advanced . . O
hormone . . O
receptor . . O
- . . O
positive . . O
, . . O
her2 . . O
- . . O
negative . . O
breast . . O
cancer . . O
study . . O
, . . O
the . . O
incidence . . O
of . . O
deaths . . B-AdverseReaction
due . . O
to . . O
any . . O
cause . . O
within . . O
28 . . O
days . . O
of . . O
the . . O
last . . O
afinitor . . O
dose . . O
was . . O
6% . . O
in . . O
patients . . O
> . . O
= . . O
65 . . O
years . . O
of . . O
age . . O
compared . . O
to . . O
2% . . O
in . . O
patients . . O
< . . O
65 . . O
years . . O
of . . O
age . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
myopathy . . B-AdverseReaction
, . . O
including . . O
rhabdomyolysis . . B-AdverseReaction
. . . O

non . . B-AdverseReaction
- . . I-AdverseReaction
gi . . I-AdverseReaction
fistulas . . I-AdverseReaction
including . . O
tracheal . . O
/ . . O
esophageal . . O
were . . O
reported . . O
in . . O
4% . . O
of . . O
cometriq . . O
- . . O
treated . . O
patients . . O
. . . O

eliglustat . . O
is . . O
a . . O
cyp2d6 . . O
and . . O
cyp3a . . O
substrate . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

in . . O
vitro . . O
studies . . O
showed . . O
no . . O
evidence . . O
of . . O
cross . . O
- . . O
reactivity . . O
between . . O
anti . . O
- . . O
drug . . O
- . . O
antibody . . O
positive . . O
patient . . O
sera . . O
and . . O
a . . O
series . . O
of . . O
relevant . . O
mmps . . O
. . . O

the . . O
incidence . . O
of . . O
nonfatal . . O
serious . . O
adverse . . O
events . . O
was . . O
24.2% . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
25.0% . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

administer . . O
insulin . . O
therapy . . O
as . . O
necessary . . O
in . . O
patients . . O
with . . O
hyperglycemia . . O
. . . O

the . . O
majority . . O
of . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
presented . . O
intable . . O
2occurred . . O
within . . O
the . . O
first . . O
2 . . O
weeks . . O
of . . O
treatment . . O
and . . O
tended . . O
to . . O
resolve . . O
over . . O
time . . O
with . . O
continued . . O
dosing . . O
. . . O

discontinue . . O
sirturo . . O
and . . O
all . . O
other . . O
qt . . O
prolonging . . O
drugs . . O
if . . O
the . . O
patient . . O
develops . . O
: . . O

( . . O
6.1 . . O
, . . O
6.2 . . O
, . . O
6.3 . . O
) . . O

excerpt . . O
: . . O
severe . . B-Severity
, . . O
potentially . . O
life . . B-Severity
threatening . . I-Severity
and . . O
fatal . . B-AdverseReaction
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

there . . O
were . . O
insufficient . . O
numbers . . O
of . . O
patients . . O
with . . O
biopsy . . O
- . . O
proven . . O
hepatitis . . O
to . . O
characterize . . O
the . . O
clinical . . O
course . . O
of . . O
this . . O
event . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
certolizumab . . O
pegol . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
incidence . . O
of . . O
antibodies . . O
to . . O
voraxaze . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

recipients . . O
without . . O
immunity . . O
to . . O
epstein . . O
- . . O
barr . . O
virus . . O
( . . O
ebv . . O
) . . O
are . . O
at . . O
a . . O
particularly . . O
increased . . O
risk . . O
; . . O
therefore . . O
, . . O
use . . O
in . . O
ebv . . O
seropositive . . O
patients . . O
only . . O
. . . O

one . . O
halaven . . O
- . . O
treated . . O
patient . . O
without . . O
documented . . O
liver . . O
metastases . . O
had . . O
concomitant . . O
grade . . B-Severity
2 . . I-Severity
elevations . . B-AdverseReaction
in . . I-AdverseReaction
bilirubin . . I-AdverseReaction
and . . O
alt . . O
; . . O
these . . O
abnormalities . . O
resolved . . O
and . . O
did . . O
not . . O
recur . . O
with . . O
re . . O
- . . O
exposure . . O
to . . O
halaven . . O
. . . O

5.4 . . O
qt . . O
prolongation . . O

for . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
transaminase . . O
elevations . . O
, . . O
more . . O
frequent . . O
monitoring . . O
of . . O
liver . . O
function . . O
tests . . O
should . . O
be . . O
considered . . O
. . . O

treatment . . O
- . . O
experienced . . O
, . . O
integrase . . O
strand . . O
transfer . . O
inhibitor . . O
- . . O
naive . . O
subjects . . O
: . . O
laboratory . . O
abnormalities . . O
observed . . O
in . . O
sailing . . O
were . . O
generally . . O
similar . . O
compared . . O
with . . O
observations . . O
seen . . O
in . . O
the . . O
treatment . . O
- . . O
naive . . O
( . . O
spring . . O
- . . O
2 . . O
and . . O
single . . O
) . . O
trials . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
20% . . O
) . . O
were . . O
nausea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

the . . O
rate . . O
of . . O
adverse . . O
events . . O
leading . . O
to . . O
discontinuation . . O
was . . O
4% . . O
of . . O
subjects . . O
at . . O
week . . O
48 . . O
. . . O

hcv . . O
- . . O
rna . . O
levels . . O
should . . O
be . . O
monitored . . O
at . . O
treatment . . O
weeks . . O
4 . . O
, . . O
8 . . O
, . . O
12 . . O
, . . O
and . . O
24 . . O
, . . O
at . . O
the . . O
end . . O
of . . O
treatment . . O
, . . O
during . . O
treatment . . O
follow . . O
- . . O
up . . O
, . . O
and . . O
for . . O
other . . O
time . . O
points . . O
as . . O
clinically . . O
indicated . . O
. . . O

other . . O
adverse . . O
reactions . . O
occurring . . O
more . . O
frequently . . O
on . . O
invokana . . O
than . . O
on . . O
comparator . . O
were . . O
: . . O

the . . O
median . . O
number . . O
of . . O
cycles . . O
initiated . . O
was . . O
22 . . O
cycles . . O
for . . O
the . . O
krd . . O
arm . . O
and . . O
14 . . O
cycles . . O
for . . O
the . . O
rd . . O
arm . . O
. . . O

5.3 . . O
hypoglycemia . . O
with . . O
concomitant . . O
use . . O
of . . O
insulin . . O
secretagogues . . O
or . . O
insulin . . O

measure . . O
liver . . O
tests . . O
promptly . . O
in . . O
patients . . O
who . . O
report . . O
symptoms . . O
that . . O
may . . O
indicate . . O
liver . . O
injury . . O
, . . O
including . . O
fatigue . . O
, . . O
anorexia . . O
, . . O
right . . O
upper . . O
abdominal . . O
discomfort . . O
, . . O
dark . . O
urine . . O
or . . O
jaundice . . O
. . . O

the . . O
impact . . O
of . . O
long . . O
- . . O
term . . O
treatment . . O
with . . O
cimzia . . O
on . . O
the . . O
development . . O
of . . O
autoimmune . . O
diseases . . O
is . . O
unknown . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
uveitis . . O
and . . O
patients . . O
with . . O
diabetes . . O
mellitus . . O
are . . O
at . . O
increased . . O
risk . . B-Factor
of . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
during . . O
gilenya . . O
therapy . . O
. . . O

monitor . . O
lipase . . O
and . . O
amylase . . O
prior . . O
to . . O
the . . O
start . . O
of . . O
zykadia . . O
treatment . . O
and . . O
periodically . . O
thereafter . . O
as . . O
clinically . . O
indicated . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

patients . . O
in . . O
the . . O
study . . O
received . . O
a . . O
median . . O
of . . O
4 . . O
doses . . O
( . . O
range . . O
: . . O
1-4 . . O
doses . . O
) . . O
. . . O

the . . O
population . . O
had . . O
a . . O
mean . . O
age . . O
of . . O
39 . . O
( . . O
range . . O
: . . O
18 . . O
to . . O
75 . . O
) . . O
, . . O
94% . . O
were . . O
female . . O
, . . O
and . . O
52% . . O
were . . O
caucasian . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
beleodaq . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
13 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
increases . . O
from . . O
baseline . . O
in . . O
mean . . O
serum . . O
phosphorus . . O
levels . . O
were . . O
reported . . O
at . . O
week . . O
24 . . O
in . . O
farxiga . . O
- . . O
treated . . O
patients . . O
compared . . O
with . . O
placebo . . O
- . . O
treated . . O
patients . . O
( . . O
mean . . O
increase . . O
of . . O
0.13 . . O
versus . . O
- . . O
0.04 . . O
mg . . O
/ . . O
dl . . O
, . . O
respectively . . O
) . . O
. . . O

cdad . . O
must . . O
be . . O
considered . . O
in . . O
all . . O
patients . . O
who . . O
present . . O
with . . O
diarrhea . . O
following . . O
antibiotic . . O
use . . O
. . . O

5.5 . . O
macrophage . . O
activation . . O
syndrome . . O

these . . O
patients . . O
were . . O
managed . . O
without . . O
surgical . . O
intervention . . O
, . . O
but . . O
the . . O
long . . O
- . . O
term . . O
consequences . . O
are . . O
unknown . . O
. . . O

if . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
are . . O
permanently . . O
discontinued . . O
, . . O
then . . O
victrelis . . O
must . . O
also . . O
be . . O
discontinued . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

in . . O
the . . O
controlled . . O
portions . . O
of . . O
clinical . . O
trials . . O
of . . O
all . . O
the . . O
tnf . . O
blockers . . O
, . . O
more . . O
cases . . O
of . . O
lymphoma . . B-AdverseReaction
have . . O
been . . O
observed . . O
among . . O
patients . . O
receiving . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
compared . . O
to . . O
control . . O
patients . . O
. . . O

table . . O
3 . . O
shows . . O
the . . O
incidence . . O
of . . O
sexual . . B-AdverseReaction
function . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
that . . O
occurred . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
pristiq . . O
treated . . O
mdd . . O
patients . . O
in . . O
any . . O
fixed . . O
- . . O
dose . . O
group . . O
( . . O
pre . . O
- . . O
marketing . . O
pooled . . O
8 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
fixed . . O
- . . O
dose . . O
, . . O
clinical . . O
studies . . O
) . . O
. . . O

immune . . O
system . . O
disorder . . O
: . . O
hypersensitivity . . B-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O

permanently . . O
discontinue . . O
tafinlar . . O
for . . O
ras . . O
mutation . . O
- . . O
positive . . O
non . . O
- . . O
cutaneous . . O
malignancies . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
there . . O
was . . O
a . . O
statistically . . O
significant . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
risk . . B-Factor
by . . O
week . . O
120 . . O
in . . O
the . . O
sirturo . . O
treatment . . O
group . . O
compared . . O
to . . O
the . . O
placebo . . O
treatment . . O
group . . O
( . . O
9 . . O
/ . . O
79 . . O
( . . O
11.4% . . O
) . . O
versus . . O
2 . . O
/ . . O
81 . . O
( . . O
2.5% . . O
) . . O
, . . O
p . . O
- . . O
value . . O
= . . O
0.03 . . O
, . . O
an . . O
exact . . O
95% . . O
confidence . . O
interval . . O
of . . O
the . . O
difference . . O
[ . . O
1.1% . . O
, . . O
18.2% . . O
] . . O
) . . O
. . . O

( . . O
5.12 . . O
) . . O
* . . O
priapism . . B-AdverseReaction
: . . O
cases . . O
have . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
fanapt . . O
treatment . . O
. . . O

there . . O
are . . O
no . . O
adequate . . O
and . . O
well . . O
controlled . . O
studies . . O
of . . O
bosulif . . O
in . . O
pregnant . . O
women . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
data . . O
reflect . . O
the . . O
percentage . . O
of . . O
patients . . O
whose . . O
test . . O
results . . O
were . . O
considered . . O
positive . . O
for . . O
antibodies . . O
to . . O
certolizumab . . O
pegol . . O
in . . O
an . . O
elisa . . O
, . . O
and . . O
are . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
25% . . O
) . . O
were . . O
neutropenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
/ . . O
fatigue . . B-AdverseReaction
, . . O
alopecia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
constipation . . B-AdverseReaction
( . . O
6 . . O
) . . O

if . . O
atrial . . O
fibrillation . . O
persists . . O
, . . O
consider . . O
the . . O
risks . . O
and . . O
benefits . . O
of . . O
imbruvica . . O
treatment . . O
and . . O
dose . . O
modification . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

table . . O
2 . . O
identifies . . O
the . . O
shift . . O
from . . O
baseline . . O
to . . O
lowest . . O
observed . . O
estimated . . O
glomerular . . O
filtration . . O
rate . . O
( . . O
egfr . . O
) . . O
during . . O
bosulif . . O
therapy . . O
for . . O
patients . . O
in . . O
the . . O
global . . O
ph+ . . O
leukemia . . O
studies . . O
. . . O

patients . . O
with . . O
tuberculosis . . O
have . . O
frequently . . O
presented . . O
with . . O
disseminated . . O
or . . O
extrapulmonary . . O
disease . . O
. . . O

all . . O
men . . O
were . . O
instructed . . O
to . . O
take . . O
at . . O
least . . O
1000 . . O
mg . . O
of . . O
calcium . . O
and . . O
800 . . O
iu . . O
of . . O
vitamin . . O
d . . O
supplementation . . O
per . . O
day . . O
. . . O

6 . . O
adverse . . O
reactions . . O

immunogenicity . . O
assay . . O
results . . O
are . . O
highly . . O
dependent . . O
on . . O
several . . O
factors . . O
including . . O
assay . . O
sensitivity . . O
and . . O
specificity . . O
, . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

rash . . B-AdverseReaction

cases . . O
of . . O
reactivation . . B-AdverseReaction
of . . I-AdverseReaction
tuberculosis . . I-AdverseReaction
or . . O
new . . O
tuberculosis . . B-AdverseReaction
infections . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
patients . . O
receiving . . O
cimzia . . O
, . . O
including . . O
patients . . O
who . . O
have . . O
previously . . O
received . . O
treatment . . O
for . . O
latent . . O
or . . O
active . . O
tuberculosis . . O
. . . O

in . . O
studies . . O
1 . . O
and . . O
2 . . O
, . . O
serious . . O
adverse . . O
reactions . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
were . . O
reported . . O
in . . O
31% . . O
of . . O
patients . . O
receiving . . O
adcetris . . O
. . . O

multaq . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
nyha . . O
class . . O
iv . . O
heart . . O
failure . . O
or . . O
symptomatic . . O
heart . . O
failure . . O
with . . O
recent . . O
decompensation . . O
requiring . . O
hospitalization . . O
because . . O
it . . O
doubles . . O
the . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
. . . O

the . . O
long . . O
- . . O
term . . O
effects . . O
of . . O
antibodies . . O
to . . O
kalbitor . . O
are . . O
not . . O
known . . O
. . . O

it . . O
should . . O
be . . O
recognized . . O
that . . O
symptoms . . O
of . . O
the . . O
underlying . . O
disease . . O
being . . O
treated . . O
may . . O
be . . O
similar . . O
to . . O
symptoms . . O
of . . O
hypersensitivity . . O
. . . O

established . . O
microvascular . . O
complications . . O
of . . O
diabetes . . O
at . . O
baseline . . O
included . . O
diabetic . . O
nephropathy . . O
( . . O
7% . . O
) . . O
, . . O
retinopathy . . O
( . . O
8% . . O
) . . O
, . . O
or . . O
neuropathy . . O
( . . O
16% . . O
) . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

for . . O
uloric . . O
80 . . O
mg . . O
, . . O
1377 . . O
subjects . . O
were . . O
treated . . O
for . . O
> . . O
= . . O
6 . . O
months . . O
, . . O
674 . . O
patients . . O
were . . O
treated . . O
for . . O
> . . O
= . . O
1 . . O
year . . O
and . . O
515 . . O
patients . . O
were . . O
treated . . O
for . . O
> . . O
= . . O
2 . . O
years . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O

table . . O
1 . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

if . . O
reactivation . . O
occurs . . O
, . . O
stop . . O
simponi . . O
aria . . O
and . . O
begin . . O
anti . . O
- . . O
viral . . O
therapy . . O
( . . O
5.1 . . O
) . . O
. . . O

( . . O
6.1 . . O
) . . O
* . . O
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
- . . O
associated . . O
thrombocytopenia . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
10% . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
were . . O
: . . O
anemia . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
influenza . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
illness . . I-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
chills . . B-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
, . . O
alopecia . . B-AdverseReaction
, . . O
and . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
. . . O

* . . O
are . . O
breastfeeding . . O
or . . O
plan . . O
to . . O
breastfeed . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

additional . . O
safety . . O
information . . O
was . . O
collected . . O
from . . O
clinical . . O
records . . O
submitted . . O
by . . O
treating . . O
physicians . . O
. . . O

[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
. . . O
] . . O

excerpt . . O
: . . O
* . . O
serious . . B-Severity
hypersensitivity . . O
( . . O
anaphylactic . . O
) . . O
reactions . . O
have . . O
been . . O
reported . . O
with . . O
beta . . O
- . . O
lactam . . O
antibacterial . . O
drugs . . O
, . . O
including . . O
teflaro . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

the . . O
table . . O
below . . O
lists . . O
the . . O
adverse . . O
drug . . O
reactions . . O
that . . O
occurred . . O
in . . O
at . . O
least . . O
1% . . O
of . . O
patients . . O
treated . . O
with . . O
ferriprox . . O
in . . O
clinical . . O
trials . . O
. . . O

malignancies . . B-AdverseReaction
, . . O
some . . O
fatal . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
among . . O
children . . O
, . . O
adolescents . . O
, . . O
and . . O
young . . O
adults . . O
who . . O
received . . O
treatment . . O
with . . O
tnf . . O
- . . O
blocking . . O
agents . . O
( . . O
initiation . . O
of . . O
therapy . . O
< . . O
= . . O
18 . . O
years . . O
of . . O
age . . O
) . . O
, . . O
of . . O
which . . O
simponi . . O
aria . . O
is . . O
a . . O
member . . O
. . . O

the . . O
rates . . O
of . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
events . . O
resulting . . O
in . . O
permanent . . O
discontinuation . . O
were . . O
20% . . O
and . . O
6% . . O
for . . O
the . . O
afinitor . . O
and . . O
placebo . . O
treatment . . O
groups . . O
, . . O
respectively . . O
. . . O

do . . O
not . . O
administer . . O
kalbitor . . O
to . . O
patients . . O
with . . O
known . . O
clinical . . O
hypersensitivity . . O

5 . . O
warnings . . O
and . . O
precautions . . O

breo . . O
ellipta . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
the . . O
relief . . O
of . . O
acute . . O
symptoms . . O
and . . O
extra . . O
doses . . O
should . . O
not . . O
be . . O
used . . O
for . . O
that . . O
purpose . . O
. . . O

beta . . B-DrugClass
- . . I-DrugClass
agonist . . I-DrugClass
medications . . I-DrugClass
may . . O
produce . . O
transient . . B-Severity
hyperglycemia . . B-AdverseReaction
in . . O
some . . O
patients . . O
. . . O

none . . O
of . . O
the . . O
patients . . O
tested . . O
positive . . O
for . . O
neutralizing . . O
antibodies . . O
, . . O
as . . O
was . . O
assessed . . O
using . . O
a . . O
chemiluminescent . . O
cell . . O
- . . O
based . . O
in . . O
vitro . . O
biological . . O
assay . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
risk . . B-Factor
for . . O
hepatic . . B-AdverseReaction
decompensation . . I-AdverseReaction
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

the . . O
safety . . O
and . . O
effectiveness . . O
of . . O
horizant . . O
in . . O
patients . . O
with . . O
epilepsy . . O
have . . O
not . . O
been . . O
studied . . O
. . . O

angioedema . . O
. . . O

in . . O
clinical . . O
trials . . O
evaluating . . O
breo . . O
ellipta . . O
in . . O
subjects . . O
with . . O
copd . . O
or . . O
asthma . . O
, . . O
there . . O
was . . O
no . . O
evidence . . O
of . . O
a . . O
treatment . . O
effect . . O
on . . O
serum . . O
glucose . . O
or . . O
potassium . . O
. . . O

table . . O
1 . . O
age . . O
range . . O
drug . . O
- . . O
placebo . . O
difference . . O
in . . O
number . . O
of . . O
cases . . O
of . . O
suicidality . . B-AdverseReaction
per . . O
1,000 . . O
patients . . O
treated . . O
increases . . O
compared . . O
to . . O
placebo . . O
< . . O
18 . . O
14 . . O
additional . . O
cases . . O
18 . . O
to . . O
24 . . O
5 . . O
additional . . O
cases . . O
decreases . . O
compared . . O
to . . O
placebo . . O
25 . . O
to . . O
64 . . O
1 . . O
fewer . . O
case . . O
> . . O
= . . O
65 . . O
6 . . O
fewer . . O
cases . . O
no . . B-Negation
suicides . . B-AdverseReaction
occurred . . O
in . . O
any . . O
of . . O
the . . O
pediatric . . O
studies . . O
. . . O

it . . O
is . . O
important . . O
to . . O
emphasize . . O
that . . O
, . . O
although . . O
the . . O
reactions . . O
reported . . O
occurred . . O
during . . O
treatment . . O
with . . O
fanapt . . O
, . . O
they . . O
were . . O
not . . O
necessarily . . O
caused . . O
by . . O
it . . O
. . . O

these . . O
risks . . O
importantly . . O
may . . O
limit . . O
the . . O
role . . O
of . . O
adreview . . O
in . . O
the . . O
diagnostic . . O
evaluation . . O
of . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
. . . O

there . . O
is . . O
no . . O
experience . . O
with . . O
antifibrinolytic . . O
agents . . O
( . . O
tranexamic . . O
acid . . O
, . . O
aminocaproic . . O
acid . . O
) . . O
in . . O
individuals . . O
receiving . . O
apixaban . . O
. . . O

among . . O
the . . O
477 . . O
patients . . O
in . . O
studies . . O
1 . . O
, . . O
2 . . O
, . . O
and . . O
3 . . O
treated . . O
with . . O
the . . O
nulojix . . O
regimen . . O
of . . O
higher . . O
cumulative . . O
dose . . O
and . . O
more . . O
frequent . . O
dosing . . O
than . . O
recommended . . O
, . . O
there . . O
were . . O
8 . . O
cases . . O
of . . O
ptld . . B-AdverseReaction
: . . O
2 . . O
in . . O
ebv . . O
seropositive . . O
patients . . O
and . . O
6 . . O
in . . O
ebv . . O
seronegative . . O
or . . O
serostatus . . O
unknown . . O
patients . . O
. . . O

increased . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
after . . O
premature . . O
discontinuation . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
? . . O

doses . . O
of . . O
the . . O
related . . O
beta2 . . B-DrugClass
- . . I-DrugClass
agonist . . I-DrugClass
albuterol . . O
, . . O
when . . O
administered . . O
intravenously . . O
, . . O
have . . O
been . . O
reported . . O
to . . O
aggravate . . B-AdverseReaction
pre . . I-AdverseReaction
- . . I-AdverseReaction
existing . . I-AdverseReaction
diabetes . . I-AdverseReaction
mellitus . . I-AdverseReaction
and . . O
ketoacidosis . . O
. . . O

5.3 . . O
radiation . . O
risks . . O

cardiac . . O
disorders . . O
: . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
angina . . B-AdverseReaction
pectoris . . I-AdverseReaction
, . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
following . . O
datscan . . O
administration . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

the . . O
incidence . . O
of . . O
diplopia . . B-AdverseReaction
was . . O
greater . . O
with . . O
the . . O
concomitant . . O
use . . O
of . . O
aptiom . . O
and . . O
carbamazepine . . O
compared . . O
to . . O
the . . O
use . . O
of . . O
aptiom . . O
without . . O
carbamazepine . . O
( . . O
up . . O
to . . O
16% . . O
vs . . O
. . . O
6% . . O
, . . O
respectively . . O
) . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

table . . O
3 . . O
and . . O
table . . O
4 . . O
present . . O
adverse . . O
drug . . O
reactions . . O
and . . O
laboratory . . O
abnormalities . . O
identified . . O
from . . O
analyses . . O
of . . O
trial . . O
1 . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

during . . O
clinical . . O
studies . . O
in . . O
dupuytren's . . O
contracture . . O
and . . O
peyronie's . . O
disease . . O
, . . O
patients . . O
were . . O
tested . . O
at . . O
multiple . . O
time . . O
points . . O
for . . O
antibodies . . O
to . . O
the . . O
protein . . O
components . . O
of . . O
xiaflex . . O
( . . O
aux . . O
- . . O
i . . O
and . . O
aux . . O
- . . O
ii . . O
) . . O
. . . O

management . . O
of . . O
cardiac . . O
failure . . O
may . . O
require . . O
permanent . . O
discontinuation . . O
of . . O
inlyta . . O
. . . O

deaths . . B-AdverseReaction
due . . O
to . . O
causes . . O
other . . O
than . . O
disease . . O
progression . . O
within . . O
30 . . O
days . . O
of . . O
last . . O
study . . O
drug . . O
dose . . O
were . . O
reported . . O
in . . O
18 . . O
( . . O
5% . . O
) . . O
jevtana . . O
- . . O
treated . . O
patients . . O
and . . O
3 . . O
( . . O
< . . O
1% . . O
) . . O
mitoxantrone . . O
- . . O
treated . . O
patients . . O
. . . O

ilaris . . O
should . . O
not . . O
be . . O
administered . . O
to . . O
any . . O
patients . . O
with . . O
known . . O
clinical . . O
hypersensitivity . . O
to . . O
ilaris . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
, . . O
promacta . . O
in . . O
combination . . O
with . . O
interferon . . O
and . . O
ribavirin . . O
may . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
hepatic . . B-AdverseReaction
decompensation . . I-AdverseReaction
. . . O

in . . O
a . . O
3 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
bipolar . . O
i . . O
pediatric . . O
trial . . O
, . . O
the . . O
incidence . . O
of . . O
somnolence . . B-AdverseReaction
( . . O
including . . O
sedation . . B-AdverseReaction
and . . O
hypersomnia . . B-AdverseReaction
) . . O
for . . O
placebo . . O
, . . O
saphris . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
, . . O
5 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
10 . . O
mg . . O
twice . . O
daily . . O
, . . O
was . . O
12% . . O
( . . O
12 . . O
/ . . O
101 . . O
) . . O
, . . O
46% . . O
( . . O
48 . . O
/ . . O
104 . . O
) . . O
, . . O
53% . . O
( . . O
52 . . O
/ . . O
99 . . O
) . . O
, . . O
and . . O
49% . . O
( . . O
49 . . O
/ . . O
99 . . O
) . . O
, . . O
respectively . . O
. . . O

four . . O
placebo . . O
- . . O
controlled . . O
add . . O
- . . O
on . . O
combination . . O
therapy . . O
trials . . O
of . . O
26 . . O
weeks . . O
duration . . O
were . . O
also . . O
conducted . . O
: . . O
with . . O
metformin . . O
, . . O
with . . O
a . . O
sulfonylurea . . O
, . . O
with . . O
a . . O
thiazolidinedione . . O
and . . O
with . . O
insulin . . O
. . . O

the . . O
majority . . O
of . . O
these . . O
immune . . O
- . . O
mediated . . O
reactions . . O
initially . . O
manifested . . O
during . . O
treatment . . O
; . . O
however . . O
, . . O
a . . O
minority . . O
occurred . . O
weeks . . O
to . . O
months . . O
after . . O
discontinuation . . O
of . . O
yervoy . . O
. . . O

number . . O
( . . O
% . . O
) . . O
of . . O
patients . . O
placebon . . O
= . . O
995 . . O
jardiance . . O
10 . . O
mgn . . O
= . . O
999 . . O
jardiance . . O
25 . . O
mgn . . O
= . . O
977 . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
a . . O
7.6% . . O
9.3% . . O
7.6% . . O
female . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
b . . O
1.5% . . O
5.4% . . O
6.4% . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
3.8% . . O
3.1% . . O
4.0% . . O
increased . . B-AdverseReaction
urination . . I-AdverseReaction
c . . O
1.0% . . O
3.4% . . O
3.2% . . O
dyslipidemia . . B-AdverseReaction
3.4% . . O
3.9% . . O
2.9% . . O
arthralgia . . B-AdverseReaction
2.2% . . O
2.4% . . O
2.3% . . O
male . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
d . . O
0.4% . . O
3.1% . . O
1.6% . . O
nausea . . B-AdverseReaction
1.4% . . O
2.3% . . O
1.1% . . O
thirst . . B-AdverseReaction
( . . O
including . . O
polydipsia . . B-AdverseReaction
) . . O
was . . O
reported . . O
in . . O
0% . . O
, . . O
1.7% . . O
, . . O
and . . O
1.5% . . O
for . . O
placebo . . O
, . . O
jardiance . . O
10 . . O
mg . . O
, . . O
and . . O
jardiance . . O
25 . . O
mg . . O
, . . O
respectively . . O
. . . O

grade . . B-Severity
3 . . I-Severity
cutaneous . . B-AdverseReaction
reactions . . I-AdverseReaction
characterized . . O
by . . O
bullous . . O
, . . O
blistering . . O
, . . O
and . . O
exfoliating . . B-AdverseReaction
lesions . . I-AdverseReaction
occurred . . O
in . . O
6 . . O
( . . O
0.15% . . O
) . . O
of . . O
the . . O
3865 . . O
patients . . O
who . . O
received . . O
gilotrif . . O
across . . O
clinical . . O
trials . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

medical . . O
history . . O
of . . O
hypertension . . O
was . . O
balanced . . O
between . . O
arms . . O
. . . O

6 . . O
adverse . . O
reactions . . O

5.9 . . O
macrovascular . . O
outcomes . . O

urinary . . B-AdverseReaction
retention . . I-AdverseReaction
was . . O
reported . . O
as . . O
an . . O
adverse . . O
event . . O
in . . O
29 . . O
of . . O
1,365 . . O
( . . O
approximately . . O
2% . . O
) . . O
patients . . O
treated . . O
with . . O
potiga . . O
in . . O
the . . O
open . . O
- . . O
label . . O
and . . O
placebo . . O
- . . O
controlled . . O
epilepsy . . O
database . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

the . . O
following . . O
serious . . O
reactions . . O
are . . O
described . . O
below . . O
or . . O
elsewhere . . O
in . . O
the . . O
prescribing . . O
information . . O
: . . O

monitor . . O
patients . . O
for . . O
symptoms . . O
of . . O
neuropathy . . O
, . . O
such . . O
as . . O
hypoesthesia . . O
, . . O
hyperesthesia . . O
, . . O
paresthesia . . O
, . . O
discomfort . . O
, . . O
a . . O
burning . . O
sensation . . O
, . . O
neuropathic . . O
pain . . O
, . . O
or . . O
weakness . . O
. . . O

in . . O
addition . . O
to . . O
cases . . O
of . . O
jc . . B-AdverseReaction
virus . . I-AdverseReaction
- . . O
associated . . O
pml . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
, . . O
cases . . O
of . . O
polyoma . . B-AdverseReaction
virus . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
nephropathy . . I-AdverseReaction
( . . O
pvan . . B-AdverseReaction
) . . O
, . . O
mostly . . O
due . . O
to . . O
bk . . B-AdverseReaction
virus . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
. . . O

the . . O
safety . . O
of . . O
prolia . . O
in . . O
the . . O
treatment . . O
of . . O
bone . . O
loss . . O
in . . O
women . . O
with . . O
nonmetastatic . . O
breast . . O
cancer . . O
receiving . . O
aromatase . . O
inhibitor . . O
( . . O
ai . . O
) . . O
therapy . . O
was . . O
assessed . . O
in . . O
a . . O
2 . . O
- . . O
year . . O
, . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
multinational . . O
study . . O
of . . O
252 . . O
postmenopausal . . O
women . . O
aged . . O
35 . . O
to . . O
84 . . O
years . . O
. . . O

monitor . . O
serum . . O
potassium . . O
and . . O
magnesium . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
electrolyte . . O
disturbances . . O
. . . O

5.5 . . O
gastrointestinal . . O
toxicity . . O

5.6 . . O
suicidal . . O
behavior . . O
and . . O
ideation . . O

discontinue . . O
sirturo . . O
if . . O
significant . . O
ventricular . . O
arrhythmia . . O
or . . O
qtcf . . O
interval . . O
> . . O
500 . . O
ms . . O
develops . . O
. . . O

infections . . O
in . . O
study . . O
1 . . O
, . . O
1% . . O
of . . O
patients . . O
treated . . O
with . . O
xtandi . . O
compared . . O
to . . O
0.3% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
died . . B-AdverseReaction
from . . O
infections . . B-AdverseReaction
or . . O
sepsis . . B-AdverseReaction
. . . O

the . . O
median . . O
time . . O
to . . O
onset . . O
of . . O
moderate . . B-Severity
, . . O
severe . . B-Severity
, . . O
or . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
dermatitis . . I-AdverseReaction
was . . O
3.1 . . O
weeks . . O
and . . O
ranged . . O
up . . O
to . . O
17.3 . . O
weeks . . O
from . . O
the . . O
initiation . . O
of . . O
yervoy . . O
. . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
of . . O
pradaxa . . O
were . . O
bleeding . . B-AdverseReaction
and . . O
gastrointestinal . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
dyspepsia . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
abdominal . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
and . . O
diarrhea . . B-AdverseReaction
) . . O
. . . O

cases . . O
of . . O
skin . . B-AdverseReaction
laceration . . I-AdverseReaction
requiring . . O
skin . . O
graft . . O
after . . O
finger . . O
extension . . O
procedures . . O
have . . O
been . . O
reported . . O
post . . O
- . . O
marketing . . O
. . . O

6 . . O
adverse . . O
reactions . . O

of . . O
the . . O
total . . O
population . . O
across . . O
the . . O
three . . O
trials . . O
, . . O
229 . . O
patients . . O
received . . O
a . . O
dose . . O
of . . O
125 . . O
mg . . O
twice . . O
a . . O
day . . O
for . . O
a . . O
mean . . O
duration . . O
of . . O
141 . . O
days . . O
, . . O
69 . . O
patients . . O
received . . O
a . . O
dose . . O
of . . O
250 . . O
mg . . O
twice . . O
a . . O
day . . O
for . . O
a . . O
mean . . O
duration . . O
of . . O
139 . . O
days . . O
, . . O
102 . . O
patients . . O
received . . O
a . . O
dose . . O
of . . O
250 . . O
mg . . O
four . . O
times . . O
a . . O
day . . O
for . . O
a . . O
mean . . O
duration . . O
of . . O
14 . . O
days . . O
, . . O
54 . . O
patients . . O
received . . O
a . . O
dose . . O
of . . O
500 . . O
mg . . O
twice . . O
a . . O
day . . O
for . . O
a . . O
mean . . O
duration . . O
of . . O
146 . . O
days . . O
, . . O
and . . O
242 . . O
patients . . O
received . . O
a . . O
dose . . O
of . . O
500 . . O
mg . . O
four . . O
times . . O
a . . O
day . . O
for . . O
a . . O
mean . . O
duration . . O
of . . O
14 . . O
days . . O
. . . O

this . . O
product . . O
contains . . O
albumin . . O
, . . O
a . . O
derivative . . O
of . . O
human . . O
blood . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
blinded . . O
study . . O
treatment . . O
was . . O
52 . . O
weeks . . O
( . . O
range . . O
24 . . O
to . . O
89 . . O
weeks . . O
) . . O
for . . O
patients . . O
receiving . . O
afinitor . . O
and . . O
47 . . O
weeks . . O
( . . O
range . . O
14 . . O
to . . O
88 . . O
weeks . . O
) . . O
for . . O
those . . O
receiving . . O
placebo . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

the . . O
only . . O
treatment . . O
- . . O
emergent . . O
adr . . O
of . . O
moderate . . B-Severity
to . . O
severe . . B-Severity
intensity . . O
with . . O
at . . O
least . . O
2% . . O
frequency . . O
in . . O
either . . O
treatment . . O
group . . O
was . . O
diarrhea . . B-AdverseReaction
, . . O
2% . . O
( . . O
6 . . O
of . . O
354 . . O
) . . O
in . . O
subjects . . O
receiving . . O
tivicay . . O
50 . . O
mg . . O
once . . O
daily . . O
+ . . O
background . . O
regimen . . O
and . . O
1% . . O
( . . O
5 . . O
of . . O
361 . . O
) . . O
in . . O
subjects . . O
receiving . . O
raltegravir . . O
400 . . O
mg . . O
twice . . O
daily . . O
+ . . O
background . . O
regimen . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

imaging . . O
errors . . O
have . . O
been . . O
reported . . O
with . . O
11 . . O
c . . O
- . . O
choline . . O
pet . . O
and . . O
pet . . O
/ . . O
ct . . O
imaging . . O
. . . O

severe . . O
renal . . O
or . . O
hepatic . . O
failure . . O
may . . O
impair . . O
eovist . . O
imaging . . O
performance . . O
. . . O

congestive . . O
heart . . O
failure . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
reactions . . O
were . . O
copd . . B-AdverseReaction
exacerbation . . I-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
angina . . B-AdverseReaction
pectoris . . I-AdverseReaction
, . . O
and . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
, . . O
which . . O
occurred . . O
at . . O
similar . . O
rates . . O
across . . O
treatment . . O
groups . . O
. . . O

in . . O
clinical . . O
trials . . O
in . . O
hiv . . O
- . . O
1 . . O
infected . . O
adults . . O
, . . O
tenofovir . . O
df . . O
( . . O
a . . O
component . . O
of . . O
stribild . . O
) . . O
was . . O
associated . . O
with . . O
slightly . . O
greater . . O
decreases . . B-AdverseReaction
in . . I-AdverseReaction
bone . . I-AdverseReaction
mineral . . I-AdverseReaction
density . . I-AdverseReaction
( . . O
bmd . . O
) . . O
and . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
biochemical . . I-AdverseReaction
markers . . I-AdverseReaction
of . . I-AdverseReaction
bone . . I-AdverseReaction
metabolism . . I-AdverseReaction
, . . O
suggesting . . O
increased . . B-AdverseReaction
bone . . I-AdverseReaction
turnover . . I-AdverseReaction
relative . . O
to . . O
comparators . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
natazia . . O
. . . O

discontinue . . O
cometriq . . O
in . . O
patients . . O
who . . O
develop . . O
an . . O
acute . . O
myocardial . . O
infarction . . O
or . . O
any . . O
other . . O
clinically . . O
significant . . O
arterial . . O
thromboembolic . . O
complication . . O
. . . O

excerpt . . O
: . . O
* . . O
northera . . O
can . . B-Factor
cause . . O
supine . . B-AdverseReaction
hypertension . . I-AdverseReaction
and . . O
may . . B-Factor
increase . . O
cardiovascular . . B-AdverseReaction
risk . . I-AdverseReaction
if . . O
supine . . B-AdverseReaction
hypertension . . I-AdverseReaction
is . . O
not . . O
well . . O
- . . O
managed . . O
( . . O
5.1 . . O
) . . O
. . . O

in . . O
the . . O
remaining . . O
patients . . O
, . . O
symptoms . . O
resolved . . O
within . . O
3 . . O
to . . O
4 . . O
weeks . . O
. . . O

anyone . . O
considering . . O
prescribing . . O
horizant . . O
must . . O
balance . . O
the . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
with . . O
the . . O
risk . . O
of . . O
untreated . . O
illness . . O
. . . O

in . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
bipolar . . O
adult . . O
mania . . O
trials . . O
, . . O
the . . O
mean . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
transaminase . . I-AdverseReaction
levels . . I-AdverseReaction
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
was . . O
8.9 . . O
units . . O
/ . . O
l . . O
compared . . O
to . . O
a . . O
decrease . . O
of . . O
4.9 . . O
units . . O
/ . . O
l . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

use . . O
inlyta . . O
with . . O
caution . . O
in . . O
patients . . O
who . . O
are . . O
at . . O
risk . . O
for . . O
, . . O
or . . O
who . . O
have . . O
a . . O
history . . O
of . . O
, . . O
these . . O
events . . O
. . . O

patients . . O
with . . O
acute . . O
respiratory . . O
illness . . O
may . . O
be . . O
at . . O
risk . . O
of . . O
serious . . O
acute . . O
exacerbation . . O
of . . O
their . . O
respiratory . . O
compromise . . O
due . . O
to . . O
hypersensitivity . . O
reactions . . O
, . . O
and . . O
require . . O
additional . . O
monitoring . . O
( . . O
5.1 . . O
, . . O
5.2 . . O
, . . O
6 . . O
) . . O
. . . O

* . . O
increased . . B-AdverseReaction
toxicity . . I-AdverseReaction
in . . O
the . . O
presence . . O
of . . O
severe . . O
renal . . O
impairment . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O

nsf . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
fatal . . B-AdverseReaction
or . . O
debilitating . . B-Severity
fibrosis . . B-AdverseReaction
affecting . . O
the . . O
skin . . O
, . . O
muscle . . O
and . . O
internal . . O
organs . . O
. . . O

patients . . O
were . . O
between . . O
the . . O
ages . . O
of . . O
16 . . O
and . . O
63 . . O
on . . O
the . . O
date . . O
of . . O
the . . O
first . . O
dose . . O
of . . O
study . . O
drug . . O
, . . O
and . . O
included . . O
20 . . O
males . . O
and . . O
20 . . O
females . . O
. . . O

there . . O
was . . O
no . . B-Negation
fatal . . B-AdverseReaction
pneumonia . . B-AdverseReaction
in . . O
subjects . . O
receiving . . O
vilanterol . . O
or . . O
fluticasone . . O
furoate . . O
/ . . O
vilanterol . . O
50 . . O
mcg . . O
/ . . O
25 . . O
mcg . . O
. . . O

* . . O
use . . O
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
[ . . O
seeboxed . . O
warningand . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1and5.2 . . O
) . . O
] . . O
* . . O
neuroleptic . . B-AdverseReaction
malignant . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
tardive . . B-AdverseReaction
dyskinesia . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
metabolic . . B-AdverseReaction
changes . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
contraindications . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
and . . O
patient . . O
counseling . . O
information . . O
( . . O
17 . . O
) . . O
] . . O
* . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
including . . O
oral . . O
ulcers . . O
, . . O
blisters . . O
, . . O
peeling . . O
/ . . O
sloughing . . O
and . . O
inflammation . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
* . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
syncope . . B-AdverseReaction
, . . O
and . . O
other . . O
hemodynamic . . B-AdverseReaction
effects . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
leukopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
and . . O
agranulocytosis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
* . . O
qt . . B-AdverseReaction
interval . . I-AdverseReaction
prolongation . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O
* . . O
hyperprolactinemia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.10 . . O
) . . O
] . . O
* . . O
seizures . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.11 . . O
) . . O
] . . O
* . . O
potential . . B-Factor
for . . O
cognitive . . O
and . . O
motor . . B-AdverseReaction
impairment . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.12 . . O
) . . O
] . . O
* . . O
body . . O
temperature . . O
regulation . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.13 . . O
) . . O
] . . O
* . . O
suicide . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.14 . . O
) . . O
] . . O
* . . O
dysphagia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.15 . . O
) . . O
] . . O
* . . O
use . . O
in . . O
patients . . O
with . . O
concomitant . . O
illness . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.16 . . O
) . . O
] . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
and . . O
at . . O
least . . O
twice . . O
the . . O
rate . . O
of . . O
placebo . . O
) . . O
reported . . O
with . . O
acute . . O
treatment . . O
in . . O
adults . . O
with . . O
schizophrenia . . O
were . . O
akathisia . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
, . . O
and . . O
somnolence . . B-AdverseReaction
. . . O

however . . O
, . . O
epidemiological . . O
studies . . O
suggest . . O
an . . O
increased . . O
risk . . O
of . . O
treatment . . O
- . . O
emergent . . O
hyperglycemia . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
the . . O
atypical . . B-DrugClass
antipsychotics . . I-DrugClass
included . . O
in . . O
these . . O
studies . . O
. . . O

of . . O
the . . O
patients . . O
who . . O
reported . . O
neuropathy . . B-AdverseReaction
, . . O
59% . . O
had . . O
complete . . O
resolution . . O
and . . O
41% . . O
had . . O
residual . . B-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
26% . . O
partial . . O
improvement . . O
, . . O
15% . . O
no . . O
improvement . . O
) . . O
at . . O
the . . O
time . . O
of . . O
their . . O
last . . O
evaluation . . O
. . . O

demographic . . O
differences . . O
in . . O
adverse . . O
reactions . . O
in . . O
clinical . . O
trials . . O

* . . O
119 . . O
patients . . O
with . . O
cp . . O
cml . . O
previously . . O
treated . . O
with . . O
both . . O
imatinib . . O
and . . O
at . . O
least . . O
1 . . O
additional . . O
tki . . O
who . . O
had . . O
a . . O
median . . O
duration . . O
of . . O
bosulif . . O
treatment . . O
of . . O
9 . . O
months . . O
and . . O
a . . O
median . . O
dose . . O
intensity . . O
of . . O
475 . . O
mg . . O
/ . . O
day . . O
. . . O

discontinue . . O
trametinib . . O
if . . O
no . . O
improvement . . O
after . . O
3 . . O
weeks . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

( . . O
5.2,5.3 . . O
) . . O
* . . O
hemorrhagic . . B-AdverseReaction
events . . I-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
events . . O
, . . O
have . . O
been . . O
reported . . O
. . . O

* . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
and . . O
eosinophilic . . B-AdverseReaction
pneumonia . . I-AdverseReaction
: . . O
can . . O
occur . . O
( . . O
5.10 . . O
) . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
- . . O
musculoskeletal . . B-AdverseReaction
stiffness . . I-AdverseReaction
. . . O

based . . O
on . . O
effective . . O
donor . . O
screening . . O
and . . O
product . . O
manufacturing . . O
processes . . O
, . . O
it . . O
carries . . O
an . . O
extremely . . O
remote . . O
risk . . B-Factor
for . . O
transmission . . O
of . . O
viral . . B-AdverseReaction
diseases . . I-AdverseReaction
. . . O

bepreve . . O
should . . O
not . . O
be . . O
used . . O
to . . O
treat . . O
contact . . O
lens . . O
- . . O
related . . O
irritation . . O
. . . O

prescribers . . O
should . . O
advise . . O
patients . . O
against . . O
engaging . . O
in . . O
hazardous . . O
activities . . O
requiring . . O
mental . . O
alertness . . O
, . . O
such . . O
as . . O
operating . . O
motor . . O
vehicles . . O
or . . O
dangerous . . O
machinery . . O
, . . O
until . . O
the . . O
effect . . O
of . . O
aptiom . . O
is . . O
known . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
: . . O
cases . . O
of . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
( . . O
including . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
) . . O
, . . O
some . . O
with . . O
a . . O
fatal . . B-AdverseReaction
outcome . . O
, . . O
have . . O
been . . O
observed . . O
. . . O

* . . O
hypersensitivity . . B-AdverseReaction
reactions . . O
: . . O
discontinue . . O
trulicity . . O
if . . O
suspected . . O
. . . O

eight . . O
patients . . O
had . . O
a . . O
new . . O
cytogenetic . . B-AdverseReaction
abnormality . . I-AdverseReaction
reported . . O
on . . O
therapy . . O
, . . O
including . . O
5 . . O
patients . . O
who . . O
had . . O
complex . . O
changes . . B-AdverseReaction
in . . I-AdverseReaction
chromosome . . I-AdverseReaction
7 . . I-AdverseReaction
. . . O

antiemetic . . O
prophylaxis . . O
is . . O
recommended . . O
. . . O

table . . O
7 . . O
: . . O
percentage . . O
of . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactions . . O
in . . O
short . . O
- . . O
term . . O
, . . O
fixed . . O
- . . O
or . . O
flexible . . O
- . . O
dose . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
in . . O
adult . . O
patients . . O
* . . O
body . . O
system . . O
or . . O
organ . . O
class . . O
placebo . . O
( . . O
% . . O
) . . O
fanapt . . O
10-16 . . O
mg . . O
/ . . O
day . . O
( . . O
% . . O
) . . O
fanapt . . O
20-24 . . O
mg . . O
/ . . O
day . . O
( . . O
% . . O
) . . O
dictionary . . O
- . . O
derived . . O
term . . O
( . . O
n . . O
= . . O
587 . . O
) . . O
( . . O
n . . O
= . . O
483 . . O
) . . O
( . . O
n . . O
= . . O
391 . . O
) . . O
body . . O
as . . O
a . . O
whole . . O
arthralgia . . B-AdverseReaction
2 . . O
3 . . O
3 . . O
fatigue . . B-AdverseReaction
3 . . O
4 . . O
6 . . O
musculoskeletal . . B-AdverseReaction
stiffness . . I-AdverseReaction
1 . . O
1 . . O
3 . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
1 . . O
1 . . O
9 . . O
cardiac . . O
disorders . . O
tachycardia . . B-AdverseReaction
1 . . O
3 . . O
12 . . O
eye . . O
disorders . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
2 . . O
3 . . O
1 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
8 . . O
7 . . O
10 . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
1 . . O
8 . . O
10 . . O
diarrhea . . B-AdverseReaction
4 . . O
5 . . O
7 . . O
abdominal . . B-AdverseReaction
discomfort . . I-AdverseReaction
1 . . O
1 . . O
3 . . O
infections . . O
nasopharyngitis . . B-AdverseReaction
3 . . O
4 . . O
3 . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
1 . . O
2 . . O
3 . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
7 . . O
10 . . O
20 . . O
somnolence . . B-AdverseReaction
5 . . O
9 . . O
15 . . O
extrapyramidal . . B-AdverseReaction
disorder . . I-AdverseReaction
4 . . O
5 . . O
4 . . O
tremor . . B-AdverseReaction
2 . . O
3 . . O
3 . . O
lethargy . . B-AdverseReaction
1 . . O
3 . . O
1 . . O
reproductive . . O
system . . O
ejaculation . . B-AdverseReaction
failure . . I-AdverseReaction
< . . O
1 . . O
2 . . O
2 . . O
respiratory . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
2 . . O
5 . . O
8 . . O
dyspnea . . B-AdverseReaction
< . . O
1 . . O
2 . . O
2 . . O
skin . . O
rash . . B-AdverseReaction
2 . . O
3 . . O
2 . . O
vascular . . O
disorders . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
1 . . O
3 . . O
5 . . O
hypotension . . B-AdverseReaction
< . . O
1 . . O
< . . O
1 . . O
3 . . O
* . . O
table . . O
includes . . O
adverse . . O
reactions . . O
that . . O
were . . O
reported . . O
in . . O
2% . . O
or . . O
more . . O
of . . O
patients . . O
in . . O
any . . O
of . . O
the . . O
fanapt . . O
dose . . O
groups . . O
and . . O
which . . O
occurred . . O
at . . O
greater . . O
incidence . . O
than . . O
in . . O
the . . O
placebo . . O
- . . O
group . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

there . . O
have . . O
been . . O
postmarketing . . O
reports . . O
of . . O
acute . . B-AdverseReaction
pancreatitis . . I-AdverseReaction
in . . O
patients . . O
taking . . O
nesina . . O
. . . O

the . . O
reactions . . O
listed . . O
are . . O
those . . O
that . . O
could . . O
be . . O
of . . O
clinical . . O
importance . . O
, . . O
as . . O
well . . O
as . . O
reactions . . O
that . . O
are . . O
plausibly . . O
drug . . O
- . . O
related . . O
on . . O
pharmacologic . . O
or . . O
other . . O
grounds . . O
. . . O

the . . O
adverse . . O
events . . O
in . . O
the . . O
first . . O
12 . . O
cycles . . O
of . . O
therapy . . O
that . . O
occurred . . O
at . . O
a . . O
rate . . O
of . . O
10% . . O
or . . O
greater . . O
in . . O
the . . O
krd . . O
arm . . O
are . . O
presented . . O
in . . O
table . . O
5 . . O
. . . O

5.12 . . O
hepatic . . O
impairment . . O

elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
treated . . O
with . . O
antipsychotic . . B-DrugClass
drugs . . I-DrugClass
are . . O
at . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
. . . O

some . . O
patients . . O
( . . O
13% . . O
) . . O
received . . O
premedication . . O
, . . O
which . . O
may . . O
have . . O
mitigated . . O
or . . O
masked . . O
a . . O
hypersensitivity . . O
response . . O
; . . O
however . . O
, . . O
there . . O
is . . O
insufficient . . O
evidence . . O
to . . O
determine . . O
whether . . O
premedication . . O
diminishes . . O
the . . O
frequency . . O
or . . O
severity . . O
of . . O
hypersensitivity . . O
reactions . . O
. . . O

in . . O
a . . O
3 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
pediatric . . O
trial . . O
with . . O
bipolar . . O
i . . O
disorder . . O
, . . O
the . . O
mean . . O
increases . . O
( . . O
at . . O
endpoint . . O
) . . O
in . . O
prolactin . . O
levels . . O
were . . O
3.2 . . O
ng . . O
/ . . O
ml . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
, . . O
2.1 . . O
ng . . O
/ . . O
ml . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
5 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
6.4 . . O
ng . . O
/ . . O
ml . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
10 . . O
mg . . O
twice . . O
daily . . O
compared . . O
to . . O
an . . O
increase . . O
of . . O
2.5 . . O
ng . . O
/ . . O
ml . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

one . . O
of . . O
the . . O
476 . . O
patients . . O
treated . . O
with . . O
cyclosporine . . O
developed . . O
ptld . . B-AdverseReaction
, . . O
without . . O
cns . . O
involvement . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
arterial . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
have . . O
been . . O
reported . . O
, . . O
including . . O
deaths . . B-AdverseReaction
. . . O

5.14 . . O
other . . O
conditions . . O

the . . O
incidence . . O
of . . O
new . . B-AdverseReaction
- . . I-AdverseReaction
onset . . I-AdverseReaction
diabetes . . I-AdverseReaction
after . . I-AdverseReaction
transplantation . . I-AdverseReaction
( . . O
nodat . . B-AdverseReaction
) . . O
was . . O
defined . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
as . . O
use . . O
of . . O
an . . O
antidiabetic . . O
agent . . O
for . . O
> . . O
= . . O
30 . . O
days . . O
or . . O
> . . O
= . . O
2 . . O
fasting . . O
plasma . . O
glucose . . O
values . . O
> . . O
= . . O
126 . . O
mg . . O
/ . . O
dl . . O
( . . O
7.0 . . O
mmol . . O
/ . . O
l . . O
) . . O
post . . O
- . . O
transplantation . . O
. . . O

adverse . . O
reactions . . O
pooled . . O
phase . . O
3 . . O
clinical . . O
trials . . O
( . . O
four . . O
trials . . O
, . . O
two . . O
in . . O
absssi . . O
and . . O
two . . O
in . . O
cabp . . O
) . . O
teflaro . . O
( . . O
n . . O
= . . O
1300 . . O
) . . O
pooled . . O
comparators . . O
a . . O
( . . O
n . . O
= . . O
1297 . . O
) . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
5 . . O
% . . O
3 . . O
% . . O
nausea . . B-AdverseReaction
4 . . O
% . . O
4 . . O
% . . O
constipation . . B-AdverseReaction
2 . . O
% . . O
2 . . O
% . . O
vomiting . . B-AdverseReaction
2 . . O
% . . O
2 . . O
% . . O
laboratory . . O
investigations . . O
increased . . B-AdverseReaction
transaminases . . I-AdverseReaction
2% . . O
3 . . O
% . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
hypokalemia . . B-AdverseReaction
2 . . O
% . . O
3 . . O
% . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
3% . . O
2% . . O
vascular . . O
disorders . . O
phlebitis . . B-AdverseReaction
2% . . O
1% . . O
other . . O
adverse . . O
reactions . . O
observed . . O
during . . O
clinical . . O
trials . . O
of . . O
teflaro . . O

all . . O
patients . . O
were . . O
naive . . O
to . . O
enzyme . . O
replacement . . O
therapy . . O
. . . O

more . . O
patients . . O
experienced . . O
these . . O
events . . O
during . . O
pristiq . . O
treatment . . O
as . . O
compared . . O
to . . O
placebo . . O
. . . O

febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
treatment . . O
with . . O
adcetris . . O
. . . O

study . . O
2 . . O
enrolled . . O
patients . . O
with . . O
a . . O
median . . O
age . . O
of . . O
17 . . O
years . . O
( . . O
6 . . O
months . . O
to . . O
85 . . O
years . . O
) . . O
; . . O
64% . . O
were . . O
male . . O
, . . O
and . . O
the . . O
underlying . . O
malignancies . . O
were . . O
osteogenic . . O
sarcoma . . O
in . . O
32% . . O
, . . O
and . . O
leukemia . . O
or . . O
lymphoma . . O
in . . O
62% . . O
of . . O
patients . . O
. . . O

discontinue . . O
erwinaze . . O
for . . O
a . . O
thrombotic . . O
or . . O
hemorrhagic . . O
event . . O
until . . O
symptoms . . O
resolve . . O
; . . O
after . . O
resolution . . O
, . . O
treatment . . O
with . . O
erwinaze . . O
may . . O
be . . O
resumed . . O
. . . O

perform . . O
appropriate . . O
monitoring . . O
and . . O
treat . . O
hyperglycemia . . O
with . . O
insulin . . O
, . . O
as . . O
necessary . . O
( . . O
5.3 . . O
) . . O
* . . O
thrombosis . . B-AdverseReaction
, . . O
hemorrhage . . B-AdverseReaction
: . . O
discontinue . . O
erwinaze . . O
until . . O
resolved . . O
( . . O
5.4 . . O
) . . O
5.1 . . O
hypersensitivity . . O
reactions . . O

adverse . . O
reactions . . O
of . . O
sinus . . B-AdverseReaction
tachycardia . . I-AdverseReaction
were . . O
reported . . O
more . . O
frequently . . O
in . . O
patients . . O
exposed . . O
to . . O
trulicity . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
arthritis . . B-AdverseReaction
, . . O
joint . . B-AdverseReaction
stiffness . . I-AdverseReaction
, . . O
joint . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
/ . . O
twitching . . O
/ . . O
tightness . . O
/ . . O
weakness . . O
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
/ . . O
stiffness . . O
, . . O
myalgia . . B-AdverseReaction
. . . O

dysphagia . . B-AdverseReaction
was . . O
reported . . O
in . . O
0.2% . . O
and . . O
0% . . O
( . . O
1 . . O
/ . . O
572 . . O
, . . O
0 . . O
/ . . O
379 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
therapeutic . . O
doses . . O
( . . O
5-10 . . O
mg . . O
twice . . O
daily . . O
) . . O
of . . O
saphris . . O
as . . O
compared . . O
to . . O
0% . . O
( . . O
0 . . O
/ . . O
378 . . O
, . . O
0 . . O
/ . . O
203 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
in . . O
short . . O
- . . O
term . . O
schizophrenia . . O
and . . O
bipolar . . O
mania . . O
adult . . O
trials . . O
, . . O
respectively . . O
. . . O

in . . O
the . . O
single . . O
- . . O
arm . . O
phase . . O
1 . . O
/ . . O
2 . . O
clinical . . O
trial . . O
in . . O
546 . . O
patients . . O
with . . O
cml . . O
treated . . O
with . . O
prior . . O
therapy . . O
, . . O
severe . . B-Severity
fluid . . B-AdverseReaction
retention . . I-AdverseReaction
was . . O
reported . . O
in . . O
14 . . O
patients . . O
( . . O
3% . . O
) . . O
. . . O

the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
( . . O
occurring . . O
in . . O
at . . O
least . . O
1% . . O
of . . O
subjects . . O
) . . O
in . . O
vizamyl . . O
- . . O
treated . . O
subjects . . O
are . . O
shown . . O
in . . O
table . . O
2 . . O
. . . O

d . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
lower . . I-AdverseReaction
, . . O
and . . O
abdominal . . B-AdverseReaction
discomfort . . I-AdverseReaction
. . . O

discontinue . . O
cometriq . . O
for . . O
perforation . . O
or . . O
for . . O
fistula . . O
formation . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

at . . O
month . . O
1 . . O
after . . O
transplantation . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
, . . O
the . . O
frequency . . O
of . . O
2+ . . O
proteinuria . . B-AdverseReaction
on . . O
urine . . O
dipstick . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
was . . O
33% . . O
( . . O
130 . . O
/ . . O
390 . . O
) . . O
and . . O
28% . . O
( . . O
107 . . O
/ . . O
384 . . O
) . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
cyclosporine . . O
control . . O
regimen . . O
. . . O

dizziness . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
and . . O
fatigue . . B-AdverseReaction
were . . O
all . . O
reported . . O
at . . O
lower . . O
incidences . . O
during . . O
the . . O
aed . . O
withdrawal . . O
phase . . O
and . . O
monotherapy . . O
phase . . O
compared . . O
with . . O
the . . O
titration . . O
phase . . O
. . . O

in . . O
the . . O
controlled . . O
phase . . O
of . . O
trial . . O
1 . . O
, . . O
through . . O
week . . O
24 . . O
, . . O
alt . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
5 . . B-Severity
* . . I-Severity
uln . . I-Severity
occurred . . O
in . . O
0.8% . . O
of . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
and . . O
0% . . O
of . . O
control . . O
- . . O
treated . . O
patients . . O
and . . O
alt . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
3 . . B-Severity
* . . I-Severity
uln . . I-Severity
occurred . . O
in . . O
2.3% . . O
of . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
and . . O
2.5% . . O
of . . O
control . . O
- . . O
treated . . O
patients . . O
. . . O

keep . . O
out . . O
of . . O
reach . . O
of . . O
children . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
risk . . B-Factor
of . . O
anaphylaxis . . B-AdverseReaction

all . . O
patients . . O
taking . . O
potiga . . O
should . . O
have . . O
baseline . . O
and . . O
periodic . . O
( . . O
every . . O
6 . . O
months . . O
) . . O
systematic . . O
visual . . O
monitoring . . O
by . . O
an . . O
ophthalmic . . O
professional . . O
. . . O

table . . O
5 . . O
. . . O

avoid . . O
using . . O
zykadia . . O
in . . O
combination . . O
with . . O
other . . O
agents . . O
known . . O
to . . O
cause . . O
bradycardia . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
beta . . O
- . . O
blockers . . O
, . . O
non . . O
- . . O
dihydropyridine . . O
calcium . . O
channel . . O
blockers . . O
, . . O
clonidine . . O
, . . O
and . . O
digoxin . . O
) . . O
to . . O
the . . O
extent . . O
possible . . O
. . . O

in . . O
the . . O
case . . O
of . . O
persistent . . O
hypertension . . O
despite . . O
use . . O
of . . O
anti . . O
- . . O
hypertensive . . O
medications . . O
, . . O
reduce . . O
the . . O
inlyta . . O
dose . . O
. . . O

* . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
can . . B-Factor
occur . . O
with . . O
sirturo . . O
. . . O

rped . . B-AdverseReaction
occurred . . O
in . . O
2% . . O
( . . O
1 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

the . . O
use . . O
of . . O
corticosteroids . . O
may . . O
be . . O
indicated . . B-Factor
. . . O

withhold . . O
tafinlar . . O
for . . O
grade . . O
3 . . O
hemorrhagic . . O
events . . O
; . . O
if . . O
improved . . O
resume . . O
at . . O
a . . O
lower . . O
dose . . O
level . . O
. . . O

male . . O
patients . . O
who . . O
developed . . O
genital . . O
mycotic . . O
infections . . O
on . . O
invokana . . O
were . . O
more . . O
likely . . O
to . . O
experience . . O
recurrent . . O
infections . . O
( . . O
22% . . O
on . . O
invokana . . O
versus . . O
none . . O
on . . O
placebo . . O
) . . O
, . . O
and . . O
require . . O
treatment . . O
with . . O
oral . . O
or . . O
topical . . O
antifungal . . O
agents . . O
and . . O
anti . . O
- . . O
microbial . . O
agents . . O
than . . O
patients . . O
on . . O
comparators . . O
. . . O

the . . O
usefulness . . O
of . . O
hemodialysis . . O
in . . O
the . . O
prevention . . O
of . . O
nsf . . O
is . . O
unknown . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12 . . O
) . . O
] . . O
. . . O

if . . O
pathology . . O
and . . O
pregnancy . . O
are . . O
excluded . . O
, . . O
bleeding . . O
irregularities . . O
may . . O
resolve . . O
over . . O
time . . O
or . . O
with . . O
a . . O
change . . O
to . . O
a . . O
different . . O
coc . . O
. . . O

( . . O
n . . O
= . . O
134 . . O
) . . O
40 . . O
mg . . O
daily . . O
( . . O
n . . O
= . . O
757 . . O
) . . O
80 . . O
mg . . O
daily . . O
( . . O
n . . O
= . . O
1279 . . O
) . . O
( . . O
n . . O
= . . O
1277 . . O
) . . O
liver . . B-AdverseReaction
function . . I-AdverseReaction
abnormalities . . I-AdverseReaction
0.7% . . O
6.6% . . O
4.6% . . O
4.2% . . O
nausea . . B-AdverseReaction
0.7% . . O
1.1% . . O
1.3% . . O
0.8% . . O
arthralgia . . B-AdverseReaction
0% . . O
1.1% . . O
0.7% . . O
0.7% . . O
rash . . B-AdverseReaction
0.7% . . O
0.5% . . O
1.6% . . O
1.6% . . O
the . . O
most . . O
common . . O
adverse . . O
reaction . . O
leading . . O
to . . O
discontinuation . . O
from . . O
therapy . . O
was . . O
liver . . B-AdverseReaction
function . . I-AdverseReaction
abnormalities . . I-AdverseReaction
in . . O
1.8% . . O
of . . O
uloric . . O
40 . . O
mg . . O
, . . O
1.2% . . O
of . . O
uloric . . O
80 . . O
mg . . O
, . . O
and . . O
in . . O
0.9% . . O
of . . O
allopurinol . . O
- . . O
treated . . O
subjects . . O
. . . O

table . . O
5 . . O
: . . O
incidence . . O
of . . O
majormajor . . O
episodes . . O
of . . O
hypoglycemia . . B-AdverseReaction
were . . O
defined . . O
as . . O
symptomatic . . O
episodes . . O
requiring . . O
external . . O
( . . O
third . . O
party . . O
) . . O
assistance . . O
due . . O
to . . O
severe . . B-Severity
impairment . . B-AdverseReaction
in . . I-AdverseReaction
consciousness . . I-AdverseReaction
or . . O
behavior . . O
with . . O
a . . O
capillary . . O
or . . O
plasma . . B-AdverseReaction
glucose . . I-AdverseReaction
value . . I-AdverseReaction
< . . I-AdverseReaction
54 . . I-AdverseReaction
mg . . I-AdverseReaction
/ . . I-AdverseReaction
dl . . I-AdverseReaction
and . . O
prompt . . O
recovery . . O
after . . O
glucose . . O
or . . O
glucagon . . O
administration . . O
. . . O
and . . O
minorminor . . O
episodes . . O
of . . O
hypoglycemia . . B-AdverseReaction
were . . O
defined . . O
as . . O
either . . O
a . . O
symptomatic . . O
episode . . O
with . . O
a . . O
capillary . . O
or . . O
plasma . . B-AdverseReaction
glucose . . I-AdverseReaction
measurement . . I-AdverseReaction
< . . I-AdverseReaction
63 . . I-AdverseReaction
mg . . I-AdverseReaction
/ . . I-AdverseReaction
dl . . I-AdverseReaction
regardless . . O
of . . O
need . . O
for . . O
external . . O
assistance . . O
, . . O
or . . O
an . . O
asymptomatic . . O
capillary . . O
or . . O
plasma . . B-AdverseReaction
glucose . . I-AdverseReaction
measurement . . I-AdverseReaction
< . . I-AdverseReaction
63 . . I-AdverseReaction
mg . . I-AdverseReaction
/ . . I-AdverseReaction
dl . . I-AdverseReaction
that . . O
does . . O
not . . O
qualify . . O
as . . O
a . . O
major . . O
episode . . O
. . . O

cleviprex . . O
was . . O
infused . . O
for . . O
< . . O
24 . . O
hours . . O
in . . O
the . . O
majority . . O
of . . O
patients . . O
( . . O
n . . O
= . . O
1199 . . O
) . . O
; . . O
it . . O
was . . O
infused . . O
as . . O
a . . O
continuous . . O
infusion . . O
in . . O
an . . O
additional . . O
93 . . O
patients . . O
for . . O
durations . . O
between . . O
24 . . O
and . . O
72 . . O
hours . . O
. . . O

study . . O
1 . . O
enrolled . . O
1195 . . O
patients . . O
with . . O
metastatic . . O
crpc . . O
who . . O
had . . O
received . . O
prior . . O
docetaxel . . O
chemotherapy . . O
. . . O

utis . . O
in . . O
ampyra . . O
- . . O
treated . . O
patients . . O
should . . O
be . . O
evaluated . . O
and . . O
treated . . O
as . . O
clinically . . O
indicated . . O
. . . O

in . . O
some . . O
patients . . O
, . . O
concomitant . . O
use . . O
of . . O
these . . O
two . . O
drug . . O
classes . . O
can . . B-Factor
lower . . O
blood . . O
pressure . . O
significantly . . O
leading . . O
to . . O
symptomatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
dizziness . . B-AdverseReaction
, . . O
lightheadedness . . B-AdverseReaction
, . . O
fainting . . B-AdverseReaction
) . . O
. . . O

( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . O
hematoma . . O
: . . O
epidural . . O
or . . O
spinal . . B-AdverseReaction
hematomas . . I-AdverseReaction
may . . B-Factor
occur . . O
in . . O
patients . . O
treated . . O
with . . O
eliquis . . O
who . . O
are . . O
receiving . . O
neuraxial . . O
anesthesia . . O
or . . O
undergoing . . O
spinal . . O
puncture . . O
. . . O

as . . O
with . . O
other . . O
inhaled . . O
beta2 . . O
- . . O
agonists . . O
, . . O
arcapta . . O
neohaler . . O
may . . B-Factor
produce . . O
paradoxical . . B-AdverseReaction
bronchospasm . . I-AdverseReaction
that . . O
may . . O
be . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
. . . O

one . . O
patient . . O
with . . O
a . . O
history . . O
of . . O
wolff . . O
- . . O
parkinson . . O
- . . O
white . . O
syndrome . . O
experienced . . O
a . . O
serious . . O
adverse . . O
reaction . . O
of . . O
supraventricular . . B-AdverseReaction
tachycardia . . I-AdverseReaction
. . . O

the . . O
following . . O
additional . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
less . . O
than . . O
10% . . O
of . . O
afinitor . . O
- . . O
treated . . O
patients . . O
: . . O
epistaxis . . B-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
otitis . . B-AdverseReaction
media . . I-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
depression . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
abnormal . . B-AdverseReaction
taste . . I-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
increased . . O
blood . . O
luteinizing . . O
hormone . . O
( . . O
lh . . O
) . . O
levels . . O
( . . O
4% . . O
) . . O
, . . O
increased . . O
blood . . O
follicle . . O
stimulating . . O
hormone . . O
( . . O
fsh . . O
) . . O
levels . . O
( . . O
3% . . O
) . . O
, . . O
hypersensitivity . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
ovarian . . B-AdverseReaction
cyst . . I-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
pneumonitis . . B-AdverseReaction
( . . O
1% . . O
) . . O
, . . O
and . . O
angioedema . . B-AdverseReaction
( . . O
1% . . O
) . . O
. . . O

5.5 . . O
metabolic . . O
changes . . O

dermatologic . . O
reactions . . O
epidermal . . O
and . . O
dermal . . B-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
such . . O
as . . O
dermatitis . . B-AdverseReaction
, . . O
eczema . . B-AdverseReaction
, . . O
and . . O
rashes . . B-AdverseReaction
) . . O
were . . O
reported . . O
in . . O
4 . . O
patients . . O
( . . O
3.3% . . O
) . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
5 . . O
patients . . O
( . . O
4.2% . . O
) . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

elevating . . O
the . . O
head . . O
of . . O
the . . O
bed . . O
lessens . . O
the . . O
risk . . O
of . . O
supine . . O
hypertension . . O
, . . O
and . . O
blood . . O
pressure . . O
should . . O
be . . O
measured . . O
in . . O
this . . O
position . . O
. . . O

initiation . . O
of . . O
eliquis . . O
is . . O
not . . O
recommended . . O
as . . O
an . . O
alternative . . O
to . . O
unfractionated . . O
heparin . . O
for . . O
the . . O
initial . . O
treatment . . O
of . . O
patients . . O
with . . O
pe . . O
who . . O
present . . O
with . . O
hemodynamic . . O
instability . . O
or . . O
who . . O
may . . O
receive . . O
thrombolysis . . O
or . . O
pulmonary . . O
embolectomy . . O
. . . O

vascular . . O
disorders . . O
: . . O
hypertension . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
( . . O
< . . O
1% . . O
) . . O

table . . O
7 . . O
: . . O
most . . O
commonly . . O
reported . . O
adverse . . O
events . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
with . . O
kyprolis . . O
monotherapy . . O
a . . O
pneumonia . . B-AdverseReaction
includes . . O
the . . O
preferred . . O
terms . . O
of . . O
pneumonia . . B-AdverseReaction
, . . O
bronchopneumonia . . B-AdverseReaction
. . . O
b . . O
peripheral . . B-AdverseReaction
neuropathies . . I-AdverseReaction
nec . . I-AdverseReaction
includes . . O
the . . O
preferred . . O
terms . . O
under . . O
hlt . . O
peripheral . . B-AdverseReaction
neuropathies . . I-AdverseReaction
nec . . I-AdverseReaction
. . . O
c . . O
dyspnea . . B-AdverseReaction
includes . . O
the . . O
preferred . . O
terms . . O
of . . O
dyspnea . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
exertional . . I-AdverseReaction
. . . O
d . . O
hypertension . . B-AdverseReaction
includes . . O
the . . O
preferred . . O
terms . . O
of . . O
hypertension . . B-AdverseReaction
, . . O
hypertensive . . B-AdverseReaction
crisis . . I-AdverseReaction
, . . O
and . . O
hypertensive . . B-AdverseReaction
emergency . . I-AdverseReaction
. . . O

causes . . O
of . . O
death . . B-AdverseReaction
on . . O
the . . O
afinitor . . O
arm . . O
included . . O
one . . O
case . . O
of . . O
each . . O
of . . O
the . . O
following . . O
: . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
death . . B-AdverseReaction
( . . O
cause . . O
unknown . . O
) . . O
, . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
and . . O
sepsis . . B-AdverseReaction
. . . O

lenses . . O
may . . O
be . . O
reinserted . . O
after . . O
10 . . O
minutes . . O
following . . O
administration . . O
of . . O
bepreve . . O
. . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
hypertension . . B-AdverseReaction
was . . O
reported . . O
in . . O
145 . . O
/ . . O
359 . . O
patients . . O
( . . O
40% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
103 . . O
/ . . O
355 . . O
patients . . O
( . . O
29% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

patients . . O
should . . O
be . . O
instructed . . O
to . . O
discontinue . . O
tecfidera . . O
and . . O
seek . . O
immediate . . O
medical . . O
care . . O
should . . O
they . . O
experience . . O
signs . . O
and . . O
symptoms . . O
of . . O
anaphylaxis . . O
or . . O
angioedema . . O
. . . O

excerpt . . O
: . . O
use . . O
of . . O
victrelis . . O
with . . O
ribavirin . . O
and . . O
peginterferon . . O
alfa . . O
: . . O

twenty . . O
- . . O
two . . O
percent . . O
( . . O
109 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
developed . . O
a . . O
new . . O
or . . O
worsening . . O
neuropathy . . B-AdverseReaction
that . . O
had . . O
not . . O
recovered . . O
within . . O
a . . O
median . . O
follow . . O
- . . O
up . . O
duration . . O
of . . O
269 . . O
days . . O
( . . O
range . . O
25-662 . . O
days . . O
) . . O
. . . O

5.3 . . O
hypoglycemia . . O
with . . O
concomitant . . O
use . . O
with . . O
insulin . . O
and . . O
insulin . . O
secretagogues . . O

excerpt . . O
: . . O
* . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
: . . O
monitor . . O
patients . . O
for . . O
neuropathy . . O
and . . O
institute . . O
dose . . O
modifications . . O
accordingly . . O
( . . O
5.1 . . O
) . . O
. . . O

table . . O
1 . . O
: . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactionsincludes . . O
adverse . . O
reactions . . O
at . . O
least . . O
possibly . . O
, . . O
probably . . O
, . . O
or . . O
very . . O
likely . . O
related . . O
to . . O
the . . O
drug . . O
. . . O
of . . O
at . . O
least . . O
moderate . . O
intensityintensities . . O
are . . O
defined . . O
as . . O
follows . . O
: . . O
moderate . . O
( . . O
discomfort . . O
enough . . O
to . . O
cause . . O
interference . . O
with . . O
usual . . O
activity . . O
) . . O
; . . O
severe . . O
( . . O
incapacitating . . O
with . . O
inability . . O
to . . O
work . . O
or . . O
do . . O
usual . . O
activity . . O
) . . O
. . . O

6 . . O
adverse . . O
reactions . . O

( . . O
5.6 . . O
) . . O
* . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
: . . O
dizziness . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
and . . O
syncope . . B-AdverseReaction
can . . B-Factor
occur . . O
with . . O
standing . . O
. . . O

common . . O
adverse . . O
events . . O
( . . O
> . . O
= . . O
5% . . O
in . . O
any . . O
xeomin . . O
treatment . . O
group . . O
) . . O
observed . . O
in . . O
patients . . O
who . . O
received . . O
xeomin . . O
( . . O
120 . . O
units . . O
or . . O
240 . . O
units . . O
) . . O
included . . O
dysphagia . . B-AdverseReaction
, . . O
neck . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
muscle . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
approval . . O
use . . O
of . . O
prolia . . O
: . . O

titration . . O
was . . O
used . . O
over . . O
the . . O
first . . O
5 . . O
days . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

includes . . O
13 . . O
subjects . . O
with . . O
major . . B-Severity
bleeding . . B-AdverseReaction
events . . O
that . . O
occurred . . O
before . . B-Negation
the . . I-Negation
first . . I-Negation
dose . . I-Negation
of . . O
apixaban . . O
( . . O
administered . . O
12 . . O
to . . O
24 . . O
hours . . O
post . . O
surgery . . O
) . . O
. . . O
? . . O

the . . O
overall . . O
trial . . O
population . . O
had . . O
a . . O
median . . O
age . . O
of . . O
61 . . O
years . . O
; . . O
61% . . O
of . . O
patients . . O
in . . O
the . . O
gilotrif . . O
arm . . O
and . . O
60% . . O
of . . O
patients . . O
in . . O
the . . O
pemetrexed . . O
/ . . O
cisplatin . . O
arm . . O
were . . O
younger . . O
than . . O
65 . . O
years . . O
. . . O

in . . O
animal . . O
reproduction . . O
studies . . O
, . . O
oral . . O
administration . . O
of . . O
crizotinib . . O
in . . O
pregnant . . O
rats . . B-Animal
during . . O
organogenesis . . O
at . . O
exposures . . O
similar . . O
to . . O
those . . O
observed . . O
with . . O
the . . O
maximum . . O
recommended . . O
human . . O
dose . . O
resulted . . O
in . . O
embryotoxicity . . B-AdverseReaction
and . . O
fetotoxicity . . B-AdverseReaction
. . . O

across . . O
controlled . . O
and . . O
uncontrolled . . O
trials . . O
in . . O
patients . . O
receiving . . O
adjunctive . . O
therapy . . O
for . . O
partial . . O
- . . O
onset . . O
seizures . . O
, . . O
1195 . . O
patients . . O
received . . O
aptiom . . O
, . . O
of . . O
whom . . O
586 . . O
were . . O
treated . . O
for . . O
longer . . O
than . . O
6 . . O
months . . O
and . . O
462 . . O
for . . O
longer . . O
than . . O
12 . . O
months . . O
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
extensive . . O
or . . O
intensive . . O
chemotherapy . . O
may . . O
be . . O
at . . O
higher . . O
risk . . O
of . . O
life . . O
threatening . . O
infections . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

in . . O
double . . O
- . . O
blind . . O
placebo . . O
- . . O
controlled . . O
short . . O
- . . O
term . . O
studies . . O
, . . O
where . . O
the . . O
dose . . O
was . . O
increased . . O
slowly . . O
, . . O
as . . O
recommended . . O
above . . O
, . . O
syncope . . B-AdverseReaction
was . . O
reported . . O
in . . O
0.4% . . O
( . . O
5 . . O
/ . . O
1344 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
fanapt . . O
, . . O
compared . . O
with . . O
0.2% . . O
( . . O
1 . . O
/ . . O
587 . . O
) . . O
on . . O
placebo . . O
. . . O

suicide . . O
is . . O
a . . O
known . . O
risk . . O
of . . O
depression . . O
and . . O
certain . . O
other . . O
psychiatric . . O
disorders . . O
, . . O
and . . O
these . . O
disorders . . O
themselves . . O
are . . O
the . . O
strongest . . O
predictors . . O
of . . O
suicide . . O
. . . O

monitor . . O
patients . . O
for . . O
the . . O
development . . O
of . . O
severe . . O
cutaneous . . O
reactions . . O
and . . O
discontinue . . O
zydelig . . O
. . . O

5.2 . . O
neurological . . O
toxicities . . O

( . . O
5.4 . . O
) . . O

the . . O
incidence . . O
of . . O
non . . O
- . . O
hematologic . . O
, . . O
non . . O
- . . O
infectious . . O
, . . O
adverse . . O
events . . O
( . . O
all . . O
grades . . O
) . . O
in . . O
study . . O
1 . . O
, . . O
study . . O
2 . . O
, . . O
and . . O
the . . O
emtp . . O
trial . . O
is . . O
provided . . O
in . . O
table . . O
1 . . O
. . . O

the . . O
risk . . O
of . . O
vte . . B-AdverseReaction
in . . O
women . . O
using . . O
cocs . . B-DrugClass
has . . O
been . . O
estimated . . O
to . . O
be . . O
3 . . O
to . . O
9 . . O
per . . O
10,000 . . O
woman . . O
- . . O
years . . O
. . . O

genital . . O
mycotic . . O
infections . . O

do . . O
not . . O
take . . O
duavee . . O
if . . O
you . . O
: . . O

given . . O
these . . O
considerations . . O
, . . O
saphris . . O
should . . O
be . . O
prescribed . . O
in . . O
a . . O
manner . . O
that . . O
is . . O
most . . O
likely . . O
to . . O
minimize . . O
the . . O
occurrence . . O
of . . O
td . . O
. . . O

as . . O
appropriate . . O
, . . O
administer . . O
prophylactic . . O
antibiotics . . O
and . . O
employ . . O
surveillance . . O
testing . . O
during . . O
treatment . . O
with . . O
blincyto . . O
. . . O

( . . O
2.2 . . O
, . . O
5.3 . . O
) . . O
* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
: . . O
monitor . . O
patients . . O
with . . O
advanced . . O
stage . . O
disease . . O
and . . O
/ . . O
or . . O
high . . O
tumor . . O
burden . . O
and . . O
take . . O
appropriate . . O
precautions . . O
. . . O

thus . . O
, . . O
the . . O
ability . . O
to . . O
differentiate . . O
the . . O
adverse . . O
event . . O
profile . . O
between . . O
treatments . . O
is . . O
limited . . O
. . . O

in . . O
studies . . O
1 . . O
and . . O
2 . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
associated . . O
with . . O
infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
chills . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
dyspnea . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
pruritus . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
pyrexia . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
and . . O
cough . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

a . . O
total . . O
of . . O
58 . . O
patient . . O
samples . . O
that . . O
were . . O
either . . O
transiently . . O
or . . O
persistently . . O
positive . . O
for . . O
anti . . O
- . . O
brentuximab . . O
vedotin . . O
antibodies . . O
were . . O
tested . . O
for . . O
the . . O
presence . . O
of . . O
neutralizing . . O
antibodies . . O
. . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
15% . . O
) . . O
are . . O
gastritis . . B-AdverseReaction
- . . O
like . . O
symptoms . . O
and . . O
bleeding . . B-AdverseReaction
( . . O
6.1 . . O
) . . O

extensive . . O
epidemiological . . O
studies . . O
have . . O
revealed . . O
no . . B-Negation
increased . . O
risk . . O
of . . O
birth . . B-AdverseReaction
defects . . I-AdverseReaction
in . . O
women . . O
who . . O
have . . O
used . . O
oral . . O
contraceptives . . O
prior . . O
to . . O
pregnancy . . O
. . . O

the . . O
gbca . . B-DrugClass
- . . O
associated . . O
nsf . . B-AdverseReaction
risk . . O
appears . . O
highest . . O
for . . O
patients . . O
with . . O
chronic . . O
, . . O
severe . . O
kidney . . O
disease . . O
( . . O
gfr . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m . . O
2 . . O
) . . O
as . . O
well . . O
as . . O
patients . . O
with . . O
acute . . O
kidney . . O
injury . . O
. . . O

skin . . O
and . . O
appendages . . O
- . . O
pruritus . . B-AdverseReaction

5.3 . . O
elevated . . O
blood . . O
pressure . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

these . . O
symptoms . . O
have . . O
been . . O
reported . . O
hours . . O
to . . O
weeks . . O
after . . O
injection . . O
. . . O

the . . O
detection . . O
of . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

# . . O
most . . O
herpes . . O
infections . . O
were . . O
non . . B-Severity
- . . I-Severity
serious . . I-Severity
and . . O
1 . . O
led . . O
to . . O
treatment . . O
discontinuation . . O
. . . O

excerpt . . O
: . . O
* . . O
ampyra . . O
can . . B-Factor
cause . . O
seizures . . B-AdverseReaction
; . . O
the . . O
risk . . B-Factor
of . . O
seizures . . B-AdverseReaction
increases . . O
with . . O
increasing . . O
ampyra . . O
doses . . O
; . . O
discontinue . . O
ampyra . . O
and . . O
do . . O
not . . O
restart . . O
if . . O
a . . O
seizure . . O
occurs . . O
( . . O
5.1 . . O
) . . O
* . . O
ampyra . . O
should . . O
not . . O
be . . O
taken . . O
with . . O
other . . O
forms . . O
of . . O
4 . . O
- . . O
aminopyridine . . O
( . . O
4 . . O
- . . O
ap . . O
, . . O
fampridine . . O
) . . O
, . . O
since . . O
the . . O
active . . O
ingredient . . O
is . . O
the . . O
same . . O
( . . O
5.3 . . O
) . . O
* . . O
ampyra . . O
can . . B-Factor
cause . . O
anaphylaxis . . B-AdverseReaction
. . . O

the . . O
median . . O
duration . . O
of . . O
adverse . . O
reactions . . O
was . . O
4.0 . . O
days . . O
in . . O
both . . O
treatment . . O
groups . . O
. . . O

the . . O
risk . . O
differences . . O
( . . O
drug . . O
vs . . O
. . . O
placebo . . O
) . . O
, . . O
however . . O
, . . O
were . . O
relatively . . O
stable . . O
within . . O
age . . O
strata . . O
and . . O
across . . O
indications . . O
. . . O

pregnancy . . O
should . . O
be . . O
ruled . . O
out . . O
in . . O
the . . O
event . . O
of . . O
amenorrhea . . O
occurring . . O
in . . O
two . . O
or . . O
more . . O
consecutive . . O
cycles . . O
. . . O

because . . O
of . . O
a . . O
risk . . O
for . . O
bradyarrhythmia . . O
and . . O
atrioventricular . . O
( . . O
av . . O
) . . O
blocks . . O
, . . O
patients . . O
should . . O
be . . O
monitored . . O
during . . O
gilenya . . O
treatment . . O
initiation . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

by . . O
year . . O
3 . . O
, . . O
one . . O
or . . O
more . . O
antihypertensive . . O
medications . . O
were . . O
used . . O
in . . O
85% . . O
of . . O
nulojix . . O
- . . O
treated . . O
patients . . O
and . . O
92% . . O
of . . O
cyclosporine . . O
- . . O
treated . . O
patients . . O
. . . O

in . . O
patients . . O
who . . O
do . . O
require . . O
chronic . . O
treatment . . O
, . . O
the . . O
smallest . . O
dose . . O
and . . O
the . . O
shortest . . O
duration . . O
of . . O
treatment . . O
producing . . O
a . . O
satisfactory . . O
clinical . . O
response . . O
should . . O
be . . O
sought . . O
. . . O

almost . . O
all . . O
of . . O
these . . O
patients . . O
had . . O
received . . O
treatment . . O
with . . O
the . . O
immunosuppressants . . O
azathioprine . . O
and . . O
/ . . O
or . . O
6 . . O
- . . O
mercaptopurine . . O
( . . O
6 . . O
- . . O
mp . . O
) . . O
concomitantly . . O
with . . O
a . . O
tnf . . O
blocker . . O
at . . O
or . . O
prior . . O
to . . O
diagnosis . . O
. . . O

capillary . . B-AdverseReaction
leak . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
cls . . B-AdverseReaction
) . . O
can . . O
occur . . O
in . . O
patients . . O
receiving . . O
human . . B-DrugClass
granulocyte . . I-DrugClass
colony . . I-DrugClass
- . . I-DrugClass
stimulating . . I-DrugClass
factors . . I-DrugClass
and . . O
is . . O
characterized . . O
by . . O
hypotension . . B-AdverseReaction
, . . O
hypoalbuminemia . . B-AdverseReaction
, . . O
edema . . B-AdverseReaction
and . . O
hemoconcentration . . B-AdverseReaction
. . . O

vascular . . O
disorders . . O
: . . O
thrombophlebitis . . B-AdverseReaction
, . . O
vasculitis . . B-AdverseReaction
. . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
reactions . . O
were . . O
serious . . B-Severity
infections . . B-AdverseReaction
( . . O
6.0% . . O
and . . O
5.2% . . O
in . . O
the . . O
groups . . O
receiving . . O
benlysta . . O
and . . O
placebo . . O
, . . O
respectively . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

in . . O
this . . O
setting . . O
, . . O
a . . O
re . . O
- . . O
evaluation . . O
of . . O
the . . O
patient . . O
and . . O
the . . O
copd . . O
treatment . . O
regimen . . O
should . . O
be . . O
undertaken . . O
at . . O
once . . O
. . . O

all . . O
patients . . O
treated . . O
with . . O
vimizim . . O
2 . . O
mg . . O
/ . . O
kg . . O
once . . O
per . . O
week . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
trial . . O
developed . . O
anti . . O
- . . O
drug . . O
antibodies . . O
by . . O
week . . O
4 . . O
. . . O

table . . O
9 . . O
: . . O
key . . O
laboratory . . O
abnormalities . . O
reported . . O
in . . O
afinitor . . O
- . . O
treated . . O
patients . . O
with . . O
renal . . O
angiomyolipoma . . O
grading . . O
according . . O
to . . O
ctcae . . O
version . . O
3.0 . . O
afinitor . . O
n . . O
= . . O
79 . . O
placebo . . O
n . . O
= . . O
39 . . O
all . . O
grades . . O
% . . O
grade . . O
3 . . O
% . . O
grade . . O
4 . . O
% . . O
all . . O
grades . . O
% . . O
grade . . O
3 . . O
% . . O
grade . . O
4 . . O
% . . O
hematology . . O
anemia . . O
61 . . O
0 . . O
0 . . O
49 . . O
0 . . O
0 . . O
leucopenia . . B-AdverseReaction
37 . . O
0 . . O
0 . . O
21 . . O
0 . . O
0 . . O
neutropenia . . B-AdverseReaction
25 . . O
0 . . O
1 . . O
26 . . O
0 . . O
0 . . O
lymphopenia . . B-AdverseReaction
20 . . O
1 . . O
0 . . O
8 . . O
0 . . O
0 . . O
thrombocytopenia . . B-AdverseReaction
19 . . O
0 . . O
0 . . O
3 . . O
0 . . O
0 . . O
clinical . . O
chemistry . . O
hypercholesterolemia . . B-AdverseReaction
85 . . O
1 . . O
0 . . O
46 . . O
0 . . O
0 . . O
hypertriglyceridemia . . B-AdverseReaction
52 . . O
0 . . O
0 . . O
10 . . O
0 . . O
0 . . O
hypophosphatemia . . B-AdverseReaction
49 . . O
5 . . O
0 . . O
15 . . O
0 . . O
0 . . O
alkaline . . B-AdverseReaction
phosphatase . . I-AdverseReaction
increased . . I-AdverseReaction
32 . . O
1 . . O
0 . . O
10 . . O
0 . . O
0 . . O
elevated . . B-AdverseReaction
aspartate . . I-AdverseReaction
transaminase . . I-AdverseReaction
( . . O
ast . . O
) . . O
23 . . O
1 . . O
0 . . O
8 . . O
0 . . O
0 . . O
elevated . . B-AdverseReaction
alanine . . I-AdverseReaction
transaminase . . I-AdverseReaction
( . . O
alt . . O
) . . O
20 . . O
1 . . O
0 . . O
15 . . O
0 . . O
0 . . O
fasting . . B-AdverseReaction
hyperglycemia . . I-AdverseReaction
14 . . O
0 . . O
0 . . O
8 . . O
0 . . O
0 . . O
6.5 . . O
clinical . . O
study . . O
experience . . O
in . . O
subependymal . . O
giant . . O
cell . . O
astrocytoma . . O
with . . O
tuberous . . O
sclerosis . . O
complex . . O
the . . O
data . . O
described . . O
below . . O
are . . O
based . . O
on . . O
a . . O
randomized . . O
( . . O
2 . . O
: . . O
1 . . O
) . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trial . . O
( . . O
study . . O
1 . . O
) . . O
of . . O
afinitor . . O
in . . O
117 . . O
patients . . O
with . . O
subependymal . . O
giant . . O
cell . . O
astrocytoma . . O
( . . O
sega . . O
) . . O
and . . O
tuberous . . O
sclerosis . . O
complex . . O
( . . O
tsc . . O
) . . O
. . . O

5.6 . . O
ocular . . O
toxicities . . O

patients . . O
greater . . O
than . . O
65 . . O
years . . O
of . . O
age . . O
, . . O
patients . . O
with . . O
co . . O
- . . O
morbid . . O
conditions . . O
and . . O
/ . . O
or . . O
patients . . O
taking . . O
concomitant . . O
immunosuppressants . . O
such . . O
as . . O
corticosteroids . . O
or . . O
methotrexate . . O
may . . O
be . . O
at . . O
greater . . O
risk . . O
of . . O
infection . . O
. . . O

in . . O
a . . O
placebo . . O
- . . O
controlled . . O
study . . O
in . . O
patients . . O
with . . O
permanent . . O
atrial . . O
fibrillation . . O
, . . O
dronedarone . . O
was . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
stroke . . B-AdverseReaction
, . . O
particularly . . O
in . . O
the . . O
first . . O
two . . O
weeks . . O
of . . O
therapy . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.4 . . O
) . . O
] . . O
. . . O

extrapyramidal . . B-AdverseReaction
symptoms . . I-AdverseReaction
included . . O
dystonia . . B-AdverseReaction
, . . O
oculogyration . . B-AdverseReaction
, . . O
dyskinesia . . B-AdverseReaction
, . . O
tardive . . B-AdverseReaction
dyskinesia . . I-AdverseReaction
, . . O
muscle . . B-AdverseReaction
rigidity . . I-AdverseReaction
, . . O
parkinsonism . . B-AdverseReaction
, . . O
tremor . . B-AdverseReaction
, . . O
and . . O
extrapyramidal . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
excluding . . B-Negation
akathisia . . B-AdverseReaction
) . . O
. . . O
? . . O

at . . O
study . . O
baseline . . O
, . . O
approximately . . O
25% . . O
had . . O
mild . . O
, . . O
50% . . O
had . . O
moderate . . O
, . . O
and . . O
25% . . O
had . . O
severe . . O
cervical . . O
dystonia . . O
. . . O

5.9 . . O
effects . . O
on . . O
bleeding . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

for . . O
events . . O
of . . O
akathisia . . B-AdverseReaction
, . . O
incidences . . O
were . . O
2% . . O
, . . O
2% . . O
, . . O
and . . O
1% . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
2.5 . . O
mg . . O
, . . O
5 . . O
mg . . O
, . . O
and . . O
10 . . O
mg . . O
twice . . O
daily . . O
, . . O
respectively . . O
, . . O
as . . O
compared . . O
to . . O
0% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

5.3 . . O
qt . . O
interval . . O
prolongation . . O

the . . O
risk . . O
did . . O
not . . O
vary . . O
substantially . . O
by . . O
age . . O
( . . O
5 . . O
to . . O
100 . . O
years . . O
) . . O
in . . O
the . . O
clinical . . O
trials . . O
analyzed . . O
. . . O

5.3 . . O
other . . O
malignancies . . O

no . . O
definite . . O
causality . . O
assessment . . O
or . . O
benefit . . O
risk . . O
assessment . . O
could . . O
be . . O
made . . O
for . . O
these . . O
events . . O
due . . O
to . . O
the . . O
presence . . O
of . . O
confounding . . O
factors . . O
and . . O
lack . . O
of . . O
randomization . . O
of . . O
esa . . O
use . . O
. . . O

report . . O
any . . O
diagnosis . . O
of . . O
nsf . . O
following . . O
gadavist . . O
administration . . O
to . . O
bayer . . O
healthcare . . O
( . . O
1-888-842-2937 . . O
) . . O
or . . O
fda . . O
( . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
) . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
asthenia . . B-AdverseReaction
. . . O

adverse . . O
reactions . . O
that . . O
led . . O
to . . O
dose . . O
delays . . O
in . . O
more . . O
than . . O
5% . . O
of . . O
adcetris . . O
- . . O
treated . . O
patients . . O
in . . O
study . . O
3 . . O
were . . O
neutropenia . . B-AdverseReaction
( . . O
22% . . O
) . . O
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
16% . . O
) . . O
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
and . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
6% . . O
) . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

( . . O
2.3 . . O
, . . O
5.3 . . O
) . . O
* . . O
fluid . . B-AdverseReaction
retention . . I-AdverseReaction
: . . O
monitor . . O
patients . . O
and . . O
manage . . O
using . . O
standard . . O
of . . O
care . . O
treatment . . O
. . . O

avoid . . O
use . . O
of . . O
gbcas . . O
in . . O
these . . O
patients . . O
unless . . O
the . . O
diagnostic . . O
information . . O
is . . O
essential . . O
and . . O
not . . O
available . . O
with . . O
non . . O
- . . O
contrasted . . O
mri . . O
or . . O
other . . O
modalities . . O
. . . O

all . . O
infections . . B-AdverseReaction
? . . O

image . . O
interpretation . . O
should . . O
be . . O
performed . . O
independently . . O
of . . O
the . . O
patient's . . O
clinical . . O
information . . O
. . . O

opportunistic . . O
infections . . O
such . . O
as . . O
pneumocystis . . O
jiroveci . . O
pneumonia . . O
( . . O
pjp . . O
) . . O
should . . O
be . . O
considered . . O
in . . O
the . . O
differential . . O
diagnosis . . O
. . . O

in . . O
an . . O
uncontrolled . . O
open . . O
- . . O
label . . O
ecg . . O
study . . O
in . . O
26 . . O
patients . . O
, . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
was . . O
observed . . O
on . . O
day . . O
8 . . O
, . . O
independent . . O
of . . O
eribulin . . O
concentration . . O
, . . O
with . . O
no . . B-Negation
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
observed . . O
on . . O
day . . O
1 . . O
. . . O

clinical . . O
monitoring . . O
of . . O
weight . . O
is . . O
recommended . . O
. . . O

frequently . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
neurological . . O
impairment . . O
. . . O

nervous . . O
system . . O
disorders . . O
: . . O
encephalopathy . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
paresthesia . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
aphasia . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
convulsion . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
memory . . B-AdverseReaction
impairment . . I-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
cognitive . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
1% . . O
) . . O
, . . O
speech . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
< . . O
1% . . O
) . . O

in . . O
the . . O
whi . . O
estrogen . . O
- . . O
alone . . O
substudy . . O
, . . O
no . . O
overall . . O
effect . . O
on . . O
coronary . . B-AdverseReaction
heart . . I-AdverseReaction
disease . . I-AdverseReaction
( . . O
chd . . B-AdverseReaction
) . . O
events . . O
( . . O
defined . . O
as . . O
nonfatal . . B-Severity
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
silent . . B-AdverseReaction
myocardial . . I-AdverseReaction
infarction . . I-AdverseReaction
, . . O
or . . O
chd . . B-AdverseReaction
death . . I-AdverseReaction
) . . O
was . . O
reported . . O
in . . O
women . . O
receiving . . O
estrogen . . B-DrugClass
- . . O
alone . . O
compared . . O
to . . O
placebo . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.5 . . O
) . . O
] . . O
. . . O

* . . O
increased . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
and . . O
behavior . . O
in . . O
children . . O
, . . O
adolescents . . O
and . . O
young . . O
adults . . O
taking . . O
antidepressants . . B-DrugClass
( . . O
5.1 . . O
) . . O
. . . O

data . . O
from . . O
a . . O
large . . O
placebo . . O
- . . O
controlled . . O
us . . O
study . . O
that . . O
compared . . O
the . . O
safety . . O
of . . O
another . . O
long . . B-DrugClass
- . . I-DrugClass
acting . . I-DrugClass
beta . . I-DrugClass
2 . . I-DrugClass
- . . I-DrugClass
adrenergic . . I-DrugClass
agonist . . I-DrugClass
( . . O
salmeterol . . O
) . . O
or . . O
placebo . . O
added . . O
to . . O
usual . . O
asthma . . O
therapy . . O
showed . . O
an . . O
increase . . O
in . . O
asthma . . O
- . . O
related . . O
deaths . . B-AdverseReaction
in . . O
patients . . O
receiving . . O
salmeterol . . O
. . . O

serious . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
109 . . O
/ . . O
1778 . . O
( . . O
6.1% . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
dalvance . . O
and . . O
in . . O
80 . . O
/ . . O
1224 . . O
( . . O
6.5% . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
comparator . . O
. . . O

* . . O
a . . O
28 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
us . . O
study . . O
comparing . . O
the . . O
safety . . O
of . . O
another . . O
long . . B-DrugClass
- . . I-DrugClass
acting . . I-DrugClass
beta . . I-DrugClass
2 . . I-DrugClass
- . . I-DrugClass
adrenergic . . I-DrugClass
agonist . . I-DrugClass
( . . O
salmeterol . . O
) . . O
with . . O
placebo . . O
, . . O
each . . O
added . . O
to . . O
usual . . O
asthma . . O
therapy . . O
, . . O
showed . . O
an . . O
increase . . O
in . . O
asthma . . O
- . . O
related . . O
deaths . . B-AdverseReaction
in . . O
patients . . O
receiving . . O
salmeterol . . O
( . . O
13 . . O
/ . . O
13,176 . . O
in . . O
patients . . O
treated . . O
with . . O
salmeterol . . O
vs . . O
. . . O
3 . . O
/ . . O
13,179 . . O
in . . O
patients . . O
treated . . O
with . . O
placebo . . O
; . . O
rr . . O
4.37 . . O
, . . O
95% . . O
ci . . O
1.25 . . O
, . . O
15.34 . . O
) . . O
. . . O

patients . . O
> . . O
= . . O
65 . . O
years . . O
of . . O
age . . O
are . . O
more . . O
likely . . O
to . . O
experience . . O
certain . . O
adverse . . O
reactions . . O
, . . O
including . . O
neutropenia . . B-AdverseReaction
and . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
) . . O
] . . O
. . . O

trulicity . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
a . . O
personal . . O
or . . O
family . . O
history . . O
of . . O
mtc . . O
or . . O
in . . O
patients . . O
with . . O
men . . O
2 . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

stribild . . O
is . . O
not . . O
recommended . . O
for . . O
coadministration . . O
with . . O
the . . O
following . . O
: . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
acorda . . O
therapeutics . . O
at . . O
1-800-367-5109 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

by . . O
a . . O
healthcare . . O
professional . . O
with . . O
appropriate . . O
medical . . O
support . . O
to . . O
manage . . O

( . . O
5.3 . . O
) . . O
* . . O
tardive . . B-AdverseReaction
dyskinesia . . I-AdverseReaction
: . . O
discontinue . . O
if . . O
clinically . . O
appropriate . . O
. . . O

serious . . O
adverse . . O
reactions . . O

these . . O
hematomas . . B-AdverseReaction
may . . B-Factor
result . . O

* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
anaphylacticshock . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
pharyngolaryngeal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
face . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
rhinitis . . B-AdverseReaction
, . . O
conjunctivitis . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
hypoesthesia . . B-AdverseReaction
, . . O
sneezing . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
and . . O
pallor . . B-AdverseReaction
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
tachycardia . . B-AdverseReaction
* . . O
restlessness . . B-AdverseReaction

the . . O
following . . O
risks . . B-Factor
, . . O
including . . O
appropriate . . O
action . . O
to . . O
be . . O
taken . . O
, . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
label . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.1-5.13 . . O
) . . O
] . . O
: . . O
hypertension . . B-AdverseReaction
, . . O
arterial . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
, . . O
venous . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
, . . O
hemorrhage . . B-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
gastrointestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
and . . O
fistula . . B-AdverseReaction
formation . . I-AdverseReaction
, . . O
thyroid . . B-AdverseReaction
dysfunction . . I-AdverseReaction
, . . O
wound . . B-AdverseReaction
healing . . I-AdverseReaction
complications . . I-AdverseReaction
, . . O
rpls . . B-AdverseReaction
, . . O
proteinuria . . B-AdverseReaction
, . . O
elevation . . B-AdverseReaction
of . . I-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
, . . O
hepatic . . B-AdverseReaction
impairment . . I-AdverseReaction
and . . O
fetal . . O
development . . O
. . . O

adverse . . O
reactions . . O
observed . . O
in . . O
these . . O
studies . . O
were . . O
generally . . O
similar . . O
to . . O
those . . O
observed . . O
and . . O
attributed . . O
to . . O
drug . . O
in . . O
adjunctive . . O
placebo . . O
- . . O
controlled . . O
studies . . O
. . . O

the . . O
evaluation . . O
of . . O
adverse . . O
reactions . . O
in . . O
patients . . O
treated . . O
with . . O
voraxaze . . O
is . . O
confounded . . O
by . . O
the . . O
population . . O
in . . O
which . . O
it . . O
was . . O
studied . . O
, . . O
patients . . O
with . . O
toxic . . O
plasma . . O
methotrexate . . O
levels . . O
due . . O
to . . O
impaired . . O
renal . . O
function . . O
. . . O

( . . O
5.6 . . O
) . . O
5.1 . . O
risk . . O
of . . O
thyroid . . O
c . . O
- . . O
cell . . O
tumors . . O

excerpt . . O
: . . O
most . . O
common . . O
all . . O
grades . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
are . . O
neutropenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
hematuria . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
anorexia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
dysgeusia . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
and . . O
alopecia . . B-AdverseReaction
. . . O

a . . O
potentially . . B-Factor
fatal . . B-AdverseReaction
symptom . . O
complex . . O
sometimes . . O
referred . . O
to . . O
as . . O
neuroleptic . . B-AdverseReaction
malignant . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
nms . . B-AdverseReaction
) . . O
has . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
administration . . O
of . . O
antipsychotic . . O
drugs . . O
, . . O
including . . O
saphris . . O
. . . O

* . . O
increased . . O
risk . . B-Factor
for . . O
developing . . O
post . . B-AdverseReaction
- . . I-AdverseReaction
transplant . . I-AdverseReaction
lymphoproliferative . . I-AdverseReaction
disorder . . I-AdverseReaction
( . . O
ptld . . B-AdverseReaction
) . . O
, . . O
predominantly . . O
involving . . O
the . . O
central . . O
nervous . . O
system . . O
( . . O
cns . . O
) . . O
. . . O

there . . O
are . . O
no . . O
adequate . . O
and . . O
well . . O
- . . O
controlled . . O
studies . . O
of . . O
halaven . . O
in . . O
pregnant . . O
women . . O
. . . O

doses . . O
of . . O
toviaz . . O
greater . . O
than . . O
4 . . O
mg . . O
are . . O
not . . O
recommended . . O
in . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
and . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

( . . O
6.1 . . O
) . . O

estrogens . . O
may . . O
increase . . O
the . . O
chances . . O
of . . O
getting . . O
certain . . O
types . . O
of . . O
cancers . . O
, . . O
including . . O
cancer . . O
of . . O
the . . O
breast . . O
or . . O
uterus . . O
. . . O

5.11 . . O
interference . . O
with . . O
laboratory . . O
tests . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

in . . O
patients . . O
with . . O
a . . O
pre . . O
- . . O
existing . . O
low . . O
wbc . . O
/ . . O
anc . . O
or . . O
drug . . O
- . . O
induced . . O
leukopenia . . O
/ . . O
neutropenia . . O
, . . O
perform . . O
a . . O
complete . . O
blood . . O
count . . O
( . . O
cbc . . O
) . . O
frequently . . O
during . . O
the . . O
first . . O
few . . O
months . . O
of . . O
therapy . . O
. . . O

5.1 . . O
nephrogenic . . O
systemic . . O
fibrosis . . O
( . . O
nsf . . O
) . . O

( . . O
5.6 . . O
) . . O
. . . O

* . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
: . . O
closely . . O
monitor . . O
patients . . O
for . . O
the . . O
emergence . . O
of . . O
bacterial . . O
, . . O
fungal . . O
or . . O
viral . . O
infections . . O
( . . O
5.4 . . O
) . . O
. . . O

rapid . . O
titration . . O
at . . O
greater . . O
than . . O
the . . O
recommended . . O
doses . . O
appeared . . O
to . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
psychosis . . B-AdverseReaction
and . . O
hallucinations . . B-AdverseReaction
. . . O

in . . O
the . . O
pooled . . O
analysis . . O
of . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
, . . O
the . . O
incidence . . O
of . . O
renal . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
was . . O
3.7% . . O
with . . O
placebo . . O
, . . O
8.9% . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
9.3% . . O
with . . O
invokana . . O
300 . . O
mg . . O
. . . O

adverse . . O
reactions . . O
leading . . O
to . . O
permanent . . O
discontinuation . . O
in . . O
the . . O
afinitor . . O
arm . . O
were . . O
hypersensitivity . . B-AdverseReaction
/ . . O
angioedema . . B-AdverseReaction
/ . . O
bronchospasm . . B-AdverseReaction
, . . O
convulsion . . B-AdverseReaction
, . . O
and . . O
hypophosphatemia . . B-AdverseReaction
. . . O

some . . O
events . . O
occurred . . O
when . . O
treanda . . O
was . . O
given . . O
in . . O
combination . . O
with . . O
other . . O
anticancer . . O
agents . . O
. . . O

in . . O
patients . . O
who . . O
develop . . O
severe . . O
hepatic . . O
impairment . . O
while . . O
taking . . O
gilotrif . . O
, . . O
treatment . . O
should . . O
be . . O
discontinued . . O
. . . O

the . . O
proportion . . O
of . . O
subjects . . O
who . . O
discontinued . . O
study . . O
drug . . O
due . . O
to . . O
anemia . . B-AdverseReaction
was . . O
1% . . O
in . . O
subjects . . O
treated . . O
with . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
and . . O
1% . . O
in . . O
subjects . . O
who . . O
received . . O
pegintron . . O
/ . . O
rebetol . . O
. . . O

medicines . . O
are . . O
sometimes . . O
prescribed . . O
for . . O
purposes . . O
other . . O
than . . O
those . . O
listed . . O
in . . O
a . . O
patient . . O
information . . O
leaflet . . O
. . . O

ensure . . O
catheter . . O
and . . O
venous . . O
patency . . O
before . . O
the . . O
injection . . O
of . . O
dotarem . . O
. . . O

infliximab . . O
was . . O
administered . . O
to . . O
5 . . O
of . . O
the . . O
62 . . O
patients . . O
( . . O
8% . . O
) . . O
with . . O
moderate . . B-Severity
, . . O
severe . . B-Severity
, . . O
or . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
enterocolitis . . I-AdverseReaction
following . . O
inadequate . . O
response . . O
to . . O
corticosteroids . . O
. . . O

opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
have . . O
also . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
ilaris . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

5.8 . . O
concomitant . . O
administration . . O
with . . O
cyp3a4 . . O
inhibitors . . O

the . . O
majority . . O
( . . O
95% . . O
) . . O
of . . O
these . . O
patients . . O
had . . O
grade . . B-Severity
1 . . I-Severity
visual . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
. . . O

immunogenicity . . O

behaviors . . O
of . . O
concern . . O
should . . O
be . . O
reported . . O
immediately . . O
to . . O
healthcare . . O
providers . . O
. . . O

* . . O
? . . O

patients . . O
should . . O
be . . O
monitored . . O
for . . O
the . . O
emergence . . O
of . . O
serotonin . . O
syndrome . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

baseline . . O
renal . . O
function . . O
was . . O
normal . . O
or . . O
mildly . . O
impaired . . O
in . . O
92% . . O
of . . O
patients . . O
and . . O
moderately . . O
impaired . . O
in . . O
8% . . O
of . . O
patients . . O
( . . O
mean . . O
egfr . . O
86 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
. . . O

the . . O
most . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
in . . O
this . . O
trial . . O
for . . O
the . . O
1,200 . . O
mg . . O
dose . . O
of . . O
horizant . . O
were . . O
dizziness . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
( . . O
see . . O
table . . O
5 . . O
) . . O
. . . O

( . . O
5.1 . . O
, . . O
13.1 . . O
) . . O
* . . O
tanzeum . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
a . . O
personal . . O
or . . O
family . . O
history . . O
of . . O
mtc . . O
or . . O
in . . O
patients . . O
with . . O
multiple . . O
endocrine . . O
neoplasia . . O
syndrome . . O
type . . O
2 . . O
( . . O
men . . O
2 . . O
) . . O
. . . O

patients . . O
or . . O
caregivers . . O
should . . O
be . . O
advised . . O
to . . O
seek . . O
immediate . . O
medical . . O
care . . O
if . . O
swallowing . . O
, . . O
speech . . O
, . . O
or . . O
respiratory . . O
disorders . . O
occur . . O
. . . O

insulin . . O
and . . O
insulin . . O
secretagogues . . O
are . . O
known . . O
to . . O
cause . . O
hypoglycemia . . O
. . . O

discontinue . . O
cometriq . . O
in . . O
patients . . O
with . . O
perforation . . O
or . . O
fistula . . O
. . . O

extravasation . . O
into . . O
tissues . . O
during . . O
eovist . . O
administration . . O
may . . B-Factor
result . . O
in . . O
local . . O
tissue . . O
reactions . . O
. . . O

table . . O
4 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
in . . O
either . . O
group . . O
undergoing . . O
hip . . O
or . . O
knee . . O
replacement . . O
surgery . . O
eliquis . . O
, . . O
n . . O
( . . O
% . . O
) . . O
2.5 . . O
mg . . O
po . . O
bidn . . O
= . . O
5924 . . O
enoxaparin . . O
, . . O
n . . O
( . . O
% . . O
) . . O
40 . . O
mg . . O
sc . . O
qd . . O
or30 . . O
mg . . O
sc . . O
q12hn . . O
= . . O
5904 . . O
nausea . . B-AdverseReaction
153 . . O
( . . O
2.6 . . O
) . . O
159 . . O
( . . O
2.7 . . O
) . . O
anemia . . B-AdverseReaction
( . . O
including . . O
postoperative . . O
and . . O
hemorrhagic . . B-AdverseReaction
anemia . . I-AdverseReaction
, . . O
and . . O
respective . . O
laboratory . . O
parameters . . O
) . . O
153 . . O
( . . O
2.6 . . O
) . . O
178 . . O
( . . O
3.0 . . O
) . . O
contusion . . B-AdverseReaction
83 . . O
( . . O
1.4 . . O
) . . O
115 . . O
( . . O
1.9 . . O
) . . O
hemorrhage . . B-AdverseReaction
( . . O
including . . O
hematoma . . B-AdverseReaction
, . . O
and . . O
vaginal . . O
and . . O
urethral . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
) . . O
67 . . O
( . . O
1.1 . . O
) . . O
81 . . O
( . . O
1.4 . . O
) . . O
postprocedural . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
( . . O
including . . O
postprocedural . . B-AdverseReaction
hematoma . . I-AdverseReaction
, . . O
wound . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
vessel . . B-AdverseReaction
puncture . . I-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
and . . O
catheter . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
) . . O
54 . . O
( . . O
0.9 . . O
) . . O
60 . . O
( . . O
1.0 . . O
) . . O
transaminases . . B-AdverseReaction
increased . . I-AdverseReaction
( . . O
including . . O
alanine . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
and . . O
alanine . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
abnormal . . I-AdverseReaction
) . . O
50 . . O
( . . O
0.8 . . O
) . . O
71 . . O
( . . O
1.2 . . O
) . . O
aspartate . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
47 . . O
( . . O
0.8 . . O
) . . O
69 . . O
( . . O
1.2 . . O
) . . O
gamma . . B-AdverseReaction
- . . I-AdverseReaction
glutamyltransferase . . I-AdverseReaction
increased . . I-AdverseReaction
38 . . O
( . . O
0.6 . . O
) . . O
65 . . O
( . . O
1.1 . . O
) . . O
less . . O
common . . O
adverse . . O
reactions . . O
in . . O
apixaban . . O
- . . O
treated . . O
patients . . O
undergoing . . O
hip . . O
or . . O
knee . . O
replacement . . O
surgery . . O
occurring . . O
at . . O
a . . O
frequency . . O
of . . O
> . . O
= . . O
0.1% . . O
to . . O
< . . O
1% . . O
: . . O

monitor . . O
blood . . O
pressure . . O
, . . O
both . . O
in . . O
the . . O
supine . . O
position . . O
and . . O
in . . O
the . . O
recommended . . O
head . . O
- . . O
elevated . . O
sleeping . . O
position . . O
. . . O

5.9 . . O
drug . . O
- . . O
drug . . O
interactions . . O

discoloration . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
palate . . I-AdverseReaction
, . . O
sclera . . O
, . . O
and . . O
conjunctiva . . O
has . . O
also . . O
been . . O
reported . . O
. . . O

patients . . O
with . . O
bilirubin . . O
> . . O
1.5 . . O
* . . O
uln . . O
also . . O
had . . O
a . . O
higher . . O
incidence . . O
of . . O
grade . . B-Severity
4 . . I-Severity
neutropenia . . B-AdverseReaction
and . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
. . . O

in . . O
a . . O
pool . . O
of . . O
nine . . O
clinical . . O
trials . . O
with . . O
mean . . O
duration . . O
of . . O
exposure . . O
to . . O
invokana . . O
of . . O
85 . . O
weeks . . O
, . . O
the . . O
proportion . . O
of . . O
patients . . O
who . . O
experienced . . O
falls . . B-AdverseReaction
was . . O
1.3% . . O
, . . O
1.5% . . O
, . . O
and . . O
2.1% . . O
with . . O
comparator . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
mouth . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction

in . . O
the . . O
two . . O
randomized . . O
clinical . . O
trials . . O
, . . O
grade . . B-Severity
3 . . I-Severity
to . . I-Severity
4 . . I-Severity
hypertension . . B-AdverseReaction
occurred . . O
in . . O
2% . . O
of . . O
patients . . O
, . . O
grade . . B-Severity
3 . . I-Severity
to . . I-Severity
4 . . I-Severity
hypokalemia . . B-AdverseReaction
in . . O
4% . . O
of . . O
patients . . O
, . . O
and . . O
grade . . B-Severity
3 . . I-Severity
to . . I-Severity
4 . . I-Severity
edema . . B-AdverseReaction
in . . O
1% . . O
of . . O
patients . . O
treated . . O
with . . O
zytiga . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

the . . O
information . . O
presented . . O
in . . O
these . . O
sections . . O
was . . O
derived . . O
from . . O
pooled . . O
data . . O
from . . O
4 . . O
placebo . . O
- . . O
controlled . . O
, . . O
4 . . O
- . . O
or . . O
6 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
or . . O
flexible . . O
- . . O
dose . . O
studies . . O
in . . O
patients . . O
who . . O
received . . O
fanapt . . O
at . . O
daily . . O
doses . . O
within . . O
a . . O
range . . O
of . . O
10 . . O
to . . O
24 . . O
mg . . O
( . . O
n . . O
= . . O
874 . . O
) . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
extravasation . . B-AdverseReaction
: . . O
assure . . O
good . . O
venous . . O
access . . O
and . . O
monitor . . O
infusion . . O
site . . O
during . . O
and . . O
after . . O
administration . . O
. . . O

table . . O
3 . . O
gives . . O
the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
subjects . . O
with . . O
partial . . O
- . . O
onset . . O
seizures . . O
in . . O
any . . O
aptiom . . O
treatment . . O
group . . O
and . . O
for . . O
which . . O
the . . O
incidence . . O
was . . O
greater . . O
than . . O
placebo . . O
during . . O
the . . O
controlled . . O
clinical . . O
trials . . O
. . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
fluid . . B-AdverseReaction
retention . . I-AdverseReaction
, . . O
hypertriglyceridemia . . B-AdverseReaction

patients . . O
with . . O
myelosuppression . . B-AdverseReaction
following . . O
treatment . . O
with . . O
treanda . . O
are . . O
more . . O
susceptible . . B-Factor
to . . O
infections . . B-AdverseReaction
. . . O

prepare . . O
to . . O
treat . . O
acute . . O
pain . . O
during . . O
and . . O
following . . O
the . . O
application . . O
procedure . . O
with . . O
local . . O
cooling . . O
( . . O
such . . O
as . . O
an . . O
ice . . O
pack . . O
) . . O
and . . O
/ . . O
or . . O
appropriate . . O
analgesic . . O
medication . . O
, . . O
such . . O
as . . O
opioids . . O
. . . O

severe . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
or . . O
fatal . . B-AdverseReaction
interstitial . . O
lung . . O
disease . . O
( . . O
ild . . O
) . . O
/ . . O
pneumonitis . . O
can . . B-Factor
occur . . O
in . . O
patients . . O
treated . . O
with . . O
xalkori . . O
. . . O

5.3 . . O
liver . . O
disease . . O

* . . O
administer . . O
eovist . . O
only . . O
in . . O
situations . . O
where . . O
trained . . O
personnel . . O
and . . O
therapies . . O
are . . O
promptly . . O
available . . O
for . . O
the . . O
treatment . . O
of . . O
hypersensitivity . . O
reactions . . O
, . . O
including . . O
personnel . . O
trained . . O
in . . O
resuscitation . . O
. . . O

patients . . O
who . . O
are . . O
carriers . . O
of . . O
hbv . . O
and . . O
require . . O
treatment . . O
with . . O
tnf . . O
- . . O
blockers . . O
should . . O
be . . O
closely . . O
monitored . . O
for . . O
clinical . . O
and . . O
laboratory . . O
signs . . O
of . . O
active . . O
hbv . . O
infection . . O
throughout . . O
therapy . . O
and . . O
for . . O
several . . O
months . . O
following . . O
termination . . O
of . . O
therapy . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
ck . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
3 . . B-Severity
times . . I-Severity
uln . . I-Severity
during . . O
a . . O
3 . . O
- . . O
week . . O
trial . . O
in . . O
pediatric . . O
bipolar . . O
i . . O
disorder . . O
at . . O
any . . O
time . . O
were . . O
1% . . O
, . . O
0% . . O
, . . O
and . . O
1% . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
2.5 . . O
mg . . O
, . . O
5 . . O
mg . . O
, . . O
and . . O
10 . . O
mg . . O
twice . . O
daily . . O
, . . O
respectively . . O
, . . O
versus . . O
3% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

for . . O
this . . O
reason . . O
, . . O
cocs . . O
should . . O
not . . O
be . . O
used . . O
by . . O
women . . O
who . . O
are . . O
over . . O
35 . . O
years . . O
of . . O
age . . O
and . . O
smoke . . O
. . . O

table . . O
1 . . O
summarizes . . O
the . . O
reactions . . O
reported . . O
at . . O
a . . O
rate . . O
of . . O
at . . O
least . . O
3% . . O
in . . O
patients . . O
treated . . O
with . . O
cimzia . . O
200 . . O
mg . . O
every . . O
other . . O
week . . O
compared . . O
to . . O
placebo . . O
( . . O
saline . . O
formulation . . O
) . . O
, . . O
given . . O
concomitantly . . O
with . . O
methotrexate . . O
. . . O

experience . . O
in . . O
systemic . . O
anaplastic . . O
large . . O
cell . . O
lymphoma . . O

no . . O
data . . O
are . . O
available . . O
on . . O
the . . O
response . . O
to . . O
live . . O
vaccinations . . O
or . . O
the . . O
secondary . . O
transmission . . O
of . . O
infection . . O
by . . O
live . . O
vaccines . . O
in . . O
patients . . O
receiving . . O
cimzia . . O
. . . O

( . . O
6.1 . . O
) . . O

other . . O
important . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
in . . O
clinical . . O
trials . . O
and . . O
/ . . O
or . . O
postmarketing . . O
experience . . O
were . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
, . . O
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
fibrosis . . I-AdverseReaction
, . . O
and . . O
myelodysplastic . . B-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

5.4 . . O
negative . . O
inotropy . . O

* . . O
duavee . . O
comes . . O
in . . O
a . . O
blister . . O
package . . O
. . . O

continue . . O
to . . O
administer . . O
leucovorin . . O
after . . O
voraxaze . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
bristol . . O
- . . O
myers . . O
squibb . . O
at . . O
1-800-721-5072 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

serious . . O
adverse . . O
reactions . . O
related . . O
to . . O
asthma . . B-AdverseReaction
exacerbation . . I-AdverseReaction
were . . O
reported . . O
for . . O
2 . . O
patients . . O
in . . O
the . . O
indacaterol . . O
300 . . O
mcg . . O
group . . O
, . . O
3 . . O
patients . . O
in . . O
the . . O
indacaterol . . O
600 . . O
mcg . . O
group . . O
, . . O
and . . O
no . . O
patients . . O
in . . O
the . . O
salmeterol . . O
active . . O
control . . O
group . . O
. . . O

* . . O
hypertension . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
and . . O
fluid . . B-AdverseReaction
retention . . I-AdverseReaction
due . . O
to . . O
mineralocorticoid . . B-AdverseReaction
excess . . I-AdverseReaction
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

6 . . O
adverse . . O
reactions . . O

withhold . . O
yervoy . . O
dosing . . O
for . . O
moderate . . O
enterocolitis . . O
; . . O
administer . . O
anti . . O
- . . O
diarrheal . . O
treatment . . O
and . . O
, . . O
if . . O
persistent . . O
for . . O
more . . O
than . . O
1 . . O
week . . O
, . . O
initiate . . O
systemic . . O
corticosteroids . . O
at . . O
a . . O
dose . . O
of . . O
0.5 . . O
mg . . O
/ . . O
kg . . O
/ . . O
day . . O
prednisone . . O
or . . O
equivalent . . O
. . . O

* . . O
pancreatitis . . B-AdverseReaction

the . . O
safety . . O
of . . O
horizant . . O
in . . O
doses . . O
ranging . . O
from . . O
600 . . O
to . . O
2,400 . . O
mg . . O
has . . O
been . . O
evaluated . . O
in . . O
515 . . O
patients . . O
with . . O
rls . . O
in . . O
3 . . O
double . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
12 . . O
week . . O
clinical . . O
trials . . O
. . . O

if . . O
an . . O
infection . . O
develops . . O
, . . O
monitor . . O
carefully . . O
, . . O
and . . O
stop . . O
cimzia . . O
if . . O
infection . . O
becomes . . O
serious . . O
( . . O
5.1 . . O
) . . O
* . . O
invasive . . B-AdverseReaction
fungal . . I-AdverseReaction
infections . . I-AdverseReaction
- . . O
for . . O
patients . . O
who . . O
develop . . O
a . . O
systemic . . O
illness . . O
on . . O
cimzia . . O
, . . O
consider . . O
empiric . . O
antifungal . . O
therapy . . O
for . . O
those . . O
who . . O
reside . . O
or . . O
travel . . O
to . . O
regions . . O
where . . O
mycoses . . O
are . . O
endemic . . O
( . . O
5.1 . . O
) . . O
* . . O
cases . . O
of . . O
lymphoma . . B-AdverseReaction
and . . O
other . . O
malignancies . . B-AdverseReaction
have . . O
been . . O
observed . . O
among . . O
patients . . O
receiving . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
( . . O
5.2 . . O
) . . O
* . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
, . . I-AdverseReaction
worsening . . I-AdverseReaction
or . . O
new . . O
onset . . O
may . . B-Factor
occur . . O
( . . O
5.3 . . O
) . . O
* . . O
anaphylaxis . . B-AdverseReaction
or . . O
serious . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
may . . B-Factor
occur . . O
( . . O
5.4 . . O
) . . O
* . . O
hepatitis . . B-AdverseReaction
b . . I-AdverseReaction
virus . . I-AdverseReaction
reactivation . . I-AdverseReaction
- . . O
test . . O
for . . O
hbv . . O
infection . . O
before . . O
starting . . O
cimzia . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
imbruvica . . O
in . . O
an . . O
open . . O
label . . O
clinical . . O
trial . . O
( . . O
study . . O
1 . . O
) . . O
that . . O
included . . O
48 . . O
patients . . O
with . . O
previously . . O
treated . . O
cll . . O
and . . O
a . . O
randomized . . O
clinical . . O
trial . . O
( . . O
study . . O
2 . . O
) . . O
that . . O
included . . O
391 . . O
randomized . . O
patients . . O
with . . O
previously . . O
treated . . O
cll . . O
or . . O
sll . . O
. . . O

bleeding . . B-AdverseReaction
events . . O
for . . O
the . . O
4 . . O
pivotal . . O
studies . . O
were . . O
classified . . O
as . . O
major . . B-Severity
bleeding . . B-AdverseReaction
events . . O
if . . O
at . . O
least . . O
one . . O
of . . O
the . . O
following . . O
criteria . . O
applied . . O
: . . O
fatal . . B-AdverseReaction
bleeding . . B-AdverseReaction
, . . O
symptomatic . . B-AdverseReaction
bleeding . . I-AdverseReaction
in . . I-AdverseReaction
a . . I-AdverseReaction
critical . . I-AdverseReaction
area . . I-AdverseReaction
or . . O
organ . . O
( . . O
intraocular . . O
, . . O
intracranial . . O
, . . O
intraspinal . . O
or . . O
intramuscular . . O
with . . O
compartment . . B-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
retroperitoneal . . B-AdverseReaction
bleeding . . I-AdverseReaction
, . . O
intra . . B-AdverseReaction
- . . I-AdverseReaction
articular . . I-AdverseReaction
bleeding . . I-AdverseReaction
, . . O
or . . O
pericardial . . B-AdverseReaction
bleeding . . I-AdverseReaction
) . . O
, . . O
bleeding . . B-AdverseReaction
causing . . O
a . . O
fall . . B-AdverseReaction
in . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
level . . I-AdverseReaction
of . . O
2.0 . . B-Severity
g . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
1.24 . . O
mmol . . O
/ . . O
l . . O
or . . O
more . . O
, . . O
or . . O
leading . . O
to . . O
transfusion . . O
of . . O
2 . . O
or . . O
more . . O
units . . O
of . . O
whole . . O
blood . . O
or . . O
red . . O
cells . . O
) . . O
. . . O

major . . O
neuropsychiatric . . B-AdverseReaction
symptoms . . I-AdverseReaction
in . . O
placebo . . O
- . . O
controlled . . O
epilepsy . . O
trials . . O

undesirable . . B-AdverseReaction
alterations . . I-AdverseReaction
in . . I-AdverseReaction
lipids . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
atypical . . B-DrugClass
antipsychotics . . I-DrugClass
. . . O

if . . O
a . . O
patient . . O
is . . O
exposed . . O
to . . O
measles . . O
, . . O
prophylaxis . . O
with . . O
pooled . . O
intramuscular . . O
immunoglobulin . . O
( . . O
ig . . O
) . . O
may . . O
be . . O
indicated . . O
. . . O

the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
event . . O
in . . O
patients . . O
treated . . O
with . . O
toviaz . . O
was . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
. . . O

the . . O
occurrence . . O
of . . O
adverse . . O
reactions . . O
was . . O
also . . O
evaluated . . O
in . . O
a . . O
larger . . O
pool . . O
of . . O
patients . . O
with . . O
type . . O
2 . . O
diabetes . . O
participating . . O
in . . O
7 . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
oral . . B-AdverseReaction
ulceration . . I-AdverseReaction
: . . O
mouth . . B-AdverseReaction
ulcers . . I-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
and . . O
oral . . B-AdverseReaction
mucositis . . I-AdverseReaction
are . . O
common . . O
. . . O

apparent . . O
homogeneity . . O
or . . O
heterogeneity . . O
among . . O
groups . . O
should . . O
not . . O
be . . O
over . . O
- . . O
interpreted . . O
. . . O

because . . O
there . . O
was . . O
no . . O
apparent . . O
dose . . O
- . . O
related . . O
increase . . O
in . . O
the . . O
majority . . O
of . . O
adverse . . O
events . . O
observed . . O
with . . O
benlysta . . O
, . . O
the . . O
safety . . O
data . . O
summarized . . O
below . . O
are . . O
presented . . O
for . . O
the . . O
3 . . O
doses . . O
pooled . . O
, . . O
unless . . O
otherwise . . O
indicated . . O
; . . O
the . . O
adverse . . O
reaction . . O
table . . O
displays . . O
the . . O
results . . O
for . . O
the . . O
recommended . . O
dose . . O
of . . O
10 . . O
mg . . O
/ . . O
kg . . O
compared . . O
with . . O
placebo . . O
. . . O

adverse . . O
reactions . . O
( . . O
> . . O
= . . O
3% . . O
) . . O
from . . O
three . . O
placebo . . O
- . . O
controlled . . O
trials . . O
in . . O
adults . . O
with . . O
chronic . . O
immune . . O
( . . O
idiopathic . . O
) . . O
thrombocytopenia . . O
adverse . . O
reaction . . O
promacta . . O
50 . . O
mg . . O
n . . O
= . . O
241 . . O
( . . O
% . . O
) . . O
placebo . . O
n . . O
= . . O
128 . . O
( . . O
% . . O
) . . O
nausea . . B-AdverseReaction
9 . . O
3 . . O
diarrhea . . B-AdverseReaction
9 . . O
7 . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
7 . . O
6 . . O
vomiting . . B-AdverseReaction
6 . . O
< . . O
1 . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
5 . . O
3 . . O
myalgia . . B-AdverseReaction
5 . . O
2 . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
5 . . O
3 . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
4 . . O
3 . . O
increased . . B-AdverseReaction
ast . . I-AdverseReaction
4 . . O
2 . . O
pharyngitis . . B-AdverseReaction
4 . . O
2 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
3 . . O
2 . . O
influenza . . B-AdverseReaction
3 . . O
2 . . O
paresthesia . . B-AdverseReaction
3 . . O
2 . . O
rash . . B-AdverseReaction
3 . . O
2 . . O
in . . O
the . . O
three . . O
controlled . . O
clinical . . O
chronic . . O
itp . . O
trials . . O
, . . O
alopecia . . B-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
and . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
were . . O
the . . O
adverse . . O
reactions . . O
reported . . O
in . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
promacta . . O
and . . O
in . . O
no . . O
patients . . O
who . . O
received . . O
placebo . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
below . . O
and . . O
elsewhere . . O
in . . O
labeling . . O
: . . O

the . . O
total . . O
number . . O
of . . O
nulojix . . O
patients . . O
from . . O
these . . O
three . . O
studies . . O
( . . O
949 . . O
) . . O
was . . O
compared . . O
to . . O
the . . O
pooled . . O
cyclosporine . . O
control . . O
groups . . O
from . . O
all . . O
three . . O
studies . . O
( . . O
476 . . O
patients . . O
) . . O
. . . O

excerpt . . O
: . . O
* . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
0.5% . . O
) . . O
are . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
dizziness . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
bayer . . O
healthcare . . O
pharmaceuticals . . O
inc . . O
. . . O
at . . O
1-888-842-2937 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

the . . O
results . . O
of . . O
these . . O
evaluations . . O
were . . O
consistent . . O
with . . O
a . . O
retinal . . B-AdverseReaction
dystrophy . . I-AdverseReaction
, . . O
including . . O
abnormalities . . B-AdverseReaction
in . . I-AdverseReaction
the . . I-AdverseReaction
electroretinogram . . I-AdverseReaction
and . . O
electrooculogram . . O
of . . O
both . . O
patients . . O
, . . O
with . . O
abnormal . . B-AdverseReaction
fluorescein . . I-AdverseReaction
angiography . . I-AdverseReaction
and . . O
diminished . . B-AdverseReaction
sensitivity . . I-AdverseReaction
on . . I-AdverseReaction
visual . . I-AdverseReaction
field . . I-AdverseReaction
testing . . O
in . . O
one . . O
patient . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
perforations . . B-AdverseReaction
and . . O
fistulas . . B-AdverseReaction
, . . O
and . . O
hemorrhage . . B-AdverseReaction

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
hypotension . . O
after . . O
initiating . . O
therapy . . O
. . . O

interrupt . . O
and . . O
then . . O
reduce . . O
or . . O
discontinue . . O
zydelig . . O
. . . O

blood . . O
pressure . . O
should . . O
be . . O
well . . O
- . . O
controlled . . O
prior . . O
to . . O
initiating . . O
inlyta . . O
. . . O

patients . . O
with . . O
underlying . . O
hepatitis . . O
b . . O
or . . O
c . . O
may . . O
be . . O
at . . O
increased . . O
risk . . B-Factor
for . . O
worsening . . O
or . . O
development . . O
of . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
with . . O
use . . O
of . . O
tivicay . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

6.2 . . O
clinical . . O
trials . . O
experience . . O
in . . O
pediatric . . O
subjects . . O

patients . . O
receiving . . O
immunosuppressants . . O
, . . O
including . . O
nulojix . . O
, . . O
are . . O
at . . O
increased . . O
risk . . B-Factor
of . . O
developing . . O
bacterial . . O
, . . O
viral . . O
( . . O
cytomegalovirus . . O
[ . . O
cmv . . O
] . . O
and . . O
herpes . . O
) . . O
, . . O
fungal . . O
, . . O
and . . O
protozoal . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
including . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
described . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
: . . O

the . . O
effect . . O
of . . O
fanapt . . O
on . . O
the . . O
qt . . O
interval . . O
was . . O
augmented . . O
by . . O
the . . O
presence . . O
of . . O
cyp450 . . O
2d6 . . O
or . . O
3a4 . . O
metabolic . . O
inhibition . . O
( . . O
paroxetine . . O
20 . . O
mg . . O
once . . O
daily . . O
and . . O
ketoconazole . . O
200 . . O
mg . . O
twice . . O
daily . . O
, . . O
respectively . . O
) . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
types . . O
and . . O
frequency . . O
of . . O
common . . O
adverse . . O
reactions . . O
excluding . . O
hypoglycemia . . B-AdverseReaction
were . . O
similar . . O
to . . O
those . . O
listed . . O
in . . O
table . . O
1 . . O
. . . O

monitor . . O
renal . . O
function . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
reporting . . O
severe . . O
adverse . . O
gastrointestinal . . O
reactions . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
, . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.7 . . O
) . . O
] . . O
. . . O

monitor . . O
patients . . O
closely . . O
for . . O
need . . O
of . . O
emergency . . O
cardiorespiratory . . O
support . . O
( . . O
5.2 . . O
) . . O

cases . . O
of . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
( . . O
including . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
) . . O
, . . O
some . . O
with . . O
a . . O
fatal . . B-AdverseReaction
outcome . . O
, . . O
have . . O
been . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
afinitor . . O
[ . . O
see . . O
laboratory . . O
tests . . O
and . . O
monitoring . . O
( . . O
5.8 . . O
) . . O
] . . O
. . . O

the . . O
adverse . . O
reactions . . O
reported . . O
in . . O
more . . O
than . . O
one . . O
subject . . O
within . . O
the . . O
studies . . O
are . . O
shown . . O
in . . O
table . . O
2 . . O
. . . O

doses . . O
ranged . . O
from . . O
18 . . O
to . . O
98 . . O
units . . O
/ . . O
kg . . O
, . . O
with . . O
a . . O
median . . O
dose . . O
of . . O
49 . . O
units . . O
/ . . O
kg . . O
. . . O

however . . O
, . . O
by . . O
the . . O
end . . O
of . . O
the . . O
third . . O
year . . O
, . . O
the . . O
cumulative . . O
incidence . . O
of . . O
nodat . . B-AdverseReaction
was . . O
8% . . O
( . . O
24 . . O
/ . . O
304 . . O
) . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
and . . O
10% . . O
( . . O
29 . . O
/ . . O
280 . . O
) . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
cyclosporine . . O
regimen . . O
. . . O

5.2 . . O
lack . . O
of . . O
interchangeability . . O
between . . O
botulinum . . O
toxin . . O
products . . O

post . . O
- . . O
baseline . . O
qt . . B-AdverseReaction
prolongations . . I-AdverseReaction
exceeding . . O
500 . . B-Severity
msec . . I-Severity
were . . O
reported . . O
at . . O
comparable . . O
rates . . O
for . . O
saphris . . O
and . . O
placebo . . O
in . . O
these . . O
short . . O
- . . O
term . . O
trials . . O
. . . O

5.14 . . O
glaucoma . . O
and . . O
cataracts . . O

in . . O
cases . . O
of . . O
symptomatic . . O
bradycardia . . O
that . . O
is . . O
not . . O
life . . O
- . . O
threatening . . O
, . . O
hold . . O
xalkori . . O
until . . O
recovery . . O
to . . O
asymptomatic . . O
bradycardia . . O
or . . O
to . . O
a . . O
heart . . O
rate . . O
of . . O
60 . . O
bpm . . O
or . . O
above . . O
, . . O
re . . O
- . . O
evaluate . . O
the . . O
use . . O
of . . O
concomitant . . O
medications . . O
, . . O
and . . O
adjust . . O
the . . O
dose . . O
of . . O
xalkori . . O
. . . O

six . . O
patients . . O
out . . O
of . . O
the . . O
403 . . O
who . . O
were . . O
treated . . O
with . . O
the . . O
nulojix . . O
regimen . . O
of . . O
higher . . O
cumulative . . O
dose . . O
and . . O
more . . O
frequent . . O
dosing . . O
than . . O
recommended . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
( . . O
1.5% . . O
) . . O
were . . O
reported . . O
to . . O
have . . O
developed . . O
cns . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
including . . O
2 . . O
cases . . O
of . . O
cryptococcal . . B-AdverseReaction
meningitis . . I-AdverseReaction
, . . O
one . . O
case . . O
of . . O
chagas . . B-AdverseReaction
encephalitis . . I-AdverseReaction
with . . O
cryptococcal . . B-AdverseReaction
meningitis . . I-AdverseReaction
, . . O
one . . O
case . . O
of . . O
cerebral . . B-AdverseReaction
aspergillosis . . I-AdverseReaction
, . . O
one . . O
case . . O
of . . O
west . . B-AdverseReaction
nile . . I-AdverseReaction
encephalitis . . I-AdverseReaction
, . . O
and . . O
one . . O
case . . O
of . . O
pml . . B-AdverseReaction
( . . O
discussed . . O
above . . O
) . . O
. . . O

before . . O
using . . O
dalvance . . O
, . . O
inquire . . O
carefully . . O
about . . O
previous . . O
hypersensitivity . . O
reactions . . O
to . . O
glycopeptides . . O
, . . O
and . . O
due . . O
to . . O
the . . O
possibility . . O
of . . O
cross . . O
- . . O
sensitivity . . O
, . . O
exercise . . O
caution . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
glycopeptide . . O
allergy . . O
[ . . O
see . . O
patient . . O
counseling . . O
information . . O
( . . O
17 . . O
) . . O
] . . O
. . . O

treat . . O
hypothyroidism . . O
and . . O
hyperthyroidism . . O
according . . O
to . . O
standard . . O
medical . . O
practice . . O
to . . O
maintain . . O
euthyroid . . O
state . . O
. . . O

( . . O
5.1 . . O
) . . O

( . . O
27% . . O
versus . . O
6% . . O
) . . O
and . . O
required . . O
local . . O
or . . O
systemic . . O
treatment . . O
for . . O
the . . O
reactions . . O
( . . O
36% . . O
versus . . O
11% . . O
) . . O
. . . O

arcapta . . O
neohaler . . O
is . . O
not . . O
indicated . . O
for . . O
the . . O
treatment . . O
of . . O
asthma . . O
[ . . O
see . . O
b . . O
oxed . . O
warning . . O
and . . O
w . . O
arning . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

s . . O
also . . O
includes . . O
the . . O
flexible . . O
- . . O
dose . . O
trial . . O
( . . O
n . . O
= . . O
90 . . O
) . . O
. . . O

the . . O
reactions . . O
have . . O
generally . . O
consisted . . O
of . . O
skin . . B-AdverseReaction
erythema . . I-AdverseReaction
and . . O
pruritis . . B-AdverseReaction
and . . O
have . . O
either . . O
resolved . . O
spontaneously . . O
or . . O
following . . O
the . . O
administration . . O
of . . O
corticosteroids . . O
and . . O
anti . . O
- . . O
histamines . . O
. . . O

5.4 . . O
hepatic . . O
toxicity . . O

in . . O
the . . O
event . . O
of . . O
a . . O
severe . . O
reaction . . O
, . . O
discontinue . . O
dificid . . O
. . . O

of . . O
symptoms . . O
between . . O
hypersensitivity . . O
reactions . . O
and . . O
hereditary . . O
angioedema . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
trial . . O
in . . O
at . . O
least . . O
10% . . O
of . . O
patients . . O
in . . O
the . . O
vimizim . . O
2 . . O
mg . . O
/ . . O
kg . . O
once . . O
per . . O
week . . O
group . . O
and . . O
with . . O
a . . O
higher . . O
incidence . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O

eleven . . O
cases . . O
of . . O
mas . . B-AdverseReaction
were . . O
observed . . O
in . . O
201 . . O
sjia . . O
patients . . O
treated . . O
with . . O
canakinumab . . O
in . . O
clinical . . O
trials . . O
. . . O

face . . O
/ . . O
scalp . . O
adverse . . O
reactions . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
, . . O
0.015% . . O
( . . O
n . . O
= . . O
274 . . O
) . . O
vehicle . . O
( . . O
n . . O
= . . O
271 . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
42 . . O
( . . O
15% . . O
) . . O
1 . . O
( . . O
0% . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pruritus . . I-AdverseReaction
22 . . O
( . . O
8% . . O
) . . O
3 . . O
( . . O
1% . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
infection . . I-AdverseReaction
7 . . O
( . . O
3% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
periorbital . . B-AdverseReaction
edema . . I-AdverseReaction
7 . . O
( . . O
3% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
headache . . B-AdverseReaction
6 . . O
( . . O
2% . . O
) . . O
3 . . O
( . . O
1% . . O
) . . O

patients . . O
with . . O
left . . O
ventricular . . O
outflow . . O
obstruction . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
aortic . . O
stenosis . . O
, . . O
idiopathic . . O
hypertrophic . . O
subaortic . . O
stenosis . . O
) . . O
and . . O
those . . O
with . . O
severely . . O
impaired . . O
autonomic . . O
control . . O
of . . O
blood . . O
pressure . . O
can . . O
be . . O
particularly . . O
sensitive . . O
to . . O
the . . O
actions . . O
of . . O
vasodilators . . O
, . . O
including . . O
stendra . . O
. . . O

laboratory . . O
abnormalities . . O
in . . O
treatment . . O
- . . O
experienced . . O
patients . . O

administer . . O
corticosteroid . . O
eye . . O
drops . . O
to . . O
patients . . O
who . . O
develop . . O
uveitis . . O
, . . O
iritis . . O
, . . O
or . . O
episcleritis . . O
. . . O

indwelling . . O
epidural . . O
or . . O
intrathecal . . O
catheters . . O
should . . O
not . . O
be . . O
removed . . O
earlier . . O
than . . O
24 . . O
hours . . O
after . . O
the . . O
last . . O
administration . . O
of . . O
eliquis . . O
. . . O

hypoglycemia . . O

( . . O
5.1 . . O
) . . O
* . . O
patients . . O
who . . O
fail . . O
to . . O
show . . O
substantial . . O
clinical . . O
benefit . . O
after . . O
adequate . . O
titration . . O
should . . O
be . . O
discontinued . . O
from . . O
potiga . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
30% . . O
) . . O
were . . O
stomatitis . . B-AdverseReaction
, . . O
infections . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
and . . O
diarrhea . . B-AdverseReaction
. . . O

the . . O
percentage . . O
of . . O
patients . . O
who . . O
withdrew . . O
from . . O
the . . O
study . . O
due . . O
to . . O
adverse . . O
events . . O
was . . O
6.1% . . O
and . . O
7.0% . . O
for . . O
the . . O
placebo . . O
and . . O
prolia . . O
groups . . O
, . . O
respectively . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
ge . . O
healthcare . . O
at . . O
1-800-654-0118 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

all . . O
of . . O
the . . O
thrombotic . . B-AdverseReaction
complications . . I-AdverseReaction
reported . . O
in . . O
the . . O
group . . O
that . . O
received . . O
promacta . . O
were . . O
portal . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
( . . O
pvt . . B-AdverseReaction
) . . O
. . . O

the . . O
safety . . O
of . . O
reinitiating . . O
kyprolis . . O
therapy . . O
in . . O
patients . . O
previously . . O
experiencing . . O
pres . . O
is . . O
not . . O
known . . O
. . . O

the . . O
onset . . O
tends . . O
to . . O
be . . O
within . . O
the . . O
first . . O
treatment . . O
cycle . . O
of . . O
treanda . . O
and . . O
, . . O
without . . O
intervention . . O
, . . O
may . . B-Factor
lead . . O
to . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
and . . O
death . . B-AdverseReaction
. . . O

if . . O
such . . O
signs . . O
or . . O
symptoms . . O
are . . O
present . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
evaluated . . O
immediately . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
. . . O

sustained . . B-Severity
blood . . B-AdverseReaction
pressure . . I-AdverseReaction
increases . . I-AdverseReaction
could . . O
have . . O
adverse . . O
consequences . . O
. . . O

the . . O
ophthalmologic . . O
monitoring . . O
program . . O
should . . O
include . . O
visual . . O
acuity . . O
testing . . O
and . . O
dilated . . O
fundus . . O
photography . . O
. . . O

adverse . . O
reaction . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
( . . O
n . . O
= . . O
410 . . O
) . . O
% . . O
vilanterol . . O
25 . . O
mcg . . O
( . . O
n . . O
= . . O
408 . . O
) . . O
% . . O
fluticasone . . O
furoate . . O
100 . . O
mcg . . O
( . . O
n . . O
= . . O
410 . . O
) . . O
% . . O
placebo . . O
( . . O
n . . O
= . . O
412 . . O
) . . O
% . . O
infections . . O
and . . O
infestations . . O
nasopharyngitis . . B-AdverseReaction
9 . . O
10 . . O
8 . . O
8 . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
7 . . O
5 . . O
4 . . O
3 . . O
oropharyngeal . . B-AdverseReaction
candidiasis . . I-AdverseReaction
a . . O
5 . . O
2 . . O
3 . . O
2 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
7 . . O
9 . . O
7 . . O
5 . . O
a . . O
includes . . O
oral . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
candidiasis . . B-AdverseReaction
, . . O
and . . O
fungal . . B-AdverseReaction
oropharyngitis . . I-AdverseReaction
. . . O

in . . O
some . . O
instances . . O
, . . O
hbv . . B-AdverseReaction
reactivation . . I-AdverseReaction
occurring . . O
in . . O
conjunction . . O
with . . O
tnf . . O
- . . O
blocker . . O
therapy . . O
has . . O
been . . O
fatal . . B-AdverseReaction
. . . O

table . . O
2 . . O
adverse . . O
drug . . O
reactionsfrequencies . . O
of . . O
adverse . . O
reactions . . O
are . . O
based . . O
on . . O
all . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
events . . O
, . . O
attributed . . O
to . . O
study . . O
drugs . . O
. . . O

table . . O
2 . . O
. . . O

the . . O
frequency . . O
of . . O
2+ . . O
proteinuria . . B-AdverseReaction
was . . O
similar . . O
between . . O
the . . O
two . . O
treatment . . O
groups . . O
between . . O
one . . O
and . . O
three . . O
years . . O
after . . O
transplantation . . O
( . . O
< . . O
10% . . O
in . . O
both . . O
studies . . O
) . . O
. . . O

apparent . . O
homogeneity . . O
or . . O
heterogeneity . . O
among . . O
groups . . O
should . . O
not . . O
be . . O
over . . O
- . . O
interpreted . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

in . . O
this . . O
trial . . O
, . . O
use . . O
of . . O
esas . . O
was . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . O
of . . O
thromboembolic . . O
events . . O
including . . O
pulmonary . . O
embolism . . O
, . . O
acute . . O
myocardial . . O
infarction . . O
, . . O
cerebrovascular . . O
accident . . O
, . . O
and . . O
deep . . O
vein . . O
thrombosis . . O
compared . . O
to . . O
ribavirin . . O
dose . . O
reduction . . O
alone . . O
. . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
endocrinopathies . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
* . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
who . . O
are . . O
treated . . O
with . . O
atypical . . B-DrugClass
antipsychotic . . I-DrugClass
drugs . . I-DrugClass
are . . O
at . . O
an . . O
increased . . O
risk . . O
of . . O
death . . B-AdverseReaction
and . . O
cerebrovascular . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
, . . O
including . . O
stroke . . B-AdverseReaction
. . . O

6 . . O
adverse . . O
reactions . . O

in . . O
addition . . O
, . . O
a . . O
two . . O
- . . O
week . . O
dose . . O
- . . O
ranging . . O
trial . . O
was . . O
conducted . . O
in . . O
511 . . O
adult . . O
patients . . O
with . . O
mild . . O
persistent . . O
asthma . . O
taking . . O
inhaled . . O
corticosteroids . . O
. . . O

however . . O
, . . O
the . . O
duration . . O
of . . O
exposure . . O
associated . . O
with . . O
increased . . O
risk . . O
is . . O
not . . O
consistent . . O
across . . O
all . . O
epidemiologic . . O
studies . . O
, . . O
and . . O
some . . O
report . . O
no . . O
association . . O
. . . O

immune . . O
: . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
angioedema . . B-AdverseReaction

some . . O
patients . . O
have . . O
been . . O
rechallenged . . O
and . . O
have . . O
continued . . O
to . . O
receive . . O
alglucosidase . . O
alfa . . O
under . . O
close . . O
clinical . . O
supervision . . O
. . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
grade . . B-Severity
3 . . I-Severity
/ . . O
4 . . O
arterial . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
were . . O
reported . . O
in . . O
4 . . O
/ . . O
359 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
4 . . O
/ . . O
355 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

you . . O
can . . O
ask . . O
your . . O
pharmacist . . O
or . . O
healthcare . . O
provider . . O
for . . O
information . . O
about . . O
duavee . . O
that . . O
is . . O
written . . O
for . . O
health . . O
professionals . . O
. . . O

among . . O
the . . O
patients . . O
who . . O
experienced . . O
diarrhea . . O
, . . O
the . . O
median . . O
number . . O
of . . O
episodes . . O
of . . O
diarrhea . . O
per . . O
patient . . O
during . . O
treatment . . O
with . . O
bosulif . . O
was . . O
3 . . O
( . . O
range . . O
1-221 . . O
) . . O
. . . O

( . . O
6.1 . . O
) . . O

* . . O
eye . . O
disorders . . O
: . . O
increased . . B-AdverseReaction
lacrimation . . I-AdverseReaction
* . . O
gastrointestinal . . O
disorders . . O
: . . O
dyspepsia . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
* . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
* . . O
infections . . O
and . . O
infestations . . O
: . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
* . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
hypokalemia . . B-AdverseReaction
* . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
, . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
* . . O
nervous . . O
system . . O
disorders . . O
: . . O
dysgeusia . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
* . . O
psychiatric . . O
disorders . . O
: . . O
insomnia . . B-AdverseReaction
, . . O
depression . . B-AdverseReaction
* . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
rash . . B-AdverseReaction
6 . . O
. . . O

5.14 . . O
potential . . O
for . . O
cognitive . . O
and . . O
motor . . O
impairment . . O

imbruvica . . O
may . . B-Factor
increase . . O
the . . O
risk . . O
of . . O
hemorrhage . . B-AdverseReaction
in . . O
patients . . O
receiving . . O
antiplatelet . . O
or . . O
anticoagulant . . O
therapies . . O
. . . O

withhold . . O
yervoy . . O
dosing . . O
in . . O
patients . . O
with . . O
moderate . . O
neuropathy . . O
( . . O
not . . O
interfering . . O
with . . O
daily . . O
activities . . O
) . . O
. . . O

none . . O
of . . O
the . . O
subjects . . O
tested . . O
positive . . O
for . . O
neutralizing . . O
antibodies . . O
. . . O

monitor . . O
and . . O
manage . . O
patients . . O
using . . O
standards . . O
of . . O
care . . O
, . . O
including . . O
antidiarrheals . . O
, . . O
antiemetics . . O
, . . O
and . . O
fluid . . O
replacement . . O
. . . O

they . . O
are . . O
not . . O
interchangeable . . O
with . . O
the . . O
other . . O
preparations . . O
of . . O
botulinum . . O
toxin . . O
products . . O
and . . O
, . . O
therefore . . O
, . . O
units . . O
of . . O
biological . . O
activity . . O
of . . O
xeomin . . O
cannot . . O
be . . O
compared . . O
to . . O
or . . O
converted . . O
into . . O
units . . O
of . . O
any . . O
other . . O
botulinum . . O
toxin . . O
products . . O
assessed . . O
with . . O
any . . O
other . . O
specific . . O
assay . . O
method . . O
[ . . O
see . . O
description . . O
( . . O
11 . . O
) . . O
] . . O
. . . O

errors . . O
may . . O
also . . O
occur . . O
in . . O
cases . . O
with . . O
severe . . O
brain . . O
atrophy . . O
that . . O
limits . . O
the . . O
ability . . O
to . . O
distinguish . . O
gray . . O
and . . O
white . . O
matter . . O
on . . O
the . . O
neuraceq . . O
scan . . O
. . . O

the . . O
adverse . . O
reactions . . O
reported . . O
most . . O
frequently . . O
as . . O
the . . O
reason . . O
for . . O
discontinuation . . O
of . . O
treatment . . O
included . . O
anemia . . B-AdverseReaction
, . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
multi . . B-AdverseReaction
- . . I-AdverseReaction
organ . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

the . . O
median . . O
time . . O
to . . O
onset . . O
of . . O
skin . . B-AdverseReaction
toxicity . . I-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
was . . O
37 . . O
days . . O
( . . O
range . . O
: . . O
1 . . O
to . . O
225 . . O
days . . O
) . . O
and . . O
median . . O
time . . O
to . . O
resolution . . O
of . . O
skin . . B-AdverseReaction
toxicity . . I-AdverseReaction
was . . O
33 . . O
days . . O
( . . O
range . . O
: . . O
3 . . O
to . . O
421 . . O
days . . O
) . . O
. . . O

to . . O
enroll . . O
in . . O
the . . O
e . . O
. . . O
a . . O
. . . O
s . . O
. . . O
e . . O
. . . O
program . . O
, . . O
an . . O
authorized . . O
hospital . . O
representative . . O
must . . O
acknowledge . . O
that . . O
: . . O

the . . O
imbalance . . O
in . . O
deaths . . B-AdverseReaction
is . . O
unexplained . . O
; . . O
no . . O
discernible . . O
pattern . . O
between . . O
death . . B-AdverseReaction
and . . O
sputum . . O
conversion . . O
, . . O
relapse . . O
, . . O
sensitivity . . O
to . . O
other . . O
drugs . . O
used . . O
to . . O
treat . . O
tuberculosis . . O
, . . O
hiv . . O
status . . O
, . . O
and . . O
severity . . O
of . . O
disease . . O
was . . O
observed . . O
. . . O

5.7 . . O
transferring . . O
patients . . O
from . . O
systemic . . O
corticosteroid . . O
therapy . . O

adverse . . O
reactions . . O
that . . O
occurred . . O
with . . O
a . . O
frequency . . O
> . . O
1% . . O
were . . O
associated . . O
with . . O
the . . O
injection . . O
site . . O
( . . O
1.3% . . O
) . . O
, . . O
problems . . O
such . . O
as . . O
hematoma . . O
and . . O
bruising . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
hepatotoxicity . . B-AdverseReaction
: . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
have . . O
led . . O
to . . O
drug . . O
interruption . . O
, . . O
dose . . O
modification . . O
and . . O
/ . . O
or . . O
discontinuation . . O
. . . O

these . . O
two . . O
trials . . O
also . . O
included . . O
a . . O
total . . O
of . . O
403 . . O
patients . . O
treated . . O
with . . O
a . . O
nulojix . . O
regimen . . O
of . . O
higher . . O
cumulative . . O
dose . . O
and . . O
more . . O
frequent . . O
dosing . . O
than . . O
recommended . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
increased . . B-AdverseReaction
ldl . . I-AdverseReaction
- . . I-AdverseReaction
c . . I-AdverseReaction
: . . O
monitor . . O
and . . O
treat . . O
per . . O
standard . . O
of . . O
care . . O
. . . O

table . . O
11 . . O
: . . O
key . . O
laboratory . . O
abnormalities . . O
reported . . O
in . . O
afinitor . . O
- . . O
treated . . O
patients . . O
with . . O
sega . . O
in . . O
study . . O
1 . . O
grading . . O
according . . O
to . . O
ctcae . . O
version . . O
3.0 . . O
afinitor . . O
n . . O
= . . O
78 . . O
placebo . . O
n . . O
= . . O
39 . . O
all . . O
grades . . O
% . . O
grade . . O
3 . . O
% . . O
grade . . O
4 . . O
% . . O
all . . O
grades . . O
% . . O
grade . . O
3 . . O
% . . O
grade . . O
4 . . O
% . . O
hematology . . O
elevated . . B-AdverseReaction
partial . . I-AdverseReaction
thromboplastin . . I-AdverseReaction
time . . I-AdverseReaction
72 . . O
3 . . O
0 . . O
44 . . O
5 . . O
0 . . O
neutropenia . . B-AdverseReaction
46 . . O
9 . . O
0 . . O
41 . . O
3 . . O
0 . . O
anemia . . B-AdverseReaction
41 . . O
0 . . O
0 . . O
21 . . O
0 . . O
0 . . O
clinical . . O
chemistry . . O
hypercholesterolemia . . B-AdverseReaction
81 . . O
0 . . O
0 . . O
39 . . O
0 . . O
0 . . O
elevated . . B-AdverseReaction
aspartate . . I-AdverseReaction
transaminase . . I-AdverseReaction
( . . O
ast . . O
) . . O
33 . . O
0 . . O
0 . . O
0 . . O
0 . . O
0 . . O
hypertriglyceridemia . . B-AdverseReaction
27 . . O
0 . . O
0 . . O
15 . . O
0 . . O
0 . . O
elevated . . B-AdverseReaction
alanine . . I-AdverseReaction
transaminase . . I-AdverseReaction
( . . O
alt . . O
) . . O
18 . . O
0 . . O
0 . . O
3 . . O
0 . . O
0 . . O
hypophosphatemia . . B-AdverseReaction
9 . . O
1 . . O
0 . . O
3 . . O
0 . . O
0 . . O
longer . . O
- . . O
term . . O
follow . . O
- . . O
up . . O
of . . O
34.2 . . O
months . . O
( . . O
range . . O
4.7 . . O
to . . O
47.1 . . O
months . . O
) . . O
from . . O
a . . O
non . . O
- . . O
randomized . . O
, . . O
open . . O
- . . O
label . . O
, . . O
28 . . O
- . . O
patient . . O
trial . . O
resulted . . O
in . . O
the . . O
following . . O
additional . . O
notable . . O
adverse . . O
reactions . . O
and . . O
key . . O
laboratory . . O
abnormalities . . O
: . . O
cellulitis . . B-AdverseReaction
( . . O
29% . . O
) . . O
, . . O
hyperglycemia . . B-AdverseReaction
( . . O
25% . . O
) . . O
, . . O
and . . O
elevated . . B-AdverseReaction
creatinine . . I-AdverseReaction
( . . O
14% . . O
) . . O
. . . O

additionally . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
, . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

6.2 . . O
immunogenicity . . O

* . . O
bipolar . . O
disorder . . O
adults . . O
( . . O
monotherapy . . O
) . . O
: . . O
somnolence . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
extrapyramidal . . B-AdverseReaction
symptoms . . I-AdverseReaction
other . . B-Factor
than . . I-Factor
akathisia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
weight . . I-AdverseReaction
. . . O

5.6 . . O
activation . . O
of . . O
mania . . O
/ . . O
hypomania . . O

patients . . O
were . . O
randomized . . O
in . . O
a . . O
2 . . O
: . . O
1 . . O
ratio . . O
and . . O
received . . O
alglucosidase . . O
alfa . . O
or . . O
placebo . . O
every . . O
other . . O
week . . O
for . . O
78 . . O
weeks . . O
( . . O
18 . . O
months . . O
) . . O
. . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
a . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
receiving . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
[ . . O
seeuse . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

women . . O
with . . O
hypertriglyceridemia . . O
, . . O
or . . O
a . . O
family . . O
history . . O
thereof . . O
, . . O
may . . O
be . . O
at . . O
an . . O
increased . . O
risk . . O
of . . O
pancreatitis . . B-AdverseReaction
when . . O
using . . O
cocs . . B-DrugClass
. . . O

see . . O
table . . O
2 . . O
for . . O
a . . O
listing . . O
of . . O
drugs . . O
that . . O
are . . O
contraindicated . . O
for . . O
use . . O
with . . O
victrelis . . O
due . . O
to . . O
potentially . . O
life . . O
- . . O
threatening . . O
adverse . . O
events . . O
, . . O
significant . . O
drug . . O
interactions . . O
or . . O
loss . . O
of . . O
virologic . . O
activity . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

agranulocytosis . . B-AdverseReaction
( . . O
including . . O
fatal . . B-AdverseReaction
cases . . O
) . . O
has . . O
been . . O
reported . . O
with . . O
other . . B-DrugClass
agents . . I-DrugClass
in . . I-DrugClass
the . . I-DrugClass
class . . I-DrugClass
. . . O

for . . O
patients . . O
at . . O
risk . . O
for . . O
chronically . . O
reduced . . O
renal . . O
function . . O
( . . O
for . . O
example . . O
age . . O
> . . O
60 . . O
years . . O
, . . O
hypertension . . O
or . . O
diabetes . . O
) . . O
, . . O
estimate . . O
the . . O
glomerular . . O
filtration . . O
rate . . O
( . . O
gfr . . O
) . . O
through . . O
laboratory . . O
testing . . O
( . . O
5.1 . . O
) . . O

if . . O
the . . O
patient . . O
is . . O
known . . O
or . . O
strongly . . O
suspected . . O
of . . O
having . . O
had . . O
a . . O
hypersensitivity . . O
reaction . . O
to . . O
datscan . . O
, . . O
the . . O
decision . . O
to . . O
administer . . O
datscan . . O
should . . O
be . . O
based . . O
upon . . O
an . . O
assessment . . O
of . . O
the . . O
expected . . O
benefits . . O
compared . . O
to . . O
the . . O
potential . . O
hypersensitivity . . O
risks . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
severe . . B-Severity
to . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
endocrinopathies . . I-AdverseReaction
( . . O
requiring . . O
hospitalization . . O
, . . O
urgent . . O
medical . . O
intervention . . O
, . . O
or . . O
interfering . . O
with . . O
activities . . O
of . . O
daily . . O
living . . O
; . . O
grade . . B-Severity
3-4 . . I-Severity
) . . O
occurred . . O
in . . O
9 . . O
( . . O
1.8% . . O
) . . O
yervoy . . O
- . . O
treated . . O
patients . . O
. . . O

table . . O
2 . . O
: . . O
change . . O
in . . O
glucose . . O
mean . . O
change . . O
from . . O
baseline . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
3-6 . . O
months . . O
6-12 . . O
months . . O
> . . O
12 . . O
months . . O
fanapt . . O
10-16 . . O
mg . . O
/ . . O
day . . O
1.8 . . O
( . . O
n . . O
= . . O
773 . . O
) . . O
5.4 . . O
( . . O
n . . O
= . . O
723 . . O
) . . O
5.4 . . O
( . . O
n . . O
= . . O
425 . . O
) . . O
fanapt . . O
20-24 . . O
mg . . O
/ . . O
day . . O
- . . O
3.6 . . O
( . . O
n . . O
= . . O
34 . . O
) . . O
- . . O
9.0 . . O
( . . O
n . . O
= . . O
31 . . O
) . . O
- . . O
18.0 . . O
( . . O
n . . O
= . . O
20 . . O
) . . O
dyslipidemia . . O

reproductive . . O
system . . O
and . . O
breast . . O
disorders . . O
: . . O
menstrual . . B-AdverseReaction
disorder . . I-AdverseReaction
. . . O

bone . . O
mineral . . O
density . . O
: . . O

careful . . O
monitoring . . O
and . . O
appropriate . . O
dose . . O
adjustments . . O
for . . O
adverse . . O
reactions . . O
are . . O
recommended . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
, . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
neutropenia . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction

the . . O
rates . . O
of . . O
adverse . . O
reactions . . O
were . . O
higher . . O
in . . O
the . . O
combined . . O
controlled . . O
and . . O
open . . O
- . . O
label . . O
experience . . O
than . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

no . . B-Negation
comparator . . O
- . . O
treated . . O
subject . . O
with . . O
normal . . O
baseline . . O
transaminases . . O
had . . O
post . . O
- . . O
baseline . . O
alt . . B-AdverseReaction
elevation . . I-AdverseReaction
greater . . O
than . . O
10 . . B-Severity
times . . I-Severity
uln . . I-Severity
. . . O

if . . O
neurological . . O

table . . O
5 . . O
: . . O
key . . O
laboratory . . O
abnormalities . . O
reported . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
patients . . O
with . . O
advanced . . O
pnet . . O
grading . . O
according . . O
to . . O
ctcae . . O
version . . O
3.0 . . O
laboratory . . O
parameter . . O
afinitor . . O
n . . O
= . . O
204 . . O
placebo . . O
n . . O
= . . O
203 . . O
all . . O
grades . . O
grade . . O
3-4 . . O
all . . O
grades . . O
grade . . O
3-4 . . O
% . . O
% . . O
% . . O
% . . O
hematology . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
86 . . O
15 . . O
63 . . O
1 . . O
lymphocytes . . B-AdverseReaction
decreased . . I-AdverseReaction
45 . . O
16 . . O
22 . . O
4 . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
45 . . O
3 . . O
11 . . O
0 . . O
wbc . . B-AdverseReaction
decreased . . I-AdverseReaction
43 . . O
2 . . O
13 . . O
0 . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
30 . . O
4 . . O
17 . . O
2 . . O
clinical . . O
chemistry . . O
alkaline . . B-AdverseReaction
phosphatase . . I-AdverseReaction
increased . . I-AdverseReaction
74 . . O
8 . . O
66 . . O
8 . . O
glucose . . B-AdverseReaction
( . . I-AdverseReaction
fasting . . I-AdverseReaction
) . . I-AdverseReaction
increased . . I-AdverseReaction
75 . . O
17 . . O
53 . . O
6 . . O
cholesterol . . B-AdverseReaction
increased . . I-AdverseReaction
66 . . O
0.5 . . O
22 . . O
0 . . O
bicarbonate . . B-AdverseReaction
decreased . . I-AdverseReaction
56 . . O
0 . . O
40 . . O
0 . . O
aspartate . . O
transaminase . . O
( . . O
ast . . O
) . . O
increased . . O
56 . . O
4 . . O
41 . . O
4 . . O
alanine . . O
transaminase . . O
( . . O
alt . . O
) . . O
increased . . O
48 . . O
2 . . O
35 . . O
2 . . O
phosphate . . B-AdverseReaction
decreased . . I-AdverseReaction
40 . . O
10 . . O
14 . . O
3 . . O
triglycerides . . B-AdverseReaction
increased . . I-AdverseReaction
39 . . O
0 . . O
10 . . O
0 . . O
calcium . . B-AdverseReaction
decreased . . I-AdverseReaction
37 . . O
0.5 . . O
12 . . O
0 . . O
potassium . . B-AdverseReaction
decreased . . I-AdverseReaction
23 . . O
4 . . O
5 . . O
0 . . O
creatinine . . B-AdverseReaction
increased . . I-AdverseReaction
19 . . O
2 . . O
14 . . O
0 . . O
sodium . . B-AdverseReaction
decreased . . I-AdverseReaction
16 . . O
1 . . O
16 . . O
1 . . O
albumin . . B-AdverseReaction
decreased . . I-AdverseReaction
13 . . O
1 . . O
8 . . O
0 . . O
bilirubin . . B-AdverseReaction
increased . . I-AdverseReaction
10 . . O
1 . . O
14 . . O
2 . . O
potassium . . B-AdverseReaction
increased . . I-AdverseReaction
7 . . O
0 . . O
10 . . O
0.5 . . O
6.3 . . O
clinical . . O
study . . O
experience . . O
in . . O
advanced . . O
renal . . O
cell . . O
carcinoma . . O
the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
afinitor . . O
( . . O
n . . O
= . . O
274 . . O
) . . O
and . . O
placebo . . O
( . . O
n . . O
= . . O
137 . . O
) . . O
in . . O
a . . O
randomized . . O
, . . O
controlled . . O
trial . . O
in . . O
patients . . O
with . . O
metastatic . . O
renal . . O
cell . . O
carcinoma . . O
who . . O
received . . O
prior . . O
treatment . . O
with . . O
sunitinib . . O
and . . O
/ . . O
or . . O
sorafenib . . O
. . . O

( . . O
2.3,5.2 . . O
) . . O
* . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
( . . O
ild . . B-AdverseReaction
) . . O
: . . O
occurs . . O
in . . O
1.5% . . O
of . . O
patients . . O
. . . O

progressive . . O
multifocal . . O
leukoencephalopathy . . O
( . . O
pml . . O
) . . O
is . . O
an . . O
often . . O
rapidly . . O
progressive . . O
and . . O
fatal . . O
opportunistic . . O
infection . . O
of . . O
the . . O
cns . . O
that . . O
is . . O
caused . . O
by . . O
the . . O
jc . . O
virus . . O
, . . O
a . . O
human . . O
polyoma . . O
virus . . O
. . . O

subgroup . . O
analyses . . O
of . . O
women . . O
50 . . O
to . . O
59 . . O
years . . O
of . . O
age . . O
suggest . . O
no . . B-Negation
increased . . O
risk . . O
of . . O
stroke . . B-AdverseReaction
for . . O
those . . O
women . . O
receiving . . O
conjugated . . B-DrugClass
estrogens . . I-DrugClass
( . . O
0.625 . . O
mg . . O
) . . O
- . . O
alone . . O
versus . . O
those . . O
receiving . . O
placebo . . O
( . . O
18 . . O
versus . . O
21 . . O
per . . O
10,000 . . O
women . . O
- . . O
years . . O
) . . O
. . . O

how . . O
the . . O
dose . . O
, . . O
route . . O
, . . O
and . . O
duration . . O
of . . O
corticosteroid . . O
administration . . O
affect . . O
the . . O
risk . . O
of . . O
developing . . O
a . . O
disseminated . . O
infection . . O
is . . O
not . . O
known . . O
. . . O

in . . O
this . . O
situation . . O
, . . O
the . . O
patient . . O
requires . . O
immediate . . O
reevaluation . . O
with . . O
reassessment . . O
of . . O
the . . O
treatment . . O
regimen . . O
, . . O
giving . . O
special . . O
consideration . . O
to . . O
the . . O
possible . . O
need . . O
for . . O
replacing . . O
the . . O
current . . O
strength . . O
of . . O
breo . . O
ellipta . . O
with . . O
a . . O
higher . . O
strength . . O
, . . O
adding . . O
additional . . O
inhaled . . O
corticosteroid . . O
, . . O
or . . O
initiating . . O
systemic . . O
corticosteroids . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
with . . O
peyronie's . . O
disease . . O
and . . O
at . . O
a . . O
greater . . O
incidence . . O
than . . O
placebo . . O
after . . O
up . . O
to . . O
four . . O
treatment . . O
cycles . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
combined . . O
a . . O
includes . . O
: . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
and . . O
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
were . . O
reported . . O
with . . O
the . . O
verbatim . . O
term . . O
of . . O
penile . . B-AdverseReaction
bruising . . I-AdverseReaction
or . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
bruising . . I-AdverseReaction
in . . O
87% . . O
of . . O
subjects . . O
. . . O
b . . O
includes . . O
: . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
swelling . . I-AdverseReaction
, . . O
penile . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
penile . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
local . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
scrotal . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
edema . . I-AdverseReaction
. . . O
c . . O
includes . . O
: . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
penile . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
discomfort . . I-AdverseReaction
. . . O
d . . O
includes . . O
: . . O
contusion . . B-AdverseReaction
, . . O
ecchymoses . . B-AdverseReaction
, . . O
penile . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
. . . O

patients . . O
who . . O
demonstrate . . O
hemodynamic . . O
instability . . O
on . . O
alpha . . O
- . . O
blocker . . O
therapy . . O
alone . . O
are . . O
at . . O
increased . . O
risk . . O
of . . O
symptomatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
with . . O
concomitant . . O
use . . O
of . . O
pde5 . . B-DrugClass
inhibitors . . I-DrugClass
. . . O

in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
transaminase . . O
elevations . . O
, . . O
more . . O
frequent . . O
monitoring . . O
of . . O
liver . . O
function . . O
tests . . O
should . . O
be . . O
considered . . O
. . . O

in . . O
arriving . . O
at . . O
a . . O
diagnosis . . O
, . . O
it . . O
is . . O
important . . O
to . . O
identify . . O
cases . . O
in . . O
which . . O
the . . O
clinical . . O
presentation . . O
includes . . O
both . . O
serious . . O
medical . . O
illness . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
pneumonia . . O
, . . O
systemic . . O
infection . . O
, . . O
etc . . O
. . . O
) . . O
and . . O
untreated . . O
or . . O
inadequately . . O
treated . . O
extrapyramidal . . O
signs . . O
and . . O
symptoms . . O
( . . O
eps . . O
) . . O
. . . O

excerpt . . O
: . . O
* . . O
cardiac . . B-AdverseReaction
toxicities . . I-AdverseReaction
include . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
and . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
with . . O
fatal . . B-AdverseReaction
outcome . . O
, . . O
and . . O
myocardial . . B-AdverseReaction
ischemia . . I-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
ipsen . . O
biopharmaceuticals . . O
, . . O
inc . . O
. . . O
at . . O
877-397-7671 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

there . . O
were . . O
no . . O
frequently . . O
occurring . . O
specific . . O
cardiovascular . . O
adverse . . O
reactions . . O
for . . O
arcapta . . O
neohaler . . O
75 . . O
mcg . . O
( . . O
frequency . . O
at . . O
least . . O
1% . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
. . . O

therapy . . O
with . . O
leucovorin . . O
should . . O
be . . O
continued . . O
until . . O
the . . O
methotrexate . . O
concentration . . O
has . . O
been . . O
maintained . . O
below . . O
the . . O
leucovorin . . O
treatment . . O
threshold . . O
for . . O
a . . O
minimum . . O
of . . O
3 . . O
days . . O
. . . O

table . . O
1 . . O
displays . . O
adverse . . O
reactions . . O
more . . O
common . . O
with . . O
dronedarone . . O
400 . . O
mg . . O
twice . . O
daily . . O
than . . O
with . . O
placebo . . O
in . . O
af . . O
or . . O
afl . . O
patients . . O
, . . O
presented . . O
by . . O
system . . O
organ . . O
class . . O
and . . O
by . . O
decreasing . . O
order . . O
of . . O
frequency . . O
. . . O

closely . . O
monitor . . O
patients . . O
for . . O
fever . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

table . . O
3 . . O
. . . O

none . . O
of . . O
these . . O
6 . . O
patients . . O
had . . O
neutralizing . . O
antibodies . . O
. . . O
in . . O
a . . O
study . . O
with . . O
erwinaze . . O
treatment . . O
by . . O
intravenous . . O
administration . . O
( . . O
study . . O
2 . . O
) . . O
, . . O
4 . . O
of . . O
30 . . O
( . . O
13.3% . . O
) . . O
patients . . O
treated . . O
with . . O
erwinaze . . O
developed . . O
anti . . O
- . . O
erwinaze . . O
antibodies . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
bleeding . . O
. . . O

2 . . O
one . . O
of . . O
these . . O
reactions . . O
was . . O
classified . . O
as . . O
grade . . O
3 . . O
in . . O
severity . . O
. . . O

severe . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
require . . O
immediate . . O
discontinuation . . O
of . . O
the . . O
jevtana . . O
infusion . . O
and . . O
administration . . O
of . . O
appropriate . . O
therapy . . O
. . . O

the . . O
following . . O
is . . O
a . . O
list . . O
of . . O
meddra . . O
terms . . O
that . . O
reflect . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactions . . O
in . . O
patients . . O
treated . . O
with . . O
fanapt . . O
at . . O
multiple . . O
doses . . O
> . . O
= . . O
4 . . O
mg . . O
/ . . O
day . . O
during . . O
any . . O
phase . . O
of . . O
a . . O
trial . . O
with . . O
the . . O
database . . O
of . . O
3210 . . O
fanapt . . O
- . . O
treated . . O
patients . . O
. . . O

5.2 . . O
paradoxical . . O
bronchospasm . . O

some . . O
of . . O
these . . O
events . . O
were . . O
reported . . O
in . . O
patients . . O
without . . O
known . . O
underlying . . O
renal . . O
disease . . O
. . . O

investigations . . O
- . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
liver . . B-AdverseReaction
function . . I-AdverseReaction
test . . I-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
prolactin . . I-AdverseReaction
increased . . I-AdverseReaction
. . . O

motion . . O
artifacts . . O
may . . O
distort . . O
the . . O
image . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

in . . O
a . . O
placebo . . O
controlled . . O
study . . O
in . . O
patients . . O
with . . O
permanent . . O
af . . O
increased . . O
rates . . O
of . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
were . . O
observed . . O
in . . O
patients . . O
with . . O
normal . . O
left . . O
ventricular . . O
function . . O
and . . O
no . . O
history . . O
of . . O
symptomatic . . O
heart . . O
failure . . O
, . . O
as . . O
well . . O
as . . O
those . . O
with . . O
a . . O
history . . O
of . . O
heart . . O
failure . . O
or . . O
left . . O
ventricular . . O
dysfunction . . O
. . . O

at . . O
screening . . O
, . . O
the . . O
mean . . O
postbronchodilator . . O
percent . . O
predicted . . O
fev1was . . O
48% . . O
( . . O
range . . O
: . . O
14% . . O
to . . O
87% . . O
) . . O
, . . O
the . . O
mean . . O
postbronchodilator . . O
fev1 . . O
/ . . O
forced . . O
vital . . O
capacity . . O
( . . O
fvc . . O
) . . O
ratio . . O
was . . O
47% . . O
( . . O
range . . O
: . . O
17% . . O
to . . O
88% . . O
) . . O
, . . O
and . . O
the . . O
mean . . O
percent . . O
reversibility . . O
was . . O
14% . . O
( . . O
range . . O
: . . O
- . . O
41% . . O
to . . O
152% . . O
) . . O
. . . O

adverse . . O
reactions . . O
that . . O
occurred . . O
at . . O
a . . O
frequency . . O
of . . O
> . . O
= . . O
10% . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
or . . O
cyclosporine . . O
control . . O
regimen . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
through . . O
three . . O
years . . O
are . . O
summarized . . O
by . . O
preferred . . O
term . . O
in . . O
decreasing . . O
order . . O
of . . O
frequency . . O
within . . O
table . . O
4 . . O
. . . O

5.1 . . O
laryngeal . . O
attacks . . O

5.7 . . O
withdrawal . . O
of . . O
aeds . . O

serious . . B-Severity
infections . . B-AdverseReaction
occurred . . O
at . . O
a . . O
rate . . O
of . . O
2.3% . . O
in . . O
the . . O
gilenya . . O
group . . O
versus . . O
1.6% . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

if . . O
infectious . . O
etiologies . . O
are . . O
not . . O
considered . . O
, . . O
there . . O
is . . O
a . . O
risk . . O
that . . O
patients . . O
with . . O
infectious . . O
etiologies . . O
will . . O
not . . O
receive . . O
the . . O
appropriate . . O
therapy . . O
and . . O
their . . O
disease . . O
may . . O
worsen . . O
. . . O

dalvance . . O
was . . O
discontinued . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
in . . O
53 . . O
/ . . O
1778 . . O
( . . O
3% . . O
) . . O
patients . . O
and . . O
the . . O
comparator . . O
was . . O
discontinued . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
in . . O
35 . . O
/ . . O
1224 . . O
( . . O
2.8% . . O
) . . O
patients . . O
. . . O

estrogens . . O
may . . O
cause . . O
an . . O
exacerbation . . O
of . . O
asthma . . O
, . . O
diabetes . . O
mellitus . . O
, . . O
epilepsy . . O
, . . O
migraine . . O
or . . O
porphyria . . O
, . . O
systemic . . O
lupus . . O
erythematosus . . O
, . . O
and . . O
hepatic . . O
hemangiomas . . O
and . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
women . . O
with . . O
these . . O
conditions . . O
. . . O

some . . O
of . . O
these . . O
reactions . . O
occurred . . O
after . . O
the . . O
first . . O
administration . . O
of . . O
cimzia . . O
. . . O

subjects . . O
ranged . . O
in . . O
age . . O
from . . O
18 . . O
to . . O
83 . . O
years . . O
, . . O
with . . O
an . . O
overall . . O
median . . O
age . . O
of . . O
46 . . O
years . . O
. . . O

5.6 . . O
interference . . O
with . . O
visualization . . O
of . . O
liver . . O
lesions . . O

5.4 . . O
neuropsychiatric . . O
symptoms . . O

bilirubin . . O

during . . O
the . . O
initial . . O
phase . . O
of . . O
combination . . O
antiretroviral . . O
treatment . . O
, . . O
patients . . O
whose . . O
immune . . O
system . . O
responds . . O
may . . O
develop . . O
an . . O
inflammatory . . B-AdverseReaction
response . . I-AdverseReaction
to . . O
indolent . . O
or . . O
residual . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
( . . O
such . . O
as . . O
mycobacterium . . B-AdverseReaction
avium . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
cytomegalovirus . . B-AdverseReaction
, . . O
pneumocystis . . B-AdverseReaction
jiroveci . . I-AdverseReaction
pneumonia . . I-AdverseReaction
( . . O
pcp . . B-AdverseReaction
) . . O
or . . O
tuberculosis . . B-AdverseReaction
) . . O
, . . O
which . . O
may . . O
necessitate . . O
further . . O
evaluation . . O
and . . O
treatment . . O
. . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
hypoalbuminemia . . B-AdverseReaction
( . . O
4% . . O
) . . O

the . . O
detection . . O
of . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

( . . O
1 . . O
, . . O
5.2 . . O
, . . O
7.1 . . O
, . . O
7.3 . . O
, . . O
12.3 . . O
) . . O
* . . O
neuroleptic . . B-AdverseReaction
malignant . . I-AdverseReaction
syndrome . . I-AdverseReaction
: . . O
manage . . O
with . . O
immediate . . O
discontinuation . . O
of . . O
drug . . O
and . . O
close . . O
monitoring . . O
. . . O

across . . O
clinical . . O
trials . . O
of . . O
tafinlar . . O
administered . . O
in . . O
combination . . O
with . . O
trametinib . . O
( . . O
n . . O
= . . O
202 . . O
) . . O
, . . O
8% . . O
of . . O
patients . . O
developed . . O
evidence . . O
of . . O
cardiomyopathy . . B-AdverseReaction
( . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
lvef . . I-AdverseReaction
below . . O
institutional . . B-Severity
lower . . I-Severity
limits . . I-Severity
of . . I-Severity
normal . . I-Severity
with . . O
an . . O
absolute . . B-AdverseReaction
decrease . . I-AdverseReaction
in . . I-AdverseReaction
lvef . . I-AdverseReaction
> . . O
= . . O
10% . . B-Severity
below . . I-Severity
baseline . . I-Severity
) . . O
. . . O

the . . O
malignancies . . B-AdverseReaction
occurred . . O
after . . O
a . . O
median . . O
of . . O
30 . . O
months . . O
of . . O
therapy . . O
( . . O
range . . O
1 . . O
to . . O
84 . . O
months . . O
) . . O
. . . O

renal . . O
angiomyolipoma . . O
with . . O
tsc . . O
: . . O
most . . O
common . . O
adverse . . O
reaction . . O
( . . O
incidence . . O
> . . O
= . . O
30% . . O
) . . O
is . . O
stomatitis . . B-AdverseReaction
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

if . . O
a . . O
patient . . O
develops . . O
skin . . O
discoloration . . O
, . . O
serious . . O
consideration . . O
should . . O
be . . O
given . . O
to . . O
changing . . O
to . . O
an . . O
alternate . . O
medication . . O
. . . O

closely . . O
observe . . O
patients . . O
with . . O
g6pd . . O
deficiency . . O
for . . O
signs . . O
of . . O
hemolytic . . O
anemia . . O
. . . O

( . . O
2.3,5.1 . . O
) . . O
* . . O
bullous . . O
and . . O
exfoliative . . O
skin . . O
disorders . . O
: . . O
severe . . B-Severity
bullous . . O
, . . O
blistering . . O
, . . O
and . . O
exfoliating . . O
lesions . . O
occurred . . O
in . . O
0.15% . . O
of . . O
patients . . O
. . . O

in . . O
the . . O
three . . O
controlled . . O
clinical . . O
trials . . O
in . . O
adults . . O
with . . O
chronic . . O
itp . . O
, . . O
cataracts . . B-AdverseReaction
developed . . O
or . . O
worsened . . O
in . . O
15 . . O
( . . O
7% . . O
) . . O
patients . . O
who . . O
received . . O
50 . . O
mg . . O
of . . O
promacta . . O
daily . . O
and . . O
8 . . O
( . . O
7% . . O
) . . O
placebo . . O
- . . O
group . . O
patients . . O
. . . O

of . . O
the . . O
14 . . O
patients . . O
receiving . . O
gilenya . . O
, . . O
7 . . O
patients . . O
had . . O
2 . . B-AdverseReaction
: . . I-AdverseReaction
1 . . I-AdverseReaction
av . . I-AdverseReaction
block . . I-AdverseReaction
( . . O
5 . . O
patients . . O
within . . O
the . . O
first . . O
6 . . O
hours . . O
postdose . . O
and . . O
2 . . O
patients . . O
after . . O
6 . . O
hours . . O
postdose . . O
) . . O
. . . O

advise . . O
females . . O
of . . O
reproductive . . O
potential . . O
of . . O
potential . . O
risk . . O
to . . O
a . . O
fetus . . O
. . . O

what . . O
are . . O
the . . O
ingredients . . O
in . . O
duavee . . O
? . . O

patients . . O
can . . O
have . . O
more . . O
than . . O
one . . O
site . . O
of . . O
bleeding . . B-AdverseReaction
. . . O
c . . O
confidence . . O
interval . . O
patients . . O
major . . B-Severity
bleeding . . B-AdverseReaction
event . . O
a . . O
bleeding . . B-AdverseReaction
sites . . O
for . . O
mbe . . B-AdverseReaction
b . . O
clinically . . O
relevant . . O
non . . B-Severity
- . . I-Severity
major . . I-Severity
bleeding . . B-AdverseReaction
any . . O
bleeding . . B-AdverseReaction
the . . O
rate . . O
of . . O
any . . O
gastrointestinal . . B-AdverseReaction
bleeds . . I-AdverseReaction
in . . O
patients . . O
receiving . . O
pradaxa . . O
150 . . O
mg . . O
in . . O
the . . O
full . . O
treatment . . O
period . . O
was . . O
3.1% . . O
( . . O
2.4% . . O
on . . O
warfarin . . O
) . . O
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
genital . . O
mycotic . . O
infections . . O
were . . O
more . . O
likely . . O
to . . O
have . . O
a . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infection . . I-AdverseReaction
during . . O
the . . O
study . . O
than . . O
those . . O
with . . O
no . . O
prior . . O
history . . O
( . . O
10.0% . . O
, . . O
23.1% . . O
, . . O
and . . O
25.0% . . O
versus . . O
0.8% . . O
, . . O
5.9% . . O
, . . O
and . . O
5.0% . . O
on . . O
placebo . . O
, . . O
farxiga . . O
5 . . O
mg . . O
, . . O
and . . O
farxiga . . O
10 . . O
mg . . O
, . . O
respectively . . O
) . . O
. . . O

only . . O
physicians . . O
experienced . . O
in . . O
immunosuppressive . . O
therapy . . O
and . . O
management . . O
of . . O
kidney . . O
transplant . . O
patients . . O
should . . O
prescribe . . O
nulojix . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O
: . . O
patients . . O
presenting . . O
with . . O
new . . O
- . . O
onset . . O
or . . O
deteriorating . . O
neurological . . O
signs . . O
and . . O
symptoms . . O
should . . O
be . . O
evaluated . . O
for . . O
pml . . O
by . . O
an . . O
appropriate . . O
specialist . . O
. . . O

5.1 . . O
somnolence . . O
or . . O
sedation . . O

there . . O
is . . O
no . . O
general . . O
agreement . . O
about . . O
specific . . O
pharmacological . . O
treatment . . O
regimens . . O
for . . O
nms . . O
. . . O

table . . O
8 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
afinitor . . O
- . . O
treated . . O
patients . . O
with . . O
renal . . O
angiomyolipoma . . O
grading . . O
according . . O
to . . O
ctcae . . O
version . . O
3.0 . . O
a . . O
includes . . O
stomatitis . . B-AdverseReaction
, . . O
aphthous . . B-AdverseReaction
stomatitis . . I-AdverseReaction
, . . O
mouth . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
gingival . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
glossitis . . B-AdverseReaction
, . . O
and . . O
glossodynia . . B-AdverseReaction
. . . O

5.4 . . O
cataracts . . O

rare . . O
cases . . O
of . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
have . . O
also . . O
been . . O
reported . . O
in . . O
these . . O
clinical . . O
trials . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
7 . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
, . . O
adverse . . O
reactions . . O
of . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
( . . O
1.0% . . O
) . . O
and . . O
atrial . . B-AdverseReaction
flutter . . I-AdverseReaction
( . . O
0.2% . . O
) . . O
were . . O
reported . . O
more . . O
frequently . . O
for . . O
tanzeum . . O
than . . O
for . . O
all . . O
comparators . . O
( . . O
0.5% . . O
and . . O
0% . . O
, . . O
respectively . . O
) . . O
. . . O

in . . O
three . . O
placebo . . O
- . . O
controlled . . O
trials . . O
in . . O
803 . . O
subjects . . O
with . . O
glabellar . . O
lines . . O
, . . O
535 . . O
subjects . . O
received . . O
a . . O
single . . O
dose . . O
of . . O
20 . . O
units . . O
xeomin . . O
and . . O
268 . . O
subjects . . O
received . . O
placebo . . O
. . . O

5.2 . . O
infections . . O

5.4 . . O
fluid . . O
retention . . O

fluid . . B-AdverseReaction
retention . . I-AdverseReaction
occurs . . O
with . . O
bosulif . . O
and . . O
may . . B-Factor
manifest . . O
as . . O
pericardial . . B-AdverseReaction
effusion . . I-AdverseReaction
, . . O
pleural . . B-AdverseReaction
effusion . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
. . . O

the . . O
most . . O
common . . O
adverse . . O
reaction . . O
reported . . O
for . . O
afinitor . . O
( . . O
incidence . . O
> . . O
= . . O
30% . . O
) . . O
was . . O
stomatitis . . B-AdverseReaction
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
in . . O
499 . . O
subjects . . O
with . . O
actinic . . O
keratosis . . O
, . . O
including . . O
274 . . O
subjects . . O
exposed . . O
to . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
field . . O
treatment . . O
( . . O
skin . . O
area . . O
of . . O
25 . . O
cm . . O
2 . . O
in . . O
the . . O
face . . O
or . . O
scalp . . O
regions . . O
) . . O
at . . O
a . . O
concentration . . O
of . . O
0.015% . . O
once . . O
daily . . O
for . . O
3 . . O
consecutive . . O
days . . O
, . . O
and . . O
225 . . O
subjects . . O
exposed . . O
to . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
field . . O
treatment . . O
( . . O
skin . . O
area . . O
of . . O
25 . . O
cm . . O
2 . . O
in . . O
the . . O
trunk . . O
or . . O
extremities . . O
regions . . O
) . . O
at . . O
a . . O
concentration . . O
of . . O
0.05% . . O
once . . O
daily . . O
for . . O
2 . . O
consecutive . . O
days . . O
. . . O

( . . O
4 . . O
, . . O
5.2 . . O
) . . O

withhold . . O
gilotrif . . O
for . . O
severe . . O
and . . O
prolonged . . O
cutaneous . . O
reactions . . O
. . . O

observe . . O
patients . . O
carefully . . O
when . . O
the . . O
dosage . . O
of . . O
northera . . O
is . . O
changed . . O
or . . O
when . . O
concomitant . . O
levodopa . . O
is . . O
reduced . . O
abruptly . . O
or . . O
discontinued . . O
, . . O
especially . . O
if . . O
the . . O
patient . . O
is . . O
receiving . . O
neuroleptics . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
prescribing . . O
information . . O
: . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
- . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

if . . O
heart . . O
failure . . O
develops . . O
or . . O
worsens . . O
and . . O
requires . . O
hospitalization . . O
, . . O
discontinue . . O
multaq . . O
. . . O

excerpt . . O
: . . O
* . . O
bleeding . . B-AdverseReaction
: . . O
pradaxa . . O
can . . B-Factor
cause . . O
serious . . B-Severity
and . . O
fatal . . B-AdverseReaction
bleeding . . O
( . . O
5.2 . . O
) . . O
* . . O
bioprosthetic . . O
heart . . O
valves . . O
: . . O
pradaxa . . O
use . . O
not . . O
recommended . . O
( . . O
5.4 . . O
) . . O

kyprolis . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
based . . O
on . . O
its . . O
mechanism . . O
of . . O
action . . O
and . . O
findings . . O
in . . O
animals . . O
. . . O

your . . O
healthcare . . O
provider . . O
will . . O
let . . O
you . . O
know . . O
if . . O
you . . O
need . . O
to . . O
stop . . O
taking . . O
duavee . . O
. . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
hypothyroidism . . B-AdverseReaction
was . . O
reported . . O
in . . O
69 . . O
/ . . O
359 . . O
patients . . O
( . . O
19% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
29 . . O
/ . . O
355 . . O
patients . . O
( . . O
8% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

the . . O
mechanism . . O
and . . O
clinical . . O
significance . . O
are . . O
unknown . . O
. . . O

proteinuria . . O

ankylosing . . O
spondylitis . . O
clinical . . O
study . . O

5.1 . . O
hypotension . . O

some . . O
deaths . . B-AdverseReaction
due . . O
to . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
did . . O
not . . O
have . . O
a . . O
clear . . O
etiology . . O
. . . O

the . . O
adverse . . O
reactions . . O
were . . O
not . . O
present . . O
at . . O
baseline . . O
, . . O
occurred . . O
more . . O
commonly . . O
on . . O
jardiance . . O
than . . O
on . . O
placebo . . O
and . . O
occurred . . O
in . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
jardiance . . O
10 . . O
mg . . O
or . . O
jardiance . . O
25 . . O
mg . . O
. . . O

vascular . . O
disorders . . O
: . . O
hypertension . . B-AdverseReaction
. . . O

potiga . . O
was . . O
administered . . O
as . . O
adjunctive . . O
therapy . . O
to . . O
1,365 . . O
patients . . O
with . . O
epilepsy . . O
in . . O
all . . O
controlled . . O
and . . O
uncontrolled . . O
clinical . . O
studies . . O
during . . O
the . . O
premarketing . . O
development . . O
. . . O

prior . . O
to . . O
neuraxial . . O
intervention . . O
the . . O
physician . . O
should . . O
consider . . O
the . . O
potential . . O
benefit . . O
versus . . O
the . . O
risk . . O
in . . O
anticoagulated . . O
patients . . O
or . . O
in . . O
patients . . O
to . . O
be . . O
anticoagulated . . O
for . . O
thromboprophylaxis . . O
. . . O

5.2 . . O
effects . . O
on . . O
serum . . O
liver . . O
biochemistries . . O
in . . O
patients . . O
with . . O
hepatitis . . O
b . . O
or . . O
c . . O
co . . O
- . . O
infection . . O

impairment . . B-AdverseReaction
in . . I-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
use . . O
of . . O
jardiance . . O
was . . O
associated . . O
with . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
decreases . . B-AdverseReaction
in . . I-AdverseReaction
egfr . . I-AdverseReaction
( . . O
see . . O
table . . O
2 . . O
) . . O
. . . O

table . . O
6 . . O
. . . O

* . . O
serious . . B-Severity
infections . . B-AdverseReaction
leading . . O
to . . O
hospitalization . . O
or . . O
death . . B-AdverseReaction
including . . O
tuberculosis . . B-AdverseReaction
( . . O
tb . . B-AdverseReaction
) . . O
, . . O
bacterial . . B-AdverseReaction
sepsis . . I-AdverseReaction
, . . O
invasive . . O
fungal . . O
( . . O
such . . O
as . . O
histoplasmosis . . B-AdverseReaction
) . . O
, . . O
and . . O
other . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
have . . O
occurred . . O
in . . O
patients . . O
receiving . . O
simponi . . O
aria . . O
( . . O
5.1 . . O
) . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

the . . O
most . . O
common . . O
related . . O
adverse . . O
reactions . . O
that . . O
were . . O
not . . O
hematologic . . O
, . . O
hepatic . . O
or . . O
renal . . O
events . . O
were . . O
paresthesia . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
and . . O
/ . . O
or . . O
vomiting . . B-AdverseReaction
, . . O
which . . O
each . . O
occurred . . O
in . . O
2% . . O
of . . O
patients . . O
( . . O
table . . O
1 . . O
) . . O
. . . O

5.4 . . O
clostridium . . O
difficile . . O
- . . O
associated . . O
diarrhea . . O

hypocalcemia . . O
may . . B-Factor
be . . O
exacerbated . . O
by . . O
the . . O
use . . O
of . . O
prolia . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
four . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
mean . . O
percent . . O
change . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
magnesium . . I-AdverseReaction
levels . . I-AdverseReaction
was . . O
8.1% . . O
and . . O
9.3% . . O
with . . O
invokana . . O
100 . . O
mg . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
, . . O
compared . . O
to . . O
- . . O
0.6% . . O
with . . O
placebo . . O
. . . O

* . . O
new . . O
breast . . O
lumps . . O
* . . O
unusual . . O
vaginal . . O
bleeding . . O
* . . O
changes . . O
in . . O
vision . . O
or . . O
speech . . O
* . . O
sudden . . O
new . . O
severe . . O
headaches . . O
* . . O
severe . . O
pains . . O
in . . O
your . . O
chest . . O
or . . O
legs . . O
with . . O
or . . O
without . . O
shortness . . O
of . . O
breath . . O
, . . O
weakness . . O
and . . O
fatigue . . O
less . . O
serious . . O
, . . O
but . . O
common . . O
side . . O
effects . . O
include . . O
: . . O

* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O

* . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
was . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
after . . O
xiaflex . . O
injections . . O
in . . O
5 . . O
of . . O
1044 . . O
( . . O
0.5% . . O
) . . O
xiaflex . . O
treated . . O
patients . . O
. . . O

use . . O
caution . . O
when . . O
driving . . O
or . . O
operating . . O
machinery . . O
. . . O

* . . O
pulmonary . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
monitor . . O
patients . . O
for . . O
new . . O
or . . O
worsening . . O
symptoms . . O
( . . O
5.10 . . O
) . . O
. . . O

the . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
potassium . . I-AdverseReaction
is . . O
usually . . O
transient . . O
, . . O
not . . O
requiring . . O
supplementation . . O
. . . O

fatal . . B-AdverseReaction
adverse . . O
events . . O
in . . O
xalkori . . O
- . . O
treated . . O
patients . . O
occurred . . O
in . . O
2.3% . . O
patients . . O
, . . O
consisting . . O
of . . O
septic . . B-AdverseReaction
shock . . I-AdverseReaction
, . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
and . . O
diabetic . . B-AdverseReaction
ketoacidosis . . I-AdverseReaction
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

vascular . . O
disorders . . O
: . . O
hematoma . . B-AdverseReaction
, . . O
lymphocele . . B-AdverseReaction

warning . . O
: . . O
( . . O
a . . O
) . . O
premature . . O
discontinuation . . O
of . . O
eliquis . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . B-AdverseReaction
hematoma . . I-AdverseReaction

treatment . . O
of . . O
postmenopausal . . O
women . . O
with . . O
osteoporosis . . O

patients . . O
treated . . O
with . . O
otezla . . O
should . . O
have . . O
their . . O
weight . . O
monitored . . O
regularly . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
25% . . O
) . . O
in . . O
patients . . O
with . . O
b . . O
- . . O
cell . . O
malignancies . . O
( . . O
mcl . . O
, . . O
cll . . O
, . . O
wm . . O
) . . O
were . . O
thrombocytopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
bruising . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
. . . O

in . . O
the . . O
xiaflex . . O
trials . . O
in . . O
dupuytren's . . O
contracture . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
, . . O
70% . . O
and . . O
38% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
developed . . O
an . . O
ecchymosis . . B-AdverseReaction
/ . . O
contusion . . B-AdverseReaction
or . . O
an . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
respectively . . O
( . . O
see . . O
table . . O
3 . . O
) . . O
. . . O

monitor . . O
hepatic . . O
function . . O
prior . . O
to . . O
and . . O
during . . O
treatment . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
viiv . . O
healthcare . . O
at . . O
1-877-844-8872 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

in . . O
trial . . O
2 . . O
, . . O
the . . O
incidence . . O
of . . O
basal . . B-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
was . . O
increased . . O
in . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
: . . O
9% . . O
( . . O
5 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
compared . . O
with . . O
2% . . O
( . . O
1 . . O
/ . . O
53 . . O
) . . O
of . . O
patients . . O
receiving . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

the . . O
most . . O
frequent . . O
( . . O
> . . O
= . . O
0.5% . . O
) . . O
adverse . . O
reactions . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
eovist . . O
were . . O
nausea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
and . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

bacterial . . O
, . . O
mycobacterial . . O
, . . O
viral . . O
, . . O
and . . O
fungal . . O
infections . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
approval . . O
use . . O
of . . O
picato . . O
( . . O
r . . O
) . . O
( . . O
ingenol . . O
mebutate . . O
) . . O
gel . . O
, . . O
0.015% . . O
and . . O
0.05% . . O
: . . O
hypersensitivity . . B-AdverseReaction
, . . O
allergic . . B-AdverseReaction
contact . . I-AdverseReaction
dermatitis . . I-AdverseReaction
, . . O
herpes . . B-AdverseReaction
zoster . . I-AdverseReaction
, . . O
chemical . . B-AdverseReaction
conjunctivitis . . I-AdverseReaction
, . . O
and . . O
corneal . . B-AdverseReaction
burn . . I-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O
excerpt . . O
: . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
astrazeneca . . O
at . . O
1-800 . . O
- . . O
236-9933 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
drug . . B-AdverseReaction
eruption . . I-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction

5.4 . . O
development . . O
of . . O
drug . . O
- . . O
resistant . . O
bacteria . . O

in . . O
adults . . O
, . . O
the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reactions . . O
were . . O
headache . . B-AdverseReaction
, . . O
anorexia . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
and . . O
asthenia . . B-AdverseReaction
. . . O

5.3 . . O
thrombotic . . O
events . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

5 . . O
. . . O

individuals . . O
who . . O
have . . O
already . . O
experienced . . O
naion . . O
are . . O
at . . O
increased . . O
risk . . O
of . . O
naion . . O
recurrence . . O
. . . O

women . . O
of . . O
childbearing . . O
potential . . O
should . . O
be . . O
advised . . O
to . . O
avoid . . O
becoming . . O
pregnant . . O
while . . O
receiving . . O
inlyta . . O
. . . O

table . . O
6 . . O
. . . O

nervous . . O
system . . O
disorders . . O
: . . O
dizziness . . B-AdverseReaction

most . . O
patients . . O
who . . O
developed . . O
igg . . O
antibodies . . O
did . . O
so . . O
within . . O
the . . O
first . . O
3 . . O
months . . O
of . . O
exposure . . O
( . . O
median . . O
time . . O
to . . O
seroconversion . . O
was . . O
4 . . O
weeks . . O
) . . O
. . . O

additional . . O
signs . . O
may . . B-Factor
include . . O
elevated . . B-AdverseReaction
creatine . . I-AdverseReaction
phosphokinase . . I-AdverseReaction
, . . O
myoglobinuria . . B-AdverseReaction
( . . O
rhabdomyolysis . . B-AdverseReaction
) . . O
, . . O
and . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

the . . O
effect . . O
of . . O
treatment . . O
with . . O
duavee . . O
on . . O
the . . O
risk . . O
of . . O
ovarian . . O
cancer . . O
is . . O
unknown . . O
. . . O

5.1 . . O
risk . . O
of . . O
thyroid . . O
c . . O
- . . O
cell . . O
tumors . . O

glucose . . O
intolerance . . O
has . . O
been . . O
reported . . O
in . . O
5% . . O
of . . O
patients . . O
receiving . . O
erwinaze . . O
in . . O
clinical . . O
trials . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

other . . O
reactions . . O
during . . O
the . . O
premarketing . . O
evaluation . . O
of . . O
fanapt . . O

the . . O
etiology . . O
of . . O
hepatocellular . . B-AdverseReaction
injury . . I-AdverseReaction
was . . O
possibly . . O
related . . O
to . . O
tanzeum . . O
but . . O
direct . . O
attribution . . O
to . . O
tanzeum . . O
was . . O
confounded . . O
by . . O
the . . O
presence . . O
of . . O
gallstone . . O
disease . . O
diagnosed . . O
on . . O
ultrasound . . O
3 . . O
weeks . . O
after . . O
the . . O
event . . O
. . . O

management . . O
of . . O
these . . O
events . . O
may . . O
require . . O
either . . O
temporary . . O
interruption . . O
or . . O
discontinuation . . O
of . . O
blincyto . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

specifically . . O
, . . O
nocturia . . B-AdverseReaction
was . . O
reported . . O
by . . O
0.4% . . O
, . . O
0.3% . . O
, . . O
and . . O
0.8% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
, . . O
jardiance . . O
10 . . O
mg . . O
, . . O
and . . O
jardiance . . O
25 . . O
mg . . O
, . . O
respectively . . O
. . . O

human . . O
relevance . . O
of . . O
glp . . B-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
receptor . . I-DrugClass
agonist . . I-DrugClass
induced . . O
c . . B-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
in . . O
rodents . . B-Animal
has . . O
not . . O
been . . O
determined . . O
. . . O

5.3 . . O
glucose . . O
intolerance . . O

table . . O
4 . . O
: . . O
clinical . . O
cure . . O
rates . . O
in . . O
a . . O
phase . . O
3 . . O
trial . . O
of . . O
ciai . . O
by . . O
baseline . . O
renal . . O
function . . O
( . . O
mitt . . O
population . . O
) . . O
baseline . . O
renal . . O
function . . O
zerbaxa . . O
plus . . O
metronidazolen . . O
/ . . O
n . . O
( . . O
% . . O
) . . O
meropenemn . . O
/ . . O
n . . O
( . . O
% . . O
) . . O
normal . . O
/ . . O
mild . . O
impairment . . O
( . . O
crcl . . O
> . . O
= . . O
50 . . O
ml . . O
/ . . O
min . . O
) . . O
312 . . O
/ . . O
366 . . O
( . . O
85.2 . . O
) . . O
355 . . O
/ . . O
404 . . O
( . . O
87.9 . . O
) . . O
moderate . . O
impairment . . O
( . . O
crcl . . O
30 . . O
to . . O
< . . O
= . . O
50 . . O
ml . . O
/ . . O
min . . O
) . . O
11 . . O
/ . . O
23 . . O
( . . O
47.8 . . O
) . . O
9 . . O
/ . . O
13 . . O
( . . O
69.2 . . O
) . . O
5.2 . . O
hypersensitivity . . O
reactions . . O

the . . O
small . . O
number . . O
of . . O
patients . . O
positive . . O
for . . O
antibodies . . O
to . . O
simponi . . O
aria . . O
limits . . O
the . . O
ability . . O
to . . O
draw . . O
definitive . . O
conclusions . . O
regarding . . O
the . . O
relationship . . O
between . . O
antibodies . . O
to . . O
golimumab . . O
and . . O
clinical . . O
efficacy . . O
or . . O
safety . . O
measures . . O
. . . O

treatment . . O
discontinuation . . O
due . . O
to . . O
liver . . B-AdverseReaction
enzyme . . I-AdverseReaction
increases . . I-AdverseReaction
occurred . . O
in . . O
1% . . O
of . . O
patients . . O
taking . . O
zytiga . . O
. . . O

5.4 . . O
high . . O
blood . . O
pressure . . O

patients . . O
were . . O
treated . . O
with . . O
firazyr . . O
30 . . O
mg . . O
and . . O
could . . O
receive . . O
up . . O
to . . O
3 . . O
doses . . O
of . . O
firazyr . . O
30 . . O
mg . . O
administered . . O
at . . O
least . . O
6 . . O
hours . . O
apart . . O
for . . O
each . . O
attack . . O
. . . O

serious . . B-Severity
cases . . O
of . . O
pancytopenia . . B-AdverseReaction
have . . O
been . . O
reported . . O
postmarketing . . O
in . . O
patients . . O
receiving . . O
victrelis . . O
in . . O
combination . . O
with . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
. . . O

corticosteroid . . O
utilization . . O
should . . O
be . . O
consistent . . O
with . . O
the . . O
nulojix . . O
clinical . . O
trial . . O
experience . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
and . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

entereg . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
having . . O
pancreatic . . O
or . . O
gastric . . O
anastomosis . . O
. . . O

preferred . . O
term . . O
placebo . . O
( . . O
n . . O
= . . O
506 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
otezla . . O
30 . . O
mg . . O
bid . . O
( . . O
n . . O
= . . O
920 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
diarrhea . . B-AdverseReaction
32 . . O
( . . O
6 . . O
) . . O
160 . . O
( . . O
17 . . O
) . . O
nausea . . B-AdverseReaction
35 . . O
( . . O
7 . . O
) . . O
155 . . O
( . . O
17 . . O
) . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
31 . . O
( . . O
6 . . O
) . . O
84 . . O
( . . O
9 . . O
) . . O
tension . . B-AdverseReaction
headache . . I-AdverseReaction
21 . . O
( . . O
4 . . O
) . . O
75 . . O
( . . O
8 . . O
) . . O
headache . . B-AdverseReaction
19 . . O
( . . O
4 . . O
) . . O
55 . . O
( . . O
6 . . O
) . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
* . . O
11 . . O
( . . O
2 . . O
) . . O
39 . . O
( . . O
4 . . O
) . . O
vomiting . . B-AdverseReaction
8 . . O
( . . O
2 . . O
) . . O
35 . . O
( . . O
4 . . O
) . . O
fatigue . . B-AdverseReaction
9 . . O
( . . O
2 . . O
) . . O
29 . . O
( . . O
3 . . O
) . . O
dyspepsia . . B-AdverseReaction
6 . . O
( . . O
1 . . O
) . . O
29 . . O
( . . O
3 . . O
) . . O
decrease . . B-AdverseReaction
appetite . . I-AdverseReaction
5 . . O
( . . O
1 . . O
) . . O
26 . . O
( . . O
3 . . O
) . . O
insomnia . . B-AdverseReaction
4 . . O
( . . O
1 . . O
) . . O
21 . . O
( . . O
2 . . O
) . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
4 . . O
( . . O
1 . . O
) . . O
20 . . O
( . . O
2 . . O
) . . O
migraine . . B-AdverseReaction
5 . . O
( . . O
1 . . O
) . . O
19 . . O
( . . O
2 . . O
) . . O
frequent . . B-AdverseReaction
bowel . . I-AdverseReaction
movements . . I-AdverseReaction
1 . . O
( . . O
0 . . O
) . . O
17 . . O
( . . O
2 . . O
) . . O
depression . . B-AdverseReaction
2 . . O
( . . O
0 . . O
) . . O
12 . . O
( . . O
1 . . O
) . . O
bronchitis . . B-AdverseReaction
2 . . O
( . . O
0 . . O
) . . O
12 . . O
( . . O
1 . . O
) . . O
tooth . . B-AdverseReaction
abscess . . I-AdverseReaction
0 . . O
( . . O
0 . . O
) . . O
10 . . O
( . . O
1 . . O
) . . O
folliculitis . . B-AdverseReaction
0 . . O
( . . O
0 . . O
) . . O
9 . . O
( . . O
1 . . O
) . . O
sinus . . B-AdverseReaction
headache . . I-AdverseReaction
0 . . O
( . . O
0 . . O
) . . O
9 . . O
( . . O
1 . . O
) . . O
severe . . O
worsening . . O
of . . O
psoriasis . . O
( . . O
rebound . . O
) . . O
occurred . . O
in . . O
0.3% . . O
( . . O
4 . . O
/ . . O
1184 . . O
) . . O
subjects . . O
following . . O
discontinuation . . O
of . . O
treatment . . O
with . . O
otezla . . O
. . . O

fatal . . B-AdverseReaction
bleeding . . B-AdverseReaction
events . . I-AdverseReaction
have . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
imbruvica . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

6 . . O
adverse . . O
reactions . . O

monitoring . . O

monitor . . O
patients . . O
periodically . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O

increased . . O
risk . . B-Factor
for . . O
developing . . O
post . . B-AdverseReaction
- . . I-AdverseReaction
transplant . . I-AdverseReaction
lymphoproliferative . . I-AdverseReaction
disorder . . I-AdverseReaction
( . . O
ptld . . B-AdverseReaction
) . . O
, . . O
predominantly . . O
involving . . O
the . . O
central . . O
nervous . . O
system . . O
( . . O
cns . . O
) . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
6 . . O
months . . O
exposure . . O
to . . O
eylea . . O
with . . O
a . . O
monthly . . O
2 . . O
mg . . O
dose . . O
in . . O
218 . . O
patients . . O
following . . O
crvo . . O
in . . O
2 . . O
clinical . . O
studies . . O
( . . O
copernicus . . O
and . . O
galileo . . O
) . . O
and . . O
91 . . O
patients . . O
following . . O
brvo . . O
in . . O
one . . O
clinical . . O
study . . O
( . . O
vibrant . . O
) . . O
[ . . O
seeclinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
, . . O
( . . O
14.3 . . O
) . . O
] . . O
. . . O

approximately . . O
1162 . . O
patients . . O
have . . O
received . . O
more . . O
than . . O
2 . . O
years . . O
of . . O
treatment . . O
with . . O
tecfidera . . O
. . . O

of . . O
these . . O
discontinuations . . O
, . . O
8 . . O
in . . O
the . . O
stribild . . O
group . . O
and . . O
1 . . O
in . . O
the . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
group . . O
occurred . . O
during . . O
the . . O
first . . O
48 . . O
weeks . . O
. . . O

appropriate . . O
prophylactic . . O
measures . . O
, . . O
including . . O
pretreatment . . O
nontoxic . . O
cytoreduction . . O
and . . O
on . . O
- . . O
treatment . . O
hydration . . O
, . . O
should . . O
be . . O
used . . O
for . . O
the . . O
prevention . . O
of . . O
tls . . O
during . . O
blincyto . . O
treatment . . O
. . . O

while . . O
these . . O
events . . O
are . . O
generally . . O
self . . O
- . . O
limiting . . O
, . . O
there . . O
have . . O
been . . O
reports . . O
of . . O
serious . . O
discontinuation . . O
symptoms . . O
. . . O

across . . O
clinical . . O
trials . . O
, . . O
32 . . O
of . . O
1560 . . O
patients . . O
( . . O
2.1% . . O
) . . O
had . . O
qtcf . . O
( . . O
corrected . . O
qt . . O
by . . O
the . . O
fridericia . . O
method . . O
) . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
500 . . O
ms . . O
and . . O
76 . . O
of . . O
1520 . . O
patients . . O
( . . O
5.0% . . O
) . . O
had . . O
an . . O
increase . . O
from . . O
baseline . . O
qtcf . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
60 . . B-Severity
ms . . I-Severity
by . . O
automated . . O
machine . . O
- . . O
read . . O
evaluation . . O
of . . O
ecg . . O
. . . O

monitor . . O
electrolytes . . O
if . . O
qt . . O
prolongation . . O
is . . O
detected . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
and . . O
drug . . O
interactions . . O
( . . O
7.4 . . O
) . . O
] . . O
. . . O

clinical . . O
trials . . O
of . . O
gilotrif . . O
excluded . . O
patients . . O
with . . O
an . . O
abnormal . . O
left . . O
ventricular . . O
ejection . . O
fraction . . O
( . . O
lvef . . O
) . . O
, . . O
i . . O
. . . O
e . . O
. . . O
, . . O
below . . O
the . . O
institutional . . O
lower . . O
limit . . O
of . . O
normal . . O
. . . O

the . . O
causes . . O
of . . O
death . . B-AdverseReaction
in . . O
the . . O
remaining . . O
subjects . . O
varied . . O
. . . O

* . . O
perform . . O
test . . O
for . . O
latent . . O
tb . . O
; . . O
if . . O
positive . . O
, . . O
start . . O
treatment . . O
for . . O
tb . . O
prior . . O
to . . O
starting . . O
cimzia . . O
( . . O
5.1 . . O
) . . O
. . . O

the . . O
detection . . O
of . . O
an . . O
immune . . O
response . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assays . . O
used . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

investigators . . O
graded . . O
the . . O
severity . . O
of . . O
gastrointestinal . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
occurring . . O
on . . O
0.75 . . O
mg . . O
and . . O
1.5 . . O
mg . . O
of . . O
trulicity . . O
as . . O
" . . O
mild . . B-Severity
" . . O
in . . O
58% . . O
and . . O
48% . . O
of . . O
cases . . O
, . . O
respectively . . O
, . . O
" . . O
moderate . . B-Severity
" . . O
in . . O
35% . . O
and . . O
42% . . O
of . . O
cases . . O
, . . O
respectively . . O
, . . O
or . . O
" . . O
severe . . B-Severity
" . . O
in . . O
7% . . O
and . . O
11% . . O
of . . O
cases . . O
, . . O
respectively . . O
. . . O

while . . O
this . . O
normally . . O
would . . O
be . . O
expected . . O
to . . O
be . . O
of . . O
little . . O
consequence . . O
in . . O
most . . O
patients . . O
, . . O
prior . . O
to . . O
prescribing . . O
stendra . . O
, . . O
physicians . . O
should . . O
carefully . . O
consider . . O
whether . . O
patients . . O
with . . O
underlying . . O
cardiovascular . . O
disease . . O
could . . O
be . . O
affected . . O
adversely . . O
by . . O
such . . O
vasodilatory . . O
effects . . O
, . . O
especially . . O
in . . O
combination . . O
with . . O
sexual . . O
activity . . O
. . . O

measurement . . O
of . . O
serum . . O
sodium . . O
and . . O
chloride . . O
levels . . O
should . . O
be . . O
considered . . O
during . . O
maintenance . . O
treatment . . O
with . . O
aptiom . . O
, . . O
particularly . . O
if . . O
the . . O
patient . . O
is . . O
receiving . . O
other . . O
medications . . O
known . . O
to . . O
decrease . . O
serum . . O
sodium . . O
levels . . O
and . . O
should . . O
be . . O
performed . . O
if . . O
symptoms . . O
of . . O
hyponatremia . . O
develop . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
nausea . . O
/ . . O
vomiting . . O
, . . O
malaise . . O
, . . O
headache . . O
, . . O
lethargy . . O
, . . O
confusion . . O
, . . O
irritability . . O
, . . O
muscle . . O
weakness . . O
/ . . O
spasms . . O
, . . O
obtundation . . O
, . . O
or . . O
increase . . O
in . . O
seizure . . O
frequency . . O
or . . O
severity . . O
) . . O
. . . O

two . . O
of . . O
these . . O
trials . . O
were . . O
extensions . . O
of . . O
the . . O
3 . . O
- . . O
month . . O
trials . . O
, . . O
and . . O
one . . O
was . . O
a . . O
dedicated . . O
long . . O
term . . O
safety . . O
trial . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
approval . . O
use . . O
of . . O
alglucosidase . . O
alfa . . O
. . . O

in . . O
a . . O
pooled . . O
analysis . . O
, . . O
the . . O
overall . . O
incidence . . O
of . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
was . . O
0.6% . . O
with . . O
nesina . . O
25 . . O
mg . . O
compared . . O
to . . O
0.8% . . O
with . . O
all . . O
comparators . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
treatment . . O
was . . O
8.3 . . O
months . . O
with . . O
xtandi . . O
and . . O
3.0 . . O
months . . O
with . . O
placebo . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

d . . O
includes . . O
squamous . . B-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
skin . . I-AdverseReaction
and . . O
keratoacanthoma . . B-AdverseReaction
. . . O

for . . O
patients . . O
who . . O
test . . O
positive . . O
for . . O
hepatitis . . O
b . . O
surface . . O
antigen . . O
, . . O
consultation . . O
with . . O
a . . O
physician . . O
with . . O
expertise . . O
in . . O
the . . O
treatment . . O
of . . O
hepatitis . . O
b . . O
is . . O
recommended . . O
before . . O
initiating . . O
tnf . . O
- . . O
blocker . . O
therapy . . O
. . . O

eps . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
events . . I-AdverseReaction
include . . O
: . . O
bradykinesia . . B-AdverseReaction
, . . O
dyskinesia . . B-AdverseReaction
, . . O
dystonia . . B-AdverseReaction
, . . O
oromandibular . . B-AdverseReaction
dystonia . . I-AdverseReaction
, . . O
muscle . . B-AdverseReaction
contractions . . I-AdverseReaction
involuntary . . I-AdverseReaction
, . . O
muscle . . B-AdverseReaction
twitching . . I-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
stiffness . . I-AdverseReaction
, . . O
parkinsonism . . B-AdverseReaction
, . . O
protrusion . . B-AdverseReaction
tongue . . I-AdverseReaction
, . . O
resting . . B-AdverseReaction
tremor . . I-AdverseReaction
, . . O
and . . O
tremor . . B-AdverseReaction
. . . O

* . . O
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
have . . O
emergency . . O
resuscitation . . O
equipment . . O
and . . O
personnel . . O
readily . . O
available . . O
( . . O
5.2 . . O
) . . O
. . . O

if . . O
ribavirin . . O
is . . O
permanently . . O
discontinued . . O
for . . O
management . . O
of . . O
anemia . . O
, . . O
then . . O
peginterferon . . O
alfa . . O
and . . O
victrelis . . O
must . . O
also . . O
be . . O
discontinued . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

immune . . O
system . . O
disorders . . O
: . . O
alopecia . . B-AdverseReaction
totalis . . I-AdverseReaction
. . . O

diarrhea . . B-AdverseReaction
due . . O
to . . O
zydelig . . O
responds . . O
poorly . . O
to . . O
antimotility . . O
agents . . O
. . . O

this . . O
may . . O
be . . O
associated . . O
with . . O
concomitant . . O
use . . O
of . . O
corticosteroids . . O
or . . O
other . . O
immunosuppressive . . O
agents . . O
. . . O

in . . O
animal . . O
studies . . O
, . . O
administration . . O
of . . O
ceritinib . . O
to . . O
rats . . O
and . . O
rabbits . . O
during . . O
organogenesis . . O
at . . O
maternal . . O
plasma . . O
exposures . . O
below . . O
the . . O
recommended . . O
human . . O
dose . . O
of . . O
750 . . O
mg . . O
daily . . O
caused . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
skeletal . . I-AdverseReaction
anomalies . . I-AdverseReaction
in . . O
rats . . B-Animal
and . . O
rabbits . . B-Animal
. . . O

severe . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
can . . B-Factor
occur . . O
and . . O
may . . B-Factor
include . . O
generalized . . B-AdverseReaction
rash . . I-AdverseReaction
/ . . O
erythema . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
and . . O
bronchospasm . . B-AdverseReaction
. . . O

concurrent . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
alt . . I-AdverseReaction
greater . . O
than . . O
3 . . B-Severity
times . . I-Severity
the . . I-Severity
uln . . I-Severity
and . . O
total . . O
bilirubin . . O
greater . . O
than . . O
2 . . O
times . . O
the . . O
uln . . O
, . . O
with . . O
normal . . O
alkaline . . O
phosphatase . . O
, . . O
occurred . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
patients . . O
in . . O
clinical . . O
studies . . O
. . . O

advise . . O
patients . . O
to . . O
seek . . O
prompt . . O
medical . . O
attention . . O
if . . O
they . . O
develop . . O
signs . . O
or . . O
symptoms . . O
of . . O
severe . . O
infection . . O
, . . O
including . . O
cellulitis . . O
. . . O

in . . O
symptomatic . . O
patients . . O
, . . O
rule . . O
out . . O
infectious . . O
etiologies . . O
and . . O
consider . . O
endoscopic . . O
evaluation . . O
for . . O
persistent . . O
or . . O
severe . . O
symptoms . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
post . . B-AdverseReaction
- . . I-AdverseReaction
transplant . . I-AdverseReaction
lymphoproliferative . . I-AdverseReaction
disorder . . I-AdverseReaction
, . . O
other . . O
malignancies . . B-AdverseReaction
, . . O
and . . O
serious . . B-Severity
infections . . B-AdverseReaction

orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
was . . O
reported . . O
in . . O
5% . . O
of . . O
patients . . O
given . . O
20 . . O
to . . O
24 . . O
mg . . O
/ . . O
day . . O
, . . O
3% . . O
of . . O
patients . . O
given . . O
10 . . O
to . . O
16 . . O
mg . . O
/ . . O
day . . O
, . . O
and . . O
1% . . O
of . . O
patients . . O
given . . O
placebo . . O
. . . O

elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
with . . O
cf . . O
receiving . . O
kalydeco . . O
. . . O

infections . . B-AdverseReaction
not . . O
meeting . . O
these . . O
criteria . . O
are . . O
considered . . O
non . . O
- . . O
serious . . O
. . . O

in . . O
the . . O
postmarketing . . O
experience . . O
, . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

laboratory . . O
values . . O

cognitive . . O
dysfunction . . O
- . . O
related . . O
events . . O
were . . O
serious . . B-Severity
in . . O
0.2% . . O
of . . O
aptiom . . O
- . . O
treated . . O
patients . . O
( . . O
and . . O
0.2% . . O
of . . O
placebo . . O
patients . . O
) . . O
and . . O
led . . O
to . . O
discontinuation . . O
in . . O
1% . . O
of . . O
aptiom . . O
- . . O
treated . . O
patients . . O
( . . O
and . . O
0.5% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
) . . O
. . . O

( . . O
2.2 . . O
) . . O
( . . O
4 . . O
) . . O
* . . O
severe . . B-Severity
hypersensitivity . . B-AdverseReaction
can . . B-Factor
occur . . O
and . . O
may . . B-Factor
include . . O
generalized . . B-AdverseReaction
rash . . I-AdverseReaction
/ . . O
erythema . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
and . . O
bronchospasm . . B-AdverseReaction
. . . O

all . . O
patients . . O
should . . O
be . . O
instructed . . O
to . . O
seek . . O
medical . . O
advice . . O
if . . O
signs . . O
, . . O
symptoms . . O
, . . O
or . . O
high . . O
risk . . O
exposure . . O
suggestive . . O
of . . O
tuberculosis . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
persistent . . O
cough . . O
, . . O
weight . . O
loss . . O
, . . O
subfebrile . . O
temperature . . O
) . . O
appear . . O
during . . O
or . . O
after . . O
ilaris . . O
therapy . . O
. . . O

elderly . . O
patients . . O
may . . O
be . . O
at . . O
greater . . O
risk . . O
of . . O
developing . . O
hyponatremia . . B-AdverseReaction
with . . O
ssris . . O
and . . O
snris . . B-DrugClass
. . . O

monitor . . O
and . . O
manage . . O
patients . . O
using . . O
standards . . O
of . . O
care . . O
, . . O
including . . O
anti . . O
- . . O
diarrheals . . O
, . . O
anti . . O
- . . O
emetics . . O
, . . O
or . . O
fluid . . O
replacement . . O
, . . O
as . . O
indicated . . O
. . . O

no . . O
association . . O
was . . O
seen . . O
between . . O
antibody . . O
development . . O
and . . O
the . . O
development . . O
of . . O
adverse . . O
events . . O
. . . O

of . . O
these . . O
7 . . O
patients . . O
, . . O
6 . . O
had . . O
complete . . O
resolution . . O
; . . O
time . . O
to . . O
resolution . . O
ranged . . O
up . . O
to . . O
15.6 . . O
weeks . . O
. . . O

copd . . O
may . . O
deteriorate . . O
acutely . . O
over . . O
a . . O
period . . O
of . . O
hours . . O
or . . O
chronically . . O
over . . O
several . . O
days . . O
or . . O
longer . . O
. . . O

5.1 . . O
increased . . O
mortality . . O

a . . O
case . . O
of . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O
and . . O
a . . O
case . . O
of . . O
probable . . B-Factor
pml . . B-AdverseReaction
occurred . . O
in . . O
patients . . O
with . . O
ms . . O
who . . O
received . . O
gilenya . . O
in . . O
the . . O
post . . O
marketing . . O
setting . . O
. . . O

estrogen . . O
administration . . O
leads . . O
to . . O
increased . . O
thyroid . . O
- . . O
binding . . O
globulin . . O
( . . O
tbg . . O
) . . O
levels . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
mi . . O
and . . O
stroke . . O
. . . O

in . . O
study . . O
2 . . O
, . . O
1 . . O
of . . O
871 . . O
( . . O
0.1% . . O
) . . O
chemotherapy . . O
- . . O
naive . . O
patients . . O
treated . . O
with . . O
xtandi . . O
and . . O
1 . . O
of . . O
844 . . O
( . . O
0.1% . . O
) . . O
patients . . O
treated . . O
with . . O
placebo . . O
experienced . . O
a . . O
seizure . . B-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
division . . O
of . . O
nuclear . . O
medicine . . O
, . . O
department . . O
of . . O
radiology . . O
, . . O
mayo . . O
clinic . . O
at . . O
507-284-2511 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

hematologic . . O
nadirs . . O
were . . O
observed . . O
predominantly . . O
in . . O
the . . O
third . . O
week . . O
of . . O
therapy . . O
. . . O

in . . O
those . . O
patients . . O
treated . . O
with . . O
horizant . . O
who . . O
reported . . O
somnolence . . B-AdverseReaction
, . . O
the . . O
somnolence . . B-AdverseReaction
persisted . . O
during . . O
treatment . . O
in . . O
about . . O
30% . . O
. . . O

based . . O
on . . O
the . . O
pooled . . O
data . . O
from . . O
4 . . O
placebo . . O
- . . O
controlled . . O
, . . O
4 . . O
- . . O
or . . O
6 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
or . . O
flexible . . O
- . . O
dose . . O
studies . . O
, . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
with . . O
a . . O
greater . . O
than . . O
2% . . O
incidence . . O
in . . O
the . . O
patients . . O
treated . . O
with . . O
fanapt . . O
, . . O
and . . O
for . . O
which . . O
the . . O
incidence . . O
in . . O
patients . . O
treated . . O
with . . O
fanapt . . O
20 . . O
to . . O
24 . . O
mg . . O
/ . . O
day . . O
were . . O
twice . . O
than . . O
the . . O
incidence . . O
in . . O
patients . . O
treated . . O
with . . O
fanapt . . O
10 . . O
to . . O
16 . . O
mg . . O
/ . . O
day . . O
were . . O
: . . O
abdominal . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
stiffness . . I-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
and . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
. . . O

atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
and . . O
atrial . . B-AdverseReaction
flutter . . I-AdverseReaction
( . . O
range . . O
, . . O
6 . . O
to . . O
9% . . O
) . . O
have . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
imbruvica . . O
, . . O
particularly . . O
in . . O
patients . . O
with . . O
cardiac . . O
risk . . O
factors . . O
, . . O
acute . . O
infections . . O
, . . O
and . . O
a . . O
previous . . O
history . . O
of . . O
atrial . . O
fibrillation . . O
. . . O

hepatobiliary . . O
disorders . . O
- . . O
hepatitis . . B-AdverseReaction

the . . O
incidence . . O
of . . O
grade . . O
3 . . O
or . . O
greater . . O
non . . O
- . . O
hematologic . . O
, . . O
non . . O
- . . O
infectious . . O
adverse . . O
reactions . . O
occurring . . O
with . . O
erwinaze . . O
in . . O
study . . O
1 . . O
, . . O
study . . O
2 . . O
and . . O
emtp . . O
trial . . O
is . . O
provided . . O
in . . O
table . . O
2 . . O
. . . O

5.1 . . O
eye . . O
and . . O
mucous . . O
membrane . . O
exposure . . O

psychiatric . . O
disorders . . O

5.2 . . O
patients . . O
coinfected . . O
with . . O
hiv . . O
- . . O
1 . . O
and . . O
hbv . . O

6.2 . . O
immunogenicity . . O

based . . O
on . . O
the . . O
severity . . O
of . . O
the . . O
adverse . . O
drug . . O
reaction . . O
, . . O
withhold . . O
zykadia . . O
until . . O
hyperglycemia . . O
is . . O
adequately . . O
controlled . . O
, . . O
then . . O
resume . . O
zykadia . . O
at . . O
a . . O
reduced . . O
dose . . O
as . . O
described . . O
in . . O
table . . O
1 . . O
. . . O

in . . O
hiv . . O
- . . O
1 . . O
- . . O
infected . . O
subjects . . O
with . . O
no . . O
antiretroviral . . O
treatment . . O
history . . O

when . . O
plasma . . O
ammonia . . O
level . . O
is . . O
normalized . . O
, . . O
dietary . . O
protein . . O
intake . . O
can . . O
usually . . O
be . . O
reintroduced . . O
. . . O
( . . O
5.3 . . O
) . . O

arcapta . . O
neohaler . . O
, . . O
like . . O
other . . O
beta2 . . O
- . . O
agonists . . O
, . . O
can . . B-Factor
produce . . O
a . . O
clinically . . O
significant . . B-Severity
cardiovascular . . B-AdverseReaction
effect . . I-AdverseReaction
in . . O
some . . O
patients . . O
as . . O
measured . . O
by . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
pulse . . I-AdverseReaction
rate . . I-AdverseReaction
, . . O
systolic . . O
or . . O
diastolic . . O
blood . . O
pressure . . O
, . . O
or . . O
symptoms . . O
. . . O

5.6 . . O
hepatic . . O
impairment . . O

prior . . O
to . . O
administration . . O
, . . O
question . . O
the . . O
patient . . O
for . . O
a . . O
history . . O
of . . O
prior . . O
reactions . . O
to . . O
iodine . . O
, . . O
an . . O
iodine . . O
- . . O
containing . . O
contrast . . O
agent . . O
or . . O
other . . O
products . . O
containing . . O
iodine . . O
. . . O

no . . O
discernible . . O
pattern . . O
between . . O
death . . B-AdverseReaction
and . . O
sputum . . O
culture . . O
conversion . . O
, . . O
relapse . . O
, . . O
sensitivity . . O
to . . O
other . . O
drugs . . O
used . . O
to . . O
treat . . O
tuberculosis . . O
, . . O
hiv . . O
status . . O
, . . O
or . . O
severity . . O
of . . O
disease . . O
could . . O
be . . O
observed . . O
. . . O

in . . O
a . . O
52 . . O
- . . O
week . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
comparator . . O
- . . O
controlled . . O
trial . . O
that . . O
included . . O
primarily . . O
patients . . O
with . . O
schizophrenia . . O
, . . O
the . . O
mean . . O
decrease . . O
from . . O
baseline . . O
of . . O
total . . O
cholesterol . . O
was . . O
6 . . O
mg . . O
/ . . O
dl . . O
and . . O
the . . O
mean . . O
decrease . . O
from . . O
baseline . . O
of . . O
fasting . . O
triglycerides . . O
was . . O
9.8 . . O
mg . . O
/ . . O
dl . . O
. . . O

table . . O
1 . . O
: . . O
per . . O
patient . . O
incidence . . O
of . . O
grade . . O
1 . . O
and . . O
2 . . O
adverse . . O
reactions . . O
assessed . . O
as . . O
possibly . . O
, . . O
probably . . O
, . . O
or . . O
definitely . . O
related . . O
to . . O
voraxaze . . O
excluding . . O
hematologic . . O
, . . O
hepatic . . O
, . . O
or . . O
renal . . O
adverse . . O
reactions . . O
1 . . O
this . . O
incidence . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
flushing . . B-AdverseReaction
, . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
, . . O
burning . . B-AdverseReaction
sensation . . I-AdverseReaction
. . . O

the . . O
effect . . O
that . . O
symptomatic . . O
suppression . . O
has . . O
upon . . O
the . . O
long . . O
- . . O
term . . O
course . . O
of . . O
the . . O
syndrome . . O
is . . O
unknown . . O
. . . O

the . . O
most . . O
common . . O
( . . O
per . . O
patient . . O
incidence . . O
> . . O
= . . O
10% . . O
) . . O
adverse . . O
reactions . . O
reported . . O
with . . O
prolia . . O
in . . O
patients . . O
with . . O
bone . . O
loss . . O
receiving . . O
androgen . . O
deprivation . . O
therapy . . O
for . . O
prostate . . O
cancer . . O
or . . O
adjuvant . . O
aromatase . . O
inhibitor . . O
therapy . . O
for . . O
breast . . O
cancer . . O
are . . O
arthralgia . . B-AdverseReaction
and . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

qtc . . B-AdverseReaction
interval . . I-AdverseReaction
prolongation . . I-AdverseReaction
, . . O
which . . O
may . . O
lead . . O
to . . O
an . . O
increased . . O
risk . . B-Factor
for . . O
ventricular . . B-AdverseReaction
tachyarrhythmias . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
torsade . . B-AdverseReaction
de . . I-AdverseReaction
pointes . . I-AdverseReaction
) . . O
or . . O
sudden . . B-AdverseReaction
death . . I-AdverseReaction
, . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
zykadia . . O
in . . O
clinical . . O
trials . . O
. . . O

in . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
following . . O
injection . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
were . . O
nasopharyngitis . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
. . . O

patients . . O
have . . O
frequently . . O
presented . . O
with . . O
disseminated . . O
rather . . O
than . . O
localized . . O
disease . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
by . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
stendra . . O
from . . O
3 . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
lasting . . O
3 . . O
months . . O
for . . O
stendra . . O
use . . O
as . . O
needed . . O
adverse . . O
reaction . . O
placebo . . O
( . . O
n . . O
= . . O
349 . . O
) . . O
stendra . . O
50 . . O
mg . . O
( . . O
n . . O
= . . O
217 . . O
) . . O
stendra . . O
100 . . O
mg . . O
( . . O
n . . O
= . . O
349 . . O
) . . O
stendra . . O
200 . . O
mg . . O
( . . O
n . . O
= . . O
352 . . O
) . . O
headache . . B-AdverseReaction
1.7% . . O
5.1% . . O
6.9% . . O
10.5% . . O
flushing . . B-AdverseReaction
0.0% . . O
3.2% . . O
4.3% . . O
4.0% . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
1.1% . . O
1.8% . . O
2.9% . . O
2.0% . . O
nasopharyngitis . . B-AdverseReaction
2.9% . . O
0.9% . . O
2.6% . . O
3.4% . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
1.1% . . O
3.2% . . O
2.0% . . O
1.1% . . O
adverse . . O
reactions . . O
reported . . O
by . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
1% . . O
, . . O
but . . O
less . . O
than . . O
2% . . O
of . . O
patients . . O
in . . O
any . . O
stendra . . O
dose . . O
group . . O
, . . O
and . . O
greater . . O
than . . O
placebo . . O
included . . O
: . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
uri . . B-AdverseReaction
) . . O
, . . O
bronchitis . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
sinus . . B-AdverseReaction
congestion . . I-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
. . . O

if . . O
you . . O
would . . O
like . . O
more . . O
information . . O
, . . O
talk . . O
with . . O
your . . O
healthcare . . O
provider . . O
. . . O

5.5 . . O
other . . O
serious . . O
infections . . O

how . . O
do . . O
i . . O
store . . O
duavee . . O
? . . O

in . . O
the . . O
controlled . . O
adjunctive . . O
epilepsy . . O
trials . . O
, . . O
4 . . O
/ . . O
415 . . O
patients . . O
( . . O
1.0% . . O
) . . O
treated . . O
with . . O
800 . . O
mg . . O
and . . O
6 . . O
/ . . O
410 . . O
( . . O
1.5% . . O
) . . O
patients . . O
treated . . O
with . . O
1200 . . O
mg . . O
of . . O
aptiom . . O
had . . O
at . . O
least . . O
one . . O
serum . . O
sodium . . O
value . . O
less . . O
than . . O
125 . . O
meq . . O
/ . . O
l . . O
, . . O
compared . . O
to . . O
none . . O
of . . O
the . . O
patients . . O
assigned . . O
to . . O
placebo . . O
. . . O

* . . O
serious . . B-Severity
cardiovascular . . B-AdverseReaction
events . . I-AdverseReaction
and . . O
stroke . . B-AdverseReaction
[ . . O
see . . O
boxed . . O
warning . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
vascular . . B-AdverseReaction
events . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
liver . . B-AdverseReaction
disease . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
adverse . . O
reactions . . O
commonly . . O
reported . . O
by . . O
coc . . O
users . . O
are . . O
: . . O

phosphodiesterase . . O
type . . O
5 . . O
inhibitors . . O
, . . O
including . . O
stendra . . O
, . . O
and . . O
alpha . . O
- . . O
adrenergic . . O
blocking . . O
agents . . O
are . . O
both . . O
vasodilators . . O
with . . O
blood . . O
pressure . . O
- . . O
lowering . . O
effects . . O
. . . O

table . . O
7 . . O
: . . O
change . . O
in . . O
body . . O
weight . . O
in . . O
pediatric . . O
subjects . . O
from . . O
baseline . . O
n . . O
* . . O
= . . O
number . . O
of . . O
subjects . . O
who . . O
had . . O
assessments . . O
at . . O
both . . O
baseline . . O
and . . O
endpoint . . O
. . . O

two . . O
of . . O
the . . O
four . . O
subjects . . O
had . . O
renal . . O
impairment . . O
( . . O
i . . O
. . . O
e . . O
. . . O
estimated . . O
creatinine . . O
clearance . . O
less . . O
than . . O
70 . . O
ml . . O
per . . O
minute . . O
) . . O
at . . O
baseline . . O
. . . O

5.5 . . O
renal . . O
impairment . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction

management . . O
includes . . O
mouthwashes . . O
and . . O
topical . . O
treatments . . O
. . . O

avoid . . O
use . . O
of . . O
gbcas . . O
among . . O
these . . O
patients . . O
unless . . O
the . . O
diagnostic . . O
information . . O
is . . O
essential . . O
and . . O
not . . O
available . . O
with . . O
non . . O
- . . O
contrast . . O
enhanced . . O
mri . . O
or . . O
other . . O
modalities . . O
. . . O

the . . O
clinical . . O
significance . . O
of . . O
the . . O
lower . . O
mean . . O
triglyceride . . O
values . . O
in . . O
nulojix . . O
- . . O
treated . . O
patients . . O
at . . O
one . . O
and . . O
three . . O
years . . O
is . . O
unknown . . O
. . . O

5.1 . . O
serious . . O
infections . . O

excerpt . . O
: . . O
topical . . O
ophthalmic . . O
use . . O
only . . O
. . . O

there . . O
were . . O
no . . B-Negation
reports . . O
of . . O
torsade . . B-AdverseReaction
de . . I-AdverseReaction
pointes . . I-AdverseReaction
or . . O
any . . O
other . . O
adverse . . O
reactions . . O
associated . . O
with . . O
delayed . . B-AdverseReaction
ventricular . . I-AdverseReaction
repolarization . . I-AdverseReaction
. . . O

eye . . O
disorders . . O
: . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
conjunctivitis . . B-AdverseReaction
( . . O
2% . . O
) . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
eylea . . O
in . . O
578 . . O
patients . . O
with . . O
dme . . O
treated . . O
with . . O
the . . O
2 . . O
- . . O
mg . . O
dose . . O
in . . O
2 . . O
double . . O
- . . O
masked . . O
, . . O
controlled . . O
clinical . . O
studies . . O
( . . O
vivid . . O
and . . O
vista . . O
) . . O
from . . O
baseline . . O
to . . O
week . . O
52 . . O
and . . O
from . . O
baseline . . O
to . . O
week . . O
100 . . O
[ . . O
seeclinical . . O
studies . . O
( . . O
14.4 . . O
) . . O
] . . O
. . . O

neutralizing . . O
antibodies . . O
were . . O
detected . . O
in . . O
11 . . O
of . . O
the . . O
25 . . O
patients . . O
who . . O
tested . . O
positive . . O
for . . O
anti . . O
- . . O
glucarpidase . . O
binding . . O
antibodies . . O
. . . O

5.16 . . O
use . . O
in . . O
patients . . O
with . . O
concomitant . . O
illness . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
alanine . . O
aminotransferase . . O
( . . O
alt . . O
) . . O
elevations . . O
of . . O
all . . O
grades . . O
occurred . . O
in . . O
22% . . O
of . . O
patients . . O
on . . O
both . . O
arms . . O
, . . O
with . . O
grade . . B-Severity
3 . . I-Severity
/ . . O
4 . . O
events . . O
in . . O
< . . O
1% . . O
of . . O
patients . . O
on . . O
the . . O
inlyta . . O
arm . . O
and . . O
2% . . O
of . . O
patients . . O
on . . O
the . . O
sorafenib . . O
arm . . O
. . . O

investigations . . O
: . . O
frequent . . O
- . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
; . . O
infrequent . . O
- . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
neutrophil . . B-AdverseReaction
count . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
hematocrit . . B-AdverseReaction
decreased . . I-AdverseReaction

because . . B-Factor
of . . O
the . . O
observed . . O
ophthalmologic . . O
adverse . . O
reactions . . O
, . . O
potiga . . O
should . . O
only . . O
be . . O
used . . O
in . . O
patients . . O
who . . O
have . . O
responded . . O
inadequately . . O
to . . O
several . . O
alternative . . O
treatments . . O
and . . O
for . . O
whom . . O
the . . O
benefits . . O
outweigh . . O
the . . O
risk . . O
of . . O
retinal . . O
abnormalities . . O
and . . O
potential . . O
vision . . O
loss . . O
. . . O

the . . O
mean . . O
time . . O
to . . O
nadir . . O
was . . O
13 . . O
days . . O
and . . O
the . . O
mean . . O
time . . O
to . . O
recovery . . O
from . . O
severe . . B-Severity
neutropenia . . B-AdverseReaction
( . . O
< . . O
500 . . O
/ . . O
mm . . O
3 . . O
) . . O
was . . O
8 . . O
days . . O
. . . O

corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
( . . O
penile . . B-AdverseReaction
fracture . . I-AdverseReaction
) . . O
was . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
in . . O
5 . . O
of . . O
1044 . . O
( . . O
0.5% . . O
) . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
in . . O
clinical . . O
studies . . O
. . . O

what . . O
should . . O
i . . O
tell . . O
my . . O
healthcare . . O
provider . . O
before . . O
taking . . O
duavee . . O
? . . O

life . . B-Severity
- . . I-Severity
threatening . . I-Severity
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
severe . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
presenting . . O
as . . O
respiratory . . B-AdverseReaction
distress . . I-AdverseReaction
, . . O
hypoxia . . B-AdverseReaction
, . . O
apnea . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
bradycardia . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
bronchospasm . . B-AdverseReaction
, . . O
throat . . B-AdverseReaction
tightness . . I-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
( . . O
including . . O
tongue . . O
or . . O
lip . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
periorbital . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
and . . O
face . . B-AdverseReaction
edema . . I-AdverseReaction
) . . O
, . . O
and . . O
urticaria . . B-AdverseReaction
, . . O
have . . O
occurred . . O
in . . O
some . . O
patients . . O
during . . O
and . . O
after . . O
alglucosidase . . O
alfa . . O
infusions . . O
. . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
reversible . . B-AdverseReaction
posterior . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
rpls . . B-AdverseReaction
) . . O
was . . O
reported . . O
in . . O
1 . . O
/ . . O
359 . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
none . . O
of . . O
the . . O
patients . . O
receiving . . O
sorafenib . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
paradoxical . . B-AdverseReaction
bronchospasm . . I-AdverseReaction
can . . B-Factor
occur . . O
. . . O

among . . O
the . . O
factors . . O
that . . O
may . . O
increase . . O
the . . O
risk . . O
for . . O
nsf . . O
are . . O
repeated . . O
or . . O
higher . . O
than . . O
recommended . . O
doses . . O
of . . O
a . . O
gbca . . O
and . . O
degree . . O
of . . O
renal . . O
impairment . . O
at . . O
the . . O
time . . O
of . . O
exposure . . O
. . . O

beta . . O
- . . O
adrenergic . . O
agonist . . O
medicines . . O
may . . B-Factor
produce . . O
significant . . B-Severity
hypokalemia . . B-AdverseReaction
in . . O
some . . O
patients . . O
, . . O
possibly . . O
through . . O
intracellular . . O
shunting . . O
, . . O
which . . O
has . . O
the . . O
potential . . O
to . . O
produce . . O
adverse . . O
cardiovascular . . O
effects . . O
. . . O

excerpt . . O
: . . O
* . . O
postmenopausal . . O
osteoporosis . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
5% . . O
and . . O
more . . O
common . . O
than . . O
placebo . . O
) . . O
were . . O
: . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
, . . O
hypercholesterolemia . . B-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
cystitis . . B-AdverseReaction
. . . O

before . . O
using . . O
otezla . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
depression . . O
and . . O
/ . . O
or . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
prescribers . . O
should . . O
carefully . . O
weigh . . O
the . . O
risks . . O
and . . O
benefits . . O
of . . O
treatment . . O
with . . O
otezla . . O
in . . O
such . . O
patients . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
not . . O
recommended . . O
in . . O
patients . . O
with . . O
complete . . O
gastrointestinal . . O
obstruction . . O
or . . O
in . . O
patients . . O
who . . O
have . . O
surgery . . O
for . . O
correction . . O
of . . O
complete . . O
bowel . . O
obstruction . . O
. . . O

no . . O
data . . O
are . . O
available . . O
on . . O
the . . O
secondary . . O
transmission . . O
of . . O
infection . . O
from . . O
persons . . O
receiving . . O
live . . O
vaccines . . O
to . . O
patients . . O
receiving . . O
benlysta . . O
or . . O
the . . O
effect . . O
of . . O
benlysta . . O
on . . O
new . . O
immunizations . . O
. . . O

the . . O
increased . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
with . . O
aeds . . B-DrugClass
was . . O
observed . . O
as . . O
early . . O
as . . O
1 . . O
week . . O
after . . O
starting . . O
treatment . . O
with . . O
aeds . . O
and . . O
persisted . . O
for . . O
the . . O
duration . . O
of . . O
treatment . . O
assessed . . O
. . . O

( . . O
6.1 . . O
, . . O
6.2 . . O
) . . O

in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
gastrointestinal . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
occurred . . O
more . . O
frequently . . O
among . . O
patients . . O
receiving . . O
trulicity . . O
than . . O
placebo . . O
( . . O
placebo . . O
21.3% . . O
, . . O
0.75 . . O
mg . . O
31.6% . . O
, . . O
1.5 . . O
mg . . O
41.0% . . O
) . . O
. . . O

the . . O
rates . . O
of . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
events . . O
( . . O
irrespective . . O
of . . O
causality . . O
) . . O
resulting . . O
in . . O
permanent . . O
discontinuation . . O
were . . O
14% . . O
and . . O
3% . . O
for . . O
the . . O
afinitor . . O
and . . O
placebo . . O
treatment . . O
groups . . O
, . . O
respectively . . O
. . . O

* . . O
toviaz . . O
should . . O
be . . O
administered . . O
with . . O
caution . . O
to . . O
patients . . O
with . . O
clinically . . O
significant . . O
bladder . . O
outlet . . O
obstruction . . O
because . . O
of . . O
the . . O
risk . . O
of . . O
urinary . . O
retention . . O
. . . O

( . . O
5.12 . . O
) . . O
* . . O
posterior . . B-AdverseReaction
reversible . . I-AdverseReaction
encephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
pres . . B-AdverseReaction
) . . O
: . . O
consider . . O
neuro . . O
- . . O
radiological . . O
imaging . . O
( . . O
mri . . O
) . . O
for . . O
onset . . O
of . . O
visual . . O
or . . O
neurological . . O
symptoms . . O
; . . O
discontinue . . O
kyprolis . . O
if . . O
suspected . . O
. . . O

adverse . . O
reactions . . O
in . . O
placebo . . O
- . . O
controlled . . O
and . . O
uncontrolled . . O
studies . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
and . . O
potential . . B-Factor
vision . . B-AdverseReaction
loss . . I-AdverseReaction

there . . O
was . . O
no . . O
apparent . . O
association . . O
between . . O
mean . . O
or . . O
peak . . O
igg . . O
antibody . . O
titers . . O
and . . O
the . . O
occurrence . . O
of . . O
adverse . . O
reactions . . O
. . . O

laboratory . . O
abnormalities . . O
are . . O
described . . O
separately . . O
in . . O
table . . O
9 . . O
. . . O

ensure . . O
safe . . O
handling . . O
to . . O
protect . . O
patients . . O
and . . O
health . . O
care . . O
workers . . O
from . . O
unintentional . . O
radiation . . O
exposure . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

permanently . . O
discontinue . . O
inlyta . . O
if . . O
signs . . O
or . . O
symptoms . . O
of . . O
rpls . . O
occur . . O
. . . O

counsel . . O
patients . . O
regarding . . O
the . . O
potential . . O
risk . . O
for . . O
mtc . . O
with . . O
the . . O
use . . O
of . . O
trulicity . . O
and . . O
inform . . O
them . . O
of . . O
symptoms . . O
of . . O
thyroid . . O
tumors . . O
( . . O
e . . O
. . . O
g . . O
. . . O
a . . O
mass . . O
in . . O
the . . O
neck . . O
, . . O
dysphagia . . O
, . . O
dyspnea . . O
, . . O
persistent . . O
hoarseness . . O
) . . O
. . . O

include . . O
disseminated . . O
herpetic . . O
infections . . O
in . . O
the . . O
differential . . O
diagnosis . . O
of . . O
patients . . O
who . . O
are . . O
receiving . . O
gilenya . . O
and . . O
present . . O
with . . O
an . . O
atypical . . O
ms . . O
relapse . . O
or . . O
multiorgan . . O
failure . . O
. . . O

and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

5.2 . . O
serious . . O
infections . . O

women . . O
on . . O
thyroid . . O
replacement . . O
therapy . . O
may . . O
require . . O
higher . . O
doses . . O
of . . O
thyroid . . O
hormone . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
dyslipidemia . . B-AdverseReaction
: . . O
undesirable . . O
alterations . . O
have . . O
been . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
atypical . . O
antipsychotics . . O
. . . O

the . . O
following . . O
adverse . . O
drug . . O
reactions . . O
are . . O
discussed . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

3includes . . O
the . . O
preferred . . O
terms . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
lower . . I-AdverseReaction
, . . O
and . . O
abdominal . . B-AdverseReaction
discomfort . . I-AdverseReaction
. . . O

most . . O
common . . O
adverse . . O
reactions . . O
occurring . . O
more . . O
frequently . . O
in . . O
the . . O
northera . . O
group . . O
study . . O
301 . . O
and . . O
study . . O
302 . . O
( . . O
1 . . O
to . . O
2 . . O
weeks . . O
randomized . . O
treatment . . O
) . . O
study . . O
306 . . O
( . . O
8 . . O
to . . O
10 . . O
weeks . . O
randomized . . O
treatment . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
132 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
northera . . O
( . . O
n . . O
= . . O
131 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
108 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
northera . . O
( . . O
n . . O
= . . O
114 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
headache . . B-AdverseReaction
4 . . O
( . . O
3.0 . . O
) . . O
8 . . O
( . . O
6.1 . . O
) . . O
8 . . O
( . . O
7.4 . . O
) . . O
15 . . O
( . . O
13.2 . . O
) . . O
dizziness . . B-AdverseReaction
2 . . O
( . . O
1.5 . . O
) . . O
5 . . O
( . . O
3.8 . . O
) . . O
5 . . O
( . . O
4.6 . . O
) . . O
11 . . O
( . . O
9.6 . . O
) . . O
nausea . . B-AdverseReaction
2 . . O
( . . O
1.5 . . O
) . . O
2 . . O
( . . O
1.5 . . O
) . . O
5 . . O
( . . O
4.6 . . O
) . . O
10 . . O
( . . O
8.8 . . O
) . . O
hypertension . . B-AdverseReaction
0 . . O
2 . . O
( . . O
1.5 . . O
) . . O
1 . . O
( . . O
0.9 . . O
) . . O
8 . . O
( . . O
7.0 . . O
) . . O
note . . O
: . . O
n . . O
= . . O
number . . O
of . . O
patients . . O
. . . O

multaq . . O
doubles . . O
the . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
in . . O
these . . O
patients . . O
( . . O
4 . . O
, . . O
5.1 . . O
, . . O
14.3 . . O
) . . O
. . . O

grade . . B-Severity
1-4 . . I-Severity
elevations . . O
in . . O
bilirubin . . O
occurred . . O
in . . O
3% . . O
of . . O
patients . . O
treated . . O
with . . O
xtandi . . O
( . . O
0.1% . . O
grade . . O
3-4 . . O
) . . O
and . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
( . . O
no . . O
grade . . O
3-4 . . O
) . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

of . . O
these . . O
patients . . O
, . . O
352 . . O
pediatric . . O
patients . . O
were . . O
treated . . O
with . . O
saphris . . O
for . . O
at . . O
least . . O
180 . . O
days . . O
and . . O
58 . . O
pediatric . . O
patients . . O
treated . . O
with . . O
saphris . . O
had . . O
at . . O
least . . O
1 . . O
year . . O
of . . O
exposure . . O
. . . O

to . . O
minimize . . O
contaminating . . O
the . . O
dropper . . O
tip . . O
and . . O
solution . . O
, . . O
care . . O
should . . O
be . . O
taken . . O
not . . O
to . . O
touch . . O
the . . O
eyelids . . O
or . . O
surrounding . . O
areas . . O
with . . O
the . . O
dropper . . O
tip . . O
of . . O
the . . O
bottle . . O
. . . O

5.8 . . O
drug . . O
induced . . O
liver . . O
injury . . O

test . . O
for . . O
viral . . O
hepatitis . . O
and . . O
discontinue . . O
other . . O
hepatotoxic . . O
medications . . O
if . . O
evidence . . O
of . . O
new . . O
or . . O
worsening . . O
liver . . O
dysfunction . . O
occurs . . O
. . . O

ensure . . O
that . . O
appropriate . . O
medical . . O
support . . O
measures . . O
, . . O
including . . O
cardiopulmonary . . O
resuscitation . . O
equipment . . O
, . . O
are . . O
readily . . O
available . . O
. . . O

serious . . B-Severity
and . . O
occasionally . . O
fatal . . B-AdverseReaction
hypersensitivity . . O
( . . O
anaphylactic . . O
) . . O
reactions . . O
and . . O
serious . . B-Severity
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
beta . . B-DrugClass
- . . I-DrugClass
lactam . . I-DrugClass
antibacterial . . I-DrugClass
drugs . . I-DrugClass
. . . O

( . . O
6 . . O
) . . O

treatment . . O
with . . O
cimzia . . O
should . . O
not . . O
be . . O
initiated . . O
in . . O
patients . . O
with . . O
an . . O
active . . O
infection . . O
, . . O
including . . O
clinically . . O
important . . O
localized . . O
infections . . O
. . . O

serum . . O
lipids . . O
: . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
stribild . . O
, . . O
a . . O
similar . . O
percentage . . O
of . . O
subjects . . O
receiving . . O
stribild . . O
, . . O
atripla . . O
, . . O
and . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
were . . O
on . . O
lipid . . O
lowering . . O
agents . . O
at . . O
baseline . . O
( . . O
12% . . O
, . . O
12% . . O
, . . O
and . . O
13% . . O
, . . O
respectively . . O
) . . O
. . . O

6 . . O
adverse . . O
reactions . . O

adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
4% . . O
of . . O
patients . . O
treated . . O
with . . O
nesina . . O
25 . . O
mg . . O
and . . O
more . . O
frequently . . O
than . . O
in . . O
patients . . O
who . . O
received . . O
placebo . . O
are . . O
summarized . . O
in . . O
table . . O
1 . . O
. . . O

consequently . . O
, . . O
to . . O
provide . . O
a . . O
meaningful . . O
estimate . . O
of . . O
the . . O
proportion . . O
of . . O
individuals . . O
experiencing . . O
adverse . . O
reactions . . O
, . . O
reactions . . O
were . . O
grouped . . O
in . . O
standardized . . O
categories . . O
using . . O
meddra . . O
terminology . . O
. . . O

5.1 . . O
new . . O
primary . . O
malignancies . . O

5 . . O
warnings . . O
and . . O
precautions . . O

the . . O
incidence . . O
of . . O
antibody . . O
development . . O
in . . O
patients . . O
receiving . . O
granix . . O
has . . O
not . . O
been . . O
adequately . . O
determined . . O
. . . O

6.1 . . O
clinical . . O
study . . O
experience . . O

significantly . . O
elevated . . O
serum . . O
calcitonin . . O
value . . O
may . . O
indicate . . O
mtc . . O
and . . O
patients . . O
with . . O
mtc . . O
usually . . O
have . . O
calcitonin . . O
values . . O
> . . O
50 . . O
ng . . O
/ . . O
l . . O
. . . O
if . . O
serum . . O
calcitonin . . O
is . . O
measured . . O
and . . O
found . . O
to . . O
be . . O
elevated . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
further . . O
evaluated . . O
. . . O

in . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
bipolar . . O
mania . . O
trials . . O
, . . O
the . . O
proportion . . O
of . . O
patients . . O
with . . O
total . . B-AdverseReaction
cholesterol . . I-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
240 . . B-Severity
mg . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
at . . O
endpoint . . O
) . . O
was . . O
8.7% . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
versus . . O
8.6% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

therapeutic . . O
infectious . . O
agents . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
adverse . . O
reactions . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
dysphonia . . B-AdverseReaction
, . . O
palmar . . O
- . . O
plantar . . O
erythrodysesthesia . . O
( . . O
hand . . O
- . . O
foot . . O
) . . O
syndrome . . O
, . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
and . . O
constipation . . B-AdverseReaction
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
have . . O
been . . O
associated . . O
with . . O
zydelig . . O
in . . O
clinical . . O
trials . . O
and . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
prescribing . . O
information . . O
. . . O

a . . O
majority . . O
of . . O
reported . . O
events . . O
occurred . . O
in . . O
patients . . O
who . . O
had . . O
experienced . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
or . . O
dehydration . . B-AdverseReaction
. . . O

in . . O
an . . O
exploratory . . O
clinical . . O
trial . . O
evaluating . . O
the . . O
use . . O
of . . O
the . . O
subcutaneous . . O
formulation . . O
of . . O
golimumab . . O
in . . O
patients . . O
with . . O
severe . . O
persistent . . O
asthma . . O
, . . O
more . . O
patients . . O
treated . . O
with . . O
golimumab . . O
reported . . O
malignancies . . B-AdverseReaction
compared . . O
with . . O
control . . O
patients . . O
. . . O

trulicity . . O
has . . O
not . . O
been . . O
evaluated . . O
in . . O
patients . . O
with . . O
a . . O
prior . . O
history . . O
of . . O
pancreatitis . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

6 . . O
adverse . . O
reactions . . O

* . . O
with . . O
known . . O
disturbances . . O
of . . O
electrolyte . . O
balance . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
hypokalemia . . O
or . . O
hypomagnesemia . . O
. . . O

permanently . . O
discontinue . . O
xalkori . . O
in . . O
patients . . O
who . . O
develop . . O
qtc . . O
greater . . O
than . . O
500 . . O
ms . . O
or . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
60 . . O
ms . . O
change . . O
from . . O
baseline . . O
with . . O
torsade . . O
de . . O
pointes . . O
or . . O
polymorphic . . O
ventricular . . O
tachycardia . . O
or . . O
signs . . O
/ . . O
symptoms . . O
of . . O
serious . . O
arrhythmia . . O
. . . O

3 . . O
- . . O
month . . O
and . . O
6 . . O
- . . O
month . . O
trials . . O

( . . O
5.1 . . O
) . . O

an . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
women . . O
taking . . O
cocs . . B-DrugClass
, . . O
and . . O
this . . O
increase . . O
is . . O
more . . O
likely . . O
in . . O
older . . O
women . . O
and . . O
with . . O
extended . . O
duration . . O
of . . O
use . . O
. . . O

5.4 . . O
tumor . . O
lysis . . O
syndrome . . O

however . . O
, . . O
the . . O
incidence . . O
of . . O
pruritus . . B-AdverseReaction
increased . . O
with . . O
more . . O
injections . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

* . . O
healthcare . . O
sites . . O
must . . O
be . . O
certified . . O
with . . O
the . . O
program . . O
and . . O
ensure . . O
that . . O
xiaflex . . O
is . . O
only . . O
dispensed . . O
for . . O
use . . O
by . . O
certified . . O
prescribers . . O
. . . O

chickenpox . . B-AdverseReaction
and . . O
measles . . B-AdverseReaction
, . . O
for . . O
example . . O
, . . O
can . . O
have . . O
a . . O
more . . O
serious . . B-Severity
or . . O
even . . O
fatal . . B-AdverseReaction
course . . O
in . . O
susceptible . . O
children . . O
or . . O
adults . . O
using . . O
corticosteroids . . B-DrugClass
. . . O

the . . O
greatest . . O
risk . . O
appears . . O
associated . . O
with . . O
prolonged . . O
use . . O
, . . O
with . . O
increased . . O
risks . . O
of . . O
15 . . O
- . . O
to . . O
24 . . O
- . . O
fold . . O
for . . O
5 . . O
to . . O
10 . . O
years . . O
or . . O
more . . O
of . . O
treatment . . O
. . . O

one . . O
additional . . O
patient's . . O
death . . B-AdverseReaction
was . . O
attributed . . O
to . . O
neutropenia . . B-AdverseReaction
without . . B-Negation
a . . O
documented . . O
infection . . B-AdverseReaction
. . . O

new . . O
- . . O
onset . . O
diabetes . . O
after . . O
transplantation . . O

* . . O
currently . . O
have . . O
or . . O
have . . O
had . . O
blood . . O
clots . . O
* . . O
are . . O
allergic . . O
to . . O
estrogens . . O
or . . O
bazedoxifene . . O
, . . O
the . . O
active . . O
ingredients . . O
in . . O
duavee . . O
, . . O
or . . O
any . . O
of . . O
its . . O
ingredients . . O
. . . O

empiric . . O
anti . . O
- . . O
fungal . . O
therapy . . O
should . . O
be . . O
considered . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
invasive . . O
fungal . . O
infections . . O
who . . O
develop . . O
severe . . O
systemic . . O
illness . . O
. . . O

5.4 . . O
intestinal . . O
perforation . . O

if . . O
an . . O
infection . . O
develops . . O
, . . O
monitor . . O
carefully . . O
, . . O
and . . O
stop . . O
simponi . . O
aria . . O
if . . O
infection . . O
becomes . . O
serious . . O
( . . O
5.1 . . O
) . . O
. . . O

5.4 . . O
suicidal . . O
behavior . . O
and . . O
ideation . . O

dose . . O
- . . O
related . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
phosphate . . I-AdverseReaction
levels . . O
were . . O
observed . . O
with . . O
invokana . . O
. . . O

in . . O
these . . O
trials . . O
, . . O
patients . . O
were . . O
treated . . O
with . . O
up . . O
to . . O
3 . . O
injections . . O
of . . O
0.58 . . O
mg . . O
of . . O
xiaflex . . O
or . . O
placebo . . O
with . . O
approximately . . O
4 . . O
- . . O
week . . O
intervals . . O
between . . O
injections . . O
and . . O
the . . O
patients . . O
had . . O
finger . . O
extension . . O
procedures . . O
the . . O
day . . O
after . . O
injection . . O
, . . O
if . . O
needed . . O
, . . O
to . . O
facilitate . . O
disruption . . O
of . . O
the . . O
cord . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

advise . . O
patients . . O
regarding . . O
good . . O
oral . . O
hygiene . . O
practices . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
to . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

some . . O
of . . O
these . . O
infections . . B-AdverseReaction
have . . O
been . . O
severe . . B-Severity
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
leading . . O
to . . O
sepsis . . B-AdverseReaction
, . . O
respiratory . . O
or . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
) . . O
or . . O
fatal . . B-AdverseReaction
. . . O

in . . O
some . . O
instances . . O
, . . O
hbv . . B-AdverseReaction
reactivation . . I-AdverseReaction
occurring . . O
in . . O
conjunction . . O
with . . O
tnf . . B-DrugClass
blocker . . I-DrugClass
therapy . . O
has . . O
been . . O
fatal . . B-AdverseReaction
. . . O

5.2 . . O
thyroid . . O
accumulation . . O

the . . O
incidence . . O
of . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
in . . O
male . . O
patients . . O
randomized . . O
to . . O
placebo . . O
, . . O
jardiance . . O
10 . . O
mg . . O
, . . O
and . . O
jardiance . . O
25 . . O
mg . . O
was . . O
3.2% . . O
, . . O
3.6% . . O
, . . O
and . . O
4.1% . . O
, . . O
respectively . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
) . . O
] . . O
. . . O

the . . O
incidence . . O
of . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
did . . O
not . . O
increase . . O
in . . O
the . . O
long . . O
- . . O
term . . O
safety . . O
studies . . O
with . . O
multiple . . O
re . . O
- . . O
treatments . . O
at . . O
intervals . . O
> . . O
= . . O
three . . O
months . . O
. . . O

* . . O
irregular . . B-AdverseReaction
uterine . . I-AdverseReaction
bleeding . . I-AdverseReaction
* . . O
nausea . . B-AdverseReaction
* . . O
breast . . B-AdverseReaction
tenderness . . I-AdverseReaction
* . . O
headache . . B-AdverseReaction
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
in . . O
clinical . . O
trials . . O
for . . O
natazia . . O
are . . O
headaches . . B-AdverseReaction
, . . O
irregular . . B-AdverseReaction
uterine . . I-AdverseReaction
bleeding . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
( . . O
including . . O
migraines . . B-AdverseReaction
) . . O
13% . . O
, . . O
breast . . B-AdverseReaction
tenderness . . I-AdverseReaction
, . . O
pain . . O
7% . . O
, . . O
menstrual . . B-AdverseReaction
disorders . . I-AdverseReaction
7% . . O
, . . O
nausea . . B-AdverseReaction
/ . . O
or . . O
vomiting . . B-AdverseReaction
, . . O
6% . . O
, . . O
acne . . B-AdverseReaction
4% . . O
, . . O
mood . . B-AdverseReaction
changes . . I-AdverseReaction
( . . O
3% . . O
) . . O
and . . O
increased . . B-AdverseReaction
weight . . I-AdverseReaction
. . . O

table . . O
6 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
at . . O
least . . O
10% . . O
of . . O
patients . . O
with . . O
rcc . . O
and . . O
at . . O
a . . O
higher . . O
rate . . O
in . . O
the . . O
afinitor . . O
arm . . O
than . . O
in . . O
the . . O
placebo . . O
arm . . O
grading . . O
according . . O
to . . O
ctcae . . O
version . . O
3.0 . . O
a . . O
stomatitis . . B-AdverseReaction
( . . O
including . . O
aphthous . . B-AdverseReaction
stomatitis . . I-AdverseReaction
) . . O
, . . O
and . . O
mouth . . O
and . . O
tongue . . B-AdverseReaction
ulceration . . I-AdverseReaction
. . . O
b . . O
includes . . O
all . . O
preferred . . O
terms . . O
within . . O
the . . O
' . . O
infections . . O
and . . O
infestations . . O
' . . O
system . . O
organ . . O
class . . O
, . . O
the . . O
most . . O
common . . O
being . . O
nasopharyngitis . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
pneumonia . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
bronchitis . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
and . . O
sinusitis . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
and . . O
also . . O
including . . O
aspergillosis . . B-AdverseReaction
( . . O
< . . O
1% . . O
) . . O
, . . O
candidiasis . . B-AdverseReaction
( . . O
< . . O
1% . . O
) . . O
, . . O
and . . O
sepsis . . B-AdverseReaction
( . . O
< . . O
1% . . O
) . . O
. . . O
c . . O
includes . . O
pneumonitis . . B-AdverseReaction
, . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
lung . . B-AdverseReaction
infiltration . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
alveolar . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
toxicity . . I-AdverseReaction
, . . O
and . . O
alveolitis . . B-AdverseReaction
. . . O

gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
48 . . O
4 . . O
18 . . O
2 . . O
nausea . . B-AdverseReaction
26 . . O
2 . . O
18 . . O
0 . . O
stomatitis . . B-AdverseReaction
17 . . O
1 . . O
6 . . O
1 . . O
constipation . . B-AdverseReaction
15 . . O
0 . . O
9 . . O
0 . . O
vomiting . . B-AdverseReaction
14 . . O
0 . . O
6 . . O
1 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
28 . . O
2 . . O
30 . . O
2 . . O
pyrexia . . B-AdverseReaction
24 . . O
2 . . O
15 . . O
1 . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
16 . . O
1 . . O
11 . . O
2 . . O
pneumonia . . B-AdverseReaction
15 . . O
10 . . O
13 . . O
9 . . O
sinusitis . . B-AdverseReaction
11 . . O
1 . . O
6 . . O
0 . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
10 . . O
4 . . O
5 . . O
1 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
24 . . O
3 . . O
13 . . O
0 . . O
petechiae . . B-AdverseReaction
14 . . O
0 . . O
1 . . O
0 . . O
bruising . . B-AdverseReaction
12 . . O
0 . . O
1 . . O
0 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
28 . . O
2 . . O
18 . . O
1 . . O
arthralgia . . B-AdverseReaction
17 . . O
1 . . O
7 . . O
0 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
14 . . O
1 . . O
6 . . O
0 . . O
dizziness . . B-AdverseReaction
11 . . O
0 . . O
5 . . O
0 . . O
injury . . O
, . . O
poisoning . . O
and . . O
procedural . . O
complications . . O
contusion . . B-AdverseReaction
11 . . O
0 . . O
3 . . O
0 . . O
eye . . O
disorders . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
10 . . O
0 . . O
3 . . O
0 . . O
table . . O
6 . . O
: . . O
treatment . . O
- . . O
emergentbased . . O
on . . O
laboratory . . O
measurements . . O
per . . O
iwcll . . O
criteria . . O
decrease . . B-AdverseReaction
of . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
platelets . . O
, . . O
or . . O
neutrophils . . O
in . . O
study . . O
2 . . O
imbruvica . . O
( . . O
n . . O
= . . O
195 . . O
) . . O
ofatumumab . . O
( . . O
n . . O
= . . O
191 . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
51 . . O
23 . . O
57 . . O
26 . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
52 . . O
5 . . O
45 . . O
10 . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
36 . . O
0 . . O
21 . . O
0 . . O
waldenstrom's . . O
macroglobulinemia . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

adverse . . O
reaction . . O
number . . O
( . . O
% . . O
) . . O
with . . O
adverse . . O
reaction . . O
number . . O
( . . O
% . . O
) . . O
discontinuing . . O
potiga . . O
( . . O
n . . O
= . . O
813 . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
427 . . O
) . . O
potiga . . O
( . . O
n . . O
= . . O
813 . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
427 . . O
) . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
75 . . O
( . . O
9% . . O
) . . O
11 . . O
( . . O
3% . . O
) . . O
32 . . O
( . . O
4% . . O
) . . O
4 . . O
( . . O
< . . O
1% . . O
) . . O
psychosis . . B-AdverseReaction
9 . . O
( . . O
1% . . O
) . . O
0 . . O
6 . . O
( . . O
< . . O
1% . . O
) . . O
0 . . O
hallucinationsa . . O
14 . . O
( . . O
2% . . O
) . . O
2 . . O
( . . O
< . . O
1% . . O
) . . O
6 . . O
( . . O
< . . O
1% . . O
) . . O
0 . . O
a . . O
hallucinations . . B-AdverseReaction
includes . . O
visual . . O
, . . O
auditory . . O
, . . O
and . . O
mixed . . B-AdverseReaction
hallucinations . . I-AdverseReaction
. . . O

the . . O
safety . . O
profile . . O
for . . O
subjects . . O
who . . O
completed . . O
48 . . O
weeks . . O
of . . O
treatment . . O
was . . O
similar . . O
to . . O
the . . O
safety . . O
profile . . O
for . . O
subjects . . O
who . . O
completed . . O
24 . . O
weeks . . O
of . . O
treatment . . O
. . . O

emergency . . O
resuscitation . . O
equipment . . O
and . . O
personnel . . O
should . . O
be . . O
immediately . . O
available . . O
. . . O

administration . . O
of . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
is . . O
not . . O
recommended . . O
until . . O
the . . O
skin . . O
is . . O
healed . . O
from . . O
any . . O
previous . . O
drug . . O
or . . O
surgical . . O
treatment . . O
. . . O

it . . O
is . . O
important . . O
to . . O
note . . O
that . . O
early . . O
manifestations . . O
of . . O
hypersensitivity . . B-AdverseReaction
, . . O
such . . O
as . . O
fever . . B-AdverseReaction
or . . O
lymphadenopathy . . B-AdverseReaction
, . . O
may . . B-Factor
be . . O
present . . O
even . . O
though . . O
rash . . B-AdverseReaction
is . . O
not . . B-Negation
evident . . I-Negation
. . . O

prolactin . . O
: . . O
in . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
adult . . O
schizophrenia . . O
trials . . O
, . . O
the . . O
mean . . O
decreases . . B-AdverseReaction
in . . I-AdverseReaction
prolactin . . I-AdverseReaction
levels . . I-AdverseReaction
were . . O
6.5 . . O
ng . . O
/ . . O
ml . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
10.7 . . O
ng . . O
/ . . O
ml . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
bradycardia . . B-AdverseReaction
: . . O
xalkori . . O
can . . B-Factor
cause . . O
bradycardia . . B-AdverseReaction
. . . O

the . . O
incidence . . O
of . . O
adverse . . O
events . . O
leading . . O
to . . O
study . . O
drug . . O
discontinuation . . O
for . . O
cleviprex . . O
in . . O
severe . . O
hypertension . . O
was . . O
4.8% . . O
. . . O

injection . . O
of . . O
xiaflex . . O
into . . O
collagen . . O
- . . O
containing . . O
structures . . O
such . . O
as . . O
tendons . . O
or . . O
ligaments . . O
of . . O
the . . O
hand . . O
may . . B-Factor
result . . O
in . . O
damage . . O
to . . O
those . . O
structures . . O
and . . O
possible . . B-Factor
permanent . . B-AdverseReaction
injury . . I-AdverseReaction
such . . O
as . . O
tendon . . B-AdverseReaction
rupture . . I-AdverseReaction
or . . O
ligament . . B-AdverseReaction
damage . . I-AdverseReaction
. . . O

* . . O
currently . . O
have . . O
or . . O
have . . O
had . . O
certain . . O
cancers . . O
. . . O

table . . O
1 . . O
summarizes . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
2 . . O
or . . O
more . . O
patients . . O
treated . . O
with . . O
carbaglu . . O
in . . O
the . . O
retrospective . . O
case . . O
series . . O
. . . O

a . . O
dose . . O
- . . O
dependent . . O
increase . . O
in . . O
the . . O
risk . . B-Factor
of . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
occurred . . O
in . . O
the . . O
gilenya . . O
clinical . . O
development . . O
program . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

in . . O
this . . O
clinical . . O
context . . O
, . . O
if . . O
the . . O
patient . . O
is . . O
found . . O
to . . O
have . . O
abnormal . . O
liver . . O
tests . . O
( . . O
alt . . O
greater . . O
than . . O
three . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
the . . O
reference . . O
range . . O
) . . O
, . . O
uloric . . O
treatment . . O
should . . O
be . . O
interrupted . . O
and . . O
investigation . . O
done . . O
to . . O
establish . . O
the . . O
probable . . O
cause . . O
. . . O

these . . O
data . . O
reflect . . O
exposure . . O
of . . O
2338 . . O
patients . . O
to . . O
farxiga . . O
with . . O
a . . O
mean . . O
exposure . . O
duration . . O
of . . O
21 . . O
weeks . . O
. . . O

5.6 . . O
neurological . . O
adverse . . O
reactions . . O

patients . . O
were . . O
treated . . O
with . . O
kalbitor . . O
30 . . O
mg . . O
subcutaneous . . O
or . . O
placebo . . O
. . . O

in . . O
patients . . O
whose . . O
renal . . O
function . . O
may . . O
depend . . O
on . . O
the . . O
activity . . O
of . . O
the . . O
renin . . O
- . . O
angiotensin . . O
system . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
patients . . O
with . . O
severe . . O
congestive . . O
heart . . O
failure . . O
, . . O
renal . . O
artery . . O
stenosis . . O
, . . O
or . . O
volume . . O
depletion . . O
) . . O
, . . O
treatment . . O
with . . O
angiotensin . . B-DrugClass
- . . I-DrugClass
converting . . I-DrugClass
enzyme . . I-DrugClass
inhibitors . . I-DrugClass
and . . O
angiotensin . . B-DrugClass
receptor . . I-DrugClass
blockers . . I-DrugClass
has . . O
been . . O
associated . . O
with . . O
oliguria . . B-AdverseReaction
or . . O
progressive . . B-AdverseReaction
azotemia . . I-AdverseReaction
and . . O
rarely . . O
with . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
and . . O
death . . B-AdverseReaction
. . . O

administer . . O
topical . . O
or . . O
systemic . . O
corticosteroids . . O
if . . O
there . . O
is . . O
no . . O
improvement . . O
of . . O
symptoms . . O
within . . O
1 . . O
week . . O
. . . O

a . . O
major . . O
depressive . . O
episode . . O
may . . O
be . . O
the . . O
initial . . O
presentation . . O
of . . O
bipolar . . O
disorder . . O
. . . O

infection . . B-AdverseReaction
, . . O
including . . O
pneumonia . . B-AdverseReaction
, . . O
sepsis . . B-AdverseReaction
, . . O
septic . . B-AdverseReaction
shock . . I-AdverseReaction
, . . O
and . . O
death . . B-AdverseReaction
have . . O
occurred . . O
in . . O
adult . . O
and . . O
pediatric . . O
patients . . O
in . . O
clinical . . O
trials . . O
and . . O
in . . O
postmarketing . . O
reports . . O
. . . O

metabolism . . O
and . . O
nutrition . . O
disorder . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
hyperkalemia . . B-AdverseReaction
, . . O
dehydration . . B-AdverseReaction

somnolence . . O
and . . O
fatigue . . O

study . . O
2 . . O
is . . O
an . . O
ongoing . . O
expanded . . O
access . . O
program . . O
. . . O

the . . O
nadir . . O
in . . O
serum . . O
calcium . . O
level . . O
occurs . . O
at . . O
approximately . . O
day . . O
10 . . O
after . . O
prolia . . O
dosing . . O
in . . O
subjects . . O
with . . O
normal . . O
renal . . O
function . . O
. . . O

a . . O
total . . O
of . . O
9 . . O
serious . . O
adverse . . O
reactions . . O
were . . O
reported . . O
for . . O
caps . . O
patients . . O
. . . O

excerpt . . O
: . . O
* . . O
new . . O
onset . . O
or . . O
worsening . . B-AdverseReaction
renal . . I-AdverseReaction
impairment . . I-AdverseReaction
: . . O
can . . B-Factor
include . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
and . . O
fanconi . . B-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

monitor . . O
crcl . . O
at . . O
least . . O
daily . . O
in . . O
patients . . O
with . . O
changing . . O
renal . . O
function . . O
and . . O
adjust . . O
the . . O
dose . . O
of . . O
zerbaxa . . O
accordingly . . O
. . . O

rhabdomyolysis . . B-AdverseReaction
, . . O
osteomalacia . . B-AdverseReaction
( . . O
manifested . . O
as . . O
bone . . B-AdverseReaction
pain . . I-AdverseReaction
and . . O
which . . O
may . . O
contribute . . O
to . . O
fractures . . B-AdverseReaction
) . . O
, . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
myopathy . . B-AdverseReaction

co . . O
- . . O
administration . . O
of . . O
strong . . O
cytochrome . . O
p450 . . O
enzyme . . O
inducer . . O
, . . O
rifampin . . O
, . . O
resulted . . O
in . . O
a . . O
reduction . . O
of . . O
systemic . . O
exposure . . O
of . . O
apremilast . . O
, . . O
which . . O
may . . O
result . . O
in . . O
a . . O
loss . . O
of . . O
efficacy . . O
of . . O
otezla . . O
. . . O

monitor . . O
with . . O
liver . . O
laboratory . . O
tests . . O
including . . O
alt . . O
, . . O
aspartate . . O
aminotransferase . . O
( . . O
ast . . O
) . . O
, . . O
and . . O
total . . O
bilirubin . . O
once . . O
a . . O
month . . O
and . . O
as . . O
clinically . . O
indicated . . O
, . . O
with . . O
more . . O
frequent . . O
testing . . O
in . . O
patients . . O
who . . O
develop . . O
transaminase . . O
elevations . . O
. . . O

neutropenia . . B-AdverseReaction
may . . B-Factor
precede . . O
the . . O
development . . O
of . . O
agranulocytosis . . B-AdverseReaction
. . . O

correct . . O
volume . . O
or . . O
salt . . O
depletion . . O
prior . . O
to . . O
administration . . O
of . . O
edarbi . . O
, . . O
or . . O
start . . O
treatment . . O
at . . O
40 . . O
mg . . O
. . . O

use . . O
in . . O
liver . . O
transplant . . O
patients . . O
is . . O
not . . O
recommended . . O
due . . O
to . . O
an . . O
increased . . O
risk . . O
of . . O
graft . . O
loss . . O
and . . O
death . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
. . . O

the . . O
incidence . . O
of . . O
serious . . B-Severity
infections . . B-AdverseReaction
during . . O
the . . O
controlled . . O
clinical . . O
studies . . O
was . . O
3% . . O
per . . O
patient . . O
- . . O
year . . O
for . . O
cimzia . . O
- . . O
treated . . O
patients . . O
and . . O
1% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

( . . O
5.8 . . O
) . . O

* . . O
in . . O
male . . O
and . . O
female . . O
rats . . B-Animal
, . . O
dulaglutide . . O
causes . . O
a . . O
dose . . O
- . . O
related . . O
and . . O
treatment . . O
- . . O
duration . . O
- . . O
dependent . . O
increase . . O
in . . O
the . . O
incidence . . O
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
( . . O
adenomas . . O
and . . O
carcinomas . . O
) . . O
after . . O
lifetime . . O
exposure . . O
. . . O

laboratory . . O
abnormalities . . O

low . . O
and . . O
high . . O
markedly . . B-Severity
abnormal . . O
platelet . . O
and . . O
wbc . . O
counts . . O
were . . O
observed . . O
in . . O
< . . O
0.1% . . O
of . . O
subjects . . O
. . . O

the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
20% . . O
of . . O
patients . . O
treated . . O
with . . O
the . . O
recommended . . O
dose . . O
and . . O
frequency . . O
of . . O
nulojix . . O
were . . O
anemia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
graft . . B-AdverseReaction
dysfunction . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
hyperkalemia . . B-AdverseReaction
, . . O
and . . O
leukopenia . . B-AdverseReaction
. . . O

single . . O
intraperitoneal . . O
doses . . O
of . . O
bendamustine . . O
in . . O
mice . . B-Animal
and . . O
rats . . B-Animal
administered . . O
during . . O
organogenesis . . O
caused . . O
an . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
resorptions . . I-AdverseReaction
, . . O
skeletal . . O
and . . O
visceral . . B-AdverseReaction
malformations . . I-AdverseReaction
, . . O
and . . O
decreased . . B-AdverseReaction
fetal . . I-AdverseReaction
body . . I-AdverseReaction
weights . . I-AdverseReaction
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction

epstein . . O
- . . O
barr . . O
virus . . O
serology . . O
should . . O
be . . O
ascertained . . O
before . . O
starting . . O
administration . . O
of . . O
nulojix . . O
, . . O
and . . O
only . . O
patients . . O
who . . O
are . . O
ebv . . O
seropositive . . O
should . . O
receive . . O
nulojix . . O
. . . O

contact . . O
your . . O
local . . O
genzyme . . O
representative . . O
or . . O
genzyme . . O
corporation . . O
at . . O
1-800-745-4447 . . O
for . . O
information . . O
on . . O
testing . . O
and . . O
to . . O
obtain . . O
a . . O
sample . . O
collection . . O
box . . O
. . . O

excerpt . . O
: . . O
* . . O
women . . O
taking . . O
duavee . . O
should . . O
not . . O
take . . O
progestins . . O
, . . O
additional . . O
estrogens . . O
or . . O
additional . . O
estrogen . . O
agonist . . O
/ . . O
antagonists . . O
( . . O
5.1 . . O
) . . O
* . . O
cardiovascular . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
including . . O
venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
, . . O
stroke . . B-AdverseReaction
, . . O
and . . O
retinal . . B-AdverseReaction
vascular . . I-AdverseReaction
thrombosis . . I-AdverseReaction
( . . O
5.2 . . O
, . . O
5.6 . . O
) . . O
* . . O
malignant . . B-AdverseReaction
neoplasms . . I-AdverseReaction
, . . O
including . . O
endometrial . . B-AdverseReaction
cancer . . I-AdverseReaction
, . . O
breast . . B-AdverseReaction
cancer . . I-AdverseReaction
, . . O
and . . O
ovarian . . B-AdverseReaction
cancer . . I-AdverseReaction
( . . O
5.3 . . O
) . . O
* . . O
estrogens . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
gallbladder . . B-AdverseReaction
disease . . I-AdverseReaction
( . . O
5.5 . . O
) . . O
* . . O
discontinue . . O
estrogen . . O
if . . O
loss . . O
of . . O
vision . . O
, . . O
severe . . O
hypertriglyceridemia . . O
or . . O
cholestatic . . O
jaundice . . O
occurs . . O
( . . O
5.6 . . O
, . . O
5.8 . . O
, . . O
5.9 . . O
) . . O
* . . O
monitor . . O
thyroid . . O
function . . O
in . . O
women . . O
on . . O
thyroid . . O
replacement . . O
therapy . . O
( . . O
5.10 . . O
, . . O
5.17 . . O
) . . O

5.7 . . O
macrovascular . . O
outcomes . . O

these . . O
patients . . O
may . . O
have . . O
an . . O
increased . . O
risk . . O
for . . O
a . . O
hypersensitivity . . O
reaction . . O
to . . O
gadavist . . O
. . . O

use . . O
with . . O
caution . . O
in . . O
patients . . O
who . . O
are . . O
at . . O
increased . . O
risk . . O
for . . O
these . . O
events . . O
. . . O

extravasation . . O
into . . O
tissues . . O
during . . O
gadavist . . O
administration . . O
may . . B-Factor
result . . O
in . . O
moderate . . B-Severity
irritation . . O
[ . . O
see . . O
nonclinical . . O
toxicology . . O
( . . O
13.2 . . O
) . . O
] . . O
. . . O

psychiatric . . O
disorders . . O
: . . O
bruxism . . B-AdverseReaction
, . . O
depression . . B-AdverseReaction
, . . O
obsessive . . B-AdverseReaction
- . . I-AdverseReaction
compulsive . . I-AdverseReaction
disorder . . I-AdverseReaction
. . . O

patients . . O
who . . O
are . . O
carriers . . O
of . . O
hbv . . O
and . . O
require . . O
treatment . . O
with . . O
cimzia . . O
should . . O
be . . O
closely . . O
monitored . . O
for . . O
clinical . . O
and . . O
laboratory . . O
signs . . O
of . . O
active . . O
hbv . . O
infection . . O
throughout . . O
therapy . . O
and . . O
for . . O
several . . O
months . . O
following . . O
termination . . O
of . . O
therapy . . O
. . . O

potiga . . O
can . . B-Factor
cause . . O
abnormalities . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
retina . . I-AdverseReaction
. . . O

choline . . O
c . . O
11 . . O
injection . . O
contributes . . O
to . . O
a . . O
patient's . . O
overall . . O
long . . O
- . . O
term . . O
cumulative . . O
radiation . . O
exposure . . O
. . . O

some . . O
patients . . O
with . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
have . . O
been . . O
found . . O
to . . O
have . . O
abnormal . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
. . . O

excerpt . . O
: . . O
* . . O
if . . O
infection . . O
occurs . . O
while . . O
on . . O
ferriprox . . O
, . . O
interrupt . . O
therapy . . O
and . . O
monitor . . O
the . . O
anc . . O
more . . O
frequently . . O
. . . O

the . . O
following . . O
risk . . O
is . . O
discussed . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

this . . O
risk . . O
increases . . O
with . . O
age . . O
, . . O
particularly . . O
in . . O
women . . O
over . . O
35 . . O
years . . O
of . . O
age . . O
, . . O
and . . O
with . . O
the . . O
number . . O
of . . O
cigarettes . . O
smoked . . O
. . . O

before . . O
initiating . . O
treatment . . O
with . . O
tecfidera . . O
, . . O
a . . O
cbc . . O
including . . O
lymphocyte . . O
count . . O
should . . O
be . . O
obtained . . O
. . . O

specifically . . O
, . . O
9 . . O
patients . . O
had . . O
a . . O
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
pleural . . B-AdverseReaction
effusion . . I-AdverseReaction
, . . O
3 . . O
patients . . O
experienced . . O
both . . O
grade . . B-Severity
3 . . I-Severity
or . . O
grade . . B-Severity
4 . . I-Severity
pleural . . O
and . . O
pericardial . . B-AdverseReaction
effusions . . I-AdverseReaction
, . . O
1 . . O
patient . . O
experienced . . O
grade . . B-Severity
3 . . I-Severity
peripheral . . O
and . . O
pulmonary . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
and . . O
1 . . O
patient . . O
had . . O
a . . O
grade . . B-Severity
3 . . I-Severity
edema . . B-AdverseReaction
. . . O

institute . . O
hormone . . O
replacement . . O
therapy . . O
as . . O
needed . . O
. . . O

( . . O
5.6 . . O
) . . O

other . . O
severe . . B-Severity
or . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
( . . O
grade . . O
> . . O
= . . O
3 . . O
) . . O
cutaneous . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
dermatitis . . B-AdverseReaction
exfoliative . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
erythematous . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
generalized . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
macular . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
maculo . . I-AdverseReaction
- . . I-AdverseReaction
papular . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
papular . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
pruritic . . I-AdverseReaction
, . . O
exfoliative . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
and . . O
skin . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
zydelig . . O
- . . O
treated . . O
patients . . O
. . . O

in . . O
study . . O
5 . . O
, . . O
treatment . . O
of . . O
recurrent . . O
contractures . . O
with . . O
xiaflex . . O
resulted . . O
in . . O
similar . . O
immunogenicity . . O
results . . O
as . . O
seen . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
. . . O

antipsychotic . . O
treatment . . O
itself . . O
, . . O
however . . O
, . . O
may . . O
suppress . . O
( . . O
or . . O
partially . . O
suppress . . O
) . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
the . . O
syndrome . . O
and . . O
thereby . . O
may . . O
possibly . . O
mask . . O
the . . O
underlying . . O
process . . O
. . . O

5.2 . . O
immune . . O
- . . O
mediated . . O
hepatitis . . O

pooled . . O
analyses . . O
of . . O
199 . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
( . . O
monotherapy . . O
and . . O
adjunctive . . O
therapy . . O
) . . O
of . . O
11 . . O
different . . O
aeds . . O
showed . . O
that . . O
patients . . O
randomized . . O
to . . O
1 . . O
of . . O
the . . O
aeds . . B-DrugClass
had . . O
approximately . . O
twice . . O
the . . O
risk . . O
[ . . O
adjusted . . O
relative . . O
risk . . O
1.8 . . O
, . . O
95% . . O
confidence . . O
interval . . O
( . . O
ci . . O
) . . O
: . . O
1.2 . . O
, . . O
2.7 . . O
] . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
or . . O
behavior . . O
compared . . O
with . . O
patients . . O
randomized . . O
to . . O
placebo . . O
. . . O

* . . O
if . . O
members . . O
of . . O
your . . O
family . . O
have . . O
had . . O
breast . . O
cancer . . O
or . . O
if . . O
you . . O
have . . O
ever . . O
had . . O
breast . . O
lumps . . O
or . . O
an . . O
abnormal . . O
mammogram . . O
, . . O
you . . O
may . . O
need . . O
to . . O
have . . O
breast . . O
exams . . O
more . . O
often . . O
. . . O

one . . O
( . . O
0.2% . . O
) . . O
patient . . O
died . . B-AdverseReaction
as . . O
a . . O
result . . O
of . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
and . . O
one . . O
additional . . O
patient . . O
required . . O
hospitalization . . O
for . . O
severe . . B-Severity
dermatitis . . B-AdverseReaction
. . . O

in . . O
this . . O
extension . . O
trial . . O
, . . O
all . . O
eligible . . O
patients . . O
were . . O
initially . . O
assigned . . O
to . . O
stendra . . O
100 . . O
mg . . O
. . . O

gilenya . . O
causes . . O
a . . O
dose . . O
- . . O
dependent . . O
reduction . . B-AdverseReaction
in . . I-AdverseReaction
peripheral . . I-AdverseReaction
lymphocyte . . I-AdverseReaction
count . . I-AdverseReaction
to . . O
20% . . B-Severity
- . . I-Severity
30% . . I-Severity
of . . I-Severity
baseline . . I-Severity
values . . O
because . . O
of . . O
reversible . . B-Severity
sequestration . . B-AdverseReaction
of . . I-AdverseReaction
lymphocytes . . I-AdverseReaction
in . . I-AdverseReaction
lymphoid . . I-AdverseReaction
tissues . . I-AdverseReaction
. . . O

6.3 . . O
postmarketing . . O
experience . . O

treatment . . O
of . . O
bone . . O
loss . . O
in . . O
patients . . O
receiving . . O
androgen . . O
deprivation . . O
therapy . . O
for . . O
prostate . . O
cancer . . O
or . . O
adjuvant . . O
aromatase . . O
inhibitor . . O
therapy . . O
for . . O
breast . . O
cancer . . O

dalvance . . O
is . . O
administered . . O
via . . O
intravenous . . O
infusion . . O
, . . O
using . . O
a . . O
total . . O
infusion . . O
time . . O
of . . O
30 . . O
minutes . . O
to . . O
minimize . . O
the . . O
risk . . O
of . . O
infusion . . O
- . . O
related . . O
reactions . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

discontinue . . O
kyprolis . . O
if . . O
pres . . O
is . . O
suspected . . O
and . . O
evaluate . . O
. . . O

the . . O
incidence . . O
in . . O
the . . O
dme . . O
studies . . O
from . . O
baseline . . O
to . . O
week . . O
52 . . O
was . . O
3.3% . . O
( . . O
19 . . O
out . . O
of . . O
578 . . O
) . . O
in . . O
the . . O
combined . . O
group . . O
of . . O
patients . . O
treated . . O
with . . O
eylea . . O
compared . . O
with . . O
2.8% . . O
( . . O
8 . . O
out . . O
of . . O
287 . . O
) . . O
in . . O
the . . O
control . . O
group . . O
; . . O
from . . O
baseline . . O
to . . O
week . . O
100 . . O
, . . O
the . . O
incidence . . O
was . . O
6.4% . . O
( . . O
37 . . O
out . . O
of . . O
578 . . O
) . . O
in . . O
the . . O
combined . . O
group . . O
of . . O
patients . . O
treated . . O
with . . O
eylea . . O
compared . . O
with . . O
4.2% . . O
( . . O
12 . . O
out . . O
of . . O
287 . . O
) . . O
in . . O
the . . O
control . . O
group . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction

( . . O
5.3 . . O
) . . O

bone . . B-AdverseReaction
pain . . I-AdverseReaction
was . . O
the . . O
most . . O
frequent . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reaction . . O
that . . O
occurred . . O
in . . O
at . . O
least . . O
1% . . O
or . . O
greater . . O
in . . O
patients . . O
treated . . O
with . . O
granix . . O
at . . O
the . . O
recommended . . O
dose . . O
and . . O
was . . O
numerically . . O
two . . O
times . . O
more . . O
frequent . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

in . . O
each . . O
cycle . . O
, . . O
two . . O
injections . . O
of . . O
xiaflex . . O
or . . O
two . . O
injections . . O
of . . O
placebo . . O
were . . O
administered . . O
1 . . O
to . . O
3 . . O
days . . O
apart . . O
. . . O

* . . O
potiga . . O
can . . O
cause . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
with . . O
funduscopic . . O
features . . O
similar . . O
to . . O
those . . O
seen . . O
in . . O
retinal . . O
pigment . . O
dystrophies . . O
, . . O
which . . O
are . . O
known . . O
to . . O
result . . O
in . . O
damage . . B-AdverseReaction
to . . I-AdverseReaction
the . . I-AdverseReaction
photoreceptors . . I-AdverseReaction
and . . O
vision . . B-AdverseReaction
loss . . I-AdverseReaction
. . . O

most . . O
of . . O
these . . O
events . . O
were . . O
not . . O
specific . . O
to . . O
the . . O
injection . . O
site . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

however . . O
, . . O
epidemiological . . O
studies . . O
suggest . . O
an . . O
increased . . O
risk . . O
of . . O
treatment . . O
- . . O
emergent . . O
hyperglycemia . . B-AdverseReaction
- . . O
related . . O
adverse . . O
events . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
atypical . . B-DrugClass
antipsychotics . . I-DrugClass
included . . O
in . . O
these . . O
studies . . O
. . . O

excerpt . . O
: . . O
* . . O
imaging . . O
errors . . O
have . . O
been . . O
reported . . O
; . . O
blood . . O
psa . . O
levels . . O
< . . O
2 . . O
ng . . O
/ . . O
ml . . O
have . . O
been . . O
associated . . O
with . . O
poor . . O
imaging . . O
performance . . O
( . . O
5.1 . . O
) . . O
. . . O

promptly . . O
evaluate . . O
signs . . O
and . . O
symptoms . . O
of . . O
blood . . O
loss . . O
. . . O
( . . O
5.2 . . O
) . . O
* . . O
? . . O

the . . O
risk . . O
of . . O
postpartum . . O
thromboembolism . . O
decreases . . O
after . . O
the . . O
third . . O
postpartum . . O
week . . O
, . . O
whereas . . O
the . . O
risk . . O
of . . O
ovulation . . O
increases . . O
after . . O
the . . O
third . . O
postpartum . . O
week . . O
. . . O

in . . O
caps . . O
trials . . O
one . . O
patient . . O
discontinued . . O
and . . O
in . . O
sjia . . O
trials . . O
no . . O
patients . . O
discontinued . . O
due . . O
to . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
. . . O

acute . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
dyspnea . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
pruritus . . B-AdverseReaction
, . . O
and . . O
angioedema . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
mouth . . I-AdverseReaction
, . . O
throat . . O
, . . O
and . . O
face . . O
have . . O
been . . O
reported . . O
with . . O
fidaxomicin . . O
. . . O

serious . . O
dermatologic . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
sjs . . B-AdverseReaction
) . . O
have . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
aptiom . . O
use . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
dyspnea . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
pruritus . . B-AdverseReaction
) . . O
have . . O
been . . O
reported . . O
. . . O

adverse . . O
reactions . . O
and . . O
laboratory . . O
abnormalities . . O
from . . O
the . . O
cll . . O
trial . . O
( . . O
n . . O
= . . O
48 . . O
) . . O
using . . O
single . . O
agent . . O
imbruvica . . O
420 . . O
mg . . O
daily . . O
occurring . . O
at . . O
a . . O
rate . . O
of . . O
> . . O
= . . O
10% . . O
are . . O
presented . . O
in . . O
tables . . O
3 . . O
and . . O
4 . . O
. . . O

discontinue . . O
inlyta . . O
in . . O
patients . . O
developing . . O
rpls . . O
. . . O

table . . O
5 . . O
shows . . O
the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
that . . O
were . . O
reported . . O
in . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
1% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
and . . O
at . . O
a . . O
frequency . . O
greater . . O
than . . O
placebo . . O
- . . O
treated . . O
patients . . O
after . . O
up . . O
to . . O
8 . . O
injections . . O
in . . O
the . . O
pooled . . O
placebo . . O
- . . O
controlled . . O
trials . . O
through . . O
day . . O
365 . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
if . . O
irritation . . O
of . . O
eyes . . O
or . . O
airway . . O
occurs . . O
, . . O
remove . . O
the . . O
affected . . O
individual . . O
from . . O
the . . O
vicinity . . O
of . . O
qutenza . . O
and . . O
flush . . O
the . . O
mucous . . O
membranes . . O
or . . O
eyes . . O
with . . O
water . . O
. . . O

6 . . O
adverse . . O
reactions . . O

in . . O
other . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
( . . O
9 . . O
of . . O
1044 . . O
; . . O
0.9% . . O
) . . O
, . . O
a . . O
diagnosis . . O
of . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
cannot . . B-Factor
be . . I-Factor
excluded . . I-Factor
. . . O

in . . O
the . . O
controlled . . O
clinical . . O
trials . . O
, . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
occurring . . O
on . . O
the . . O
same . . O
day . . O
of . . O
infusion . . O
) . . O
were . . O
reported . . O
in . . O
13% . . O
( . . O
191 . . O
/ . . O
1,458 . . O
) . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
and . . O
11% . . O
( . . O
76 . . O
/ . . O
675 . . O
) . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

adverse . . O
reactions . . O
in . . O
patients . . O
with . . O
imatinib . . O
- . . O
resistant . . O
or . . O
- . . O
intolerant . . O
ph+ . . O
chronic . . O
phase . . O
( . . O
cp . . O
) . . O
, . . O
accelerated . . O
phase . . O
( . . O
ap . . O
) . . O
, . . O
and . . O
blast . . O
phase . . O
( . . O
bp . . O
) . . O
cml . . O

beleodaq . . O
can . . B-Factor
cause . . O
fatal . . B-AdverseReaction
hepatotoxicity . . B-AdverseReaction
and . . O
liver . . B-AdverseReaction
function . . I-AdverseReaction
test . . I-AdverseReaction
abnormalities . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

similar . . O
proportions . . O
of . . O
patients . . O
developed . . O
protective . . O
levels . . O
of . . O
anti . . O
- . . O
vaccine . . O
antibodies . . O
between . . O
cimzia . . O
and . . O
placebo . . O
treatment . . O
groups . . O
; . . O
however . . O
patients . . O
receiving . . O
cimzia . . O
and . . O
concomitant . . O
methotrexate . . O
had . . O
a . . O
lower . . O
humoral . . O
response . . O
compared . . O
with . . O
patients . . O
receiving . . O
cimzia . . O
alone . . O
. . . O

5.1 . . O
risk . . O
for . . O
image . . O
misinterpretation . . O
and . . O
other . . O
errors . . O

study . . O
2 . . O
enrolled . . O
1088 . . O
patients . . O
with . . O
metastatic . . O
crpc . . O
who . . O
had . . O
not . . O
received . . O
prior . . O
cytotoxic . . O
chemotherapy . . O
. . . O

( . . O
6 . . O
) . . O

fatal . . B-AdverseReaction
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
was . . O
reported . . O
in . . O
2 . . O
/ . . O
359 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
1 . . O
/ . . O
355 . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

based . . O
on . . O
its . . O
mechanism . . O
of . . O
action . . O
, . . O
tafinlar . . O
may . . B-Factor
promote . . O
the . . O
growth . . O
and . . O
development . . O
of . . O
malignancies . . B-AdverseReaction
with . . O
activation . . O
of . . O
ras . . O
through . . O
mutation . . O
or . . O
other . . O
mechanisms . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

in . . O
postmarketing . . O
experience . . O
, . . O
use . . O
of . . O
nulojix . . O
in . . O
conjunction . . O
with . . O
basiliximab . . O
induction . . O
, . . O
mmf . . O
, . . O
and . . O
corticosteroid . . O
minimization . . O
to . . O
5 . . O
mg . . O
per . . O
day . . O
between . . O
day . . O
3 . . O
and . . O
week . . O
6 . . O
post . . O
- . . O
transplant . . O
was . . O
associated . . O
with . . O
an . . O
increased . . O
rate . . O
and . . O
grade . . O
of . . O
acute . . O
rejection . . O
, . . O
particularly . . O
grade . . B-Severity
iii . . I-Severity
rejection . . O
. . . O

available . . O
data . . O
from . . O
controlled . . O
clinical . . O
trials . . O
suggest . . O
that . . O
laba . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
hospitalization . . O
in . . O
pediatric . . O
and . . O
adolescent . . O
patients . . O
. . . O

in . . O
a . . O
trial . . O
carried . . O
out . . O
in . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
with . . O
a . . O
baseline . . O
egfr . . O
of . . O
30 . . O
to . . O
less . . O
than . . O
50 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
( . . O
mean . . O
baseline . . O
egfr . . O
39 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.3 . . O
) . . O
] . . O
, . . O
the . . O
proportion . . O
of . . O
patients . . O
who . . O
experienced . . O
at . . O
least . . O
one . . O
event . . O
of . . O
significant . . B-Severity
renal . . B-AdverseReaction
function . . I-AdverseReaction
decline . . I-AdverseReaction
, . . O
defined . . O
as . . O
an . . O
egfr . . B-AdverseReaction
30% . . I-AdverseReaction
lower . . I-AdverseReaction
than . . I-AdverseReaction
baseline . . I-AdverseReaction
, . . O
was . . O
6.9% . . O
with . . O
placebo . . O
, . . O
18% . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
22.5% . . O
with . . O
invokana . . O
300 . . O
mg . . O
. . . O

if . . O
skin . . O
not . . O
intended . . O
to . . O
be . . O
treated . . O
comes . . O
into . . O
contact . . O
with . . O
qutenza . . O
, . . O
apply . . O
cleansing . . O
gel . . O
and . . O
then . . O
wipe . . O
off . . O
with . . O
dry . . O
gauze . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
and . . O
at . . O
least . . O
twice . . O
the . . O
rate . . O
of . . O
placebo . . O
) . . O
reported . . O
with . . O
acute . . O
monotherapy . . O
treatment . . O
of . . O
manic . . O
or . . O
mixed . . O
episodes . . O
associated . . O
with . . O
bipolar . . O
i . . O
disorder . . O
in . . O
adults . . O
were . . O
somnolence . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
extrapyramidal . . B-AdverseReaction
symptoms . . I-AdverseReaction
other . . B-Factor
than . . I-Factor
akathisia . . B-AdverseReaction
, . . O
and . . O
increased . . B-AdverseReaction
weight . . I-AdverseReaction
and . . O
during . . O
the . . O
adjunctive . . O
therapy . . O
trial . . O
in . . O
bipolar . . O
i . . O
disorder . . O
in . . O
adults . . O
were . . O
somnolence . . B-AdverseReaction
and . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
. . . O

there . . O
have . . O
been . . O
no . . O
clinical . . O
studies . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
invokana . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
. . . O

tecfidera . . O
caused . . O
gi . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
dyspepsia . . B-AdverseReaction
) . . O
. . . O

the . . O
information . . O
below . . O
is . . O
derived . . O
from . . O
a . . O
clinical . . O
trial . . O
database . . O
for . . O
fanapt . . O
consisting . . O
of . . O
2070 . . O
patients . . O
exposed . . O
to . . O
fanapt . . O
at . . O
doses . . O
of . . O
10 . . O
mg . . O
/ . . O
day . . O
or . . O
greater . . O
, . . O
for . . O
the . . O
treatment . . O
of . . O
schizophrenia . . O
. . . O

investigations . . O
: . . O
blood . . B-AdverseReaction
urine . . I-AdverseReaction
present . . I-AdverseReaction
, . . O
occult . . B-AdverseReaction
blood . . I-AdverseReaction
positive . . I-AdverseReaction
, . . O
occult . . B-AdverseReaction
blood . . I-AdverseReaction
, . . O
red . . B-AdverseReaction
blood . . I-AdverseReaction
cells . . I-AdverseReaction
urine . . I-AdverseReaction
positive . . I-AdverseReaction

screen . . O
patients . . O
for . . O
acute . . O
kidney . . O
injury . . O
and . . O
other . . O
conditions . . O
that . . O
may . . O
reduce . . O
renal . . O
function . . O
. . . O

more . . O
cases . . O
of . . O
pneumonia . . B-AdverseReaction
in . . O
the . . O
group . . O
receiving . . O
tanzeum . . O
were . . O
serious . . B-Severity
( . . O
0.4% . . O
for . . O
tanzeum . . O
versus . . O
0.1% . . O
for . . O
all . . O
comparators . . O
) . . O
. . . O

system . . O
organ . . O
class . . O
/ . . O
preferred . . O
term . . O
placebo . . O
n . . O
= . . O
378 . . O
% . . O
saphris . . O
5 . . O
mg . . O
twice . . O
daily . . O
n . . O
= . . O
274 . . O
% . . O
saphris . . O
10 . . O
mg . . O
twice . . O
daily . . O
n . . O
= . . O
208 . . O
% . . O
all . . O
saphris . . O
s . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
n . . O
= . . O
572 . . O
% . . O
gastrointestinal . . O
disorders . . O
constipation . . B-AdverseReaction
6 . . O
7 . . O
4 . . O
5 . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
1 . . O
3 . . O
1 . . O
2 . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
1 . . O
6 . . O
7 . . O
5 . . O
salivary . . B-AdverseReaction
hypersecretion . . I-AdverseReaction
0 . . O
< . . O
1 . . O
4 . . O
2 . . O
stomach . . B-AdverseReaction
discomfort . . I-AdverseReaction
1 . . O
< . . O
1 . . O
3 . . O
2 . . O
vomiting . . B-AdverseReaction
5 . . O
4 . . O
7 . . O
5 . . O
general . . O
disorders . . O
fatigue . . B-AdverseReaction
3 . . O
4 . . O
3 . . O
3 . . O
irritability . . B-AdverseReaction
< . . O
1 . . O
2 . . O
1 . . O
2 . . O
investigations . . O
increased . . B-AdverseReaction
weight . . I-AdverseReaction
< . . O
1 . . O
2 . . O
2 . . O
3 . . O
metabolism . . O
disorders . . O
increased . . B-AdverseReaction
appetite . . I-AdverseReaction
< . . O
1 . . O
3 . . O
0 . . O
2 . . O
nervous . . O
system . . O
disorders . . O
akathisia . . B-AdverseReaction
* . . O
3 . . O
4 . . O
11 . . O
6 . . O
dizziness . . B-AdverseReaction
4 . . O
7 . . O
3 . . O
5 . . O
extrapyramidal . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
excluding . . B-Negation
akathisia . . B-AdverseReaction
) . . O
7 . . O
9 . . O
12 . . O
10 . . O
somnolence . . B-AdverseReaction
? . . O

( . . O
5.5 . . O
) . . O
* . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
pulmonary . . I-AdverseReaction
function . . I-AdverseReaction
tests . . I-AdverseReaction
( . . O
pft . . O
) . . O
: . . O
obtain . . O
pft . . O
when . . O
clinically . . O
indicated . . O
. . . O

general . . O
disorders . . O
and . . O
administrative . . O
site . . O
conditions . . O
: . . O
infrequent . . O
- . . O
edema . . B-AdverseReaction
( . . O
general . . O
, . . O
pitting . . O
, . . O
due . . O
to . . O
cardiac . . O
disease . . O
) . . O
, . . O
difficulty . . B-AdverseReaction
in . . I-AdverseReaction
walking . . I-AdverseReaction
, . . O
thirst . . B-AdverseReaction
; . . O
rare . . O
- . . O
hyperthermia . . B-AdverseReaction

there . . O
were . . O
4 . . O
suicides . . B-AdverseReaction
in . . O
drug . . O
- . . O
treated . . O
patients . . O
in . . O
the . . O
trials . . O
and . . O
none . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
but . . O
the . . O
number . . B-Factor
is . . I-Factor
too . . I-Factor
small . . I-Factor
to . . O
allow . . O
any . . O
conclusion . . O
about . . O
drug . . O
effect . . O
on . . O
suicide . . B-AdverseReaction
. . . O

adverse . . O
reactions . . O
leading . . O
to . . O
dose . . O
reduction . . O
occurred . . O
in . . O
14% . . O
of . . O
patients . . O
. . . O

among . . O
the . . O
factors . . O
that . . O
may . . O
increase . . O
the . . O
risk . . O
for . . O
nsf . . O
are . . O
repeated . . O
or . . O
higher . . O
than . . O
recommended . . O
doses . . O
of . . O
a . . O
gbca . . O
and . . O
the . . O
degree . . O
of . . O
renal . . O
impairment . . O
at . . O
the . . O
time . . O
of . . O
exposure . . O
. . . O

6.2 . . O
clinical . . O
studies . . O
experience . . O
because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rate . . O
observed . . O
in . . O
practice . . O
. . . O

table . . O
1 . . O
lists . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
gilenya . . O
- . . O
treated . . O
patients . . O
and . . O
> . . O
= . . O
1% . . O
higher . . O
rate . . O
than . . O
for . . O
placebo . . O
. . . O

in . . O
trial . . O
1 . . O
, . . O
cutaneous . . B-AdverseReaction
squamous . . I-AdverseReaction
cell . . I-AdverseReaction
carcinomas . . I-AdverseReaction
and . . O
keratoacanthomas . . B-AdverseReaction
( . . O
cuscc . . B-AdverseReaction
) . . O
occurred . . O
in . . O
7% . . O
( . . O
14 . . O
/ . . O
187 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
and . . O
in . . O
none . . O
of . . O
the . . O
patients . . O
treated . . O
with . . O
dacarbazine . . O
. . . O

hepatotoxicity . . B-AdverseReaction
may . . B-Factor
reoccur . . O
if . . O
promacta . . O
is . . O
reinitiated . . O
. . . O

avoid . . O
concurrent . . O
use . . O
of . . O
zydelig . . O
with . . O
other . . O
drugs . . O
that . . O
may . . O
cause . . O
liver . . O
toxicity . . O
. . . O

( . . O
5.7 . . O
) . . O

the . . O
causative . . O
organisms . . O
for . . O
these . . O
reactions . . O
are . . O
identified . . O
when . . O
provided . . O
by . . O
the . . O
physician . . O
. . . O

( . . O
5.1 . . O
, . . O
2.3 . . O
) . . O
* . . O
tumor . . B-AdverseReaction
promotion . . I-AdverseReaction
in . . I-AdverseReaction
braf . . I-AdverseReaction
wild . . I-AdverseReaction
- . . I-AdverseReaction
type . . I-AdverseReaction
melanoma . . I-AdverseReaction
: . . O
increased . . B-AdverseReaction
cell . . I-AdverseReaction
proliferation . . I-AdverseReaction
can . . O
occur . . O
with . . O
braf . . B-DrugClass
inhibitors . . I-DrugClass
. . . O

figure . . O
1 . . O

* . . O
using . . O
estrogens . . O
may . . O
increase . . O
your . . O
chance . . O
of . . O
getting . . O
dementia . . O
, . . O
based . . O
on . . O
a . . O
study . . O
of . . O
women . . O
65 . . O
years . . O
of . . O
age . . O
or . . O
older . . O
. . . O

swallowing . . O
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
can . . O
be . . O
life . . O
threatening . . O
and . . O
there . . O
have . . O
been . . O
reports . . O
of . . O
death . . B-AdverseReaction
. . . O

patients . . O
with . . O
multiple . . O
myeloma . . O
and . . O
a . . O
high . . O
tumor . . O
burden . . O
should . . O
be . . O
considered . . O
to . . O
be . . O
at . . O
greater . . O
risk . . O
for . . O
tls . . O
. . . O

this . . O
product . . O
contains . . O
albumin . . O
, . . O
a . . O
derivative . . O
of . . O
human . . O
blood . . O
. . . O

adverse . . O
reactions . . O
related . . O
to . . O
bleeding . . B-AdverseReaction
occurred . . O
in . . O
219 . . O
( . . O
13.3% . . O
) . . O
eliquis . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
72 . . O
( . . O
8.7% . . O
) . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

allergic . . B-AdverseReaction
reaction . . I-AdverseReaction
, . . O
including . . O
angioedema . . B-AdverseReaction

therefore . . O
, . . O
obtaining . . O
a . . O
liver . . O
test . . O
panel . . O
and . . O
assessing . . O
the . . O
patient . . O
before . . O
initiating . . O
nesina . . O
therapy . . O
is . . O
recommended . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

in . . O
the . . O
ciai . . O
trials . . O
( . . O
phase . . O
2 . . O
and . . O
3 . . O
) . . O
, . . O
death . . B-AdverseReaction
occurred . . O
in . . O
2.5% . . O
( . . O
14 . . O
/ . . O
564 . . O
) . . O
of . . O
patients . . O
receiving . . O
zerbaxa . . O
and . . O
in . . O
1.5% . . O
( . . O
8 . . O
/ . . O
536 . . O
) . . O
of . . O
patients . . O
receiving . . O
meropenem . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
in . . O
children . . O
( . . O
> . . O
12% . . O
) . . O
are . . O
pyrexia . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
anorexia . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

anaphylaxis . . O
and . . O
hereditary . . O
angioedema . . O
. . . O

more . . O
frequent . . O
renal . . O
function . . O
monitoring . . O
is . . O
recommended . . O
in . . O
patients . . O
with . . O
an . . O
egfr . . O
below . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
. . . O

( . . O
2.3 . . O
, . . O
5.4 . . O
) . . O
* . . O
renal . . B-AdverseReaction
toxicity . . I-AdverseReaction
monitor . . O
patients . . O
for . . O
renal . . O
function . . O
at . . O
baseline . . O
and . . O
during . . O
therapy . . O
with . . O
bosulif . . O
( . . O
5.5 . . O
) . . O
* . . O
embryofetal . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
may . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
amgen . . O
medical . . O
information . . O
at . . O
1-800-77 . . O
- . . O
amgen . . O
( . . O
1-800-772-6436 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

invokana . . O
can . . B-Factor
lead . . O
to . . O
hyperkalemia . . B-AdverseReaction
. . . O

in . . O
these . . O
trials . . O
, . . O
636 . . O
patients . . O
were . . O
treated . . O
with . . O
tudorza . . O
pressair . . O
at . . O
the . . O
recommended . . O
dose . . O
of . . O
400 . . O
mcg . . O
twice . . O
daily . . O
. . . O

the . . O
following . . O
adverse . . O
reaction . . O
has . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
pristiq . . O
. . . O

if . . O
pancreatitis . . O
is . . O
suspected . . O
, . . O
promptly . . O
discontinue . . O
nesina . . O
. . . O

adcetris . . O
was . . O
studied . . O
in . . O
58 . . O
patients . . O
with . . O
salcl . . O
in . . O
a . . O
single . . O
arm . . O
clinical . . O
trial . . O
in . . O
which . . O
the . . O
recommended . . O
starting . . O
dose . . O
and . . O
schedule . . O
was . . O
1.8 . . O
mg . . O
/ . . O
kg . . O
intravenously . . O
every . . O
3 . . O
weeks . . O
. . . O

patients . . O
who . . O
develop . . O
arrhythmic . . O
symptoms . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
palpitations . . O
, . . O
lightheadedness . . O
) . . O
or . . O
new . . O
onset . . O
dyspnea . . O
should . . O
have . . O
an . . O
ecg . . O
performed . . O
. . . O

serious . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
29% . . O
of . . O
patients . . O
treated . . O
with . . O
gilotrif . . O
. . . O

there . . O
have . . O
been . . O
postmarketing . . O
reports . . O
of . . O
fatal . . B-AdverseReaction
and . . O
non . . O
- . . O
fatal . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
in . . O
patients . . O
taking . . O
uloric . . O
, . . O
although . . O
the . . O
reports . . O
contain . . O
insufficient . . O
information . . O
necessary . . O
to . . O
establish . . O
the . . O
probable . . O
cause . . O
. . . O

dose . . O
- . . O
related . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
magnesium . . I-AdverseReaction
were . . O
observed . . O
early . . O
after . . O
initiation . . O
of . . O
invokana . . O
( . . O
within . . O
6 . . O
weeks . . O
) . . O
and . . O
remained . . O
elevated . . O
throughout . . O
treatment . . O
. . . O

fulyzaq . . O
is . . O
not . . O
indicated . . O
for . . O
the . . O
treatment . . O
of . . O
infectious . . O
diarrhea . . O
. . . O

the . . O
sizes . . O
of . . O
these . . O
studies . . O
were . . O
not . . O
adequate . . O
to . . O
precisely . . O
quantify . . O
the . . O
differences . . O
in . . O
serious . . O
asthma . . O
exacerbation . . O
rates . . O
between . . O
treatment . . O
groups . . O
. . . O

percentage . . O
( . . O
% . . O
) . . O
of . . O
patients . . O
yervoy3 . . O
mg . . O
/ . . O
kgn . . O
= . . O
131 . . O
yervoy3 . . O
mg . . O
/ . . O
kg . . O
+ . . O
gp100n . . O
= . . O
380 . . O
any . . O
immune . . O
- . . O
mediated . . O
adverse . . O
reaction . . O
15 . . O
12 . . O
enterocolitisa . . O
, . . O
b . . O
7 . . O
7 . . O
hepatotoxicitya . . O
1 . . O
2 . . O
dermatitisa . . O
2 . . O
3 . . O
neuropathya . . O
1 . . O
< . . O
1 . . O
endocrinopathy . . B-AdverseReaction
4 . . O
1 . . O
hypopituitarism . . B-AdverseReaction
4 . . O
1 . . O
adrenal . . B-AdverseReaction
insufficiency . . I-AdverseReaction
0 . . O
1 . . O
other . . O
pneumonitis . . B-AdverseReaction
0 . . O
< . . O
1 . . O
meningitis . . B-AdverseReaction
0 . . O
< . . O
1 . . O
nephritis . . B-AdverseReaction
1 . . O
0 . . O
eosinophiliac . . O
1 . . O
0 . . O
pericarditisa . . O
, . . O
c . . O
0 . . O
< . . O
1 . . O
across . . O
clinical . . O
studies . . O
that . . O
utilized . . O
yervoy . . O
doses . . O
ranging . . O
from . . O
0.3 . . O
to . . O
10 . . O
mg . . O
/ . . O
kg . . O
, . . O
the . . O
following . . O
adverse . . O
reactions . . O
were . . O
also . . O
reported . . O
( . . O
incidence . . O
less . . O
than . . O
1% . . O
unless . . O
otherwise . . O
noted . . O
) . . O
: . . O
urticaria . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
large . . B-AdverseReaction
intestinal . . I-AdverseReaction
ulcer . . I-AdverseReaction
, . . O
esophagitis . . B-AdverseReaction
, . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
and . . O
infusion . . B-AdverseReaction
reaction . . I-AdverseReaction
. . . O

patients . . O
with . . O
mcl . . O
who . . O
develop . . O
lymphocytosis . . O
greater . . O
than . . O
400,000 . . O
/ . . O
mcl . . O
have . . O
developed . . O
intracranial . . O
hemorrhage . . O
, . . O
lethargy . . O
, . . O
gait . . O
instability . . O
, . . O
and . . O
headache . . O
. . . O

additionally . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
, . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

hypocalcemia . . B-AdverseReaction
following . . O
prolia . . O
administration . . O
is . . O
a . . O
significant . . O
risk . . O
in . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
[ . . O
creatinine . . O
clearance . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
] . . O
or . . O
receiving . . O
dialysis . . O
. . . O

hydronephrosis . . B-AdverseReaction
was . . O
not . . B-Negation
reported . . O
in . . O
placebo . . B-Factor
patients . . O
. . . O

nsf . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
fatal . . B-AdverseReaction
or . . O
debilitating . . B-Severity
fibrosis . . B-AdverseReaction
affecting . . O
the . . O
skin . . O
, . . O
muscle . . O
and . . O
internal . . O
organs . . O
. . . O

* . . O
hepatotoxicity . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
/ . . O
pneumonitis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
qt . . B-AdverseReaction
interval . . I-AdverseReaction
prolongation . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
bradycardia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
severe . . B-Severity
visual . . B-AdverseReaction
loss . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
25% . . O
) . . O
are . . O
vision . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
edema . . B-AdverseReaction
, . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
and . . O
dysgeusia . . B-AdverseReaction
. . . O

such . . O
monitoring . . O
should . . O
include . . O
daily . . O
observation . . O
by . . O
families . . O
and . . O
caregivers . . O
. . . O

6 . . O
adverse . . O
reactions . . O

withhold . . O
gilotrif . . O
in . . O
patients . . O
who . . O
develop . . O
worsening . . O
of . . O
liver . . O
function . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

consider . . O
tuberculosis . . O
in . . O
the . . O
differential . . O
diagnosis . . O
in . . O
patients . . O
who . . O
develop . . O
a . . O
new . . O
infection . . O
during . . O
simponi . . O
aria . . O
treatment . . O
, . . O
especially . . O
in . . O
patients . . O
who . . O
have . . O
previously . . O
or . . O
recently . . O
traveled . . O
to . . O
countries . . O
with . . O
a . . O
high . . O
prevalence . . O
of . . O
tuberculosis . . O
, . . O
or . . O
who . . O
have . . O
had . . O
close . . O
contact . . O
with . . O
a . . O
person . . O
with . . O
active . . O
tuberculosis . . O
. . . O

immune . . O
system . . O
disorders . . O
: . . O
hypersensitivity . . B-AdverseReaction

in . . O
some . . O
cases . . O
the . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
transaminases . . I-AdverseReaction
were . . O
consistent . . O
with . . O
immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction
or . . O
hepatitis . . B-AdverseReaction
b . . I-AdverseReaction
reactivation . . I-AdverseReaction
particularly . . O
in . . O
the . . O
setting . . O
where . . O
anti . . O
- . . O
hepatitis . . O
therapy . . O
was . . O
withdrawn . . O
. . . O

women . . O
should . . O
be . . O
advised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
and . . O
to . . O
avoid . . O
pregnancy . . O
while . . O
on . . O
this . . O
drug . . O
. . . O

ecchymosis . . O
easily . . O
occurs . . O
in . . O
the . . O
soft . . O
tissues . . O
of . . O
the . . O
eyelid . . O
. . . O

in . . O
males . . O
, . . O
discontinuations . . O
due . . O
to . . O
genital . . O
mycotic . . O
infections . . O
occurred . . O
in . . O
0% . . O
and . . O
0.5% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
and . . O
invokana . . O
, . . O
respectively . . O
. . . O

s . . O
includes . . O
subjects . . O
treated . . O
with . . O
flexible . . O
dose . . O
of . . O
saphris . . O
5 . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
( . . O
n . . O
= . . O
90 . . O
) . . O
. . . O

5.17 . . O
drug . . O
- . . O
laboratory . . O
test . . O
interactions . . O

5 . . O
warnings . . O
and . . O
precautions . . O

do . . O
not . . O
administer . . O
ilaris . . O
to . . O
patients . . O
during . . O
an . . O
active . . O
infection . . O
requiring . . O
medical . . O
intervention . . O
. . . O

* . . O
gastrointestinal . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

during . . O
the . . O
24 . . O
- . . O
week . . O
, . . O
open . . O
- . . O
label . . O
, . . O
clinical . . O
trial . . O
in . . O
34 . . O
patients . . O
ages . . O
2 . . O
to . . O
less . . O
than . . O
6 . . O
years . . O
( . . O
trial . . O
6 . . O
) . . O
, . . O
where . . O
patients . . O
received . . O
either . . O
50 . . O
mg . . O
( . . O
less . . O
than . . O
14 . . O
kg . . O
) . . O
or . . O
75 . . O
mg . . O
( . . O
14 . . O
kg . . O
or . . O
greater . . O
) . . O
ivacaftor . . O
granules . . O
twice . . O
daily . . O
, . . O
the . . O
incidence . . O
of . . O
patients . . O
experiencing . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
( . . O
alt . . O
or . . O
ast . . O
) . . O
> . . B-Severity
3 . . I-Severity
* . . I-Severity
uln . . I-Severity
was . . O
14.7% . . O
( . . O
5 . . O
/ . . O
34 . . O
) . . O
. . . O

* . . O
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ppes . . B-AdverseReaction
) . . O
: . . O
interrupt . . O
cometriq . . O
, . . O
decrease . . O
dose . . O
. . . O

5.5 . . O
central . . O
nervous . . O
system . . O
effects . . O

serious . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
73 . . O
( . . O
50% . . O
) . . O
subjects . . O
. . . O

the . . O
pooled . . O
mean . . O
maximum . . O
dose . . O
in . . O
these . . O
studies . . O
was . . O
10 . . O
mg . . O
/ . . O
hour . . O
and . . O
the . . O
mean . . O
duration . . O
of . . O
treatment . . O
was . . O
8 . . O
hours . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
alopecia . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction

* . . O
choking . . B-AdverseReaction
has . . O
been . . O
reported . . O
by . . O
patients . . O
, . . O
some . . O
of . . O
whom . . O
may . . B-Factor
have . . O
also . . O
experienced . . O
oropharyngeal . . B-AdverseReaction
muscular . . I-AdverseReaction
dysfunction . . I-AdverseReaction
or . . O
hypoesthesia . . B-AdverseReaction
. . . O

these . . O
trials . . O
included . . O
832 . . O
patients . . O
of . . O
whom . . O
551 . . O
and . . O
281 . . O
received . . O
xiaflex . . O
and . . O
placebo . . O
, . . O
respectively . . O
. . . O

6.1 . . O
clinical . . O
study . . O
experience . . O
in . . O
advanced . . O
hormone . . O
receptor . . O
- . . O
positive . . O
, . . O
her2 . . O
- . . O
negative . . O
breast . . O
cancer . . O

( . . O
5.5 . . O
) . . O
5.1 . . O
not . . O
for . . O
acute . . O
use . . O

serious . . O
adverse . . O
events . . O
, . . O
judged . . O
to . . O
be . . O
at . . O
least . . O
possibly . . O
related . . O
to . . O
study . . O
medication . . O
by . . O
the . . O
investigator . . O
and . . O
reported . . O
more . . O
than . . O
once . . O
during . . O
the . . O
open . . O
- . . O
label . . O
treatment . . O
period . . O
of . . O
up . . O
to . . O
3 . . O
years . . O
, . . O
included . . O
urinary . . B-AdverseReaction
retention . . I-AdverseReaction
( . . O
3 . . O
cases . . O
) . . O
, . . O
diverticulitis . . B-AdverseReaction
( . . O
3 . . O
cases . . O
) . . O
, . . O
constipation . . B-AdverseReaction
( . . O
2 . . O
cases . . O
) . . O
, . . O
irritable . . B-AdverseReaction
bowel . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
2 . . O
cases . . O
) . . O
, . . O
and . . O
electrocardiogram . . O
qt . . B-AdverseReaction
corrected . . I-AdverseReaction
interval . . I-AdverseReaction
prolongation . . I-AdverseReaction
( . . O
2 . . O
cases . . O
) . . O
. . . O

clinical . . O
manifestations . . O
of . . O
nms . . B-AdverseReaction
are . . O
hyperpyrexia . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
rigidity . . I-AdverseReaction
, . . O
altered . . B-AdverseReaction
mental . . I-AdverseReaction
status . . I-AdverseReaction
, . . O
and . . O
evidence . . O
of . . O
autonomic . . B-AdverseReaction
instability . . I-AdverseReaction
( . . O
irregular . . B-AdverseReaction
pulse . . I-AdverseReaction
or . . O
blood . . O
pressure . . O
, . . O
tachycardia . . B-AdverseReaction
, . . O
diaphoresis . . B-AdverseReaction
, . . O
and . . O
cardiac . . B-AdverseReaction
dysrhythmia . . I-AdverseReaction
) . . O
. . . O

liver . . B-AdverseReaction
chemistry . . I-AdverseReaction
elevations . . I-AdverseReaction
consistent . . O
with . . O
immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction
were . . O
observed . . O
in . . O
some . . O
subjects . . O
with . . O
hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
c . . O
at . . O
the . . O
start . . O
of . . O
therapy . . O
with . . O
tivicay . . O
, . . O
particularly . . O
in . . O
the . . O
setting . . O
where . . O
anti . . O
- . . O
hepatitis . . O
therapy . . O
was . . O
withdrawn . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

laboratory . . O
p . . O
arameter . . O
afinitor . . O
10 . . O
mg . . O
/ . . O
day . . O
n . . O
= . . O
274 . . O
placebo . . O
n . . O
= . . O
137 . . O
all . . O
grades . . O
grade . . O
3 . . O
grade . . O
4 . . O
all . . O
grades . . O
grade . . O
3 . . O
grade . . O
4 . . O
% . . O
% . . O
% . . O
% . . O
% . . O
% . . O
hematology . . O
a . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
92 . . O
12 . . O
1 . . O
79 . . O
5 . . O
< . . O
1 . . O
lymphocytes . . B-AdverseReaction
decreased . . I-AdverseReaction
51 . . O
16 . . O
2 . . O
28 . . O
5 . . O
0 . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
23 . . O
1 . . O
0 . . O
2 . . O
0 . . O
< . . O
1 . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
14 . . O
0 . . O
< . . O
1 . . O
4 . . O
0 . . O
0 . . O
clinical . . O
c . . O
hemistry . . O
cholesterol . . B-AdverseReaction
increased . . I-AdverseReaction
77 . . O
4 . . O
0 . . O
35 . . O
0 . . O
0 . . O
triglycerides . . B-AdverseReaction
increased . . I-AdverseReaction
73 . . O
< . . O
1 . . O
0 . . O
34 . . O
0 . . O
0 . . O
glucose . . B-AdverseReaction
increased . . I-AdverseReaction
57 . . O
15 . . O
< . . O
1 . . O
25 . . O
1 . . O
0 . . O
creatinine . . B-AdverseReaction
increased . . I-AdverseReaction
50 . . O
1 . . O
0 . . O
34 . . O
0 . . O
0 . . O
phosphate . . B-AdverseReaction
decreased . . I-AdverseReaction
37 . . O
6 . . O
0 . . O
8 . . O
0 . . O
0 . . O
aspartate . . O
transaminase . . O
( . . O
ast . . O
) . . O
increased . . O
25 . . O
< . . O
1 . . O
< . . O
1 . . O
7 . . O
0 . . O
0 . . O
alanine . . O
transaminase . . O
( . . O
alt . . O
) . . O
increased . . O
21 . . O
1 . . O
0 . . O
4 . . O
0 . . O
0 . . O
bilirubin . . B-AdverseReaction
increased . . I-AdverseReaction
3 . . O
< . . O
1 . . O
< . . O
1 . . O
2 . . O
0 . . O
0 . . O
6.4 . . O
clinical . . O
study . . O
experience . . O
in . . O
renal . . O
angiomyolipoma . . O
with . . O
tuberous . . O
sclerosis . . O
complex . . O
the . . O
data . . O
described . . O
below . . O
are . . O
based . . O
on . . O
a . . O
randomized . . O
( . . O
2 . . O
: . . O
1 . . O
) . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trial . . O
of . . O
afinitor . . O
in . . O
118 . . O
patients . . O
with . . O
renal . . O
angiomyolipoma . . O
as . . O
a . . O
feature . . O
of . . O
tsc . . O
( . . O
n . . O
= . . O
113 . . O
) . . O
or . . O
sporadic . . O
lymphangioleiomyomatosis . . O
( . . O
n . . O
= . . O
5 . . O
) . . O
. . . O

at . . O
baseline . . O
, . . O
17% . . O
of . . O
the . . O
population . . O
in . . O
these . . O
studies . . O
reported . . O
peripheral . . O
neuropathy . . O
and . . O
4% . . O
reported . . O
retinopathy . . O
. . . O

laboratory . . O
and . . O
imaging . . O
tests . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
leading . . O
to . . O
study . . O
withdrawal . . O
for . . O
patients . . O
receiving . . O
treanda . . O
were . . O
hypersensitivity . . B-AdverseReaction
( . . O
2% . . O
) . . O
and . . O
pyrexia . . B-AdverseReaction
( . . O
1% . . O
) . . O
. . . O

in . . O
the . . O
controlled . . O
portions . . O
of . . O
clinical . . O
trials . . O
of . . O
tnf . . O
- . . O
blockers . . O
including . . O
the . . O
subcutaneous . . O
formulation . . O
of . . O
golimumab . . O
more . . O
cases . . O
of . . O
lymphoma . . B-AdverseReaction
have . . O
been . . O
observed . . O
among . . O
patients . . O
receiving . . O
anti . . O
- . . O
tnf . . O
treatment . . O
compared . . O
with . . O
patients . . O
in . . O
the . . O
control . . O
groups . . O
. . . O

6.1 . . O
retrospective . . O
case . . O
series . . O
experience . . O

in . . O
clinical . . O
trials . . O
with . . O
inlyta . . O
, . . O
gastrointestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
was . . O
reported . . O
in . . O
5 . . O
/ . . O
715 . . O
patients . . O
( . . O
1% . . O
) . . O
, . . O
including . . O
one . . O
death . . B-AdverseReaction
. . . O

5.1 . . O
serious . . O
allergic . . O
reactions . . O

5.5 . . O
viral . . O
infections . . O

other . . O
infrequent . . O
adverse . . O
reactions . . O
( . . O
occurring . . O
in . . O
less . . O
than . . O
3% . . O
of . . O
ra . . O
patients . . O
) . . O
were . . O
similar . . O
to . . O
those . . O
seen . . O
in . . O
crohn's . . O
disease . . O
patients . . O
. . . O

( . . O
6 . . O
) . . O
] . . O

discontinue . . O
xalkori . . O
in . . O
patients . . O
with . . O
new . . O
onset . . O
of . . O
severe . . O
visual . . O
loss . . O
( . . O
best . . O
corrected . . O
vision . . O
less . . O
than . . O
20 . . O
/ . . O
200 . . O
in . . O
one . . O
or . . O
both . . O
eyes . . O
) . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
in . . O
vimizim . . O
patients . . O
and . . O
occurring . . O
at . . O
a . . O
higher . . O
incidence . . O
than . . O
placebo . . O
- . . O
treated . . O
patients . . O
) . . O
were . . O
pyrexia . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
chills . . B-AdverseReaction
, . . O
and . . O
fatigue . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

consider . . O
these . . O
risks . . O
when . . O
scheduling . . O
patients . . O
for . . O
spinal . . O

of . . O
the . . O
patients . . O
in . . O
those . . O
trials . . O
, . . O
approximately . . O
95% . . O
were . . O
between . . O
18 . . O
and . . O
60 . . O
years . . O
old . . O
, . . O
approximately . . O
50% . . O
were . . O
male . . O
, . . O
and . . O
approximately . . O
80% . . O
were . . O
caucasian . . O
. . . O

adreview . . O
is . . O
cleared . . O
by . . O
glomerular . . O
filtration . . O
and . . O
is . . O
not . . O
dialyzable . . O
. . . O

serious . . B-Severity
infections . . B-AdverseReaction
included . . O
tuberculosis . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
cellulitis . . B-AdverseReaction
, . . O
and . . O
pyelonephritis . . B-AdverseReaction
. . . O

the . . O
incidence . . O
of . . O
dizziness . . B-AdverseReaction
was . . O
greater . . O
with . . O
the . . O
concomitant . . O
use . . O
of . . O
aptiom . . O
and . . O
carbamazepine . . O
compared . . O
to . . O
the . . O
use . . O
of . . O
aptiom . . O
without . . O
carbamazepine . . O
( . . O
up . . O
to . . O
37% . . O
vs . . O
. . . O
19% . . O
, . . O
respectively . . O
) . . O
. . . O

cometriq . . O
treatment . . O
results . . O
in . . O
an . . O
increased . . O
incidence . . O
of . . O
treatment . . O
- . . O
emergent . . O
hypertension . . B-AdverseReaction
with . . O
joint . . O
national . . O
committee . . O
on . . O
prevention . . O
, . . O
detection . . O
, . . O
evaluation . . O
, . . O
and . . O
treatment . . O
of . . O
high . . O
blood . . O
pressure . . O
( . . O
modified . . O
jnc . . O
criteria . . O
) . . O
stage . . B-Severity
1 . . I-Severity
or . . O
2 . . O
hypertension . . B-AdverseReaction
identified . . O
in . . O
61% . . O
in . . O
cometriq . . O
- . . O
treated . . O
patients . . O
compared . . O
with . . O
30% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
in . . O
the . . O
randomized . . O
trial . . O
. . . O

the . . O
data . . O
in . . O
table . . O
3 . . O
are . . O
derived . . O
from . . O
340 . . O
patients . . O
with . . O
alk . . O
- . . O
positive . . O
metastatic . . O
nsclc . . O
who . . O
had . . O
not . . O
received . . O
previous . . O
systemic . . O
treatment . . O
for . . O
advanced . . O
disease . . O
who . . O
received . . O
treatment . . O
in . . O
a . . O
randomized . . O
, . . O
multicenter . . O
, . . O
open . . O
- . . O
label . . O
, . . O
active . . O
- . . O
controlled . . O
trial . . O
( . . O
study . . O
1 . . O
) . . O
. . . O

monitor . . O
patients . . O
for . . O
hypertension . . O
, . . O
hypokalemia . . O
, . . O
and . . O
fluid . . O
retention . . O
at . . O
least . . O
once . . O
a . . O
month . . O
. . . O

* . . O
the . . O
risk . . B-Factor
for . . O
nsf . . B-AdverseReaction
appears . . O
highest . . O
among . . O
patients . . O
with . . O
: . . O
ochronic . . O
, . . O
severe . . O
kidney . . O
disease . . O
( . . O
gfr . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m2 . . O
) . . O
, . . O
oroacute . . O
kidney . . O
injury . . O
. . . O

because . . O
of . . O
the . . O
risks . . O
of . . O
corporal . . O
rupture . . O
( . . O
penile . . O
fracture . . O
) . . O
or . . O
other . . O
serious . . O
penile . . O
injury . . O
in . . O
the . . O
treatment . . O
of . . O
peyronie's . . O
disease . . O
, . . O
xiaflex . . O
is . . O
available . . O
only . . O
through . . O
the . . O
xiaflex . . O
rems . . O
program . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

5.8 . . O
serious . . O
skin . . O
toxicity . . O

the . . O
patient . . O
should . . O
be . . O
carefully . . O
monitored . . O
, . . O
since . . O
recurrences . . O
of . . O
nms . . O
have . . O
been . . O
reported . . O
. . . O

monitoring . . O
for . . O
proteinuria . . O
before . . O
initiation . . O
of . . O
, . . O
and . . O
periodically . . O
throughout . . O
, . . O
treatment . . O
with . . O
inlyta . . O
is . . O
recommended . . O
. . . O

antiepileptic . . O
drugs . . O
( . . O
aeds . . O
) . . O
, . . O
including . . O
aptiom . . O
, . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
in . . O
patients . . O
taking . . O
these . . O
drugs . . O
for . . O
any . . O
indication . . O
. . . O

* . . O
fatal . . B-AdverseReaction
and . . O
/ . . O
or . . O
serious . . B-Severity
hepatotoxicity . . B-AdverseReaction
occurred . . O
in . . O
14% . . O
of . . O
zydelig . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
higher . . O
risk . . B-Factor
of . . O
falls . . B-AdverseReaction
for . . O
patients . . O
treated . . O
with . . O
invokana . . O
was . . O
observed . . O
within . . O
the . . O
first . . O
few . . O
weeks . . O
of . . O
treatment . . O
. . . O

these . . O
events . . O
have . . O
been . . O
chosen . . O
for . . O
inclusion . . O
due . . O
to . . O
either . . O
their . . O
seriousness . . O
, . . O
frequency . . O
of . . O
reporting . . O
, . . O
or . . O
causal . . O
connection . . O
to . . O
breo . . O
ellipta . . O
or . . O
a . . O
combination . . O
of . . O
these . . O
factors . . O
. . . O

adjust . . O
total . . O
fluid . . O
intake . . O
as . . O
clinically . . O
appropriate . . O
in . . O
patients . . O
with . . O
baseline . . O
cardiac . . O
failure . . O
or . . O
who . . O
are . . O
at . . O
risk . . O
for . . O
cardiac . . O
failure . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

extrapyramidal . . O
symptoms . . O
: . . O
in . . O
the . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
schizophrenia . . O
and . . O
bipolar . . O
mania . . O
adult . . O
trials . . O
, . . O
data . . O
was . . O
objectively . . O
collected . . O
on . . O
the . . O
simpson . . O
angus . . O
rating . . O
scale . . O
for . . O
extrapyramidal . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
eps . . B-AdverseReaction
) . . O
, . . O
the . . O
barnes . . O
akathisia . . O
scale . . O
( . . O
for . . O
akathisia . . B-AdverseReaction
) . . O
and . . O
the . . O
assessments . . O
of . . O
involuntary . . O
movement . . O
scales . . O
( . . O
for . . O
dyskinesias . . B-AdverseReaction
) . . O
. . . O

6 . . O
adverse . . O
reactions . . O

table . . O
3 . . O
shows . . O
absolute . . O
and . . O
relative . . O
risk . . O
by . . O
indication . . O
for . . O
all . . O
evaluated . . O
aeds . . O
. . . O

6 . . O
adverse . . O
reactions . . O

the . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
was . . O
generally . . O
consistent . . O
among . . O
drugs . . O
in . . O
the . . O
data . . O
analyzed . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

for . . O
some . . O
tnf . . O
blockers . . O
, . . O
more . . O
cases . . O
of . . O
malignancies . . B-AdverseReaction
have . . O
been . . O
observed . . O
among . . O
patients . . O
receiving . . O
those . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
compared . . O
to . . O
control . . O
patients . . O
. . . O

trulicity . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
severe . . O
gastrointestinal . . O
disease . . O
, . . O
including . . O
severe . . O
gastroparesis . . O
, . . O
and . . O
is . . O
therefore . . O
not . . O
recommended . . O
in . . O
these . . O
patients . . O
. . . O

delay . . O
in . . O
stopping . . O
intelence . . O
( . . O
r . . O
) . . O
treatment . . O
after . . O
the . . O
onset . . O
of . . O
severe . . O
rash . . O
may . . O
result . . O
in . . O
a . . O
life . . O
- . . O
threatening . . O
reaction . . O
. . . O

table . . O
1 . . O
. . . O

sixty . . O
- . . O
two . . O
patients . . O
were . . O
exposed . . O
to . . O
ilaris . . O
for . . O
at . . O
least . . O
6 . . O
months . . O
, . . O
56 . . O
for . . O
at . . O
least . . O
1 . . O
year . . O
and . . O
4 . . O
for . . O
at . . O
least . . O
3 . . O
years . . O
. . . O

in . . O
both . . O
cases . . O
, . . O
the . . O
patients . . O
were . . O
taking . . O
a . . O
1.25 . . O
mg . . O
dose . . O
of . . O
fingolimod . . O
( . . O
higher . . O
than . . O
the . . O
recommended . . O
0.5 . . O
mg . . O
dose . . O
) . . O
and . . O
had . . O
received . . O
high . . O
- . . O
dose . . O
corticosteroid . . O
therapy . . O
to . . O
treat . . O
suspected . . O
ms . . O
relapses . . O
. . . O

information . . O
for . . O
complete . . O
boxed . . O
warning . . O

5 . . O
warnings . . O
and . . O
precautions . . O

in . . O
these . . O
patients . . O
, . . O
extensive . . O
dental . . O
surgery . . O
to . . O
treat . . O
onj . . O
may . . O
exacerbate . . O
the . . O
condition . . O
. . . O

* . . O
have . . O
unusual . . O
vaginal . . O
bleeding . . O
. . . O

in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
, . . O
the . . O
median . . O
time . . O
to . . O
initial . . O
onset . . O
of . . O
fever . . B-AdverseReaction
( . . O
any . . O
severity . . O
) . . O
was . . O
11 . . O
days . . O
( . . O
range . . O
: . . O
1 . . O
to . . O
202 . . O
days . . O
) . . O
and . . O
the . . O
median . . O
duration . . O
of . . O
fever . . B-AdverseReaction
was . . O
3 . . O
days . . O
( . . O
range . . O
: . . O
1 . . O
to . . O
129 . . O
days . . O
) . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
dotarem . . O
exposure . . O
in . . O
2813 . . O
patients . . O
, . . O
representing . . O
2672 . . O
adults . . O
and . . O
141 . . O
pediatric . . O
patients . . O
. . . O

5.1 . . O
hemorrhage . . O

six . . O
percent . . O
of . . O
patients . . O
receiving . . O
imbruvica . . O
in . . O
the . . O
wm . . O
trial . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
events . . O
. . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
2% . . O
) . . O
include . . O
headache . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
and . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
6.1 . . O
) . . O

re . . O
- . . O
align . . O
was . . O
terminated . . O
early . . O
due . . O
to . . O
the . . O
occurrence . . O
of . . O
significantly . . O
more . . O
thromboembolic . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
valve . . O
thrombosis . . O
, . . O
stroke . . O
, . . O
transient . . B-AdverseReaction
ischemic . . I-AdverseReaction
attack . . I-AdverseReaction
, . . O
and . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
) . . O
and . . O
an . . O
excess . . O
of . . O
major . . B-Severity
bleeding . . B-AdverseReaction
( . . O
predominantly . . O
post . . O
- . . O
operative . . O
pericardial . . B-AdverseReaction
effusions . . I-AdverseReaction
requiring . . O
intervention . . O
for . . O
hemodynamic . . O
compromise . . O
) . . O
in . . O
the . . O
pradaxa . . O
treatment . . O
arm . . O
as . . O
compared . . O
to . . O
the . . O
warfarin . . O
treatment . . O
arm . . O
. . . O

signs . . O
or . . O
symptoms . . O
that . . O
may . . O
reflect . . O
serious . . O
injury . . O
to . . O
the . . O
injected . . O
finger . . O
/ . . O
hand . . O
should . . O
be . . O
promptly . . O
evaluated . . O
because . . O
surgical . . O
intervention . . O
may . . O
be . . O
required . . O
. . . O

ilaris . . O
has . . O
been . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
serious . . B-Severity
infections . . B-AdverseReaction
. . . O

delayed . . O
adreview . . O
clearance . . O
may . . O
also . . O
reduce . . O
the . . O
target . . O
to . . O
background . . O
ratios . . O
and . . O
decrease . . O
the . . O
quality . . O
of . . O
scintigraphic . . O
images . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

at . . O
baseline . . O
, . . O
5.2% . . O
of . . O
the . . O
population . . O
reported . . O
retinopathy . . O
. . . O

possible . . O
risk . . O
factors . . O
for . . O
leukopenia . . B-AdverseReaction
/ . . O
neutropenia . . B-AdverseReaction
include . . O
preexisting . . O
low . . O
white . . O
blood . . O
cell . . O
count . . O
( . . O
wbc . . O
) . . O
and . . O
history . . O
of . . O
drug . . O
induced . . O
leukopenia . . O
/ . . O
neutropenia . . O
. . . O

monitor . . O
fasting . . O
serum . . O
glucose . . O
prior . . O
to . . O
the . . O
start . . O
of . . O
zykadia . . O
treatment . . O
and . . O
periodically . . O
thereafter . . O
as . . O
clinically . . O
indicated . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

perforations . . B-AdverseReaction
and . . O
fistulas . . B-AdverseReaction
: . . O
gastrointestinal . . B-AdverseReaction
perforations . . I-AdverseReaction
occurred . . O
in . . O
3% . . O
and . . O
fistula . . B-AdverseReaction
formation . . I-AdverseReaction
in . . O
1% . . O
of . . O
cometriqtm . . O
- . . O
treated . . O
patients . . O
. . . O

serious . . B-Severity
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
, . . O
including . . O
sagittal . . B-AdverseReaction
sinus . . I-AdverseReaction
thrombosis . . I-AdverseReaction
and . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
both . . O
e . . O
. . . O
coli . . O
and . . O
erwinia . . O
- . . O
derived . . O
l . . O
- . . O
asparaginase . . O
therapy . . O
. . . O

monitor . . O
and . . O
treat . . O
appropriately . . O
. . . O

however . . O
, . . O
the . . O
syndrome . . O
can . . O
develop . . O
, . . O
although . . O
much . . O
less . . O
commonly . . O
, . . O
after . . O
relatively . . O
brief . . O
treatment . . O
periods . . O
at . . O
low . . O
doses . . O
. . . O

treatment . . O
- . . O
experienced . . O
, . . O
integrase . . O
strand . . O
transfer . . O
inhibitor . . O
- . . O
experienced . . O
subjects . . O
: . . O
in . . O
a . . O
multicenter . . O
, . . O
open . . O
- . . O
label . . O
, . . O
single . . O
- . . O
arm . . O
trial . . O
( . . O
ing112574 . . O
, . . O
viking . . O
- . . O
3 . . O
) . . O
, . . O
183 . . O
hiv . . O
- . . O
1 . . O
- . . O
infected . . O
, . . O
antiretroviral . . O
treatment . . O
- . . O
experienced . . O
adults . . O
with . . O
virological . . O
failure . . O
and . . O
current . . O
or . . O
historical . . O
evidence . . O
of . . O
raltegravir . . O
and . . O
/ . . O
or . . O
elvitegravir . . O
resistance . . O
received . . O
tivicay . . O
50 . . O
mg . . O
twice . . O
daily . . O
with . . O
the . . O
current . . O
failing . . O
background . . O
regimen . . O
for . . O
7 . . O
days . . O
and . . O
with . . O
optimized . . O
background . . O
therapy . . O
from . . O
day . . O
8 . . O
. . . O

6 . . O
adverse . . O
reactions . . O

of . . O
thrombotic . . O
events . . O
, . . O
( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . B-AdverseReaction
hematoma . . I-AdverseReaction

( . . O
5.6 . . O
) . . O
* . . O
liver . . B-AdverseReaction
injury . . I-AdverseReaction
: . . O
liver . . O
enzyme . . O
results . . O
should . . O
be . . O
available . . O
before . . O
initiation . . O
. . . O

this . . O
imbalance . . O
has . . O
not . . O
been . . O
observed . . O
in . . O
other . . O
studies . . O
of . . O
entereg . . O
in . . O
patients . . O
treated . . O
with . . O
opioids . . O
for . . O
chronic . . O
pain . . O
, . . O
nor . . O
in . . O
patients . . O
treated . . O
within . . O
the . . O
surgical . . O
setting . . O
, . . O
including . . O
patients . . O
undergoing . . O
surgeries . . O
that . . O
included . . O
bowel . . O
resection . . O
who . . O
received . . O
entereg . . O
12 . . O
mg . . O
twice . . O
daily . . O
for . . O
up . . O
to . . O
7 . . O
days . . O
( . . O
the . . O
indicated . . O
dose . . O
and . . O
patient . . O
population . . O
; . . O
entereg . . O
12 . . O
mg . . O
, . . O
n . . O
= . . O
1,142 . . O
; . . O
placebo . . O
, . . O
n . . O
= . . O
1,120 . . O
) . . O
. . . O

i . . O
nfections . . O
and . . O
infestations . . O
: . . O
cryptococcal . . B-AdverseReaction
cutaneous . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
enteroviral . . B-AdverseReaction
encephalitis . . I-AdverseReaction
, . . O
pharyngitis . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
sepsis . . B-AdverseReaction
, . . O
furuncle . . B-AdverseReaction
, . . O
infectious . . B-AdverseReaction
hepatitis . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
pustular . . I-AdverseReaction
, . . O
subcutaneous . . B-AdverseReaction
abscess . . I-AdverseReaction
. . . O

inhaled . . O
medicines . . O
, . . O
including . . O
tudorza . . O
pressair . . O
, . . O
may . . B-Factor
cause . . O
paradoxical . . B-AdverseReaction
bronchospasm . . I-AdverseReaction
. . . O

uncontrolled . . O
hyperammonemia . . O
can . . O
rapidly . . O
result . . O
in . . O
brain . . O
injury . . O
/ . . O
damage . . O
or . . O
death . . O
, . . O
and . . O
prompt . . O
use . . O
of . . O
all . . O
therapies . . O
necessary . . O
to . . O
reduce . . O
plasma . . O
ammonia . . O
levels . . O
is . . O
essential . . O
. . . O

most . . O
adverse . . O
reactions . . O
were . . O
mild . . O
, . . O
did . . O
not . . O
lead . . O
to . . O
discontinuation . . O
of . . O
study . . O
medication . . O
, . . O
and . . O
resolved . . O
. . . O

* . . O
the . . O
risk . . B-Factor
for . . O
nsf . . B-AdverseReaction
appears . . O
highest . . O
among . . O
patients . . O
with . . O
: . . O
chronic . . O
, . . O
severe . . O
kidney . . O
disease . . O
( . . O
gfr . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m2 . . O
) . . O
, . . O
oracute . . O
kidney . . O
injury . . O
. . . O

a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
has . . O
not . . O
been . . O
established . . O
. . . O

6 . . O
adverse . . O
reactions . . O

of . . O
the . . O
63 . . O
patients . . O
with . . O
moderate . . B-Severity
dermatitis . . B-AdverseReaction
, . . O
25 . . O
( . . O
40% . . O
) . . O
were . . O
treated . . O
with . . O
systemic . . O
corticosteroids . . O
( . . O
median . . O
of . . O
60 . . O
mg . . O
/ . . O
day . . O
of . . O
prednisone . . O
or . . O
equivalent . . O
) . . O
for . . O
a . . O
median . . O
of . . O
2.1 . . O
weeks . . O
, . . O
7 . . O
( . . O
11% . . O
) . . O
were . . O
treated . . O
with . . O
only . . O
topical . . O
corticosteroids . . O
, . . O
and . . O
31 . . O
( . . O
49% . . O
) . . O
did . . O
not . . O
receive . . O
systemic . . O
or . . O
topical . . O
corticosteroids . . O
. . . O

for . . O
dlco . . O
, . . O
the . . O
reduction . . O
from . . O
baseline . . O
in . . O
percent . . O
of . . O
predicted . . O
values . . O
at . . O
the . . O
time . . O
of . . O
last . . O
assessment . . O
on . . O
drug . . O
was . . O
3.3% . . B-Severity
for . . O
gilenya . . O
0.5 . . O
mg . . O
and . . O
0.5% . . O
for . . O
placebo . . O
. . . O

* . . O
prescribers . . O
must . . O
be . . O
certified . . O
with . . O
the . . O
program . . O
by . . O
enrolling . . O
and . . O
completing . . O
training . . O
in . . O
the . . O
administration . . O
of . . O
xiaflex . . O
treatment . . O
for . . O
peyronie's . . O
disease . . O
. . . O

if . . O
patients . . O
taking . . O
fanapt . . O
experience . . O
symptoms . . O
that . . O
could . . O
indicate . . O
the . . O
occurrence . . O
of . . O
cardiac . . O
arrhythmias . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
dizziness . . O
, . . O
palpitations . . O
, . . O
or . . O
syncope . . O
, . . O
the . . O
prescriber . . O
should . . O
initiate . . O
further . . O
evaluation . . O
, . . O
including . . O
cardiac . . O
monitoring . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reaction . . O
leading . . O
to . . O
afinitor . . O
dose . . O
adjustment . . O
was . . O
stomatitis . . B-AdverseReaction
. . . O

* . . O
angioedema . . B-AdverseReaction
with . . O
concomitant . . O
use . . O
of . . O
ace . . O
inhibitors . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

table . . O
2 . . O
. . . O

hypersensitivity . . O

5.8 . . O
immune . . O
reconstitution . . O
syndrome . . O

they . . O
are . . O
not . . O
interchangeable . . O
with . . O
other . . O
preparations . . O
of . . O
botulinum . . O
toxin . . O
products . . O
and . . O
, . . O
therefore . . O
, . . O
units . . O
of . . O
biological . . O
activity . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
cannot . . O
be . . O
compared . . O
to . . O
or . . O
converted . . O
into . . O
units . . O
of . . O
any . . O
other . . O
botulinum . . O
toxin . . O
products . . O
assessed . . O
with . . O
any . . O
other . . O
specific . . O
assay . . O
method . . O
[ . . O
seedescription . . O
( . . O
11 . . O
) . . O
] . . O
. . . O

infections . . B-AdverseReaction
resulting . . O
in . . O
death . . B-AdverseReaction
occurred . . O
in . . O
0.3% . . O
( . . O
4 . . O
/ . . O
1,458 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
benlysta . . O
and . . O
in . . O
0.1% . . O
( . . O
1 . . O
/ . . O
675 . . O
) . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

long . . O
- . . O
standing . . O
hyperprolactinemia . . B-AdverseReaction
when . . O
associated . . O
with . . O
hypogonadism . . B-AdverseReaction
may . . B-Factor
lead . . O
to . . O
decreased . . B-AdverseReaction
bone . . I-AdverseReaction
density . . I-AdverseReaction
in . . O
both . . O
female . . O
and . . O
male . . O
subjects . . O
. . . O

excerpt . . O
: . . O
* . . O
severe . . B-Severity
cutaneous . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
monitor . . O
patients . . O
for . . O
the . . O
development . . O
of . . O
severe . . O
cutaneous . . O
reactions . . O
and . . O
discontinue . . O
zydelig . . O
. . . O

bradycardia . . B-AdverseReaction
was . . O
reported . . O
as . . O
an . . O
adverse . . O
drug . . O
reaction . . O
in . . O
3% . . O
of . . O
patients . . O
in . . O
study . . O
1 . . O
. . . O

if . . O
the . . O
recommended . . O
dose . . O
is . . O
exceeded . . O
, . . O
the . . O
dose . . O
should . . O
be . . O
reduced . . O
to . . O
600 . . O
mg . . O
daily . . O
for . . O
1 . . O
week . . O
prior . . O
to . . O
discontinuation . . O
to . . O
minimize . . O
the . . O
potential . . O
of . . O
withdrawal . . O
seizure . . O
. . . O

jc . . B-AdverseReaction
virus . . I-AdverseReaction
infection . . I-AdverseReaction
resulting . . O
in . . O
pml . . B-AdverseReaction
and . . O
death . . B-AdverseReaction
can . . B-Factor
occur . . O
in . . O
patients . . O
receiving . . O
adcetris . . O
( . . O
5.9 . . O
, . . O
6.2 . . O
) . . O
. . . O

patients . . O
in . . O
the . . O
treatment . . O
studies . . O
who . . O
rolled . . O
over . . O
into . . O
the . . O
re . . O
- . . O
medy . . O
study . . O
had . . O
a . . O
combined . . O
treatment . . O
duration . . O
of . . O
up . . O
to . . O
more . . O
than . . O
3 . . O
years . . O
, . . O
with . . O
mean . . O
exposure . . O
of . . O
473 . . O
days . . O
. . . O

5.2 . . O
potentiation . . O
of . . O
sedation . . O
from . . O
concomitant . . O
use . . O
with . . O
central . . O
nervous . . O
system . . O
depressants . . O

fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
pneumonitis . . B-AdverseReaction
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
zydelig . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
urticaria . . B-AdverseReaction

additionally . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
including . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

cases . . O
of . . O
acute . . O
renal . . O
failure . . O
after . . O
initiation . . O
of . . O
high . . O
dose . . O
or . . O
multiple . . O
nsaids . . O
have . . O
been . . O
reported . . O
in . . O
hiv . . O
- . . O
infected . . O
patients . . O
with . . O
risk . . O
factors . . O
for . . O
renal . . O
dysfunction . . O
who . . O
appeared . . O
stable . . O
on . . O
tenofovir . . O
df . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
irrespective . . O
of . . O
causality . . O
) . . O
leading . . O
to . . O
treatment . . O
discontinuation . . O
were . . O
pneumonitis . . B-AdverseReaction
and . . O
dyspnea . . B-AdverseReaction
. . . O

hypertoxin . . O
- . . O
producing . . O
strains . . O
of . . O
c . . O
. . . O
difficile . . O
cause . . O
increased . . O
morbidity . . O
and . . O
mortality . . O
, . . O
as . . O
these . . O
infections . . O
can . . O
be . . O
refractory . . O
to . . O
antimicrobial . . O
therapy . . O
and . . O
may . . O
require . . O
colectomy . . O
. . . O

should . . O
the . . O
physician . . O
decide . . O
to . . O
administer . . O
anticoagulation . . O
in . . O
the . . O
context . . O
of . . O
epidural . . O
or . . O
spinal . . O
anesthesia . . O
/ . . O
analgesia . . O
or . . O
lumbar . . O
puncture . . O
, . . O
monitor . . O
frequently . . O
to . . O
detect . . O
any . . O
signs . . O
or . . O
symptoms . . O
of . . O
neurological . . O
impairment . . O
, . . O
such . . O
as . . O
midline . . O
back . . O
pain . . O
, . . O
sensory . . O
and . . O
motor . . O
deficits . . O
( . . O
numbness . . O
, . . O
tingling . . O
, . . O
or . . O
weakness . . O
in . . O
lower . . O
limbs . . O
) . . O
, . . O
bowel . . O
and . . O
/ . . O
or . . O
bladder . . O
dysfunction . . O
. . . O

table . . O
6 . . O
: . . O
change . . O
in . . O
body . . O
weight . . O
fanapt . . O
fanapt . . O
placebo . . O
10-16 . . O
mg . . O
/ . . O
day . . O
20-24 . . O
mg . . O
/ . . O
day . . O
n . . O
= . . O
576 . . O
n . . O
= . . O
481 . . O
n . . O
= . . O
391 . . O
weight . . O
( . . O
kg . . O
) . . O
change . . O
from . . O
baseline . . O
- . . O
0.1 . . O
2.0 . . O
2.7 . . O
weight . . O
gain . . O
> . . O
= . . O
7% . . O
increase . . O
from . . O
baseline . . O
4% . . O
12% . . O
18% . . O
5.6 . . O
seizures . . O

therefore . . O
, . . O
xiaflex . . O
should . . O
be . . O
injected . . O
only . . O
into . . O
the . . O
collagen . . O
cord . . O
with . . O
a . . O
mp . . O
or . . O
pip . . O
joint . . O
contracture . . O
, . . O
and . . O
care . . O
should . . O
be . . O
taken . . O
to . . O
avoid . . O
injecting . . O
into . . O
tendons . . O
, . . O
nerves . . O
, . . O
blood . . O
vessels . . O
, . . O
or . . O
other . . O
collagen . . O
- . . O
containing . . O
structures . . O
of . . O
the . . O
hand . . O
. . . O

elevations . . B-AdverseReaction
of . . I-AdverseReaction
alanine . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
and . . O
aspartate . . O
aminotransferase . . O
to . . O
> . . O
= . . O
3 . . O
times . . O
the . . O
uln . . O
occurred . . O
in . . O
a . . O
small . . O
number . . O
of . . O
patients . . O
treated . . O
with . . O
both . . O
tecfidera . . O
and . . O
placebo . . O
and . . O
were . . O
balanced . . O
between . . O
groups . . O
. . . O

* . . O
retinal . . B-AdverseReaction
vein . . I-AdverseReaction
occlusion . . I-AdverseReaction
* . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
* . . O
new . . O
primary . . B-AdverseReaction
malignancies . . I-AdverseReaction
, . . I-AdverseReaction
cutaneous . . I-AdverseReaction
and . . O
non . . O
- . . O
cutaneous . . O
, . . O
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
administered . . O
as . . O
a . . O
single . . O
agent . . O
or . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

discontinuation . . O
due . . O
to . . O
any . . O
adverse . . O
event . . O
occurred . . O
in . . O
26% . . O
in . . O
the . . O
krd . . O
arm . . O
versus . . O
25% . . O
in . . O
the . . O
rd . . O
arm . . O
. . . O

the . . O
most . . O
common . . O
non . . O
- . . O
hematologic . . O
grade . . O
3 . . O
or . . O
4 . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
were . . O
fatigue . . B-AdverseReaction
( . . O
11% . . O
) . . O
, . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
and . . O
pneumonia . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
and . . O
dehydration . . B-AdverseReaction
, . . O
each . . O
reported . . O
in . . O
5% . . O
of . . O
patients . . O
. . . O

treatment . . O
- . . O
naive . . O
subjects . . O
: . . O
selected . . O
laboratory . . O
abnormalities . . O
( . . O
grades . . O
2 . . O
to . . O
4 . . O
) . . O
with . . O
a . . O
worsening . . O
grade . . O
from . . O
baseline . . O
and . . O
representing . . O
the . . O
worst . . O
- . . O
grade . . O
toxicity . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
subjects . . O
are . . O
presented . . O
in . . O
table . . O
3 . . O
. . . O

adverse . . O
reactions . . O
with . . O
> . . O
= . . O
10% . . O
incidence . . O
for . . O
any . . O
grade . . O
or . . O
> . . O
= . . O
5% . . O
incidence . . O
for . . O
grade . . O
3 . . O
or . . O
higher . . O
( . . O
n . . O
= . . O
212 . . O
) . . O
adverse . . O
reaction . . O
any . . O
gradegrading . . O
based . . O
on . . O
nci . . O
common . . O
terminology . . O
criteria . . O
for . . O
adverse . . O
events . . O
( . . O
ctcae . . O
) . . O
version . . O
4.0 . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
higher . . O
( . . O
% . . O
) . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
anemia . . B-AdverseReaction
neutropenia . . B-AdverseReaction
thrombocytopenia . . B-AdverseReaction
leukopenia . . B-AdverseReaction
251816119 . . O
23131588 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
constipation . . B-AdverseReaction
diarrheadiarrhea . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
colitis . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
enteritis . . B-AdverseReaction
, . . O
and . . O
neutropenic . . B-AdverseReaction
colitis . . I-AdverseReaction
. . . O

the . . O
most . . O
common . . O
non . . O
- . . O
hematologic . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
30% . . O
) . . O
were . . O
nausea . . B-AdverseReaction
( . . O
75% . . O
) . . O
, . . O
fatigue . . B-AdverseReaction
( . . O
57% . . O
) . . O
, . . O
vomiting . . B-AdverseReaction
( . . O
40% . . O
) . . O
, . . O
diarrhea . . B-AdverseReaction
( . . O
37% . . O
) . . O
and . . O
pyrexia . . B-AdverseReaction
( . . O
34% . . O
) . . O
. . . O

* . . O
have . . O
any . . O
unusual . . O
vaginal . . O
bleeding . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reactions . . O
in . . O
patients . . O
receiving . . O
aptiom . . O
at . . O
doses . . O
of . . O
800 . . O
mg . . O
or . . O
1200 . . O
mg . . O
( . . O
> . . O
= . . O
4% . . O
and . . O
> . . O
= . . O
2% . . O
greater . . O
than . . O
placebo . . O
) . . O
were . . O
dizziness . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
diplopia . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
vertigo . . B-AdverseReaction
, . . O
ataxia . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
and . . O
tremor . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
* . . O
not . . O
for . . O
acute . . O
use . . O
: . . O
not . . O
for . . O
use . . O
as . . O
a . . O
rescue . . O
medication . . O
. . . O

additionally . . O
in . . O
prolia . . O
- . . O
treated . . O
men . . O
with . . O
nonmetastatic . . O
prostate . . O
cancer . . O
receiving . . O
adt . . O
, . . O
a . . O
greater . . O
incidence . . O
of . . O
cataracts . . B-AdverseReaction
was . . O
observed . . O
( . . O
1.2% . . O
placebo . . O
vs . . O
. . . O
4.7% . . O
prolia . . O
) . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
treatment . . O
was . . O
2 . . O
cycles . . O
( . . O
range . . O
1 . . O
- . . O
33 . . O
cycles . . O
) . . O
. . . O

the . . O
diagnostic . . O
evaluation . . O
of . . O
patients . . O
with . . O
this . . O
syndrome . . O
is . . O
complicated . . O
. . . O

almost . . O
all . . O
these . . O
patients . . O
had . . O
received . . O
treatment . . O
with . . O
azathioprine . . O
( . . O
aza . . O
) . . O
or . . O
6 . . O
- . . O
mercaptopurine . . O
( . . O
6 . . O
- . . O
mp . . O
) . . O
concomitantly . . O
with . . O
a . . O
tnf . . O
- . . O
blocker . . O
at . . O
or . . O
prior . . O
to . . O
diagnosis . . O
. . . O

5.13 . . O
pregnancy . . O

serious . . O
adverse . . O
drug . . O
reactions . . O
reported . . O
in . . O
2% . . O
or . . O
more . . O
of . . O
patients . . O
in . . O
study . . O
1 . . O
were . . O
convulsion . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
ild . . B-AdverseReaction
/ . . O
pneumonitis . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
dehydration . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
. . . O

employment . . O
of . . O
a . . O
corticosteroid . . O
medication . . O
in . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
herpes . . O
simplex . . O
requires . . O
great . . O
caution . . O
. . . O

table . . O
8 . . O
compares . . O
the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
reported . . O
with . . O
an . . O
incidence . . O
of . . O
> . . O
= . . O
10% . . O
for . . O
patients . . O
receiving . . O
afinitor . . O
and . . O
occurring . . O
more . . O
frequently . . O
with . . O
afinitor . . O
than . . O
with . . O
placebo . . O
. . . O

( . . O
5.1 . . O
) . . O

5.2 . . O
risk . . O
of . . O
acute . . O
respiratory . . O
complications . . O

* . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
* . . O
hepatotoxicity . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
drug . . O
interactions . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
reported . . O
in . . O
10% . . O
or . . O
more . . O
of . . O
patients . . O
treated . . O
with . . O
sirturo . . O
were . . O
nausea . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
hemoptysis . . B-AdverseReaction
and . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

( . . O
5.6 . . O
, . . O
8.1 . . O
, . . O
8.3 . . O
) . . O

vascular . . O
disorders . . O
: . . O
hypotension . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
. . . O

in . . O
study . . O
1 . . O
, . . O
all . . O
grades . . O
of . . O
adverse . . O
events . . O
were . . O
reported . . O
for . . O
the . . O
following . . O
adverse . . O
events . . O
of . . O
special . . O
interest . . O
: . . O
allergy . . B-AdverseReaction
, . . O
pancreatitis . . B-AdverseReaction
, . . O
coagulopathy . . B-AdverseReaction
( . . O
hemorrhage . . B-AdverseReaction
, . . O
thrombosis . . B-AdverseReaction
or . . O
infarct . . B-AdverseReaction
) . . O
, . . O
hyperbilirubinemia . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
hyperlipidemia . . B-AdverseReaction
, . . O
ketoacidosis . . B-AdverseReaction
, . . O
and . . O
cns . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
hemorrhage . . O
, . . O
thrombosis . . O
or . . O
infarction . . O
, . . O
and . . O
cerebral . . B-AdverseReaction
venous . . I-AdverseReaction
thrombosis . . I-AdverseReaction
) . . O
and . . O
only . . O
grade . . O
3 . . O
and . . O
4 . . O
events . . O
were . . O
reported . . O
for . . O
other . . O
adverse . . O
events . . O
. . . O

* . . O
abnormal . . B-AdverseReaction
bleeding . . I-AdverseReaction
: . . O
pristiq . . O
may . . B-Factor
increase . . O
risk . . O
of . . O
bleeding . . B-AdverseReaction
events . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reaction . . O
leading . . O
to . . O
treatment . . O
discontinuation . . O
in . . O
the . . O
jevtana . . O
group . . O
was . . O
neutropenia . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

lipids . . O

prior . . O
to . . O
administration . . O
, . . O
question . . O
the . . O
patient . . O
for . . O
a . . O
history . . O
of . . O
prior . . O
reactions . . O
to . . O
datscan . . O
. . . O

stop . . O
natazia . . O
if . . O
there . . O
is . . O
unexplained . . O
loss . . O
of . . O
vision . . O
, . . O
proptosis . . O
, . . O
diplopia . . O
, . . O
papilledema . . O
, . . O
or . . O
retinal . . O
vascular . . O
lesions . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
1.1% . . O
of . . O
1024 . . O
evaluable . . O
patients . . O
tested . . O
positive . . O
for . . O
binding . . O
antibodies . . O
against . . O
ipilimumab . . O
in . . O
an . . O
electrochemiluminescent . . O
( . . O
ecl . . O
) . . O
based . . O
assay . . O
. . . O

one . . O
patient . . O
with . . O
urticaria . . B-AdverseReaction
had . . O
recurrence . . O
when . . O
invokana . . O
was . . O
re . . O
- . . O
initiated . . O
. . . O

laboratory . . O
abnormalities . . O
in . . O
the . . O
two . . O
randomized . . O
clinical . . O
trials . . O
, . . O
grade . . B-Severity
1-4 . . I-Severity
neutropenia . . O
occurred . . O
in . . O
15% . . O
of . . O
patients . . O
treated . . O
with . . O
xtandi . . O
( . . O
1% . . O
grade . . O
3-4 . . O
) . . O
and . . O
in . . O
6% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
( . . O
0.5% . . O
grade . . O
3-4 . . O
) . . O
. . . O

cocs . . B-DrugClass
also . . O
increase . . O
the . . O
risk . . O
for . . O
stroke . . B-AdverseReaction
in . . O
women . . O
with . . O
other . . O
underlying . . O
risk . . O
factors . . O
. . . O

closely . . O
observe . . O
patients . . O
during . . O
and . . O
after . . O
alglucosidase . . O
alfa . . O
administration . . O
and . . O
be . . O
prepared . . O
to . . O
manage . . O
anaphylaxis . . O
and . . O
hypersensitivity . . O
reactions . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
stribild . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
chronic . . O
hepatitis . . O
b . . O
virus . . O
( . . O
hbv . . O
) . . O
infection . . O
. . . O

across . . O
clinical . . O
trials . . O
of . . O
tafinlar . . O
( . . O
n . . O
= . . O
586 . . O
) . . O
, . . O
the . . O
incidence . . O
of . . O
cuscc . . B-AdverseReaction
was . . O
11% . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

other . . O
serious . . B-Severity
penile . . B-AdverseReaction
injury . . I-AdverseReaction
in . . O
the . . O
treatment . . O
of . . O
peyronie's . . O
disease . . O

* . . O
screen . . O
patients . . O
for . . O
acute . . O
kidney . . O
injury . . O
and . . O
other . . O
conditions . . O
that . . O
may . . O
reduce . . O
renal . . O
function . . O
. . . O

the . . O
incidence . . O
of . . O
xiaflex . . O
- . . O
associated . . O
pruritus . . B-AdverseReaction
was . . O
similar . . O
after . . O
each . . O
injection . . O
regardless . . O
of . . O
the . . O
number . . O
of . . O
injections . . O
administered . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
narrow . . I-AdverseReaction
- . . I-AdverseReaction
angle . . I-AdverseReaction
glaucoma . . I-AdverseReaction
may . . B-Factor
occur . . O
. . . O

care . . O
should . . O
be . . O
taken . . O
when . . O
switching . . O
from . . O
one . . O
biologic . . O
product . . O
to . . O
another . . O
biologic . . O
product . . O
since . . O
overlapping . . O
biological . . O
activity . . O
may . . O
further . . O
increase . . O
the . . O
risk . . O
of . . O
infection . . O
. . . O

* . . O
do . . O
not . . O
take . . O
additional . . O
estrogen . . O
products . . O
while . . O
you . . O
are . . O
taking . . O
duavee . . O
. . . O

* . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O

retinal . . B-AdverseReaction
pigment . . I-AdverseReaction
epithelial . . I-AdverseReaction
detachments . . I-AdverseReaction
( . . O
rped . . B-AdverseReaction
) . . O
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
and . . O
with . . O
trametinib . . O
as . . O
a . . O
single . . O
agent . . O
[ . . O
refer . . O
to . . O
full . . O
prescribing . . O
information . . O
for . . O
trametinib . . O
] . . O
. . . O

deaths . . B-AdverseReaction
due . . O
to . . O
adverse . . O
events . . O
within . . O
30 . . O
days . . O
of . . O
the . . O
last . . O
dose . . O
of . . O
any . . O
therapy . . O
in . . O
the . . O
krd . . O
arm . . O
occurred . . O
in . . O
27 . . O
/ . . O
392 . . O
( . . O
7% . . O
) . . O
patients . . O
compared . . O
with . . O
27 . . O
/ . . O
389 . . O
( . . O
7% . . O
) . . O
patients . . O
who . . O
died . . B-AdverseReaction
due . . O
to . . O
adverse . . O
events . . O
within . . O
30 . . O
days . . O
of . . O
the . . O
last . . O
dose . . O
of . . O
any . . O
rd . . O
therapy . . O
. . . O

the . . O
effect . . O
of . . O
treatment . . O
with . . O
duavee . . O
on . . O
the . . O
risk . . O
of . . O
breast . . O
cancer . . O
is . . O
unknown . . O
. . . O

melanoma . . B-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
tnf . . O
- . . O
blocking . . O
agents . . O
, . . O
including . . O
the . . O
subcutaneous . . O
formulation . . O
of . . O
golimumab . . O
. . . O

observational . . O
studies . . O
suggest . . O
that . . O
, . . O
similar . . O
to . . O
atypical . . O
antipsychotic . . O
drugs . . O
, . . O
treatment . . O
with . . O
conventional . . O
antipsychotic . . O
drugs . . O
may . . O
increase . . O
mortality . . O
. . . O

advise . . O
patients . . O
to . . O
seek . . O
prompt . . O
medical . . O
attention . . O
if . . O
they . . O
develop . . O
signs . . O
or . . O
symptoms . . O
of . . O
infection . . O
, . . O
including . . O
cellulitis . . O
( . . O
5.6 . . O
) . . O
* . . O
dermatologic . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
dermatitis . . B-AdverseReaction
, . . O
rashes . . B-AdverseReaction
, . . O
and . . O
eczema . . B-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

6.2 . . O
immunogenicity . . O

if . . O
it . . O
is . . O
almost . . O
time . . O
for . . O
your . . O
next . . O
dose . . O
, . . O
skip . . O
the . . O
missed . . O
dose . . O
. . . O

asthenia . . B-AdverseReaction

the . . O
risks . . O
and . . O
benefits . . O
of . . O
tnf . . O
- . . O
blocker . . O
treatment . . O
including . . O
simponi . . O
aria . . O
should . . O
be . . O
considered . . O
prior . . O
to . . O
initiating . . O
therapy . . O
in . . O
patients . . O
with . . O
a . . O
known . . O
malignancy . . O
other . . O
than . . O
a . . O
successfully . . O
treated . . O
non . . O
- . . O
melanoma . . O
skin . . O
cancer . . O
( . . O
nmsc . . O
) . . O
or . . O
when . . O
considering . . O
continuing . . O
a . . O
tnf . . O
- . . O
blocker . . O
in . . O
patients . . O
who . . O
develop . . O
a . . O
malignancy . . O
. . . O

increases . . O
in . . O
serum . . O
phosphate . . O

( . . O
5.1 . . O
) . . O
* . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
intraocular . . I-AdverseReaction
pressure . . I-AdverseReaction
have . . O
been . . O
seen . . O
within . . O
60 . . O
minutes . . O
of . . O
an . . O
intravitreal . . O
injection . . O
. . . O

* . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
severe . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
occurred . . O
in . . O
some . . O
patients . . O
during . . O
and . . O
after . . O
alglucosidase . . O
alfa . . O
infusions . . O
. . . O

adverse . . O
reactions . . O
associated . . O
with . . O
discontinuation . . O
of . . O
treatment . . O
: . . O
approximately . . O
16% . . O
( . . O
25 . . O
/ . . O
158 . . O
) . . O
of . . O
saphris . . O
- . . O
treated . . O
patients . . O
discontinued . . O
treatment . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
, . . O
compared . . O
with . . O
about . . O
11% . . O
( . . O
18 . . O
/ . . O
166 . . O
) . . O
on . . O
placebo . . O
. . . O

5.5 . . O
posterior . . O
reversible . . O
encephalopathy . . O
syndrome . . O

the . . O
clinical . . O
development . . O
program . . O
excluded . . O
patients . . O
with . . O
active . . O
autoimmune . . O
disease . . O
or . . O
those . . O
receiving . . O
systemic . . O
immunosuppression . . O
for . . O
organ . . O
transplantation . . O
. . . O

three . . O
subjects . . O
on . . O
tanzeum . . O
and . . O
one . . O
subject . . O
in . . O
the . . O
all . . O
- . . O
comparator . . O
group . . O
experienced . . O
at . . O
least . . O
one . . O
event . . O
of . . O
alt . . B-AdverseReaction
increase . . I-AdverseReaction
of . . O
10 . . O
- . . O
fold . . O
or . . O
greater . . O
above . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
. . . O

patients . . O
greater . . O
than . . O
65 . . O
years . . O
of . . O
age . . O
, . . O
patients . . O
with . . O
co . . O
- . . O
morbid . . O
conditions . . O
, . . O
and . . O
/ . . O
or . . O
patients . . O
taking . . O
concomitant . . O
immunosuppressants . . O
( . . O
e . . O
. . . O
g . . O
. . . O
corticosteroids . . O
or . . O
methotrexate . . O
) . . O
may . . O
be . . O
at . . O
a . . O
greater . . O
risk . . B-Factor
of . . O
infection . . B-AdverseReaction
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
measure . . O
the . . O
absolute . . O
neutrophil . . O
count . . O
( . . O
anc . . O
) . . O
before . . O
starting . . O
ferriprox . . O
therapy . . O
and . . O
monitor . . O
the . . O
anc . . O
weekly . . O
on . . O
therapy . . O
. . . O

premedicate . . O
all . . O
patients . . O
prior . . O
to . . O
the . . O
initiation . . O
of . . O
the . . O
infusion . . O
of . . O
jevtana . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

evaluate . . O
if . . O
diarrhea . . O
occurs . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
drug . . O
reactions . . O
reported . . O
by . . O
> . . O
= . . O
1% . . O
of . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
and . . O
with . . O
a . . O
higher . . O
incidence . . O
than . . O
placebo . . O
- . . O
treated . . O
patients . . O
in . . O
trial . . O
1 . . O
through . . O
week . . O
24 . . O
placebo . . O
+ . . O
mtx . . O
simponi . . O
aria . . O
+ . . O
mtx . . O
patients . . O
treated . . O
197 . . O
463 . . O
adverse . . O
reaction . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
such . . O
as . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
pharyngitis . . B-AdverseReaction
, . . O
laryngitis . . B-AdverseReaction
, . . O
and . . O
rhinitis . . B-AdverseReaction
) . . O
12% . . O
13% . . O
viral . . B-AdverseReaction
infections . . I-AdverseReaction
( . . O
such . . O
as . . O
influenza . . B-AdverseReaction
and . . O
herpes . . B-AdverseReaction
) . . O
3% . . O
4% . . O
bacterial . . B-AdverseReaction
infections . . I-AdverseReaction
0% . . O
1% . . O
bronchitis . . B-AdverseReaction
1% . . O
3% . . O
vascular . . B-AdverseReaction
disorders . . I-AdverseReaction
hypertension . . B-AdverseReaction
2% . . O
3% . . O
skin . . O
and . . O
subcutaneous . . O
disorders . . O
rash . . B-AdverseReaction
1% . . O
3% . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
pyrexia . . B-AdverseReaction
1% . . O
2% . . O
blood . . O
and . . O
lymphatic . . B-AdverseReaction
disorders . . I-AdverseReaction
leukopenia . . B-AdverseReaction
0% . . O
1% . . O
other . . O
and . . O
less . . O
common . . O
clinical . . O
trial . . O
adverse . . O
drug . . O
reactions . . O

if . . O
bilirubin . . O
is . . O
elevated . . O
, . . O
perform . . O
fractionation . . O
. . . O

all . . O
patients . . O
who . . O
were . . O
positive . . O
for . . O
antibodies . . O
to . . O
golimumab . . O
had . . O
neutralizing . . O
antibodies . . O
based . . O
on . . O
an . . O
in . . O
vitro . . O
cell . . O
- . . O
based . . O
assay . . O
. . . O

decreases . . B-AdverseReaction
in . . I-AdverseReaction
bone . . I-AdverseReaction
mineral . . I-AdverseReaction
density . . I-AdverseReaction
( . . O
bmd . . O
) . . O
have . . O
been . . O
observed . . O
with . . O
long . . O
- . . O
term . . O
administration . . O
of . . O
products . . O
containing . . O
inhaled . . O
corticosteroids . . B-DrugClass
. . . O

5.5 . . O
renal . . O
failure . . O

( . . O
5.2 . . O
) . . O
* . . O
hepatic . . B-AdverseReaction
effects . . I-AdverseReaction
: . . O
postmarketing . . O
reports . . O
of . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
sometimes . . O
fatal . . B-AdverseReaction
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
have . . O
been . . O
associated . . O
with . . O
treanda . . O
in . . O
clinical . . O
trials . . O
and . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
label . . O
. . . O

cimzia . . O
has . . O
not . . O
been . . O
formally . . O
studied . . O
in . . O
patients . . O
with . . O
chf . . O
; . . O
however . . O
, . . O
in . . O
clinical . . O
studies . . O
in . . O
patients . . O
with . . O
chf . . O
with . . O
another . . O
tnf . . B-DrugClass
blocker . . I-DrugClass
, . . O
worsening . . B-AdverseReaction
congestive . . I-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
chf . . O
) . . O
and . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
due . . O
to . . O
chf . . B-AdverseReaction
were . . O
observed . . O
. . . O

5.1 . . O
hepatotoxicity . . O

use . . O
of . . O
kalydeco . . O
with . . O
strong . . O
cyp3a . . O
inducers . . O
, . . O
such . . O
as . . O
rifampin . . O
, . . O
substantially . . O
decreases . . O
the . . O
exposure . . O
of . . O
ivacaftor . . O
, . . O
which . . O
may . . O
reduce . . O
the . . O
therapeutic . . O
effectiveness . . O
of . . O
kalydeco . . O
. . . O

5.4 . . O
flushing . . O

potassium . . O
levels . . O
should . . O
be . . O
within . . O
the . . O
normal . . O
range . . O
prior . . O
to . . O
administration . . O
of . . O
multaq . . O
and . . O
maintained . . O
in . . O
the . . O
normal . . O
range . . O
during . . O
administration . . O
of . . O
multaq . . O
. . . O

therefore . . O
, . . O
the . . O
use . . O
of . . O
cimzia . . O
in . . O
combination . . O
with . . O
other . . O
biological . . O
dmards . . O
is . . O
not . . O
recommended . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

* . . O
risk . . B-Factor
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
pancreatitis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
hypoglycemia . . B-AdverseReaction
with . . O
concomitant . . O
use . . O
of . . O
insulin . . O
secretagogues . . O
or . . O
insulin . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
severe . . B-Severity
gastrointestinal . . B-AdverseReaction
disease . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
, . . O
reported . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
treated . . O
with . . O
trulicity . . O
are . . O
: . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

the . . O
preservative . . O
in . . O
durezol . . O
may . . O
be . . O
absorbed . . O
by . . O
soft . . O
contact . . O
lenses . . O
. . . O

the . . O
most . . O
common . . O
grade . . O
3 . . O
/ . . O
4 . . O
laboratory . . O
abnormalities . . O
( . . O
incidence . . O
> . . O
= . . O
3% . . O
) . . O
were . . O
lymphopenia . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
potassium . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
ast . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
, . . O
and . . O
thrombocytopenia . . B-AdverseReaction
. . . O

table . . O
5 . . O
: . . O
non . . O
- . . O
hematologic . . O
adverse . . O
reactions . . O
> . . O
= . . O
10% . . O
reported . . O
in . . O
study . . O
2 . . O
imbruvica . . O
( . . O
n . . O
= . . O
195 . . O
) . . O
ofatumumab . . O
( . . O
n . . O
= . . O
191 . . O
) . . O
system . . O
organ . . O
class . . O
adr . . O
term . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
subjects . . O
with . . O
multiple . . O
events . . O
for . . O
a . . O
given . . O
adr . . O
term . . O
are . . O
counted . . O
once . . O
only . . O
for . . O
each . . O
adr . . O
term . . O
. . . O

anyone . . O
considering . . O
prescribing . . O
onfi . . O
or . . O
any . . O
other . . O
aed . . O
must . . O
balance . . O
the . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
with . . O
the . . O
risk . . O
of . . O
untreated . . O
illness . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
pruritus . . B-AdverseReaction
. . . O

inhalation . . O
of . . O
high . . O
doses . . O
of . . O
beta2 . . B-DrugClass
- . . I-DrugClass
adrenergic . . I-DrugClass
agonists . . I-DrugClass
may . . O
produce . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
plasma . . I-AdverseReaction
glucose . . I-AdverseReaction
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

during . . O
the . . O
initial . . O
phase . . O
of . . O
combination . . O
antiretroviral . . O
treatment . . O
, . . O
patients . . O
whose . . O
immune . . O
systems . . O
respond . . O
may . . B-Factor
develop . . O
an . . O
inflammatory . . B-AdverseReaction
response . . I-AdverseReaction
to . . O
indolent . . O
or . . O
residual . . B-AdverseReaction
opportunistic . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
such . . O
as . . O
mycobacterium . . B-AdverseReaction
avium . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
cytomegalovirus . . B-AdverseReaction
, . . O
pneumocystis . . B-AdverseReaction
jirovecii . . I-AdverseReaction
pneumonia . . I-AdverseReaction
[ . . O
pcp . . B-AdverseReaction
] . . O
, . . O
or . . O
tuberculosis . . B-AdverseReaction
) . . O
, . . O
which . . O
may . . O
necessitate . . O
further . . O
evaluation . . O
and . . O
treatment . . O
. . . O

patients . . O
were . . O
treated . . O
and . . O
followed . . O
for . . O
3 . . O
years . . O
. . . O

exposure . . O
to . . O
yervoy . . O
3 . . O
mg . . O
/ . . O
kg . . O
for . . O
4 . . O
doses . . O
given . . O
by . . O
intravenous . . O
infusion . . O
in . . O
previously . . O
treated . . O
patients . . O
with . . O
unresectable . . O
or . . O
metastatic . . O
melanoma . . O
was . . O
assessed . . O
in . . O
a . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
clinical . . O
study . . O
( . . O
study . . O
1 . . O
) . . O
. . . O

coartem . . O
tablets . . O
have . . O
not . . O
been . . O
studied . . O
for . . O
efficacy . . O
and . . O
safety . . O
in . . O
patients . . O
with . . O
severe . . O
hepatic . . O
and . . O
/ . . O
or . . O
renal . . O
impairment . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
) . . O
] . . O
. . . O

monitor . . O
with . . O
electrocardiograms . . O
and . . O
electrolytes . . O
in . . O
patients . . O
who . . O
have . . O
a . . O
history . . O
of . . O
or . . O
predisposition . . O
for . . O
qtc . . O
prolongation . . O
, . . O
or . . O
who . . O
are . . O
taking . . O
medications . . O
that . . O
prolong . . O
qt . . O
. . . O

there . . O
was . . O
also . . O
an . . O
increased . . O
incidence . . O
of . . O
pneumonias . . B-AdverseReaction
resulting . . O
in . . O
hospitalization . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction

post . . O
- . . O
marketing . . O
cases . . O
of . . O
a . . O
symptom . . O
complex . . O
resembling . . O
neuroleptic . . B-AdverseReaction
malignant . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
nms . . B-AdverseReaction
) . . O
have . . O
been . . O
reported . . O
with . . O
northera . . O
use . . O
during . . O
post . . O
- . . O
marketing . . O
surveillance . . O
in . . O
japan . . O
. . . O

6.6 . . O
postmarketing . . O
experience . . O

psoriatic . . O
arthritis . . O
clinical . . O
trials . . O
otezla . . O
was . . O
evaluated . . O
in . . O
3 . . O
multicenter . . O
, . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
[ . . O
studies . . O
psa . . O
- . . O
1 . . O
, . . O
psa . . O
- . . O
2 . . O
, . . O
and . . O
psa . . O
- . . O
3 . . O
] . . O
of . . O
similar . . O
design . . O
in . . O
adult . . O
patients . . O
with . . O
active . . O
psoriatic . . O
arthritis . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

the . . O
adverse . . O
events . . O
for . . O
patients . . O
with . . O
severe . . O
hypertension . . O
are . . O
based . . O
on . . O
an . . O
uncontrolled . . O
study . . O
in . . O
patients . . O
with . . O
severe . . O
hypertension . . O
( . . O
velocity . . O
, . . O
n . . O
= . . O
126 . . O
) . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
less . . O
than . . O
1% . . O
of . . O
patients . . O
treated . . O
with . . O
blincyto . . O
tested . . O
positive . . O
for . . O
binding . . O
anti . . O
- . . O
blinatumomab . . O
antibodies . . O
. . . O

exclude . . O
other . . O
potential . . O
causes . . O
of . . O
ild . . O
/ . . O
pneumonitis . . O
, . . O
and . . O
permanently . . O
discontinue . . O
xalkori . . O
in . . O
patients . . O
diagnosed . . O
with . . O
drug . . O
- . . O
related . . O
ild . . O
/ . . O
pneumonitis . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

bosulif . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

baseline . . O
estimated . . O
renal . . O
function . . O
was . . O
normal . . O
or . . O
mildly . . O
impaired . . O
( . . O
egfr . . O
> . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
in . . O
92% . . O
of . . O
the . . O
population . . O
and . . O
moderately . . O
impaired . . O
( . . O
egfr . . O
30 . . O
to . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
in . . O
8% . . O
of . . O
the . . O
population . . O
. . . O

discontinue . . O
gilotrif . . O
if . . O
ild . . O
is . . O
diagnosed . . O
. . . O

beta2 . . B-DrugClass
- . . I-DrugClass
agonist . . I-DrugClass
medications . . O
may . . O
produce . . O
significant . . B-Severity
hypokalemia . . B-AdverseReaction
in . . O
some . . O
patients . . O
, . . O
possibly . . O
through . . O
intracellular . . O
shunting . . O
, . . O
which . . O
has . . O
the . . O
potential . . O
to . . O
produce . . O
adverse . . B-AdverseReaction
cardiovascular . . I-AdverseReaction
effects . . I-AdverseReaction
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

( . . O
2.1 . . O
) . . O
( . . O
5.2 . . O
) . . O
* . . O
contraindicated . . O
if . . O
history . . O
of . . O
severe . . O
hypersensitivity . . O
reactions . . O
to . . O
jevtana . . O
or . . O
to . . O
drugs . . O
formulated . . O
with . . O
polysorbate . . O
80 . . O
. . . O

similar . . O
to . . O
the . . O
controlled . . O
studies . . O
, . . O
most . . O
adverse . . O
events . . O
of . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
and . . O
constipation . . B-AdverseReaction
were . . O
mild . . B-Severity
to . . I-Severity
moderate . . I-Severity
in . . O
intensity . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

. . . O

the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
( . . O
> . . O
20% . . O
) . . O
reported . . O
in . . O
the . . O
two . . O
randomized . . O
clinical . . O
trials . . O
that . . O
occurred . . O
more . . O
commonly . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
in . . O
the . . O
abiraterone . . O
acetate . . O
arm . . O
were . . O
anemia . . B-AdverseReaction
, . . O
elevated . . B-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
, . . O
hypertriglyceridemia . . B-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
hypercholesterolemia . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
elevated . . B-AdverseReaction
ast . . I-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
, . . O
elevated . . B-AdverseReaction
alt . . I-AdverseReaction
and . . O
hypokalemia . . B-AdverseReaction
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
event . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
any . . O
other . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

in . . O
those . . O
patients . . O
treated . . O
with . . O
horizant . . O
who . . O
reported . . O
dizziness . . B-AdverseReaction
, . . O
symptoms . . O
persisted . . O
during . . O
treatment . . O
in . . O
about . . O
20% . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

there . . O
may . . O
be . . O
new . . O
information . . O
. . . O

in . . O
the . . O
clinical . . O
trials . . O
, . . O
2 . . O
subjects . . O
who . . O
received . . O
placebo . . O
committed . . O
suicide . . B-AdverseReaction
compared . . O
to . . O
none . . B-Negation
in . . O
otezla . . O
- . . O
treated . . O
subjects . . O
. . . O

potiga . . O
should . . O
only . . O
be . . O
used . . O
in . . O
patients . . O
who . . O
have . . O
responded . . O
inadequately . . O
to . . O
several . . O
alternative . . O
treatments . . O
and . . O
for . . O
whom . . O
the . . O
benefits . . O
outweigh . . O
the . . O
potential . . O
risk . . O
of . . O
vision . . O
loss . . O
. . . O

5.5 . . O
urinary . . O
tract . . O
infections . . O

marked . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
, . . O
pre . . B-AdverseReaction
- . . I-AdverseReaction
renal . . I-AdverseReaction
azotemia . . I-AdverseReaction
and . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
often . . O
in . . O
the . . O
setting . . O
of . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
or . . O
hypovolemia . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
multaq . . O
. . . O

warning . . O
: . . O
( . . O
a . . O
) . . O
premature . . O
discontinuation . . O
of . . O
eliquis . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . B-AdverseReaction
hematoma . . I-AdverseReaction

serious . . O
adverse . . O
reactions . . O
and . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O

* . . O
severe . . B-Severity
or . . O
persistent . . B-Severity
gastrointestinal . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
hepatotoxicity . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
/ . . O
pneumonitis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
qt . . B-AdverseReaction
interval . . I-AdverseReaction
prolongation . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
* . . O
hyperglycemia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
bradycardia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
* . . O
pancreatitis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
of . . O
at . . O
least . . O
25% . . O
) . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
and . . O
constipation . . B-AdverseReaction
. . . O

dose . . O
- . . O
related . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
ldl . . I-AdverseReaction
- . . I-AdverseReaction
c . . I-AdverseReaction
occur . . O
with . . O
invokana . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

serious . . O
infections . . O

most . . O
common . . O
adverse . . O
reactions . . O

5.3 . . O
skin . . O
discoloration . . O

5.12 . . O
suicide . . O

adverse . . O
reactions . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
and . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
with . . O
> . . O
= . . O
2% . . O
incidence . . O
in . . O
subjects . . O
with . . O
asthma . . O
( . . O
trial . . O
2 . . O
) . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
spectrum . . O
pharmaceuticals . . O
, . . O
inc . . O
. . . O
at . . O
1-888-292-9617 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

( . . O
6.1 . . O
) . . O

furthermore . . O
, . . O
crim . . O
- . . O
negative . . O
infants . . O
have . . O
shown . . O
reduced . . O
clinical . . O
effect . . O
in . . O
the . . O
presence . . O
of . . O
high . . B-Severity
sustained . . I-Severity
igg . . B-AdverseReaction
antibody . . I-AdverseReaction
titers . . I-AdverseReaction
with . . I-AdverseReaction
inhibitory . . I-AdverseReaction
activity . . I-AdverseReaction
. . . O

in . . O
patients . . O
with . . O
chronically . . O
reduced . . O
renal . . O
function . . O
, . . O
acute . . B-AdverseReaction
kidney . . I-AdverseReaction
injury . . I-AdverseReaction
requiring . . O
dialysis . . O
has . . O
occurred . . O
with . . O
the . . O
use . . O
of . . O
gbcas . . B-DrugClass
. . . O

in . . O
total . . O
, . . O
536 . . O
( . . O
approximately . . O
75% . . O
) . . O
patients . . O
increased . . O
their . . O
dose . . O
to . . O
200 . . O
mg . . O
and . . O
5 . . O
( . . O
less . . O
than . . O
1% . . O
) . . O
patients . . O
reduced . . O
their . . O
dose . . O
to . . O
50 . . O
mg . . O
. . . O

avoid . . O
co . . O
- . . O
administration . . O
of . . O
strong . . O
cyp3a4 . . O
inducers . . O
, . . O
such . . O
as . . O
rifamycins . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
rifampin . . O
, . . O
rifapentine . . O
and . . O
rifabutin . . O
) . . O
, . . O
or . . O
moderate . . O
cyp3a4 . . O
inducers . . O
, . . O
such . . O
as . . O
efavirenz . . O
, . . O
during . . O
treatment . . O
with . . O
sirturo . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

exposure . . O
to . . O
everolimus . . O
was . . O
increased . . O
in . . O
patients . . O
with . . O
hepatic . . B-AdverseReaction
impairment . . I-AdverseReaction
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

the . . O
impact . . O
of . . O
discontinuation . . O
of . . O
androgen . . O
- . . O
deprivation . . O
therapy . . O
upon . . O
11 . . O
c . . O
- . . O
choline . . O
pet . . O
imaging . . O
has . . O
not . . O
been . . O
established . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7 . . O
) . . O
] . . O
. . . O

in . . O
developmental . . O
toxicity . . O
studies . . O
in . . O
mice . . B-Animal
, . . O
axitinib . . O
was . . O
teratogenic . . B-AdverseReaction
, . . O
embryotoxic . . B-AdverseReaction
and . . O
fetotoxic . . B-AdverseReaction
at . . O
maternal . . O
exposures . . O
that . . O
were . . O
lower . . O
than . . O
human . . O
exposures . . O
at . . O
the . . O
recommended . . O
clinical . . O
dose . . O
. . . O

clinical . . O
surveillance . . O
of . . O
all . . O
women . . O
taking . . O
duavee . . O
is . . O
important . . O
. . . O

if . . O
you . . O
are . . O
not . . O
sure . . O
about . . O
your . . O
dosing . . O
, . . O
call . . O
your . . O
healthcare . . O
provider . . O
. . . O

changes . . O
in . . O
serum . . O
creatinine . . O

the . . O
reduction . . O
in . . O
clinical . . O
cure . . O
rates . . O
was . . O
more . . O
marked . . O
in . . O
the . . O
zerbaxa . . O
plus . . O
metronidazole . . O
arm . . O
compared . . O
to . . O
the . . O
meropenem . . O
arm . . O
. . . O

periodic . . O
skin . . O
examination . . O
is . . O
recommended . . O
for . . O
all . . O
patients . . O
, . . O
particularly . . O
those . . O
with . . O
risk . . O
factors . . O
for . . O
skin . . O
cancer . . O
. . . O

cervical . . O
dystonia . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

adverse . . O
reactions . . O
of . . O
any . . O
cause . . O
occurred . . O
in . . O
48% . . O
of . . O
the . . O
dysport . . O
( . . O
r . . O
) . . O
- . . O
treated . . O
patients . . O
and . . O
33% . . O
of . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
label . . O
: . . O

overall . . O
, . . O
abnormalities . . O
in . . O
liver . . O
tests . . O
( . . O
alt . . O
, . . O
ast . . O
, . . O
bilirubin . . O
) . . O
were . . O
reported . . O
with . . O
similar . . O
frequency . . O
in . . O
the . . O
dalvance . . O
and . . O
comparator . . O
arms . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

an . . O
increased . . O
risk . . B-Factor
of . . O
bone . . B-AdverseReaction
fracture . . I-AdverseReaction
, . . O
occurring . . O
as . . O
early . . O
as . . O
12 . . O
weeks . . O
after . . O
treatment . . O
initiation . . O
, . . O
was . . O
observed . . O
in . . O
patients . . O
using . . O
invokana . . O
. . . O

features . . O
of . . O
acute . . O
kidney . . O
injury . . O
consist . . O
of . . O
rapid . . O
( . . O
over . . O
hours . . O
to . . O
days . . O
) . . O
and . . O
usually . . O
reversible . . O
decrease . . O
in . . O
kidney . . O
function . . O
, . . O
commonly . . O
in . . O
the . . O
setting . . O
of . . O
surgery . . O
, . . O
severe . . O
infection . . O
, . . O
injury . . O
or . . O
drug . . O
- . . O
induced . . O
kidney . . O
toxicity . . O
. . . O

* . . O
use . . O
in . . O
elderly . . O
patients . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
at . . O
an . . O
incidence . . O
of . . O
2% . . O
or . . O
more . . O
in . . O
saphris . . O
- . . O
treated . . O
patients . . O
with . . O
schizophrenia . . O
: . . O
adverse . . O
reactions . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
saphris . . O
( . . O
incidence . . O
of . . O
2% . . O
or . . O
greater . . O
, . . O
rounded . . O
to . . O
the . . O
nearest . . O
percent . . O
, . . O
and . . O
saphris . . O
incidence . . O
greater . . O
than . . O
placebo . . O
) . . O
that . . O
occurred . . O
during . . O
acute . . O
therapy . . O
( . . O
up . . O
to . . O
6 . . O
- . . O
weeks . . O
in . . O
patients . . O
with . . O
schizophrenia . . O
) . . O
are . . O
shown . . O
in . . O
table . . O
8 . . O
. . . O

6 . . O
adverse . . O
reactions . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
infrequent . . O
- . . O
increased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
dehydration . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
fluid . . B-AdverseReaction
retention . . I-AdverseReaction

fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
cases . . O
of . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
have . . O
occurred . . O
with . . O
imbruvica . . O
therapy . . O
. . . O

the . . O
safety . . O
assessment . . O
in . . O
children . . O
and . . O
adolescents . . O
is . . O
based . . O
on . . O
the . . O
week . . O
24 . . O
analysis . . O
of . . O
the . . O
single . . O
- . . O
arm . . O
, . . O
phase . . O
2 . . O
trial . . O
tmc125 . . O
- . . O
c213 . . O
in . . O
which . . O
101 . . O
antiretroviral . . O
treatment . . O
- . . O
experienced . . O
hiv . . O
- . . O
1 . . O
infected . . O
subjects . . O
6 . . O
years . . O
to . . O
less . . O
than . . O
18 . . O
years . . O
of . . O
age . . O
and . . O
weighing . . O
at . . O
least . . O
16 . . O
kg . . O
received . . O
intelence . . O
( . . O
r . . O
) . . O
in . . O
combination . . O
with . . O
other . . O
antiretroviral . . O
agents . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
] . . O
. . . O

appropriate . . O
care . . O
is . . O
advised . . O
when . . O
prescribing . . O
fanapt . . O
for . . O
patients . . O
who . . O
will . . O
be . . O
experiencing . . O
conditions . . O
which . . O
may . . O
contribute . . O
to . . O
an . . O
elevation . . O
in . . O
core . . O
body . . O
temperature . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
exercising . . O
strenuously . . O
, . . O
exposure . . O
to . . O
extreme . . O
heat . . O
, . . O
receiving . . O
concomitant . . O
medication . . O
with . . O
anticholinergic . . O
activity . . O
, . . O
or . . O
being . . O
subject . . O
to . . O
dehydration . . O
. . . O

excerpt . . O
: . . O
* . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
has . . O
occurred . . O
in . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
gbcas . . O
. . . O

monitor . . O
patients . . O
with . . O
advanced . . O
stage . . O
disease . . O
and . . O
/ . . O
or . . O
high . . O
tumor . . O
burden . . O
and . . O
take . . O
appropriate . . O
precautions . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

5.6 . . O
respiratory . . O
effects . . O

after . . O
initiation . . O
of . . O
tanzeum . . O
, . . O
observe . . O
patients . . O
carefully . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
pancreatitis . . O
( . . O
including . . O
persistent . . O
severe . . O
abdominal . . O
pain . . O
, . . O
sometimes . . O
radiating . . O
to . . O
the . . O
back . . O
and . . O
which . . O
may . . O
or . . O
may . . O
not . . O
be . . O
accompanied . . O
by . . O
vomiting . . O
) . . O
. . . O

monitor . . O
with . . O
periodic . . O
liver . . O
testing . . O
. . . O

to . . O
kalbitor . . O
[ . . O

adverse . . O
reactions . . O
reported . . O
as . . O
reasons . . O
for . . O
discontinuation . . O
of . . O
treatment . . O

( . . O
asenapine . . O
) . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

failure . . O
to . . O
block . . O
thyroid . . O
uptake . . O
of . . O
iodine . . O
123 . . O
may . . O
result . . O
in . . O
an . . O
increased . . O
long . . O
term . . O
risk . . O
for . . O
thyroid . . O
neoplasia . . O
. . . O

prolonged . . O
use . . O
of . . O
corticosteroids . . B-DrugClass
may . . O
result . . O
in . . O
glaucoma . . B-AdverseReaction
with . . O
damage . . B-AdverseReaction
to . . I-AdverseReaction
the . . I-AdverseReaction
optic . . I-AdverseReaction
nerve . . I-AdverseReaction
, . . O
defects . . B-AdverseReaction
in . . I-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
and . . O
fields . . O
of . . O
vision . . O
. . . O

samples . . O
from . . O
6 . . O
patients . . O
with . . O
confirmed . . O
binding . . O
activity . . O
to . . O
the . . O
modified . . O
cytotoxic . . O
t . . O
- . . O
lymphocyte . . O
- . . O
associated . . O
antigen . . O
4 . . O
( . . O
ctla . . O
- . . O
4 . . O
) . . O
region . . O
of . . O
the . . O
belatacept . . O
molecule . . O
were . . O
assessed . . O
by . . O
an . . O
in . . O
vitro . . O
bioassay . . O
for . . O
the . . O
presence . . O
of . . O
neutralizing . . O
antibodies . . O
. . . O

therefore . . O
, . . O
avoid . . O
the . . O
use . . O
of . . O
strong . . O
cyp3a4 . . O
inhibitors . . O
for . . O
more . . O
than . . O
14 . . O
consecutive . . O
days . . O
while . . O
on . . O
sirturo . . O
, . . O
unless . . O
the . . O
benefit . . O
of . . O
treatment . . O
with . . O
the . . O
drug . . O
combination . . O
outweighs . . O
the . . O
risk . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
pleural . . B-AdverseReaction
effusion . . I-AdverseReaction
; . . O
0.1% . . O
and . . O
less . . O
than . . O
1% . . O
- . . O
acute . . B-AdverseReaction
pulmonary . . I-AdverseReaction
edema . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
hypertension . . I-AdverseReaction

chronic . . O
hepatitis . . O
c . . O
- . . O
associated . . O
thrombocytopenia . . O
: . . O
in . . O
the . . O
two . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
955 . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
- . . O
associated . . O
thrombocytopenia . . O
received . . O
promacta . . O
. . . O

if . . O
adequate . . O
hyperglycemic . . O
control . . O
cannot . . O
be . . O
achieved . . O
with . . O
optimal . . O
medical . . O
management . . O
, . . O
permanently . . O
discontinue . . O
zykadia . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

especially . . O
tell . . O
your . . O
healthcare . . O
provider . . O
if . . O
you . . O
take . . O
other . . O
hormonal . . O
medicines . . O
, . . O
including . . O
progestins . . O
or . . O
other . . O
medicines . . O
like . . O
duavee . . O
. . . O

tables . . O
1 . . O
and . . O
2 . . O
show . . O
the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
3% . . O
) . . O
in . . O
adults . . O
and . . O
children . . O
respectively . . O
who . . O
received . . O
the . . O
6 . . O
- . . O
dose . . O
regimen . . O
of . . O
coartem . . O
tablets . . O
. . . O

elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
treated . . O
with . . O
antipsychotic . . B-DrugClass
drugs . . I-DrugClass
are . . O
at . . O
an . . O
increased . . O
risk . . O
of . . O
death . . B-AdverseReaction
. . . O

cases . . O
of . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
congenital . . I-AdverseReaction
lens . . I-AdverseReaction
opacities . . I-AdverseReaction
/ . . O
cataracts . . O
have . . O
been . . O
reported . . O
in . . O
pediatric . . O
patients . . O
treated . . O
with . . O
kalydeco . . O
. . . O

similar . . O
adverse . . O
reactions . . O
have . . O
been . . O
observed . . O
in . . O
postmarketing . . O
use . . O
as . . O
compared . . O
to . . O
the . . O
clinical . . O
trials . . O
. . . O

consider . . O
the . . O
potential . . O
for . . O
an . . O
increased . . O
risk . . O
of . . O
thromboembolism . . O
when . . O
administering . . O
promacta . . O
to . . O
patients . . O
with . . O
known . . O
risk . . O
factors . . O
for . . O
thromboembolism . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
factor . . O
v . . O
leiden . . O
, . . O
atiii . . O
deficiency . . O
, . . O
antiphospholipid . . O
syndrome . . O
, . . O
chronic . . O
liver . . O
disease . . O
) . . O
. . . O

evaluate . . O
dyspnea . . O
to . . O
exclude . . O
cardiopulmonary . . O
conditions . . O
including . . O
cardiac . . O
failure . . O
and . . O
pulmonary . . O
syndromes . . O
. . . O

somnolence . . B-AdverseReaction
includes . . O
the . . O
following . . O
events . . O
: . . O
somnolence . . B-AdverseReaction
, . . O
sedation . . B-AdverseReaction
, . . O
and . . O
hypersomnia . . B-AdverseReaction
. . . O

most . . O
of . . O
the . . O
adverse . . O
reactions . . O
appear . . O
to . . O
be . . O
dose . . O
related . . O
( . . O
especially . . O
those . . O
classified . . O
as . . O
psychiatric . . O
and . . O
nervous . . O
system . . O
symptoms . . O
) . . O
, . . O
including . . O
dizziness . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
, . . O
tremor . . B-AdverseReaction
, . . O
abnormal . . B-AdverseReaction
coordination . . I-AdverseReaction
, . . O
memory . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
, . . O
aphasia . . B-AdverseReaction
, . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
dysuria . . B-AdverseReaction
, . . O
and . . O
chromaturia . . B-AdverseReaction
. . . O

( . . O
5.8 . . O
) . . O
* . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
: . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
qt . . I-AdverseReaction
interval . . I-AdverseReaction
; . . O
avoid . . O
use . . O
with . . O
drugs . . O
that . . O
also . . O
increase . . O
the . . O
qt . . O
interval . . O
and . . O
in . . O
patients . . O
with . . O
risk . . O
factors . . O
for . . O
prolonged . . O
qt . . O
interval . . O
. . . O

the . . O
risk . . O
of . . O
developing . . O
tardive . . O
dyskinesia . . O
and . . O
the . . O
likelihood . . O
that . . O
it . . O
will . . O
become . . O
irreversible . . O
are . . O
believed . . O
to . . O
increase . . O
as . . O
the . . O
duration . . O
of . . O
treatment . . O
and . . O
the . . O
total . . O
cumulative . . O
dose . . O
of . . O
antipsychotic . . O
administered . . O
increases . . O
. . . O

nervous . . O
system . . O
disorders . . O
: . . O
cerebellar . . B-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
cerebral . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
convulsion . . B-AdverseReaction
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
, . . O
intracranial . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
psychomotor . . B-AdverseReaction
skills . . I-AdverseReaction
impaired . . I-AdverseReaction
, . . O
pyramidal . . B-AdverseReaction
tract . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
. . . O

saphris . . O
is . . O
not . . O
indicated . . O
for . . O
the . . O
treatment . . O
of . . O
dementia . . O
- . . O
related . . O
psychosis . . O
, . . O
and . . O
should . . O
not . . O
be . . O
used . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
aspiration . . O
pneumonia . . O
[ . . O
see . . O
also . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
cardiovascular . . O
or . . O
convulsive . . O
disorders . . O
, . . O
thyrotoxicosis . . O
or . . O
sensitivity . . O
to . . O
sympathomimetic . . O
drugs . . O
. . . O

monitor . . O
blood . . O
pressure . . O
during . . O
and . . O
following . . O
the . . O
treatment . . O
procedure . . O
. . . O

lymphoma . . B-AdverseReaction
and . . O
other . . O
malignancies . . B-AdverseReaction
, . . O
some . . O
fatal . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
children . . O
and . . O
adolescent . . O
patients . . O
treated . . O
with . . O
tnf . . O
blockers . . O
, . . O
of . . O
which . . O
simponi . . O
aria . . O
is . . O
a . . O
member . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

the . . O
following . . O
important . . O
adverse . . O
reactions . . O
are . . O
described . . O
elsewhere . . O
in . . O
labeling . . O
: . . O

hyperglycemia . . O
, . . O
in . . O
some . . O
cases . . O
extreme . . B-Severity
and . . O
associated . . O
with . . O
ketoacidosis . . B-AdverseReaction
or . . O
hyperosmolar . . B-AdverseReaction
coma . . I-AdverseReaction
or . . O
death . . B-AdverseReaction
, . . O
has . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
atypical . . B-DrugClass
antipsychotics . . I-DrugClass
. . . O

the . . O
common . . O
adverse . . O
reactions . . O
for . . O
cleviprex . . O
in . . O
severe . . O
hypertension . . O
included . . O
headache . . B-AdverseReaction
( . . O
6.3% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
4.8% . . O
) . . O
, . . O
and . . O
vomiting . . B-AdverseReaction
( . . O
3.2% . . O
) . . O
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
agranulocytosis . . B-AdverseReaction
. . . O

an . . O
increased . . O
risk . . O
of . . O
endometrial . . B-AdverseReaction
cancer . . I-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
the . . O
use . . O
of . . O
unopposed . . O
estrogen . . B-DrugClass
therapy . . O
in . . O
women . . O
with . . O
a . . O
uterus . . O
. . . O

permanently . . O
discontinue . . O
xtandi . . O
in . . O
patients . . O
who . . O
develop . . O
a . . O
seizure . . O
during . . O
treatment . . O
. . . O

the . . O
patients . . O
were . . O
also . . O
not . . O
taking . . O
any . . O
immunosuppressive . . O
or . . O
immunomodulatory . . O
medications . . O
concomitantly . . O
. . . O

elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
treated . . O
with . . O
atypical . . B-DrugClass
antipsychotic . . I-DrugClass
drugs . . I-DrugClass
are . . O
at . . O
an . . O
increased . . O
risk . . O
of . . O
death . . B-AdverseReaction
compared . . O
to . . O
placebo . . O
. . . O

in . . O
clinical . . O
studies . . O
with . . O
kyprolis . . O
, . . O
these . . O
events . . O
typically . . O
occurred . . O
early . . O
in . . O
the . . O
course . . O
of . . O
kyprolis . . O
therapy . . O
( . . O
< . . O
5 . . O
cycles . . O
) . . O
. . . O

table . . O
1 . . O
. . . O

table . . O
2 . . O
: . . O
incidence . . O
( . . O
% . . O
) . . O
of . . O
documented . . O
symptomatic . . O
and . . O
severe . . B-Severity
hypoglycemia . . B-AdverseReaction
adverse . . O
reactions . . O
in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
placebo . . O
trulicity . . O
0.75 . . O
mg . . O
trulicity . . O
1.5 . . O
mg . . O
add . . O
- . . O
on . . O
to . . O
metformin . . O
( . . O
26 . . O
weeks . . O
) . . O
n . . O
= . . O
177 . . O
n . . O
= . . O
302 . . O
n . . O
= . . O
304 . . O
documented . . O
symptomatic . . O
1.1% . . O
2.6% . . O
5.6% . . O
severe . . O
0 . . O
0 . . O
0 . . O
add . . O
- . . O
on . . O
to . . O
metformin . . O
+ . . O
pioglitazone . . O
( . . O
26 . . O
weeks . . O
) . . O
n . . O
= . . O
141 . . O
n . . O
= . . O
280 . . O
n . . O
= . . O
279 . . O
documented . . O
symptomatic . . O
1.4% . . O
4.6% . . O
5.0% . . O
severe . . O
0 . . O
0 . . O
0 . . O
hypoglycemia . . B-AdverseReaction
was . . O
more . . O
frequent . . O
when . . O
trulicity . . O
was . . O
used . . O
in . . O
combination . . O
with . . O
a . . O
sulfonylurea . . O
or . . O
insulin . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

( . . O
5.1 . . O
, . . O
6.1 . . O
) . . O
* . . O
impairment . . B-AdverseReaction
in . . I-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
: . . O
monitor . . O
renal . . O
function . . O
during . . O
therapy . . O
. . . O

dysport . . O
( . . O
r . . O
) . . O
is . . O
approved . . O
only . . O
for . . O
intramuscular . . O
injection . . O
. . . O

table . . O
3 . . O
. . . O

treatment . . O
- . . O
emergent . . O
laboratory . . O
abnormalities . . O
occurring . . O
at . . O
> . . O
= . . O
10% . . O
( . . O
all . . O
grades . . O
) . . O
or . . O
> . . O
= . . O
2% . . O
( . . O
grades . . O
3 . . O
or . . O
4 . . O
) . . O
] . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
in . . O
trial . . O
2 . . O
tests . . O
tafinlar . . O
plus . . O
trametinib . . O
2 . . O
mg . . O
n . . O
= . . O
55 . . O
tafinlar . . O
plus . . O
trametinib . . O
1 . . O
mg . . O
n . . O
= . . O
54 . . O
tafinlar . . O
n . . O
= . . O
53 . . O
all . . O
grades . . O
grades . . O
3 . . O
and . . O
4 . . O
all . . O
grades . . O
grades . . O
3 . . O
and . . O
4 . . O
all . . O
grades . . O
grades . . O
3 . . O
and . . O
4a . . O
hematology . . O
leukopenia . . B-AdverseReaction
62 . . O
5 . . O
46 . . O
4 . . O
21 . . O
0 . . O
lymphopenia . . B-AdverseReaction
55 . . O
22 . . O
59 . . O
19 . . O
40 . . O
6 . . O
neutropenia . . B-AdverseReaction
55 . . O
13 . . O
37 . . O
2 . . O
9 . . O
2 . . O
anemia . . B-AdverseReaction
55 . . O
4 . . O
46 . . O
7 . . O
28 . . O
0 . . O
thrombocytopenia . . B-AdverseReaction
31 . . O
4 . . O
31 . . O
2 . . O
8 . . O
0 . . O
liver . . O
function . . O
tests . . O
increased . . B-AdverseReaction
ast . . I-AdverseReaction
60 . . O
5 . . O
54 . . O
0 . . O
15 . . O
0 . . O
increased . . B-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
60 . . O
2 . . O
67 . . O
6 . . O
26 . . O
2 . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
42 . . O
4 . . O
35 . . O
4 . . O
11 . . O
0 . . O
hyperbilirubinemia . . B-AdverseReaction
15 . . O
0 . . O
7 . . O
4 . . O
0 . . O
0 . . O
chemistry . . O
hyperglycemia . . B-AdverseReaction
58 . . O
5 . . O
67 . . O
6 . . O
49 . . O
2 . . O
increased . . B-AdverseReaction
ggt . . I-AdverseReaction
56 . . O
11 . . O
54 . . O
17 . . O
38 . . O
2 . . O
hyponatremia . . B-AdverseReaction
55 . . O
11 . . O
48 . . O
15 . . O
36 . . O
2 . . O
hypoalbuminemia . . B-AdverseReaction
53 . . O
0 . . O
43 . . O
2 . . O
23 . . O
0 . . O
hypophosphatemia . . B-AdverseReaction
47 . . O
5 . . O
41 . . O
11 . . O
40 . . O
0 . . O
hypokalemia . . B-AdverseReaction
29 . . O
2 . . O
15 . . O
2 . . O
23 . . O
6 . . O
increased . . B-AdverseReaction
creatinine . . I-AdverseReaction
24 . . O
5 . . O
20 . . O
2 . . O
9 . . O
0 . . O
hypomagnesemia . . B-AdverseReaction
18 . . O
2 . . O
2 . . O
0 . . O
6 . . O
0 . . O
hyperkalemia . . B-AdverseReaction
18 . . O
0 . . O
22 . . O
0 . . O
15 . . O
4 . . O
hypercalcemia . . B-AdverseReaction
15 . . O
0 . . O
19 . . O
2 . . O
4 . . O
0 . . O
hypocalcemia . . B-AdverseReaction
13 . . O
0 . . O
20 . . O
0 . . O
9 . . O
0 . . O
a . . O
no . . O
grade . . O
4 . . O
events . . O
were . . O
reported . . O
in . . O
patients . . O
receiving . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

( . . O
6.1 . . O
) . . O

the . . O
incidence . . O
of . . O
grade . . O
> . . O
= . . O
3 . . O
hemorrhagic . . B-AdverseReaction
events . . I-AdverseReaction
was . . O
higher . . O
in . . O
cometriq . . O
- . . O
treated . . O
patients . . O
compared . . O
with . . O
placebo . . O
( . . O
3% . . O
vs . . O
. . . O
1% . . O
) . . O
. . . O

at . . O
baseline . . O
, . . O
the . . O
population . . O
had . . O
diabetes . . O
for . . O
an . . O
average . . O
of . . O
11 . . O
years . . O
, . . O
had . . O
a . . O
mean . . O
hba1c . . O
of . . O
8.0% . . O
and . . O
33% . . O
had . . O
established . . O
microvascular . . O
complications . . O
of . . O
diabetes . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
constipation . . B-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
, . . O
peptic . . B-AdverseReaction
ulcer . . I-AdverseReaction

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
5.2 . . O
) . . O

in . . O
study . . O
1 . . O
and . . O
study . . O
2 . . O
, . . O
safety . . O
information . . O
was . . O
prospectively . . O
and . . O
systematically . . O
collected . . O
. . . O

the . . O
population . . O
had . . O
a . . O
mean . . O
age . . O
of . . O
64 . . O
years . . O
( . . O
ranging . . O
from . . O
40 . . O
to . . O
89 . . O
years . . O
) . . O
, . . O
with . . O
58% . . O
males . . O
, . . O
94% . . O
caucasian . . O
, . . O
and . . O
had . . O
copd . . O
with . . O
a . . O
mean . . O
pre . . O
- . . O
bronchodilator . . O
forced . . O
expiratory . . O
volume . . O
in . . O
one . . O
second . . O
( . . O
fev1 . . O
) . . O
percent . . O
predicted . . O
of . . O
48% . . O
. . . O

the . . O
median . . O
time . . O
from . . O
onset . . O
to . . O
resolution . . O
or . . O
improvement . . O
of . . O
any . . O
grade . . O
was . . O
23 . . O
weeks . . O
( . . O
range . . O
, . . O
0.1-138 . . O
) . . O
, . . O
of . . O
grade . . O
2 . . O
was . . O
24 . . O
weeks . . O
( . . O
range . . O
, . . O
1-108 . . O
) . . O
and . . O
of . . O
grade . . O
3 . . O
was . . O
25 . . O
weeks . . O
( . . O
range . . O
, . . O
2-98 . . O
) . . O
. . . O

arcapta . . O
neohaler . . O
is . . O
not . . O
indicated . . O
for . . O
the . . O
treatment . . O
of . . O
asthma . . O
. . . O

neoplasm . . O
benign . . O
and . . O
malignant . . O
: . . O
melanoma . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
in . . O
adults . . O
( . . O
> . . O
30% . . O
) . . O
are . . O
headache . . B-AdverseReaction
, . . O
anorexia . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
and . . O
myalgia . . B-AdverseReaction
. . . O

three . . O
cases . . O
of . . O
priapism . . B-AdverseReaction
were . . O
reported . . O
in . . O
the . . O
premarketing . . O
fanapt . . O
program . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
infrequent . . O
- . . O
gastritis . . B-AdverseReaction
, . . O
salivary . . B-AdverseReaction
hypersecretion . . I-AdverseReaction
, . . O
fecal . . B-AdverseReaction
incontinence . . I-AdverseReaction
, . . O
mouth . . B-AdverseReaction
ulceration . . I-AdverseReaction
; . . O
rare . . O
- . . O
aphthous . . B-AdverseReaction
stomatitis . . I-AdverseReaction
, . . O
duodenal . . B-AdverseReaction
ulcer . . I-AdverseReaction
, . . O
hiatus . . B-AdverseReaction
hernia . . I-AdverseReaction
, . . O
hyperchlorhydria . . B-AdverseReaction
, . . O
lip . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
reflux . . B-AdverseReaction
esophagitis . . I-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction

overall . . O
, . . O
177 . . O
patients . . O
were . . O
enrolled . . O
into . . O
the . . O
study . . O
and . . O
received . . O
ilaris . . O
4 . . O
mg . . O
/ . . O
kg . . O
( . . O
up . . O
to . . O
300 . . O
mg . . O
maximum . . O
) . . O
in . . O
part . . O
i . . O
, . . O
and . . O
100 . . O
patients . . O
received . . O
ilaris . . O
4 . . O
mg . . O
/ . . O
kg . . O
( . . O
up . . O
to . . O
300 . . O
mg . . O
maximum . . O
) . . O
every . . O
4 . . O
weeks . . O
or . . O
placebo . . O
in . . O
part . . O
ii . . O
. . . O

the . . O
onset . . O
of . . O
vision . . B-AdverseReaction
disorder . . I-AdverseReaction
generally . . O
was . . O
within . . O
the . . O
first . . O
week . . O
of . . O
drug . . O
administration . . O
. . . O

the . . O
risk . . O
of . . O
thromboembolic . . B-AdverseReaction
disease . . I-AdverseReaction
due . . O
to . . O
oral . . B-DrugClass
contraceptives . . I-DrugClass
gradually . . O
disappears . . O
after . . O
coc . . O
use . . O
is . . O
discontinued . . O
. . . O

5.2 . . O
therapeutic . . O
monitoring . . O

( . . O
2.1 . . O
) . . O
monitor . . O
for . . O
tls . . O
, . . O
including . . O
uric . . O
acid . . O
levels . . O
and . . O
treat . . O
promptly . . O
. . . O

there . . O
is . . O
a . . O
potential . . B-Factor
for . . O
cardiac . . B-AdverseReaction
risk . . I-AdverseReaction
during . . O
sexual . . O
activity . . O
in . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
cardiovascular . . O
disease . . O
. . . O

measure . . O
serum . . O
transaminases . . O
( . . O
alt . . O
and . . O
ast . . O
) . . O
and . . O
bilirubin . . O
levels . . O
prior . . O
to . . O
starting . . O
treatment . . O
with . . O
zytiga . . O
, . . O
every . . O
two . . O
weeks . . O
for . . O
the . . O
first . . O
three . . O
months . . O
of . . O
treatment . . O
and . . O
monthly . . O
thereafter . . O
. . . O

the . . O
most . . O
common . . O
reasons . . O
for . . O
dose . . O
reductions . . O
were . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
or . . O
colitis . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
. . . O

in . . O
addition . . O
, . . O
patients . . O
should . . O
be . . O
observed . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
adrenal . . O
insufficiency . . O
, . . O
such . . O
as . . O
fatigue . . O
, . . O
lassitude . . O
, . . O
weakness . . O
, . . O
nausea . . O
and . . O
vomiting . . O
, . . O
and . . O
hypotension . . O
. . . O

hepatobiliary . . O
disorders . . O
: . . O
gallbladder . . B-AdverseReaction
disease . . I-AdverseReaction
, . . O
hepatitis . . B-AdverseReaction

proteinuria . . B-AdverseReaction
( . . O
all . . O
grades . . O
) . . O
occurred . . O
in . . O
52% . . O
of . . O
subjects . . O
receiving . . O
stribild . . O
, . . O
41% . . O
of . . O
subjects . . O
receiving . . O
atripla . . O
, . . O
and . . O
42% . . O
of . . O
subjects . . O
receiving . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
. . . O

if . . O
the . . O
decision . . O
has . . O
been . . O
made . . O
to . . O
discontinue . . O
treatment . . O
, . . O
medication . . O
should . . O
be . . O
tapered . . O
, . . O
as . . O
rapidly . . O
as . . O
is . . O
feasible . . O
, . . O
but . . O
with . . O
recognition . . O
that . . O
abrupt . . O
discontinuation . . O
can . . O
be . . O
associated . . O
with . . O
certain . . O
symptoms . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
for . . O
a . . O
description . . O
of . . O
the . . O
risks . . O
of . . O
discontinuation . . O
of . . O
pristiq . . O
] . . O
. . . O

common . . O
adverse . . O
reactions . . O
in . . O
placebo . . O
- . . O
controlled . . O
mdd . . O
studies . . O

what . . O
is . . O
the . . O
most . . O
important . . O
information . . O
i . . O
should . . O
know . . O
about . . O
duavee . . O
? . . O

evaluate . . O
if . . O
diarrhea . . O
occurs . . O
. . . O

* . . O
fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
pneumonitis . . B-AdverseReaction
can . . O
occur . . O
in . . O
zydelig . . O
- . . O
treated . . O
patients . . O
. . . O

immune . . O
system . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
drug . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
; . . O
0.1% . . O
and . . O
less . . O
than . . O
1% . . O
- . . O
anaphylactic . . B-AdverseReaction
shock . . I-AdverseReaction

across . . O
all . . O
yervoy . . O
- . . O
treated . . O
patients . . O
( . . O
n . . O
= . . O
511 . . O
) . . O
, . . O
5 . . O
( . . O
1% . . O
) . . O
patients . . O
developed . . O
intestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
, . . O
4 . . O
( . . O
0.8% . . O
) . . O
patients . . O
died . . B-AdverseReaction
as . . O
a . . O
result . . O
of . . O
complications . . O
, . . O
and . . O
26 . . O
( . . O
5% . . O
) . . O
patients . . O
were . . O
hospitalized . . O
for . . O
severe . . B-Severity
enterocolitis . . B-AdverseReaction
. . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
were . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
and . . O
pneumonia . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
and . . O
greater . . O
than . . O
control . . O
) . . O
are . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
erythema . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pruritus . . I-AdverseReaction
and . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
papules . . I-AdverseReaction
. . . O

hepatic . . O
: . . O
liver . . B-AdverseReaction
injury . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O

serious . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
occurred . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
patients . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

withhold . . O
or . . O
discontinue . . O
gilotrif . . O
for . . O
severe . . O
or . . O
worsening . . O
liver . . O
tests . . O
. . . O

the . . O
use . . O
of . . O
arcapta . . O
neohaler . . O
in . . O
this . . O
setting . . O
is . . O
inappropriate . . O
. . . O

therefore . . O
, . . O
patients . . O
should . . O
be . . O
monitored . . O
for . . O
decreased . . O
efficacy . . O
and . . O
food . . O
consumption . . O
should . . O
be . . O
encouraged . . O
while . . O
taking . . O
coartem . . O
tablets . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
, . . O
drug . . O
interactions . . O
( . . O
7.4 . . O
) . . O
, . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

tecfidera . . O
can . . B-Factor
cause . . O
anaphylaxis . . B-AdverseReaction
and . . O
angioedema . . B-AdverseReaction
after . . O
the . . O
first . . O
dose . . O
or . . O
at . . O
any . . O
time . . O
during . . O
treatment . . O
. . . O

a . . O
penile . . O
modeling . . O
procedure . . O
was . . O
performed . . O
at . . O
the . . O
study . . O
site . . O
on . . O
patients . . O
1 . . O
to . . O
3 . . O
days . . O
after . . O
the . . O
second . . O
injection . . O
of . . O
the . . O
cycle . . O
. . . O

for . . O
patients . . O
receiving . . O
hemodialysis . . O
, . . O
consider . . O
the . . O
prompt . . O
initiation . . O
of . . O
hemodialysis . . O
following . . O
the . . O
administration . . O
of . . O
a . . O
gbca . . O
in . . O
order . . O
to . . O
enhance . . O
the . . O
contrast . . O
agent's . . O
elimination . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

four . . O
placebo . . O
- . . O
controlled . . O
and . . O
one . . O
active . . O
- . . O
controlled . . O
trials . . O
of . . O
16 . . O
weeks . . O
up . . O
through . . O
two . . O
years . . O
in . . O
duration . . O
were . . O
conducted . . O
in . . O
combination . . O
with . . O
metformin . . O
, . . O
in . . O
combination . . O
with . . O
pioglitazone . . O
and . . O
with . . O
pioglitazone . . O
added . . O
to . . O
a . . O
background . . O
of . . O
metformin . . O
therapy . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
toxicities . . B-AdverseReaction
: . . O
hepatic . . O
, . . O
severe . . B-Severity
diarrhea . . B-AdverseReaction
, . . O
colitis . . B-AdverseReaction
, . . O
pneumonitis . . B-AdverseReaction
, . . O
and . . O
intestinal . . B-AdverseReaction
perforation . . I-AdverseReaction

based . . O
on . . O
the . . O
experience . . O
in . . O
the . . O
entire . . O
clinical . . O
program . . O
for . . O
melanoma . . O
, . . O
the . . O
incidence . . O
and . . O
severity . . O
of . . O
enterocolitis . . B-AdverseReaction
and . . O
hepatitis . . B-AdverseReaction
appear . . O
to . . O
be . . O
dose . . O
dependent . . O
. . . O

the . . O
safety . . O
of . . O
the . . O
combination . . O
of . . O
victrelis . . O
800 . . O
mg . . O
three . . O
times . . O
daily . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
was . . O
assessed . . O
in . . O
2095 . . O
subjects . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
in . . O
one . . O
phase . . O
2 . . O
, . . O
open . . O
- . . O
label . . O
trial . . O
and . . O
two . . O
phase . . O
3 . . O
, . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
. . . O

do . . O
not . . O
administer . . O
beleodaq . . O
to . . O
patients . . O
with . . O
an . . O
active . . O
infection . . O
. . . O

ampyra . . O
can . . B-Factor
cause . . O
anaphylaxis . . B-AdverseReaction
and . . O
severe . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
. . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
neuropathies . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

six . . O
of . . O
these . . O
patients . . O
again . . O
experienced . . O
liver . . O
test . . O
abnormalities . . O
( . . O
predominantly . . O
grade . . B-Severity
1 . . I-Severity
) . . O
resulting . . O
in . . O
discontinuation . . O
of . . O
promacta . . O
in . . O
one . . O
patient . . O
. . . O

chloasma . . B-AdverseReaction
may . . B-Factor
occasionally . . O
occur . . O
, . . O
especially . . O
in . . O
women . . O
with . . O
a . . O
history . . O
of . . O
chloasma . . O
gravidarum . . O
. . . O

these . . O
wound . . O
- . . O
related . . O
complications . . O
may . . O
require . . O
surgical . . O
intervention . . O
. . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
that . . O
led . . O
to . . O
discontinuation . . O
in . . O
gilotrif . . O
- . . O
treated . . O
patients . . O
were . . O
diarrhea . . B-AdverseReaction
( . . O
1.3% . . O
) . . O
, . . O
ild . . B-AdverseReaction
( . . O
0.9% . . O
) . . O
, . . O
and . . O
paronychia . . B-AdverseReaction
( . . O
0.9% . . O
) . . O
. . . O

in . . O
studies . . O
102 . . O
and . . O
103 . . O
, . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
decreases . . B-AdverseReaction
in . . I-AdverseReaction
estimated . . I-AdverseReaction
creatinine . . I-AdverseReaction
clearance . . I-AdverseReaction
occurred . . O
early . . O
in . . O
treatment . . O
with . . O
stribild . . O
, . . O
after . . O
which . . O
they . . O
stabilized . . O
. . . O

the . . O
majority . . O
of . . O
the . . O
patients . . O
were . . O
white . . O
( . . O
87.7% . . O
) . . O
, . . O
10.3% . . O
were . . O
asian . . O
, . . O
and . . O
1.9% . . O
were . . O
black . . O
with . . O
a . . O
mean . . O
crcl . . O
of . . O
105.6 . . O
ml . . O
/ . . O
min . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
elderly . . O
patients . . O
: . . O
patients . . O
> . . O
= . . O
65 . . O
years . . O
of . . O
age . . O
were . . O
more . . O
likely . . O
to . . O
experience . . O
fatal . . B-AdverseReaction
outcomes . . O
not . . O
related . . O
to . . O
disease . . O
progression . . O
and . . O
certain . . O
adverse . . O
reactions . . O
, . . O
including . . O
neutropenia . . B-AdverseReaction
and . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
. . . O

the . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
was . . O
generally . . O
consistent . . O
among . . O
drugs . . O
in . . O
the . . O
data . . O
analyzed . . O
. . . O

5.6 . . O
effects . . O
on . . O
ability . . O
to . . O
drive . . O
and . . O
use . . O
machines . . O

avoid . . O
the . . O
use . . O
of . . O
potassium . . O
iodide . . O
oral . . O
solution . . O
or . . O
lugol's . . O
solution . . O
in . . O
patients . . O
who . . O
are . . O
sensitive . . O
to . . O
such . . O
products . . O
. . . O

a . . O
total . . O
of . . O
242 . . O
( . . O
14.9% . . O
) . . O
patients . . O
had . . O
a . . O
heart . . B-AdverseReaction
rate . . I-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
50 . . I-AdverseReaction
beats . . I-AdverseReaction
per . . I-AdverseReaction
minute . . I-AdverseReaction
. . . O

one . . O
death . . B-AdverseReaction
occurred . . O
during . . O
the . . O
24 . . O
- . . O
week . . O
sirturo . . O
treatment . . O
period . . O
. . . O

5.4 . . O
genital . . O
mycotic . . O
infections . . O

more . . O
serious . . B-Severity
or . . O
even . . O
fatal . . B-AdverseReaction
course . . O
of . . O
chickenpox . . B-AdverseReaction
or . . O
measles . . B-AdverseReaction
can . . B-Factor
occur . . O
in . . O
susceptible . . O
patients . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
severe . . B-Severity
visual . . B-AdverseReaction
loss . . I-AdverseReaction
: . . O
reported . . O
in . . O
0.2% . . O
of . . O
patients . . O
. . . O

monitor . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
bleeding . . O
. . . O

5.2 . . O
malignancies . . O

the . . O
risk . . O
of . . O
symptoms . . O
is . . O
probably . . O
greatest . . O
in . . O
children . . O
treated . . O
for . . O
spasticity . . O
but . . O
symptoms . . O
can . . O
also . . O
occur . . O
in . . O
adults . . O
, . . O
particularly . . O
in . . O
those . . O
patients . . O
who . . O
have . . O
underlying . . O
conditions . . O
that . . O
would . . O
predispose . . O
them . . O
to . . O
these . . O
symptoms . . O
. . . O

a . . O
causal . . O
relationship . . O
has . . O
not . . O
been . . O
established . . O
. . . O

to . . O
reduce . . O
this . . O

( . . O
5.3 . . O
) . . O
* . . O
toviaz . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
being . . O
treated . . O
for . . O
narrow . . O
- . . O
angle . . O
glaucoma . . O
, . . O
and . . O
only . . O
where . . O
the . . O
potential . . O
benefits . . O
outweigh . . O
the . . O
risks . . O
( . . O
5.4 . . O
) . . O
* . . O
central . . B-AdverseReaction
nervous . . I-AdverseReaction
system . . I-AdverseReaction
effects . . I-AdverseReaction
: . . O
somnolence . . B-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
toviaz . . O
. . . O

( . . O
6.1 . . O
) . . O

severe . . B-Severity
acute . . B-AdverseReaction
exacerbations . . I-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
coinfected . . O
with . . O
hiv . . O
- . . O
1 . . O
and . . O
hbv . . O
who . . O
have . . O
discontinued . . O
emtriva . . O
or . . O
viread . . O
, . . O
two . . O
of . . O
the . . O
components . . O
of . . O
stribild . . O
. . . O

* . . O
with . . O
a . . O
family . . O
history . . O
of . . O
congenital . . O
prolongation . . O
of . . O
the . . O
qt . . O
interval . . O
or . . O
sudden . . O
death . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

if . . O
diagnosed . . O
, . . O
withhold . . O
tafinlar . . O
for . . O
up . . O
to . . O
6 . . O
weeks . . O
until . . O
uveitis . . O
/ . . O
iritis . . O
resolves . . O
to . . O
grade . . O
0-1 . . O
. . . O

neuraceq . . O
, . . O
similar . . O
to . . O
other . . O
radiopharmaceuticals . . O
, . . O
contributes . . O
to . . O
a . . O
patient's . . O
overall . . O
long . . B-AdverseReaction
- . . I-AdverseReaction
term . . I-AdverseReaction
cumulative . . I-AdverseReaction
radiation . . I-AdverseReaction
exposure . . I-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O

anti . . O
- . . O
ecallantide . . O
ige . . O
antibodies . . O
were . . O
detected . . O
at . . O
a . . O
rate . . O
of . . O
4.7% . . O
for . . O
tested . . O
patients . . O
, . . O
and . . O
anti . . O
- . . O
p . . O
. . . O
pastoris . . O
ige . . O
antibodies . . O
were . . O
also . . O
detected . . O
at . . O
a . . O
rate . . O
of . . O
20.2% . . O
. . . O

start . . O
natazia . . O
no . . O
earlier . . O
than . . O
4 . . O
weeks . . O
after . . O
delivery . . O
, . . O
in . . O
women . . O
who . . O
are . . O
not . . O
breastfeeding . . O
. . . O

patients . . O
treated . . O
with . . O
simponi . . O
aria . . O
may . . O
receive . . O
vaccinations . . O
, . . O
except . . O
for . . O
live . . O
vaccines . . O
. . . O

the . . O
increased . . O
risk . . B-Factor
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
is . . O
considered . . O
a . . O
class . . O
effect . . O
of . . O
the . . O
long . . O
- . . O
acting . . O
beta . . O
2 . . O
- . . O
adrenergic . . O
agonists . . O
, . . O
including . . O
arcapta . . O
neohaler . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
: . . O
dehydration . . B-AdverseReaction
, . . O
thrombotic . . B-AdverseReaction
thrombocytopenic . . I-AdverseReaction
purpura . . I-AdverseReaction
/ . . O
hemolytic . . B-AdverseReaction
uremic . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ttp . . B-AdverseReaction
/ . . O
hus . . B-AdverseReaction
) . . O
, . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
including . . O
fatal . . B-AdverseReaction
outcomes . . O
, . . O
and . . O
posterior . . B-AdverseReaction
reversible . . I-AdverseReaction
encephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
pres . . B-AdverseReaction
) . . O
. . . O

because . . O
this . . O
disorder . . O
is . . O
variable . . O
in . . O
its . . O
expression . . O
, . . O
other . . O
organ . . O
systems . . O
not . . O
noted . . O
here . . O
may . . O
be . . O
involved . . O
. . . O

note . . O
: . . O
the . . O
figure . . O
above . . O
presents . . O
effects . . O
in . . O
various . . O
subgroups . . O
, . . O
all . . O
of . . O
which . . O
are . . O
baseline . . O
characteristics . . O
and . . O
all . . O
of . . O
which . . O
were . . O
pre . . O
- . . O
specified . . O
, . . O
if . . O
not . . O
the . . O
groupings . . O
. . . O

as . . O
with . . O
all . . O
antiepileptic . . O
drugs . . O
, . . O
onfi . . O
should . . O
be . . O
withdrawn . . O
gradually . . O
to . . O
minimize . . O
the . . O
risk . . O
of . . O
precipitating . . O
seizures . . O
, . . O
seizure . . O
exacerbation . . O
, . . O
or . . O
status . . O
epilepticus . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
hypothyroidism . . B-AdverseReaction
requiring . . O
thyroid . . O
hormone . . O
replacement . . O
has . . O
been . . O
reported . . O
. . . O

these . . O
symptoms . . O
have . . O
been . . O
reported . . O
hours . . O
to . . O
weeks . . O
after . . O
injection . . O
. . . O

in . . O
clinical . . O
trials . . O
with . . O
vimizim . . O
, . . O
44 . . O
of . . O
235 . . O
( . . O
18.7% . . O
) . . O
patients . . O
experienced . . O
hypersensitivity . . B-AdverseReaction
reactions . . O
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
. . . O

dolutegravir . . O
has . . O
been . . O
shown . . O
to . . O
increase . . B-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
due . . O
to . . O
inhibition . . O
of . . O
tubular . . O
secretion . . O
of . . O
creatinine . . O
without . . O
affecting . . O
renal . . O
glomerular . . O
function . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

hypokalemia . . O
( . . O
and . . O
/ . . O
or . . O
hypomagnesemia . . O
) . . O
may . . O
increase . . O
the . . O
risk . . O
of . . O
qt . . O
prolongation . . O
and . . O
arrhythmia . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
interrupt . . O
ferriprox . . O
if . . O
infection . . O
develops . . O
and . . O
monitor . . O
the . . O
anc . . O
more . . O
frequently . . O
. . . O

some . . O
studies . . O
suggest . . O
that . . O
cocs . . B-DrugClass
are . . O
associated . . O
with . . O
an . . O
increase . . O
in . . O
the . . O
risk . . O
of . . O
cervical . . B-AdverseReaction
cancer . . I-AdverseReaction
or . . O
intraepithelial . . O
neoplasia . . O
. . . O

* . . O
women . . O
taking . . O
duavee . . O
should . . O
not . . O
take . . O
additional . . O
estrogens . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
there . . O
is . . O
an . . O
increased . . O
risk . . O
of . . O
endometrial . . B-AdverseReaction
cancer . . I-AdverseReaction
in . . O
a . . O
woman . . O
with . . O
a . . O
uterus . . O
who . . O
uses . . O
unopposed . . O
estrogens . . B-DrugClass
. . . O

development . . O
of . . O
cardiomyopathy . . B-AdverseReaction
resolved . . O
in . . O
all . . O
five . . O
patients . . O
following . . O
dose . . O
reduction . . O
( . . O
4 . . O
/ . . O
55 . . O
) . . O
and . . O
/ . . O
or . . O
dose . . O
interruption . . O
( . . O
1 . . O
/ . . O
55 . . O
) . . O
. . . O

table . . O
6 . . O
lists . . O
the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
in . . O
any . . O
dysport . . O
( . . O
r . . O
) . . O
dose . . O
group . . O
and . . O
more . . O
frequent . . O
than . . O
placebo . . O
in . . O
double . . O
blind . . O
studies . . O
evaluating . . O
the . . O
treatment . . O
of . . O
upper . . O
limb . . O
spasticity . . O
in . . O
adults . . O
with . . O
dysport . . O
( . . O
r . . O
) . . O
. . . O

adverse . . O
reactions . . O
incidence . . O
in . . O
placebo . . O
- . . O
controlled . . O
adjunctive . . O
trials . . O
in . . O
adult . . O
patients . . O
with . . O
partial . . O
- . . O
onset . . O
seizures . . O
( . . O
adverse . . O
reactions . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
potiga . . O
in . . O
any . . O
treatment . . O
group . . O
and . . O
numerically . . O
more . . O
frequent . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O
) . . O

testing . . O
was . . O
performed . . O
in . . O
patients . . O
who . . O
experienced . . O
moderate . . B-Severity
to . . I-Severity
severe . . I-Severity
or . . O
recurrent . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
for . . O
which . . O
mast . . O
- . . O
cell . . O
activation . . O
was . . O
suspected . . O
. . . O

* . . O
fatal . . B-AdverseReaction
and . . O
/ . . O
or . . O
serious . . B-Severity
and . . O
severe . . B-Severity
diarrhea . . B-AdverseReaction
or . . O
colitis . . B-AdverseReaction
occurred . . O
in . . O
14% . . O
of . . O
zydelig . . O
- . . O
treated . . O
patients . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorder . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
myalgia . . B-AdverseReaction

consider . . O
interrupting . . O
therapy . . O
with . . O
benlysta . . O
in . . O
patients . . O
who . . O
develop . . O
a . . O
new . . O
infection . . O
while . . O
undergoing . . O
treatment . . O
with . . O
benlysta . . O
and . . O
monitor . . O
these . . O
patients . . O
closely . . O
. . . O

the . . O
incidence . . O
rates . . O
of . . O
adjudicated . . O
bone . . B-AdverseReaction
fractures . . I-AdverseReaction
were . . O
1.1 . . O
, . . O
1.4 . . O
, . . O
and . . O
1.5 . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
of . . O
exposure . . O
in . . O
the . . O
comparator . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
groups . . O
, . . O
respectively . . O
. . . O

in . . O
addition . . O
to . . O
the . . O
reactions . . O
shown . . O
in . . O
tables . . O
2 . . O
and . . O
3 . . O
, . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
2% . . O
of . . O
subjects . . O
treated . . O
with . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
included . . O
viral . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
pharyngitis . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
and . . O
arthralgia . . B-AdverseReaction
. . . O

the . . O
risk . . O
did . . O
not . . O
vary . . O
substantially . . O
by . . O
age . . O
( . . O
5-100 . . O
years . . O
) . . O
in . . O
the . . O
clinical . . O
trials . . O
analyzed . . O
. . . O

among . . O
patients . . O
with . . O
normal . . O
baseline . . O
alt . . O
levels . . O
, . . O
more . . O
dalvance . . O
- . . O
than . . O
comparator . . O
- . . O
treated . . O
patients . . O
had . . O
post . . O
- . . O
baseline . . O
alt . . B-AdverseReaction
elevations . . I-AdverseReaction
greater . . O
than . . O
3 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . O
uln . . O
) . . O
, . . O
12 . . O
( . . O
0.8% . . O
) . . O
vs . . O
. . . O
2 . . O
( . . O
0.2% . . O
) . . O
, . . O
respectively . . O
including . . O
three . . O
subjects . . O
with . . O
post . . O
- . . O
baseline . . O
alt . . B-AdverseReaction
values . . I-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
10 . . I-AdverseReaction
times . . I-AdverseReaction
uln . . I-AdverseReaction
. . . O

withhold . . O
kyprolis . . O
if . . O
suspected . . O
. . . O

6.4 . . O
laboratory . . O
findings . . O

( . . O
5.8 . . O
, . . O
8.1 . . O
, . . O
8.7 . . O
) . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
sanofi . . O
- . . O
aventis . . O
u . . O
. . . O
s . . O
. . . O
llc . . O
at . . O
1-800-633-1610 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

if . . O
a . . O
patient . . O
requires . . O
antipsychotic . . O
drug . . O
treatment . . O
after . . O
recovery . . O
from . . O
nms . . O
, . . O
the . . O
potential . . O
reintroduction . . O
of . . O
drug . . O
therapy . . O
should . . O
be . . O
carefully . . O
considered . . O
. . . O

warning . . O
: . . O
endometrial . . B-AdverseReaction
cancer . . I-AdverseReaction
, . . O
cardiovascular . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
and . . O
probable . . B-Factor
dementia . . B-AdverseReaction

restless . . O
legs . . O
syndrome . . O
: . . O
the . . O
exposure . . O
to . . O
horizant . . O
in . . O
1,201 . . O
patients . . O
with . . O
rls . . O
included . . O
613 . . O
exposed . . O
for . . O
at . . O
least . . O
6 . . O
months . . O
and . . O
371 . . O
exposed . . O
for . . O
at . . O
least . . O
1 . . O
year . . O
. . . O

table . . O
4 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
receiving . . O
teflaro . . O
in . . O
the . . O
pooled . . O
phase . . O
3 . . O
clinical . . O
trials . . O
a . . O
comparators . . O
included . . O
vancomycin . . O
1 . . O
gram . . O
iv . . O
every . . O
12h . . O
plus . . O
aztreonam . . O
1 . . O
gram . . O
iv . . O
every . . O
12h . . O
in . . O
the . . O
phase . . O
3 . . O
absssi . . O
trials . . O
, . . O
and . . O
ceftriaxone . . O
1 . . O
gram . . O
iv . . O
every . . O
24h . . O
in . . O
the . . O
phase . . O
3 . . O
cabp . . O
trials . . O
. . . O

changes . . O
in . . O
selected . . O
hematological . . O
parameters . . O
during . . O
treatment . . O
of . . O
adult . . O
subjects . . O
with . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
and . . O
rebetol . . O
are . . O
described . . O
in . . O
table . . O
4 . . O
. . . O

5.5 . . O
increase . . O
in . . O
blood . . O
pressure . . O

based . . O
on . . O
the . . O
severity . . O
of . . O
the . . O
laboratory . . O
abnormalities . . O
, . . O
withhold . . O
zykadia . . O
with . . O
resumption . . O
at . . O
a . . O
reduced . . O
dose . . O
as . . O
described . . O
in . . O
table . . O
1 . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
severe . . O
hypersensitivity . . O
to . . O
milk . . O
proteins . . O
. . . O

5.5 . . O
immune . . O
- . . O
mediated . . O
endocrinopathies . . O

the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
( . . O
occurring . . O
in . . O
at . . O
least . . O
0.5% . . O
of . . O
subjects . . O
) . . O
during . . O
neuraceq . . O
clinical . . O
trials . . O
are . . O
shown . . O
in . . O
table . . O
2 . . O
. . . O

the . . O
most . . O
common . . O
grade . . B-Severity
3-4 . . I-Severity
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
5% . . O
) . . O
were . . O
stomatitis . . B-AdverseReaction
and . . O
diarrhea . . B-AdverseReaction
. . . O

most . . O
common . . O
adverse . . O
reactions . . O

( . . O
5.8 . . O
) . . O

consider . . O
the . . O
benefits . . O
and . . O
risks . . O
before . . O
neuraxial . . O
intervention . . O
in . . O
patients . . O
anticoagulated . . O
or . . O
to . . O
be . . O
anticoagulated . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
within . . O
one . . O
hour . . O
of . . O
infusion . . O
were . . O
reported . . O
in . . O
5% . . O
of . . O
patients . . O
treated . . O
with . . O
the . . O
recommended . . O
dose . . O
of . . O
nulojix . . O
, . . O
similar . . O
to . . O
the . . O
placebo . . O
rate . . O
. . . O

in . . O
the . . O
four . . O
pooled . . O
phase . . O
3 . . O
clinical . . O
trials . . O
, . . O
serious . . O
adverse . . O
reactions . . O
( . . O
sars . . O
) . . O
occurred . . O
in . . O
98 . . O
/ . . O
1300 . . O
( . . O
7.5% . . O
) . . O
of . . O
patients . . O
receiving . . O
teflaro . . O
and . . O
100 . . O
/ . . O
1297 . . O
( . . O
7.7% . . O
) . . O
of . . O
patients . . O
receiving . . O
comparator . . O
drugs . . O
. . . O

if . . O
an . . O
allergic . . O
reaction . . O
to . . O
teflaro . . O
occurs . . O
, . . O
discontinue . . O
teflaro . . O
and . . O
institute . . O
appropriate . . O
treatment . . O
and . . O
supportive . . O
measures . . O
. . . O

rash . . B-AdverseReaction
occurred . . O
most . . O
commonly . . O
during . . O
the . . O
first . . O
6 . . O
weeks . . O
of . . O
therapy . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
wyeth . . O
pharmaceuticals . . O
inc . . O
. . . O
, . . O
a . . O
subsidiary . . O
of . . O
pfizer . . O
inc . . O
. . . O
, . . O
at . . O
1-800-438-1985 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

dampa . . O
interferes . . O
with . . O
the . . O
measurement . . O
of . . O
methotrexate . . O
concentration . . O
using . . O
immunoassays . . O
resulting . . O
in . . O
an . . O
erroneous . . O
measurement . . O
which . . O
overestimates . . O
the . . O
methotrexate . . O
concentration . . O
. . . O

1 . . O
) . . O
] . . O
. . . O

monotherapy . . O
historical . . O
control . . O
trials . . O

in . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
schizophrenia . . O
adult . . O
trials . . O
, . . O
the . . O
mean . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
transaminase . . I-AdverseReaction
levels . . I-AdverseReaction
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
was . . O
1.6 . . O
units . . O
/ . . O
l . . O
compared . . O
to . . O
a . . O
decrease . . O
of . . O
0.4 . . O
units . . O
/ . . O
l . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

excerpt . . O
: . . O
serious . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
following . . O
adreview . . O
administration . . O
. . . O

table . . O
2 . . O
shows . . O
the . . O
incidence . . O
of . . O
common . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
pristiq . . O
treated . . O
mdd . . O
patients . . O
and . . O
twice . . O
the . . O
rate . . O
of . . O
placebo . . O
at . . O
any . . O
dose . . O
in . . O
the . . O
pre . . O
- . . O
marketing . . O
pooled . . O
8 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
fixed . . O
dose . . O
clinical . . O
studies . . O

only . . O
use . . O
sirturo . . O
when . . O
an . . O
effective . . O
treatment . . O
regimen . . O
cannot . . O
otherwise . . O
be . . O
provided . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

in . . O
addition . . O
, . . O
because . . O
ilaris . . O
may . . B-Factor
interfere . . B-AdverseReaction
with . . I-AdverseReaction
normal . . I-AdverseReaction
immune . . I-AdverseReaction
response . . I-AdverseReaction
to . . O
new . . O
antigens . . O
, . . O
vaccinations . . O
may . . O
not . . O
be . . O
effective . . O
in . . O
patients . . O
receiving . . O
ilaris . . O
. . . O

the . . O
median . . O
time . . O
to . . O
onset . . O
was . . O
7.4 . . O
weeks . . O
( . . O
range . . O
: . . O
1.6-13.4 . . O
) . . O
and . . O
6.3 . . O
weeks . . O
( . . O
range . . O
: . . O
0.3-18.9 . . O
) . . O
after . . O
the . . O
initiation . . O
of . . O
yervoy . . O
for . . O
patients . . O
with . . O
grade . . B-Severity
3-5 . . I-Severity
enterocolitis . . B-AdverseReaction
and . . O
with . . O
grade . . B-Severity
2 . . I-Severity
enterocolitis . . B-AdverseReaction
, . . O
respectively . . O
. . . O

the . . O
data . . O
in . . O
table . . O
1 . . O
is . . O
derived . . O
from . . O
four . . O
26 . . O
- . . O
week . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

treatment . . O
- . . O
emergent . . O
adverse . . O
drug . . O
reactions . . O
( . . O
adrs . . O
) . . O

such . . O
an . . O
event . . O
may . . O
be . . O
a . . O
sign . . O
of . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
arteritic . . I-AdverseReaction
anterior . . I-AdverseReaction
ischemic . . I-AdverseReaction
optic . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
naion . . B-AdverseReaction
) . . O
, . . O
a . . O
rare . . O
condition . . O
and . . O
a . . O
cause . . O
of . . O
decreased . . B-AdverseReaction
vision . . I-AdverseReaction
including . . O
permanent . . B-AdverseReaction
loss . . I-AdverseReaction
of . . I-AdverseReaction
vision . . I-AdverseReaction
that . . O
has . . O
been . . O
reported . . O
rarely . . O
postmarketing . . O
in . . O
temporal . . O
association . . O
with . . O
the . . O
use . . O
of . . O
all . . O
pde5 . . B-DrugClass
inhibitors . . I-DrugClass
. . . O

patients . . O
with . . O
ra . . O
and . . O
other . . O
chronic . . O
inflammatory . . O
diseases . . O
, . . O
particularly . . O
patients . . O
with . . O
highly . . O
active . . O
disease . . O
and . . O
/ . . O
or . . O
chronic . . O
exposure . . O
to . . O
immunosuppressant . . O
therapies . . O
, . . O
may . . O
be . . O
at . . O
higher . . O
risk . . B-Factor
( . . O
up . . O
to . . O
several . . O
fold . . O
) . . O
than . . O
the . . O
general . . O
population . . O
for . . O
the . . O
development . . O
of . . O
lymphoma . . B-AdverseReaction
, . . O
even . . O
in . . O
the . . O
absence . . O
of . . O
tnf . . O
- . . O
blocking . . O
therapy . . O
. . . O

it . . O
is . . O
recommended . . O
that . . O
all . . O
patients . . O
with . . O
hiv . . O
- . . O
1 . . O
be . . O
tested . . O
for . . O
the . . O
presence . . O
of . . O
chronic . . O
hepatitis . . O
b . . O
virus . . O
( . . O
hbv . . O
) . . O
before . . O
initiating . . O
antiretroviral . . O
therapy . . O
. . . O

the . . O
infusion . . O
rate . . O
may . . O
be . . O
slowed . . O
or . . O
interrupted . . O
if . . O
the . . O
patient . . O
develops . . O
an . . O
infusion . . O
reaction . . O
. . . O

table . . O
1 . . O
summarizes . . O
all . . O
adverse . . O
reactions . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
with . . O
postherpetic . . O
neuralgia . . O
in . . O
the . . O
qutenza . . O
group . . O
for . . O
which . . O
the . . O
incidence . . O
was . . O
greater . . O
than . . O
in . . O
the . . O
control . . O
group . . O
. . . O

cases . . O
of . . O
mtc . . B-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
liraglutide . . O
, . . O
another . . O
glp . . B-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
receptor . . I-DrugClass
agonist . . I-DrugClass
, . . O
have . . O
been . . O
reported . . O
in . . O
the . . O
postmarketing . . O
period . . O
; . . O
the . . O
data . . O
in . . O
these . . O
reports . . O
are . . O
insufficient . . O
to . . O
establish . . O
or . . O
exclude . . O
a . . O
causal . . O
relationship . . O
between . . O
mtc . . B-AdverseReaction
and . . O
glp . . O
- . . O
1 . . O
receptor . . O
agonist . . O
use . . O
in . . O
humans . . O
. . . O

in . . O
the . . O
clinical . . O
trials . . O
, . . O
blood . . O
counts . . O
were . . O
monitored . . O
every . . O
week . . O
initially . . O
. . . O

6.2 . . O
post . . O
marketing . . O
experience . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
hemorrhagic . . B-AdverseReaction
anemia . . I-AdverseReaction

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
reported . . O
for . . O
afinitor . . O
( . . O
incidence . . O
> . . O
= . . O
30% . . O
) . . O
were . . O
stomatitis . . B-AdverseReaction
and . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
. . . O

the . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
at . . O
least . . O
5% . . O
of . . O
the . . O
nhl . . O
patients . . O
, . . O
regardless . . O
of . . O
severity . . O
, . . O
are . . O
shown . . O
in . . O
table . . O
3 . . O
. . . O

ask . . O
patients . . O
about . . O
symptoms . . O
suggestive . . O
of . . O
infusion . . O
reactions . . O
after . . O
their . . O
first . . O
cycle . . O
of . . O
therapy . . O
. . . O

based . . O
on . . O
patient . . O
diaries . . O
, . . O
amenorrhea . . O
occurs . . O
in . . O
approximately . . O
16% . . O
of . . O
cycles . . O
in . . O
women . . O
using . . O
natazia . . O
. . . O

( . . O
2.3,5.5 . . O
) . . O
* . . O
embryofetal . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

the . . O
clinical . . O
relevance . . O
of . . O
this . . O
finding . . O
is . . O
unknown . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O

arthralgias . . B-AdverseReaction
and . . O
muscle . . B-AdverseReaction
pain . . I-AdverseReaction
or . . O
weakness . . O
have . . O
also . . O
been . . O
reported . . O
in . . O
cases . . O
of . . O
proximal . . B-AdverseReaction
renal . . I-AdverseReaction
tubulopathy . . I-AdverseReaction
. . . O

at . . O
the . . O
recommended . . O
dose . . O
of . . O
50 . . O
mg . . O
, . . O
the . . O
discontinuation . . O
rate . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
for . . O
pristiq . . O
( . . O
4.1% . . O
) . . O
was . . O
similar . . O
to . . O
the . . O
rate . . O
for . . O
placebo . . O
( . . O
3.8% . . O
) . . O
. . . O

for . . O
more . . O
information . . O
, . . O
go . . O
to . . O
www . . O
. . . O
duavee . . O
. . . O
com . . O
, . . O
or . . O
call . . O
1-800-438-1985 . . O
. . . O

in . . O
some . . O
cases . . O
glucose . . O
intolerance . . O
may . . O
be . . O
irreversible . . B-Severity
. . . O

if . . O
the . . O
qtc . . O
bazett . . O
interval . . O
is . . O
> . . O
= . . O
500 . . O
ms . . O
, . . O
discontinue . . O
multaq . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

the . . O
caps . . O
clinical . . O
studies . . O
employed . . O
the . . O
biosensor . . O
binding . . O
assay . . O
, . . O
and . . O
most . . O
of . . O
the . . O
sjia . . O
clinical . . O
studies . . O
employed . . O
the . . O
bridging . . O
assay . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
posterior . . B-AdverseReaction
reversible . . I-AdverseReaction
encephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
pres . . B-AdverseReaction
) . . O
: . . O
if . . O
suspected . . O
, . . O
discontinue . . O
gilenya . . O
. . . O

excerpt . . O
: . . O
* . . O
copd . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3% . . O
) . . O
are . . O
nasopharyngitis . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
oral . . B-AdverseReaction
candidiasis . . I-AdverseReaction
. . . O

the . . O
risk . . O
appears . . O
lower . . O
for . . O
patients . . O
with . . O
chronic . . O
, . . O
moderate . . O
kidney . . O
disease . . O
( . . O
gfr . . O
30 . . O
- . . O
59 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
and . . O
little . . O
, . . O
if . . O
any . . O
, . . O
for . . O
patients . . O
with . . O
chronic . . O
, . . O
mild . . O
kidney . . O
disease . . O
( . . O
gfr . . O
60 . . O
- . . O
89 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
. . . O

in . . O
patients . . O
who . . O
had . . O
thyroid . . O
stimulating . . O
hormone . . O
( . . O
tsh . . O
) . . O
< . . O
5 . . O
muu . . O
/ . . O
ml . . O
before . . O
treatment . . O
, . . O
elevations . . B-AdverseReaction
of . . I-AdverseReaction
tsh . . I-AdverseReaction
to . . O
> . . O
= . . B-Severity
10 . . I-Severity
muu . . I-Severity
/ . . I-Severity
ml . . I-Severity
occurred . . O
in . . O
79 . . O
/ . . O
245 . . O
patients . . O
( . . O
32% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
25 . . O
/ . . O
232 . . O
patients . . O
( . . O
11% . . O
) . . O
receiving . . O
sorafenib . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

bladder . . O
cancer . . O
risk . . O
factors . . O
and . . O
hematuria . . O
( . . O
a . . O
potential . . O
indicator . . O
of . . O
pre . . O
- . . O
existing . . O
tumors . . O
) . . O
were . . O
balanced . . O
between . . O
treatment . . O
arms . . O
at . . O
baseline . . O
. . . O

these . . O
patients . . O
were . . O
managed . . O
without . . O
surgical . . O
intervention . . O
, . . O
but . . O
the . . O
long . . O
- . . O
term . . O
consequences . . O
are . . O
unknown . . O
. . . O

no . . B-Factor
trial . . I-Factor
adequate . . I-Factor
to . . O
determine . . O
whether . . O
the . . O
rate . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
is . . O
increased . . O
in . . O
subjects . . O
treated . . O
with . . O
breo . . O
ellipta . . O
has . . O
been . . O
conducted . . O
. . . O

adverse . . O
events . . O
of . . O
hematuria . . B-AdverseReaction
, . . O
including . . O
those . . O
requiring . . O
medical . . O
intervention . . O
, . . O
were . . O
more . . O
common . . O
in . . O
jevtana . . O
- . . O
treated . . O
patients . . O
. . . O

cometriq . . O
treatment . . O
results . . O
in . . O
an . . O
increased . . O
incidence . . O
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
: . . O
6% . . O
vs . . O
. . . O
3% . . O
and . . O
arterial . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
: . . O
2% . . O
vs . . O
. . . O
0% . . O
in . . O
cometriq . . O
- . . O
treated . . O
and . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
respectively . . O
) . . O
. . . O

5.4 . . O
drug . . O
interactions . . O
with . . O
cyp2d6 . . O

6 . . O
adverse . . O
reactions . . O

[ . . O
see . . O
c . . O
ontraindications . . O
( . . O
4 . . O
) . . O
, . . O
w . . O
arnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

agranulocytosis . . B-AdverseReaction
( . . O
including . . O
fatal . . B-AdverseReaction
cases . . O
) . . O
has . . O
also . . O
been . . O
reported . . O
. . . O

6.2 . . O
post . . O
- . . O
marketing . . O
and . . O
other . . O
clinical . . O
experience . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
ilaris . . O
therapy . . O
. . . O

control . . O
hypertension . . O
and . . O
correct . . O
hypokalemia . . O
before . . O
treatment . . O
. . . O

of . . O
the . . O
patients . . O
who . . O
reported . . O
neuropathy . . B-AdverseReaction
, . . O
51% . . O
had . . O
residual . . B-AdverseReaction
neuropathy . . I-AdverseReaction
at . . O
the . . O
time . . O
of . . O
their . . O
last . . O
evaluation . . O
. . . O

5.2 . . O
concomitant . . O
use . . O
of . . O
cyp3a4 . . O
inhibitors . . O

( . . O
2.4 . . O
, . . O
5.1 . . O
) . . O
* . . O
cardiovascular . . B-AdverseReaction
events . . I-AdverseReaction
: . . O
a . . O
higher . . O
rate . . O
of . . O
cardiovascular . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
was . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
uloric . . O
than . . O
allopurinol . . O
in . . O
clinical . . O
trials . . O
. . . O

5.1 . . O
imaging . . O
errors . . O

pristiq . . O
has . . O
not . . O
been . . O
systematically . . O
evaluated . . O
in . . O
patients . . O
with . . O
a . . O
seizure . . O
disorder . . O
. . . O

excerpt . . O
: . . O
in . . O
clinical . . O
trials . . O
, . . O
the . . O
most . . O
common . . O
related . . O
adverse . . O
events . . O
( . . O
occurring . . O
in . . O
> . . O
1% . . O
of . . O
patients . . O
) . . O
were . . O
paraesthesia . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
and . . O
/ . . O
or . . O
vomiting . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
and . . O
headache . . B-AdverseReaction
. . . O

orally . . B-DrugClass
inhaled . . I-DrugClass
corticosteroids . . I-DrugClass
may . . O
cause . . O
a . . O
reduction . . B-AdverseReaction
in . . I-AdverseReaction
growth . . I-AdverseReaction
velocity . . I-AdverseReaction
when . . O
administered . . O
to . . O
children . . O
and . . O
adolescents . . O
. . . O

5.4 . . O
use . . O
with . . O
medications . . O
known . . O
to . . O
cause . . O
hypoglycemia . . O

pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
and . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
have . . O
also . . O
been . . O
reported . . O
in . . O
clinical . . O
trials . . O
. . . O

hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
hepatitis . . O
c . . O
virus . . O
co . . O
- . . O
infection . . O
: . . O
in . . O
phase . . O
3 . . O
trials . . O
, . . O
subjects . . O
with . . O
hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
c . . O
virus . . O
co . . O
- . . O
infection . . O
were . . O
permitted . . O
to . . O
enroll . . O
provided . . O
that . . O
baseline . . O
liver . . O
chemistry . . O
tests . . O
did . . O
not . . O
exceed . . O
5 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
. . . O

patients . . O
received . . O
erwinaze . . O
according . . O
to . . O
several . . O
schedules . . O
, . . O
and . . O
treatment . . O
center . . O
specifications . . O
with . . O
doses . . O
that . . O
ranged . . O
from . . O
20,000 . . O
to . . O
25,000 . . O
international . . O
units . . O
/ . . O
m . . O
2 . . O
. . . O

treatment . . O
with . . O
blincyto . . O
was . . O
associated . . O
with . . O
transient . . B-Severity
elevations . . B-AdverseReaction
in . . I-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

the . . O
incidence . . O
of . . O
xiaflex . . O
- . . O
associated . . O
pruritus . . B-AdverseReaction
increased . . O
after . . O
more . . O
xiaflex . . O
injections . . O
in . . O
patients . . O
with . . O
dupuytren's . . O
contracture . . O
. . . O

potentially . . B-Factor
serious . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . O
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
, . . O
have . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
kalbitor . . O
. . . O

all . . O
patients . . O
also . . O
received . . O
basiliximab . . O
induction . . O
, . . O
mycophenolate . . O
mofetil . . O
, . . O
and . . O
corticosteroids . . O
. . . O

an . . O
additional . . O
51 . . O
subjects . . O
from . . O
a . . O
separate . . O
repeat . . O
dose . . O
study . . O
were . . O
tested . . O
for . . O
the . . O
presence . . O
of . . O
neutralizing . . O
antibodies . . O
only . . O
. . . O

monitor . . O
for . . O
symptoms . . O
( . . O
5.4 . . O
) . . O
* . . O
atypical . . B-AdverseReaction
femoral . . I-AdverseReaction
fractures . . I-AdverseReaction
: . . O
have . . O
been . . O
reported . . O
. . . O

5.1 . . O
immune . . O
- . . O
mediated . . O
enterocolitis . . O

fatal . . B-AdverseReaction
adverse . . O
events . . O
occurred . . O
in . . O
15% . . O
of . . O
patients . . O
. . . O

toviaz . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
severe . . O
hepatic . . O
impairment . . O
and . . O
therefore . . O
is . . O
not . . O
recommended . . O
for . . O
use . . O
in . . O
this . . O
patient . . O
population . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.7 . . O
) . . O
and . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
the . . O
exposure . . O
to . . O
cimzia . . O
in . . O
2,367 . . O
ra . . O
patients . . O
, . . O
including . . O
2,030 . . O
exposed . . O
for . . O
at . . O
least . . O
6 . . O
months . . O
, . . O
1,663 . . O
exposed . . O
for . . O
at . . O
least . . O
one . . O
year . . O
and . . O
282 . . O
for . . O
at . . O
least . . O
2 . . O
years . . O
; . . O
and . . O
1,774 . . O
in . . O
adequate . . O
and . . O
well . . O
- . . O
controlled . . O
studies . . O
. . . O

transaminase . . O
elevations . . O
were . . O
more . . O
common . . O
in . . O
patients . . O
who . . O
had . . O
abnormal . . O
transaminases . . O
at . . O
baseline . . O
. . . O

postmarketing . . O
cases . . O
of . . O
hepatosplenic . . B-AdverseReaction
t . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
lymphoma . . I-AdverseReaction
( . . O
hstcl . . B-AdverseReaction
) . . O
, . . O
a . . O
rare . . O
type . . O
of . . O
t . . O
- . . O
cell . . O
lymphoma . . O
that . . O
has . . O
a . . O
very . . O
aggressive . . O
disease . . O
course . . O
and . . O
is . . O
usually . . O
fatal . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
tnf . . O
blockers . . O
, . . O
including . . O
cimzia . . O
. . . O

table . . O
2 . . O
: . . O
laboratory . . O
abnormalities . . O
of . . O
interest . . O
in . . O
study . . O
1 . . O
abiraterone . . O
( . . O
n . . O
= . . O
791 . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
394 . . O
) . . O
laboratory . . O
abnormality . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3-4 . . O
( . . O
% . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3-4 . . O
( . . O
% . . O
) . . O
hypertriglyceridemia . . B-AdverseReaction
62.5 . . O
0.4 . . O
53.0 . . O
0 . . O
high . . B-AdverseReaction
ast . . I-AdverseReaction
30.6 . . O
2.1 . . O
36.3 . . O
1.5 . . O
hypokalemia . . B-AdverseReaction
28.3 . . O
5.3 . . O
19.8 . . O
1.0 . . O
hypophosphatemia . . B-AdverseReaction
23.8 . . O
7.2 . . O
15.7 . . O
5.8 . . O
high . . B-AdverseReaction
alt . . I-AdverseReaction
11.1 . . O
1.4 . . O
10.4 . . O
0.8 . . O
high . . B-AdverseReaction
total . . I-AdverseReaction
bilirubin . . I-AdverseReaction
6.6 . . O
0.1 . . O
4.6 . . O
0 . . O
study . . O
2 . . O
: . . O
metastatic . . O
crpc . . O
prior . . O
to . . O
chemotherapy . . O

acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

the . . O
dose . . O
was . . O
reduced . . O
in . . O
79% . . O
of . . O
patients . . O
receiving . . O
cometriq . . O
compared . . O
to . . O
9% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

some . . O
patients . . O
have . . O
been . . O
able . . O
to . . O
be . . O
rechallenged . . O
and . . O
have . . O
continued . . O
to . . O
receive . . O
alglucosidase . . O
alfa . . O
under . . O
close . . O
clinical . . O
supervision . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O
in . . O
adult . . O
subjects . . O

gadolinium . . B-DrugClass
- . . I-DrugClass
based . . I-DrugClass
contrast . . I-DrugClass
agents . . I-DrugClass
( . . O
gbcas . . O
) . . O
increase . . O
the . . O
risk . . O
for . . O
nsf . . B-AdverseReaction
among . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
the . . O
drugs . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

avoid . . O
use . . O
of . . O
gbcas . . O
in . . O
these . . O
patients . . O
unless . . O
the . . O
diagnostic . . O
information . . O
is . . O
essential . . O
and . . O
not . . O
available . . O
with . . O
non . . O
- . . O
contrasted . . O
mri . . O
or . . O
other . . O
modalities . . O
. . . O

in . . O
phase . . O
2 . . O
and . . O
phase . . O
3 . . O
clinical . . O
studies . . O
, . . O
12 . . O
( . . O
3.4 . . O
cases . . O
per . . O
1000 . . O
patient . . O
years . . O
) . . O
pancreatitis . . B-AdverseReaction
related . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
patients . . O
exposed . . O
to . . O
trulicity . . O
versus . . O
3 . . O
in . . O
non . . O
- . . O
incretin . . O
comparators . . O
( . . O
2.7 . . O
cases . . O
per . . O
1000 . . O
patient . . O
years . . O
) . . O
. . . O

breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
were . . O
reported . . O
by . . O
approximately . . O
3% . . O
of . . O
patients . . O
following . . O
dysport . . O
( . . O
r . . O
) . . O
administration . . O
and . . O
in . . O
1% . . O
of . . O
placebo . . O
patients . . O
in . . O
clinical . . O
trials . . O
during . . O
the . . O
double . . O
- . . O
blind . . O
phase . . O
. . . O

6.1 . . O
adverse . . O
reactions . . O
in . . O
clinical . . O
trials . . O

6.1 . . O
clinical . . O
studies . . O
experience . . O

in . . O
addition . . O
to . . O
the . . O
reactions . . O
shown . . O
in . . O
table . . O
1 . . O
, . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3% . . O
of . . O
the . . O
subjects . . O
treated . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
( . . O
n . . O
= . . O
806 . . O
) . . O
for . . O
12 . . O
months . . O
included . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
, . . O
bronchitis . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
pharyngitis . . B-AdverseReaction
, . . O
and . . O
pyrexia . . B-AdverseReaction
. . . O

( . . O
5.8 . . O
) . . O

immune . . O
system . . O
disorders . . O
: . . O
anaphylaxis . . B-AdverseReaction
, . . O
anaphylactic . . B-AdverseReaction
reaction . . I-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
lundbeck . . O
at . . O
1-800-455-1141 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
who . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
reactions . . O
was . . O
13% . . O
for . . O
the . . O
recommended . . O
nulojix . . O
regimen . . O
and . . O
19% . . O
for . . O
the . . O
cyclosporine . . O
control . . O
arm . . O
through . . O
three . . O
years . . O
of . . O
treatment . . O
. . . O

reproductive . . O
system . . O
and . . O
breast . . O
disorders . . O
: . . O
frequent . . O
- . . O
erectile . . B-AdverseReaction
dysfunction . . I-AdverseReaction
; . . O
infrequent . . O
- . . O
testicular . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
amenorrhea . . B-AdverseReaction
, . . O
breast . . B-AdverseReaction
pain . . I-AdverseReaction
; . . O
rare . . O
- . . O
menstruation . . B-AdverseReaction
irregular . . I-AdverseReaction
, . . O
gynecomastia . . B-AdverseReaction
, . . O
menorrhagia . . B-AdverseReaction
, . . O
metrorrhagia . . B-AdverseReaction
, . . O
postmenopausal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
prostatitis . . B-AdverseReaction
. . . O

prescribing . . O
dificid . . O
in . . O
the . . O
absence . . O
of . . O
a . . O
proven . . O
or . . O
strongly . . O
suspected . . O
c . . O
. . . O
difficile . . O
infection . . O
is . . O
unlikely . . O
to . . O
provide . . O
benefit . . O
to . . O
the . . O
patient . . O
and . . O
increases . . O
the . . O
risk . . O
of . . O
the . . O
development . . O
of . . O
drug . . O
- . . O
resistant . . O
bacteria . . O
. . . O

since . . O
entereg . . O
acts . . O
peripherally . . O
, . . O
clinical . . O
signs . . O
and . . O
symptoms . . O
of . . O
increased . . O
sensitivity . . O
would . . O
be . . O
related . . O
to . . O
the . . O
gastrointestinal . . O
tract . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
and . . O
vomiting . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
) . . O
. . . O

( . . O
5.1 . . O
) . . O

the . . O
risk . . B-Factor
of . . O
impaired . . B-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
with . . O
jardiance . . O
is . . O
increased . . O
in . . O
elderly . . O
patients . . O
and . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
. . . O

5.4 . . O
bacterial . . O
infections . . O

( . . O
5.6 . . O
) . . O
* . . O
macrovascular . . O
outcomes . . O
: . . O
there . . O
have . . O
been . . O
no . . O
clinical . . O
studies . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
farxiga . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
. . . O

5.2 . . O
corporal . . O
rupture . . O
( . . O
penile . . O
fracture . . O
) . . O
or . . O
other . . O
serious . . O
injury . . O
to . . O
the . . O
penis . . O
in . . O
the . . O
treatment . . O
of . . O
peyronie's . . O
disease . . O

skin . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
treanda . . O
treatment . . O
in . . O
clinical . . O
trials . . O
and . . O
postmarketing . . O
safety . . O
reports . . O
, . . O
including . . O
rash . . B-AdverseReaction
, . . O
toxic . . B-AdverseReaction
skin . . I-AdverseReaction
reactions . . I-AdverseReaction
and . . O
bullous . . B-AdverseReaction
exanthema . . I-AdverseReaction
. . . O

the . . O
safety . . O
of . . O
eliquis . . O
was . . O
evaluated . . O
in . . O
the . . O
aristotle . . O
and . . O
averroes . . O
studies . . O
[ . . O
seeclinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
, . . O
including . . O
11,284 . . O
patients . . O
exposed . . O
to . . O
eliquis . . O
5 . . O
mg . . O
twice . . O
daily . . O
and . . O
602 . . O
patients . . O
exposed . . O
to . . O
eliquis . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

anemia . . B-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
therapy . . O
. . . O

in . . O
3865 . . O
patients . . O
who . . O
received . . O
gilotrif . . O
across . . O
clinical . . O
trials . . O
, . . O
10.1% . . O
had . . O
liver . . B-AdverseReaction
test . . I-AdverseReaction
abnormalities . . I-AdverseReaction
, . . O
of . . O
which . . O
7 . . O
( . . O
0.18% . . O
) . . O
were . . O
fatal . . B-AdverseReaction
. . . O

these . . O
hematomas . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
long . . O
- . . O
term . . O
or . . O
permanent . . B-AdverseReaction
paralysis . . I-AdverseReaction
. . . O

review . . O
the . . O
full . . O
prescribing . . O
information . . O
for . . O
trametinib . . O
prior . . O
to . . O
initiation . . O
of . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

arcapta . . O
neohaler . . O
, . . O
like . . O
other . . O
sympathomimetic . . O
amines . . O
, . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
convulsive . . O
disorders . . O
or . . O
thyrotoxicosis . . O
, . . O
and . . O
in . . O
patients . . O
who . . O
are . . O
unusually . . O
responsive . . O
to . . O
sympathomimetic . . O
amines . . O
. . . O

5.11 . . O
vaccinations . . O

during . . O
controlled . . O
clinical . . O
studies . . O
, . . O
the . . O
proportion . . O
of . . O
patients . . O
with . . O
serious . . O
adverse . . O
reactions . . O
was . . O
10% . . O
for . . O
cimzia . . O
and . . O
9% . . O
for . . O
placebo . . O
. . . O

patients . . O
should . . O
be . . O
cautioned . . O
about . . O
operating . . O
hazardous . . O
machinery . . O
, . . O
including . . O
automobiles . . O
, . . O
until . . O
they . . O
are . . O
reasonably . . O
certain . . O
that . . O
therapy . . O
with . . O
fanapt . . O
does . . O
not . . O
affect . . O
them . . O
adversely . . O
. . . O

the . . O
population . . O
was . . O
45-77 . . O
years . . O
of . . O
age . . O
, . . O
63% . . O
male . . O
, . . O
100% . . O
white . . O
, . . O
and . . O
were . . O
treatment . . O
naive . . O
. . . O

vertigo . . O
has . . O
been . . O
reported . . O
in . . O
9% . . O
to . . O
14% . . O
of . . O
patients . . O
in . . O
caps . . O
studies . . O
, . . O
exclusively . . O
in . . O
mws . . O
patients . . O
, . . O
and . . O
reported . . O
as . . O
a . . O
serious . . B-Severity
adverse . . O
event . . O
in . . O
two . . O
cases . . O
. . . O

urogenital . . O
- . . O
balanitis . . B-AdverseReaction
, . . O
erection . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
hematuria . . B-AdverseReaction
, . . O
nephrolithiasis . . B-AdverseReaction
, . . O
pollakiuria . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction

consider . . O
dpp . . O
- . . O
4 . . O
inhibitors . . O
as . . O
a . . O
possible . . O
cause . . O
for . . O
severe . . O
joint . . O
pain . . O
and . . O
discontinue . . O
drug . . O
if . . O
appropriate . . O
. . . O

5.2 . . O
hepatotoxicity . . O

( . . O
5.5 . . O
) . . O
* . . O
embryofetal . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

5.4 . . O
risk . . O
of . . O
serious . . O
adverse . . O
reactions . . O
in . . O
patients . . O
with . . O
severe . . O
hepatic . . O
impairment . . O

the . . O
effects . . O
of . . O
xeomin . . O
and . . O
all . . O
botulinum . . O
toxin . . O
products . . O
may . . B-Factor
spread . . B-AdverseReaction
from . . I-AdverseReaction
the . . I-AdverseReaction
area . . I-AdverseReaction
of . . I-AdverseReaction
injection . . I-AdverseReaction
to . . O
produce . . O
symptoms . . O
consistent . . O
with . . O
botulinum . . O
toxin . . B-AdverseReaction
effects . . I-AdverseReaction
. . . O

monitor . . O
electrocardiograms . . O
and . . O
electrolytes . . O
in . . O
patients . . O
with . . O
congestive . . O
heart . . O
failure . . O
, . . O
bradyarrhythmias . . O
, . . O
electrolyte . . O
abnormalities . . O
, . . O
or . . O
those . . O
who . . O
are . . O
taking . . O
medications . . O
that . . O
are . . O
known . . O
to . . O
prolong . . O
the . . O
qtc . . O
interval . . O
. . . O

* . . O
hypotension . . B-AdverseReaction
and . . O
reflex . . B-AdverseReaction
tachycardia . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
2% . . O
) . . O
are . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
vomiting . . B-AdverseReaction
. . . O

5.1 . . O
hypersensitivity . . O
reactions . . O

5.2 . . O
contact . . O
lens . . O
use . . O

gastrointestinal . . O
disorders . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
besivance . . O
in . . O
approximately . . O
1,000 . . O
patients . . O
between . . O
1 . . O
and . . O
98 . . O
years . . O
old . . O
with . . O
clinical . . O
signs . . O
and . . O
symptoms . . O
of . . O
bacterial . . O
conjunctivitis . . O
. . . O

some . . O
events . . O
have . . O
been . . O
fatal . . B-AdverseReaction
. . . O

monitor . . O
liver . . O
function . . O
tests . . O
before . . O
treatment . . O
and . . O
before . . O
the . . O
start . . O
of . . O
each . . O
cycle . . O
. . . O

other . . O
findings . . O
: . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
and . . O
/ . . O
or . . O
oral . . B-AdverseReaction
paresthesia . . I-AdverseReaction
may . . O
occur . . O
directly . . O
after . . O
administration . . O
of . . O
saphris . . O
and . . O
usually . . O
resolves . . O
within . . O
1 . . O
hour . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O

urinary . . B-AdverseReaction
retention . . I-AdverseReaction
was . . O
generally . . O
reported . . O
within . . O
the . . O
first . . O
6 . . O
months . . O
of . . O
treatment . . O
, . . O
but . . O
was . . O
also . . O
observed . . O
later . . O
. . . O

warning . . O
: . . O
fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
toxicities . . B-AdverseReaction
: . . O
hepatic . . O
, . . O
severe . . B-Severity
diarrhea . . B-AdverseReaction
, . . O
colitis . . B-AdverseReaction
, . . O
pneumonitis . . B-AdverseReaction
, . . O
and . . O
intestinal . . B-AdverseReaction
perforation . . I-AdverseReaction

jardiance . . O
may . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
hypotension . . B-AdverseReaction
in . . O
patients . . O
at . . O
risk . . O
for . . O
volume . . O
contraction . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
, . . O
8.6 . . O
) . . O
] . . O
. . . O

before . . O
initiating . . O
therapy . . O
with . . O
zerbaxa . . O
, . . O
make . . O
careful . . O
inquiry . . O
about . . O
previous . . O
hypersensitivity . . O
reactions . . O
to . . O
other . . O
cephalosporins . . O
, . . O
penicillins . . O
, . . O
or . . O
other . . O
beta . . O
- . . O
lactams . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
uterine . . B-AdverseReaction
bleeding . . I-AdverseReaction
: . . O
evaluate . . O
irregular . . O
bleeding . . O
or . . O
amenorrhea . . O
. . . O

there . . O
is . . O
no . . O
known . . O
treatment . . O
for . . O
established . . O
cases . . O
of . . O
td . . O
, . . O
although . . O
the . . O
syndrome . . O
may . . O
remit . . O
, . . O
partially . . O
or . . O
completely . . O
, . . O
if . . O
antipsychotic . . O
treatment . . O
is . . O
withdrawn . . O
. . . O

therefore . . O
, . . O
the . . O
combination . . O
of . . O
anakinra . . O
with . . O
tnf . . O
- . . O
blockers . . O
, . . O
including . . O
simponi . . O
aria . . O
, . . O
is . . O
not . . O
recommended . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
] . . O
. . . O

the . . O
role . . O
of . . O
lymphopenia . . B-AdverseReaction
in . . O
this . . O
case . . O
is . . O
unknown . . O
. . . O

table . . O
4 . . O
selected . . O
hematological . . O
parameters . . O
previously . . O
untreated . . O
( . . O
sprint . . O
- . . O
1 . . O
and . . O
sprint . . O
- . . O
2 . . O
) . . O
previous . . O
treatment . . O
failures . . O
( . . O
respond . . O
- . . O
2 . . O
) . . O
percentage . . O
of . . O
subjects . . O
reporting . . O
selected . . O
hematological . . O
parameters . . O
percentage . . O
of . . O
subjects . . O
reporting . . O
selected . . O
hematological . . O
parameters . . O
hematological . . O
parameters . . O
victrelis . . O
+ . . O
pegintron . . O
+ . . O
rebetol . . O
( . . O
n . . O
= . . O
1225 . . O
) . . O
pegintron . . O
+ . . O
rebetol . . O
( . . O
n . . O
= . . O
467 . . O
) . . O
victrelis . . O
+ . . O
pegintron . . O
+ . . O
rebetol . . O
( . . O
n . . O
= . . O
323 . . O
) . . O
pegintron . . O
+ . . O
rebetol . . O
( . . O
n . . O
= . . O
80 . . O
) . . O
hemoglobin . . B-AdverseReaction
( . . I-AdverseReaction
g . . I-AdverseReaction
/ . . I-AdverseReaction
dl . . I-AdverseReaction
) . . I-AdverseReaction
< . . I-AdverseReaction
10 . . I-AdverseReaction
49 . . O
29 . . O
49 . . O
25 . . O
< . . O
8.5 . . O
6 . . O
3 . . O
10 . . O
1 . . O
neutrophils . . B-AdverseReaction
( . . I-AdverseReaction
* . . I-AdverseReaction
10 . . I-AdverseReaction
9 . . I-AdverseReaction
/ . . I-AdverseReaction
l . . I-AdverseReaction
) . . I-AdverseReaction
< . . I-AdverseReaction
0.75 . . I-AdverseReaction
31 . . O
18 . . O
26 . . O
13 . . O
< . . O
0.5 . . O
8 . . O
4 . . O
7 . . O
4 . . O
platelets . . B-AdverseReaction
( . . I-AdverseReaction
* . . I-AdverseReaction
10 . . I-AdverseReaction
9 . . I-AdverseReaction
/ . . I-AdverseReaction
l . . I-AdverseReaction
) . . I-AdverseReaction
< . . I-AdverseReaction
50 . . I-AdverseReaction
3 . . O
1 . . O
4 . . O
0 . . O
< . . O
25 . . O
< . . O
1 . . O
0 . . O
0 . . O
0 . . O
6.2 . . O
postmarketing . . O
experience . . O
the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
victrelis . . O
in . . O
combination . . O
with . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
. . . O

there . . O
is . . O
substantial . . O
evidence . . O
that . . O
cocs . . O
do . . O
not . . B-Negation
increase . . O
the . . O
incidence . . O
of . . O
breast . . B-AdverseReaction
cancer . . I-AdverseReaction
. . . O

severe . . B-Severity
hypoglycemia . . B-AdverseReaction
occurred . . O
in . . O
0% . . O
and . . O
0.7% . . O
of . . O
patients . . O
when . . O
trulicity . . O
0.75 . . O
mg . . O
and . . O
1.5 . . O
mg . . O
, . . O
respectively . . O
, . . O
was . . O
co . . O
- . . O
administered . . O
with . . O
a . . O
sulfonylurea . . O
. . . O

palpitations . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
. . . O

table . . O
3 . . O
: . . O
key . . O
laboratory . . O
abnormalities . . O
occurring . . O
in . . O
> . . O
10% . . O
( . . O
all . . O
nci . . O
ctcae . . O
grades . . O
) . . O
of . . O
alk . . O
- . . O
positive . . O
patients . . O
treated . . O
with . . O
zykadia . . O
in . . O
study . . O
1 . . O
zykadian . . O
= . . O
255 . . O
all . . O
grades . . O
grade . . O
3-4 . . O
% . . O
% . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
84 . . O
5 . . O
alanine . . O
transaminase . . O
( . . O
alt . . O
) . . O
increased . . O
80 . . O
27 . . O
aspartate . . O
transaminase . . O
( . . O
ast . . O
) . . O
increased . . O
75 . . O
13 . . O
creatinine . . B-AdverseReaction
increased . . I-AdverseReaction
58 . . O
2 . . O
glucose . . B-AdverseReaction
increased . . I-AdverseReaction
49 . . O
13 . . O
phosphate . . B-AdverseReaction
decreased . . I-AdverseReaction
36 . . O
7 . . O
lipase . . B-AdverseReaction
increased . . I-AdverseReaction
28 . . O
10 . . O
bilirubin . . O
( . . O
total . . O
) . . O
increased . . O
15 . . O
1 . . O

in . . O
study . . O
3 . . O
, . . O
22 . . O
/ . . O
230 . . O
( . . O
9.6% . . O
) . . O
patients . . O
had . . O
alanine . . O
aminotransferase . . O
or . . O
aspartate . . O
aminotransferase . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
during . . O
the . . O
overall . . O
treatment . . O
period . . O
. . . O

insulin . . O
and . . O
insulin . . O
secretagogues . . O
are . . O
known . . O
to . . O
cause . . O
hypoglycemia . . O
. . . O

five . . O
patients . . O
experienced . . O
fatal . . B-AdverseReaction
infectious . . B-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
sepsis . . B-AdverseReaction
or . . O
septic . . B-AdverseReaction
shock . . I-AdverseReaction
) . . O
. . . O

isolated . . O
delayed . . O
onset . . O
events . . O
, . . O
including . . O
transient . . B-Severity
asystole . . B-AdverseReaction
and . . O
unexplained . . O
death . . B-AdverseReaction
, . . O
have . . O
occurred . . O
within . . O
24 . . O
hours . . O
of . . O
the . . O
first . . O
dose . . O
. . . O

depending . . O
on . . O
the . . O
severity . . O
of . . O
hyponatremia . . O
, . . O
the . . O
dose . . O
of . . O
aptiom . . O
may . . O
need . . O
to . . O
be . . O
reduced . . O
or . . O
discontinued . . O
. . . O

patients . . O
with . . O
thyroid . . O
nodules . . O
noted . . O
on . . O
physical . . O
examination . . O
or . . O
neck . . O
imaging . . O
should . . O
also . . O
be . . O
further . . O
evaluated . . O
. . . O

assessment . . O
of . . O
the . . O
incidence . . O
of . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

however . . O
, . . O
there . . O
is . . O
controversy . . O
about . . O
the . . O
extent . . O
to . . O
which . . O
these . . O
findings . . O
may . . O
be . . O
due . . O
to . . O
differences . . O
in . . O
sexual . . O
behavior . . O
and . . O
other . . O
factors . . O
. . . O

5.3 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
was . . O
studied . . O
in . . O
2,369 . . O
subjects . . O
and . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
was . . O
studied . . O
in . . O
956 . . O
subjects . . O
. . . O

anti . . O
- . . O
belatacept . . O
antibody . . O
development . . O
was . . O
not . . O
associated . . O
with . . O
altered . . O
clearance . . O
of . . O
belatacept . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
: . . O
eye . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
flu . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
symptoms . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
allergic . . B-AdverseReaction
dermatitis . . I-AdverseReaction
, . . O
localized . . B-AdverseReaction
allergic . . I-AdverseReaction
reactions . . I-AdverseReaction
like . . O
swelling . . O
, . . O
edema . . O
, . . O
erythema . . O
, . . O
pruritus . . O
or . . O
rash . . O
, . . O
herpes . . B-AdverseReaction
zoster . . I-AdverseReaction
, . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
muscle . . B-AdverseReaction
spasm . . I-AdverseReaction
, . . O
dysarthria . . B-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction
. . . O

major . . B-Severity
bleeding . . B-AdverseReaction
events . . O
within . . O
each . . O
subcategory . . O
were . . O
counted . . O
once . . O
per . . O
patient . . O
, . . O
but . . O
patients . . O
may . . O
have . . O
contributed . . O
events . . O
to . . O
multiple . . O
subcategories . . O
. . . O
bannual . . O
event . . O
rate . . O
per . . O
100 . . O
pt . . O
- . . O
years . . O
= . . O
100 . . O
* . . O
number . . O
of . . O
subjects . . O
with . . O
event . . O
/ . . O
subject . . O
- . . O
years . . O
. . . O

* . . O
a . . O
data . . O
presented . . O
are . . O
to . . O
the . . O
primary . . O
endpoint . . O
and . . O
include . . O
only . . O
events . . O
occurring . . O
on . . O
- . . O
therapy . . O
with . . O
randomized . . O
medications . . O
and . . O
excludes . . O
events . . O
occurring . . O
after . . O
use . . O
of . . O
glycemic . . O
rescue . . O
medications . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
primarily . . O
metformin . . O
or . . O
insulin . . O
) . . O
. . . O

non . . B-AdverseReaction
- . . I-AdverseReaction
infectious . . I-AdverseReaction
pneumonitis . . I-AdverseReaction
is . . O
a . . O
class . . O
effect . . O
of . . O
rapamycin . . O
derivatives . . O
, . . O
including . . O
afinitor . . O
. . . O

a . . O
similar . . O
trend . . O
was . . O
also . . O
seen . . O
in . . O
the . . O
cuti . . O
trial . . O
. . . O

there . . O
are . . O
no . . O
adequate . . O
and . . O
well . . O
- . . O
controlled . . O
studies . . O
in . . O
pregnant . . O
women . . O
using . . O
jevtana . . O
. . . O

the . . O
following . . O
adverse . . O
reaction . . O
is . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
label . . O
: . . O

5.4 . . O
use . . O
in . . O
children . . O

short . . O
- . . O
term . . O
studies . . O
did . . O
not . . B-Negation
show . . O
an . . O
increase . . O
in . . O
the . . O
risk . . O
of . . O
suicidality . . B-AdverseReaction
with . . O
antidepressants . . O
compared . . O
to . . O
placebo . . O
in . . O
adults . . O
beyond . . O
age . . O
24 . . O
; . . O
there . . O
was . . O
a . . O
reduction . . O
with . . O
antidepressants . . O
compared . . O
to . . O
placebo . . O
in . . O
adults . . O
aged . . O
65 . . O
and . . O
older . . O
. . . O

antibodies . . O
against . . O
ilaris . . O
were . . O
observed . . O
in . . O
approximately . . O
1.5% . . O
and . . O
3.1% . . O
of . . O
the . . O
patients . . O
treated . . O
with . . O
ilaris . . O
for . . O
caps . . O
and . . O
sjia . . O
, . . O
respectively . . O
. . . O

( . . O
ctcae . . O
) . . O
version . . O
3 . . O
scale . . O
. . . O

gingival . . B-AdverseReaction
bleeding . . I-AdverseReaction
, . . O
hemoptysis . . B-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
ocular . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
( . . O
including . . O
conjunctival . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
) . . O
, . . O
rectal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction

blood . . O
pressure . . O
should . . O
be . . O
well . . O
- . . O
controlled . . O
prior . . O
to . . O
initiating . . O
inlyta . . O
. . . O

5.3 . . O
drug . . O
interactions . . O
with . . O
cyp3a4 . . O

patients . . O
with . . O
severe . . O
hepatic . . O
impairment . . O
may . . O
be . . O
at . . O
higher . . O
risk . . O
of . . O
serious . . O
adverse . . O
reactions . . O
( . . O
including . . O
dose . . O
- . . O
related . . O
serious . . O
adverse . . O
reactions . . O
) . . O
because . . O
up . . O
to . . O
10 . . O
- . . O
fold . . O
higher . . O
plasma . . O
levels . . O
of . . O
drug . . O
have . . O
been . . O
observed . . O
in . . O
such . . O
patients . . O
compared . . O
with . . O
patients . . O
with . . O
normal . . O
hepatic . . O
function . . O
. . . O

5.2 . . O
infections . . O

* . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
lymphopenia . . B-AdverseReaction
* . . O
gastrointestinal . . O
disorders . . O
: . . O
pancreatitis . . B-AdverseReaction
* . . O
hepatobiliary . . O
disorders . . O
: . . O
hepatotoxicity . . B-AdverseReaction
* . . O
immune . . O
system . . O
disorders . . O
: . . O
drug . . O
hypersensitivity . . B-AdverseReaction
* . . O
infections . . O
and . . O
infestations . . O
: . . O
pneumonia . . B-AdverseReaction
, . . O
sepsis . . B-AdverseReaction
/ . . O
neutropenic . . B-AdverseReaction
sepsis . . I-AdverseReaction
* . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
hypomagnesemia . . B-AdverseReaction
, . . O
dehydration . . B-AdverseReaction
* . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
* . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
pruritus . . B-AdverseReaction

if . . O
ribavirin . . O
is . . O
permanently . . O
discontinued . . O
, . . O
then . . O
peginterferon . . O
alfa . . O
and . . O
victrelis . . O
must . . O
also . . O
be . . O
discontinued . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

inform . . O
patients . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
anaphylaxis . . O
, . . O
and . . O
instruct . . O
them . . O
to . . O
seek . . O
immediate . . O
medical . . O
care . . O
should . . O
signs . . O
and . . O
symptoms . . O
occur . . O
. . . O

cigarette . . O
smoking . . O
increases . . O
the . . O
risk . . O
of . . O
serious . . O
cardiovascular . . B-AdverseReaction
events . . I-AdverseReaction
from . . O
combination . . B-DrugClass
oral . . I-DrugClass
contraceptives . . I-DrugClass
( . . O
coc . . O
) . . O
use . . O
. . . O

eye . . O
disorders . . O
: . . O
frequent . . O
- . . O
conjunctivitis . . B-AdverseReaction
( . . O
including . . O
allergic . . O
) . . O
; . . O
infrequent . . O
- . . O
dry . . B-AdverseReaction
eye . . I-AdverseReaction
, . . O
blepharitis . . B-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
lenticular . . B-AdverseReaction
opacities . . I-AdverseReaction
, . . O
cataract . . B-AdverseReaction
, . . O
hyperemia . . B-AdverseReaction
( . . O
including . . O
conjunctival . . O
) . . O

there . . O
have . . O
been . . O
reports . . O
of . . O
severe . . B-Severity
hepatic . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
acute . . B-AdverseReaction
liver . . I-AdverseReaction
failure . . I-AdverseReaction
in . . O
patients . . O
receiving . . O
tnf . . B-DrugClass
- . . I-DrugClass
blockers . . I-DrugClass
. . . O

in . . O
the . . O
controlled . . O
and . . O
uncontrolled . . O
portions . . O
of . . O
trial . . O
1 . . O
, . . O
in . . O
simponi . . O
aria . . O
treated . . O
patients . . O
, . . O
the . . O
incidence . . O
of . . O
active . . B-AdverseReaction
tb . . I-AdverseReaction
per . . O
100 . . O
patient . . O
- . . O
years . . O
was . . O
0.31 . . O
( . . O
95% . . O
ci . . O
: . . O
0.06 . . O
; . . O
0.92 . . O
) . . O
and . . O
the . . O
incidence . . O
of . . O
other . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
per . . O
100 . . O
patient . . O
- . . O
years . . O
was . . O
0.42 . . O
( . . O
95% . . O
ci . . O
: . . O
0.11 . . O
, . . O
1.07 . . O
) . . O
. . . O

( . . O
5.1 . . O
, . . O
5.2 . . O
, . . O
5.3 . . O
, . . O
5.4 . . O
, . . O
5.5 . . O
) . . O

tafinlar . . O
, . . O
which . . O
contains . . O
a . . O
sulfonamide . . O
moiety . . O
, . . O
confers . . O
a . . O
potential . . O
risk . . B-Factor
of . . O
hemolytic . . B-AdverseReaction
anemia . . I-AdverseReaction
in . . O
patients . . O
with . . O
glucose . . O
- . . O
6 . . O
- . . O
phosphate . . O
dehydrogenase . . O
( . . O
g6pd . . O
) . . O
deficiency . . O
. . . O

the . . O
incidence . . O
of . . O
rash . . B-AdverseReaction
was . . O
higher . . O
in . . O
women . . O
compared . . O
to . . O
men . . O
in . . O
the . . O
intelence . . O
( . . O
r . . O
) . . O
arm . . O
in . . O
the . . O
phase . . O
3 . . O
trials . . O
( . . O
rash . . B-AdverseReaction
> . . O
= . . O
grade . . B-Severity
2 . . I-Severity
was . . O
reported . . O
in . . O
9 . . O
/ . . O
60 . . O
[ . . O
15.0% . . O
] . . O
women . . O
versus . . O
51 . . O
/ . . O
539 . . O
[ . . O
9.5% . . O
] . . O
men . . O
; . . O
discontinuations . . O
due . . O
to . . O
rash . . B-AdverseReaction
were . . O
reported . . O
in . . O
3 . . O
/ . . O
60 . . O
[ . . O
5.0% . . O
] . . O
women . . O
versus . . O
10 . . O
/ . . O
539 . . O
[ . . O
1.9% . . O
] . . O
men . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

discontinue . . O
if . . O
evidence . . O
of . . O
liver . . O
injury . . O
. . . O

5.9 . . O
preparation . . O
and . . O
administration . . O
errors . . O

a . . O
higher . . O
risk . . B-Factor
of . . O
serious . . B-Severity
infections . . B-AdverseReaction
was . . O
also . . O
observed . . O
in . . O
combination . . O
use . . O
of . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
with . . O
abatacept . . O
and . . O
rituximab . . O
. . . O

both . . O
granix . . O
and . . O
the . . O
non . . O
- . . O
us . . O
- . . O
approved . . O
filgrastim . . O
product . . O
were . . O
administered . . O
at . . O
5 . . O
mcg . . O
/ . . O
kg . . O
subcutaneously . . O
once . . O
daily . . O
beginning . . O
one . . O
day . . O
after . . O
chemotherapy . . O
for . . O
at . . O
least . . O
five . . O
days . . O
and . . O
continued . . O
to . . O
a . . O
maximum . . O
of . . O
14 . . O
days . . O
or . . O
until . . O
an . . O
anc . . O
of . . O
> . . O
= . . O
10,000 . . O
x . . O
10 . . O
6 . . O
/ . . O
l . . O
after . . O
nadir . . O
was . . O
reached . . O
. . . O

laboratory . . O
parameters . . O
: . . O
activated . . B-AdverseReaction
partial . . I-AdverseReaction
thromboplastin . . I-AdverseReaction
time . . I-AdverseReaction
prolonged . . I-AdverseReaction
, . . O
creatine . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
bicarbonate . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
sodium . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
eeg . . B-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
glucose . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
cholesterol . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
triglycerides . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
amylase . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
potassium . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
tsh . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
platelet . . B-AdverseReaction
count . . I-AdverseReaction
decreased . . I-AdverseReaction
, . . O
hematocrit . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
mcv . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
rbc . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
creatinine . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
urea . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
bun . . B-AdverseReaction
/ . . I-AdverseReaction
creatinine . . I-AdverseReaction
ratio . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
creatine . . O
phosphokinase . . O
( . . O
cpk . . O
) . . O
increased . . O
, . . O
alkaline . . B-AdverseReaction
phosphatase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
ldh . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
psa . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
urine . . B-AdverseReaction
output . . I-AdverseReaction
increased . . I-AdverseReaction
/ . . O
decreased . . O
, . . O
lymphocyte . . B-AdverseReaction
count . . I-AdverseReaction
decreased . . I-AdverseReaction
, . . O
neutrophil . . B-AdverseReaction
count . . I-AdverseReaction
decreased . . I-AdverseReaction
, . . O
wbc . . B-AdverseReaction
increased . . I-AdverseReaction
/ . . O
decreased . . O
, . . O
coagulation . . B-AdverseReaction
test . . I-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
low . . O
density . . O
lipoprotein . . O
( . . O
ldl . . O
) . . O
increased . . O
, . . O
prothrombin . . B-AdverseReaction
time . . I-AdverseReaction
prolonged . . I-AdverseReaction
, . . O
urinary . . B-AdverseReaction
casts . . I-AdverseReaction
, . . O
urine . . B-AdverseReaction
positive . . I-AdverseReaction
for . . I-AdverseReaction
white . . I-AdverseReaction
blood . . I-AdverseReaction
cells . . I-AdverseReaction
and . . O
protein . . O
. . . O

controlled . . O
studies . . O
with . . O
crohn's . . O
disease . . O

sixty . . O
- . . O
one . . O
patients . . O
( . . O
47.3% . . O
) . . O
experienced . . O
serious . . O
adverse . . O
reactions . . O
while . . O
taking . . O
beleodaq . . O
or . . O
within . . O
30 . . O
days . . O
after . . O
their . . O
last . . O
dose . . O
of . . O
beleodaq . . O
. . . O

injection . . O
into . . O
these . . O
structures . . O
may . . B-Factor
result . . O
in . . O
possible . . O
permanent . . B-AdverseReaction
injury . . I-AdverseReaction
such . . O
as . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
( . . O
penile . . B-AdverseReaction
fracture . . I-AdverseReaction
) . . O
. . . O

* . . O
women . . O
taking . . O
duavee . . O
should . . O
not . . O
take . . O
additional . . O
estrogens . . O
( . . O
5.1 . . O
) . . O
* . . O
there . . O
is . . O
an . . O
increased . . O
risk . . O
of . . O
endometrial . . B-AdverseReaction
cancer . . I-AdverseReaction
in . . O
a . . O
woman . . O
with . . O
a . . O
uterus . . O
who . . O
uses . . O
unopposed . . O
estrogens . . B-DrugClass
( . . O
5.1 . . O
, . . O
5.3 . . O
) . . O
* . . O
estrogen . . O
therapy . . O
should . . O
not . . O
be . . O
used . . O
for . . O
the . . O
prevention . . O
of . . O
cardiovascular . . O
disease . . O
or . . O
dementia . . O
( . . O
5.2 . . O
, . . O
5.4 . . O
) . . O
* . . O
the . . O
women's . . O
health . . O
initiative . . O
( . . O
whi . . O
) . . O
estrogen . . B-DrugClass
- . . O
alone . . O
substudy . . O
reported . . O
increased . . O
risks . . O
of . . O
stroke . . B-AdverseReaction
and . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
( . . O
dvt . . B-AdverseReaction
) . . O
( . . O
5.2 . . O
) . . O
* . . O
the . . O
whi . . O
memory . . O
study . . O
( . . O
whims . . O
) . . O
estrogen . . B-DrugClass
- . . O
alone . . O
ancillary . . O
study . . O
of . . O
whi . . O
reported . . O
an . . O
increased . . O
risk . . O
of . . O
probable . . O
dementia . . B-AdverseReaction
in . . O
postmenopausal . . O
women . . O
65 . . O
years . . O
of . . O
age . . O
and . . O
older . . O
( . . O
5.4 . . O
) . . O

clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
diarrhea . . I-AdverseReaction
( . . O
cdad . . B-AdverseReaction
) . . O
has . . O
been . . O
reported . . O
for . . O
nearly . . O
all . . O
systemic . . O
antibacterial . . O
agents . . O
, . . O
including . . O
teflaro . . O
, . . O
and . . O
may . . O
range . . O
in . . O
severity . . O
from . . O
mild . . B-Severity
diarrhea . . B-AdverseReaction
to . . O
fatal . . B-AdverseReaction
colitis . . B-AdverseReaction
. . . O

the . . O
following . . O
have . . O
been . . O
observed . . O
with . . O
benlysta . . O
and . . O
are . . O
discussed . . O
in . . O
detail . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O
: . . O

disruption . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
body's . . I-AdverseReaction
ability . . I-AdverseReaction
to . . I-AdverseReaction
reduce . . I-AdverseReaction
core . . I-AdverseReaction
body . . I-AdverseReaction
temperature . . I-AdverseReaction
has . . O
been . . O
attributed . . O
to . . O
antipsychotic . . B-DrugClass
agents . . I-DrugClass
. . . O

signs . . O
and . . O
symptoms . . O
have . . O
included . . O
difficulty . . B-AdverseReaction
breathing . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
and . . O
swelling . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
throat . . I-AdverseReaction
and . . O
tongue . . O
. . . O

measure . . O
serum . . O
alt . . O
, . . O
ast . . O
, . . O
and . . O
bilirubin . . O
prior . . O
to . . O
initiation . . O
of . . O
promacta . . O
, . . O
every . . O
2 . . O
weeks . . O
during . . O
the . . O
dose . . O
adjustment . . O
phase . . O
, . . O
and . . O
monthly . . O
following . . O
establishment . . O
of . . O
a . . O
stable . . O
dose . . O
. . . O

5.3 . . O
immune . . O
- . . O
mediated . . O
dermatitis . . O

closely . . O
observe . . O
patients . . O
during . . O
and . . O
after . . O
vimizim . . O
administration . . O
and . . O
be . . O
prepared . . O
to . . O
manage . . O
anaphylaxis . . O
. . . O

6.3 . . O
immunogenicity . . O

5.5 . . O
severe . . O
and . . O
disabling . . O
arthralgia . . O

the . . O
most . . O
common . . O
reasons . . O
for . . O
interruption . . O
or . . O
discontinuations . . O
were . . O
diarrhea . . B-AdverseReaction
( . . O
11% . . O
) . . O
, . . O
pneumonia . . B-AdverseReaction
( . . O
11% . . O
) . . O
, . . O
and . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
( . . O
10% . . O
) . . O
. . . O

women . . O
who . . O
currently . . O
have . . O
or . . O
have . . O
had . . O
breast . . O
cancer . . O
should . . O
not . . O
use . . O
natazia . . O
because . . O
breast . . O
cancer . . O
is . . O
a . . O
hormonally . . O
- . . O
sensitive . . O
tumor . . O
. . . O

in . . O
the . . O
controlled . . O
adjunctive . . O
therapy . . O
epilepsy . . O
trials . . O
( . . O
study . . O
3 . . O
, . . O
study . . O
4 . . O
, . . O
and . . O
study . . O
5 . . O
) . . O
, . . O
the . . O
rate . . O
of . . O
discontinuation . . O
as . . O
a . . O
result . . O
of . . O
any . . O
adverse . . O
reaction . . O
was . . O
14% . . O
for . . O
the . . O
800 . . O
mg . . O
dose . . O
, . . O
25% . . O
for . . O
the . . O
1200 . . O
mg . . O
dose . . O
, . . O
and . . O
7% . . O
in . . O
subjects . . O
randomized . . O
to . . O
placebo . . O
. . . O

this . . O
trial . . O
involved . . O
saphris . . O
doses . . O
of . . O
5 . . O
mg . . O
, . . O
10 . . O
mg . . O
, . . O
15 . . O
mg . . O
, . . O
and . . O
20 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
placebo . . O
, . . O
and . . O
was . . O
conducted . . O
in . . O
151 . . O
clinically . . O
stable . . O
patients . . O
with . . O
schizophrenia . . O
, . . O
with . . O
electrocardiographic . . O
assessments . . O
throughout . . O
the . . O
dosing . . O
interval . . O
at . . O
baseline . . O
and . . O
steady . . O
state . . O
. . . O

5.6 . . O
thyroid . . O
accumulation . . O

in . . O
studies . . O
of . . O
ace . . B-DrugClass
inhibitors . . I-DrugClass
in . . O
patients . . O
with . . O
unilateral . . O
or . . O
bilateral . . O
renal . . O
artery . . O
stenosis . . O
, . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
or . . O
blood . . O
urea . . O
nitrogen . . O
have . . O
been . . O
reported . . O
. . . O

use . . O
with . . O
drugs . . O
that . . O
prolong . . O
the . . O
qt . . O
interval . . O
may . . B-Factor
cause . . O
additive . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
. . . O

5.3 . . O
drug . . O
reaction . . O
with . . O
eosinophilia . . O
and . . O
systemic . . O
symptoms . . O
( . . O
dress . . O
) . . O
/ . . O
multiorgan . . O
hypersensitivity . . O

non . . B-AdverseReaction
- . . I-AdverseReaction
infectious . . I-AdverseReaction
pneumonitis . . I-AdverseReaction
was . . O
reported . . O
in . . O
up . . O
to . . O
19% . . O
of . . O
patients . . O
treated . . O
with . . O
afinitor . . O
in . . O
clinical . . O
trials . . O
. . . O

injury . . O
, . . O
poisoning . . O
, . . O
and . . O
procedural . . O
complications . . O
: . . O
wound . . B-AdverseReaction
secretion . . I-AdverseReaction
, . . O
incision . . B-AdverseReaction
- . . I-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
( . . O
including . . O
incision . . B-AdverseReaction
- . . I-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
) . . O
, . . O
operative . . B-AdverseReaction
hemorrhage . . I-AdverseReaction

in . . O
the . . O
pool . . O
of . . O
four . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
dose . . O
- . . O
related . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
ldl . . I-AdverseReaction
- . . I-AdverseReaction
c . . I-AdverseReaction
with . . O
invokana . . O
were . . O
observed . . O
. . . O

trials . . O
3 . . O
and . . O
4 . . O
included . . O
3,255 . . O
subjects . . O
, . . O
of . . O
which . . O
57% . . O
were . . O
male . . O
and . . O
85% . . O
were . . O
white . . O
. . . O

dose . . O
modification . . O
due . . O
to . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
or . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
occurred . . O
in . . O
38% . . O
of . . O
patients . . O
. . . O

and . . O
hereditary . . O
angioedema . . O
and . . O
patients . . O
should . . O
be . . O
monitored . . O
closely . . O
. . . O

table . . O
4 . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
subjects . . O
treated . . O
with . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
and . . O
at . . O
higher . . O
frequency . . O
than . . O
vehicle . . O
( . . O
trunk . . O
/ . . O
extremities . . O
trials . . O
) . . O

in . . O
the . . O
emtp . . O
trial . . O
, . . O
safety . . O
data . . O
were . . O
derived . . O
from . . O
case . . O
report . . O
forms . . O
that . . O
collected . . O
adverse . . O
event . . O
information . . O
. . . O

the . . O
data . . O
presented . . O
below . . O
are . . O
based . . O
on . . O
information . . O
collected . . O
from . . O
study . . O
1 . . O
, . . O
a . . O
single . . O
- . . O
arm . . O
, . . O
multi . . O
- . . O
center . . O
, . . O
open . . O
- . . O
label . . O
, . . O
safety . . O
and . . O
clinical . . O
pharmacology . . O
trial . . O
( . . O
intramuscular . . O
administration . . O
) . . O
, . . O
the . . O
erwinaze . . O
master . . O
treatment . . O
protocol . . O
( . . O
emtp . . O
) . . O
, . . O
an . . O
expanded . . O
access . . O
program . . O
( . . O
both . . O
intramuscular . . O
, . . O
intravenous . . O
, . . O
and . . O
other . . O
or . . O
unknown . . O
administration . . O
) . . O
, . . O
and . . O
study . . O
2 . . O
, . . O
a . . O
single . . O
- . . O
arm . . O
, . . O
multi . . O
- . . O
center . . O
, . . O
open . . O
- . . O
label . . O
, . . O
pharmacokinetic . . O
( . . O
pk . . O
) . . O
study . . O
trial . . O
of . . O
intravenous . . O
administration . . O
of . . O
erwinaze . . O
. . . O
study . . O
1 . . O
enrolled . . O
58 . . O
patients . . O
treated . . O
on . . O
national . . O
cancer . . O
institute . . O
( . . O
nci . . O
) . . O
- . . O
sponsored . . O
cooperative . . O
group . . O
all . . O
protocols . . O
who . . O
were . . O
unable . . O
to . . O
continue . . O
to . . O
receive . . O
pegaspargase . . O
due . . O
to . . O
hypersensitivity . . O
reactions . . O
. . . O

6.1 . . O
clinical . . O
trial . . O
experience . . O

prosthetic . . O
heart . . O
valves . . O
: . . O
eliquis . . O
use . . O
not . . O
recommended . . O
. . . O
( . . O
5.4 . . O
) . . O
5.1 . . O
increased . . O
risk . . O
of . . O
thrombotic . . O
events . . O
after . . O
premature . . O
discontinuation . . O

5.2 . . O
hypersensitivity . . O
reactions . . O

for . . O
patients . . O
who . . O
reside . . O
or . . O
travel . . O
in . . O
regions . . O
where . . O
mycoses . . O
are . . O
endemic . . O
, . . O
invasive . . O
fungal . . O
infection . . O
should . . O
be . . O
suspected . . O
if . . O
they . . O
develop . . O
a . . O
serious . . O
systemic . . O
illness . . O
. . . O

less . . O
common . . O
adverse . . O
reactions . . O

in . . O
study . . O
2 . . O
only . . O
voraxaze . . O
- . . O
related . . O
adverse . . O
reactions . . O
were . . O
collected . . O
and . . O
severity . . O
was . . O
graded . . O
according . . O
to . . O
nci . . O
ctcae . . O
version . . O
3 . . O
. . . O

monitor . . O
alt . . O
, . . O
aspartate . . O
aminotransferase . . O
( . . O
ast . . O
) . . O
and . . O
bilirubin . . O
before . . O
initiation . . O
of . . O
and . . O
periodically . . O
throughout . . O
treatment . . O
with . . O
inlyta . . O
. . . O

5.6 . . O
fungal . . O
infections . . O

since . . O
no . . O
data . . O
are . . O
available . . O
on . . O
either . . O
the . . O
efficacy . . O
or . . O
on . . O
the . . O
risks . . O
of . . O
secondary . . O
transmission . . O
of . . O
infection . . O
by . . O
live . . O
vaccines . . O
in . . O
patients . . O
receiving . . O
ilaris . . O
, . . O
live . . O
vaccines . . O
should . . O
not . . O
be . . O
given . . O
concurrently . . O
with . . O
ilaris . . O
. . . O

infections . . O

a . . O
negative . . O
image . . O
does . . O
not . . O
rule . . O
out . . O
the . . O
presence . . O
of . . O
recurrent . . O
prostate . . O
cancer . . O
and . . O
a . . O
positive . . O
image . . O
does . . O
not . . O
confirm . . O
the . . O
presence . . O
of . . O
recurrent . . O
cancer . . O
. . . O

the . . O
most . . O
common . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reaction . . O
that . . O
occurred . . O
at . . O
an . . O
incidence . . O
of . . O
at . . O
least . . O
1% . . O
or . . O
greater . . O
in . . O
patients . . O
treated . . O
with . . O
granix . . O
at . . O
the . . O
recommended . . O
dose . . O
and . . O
was . . O
numerically . . O
two . . O
times . . O
more . . O
frequent . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
was . . O
bone . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

5.4 . . O
immune . . O
- . . O
mediated . . O
neuropathies . . O

ilaris . . O
should . . O
not . . O
be . . O
administered . . O
to . . O
any . . O
patients . . O
with . . O
known . . O
clinical . . O
hypersensitivity . . O
to . . O
ilaris . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
including . . O
cases . . O
with . . O
fatal . . B-AdverseReaction
outcomes . . O
, . . O
has . . O
been . . O
reported . . O
. . . O

delay . . O
in . . O
diagnosis . . O
and . . O
treatment . . O
may . . O
lead . . O
to . . O
permanent . . O
neurological . . O
sequelae . . O
. . . O

if . . O
this . . O
product . . O
is . . O
to . . O
be . . O
given . . O
to . . O
a . . O
patient . . O
with . . O
a . . O
cephalosporin . . O
, . . O
penicillin . . O
, . . O
or . . O
other . . O
beta . . O
- . . O
lactam . . O
allergy . . O
, . . O
exercise . . O
caution . . O
because . . O
cross . . O
sensitivity . . O
has . . O
been . . O
established . . O
. . . O

hypertension . . O

chronic . . O
antipsychotic . . O
treatment . . O
should . . O
generally . . O
be . . O
reserved . . O
for . . O
patients . . O
who . . O
suffer . . O
from . . O
a . . O
chronic . . O
illness . . O
that . . O
( . . O
1 . . O
) . . O
is . . O
known . . O
to . . O
respond . . O
to . . O
antipsychotic . . O
drugs . . O
, . . O
and . . O
( . . O
2 . . O
) . . O
for . . O
whom . . O
alternative . . O
, . . O
equally . . O
effective . . O
, . . O
but . . O
potentially . . O
less . . O
harmful . . O
treatments . . O
are . . O
not . . O
available . . O
or . . O
appropriate . . O
. . . O

in . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
bipolar . . O
mania . . O
adult . . O
trials . . O
, . . O
the . . O
mean . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
prolactin . . I-AdverseReaction
levels . . I-AdverseReaction
was . . O
4.9 . . O
ng . . O
/ . . O
ml . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
a . . O
decrease . . O
of . . O
0.2 . . O
ng . . O
/ . . O
ml . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

rare . . O
reports . . O
of . . O
pancytopenia . . B-AdverseReaction
, . . O
including . . O
aplastic . . B-AdverseReaction
anemia . . I-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
with . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
. . . O

at . . O
three . . O
years . . O
after . . O
transplantation . . O
, . . O
systolic . . O
blood . . O
pressures . . O
were . . O
6 . . O
mmhg . . O
lower . . O
and . . O
diastolic . . O
blood . . O
pressures . . O
were . . O
3 . . O
mmhg . . O
lower . . O
in . . O
nulojix . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
cyclosporine . . O
- . . O
treated . . O
patients . . O
. . . O

ssris . . O
and . . O
snris . . O
, . . O
including . . O
pristiq . . O
, . . O
may . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
bleeding . . B-AdverseReaction
events . . O
. . . O

serum . . O
creatinine . . O
levels . . O
and . . O
estimated . . O
gfr . . O
may . . O
not . . O
reliably . . O
assess . . O
renal . . O
function . . O
in . . O
the . . O
setting . . O
of . . O
acute . . O
kidney . . O
injury . . O
. . . O

discontinue . . O
cometriq . . O
for . . O
hypertensive . . O
crisis . . O
. . . O

observational . . O
studies . . O
suggest . . O
that . . O
, . . O
similar . . O
to . . O
atypical . . O
antipsychotic . . O
drugs . . O
, . . O
treatment . . O
with . . O
conventional . . O
antipsychotic . . O
drugs . . O
may . . O
increase . . O
mortality . . O
. . . O

splenic . . B-AdverseReaction
rupture . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O

6.2 . . O
immunogenicity . . O

patients . . O
should . . O
be . . O
informed . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
an . . O
acute . . O
hypersensitivity . . O
reaction . . O
and . . O
be . . O
instructed . . O
to . . O
seek . . O
immediate . . O
medical . . O
care . . O
should . . O
a . . O
reaction . . O
occur . . O
. . . O

advise . . O
all . . O
patients . . O
to . . O
seek . . O
immediate . . O
medical . . O
attention . . O
if . . O
they . . O
develop . . O
signs . . O
and . . O
symptoms . . O
suggestive . . O
of . . O
blood . . O
dyscrasias . . O
or . . O
infection . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
persistent . . O
fever . . O
, . . O
bruising . . O
, . . O
bleeding . . O
, . . O
pallor . . O
) . . O
while . . O
on . . O
cimzia . . O
. . . O

( . . O
5.11 . . O
) . . O
* . . O
the . . O
starting . . O
dose . . O
of . . O
inlyta . . O
should . . O
be . . O
decreased . . O
if . . O
used . . O
in . . O
patients . . O
with . . O
moderate . . O
hepatic . . O
impairment . . O
. . . O

a . . O
subset . . O
of . . O
patients . . O
experienced . . O
a . . O
recurrence . . O
of . . O
symptoms . . O
when . . O
restarting . . O
the . . O
same . . O
drug . . O
or . . O
a . . O
different . . O
dpp . . O
- . . O
4 . . O
inhibitor . . O
. . . O

treatment . . O
with . . O
edarbi . . O
was . . O
well . . O
- . . O
tolerated . . O
with . . O
an . . O
overall . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
similar . . O
to . . O
placebo . . O
. . . O

( . . O
a . . O
) . . O
premature . . O
discontinuation . . O
of . . O
eliquis . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
: . . O
premature . . O
discontinuation . . O
of . . O
any . . O
oral . . O
anticoagulant . . O
, . . O
including . . O
eliquis . . O
, . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
. . . O

6.2 . . O
postmarketing . . O
experience . . O

higher . . O
than . . O
recommended . . O
dosing . . O
or . . O
repeat . . O
dosing . . O
appear . . O
to . . O
increase . . O
the . . O
risk . . O
. . . O

closely . . O
monitor . . O
patients . . O
for . . O
the . . O
development . . O
of . . O
signs . . O
and . . O
symptoms . . O
of . . O
infection . . O
during . . O
and . . O
after . . O
treatment . . O
with . . O
simponi . . O
aria . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

serious . . B-Severity
infections . . B-AdverseReaction
observed . . O
included . . O
bacterial . . O
and . . O
viral . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
and . . O
pyelonephritis . . B-AdverseReaction
. . . O

cardiac . . O
disorders . . O
: . . O
tachycardia . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
congestive . . B-AdverseReaction
cardiac . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
1% . . O
) . . O

the . . O
mean . . O
change . . O
from . . O
baseline . . O
observed . . O
for . . O
selected . . O
lipid . . O
values . . O
is . . O
presented . . O
in . . O
table . . O
4 . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
monitor . . O
for . . O
suicidal . . O
thoughts . . O
or . . O
behaviors . . O
. . . O

in . . O
acute . . O
purulent . . O
conditions . . O
, . . O
steroids . . O
may . . O
mask . . O
infection . . O
or . . O
enhance . . O
existing . . O
infection . . O
. . . O

hypersensitivity . . O
reactions . . O
in . . O
the . . O
4 . . O
pivotal . . O
studies . . O
, . . O
drug . . O
hypersensitivity . . B-AdverseReaction
( . . O
including . . O
urticaria . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
pruritus . . B-AdverseReaction
) . . O
, . . O
allergic . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
anaphylactic . . B-AdverseReaction
reaction . . I-AdverseReaction
, . . O
and . . O
anaphylactic . . B-AdverseReaction
shock . . I-AdverseReaction
were . . O
reported . . O
in . . O
0.1% . . O
of . . O
patients . . O
receiving . . O
pradaxa . . O
. . . O

5.6 . . O
increased . . O
toxicity . . O
in . . O
the . . O
presence . . O
of . . O
severe . . O
renal . . O
impairment . . O

in . . O
pooled . . O
clinical . . O
trials . . O
, . . O
the . . O
incidence . . O
of . . O
agranulocytosis . . B-AdverseReaction
was . . O
1.7% . . O
of . . O
patients . . O
. . . O

the . . O
majority . . O
of . . O
the . . O
tb . . B-AdverseReaction
cases . . O
occurred . . O
in . . O
countries . . O
with . . O
a . . O
high . . O
incidence . . O
rate . . O
of . . O
tb . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

* . . O
long . . O
- . . O
acting . . O
beta2 . . O
- . . O
adrenergic . . O
agonists . . O
( . . O
laba . . B-DrugClass
) . . O
, . . O
such . . O
as . . O
vilanterol . . O
, . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
. . . O

the . . O
median . . O
duration . . O
of . . O
study . . O
treatment . . O
was . . O
10.9 . . O
months . . O
for . . O
patients . . O
in . . O
the . . O
xalkori . . O
arm . . O
and . . O
4.1 . . O
months . . O
for . . O
patients . . O
in . . O
the . . O
chemotherapy . . O
arm . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
to . . O
treanda . . O
have . . O
occurred . . O
commonly . . O
in . . O
clinical . . O
trials . . O
. . . O

item{ . . O
bacterial . . O
infections . . O
- . . O
prolonged . . O
use . . O
of . . O
corticosteroids . . B-DrugClass
may . . O
suppress . . B-AdverseReaction
the . . I-AdverseReaction
host . . I-AdverseReaction
response . . I-AdverseReaction
and . . O
thus . . O
increase . . O
the . . O
hazard . . O
of . . O
secondary . . B-AdverseReaction
ocular . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

permanently . . O
discontinue . . O
xtandi . . O
in . . O
patients . . O
who . . O
develop . . O
a . . O
seizure . . O
during . . O
treatment . . O
. . . O

in . . O
a . . O
historically . . O
controlled . . O
post . . O
- . . O
marketing . . O
trial . . O
, . . O
the . . O
incidence . . O
of . . O
skin . . B-AdverseReaction
laceration . . I-AdverseReaction
( . . O
22% . . O
) . . O
was . . O
higher . . O
for . . O
subjects . . O
treated . . O
with . . O
two . . O
concurrent . . O
injections . . O
of . . O
xiaflex . . O
compared . . O
with . . O
subjects . . O
treated . . O
with . . O
up . . O
to . . O
three . . O
single . . O
injections . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
premarketing . . O
trials . . O
( . . O
9% . . O
) . . O
. . . O

initiate . . O
systemic . . O
corticosteroids . . O
at . . O
a . . O
dose . . O
of . . O
1 . . O
to . . O
2 . . O
mg . . O
/ . . O
kg . . O
/ . . O
day . . O
prednisone . . O
or . . O
equivalent . . O
for . . O
severe . . O
immune . . O
- . . O
mediated . . O
adverse . . O
reactions . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
belimumab . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

physicians . . O
should . . O
remain . . O
vigilant . . O
for . . O
the . . O
possible . . O
development . . O
of . . O
pneumonia . . O
in . . O
patients . . O
with . . O
copd . . O
as . . O
the . . O
clinical . . O
features . . O
of . . O
such . . O
infections . . O
overlap . . O
with . . O
the . . O
symptoms . . O
of . . O
copd . . O
exacerbations . . O
. . . O

use . . O
of . . O
cocs . . B-DrugClass
also . . O
increases . . O
the . . O
risk . . O
of . . O
arterial . . B-AdverseReaction
thromboses . . I-AdverseReaction
such . . O
as . . O
strokes . . B-AdverseReaction
and . . O
myocardial . . B-AdverseReaction
infarctions . . I-AdverseReaction
, . . O
especially . . O
in . . O
women . . O
with . . O
other . . O
risk . . O
factors . . O
for . . O
these . . O
events . . O
. . . O

5.4 . . O
allergic . . O
reactions . . O

there . . O
were . . O
no . . O
patients . . O
with . . O
kidney . . O
failure . . O
at . . O
baseline . . O
. . . O

other . . O
adverse . . O
reactions . . O

drugs . . O
which . . O
interfere . . O
with . . O
norepinephrine . . O
uptake . . O
in . . O
neuroendocrine . . O
tumors . . O
may . . O
lead . . O
to . . O
false . . O
negative . . O
imaging . . O
results . . O
. . . O

inlyta . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
severe . . O
hepatic . . O
impairment . . O
. . . O

treatment . . O
for . . O
latent . . O
infection . . O
should . . O
be . . O
initiated . . O
prior . . O
to . . O
cimzia . . O
use . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
hypertension . . B-AdverseReaction
including . . O
hypertensive . . B-AdverseReaction
crisis . . I-AdverseReaction
: . . O
monitor . . O
blood . . O
pressure . . O
regularly . . O
. . . O

therefore . . O
, . . O
if . . O
entereg . . O
is . . O
administered . . O
to . . O
these . . O
patients . . O
, . . O
they . . O
should . . O
be . . O
monitored . . O
for . . O
gastrointestinal . . O
adverse . . O
reactions . . O
. . . O

a . . O
majority . . O
of . . O
reported . . O
events . . O
occurred . . O
in . . O
patients . . O
who . . O
had . . O
experienced . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
or . . O
dehydration . . B-AdverseReaction
. . . O

breo . . O
ellipta . . O
for . . O
the . . O
treatment . . O
of . . O
asthma . . O
was . . O
studied . . O
in . . O
18 . . O
double . . O
- . . O
blind . . O
, . . O
parallel . . O
- . . O
group . . O
, . . O
controlled . . O
trials . . O
( . . O
11 . . O
with . . O
placebo . . O
) . . O
of . . O
4 . . O
to . . O
76 . . O
weeks . . O
' . . O
duration . . O
, . . O
which . . O
enrolled . . O
9,969 . . O
subjects . . O
with . . O
asthma . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O

5.6 . . O
other . . O
malignancies . . O

gadolinium . . B-DrugClass
- . . I-DrugClass
based . . I-DrugClass
contrast . . I-DrugClass
agents . . I-DrugClass
( . . O
gbcas . . O
) . . O
increase . . O
the . . O
risk . . O
for . . O
nsf . . B-AdverseReaction
among . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
the . . O
drugs . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
cleviprex . . O
: . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
triglycerides . . I-AdverseReaction
, . . O
ileus . . B-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
oxygen . . I-AdverseReaction
saturation . . I-AdverseReaction
( . . O
possible . . B-Factor
pulmonary . . B-AdverseReaction
shunting . . I-AdverseReaction
) . . O
and . . O
reflex . . B-AdverseReaction
tachycardia . . I-AdverseReaction
. . . O

caution . . O
patients . . O
about . . O
risk . . O
of . . O
bleeding . . O
associated . . O
with . . O
concomitant . . O
use . . O
of . . O
pristiq . . O
and . . O
nsaids . . O
, . . O
aspirin . . O
, . . O
or . . O
other . . O
drugs . . O
that . . O
affect . . O
coagulation . . O
( . . O
5.4 . . O
) . . O
. . . O

nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
and . . O
diarrhea . . B-AdverseReaction
occur . . O
with . . O
beleodaq . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
and . . O
may . . O
require . . O
the . . O
use . . O
of . . O
antiemetic . . O
and . . O
antidiarrheal . . O
medications . . O
. . . O

in . . O
the . . O
controlled . . O
portions . . O
of . . O
clinical . . O
studies . . O
of . . O
some . . O
tnf . . O
blockers . . O
, . . O
more . . O
cases . . O
of . . O
malignancies . . B-AdverseReaction
have . . O
been . . O
observed . . O
among . . O
patients . . O
receiving . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
compared . . O
to . . O
control . . O
patients . . O
. . . O

discontinuation . . O
of . . O
prolia . . O
therapy . . O
should . . O
be . . O
considered . . O
based . . O
on . . O
individual . . O
benefit . . O
- . . O
risk . . O
assessment . . O
. . . O

one . . O
death . . B-AdverseReaction
occurred . . O
during . . O
the . . O
24 . . O
weeks . . O
of . . O
administration . . O
of . . O
sirturo . . O
. . . O

in . . O
addition . . O
to . . O
the . . O
reactions . . O
shown . . O
in . . O
tables . . O
2 . . O
and . . O
3 . . O
, . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
2% . . O
of . . O
the . . O
subjects . . O
treated . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
or . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
for . . O
12 . . O
months . . O
included . . O
pyrexia . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
extrasystoles . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
abdominal . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
allergic . . B-AdverseReaction
rhinitis . . I-AdverseReaction
, . . O
pharyngitis . . B-AdverseReaction
, . . O
rhinitis . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
supraventricular . . B-AdverseReaction
extrasystoles . . I-AdverseReaction
, . . O
ventricular . . B-AdverseReaction
extrasystoles . . I-AdverseReaction
, . . O
acute . . B-AdverseReaction
sinusitis . . I-AdverseReaction
, . . O
and . . O
pneumonia . . B-AdverseReaction
. . . O

in . . O
these . . O
trials . . O
, . . O
which . . O
had . . O
a . . O
median . . O
treatment . . O
duration . . O
of . . O
12 . . O
weeks . . O
, . . O
the . . O
estimated . . O
incidence . . O
rate . . O
of . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
or . . O
ideation . . O
among . . O
27,863 . . O
aed . . B-DrugClass
treated . . O
patients . . O
was . . O
0.43% . . O
, . . O
compared . . O
to . . O
0.24% . . O
among . . O
16,029 . . O
placebo . . O
treated . . O
patients . . O
, . . O
representing . . O
an . . O
increase . . O
of . . O
approximately . . O
one . . O
case . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
or . . O
behavior . . O
for . . O
every . . O
530 . . O
patients . . O
treated . . O
. . . O

median . . O
duration . . O
of . . O
treatment . . O
was . . O
5.2 . . O
months . . O
for . . O
patients . . O
who . . O
received . . O
xalkori . . O
after . . O
cross . . O
over . . O
from . . O
chemotherapy . . O
. . . O

* . . O
anaphylaxis . . O
and . . O
hypersensitivity . . O
reactions . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
* . . O
laba . . B-DrugClass
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
and . . O
asthma . . O
- . . O
related . . O
hospitalizations . . O
. . . O

a . . O
reaction . . O
was . . O
considered . . O
treatment . . O
emergent . . O
if . . O
it . . O
occurred . . O
for . . O
the . . O
first . . O
time . . O
or . . O
worsened . . O
while . . O
receiving . . O
therapy . . O
following . . O
baseline . . O
evaluation . . O
. . . O

( . . O
6 . . O
) . . O

the . . O
development . . O
of . . O
a . . O
potentially . . B-Factor
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
serotonin . . B-AdverseReaction
syndrome . . I-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
snris . . O
and . . O
ssris . . O
, . . O
including . . O
pristiq . . O
, . . O
alone . . O
but . . O
particularly . . O
with . . O
concomitant . . O
use . . O
of . . O
other . . O
serotonergic . . O
drugs . . O
( . . O
including . . O
triptans . . O
, . . O
tricyclic . . O
antidepressants . . O
, . . O
fentanyl . . O
, . . O
lithium . . O
, . . O
tramadol . . O
, . . O
tryptophan . . O
, . . O
buspirone . . O
, . . O
and . . O
st . . O
. . . O
john's . . O
wort . . O
) . . O
, . . O
and . . O
with . . O
drugs . . O
that . . O
impair . . O
metabolism . . O
of . . O
serotonin . . O
( . . O
in . . O
particular . . O
, . . O
maois . . O
, . . O
both . . O
those . . O
intended . . O
to . . O
treat . . O
psychiatric . . O
disorders . . O
and . . O
also . . O
others . . O
, . . O
such . . O
as . . O
linezolid . . O
and . . O
intravenous . . O
methylene . . O
blue . . O
) . . O
. . . O

estrogens . . O
may . . B-Factor
cause . . O
some . . O
degree . . O
of . . O
fluid . . B-AdverseReaction
retention . . I-AdverseReaction
. . . O

( . . O
5.9 . . O
) . . O
* . . O
monitor . . O
for . . O
proteinuria . . O
before . . O
initiation . . O
of . . O
, . . O
and . . O
periodically . . O
throughout . . O
, . . O
treatment . . O
with . . O
inlyta . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
are . . O
: . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
fall . . B-AdverseReaction
and . . O
depression . . B-AdverseReaction
. . . O
( . . O
6.1 . . O
) . . O

permanently . . O
discontinue . . O
yervoy . . O
in . . O
patients . . O
with . . O
grade . . O
3-5 . . O
hepatotoxicity . . O
and . . O
administer . . O
systemic . . O
corticosteroids . . O
at . . O
a . . O
dose . . O
of . . O
1 . . O
to . . O
2 . . O
mg . . O
/ . . O
kg . . O
/ . . O
day . . O
of . . O
prednisone . . O
or . . O
equivalent . . O
. . . O

trulicity . . O
0.75 . . O
mg . . O
and . . O
1.5 . . O
mg . . O
resulted . . O
in . . O
a . . O
mean . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
heart . . I-AdverseReaction
rate . . I-AdverseReaction
( . . O
hr . . O
) . . O
of . . O
2-4 . . O
beats . . O
per . . O
minute . . O
( . . O
bpm . . O
) . . O
. . . O

it . . O
is . . O
generally . . O
believed . . O
( . . O
though . . O
not . . O
established . . O
in . . O
controlled . . O
studies . . O
) . . O
that . . O
treating . . O
such . . O
an . . O
episode . . O
with . . O
an . . O
antidepressant . . B-DrugClass
alone . . O
may . . O
increase . . O
the . . O
likelihood . . O
of . . O
precipitation . . O
of . . O
a . . O
mixed . . O
/ . . O
manic . . O
episode . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
bipolar . . O
disorder . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

all . . O
other . . O
patients . . O
were . . O
eligible . . O
for . . O
these . . O
studies . . O
if . . O
the . . O
plasma . . O
methotrexate . . O
level . . O
was . . O
greater . . O
than . . O
10 . . O
mumol . . O
/ . . O
l . . O
more . . O
than . . O
42 . . O
hours . . O
after . . O
the . . O
start . . O
of . . O
the . . O
methotrexate . . O
or . . O
the . . O
plasma . . O
level . . O
was . . O
greater . . O
than . . O
2 . . O
standard . . O
deviations . . O
above . . O
the . . O
mean . . O
methotrexate . . O
excretion . . O
curve . . O
at . . O
least . . O
12 . . O
hours . . O
following . . O
methotrexate . . O
and . . O
the . . O
serum . . O
creatinine . . O
was . . O
greater . . O
than . . O
1.5 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
or . . O
the . . O
creatinine . . O
clearance . . O
was . . O
less . . O
than . . O
60 . . O
ml . . O
/ . . O
min . . O
at . . O
least . . O
12 . . O
hours . . O
following . . O
methotrexate . . O
administration . . O
. . . O

the . . O
risk . . O
may . . O
also . . O
be . . O
increased . . O
by . . O
traumatic . . O
or . . O
repeated . . O
epidural . . O
or . . O
spinal . . O
puncture . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
- . . O
urticaria . . B-AdverseReaction

the . . O
most . . O
frequent . . O
infections . . B-AdverseReaction
( . . O
> . . O
5% . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
) . . O
were . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
and . . O
influenza . . B-AdverseReaction
. . . O

consider . . O
other . . O
antidiabetic . . O
therapies . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
pancreatitis . . O
. . . O

the . . O
population . . O
in . . O
these . . O
studies . . O
was . . O
69% . . O
white . . O
, . . O
7% . . O
black . . O
or . . O
african . . O
american . . O
, . . O
13% . . O
asian . . O
; . . O
30% . . O
were . . O
of . . O
hispanic . . O
or . . O
latino . . O
ethnicity . . O
. . . O

in . . O
addition . . O
, . . O
the . . O
incidence . . O
of . . O
grade . . B-Severity
1-3 . . I-Severity
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
was . . O
7% . . O
. . . O

symptomatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
can . . B-Factor
occur . . O
after . . O
initiating . . O
farxiga . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
particularly . . O
in . . O
patients . . O
with . . O
impaired . . O
renal . . O
function . . O
( . . O
egfr . . O
less . . O
than . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
, . . O
elderly . . O
patients . . O
, . . O
or . . O
patients . . O
on . . O
loop . . O
diuretics . . O
. . . O

this . . O
, . . O
in . . O
turn . . O
, . . O
may . . B-Factor
inhibit . . B-AdverseReaction
reproductive . . I-AdverseReaction
function . . I-AdverseReaction
by . . O
impairing . . B-AdverseReaction
gonadalsteroidogenesis . . I-AdverseReaction
in . . O
both . . O
female . . O
and . . O
male . . O
patients . . O
. . . O

table . . O
5 . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
gastrointestinal . . B-AdverseReaction
complaints . . I-AdverseReaction
occurred . . O
more . . O
frequently . . O
among . . O
patients . . O
receiving . . O
tanzeum . . O
( . . O
39% . . O
) . . O
than . . O
patients . . O
receiving . . O
placebo . . O
( . . O
33% . . O
) . . O
. . . O

increased . . O
mortality . . O

grade . . B-Severity
3-4 . . I-Severity
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
occurred . . O
in . . O
0.2% . . O
of . . O
patients . . O
taking . . O
placebo . . B-Factor
. . . O

serious . . B-Severity
infections . . B-AdverseReaction
and . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
such . . O
as . . O
pneumonia . . B-AdverseReaction
, . . O
bacteremia . . B-AdverseReaction
, . . O
and . . O
sepsis . . B-AdverseReaction
or . . O
septic . . B-AdverseReaction
shock . . I-AdverseReaction
( . . O
including . . O
fatal . . B-AdverseReaction
outcomes . . O
) . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
adcetris . . O
. . . O

discontinue . . O
zydelig . . O
for . . O
intestinal . . O
perforation . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

consider . . O
the . . O
benefit . . O
- . . O
risk . . O
profile . . O
in . . O
such . . O
patients . . O
before . . O
treating . . O
with . . O
prolia . . O
. . . O

the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
positivity . . O
in . . O
an . . O
assay . . O
is . . O
highly . . O
dependent . . O
on . . O
several . . O
factors . . O
, . . O
including . . O
assay . . O
sensitivity . . O
and . . O
specificity . . O
, . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

the . . O
patient . . O
recovered . . O
fully . . O
following . . O
discontinuation . . O
of . . O
bosulif . . O
. . . O

5.6 . . O
liver . . O
transplant . . O

abrupt . . O
discontinuation . . O
of . . O
onfi . . O
should . . O
be . . O
avoided . . O
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
eosinophilia . . B-AdverseReaction

* . . O
severe . . B-Severity
skin . . O
and . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

use . . O
with . . O
drugs . . O
that . . O
prolong . . O
the . . O
qt . . O
interval . . O
may . . B-Factor
cause . . O
additive . . B-AdverseReaction
qt . . I-AdverseReaction
prolongation . . I-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
novartis . . O
pharmaceuticals . . O
corporation . . O
at . . O
1-888-669-6682 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

twenty . . O
- . . O
five . . O
patients . . O
( . . O
19.4% . . O
) . . O
discontinued . . O
treatment . . O
with . . O
beleodaq . . O
due . . O
to . . O
adverse . . O
reactions . . O
. . . O

general . . O
disorders . . O
and . . O
administrative . . O
site . . O
conditions . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
includes . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
and . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
) . . O
, . . O
pain . . B-AdverseReaction

* . . O
concomitant . . O
neuromuscular . . O
disorders . . O
may . . O
exacerbate . . O
clinical . . O
effects . . O
of . . O
treatment . . O
( . . O
5.5 . . O
) . . O
. . . O

premature . . O
discontinuation . . O
of . . O
pradaxa . . O
increases . . O
the . . O
risk . . O
of . . O
thrombotic . . O

in . . O
the . . O
randomized . . O
controlled . . O
studies . . O
, . . O
there . . O
was . . O
a . . O
higher . . O
rate . . O
of . . O
cardiovascular . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
cardiovascular . . B-AdverseReaction
deaths . . I-AdverseReaction
, . . O
non . . B-Severity
- . . I-Severity
fatal . . I-Severity
myocardial . . B-AdverseReaction
infarctions . . I-AdverseReaction
, . . O
and . . O
non . . B-Severity
- . . I-Severity
fatal . . I-Severity
strokes . . B-AdverseReaction
) . . O
in . . O
patients . . O
treated . . O
with . . O
uloric . . O
( . . O
0.74 . . O
per . . O
100 . . O
p . . O
- . . O
y . . O
[ . . O
95% . . O
confidence . . O
interval . . O
( . . O
ci . . O
) . . O
0.36-1.37 . . O
] . . O
) . . O
than . . O
allopurinol . . O
( . . O
0.60 . . O
per . . O
100 . . O
p . . O
- . . O
y . . O
[ . . O
95% . . O
ci . . O
0.16-1.53 . . O
] . . O
) . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

an . . O
analyses . . O
of . . O
adjudicated . . O
events . . O
revealed . . O
5 . . O
cases . . O
of . . O
confirmed . . O
pancreatitis . . B-AdverseReaction
in . . O
patients . . O
exposed . . O
to . . O
trulicity . . O
( . . O
1.4 . . O
cases . . O
per . . O
1000 . . O
patient . . O
years . . O
) . . O
versus . . O
1 . . O
case . . O
in . . O
non . . O
- . . O
incretin . . O
comparators . . O
( . . O
0.88 . . O
cases . . O
per . . O
1000 . . O
patient . . O
years . . O
) . . O
. . . O

documented . . O
symptomatic . . B-AdverseReaction
hypoglycemia . . I-AdverseReaction
occurred . . O
in . . O
85% . . O
and . . O
80% . . O
of . . O
patients . . O
when . . O
trulicity . . O
0.75 . . O
mg . . O
and . . O
1.5 . . O
mg . . O
, . . O
respectively . . O
, . . O
was . . O
co . . O
- . . O
administered . . O
with . . O
prandial . . O
insulin . . O
. . . O

routine . . O
monitoring . . O
of . . O
serum . . O
calcitonin . . O
or . . O
using . . O
thyroid . . O
ultrasound . . O
is . . O
of . . O
uncertain . . O
value . . O
for . . O
early . . O
detection . . O
of . . O
mtc . . O
in . . O
patients . . O
treated . . O
with . . O
tanzeum . . O
. . . O

psychiatric . . O
disorders . . O
: . . O
psychotic . . B-AdverseReaction
behavior . . I-AdverseReaction
including . . O
aggressive . . B-AdverseReaction
thoughts . . I-AdverseReaction
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
approval . . O
use . . O
of . . O
afinitor . . O
. . . O

cytokine . . O
release . . O
syndrome . . O
( . . O
crs . . O
) . . O
, . . O
which . . O
may . . B-Factor
be . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
or . . O
fatal . . B-AdverseReaction
, . . O
occurred . . O
in . . O
patients . . O
receiving . . O
blincyto . . O
. . . O

sjia . . O
study . . O
2 . . O
was . . O
a . . O
two . . O
- . . O
part . . O
study . . O
with . . O
an . . O
open . . O
- . . O
label . . O
, . . O
single . . O
- . . O
arm . . O
active . . O
treatment . . O
period . . O
( . . O
part . . O
i . . O
) . . O
followed . . O
by . . O
a . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
event . . O
- . . O
driven . . O
withdrawal . . O
design . . O
( . . O
part . . O
ii . . O
) . . O
. . . O

the . . O
majority . . O
of . . O
these . . O
cases . . O
were . . O
mild . . O
to . . O
moderate . . O
and . . O
occurred . . O
during . . O
the . . O
first . . O
year . . O
of . . O
exposure . . O
. . . O

5.8 . . O
seizure . . O

at . . O
these . . O
doses . . O
, . . O
saphris . . O
was . . O
associated . . O
with . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
qtc . . I-AdverseReaction
interval . . I-AdverseReaction
ranging . . O
from . . O
2 . . B-Severity
to . . I-Severity
5 . . I-Severity
msec . . I-Severity
compared . . O
to . . O
placebo . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
1-877-663-0412 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

the . . O
effects . . O
of . . O
saphris . . O
on . . O
the . . O
qt . . O
/ . . O
qtc . . O
interval . . O
were . . O
evaluated . . O
in . . O
a . . O
dedicated . . O
adult . . O
qt . . O
study . . O
. . . O

adverse . . O
reactions . . O
that . . O
led . . O
to . . O
discontinuation . . O
of . . O
zydelig . . O
occurred . . O
in . . O
11 . . O
( . . O
10% . . O
) . . O
subjects . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

of . . O
the . . O
64 . . O
dulaglutide . . O
- . . O
treated . . O
patients . . O
that . . O
developed . . O
dulaglutide . . O
adas . . O
, . . O
34 . . O
patients . . O
( . . O
0.9% . . O
of . . O
the . . O
overall . . O
population . . O
) . . O
had . . O
dulaglutide . . O
- . . O
neutralizing . . O
antibodies . . O
, . . O
and . . O
36 . . O
patients . . O
( . . O
0.9% . . O
of . . O
the . . O
overall . . O
population . . O
) . . O
developed . . O
antibodies . . O
against . . O
native . . O
glp . . O
- . . O
1 . . O
. . . O

* . . O
radiation . . B-AdverseReaction
risk . . I-AdverseReaction
: . . O
choline . . O
c . . O
11 . . O
injection . . O
contributes . . O
to . . O
a . . O
patient's . . O
long . . O
- . . O
term . . O
cumulative . . O
radiation . . O
exposure . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
erwinaze . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

hepatobiliary . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
hepatotoxicity . . B-AdverseReaction
( . . O
includes . . O
hepatotoxicity . . B-AdverseReaction
, . . O
toxic . . B-AdverseReaction
hepatitis . . I-AdverseReaction
, . . O
and . . O
cytolytic . . B-AdverseReaction
hepatitis . . I-AdverseReaction
) . . O
, . . O
abnormal . . B-AdverseReaction
hepatic . . I-AdverseReaction
function . . I-AdverseReaction
( . . O
includes . . O
abnormal . . B-AdverseReaction
hepatic . . I-AdverseReaction
function . . I-AdverseReaction
, . . O
liver . . B-AdverseReaction
disorder . . I-AdverseReaction
) . . O
; . . O
0.1% . . O
and . . O
less . . O
than . . O
1% . . O
- . . O
liver . . B-AdverseReaction
injury . . I-AdverseReaction

females . . O
of . . O
reproductive . . O
potential . . O
should . . O
avoid . . O
becoming . . O
pregnant . . O
while . . O
being . . O
treated . . O
. . . O

most . . O
patients . . O
( . . O
> . . O
70% . . O
) . . O
in . . O
both . . O
trials . . O
were . . O
enrolled . . O
in . . O
eastern . . O
europe . . O
and . . O
were . . O
white . . O
. . . O

in . . O
2 . . O
of . . O
the . . O
trials . . O
( . . O
trial . . O
1 . . O
and . . O
trial . . O
3 . . O
) . . O
, . . O
treatment . . O
was . . O
given . . O
for . . O
48 . . O
weeks . . O
, . . O
while . . O
in . . O
the . . O
other . . O
trial . . O
( . . O
trial . . O
2 . . O
) . . O
treatment . . O
was . . O
given . . O
for . . O
72 . . O
weeks . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

in . . O
the . . O
clinical . . O
trials . . O
, . . O
health . . O
care . . O
providers . . O
observed . . O
during . . O
clinic . . O
visits . . O
that . . O
an . . O
average . . O
of . . O
24% . . O
of . . O
patients . . O
experienced . . O
a . . O
cough . . B-AdverseReaction
on . . O
at . . O
least . . O
20% . . O
of . . O
visits . . O
following . . O
inhalation . . O
of . . O
the . . O
recommended . . O
75 . . O
mcg . . O
dose . . O
of . . O
arcapta . . O
neohaler . . O
compared . . O
to . . O
7% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

patient . . O
presenting . . O
with . . O
an . . O
atypical . . O
femur . . O
fracture . . O
should . . O
also . . O
be . . O
assessed . . O
for . . O
symptoms . . O
and . . O
signs . . O
of . . O
fracture . . O
in . . O
the . . O
contralateral . . O
limb . . O
. . . O

* . . O
fatal . . B-AdverseReaction
anaphylaxis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

avoid . . O
use . . O
of . . O
gbcas . . O
among . . O
these . . O
patients . . O
unless . . O
the . . O
diagnostic . . O
information . . O
is . . O
essential . . O
and . . O
not . . O
available . . O
with . . O
non . . O
- . . O
contrast . . O
mri . . O
or . . O
other . . O
modalities . . O
. . . O

patients . . O
should . . O
be . . O
observed . . O
for . . O
an . . O
appropriate . . O
period . . O
of . . O
time . . O
after . . O
administration . . O
of . . O
kalbitor . . O
, . . O
taking . . O
into . . O
account . . O
the . . O
time . . O
to . . O
onset . . O
of . . O
anaphylaxis . . O
seen . . O
in . . O
clinical . . O
trials . . O
. . . O

across . . O
the . . O
development . . O
program . . O
of . . O
zykadia . . O
, . . O
one . . O
of . . O
304 . . O
patients . . O
( . . O
less . . O
than . . O
1% . . O
) . . O
treated . . O
with . . O
zykadia . . O
doses . . O
ranging . . O
from . . O
50 . . O
to . . O
750 . . O
mg . . O
was . . O
found . . O
to . . O
have . . O
a . . O
qtc . . B-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
500 . . I-AdverseReaction
msec . . I-AdverseReaction
and . . O
3% . . O
of . . O
patients . . O
had . . O
an . . O
increase . . B-AdverseReaction
from . . I-AdverseReaction
baseline . . I-AdverseReaction
qtc . . I-AdverseReaction
greater . . O
than . . O
60 . . B-Severity
msec . . I-Severity
. . . O

2includes . . O
the . . O
preferred . . O
terms . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
, . . O
oral . . B-AdverseReaction
paresthesia . . I-AdverseReaction
, . . O
and . . O
oral . . B-AdverseReaction
dysesthesia . . I-AdverseReaction
. . . O

5.12 . . O
potential . . O
for . . O
cognitive . . O
and . . O
motor . . O
impairment . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
infectious . . I-AdverseReaction
pneumonitis . . I-AdverseReaction
. . . O

of . . O
the . . O
2,254 . . O
subjects . . O
, . . O
70% . . O
were . . O
male . . O
and . . O
84% . . O
were . . O
white . . O
. . . O

in . . O
unapproved . . O
uses . . O
, . . O
including . . O
spasticity . . O
in . . O
children . . O
and . . O
in . . O
approved . . O
indications . . O
, . . O
symptoms . . O
consistent . . O
with . . O
spread . . B-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effect . . I-AdverseReaction
have . . O
been . . O
reported . . O
at . . O
doses . . O
comparable . . O
to . . O
or . . O
lower . . O
than . . O
the . . O
maximum . . O
recommended . . O
total . . O
dose . . O
. . . O

xalkori . . O
was . . O
discontinued . . O
for . . O
adverse . . O
reactions . . O
in . . O
15% . . O
of . . O
patients . . O
. . . O

use . . O
of . . O
ocular . . O
steroids . . B-DrugClass
may . . O
prolong . . O
the . . O
course . . O
and . . O
may . . O
exacerbate . . O
the . . O
severity . . O
of . . O
many . . O
viral . . O
infections . . O
of . . O
the . . O
eye . . O
( . . O
including . . O
herpes . . O
simplex . . O
) . . O
. . . O

* . . O
invasive . . B-AdverseReaction
fungal . . I-AdverseReaction
infections . . I-AdverseReaction
, . . O
including . . O
histoplasmosis . . B-AdverseReaction
, . . O
coccidioidomycosis . . B-AdverseReaction
, . . O
candidiasis . . B-AdverseReaction
, . . O
aspergillosis . . B-AdverseReaction
, . . O
blastomycosis . . B-AdverseReaction
and . . O
pneumocystosis . . B-AdverseReaction
. . . O

( . . O
5.6 . . O
, . . O
5.7 . . O
) . . O

these . . O
18 . . O
patients . . O
experienced . . O
26 . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
during . . O
infusion . . O
with . . O
signs . . O
and . . O
symptoms . . O
including . . O
cough . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
throat . . B-AdverseReaction
tightness . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
cyanosis . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
and . . O
gastrointestinal . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
nausea . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
retching . . B-AdverseReaction
, . . O
and . . O
vomiting . . B-AdverseReaction
) . . O
in . . O
conjunction . . O
with . . O
urticaria . . B-AdverseReaction
. . . O

based . . O
on . . O
findings . . O
in . . O
animals . . B-Animal
, . . O
imbruvica . . O
can . . O
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

( . . O
5.6 . . O
) . . O

in . . O
general . . O
, . . O
somnolence . . B-AdverseReaction
and . . O
sedation . . B-AdverseReaction
begin . . O
within . . O
the . . O
first . . O
month . . O
of . . O
treatment . . O
and . . O
may . . O
diminish . . O
with . . O
continued . . O
treatment . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

patients . . O
who . . O
experience . . O
reduced . . O
clinical . . O
response . . O
may . . O
also . . O
be . . O
tested . . O
for . . O
inhibitory . . O
antibody . . O
activity . . O
. . . O

the . . O
most . . O
commonly . . O
occurring . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
were . . O
thrombocytopenia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
bruising . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
and . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
( . . O
see . . O
tables . . O
1 . . O
and . . O
2 . . O
) . . O
. . . O

( . . O
5.3 . . O
) . . O

in . . O
post . . O
- . . O
marketing . . O
experience . . O
, . . O
severe . . B-Severity
and . . O
occasionally . . O
incapacitating . . B-Severity
bone . . O
, . . O
joint . . O
, . . O
and . . O
/ . . O
or . . O
muscle . . B-AdverseReaction
pain . . I-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
prolia . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

renal . . O
replacement . . O
therapy . . O
was . . O
not . . O
required . . O
for . . O
these . . O
subjects . . O
. . . O

a . . O
causal . . O
relationship . . O
has . . O
not . . O
been . . O
established . . O
. . . O

the . . O
most . . O
common . . O
fatal . . B-AdverseReaction
adverse . . O
reactions . . O
in . . O
jevtana . . O
- . . O
treated . . O
patients . . O
were . . O
infections . . B-AdverseReaction
( . . O
n . . O
= . . O
5 . . O
) . . O
and . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
( . . O
n . . O
= . . O
4 . . O
) . . O
. . . O

warning . . O
: . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
and . . O
behaviors . . O

* . . O
patients . . O
who . . O
have . . O
suffered . . O
a . . O
myocardial . . O
infarction . . O
, . . O
stroke . . O
, . . O
life . . O
- . . O
threatening . . O
arrhythmia . . O
, . . O
or . . O
coronary . . O
revascularization . . O
within . . O
the . . O
last . . O
6 . . O
months . . O
; . . O
* . . O
patients . . O
with . . O
resting . . O
hypotension . . O
( . . O
blood . . O
pressure . . O
less . . O
than . . O
90 . . O
/ . . O
50 . . O
mmhg . . O
) . . O
or . . O
hypertension . . O
( . . O
blood . . O
pressure . . O
greater . . O
than . . O
170 . . O
/ . . O
100 . . O
mmhg . . O
) . . O
; . . O
* . . O
patients . . O
with . . O
unstable . . O
angina . . O
, . . O
angina . . O
with . . O
sexual . . O
intercourse . . O
, . . O
or . . O
new . . O
york . . O
heart . . O
association . . O
class . . O
2 . . O
or . . O
greater . . O
congestive . . O
heart . . O
failure . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
arterial . . O
and . . O
venous . . B-AdverseReaction
thrombotic . . I-AdverseReaction
events . . I-AdverseReaction
have . . O
been . . O
observed . . O
and . . O
can . . B-Factor
be . . O
fatal . . B-AdverseReaction
. . . O

the . . O
patients . . O
received . . O
a . . O
median . . O
of . . O
5 . . O
( . . O
range . . O
1-20 . . O
) . . O
prior . . O
regimens . . O
. . . O

antibody . . O
titers . . O
for . . O
cellular . . O
uptake . . O
inhibition . . O
were . . O
present . . O
in . . O
18 . . O
of . . O
59 . . O
( . . O
31% . . O
) . . O
patients . . O
by . . O
week . . O
78 . . O
. . . O

6 . . O
adverse . . O
reactions . . O

it . . O
is . . O
unknown . . O
if . . O
treatment . . O
with . . O
benlysta . . O
is . . O
associated . . O
with . . O
increased . . O
risk . . O
for . . O
these . . O
events . . O
. . . O

if . . O
you . . O
have . . O
or . . O
have . . O
had . . O
cancer . . O
, . . O
talk . . O
with . . O
your . . O
healthcare . . O
provider . . O
about . . O
whether . . O
you . . O
should . . O
use . . O
duavee . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
lactic . . B-AdverseReaction
acidosis . . I-AdverseReaction
/ . . O
severe . . B-Severity
hepatomegaly . . B-AdverseReaction
with . . O
steatosis . . B-AdverseReaction
and . . O
post . . O
treatment . . O
acute . . B-AdverseReaction
exacerbation . . I-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction

estrogen . . O
agonist . . O
/ . . O
antagonists . . O
( . . O
including . . O
bazedoxifene . . O
, . . O
a . . O
component . . O
of . . O
duavee . . O
) . . O
and . . O
estrogens . . O
individually . . O
are . . O
known . . O
to . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
vte . . B-AdverseReaction
. . . O

5.3 . . O
malignancy . . O

( . . O
5.12 . . O
, . . O
8.1 . . O
) . . O

5.8 . . O
concomitant . . O
use . . O
with . . O
other . . O
biologic . . O
therapies . . O
or . . O
intravenous . . O
cyclophosphamide . . O

duavee . . O
has . . O
been . . O
shown . . O
to . . O
reduce . . B-Factor
the . . I-Factor
risk . . I-Factor
of . . O
endometrial . . B-AdverseReaction
hyperplasia . . I-AdverseReaction
, . . O
which . . O
may . . O
be . . O
a . . O
precursor . . O
to . . O
endometrial . . O
cancer . . O
. . . O

there . . O
were . . O
too . . O
few . . O
cases . . O
to . . O
determine . . O
whether . . O
the . . O
emergence . . O
of . . O
these . . O
events . . O
is . . O
related . . O
to . . O
farxiga . . O
. . . O

no . . O
cases . . O
of . . O
transmission . . O
of . . O
viral . . O
diseases . . O
or . . O
cjd . . O
have . . O
ever . . O
been . . O
reported . . O
for . . O
albumin . . O
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
thrombocytopenia . . B-AdverseReaction
( . . O
including . . O
platelet . . B-AdverseReaction
count . . I-AdverseReaction
decreases . . I-AdverseReaction
) . . O

5.7 . . O
pheochromocytoma . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
described . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
: . . O

of . . O
the . . O
total . . O
8,394 . . O
patients . . O
exposed . . O
to . . O
at . . O
least . . O
one . . O
dose . . O
of . . O
pristiq . . O
; . . O
2,116 . . O
were . . O
exposed . . O
to . . O
pristiq . . O
for . . O
6 . . O
months . . O
, . . O
representing . . O
1,658 . . O
patient . . O
- . . O
years . . O
of . . O
exposure . . O
, . . O
and . . O
421 . . O
were . . O
exposed . . O
for . . O
one . . O
year . . O
, . . O
representing . . O
416 . . O
patient . . O
- . . O
years . . O
of . . O
exposure . . O
. . . O

rehydrate . . O
and . . O
treat . . O
with . . O
anti . . O
- . . O
emetics . . O
and . . O
anti . . O
- . . O
diarrheals . . O
as . . O
needed . . O
. . . O

* . . O
when . . O
pregnancy . . O
is . . O
detected . . O
, . . O
discontinue . . O
edarbi . . O
as . . O
soon . . O
as . . O
possible . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

insulin . . O
and . . O
insulin . . O
secretagogues . . O
are . . O
known . . O
to . . O
cause . . O
hypoglycemia . . O
. . . O

( . . O
5.1 . . O
) . . O

withhold . . O
trametinib . . O
for . . O
any . . O
fever . . O
higher . . O
than . . O
104of . . O
. . . O

eleven . . O
patients . . O
( . . O
26% . . O
) . . O
were . . O
treated . . O
for . . O
greater . . O
than . . O
6 . . O
months . . O
and . . O
7 . . O
patients . . O
( . . O
16% . . O
) . . O
were . . O
treated . . O
for . . O
greater . . O
than . . O
1 . . O
year . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
the . . O
majority . . O
of . . O
patients . . O
developed . . O
igg . . O
antibodies . . O
to . . O
alglucosidase . . O
alfa . . O
, . . O
typically . . O
within . . O
3 . . O
months . . O
of . . O
treatment . . O
. . . O

treatment . . O
with . . O
xeomin . . O
and . . O
other . . O
botulinum . . O
toxin . . O
products . . O
can . . B-Factor
result . . O
in . . O
swallowing . . O
or . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
. . . O

ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
may . . B-Factor
cause . . O
allergic . . O
or . . O
irritant . . B-AdverseReaction
dermatitis . . I-AdverseReaction
. . . O

pooled . . O
data . . O
from . . O
the . . O
4 . . O
placebo . . O
- . . O
controlled . . O
, . . O
4 . . O
- . . O
or . . O
6 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
or . . O
flexible . . O
- . . O
dose . . O
studies . . O
provided . . O
information . . O
regarding . . O
treatment . . O
- . . O
emergent . . O
eps . . B-AdverseReaction
. . . O

information . . O
on . . O
selected . . O
significant . . O
adverse . . O
reactions . . O
observed . . O
during . . O
clinical . . O
trials . . O
is . . O
summarized . . O
below . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

serotonin . . B-AdverseReaction
syndrome . . I-AdverseReaction
symptoms . . O
may . . B-Factor
include . . O
mental . . B-AdverseReaction
status . . I-AdverseReaction
changes . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
agitation . . B-AdverseReaction
, . . O
hallucinations . . B-AdverseReaction
, . . O
delirium . . B-AdverseReaction
, . . O
and . . O
coma . . B-AdverseReaction
) . . O
, . . O
autonomic . . B-AdverseReaction
instability . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
tachycardia . . B-AdverseReaction
, . . O
labile . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
diaphoresis . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
hyperthermia . . B-AdverseReaction
) . . O
, . . O
neuromuscular . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
tremor . . B-AdverseReaction
, . . O
rigidity . . B-AdverseReaction
, . . O
myoclonus . . B-AdverseReaction
, . . O
hyperreflexia . . B-AdverseReaction
, . . O
incoordination . . B-AdverseReaction
) . . O
, . . O
seizures . . B-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
gastrointestinal . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
) . . O
. . . O

treatment . . O
- . . O
emergent . . O
adrs . . O
occurring . . O
in . . O
less . . O
than . . O
2% . . O
of . . O
subjects . . O
( . . O
599 . . O
subjects . . O
) . . O
receiving . . O
intelence . . O
( . . O
r . . O
) . . O
and . . O
of . . O
at . . O
least . . O
moderate . . O
intensity . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
grade . . O
2 . . O
) . . O
are . . O
listed . . O
below . . O
by . . O
body . . O
system . . O
: . . O

the . . O
safety . . O
data . . O
described . . O
below . . O
are . . O
based . . O
on . . O
the . . O
confirmatory . . O
6 . . O
- . . O
and . . O
12 . . O
- . . O
month . . O
trials . . O
. . . O

5.9 . . O
qt . . O
prolongation . . O

use . . O
of . . O
drugs . . B-DrugClass
that . . I-DrugClass
act . . I-DrugClass
on . . I-DrugClass
the . . I-DrugClass
renin . . I-DrugClass
- . . I-DrugClass
angiotensin . . I-DrugClass
system . . I-DrugClass
during . . O
the . . O
second . . O
and . . O
third . . O
trimesters . . O
of . . O
pregnancy . . O
reduces . . B-AdverseReaction
fetal . . I-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
and . . O
increases . . O
fetal . . O
and . . O
neonatal . . B-AdverseReaction
morbidity . . I-AdverseReaction
and . . O
death . . O
. . . O

these . . O
consisted . . O
mainly . . O
of . . O
dyspnea . . B-AdverseReaction
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
3% . . O
; . . O
2 . . O
or . . O
more . . O
patients . . O
) . . O
observed . . O
in . . O
alglucosidase . . O
alfa . . O
- . . O
treated . . O
patients . . O
were . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
included . . O
anaphylaxis . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
/ . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
, . . O
paresthesia . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
local . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
throat . . B-AdverseReaction
tightness . . I-AdverseReaction
. . . O

the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
( . . O
> . . O
25% . . O
) . . O
were . . O
increased . . B-AdverseReaction
ast . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
alp . . I-AdverseReaction
, . . O
hypocalcemia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
, . . O
and . . O
hyperbilirubinemia . . B-AdverseReaction
. . . O

studies . . O
1 . . O
and . . O
2 . . O
were . . O
not . . O
designed . . O
to . . O
support . . O
comparative . . O
claims . . O
for . . O
nulojix . . O
for . . O
the . . O
adverse . . O
reactions . . O
reported . . O
in . . O
this . . O
table . . O
. . . O

adult . . O
patients . . O
: . . O
pooled . . O
data . . O
from . . O
the . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
schizophrenia . . O
and . . O
bipolar . . O
mania . . O
trials . . O
are . . O
presented . . O
in . . O
table . . O
3 . . O
. . . O

5.3 . . O
gastrointestinal . . O
- . . O
related . . O
adverse . . O
reactions . . O
in . . O
opioid . . O
- . . O
tolerant . . O
patients . . O

galactorrhea . . B-AdverseReaction
, . . O
amenorrhea . . B-AdverseReaction
, . . O
gynecomastia . . B-AdverseReaction
, . . O
and . . O
impotence . . B-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
prolactin . . B-DrugClass
- . . I-DrugClass
elevating . . I-DrugClass
compounds . . I-DrugClass
. . . O

data . . O
from . . O
a . . O
large . . O
placebo . . O
- . . O
controlled . . O
us . . O
trial . . O
that . . O
compared . . O
the . . O
safety . . O
of . . O
another . . O
laba . . B-DrugClass
( . . O
salmeterol . . O
) . . O
or . . O
placebo . . O
added . . O
to . . O
usual . . O
asthma . . O
therapy . . O
showed . . O
an . . O
increase . . O
in . . O
asthma . . O
- . . O
related . . O
deaths . . B-AdverseReaction
in . . O
subjects . . O
receiving . . O
salmeterol . . O
. . . O

because . . O
these . . O
reactions . . O
may . . O
worsen . . O
renal . . O
function . . O
, . . O
use . . O
caution . . O
when . . O
initiating . . O
or . . O
escalating . . O
doses . . O
of . . O
trulicity . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
. . . O

in . . O
a . . O
trial . . O
of . . O
tanzeum . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.3 . . O
) . . O
] . . O
, . . O
the . . O
frequency . . O
of . . O
such . . O
gastrointestinal . . B-AdverseReaction
reactions . . I-AdverseReaction
increased . . O
as . . O
renal . . B-AdverseReaction
function . . I-AdverseReaction
declined . . I-AdverseReaction
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

activation . . B-AdverseReaction
of . . I-AdverseReaction
mania . . I-AdverseReaction
/ . . O
hypomania . . O
has . . O
also . . O
been . . O
reported . . O
in . . O
a . . O
small . . O
proportion . . O
of . . O
patients . . O
with . . O
major . . O
affective . . O
disorder . . O
who . . O
were . . O
treated . . O
with . . O
other . . O
marketed . . O
antidepressants . . B-DrugClass
. . . O

overall . . O
, . . O
the . . O
rate . . O
of . . O
ptld . . B-AdverseReaction
in . . O
949 . . O
patients . . O
treated . . O
with . . O
any . . O
of . . O
the . . O
nulojix . . O
regimens . . O
was . . O
9 . . O
- . . O
fold . . O
higher . . O
in . . O
those . . O
who . . O
were . . O
ebv . . O
seronegative . . O
or . . O
ebv . . O
serostatus . . O
unknown . . O
( . . O
8 . . O
/ . . O
139 . . O
) . . O
compared . . O
to . . O
those . . O
who . . O
were . . O
ebv . . O
seropositive . . O
( . . O
5 . . O
/ . . O
810 . . O
patients . . O
) . . O
. . . O

amyvid . . O
scan . . O
results . . O
are . . O
indicative . . O
of . . O
the . . O
brain . . O
neuritic . . O
amyloid . . O
plaque . . O
content . . O
only . . O
at . . O
the . . O
time . . O
of . . O
image . . O
acquisition . . O
and . . O
a . . O
negative . . O
scan . . O
result . . O
does . . O
not . . O
preclude . . O
the . . O
development . . O
of . . O
brain . . O
amyloid . . O
in . . O
the . . O
future . . O
. . . O

patients . . O
should . . O
be . . O
monitored . . O
for . . O
signs . . O
of . . O
anticholinergic . . O
cns . . O
effects . . O
, . . O
particularly . . O
after . . O
beginning . . O
treatment . . O
or . . O
increasing . . O
the . . O
dose . . O
. . . O

if . . O
such . . O
reactions . . O
occur . . O
, . . O
discontinue . . O
further . . O
administration . . O
of . . O
cimzia . . O
and . . O
institute . . O
appropriate . . O
therapy . . O
. . . O

isolated . . O
cases . . O
of . . O
unusual . . O
or . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
aspergillosis . . B-AdverseReaction
, . . O
atypical . . B-AdverseReaction
mycobacterial . . I-AdverseReaction
infections . . I-AdverseReaction
, . . O
cytomegalovirus . . O
, . . O
herpes . . B-AdverseReaction
zoster . . I-AdverseReaction
) . . O
were . . O
reported . . O
during . . O
ilaris . . O
treatment . . O
. . . O

myelosuppression . . O
may . . O
require . . O
dose . . O
delays . . O
and . . O
/ . . O
or . . O
subsequent . . O
dose . . O
reductions . . O
if . . O
recovery . . O
to . . O
the . . O
recommended . . O
values . . O
has . . O
not . . O
occurred . . O
by . . O
the . . O
first . . O
day . . O
of . . O
the . . O
next . . O
scheduled . . O
cycle . . O
. . . O

the . . O
data . . O
combined . . O
eight . . O
clinical . . O
trials . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
and . . O
reflect . . O
exposure . . O
of . . O
6177 . . O
patients . . O
to . . O
invokana . . O
. . . O

pancreatitis . . B-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
4% . . O
of . . O
patients . . O
in . . O
clinical . . O
trials . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

bone . . B-AdverseReaction
marrow . . I-AdverseReaction
suppression . . I-AdverseReaction
manifested . . O
as . . O
neutropenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
and . . O
/ . . O
or . . O
pancytopenia . . B-AdverseReaction
may . . B-Factor
occur . . O
. . . O

table . . O
3 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
by . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
stendra . . O
in . . O
a . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trial . . O
lasting . . O
3 . . O
months . . O
in . . O
patients . . O
who . . O
underwent . . O
bilateral . . O
nerve . . O
- . . O
sparing . . O
radical . . O
prostatectomy . . O
adverse . . O
reaction . . O
placebo . . O
( . . O
n . . O
= . . O
100 . . O
) . . O
stendra . . O
100 . . O
mg . . O
( . . O
n . . O
= . . O
99 . . O
) . . O
stendra . . O
200 . . O
mg . . O
( . . O
n . . O
= . . O
99 . . O
) . . O
headache . . B-AdverseReaction
1.0% . . O
8.1% . . O
12.1% . . O
flushing . . B-AdverseReaction
0.0% . . O
5.1% . . O
10.1% . . O
nasopharyngitis . . B-AdverseReaction
0.0% . . O
3.0% . . O
5.1% . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infection . . I-AdverseReaction
0.0% . . O
2.0% . . O
3.0% . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
1.0% . . O
3.0% . . O
1.0% . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
1.0% . . O
3.0% . . O
2.0% . . O
electrocardiogram . . B-AdverseReaction
abnormal . . I-AdverseReaction
0.0% . . O
1.0% . . O
3.0% . . O
dizziness . . B-AdverseReaction
0.0% . . O
1.0% . . O
2.0% . . O
a . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
2 . . O
months . . O
study . . O
was . . O
conducted . . O
in . . O
435 . . O
subjects . . O
with . . O
a . . O
mean . . O
age . . O
of . . O
58.2 . . O
years . . O
( . . O
range . . O
24 . . O
to . . O
86 . . O
years . . O
) . . O
to . . O
determine . . O
the . . O
time . . O
to . . O
onset . . O
of . . O
effect . . O
of . . O
stendra . . O
, . . O
defined . . O
as . . O
the . . O
time . . O
to . . O
the . . O
first . . O
occurrence . . O
of . . O
an . . O
erection . . O
sufficient . . O
for . . O
sexual . . O
intercourse . . O
. . . O

events . . O
: . . O
premature . . O
discontinuation . . O
of . . O
any . . O
oral . . O
anticoagulant . . O
, . . O
including . . O

gastrointestinal . . O
disorders . . O
: . . O
stomatitis . . B-AdverseReaction
, . . O
pancreatitis . . B-AdverseReaction
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

if . . O
cdad . . O
is . . O
suspected . . O
or . . O
confirmed . . O
, . . O
antibacterials . . O
not . . O
directed . . O
against . . O
c . . O
. . . O
difficile . . O
should . . O
be . . O
discontinued . . O
, . . O
if . . O
possible . . O
. . . O

incidence . . O
of . . O
adverse . . O
reactions . . O
in . . O
12 . . O
week . . O
rls . . O
studies . . O
reported . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
600 . . O
or . . O
1,200 . . O
mg . . O
of . . O
horizant . . O
and . . O
numerically . . O
greater . . O
than . . O
placebo . . O
body . . O
system . . O
/ . . O
adverse . . O
reaction . . O
placebo . . O
a . . O
( . . O
n . . O
= . . O
245 . . O
) . . O
% . . O
horizant600 . . O
mg . . O
/ . . O
day . . O
b . . O
( . . O
n . . O
= . . O
163 . . O
) . . O
% . . O
horizant1,200 . . O
mg . . O
/ . . O
day . . O
c . . O
( . . O
n . . O
= . . O
269 . . O
) . . O
% . . O
nervous . . O
system . . O
disorders . . O
somnolence . . B-AdverseReaction
/ . . O
sedation . . B-AdverseReaction
6 . . O
20 . . O
27 . . O
dizziness . . B-AdverseReaction
4 . . O
13 . . O
22 . . O
headache . . B-AdverseReaction
11 . . O
12 . . O
15 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
5 . . O
6 . . O
7 . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
2 . . O
3 . . O
4 . . O
flatulence . . B-AdverseReaction
< . . O
1 . . O
3 . . O
2 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
4 . . O
6 . . O
7 . . O
irritability . . B-AdverseReaction
1 . . O
4 . . O
4 . . O
feeling . . B-AdverseReaction
drunk . . I-AdverseReaction
0 . . O
1 . . O
3 . . O
feeling . . B-AdverseReaction
abnormal . . I-AdverseReaction
< . . O
1 . . O
< . . O
1 . . O
3 . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
1 . . O
< . . O
1 . . O
3 . . O
metabolism . . O
and . . O
nutritional . . O
disorders . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
2 . . O
2 . . O
3 . . O
increased . . B-AdverseReaction
appetite . . I-AdverseReaction
< . . O
1 . . O
2 . . O
2 . . O
ear . . O
and . . O
labyrinth . . O
disorders . . O
vertigo . . B-AdverseReaction
0 . . O
1 . . O
3 . . O
psychiatric . . O
disorders . . O
depression . . B-AdverseReaction
< . . O
1 . . O
< . . O
1 . . O
3 . . O
libido . . B-AdverseReaction
decreased . . I-AdverseReaction
< . . O
1 . . O
< . . O
1 . . O
2 . . O
a . . O
placebo . . O
was . . O
a . . O
treatment . . O
arm . . O
in . . O
each . . O
of . . O
the . . O
3 . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
12 . . O
- . . O
week . . O
clinical . . O
trials . . O
. . . O
b . . O
the . . O
600 . . O
- . . O
mg . . O
dose . . O
of . . O
horizant . . O
was . . O
a . . O
treatment . . O
arm . . O
in . . O
2 . . O
of . . O
the . . O
3 . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
12 . . O
- . . O
week . . O
clinical . . O
trials . . O
. . . O
c . . O
the . . O
1,200 . . O
- . . O
mg . . O
dose . . O
of . . O
horizant . . O
was . . O
a . . O
treatment . . O
arm . . O
in . . O
each . . O
of . . O
the . . O
3 . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
12 . . O
- . . O
week . . O
clinical . . O
trials . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

dose . . O
adjustments . . O
( . . O
interruptions . . O
or . . O
reductions . . O
) . . O
due . . O
to . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
55% . . O
of . . O
afinitor . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
abnormalities . . O
seen . . O
in . . O
patients . . O
treated . . O
with . . O
potiga . . O
have . . O
funduscopic . . O
features . . O
similar . . O
to . . O
those . . O
seen . . O
in . . O
retinal . . O
pigment . . O
dystrophies . . O
that . . O
are . . O
known . . O
to . . O
result . . O
in . . O
damage . . B-AdverseReaction
to . . I-AdverseReaction
photoreceptors . . I-AdverseReaction
and . . O
vision . . B-AdverseReaction
loss . . I-AdverseReaction
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

* . . O
trulicity . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
a . . O
personal . . O
or . . O
family . . O
history . . O
of . . O
mtc . . O
and . . O
in . . O
patients . . O
with . . O
multiple . . O
endocrine . . O
neoplasia . . O
syndrome . . O
type . . O
2 . . O
( . . O
men . . O
2 . . O
) . . O
. . . O

as . . O
with . . O
other . . O
inhaled . . O
beta2 . . O
- . . O
adrenergic . . O
drugs . . O
, . . O
arcapta . . O
neohaler . . O
should . . O
not . . O
be . . O
used . . O
more . . O
often . . O
, . . O
at . . O
higher . . O
doses . . O
than . . O
recommended . . O
, . . O
or . . O
in . . O
conjunction . . O
with . . O
other . . O
medications . . O
containing . . O
long . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonists . . O
, . . O
as . . O
an . . O
overdose . . O
may . . O
result . . O
. . . O

withdrawal . . O
symptoms . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
convulsions . . O
, . . O
psychosis . . O
, . . O
hallucinations . . O
, . . O
behavioral . . O
disorder . . O
, . . O
tremor . . O
, . . O
and . . O
anxiety . . O
) . . O
have . . O
been . . O
reported . . O
following . . O
abrupt . . O
discontinuance . . O
of . . O
benzodiazepines . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

5.4 . . O
application . . O
associated . . O
pain . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
2% . . O
and . . O
more . . O
common . . O
than . . O
placebo . . O
) . . O
are . . O
cough . . B-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
and . . O
nausea . . B-AdverseReaction
. . . O

errors . . O
may . . O
occur . . O
while . . O
using . . O
vizamyl . . O
pet . . O
images . . O
to . . O
estimate . . O
brain . . O
neuritic . . O
plaque . . O
density . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

because . . O
of . . O
the . . O
potential . . O
risk . . O
of . . O
myocardial . . O
infarction . . O
with . . O
long . . O
- . . O
term . . O
use . . O
, . . O
entereg . . O
is . . O
available . . O
only . . O
through . . O
a . . O
restricted . . O
program . . O
for . . O
short . . O
- . . O
term . . O
use . . O
( . . O
15 . . O
doses . . O
) . . O
under . . O
a . . O
risk . . O
evaluation . . O
and . . O
mitigation . . O
strategy . . O
( . . O
rems . . O
) . . O
called . . O
the . . O
entereg . . O
access . . O
support . . O
and . . O
education . . O
( . . O
e . . O
. . . O
a . . O
. . . O
s . . O
. . . O
e . . O
. . . O
( . . O
r . . O
) . . O
) . . O
program . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
and . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

immunogenicity . . O
assay . . O
results . . O
are . . O
highly . . O
dependent . . O
on . . O
several . . O
factors . . O
including . . O
assay . . O
sensitivity . . O
and . . O
specificity . . O
, . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
. . . O
] . . O

dyspnea . . O
was . . O
reported . . O
in . . O
28% . . O
of . . O
patients . . O
treated . . O
with . . O
kyprolis . . O
and . . O
was . . O
grade . . B-Severity
3 . . I-Severity
or . . O
greater . . O
in . . O
4% . . O
of . . O
patients . . O
. . . O

the . . O
use . . O
of . . O
clinical . . O
information . . O
in . . O
the . . O
interpretation . . O
of . . O
amyvid . . O
images . . O
has . . O
not . . O
been . . O
evaluated . . O
and . . O
may . . O
lead . . O
to . . O
errors . . O
. . . O

5.3 . . O
decreased . . O
gastrointestinal . . O
motility . . O

defined . . O
as . . O
clinically . . O
overt . . O
bleeding . . B-AdverseReaction
accompanied . . O
by . . O
one . . O
or . . O
more . . O
of . . O
the . . O
following . . O
: . . O
a . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
of . . O
> . . O
= . . O
2 . . B-Severity
g . . I-Severity
/ . . I-Severity
dl . . I-Severity
, . . O
a . . O
transfusion . . O
of . . O
2 . . O
or . . O
more . . O
units . . O
of . . O
packed . . O
red . . O
blood . . O
cells . . O
, . . O
bleeding . . B-AdverseReaction
at . . I-AdverseReaction
a . . I-AdverseReaction
critical . . I-AdverseReaction
site . . I-AdverseReaction
: . . O
intracranial . . O
, . . O
intraspinal . . O
, . . O
intraocular . . O
, . . O
pericardial . . O
, . . O
intra . . O
- . . O
articular . . O
, . . O
intramuscular . . O
with . . O
compartment . . B-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
retroperitoneal . . O
or . . O
with . . O
fatal . . B-AdverseReaction
outcome . . I-AdverseReaction
. . . O
? . . O

5.8 . . O
leukopenia . . O
, . . O
neutropenia . . O
, . . O
and . . O
agranulocytosis . . O

adverse . . O
reactions . . O
are . . O
listed . . O
according . . O
to . . O
meddra . . O
version . . O
15.0 . . O
system . . O
organ . . O
class . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
treanda . . O
. . . O

5.7 . . O
renal . . O
impairment . . O

a . . O
total . . O
of . . O
56% . . O
of . . O
patients . . O
were . . O
female . . O
and . . O
45% . . O
of . . O
patients . . O
were . . O
asian . . O
. . . O

in . . O
the . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trial . . O
in . . O
late . . O
- . . O
onset . . O
patients . . O
, . . O
all . . O
alglucosidase . . O
alfa . . O
- . . O
treated . . O
patients . . O
with . . O
available . . O
samples . . O
( . . O
n . . O
= . . O
59 . . O
, . . O
100% . . O
) . . O
developed . . O
igg . . O
antibodies . . O
to . . O
alglucosidase . . O
alfa . . O
. . . O

6 . . O
adverse . . O
reactions . . O

ecg . . O
measurements . . O
were . . O
only . . O
recorded . . O
in . . O
a . . O
limited . . O
number . . O
of . . O
patients . . O
in . . O
an . . O
open . . O
- . . O
label . . O
study . . O
without . . O
a . . O
placebo . . O
or . . O
active . . O
control . . O
. . . O

for . . O
patients . . O
at . . O
highest . . O
risk . . O
for . . O
nsf . . O
, . . O
do . . O
not . . O
exceed . . O
the . . O
recommended . . O
dotarem . . O
dose . . O
and . . O
allow . . O
a . . O
sufficient . . O
period . . O
of . . O
time . . O
for . . O
elimination . . O
of . . O
the . . O
drug . . O
prior . . O
to . . O
re . . O
- . . O
administration . . O
. . . O

risk . . O
factors . . O
for . . O
bleeding . . O
include . . O
the . . O
concomitant . . O
use . . O
of . . O
other . . O
drugs . . O
that . . O
increase . . O
the . . O
risk . . O
of . . O
bleeding . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
anti . . O
- . . O
platelet . . O
agents . . O
, . . O
heparin . . O
, . . O
fibrinolytic . . O
therapy . . O
, . . O
and . . O
chronic . . O
use . . O
of . . O
nsaids . . O
) . . O
. . . O

5.7 . . O
fat . . O
redistribution . . O

a . . O
transient . . B-Severity
increase . . B-AdverseReaction
in . . I-AdverseReaction
mean . . I-AdverseReaction
eosinophil . . I-AdverseReaction
counts . . I-AdverseReaction
was . . O
seen . . O
during . . O
the . . O
first . . O
2 . . O
months . . O
of . . O
therapy . . O
. . . O

the . . O
changes . . B-AdverseReaction
in . . I-AdverseReaction
fev1 . . I-AdverseReaction
appear . . O
to . . O
be . . O
reversible . . B-Severity
after . . O
treatment . . O
discontinuation . . O
. . . O

at . . O
the . . O
end . . O
of . . O
treatment . . O
, . . O
4.6% . . O
with . . O
placebo . . O
, . . O
3.4% . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
2.2% . . O
with . . O
invokana . . O
300 . . O
mg . . O
had . . O
a . . O
significant . . B-Severity
renal . . B-AdverseReaction
function . . I-AdverseReaction
decline . . I-AdverseReaction
. . . O

individuals . . O
with . . O
peripheral . . O
motor . . O
neuropathic . . O
diseases . . O
, . . O
amyotrophic . . O
lateral . . O
sclerosis . . O
, . . O
or . . O
neuromuscular . . O
junctional . . O
disorders . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
myasthenia . . O
gravis . . O
or . . O
lambert . . O
- . . O
eaton . . O
syndrome . . O
) . . O
should . . O
be . . O
monitored . . O
particularly . . O
closely . . O
when . . O
given . . O
botulinum . . O
toxin . . O
. . . O

inlyta . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
who . . O
have . . O
evidence . . O
of . . O
untreated . . O
brain . . O
metastasis . . O
or . . O
recent . . O
active . . O
gastrointestinal . . O
bleeding . . O
and . . O
should . . O
not . . O
be . . O
used . . O
in . . O
those . . O
patients . . O
. . . O

the . . O
following . . O
serious . . O
reactions . . O
are . . O
described . . O
below . . O
or . . O
elsewhere . . O
in . . O
the . . O
prescribing . . O
information . . O
: . . O

use . . O
of . . O
invokana . . O
has . . O
been . . O
associated . . O
with . . O
an . . O
increased . . O
incidence . . O
of . . O
renal . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
creatinine . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
glomerular . . I-AdverseReaction
filtration . . I-AdverseReaction
rate . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
and . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
) . . O
, . . O
particularly . . O
in . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
. . . O

patient . . O
monitoring . . O
may . . O
help . . O
detect . . O
patients . . O
at . . O
risk . . O
for . . O
pvan . . O
. . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
a . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

bleeding . . B-AdverseReaction
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
? . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
of . . O
prolia . . O
in . . O
patients . . O
with . . O
postmenopausal . . O
osteoporosis . . O
are . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
and . . O
constipation . . B-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
call . . O
877-377-3784 . . O
or . . O
contact . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

based . . O
on . . O
animal . . B-Animal
studies . . O
, . . O
gilenya . . O
may . . O
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

protamine . . O
sulfate . . O
and . . O
vitamin . . O
k . . O
are . . O
not . . O
expected . . O
to . . O
affect . . O
the . . O
anticoagulant . . O
activity . . O
of . . O
dabigatran . . O
. . . O

6.1 . . O
clinical . . O
trial . . O
experience . . O

5.3 . . O
risk . . O
of . . O
acute . . O
cardiorespiratory . . O
failure . . O

patients . . O
should . . O
receive . . O
premedication . . O
. . . O

elevations . . B-AdverseReaction
in . . I-AdverseReaction
alanine . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
( . . O
alt . . O
) . . O
greater . . O
than . . O
5 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . O
uln . . O
) . . O
occurred . . O
in . . O
27% . . O
of . . O
255 . . O
patients . . O
in . . O
study . . O
1 . . O
. . . O

gilenya . . O
has . . O
not . . O
been . . O
tested . . O
in . . O
ms . . O
patients . . O
with . . O
compromised . . O
respiratory . . O
function . . O
. . . O

5.5 . . O
beta . . O
- . . O
blocker . . O
withdrawal . . O

gi . . B-AdverseReaction
bleed . . I-AdverseReaction
includes . . O
upper . . O
gi . . O
, . . O
lower . . O
gi . . O
, . . O
and . . O
rectal . . B-AdverseReaction
bleeding . . I-AdverseReaction
. . . O
* . . O
* . . O
fatal . . B-AdverseReaction
bleeding . . B-AdverseReaction
is . . O
an . . O
adjudicated . . O
death . . B-AdverseReaction
with . . O
the . . O
primary . . O
cause . . O
of . . O
death . . B-AdverseReaction
as . . O
intracranial . . B-AdverseReaction
bleeding . . I-AdverseReaction
or . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
intracranial . . I-AdverseReaction
bleeding . . I-AdverseReaction
during . . O
the . . O
on . . O
- . . O
treatment . . O
period . . O
. . . O

incidence . . O
and . . O
rate . . O
of . . O
hypoglycemiaadverse . . O
reactions . . O
of . . O
hypoglycemia . . B-AdverseReaction
were . . O
based . . O
on . . O
all . . O
reports . . O
of . . O
symptomatic . . B-Severity
and . . O
asymptomatic . . O
hypoglycemia . . B-AdverseReaction
; . . O
a . . O
concurrent . . O
glucose . . O
measurement . . O
was . . O
not . . O
required . . O
; . . O
intent . . O
- . . O
to . . O
- . . O
treat . . O
population . . O
. . . O
in . . O
placebo . . O
and . . O
active . . O
- . . O
controlled . . O
studies . . O
when . . O
nesina . . O
was . . O
used . . O
as . . O
add . . O
- . . O
on . . O
therapy . . O
to . . O
glyburide . . O
, . . O
insulin . . O
, . . O
metformin . . O
, . . O
pioglitazone . . O
or . . O
compared . . O
to . . O
glipizide . . O
add . . O
- . . O
on . . O
to . . O
glyburide . . O
( . . O
26 . . O
weeks . . O
) . . O
nesina . . O
25 . . O
mg+ . . O
glyburide . . O
placebo+ . . O
glyburide . . O
n . . O
= . . O
198 . . O
n . . O
= . . O
99 . . O
overall . . O
( . . O
% . . O
) . . O
19 . . O
( . . O
9.6 . . O
) . . O
11 . . O
( . . O
11.1 . . O
) . . O
severe . . O
( . . O
% . . O
) . . O
severe . . B-Severity
events . . O
of . . O
hypoglycemia . . B-AdverseReaction
were . . O
defined . . O
as . . O
those . . O
events . . O
requiring . . O
medical . . O
assistance . . O
or . . O
exhibiting . . O
depressed . . O
level . . O
or . . O
loss . . O
of . . O
consciousness . . O
or . . O
seizure . . O
. . . O

the . . O
use . . O
of . . O
erythropoiesis . . O
stimulating . . O
agents . . O
( . . O
esas . . O
) . . O
was . . O
permitted . . O
for . . O
management . . O
of . . O
anemia . . O
, . . O
at . . O
the . . O
investigator's . . O
discretion . . O
, . . O
with . . O
or . . O
without . . O
ribavirin . . O
dose . . O
reduction . . O
in . . O
the . . O
phase . . O
2 . . O
and . . O
3 . . O
clinical . . O
trials . . O
. . . O

the . . O
administration . . O
of . . O
antihistamines . . O
, . . O
steroids . . O
, . . O
bronchodilators . . O
, . . O
and . . O
/ . . O
or . . O
epinephrine . . O
may . . O
reduce . . O
the . . O
severity . . O
of . . O
the . . O
reactions . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

( . . O
2.4 . . O
, . . O
5.2 . . O
) . . O
* . . O
hepatic . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
monitor . . O
liver . . O
enzymes . . O
at . . O
least . . O
monthly . . O
for . . O
the . . O
first . . O
three . . O
months . . O
and . . O
as . . O
needed . . O
. . . O

the . . O
most . . O
frequent . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
for . . O
subjects . . O
treated . . O
with . . O
zydelig . . O
were . . O
pneumonia . . B-AdverseReaction
( . . O
17% . . O
) . . O
, . . O
pyrexia . . B-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
sepsis . . B-AdverseReaction
( . . O
8% . . O
) . . O
, . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
( . . O
5% . . O
) . . O
and . . O
diarrhea . . B-AdverseReaction
( . . O
5% . . O
) . . O
. . . O

6 . . O
adverse . . O
reactions . . O

treatment . . O
of . . O
caps . . O

5.2 . . O
use . . O
of . . O
qt . . O
prolonging . . O
drugs . . O
and . . O
other . . O
antimalarials . . O
halofantrine . . O
and . . O
coartem . . O
tablets . . O
should . . O
not . . O
be . . O
administered . . O
within . . O
1 . . O
month . . O
of . . O
each . . O
other . . O
due . . O
to . . O
the . . O
long . . O
elimination . . O
half . . O
- . . O
life . . O
of . . O
lumefantrine . . O
( . . O
3 . . O
to . . O
6 . . O
days . . O
) . . O
and . . O
potential . . O
additive . . O
effects . . O
on . . O
the . . O
qt . . O
interval . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

injury . . O
, . . O
poisoning . . O
, . . O
and . . O
procedural . . O
complications . . O
: . . O
wound . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
postprocedural . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
traumatic . . B-AdverseReaction
hematoma . . I-AdverseReaction
, . . O
periorbital . . B-AdverseReaction
hematoma . . I-AdverseReaction

diarrhea . . O
, . . O
nausea . . O
, . . O
vomiting . . O
, . . O
or . . O
abdominal . . O
pain . . O
occurred . . O
in . . O
96% . . O
of . . O
255 . . O
patients . . O
including . . O
severe . . B-Severity
cases . . O
in . . O
14% . . O
of . . O
patients . . O
treated . . O
with . . O
zykadia . . O
in . . O
study . . O
1 . . O
. . . O

withhold . . O
xalkori . . O
in . . O
patients . . O
who . . O
develop . . O
qtc . . O
greater . . O
than . . O
500 . . O
ms . . O
on . . O
at . . O
least . . O
2 . . O
separate . . O
ecgs . . O
until . . O
recovery . . O
to . . O
a . . O
qtc . . O
less . . O
than . . O
or . . O
equal . . O
to . . O
480 . . O
ms . . O
, . . O
then . . O
resume . . O
xalkori . . O
at . . O
a . . O
reduced . . O
dose . . O
as . . O
described . . O
in . . O
table . . O
2 . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

table . . O
2 . . O
shows . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactions . . O
and . . O
the . . O
category . . O
of . . O
" . . O
any . . O
common . . O
adverse . . O
event . . O
" . . O
in . . O
escape . . O
- . . O
1 . . O
and . . O
escape . . O
- . . O
2 . . O
where . . O
the . . O
rate . . O
on . . O
cleviprex . . O
exceeded . . O
the . . O
rate . . O
on . . O
placebo . . O
by . . O
at . . O
least . . O
5% . . O
( . . O
common . . O
adverse . . O
reactions . . O
) . . O
. . . O

increased . . B-AdverseReaction
levels . . I-AdverseReaction
of . . I-AdverseReaction
thyroid . . I-AdverseReaction
stimulating . . I-AdverseReaction
hormone . . I-AdverseReaction
( . . O
tsh . . O
) . . O
were . . O
observed . . O
in . . O
57% . . O
of . . O
patients . . O
receiving . . O
cometriq . . O
after . . O
the . . O
first . . O
dose . . O
compared . . O
to . . O
19% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
( . . O
regardless . . O
of . . O
baseline . . O
value . . O
) . . O
. . . O

magnetic . . O
resonance . . O
imaging . . O
is . . O
necessary . . O
to . . O
confirm . . O
the . . O
diagnosis . . O
of . . O
rpls . . O
. . . O

in . . O
the . . O
clinical . . O
study . . O
of . . O
7808 . . O
postmenopausal . . O
women . . O
with . . O
osteoporosis . . O
, . . O
the . . O
incidence . . O
of . . O
infections . . B-AdverseReaction
resulting . . O
in . . O
death . . B-AdverseReaction
was . . O
0.2% . . O
in . . O
both . . O
placebo . . O
and . . O
prolia . . O
treatment . . O
groups . . O
. . . O

events . . O
related . . O
to . . O
visual . . B-AdverseReaction
changes . . I-AdverseReaction
were . . O
also . . O
observed . . O
in . . O
monotherapy . . O
trials . . O
. . . O

additional . . O
adverse . . O
drug . . O
reactions . . O
reported . . O
in . . O
greater . . O
than . . O
2% . . O
( . . O
and . . O
higher . . O
than . . O
on . . O
placebo . . O
) . . O
in . . O
patients . . O
dosed . . O
with . . O
150 . . O
, . . O
300 . . O
or . . O
600 . . O
mcg . . O
for . . O
up . . O
to . . O
12 . . O
months . . O
were . . O
as . . O
follows . . O
: . . O

5.2 . . O
hemorrhage . . O

grade . . B-Severity
3-4 . . I-Severity
neutropenia . . B-AdverseReaction
has . . O
been . . O
observed . . O
in . . O
82% . . O
of . . O
patients . . O
treated . . O
with . . O
jevtana . . O
in . . O
the . . O
randomized . . O
trial . . O
. . . O

patients . . O
with . . O
preexisting . . O
liver . . O
disease . . O
may . . O
be . . O
at . . O
increased . . O
risk . . B-Factor
of . . O
developing . . O
elevated . . B-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
when . . O
taking . . O
gilenya . . O
. . . O

somnolence . . B-AdverseReaction
led . . O
to . . O
withdrawal . . O
in . . O
< . . O
1% . . O
of . . O
patients . . O
receiving . . O
1,200 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
compared . . O
with . . O
2% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

when . . O
neuraxial . . O
anesthesia . . O
( . . O
spinal . . O
/ . . O
epidural . . O
anesthesia . . O
) . . O
or . . O
spinal . . O
/ . . O
epidural . . O
puncture . . O
is . . O
employed . . O
, . . O
patients . . O
treated . . O
with . . O
antithrombotic . . O
agents . . O
for . . O
prevention . . O
of . . O
thromboembolic . . O
complications . . O
are . . O
at . . O
risk . . B-Factor
of . . O
developing . . O
an . . O
epidural . . O
or . . O
spinal . . B-AdverseReaction
hematoma . . I-AdverseReaction
which . . O
can . . B-Factor
result . . O
in . . O
long . . O
- . . O
term . . O
or . . O
permanent . . B-AdverseReaction
paralysis . . I-AdverseReaction
. . . O

nervous . . O
system . . O
disorders . . O
: . . O
headache . . B-AdverseReaction
, . . O
burning . . B-AdverseReaction
sensation . . I-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
dysgeusia . . B-AdverseReaction
, . . O
hyperesthesia . . B-AdverseReaction
, . . O
hypoesthesia . . B-AdverseReaction

subjects . . O
treated . . O
with . . O
apixaban . . O
with . . O
diabetes . . O
bled . . B-AdverseReaction
more . . O
( . . O
3.0% . . O
per . . O
year . . O
) . . O
than . . O
did . . O
subjects . . O
without . . O
diabetes . . O
( . . O
1.9% . . O
per . . O
year . . O
) . . O
. . . O

* . . O
using . . O
estrogens . . O
may . . O
increase . . O
your . . O
chance . . O
of . . O
getting . . O
cancer . . O
of . . O
the . . O
uterus . . O
( . . O
womb . . O
) . . O
. . . O

adverse . . O
reactions . . O
collected . . O
in . . O
clinical . . O
trials . . O
included . . O
signs . . O
and . . O
symptoms . . O
at . . O
baseline . . O
but . . O
only . . O
treatment . . O
emergent . . O
adverse . . O
events . . O
, . . O
defined . . O
as . . O
events . . O
that . . O
appeared . . O
or . . O
worsened . . O
after . . O
the . . O
start . . O
of . . O
treatment . . O
, . . O
are . . O
presented . . O
below . . O
. . . O

5.5 . . O
imaging . . O
errors . . O
due . . O
to . . O
conditions . . O
that . . O
affect . . O
the . . O
sympathetic . . O
nervous . . O
system . . O

5.5 . . O
use . . O
with . . O
abatacept . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
associated . . O
with . . O
infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
nausea . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
chills . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
dyspnea . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
headache . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
pruritus . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
rash . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
and . . O
vomiting . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
abdominal . . B-AdverseReaction
distension . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
tenderness . . I-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
, . . O
flatulence . . B-AdverseReaction
, . . O
intestinal . . B-AdverseReaction
obstruction . . I-AdverseReaction
, . . O
megacolon . . B-AdverseReaction

saphris . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
[ . . O
see . . O
alsoboxed . . O
warningand . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

( . . O
6.1 . . O
) . . O

clinical . . O
experience . . O
with . . O
saphris . . O
in . . O
patients . . O
with . . O
certain . . O
concomitant . . O
systemic . . O
illnesses . . O
is . . O
limited . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
( . . O
a . . O
) . . O
premature . . O
discontinuation . . O
of . . O
eliquis . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . B-AdverseReaction
hematoma . . I-AdverseReaction

the . . O
safety . . O
of . . O
reinitiating . . O
inlyta . . O
therapy . . O
in . . O
patients . . O
previously . . O
experiencing . . O
rpls . . O
is . . O
not . . O
known . . O
. . . O

( . . O
5.1 . . O
) . . O

approximately . . O
half . . O
of . . O
the . . O
patients . . O
( . . O
49% . . O
) . . O
were . . O
male . . O
. . . O

warning . . O
: . . O
increased . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
, . . O
stroke . . B-AdverseReaction
and . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
in . . O
patients . . O
with . . O
decompensated . . O
heart . . O
failure . . O
or . . O
permanent . . O
atrial . . O
fibrillation . . O

the . . O
occurrence . . O
of . . O
bone . . B-AdverseReaction
fractures . . I-AdverseReaction
was . . O
evaluated . . O
in . . O
a . . O
pool . . O
of . . O
nine . . O
clinical . . O
trials . . O
with . . O
a . . O
mean . . O
duration . . O
of . . O
exposure . . O
to . . O
invokana . . O
of . . O
85 . . O
weeks . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
perforations . . B-AdverseReaction
and . . O
fistulas . . B-AdverseReaction
, . . O
andhemorrhage . . O

* . . O
drugs . . B-DrugClass
that . . I-DrugClass
act . . I-DrugClass
directly . . I-DrugClass
on . . I-DrugClass
the . . I-DrugClass
renin . . I-DrugClass
- . . I-DrugClass
angiotensin . . I-DrugClass
system . . I-DrugClass
can . . O
cause . . O
injury . . O
and . . O
death . . B-AdverseReaction
to . . I-AdverseReaction
the . . I-AdverseReaction
developing . . I-AdverseReaction
fetus . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

delay . . O
in . . O
stopping . . O
treatment . . O
with . . O
tivicay . . O
or . . O
other . . O
suspect . . O
agents . . O
after . . O
the . . O
onset . . O
of . . O
hypersensitivity . . O
may . . O
result . . O
in . . O
a . . O
life . . O
- . . O
threatening . . O
reaction . . O
. . . O

the . . O
patients . . O
had . . O
no . . O
other . . O
identified . . O
systemic . . O
medical . . O
conditions . . O
resulting . . O
in . . O
compromised . . B-AdverseReaction
immune . . I-AdverseReaction
system . . I-AdverseReaction
function . . O
and . . O
had . . O
not . . O
previously . . O
been . . O
treated . . O
with . . O
natalizumab . . B-Negation
, . . O
which . . O
has . . O
a . . O
known . . O
association . . O
with . . O
pml . . B-AdverseReaction
. . . O

( . . O
6 . . O
) . . O

6.2 . . O
postmarketing . . O
experience . . O

table . . O
2 . . O
: . . O
laboratory . . O
data . . O
/ . . O
ecg . . O
parameters . . O
not . . O
necessarily . . O
reported . . O
as . . O
adverse . . O
events . . O
placebo . . O
multaq . . O
400 . . O
mg . . O
twice . . O
daily . . O
( . . O
n . . O
= . . O
2875 . . O
) . . O
( . . O
n . . O
= . . O
3282 . . O
) . . O
early . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
creatinine . . I-AdverseReaction
> . . O
= . . O
10% . . O
21% . . O
51% . . O
( . . O
n . . O
= . . O
2237 . . O
) . . O
( . . O
n . . O
= . . O
2701 . . O
) . . O
qtc . . B-AdverseReaction
prolonged . . I-AdverseReaction
19% . . O
28% . . O
assessment . . O
of . . O
demographic . . O
factors . . O
such . . O
as . . O
gender . . O
or . . O
age . . O
on . . O
the . . O
incidence . . O
of . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
events . . O
did . . O
not . . O
suggest . . O
an . . O
excess . . O
of . . O
adverse . . O
events . . O
in . . O
any . . O
particular . . O
sub . . O
- . . O
group . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
simponi . . O
aria . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

warning . . O
: . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

in . . O
a . . O
multicenter . . O
, . . O
open . . O
- . . O
label . . O
trial . . O
( . . O
flamingo . . O
) . . O
, . . O
243 . . O
subjects . . O
received . . O
tivicay . . O
50 . . O
mg . . O
once . . O
daily . . O
versus . . O
242 . . O
subjects . . O
who . . O
received . . O
darunavir . . O
800 . . O
mg . . O
/ . . O
ritonavir . . O
100 . . O
mg . . O
once . . O
daily . . O
, . . O
both . . O
in . . O
combination . . O
with . . O
investigator . . O
- . . O
selected . . O
nrti . . O
background . . O
regimen . . O
( . . O
either . . O
epzicom . . O
or . . O
truvada . . O
) . . O
. . . O

at . . O
baseline . . O
, . . O
the . . O
population . . O
had . . O
diabetes . . O
for . . O
an . . O
average . . O
of . . O
8 . . O
years . . O
and . . O
had . . O
a . . O
mean . . O
hba1c . . O
of . . O
8.2% . . O
. . . O

monitor . . O
patients . . O
for . . O
these . . O
consequences . . O
. . . O

if . . O
anemia . . O
develops . . O
during . . O
or . . O
after . . O
therapy . . O
, . . O
a . . O
diagnostic . . O
workup . . O
for . . O
drug . . O
- . . O
induced . . O
hemolytic . . O
anemia . . O
should . . O
be . . O
performed . . O
and . . O
consideration . . O
given . . O
to . . O
discontinuation . . O
of . . O
teflaro . . O
. . . O

for . . O
cases . . O
of . . O
grade . . O
3 . . O
non . . O
- . . O
infectious . . O
pneumonitis . . O
interrupt . . O
afinitor . . O
until . . O
resolution . . O
to . . O
less . . O
than . . O
or . . O
equal . . O
to . . O
grade . . O
1 . . O
. . . O

intracranial . . B-AdverseReaction
bleed . . I-AdverseReaction
includes . . O
intracerebral . . O
, . . O
intraventricular . . O
, . . O
subdural . . O
, . . O
and . . O
subarachnoid . . B-AdverseReaction
bleeding . . I-AdverseReaction
. . . O

for . . O
patients . . O
with . . O
mild . . O
( . . O
child . . O
- . . O
pugh . . O
class . . O
a . . O
) . . O
or . . O
moderate . . O
( . . O
child . . O
- . . O
pugh . . O
class . . O
b . . O
) . . O
hepatic . . O
impairment . . O
, . . O
a . . O
dose . . O
reduction . . O
is . . O
recommended . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

dysphagia . . B-AdverseReaction
may . . O
persist . . O
for . . O
several . . O
months . . O
, . . O
and . . O
require . . O
use . . O
of . . O
a . . O
feeding . . O
tube . . O
to . . O
maintain . . O
adequate . . O
nutrition . . O
and . . O
hydration . . O
. . . O

toviaz . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
myasthenia . . O
gravis . . O
, . . O
a . . O
disease . . O
characterized . . O
by . . O
decreased . . O
cholinergic . . O
activity . . O
at . . O
the . . O
neuromuscular . . O
junction . . O
. . . O

if . . O
a . . O
patient . . O
develops . . O
symptoms . . O
suggestive . . O
of . . O
a . . O
lupus . . O
- . . O
like . . O
syndrome . . O
following . . O
treatment . . O
with . . O
cimzia . . O
, . . O
discontinue . . O
treatment . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

if . . O
the . . O
potential . . O
benefit . . O
for . . O
reinitiating . . O
treatment . . O
with . . O
promacta . . O
is . . O
considered . . O
to . . O
outweigh . . O
the . . O
risk . . O
for . . O
hepatotoxicity . . O
, . . O
then . . O
consider . . O
cautiously . . O
reintroducing . . O
promacta . . O
and . . O
measure . . O
serum . . O
liver . . O
tests . . O
weekly . . O
during . . O
the . . O
dose . . O
adjustment . . O
phase . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
5.3 . . O
) . . O
* . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
: . . O
monitor . . O
and . . O
treat . . O
if . . O
indicated . . O
. . . O

table . . O
4 . . O
identifies . . O
the . . O
clinically . . O
relevant . . O
or . . O
severe . . O
grade . . O
3 . . O
/ . . O
4 . . O
laboratory . . O
test . . O
abnormalities . . O
for . . O
the . . O
phase . . O
1 . . O
/ . . O
2 . . O
cml . . O
safety . . O
population . . O
. . . O

inhibitors . . O
of . . O
cyp3a4 . . O
may . . O
reduce . . O
stendra . . O
clearance . . O
and . . O
increase . . O
plasma . . O
concentrations . . O
of . . O
avanafil . . O
. . . O

figure . . O
1 . . O
adjudicated . . O
major . . B-Severity
bleeding . . B-AdverseReaction
by . . O
baseline . . O
characteristics . . O
including . . O
hemorrhagic . . O
stroke . . O
treated . . O
patients . . O

discontinuations . . O
resulting . . O
from . . O
these . . O
reactions . . O
were . . O
more . . O
common . . O
in . . O
the . . O
drug . . O
- . . O
treated . . O
group . . O
( . . O
see . . O
table . . O
2 . . O
) . . O
. . . O

the . . O
risk . . O
of . . O
symptoms . . O
is . . O
probably . . O
greatest . . O
in . . O
children . . O
treated . . O
for . . O
spasticity . . O
but . . O
symptoms . . O
can . . O
occur . . O
in . . O
adults . . O
treated . . O
for . . O
spasticity . . O
and . . O
other . . O
conditions . . O
, . . O
and . . O
particularly . . O
in . . O
those . . O
patients . . O
who . . O
have . . O
underlying . . O
conditions . . O
that . . O
would . . O
predispose . . O
them . . O
to . . O
these . . O
symptoms . . O
. . . O

avoid . . O
use . . O
of . . O
gbcas . . O
in . . O
these . . O
patients . . O
unless . . O
the . . O
diagnostic . . O
information . . O
is . . O
essential . . O
and . . O
not . . O
available . . O
with . . O
non . . O
- . . O
contrasted . . O
mri . . O
or . . O
other . . O
modalities . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
bepreve . . O
should . . O
not . . O
be . . O
used . . O
to . . O
treat . . O
contact . . O
lens . . O
- . . O
related . . O
irritation . . O
. . . O

serious . . O
adverse . . O
events . . O
were . . O
reported . . O
in . . O
60% . . O
of . . O
the . . O
patients . . O
in . . O
the . . O
krd . . O
arm . . O
and . . O
54% . . O
of . . O
the . . O
patients . . O
in . . O
the . . O
rd . . O
arm . . O
. . . O

excerpt . . O
: . . O
* . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
has . . O
occurred . . O
in . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
gbcas . . O
. . . O

anaphylaxis . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
patients . . O
during . . O
and . . O
up . . O
to . . O
3 . . O
hours . . O
after . . O
alglucosidase . . O
alfa . . O
infusion . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
more . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

temporarily . . O
suspend . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
permanently . . O
discontinue . . O
xalkori . . O
. . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
potential . . O
for . . O
immunogenicity . . O
. . . O

bleeding . . B-AdverseReaction
events . . O
related . . O
to . . O
ssris . . O
and . . O
snris . . B-DrugClass
have . . O
ranged . . O
from . . O
ecchymosis . . B-AdverseReaction
, . . O
hematoma . . B-AdverseReaction
, . . O
epistaxis . . B-AdverseReaction
, . . O
and . . O
petechiae . . B-AdverseReaction
to . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
hemorrhages . . B-AdverseReaction
. . . O

table . . O
2 . . O
summarizes . . O
all . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
( . . O
2 . . O
or . . O
more . . O
patients . . O
) . . O
treated . . O
with . . O
alglucosidase . . O
alfa . . O
in . . O
clinical . . O
trials . . O
described . . O
above . . O
. . . O

there . . O
is . . O
no . . O
indication . . O
for . . O
premenopausal . . O
use . . O
of . . O
duavee . . O
. . . O

dihydropyridine . . B-DrugClass
calcium . . I-DrugClass
channel . . I-DrugClass
blockers . . I-DrugClass
can . . O
produce . . O
negative . . B-AdverseReaction
inotropic . . I-AdverseReaction
effects . . I-AdverseReaction
and . . O
exacerbate . . B-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

the . . O
safety . . O
of . . O
conjugated . . O
estrogens . . O
/ . . O
bazedoxifene . . O
was . . O
evaluated . . O
in . . O
four . . O
phase . . O
3 . . O
clinical . . O
trials . . O
ranging . . O
from . . O
12 . . O
weeks . . O
to . . O
24 . . O
months . . O
in . . O
duration . . O
and . . O
enrolling . . O
6,210 . . O
postmenopausal . . O
women . . O
age . . O
40 . . O
to . . O
75 . . O
years . . O
( . . O
mean . . O
age . . O
55 . . O
years . . O
) . . O
. . . O

evaluate . . O
for . . O
tuberculosis . . O
and . . O
initiate . . O
treatment . . O
for . . O
latent . . O
infection . . O
prior . . O
to . . O
nulojix . . O
use . . O
. . . O

oral . . O
contraceptives . . O
must . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
women . . O
with . . O
cardiovascular . . O
disease . . O
risk . . O
factors . . O
. . . O

5.2 . . O
anemia . . O
( . . O
use . . O
with . . O
ribavirin . . O
and . . O
peginterferon . . O
alfa . . O
) . . O

* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
tls . . B-AdverseReaction
) . . O
: . . O
monitor . . O
patients . . O
at . . O
risk . . O
for . . O
tls . . O
( . . O
e . . O
. . . O
g . . O
. . . O
high . . O
tumor . . O
burden . . O
) . . O
( . . O
5.6 . . O
) . . O
. . . O

neutralizing . . O
antibodies . . O
were . . O
assayed . . O
for . . O
all . . O
patients . . O
( . . O
204 . . O
) . . O
in . . O
study . . O
1 . . O
. . . O

in . . O
this . . O
pool . . O
, . . O
a . . O
total . . O
of . . O
2,116 . . O
patients . . O
with . . O
type . . O
2 . . O
diabetes . . O
were . . O
treated . . O
with . . O
tanzeum . . O
for . . O
a . . O
mean . . O
duration . . O
of . . O
75 . . O
weeks . . O
. . . O

this . . O
may . . O
require . . O
protective . . O
drops . . O
, . . O
ointment . . O
, . . O
therapeutic . . O
soft . . O
contact . . O
lenses . . O
, . . O
or . . O
closure . . O
of . . O
the . . O
eye . . O
by . . O
patching . . O
or . . O
other . . O
means . . O
. . . O

elderly . . O
population . . O
: . . O

severe . . B-Severity
, . . O
potentially . . B-Factor
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
and . . O
fatal . . B-AdverseReaction
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

6.2 . . O
endogenous . . O
anterior . . O
uveitis . . O

tudorza . . O
pressair . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
narrow . . O
- . . O
angle . . O
glaucoma . . O
. . . O

the . . O
clinical . . O
significance . . O
of . . O
cmv . . O
serology . . O
as . . O
a . . O
risk . . O
factor . . O
for . . O
ptld . . B-AdverseReaction
remains . . O
to . . O
be . . O
determined . . O
; . . O
however . . O
, . . O
these . . O
findings . . O
should . . O
be . . O
considered . . O
when . . O
prescribing . . O
nulojix . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

5.5 . . O
risk . . O
of . . O
bleeding . . O
in . . O
patients . . O
with . . O
abnormal . . O
coagulation . . O

treatment . . O
and . . O
reduction . . O
in . . O
the . . O
risk . . O
of . . O
recurrence . . O
of . . O
deep . . O
venous . . O
thrombosis . . O
and . . O
pulmonary . . O
embolism . . O

there . . O
were . . O
no . . O
new . . O
clinically . . O
relevant . . O
aes . . O
that . . O
emerged . . O
in . . O
the . . O
later . . O
treatment . . O
cycles . . O
. . . O

record . . O
the . . O
specific . . O
gbca . . O
and . . O
the . . O
dose . . O
administered . . O
to . . O
a . . O
patient . . O
. . . O

to . . O
manage . . O
gastrointestinal . . O
toxicity . . O
, . . O
withhold . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
discontinue . . O
bosulif . . O
as . . O
necessary . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

5.3 . . O
unintended . . O
skin . . O
exposure . . O

5.10 . . O
pulmonary . . O
toxicity . . O

vascular . . O
disorders . . O
: . . O
capillary . . B-AdverseReaction
leak . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
< . . O
1% . . O
) . . O
. . . O

6.1 . . O
adverse . . O
reactions . . O
from . . O
clinical . . O
trials . . O
experience . . O

* . . O
corrugator . . O
injections . . O
should . . O
be . . O
placed . . O
at . . O
least . . O
1 . . O
cm . . O
above . . O
the . . O
bony . . O
supraorbital . . O
ridge . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

saphris . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
with . . O
flexible . . O
dosing . . O
. . . O

dose . . O
reductions . . O
due . . O
to . . O
adverse . . O
reactions . . O
were . . O
required . . O
in . . O
57% . . O
of . . O
gilotrif . . O
- . . O
treated . . O
patients . . O
. . . O

table . . O
1 . . O
investigator . . O
assessment . . O
of . . O
maximal . . O
local . . B-AdverseReaction
skin . . I-AdverseReaction
reactions . . I-AdverseReaction
in . . O
the . . O
treatment . . O
area . . O
during . . O
the . . O
57 . . O
days . . O
post . . O
treatment . . O
period . . O
( . . O
face . . O
/ . . O
scalp . . O
trials . . O
) . . O

these . . O
events . . O
were . . O
not . . O
treatment . . O
limiting . . O
. . . O

hypoglycemia . . O

the . . O
following . . O
may . . O
increase . . O
the . . O
risk . . B-Factor
for . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
when . . O
patients . . O
are . . O
receiving . . O
sirturo . . O
: . . O

* . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
* . . O
cardiac . . O
disorders . . O
: . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
congestive . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
ischemia . . I-AdverseReaction
* . . O
eye . . O
disorders . . O
: . . O
cataract . . B-AdverseReaction
, . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
* . . O
gastrointestinal . . O
disorders . . O
: . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
toothache . . B-AdverseReaction
* . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
chills . . B-AdverseReaction
, . . O
infusion . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
multi . . B-AdverseReaction
- . . I-AdverseReaction
organ . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
pain . . B-AdverseReaction
* . . O
infections . . O
and . . O
infestations . . O
: . . O
influenza . . B-AdverseReaction
, . . O
sepsis . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
viral . . B-AdverseReaction
infection . . I-AdverseReaction
* . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
dehydration . . B-AdverseReaction
, . . O
hyperkalemia . . B-AdverseReaction
, . . O
hyperuricemia . . B-AdverseReaction
, . . O
hypoalbuminemia . . B-AdverseReaction
, . . O
hyponatremia . . B-AdverseReaction
, . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
* . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
* . . O
nervous . . O
system . . O
disorders . . O
: . . O
hypoesthesia . . B-AdverseReaction
, . . O
paresthesia . . B-AdverseReaction
, . . O
deafness . . B-AdverseReaction
* . . O
psychiatric . . O
disorders . . O
: . . O
anxiety . . B-AdverseReaction
, . . O
delirium . . B-AdverseReaction
* . . O
renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
acute . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
* . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
dysphonia . . B-AdverseReaction
, . . O
epistaxis . . B-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
edema . . I-AdverseReaction
* . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
erythema . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
* . . O
vascular . . O
disorders . . O
: . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
grade . . B-Severity
3 . . I-Severity
and . . O
higher . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
during . . O
cycles . . O
1-12 . . O
with . . O
a . . O
substantial . . O
difference . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
between . . O
the . . O
two . . O
arms . . O
were . . O
neutropenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
and . . O
hypophosphatemia . . B-AdverseReaction
. . . O

pancreatitis . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
amylase . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction

the . . O
initial . . O
prescription . . O
and . . O
renewal . . O
of . . O
the . . O
medication . . O
order . . O
beyond . . O
28 . . O
days . . O
should . . O
be . . O
made . . O
by . . O
a . . O
physician . . O
only . . O
after . . O
examination . . O
of . . O
the . . O
patient . . O
with . . O
the . . O
aid . . O
of . . O
magnification . . O
such . . O
as . . O
slit . . O
lamp . . O
biomicroscopy . . O
and . . O
, . . O
where . . O
appropriate . . O
, . . O
fluorescein . . O
staining . . O
. . . O

redistribution . . O
/ . . O
accumulation . . B-AdverseReaction
of . . I-AdverseReaction
body . . I-AdverseReaction
fat . . I-AdverseReaction
, . . O
including . . O
central . . B-AdverseReaction
obesity . . I-AdverseReaction
, . . O
dorsocervical . . B-AdverseReaction
fat . . I-AdverseReaction
enlargement . . I-AdverseReaction
( . . O
buffalo . . B-AdverseReaction
hump . . I-AdverseReaction
) . . O
, . . O
peripheral . . O
wasting . . O
, . . O
facial . . B-AdverseReaction
wasting . . I-AdverseReaction
, . . O
breast . . B-AdverseReaction
enlargement . . I-AdverseReaction
, . . O
and . . O
" . . O
cushingoid . . B-AdverseReaction
appearance . . I-AdverseReaction
" . . O
have . . O
been . . O
observed . . O
in . . O
patients . . O
receiving . . O
antiretroviral . . O
therapy . . O
. . . O

( . . O
6.1 . . O
) . . O

permanently . . O
discontinue . . O
yervoy . . O
in . . O
patients . . O
with . . O
severe . . O
neuropathy . . O
( . . O
interfering . . O
with . . O
daily . . O
activities . . O
) . . O
such . . O
as . . O
guillain . . O
- . . O
barre . . O
- . . O
like . . O
syndromes . . O
. . . O

table . . O
1 . . O
presents . . O
adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
10% . . O
patients . . O
who . . O
received . . O
inlyta . . O
or . . O
sorafenib . . O
. . . O

pre . . O
- . . O
medicate . . O
in . . O
subsequent . . O
cycles . . O
for . . O
milder . . O
reactions . . O
. . . O

discontinuation . . O
from . . O
study . . O
due . . O
to . . O
genital . . B-AdverseReaction
infection . . I-AdverseReaction
occurred . . O
in . . O
0% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
and . . O
0.2% . . O
of . . O
patients . . O
treated . . O
with . . O
farxiga . . O
10 . . O
mg . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
vimizim . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

the . . O
majority . . O
( . . O
4 . . O
of . . O
5 . . O
patients . . O
) . . O
of . . O
fatal . . B-AdverseReaction
infection . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
occurred . . O
after . . O
a . . O
single . . O
dose . . O
of . . O
jevtana . . O
. . . O

* . . O
hematologic . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
infection . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
hepatotoxicity . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
gastrointestinal . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
observed . . O
in . . O
the . . O
trial . . O
of . . O
patients . . O
with . . O
relapsed . . O
or . . O
refractory . . O
ptcl . . O
treated . . O
with . . O
beleodaq . . O
were . . O
nausea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
and . . O
vomiting . . B-AdverseReaction
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

any . . O
patient . . O
who . . O
presents . . O
with . . O
thigh . . O
or . . O
groin . . O
pain . . O
should . . O
be . . O
suspected . . O
of . . O
having . . O
an . . O
atypical . . O
fracture . . O
and . . O
should . . O
be . . O
evaluated . . O
to . . O
rule . . O
out . . O
an . . O
incomplete . . O
femur . . O
fracture . . O
. . . O

5.1 . . O
hypersensitivity . . O
reactions . . O

remove . . O
contact . . O
lenses . . O
prior . . O
to . . O
instillation . . O
of . . O
bepreve . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
ttp . . O
/ . . O
hus . . O
. . . O

patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
at . . O
baseline . . O
had . . O
larger . . O
mean . . O
changes . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
, . . O
8.6 . . O
) . . O
] . . O
. . . O

you . . O
and . . O
your . . O
healthcare . . O
provider . . O
should . . O
decide . . O
if . . O
you . . O
will . . O
take . . O
duavee . . O
or . . O
breastfeed . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
described . . O
below . . O
and . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

hyponatremia . . B-AdverseReaction
may . . B-Factor
occur . . O
as . . O
a . . O
result . . O
of . . O
treatment . . O
with . . O
ssris . . O
and . . O
snris . . O
, . . O
including . . O
pristiq . . O
. . . O

in . . O
caps . . O
study . . O
1 . . O
, . . O
no . . O
pattern . . O
was . . O
observed . . O
for . . O
any . . O
type . . O
or . . O
frequency . . O
of . . O
adverse . . O
events . . O
throughout . . O
the . . O
three . . O
study . . O
periods . . O
. . . O

there . . O
were . . O
no . . B-Negation
reports . . O
of . . O
seizures . . B-AdverseReaction
in . . O
pediatric . . O
patients . . O
treated . . O
with . . O
saphris . . O
in . . O
a . . O
3 . . O
- . . O
week . . O
- . . O
term . . O
, . . O
bipolar . . O
mania . . O
trial . . O
. . . O

5.2 . . O
hypersensitivity . . O
reactions . . O

6.3 . . O
postmarketing . . O
experience . . O

required . . O
components . . O
of . . O
the . . O
xiaflex . . O
rems . . O
program . . O
include . . O
the . . O
following . . O
: . . O

immune . . O
system . . O
disorders . . O
: . . O
serious . . B-Severity
systemic . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
including . . O
anaphylactic . . B-AdverseReaction
reaction . . I-AdverseReaction
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.10 . . O
) . . O
] . . O
, . . O
sarcoidosis . . B-AdverseReaction

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
seattle . . O
genetics . . O
, . . O
inc . . O
. . . O
at . . O
1-855-473-2436 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

the . . O
elevation . . O
has . . O
a . . O
rapid . . O
onset . . O
, . . O
reaches . . O
a . . O
plateau . . O
after . . O
7 . . O
days . . O
and . . O
is . . O
reversible . . O
after . . O
discontinuation . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
associated . . O
with . . O
promacta . . O
are . . O
described . . O
in . . O
other . . O
sections . . O
. . . O

for . . O
those . . O
patients . . O
continued . . O
on . . O
potiga . . O
, . . O
dizziness . . B-AdverseReaction
and . . O
somnolence . . B-AdverseReaction
appeared . . O
to . . O
diminish . . O
with . . O
continued . . O
use . . O
. . . O

evaluate . . O
for . . O
retinal . . O
vein . . O
thrombosis . . O
immediately . . O
. . . O

5.2 . . O
hypersensitivity . . O

the . . O
transfusion . . O
rate . . O
was . . O
4% . . O
in . . O
subjects . . O
randomized . . O
to . . O
receive . . O
ribavirin . . O
dose . . O
reduction . . O
and . . O
2% . . O
in . . O
subjects . . O
randomized . . O
to . . O
receive . . O
esa . . O
. . . O

the . . O
most . . O
common . . O
grade . . O
3-4 . . O
laboratory . . O
abnormality . . O
( . . O
incidence . . O
> . . O
= . . O
3% . . O
) . . O
was . . O
hypophosphatemia . . B-AdverseReaction
. . . O

closer . . O
monitoring . . O
is . . O
recommended . . O
for . . O
patients . . O
who . . O
have . . O
other . . O
risk . . O
factors . . O
for . . O
urinary . . O
retention . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
benign . . O
prostatic . . O
hyperplasia . . O
[ . . O
bph . . O
] . . O
) . . O
, . . O
patients . . O
who . . O
are . . O
unable . . O
to . . O
communicate . . O
clinical . . O
symptoms . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
cognitively . . O
impaired . . O
patients . . O
) . . O
, . . O
or . . O
patients . . O
who . . O
use . . O
concomitant . . O
medications . . O
that . . O
may . . O
affect . . O
voiding . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
anticholinergics . . O
) . . O
. . . O

instances . . O
of . . O
suicidal . . B-AdverseReaction
ideation . . I-AdverseReaction
and . . O
behavior . . O
have . . O
been . . O
observed . . O
in . . O
0.2% . . O
( . . O
3 . . O
/ . . O
1441 . . O
) . . O
of . . O
subjects . . O
while . . O
receiving . . O
otezla . . O
, . . O
compared . . O
to . . O
none . . O
in . . O
placebo . . O
treated . . O
subjects . . O
( . . O
0 . . O
/ . . O
495 . . O
) . . O
. . . O

5.13 . . O
reduction . . O
in . . O
bone . . O
mineral . . O
density . . O

patients . . O
with . . O
smaller . . O
neck . . O
muscle . . O
mass . . O
and . . O
patients . . O
who . . O
require . . O
bilateral . . O
injections . . O
into . . O
the . . O
sternocleidomastoid . . O
muscles . . O
have . . O
been . . O
reported . . O
to . . O
be . . O
at . . O
greater . . O
risk . . B-Factor
of . . O
dysphagia . . B-AdverseReaction
. . . O

5.3 . . O
ischemic . . O
heart . . O
disease . . O
, . . O
arrhythmias . . O
, . . O
and . . O
congestive . . O
heart . . O
failure . . O

5.7 . . O
neutropenia . . O

table . . O
10 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
2% . . O
or . . O
more . . O
of . . O
pediatric . . O
patients . . O
( . . O
ages . . O
10 . . O
to . . O
17 . . O
years . . O
) . . O
in . . O
any . . O
saphris . . O
dose . . O
group . . O
and . . O
which . . O
occurred . . O
at . . O
greater . . O
incidence . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
in . . O
a . . O
3 . . O
- . . O
week . . O
bipolar . . O
mania . . O
trial . . O
1includes . . O
the . . O
preferred . . O
terms . . O
tachycardia . . B-AdverseReaction
and . . O
heart . . B-AdverseReaction
rate . . I-AdverseReaction
increased . . I-AdverseReaction
. . . O

increased . . B-AdverseReaction
susceptibility . . I-AdverseReaction
to . . I-AdverseReaction
infection . . I-AdverseReaction
and . . O
the . . O
possible . . O
development . . O
of . . O
malignancies . . B-AdverseReaction
may . . B-Factor
result . . O
from . . O
immunosuppression . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
, . . O
5.3 . . O
, . . O
5.4 . . O
, . . O
5.5 . . O
) . . O
] . . O
. . . O

saphris . . O
should . . O
be . . O
used . . O
cautiously . . O
when . . O
treating . . O
patients . . O
who . . O
receive . . O
treatment . . O
with . . O
other . . O
drugs . . O
that . . O
can . . O
induce . . O
hypotension . . O
, . . O
bradycardia . . O
, . . O
respiratory . . O
or . . O
central . . O
nervous . . O
system . . O
depression . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

the . . O
following . . O
selected . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
zerbaxa . . O
- . . O
treated . . O
subjects . . O
at . . O
a . . O
rate . . O
of . . O
less . . O
than . . O
1% . . O
: . . O

5.1 . . O
hematologic . . O
toxicity . . O

the . . O
risk . . B-Factor
of . . O
hypoglycemia . . B-AdverseReaction
is . . O
increased . . O
when . . O
trulicity . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
insulin . . O
secretagogues . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
sulfonylureas . . O
) . . O
or . . O
insulin . . O
. . . O

avoid . . O
use . . O
of . . O
gbcas . . O
in . . O
these . . O
patients . . O
unless . . O
the . . O
diagnostic . . O
information . . O
is . . O
essential . . O
and . . O
not . . O
available . . O
with . . O
non . . O
- . . O
contrasted . . O
mri . . O
or . . O
other . . O
modalities . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
mi . . O
and . . O
stroke . . O
. . . O

a . . O
randomized . . O
, . . O
parallel . . O
- . . O
arm . . O
, . . O
open . . O
- . . O
label . . O
clinical . . O
trial . . O
was . . O
conducted . . O
in . . O
previously . . O
untreated . . O
chc . . O
subjects . . O
with . . O
genotype . . O
1 . . O
infection . . O
to . . O
compare . . O
use . . O
of . . O
an . . O
esa . . O
versus . . O
ribavirin . . O
dose . . O
reduction . . O
for . . O
initial . . O
management . . O
of . . O
anemia . . O
during . . O
therapy . . O
with . . O
victrelis . . O
in . . O
combination . . O
with . . O
peginterferon . . O
alfa . . O
- . . O
2b . . O
and . . O
ribavirin . . O
. . . O

excerpt . . O
: . . O
warnings . . O
: . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
; . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction

adreview . . O
safety . . O
and . . O
effectiveness . . O
have . . O
not . . O
been . . O
established . . O
in . . O
neonates . . O
( . . O
pediatric . . O
patients . . O
below . . O
the . . O
age . . O
of . . O
1 . . O
month . . O
) . . O
. . . O

withhold . . O
zykadia . . O
in . . O
patients . . O
who . . O
develop . . O
a . . O
qtc . . O
interval . . O
greater . . O
than . . O
500 . . O
msec . . O
on . . O
at . . O
least . . O
2 . . O
separate . . O
ecgs . . O
until . . O
the . . O
qtc . . O
interval . . O
is . . O
less . . O
than . . O
481 . . O
msec . . O
or . . O
recovery . . O
to . . O
baseline . . O
if . . O
the . . O
qtc . . O
interval . . O
is . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
481 . . O
msec . . O
, . . O
then . . O
resume . . O
zykadia . . O
at . . O
a . . O
reduced . . O
dose . . O
as . . O
described . . O
in . . O
table . . O
1 . . O
. . . O

placement . . O
or . . O
removal . . O
of . . O
an . . O
epidural . . O
catheter . . O
or . . O
lumbar . . O
puncture . . O
is . . O
best . . O
performed . . O
when . . O
the . . O
anticoagulant . . O
effect . . O
of . . O
dabigatran . . O
is . . O
low . . O
; . . O
however . . O
, . . O
the . . O
exact . . O
timing . . O
to . . O
reach . . O
a . . O
sufficiently . . O
low . . O
anticoagulant . . O
effect . . O
in . . O
each . . O
patient . . O
is . . O
not . . O
known . . O
. . . O

pneumonia . . O

5.12 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

fanapt . . O
should . . O
also . . O
be . . O
avoided . . O
in . . O
patients . . O
with . . O
congenital . . O
long . . O
qt . . O
syndrome . . O
and . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
cardiac . . O
arrhythmias . . O
. . . O

duavee . . O
is . . O
not . . O
for . . O
use . . O
in . . O
children . . O
. . . O

5.2 . . O
radiation . . O
risk . . O

a . . O
transient . . O
hypotensive . . O
response . . O
is . . O
not . . O
a . . O
contraindication . . O
to . . O
further . . O
treatment . . O
, . . O
which . . O
usually . . O
can . . O
be . . O
continued . . O
without . . O
difficulty . . O
once . . O
the . . O
blood . . O
pressure . . O
has . . O
stabilized . . O
. . . O

item{ . . O
fungal . . O
infections . . O
- . . O
fungal . . B-AdverseReaction
infections . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
cornea . . I-AdverseReaction
are . . O
particularly . . O
prone . . O
to . . O
develop . . O
coincidentally . . O
with . . O
long . . O
- . . O
term . . O
local . . O
steroid . . B-DrugClass
application . . O
. . . O

caution . . O
should . . O
be . . O
exercised . . O
when . . O
administering . . O
alglucosidase . . O
alfa . . O
to . . O
patients . . O
susceptible . . O
to . . O
fluid . . O
volume . . O
overload . . O
. . . O

treatment . . O
of . . O
latent . . O
tuberculosis . . O
infection . . O
should . . O
be . . O
initiated . . O
prior . . O
to . . O
nulojix . . O
use . . O
. . . O

the . . O
safety . . O
of . . O
inlyta . . O
has . . O
been . . O
evaluated . . O
in . . O
715 . . O
patients . . O
in . . O
monotherapy . . O
studies . . O
, . . O
which . . O
included . . O
537 . . O
patients . . O
with . . O
advanced . . O
rcc . . O
. . . O

gastrointestinal . . O
adverse . . O
reactions . . O
in . . O
the . . O
four . . O
pivotal . . O
studies . . O
, . . O
patients . . O
on . . O
pradaxa . . O
150 . . O
mg . . O
had . . O
a . . O
similar . . O
incidence . . O
of . . O
gastrointestinal . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
24.7% . . O
vs . . O
. . . O
22.7% . . O
on . . O
warfarin . . O
) . . O
. . . O

5.4 . . O
development . . O
of . . O
drug . . O
- . . O
resistant . . O
bacteria . . O

the . . O
safety . . O
evaluation . . O
of . . O
dronedarone . . O
400 . . O
mg . . O
twice . . O
daily . . O
in . . O
patients . . O
with . . O
af . . O
or . . O
afl . . O
is . . O
based . . O
on . . O
5 . . O
placebo . . O
controlled . . O
studies . . O
, . . O
athena . . O
, . . O
euridis . . O
, . . O
adonis . . O
, . . O
erato . . O
and . . O
dafne . . O
. . . O

* . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
and . . O
potential . . B-Factor
vision . . B-AdverseReaction
loss . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
urinary . . B-AdverseReaction
retention . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
skin . . B-AdverseReaction
discoloration . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
neuropsychiatric . . B-AdverseReaction
symptoms . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
dizziness . . B-AdverseReaction
and . . O
somnolence . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
qt . . B-AdverseReaction
interval . . I-AdverseReaction
effect . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
and . . O
ideation . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
withdrawal . . B-AdverseReaction
seizures . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
4% . . O
and . . O
twice . . O
placebo . . O
) . . O
were . . O
dizziness . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
, . . O
vertigo . . B-AdverseReaction
, . . O
tremor . . B-AdverseReaction
, . . O
abnormal . . B-AdverseReaction
coordination . . I-AdverseReaction
, . . O
diplopia . . B-AdverseReaction
, . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
attention . . I-AdverseReaction
, . . O
memory . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
, . . O
aphasia . . B-AdverseReaction
, . . O
dysarthria . . B-AdverseReaction
, . . O
and . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
of . . O
cimzia . . O
were . . O
tuberculosis . . B-AdverseReaction
infections . . I-AdverseReaction
( . . O
0.5% . . O
) . . O
; . . O
and . . O
pyrexia . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
( . . O
0.3% . . O
) . . O
. . . O

antigen . . O
and . . O
antibody . . O
testing . . O
for . . O
histoplasmosis . . O
may . . O
be . . O
negative . . O
in . . O
some . . O
patients . . O
with . . O
active . . O
infection . . O
. . . O

inform . . O
patients . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
anaphylaxis . . O
, . . O
hypersensitivity . . O
reactions . . O
, . . O
and . . O
immune . . O
- . . O
mediated . . O
reactions . . O
and . . O
have . . O
them . . O
seek . . O
immediate . . O
medical . . O
care . . O
should . . O
signs . . O
and . . O
symptoms . . O
occur . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
, . . O
5.2 . . O
) . . O
] . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
another . . O
section . . O
of . . O
the . . O
label . . O
: . . O

in . . O
clinical . . O
studies . . O
, . . O
treatment . . O
with . . O
invokana . . O
was . . O
associated . . O
with . . O
a . . O
dose . . O
- . . O
dependent . . O
increase . . O
in . . O
the . . O
incidence . . O
of . . O
volume . . B-AdverseReaction
depletion . . I-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
hypotension . . B-AdverseReaction
, . . O
postural . . B-AdverseReaction
dizziness . . I-AdverseReaction
, . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
syncope . . B-AdverseReaction
, . . O
and . . O
dehydration . . B-AdverseReaction
) . . O
. . . O

5.3 . . O
hepatic . . O
effects . . O

5.4 . . O
extravasation . . O
and . . O
injection . . O
site . . O
reactions . . O

5.7 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

in . . O
controlled . . O
clinical . . O
trials . . O
, . . O
clinically . . O
relevant . . O
changes . . O
in . . O
standard . . O
laboratory . . O
parameters . . O
were . . O
uncommon . . O
with . . O
administration . . O
of . . O
edarbi . . O
. . . O

hemoglobin . . O

withhold . . O
gilotrif . . O
for . . O
severe . . O
and . . O
prolonged . . O
diarrhea . . O
not . . O
responsive . . O
to . . O
anti . . O
- . . O
diarrheal . . O
agents . . O
. . . O

benlysta . . O
should . . O
be . . O
administered . . O
by . . O
healthcare . . O
providers . . O
prepared . . O
to . . O
manage . . O
anaphylaxis . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

most . . O
patients . . O
who . . O
developed . . O
these . . O
infections . . B-AdverseReaction
were . . O
taking . . O
concomitant . . O
immunosuppressants . . O
such . . O
as . . O
methotrexate . . O
or . . O
corticosteroids . . O
. . . O

( . . O
4 . . O
) . . O
( . . O
5.2 . . O
) . . O
* . . O
gastrointestinal . . B-AdverseReaction
disorders . . I-AdverseReaction
: . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
and . . O
diarrhea . . B-AdverseReaction
may . . B-Factor
occur . . O
. . . O

extrapyramidal . . O
symptoms . . O
( . . O
eps . . O
) . . O
in . . O
clinical . . O
trials . . O

withhold . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
discontinue . . O
bosulif . . O
. . . O

vision . . O
disorders . . O

in . . O
non . . O
- . . O
clinical . . O
studies . . O
in . . O
rats . . B-Animal
and . . O
rabbits . . B-Animal
, . . O
cabazitaxel . . O
was . . O
embryotoxic . . B-AdverseReaction
, . . O
fetotoxic . . B-AdverseReaction
, . . O
and . . O
abortifacient . . B-AdverseReaction
at . . O
exposures . . O
significantly . . O
lower . . O
than . . O
those . . O
expected . . O
at . . O
the . . O
recommended . . O
human . . O
dose . . O
level . . O
. . . O

compromise . . O
is . . O
noted . . O
, . . O
urgent . . O
treatment . . O
is . . O
necessary . . O
[ . . O
see . . O
warnings . . O

in . . O
general . . O
, . . O
limiting . . O
the . . O
dose . . O
injected . . O
into . . O
the . . O
sternocleidomastoid . . O
muscle . . O
may . . O
decrease . . O
the . . O
occurrence . . O
of . . O
dysphagia . . O
. . . O

errors . . O
may . . O
also . . O
occur . . O
due . . O
to . . O
motion . . O
artifacts . . O
that . . O
result . . O
in . . O
image . . O
distortion . . O
. . . O

other . . O
common . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
greater . . O
than . . O
1% . . O
of . . O
patients . . O
included . . O
pyrexia . . B-AdverseReaction
, . . O
transaminase . . B-AdverseReaction
increase . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
. . . O

plasma . . O
zinc . . O
concentration . . O

after . . O
five . . O
years . . O
more . . O
than . . O
90 . . O
percent . . O
of . . O
patients . . O
remained . . O
seropositive . . O
for . . O
anti . . O
- . . O
aux . . O
- . . O
i . . O
and . . O
anti . . O
- . . O
aux . . O
- . . O
ii . . O
antibody . . O
( . . O
study . . O
4 . . O
) . . O
. . . O

avoid . . O
concurrent . . O
use . . O
of . . O
zydelig . . O
and . . O
other . . O
drugs . . O
that . . O
cause . . O
diarrhea . . O
. . . O

patients . . O
experiencing . . O
seizure . . B-AdverseReaction
were . . O
permanently . . O
discontinued . . O
from . . O
therapy . . O
and . . O
all . . O
seizure . . O
events . . O
resolved . . O
. . . O

the . . O
most . . O
commonly . . O
occurring . . O
adverse . . O
reactions . . O
in . . O
study . . O
1 . . O
and . . O
study . . O
2 . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
were . . O
thrombocytopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
pyrexia . . B-AdverseReaction
. . . O

5.2 . . O
e . . O
. . . O
a . . O
. . . O
s . . O
. . . O
e . . O
. . . O
entereg . . O
rems . . O
program . . O

for . . O
patients . . O
at . . O
risk . . O
for . . O
chronically . . O
reduced . . O
renal . . O
function . . O
( . . O
for . . O
example . . O
, . . O
age . . O
> . . O
60 . . O
years . . O
, . . O
hypertension . . O
or . . O
diabetes . . O
) . . O
, . . O
estimate . . O
the . . O
glomerular . . O
filtration . . O
rate . . O
( . . O
gfr . . O
) . . O
through . . O
laboratory . . O
testing . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
ilaris . . O
has . . O
not . . O
been . . O
administered . . O
concomitantly . . O
with . . O
tumor . . O
necrosis . . O
factor . . O
( . . O
tnf . . O
) . . O
inhibitors . . O
. . . O

* . . O
? . . O

administration . . O
of . . O
ilaris . . O
should . . O
be . . O
discontinued . . O
if . . O
a . . O
patient . . O
develops . . O
a . . O
serious . . O
infection . . O
. . . O

discontinue . . O
saphris . . O
in . . O
patients . . O
with . . O
severe . . O
neutropenia . . O
( . . O
absolute . . O
neutrophil . . O
count . . O
< . . O
1000 . . O
/ . . O
mm . . O
3 . . O
) . . O
and . . O
follow . . O
their . . O
wbc . . O
until . . O
recovery . . O
. . . O

delay . . O
or . . O
discontinue . . O
jevtana . . O
. . . O

studies . . O
have . . O
shown . . O
an . . O
increased . . O
risk . . O
of . . O
developing . . O
hepatocellular . . B-AdverseReaction
carcinoma . . I-AdverseReaction
in . . O
long . . O
- . . O
term . . O
( . . O
> . . O
8 . . O
years . . O
) . . O
coc . . B-DrugClass
users . . O
. . . O

the . . O
following . . O
adverse . . O
events . . O
were . . O
reported . . O
in . . O
crohn's . . O
disease . . O
patients . . O
who . . O
were . . O
antibody . . O
- . . O
positive . . O
( . . O
n . . O
= . . O
100 . . O
) . . O
at . . O
an . . O
incidence . . O
at . . O
least . . O
3% . . O
higher . . O
compared . . O
to . . O
antibody . . O
- . . O
negative . . O
patients . . O
( . . O
n . . O
= . . O
1,242 . . O
) . . O
: . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
, . . O
erythema . . B-AdverseReaction
nodosum . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
erythema . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
, . . O
and . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
. . . O

data . . O
from . . O
this . . O
safety . . O
study . . O
indicate . . O
that . . O
the . . O
greatest . . O
risk . . O
of . . O
vte . . B-AdverseReaction
is . . O
present . . O
after . . O
initially . . O
starting . . O
a . . O
coc . . B-DrugClass
or . . O
restarting . . O
( . . O
following . . O
a . . O
4 . . O
week . . O
or . . O
greater . . O
pill . . O
- . . O
free . . O
interval . . O
) . . O
the . . O
same . . O
or . . O
a . . O
different . . O
coc . . O
. . . O

in . . O
the . . O
controlled . . O
adjunctive . . O
epilepsy . . O
trials . . O
, . . O
these . . O
events . . O
were . . O
reported . . O
in . . O
1% . . O
of . . O
placebo . . O
patients . . O
, . . O
4% . . O
of . . O
patients . . O
randomized . . O
to . . O
receive . . O
800 . . O
mg . . O
/ . . O
day . . O
aptiom . . O
, . . O
and . . O
7% . . O
of . . O
patients . . O
randomized . . O
to . . O
receive . . O
1200 . . O
mg . . O
/ . . O
day . . O
aptiom . . O
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
chronic . . O
or . . O
recurrent . . O
urinary . . O
tract . . O
infections . . O
were . . O
more . . O
likely . . O
to . . O
experience . . O
a . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
. . . O

overall . . O
, . . O
3.9% . . O
of . . O
patients . . O
reported . . O
at . . O
least . . O
one . . O
adverse . . O
reaction . . O
, . . O
primarily . . O
occurring . . O
immediately . . O
or . . O
several . . O
days . . O
following . . O
dotarem . . O
administration . . O
. . . O

therefore . . O
, . . O
the . . O
use . . O
of . . O
cytochrome . . O
p450 . . O
enzyme . . O
inducers . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
rifampin . . O
, . . O
phenobarbital . . O
, . . O
carbamazepine . . O
, . . O
phenytoin . . O
) . . O
with . . O
otezla . . O
is . . O
not . . O
recommended . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

retinal . . O
pigment . . O
epithelial . . O
detachment . . O
( . . O
rped . . O
) . . O
: . . O

evaluation . . O
of . . O
airway . . O
patency . . O
should . . O
be . . O
considered . . O
prior . . O
to . . O
initiation . . O
of . . O
treatment . . O
with . . O
vimizim . . O
. . . O

table . . O
3 . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
eylea . . O
in . . O
1824 . . O
patients . . O
with . . O
wet . . O
amd . . O
, . . O
including . . O
1223 . . O
patients . . O
treated . . O
with . . O
the . . O
2 . . O
- . . O
mg . . O
dose . . O
, . . O
in . . O
2 . . O
double . . O
- . . O
masked . . O
, . . O
active . . O
- . . O
controlled . . O
clinical . . O
studies . . O
( . . O
view1 . . O
and . . O
view2 . . O
) . . O
for . . O
12 . . O
months . . O
[ . . O
seeclinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

vizamyl . . O
, . . O
similar . . O
to . . O
other . . O
radiopharmaceuticals . . O
, . . O
contributes . . O
to . . O
a . . O
patient's . . O
overall . . O
long . . B-AdverseReaction
- . . I-AdverseReaction
term . . I-AdverseReaction
cumulative . . I-AdverseReaction
radiation . . I-AdverseReaction
exposure . . I-AdverseReaction
. . . O

during . . O
the . . O
controlled . . O
trials . . O
in . . O
patients . . O
with . . O
rls . . O
, . . O
somnolence . . B-AdverseReaction
/ . . O
sedation . . B-AdverseReaction
was . . O
reported . . O
in . . O
20% . . O
of . . O
patients . . O
treated . . O
with . . O
600 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
compared . . O
with . . O
6% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
25% . . O
of . . O
patients . . O
treated . . O
with . . O
xiaflex . . O
and . . O
at . . O
an . . O
incidence . . O
greater . . O
than . . O
placebo . . O
were . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
swelling . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
injected . . I-AdverseReaction
hand . . I-AdverseReaction
) . . O
, . . O
contusion . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
and . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
the . . I-AdverseReaction
injected . . I-AdverseReaction
extremity . . I-AdverseReaction
. . . O

( . . O
5.1 . . O
) . . O
* . . O
if . . O
retinal . . O
pigmentary . . O
abnormalities . . O
or . . O
vision . . O
changes . . O
are . . O
detected . . O
, . . O
potiga . . O
should . . O
be . . O
discontinued . . O
unless . . O
no . . O
other . . O
suitable . . O
treatment . . O
options . . O
are . . O
available . . O
and . . O
the . . O
benefits . . O
of . . O
treatment . . O
outweigh . . O
the . . O
potential . . O
risk . . O
of . . O
vision . . O
loss . . O
. . . O

seven . . O
of . . O
the . . O
patients . . O
treated . . O
with . . O
promacta . . O
in . . O
the . . O
controlled . . O
trials . . O
with . . O
hepatobiliary . . B-AdverseReaction
laboratory . . I-AdverseReaction
abnormalities . . I-AdverseReaction
were . . O
re . . O
- . . O
exposed . . O
to . . O
promacta . . O
in . . O
the . . O
extension . . O
trial . . O
. . . O

these . . O
metabolic . . O
changes . . O
include . . O
hyperglycemia . . B-AdverseReaction
, . . O
dyslipidemia . . B-AdverseReaction
, . . O
and . . O
body . . B-AdverseReaction
weight . . I-AdverseReaction
gain . . I-AdverseReaction
[ . . O
see . . O
patient . . O
counseling . . O
information . . O
( . . O
17.3 . . O
) . . O
] . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
women . . O
of . . O
childbearing . . O
potential . . O
should . . O
use . . O
effective . . O
contraception . . O
during . . O
and . . O
for . . O
2 . . O
months . . O
after . . O
stopping . . O
gilenya . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
other . . O
malignancies . . B-AdverseReaction
: . . O
pre . . O
- . . O
malignant . . O
and . . O
malignant . . B-AdverseReaction
diseases . . I-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

such . . O
patients . . O
should . . O
undergo . . O
a . . O
prompt . . O
medical . . O
evaluation . . O
, . . O
and . . O
discontinuation . . O
of . . O
pristiq . . O
should . . O
be . . O
considered . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
asthenia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
reported . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
with . . O
xeomin . . O
. . . O

patients . . O
should . . O
be . . O
monitored . . O
for . . O
the . . O
development . . O
of . . O
systemic . . O
immune . . O
- . . O
mediated . . O
reactions . . O
involving . . O
skin . . O
and . . O
other . . O
organs . . O
while . . O
receiving . . O
alglucosidase . . O
alfa . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
elsewhere . . O
in . . O
the . . O
label . . O
: . . O

immunogenicity . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
, . . O
reported . . O
in . . O
at . . O
least . . O
10% . . O
of . . O
patients . . O
, . . O
that . . O
led . . O
to . . O
dose . . O
reductions . . O
or . . O
interruptions . . O
were . . O
: . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
( . . O
29% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
20% . . O
) . . O
, . . O
increased . . B-AdverseReaction
ast . . I-AdverseReaction
( . . O
16% . . O
) . . O
, . . O
diarrhea . . B-AdverseReaction
( . . O
16% . . O
) . . O
, . . O
and . . O
vomiting . . B-AdverseReaction
( . . O
16% . . O
) . . O
. . . O

do . . O
not . . O
rechallenge . . O
patients . . O
who . . O
develop . . O
neutropenia . . O
with . . O
ferriprox . . O
unless . . O
potential . . O
benefits . . O
outweigh . . O
potential . . O
risks . . O
. . . O

a . . O
causal . . O
relationship . . O
with . . O
uloric . . O
has . . O
not . . O
been . . O
established . . O
. . . O

patients . . O
should . . O
be . . O
monitored . . O
during . . O
and . . O
for . . O
an . . O
appropriate . . O
period . . O
of . . O
time . . O
after . . O
administration . . O
of . . O
benlysta . . O
. . . O

prescribing . . O
zerbaxa . . O
in . . O
the . . O
absence . . O
of . . O
a . . O
proven . . O
or . . O
strongly . . O
suspected . . O
bacterial . . O
infection . . O
is . . O
unlikely . . O
to . . O
provide . . O
benefit . . O
to . . O
the . . O
patient . . O
and . . O
risks . . O
the . . O
development . . O
of . . O
drug . . O
- . . O
resistant . . O
bacteria . . O
. . . O

administer . . O
systemic . . O
corticosteroids . . O
at . . O
a . . O
dose . . O
of . . O
1 . . O
to . . O
2 . . O
mg . . O
/ . . O
kg . . O
/ . . O
day . . O
of . . O
prednisone . . O
or . . O
equivalent . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
bausch . . O
& . . O
lomb . . O
incorporated . . O
at . . O
1-800-323-0000 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

report . . O
any . . O
diagnosis . . O
of . . O
nsf . . O
following . . O
eovist . . O
administration . . O
to . . O
bayer . . O
healthcare . . O
( . . O
1-888-842-2937 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
) . . O
. . . O

in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
10% . . O
and . . O
> . . O
placebo . . O
) . . O
for . . O
gilenya . . O
0.5 . . O
mg . . O
were . . O
headache . . B-AdverseReaction
, . . O
liver . . B-AdverseReaction
transaminase . . I-AdverseReaction
elevation . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
. . . O

* . . O
hematologic . . B-AdverseReaction
toxicities . . I-AdverseReaction
: . . O
monitor . . O
complete . . O
blood . . O
counts . . O
prior . . O
to . . O
each . . O
dose . . O
of . . O
adcetris . . O
. . . O

5.4 . . O
extravasation . . O
and . . O
injection . . O
site . . O
reactions . . O

table . . O
4 . . O
: . . O
adverse . . O
reactions . . O
in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
adverse . . O
reactions . . O
xeomin . . O
( . . O
n . . O
= . . O
535 . . O
) . . O
( . . O
% . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
268 . . O
) . . O
( . . O
% . . O
) . . O
nervous . . O
system . . O
disorders . . O
33 . . O
( . . O
6.1 . . O
) . . O
6 . . O
( . . O
2.2 . . O
) . . O
headache . . B-AdverseReaction
1 . . O
29 . . O
( . . O
5.4 . . O
) . . O
6 . . O
( . . O
2.2 . . O
) . . O
facial . . B-AdverseReaction
paresis . . I-AdverseReaction
( . . O
brow . . B-AdverseReaction
ptosis . . I-AdverseReaction
) . . O
4 . . O
( . . O
0.7 . . O
) . . O
0 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
5 . . O
( . . O
0.9 . . O
) . . O
2 . . O
( . . O
0.7 . . O
) . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
3 . . O
( . . O
0.6 . . O
) . . O
0 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
1 . . O
( . . O
0.2 . . O
) . . O
0 . . O
facial . . B-AdverseReaction
pain . . I-AdverseReaction
1 . . O
( . . O
0.2 . . O
) . . O
0 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
swelling . . I-AdverseReaction
0 . . O
1 . . O
( . . O
0.4 . . O
) . . O
sensation . . B-AdverseReaction
of . . I-AdverseReaction
pressure . . I-AdverseReaction
0 . . O
1 . . O
( . . O
0.4 . . O
) . . O
eye . . O
disorders . . O
5 . . O
( . . O
0.9 . . O
) . . O
0 . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
2 . . O
( . . O
0.4 . . O
) . . O
0 . . O
blepharospasm . . B-AdverseReaction
1 . . O
( . . O
0.2 . . O
) . . O
0 . . O
eye . . B-AdverseReaction
disorder . . I-AdverseReaction
1(0.2 . . O
) . . O
0 . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
1(0.2 . . O
) . . O
0 . . O
in . . O
open . . O
label . . O
, . . O
multiple . . O
dose . . O
trials . . O
, . . O
adverse . . O
reactions . . O
were . . O
reported . . O
for . . O
105 . . O
of . . O
the . . O
800 . . O
subjects . . O
( . . O
13.1% . . O
) . . O
. . . O

5.1 . . O
contamination . . O
of . . O
tip . . O
and . . O
solution . . O

use . . O
of . . O
tnf . . O
blockers . . O
, . . O
including . . O
cimzia . . O
, . . O
has . . O
been . . O
associated . . O
with . . O
reactivation . . B-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction
virus . . I-AdverseReaction
( . . O
hbv . . O
) . . O
in . . O
patients . . O
who . . O
are . . O
chronic . . O
carriers . . O
of . . O
this . . O
virus . . O
. . . O

grade . . B-Severity
3-4 . . I-Severity
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
occurred . . O
in . . O
1.6% . . O
of . . O
patients . . O
taking . . O
zytiga . . O
and . . O
led . . O
to . . O
5 . . O
treatment . . O
discontinuations . . O
and . . O
2 . . O
deaths . . B-AdverseReaction
. . . O

any . . O
type . . O
of . . O
hemorrhagic . . B-AdverseReaction
stroke . . I-AdverseReaction
was . . O
adjudicated . . O
and . . O
counted . . O
as . . O
an . . O
intracranial . . O
major . . B-Severity
bleed . . O
. . . O

grade . . B-Severity
2 . . I-Severity
or . . O
higher . . O
laboratory . . O
abnormalities . . O
that . . O
represent . . O
a . . O
worsening . . O
from . . O
baseline . . O
of . . O
ast . . O
, . . O
alt . . O
or . . O
total . . O
bilirubin . . O
occurred . . O
in . . O
27.8% . . O
, . . O
25.0% . . O
and . . O
7.1% . . O
respectively . . O
, . . O
of . . O
intelence . . O
( . . O
r . . O
) . . O
- . . O
treated . . O
co . . O
- . . O
infected . . O
subjects . . O
as . . O
compared . . O
to . . O
6.7% . . O
, . . O
7.5% . . O
and . . O
1.8% . . O
of . . O
non . . O
- . . O
co . . O
- . . O
infected . . O
intelence . . O
( . . O
r . . O
) . . O
- . . O
treated . . O
subjects . . O
. . . O

jevtana . . O
is . . O
contraindicated . . O
in . . O
patients . . O
who . . O
have . . O
a . . O
history . . O
of . . O
severe . . O
hypersensitivity . . O
reactions . . O
to . . O
cabazitaxel . . O
or . . O
to . . O
other . . O
drugs . . O
formulated . . O
with . . O
polysorbate . . O
80 . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
, . . O
contraindications . . O
( . . O
4 . . O
) . . O
, . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

patients . . O
ranged . . O
in . . O
age . . O
from . . O
18 . . O
to . . O
83 . . O
years . . O
, . . O
with . . O
an . . O
overall . . O
median . . O
age . . O
of . . O
51 . . O
years . . O
. . . O

* . . O
active . . B-AdverseReaction
tuberculosis . . I-AdverseReaction
, . . O
including . . O
reactivation . . B-AdverseReaction
of . . I-AdverseReaction
latent . . I-AdverseReaction
tuberculosis . . I-AdverseReaction
. . . O

six . . O
percent . . O
( . . O
6% . . O
) . . O
of . . O
tecfidera . . O
patients . . O
and . . O
< . . O
1% . . O
of . . O
placebo . . O
patients . . O
experienced . . O
lymphocyte . . B-AdverseReaction
counts . . I-AdverseReaction
< . . I-AdverseReaction
0.5 . . I-AdverseReaction
x . . I-AdverseReaction
10 . . I-AdverseReaction
9 . . I-AdverseReaction
/ . . I-AdverseReaction
l . . I-AdverseReaction
( . . O
lower . . O
limit . . O
of . . O
normal . . O
0.91 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
) . . O
. . . O

nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
and . . O
severe . . B-Severity
diarrhea . . B-AdverseReaction
, . . O
at . . O
times . . O
, . . O
may . . B-Factor
occur . . O
. . . O

injection . . O
site . . O
reactions . . O

duavee . . O
is . . O
a . . O
prescription . . O
medicine . . O
that . . O
contains . . O
a . . O
mixture . . O
of . . O
estrogens . . O
and . . O
bazedoxifene . . O
. . . O

if . . O
anaphylaxis . . O
or . . O
severe . . O
hypersensitivity . . O
reactions . . O
occur . . O
, . . O
immediately . . O
discontinue . . O
administration . . O
of . . O
alglucosidase . . O
alfa . . O
, . . O
and . . O
initiate . . O
appropriate . . O
medical . . O
treatment . . O
. . . O

in . . O
a . . O
placebo . . O
- . . O
controlled . . O
trial . . O
of . . O
promacta . . O
in . . O
patients . . O
with . . O
chronic . . O
liver . . O
diseaseand . . O
thrombocytopenia . . O
not . . O
related . . O
to . . O
itp . . O
, . . O
six . . O
patients . . O
treated . . O
with . . O
promacta . . O
and . . O
one . . O
patient . . O
in . . O
the . . O
placebo . . O
group . . O
developed . . O
portal . . B-AdverseReaction
vein . . I-AdverseReaction
thromboses . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

because . . O
these . . O
reactions . . O
were . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

test . . O
patients . . O
for . . O
latent . . O
tuberculosis . . O
before . . O
simponi . . O
aria . . O
use . . O
and . . O
during . . O
therapy . . O
. . . O

patients . . O
should . . O
not . . O
wear . . O
contact . . O
lenses . . O
if . . O
they . . O
have . . O
signs . . O
or . . O
symptoms . . O
of . . O
bacterial . . O
conjunctivitis . . O
or . . O
during . . O
the . . O
course . . O
of . . O
therapy . . O
with . . O
besivance . . O
. . . O

warning . . O
: . . O
potential . . O
risk . . B-Factor
of . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
with . . O
long . . O
- . . O
term . . O
use . . O
: . . O
for . . O
short . . O
- . . O
term . . O
hospital . . O
use . . O
only . . O

decreases . . O
in . . O
hemoglobin . . O
may . . O
require . . O
a . . O
decrease . . O
in . . O
dosage . . O
or . . O
discontinuation . . O
of . . O
ribavirin . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
and . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
[ . . O
see . . O
prescribing . . O
information . . O
for . . O
ribavirin . . O
] . . O
. . . O

adverse . . O
reactions . . O
related . . O
to . . O
volume . . B-AdverseReaction
depletion . . I-AdverseReaction
( . . O
including . . O
reports . . O
of . . O
dehydration . . B-AdverseReaction
, . . O
hypovolemia . . B-AdverseReaction
, . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
or . . O
hypotension . . B-AdverseReaction
) . . O
are . . O
shown . . O
in . . O
table . . O
2 . . O
for . . O
the . . O
12 . . O
- . . O
study . . O
and . . O
13 . . O
- . . O
study . . O
, . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
pools . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

the . . O
criterion . . O
for . . O
allowing . . O
patients . . O
to . . O
receive . . O
a . . O
second . . O
glucarpidase . . O
dose . . O
was . . O
not . . O
specified . . O
in . . O
the . . O
protocol . . O
. . . O

carefully . . O
monitor . . O
prediabetic . . O
and . . O
diabetic . . O
women . . O
who . . O
are . . O
taking . . O
natazia . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
- . . O
site . . O
conditions . . O
: . . O
injection . . B-AdverseReaction
- . . I-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
, . . O
vessel . . B-AdverseReaction
puncture . . I-AdverseReaction
- . . I-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction

the . . O
most . . O
common . . O
serious . . O
adverse . . O
reactions . . O
( . . O
> . . O
2% . . O
) . . O
were . . O
pneumonia . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
infection . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
creatinine . . I-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
and . . O
multi . . B-AdverseReaction
- . . I-AdverseReaction
organ . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

the . . O
incidence . . O
of . . O
grade . . B-Severity
3 . . I-Severity
hyperglycemia . . B-AdverseReaction
based . . O
on . . O
laboratory . . O
values . . O
was . . O
6% . . O
( . . O
12 . . O
/ . . O
187 . . O
) . . O
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
compared . . O
with . . O
none . . O
of . . O
the . . O
dacarbazine . . O
- . . O
treated . . O
patients . . O
. . . O

( . . O
2.2 . . O
, . . O
5.7 . . O
) . . O
* . . O
embryofetal . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
zykadia . . O
may . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

treatment . . O
with . . O
antibacterial . . O
agents . . O
can . . O
alter . . O
the . . O
normal . . O
flora . . O
of . . O
the . . O
colon . . O
, . . O
and . . O
may . . O
permit . . O
overgrowth . . O
of . . O
c . . O
. . . O
difficile . . O
. . . O

5.4 . . O
serious . . O
dermatological . . O
reactions . . O

anaphylaxis . . B-AdverseReaction
was . . O
reported . . O
in . . O
4% . . O
of . . O
patients . . O
with . . O
hae . . O
. . . O

such . . O
monitoring . . O
may . . O
increase . . O
the . . O
risk . . O
of . . O
unnecessary . . O
procedures . . O
, . . O
due . . O
to . . O
the . . O
low . . O
test . . O
specificity . . O
for . . O
serum . . O
calcitonin . . O
and . . O
a . . O
high . . O
background . . O
incidence . . O
of . . O
thyroid . . O
disease . . O
. . . O

among . . O
299 . . O
patients . . O
with . . O
chronic . . O
itp . . O
who . . O
received . . O
promacta . . O
in . . O
the . . O
single . . O
- . . O
arm . . O
extension . . O
trial . . O
, . . O
the . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
a . . O
pattern . . O
similar . . O
to . . O
that . . O
seen . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

cases . . O
of . . O
lymphoma . . B-AdverseReaction
have . . O
occurred . . O
in . . O
premarketing . . O
clinical . . O
trials . . O
and . . O
in . . O
the . . O
postmarketing . . O
setting . . O
. . . O

temporarily . . O
suspend . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
permanently . . O
discontinue . . O
xalkori . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
distant . . B-AdverseReaction
spread . . I-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effect . . I-AdverseReaction

6.1 . . O
clinical . . O
trials . . O
experience . . O

because . . O
fanapt . . O
was . . O
not . . O
marketed . . O
at . . O
the . . O
time . . O
these . . O
studies . . O
were . . O
performed . . O
, . . O
it . . O
is . . O
not . . O
known . . O
if . . O
fanapt . . O
is . . O
associated . . O
with . . O
this . . O
increased . . O
risk . . O
. . . O

carcinogenicity . . O
of . . O
albiglutide . . O
could . . O
not . . O
be . . O
assessed . . O
in . . O
rodents . . O
due . . O
to . . O
the . . O
rapid . . O
development . . O
of . . O
drug . . O
- . . O
clearing . . O
, . . O
anti . . O
- . . O
drug . . O
antibodies . . O
[ . . O
see . . O
nonclinical . . O
toxicology . . O
( . . O
13.1 . . O
) . . O
] . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
astrazeneca . . O
at . . O
1-800-236-9933 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

common . . O
adverse . . O
reactions . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

table . . O
5 . . O
presents . . O
the . . O
most . . O
common . . O
treatment . . O
- . . O
related . . O
adverse . . O
reactions . . O
( . . O
experienced . . O
by . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3% . . O
of . . O
patients . . O
receiving . . O
promacta . . O
) . . O
from . . O
the . . O
extension . . O
trial . . O
. . . O

a . . O
majority . . O
of . . O
qutenza . . O
- . . O
treated . . O
patients . . O
in . . O
clinical . . O
studies . . O
had . . O
adverse . . O
reactions . . O
with . . O
a . . O
maximum . . O
intensity . . O
of . . O
" . . O
mild . . O
" . . O
or . . O
" . . O
moderate . . O
" . . O
. . . O

in . . O
study . . O
3 . . O
, . . O
67% . . O
of . . O
patients . . O
treated . . O
with . . O
adcetris . . O
experienced . . O
any . . O
grade . . O
of . . O
neuropathy . . B-AdverseReaction
. . . O

across . . O
the . . O
340 . . O
patients . . O
who . . O
were . . O
treated . . O
in . . O
study . . O
1 . . O
, . . O
the . . O
median . . O
age . . O
was . . O
53 . . O
years . . O
; . . O
16% . . O
of . . O
patients . . O
were . . O
older . . O
than . . O
65 . . O
years . . O
. . . O

in . . O
short . . O
- . . O
term . . O
placebo . . O
- . . O
controlled . . O
bipolar . . O
mania . . O
adult . . O
trials . . O
, . . O
the . . O
incidence . . O
of . . O
eps . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
events . . I-AdverseReaction
, . . O
excluding . . B-Negation
events . . O
related . . O
to . . O
akathisia . . B-AdverseReaction
, . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
was . . O
7% . . O
versus . . O
2% . . O
for . . O
placebo . . O
; . . O
and . . O
the . . O
incidence . . O
of . . O
akathisia . . B-AdverseReaction
- . . O
related . . O
events . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
was . . O
4% . . O
versus . . O
2% . . O
for . . O
placebo . . O
. . . O

after . . O
resolution . . O
, . . O
treatment . . O
with . . O
erwinaze . . O
may . . O
be . . O
resumed . . O
. . . O

keep . . O
duavee . . O
and . . O
all . . O
other . . O
medicines . . O
out . . O
of . . O
the . . O
reach . . O
of . . O
children . . O
. . . O

adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
from . . O
one . . O
open . . O
- . . O
label . . O
trial . . O
in . . O
adults . . O
with . . O
severe . . O
aplastic . . O
anemia . . O
adverse . . O
reaction . . O
promacta . . O
( . . O
n . . O
= . . O
43 . . O
) . . O
( . . O
% . . O
) . . O
nausea . . B-AdverseReaction
33 . . O
fatigue . . B-AdverseReaction
28 . . O
cough . . B-AdverseReaction
23 . . O
diarrhea . . B-AdverseReaction
21 . . O
headache . . B-AdverseReaction
21 . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
19 . . O
dyspnea . . B-AdverseReaction
14 . . O
pyrexia . . B-AdverseReaction
14 . . O
dizziness . . B-AdverseReaction
14 . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
14 . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
14 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
12 . . O
ecchymosis . . B-AdverseReaction
12 . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
12 . . O
transaminases . . B-AdverseReaction
increased . . I-AdverseReaction
12 . . O
arthralgia . . B-AdverseReaction
12 . . O
rhinorrhea . . B-AdverseReaction
12 . . O
in . . O
this . . O
trial . . O
, . . O
patients . . O
had . . O
bone . . O
marrow . . O
aspirates . . O
evaluated . . O
for . . O
cytogenetic . . O
abnormalities . . O
. . . O

there . . O
were . . O
no . . B-Negation
asthma . . O
- . . O
related . . O
deaths . . B-AdverseReaction
or . . O
asthma . . O
- . . O
related . . O
intubations . . O
observed . . O
in . . O
this . . O
trial . . O
. . . O

more . . O
hepatic . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
reported . . O
with . . O
the . . O
use . . O
of . . O
sirturo . . O
plus . . O
other . . O
drugs . . O
used . . O
to . . O
treat . . O
tuberculosis . . O
compared . . O
to . . O
other . . O
drugs . . O
used . . O
to . . O
treat . . O
tuberculosis . . O
without . . O
the . . O
addition . . O
of . . O
sirturo . . O
. . . O

this . . O
list . . O
also . . O
includes . . O
adverse . . O
reactions . . O
( . . O
less . . O
than . . O
1% . . O
of . . O
subjects . . O
) . . O
associated . . O
with . . O
organ . . O
systems . . O
from . . O
warnings . . O
and . . O
precautions . . O
. . . O

afinitor . . O
may . . O
be . . O
reintroduced . . O
at . . O
a . . O
daily . . O
dose . . O
approximately . . O
50% . . O
lower . . O
than . . O
the . . O
dose . . O
previously . . O
administered . . O
[ . . O
see . . O
table . . O
1 . . O
in . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

there . . O
was . . O
a . . O
6 . . O
- . . O
fold . . O
increase . . O
in . . O
the . . O
risk . . B-Factor
of . . O
ctcae . . O
grade . . B-Severity
3-4 . . I-Severity
hyperglycemia . . B-AdverseReaction
in . . O
patients . . O
with . . O
diabetes . . O
or . . O
glucose . . O
intolerance . . O
and . . O
a . . O
2 . . O
- . . O
fold . . O
increase . . O
in . . O
patients . . O
taking . . O
corticosteroids . . O
. . . O

if . . O
liver . . O
injury . . O
is . . O
detected . . O
, . . O
promptly . . O
interrupt . . O
uloric . . O
and . . O
assess . . O
patient . . O
for . . O
probable . . O
cause . . O
, . . O
then . . O
treat . . O
cause . . O
if . . O
possible . . O
, . . O
to . . O
resolution . . O
or . . O
stabilization . . O
. . . O

5.2 . . O
peripheral . . O
neuropathy . . O

approximately . . O
57% . . O
of . . O
the . . O
patients . . O
were . . O
male . . O
. . . O

proteinuria . . B-AdverseReaction
was . . O
observed . . O
in . . O
4 . . O
( . . O
2% . . O
) . . O
of . . O
patients . . O
receiving . . O
cometriq . . O
, . . O
including . . O
one . . O
with . . O
nephrotic . . B-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
as . . O
compared . . O
to . . O
none . . O
of . . O
the . . O
patients . . O
receiving . . O
placebo . . O
. . . O

6 . . O
adverse . . O
reactions . . O

* . . O
administer . . O
dotarem . . O
only . . O
in . . O
situations . . O
where . . O
trained . . O
personnel . . O
and . . O
therapies . . O
are . . O
promptly . . O
available . . O
for . . O
the . . O
treatment . . O
of . . O
hypersensitivity . . O
reactions . . O
, . . O
including . . O
personnel . . O
trained . . O
in . . O
resuscitation . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
risk . . B-Factor
of . . O
anaphylaxis . . B-AdverseReaction

careful . . O
consideration . . O
should . . O
be . . O
given . . O
to . . O
this . . O
potential . . O
risk . . O
prior . . O
to . . O
initiating . . O
therapy . . O
in . . O
patients . . O
with . . O
these . . O
conditions . . O
. . . O

in . . O
the . . O
controlled . . O
and . . O
uncontrolled . . O
clinical . . O
studies . . O
of . . O
xiaflex . . O
in . . O
peyronie's . . O
disease . . O
, . . O
1044 . . O
patients . . O
received . . O
a . . O
total . . O
of . . O
7466 . . O
xiaflex . . O
injections . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

in . . O
an . . O
additional . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
study . . O
lasting . . O
up . . O
to . . O
3 . . O
months . . O
in . . O
298 . . O
men . . O
who . . O
had . . O
undergone . . O
bilateral . . O
nerve . . O
- . . O
sparing . . O
radical . . O
prostatectomy . . O
for . . O
prostate . . O
cancer . . O
, . . O
the . . O
mean . . O
age . . O
of . . O
patients . . O
was . . O
58.4 . . O
years . . O
( . . O
range . . O
40 . . O
- . . O
70 . . O
) . . O
. . . O

the . . O
incidence . . O
of . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

( . . O
5.5 . . O
) . . O

discontinue . . O
and . . O
do . . O
not . . O
restart . . O
ampyra . . O
if . . O
this . . O
occurs . . O
( . . O
5.4 . . O
) . . O

* . . O
hospital . . O
staff . . O
who . . O
prescribe . . O
, . . O
dispense . . O
, . . O
or . . O
administer . . O
entereg . . O
have . . O
been . . O
provided . . O
the . . O
educational . . O
materials . . O
on . . O
the . . O
need . . O
to . . O
limit . . O
use . . O
of . . O
entereg . . O
to . . O
short . . O
- . . O
term . . O
, . . O
inpatient . . O
use . . O
; . . O
* . . O
patients . . O
will . . O
not . . O
receive . . O
more . . O
than . . O
15 . . O
doses . . O
of . . O
entereg . . O
; . . O
and . . O
* . . O
entereg . . O
will . . O
not . . O
be . . O
dispensed . . O
to . . O
patients . . O
after . . O
they . . O
have . . O
been . . O
discharged . . O
from . . O
the . . O
hospital . . O
. . . O

immune . . O
system . . O
disorders . . O
: . . O
guillain . . B-AdverseReaction
- . . I-AdverseReaction
barre . . I-AdverseReaction
syndrome . . I-AdverseReaction

other . . O
important . . O
considerations . . O
in . . O
the . . O
differential . . O
diagnosis . . O
include . . O
central . . O
anticholinergic . . O
toxicity . . O
, . . O
heat . . O
stroke . . O
, . . O
drug . . O
fever . . O
, . . O
and . . O
primary . . O
central . . O
nervous . . O
system . . O
pathology . . O
. . . O

in . . O
controlled . . O
trials . . O
, . . O
the . . O
concurrent . . O
administration . . O
of . . O
another . . O
tnf . . O
- . . O
blocker . . O
and . . O
abatacept . . O
was . . O
associated . . O
with . . O
a . . O
greater . . O
proportion . . O
of . . O
serious . . O
infections . . O
than . . O
the . . O
use . . O
of . . O
a . . O
tnf . . O
- . . O
blocker . . O
alone . . O
; . . O
and . . O
the . . O
combination . . O
therapy . . O
, . . O
compared . . O
to . . O
the . . O
use . . O
of . . O
a . . O
tnf . . O
- . . O
blocker . . O
alone . . O
, . . O
has . . O
not . . O
demonstrated . . O
improved . . O
clinical . . O
benefit . . O
in . . O
the . . O
treatment . . O
of . . O
ra . . O
. . . O

two . . O
suicides . . B-AdverseReaction
( . . O
0.1% . . O
) . . O
were . . O
reported . . O
in . . O
patients . . O
receiving . . O
benlysta . . O
. . . O

6 . . O
24 . . O
psychiatric . . O
disorders . . O
anxiety . . B-AdverseReaction
2 . . O
4 . . O
depression . . B-AdverseReaction
1 . . O
2 . . O
insomnia . . B-AdverseReaction
5 . . O
6 . . O
monotherapy . . O
in . . O
pediatric . . O
patients . . O
with . . O
bipolar . . O
mania . . O
: . . O
the . . O
following . . O
findings . . O
are . . O
based . . O
on . . O
a . . O
3 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
trial . . O
for . . O
bipolar . . O
mania . . O
in . . O
which . . O
saphris . . O
was . . O
administered . . O
at . . O
doses . . O
of . . O
2.5 . . O
mg . . O
, . . O
5 . . O
mg . . O
, . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
. . . O

decreases . . B-AdverseReaction
in . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
neutrophils . . O
, . . O
and . . O
platelets . . O
may . . B-Factor
also . . O
occur . . O
. . . O

the . . O
stated . . O
frequencies . . O
of . . O
adverse . . O
reactions . . O
represent . . O
the . . O
proportions . . O
of . . O
individuals . . O
who . . O
experienced . . O
a . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reaction . . O
of . . O
the . . O
type . . O
listed . . O
. . . O

* . . O
drug . . O
- . . O
related . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
anaphylaxis . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
facial . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
and . . O
erythema . . B-AdverseReaction
* . . O
hypocalcemia . . B-AdverseReaction
: . . O
severe . . B-Severity
symptomatic . . B-AdverseReaction
hypocalcemia . . I-AdverseReaction
* . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
including . . O
severe . . B-Severity
cases . . O
* . . O
parathyroid . . O
hormone . . O
( . . O
pth . . O
) . . O
: . . O
marked . . B-Severity
elevation . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
pth . . I-AdverseReaction
in . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
( . . O
creatinine . . O
clearance . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
) . . O
or . . O
receiving . . O
dialysis . . O
. . . O

potiga . . O
can . . B-Factor
cause . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
with . . O
funduscopic . . O
features . . O
similar . . O
to . . O
those . . O
seen . . O
in . . O
retinal . . O
pigment . . O
dystrophies . . O
, . . O
which . . O
are . . O
known . . O
to . . O
result . . O
in . . O
damage . . B-AdverseReaction
to . . I-AdverseReaction
the . . I-AdverseReaction
photoreceptors . . I-AdverseReaction
and . . O
vision . . B-AdverseReaction
loss . . I-AdverseReaction
. . . O

excerpt . . O
: . . O
* . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
has . . O
occurred . . O
in . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
gbcas . . O
. . . O

anaphylaxis . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction
reactions . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
vimizim . . O
. . . O

physicians . . O
should . . O
consider . . O
whether . . O
their . . O
patients . . O
with . . O
underlying . . O
naion . . O
risk . . O
factors . . O
could . . O
be . . O
adversely . . O
affected . . O
by . . O
use . . O
of . . O
pde5 . . O
inhibitors . . O
. . . O

electrocardiographic . . O
findings . . O

agranulocytosis . . B-AdverseReaction
and . . O
neutropenia . . B-AdverseReaction
usually . . O
resolve . . O
upon . . O
discontinuation . . O
of . . O
ferriprox . . O
, . . O
but . . O
there . . O
have . . O
been . . O
reports . . O
of . . O
agranulocytosis . . B-AdverseReaction
leading . . O
to . . O
death . . B-AdverseReaction
. . . O

swallowing . . O
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
can . . O
be . . O
life . . O
threatening . . O
and . . O
there . . O
have . . O
been . . O
reports . . O
of . . O
death . . B-AdverseReaction
. . . O

severe . . O
pancreatitis . . O
is . . O
a . . O
contraindication . . O
to . . O
additional . . O
asparaginase . . O
administration . . O
. . . O

have . . O
resuscitation . . O
equipment . . O
and . . O
trained . . O
personnel . . O
available . . O
at . . O
time . . O
of . . O
vizamyl . . O
administration . . O
( . . O
5.1 . . O
) . . O
* . . O
image . . O
interpretation . . O
errors . . O
( . . O
especially . . O
false . . O
positives . . O
) . . O
have . . O
been . . O
observed . . O
( . . O
5.2 . . O
) . . O
* . . O
radiation . . B-AdverseReaction
risk . . I-AdverseReaction
: . . O
vizamyl . . O
, . . O
similar . . O
to . . O
all . . O
radiopharmaceuticals . . O
, . . O
contributes . . O
to . . O
a . . O
patient's . . O
long . . B-AdverseReaction
- . . I-AdverseReaction
term . . I-AdverseReaction
cumulative . . I-AdverseReaction
radiation . . I-AdverseReaction
exposure . . I-AdverseReaction
. . . O

the . . O
common . . O
adverse . . O
events . . O
occurring . . O
at . . O
a . . O
rate . . O
of . . O
10% . . O
or . . O
greater . . O
with . . O
kyprolis . . O
monotherapy . . O
are . . O
presented . . O
in . . O
table . . O
7 . . O
. . . O

women . . O
with . . O
normal . . O
thyroid . . O
function . . O
can . . O
compensate . . O
for . . O
the . . O
increased . . B-AdverseReaction
tbg . . I-AdverseReaction
by . . O
making . . O
more . . O
thyroid . . O
hormone . . O
, . . O
thus . . O
maintaining . . O
free . . O
t4 . . O
and . . O
t3 . . O
serum . . O
concentrations . . O
in . . O
the . . O
normal . . O
range . . O
. . . O

5.1 . . O
angioedema . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction

monitor . . O
for . . O
infection . . O
during . . O
treatment . . O
and . . O
for . . O
2 . . O
months . . O
after . . O
discontinuation . . O
. . . O

5.3 . . O
acute . . O
kidney . . O
injury . . O

promacta . . O
inhibits . . O
udp . . O
- . . O
glucuronosyltransferase . . O
( . . O
ugt . . O
) . . O
1a1 . . O
and . . O
organic . . O
anion . . O
- . . O
transporting . . O
polypeptide . . O
( . . O
oatp . . O
) . . O
1b1 . . O
, . . O
which . . O
may . . B-Factor
lead . . O
to . . O
indirect . . B-AdverseReaction
hyperbilirubinemia . . I-AdverseReaction
. . . O

adverse . . O
reactions . . O
reported . . O
within . . O
48 . . O
weeks . . O
of . . O
treatment . . O
and . . O
in . . O
at . . O
least . . O
1% . . O
of . . O
subjects . . O
treated . . O
with . . O
jublia . . O
and . . O
those . . O
reported . . O
in . . O
subjects . . O
treated . . O
with . . O
the . . O
vehicle . . O
are . . O
presented . . O
in . . O
table . . O
1 . . O
. . . O

5.6 . . O
macrovascular . . O
outcomes . . O

one . . O
patient . . O
( . . O
0.4% . . O
) . . O
required . . O
permanent . . O
discontinuation . . O
due . . O
to . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
, . . O
and . . O
jaundice . . B-AdverseReaction
. . . O

nausea . . B-AdverseReaction
and . . O
vomiting . . B-AdverseReaction
also . . O
occurred . . O
with . . O
these . . O
events . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
potential . . O
risk . . B-Factor
of . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
with . . O
long . . O
- . . O
term . . O
use . . O
: . . O
for . . O
short . . O
- . . O
term . . O
hospital . . O
use . . O
only . . O

liver . . O
enzymes . . O
should . . O
be . . O
monitored . . O
in . . O
patients . . O
who . . O
develop . . O
symptoms . . O
suggestive . . O
of . . O
hepatic . . O
dysfunction . . O
, . . O
such . . O
as . . O
unexplained . . O
nausea . . O
, . . O
vomiting . . O
, . . O
abdominal . . O
pain . . O
, . . O
fatigue . . O
, . . O
anorexia . . O
, . . O
or . . O
jaundice . . O
and . . O
/ . . O
or . . O
dark . . O
urine . . O
. . . O

consider . . O
empiric . . O
anti . . O
- . . O
fungal . . O
therapy . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
invasive . . O
fungal . . O
infections . . O
who . . O
develop . . O
severe . . O
systemic . . O
illness . . O
. . . O

monitor . . O
alt . . O
, . . O
ast . . O
and . . O
bilirubin . . O
before . . O
initiation . . O
of . . O
, . . O
and . . O
periodically . . O
throughout . . O
, . . O
treatment . . O
with . . O
inlyta . . O
. . . O

* . . O
in . . O
those . . O
patients . . O
already . . O
taking . . O
an . . O
optimized . . O
dose . . O
of . . O
a . . O
pde5 . . O
inhibitor . . O
, . . O
alpha . . O
- . . O
blocker . . O
therapy . . O
should . . O
be . . O
initiated . . O
at . . O
the . . O
lowest . . O
dose . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

* . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
anaphylaxis . . B-AdverseReaction
and . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O

no . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
greater . . O
than . . O
5% . . O
of . . O
patients . . O
receiving . . O
teflaro . . O
. . . O

treanda . . O
extravasations . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
post . . O
marketing . . O
resulting . . O
in . . O
hospitalizations . . O
from . . O
erythema . . B-AdverseReaction
, . . O
marked . . B-Severity
swelling . . B-AdverseReaction
, . . O
and . . O
pain . . B-AdverseReaction
. . . O

5.2 . . O
management . . O
of . . O
immunosuppression . . O

common . . O
adverse . . O
reactions . . O
in . . O
placebo . . O
- . . O
controlled . . O
perioperative . . O
studies . . O
. . . O

infections . . O
and . . O
infestations . . O
: . . O
superficial . . B-AdverseReaction
fungal . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
abscess . . B-AdverseReaction
, . . O
lower . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
pneumonia . . B-AdverseReaction
) . . O
, . . O
pyelonephritis . . B-AdverseReaction

monitor . . O
patients . . O
for . . O
fever . . O
. . . O

none . . O
of . . O
the . . O
59 . . O
evaluable . . O
patients . . O
tested . . O
positive . . O
for . . O
inhibition . . O
of . . O
enzyme . . O
activity . . O
. . . O

consider . . O
measures . . O
to . . O
prevent . . O
severe . . O
reactions . . O
, . . O
including . . O
antihistamines . . O
, . . O
antipyretics . . O
and . . O
corticosteroids . . O
in . . O
subsequent . . O
cycles . . O
in . . O
patients . . O
who . . O
have . . O
experienced . . O
grade . . O
1 . . O
or . . O
2 . . O
infusion . . O
reactions . . O
. . . O

blood . . O
glucose . . O
and . . O
lipids . . O

* . . O
in . . O
those . . O
patients . . O
who . . O
are . . O
stable . . O
on . . O
alpha . . O
- . . O
blocker . . O
therapy . . O
, . . O
pde5 . . O
inhibitors . . O
should . . O
be . . O
initiated . . O
at . . O
the . . O
lowest . . O
dose . . O
( . . O
stendra . . O
50 . . O
mg . . O
) . . O
. . . O

stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
sjs . . B-AdverseReaction
) . . O
and . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
( . . O
ten . . B-AdverseReaction
) . . O
, . . O
including . . O
fatal . . B-AdverseReaction
outcomes . . O
, . . O
have . . O
been . . O
reported . . O
with . . O
adcetris . . O
. . . O

the . . O
values . . O
did . . O
not . . O
exceed . . O
more . . O
than . . O
3 . . O
times . . O
the . . O
baseline . . O
values . . O
and . . O
returned . . O
to . . O
baseline . . O
within . . O
1 . . O
to . . O
4 . . O
days . . O
. . . O

flushing . . B-AdverseReaction
symptoms . . O
generally . . O
began . . O
soon . . O
after . . O
initiating . . O
tecfidera . . O
and . . O
usually . . O
improved . . O
or . . O
resolved . . O
over . . O
time . . O
. . . O

in . . O
the . . O
event . . O
of . . O
new . . O
or . . O
worsening . . O
pulmonary . . O
symptoms . . O
, . . O
hold . . O
adcetris . . O
dosing . . O
during . . O
evaluation . . O
and . . O
until . . O
symptomatic . . O
improvement . . O
. . . O

discontinue . . O
for . . O
nephrotic . . O
syndrome . . O
. . . O

* . . O
xiaflex . . O
is . . O
available . . O
for . . O
the . . O
treatment . . O
of . . O
peyronie's . . O
disease . . O
only . . O
through . . O
a . . O
restricted . . O
program . . O
called . . O
the . . O
xiaflex . . O
rems . . O
program . . O
( . . O
5.3 . . O
) . . O
. . . O

renal . . B-AdverseReaction
cysts . . I-AdverseReaction
occurred . . O
in . . O
8 . . O
( . . O
5% . . O
) . . O
patients . . O
treated . . O
with . . O
xalkori . . O
and . . O
1 . . O
( . . O
1% . . O
) . . O
patient . . O
treated . . O
with . . O
chemotherapy . . O
in . . O
study . . O
1 . . O
. . . O

patients . . O
, . . O
their . . O
caregivers . . O
, . . O
and . . O
families . . O
should . . O
be . . O
informed . . O
that . . O
aeds . . O
increase . . O
the . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
and . . O
should . . O
be . . O
advised . . O
of . . O
the . . O
need . . O
to . . O
be . . O
alert . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
depression . . O
; . . O
any . . O
unusual . . O
changes . . O
in . . O
mood . . O
or . . O
behavior . . O
; . . O
or . . O
the . . O
emergence . . O
of . . O
suicidal . . O
thoughts . . O
, . . O
behavior . . O
, . . O
or . . O
thoughts . . O
about . . O
self . . O
- . . O
harm . . O
. . . O

based . . O
on . . O
the . . O
pooled . . O
data . . O
from . . O
4 . . O
placebo . . O
- . . O
controlled . . O
, . . O
4 . . O
- . . O
or . . O
6 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
or . . O
flexible . . O
- . . O
dose . . O
studies . . O
, . . O
there . . O
was . . O
no . . O
difference . . O
in . . O
the . . O
incidence . . O
of . . O
discontinuation . . O
due . . O
to . . O
adverse . . O
events . . O
between . . O
fanapt . . O
- . . O
treated . . O
( . . O
5% . . O
) . . O
and . . O
placebo . . O
- . . O
treated . . O
( . . O
5% . . O
) . . O
patients . . O
. . . O

in . . O
the . . O
controlled . . O
phase . . O
of . . O
trial . . O
1 . . O
through . . O
week . . O
24 . . O
, . . O
infections . . B-AdverseReaction
were . . O
observed . . O
in . . O
27% . . O
of . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
compared . . O
with . . O
24% . . O
of . . O
control . . O
- . . O
treated . . O
patients . . O
, . . O
and . . O
serious . . B-Severity
infections . . B-AdverseReaction
were . . O
observed . . O
in . . O
0.9% . . O
of . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
and . . O
0.0% . . O
of . . O
control . . O
- . . O
treated . . O
patients . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
kalbitor . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

* . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
can . . B-Factor
occur . . O
. . . O

6 . . O
adverse . . O
reactions . . O

eye . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
including . . O
severe . . B-Severity
eye . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
chemical . . B-AdverseReaction
conjunctivitis . . I-AdverseReaction
, . . O
corneal . . B-AdverseReaction
burn . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
, . . O
periorbital . . B-AdverseReaction
edema . . I-AdverseReaction
can . . B-Factor
occur . . O
after . . O
exposure . . O
. . . O

drugs . . O
that . . O
inhibit . . O
cyp2d6 . . O
and . . O
cyp3a . . O
metabolism . . O
pathways . . O
may . . O
significantly . . O
increase . . O
the . . O
exposure . . O
to . . O
eliglustat . . O
and . . O
result . . O
in . . O
prolongation . . O
of . . O
the . . O
pr . . O
, . . O
qtc . . O
, . . O
and . . O
/ . . O
or . . O
qrs . . O
cardiac . . O
intervals . . O
that . . O
could . . B-Factor
result . . O
in . . O
cardiac . . B-AdverseReaction
arrhythmias . . I-AdverseReaction
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

postmarketing . . O
safety . . O
data . . O
from . . O
xeomin . . O
and . . O
other . . O
approved . . O
botulinum . . O
toxins . . O
suggest . . O
that . . O
botulinum . . O
toxin . . O
effects . . O
may . . B-Factor
, . . O
in . . O
some . . O
cases . . O
, . . O
be . . O
observed . . O
beyond . . O
the . . O
site . . O
of . . O
local . . O
injection . . O
. . . O

in . . O
patients . . O
of . . O
all . . O
ages . . O
who . . O
are . . O
started . . O
on . . O
antidepressant . . O
therapy . . O
, . . O
monitor . . O
closely . . O
for . . O
worsening . . O
, . . O
and . . O
for . . O
emergence . . O
of . . O
suicidal . . O
thoughts . . O
and . . O
behaviors . . O
. . . O

* . . O
screen . . O
patients . . O
for . . O
acute . . O
kidney . . O
injury . . O
and . . O
other . . O
conditions . . O
that . . O
may . . O
reduce . . O
renal . . O
function . . O
. . . O

these . . O
patients . . O
may . . O
have . . O
an . . O
increased . . O
risk . . B-Factor
for . . O
a . . O
hypersensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
to . . O
eovist . . O
. . . O

an . . O
increased . . O
rate . . O
of . . O
stroke . . B-AdverseReaction
was . . O
observed . . O
during . . O
the . . O
transition . . O
from . . O
eliquis . . O
to . . O
warfarin . . O
in . . O
clinical . . O
trials . . O
in . . O
atrial . . O
fibrillation . . O
patients . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
reported . . O
with . . O
prolia . . O
in . . O
men . . O
with . . O
osteoporosis . . O
are . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
and . . O
nasopharyngitis . . B-AdverseReaction
. . . O

5.3 . . O
neutropenia . . O
( . . O
use . . O
with . . O
ribavirin . . O
and . . O
peginterferon . . O
alfa . . O
) . . O

table . . O
3 . . O
. . . O

5.12 . . O
cardiovascular . . O
effects . . O

the . . O
finding . . O
of . . O
increased . . O
risk . . O
with . . O
aeds . . O
of . . O
varying . . O
mechanism . . O
of . . O
action . . O
and . . O
across . . O
a . . O
range . . O
of . . O
indications . . O
suggests . . O
that . . O
the . . O
risk . . O
applies . . O
to . . O
all . . O
aeds . . O
used . . O
for . . O
any . . O
indication . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
adreview . . O
contains . . O
benzyl . . O
alcohol . . O
( . . O
10.3 . . O
mg . . O
/ . . O
ml . . O
) . . O
which . . O
may . . O
cause . . O
serious . . O
reactions . . O
in . . O
premature . . O
or . . O
low . . O
birth . . O
- . . O
weight . . O
infants . . O
. . . O

in . . O
the . . O
two . . O
clinical . . O
trials . . O
in . . O
infantile . . O
- . . O
onset . . O
patients . . O
, . . O
the . . O
majority . . O
of . . O
patients . . O
( . . O
34 . . O
of . . O
38 . . O
; . . O
89% . . O
) . . O
tested . . O
positive . . O
for . . O
igg . . O
antibodies . . O
to . . O
alglucosidase . . O
alfa . . O
. . . O

infections . . O
and . . O
infestations . . O
: . . O
vulvovaginal . . B-AdverseReaction
candidiasis . . I-AdverseReaction

adult . . O
patients . . O
: . . O
pooled . . O
data . . O
from . . O
the . . O
short . . O
- . . O
term . . O
placebo . . O
- . . O
controlled . . O
schizophrenia . . O
and . . O
bipolar . . O
mania . . O
trials . . O
are . . O
presented . . O
in . . O
table . . O
1 . . O
. . . O

monitor . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
enterocolitis . . O
( . . O
such . . O
as . . O
diarrhea . . O
, . . O
abdominal . . O
pain . . O
, . . O
mucus . . O
or . . O
blood . . O
in . . O
stool . . O
, . . O
with . . O
or . . O
without . . O
fever . . O
) . . O
and . . O
of . . O
bowel . . O
perforation . . O
( . . O
such . . O
as . . O
peritoneal . . O
signs . . O
and . . O
ileus . . O
) . . O
. . . O

mean . . O
changes . . O
( . . O
percent . . O
changes . . O
) . . O
from . . O
baseline . . O
in . . O
non . . O
- . . O
hdl . . O
- . . O
c . . O
relative . . O
to . . O
placebo . . O
were . . O
2.1 . . B-Severity
mg . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
1.5% . . O
) . . O
and . . O
5.1 . . B-Severity
mg . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
3.6% . . O
) . . O
with . . O
invokana . . O
100 . . O
mg . . O
and . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

neuropathy . . B-AdverseReaction
, . . O
most . . O
commonly . . O
sensory . . O
in . . O
nature . . O
, . . O
occurred . . O
in . . O
419 . . O
( . . O
25% . . O
) . . O
of . . O
1669 . . O
patients . . O
. . . O

cabazitaxel . . O
is . . O
extensively . . O
metabolized . . O
in . . O
the . . O
liver . . O
. . . O

pr . . O
interval . . O
prolongation . . O
and . . O
adverse . . O
reactions . . O
of . . O
first . . O
degree . . O
atrioventricular . . O
( . . O
av . . O
) . . O
block . . O

treatment . . O
with . . O
stribild . . O
should . . O
be . . O
suspended . . O
in . . O
any . . O
patient . . O
who . . O
develops . . O
clinical . . O
or . . O
laboratory . . O
findings . . O
suggestive . . O
of . . O
lactic . . O
acidosis . . O
or . . O
pronounced . . O
hepatotoxicity . . O
( . . O
which . . O
may . . O
include . . O
hepatomegaly . . O
and . . O
steatosis . . O
even . . O
in . . O
the . . O
absence . . O
of . . O
marked . . O
transaminase . . O
elevations . . O
) . . O
. . . O

caution . . O
should . . O
be . . O
exercised . . O
when . . O
administering . . O
dysport . . O
( . . O
r . . O
) . . O
to . . O
patients . . O
with . . O
surgical . . O
alterations . . O
to . . O
the . . O
facial . . O
anatomy . . O
, . . O
excessive . . O
weakness . . O
or . . O
atrophy . . O
in . . O
the . . O
target . . O
muscle . . O
( . . O
s . . O
) . . O
, . . O
marked . . O
facial . . O
asymmetry . . O
, . . O
inflammation . . O
at . . O
the . . O
injection . . O
site . . O
( . . O
s . . O
) . . O
, . . O
ptosis . . O
, . . O
excessive . . O
dermatochalasis . . O
, . . O
deep . . O
dermal . . O
scarring . . O
, . . O
thick . . O
sebaceous . . O
skin . . O
[ . . O
seedosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
] . . O
or . . O
the . . O
inability . . O
to . . O
substantially . . O
lessen . . O
glabellar . . O
lines . . O
by . . O
physically . . O
spreading . . O
them . . O
apart . . O
[ . . O
seeclinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
] . . O
. . . O

this . . O
drop . . O
in . . O
body . . O
estrogen . . O
levels . . O
causes . . O
the . . O
" . . O
change . . O
of . . O
life . . O
" . . O
or . . O
menopause . . O
( . . O
the . . O
end . . O
of . . O
monthly . . O
menstrual . . O
periods . . O
) . . O
. . . O

* . . O
if . . O
you . . O
take . . O
a . . O
calcium . . O
or . . O
vitamin . . O
d . . O
supplement . . O
, . . O
you . . O
may . . O
take . . O
it . . O
at . . O
the . . O
same . . O
time . . O
you . . O
take . . O
duavee . . O
. . . O

non . . O
- . . O
steroidal . . O
anti . . O
- . . O
inflammatory . . O
drugs . . O
( . . O
nsaids . . O
) . . O
, . . O
platelet . . O
inhibitors . . O
, . . O

the . . O
reporting . . O
rate . . O
of . . O
these . . O
reactions . . O
associated . . O
with . . O
oxcarbazepine . . O
use . . O
exceeds . . O
the . . O
background . . O
incidence . . O
rate . . O
estimates . . O
by . . O
a . . O
factor . . O
of . . O
3 . . O
- . . O
to . . O
10 . . O
- . . O
fold . . O
. . . O

procedural . . O
complications . . O
: . . O
contusion . . B-AdverseReaction
. . . O

6.1 . . O
clinical . . O
trial . . O
experience . . O

5.7 . . O
orthostatic . . O
hypotension . . O
, . . O
syncope . . O
, . . O
and . . O
other . . O
hemodynamic . . O
effects . . O

* . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

5.5 . . O
hyponatremia . . O

increase . . B-AdverseReaction
in . . I-AdverseReaction
hematocrit . . I-AdverseReaction
in . . O
a . . O
pool . . O
of . . O
four . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
median . . O
hematocrit . . B-AdverseReaction
decreased . . I-AdverseReaction
by . . O
1.3% . . O
in . . O
placebo . . B-Factor
and . . O
increased . . O
by . . O
2.8% . . O
in . . O
jardiance . . O
10 . . O
mg . . O
and . . O
2.8% . . O
in . . O
jardiance . . O
25 . . O
mg . . O
treated . . O
patients . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
: . . O
monitor . . O
serum . . O
creatinine . . O
regularly . . O
( . . O
5.2 . . O
) . . O
* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
tls . . B-AdverseReaction
) . . O
: . . O
administer . . O
pre . . O
- . . O
treatment . . O
hydration . . O
. . . O

serious . . O
adverse . . O
events . . O
were . . O
reported . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
in . . O
50% . . O
of . . O
patients . . O
in . . O
the . . O
pooled . . O
kyprolis . . O
monotherapy . . O
studies . . O
( . . O
n . . O
= . . O
598 . . O
) . . O
. . . O

routine . . O
monitoring . . O
of . . O
serum . . O
calcitonin . . O
or . . O
using . . O
thyroid . . O
ultrasound . . O
is . . O
of . . O
uncertain . . O
value . . O
for . . O
early . . O
detection . . O
of . . O
mtc . . O
in . . O
patients . . O
treated . . O
with . . O
trulicity . . O
[ . . O
see . . O
contraindications . . O
( . . O
4.1 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
. . . O
] . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
included . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
sepsis . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
device . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
tremor . . B-AdverseReaction
, . . O
encephalopathy . . B-AdverseReaction
, . . O
infection . . B-AdverseReaction
, . . O
overdose . . B-AdverseReaction
, . . O
confusion . . B-AdverseReaction
, . . O
staphylococcal . . B-AdverseReaction
bacteremia . . I-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

( . . O
6 . . O
) . . O

in . . O
the . . O
two . . O
controlled . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
and . . O
thrombocytopenia . . O
, . . O
cataracts . . B-AdverseReaction
developed . . O
or . . O
worsened . . O
in . . O
8% . . O
patients . . O
treated . . O
with . . O
promacta . . O
and . . O
5% . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

s . . O
a . . O
medically . . O
important . . O
event . . O
that . . O
may . . O
be . . O
life . . O
- . . O
threatening . . O
or . . O
result . . O
in . . O
death . . B-AdverseReaction
or . . O
hospitalization . . O
or . . O
prolongation . . O
of . . O
existing . . O
hospitalization . . O
. . . O

the . . O
percentage . . O
of . . O
patients . . O
who . . O
exceeded . . O
a . . O
predetermined . . O
threshold . . O
value . . O
is . . O
shown . . O
in . . O
table . . O
4 . . O
. . . O

the . . O
following . . O
are . . O
discussed . . O
in . . O
more . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

there . . O
is . . O
no . . O
general . . O
agreement . . O
about . . O
specific . . O
pharmacological . . O
treatment . . O
regimens . . O
for . . O
nms . . O
. . . O

the . . O
adverse . . O
events . . O
occurring . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
xeomin . . O
- . . O
treated . . O
patients . . O
and . . O
greater . . O
than . . O
placebo . . O
in . . O
the . . O
phase . . O
3 . . O
study . . O
were . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
, . . O
dry . . B-AdverseReaction
eye . . I-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
visual . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
and . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
. . . O

in . . O
addition . . O
, . . O
two . . O
cases . . O
of . . O
ptld . . B-AdverseReaction
involving . . O
the . . O
liver . . O
allograft . . O
( . . O
one . . O
fatal . . B-AdverseReaction
) . . O
and . . O
one . . O
fatal . . B-AdverseReaction
case . . O
of . . O
pml . . B-AdverseReaction
were . . O
observed . . O
among . . O
the . . O
147 . . O
patients . . O
randomized . . O
to . . O
nulojix . . O
. . . O

the . . O
incidence . . O
of . . O
new . . O
cases . . O
of . . O
infections . . B-AdverseReaction
in . . O
controlled . . O
clinical . . O
studies . . O
in . . O
rheumatoid . . O
arthritis . . O
was . . O
0.91 . . O
per . . O
patient . . O
- . . O
year . . O
for . . O
all . . O
cimzia . . O
- . . O
treated . . O
patients . . O
and . . O
0.72 . . O
per . . O
patient . . O
- . . O
year . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

( . . O
5.7 . . O
, . . O
2.3 . . O
) . . O
* . . O
serious . . B-Severity
skin . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
monitor . . O
for . . O
skin . . O
toxicities . . O
and . . O
for . . O
secondary . . O
infections . . O
. . . O

5.1 . . O
nephrogenic . . O
systemic . . O
fibrosis . . O

patients . . O
with . . O
histoplasmosis . . B-AdverseReaction
or . . O
other . . O
invasive . . B-AdverseReaction
fungal . . I-AdverseReaction
infections . . I-AdverseReaction
may . . B-Factor
present . . O
with . . O
disseminated . . O
, . . O
rather . . O
than . . O
localized . . O
disease . . O
. . . O

concomitant . . O
administration . . O
of . . O
drugs . . O
associated . . O
with . . O
onj . . O
may . . O
increase . . O
the . . O
risk . . O
of . . O
developing . . O
onj . . O
. . . O

patients . . O
have . . O
frequently . . O
presented . . O
with . . O
disseminated . . O
rather . . O
than . . O
localized . . O
disease . . O
. . . O

table . . O
4 . . O
presents . . O
the . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
subjects . . O
treated . . O
with . . O
stendra . . O
. . . O

to . . O
minimize . . O
the . . O
risk . . O
for . . O
thrombotic . . O
/ . . O
thromboembolic . . O
complications . . O
, . . O
do . . O
not . . O
use . . O
promacta . . O
in . . O
an . . O
attempt . . O
to . . O
normalize . . O
platelet . . O
counts . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
patients . . O
who . . O
receive . . O
prolonged . . O
cleviprex . . O
infusions . . O
and . . O
are . . O
not . . O
transitioned . . O
to . . O
other . . O
antihypertensive . . O
therapies . . O
should . . O
be . . O
monitored . . O
for . . O
the . . O
possibility . . O
of . . O
rebound . . O
hypertension . . O
for . . O
at . . O
least . . O
8 . . O
hours . . O
after . . O
the . . O
infusion . . O
is . . O
stopped . . O
. . . O

consider . . O
whether . . O
to . . O
restart . . O
kyprolis . . O
based . . O
on . . O
a . . O
benefit . . O
/ . . O
risk . . O
assessment . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
- . . O
cardiac . . O
toxicities . . O
( . . O
5.1 . . O
) . . O
, . . O
pulmonary . . O
toxicity . . O
( . . O
5.4 . . O
) . . O
, . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

thrombotic . . O
/ . . O
thromboembolic . . B-AdverseReaction
complications . . I-AdverseReaction
may . . B-Factor
result . . O
from . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
platelet . . I-AdverseReaction
counts . . I-AdverseReaction
with . . O
promacta . . O
. . . O

breathing . . O
difficulty . . O

6.1 . . O
clinical . . O
studies . . O
experience . . O

patients . . O
receiving . . O
pristiq . . O
should . . O
have . . O
regular . . O
monitoring . . O
of . . O
blood . . O
pressure . . O
since . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
were . . O
observed . . O
in . . O
clinical . . O
studies . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

* . . O
bone . . B-AdverseReaction
marrow . . I-AdverseReaction
suppression . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

5.10 . . O
body . . O
temperature . . O
regulation . . O

( . . O
5.1 . . O
) . . O
* . . O
do . . O
not . . O
initiate . . O
in . . O
acutely . . O
deteriorating . . O
copd . . O
or . . O
asthma . . O
. . . O

patients . . O
were . . O
ineligible . . O
if . . O
ast . . O
and . . O
/ . . O
or . . O
alt . . O
> . . O
= . . O
2.5 . . O
* . . O
uln . . O
and . . O
patients . . O
were . . O
excluded . . O
if . . O
they . . O
had . . O
liver . . O
metastases . . O
. . . O

all . . O
reports . . O
with . . O
methylene . . O
blue . . O
that . . O
provided . . O
information . . O
on . . O
the . . O
route . . O
of . . O
administration . . O
involved . . O
intravenous . . O
administration . . O
in . . O
the . . O
dose . . O
range . . O
of . . O
1 . . O
mg . . O
/ . . O
kg . . O
to . . O
8 . . O
mg . . O
/ . . O
kg . . O
. . . O
no . . O
reports . . O
involved . . O
the . . O
administration . . O
of . . O
methylene . . O
blue . . O
by . . O
other . . O
routes . . O
( . . O
such . . O
as . . O
oral . . O
tablets . . O
or . . O
local . . O
tissue . . O
injection . . O
) . . O
or . . O
at . . O
lower . . O
doses . . O
. . . O

increases . . B-AdverseReaction
in . . I-AdverseReaction
creatinine . . I-AdverseReaction
1.5 . . B-Severity
to . . I-Severity
3 . . I-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
occurred . . O
in . . O
9% . . O
of . . O
patients . . O
. . . O

6 . . O
adverse . . O
reactions . . O

exercise . . O
caution . . O
in . . O
considering . . O
the . . O
use . . O
of . . O
cimzia . . O
in . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
or . . O
recent . . O
- . . O
onset . . O
central . . O
or . . O
peripheral . . O
nervous . . O
system . . O
demyelinating . . O
disorders . . O
. . . O

patients . . O
were . . O
between . . O
the . . O
ages . . O
of . . O
18 . . O
and . . O
69 . . O
on . . O
the . . O
date . . O
of . . O
the . . O
first . . O
dose . . O
of . . O
cerdelga . . O
, . . O
and . . O
included . . O
87 . . O
females . . O
and . . O
72 . . O
males . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
in . . O
> . . O
= . . O
13% . . O
of . . O
patients . . O
are . . O
: . . O
infections . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
tonsilitis . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
ear . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

table . . O
3 . . O
: . . O
most . . O
common . . O
teaes . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
and . . O
greater . . O
than . . O
placebo . . O
: . . O
double . . O
- . . O
blind . . O
phase . . O
of . . O
clinical . . O
trial . . O
double . . O
- . . O
blind . . O
phase . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
xeomin . . O
( . . O
n . . O
= . . O
74 . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
34 . . O
) . . O
subjects . . O
with . . O
teaes . . O
70% . . O
62% . . O
eye . . O
disorders . . O
38% . . O
21% . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
19% . . O
9% . . O
dry . . B-AdverseReaction
eye . . I-AdverseReaction
16% . . O
12% . . O
visual . . B-AdverseReaction
impairment . . I-AdverseReaction
12% . . O
6% . . O
gastrointestinal . . O
disorders . . O
30% . . O
15% . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
16% . . O
3% . . O
diarrhoea . . B-AdverseReaction
8% . . O
- . . O
infections . . O
and . . O
infestations . . O
20% . . O
15% . . O
nasopharyngitis . . B-AdverseReaction
5% . . O
3% . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
5% . . O
3% . . O
nervous . . O
system . . O
disorders . . O
14% . . O
9% . . O
headache . . B-AdverseReaction
7% . . O
3% . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
11% . . O
9% . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
11% . . O
3% . . O
dyspnoea . . B-AdverseReaction
5% . . O
3% . . O
glabellar . . O
lines . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
genital . . O
mycotic . . O
infections . . O
and . . O
uncircumcised . . O
males . . O
were . . O
more . . O
likely . . O
to . . O
develop . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

sinus . . B-AdverseReaction
tachycardia . . I-AdverseReaction
was . . O
reported . . O
in . . O
3.0% . . O
, . . O
2.8% . . O
, . . O
and . . O
5.6% . . O
of . . O
patient . . O
treated . . O
with . . O
placebo . . O
, . . O
trulicity . . O
0.75 . . O
mg . . O
and . . O
trulicity . . O
1.5 . . O
mg . . O
, . . O
respectively . . O
. . . O

in . . O
patients . . O
treated . . O
for . . O
these . . O
two . . O
indications . . O
, . . O
there . . O
was . . O
no . . O
apparent . . O
correlation . . O
of . . O
antibody . . O
frequency . . O
, . . O
antibody . . O
titers . . O
, . . O
or . . O
neutralizing . . O
status . . O
to . . O
clinical . . O
response . . O
or . . O
adverse . . O
reactions . . O
. . . O

( . . O
5.1 . . O
, . . O
5.2 . . O
) . . O

a . . O
decision . . O
on . . O
whether . . O
or . . O
not . . O
to . . O
discontinue . . O
gilenya . . O
therapy . . O
should . . O
include . . O
an . . O
assessment . . O
of . . O
the . . O
potential . . O
benefits . . O
and . . O
risks . . O
for . . O
the . . O
individual . . O
patient . . O
. . . O

the . . O
patient . . O
was . . O
also . . O
not . . O
taking . . O
any . . O
immunosuppressive . . O
or . . O
immunomodulatory . . O
medications . . O
concomitantly . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
exposure . . O
was . . O
6.1 . . O
months . . O
( . . O
range . . O
0.3 . . O
to . . O
26.4 . . O
months . . O
) . . O
. . . O

there . . O
have . . O
been . . O
post . . O
- . . O
marketing . . O
reports . . O
of . . O
pancytopenia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
aplastic . . B-AdverseReaction
anemia . . I-AdverseReaction
, . . O
and . . O
thrombocytopenia . . B-AdverseReaction
in . . O
patients . . O
receiving . . O
tnf . . O
- . . O
blockers . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

bleeding . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O

when . . O
vasodilators . . O
are . . O
taken . . O
in . . O
combination . . O
, . . O
blood . . O
- . . O
pressure . . O
- . . O
lowering . . O
effects . . O
of . . O
each . . O
individual . . O
compound . . O
may . . O
be . . O
increased . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reaction . . O
reported . . O
in . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
besivance . . O
was . . O
conjunctival . . B-AdverseReaction
redness . . I-AdverseReaction
. . . O

all . . O
patients . . O
were . . O
treated . . O
with . . O
ilaris . . O
150 . . O
mg . . O
subcutaneously . . O
or . . O
2 . . O
mg . . O
/ . . O
kg . . O
if . . O
body . . O
weight . . O
was . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
15 . . O
kg . . O
and . . O
less . . O
than . . O
or . . O
equal . . O
to . . O
40 . . O
kg . . O
( . . O
see . . O
table . . O
1 . . O
) . . O
. . . O

opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
due . . O
to . . O
bacterial . . O
, . . O
mycobacterial . . O
, . . O
invasive . . O
fungal . . O
, . . O
viral . . O
, . . O
or . . O
parasitic . . O
organisms . . O
including . . O
aspergillosis . . B-AdverseReaction
, . . O
blastomycosis . . B-AdverseReaction
, . . O
candidiasis . . B-AdverseReaction
, . . O
coccidioidomycosis . . B-AdverseReaction
, . . O
histoplasmosis . . B-AdverseReaction
, . . O
legionellosis . . B-AdverseReaction
, . . O
listeriosis . . B-AdverseReaction
, . . O
pneumocystosis . . B-AdverseReaction
, . . O
and . . O
tuberculosis . . B-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
tnf . . B-DrugClass
- . . I-DrugClass
blockers . . I-DrugClass
. . . O

recommended . . O
doses . . O
of . . O
immunosuppressants . . O
should . . O
not . . O
be . . O
exceeded . . O
. . . O

( . . O
6.2 . . O
) . . O

* . . O
while . . O
the . . O
effect . . O
of . . O
weak . . O
cyp3a4 . . O
inhibitors . . O
( . . O
e . . O
. . . O
g . . O
. . . O
cimetidine . . O
) . . O
was . . O
not . . O
examined . . O
by . . O
clinical . . O
study . . O
, . . O
some . . O
pharmacokinetic . . O
interaction . . O
is . . O
expected . . O
, . . O
albeit . . O
less . . O
than . . O
that . . O
observed . . O
with . . O
moderate . . O
cyp3a4 . . O
inhibitors . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
and . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

a . . O
single . . O
event . . O
of . . O
serum . . B-AdverseReaction
sickness . . I-AdverseReaction
was . . O
reported . . O
in . . O
a . . O
patient . . O
treated . . O
with . . O
nesina . . O
25 . . O
mg . . O
. . . O

patients . . O
should . . O
be . . O
closely . . O
monitored . . O
for . . O
signs . . O
or . . O
symptoms . . O
of . . O
these . . O
events . . O
. . . O

the . . O
median . . O
age . . O
was . . O
54 . . O
years . . O
, . . O
57% . . O
were . . O
male . . O
, . . O
and . . O
> . . O
99% . . O
were . . O
white . . O
. . . O

excerpt . . O
: . . O
* . . O
gout . . B-AdverseReaction
flare . . I-AdverseReaction
: . . O
an . . O
increase . . O
in . . O
gout . . B-AdverseReaction
flares . . I-AdverseReaction
is . . O
frequently . . O
observed . . O
during . . O
initiation . . O
of . . O
anti . . O
- . . O
hyperuricemic . . O
agents . . O
, . . O
including . . O
uloric . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

( . . O
5.10 . . O
) . . O
* . . O
use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
cardiovascular . . O
disorders . . O
because . . O
of . . O
beta . . O
- . . O
adrenergic . . O
stimulation . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
. . . O
] . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
pfizer . . O
, . . O
inc . . O
at . . O
1-800-438-1985 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

pneumocystis . . B-AdverseReaction
jiroveci . . I-AdverseReaction
pneumonia . . I-AdverseReaction
, . . O
some . . O
with . . O
a . . O
fatal . . B-AdverseReaction
outcome . . O
, . . O
has . . O
been . . O
reported . . O
in . . O
patients . . O
who . . O
received . . O
everolimus . . O
. . . O

the . . O
most . . O
common . . O
infusion . . O
reaction . . O
in . . O
simponi . . O
aria . . O
treated . . O
patients . . O
was . . O
rash . . B-AdverseReaction
. . . O

in . . O
an . . O
open . . O
- . . O
label . . O
, . . O
long . . O
- . . O
term . . O
extension . . O
study . . O
of . . O
two . . O
of . . O
these . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
total . . O
duration . . O
of . . O
treatment . . O
was . . O
up . . O
to . . O
52 . . O
weeks . . O
. . . O

5.5 . . O
capillary . . O
leak . . O
syndrome . . O

table . . O
4 . . O
. . . O

pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
( . . O
7.7% . . O
placebo . . O
vs . . O
. . . O
9.9% . . O
prolia . . O
) . . O
and . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
3.8% . . O
placebo . . O
vs . . O
. . . O
6.0% . . O
prolia . . O
) . . O
have . . O
also . . O
been . . O
reported . . O
in . . O
clinical . . O
trials . . O
. . . O

5.3 . . O
local . . O
skin . . O
reactions . . O

the . . O
laboratory . . O
findings . . O
in . . O
these . . O
4 . . O
subjects . . O
improved . . O
but . . O
did . . O
not . . O
completely . . O
resolve . . O
in . . O
all . . O
subjects . . O
upon . . O
discontinuation . . O
of . . O
stribild . . O
. . . O

systemic . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . O
were . . O
observed . . O
in . . O
patients . . O
receiving . . O
trulicity . . O
in . . O
clinical . . O
trials . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
occurred . . O
during . . O
or . . O
shortly . . O
after . . O
exposure . . O
to . . O
qutenza . . O
. . . O

6 . . O
adverse . . O
reactions . . O

at . . O
week . . O
24 . . O
, . . O
the . . O
mean . . O
changes . . O
from . . O
baseline . . O
in . . O
hematocrit . . O
were . . O
- . . O
0.33% . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
2.30% . . O
in . . O
the . . O
farxiga . . O
10 . . O
mg . . O
group . . O
. . . O

5.6 . . O
depression . . O

gilotrif . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
keratitis . . O
, . . O
ulcerative . . O
keratitis . . O
, . . O
or . . O
severe . . O
dry . . O
eye . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

excerpt . . O
: . . O
* . . O
vascular . . O
risks . . O
: . . O
stop . . O
natazia . . O
if . . O
a . . O
thrombotic . . O
event . . O
occurs . . O
. . . O

discontinue . . O
infusion . . O
immediately . . O
if . . O
hypersensitivity . . O
is . . O
observed . . O
and . . O
treat . . O
as . . O
indicated . . O
. . . O

1 . . O
includes . . O
hypokalemia . . B-AdverseReaction
, . . O
blood . . B-AdverseReaction
potassium . . I-AdverseReaction
decreasedsoc . . O
= . . O
system . . O
organ . . O
class . . O
gilotrifn . . O
= . . O
229 . . O
pemetrexed . . O
/ . . O
cisplatinn . . O
= . . O
111 . . O
adverse . . O
reaction . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grades . . O
3-4 . . O
( . . O
% . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grades . . O
3-4 . . O
( . . O
% . . O
) . . O
alanine . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
11 . . O
2 . . O
4 . . O
0 . . O
hypokalemia . . B-AdverseReaction
1 . . O
11 . . O
4 . . O
5 . . O
4 . . O
aspartate . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
8 . . O
2 . . O
2 . . O
1 . . O
6.2 . . O
postmarketing . . O
experience . . O
the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
gilotrif . . O
. . . O

before . . O
starting . . O
fulyzaq . . O
, . . O
rule . . O
out . . O
infectious . . O
etiologies . . O
of . . O
diarrhea . . O
. . . O

most . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
( . . O
> . . O
5% . . O
of . . O
patients . . O
) . . O
are . . O
: . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
neck . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
dysphonia . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
eye . . B-AdverseReaction
disorders . . I-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O

approximately . . O
two . . O
- . . O
thirds . . O
of . . O
patients . . O
with . . O
psychosis . . B-AdverseReaction
in . . O
controlled . . O
trials . . O
had . . O
no . . O
prior . . O
psychiatric . . O
history . . O
. . . O

dose . . O
delays . . O
were . . O
reported . . O
in . . O
28% . . O
of . . O
jevtana . . O
- . . O
treated . . O
patients . . O
and . . O
15% . . O
of . . O
mitoxantrone . . O
- . . O
treated . . O
patients . . O
. . . O

most . . O
events . . O
( . . O
95% . . O
) . . O
were . . O
grade . . O
1 . . O
or . . O
grade . . O
2 . . O
in . . O
severity . . O
. . . O

gastrointestinal . . O
adverse . . O
reactions . . O

6.2 . . O
postmarketing . . O
experience . . O

management . . O
of . . O
hypersensitivity . . O
reactions . . O
should . . O
be . . O
based . . O
on . . O
the . . O
severity . . O
of . . O
the . . O
reaction . . O
and . . O
include . . O
slowing . . O
or . . O
temporary . . O
interruption . . O
of . . O
the . . O
infusion . . O
and . . O
/ . . O
or . . O
administration . . O
of . . O
additional . . O
antihistamines . . O
, . . O
antipyretics . . O
, . . O
and . . O
/ . . O
or . . O
corticosteroids . . O
for . . O
mild . . O
reactions . . O
. . . O

of . . O
these . . O
patients . . O
, . . O
one . . O
simponi . . O
aria . . O
- . . O
treated . . O
patient . . O
and . . O
no . . B-Negation
control . . O
- . . O
treated . . O
patients . . O
had . . O
newly . . B-AdverseReaction
positive . . I-AdverseReaction
anti . . I-AdverseReaction
- . . I-AdverseReaction
dsdna . . I-AdverseReaction
antibodies . . I-AdverseReaction
. . . O

among . . O
subjects . . O
( . . O
previously . . O
untreated . . O
subjects . . O
or . . O
those . . O
who . . O
failed . . O
previous . . O
therapy . . O
) . . O
who . . O
received . . O
victrelis . . O
in . . O
combination . . O
with . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
, . . O
the . . O
following . . O
adverse . . O
drug . . O
reactions . . O
were . . O
reported . . O
. . . O

the . . O
safety . . O
of . . O
toviaz . . O
was . . O
evaluated . . O
in . . O
phase . . O
2 . . O
and . . O
3 . . O
controlled . . O
trials . . O
in . . O
a . . O
total . . O
of . . O
2859 . . O
patients . . O
with . . O
overactive . . O
bladder . . O
, . . O
of . . O
which . . O
2288 . . O
were . . O
treated . . O
with . . O
fesoterodine . . O
. . . O

ribavirin . . O
may . . B-Factor
cause . . O
birth . . B-AdverseReaction
defects . . I-AdverseReaction
and . . O
/ . . O
or . . O
death . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
exposed . . I-AdverseReaction
fetus . . I-AdverseReaction
. . . O

deaths . . B-AdverseReaction
due . . O
to . . O
adverse . . O
events . . O
within . . O
30 . . O
days . . O
of . . O
the . . O
last . . O
dose . . O
of . . O
kyprolis . . O
occurred . . O
in . . O
30 . . O
/ . . O
598 . . O
( . . O
5% . . O
) . . O
patients . . O
receiving . . O
kyprolis . . O
monotherapy . . O
. . . O

immediately . . O
discontinue . . O
treatment . . O
if . . O
severe . . O
hypersensitivity . . O
, . . O
severe . . O
rash . . O
or . . O
rash . . O
with . . O
systemic . . O
symptoms . . O
or . . O
liver . . O
transaminase . . O
elevations . . O
develops . . O
and . . O
monitor . . O
clinical . . O
status . . O
, . . O
including . . O
liver . . O
transaminases . . O
closely . . O
. . . O

higher . . O
than . . O
recommended . . O
dosing . . O
or . . O
repeated . . O
dosing . . O
appears . . O
to . . O
increase . . O
the . . O
risk . . O
( . . O
5.1 . . O
) . . O
* . . O
anaphylactic . . O
and . . O
other . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
with . . O
cardiovascular . . O
, . . O
respiratory . . O
or . . O
cutaneous . . B-AdverseReaction
manifestations . . I-AdverseReaction
, . . O
ranging . . O
from . . O
mild . . B-Severity
to . . O
severe . . B-Severity
, . . O
including . . O
death . . B-AdverseReaction
, . . O
have . . O
occurred . . O
. . . O

use . . O
zytiga . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
cardiovascular . . O
disease . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
eylea . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

serious . . O
adverse . . O
events . . O
that . . O
may . . O
be . . O
associated . . O
with . . O
crs . . B-AdverseReaction
included . . O
pyrexia . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
alanine . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
aspartate . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
, . . O
and . . O
increased . . B-AdverseReaction
total . . I-AdverseReaction
bilirubin . . I-AdverseReaction
; . . O
these . . O
events . . O
infrequently . . O
led . . O
to . . O
blincyto . . O
discontinuation . . O
. . . O

in . . O
the . . O
trial . . O
, . . O
dosage . . O
adjustments . . O
due . . O
to . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
12% . . O
of . . O
beleodaq . . O
- . . O
treated . . O
patients . . O
. . . O

( . . O
5.15 . . O
) . . O
* . . O
be . . O
alert . . O
to . . O
hypokalemia . . O
and . . O
hyperglycemia . . O
. . . O

table . . O
3 . . O
summarizes . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
at . . O
least . . O
3% . . O
of . . O
alglucosidase . . O
alfa . . O
- . . O
treated . . O
patients . . O
and . . O
with . . O
a . . O
higher . . O
incidence . . O
than . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
during . . O
the . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
study . . O
described . . O
above . . O
. . . O

* . . O
anemia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
neutropenia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
pancytopenia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
hypersensitivity . . B-AdverseReaction
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
( . . O
more . . O
than . . O
35% . . O
of . . O
subjects . . O
regardless . . O
of . . O
investigator's . . O
causality . . O
assessment . . O
) . . O
in . . O
adult . . O
subjects . . O
were . . O
fatigue . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
dysgeusia . . B-AdverseReaction
when . . O
victrelis . . O
was . . O
used . . O
in . . O
combination . . O
with . . O
pegintron . . O
and . . O
rebetol . . O
. . . O

in . . O
the . . O
controlled . . O
clinical . . O
trials . . O
, . . O
psychiatric . . B-AdverseReaction
events . . I-AdverseReaction
were . . O
reported . . O
more . . O
frequently . . O
with . . O
benlysta . . O
( . . O
16% . . O
) . . O
than . . O
with . . O
placebo . . O
( . . O
12% . . O
) . . O
, . . O
related . . O
primarily . . O
to . . O
depression . . B-AdverseReaction
- . . O
related . . O
events . . O
( . . O
6.3% . . O
benlysta . . O
and . . O
4.7% . . O
placebo . . O
) . . O
, . . O
insomnia . . B-AdverseReaction
( . . O
6.0% . . O
benlysta . . O
and . . O
5.3% . . O
placebo . . O
) . . O
, . . O
and . . O
anxiety . . B-AdverseReaction
( . . O
3.9% . . O
benlysta . . O
and . . O
2.8% . . O
placebo . . O
) . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

severe . . B-Severity
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
was . . O
also . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
in . . O
39 . . O
of . . O
1044 . . O
( . . O
3.7% . . O
) . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
( . . O
5.2 . . O
) . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2 . . O
% . . O
) . . O
are . . O
local . . B-AdverseReaction
skin . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pruritus . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
irritation . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
periorbital . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
and . . O
headache . . B-AdverseReaction
. . . O

in . . O
addition . . O
to . . O
cases . . O
of . . O
gastrointestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
, . . O
fistulas . . O
were . . O
reported . . O
in . . O
4 . . O
/ . . O
715 . . O
patients . . O
( . . O
1% . . O
) . . O
. . . O

patient . . O
exposure . . O

cases . . O
of . . O
mtc . . B-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
liraglutide . . B-DrugClass
, . . O
another . . O
glp . . O
- . . O
1 . . O
receptor . . O
agonist . . O
, . . O
have . . O
been . . O
reported . . O
in . . O
the . . O
postmarketing . . O
period . . O
; . . O
the . . O
data . . O
in . . O
these . . O
reports . . O
are . . O
insufficient . . O
to . . O
establish . . O
or . . O
exclude . . O
a . . O
causal . . O
relationship . . O
between . . O
mtc . . B-AdverseReaction
and . . O
glp . . B-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
receptor . . I-DrugClass
agonist . . I-DrugClass
use . . O
in . . O
humans . . O
. . . O

warning . . O
: . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction

there . . O
is . . O
insufficient . . O
information . . O
to . . O
determine . . O
the . . O
reversibility . . O
of . . O
the . . O
decrease . . B-AdverseReaction
of . . I-AdverseReaction
dlco . . I-AdverseReaction
after . . O
drug . . O
discontinuation . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
psoriatic . . O
arthritis . . O
who . . O
discontinued . . O
treatment . . O
due . . O
to . . O
any . . O
adverse . . O
reaction . . O
was . . O
4.6% . . O
for . . O
patients . . O
taking . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
and . . O
1.2% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

all . . O
patients . . O
started . . O
the . . O
study . . O
at . . O
a . . O
dose . . O
of . . O
100 . . O
mg . . O
/ . . O
m . . O
2 . . O
intravenously . . O
over . . O
30 . . O
minutes . . O
on . . O
days . . O
1 . . O
and . . O
2 . . O
every . . O
28 . . O
days . . O
. . . O

in . . O
addition . . O
to . . O
the . . O
adverse . . O
reactions . . O
presented . . O
in . . O
table . . O
1 . . O
, . . O
dizziness . . B-AdverseReaction
was . . O
reported . . O
in . . O
more . . O
than . . O
1% . . O
of . . O
uloric . . O
- . . O
treated . . O
subjects . . O
although . . O
not . . O
at . . O
a . . O
rate . . O
more . . O
than . . O
0.5% . . O
greater . . O
than . . O
placebo . . O
. . . O

hypersensitivity . . O
reactions . . O

the . . O
concomitant . . O
use . . O
of . . O
pradaxa . . O
with . . O
p . . O
- . . O
gp . . O
inducers . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
rifampin . . O
) . . O
reduces . . O
exposure . . O
to . . O
dabigatran . . O
and . . O
should . . O
generally . . O
be . . O
avoided . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
a . . O
potential . . O
for . . O
immunogenicity . . O
. . . O

placebo . . O
- . . O
controlled . . O
experience . . O

the . . O
incidence . . O
of . . O
serious . . O
adverse . . O
events . . O
was . . O
9.2% . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
14.7% . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

after . . O
initiation . . O
of . . O
trulicity . . O
, . . O
observe . . O
patients . . O
carefully . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
pancreatitis . . O
, . . O
including . . O
persistent . . O
severe . . O
abdominal . . O
pain . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

given . . O
the . . O
similarity . . O
in . . O
hypersensitivity . . O
symptoms . . O
and . . O
acute . . O
hae . . O
symptoms . . O
, . . O
patients . . O
should . . O
be . . O
monitored . . O
closely . . O
in . . O
the . . O
event . . O
of . . O
a . . O
hypersensitivity . . O
reaction . . O
. . . O

serious . . B-Severity
acute . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
urticaria . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
) . . O
have . . O
been . . O
observed . . O
during . . O
combination . . O
therapy . . O
with . . O
victrelis . . O
, . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
subjects . . O
with . . O
impaired . . O
renal . . O
function . . O
were . . O
more . . O
likely . . O
to . . O
have . . O
greater . . O
reductions . . O
in . . O
serum . . O
calcium . . O
levels . . O
compared . . O
to . . O
subjects . . O
with . . O
normal . . O
renal . . O
function . . O
. . . O

5.6 . . O
increased . . O
low . . O
- . . O
density . . O
lipoprotein . . O
cholesterol . . O
( . . O
ldl . . O
- . . O
c . . O
) . . O

table . . O
2 . . O
. . . O

the . . O
adrs . . O
observed . . O
in . . O
flamingo . . O
were . . O
generally . . O
consistent . . O
with . . O
those . . O
seen . . O
in . . O
spring . . O
- . . O
2 . . O
and . . O
single . . O
. . . O

however . . O
, . . O
the . . O
development . . O
of . . O
neutralizing . . O
antibodies . . O
may . . O
be . . O
underreported . . O
due . . O
to . . O
lack . . O
of . . O
assay . . O
sensitivity . . O
. . . O

these . . O
exclusion . . O
criteria . . O
included . . O
a . . O
history . . O
of . . O
seizure . . O
, . . O
underlying . . O
brain . . O
injury . . O
with . . O
loss . . O
of . . O
consciousness . . O
, . . O
transient . . O
ischemic . . O
attack . . O
within . . O
the . . O
past . . O
12 . . O
months . . O
, . . O
cerebral . . O
vascular . . O
accident . . O
, . . O
brain . . O
metastases . . O
, . . O
and . . O
brain . . O
arteriovenous . . O
malformation . . O
. . . O

6.1 . . O
clinical . . O
studies . . O
experience . . O

during . . O
periods . . O
of . . O
stress . . O
, . . O
a . . O
severe . . O
copd . . O
exacerbation . . O
, . . O
or . . O
a . . O
severe . . O
asthma . . O
attack . . O
, . . O
patients . . O
who . . O
have . . O
been . . O
withdrawn . . O
from . . O
systemic . . O
corticosteroids . . O
should . . O
be . . O
instructed . . O
to . . O
resume . . O
oral . . O
corticosteroids . . O
( . . O
in . . O
large . . O
doses . . O
) . . O
immediately . . O
and . . O
to . . O
contact . . O
their . . O
physicians . . O
for . . O
further . . O
instruction . . O
. . . O

capillary . . B-AdverseReaction
leak . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O

pradaxa's . . O
anticoagulant . . O
activity . . O
and . . O
half . . O
- . . O
life . . O
are . . O
increased . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

given . . O
the . . O
similarity . . O
in . . O
hypersensitivity . . O
symptoms . . O
and . . O
acute . . O
hae . . O
symptoms . . O
, . . O
monitor . . O
patients . . O
closely . . O
for . . O
hypersensitivity . . O
reactions . . O
( . . O
5 . . O
) . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
which . . O
enrolled . . O
patients . . O
who . . O
previously . . O
received . . O
docetaxel . . O
, . . O
7 . . O
of . . O
800 . . O
( . . O
0.9% . . O
) . . O
patients . . O
treated . . O
with . . O
xtandi . . O
experienced . . O
a . . O
seizure . . B-AdverseReaction
and . . O
no . . B-Negation
patients . . O
treated . . O
with . . O
placebo . . O
experienced . . O
a . . O
seizure . . B-AdverseReaction
. . . O

multaq . . O
is . . O
contraindicated . . O
in . . O
patients . . O
in . . O
atrial . . O
fibrillation . . O
( . . O
af . . O
) . . O
who . . O
will . . O
not . . O
or . . O
cannot . . O
be . . O
cardioverted . . O
into . . O
normal . . O
sinus . . O
rhythm . . O
. . . O

polyoma . . B-AdverseReaction
virus . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
nephropathy . . I-AdverseReaction
can . . B-Factor
lead . . O
to . . O
kidney . . B-AdverseReaction
graft . . I-AdverseReaction
loss . . I-AdverseReaction
; . . O
consider . . O
reduction . . O
in . . O
immunosuppression . . O
. . . O

it . . O
is . . O
important . . O
to . . O
note . . O
that . . O
early . . O
manifestations . . O
of . . O
hypersensitivity . . B-AdverseReaction
, . . O
such . . O
as . . O
fever . . B-AdverseReaction
or . . O
lymphadenopathy . . B-AdverseReaction
, . . O
may . . O
be . . O
present . . O
even . . O
though . . O
rash . . B-AdverseReaction
is . . O
not . . B-Negation
evident . . I-Negation
. . . O

* . . O
receiving . . O
other . . O
medications . . O
that . . O
prolong . . O
the . . O
qt . . O
interval . . O
, . . O
such . . O
as . . O
class . . O
ia . . O
( . . O
quinidine . . O
, . . O
procainamide . . O
, . . O
disopyramide . . O
) . . O
, . . O
or . . O
class . . O
iii . . O
( . . O
amiodarone . . O
, . . O
sotalol . . O
) . . O
antiarrhythmic . . O
agents . . O
; . . O
antipsychotics . . O
( . . O
pimozide . . O
, . . O
ziprasidone . . O
) . . O
; . . O
antidepressants . . O
; . . O
certain . . O
antibiotics . . O
( . . O
macrolide . . O
antibiotics . . O
, . . O
fluoroquinolone . . O
antibiotics . . O
, . . O
imidazole . . O
, . . O
and . . O
triazole . . O
antifungal . . O
agents . . O
) . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.6 . . O
) . . O
] . . O
. . . O

retinal . . B-AdverseReaction
detachments . . I-AdverseReaction
resulting . . O
from . . O
trametinib . . O
are . . O
often . . O
bilateral . . O
and . . O
multifocal . . O
, . . O
occurring . . O
in . . O
the . . O
macular . . O
region . . O
of . . O
the . . O
retina . . O
. . . O

the . . O
population . . O
in . . O
these . . O
studies . . O
was . . O
48% . . O
white . . O
, . . O
13% . . O
african . . O
/ . . O
african . . O
american . . O
, . . O
7% . . O
asian . . O
, . . O
and . . O
29% . . O
hispanic . . O
/ . . O
latino . . O
. . . O

eye . . O
disorders . . O
: . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
. . . O

table . . O
1 . . O
table . . O
2 . . O
6.2 . . O
immunogenicity . . O

during . . O
clinical . . O
trials . . O
, . . O
141 . . O
pediatric . . O
patients . . O
( . . O
7 . . O
aged . . O
< . . O
24 . . O
months . . O
, . . O
33 . . O
aged . . O
2 . . O
- . . O
5 . . O
years . . O
, . . O
58 . . O
aged . . O
6 . . O
- . . O
11 . . O
years . . O
and . . O
43 . . O
aged . . O
12 . . O
- . . O
17 . . O
) . . O
received . . O
dotarem . . O
. . . O

neovascular . . O
( . . O
wet . . O
) . . O
age . . O
- . . O
related . . O
macular . . O
degeneration . . O
( . . O
amd . . O
) . . O

treatment . . O
of . . O
cervical . . O
dystonia . . O
with . . O
botulinum . . O
toxins . . O
may . . B-Factor
weaken . . B-AdverseReaction
neck . . I-AdverseReaction
muscles . . I-AdverseReaction
that . . O
serve . . O
as . . O
accessory . . O
muscles . . O
of . . O
ventilation . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
treatment . . O
- . . O
naive . . O
gd1 . . O
patients . . O
and . . O
more . . O
frequently . . O
than . . O
placebo . . O
( . . O
trial . . O
1 . . O
) . . O
cerdelga . . O
( . . O
n . . O
= . . O
20 . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
20 . . O
) . . O
adverse . . O
reaction . . O
patientsn . . O
( . . O
% . . O
) . . O
patientsn . . O
( . . O
% . . O
) . . O
arthralgia . . B-AdverseReaction
9 . . O
( . . O
45 . . O
) . . O
2 . . O
( . . O
10 . . O
) . . O
headache . . B-AdverseReaction
8 . . O
( . . O
40 . . O
) . . O
6 . . O
( . . O
30 . . O
) . . O
migraine . . B-AdverseReaction
2 . . O
( . . O
10 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
flatulence . . B-AdverseReaction
2 . . O
( . . O
10 . . O
) . . O
1 . . O
( . . O
5 . . O
) . . O
nausea . . B-AdverseReaction
2 . . O
( . . O
10 . . O
) . . O
1 . . O
( . . O
5 . . O
) . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
2 . . O
( . . O
10 . . O
) . . O
1 . . O
( . . O
5 . . O
) . . O
table . . O
2 . . O
presents . . O
the . . O
profile . . O
from . . O
the . . O
12 . . O
- . . O
month . . O
open . . O
- . . O
label . . O
, . . O
randomized . . O
, . . O
imiglucerase . . O
- . . O
controlled . . O
trial . . O
of . . O
159 . . O
treated . . O
patients . . O
switching . . O
from . . O
enzyme . . O
replacement . . O
therapy . . O
( . . O
ert . . O
) . . O
( . . O
trial . . O
2 . . O
) . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
an . . O
unknown . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

lymphomas . . O

in . . O
spring . . O
- . . O
2 . . O
, . . O
822 . . O
subjects . . O
were . . O
randomized . . O
and . . O
received . . O
at . . O
least . . O
1 . . O
dose . . O
of . . O
either . . O
tivicay . . O
50 . . O
mg . . O
once . . O
daily . . O
or . . O
raltegravir . . O
400 . . O
mg . . O
twice . . O
daily . . O
, . . O
both . . O
in . . O
combination . . O
with . . O
fixed . . O
- . . O
dose . . O
dual . . O
nucleoside . . O
reverse . . O
transcriptase . . O
inhibitor . . O
( . . O
nrti . . O
) . . O
treatment . . O
( . . O
either . . O
abacavir . . O
sulfate . . O
and . . O
lamivudine . . O
[ . . O
epzicom . . O
( . . O
r . . O
) . . O
] . . O
or . . O
emtricitabine . . O
/ . . O
tenofovir . . O
[ . . O
truvada . . O
( . . O
r . . O
) . . O
] . . O
) . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
post . . B-AdverseReaction
- . . I-AdverseReaction
transplant . . I-AdverseReaction
lymphoproliferative . . I-AdverseReaction
disorder . . I-AdverseReaction
, . . O
other . . O
malignancies . . B-AdverseReaction
, . . O
and . . O
serious . . B-Severity
infections . . B-AdverseReaction

there . . O
were . . O
no . . B-Negation
reports . . O
of . . O
prolactin . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
4 . . B-Severity
times . . I-Severity
uln . . I-Severity
( . . O
at . . O
endpoint . . O
) . . O
for . . O
patients . . O
treated . . O
with . . O
saphris . . O
or . . O
placebo . . O
. . . O

* . . O
serious . . B-Severity
dermatologic . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
discontinue . . O
if . . O
stevens . . O
- . . O
johnson . . O
syndrome . . O
or . . O
toxic . . O
epidermal . . O
necrolysis . . O
occurs . . O
( . . O
5.10 . . O
) . . O
. . . O

all . . O
patients . . O
received . . O
at . . O
least . . O
one . . O
dose . . O
of . . O
blincyto . . O
. . . O

this . . O
patient . . O
information . . O
has . . O
been . . O
approved . . O
by . . O
the . . O
u . . O
. . . O
s . . O
. . . O
food . . O
and . . O
drug . . O
administration . . O
. . . O

* . . O
embryofetal . . B-AdverseReaction
toxicity . . I-AdverseReaction
( . . O
use . . O
with . . O
ribavirin . . O
and . . O
peginterferon . . O
alfa . . O
) . . O
: . . O
ribavirin . . O
may . . B-Factor
cause . . O
birth . . B-AdverseReaction
defects . . I-AdverseReaction
and . . O
fetal . . B-AdverseReaction
death . . I-AdverseReaction
; . . O
avoid . . O
pregnancy . . O
in . . O
female . . O
patients . . O
and . . O
female . . O
partners . . O
of . . O
male . . O
patients . . O
. . . O

a . . O
study . . O
of . . O
cardiac . . O
conduction . . O
showed . . O
that . . O
potiga . . O
produced . . O
a . . O
mean . . O
7.7 . . B-Severity
- . . I-Severity
msec . . I-Severity
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
in . . O
healthy . . O
volunteers . . O
titrated . . O
to . . O
400 . . O
mg . . O
3 . . O
times . . O
daily . . O
. . . O

the . . O
causal . . O
relationship . . O
of . . O
these . . O
events . . O
to . . O
cimzia . . O
remains . . O
unclear . . O
. . . O

* . . O
discontinue . . O
simponi . . O
aria . . O
if . . O
a . . O
patient . . O
develops . . O
a . . O
serious . . O
infection . . O
or . . O
sepsis . . O
( . . O
5.1 . . O
) . . O
. . . O

the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
associated . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
is . . O
shown . . O
in . . O
table . . O
2 . . O
. . . O

if . . O
pancreatitis . . O
is . . O
confirmed . . O
, . . O
tanzeum . . O
should . . O
not . . O
be . . O
restarted . . O
. . . O

serious . . O
infections . . O
s . . B-Severity
erious . . I-Severity
infection . . B-AdverseReaction
was . . O
reported . . O
in . . O
1 . . O
patient . . O
( . . O
0.8% . . O
) . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
no . . B-Negation
patients . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

if . . O
this . . O
occurs . . O
, . . O
treatment . . O
with . . O
tudorza . . O
pressair . . O
should . . O
be . . O
stopped . . O
and . . O
other . . O
treatments . . O
considered . . O
. . . O

6 . . O
- . . O
month . . O
trials . . O

in . . O
unapproved . . O
uses . . O
, . . O
including . . O
spasticity . . O
in . . O
children . . O
and . . O
adults . . O
, . . O
and . . O
in . . O
approved . . O
indications . . O
, . . O
symptoms . . O
consistent . . O
with . . O
spread . . B-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effect . . I-AdverseReaction
have . . O
been . . O
reported . . O
at . . O
doses . . O
comparable . . O
to . . O
or . . O
lower . . O
than . . O
doses . . O
used . . O
to . . O
treat . . O
cervical . . O
dystonia . . O
. . . O

in . . O
patients . . O
who . . O
develop . . O
serious . . O
allergic . . O
reactions . . O
, . . O
discontinue . . O
zydelig . . O
permanently . . O
and . . O
institute . . O
appropriate . . O
supportive . . O
measures . . O
. . . O

adverse . . O
reactions . . O
led . . O
to . . O
treatment . . O
discontinuation . . O
in . . O
32% . . O
of . . O
adcetris . . O
- . . O
treated . . O
patients . . O
in . . O
study . . O
3 . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
asthenia . . B-AdverseReaction
, . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
/ . . O
discomfort . . O
, . . O
edema . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
feeling . . B-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
, . . O
influenza . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
symptoms . . I-AdverseReaction
, . . O
mass . . B-AdverseReaction
, . . O
pain . . B-AdverseReaction
, . . O
thirst . . B-AdverseReaction
. . . O

study . . O
1 . . O
cns . . B-AdverseReaction
ptld . . I-AdverseReaction
1 . . O
1 . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
cnsptld . . I-AdverseReaction
1 . . O
2 . . O
1 . . O
study . . O
2 . . O
cns . . B-AdverseReaction
ptld . . I-AdverseReaction
1 . . O
1 . . O
1 . . O
1 . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
cnsptld . . I-AdverseReaction
1 . . O
study . . O
3 . . O
cns . . B-AdverseReaction
ptld . . I-AdverseReaction
2 . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
cnsptld . . I-AdverseReaction
1 . . O
total . . O
( . . O
% . . O
) . . O
2 . . O
( . . O
0.5 . . O
) . . O
5 . . O
( . . O
11.6 . . O
) . . O
1 . . O
( . . O
3.6 . . O
) . . O
3 . . O
( . . O
0.7 . . O
) . . O
2 . . O
( . . O
4.1 . . O
) . . O
0 . . O
0 . . O
1 . . O
( . . O
1.8 . . O
) . . O
0 . . O
ebv . . O
seropositive . . O
subpopulation . . O
among . . O
the . . O
806 . . O
ebv . . O
seropositive . . O
patients . . O
with . . O
known . . O
cmv . . O
serostatus . . O
treated . . O
with . . O
either . . O
nulojix . . O
regimen . . O
in . . O
studies . . O
1 . . O
, . . O
2 . . O
, . . O
and . . O
3 . . O
, . . O
two . . O
percent . . O
( . . O
2% . . O
; . . O
4 . . O
/ . . O
210 . . O
) . . O
of . . O
cmv . . O
seronegative . . O
patients . . O
developed . . O
ptld . . B-AdverseReaction
compared . . O
to . . O
0.2% . . O
( . . O
1 . . O
/ . . O
596 . . O
) . . O
of . . O
cmv . . O
seropositive . . O
patients . . O
. . . O

a . . O
number . . O
of . . O
reports . . O
note . . O
that . . O
patients . . O
were . . O
also . . O
receiving . . O
treatment . . O
with . . O
glucocorticoids . . O
( . . O
e . . O
. . . O
g . . O
. . . O
prednisone . . O
) . . O
at . . O
the . . O
time . . O
of . . O
fracture . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

bk . . B-AdverseReaction
virus . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
nephropathy . . I-AdverseReaction
was . . O
reported . . O
in . . O
6 . . O
nulojix . . O
patients . . O
( . . O
4 . . O
of . . O
which . . O
resulted . . O
in . . O
graft . . O
loss . . O
) . . O
and . . O
6 . . O
cyclosporine . . O
patients . . O
( . . O
none . . O
of . . O
which . . O
resulted . . O
in . . O
graft . . O
loss . . O
) . . O
by . . O
year . . O
3 . . O
. . . O

the . . O
adverse . . O
reactions . . O
described . . O
in . . O
this . . O
section . . O
reflect . . O
gadavist . . O
exposure . . O
in . . O
6,330 . . O
subjects . . O
( . . O
including . . O
184 . . O
pediatric . . O
patients . . O
, . . O
ages . . O
0 . . O
to . . O
17 . . O
years . . O
) . . O
with . . O
the . . O
majority . . O
receiving . . O
the . . O
recommended . . O
dose . . O
. . . O

caution . . O
should . . O
be . . O
exercised . . O
when . . O
considering . . O
the . . O
coadministration . . O
of . . O
breo . . O
ellipta . . O
with . . O
long . . O
- . . O
term . . O
ketoconazole . . O
and . . O
other . . O
known . . O
strong . . O
cyp3a4 . . O
inhibitors . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
ritonavir . . O
, . . O
clarithromycin . . O
, . . O
conivaptan . . O
, . . O
indinavir . . O
, . . O
itraconazole . . O
, . . O
lopinavir . . O
, . . O
nefazodone . . O
, . . O
nelfinavir . . O
, . . O
saquinavir . . O
, . . O
telithromycin . . O
, . . O
troleandomycin . . O
, . . O
voriconazole . . O
) . . O
because . . O
increased . . O
systemic . . O
corticosteroid . . O
and . . O
increased . . O
cardiovascular . . O
adverse . . O
effects . . O
may . . O
occur . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
, . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

( . . O
5.1,5.2,12.3 . . O
) . . O
* . . O
antimalarials . . O
should . . O
not . . O
be . . O
given . . O
concomitantly . . O
, . . O
unless . . O
there . . O
is . . O
no . . O
other . . O
treatment . . O
option . . O
, . . O
due . . O
to . . O
limited . . O
safety . . O
data . . O
. . . O

the . . O
distance . . O
of . . O
a . . O
z . . O
- . . O
score . . O
from . . O
0 . . O
represents . . O
the . . O
distance . . O
of . . O
a . . O
percentile . . O
from . . O
the . . O
median . . O
, . . O
measured . . O
in . . O
standard . . O
deviations . . O
( . . O
sd . . O
) . . O
. . . O

permanently . . O
discontinue . . O
in . . O
patients . . O
with . . O
ild . . O
/ . . O
pneumonitis . . O
. . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
that . . O
led . . O
to . . O
dose . . O
reduction . . O
in . . O
the . . O
patients . . O
treated . . O
with . . O
gilotrif . . O
were . . O
diarrhea . . B-AdverseReaction
( . . O
20% . . O
) . . O
, . . O
rash . . B-AdverseReaction
/ . . O
acne . . B-AdverseReaction
( . . O
19% . . O
) . . O
, . . O
paronychia . . B-AdverseReaction
( . . O
14% . . O
) . . O
, . . O
and . . O
stomatitis . . B-AdverseReaction
( . . O
10% . . O
) . . O
. . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
a . . O
potential . . O
for . . O
immunogenicity . . O
. . . O

bleeding . . B-AdverseReaction
events . . O
were . . O
counted . . O
during . . O
treatment . . O
or . . O
within . . O
2 . . O
days . . O
of . . O
stopping . . O
study . . O
treatment . . O
( . . O
on . . O
- . . O
treatment . . O
period . . O
) . . O
. . . O

long . . B-AdverseReaction
- . . I-AdverseReaction
term . . I-AdverseReaction
cumulative . . I-AdverseReaction
radiation . . I-AdverseReaction
exposure . . I-AdverseReaction
is . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
cancer . . B-AdverseReaction
. . . O

the . . O
most . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
in . . O
pristiq . . O
treated . . O
mdd . . O
patients . . O
in . . O
pre . . O
- . . O
marketing . . O
pooled . . O
8 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
fixed . . O
- . . O
dose . . O
studies . . O
( . . O
incidence . . O
> . . O
= . . O
5% . . O
and . . O
at . . O
least . . O
twice . . O
the . . O
rate . . O
of . . O
placebo . . O
in . . O
the . . O
50 . . O
or . . O
100 . . O
mg . . O
dose . . O
groups . . O
) . . O
were . . O
: . . O
nausea . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
anxiety . . B-AdverseReaction
, . . O
and . . O
specific . . O
male . . B-AdverseReaction
sexual . . I-AdverseReaction
function . . I-AdverseReaction
disorders . . I-AdverseReaction
. . . O

serum . . O
transaminase . . O
levels . . O
returned . . O
to . . O
normal . . O
within . . O
approximately . . O
2 . . O
months . . O
after . . O
discontinuation . . O
of . . O
gilenya . . O
. . . O

anaphylaxis . . B-AdverseReaction
has . . O
been . . O
reported . . O

increased . . O
mortality . . O

use . . O
caution . . O
in . . O
patients . . O
with . . O
hemoglobin . . O
< . . O
10 . . O
g . . O
/ . . O
dl . . O
. . . O
( . . O
2.2 . . O
) . . O
( . . O
4 . . O
) . . O
( . . O
5.1 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
: . . O
severe . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
can . . B-Factor
occur . . O
. . . O

while . . O
adequate . . O
hydration . . O
is . . O
required . . O
prior . . O
to . . O
each . . O
dose . . O
in . . O
cycle . . O
1 . . O
, . . O
all . . O
patients . . O
should . . O
also . . O
be . . O
monitored . . O
for . . O
evidence . . O
of . . O
volume . . O
overload . . O
, . . O
especially . . O
patients . . O
at . . O
risk . . O
for . . O
cardiac . . O
failure . . O
. . . O

there . . O
is . . O
no . . O
clinical . . O
trial . . O
experience . . O
re . . O
- . . O
administering . . O
xtandi . . O
to . . O
patients . . O
who . . O
experienced . . O
seizure . . O
. . . O

warning . . O
: . . O
cytokine . . B-AdverseReaction
release . . I-AdverseReaction
syndrome . . I-AdverseReaction
and . . O

6 . . O
adverse . . O
reactions . . O

( . . O
5.3 . . O
) . . O
* . . O
fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
intestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
can . . O
occur . . O
in . . O
zydelig . . O
- . . O
treated . . O
patients . . O
across . . O
clinical . . O
trials . . O
. . . O

patients . . O
should . . O
not . . O
wear . . O
contact . . O
lenses . . O
if . . O
they . . O
have . . O
signs . . O
or . . O
symptoms . . O
of . . O
bacterial . . O
conjunctivitis . . O
or . . O
during . . O
the . . O
course . . O
of . . O
therapy . . O
with . . O
besivance . . O
( . . O
5.3 . . O
) . . O

5.1 . . O
serious . . O
infections . . O

these . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
included . . O
oral . . O
ulcers . . O
, . . O
blisters . . O
, . . O
peeling . . O
/ . . O
sloughing . . O
, . . O
and . . O
inflammation . . O
. . . O

other . . O
clinically . . O
important . . O
adverse . . O
reactions . . O
( . . O
n . . O
= . . O
202 . . O
) . . O
observed . . O
in . . O
< . . O
10% . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
were . . O
: . . O

most . . O
patients . . O
responded . . O
to . . O
corticosteroids . . O
. . . O

increase . . O
in . . O
serum . . O
inorganic . . O
phosphorus . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
chills . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
impaired . . B-AdverseReaction
wound . . I-AdverseReaction
healing . . I-AdverseReaction
( . . O
< . . O
1% . . O
) . . O

prolonged . . B-AdverseReaction
erection . . I-AdverseReaction
greater . . O
than . . O
4 . . B-Severity
hours . . I-Severity
and . . O
priapism . . B-AdverseReaction
( . . O
painful . . B-AdverseReaction
erections . . I-AdverseReaction
greater . . O
than . . O
6 . . B-Severity
hours . . I-Severity
in . . O
duration . . O
) . . O
have . . O
been . . O
reported . . O
with . . O
other . . O
pde5 . . B-DrugClass
inhibitors . . I-DrugClass
. . . O

during . . O
the . . O
controlled . . O
period . . O
of . . O
the . . O
trials . . O
in . . O
psoriasis . . O
, . . O
weight . . B-AdverseReaction
decrease . . I-AdverseReaction
between . . B-Severity
5% . . I-Severity
- . . I-Severity
10% . . I-Severity
of . . I-Severity
body . . I-Severity
weight . . I-Severity
occurred . . O
in . . O
12% . . O
( . . O
96 . . O
/ . . O
784 . . O
) . . O
of . . O
subjects . . O
treated . . O
with . . O
otezla . . O
compared . . O
to . . O
5% . . O
( . . O
19 . . O
/ . . O
382 . . O
) . . O
treated . . O
with . . O
placebo . . O
. . . O

all . . O
serious . . O
adverse . . O
events . . O
were . . O
judged . . O
to . . O
be . . O
not . . O
related . . O
or . . O
unlikely . . O
to . . O
be . . O
related . . O
to . . O
study . . O
medication . . O
by . . O
the . . O
investigator . . O
, . . O
except . . O
for . . O
four . . O
patients . . O
receiving . . O
toviaz . . O
who . . O
reported . . O
one . . O
serious . . O
adverse . . O
event . . O
each . . O
: . . O
angina . . B-AdverseReaction
, . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
gastroenteritis . . B-AdverseReaction
, . . O
and . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
on . . O
ecg . . O
. . . O

instruct . . O
patients . . O
receiving . . O
gilenya . . O
to . . O
report . . O
symptoms . . O
of . . O
infections . . O
to . . O
a . . O
physician . . O
. . . O

patients . . O
with . . O
a . . O
prior . . O
dermatologic . . O
reaction . . O
with . . O
either . . O
oxcarbazepine . . O
or . . O
aptiom . . O
should . . O
not . . O
be . . O
treated . . O
with . . O
aptiom . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

stribild . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
chronic . . O
hbv . . O
infection . . O
and . . O
the . . O
safety . . O
and . . O
efficacy . . O
of . . O
stribild . . O
have . . O
not . . O
been . . O
established . . O
in . . O
patients . . O
coinfected . . O
with . . O
hbv . . O
and . . O
hiv . . O
- . . O
1 . . O
. . . O

for . . O
patients . . O
at . . O
risk . . O
for . . O
chronically . . O
reduced . . O
renal . . O
function . . O
( . . O
e . . O
. . . O
g . . O
. . . O
age . . O
> . . O
60 . . O
years . . O
, . . O
hypertension . . O
, . . O
diabetes . . O
) . . O
, . . O
estimate . . O
the . . O
glomerular . . O
filtration . . O
rate . . O
( . . O
gfr . . O
) . . O
through . . O
laboratory . . O
testing . . O
( . . O
5.1 . . O
) . . O
. . . O

the . . O
most . . O
common . . O
grade . . B-Severity
3-4 . . I-Severity
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
3% . . O
) . . O
were . . O
infections . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
dehydration . . B-AdverseReaction
, . . O
pneumonitis . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
asthenia . . B-AdverseReaction
. . . O

the . . O
majority . . O
of . . O
reported . . O
tnf . . O
blocker . . O
cases . . O
occurred . . O
in . . O
adolescent . . O
and . . O
young . . O
adult . . O
males . . O
with . . O
crohn's . . O
disease . . O
or . . O
ulcerative . . O
colitis . . O
. . . O

hepatobiliary . . O
disorders . . O
: . . O
cholelithiasis . . B-AdverseReaction
/ . . O
cholecystitis . . B-AdverseReaction
, . . O
hepatic . . B-AdverseReaction
steatosis . . I-AdverseReaction
, . . O
hepatitis . . B-AdverseReaction
, . . O
hepatomegaly . . B-AdverseReaction
. . . O

other . . O
xiaflex . . O
- . . O
associated . . O
serious . . O
local . . O
adverse . . O
reactions . . O
included . . O
pulley . . B-AdverseReaction
rupture . . I-AdverseReaction
, . . O
ligament . . B-AdverseReaction
injury . . I-AdverseReaction
, . . O
complex . . B-AdverseReaction
regional . . I-AdverseReaction
pain . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
crps . . B-AdverseReaction
) . . O
, . . O
sensory . . B-AdverseReaction
abnormality . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
hand . . I-AdverseReaction
, . . O
and . . O
skin . . B-AdverseReaction
laceration . . I-AdverseReaction
( . . O
tear . . O
) . . O
. . . O

( . . O
6.1 . . O
) . . O

there . . O
was . . O
one . . O
death . . B-AdverseReaction
due . . O
to . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
on . . O
the . . O
placebo . . B-Factor
arm . . O
. . . O

vilanterol . . O
, . . O
like . . O
other . . O
beta2 . . O
- . . O
agonists . . O
, . . O
can . . B-Factor
produce . . O
a . . O
clinically . . O
significant . . O
cardiovascular . . O
effect . . O
in . . O
some . . O
patients . . O
as . . O
measured . . O
by . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
pulse . . I-AdverseReaction
rate . . I-AdverseReaction
, . . O
systolic . . O
or . . O
diastolic . . O
blood . . O
pressure . . O
, . . O
and . . O
also . . O
cardiac . . B-AdverseReaction
arrhythmias . . I-AdverseReaction
, . . O
such . . O
as . . O
supraventricular . . B-AdverseReaction
tachycardia . . I-AdverseReaction
and . . O
extrasystoles . . B-AdverseReaction
. . . O

potiga . . O
caused . . O
urinary . . B-AdverseReaction
retention . . I-AdverseReaction
in . . O
clinical . . O
trials . . O
. . . O

if . . O
retinal . . O
pigmentary . . O
abnormalities . . O
or . . O
vision . . O
changes . . O
are . . O
detected . . O
, . . O
potiga . . O
should . . O
be . . O
discontinued . . O
unless . . O
no . . O
other . . O
suitable . . O
treatment . . O
options . . O
are . . O
available . . O
and . . O
the . . O
benefits . . O
of . . O
treatment . . O
outweigh . . O
the . . O
potential . . O
risk . . O
of . . O
vision . . O
loss . . B-Factor
. . . O

when . . O
coartem . . O
tablets . . O
are . . O
coadministered . . O
with . . O
inducers . . O
of . . O
cyp3a4 . . O
it . . O
may . . O
result . . O
in . . O
decreased . . O
concentrations . . O
of . . O
artemether . . O
and . . O
/ . . O
or . . O
lumefantrine . . O
and . . O
loss . . O
of . . O
antimalarial . . O
efficacy . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
drug . . O
interactions . . O
( . . O
7 . . O
) . . O
] . . O
. . . O

cryptococcal . . O
infections . . O

hypersensitivity . . B-AdverseReaction
reactions . . O
have . . O
been . . O
reported . . O
and . . O
were . . O
characterized . . O
by . . O
rash . . B-AdverseReaction
, . . O
constitutional . . O
findings . . O
, . . O
and . . O
sometimes . . O
organ . . B-AdverseReaction
dysfunction . . I-AdverseReaction
, . . O
including . . O
liver . . B-AdverseReaction
injury . . I-AdverseReaction
. . . O

jevtana . . O
is . . O
not . . O
indicated . . O
for . . O
use . . O
in . . O
female . . O
patients . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

treatment . . O
- . . O
emergent . . O
adverse . . O
drug . . O
reactions . . O
of . . O
at . . O
least . . O
moderate . . O
intensity . . O
( . . O
grades . . O
2 . . O
to . . O
4 . . O
) . . O
and . . O
at . . O
least . . O
2% . . O
frequency . . O
in . . O
treatment . . O
- . . O
naive . . O
subjects . . O
in . . O
spring . . O
- . . O
2 . . O
and . . O
single . . O
trials . . O
( . . O
week . . O
96 . . O
analysis . . O
) . . O
system . . O
organ . . O
class . . O
/ . . O
preferred . . O
term . . O
spring . . O
- . . O
2 . . O
single . . O
tivicay . . O
50 . . O
mg . . O
once . . O
daily . . O
+ . . O
2 . . O
nrtis . . O
( . . O
n . . O
= . . O
403 . . O
) . . O
raltegravir . . O
400 . . O
mg . . O
twice . . O
daily . . O
+ . . O
2 . . O
nrtis . . O
( . . O
n . . O
= . . O
405 . . O
) . . O
tivicay . . O
50 . . O
mg . . O
+ . . O
epzicom . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
414 . . O
) . . O
atripla . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
419 . . O
) . . O
psychiatric . . O
insomnia . . B-AdverseReaction
< . . O
1% . . O
< . . O
1% . . O
3% . . O
2% . . O
depression . . B-AdverseReaction
< . . O
1% . . O
< . . O
1% . . O
1% . . O
2% . . O
abnormal . . B-AdverseReaction
dreams . . I-AdverseReaction
< . . O
1% . . O
< . . O
1% . . O
< . . O
1% . . O
2% . . O
nervous . . O
system . . O
dizziness . . B-AdverseReaction
< . . O
1% . . O
< . . O
1% . . O
< . . O
1% . . O
5% . . O
headache . . B-AdverseReaction
< . . O
1% . . O
< . . O
1% . . O
2% . . O
2% . . O
gastrointestinal . . O
nausea . . B-AdverseReaction
1% . . O
1% . . O
< . . O
1% . . O
3% . . O
diarrhea . . B-AdverseReaction
< . . O
1% . . O
< . . O
1% . . O
< . . O
1% . . O
2% . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
rasha . . O
0 . . O
< . . O
1% . . O
< . . O
1% . . O
6% . . O
general . . O
disorders . . O
fatigue . . B-AdverseReaction
< . . O
1% . . O
< . . O
1% . . O
2% . . O
2% . . O
ear . . O
and . . O
labyrinth . . O
vertigo . . B-AdverseReaction
0 . . O
< . . O
1% . . O
0 . . O
2% . . O
a . . O
includes . . O
pooled . . O
terms . . O
: . . O
rash . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
generalized . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
macular . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
maculo . . I-AdverseReaction
- . . I-AdverseReaction
papular . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
pruritic . . I-AdverseReaction
, . . O
and . . O
drug . . B-AdverseReaction
eruption . . I-AdverseReaction
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

median . . O
duration . . O
of . . O
treatment . . O
was . . O
7 . . O
cycles . . O
( . . O
range . . O
, . . O
1-16 . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
] . . O
. . . O

( . . O
5.1 . . O
) . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
thrombocytosis . . B-AdverseReaction
, . . O
pancytopenia . . B-AdverseReaction
. . . O

no . . O
serious . . O
events . . O
were . . O
reported . . O
through . . O
year . . O
3 . . O
. . . O

adrenal . . B-AdverseReaction
insufficiency . . I-AdverseReaction
occurred . . O
in . . O
the . . O
two . . O
randomized . . O
clinical . . O
studies . . O
in . . O
0.5% . . O
of . . O
patients . . O
taking . . O
zytiga . . O
and . . O
in . . O
0.2% . . O
of . . O
patients . . O
taking . . O
placebo . . O
. . . O

severe . . O
elevations . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
6.5 . . O
meq . . O
/ . . O
l . . O
) . . O
occurred . . O
in . . O
0.4% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
, . . O
no . . O
patients . . O
treated . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
1.3% . . O
of . . O
patients . . O
treated . . O
with . . O
invokana . . O
300 . . O
mg . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
of . . O
trametinib . . O
as . . O
a . . O
single . . O
agent . . O
, . . O
which . . O
may . . O
occur . . O
when . . O
tafinlar . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
, . . O
are . . O
not . . O
described . . O
in . . O
the . . O
full . . O
prescribing . . O
information . . O
for . . O
tafinlar . . O
: . . O

because . . O
this . . O
disorder . . O
is . . O
variable . . O
in . . O
its . . O
expression . . O
, . . O
other . . O
organ . . O
systems . . O
not . . O
noted . . O
here . . O
may . . O
be . . O
involved . . O
. . . O

appropriate . . O
medical . . O
support . . O
and . . O
monitoring . . O
measures . . O
should . . O
be . . O
available . . O
during . . O
infusion . . O
( . . O
5.3 . . O
) . . O
. . . O

table . . O
2 . . O
adverse . . O
reactions . . O
with . . O
a . . O
per . . O
- . . O
patient . . O
incidence . . O
of . . O
at . . O
least . . O
10% . . O
in . . O
study . . O
1 . . O
meddra . . O
ver . . O
10.0 . . O
halaven . . O
n . . O
= . . O
503 . . O
control . . O
group . . O
n . . O
= . . O
247 . . O
all . . O
grades . . O
> . . O
= . . O
grade . . O
3 . . O
all . . O
grades . . O
> . . O
= . . O
grade . . O
3 . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
a . . O
neutropenia . . B-AdverseReaction
82% . . O
57% . . O
53% . . O
23% . . O
anemia . . B-AdverseReaction
58% . . O
2% . . O
55% . . O
4% . . O
nervous . . O
system . . O
disorders . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
b . . O
35% . . O
8% . . O
16% . . O
2% . . O
headache . . B-AdverseReaction
19% . . O
< . . O
1% . . O
12% . . O
< . . O
1% . . O
general . . O
disorders . . O
and . . O
administrative . . O
site . . O
conditions . . O
asthenia . . B-AdverseReaction
/ . . O
fatigue . . B-AdverseReaction
54% . . O
10% . . O
40% . . O
11% . . O
mucosal . . B-AdverseReaction
inflammation . . I-AdverseReaction
9% . . O
1% . . O
10% . . O
2% . . O
pyrexia . . B-AdverseReaction
21% . . O
< . . O
1% . . O
13% . . O
< . . O
1% . . O
gastrointestinal . . O
disorders . . O
constipation . . B-AdverseReaction
25% . . O
1% . . O
21% . . O
1% . . O
diarrhea . . B-AdverseReaction
18% . . O
0 . . O
18% . . O
0 . . O
nausea . . B-AdverseReaction
35% . . O
1% . . O
28% . . O
3% . . O
vomiting . . B-AdverseReaction
18% . . O
1% . . O
18% . . O
1% . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
arthralgia . . B-AdverseReaction
/ . . O
myalgia . . B-AdverseReaction
22% . . O
< . . O
1% . . O
12% . . O
1% . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
16% . . O
1% . . O
7% . . O
2% . . O
bone . . B-AdverseReaction
pain . . I-AdverseReaction
12% . . O
2% . . O
9% . . O
2% . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
11% . . O
1% . . O
10% . . O
1% . . O
investigations . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
21% . . O
1% . . O
14% . . O
< . . O
1% . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
anorexia . . B-AdverseReaction
20% . . O
1% . . O
13% . . O
1% . . O
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
14% . . O
0 . . O
9% . . O
0 . . O
dyspnea . . B-AdverseReaction
16% . . O
4% . . O
13% . . O
4% . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
alopecia . . B-AdverseReaction
45% . . O
na . . O
c . . O
10% . . O
na . . O
c . . O
infections . . O
and . . O
infestations . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
10% . . O
1% . . O
5% . . O
0 . . O
a . . O
. . . O
based . . O
upon . . O
laboratory . . O
data . . O
. . . O
b . . O
includes . . O
neuropathy . . B-AdverseReaction
peripheral . . I-AdverseReaction
, . . O
neuropathy . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
polyneuropathy . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensoryneuropathy . . I-AdverseReaction
, . . O
and . . O
paraesthesia . . B-AdverseReaction
. . . O
c . . O
not . . O
applicable . . O
; . . O
( . . O
grading . . O
system . . O
does . . O
not . . O
specify . . O
> . . O
grade . . O
2 . . O
for . . O
alopecia . . B-AdverseReaction
) . . O
. . . O

there . . O
are . . O
reports . . O
of . . O
pre . . O
- . . O
malignant . . O
and . . O
malignant . . B-AdverseReaction
diseases . . I-AdverseReaction
that . . O
have . . O
developed . . O
in . . O
patients . . O
who . . O
have . . O
been . . O
treated . . O
with . . O
treanda . . O
, . . O
including . . O
myelodysplastic . . B-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
myeloproliferative . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
acute . . B-AdverseReaction
myeloid . . I-AdverseReaction
leukemia . . I-AdverseReaction
and . . O
bronchial . . B-AdverseReaction
carcinoma . . I-AdverseReaction
. . . O

treatment . . O
with . . O
otezla . . O
is . . O
associated . . O
with . . O
an . . O
increase . . O
in . . O
adverse . . O
reactions . . O
of . . O
depression . . B-AdverseReaction
. . . O

the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
( . . O
incidence . . O
> . . O
= . . O
50% . . O
) . . O
were . . O
decreased . . B-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
alkaline . . B-AdverseReaction
phosphatase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
hypercholesterolemia . . B-AdverseReaction
, . . O
bicarbonate . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
and . . O
increased . . B-AdverseReaction
aspartate . . I-AdverseReaction
transaminase . . I-AdverseReaction
( . . O
ast . . O
) . . O
. . . O

immediate . . O
gentle . . O
pressure . . O
at . . O
the . . O
injection . . O
site . . O
can . . O
limit . . O
that . . O
risk . . O
. . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
venous . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
were . . O
reported . . O
in . . O
11 . . O
/ . . O
359 . . O
patients . . O
( . . O
3% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
2 . . O
/ . . O
355 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

g . . O
- . . O
csf . . O
may . . O
be . . O
administered . . O
to . . O
reduce . . O
the . . O
risks . . O
of . . O
neutropenia . . O
complications . . O
associated . . O
with . . O
jevtana . . O
use . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
glaxosmithkline . . O
at . . O
1-877-423-6597 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

asthma . . O
- . . O
related . . O
hospitalizations . . O
occurred . . O
in . . O
10 . . O
subjects . . O
( . . O
1% . . O
) . . O
treated . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
compared . . O
with . . O
7 . . O
subjects . . O
( . . O
0.7% . . O
) . . O
treated . . O
with . . O
fluticasone . . O
furoate . . O
100 . . O
mcg . . O
. . . O

if . . O
you . . O
think . . O
you . . O
may . . O
be . . O
pregnant . . O
, . . O
you . . O
should . . O
have . . O
a . . O
pregnancy . . O
test . . O
and . . O
know . . O
the . . O
results . . O
. . . O

abnormal . . O
thyroid . . O
function . . O
tests . . O
should . . O
be . . O
clinically . . O
evaluated . . O
. . . O

the . . O
next . . O
dose . . O
of . . O
eliquis . . O
should . . O
not . . O
be . . O
administered . . O
earlier . . O
than . . O
5 . . O
hours . . O
after . . O
the . . O
removal . . O
of . . O
the . . O
catheter . . O
. . . O

episodes . . O
of . . O
sinus . . B-AdverseReaction
tachycardia . . I-AdverseReaction
, . . O
associated . . O
with . . O
a . . O
concomitant . . O
increase . . O
from . . O
baseline . . O
in . . O
heart . . O
rate . . O
of . . O
> . . O
= . . O
15 . . O
beats . . O
per . . O
minute . . O
, . . O
were . . O
reported . . O
in . . O
0.7% . . O
, . . O
1.3% . . O
and . . O
2.2% . . O
of . . O
patient . . O
treated . . O
with . . O
placebo . . O
, . . O
trulicity . . O
0.75 . . O
mg . . O
and . . O
trulicity . . O
1.5 . . O
mg . . O
, . . O
respectively . . O
. . . O

discontinue . . O
permanently . . O
if . . O
a . . O
clinically . . O
significant . . O
reaction . . O
occurs . . O
( . . O
5.2 . . O
) . . O
* . . O
hypocalcemia . . B-AdverseReaction
: . . O
must . . O
be . . O
corrected . . O
before . . O
initiating . . O
prolia . . O
. . . O

the . . O
most . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
( . . O
those . . O
occurring . . O
at . . O
an . . O
incidence . . O
of . . O
greater . . O
than . . O
5% . . O
in . . O
the . . O
northera . . O
group . . O
and . . O
with . . O
at . . O
least . . O
a . . O
3% . . O
greater . . O
incidence . . O
in . . O
the . . O
northera . . O
group . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
) . . O
in . . O
northera . . O
- . . O
treated . . O
patients . . O
during . . O
the . . O
three . . O
placebo . . O
- . . O
controlled . . O
trials . . O
were . . O
headache . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
. . . O

5.4 . . O
effects . . O
on . . O
eye . . O

advise . . O
females . . O
of . . O
reproductive . . O
potential . . O
to . . O
use . . O
effective . . O
contraception . . O
during . . O
treatment . . O
with . . O
zykadia . . O
and . . O
for . . O
at . . O
least . . O
2 . . O
weeks . . O
following . . O
completion . . O
of . . O
therapy . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.7 . . O
) . . O
] . . O
. . . O

table . . O
6 . . O
describes . . O
grade . . O
3-4 . . O
laboratory . . O
abnormalities . . O
reported . . O
at . . O
a . . O
rate . . O
of . . O
> . . O
= . . O
10% . . O
in . . O
the . . O
krd . . O
arm . . O
for . . O
patients . . O
who . . O
received . . O
combination . . O
therapy . . O
. . . O

additionally . . O
, . . O
serum . . O
phosphorus . . O
should . . O
be . . O
measured . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
renal . . O
impairment . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
withdrawal . . O
in . . O
patients . . O
receiving . . O
potiga . . O
were . . O
dizziness . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
fatigue . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
and . . O
somnolence . . B-AdverseReaction
( . . O
3% . . O
) . . O
. . . O

if . . B-Factor
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
a . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
she . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . B-Factor
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

perform . . O
dermatologic . . O
evaluations . . O
prior . . O
to . . O
initiation . . O
of . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
or . . O
in . . O
combination . . O
with . . O
trametinib . . O
, . . O
every . . O
2 . . O
months . . O
while . . O
on . . O
therapy . . O
, . . O
and . . O
for . . O
up . . O
to . . O
6 . . O
months . . O
following . . O
discontinuation . . O
of . . O
tafinlar . . O
. . . O

discontinue . . O
treanda . . O
for . . O
patients . . O
with . . O
grade . . O
4 . . O
infusion . . O
reactions . . O
. . . O

for . . O
those . . O
patients . . O
who . . O
reported . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
most . . O
had . . O
their . . O
first . . O
occurrence . . O
of . . O
the . . O
event . . O
within . . O
the . . O
first . . O
month . . O
of . . O
treatment . . O
. . . O

if . . O
pancreatitis . . O
is . . O
confirmed . . O
, . . O
trulicity . . O
should . . O
not . . O
be . . O
restarted . . O
. . . O

before . . O
initiating . . O
treatment . . O
with . . O
gilenya . . O
, . . O
a . . O
recent . . O
cbc . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
within . . O
6 . . O
months . . O
or . . O
after . . O
discontinuation . . O
of . . O
prior . . O
therapy . . O
) . . O
should . . O
be . . O
available . . O
. . . O

( . . O
24 . . O
weeks . . O
) . . O
n . . O
= . . O
197 . . O
n . . O
= . . O
212 . . O
n . . O
= . . O
196 . . O
major . . O
[ . . O
n . . O
( . . O
% . . O
) . . O
] . . O
1 . . O
( . . O
0.5 . . O
) . . O
1 . . O
( . . O
0.5 . . O
) . . O
1 . . O
( . . O
0.5 . . O
) . . O
minor . . O
[ . . O
n . . O
( . . O
% . . O
) . . O
] . . O
67 . . O
( . . O
34.0 . . O
) . . O
92 . . O
( . . O
43.4 . . O
) . . O
79 . . O
( . . O
40.3 . . O
) . . O
genital . . O
mycotic . . O
infections . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
were . . O
more . . O
frequent . . O
with . . O
farxiga . . O
treatment . . O
. . . O

yervoy . . O
was . . O
discontinued . . O
for . . O
adverse . . O
reactions . . O
in . . O
10% . . O
of . . O
patients . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O
: . . O
adults . . O

severe . . O
hypersensitivity . . O
: . . O
severe . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
can . . B-Factor
occur . . O
and . . O
may . . B-Factor
include . . O
generalized . . B-AdverseReaction
rash . . I-AdverseReaction
/ . . O
erythema . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
and . . O
bronchospasm . . B-AdverseReaction
. . . O

entereg . . O
is . . O
not . . O
recommended . . O
for . . O
use . . O
in . . O
these . . O
patients . . O
. . . O

the . . O
use . . O
of . . O
cocs . . B-DrugClass
increases . . O
the . . O
risk . . O
of . . O
venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
. . . O

nervous . . O
system . . O
disorders . . O
- . . O
dizziness . . B-AdverseReaction
, . . O
convulsion . . B-AdverseReaction

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
in . . O
the . . O
221 . . O
patients . . O
treated . . O
with . . O
kalydeco . . O
were . . O
headache . . B-AdverseReaction
( . . O
17% . . O
) . . O
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
16% . . O
) . . O
, . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
( . . O
16% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
10% . . O
) . . O
, . . O
rash . . B-AdverseReaction
( . . O
10% . . O
) . . O
, . . O
rhinitis . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
dizziness . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
arthralgia . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
and . . O
bacteria . . B-AdverseReaction
in . . I-AdverseReaction
sputum . . I-AdverseReaction
( . . O
5% . . O
) . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

the . . O
most . . O
common . . O
reason . . O
for . . O
dose . . O
reduction . . O
was . . O
anemia . . B-AdverseReaction
, . . O
which . . O
occurred . . O
more . . O
frequently . . O
in . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
than . . O
in . . O
subjects . . O
receiving . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
. . . O

table . . O
3 . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
subjects . . O
treated . . O
with . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
and . . O
at . . O
higher . . O
frequency . . O
than . . O
vehicle . . O
( . . O
face . . O
/ . . O
scalp . . O
trials . . O
) . . O

therefore . . O
, . . O
remove . . O
qutenza . . O
patches . . O
gently . . O
and . . O
slowly . . O
by . . O
rolling . . O
the . . O
adhesive . . O
side . . O
inward . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

6.1 . . O
clinical . . O
study . . O
experience . . O

( . . O
5.6 . . O
) . . O

endometrial . . O
biopsies . . O
performed . . O
in . . O
a . . O
subset . . O
of . . O
subjects . . O
in . . O
a . . O
phase . . O
3 . . O
natazia . . O
clinical . . O
trial . . O
did . . O
not . . O
reveal . . O
any . . O
unexpected . . O
or . . O
concerning . . O
findings . . O
for . . O
subjects . . O
taking . . O
cocs . . O
. . . O

6.3 . . O
postmarketing . . O
experience . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
described . . O
in . . O
more . . O
detail . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O
of . . O
the . . O
label . . O
: . . O

in . . O
these . . O
two . . O
studies . . O
combined . . O
, . . O
554 . . O
patients . . O
received . . O
toviaz . . O
4 . . O
mg . . O
/ . . O
day . . O
and . . O
566 . . O
patients . . O
received . . O
toviaz . . O
8 . . O
mg . . O
/ . . O
day . . O
. . . O

6.1 . . O
clinical . . O
trial . . O
experience . . O

warning . . O
: . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

no . . B-Negation
grade . . B-Severity
4 . . I-Severity
infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
reported . . O
. . . O

adverse . . B-AdverseReaction
reactions . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
hematologic . . I-AdverseReaction
system . . I-AdverseReaction
, . . O
including . . O
medically . . B-Severity
significant . . I-Severity
cytopenia . . B-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
leukopenia . . B-AdverseReaction
, . . O
pancytopenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
) . . O
have . . O
been . . O
infrequently . . O
reported . . O
with . . O
cimzia . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

general . . O
information . . O
about . . O
the . . O
safe . . O
and . . O
effective . . O
use . . O
of . . O
duavee . . O

long . . B-AdverseReaction
- . . I-AdverseReaction
term . . I-AdverseReaction
cumulative . . I-AdverseReaction
radiation . . I-AdverseReaction
exposure . . I-AdverseReaction
is . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
cancer . . B-AdverseReaction
. . . O

serious . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
54 . . O
( . . O
49% . . O
) . . O
subjects . . O
treated . . O
with . . O
zydelig . . O
+ . . O
rituximab . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

discontinue . . O
promptly . . O
if . . O
pancreatitis . . O
is . . O
suspected . . O
. . . O

hepatobiliary . . O
disorders . . O
: . . O
hepatitis . . B-AdverseReaction
. . . O

given . . O
the . . O
similar . . O
structural . . O
formula . . O
of . . O
atropine . . O
to . . O
aclidinium . . O
, . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
hypersensitivity . . O
reactions . . O
to . . O
atropine . . O
should . . O
be . . O
closely . . O
monitored . . O
for . . O
similar . . O
hypersensitivity . . O
reactions . . O
to . . O
tudorza . . O
pressair . . O
. . . O

interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
and . . O
eosinophilic . . B-AdverseReaction
pneumonia . . I-AdverseReaction
associated . . O
with . . O
venlafaxine . . B-DrugClass
( . . O
the . . O
parent . . O
drug . . O
of . . O
pristiq . . O
) . . O
therapy . . O
have . . O
been . . O
rarely . . O
reported . . O
. . . O

tumor . . O
lysis . . O
syndrome . . O
( . . O
tls . . O
) . . O
, . . O
which . . O
may . . B-Factor
be . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
or . . O
fatal . . B-AdverseReaction
, . . O
has . . O
been . . O
observed . . O
in . . O
patients . . O
receiving . . O
blincyto . . O
. . . O

for . . O
patients . . O
whose . . O
sera . . O
tested . . O
positive . . O
in . . O
the . . O
screening . . O
immunoassay . . O
, . . O
an . . O
in . . O
vitro . . O
biological . . O
assay . . O
was . . O
performed . . O
to . . O
detect . . O
neutralizing . . O
antibodies . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
hematuria . . B-AdverseReaction
( . . O
including . . O
respective . . O
laboratory . . O
parameters . . O
) . . O

5.3 . . O
hypoglycemia . . O
with . . O
concomitant . . O
use . . O
of . . O
insulin . . O
secretagogues . . O
or . . O
insulin . . O

the . . O
duration . . O
of . . O
driving . . B-AdverseReaction
impairment . . I-AdverseReaction
after . . O
starting . . O
therapy . . O
with . . O
horizant . . O
is . . O
unknown . . O
. . . O

immune . . O
system . . O
disorders . . O

hyperglycemia . . O
and . . O
diabetes . . O
mellitus . . O

serum . . O
chemistry . . O
abnormalities . . O
alt . . B-AdverseReaction
increased . . I-AdverseReaction
73 . . O
( . . O
50 . . O
) . . O
20 . . O
( . . O
14 . . O
) . . O
7 . . O
( . . O
5 . . O
) . . O
ast . . B-AdverseReaction
increased . . I-AdverseReaction
60 . . O
( . . O
41 . . O
) . . O
12 . . O
( . . O
8 . . O
) . . O
6 . . O
( . . O
4 . . O
) . . O
hematology . . O
abnormalities . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
78 . . O
( . . O
53 . . O
) . . O
20 . . O
( . . O
14 . . O
) . . O
16 . . O
( . . O
11 . . O
) . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
41 . . O
( . . O
28 . . O
) . . O
3 . . O
( . . O
2 . . O
) . . O
0 . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
38 . . O
( . . O
26 . . O
) . . O
4 . . O
( . . O
3 . . O
) . . O
5 . . O
( . . O
3 . . O
) . . O

there . . O
were . . O
no . . B-Negation
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
reported . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
; . . O
however . . O
, . . O
grade . . B-Severity
1 . . I-Severity
or . . O
2 . . O
infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
reported . . O
for . . O
19 . . O
patients . . O
( . . O
12% . . O
) . . O
. . . O

most . . O
studies . . O
show . . O
no . . O
significant . . O
increased . . O
risk . . O
associated . . O
with . . O
use . . O
of . . O
estrogens . . O
for . . O
less . . O
than . . O
1 . . O
year . . O
. . . O

the . . O
most . . O
common . . O
reported . . O
adverse . . O
reaction . . O
occurring . . O
in . . O
approximately . . O
25% . . O
of . . O
subjects . . O
was . . O
a . . O
mild . . B-Severity
taste . . B-AdverseReaction
following . . I-AdverseReaction
instillation . . I-AdverseReaction
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

serum . . O
follicle . . O
stimulating . . O
hormone . . O
( . . O
fsh . . O
) . . O
and . . O
estradiol . . O
levels . . O
have . . O
not . . O
been . . O
shown . . O
to . . O
be . . O
useful . . O
in . . O
the . . O
management . . O
of . . O
moderate . . O
to . . O
severe . . O
vasomotor . . O
symptoms . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
35% . . O
were . . O
black . . O
, . . O
17.5% . . O
were . . O
hispanic . . O
, . . O
12.5% . . O
were . . O
white . . O
, . . O
9.4% . . O
were . . O
asian . . O
, . . O
and . . O
25.6% . . O
were . . O
of . . O
another . . O
race . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
four . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
, . . O
female . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
vulvovaginal . . B-AdverseReaction
mycotic . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
vulvovaginal . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
and . . O
vulvovaginitis . . B-AdverseReaction
) . . O
occurred . . O
in . . O
3.2% . . O
, . . O
10.4% . . O
, . . O
and . . O
11.4% . . O
of . . O
females . . O
treated . . O
with . . O
placebo . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

at . . O
baseline . . O
, . . O
the . . O
population . . O
had . . O
diabetes . . O
for . . O
an . . O
average . . O
of . . O
8.0 . . O
years . . O
and . . O
had . . O
a . . O
mean . . O
hba1c . . O
of . . O
8.0% . . O
. . . O

observe . . O
for . . O
hypersensitivity . . O
signs . . O
and . . O
symptoms . . O
following . . O
vizamyl . . O
administration . . O
. . . O

during . . O
the . . O
clinical . . O
trial . . O
, . . O
the . . O
patient . . O
experienced . . O
prolonged . . B-Severity
lymphopenia . . B-AdverseReaction
( . . O
lymphocyte . . O
counts . . O
predominantly . . O
< . . O
0.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
for . . O
3.5 . . O
years . . O
) . . O
while . . O
taking . . O
tecfidera . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

41.1% . . O
were . . O
current . . O
or . . O
previous . . O
smokers . . O
. . . O

table . . O
1 . . O
shows . . O
adverse . . O
reactions . . O
reported . . O
in . . O
study . . O
1 . . O
that . . O
occurred . . O
at . . O
a . . O
> . . O
= . . O
2% . . O
higher . . O
frequency . . O
in . . O
the . . O
xtandi . . O
arm . . O
compared . . O
to . . O
the . . O
placebo . . O
arm . . O
. . . O

ocular . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
occurring . . O
in . . O
5-15% . . O
of . . O
subjects . . O
in . . O
clinical . . O
studies . . O
with . . O
durezol . . O
included . . O
corneal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
ciliary . . O
and . . O
conjunctival . . B-AdverseReaction
hyperemia . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
photophobia . . B-AdverseReaction
, . . O
posterior . . B-AdverseReaction
capsule . . I-AdverseReaction
opacification . . I-AdverseReaction
, . . O
anterior . . B-AdverseReaction
chamber . . I-AdverseReaction
cells . . I-AdverseReaction
, . . O
anterior . . B-AdverseReaction
chamber . . I-AdverseReaction
flare . . I-AdverseReaction
, . . O
conjunctival . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
and . . O
blepharitis . . B-AdverseReaction
. . . O

impaired . . B-AdverseReaction
glucose . . I-AdverseReaction
tolerance . . I-AdverseReaction
. . . O

in . . O
patients . . O
with . . O
abnormal . . O
liver . . O
tests . . O
, . . O
nesina . . O
should . . O
be . . O
initiated . . O
with . . O
caution . . O
. . . O

the . . O
safety . . O
of . . O
resuming . . O
tnf . . O
blocker . . O
therapy . . O
after . . O
hbv . . O
reactivation . . O
is . . O
controlled . . O
is . . O
not . . O
known . . O
. . . O

consider . . O
alternative . . O
contraception . . O
for . . O
women . . O
with . . O
uncontrolled . . O
dyslipidemia . . O
. . . O

patients . . O
should . . O
be . . O
monitored . . O
for . . O
igg . . O
antibody . . O
formation . . O
every . . O
3 . . O
months . . O
for . . O
2 . . O
years . . O
and . . O
then . . O
annually . . O
thereafter . . O
. . . O

antibody . . O
formation . . O
was . . O
associated . . O
with . . O
lowered . . O
drug . . O
plasma . . O
concentration . . O
and . . O
reduced . . O
efficacy . . O
. . . O

key . . O
laboratory . . O
abnormalities . . O
are . . O
presented . . O
in . . O
table . . O
7 . . O
. . . O

liver . . O
enzyme . . O
abnormalities . . O

these . . O
were . . O
commonly . . O
dyspepsia . . B-AdverseReaction
( . . O
including . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
and . . O
epigastric . . B-AdverseReaction
discomfort . . I-AdverseReaction
) . . O
and . . O
gastritis . . B-AdverseReaction
- . . O
like . . O
symptoms . . O
( . . O
including . . O
gerd . . B-AdverseReaction
, . . O
esophagitis . . B-AdverseReaction
, . . O
erosive . . B-AdverseReaction
gastritis . . I-AdverseReaction
, . . O
gastric . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
hemorrhagic . . B-AdverseReaction
gastritis . . I-AdverseReaction
, . . O
hemorrhagic . . B-AdverseReaction
erosive . . I-AdverseReaction
gastritis . . I-AdverseReaction
, . . O
and . . O
gastrointestinal . . B-AdverseReaction
ulcer . . I-AdverseReaction
) . . O
. . . O

administer . . O
this . . O
product . . O
in . . O
a . . O
setting . . O
with . . O
resuscitation . . O
equipment . . O
and . . O
other . . O
agents . . O
necessary . . O
to . . O
treat . . O
anaphylaxis . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
accredo . . O
health . . O
group . . O
inc . . O
. . . O
at . . O
1-888-454-8860 . . O
, . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

the . . O
percentage . . O
of . . O
patients . . O
who . . O
withdrew . . O
from . . O
the . . O
study . . O
due . . O
to . . O
adverse . . O
events . . O
was . . O
2.1% . . O
and . . O
2.4% . . O
for . . O
the . . O
placebo . . O
and . . O
prolia . . O
groups . . O
, . . O
respectively . . O
. . . O

* . . O
bacterial . . O
, . . O
viral . . O
, . . O
and . . O
other . . O
infections . . B-AdverseReaction
due . . I-AdverseReaction
to . . I-AdverseReaction
opportunistic . . I-AdverseReaction
pathogens . . I-AdverseReaction
, . . O
including . . O
legionella . . O
and . . O
listeria . . O
. . . O

( . . O
6.2 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
glaxosmithkline . . O
at . . O
1-888-825-5249 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

( . . O
2.2 . . O
, . . O
5.6 . . O
) . . O
* . . O
pancreatitis . . B-AdverseReaction
: . . O
elevations . . B-AdverseReaction
of . . I-AdverseReaction
lipase . . I-AdverseReaction
and . . O
/ . . O
or . . O
amylase . . O
and . . O
pancreatitis . . B-AdverseReaction
can . . B-Factor
occur . . O
. . . O

approximately . . O
half . . O
of . . O
the . . O
patients . . O
( . . O
54% . . O
) . . O
were . . O
male . . O
. . . O

table . . O
3 . . O
shows . . O
absolute . . O
and . . O
relative . . O
risk . . O
by . . O
indication . . O
for . . O
all . . O
evaluated . . O
aeds . . O
. . . O

these . . O
findings . . O
confirm . . O
the . . O
myelosuppressive . . B-AdverseReaction
effects . . I-AdverseReaction
seen . . O
in . . O
patients . . O
treated . . O
with . . O
treanda . . O
. . . O

laboratory . . O
findings . . O

monitor . . O
for . . O
the . . O
development . . O
of . . O
severe . . O
diarrhea . . O
or . . O
colitis . . O
. . . O

new . . O
onset . . O
or . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
pre . . I-AdverseReaction
- . . I-AdverseReaction
existing . . I-AdverseReaction
cardiac . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
congestive . . B-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
ejection . . I-AdverseReaction
fraction . . I-AdverseReaction
) . . O
, . . O
restrictive . . B-AdverseReaction
cardiomyopathy . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
ischemia . . I-AdverseReaction
, . . O
and . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
including . . O
fatalities . . B-AdverseReaction
have . . O
occurred . . O
following . . O
administration . . O
of . . O
kyprolis . . O
. . . O

the . . O
following . . O
adverse . . O
reaction . . O
has . . O
been . . O
identified . . O
during . . O
postapproval . . O
use . . O
of . . O
teflaro . . O
. . . O

activated . . O
oral . . O
charcoal . . O
reduces . . O
absorption . . O
of . . O
apixaban . . O
, . . O
thereby . . O
lowering . . O
apixaban . . O
plasma . . O
concentration . . O
[ . . O
seeoverdosage . . O
( . . O
10 . . O
) . . O
] . . O
. . . O

one . . O
patient . . O
developed . . O
pml . . B-AdverseReaction
after . . O
taking . . O
gilenya . . O
for . . O
approximately . . O
2.5 . . O
years . . O
. . . O

other . . O
infrequent . . O
adverse . . O
reactions . . O
, . . O
not . . O
described . . O
elsewhere . . O
in . . O
the . . O
label . . O
, . . O
occurring . . O
at . . O
an . . O
incidence . . O
of . . O
< . . O
2% . . O
in . . O
mdd . . O
patients . . O
treated . . O
with . . O
pristiq . . O
were . . O
: . . O

excerpt . . O
: . . O
warning . . O
: . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O

of . . O
pradaxa . . O
increases . . O
the . . O
risk . . O
of . . O
thrombotic . . O
eventspremature . . O

if . . O
super . . O
- . . O
infection . . O
occurs . . O
, . . O
discontinue . . O
use . . O
and . . O
institute . . O
alternative . . O
therapy . . O
. . . O

the . . O
safety . . O
population . . O
( . . O
received . . O
at . . O
least . . O
1 . . O
dose . . O
of . . O
bosulif . . O
) . . O
included . . O
546 . . O
cml . . O
patients . . O
: . . O

* . . O
blood . . O
psa . . O
levels . . O
< . . O
2 . . O
ng . . O
/ . . O
ml . . O
have . . O
been . . O
associated . . O
with . . O
poor . . O
performance . . O
of . . O
11 . . O
c . . O
- . . O
choline . . O
pet . . O
imaging . . O
( . . O
higher . . O
numbers . . O
of . . O
false . . O
positive . . O
and . . O
false . . O
negative . . O
results . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
were . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
which . . O
occurred . . O
in . . O
almost . . O
all . . O
patients . . O
( . . O
97% . . O
) . . O
in . . O
clinical . . O
trials . . O
. . . O

hyperprolactinemia . . B-AdverseReaction
may . . B-Factor
suppress . . B-AdverseReaction
hypothalamic . . I-AdverseReaction
gnrh . . I-AdverseReaction
, . . O
resulting . . O
in . . O
reduced . . B-AdverseReaction
pituitary . . I-AdverseReaction
gonadotropin . . I-AdverseReaction
secretion . . I-AdverseReaction
. . . O

patients . . O
receiving . . O
any . . O
therapy . . O
for . . O
chronic . . O
infection . . O
should . . O
not . . O
begin . . O
therapy . . O
with . . O
benlysta . . O
. . . O

the . . O
incidence . . O
of . . O
serious . . O
adverse . . O
events . . O
was . . O
30.6% . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
34.6% . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

periodic . . O
skin . . O
examinations . . O
are . . O
recommended . . O
for . . O
all . . O
patients . . O
, . . O
particularly . . O
those . . O
with . . O
risk . . O
factors . . O
for . . O
skin . . O
cancer . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
four . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
, . . O
male . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
candidal . . B-AdverseReaction
balanitis . . I-AdverseReaction
, . . O
balanoposthitis . . B-AdverseReaction
) . . O
occurred . . O
in . . O
0.6% . . O
, . . O
4.2% . . O
, . . O
and . . O
3.7% . . O
of . . O
males . . O
treated . . O
with . . O
placebo . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
label . . O
: . . O

neutropenia . . B-AdverseReaction
may . . B-Factor
precede . . O
the . . O
development . . O
of . . O
agranulocytosis . . B-AdverseReaction
. . . O

the . . O
majority . . O
of . . O
patients . . O
in . . O
the . . O
active . . O
group . . O
were . . O
between . . O
the . . O
ages . . O
of . . O
18 . . O
and . . O
64 . . O
. . . O

( . . O
6.1 . . O
) . . O
excerpt . . O
: . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
glaxosmithkline . . O
at . . O
1-888-825-5249 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
drug . . O
reactions . . O
that . . O
occurred . . O
in . . O
at . . O
least . . O
1% . . O
of . . O
patients . . O
and . . O
were . . O
more . . O
frequent . . O
than . . O
placebo . . O
placebo . . O
dronedarone . . O
400 . . O
mg . . O
twice . . O
daily . . O
( . . O
n . . O
= . . O
2875 . . O
) . . O
( . . O
n . . O
= . . O
3282 . . O
) . . O
gastrointestinal . . O
diarrhea . . B-AdverseReaction
6% . . O
9% . . O
nausea . . B-AdverseReaction
3% . . O
5% . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
3% . . O
4% . . O
vomiting . . B-AdverseReaction
1% . . O
2% . . O
dyspeptic . . B-AdverseReaction
signs . . I-AdverseReaction
and . . I-AdverseReaction
symptoms . . I-AdverseReaction
1% . . O
2% . . O
general . . O
asthenic . . B-AdverseReaction
conditions . . I-AdverseReaction
5% . . O
7% . . O
cardiac . . O
bradycardia . . B-AdverseReaction
1% . . O
3% . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
including . . O
rashes . . B-AdverseReaction
( . . O
generalized . . O
, . . O
macular . . O
, . . O
maculo . . O
- . . O
papular . . O
, . . O
erythematous . . O
) . . O
, . . O
pruritus . . B-AdverseReaction
, . . O
eczema . . B-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
allergic . . I-AdverseReaction
3% . . O
5% . . O
photosensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
and . . O
dysgeusia . . B-AdverseReaction
have . . O
also . . O
been . . O
reported . . O
at . . O
an . . O
incidence . . O
less . . O
than . . O
1% . . O
in . . O
patients . . O
treated . . O
with . . O
multaq . . O
. . . O

5.5 . . O
pneumonia . . O

excluded . . O
from . . O
this . . O
list . . O
are . . O
those . . O
events . . O
that . . O
were . . O
minor . . O
, . . O
those . . O
with . . O
no . . O
plausible . . O
relation . . O
to . . O
drug . . O
use . . O
, . . O
and . . O
reports . . O
too . . O
imprecise . . O
to . . O
be . . O
meaningful . . O
. . . O

similar . . O
adverse . . O
reactions . . O
have . . O
been . . O
observed . . O
postmarketing . . O
as . . O
described . . O
for . . O
clinical . . O
trial . . O
experience . . O
. . . O

this . . O
patient . . O
had . . O
pretreatment . . O
calcitonin . . O
levels . . O
approximately . . O
8 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
( . . O
uln . . O
) . . O
. . . O

upper . . O
limb . . O
spasticity . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
novartis . . O
pharmaceuticals . . O
corporation . . O
at . . O
1-888-669-6682 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

patients . . O
treated . . O
with . . O
dronedarone . . O
should . . O
undergo . . O
monitoring . . O
of . . O
cardiac . . O
rhythm . . O
no . . O
less . . O
often . . O
than . . O
every . . O
3 . . O
months . . O
. . . O

5.4 . . O
hypersensitivity . . O
reactions . . O

5.6 . . O
embryofetal . . O
toxicity . . O

exposure . . O
to . . O
sunlight . . O
and . . O
ultraviolet . . O
( . . O
uv . . O
) . . O
light . . O
should . . O
be . . O
limited . . O
by . . O
wearing . . O
protective . . O
clothing . . O
and . . O
using . . O
a . . O
sunscreen . . O
with . . O
a . . O
high . . O
protection . . O
factor . . O
. . . O

in . . O
rare . . O
instances . . O
severe . . B-Severity
anaphylactic . . O
and . . O
anaphylactoid . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
occurred . . O
, . . O
particularly . . O
in . . O
the . . O
second . . O
and . . O
subsequent . . O
cycles . . O
of . . O
therapy . . O
. . . O

these . . O
bleeding . . B-AdverseReaction
and . . O
thromboembolic . . B-AdverseReaction
events . . I-AdverseReaction
were . . O
seen . . O
both . . O
in . . O
patients . . O
who . . O
were . . O
initiated . . O
on . . O
pradaxa . . O
post . . O
- . . O
operatively . . O
within . . O
three . . O
days . . O
of . . O
mechanical . . O
bileaflet . . O
valve . . O
implantation . . O
, . . O
as . . O
well . . O
as . . O
in . . O
patients . . O
whose . . O
valves . . O
had . . O
been . . O
implanted . . O
more . . O
than . . O
three . . O
months . . O
prior . . O
to . . O
enrollment . . O
. . . O

serious . . O
adverse . . O
events . . O
were . . O
reported . . O
in . . O
58 . . O
patients . . O
( . . O
34% . . O
) . . O
treated . . O
with . . O
xalkori . . O
. . . O

small . . B-Severity
reversible . . B-Severity
increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
are . . O
seen . . O
in . . O
patients . . O
receiving . . O
80 . . O
mg . . O
of . . O
edarbi . . O
. . . O

no . . O
new . . O
adverse . . O
reactions . . O
were . . O
reported . . O
. . . O

5.4 . . O
renal . . O
failure . . O

estimated . . O
creatinine . . O
clearance . . O
, . . O
urine . . O
glucose . . O
and . . O
urine . . O
protein . . O
should . . O
be . . O
documented . . O
in . . O
all . . O
patients . . O
prior . . O
to . . O
initiating . . O
therapy . . O
. . . O

anti . . O
- . . O
belatacept . . O
antibody . . O
titers . . O
did . . O
not . . O
increase . . O
during . . O
treatment . . O
in . . O
these . . O
29 . . O
patients . . O
. . . O

uveitis . . O
and . . O
iritis . . O
: . . O

the . . O
risk . . B-Factor
of . . O
vte . . B-AdverseReaction
is . . O
highest . . O
during . . O
the . . O
first . . O
year . . O
of . . O
use . . O
. . . O

some . . O
patients . . O
( . . O
13% . . O
) . . O
received . . O
premedication . . O
, . . O
which . . O
may . . O
have . . O
mitigated . . O
or . . O
masked . . O
an . . O
infusion . . O
reaction . . O
; . . O
however . . O
, . . O
there . . O
is . . O
insufficient . . O
evidence . . O
to . . O
determine . . O
whether . . O
premedication . . O
diminishes . . O
the . . O
frequency . . O
or . . O
severity . . O
of . . O
infusion . . O
reactions . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
incidence . . O
of . . O
antibodies . . O
to . . O
yervoy . . O
with . . O
the . . O
incidences . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
potiga . . O
can . . B-Factor
cause . . O
skin . . B-AdverseReaction
discoloration . . I-AdverseReaction
. . . O

during . . O
clinical . . O
trials . . O
, . . O
no . . B-Negation
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

5.7 . . O
orthostatic . . O
hypotension . . O
and . . O
syncope . . O

* . . O
the . . O
risk . . B-Factor
for . . O
nsf . . B-AdverseReaction
appears . . O
highest . . O
among . . O
patients . . O
with . . O
: . . O
chronic . . O
, . . O
severe . . O
kidney . . O
disease . . O
( . . O
gfr . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m2 . . O
) . . O
, . . O
oracute . . O
kidney . . O
injury . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

do . . O
not . . O
use . . O
breo . . O
ellipta . . O
for . . O
patients . . O
whose . . O
asthma . . O
is . . O
adequately . . O
controlled . . O
on . . O
low . . O
- . . O
or . . O
medium . . O
- . . O
dose . . O
inhaled . . O
corticosteroids . . O
. . . O

acute . . B-AdverseReaction
cardiorespiratory . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
possibly . . O
associated . . O
with . . O
fluid . . B-AdverseReaction
overload . . I-AdverseReaction
, . . O
has . . O
been . . O
reported . . O
in . . O
infantile . . O
- . . O
onset . . O
pompe . . O
disease . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
hypertrophic . . O
cardiomyopathy . . O
[ . . O
seeboxed . . O
warningandwarning . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

advise . . O
females . . O
of . . O
reproductive . . O
potential . . O
to . . O
avoid . . O
becoming . . O
pregnant . . O
while . . O
taking . . O
zydelig . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
neutropenia . . B-AdverseReaction
: . . O
monitor . . O
blood . . O
counts . . O
. . . O

the . . O
single . . O
- . . O
arm . . O
phase . . O
1 . . O
/ . . O
2 . . O
clinical . . O
trial . . O
( . . O
study . . O
1 . . O
) . . O
enrolled . . O
patients . . O
with . . O
ph+ . . O
chronic . . O
, . . O
accelerated . . O
, . . O
or . . O
blast . . O
phase . . O
chronic . . O
myelogenous . . O
leukemia . . O
( . . O
cml . . O
) . . O
and . . O
with . . O
resistance . . O
or . . O
intolerance . . O
to . . O
prior . . O
therapy . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

prophylaxis . . O
for . . O
pjp . . O
should . . O
be . . O
considered . . O
when . . O
concomitant . . O
use . . O
of . . O
corticosteroids . . O
or . . O
other . . O
immunosuppressive . . O
agents . . O
are . . O
required . . O
. . . O

extrapyramidal . . B-AdverseReaction
symptoms . . I-AdverseReaction
included . . O
: . . O
dystonia . . B-AdverseReaction
, . . O
blepharospasm . . B-AdverseReaction
, . . O
torticollis . . B-AdverseReaction
, . . O
dyskinesia . . B-AdverseReaction
, . . O
tardive . . B-AdverseReaction
dyskinesia . . I-AdverseReaction
, . . O
muscle . . B-AdverseReaction
rigidity . . I-AdverseReaction
, . . O
parkinsonism . . B-AdverseReaction
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
, . . O
masked . . B-AdverseReaction
facies . . I-AdverseReaction
, . . O
and . . O
tremor . . B-AdverseReaction
( . . O
excluding . . B-Negation
akathisia . . B-AdverseReaction
) . . O
. . . O
? . . O

* . . O
trulicity . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
a . . O
personal . . O
or . . O
family . . O
history . . O
of . . O
mtc . . O
and . . O
in . . O
patients . . O
with . . O
multiple . . O
endocrine . . O
neoplasia . . O
syndrome . . O
type . . O
2 . . O
( . . O
men . . O
2 . . O
) . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
forest . . O
laboratories . . O
, . . O
llc . . O
, . . O
at . . O
1-800-678-1605 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

after . . O
withdrawal . . O
from . . O
systemic . . O
corticosteroids . . O
, . . O
a . . O
number . . O
of . . O
months . . O
are . . O
required . . O
for . . O
recovery . . O
of . . O
hypothalamic . . O
- . . O
pituitary . . O
- . . O
adrenal . . O
( . . O
hpa . . O
) . . O
function . . O
. . . O

table . . O
1 . . O
: . . O
non . . O
- . . O
hematologic . . O
adverse . . O
reactions . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
patients . . O
with . . O
mcl . . O
( . . O
n . . O
= . . O
111 . . O
) . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
51 . . O
5 . . O
nausea . . B-AdverseReaction
31 . . O
0 . . O
constipation . . B-AdverseReaction
25 . . O
0 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
24 . . O
5 . . O
vomiting . . B-AdverseReaction
23 . . O
0 . . O
stomatitis . . B-AdverseReaction
17 . . O
1 . . O
dyspepsia . . B-AdverseReaction
11 . . O
0 . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
34 . . O
0 . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
14 . . O
3 . . O
pneumonia . . B-AdverseReaction
14 . . O
7 . . O
skin . . B-AdverseReaction
infections . . I-AdverseReaction
14 . . O
5 . . O
sinusitis . . B-AdverseReaction
13 . . O
1 . . O
general . . O
disorders . . O
and . . O
administrative . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
41 . . O
5 . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
35 . . O
3 . . O
pyrexia . . B-AdverseReaction
18 . . O
1 . . O
asthenia . . B-AdverseReaction
14 . . O
3 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
bruising . . B-AdverseReaction
30 . . O
0 . . O
rash . . B-AdverseReaction
25 . . O
3 . . O
petechiae . . B-AdverseReaction
11 . . O
0 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
37 . . O
1 . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
14 . . O
0 . . O
arthralgia . . B-AdverseReaction
11 . . O
0 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
dyspnea . . B-AdverseReaction
27 . . O
4 . . O
cough . . B-AdverseReaction
19 . . O
0 . . O
epistaxis . . B-AdverseReaction
11 . . O
0 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
21 . . O
2 . . O
dehydration . . B-AdverseReaction
12 . . O
4 . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
14 . . O
0 . . O
headache . . B-AdverseReaction
13 . . O
0 . . O
table . . O
2 . . O
: . . O
treatment . . O
- . . O
emergentbased . . O
on . . O
laboratory . . O
measurements . . O
and . . O
adverse . . O
reactions . . O
decrease . . B-AdverseReaction
of . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
platelets . . O
, . . O
or . . O
neutrophils . . O
in . . O
patients . . O
with . . O
mcl . . O
( . . O
n . . O
= . . O
111 . . O
) . . O
percent . . O
of . . O
patients . . O
( . . O
n . . O
= . . O
111 . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
57 . . O
17 . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
47 . . O
29 . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
41 . . O
9 . . O
ten . . O
patients . . O
( . . O
9% . . O
) . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
reactions . . O
in . . O
the . . O
trial . . O
( . . O
n . . O
= . . O
111 . . O
) . . O
. . . O

because . . O
horizant . . O
is . . O
a . . O
prodrug . . O
of . . O
gabapentin . . O
, . . O
horizant . . O
also . . O
increases . . O
this . . O
risk . . O
. . . O

mean . . O
changes . . O
( . . O
percent . . O
changes . . O
) . . O
from . . O
baseline . . O
in . . O
ldl . . O
- . . O
c . . O
relative . . O
to . . O
placebo . . O
were . . O
4.4 . . B-Severity
mg . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
4.5% . . O
) . . O
and . . O
8.2 . . B-Severity
mg . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
8.0% . . O
) . . O
with . . O
invokana . . O
100 . . O
mg . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

administration . . O
reactions . . O

alt . . O
or . . O
ast . . B-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
or . . I-AdverseReaction
equal . . I-AdverseReaction
to . . I-AdverseReaction
3 . . I-AdverseReaction
x . . I-AdverseReaction
uln . . I-AdverseReaction
was . . O
reported . . O
in . . O
34% . . O
and . . O
38% . . O
of . . O
patients . . O
for . . O
promacta . . O
and . . O
placebo . . O
, . . O
respectively . . O
. . . O

5.3 . . O
xiaflex . . O
rems . . O
program . . O

bleeding . . B-AdverseReaction
results . . O
from . . O
the . . O
amplify . . O
- . . O
ext . . O
study . . O
are . . O
summarized . . O
in . . O
table . . O
7 . . O
. . . O

cardiovascular . . O
- . . O
angina . . B-AdverseReaction
, . . O
unstable . . B-AdverseReaction
angina . . I-AdverseReaction
, . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
, . . O
palpitations . . B-AdverseReaction

6 . . O
adverse . . O
reactions . . O

for . . O
the . . O
100 . . O
mg . . O
dose . . O
of . . O
pristiq . . O
the . . O
discontinuation . . O
rate . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
was . . O
8.7% . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

* . . O
new . . O
or . . O
worsening . . B-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
liver . . B-AdverseReaction
injury . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
pulmonary . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
hypokalemia . . B-AdverseReaction
and . . O
hypomagnesemia . . B-AdverseReaction
with . . O
potassium . . O
- . . O
depleting . . O
diuretics . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
and . . O
asthenia . . B-AdverseReaction
( . . O
6 . . O
) . . O

discontinue . . O
tivicay . . O
and . . O
other . . O
suspect . . O
agents . . O
immediately . . O
if . . O
signs . . O
or . . O
symptoms . . O
of . . O
hypersensitivity . . O
reactions . . O
develop . . O
( . . O
including . . O
, . . O
but . . O
not . . O
limited . . O
to . . O
, . . O
severe . . O
rash . . O
or . . O
rash . . O
accompanied . . O
by . . O
fever . . O
, . . O
general . . O
malaise . . O
, . . O
fatigue . . O
, . . O
muscle . . O
or . . O
joint . . O
aches . . O
, . . O
blisters . . O
or . . O
peeling . . O
of . . O
the . . O
skin . . O
, . . O
oral . . O
blisters . . O
or . . O
lesions . . O
, . . O
conjunctivitis . . O
, . . O
facial . . O
edema . . O
, . . O
hepatitis . . O
, . . O
eosinophilia . . O
, . . O
angioedema . . O
, . . O
difficulty . . O
breathing . . O
) . . O
. . . O

if . . O
grade . . O
3 . . O
or . . O
4 . . O
neutropenia . . O
develops . . O
, . . O
consider . . O
dose . . O
delays . . O
, . . O
reductions . . O
, . . O
discontinuation . . O
, . . O
or . . O
g . . O
- . . O
csf . . O
prophylaxis . . O
with . . O
subsequent . . O
adcetris . . O
doses . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

( . . O
5.13 . . O
) . . O
* . . O
potential . . B-Factor
for . . O
cognitive . . O
and . . O
motor . . B-AdverseReaction
impairment . . I-AdverseReaction
: . . O
use . . O
caution . . O
when . . O
operating . . O
machinery . . O
. . . O

infections . . B-AdverseReaction
leading . . O
to . . O
discontinuation . . O
of . . O
treatment . . O
occurred . . O
in . . O
0.7% . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
and . . O
1.0% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

patients . . O
treated . . O
with . . O
simponi . . O
aria . . O
are . . O
at . . O
increased . . O
risk . . B-Factor
for . . O
developing . . O
serious . . B-Severity
infections . . B-AdverseReaction
that . . O
may . . B-Factor
lead . . O
to . . O
hospitalization . . O
or . . O
death . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

information . . O
on . . O
the . . O
consequences . . O
, . . O
reversibility . . O
, . . O
time . . O
to . . O
onset . . O
, . . O
and . . O
pathophysiology . . O
of . . O
the . . O
skin . . B-AdverseReaction
abnormalities . . I-AdverseReaction
remains . . O
incomplete . . O
. . . O

lab . . O
- . . O
0583-1.0 . . O

5.3 . . O
nutritional . . O
management . . O

if . . O
such . . O
effects . . O
occur . . O
, . . O
breo . . O
ellipta . . O
may . . O
need . . O
to . . O
be . . O
discontinued . . O
. . . O

if . . O
hypersensitivity . . O
reactions . . O
occur . . O
, . . O
discontinue . . O
use . . O
of . . O
farxiga . . O
; . . O
treat . . O
per . . O
standard . . O
of . . O
care . . O
and . . O
monitor . . O
until . . O
signs . . O
and . . O
symptoms . . O
resolve . . O
. . . O

* . . O
for . . O
patients . . O
at . . O
highest . . O
risk . . O
for . . O
nsf . . O
, . . O
do . . O
not . . O
exceed . . O
the . . O
recommended . . O
gadavist . . O
dose . . O
and . . O
allow . . O
a . . O
sufficient . . O
period . . O
of . . O
time . . O
for . . O
elimination . . O
of . . O
the . . O
drug . . O
from . . O
the . . O
body . . O
prior . . O
to . . O
any . . O
re . . O
- . . O
administration . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

as . . O
in . . O
controlled . . O
clinical . . O
trials . . O
, . . O
a . . O
dose . . O
- . . O
dependent . . O
increase . . O
in . . O
the . . O
incidence . . O
of . . O
seizures . . B-AdverseReaction
has . . O
been . . O
observed . . O
in . . O
open . . O
- . . O
label . . O
clinical . . O
trials . . O
with . . O
ampyra . . O
in . . O
patients . . O
with . . O
ms . . O
as . . O
follows . . O
: . . O
ampyra . . O
10 . . O
mg . . O
twice . . O
daily . . O
0.41 . . O
per . . O
100 . . O
person . . O
- . . O
years . . O
( . . O
95% . . O
confidence . . O
interval . . O
0.13-0.96 . . O
) . . O
; . . O
dalfampridine . . O
15 . . O
mg . . O
twice . . O
daily . . O
1.7 . . O
per . . O
100 . . O
person . . O
- . . O
years . . O
( . . O
95% . . O
confidence . . O
interval . . O
0.21-6.28 . . O
) . . O
. . . O

( . . O
6.5 . . O
) . . O

treatment . . O
of . . O
latent . . O
tuberculosis . . O
infection . . O
prior . . O
to . . O
therapy . . O
with . . O
tnf . . O
- . . O
blockers . . O
has . . O
been . . O
shown . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
tuberculosis . . O
reactivation . . O
during . . O
therapy . . O
. . . O

onj . . B-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
denosumab . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

patients . . O
who . . O
have . . O
experienced . . O
anaphylaxis . . O
or . . O
hypersensitivity . . O
reactions . . O
should . . O
be . . O
treated . . O
with . . O
caution . . O
when . . O
they . . O
are . . O
re . . O
- . . O
administered . . O
alglucosidase . . O
alfa . . O
. . . O

patients . . O
in . . O
sjia . . O
study . . O
1 . . O
received . . O
a . . O
single . . O
dose . . O
of . . O
ilaris . . O
4 . . O
mg . . O
/ . . O
kg . . O
( . . O
n . . O
= . . O
43 . . O
) . . O
or . . O
placebo . . O
( . . O
n . . O
= . . O
41 . . O
) . . O
via . . O
subcutaneous . . O
injection . . O
and . . O
were . . O
assessed . . O
at . . O
day . . O
15 . . O
for . . O
the . . O
efficacy . . O
endpoints . . O
and . . O
had . . O
a . . O
safety . . O
analysis . . O
up . . O
to . . O
day . . O
29 . . O
. . . O

* . . O
pancreatitis . . B-AdverseReaction
: . . O
has . . O
been . . O
reported . . O
in . . O
clinical . . O
trials . . O
. . . O

temporarily . . O
suspend . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
permanently . . O
discontinue . . O
xalkori . . O
. . . O

osteonecrosis . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
jaw . . I-AdverseReaction
onj . . B-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
the . . O
osteoporosis . . O
clinical . . O
trial . . O
program . . O
in . . O
patients . . O
treated . . O
with . . O
prolia . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

in . . O
short . . O
- . . O
term . . O
, . . O
fixed . . O
- . . O
dose . . O
, . . O
placebo . . O
- . . O
controlled . . O
schizophrenia . . O
adult . . O
trials . . O
, . . O
somnolence . . B-AdverseReaction
was . . O
reported . . O
in . . O
15% . . O
( . . O
41 . . O
/ . . O
274 . . O
) . . O
of . . O
patients . . O
on . . O
saphris . . O
5 . . O
mg . . O
twice . . O
daily . . O
and . . O
in . . O
13% . . O
( . . O
26 . . O
/ . . O
208 . . O
) . . O
of . . O
patients . . O
on . . O
saphris . . O
10 . . O
mg . . O
twice . . O
daily . . O
compared . . O
to . . O
7% . . O
( . . O
26 . . O
/ . . O
378 . . O
) . . O
of . . O
placebo . . O
patients . . O
. . . O

local . . B-AdverseReaction
skin . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
erythema . . O
, . . O
flaking . . O
/ . . O
scaling . . O
, . . O
crusting . . O
, . . O
swelling . . O
, . . O
vesiculation . . O
/ . . O
pustulation . . O
, . . O
and . . O
erosion . . O
/ . . O
ulceration . . O
were . . O
assessed . . O
within . . O
the . . O
selected . . O
treatment . . O
area . . O
and . . O
graded . . O
by . . O
the . . O
investigator . . O
on . . O
a . . O
scale . . O
of . . O
0 . . O
to . . O
4 . . O
. . . O

in . . O
the . . O
3 . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
199 . . O
of . . O
813 . . O
patients . . O
( . . O
25% . . O
) . . O
receiving . . O
potiga . . O
and . . O
45 . . O
of . . O
427 . . O
patients . . O
( . . O
11% . . O
) . . O
receiving . . O
placebo . . O
discontinued . . O
treatment . . O
because . . O
of . . O
adverse . . O
reactions . . O
. . . O

5.4 . . O
tumor . . O
lysis . . O
syndrome . . O

there . . O
is . . O
evidence . . O
to . . O
suggest . . O
that . . O
some . . O
patients . . O
who . . O
develop . . O
high . . O
and . . O
sustained . . O
igg . . O
antibody . . O
titers . . O
may . . B-Factor
experience . . O
reduced . . B-AdverseReaction
clinical . . I-AdverseReaction
efficacy . . I-AdverseReaction
to . . O
alglucosidase . . O
alfa . . O
treatment . . O
, . . O
such . . O
as . . O
loss . . B-AdverseReaction
of . . I-AdverseReaction
motor . . I-AdverseReaction
function . . I-AdverseReaction
, . . O
ventilator . . O
dependence . . O
, . . O
or . . O
death . . B-AdverseReaction
. . . O

strictly . . O
avoid . . O
intramuscular . . O
administration . . O
of . . O
eovist . . O
because . . O
it . . O
may . . O
cause . . O
myocyte . . O
necrosis . . O
and . . O
inflammation . . O
[ . . O
see . . O
nonclinical . . O
toxicology . . O
( . . O
13.2 . . O
) . . O
] . . O
. . . O

treatment . . O
- . . O
emergent . . O
adrs . . O
of . . O
moderate . . O
to . . O
severe . . O
intensity . . O
observed . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
subjects . . O
in . . O
either . . O
treatment . . O
arm . . O
in . . O
spring . . O
- . . O
2 . . O
and . . O
single . . O
trials . . O
are . . O
provided . . O
in . . O
table . . O
2 . . O
. . . O

a . . O
treatment . . O
- . . O
related . . O
death . . B-AdverseReaction
from . . O
ventricular . . B-AdverseReaction
fibrillation . . I-AdverseReaction
was . . O
reported . . O
in . . O
another . . O
monotherapy . . O
clinical . . O
trial . . O
with . . O
beleodaq . . O
. . . O

all . . O
reported . . O
reactions . . O
are . . O
included . . O
except . . O
those . . O
already . . O
listed . . O
in . . O
table . . O
7 . . O
, . . O
or . . O
other . . O
parts . . O
of . . O
the . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
section . . O
, . . O
those . . O
considered . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
( . . O
5 . . O
) . . O
, . . O
those . . O
reaction . . O
terms . . O
which . . O
were . . O
so . . O
general . . O
as . . O
to . . O
be . . O
uninformative . . O
, . . O
reactions . . O
reported . . O
in . . O
fewer . . O
than . . O
3 . . O
patients . . O
and . . O
which . . O
were . . O
neither . . O
serious . . O
nor . . O
life . . O
- . . O
threatening . . O
, . . O
reactions . . O
that . . O
are . . O
otherwise . . O
common . . O
as . . O
background . . O
reactions . . O
, . . O
and . . O
reactions . . O
considered . . O
unlikely . . O
to . . O
be . . O
drug . . O
related . . O
. . . O

5.6 . . O
discontinuation . . O
of . . O
horizant . . O

monitor . . O
weight . . O
. . . O

in . . O
trial . . O
2 . . O
, . . O
cardiomyopathy . . B-AdverseReaction
occurred . . O
in . . O
9% . . O
( . . O
5 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
and . . O
in . . O
none . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

the . . O
mean . . O
age . . O
was . . O
39 . . O
years . . O
; . . O
adolescents . . O
( . . O
aged . . O
12 . . O
to . . O
17 . . O
years . . O
) . . O
made . . O
up . . O
16% . . O
of . . O
the . . O
population . . O
. . . O

no . . O
apparent . . O
correlation . . O
of . . O
antibody . . O
development . . O
to . . O
clinical . . O
response . . O
or . . O
adverse . . O
events . . O
was . . O
observed . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
pneumonitis . . B-AdverseReaction
can . . O
occur . . O
in . . O
zydelig . . O
- . . O
treated . . O
patients . . O
. . . O

atypical . . B-DrugClass
antipsychotic . . I-DrugClass
drugs . . I-DrugClass
have . . O
been . . O
associated . . O
with . . O
metabolic . . B-AdverseReaction
changes . . I-AdverseReaction
that . . O
may . . O
increase . . O
cardiovascular . . O
/ . . O
cerebrovascular . . O
risk . . O
. . . O

in . . O
placebo . . O
- . . O
controlled . . O
and . . O
open . . O
- . . O
label . . O
rheumatoid . . O
arthritis . . O
studies . . O
, . . O
cases . . O
of . . O
new . . O
or . . O
worsening . . B-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
have . . O
been . . O
reported . . O
for . . O
cimzia . . O
- . . O
treated . . O
patients . . O
. . . O

seven . . O
( . . O
54% . . O
) . . O
yervoy . . O
- . . O
treated . . O
patients . . O
with . . O
severe . . B-Severity
dermatitis . . B-AdverseReaction
received . . O
high . . O
- . . O
dose . . O
corticosteroids . . O
( . . O
median . . O
dose . . O
60 . . O
mg . . O
prednisone . . O
/ . . O
day . . O
or . . O
equivalent . . O
) . . O
for . . O
up . . O
to . . O
14.9 . . O
weeks . . O
followed . . O
by . . O
corticosteroid . . O
taper . . O
. . . O

after . . O
cross . . O
- . . O
over . . O
to . . O
open . . O
- . . O
label . . O
afinitor . . O
, . . O
there . . O
were . . O
three . . O
additional . . O
deaths . . B-AdverseReaction
, . . O
one . . O
due . . O
to . . O
hypoglycemia . . B-AdverseReaction
and . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
in . . O
a . . O
patient . . O
with . . O
insulinoma . . O
, . . O
one . . O
due . . O
to . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
with . . O
congestive . . B-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
and . . O
the . . O
other . . O
due . . O
to . . O
sudden . . B-AdverseReaction
death . . I-AdverseReaction
. . . O

cases . . O
of . . O
pulmonary . . B-AdverseReaction
toxicity . . I-AdverseReaction
have . . O
also . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
adcetris . . O
. . . O

( . . O
8.4 . . O
) . . O

imaging . . O
appears . . O
to . . O
overestimate . . O
the . . O
incidence . . O
of . . O
clinical . . O
pneumonitis . . O
. . . O

5.6 . . O
qt . . O
interval . . O
effect . . O

nervous . . O
system . . O
disorders . . O
: . . O
ataxia . . B-AdverseReaction
, . . O
clonus . . B-AdverseReaction
, . . O
fine . . B-AdverseReaction
motor . . I-AdverseReaction
delay . . I-AdverseReaction
, . . O
hyperreflexia . . B-AdverseReaction
, . . O
hypoesthesia . . B-AdverseReaction
, . . O
nystagmus . . B-AdverseReaction
, . . O
tremor . . B-AdverseReaction

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
rhabdomyolysis . . B-AdverseReaction
. . . O

clinically . . O
notable . . O
decreases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
potassium . . I-AdverseReaction
or . . O
changes . . B-AdverseReaction
in . . I-AdverseReaction
blood . . I-AdverseReaction
glucose . . I-AdverseReaction
were . . O
infrequent . . O
during . . O
clinical . . O
studies . . O
with . . O
long . . O
- . . O
term . . O
administration . . O
of . . O
arcapta . . O
neohaler . . O
with . . O
the . . O
rates . . O
similar . . O
to . . O
those . . O
for . . O
placebo . . O
controls . . O
. . . O

when . . O
such . . O
an . . O
infection . . O
develops . . O
, . . O
it . . O
should . . O
be . . O
treated . . O
with . . O
appropriate . . O
local . . O
or . . O
systemic . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
oral . . O
) . . O
antifungal . . O
therapy . . O
while . . O
treatment . . O
with . . O
breo . . O
ellipta . . O
continues . . O
, . . O
but . . O
at . . O
times . . O
therapy . . O
with . . O
breo . . O
ellipta . . O
may . . O
need . . O
to . . O
be . . O
interrupted . . O
. . . O

table . . O
1 . . O
. . . O

placebo . . O
plus . . O
prednisone . . O
5 . . O
mg . . O
twice . . O
daily . . O
was . . O
given . . O
to . . O
control . . O
patients . . O
. . . O

approximately . . O
one . . O
third . . O
of . . O
the . . O
patients . . O
who . . O
had . . O
eye . . O
examinations . . O
performed . . O
after . . O
approximately . . O
4 . . O
years . . O
of . . O
treatment . . O
were . . O
found . . O
to . . O
have . . O
retinal . . B-AdverseReaction
pigmentary . . I-AdverseReaction
abnormalities . . I-AdverseReaction
. . . O

patients . . O
, . . O
their . . O
caregivers . . O
, . . O
and . . O
families . . O
should . . O
be . . O
informed . . O
that . . O
aeds . . O
increase . . O
the . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
and . . O
should . . O
be . . O
advised . . O
of . . O
the . . O
need . . O
to . . O
be . . O
alert . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
depression . . O
; . . O
any . . O
unusual . . O
changes . . O
in . . O
mood . . O
or . . O
behavior . . O
; . . O
or . . O
the . . O
emergence . . O
of . . O
suicidal . . O
thoughts . . O
, . . O
behavior . . O
, . . O
or . . O
thoughts . . O
about . . O
self . . O
- . . O
harm . . O
. . . O

* . . O
cytokine . . O
release . . O
syndrome . . O
( . . O
crs . . O
) . . O
, . . O
which . . O
may . . B-Factor
be . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
or . . O
fatal . . B-AdverseReaction
, . . O
occurred . . O
in . . O
patients . . O
receiving . . O
blincyto . . O
. . . O

avoid . . O
eye . . O
exposure . . O
. . . O

of . . O
the . . O
34 . . O
patients . . O
with . . O
grade . . B-Severity
3-5 . . I-Severity
enterocolitis . . B-AdverseReaction
, . . O
74% . . O
experienced . . O
complete . . O
resolution . . O
, . . O
3% . . O
experienced . . O
improvement . . O
to . . O
grade . . O
2 . . O
severity . . O
, . . O
and . . O
24% . . O
did . . O
not . . O
improve . . O
. . . O

should . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
emerge . . O
during . . O
treatment . . O
, . . O
the . . O
prescriber . . O
needs . . O
to . . O
consider . . O
whether . . O
the . . O
emergence . . O
of . . O
these . . O
symptoms . . O
in . . O
any . . O
given . . O
patient . . O
may . . O
be . . O
related . . O
to . . O
the . . O
illness . . O
being . . O
treated . . O
. . . O

mean . . O
values . . O
of . . O
total . . O
cholesterol . . O
, . . O
hdl . . O
, . . O
ldl . . O
, . . O
and . . O
triglycerides . . O
were . . O
reported . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
. . . O

6.2 . . O
post . . O
marketing . . O
experience . . O

bleeding . . O
in . . O
patients . . O
with . . O
nonvalvular . . O
atrial . . O
fibrillation . . O
in . . O
aristotle . . O
and . . O
averroes . . O

6 . . O
adverse . . O
reactions . . O

monitor . . O
signs . . O
and . . O
symptoms . . O
. . . O

diagnostic . . O
studies . . O
including . . O
a . . O
direct . . O
coombs' . . O
test . . O
, . . O
should . . O
be . . O
performed . . O
. . . O

contraception . . O
and . . O
heavy . . O
menstrual . . O
bleeding . . O
studies . . O

5.2 . . O
adrenocortical . . O
insufficiency . . O

october . . O
2013 . . O

a . . O
total . . O
of . . O
169 . . O
patients . . O
in . . O
the . . O
chemotherapy . . O
arm . . O
received . . O
pemetrexed . . O
500 . . O
mg . . O
/ . . O
m . . O
2 . . O
in . . O
combination . . O
with . . O
cisplatin . . O
75 . . O
mg . . O
/ . . O
m . . O
2 . . O
( . . O
n . . O
= . . O
91 . . O
) . . O
or . . O
carboplatin . . O
at . . O
a . . O
dose . . O
calculated . . O
to . . O
produce . . O
an . . O
area . . O
under . . O
the . . O
concentration . . O
- . . O
time . . O
curve . . O
( . . O
auc . . O
) . . O
of . . O
5 . . O
or . . O
6 . . O
mg . . O
? . . O
min . . O
/ . . O
ml . . O
( . . O
n . . O
= . . O
78 . . O
) . . O
. . . O

table . . O
1 . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
1% . . O
) . . O
in . . O
wet . . O
amd . . O
studies . . O
adverse . . O
reactions . . O
eylea . . O
( . . O
n . . O
= . . O
1824 . . O
) . . O
active . . O
control . . O
( . . O
ranibizumab . . O
) . . O
( . . O
n . . O
= . . O
595 . . O
) . . O
conjunctival . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
25% . . O
28% . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
9% . . O
9% . . O
cataract . . B-AdverseReaction
7% . . O
7% . . O
vitreous . . B-AdverseReaction
detachment . . I-AdverseReaction
6% . . O
6% . . O
vitreous . . B-AdverseReaction
floaters . . I-AdverseReaction
6% . . O
7% . . O
intraocular . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
5% . . O
7% . . O
ocular . . B-AdverseReaction
hyperemia . . I-AdverseReaction
4% . . O
8% . . O
corneal . . B-AdverseReaction
epithelium . . I-AdverseReaction
defect . . I-AdverseReaction
4% . . O
5% . . O
detachment . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
retinal . . I-AdverseReaction
pigment . . I-AdverseReaction
epithelium . . I-AdverseReaction
3% . . O
3% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
3% . . O
3% . . O
foreign . . B-AdverseReaction
body . . I-AdverseReaction
sensation . . I-AdverseReaction
in . . I-AdverseReaction
eyes . . I-AdverseReaction
3% . . O
4% . . O
lacrimation . . B-AdverseReaction
increased . . I-AdverseReaction
3% . . O
1% . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
2% . . O
2% . . O
intraocular . . B-AdverseReaction
inflammation . . I-AdverseReaction
2% . . O
3% . . O
retinal . . B-AdverseReaction
pigment . . I-AdverseReaction
epithelium . . I-AdverseReaction
tear . . I-AdverseReaction
2% . . O
1% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
1% . . O
2% . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
1% . . O
2% . . O
corneal . . B-AdverseReaction
edema . . I-AdverseReaction
1% . . O
1% . . O
less . . O
common . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
in . . O
< . . O
1% . . O
of . . O
the . . O
patients . . O
treated . . O
with . . O
eylea . . O
were . . O
hypersensitivity . . B-AdverseReaction
, . . O
retinal . . B-AdverseReaction
detachment . . I-AdverseReaction
, . . O
retinal . . B-AdverseReaction
tear . . I-AdverseReaction
, . . O
and . . O
endophthalmitis . . B-AdverseReaction
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
anemia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
lymphadenopathy . . B-AdverseReaction
, . . O
pancytopenia . . B-AdverseReaction
, . . O
and . . O
thrombophilia . . B-AdverseReaction
. . . O

( . . O
5.3 . . O
) . . O

advise . . O
patients . . O
to . . O
refrain . . O
from . . O
driving . . O
and . . O
engaging . . O
in . . O
hazardous . . O
occupations . . O
or . . O
activities . . O
such . . O
as . . O
operating . . O
heavy . . O
or . . O
potentially . . O
dangerous . . O
machinery . . O
while . . O
blincyto . . O
is . . O
being . . O
administered . . O
. . . O

* . . O
ferriprox . . O
can . . B-Factor
cause . . O
agranulocytosis . . B-AdverseReaction
that . . O
can . . B-Factor
lead . . O
to . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
death . . B-AdverseReaction
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

table . . O
5 . . O
: . . O
change . . O
in . . O
body . . O
weight . . O
in . . O
adult . . O
patients . . O
from . . O
baseline . . O
n . . O
* . . O
= . . O
number . . O
of . . O
subjects . . O
who . . O
had . . O
assessments . . O
at . . O
both . . O
baseline . . O
and . . O
endpoint . . O
. . . O

treatment . . O
with . . O
dysport . . O
( . . O
r . . O
) . . O
and . . O
other . . O
botulinum . . O
toxin . . O
products . . O
can . . B-Factor
result . . O
in . . O
swallowing . . O
or . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
. . . O

drugs . . O
that . . O
prolong . . O
the . . O
qt . . O
interval . . O
, . . O
including . . O
antimalarials . . O
such . . O
as . . O
quinine . . O
and . . O
quinidine . . O
, . . O
should . . O
be . . O
used . . O
cautiously . . O
following . . O
coartem . . O
tablets . . O
, . . O
due . . O
to . . O
the . . O
long . . O
elimination . . O
half . . O
- . . O
life . . O
of . . O
lumefantrine . . O
( . . O
3 . . O
to . . O
6 . . O
days . . O
) . . O
and . . O
the . . O
potential . . O
for . . O
additive . . O
effects . . O
on . . O
the . . O
qt . . O
interval . . O
; . . O
ecg . . O
monitoring . . O
is . . O
advised . . O
if . . O
use . . O
of . . O
drugs . . O
that . . O
prolong . . O
the . . O
qt . . O
interval . . O
is . . O
medically . . O
required . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
, . . O
drug . . O
interactions . . O
( . . O
7.7 . . O
) . . O
, . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

adverse . . O
reactions . . O

unless . . O
an . . O
alternate . . O
etiology . . O
has . . O
been . . O
identified . . O
, . . O
signs . . O
or . . O
symptoms . . O
of . . O
endocrinopathies . . O
should . . O
be . . O
considered . . O
immune . . O
- . . O
mediated . . O
. . . O

the . . O
use . . O
of . . O
stendra . . O
offers . . O
no . . O
protection . . O
against . . O
sexually . . O
transmitted . . O
diseases . . O
. . . O

ensure . . O
catheter . . O
and . . O
venous . . O
patency . . O
before . . O
the . . O
injection . . O
of . . O
gadavist . . O
. . . O

these . . O
may . . B-Factor
include . . O
asthenia . . B-AdverseReaction
, . . O
generalized . . B-AdverseReaction
muscle . . I-AdverseReaction
weakness . . I-AdverseReaction
, . . O
diplopia . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
ptosis . . B-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
, . . O
dysphonia . . B-AdverseReaction
, . . O
dysarthria . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
incontinence . . I-AdverseReaction
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
. . . O

gadavist . . O
mri . . O
of . . O
the . . O
breast . . O
overestimated . . O
the . . O
histologically . . O
confirmed . . O
extent . . O
of . . O
malignancy . . O
in . . O
the . . O
diseased . . O
breast . . O
in . . O
up . . O
to . . O
50% . . O
of . . O
the . . O
patients . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
] . . O
. . . O

( . . O
5.1 . . O
) . . O

the . . O
mechanism . . O
and . . O
long . . O
- . . O
term . . O
consequences . . O
of . . O
these . . O
events . . O
are . . O
currently . . O
unknown . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

in . . O
a . . O
clinical . . O
trial . . O
of . . O
over . . O
7800 . . O
women . . O
with . . O
postmenopausal . . O
osteoporosis . . O
, . . O
serious . . B-Severity
infections . . B-AdverseReaction
leading . . O
to . . O
hospitalization . . O
were . . O
reported . . O
more . . O
frequently . . O
in . . O
the . . O
prolia . . O
group . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

higher . . O
proportions . . O
of . . O
patients . . O
with . . O
marked . . O
laboratory . . O
abnormalities . . O
of . . O
hyperphosphatemia . . B-AdverseReaction
( . . O
> . . O
= . . O
5.6 . . O
mg . . O
/ . . O
dl . . O
for . . O
age . . O
17-65 . . O
years . . O
or . . O
> . . O
= . . O
5.1 . . O
mg . . O
/ . . O
dl . . O
for . . O
age . . O
> . . O
= . . O
66 . . O
years . . O
) . . O
were . . O
reported . . O
on . . O
farxiga . . O
at . . O
week . . O
24 . . O
( . . O
0.9% . . O
versus . . O
1.7% . . O
for . . O
placebo . . O
and . . O
farxiga . . O
10 . . O
mg . . O
, . . O
respectively . . O
) . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

no . . O
association . . O
between . . O
anti . . O
- . . O
icatibant . . O
antibodies . . O
and . . O
efficacy . . O
was . . O
observed . . O
. . . O

5.3 . . O
interstitial . . O
lung . . O
disease . . O
( . . O
ild . . O
) . . O

mean . . O
percent . . O
changes . . O
from . . O
baseline . . O
at . . O
week . . O
24 . . O
, . . O
were . . O
0.0% . . O
versus . . O
2.5% . . O
for . . O
total . . O
cholesterol . . O
and . . O
- . . O
1.0% . . O
versus . . O
2.9% . . O
for . . O
ldl . . O
cholesterol . . O
, . . O
in . . O
the . . O
placebo . . O
and . . O
farxiga . . O
10 . . O
mg . . O
groups . . O
, . . O
respectively . . O
. . . O

study . . O
1 . . O
, . . O
conducted . . O
by . . O
the . . O
national . . O
cancer . . O
institute . . O
( . . O
nci . . O
) . . O
, . . O
enrolled . . O
184 . . O
patients . . O
; . . O
safety . . O
information . . O
is . . O
available . . O
for . . O
149 . . O
patients . . O
. . . O

use . . O
of . . O
simponi . . O
aria . . O
in . . O
patients . . O
under . . O
18 . . O
years . . O
of . . O
age . . O
has . . O
not . . O
been . . O
established . . O
. . . O

twenty . . O
percent . . O
of . . O
the . . O
patients . . O
experienced . . O
an . . O
increase . . O
in . . O
either . . O
alt . . O
or . . O
ast . . O
. . . O

* . . O
hepatic . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.5 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

these . . O
grade . . B-Severity
iii . . I-Severity
rejections . . O
occurred . . O
in . . O
patients . . O
with . . O
4 . . O
to . . O
6 . . O
hla . . O
mismatches . . O
. . . O

deaths . . B-AdverseReaction
during . . O
double . . O
- . . O
blind . . O
treatment . . O
where . . O
an . . O
adverse . . O
event . . O
was . . O
the . . O
primary . . O
cause . . O
occurred . . O
in . . O
seven . . O
patients . . O
on . . O
afinitor . . O
and . . O
one . . O
patient . . O
on . . O
placebo . . O
. . . O

5.8 . . O
hypercorticism . . O
and . . O
adrenal . . O
suppression . . O

in . . O
some . . O
women . . O
, . . O
the . . O
symptoms . . O
are . . O
mild . . O
, . . O
and . . O
they . . O
will . . O
not . . O
need . . O
to . . O
take . . O
medicines . . O
. . . O

table . . O
8 . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
liver . . B-AdverseReaction
test . . I-AdverseReaction
abnormalities . . I-AdverseReaction
of . . O
any . . O
grade . . O
occurred . . O
in . . O
17.5% . . O
of . . O
the . . O
patients . . O
treated . . O
with . . O
gilotrif . . O
. . . O

as . . O
with . . O
other . . O
drugs . . O
that . . O
antagonize . . O
dopamine . . O
d2 . . O
receptors . . O
, . . O
fanapt . . O
elevates . . B-AdverseReaction
prolactin . . I-AdverseReaction
levels . . I-AdverseReaction
. . . O

risk . . O
of . . O
infections . . O

an . . O
earlier . . O
onset . . O
cannot . . O
be . . O
ruled . . O
out . . O
, . . O
and . . O
it . . O
is . . O
possible . . O
that . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
were . . O
present . . O
earlier . . O
in . . O
the . . O
course . . O
of . . O
exposure . . O
to . . O
potiga . . O
. . . O

5.7 . . O
suicidal . . O
behavior . . O
and . . O
ideation . . O

some . . O
of . . O
these . . O
reactions . . O
occurred . . O
after . . O
the . . O
first . . O
administration . . O
of . . O
golimumab . . O
. . . O

since . . O
onfi . . O
has . . O
a . . O
central . . O
nervous . . O
system . . O
( . . O
cns . . O
) . . O
depressant . . O
effect . . O
, . . O
patients . . O
or . . O
their . . O
caregivers . . O
should . . O
be . . O
cautioned . . O
against . . O
simultaneous . . O
use . . O
with . . O
other . . O
cns . . O
depressant . . O
drugs . . O
or . . O
alcohol . . O
, . . O
and . . O
cautioned . . O
that . . O
the . . O
effects . . O
of . . O
other . . O
cns . . O
depressant . . O
drugs . . O
or . . O
alcohol . . O
may . . O
be . . O
potentiated . . O
. . . O

three . . O
active . . O
- . . O
controlled . . O
trials . . O
of . . O
52 . . O
weeks . . O
in . . O
duration . . O
were . . O
conducted . . O
in . . O
patients . . O
treated . . O
with . . O
pioglitazone . . O
and . . O
metformin . . O
, . . O
in . . O
combination . . O
with . . O
metformin . . O
and . . O
as . . O
monotherapy . . O
compared . . O
to . . O
glipizide . . O
. . . O

some . . O
patients . . O
with . . O
dupuytren's . . O
contracture . . O
developed . . O
ige . . O
- . . O
anti . . O
- . . O
drug . . O
antibodies . . O
in . . O
greater . . O
proportions . . O
and . . O
higher . . O
titers . . O
with . . O
successive . . O
xiaflex . . O
injections . . O
. . . O

braf . . O
v600e . . O
unresectable . . O
or . . O
metastatic . . O
melanoma . . O
: . . O

table . . O
7 . . O
: . . O
bleeding . . B-AdverseReaction
results . . O
in . . O
the . . O
amplify . . O
- . . O
ext . . O
study . . O
eliquis . . O
2.5 . . O
mg . . O
bidn . . O
= . . O
840n . . O
( . . O
% . . O
) . . O
eliquis . . O
5 . . O
mg . . O
bidn . . O
= . . O
811n . . O
( . . O
% . . O
) . . O
placebon . . O
= . . O
826n . . O
( . . O
% . . O
) . . O
* . . O
crnm . . B-AdverseReaction
= . . O
clinically . . B-AdverseReaction
relevant . . I-AdverseReaction
nonmajor . . I-AdverseReaction
bleeding . . I-AdverseReaction
. . . O
events . . O
associated . . O
with . . O
each . . O
endpoint . . O
were . . O
counted . . O
once . . O
per . . O
subject . . O
, . . O
but . . O
subjects . . O
may . . O
have . . O
contributed . . O
events . . O
to . . O
multiple . . O
endpoints . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
urinary . . I-AdverseReaction
retention . . I-AdverseReaction
may . . B-Factor
occur . . O
. . . O

table . . O
4 . . O
: . . O
laboratory . . O
abnormalities . . O
in . . O
> . . O
15% . . O
of . . O
patients . . O
in . . O
the . . O
zytiga . . O
arm . . O
of . . O
study . . O
2 . . O
abiraterone . . O
( . . O
n . . O
= . . O
542 . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
540 . . O
) . . O
laboratory . . O
abnormality . . O
grade . . O
1-4% . . O
grade . . O
3-4% . . O
grade . . O
1-4% . . O
grade . . O
3-4% . . O
hematology . . O
lymphopenia . . B-AdverseReaction
38.2 . . O
8.7 . . O
31.7 . . O
7.4 . . O
chemistry . . O
hyperglycemia . . B-AdverseReaction
56.6 . . O
6.5 . . O
50.9 . . O
5.2 . . O
high . . B-AdverseReaction
alt . . I-AdverseReaction
41.9 . . O
6.1 . . O
29.1 . . O
0.7 . . O
high . . B-AdverseReaction
ast . . I-AdverseReaction
37.3 . . O
3.1 . . O
28.7 . . O
1.1 . . O
hypernatremia . . B-AdverseReaction
32.8 . . O
0.4 . . O
25.0 . . O
0.2 . . O
hypokalemia . . B-AdverseReaction
17.2 . . O
2.8 . . O
10.2 . . O
1.7 . . O
cardiovascular . . O
adverse . . O
reactions . . O
: . . O

6.1 . . O
clinical . . O
studies . . O

if . . O
formation . . O
of . . O
anti . . O
- . . O
blinatumomab . . O
antibodies . . O
with . . O
a . . O
clinically . . O
significant . . O
effect . . O
is . . O
suspected . . O
, . . O
contact . . O
amgen . . O
at . . O
1-800-77 . . O
- . . O
amgen . . O
( . . O
1-800-772-6436 . . O
) . . O
to . . O
discuss . . O
antibody . . O
testing . . O
. . . O

in . . O
the . . O
postmarketing . . O
setting . . O
, . . O
third . . B-AdverseReaction
- . . I-AdverseReaction
degree . . I-AdverseReaction
av . . I-AdverseReaction
block . . I-AdverseReaction
and . . O
av . . B-AdverseReaction
block . . I-AdverseReaction
with . . O
junctional . . B-AdverseReaction
escape . . I-AdverseReaction
have . . O
been . . O
observed . . O
during . . O
the . . O
first . . O
- . . O
dose . . O
6 . . O
- . . O
hour . . O
observation . . O
period . . O
with . . O
gilenya . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
- . . O
urinary . . B-AdverseReaction
retention . . I-AdverseReaction
. . . O

blood . . O
pressure . . O
should . . O
be . . O
monitored . . O
during . . O
treatment . . O
with . . O
gilenya . . O
. . . O

overall . . O
, . . O
the . . O
mean . . O
age . . O
of . . O
patients . . O
in . . O
the . . O
phn . . O
studies . . O
ranged . . O
from . . O
61 . . O
to . . O
64 . . O
years . . O
of . . O
age . . O
across . . O
dose . . O
groups . . O
; . . O
the . . O
majority . . O
of . . O
patients . . O
were . . O
male . . O
( . . O
45% . . O
to . . O
61% . . O
) . . O
and . . O
caucasian . . O
( . . O
80% . . O
to . . O
98% . . O
) . . O
. . . O

the . . O
changes . . O
averaged . . O
less . . O
than . . O
10 . . O
mm . . O
hg . . O
, . . O
although . . O
some . . O
patients . . O
had . . O
greater . . O
increases . . O
and . . O
these . . O
changes . . O
lasted . . O
for . . O
approximately . . O
two . . O
hours . . O
after . . O
patch . . O
removal . . O
. . . O

pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
and . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
have . . O
also . . O
been . . O
reported . . O
in . . O
clinical . . O
trials . . O
( . . O
6.1 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
amgen . . O
inc . . O
. . . O
at . . O
1-800-77 . . O
- . . O
amgen . . O
( . . O
1-800-772-6436 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

grade . . B-Severity
3 . . I-Severity
or . . O
greater . . O
infections . . B-AdverseReaction
occurred . . O
in . . O
14% . . O
to . . O
26% . . O
of . . O
patients . . O
. . . O

all . . O
of . . O
these . . O
patients . . O
who . . O
received . . O
fanapt . . O
were . . O
participating . . O
in . . O
multiple . . O
- . . O
dose . . O
clinical . . O
trials . . O
. . . O

use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
known . . O
cardiovascular . . O
or . . O
cerebrovascular . . O
disease . . O
, . . O
and . . O
in . . O
antipsychotic . . O
- . . O
naive . . O
patients . . O
. . . O

in . . O
trial . . O
1 . . O
, . . O
the . . O
incidence . . O
of . . O
new . . O
primary . . B-AdverseReaction
malignant . . I-AdverseReaction
melanomas . . I-AdverseReaction
was . . O
2% . . O
( . . O
3 . . O
/ . . O
187 . . O
) . . O
for . . O
patients . . O
receiving . . O
tafinlar . . O
while . . O
no . . O
dacarbazine . . O
- . . O
treated . . O
patient . . O
was . . O
diagnosed . . O
with . . O
new . . O
primary . . O
malignant . . O
melanoma . . O
. . . O

patients . . O
should . . O
be . . O
advised . . O
to . . O
elevate . . O
the . . O
head . . O
of . . O
the . . O
bed . . O
when . . O
resting . . O
or . . O
sleeping . . O
. . . O

elderly . . O
patients . . O
and . . O
patients . . O
with . . O
impaired . . O
renal . . O
function . . O
may . . O
be . . O
more . . O
susceptible . . O
to . . O
these . . O
changes . . O
. . . O

the . . O
safety . . O
of . . O
eliquis . . O
has . . O
been . . O
evaluated . . O
in . . O
the . . O
amplify . . O
and . . O
amplify . . O
- . . O
ext . . O
studies . . O
, . . O
including . . O
2676 . . O
patients . . O
exposed . . O
to . . O
eliquis . . O
10 . . O
mg . . O
twice . . O
daily . . O
, . . O
3359 . . O
patients . . O
exposed . . O
to . . O
eliquis . . O
5 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
840 . . O
patients . . O
exposed . . O
to . . O
eliquis . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
. . . O

( . . O
5.6 . . O
) . . O
5.1 . . O
diarrhea . . O

cardiac . . O
disorders . . O
: . . O
tachycardia . . B-AdverseReaction
( . . O
8% . . O
) . . O

additionally . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

* . . O
endophthalmitis . . B-AdverseReaction
and . . O
retinal . . B-AdverseReaction
detachments . . I-AdverseReaction
* . . O
increased . . B-AdverseReaction
intraocular . . I-AdverseReaction
pressure . . I-AdverseReaction
* . . O
thromboembolic . . B-AdverseReaction
events . . I-AdverseReaction
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
reported . . O
in . . O
patients . . O
receiving . . O
eylea . . O
were . . O
conjunctival . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
cataract . . B-AdverseReaction
, . . O
vitreous . . B-AdverseReaction
floaters . . I-AdverseReaction
, . . O
intraocular . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
and . . O
vitreous . . B-AdverseReaction
detachment . . I-AdverseReaction
. . . O

unless . . O
an . . O
alternate . . O
etiology . . O
has . . O
been . . O
identified . . O
, . . O
signs . . O
or . . O
symptoms . . O
of . . O
dermatitis . . O
should . . O
be . . O
considered . . O
immune . . O
- . . O
mediated . . O
. . . O

use . . O
of . . O
nulojix . . O
in . . O
liver . . O
transplant . . O
patients . . O
is . . O
not . . O
recommended . . O
[ . . O
see . . O
boxed . . O
warning . . O
] . . O
. . . O

* . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
: . . O
monitor . . O
renal . . O
function . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
reporting . . O
severe . . O
adverse . . O
gastrointestinal . . O
reactions . . O
( . . O
5.5 . . O
) . . O
. . . O

these . . O
patients . . O
may . . O
be . . O
at . . O
greater . . O
risk . . O
for . . O
cardiac . . O
complications . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8 . . O
) . . O
] . . O
. . . O

serious . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
64 . . O
patients . . O
( . . O
37.2% . . O
) . . O
treated . . O
with . . O
xalkori . . O
and . . O
40 . . O
patients . . O
( . . O
23.4% . . O
) . . O
in . . O
the . . O
chemotherapy . . O
arm . . O
. . . O

table . . O
2 . . O
: . . O
severe . . B-Severity
to . . O
fatal . . B-AdverseReaction
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
in . . O
study . . O
1 . . O
a . . O
including . . O
fatal . . B-AdverseReaction
outcome . . O
. . . O
b . . O
including . . O
intestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
. . . O
c . . O
underlying . . O
etiology . . O
not . . O
established . . O
. . . O

the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
( . . O
incidence . . O
> . . O
= . . O
50% . . O
) . . O
were . . O
hypercholesterolemia . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
aspartate . . I-AdverseReaction
transaminase . . I-AdverseReaction
( . . O
ast . . O
) . . O
, . . O
anemia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
alanine . . I-AdverseReaction
transaminase . . I-AdverseReaction
( . . O
alt . . O
) . . O
, . . O
and . . O
hypertriglyceridemia . . B-AdverseReaction
. . . O

they . . O
may . . O
be . . O
bilateral . . O
and . . O
many . . O
patients . . O
report . . O
prodromal . . O
pain . . O
in . . O
the . . O
affected . . O
area . . O
, . . O
usually . . O
presenting . . O
as . . O
dull . . O
, . . O
aching . . O
thigh . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
weeks . . O
to . . O
months . . O
before . . O
a . . O
complete . . O
fracture . . O
occurs . . O
. . . O

additionally . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

incidence . . O
( . . O
% . . O
) . . O
of . . O
hypoglycemia . . O
in . . O
clinical . . O
trials . . O
of . . O
tanzeum . . O
a . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
that . . O
led . . O
to . . O
dose . . O
reduction . . O
in . . O
these . . O
patients . . O
were . . O
nausea . . B-AdverseReaction
( . . O
1.8% . . O
) . . O
and . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
( . . O
1.8% . . O
) . . O
. . . O

5.8 . . O
qt . . O
interval . . O
prolongation . . O

table . . O
1 . . O
shows . . O
common . . O
adverse . . O
reactions . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
invokana . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

* . . O
effects . . O
on . . O
serum . . O
liver . . O
biochemistries . . O
in . . O
patients . . O
with . . O
hepatitis . . O
b . . O
or . . O
c . . O
co . . O
- . . O
infection . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

e . . O
cases . . O
of . . O
cutaneous . . B-AdverseReaction
squamous . . I-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
were . . O
required . . O
to . . O
be . . O
reported . . O
as . . O
grade . . B-Severity
3 . . I-Severity
per . . O
protocol . . O
. . . O

afinitor . . O
10 . . O
mg . . O
/ . . O
day . . O
n . . O
= . . O
274 . . O
placebo . . O
n . . O
= . . O
137 . . O
all . . O
grades . . O
grade . . O
3 . . O
grade . . O
4 . . O
all . . O
grades . . O
grade . . O
3 . . O
grade . . O
4 . . O
% . . O
% . . O
% . . O
% . . O
% . . O
% . . O
any . . O
a . . O
dverse . . O
r . . O
eaction . . O
97 . . O
52 . . O
13 . . O
93 . . O
23 . . O
5 . . O
gastrointestinal . . O
d . . O
isorders . . O
stomatitis . . B-AdverseReaction
a . . O
44 . . O
4 . . O
< . . O
1 . . O
8 . . O
0 . . O
0 . . O
diarrhea . . B-AdverseReaction
30 . . O
1 . . O
0 . . O
7 . . O
0 . . O
0 . . O
nausea . . B-AdverseReaction
26 . . O
1 . . O
0 . . O
19 . . O
0 . . O
0 . . O
vomiting . . B-AdverseReaction
20 . . O
2 . . O
0 . . O
12 . . O
0 . . O
0 . . O
infections . . O
and . . O
i . . O
nfestations . . O
b . . O
37 . . O
7 . . O
3 . . O
18 . . O
1 . . O
0 . . O
general . . O
d . . O
isorders . . O
and . . O
a . . O
dministration . . O
s . . O
ite . . O
c . . O
onditions . . O
asthenia . . B-AdverseReaction
33 . . O
3 . . O
< . . O
1 . . O
23 . . O
4 . . O
0 . . O
fatigue . . B-AdverseReaction
31 . . O
5 . . O
0 . . O
27 . . O
3 . . O
< . . O
1 . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
25 . . O
< . . O
1 . . O
0 . . O
8 . . O
< . . O
1 . . O
0 . . O
pyrexia . . B-AdverseReaction
20 . . O
< . . O
1 . . O
0 . . O
9 . . O
0 . . O
0 . . O
mucosal . . B-AdverseReaction
inflammation . . I-AdverseReaction
19 . . O
1 . . O
0 . . O
1 . . O
0 . . O
0 . . O
respiratory . . O
, . . O
t . . O
horacic . . O
and . . O
m . . O
ediastinal . . O
d . . O
isorders . . O
cough . . B-AdverseReaction
30 . . O
< . . O
1 . . O
0 . . O
16 . . O
0 . . O
0 . . O
dyspnea . . B-AdverseReaction
24 . . O
6 . . O
1 . . O
15 . . O
3 . . O
0 . . O
epistaxis . . B-AdverseReaction
18 . . O
0 . . O
0 . . O
0 . . O
0 . . O
0 . . O
pneumonitis . . B-AdverseReaction
c . . O
14 . . O
4 . . O
0 . . O
0 . . O
0 . . O
0 . . O
skin . . O
and . . O
s . . O
ubcutaneous . . O
t . . O
issue . . O
d . . O
isorders . . O
rash . . B-AdverseReaction
29 . . O
1 . . O
0 . . O
7 . . O
0 . . O
0 . . O
pruritus . . B-AdverseReaction
14 . . O
< . . O
1 . . O
0 . . O
7 . . O
0 . . O
0 . . O
dry . . B-AdverseReaction
skin . . I-AdverseReaction
13 . . O
< . . O
1 . . O
0 . . O
5 . . O
0 . . O
0 . . O
metabolism . . O
and . . O
n . . O
utrition . . O
d . . O
isorders . . O
anorexia . . B-AdverseReaction
25 . . O
1 . . O
0 . . O
14 . . O
< . . O
1 . . O
0 . . O
nervous . . O
s . . O
ystem . . O
d . . O
isorders . . O
headache . . B-AdverseReaction
19 . . O
< . . O
1 . . O
< . . O
1 . . O
9 . . O
< . . O
1 . . O
0 . . O
dysgeusia . . B-AdverseReaction
10 . . O
0 . . O
0 . . O
2 . . O
0 . . O
0 . . O
musculoskeletal . . O
and . . O
c . . O
onnective . . O
t . . O
issue . . O
d . . O
isorders . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
10 . . O
1 . . O
0 . . O
7 . . O
0 . . O
0 . . O
medi . . O
an . . O
d . . O
uration . . O
of . . O
t . . O
reatment . . O
( . . O
d . . O
) . . O
141 . . O
60 . . O
other . . O
notable . . O
adverse . . O
reactions . . O
occurring . . O
more . . O
frequently . . O
with . . O
afinitor . . O
than . . O
with . . O
placebo . . O
, . . O
but . . O
with . . O
an . . O
incidence . . O
of . . O
< . . O
10% . . O
include . . O
: . . O

the . . O
safety . . O
of . . O
icatibant . . O
was . . O
evaluated . . O
in . . O
three . . O
controlled . . O
trials . . O
that . . O
included . . O
223 . . O
patients . . O
who . . O
received . . O
firazyr . . O
30 . . O
mg . . O
( . . O
n . . O
= . . O
113 . . O
) . . O
, . . O
placebo . . O
( . . O
n . . O
= . . O
75 . . O
) . . O
, . . O
or . . O
comparator . . O
( . . O
n . . O
= . . O
38 . . O
) . . O
. . . O

in . . O
this . . O
analysis . . O
, . . O
6.9% . . O
of . . O
58 . . O
evaluable . . O
patients . . O
, . . O
who . . O
were . . O
treated . . O
with . . O
0.3 . . O
mg . . O
/ . . O
kg . . O
dose . . O
, . . O
tested . . O
positive . . O
for . . O
binding . . O
antibodies . . O
against . . O
ipilimumab . . O
. . . O

table . . O
4 . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O

if . . O
significant . . O
reductions . . O
in . . O
bmd . . O
are . . O
seen . . O
and . . O
breo . . O
ellipta . . O
is . . O
still . . O
considered . . O
medically . . O
important . . O
for . . O
that . . O
patient's . . O
copd . . O
therapy . . O
, . . O
use . . O
of . . O
medicine . . O
to . . O
treat . . O
or . . O
prevent . . O
osteoporosis . . O
should . . O
be . . O
strongly . . O
considered . . O
. . . O

this . . O
trial . . O
did . . O
not . . O
have . . O
a . . O
placebo . . O
arm . . O
. . . O

the . . O
incidence . . O
of . . O
rash . . B-AdverseReaction
was . . O
higher . . O
in . . O
females . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O

* . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
muscle . . B-AdverseReaction
spasm . . I-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
* . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
* . . O
metabolism . . O
and . . O
nutrition . . O
disorder . . O
: . . O
diabetes . . B-AdverseReaction
mellitus . . I-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
* . . O
infections . . O
and . . O
infestations . . O
: . . O
sinusitis . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
c . . O
ough . . O
experienced . . O
p . . O
ost . . O
- . . O
inhalation . . O

discontinuations . . O
due . . O
to . . O
elevated . . B-AdverseReaction
hepatic . . I-AdverseReaction
transaminases . . I-AdverseReaction
were . . O
< . . O
1% . . O
and . . O
were . . O
similar . . O
in . . O
patients . . O
treated . . O
with . . O
tecfidera . . O
or . . O
placebo . . O
. . . O

injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
characterized . . O
by . . O
local . . O
pruritus . . O
, . . O
erythema . . O
, . . O
pain . . O
, . . O
irritation . . O
, . . O
urticaria . . O
, . . O
and . . O
/ . . O
or . . O
bruising . . O
. . . O

5.2 . . O
hyperpyrexia . . O
and . . O
confusion . . O

5 . . O
. . . O

5.4 . . O
dysphagia . . O
and . . O
breathing . . O
difficulties . . O
in . . O
treatment . . O
of . . O
cervical . . O
dystonia . . O

excerpt . . O
: . . O
* . . O
psoriatic . . O
arthritis . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
* . . O
psoriasis . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
, . . O
including . . O
tension . . B-AdverseReaction
headache . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
celgene . . O
corporation . . O
at . . O
1-888-423-5436 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

in . . O
some . . O
cases . . O
, . . O
hyperglycemia . . O
has . . O
resolved . . O
when . . O
the . . O
atypical . . O
antipsychotic . . O
was . . O
discontinued . . O
; . . O
however . . O
, . . O
some . . O
patients . . O
required . . O
continuation . . O
of . . O
anti . . O
- . . O
diabetic . . O
treatment . . O
despite . . O
discontinuation . . O
of . . O
the . . O
antipsychotic . . O
drug . . O
. . . O

women . . O
who . . O
are . . O
not . . O
pregnant . . O
and . . O
use . . O
natazia . . O
, . . O
may . . B-Factor
experience . . O
amenorrhea . . B-AdverseReaction
. . . O

in . . O
order . . O
to . . O
prevent . . O
gout . . O
flares . . O
when . . O
uloric . . O
is . . O
initiated . . O
, . . O
concurrent . . O
prophylactic . . O
treatment . . O
with . . O
an . . O
nsaid . . O
or . . O
colchicine . . O
is . . O
recommended . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
) . . O
] . . O
. . . O

the . . O
adverse . . O
reaction . . O
profile . . O
of . . O
cerdelga . . O
is . . O
based . . O
on . . O
two . . O
controlled . . O
studies . . O
, . . O
trials . . O
1 . . O
and . . O
2 . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
described . . O
below . . O
and . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

5 . . O
warnings . . O
and . . O
precautions . . O

the . . O
incidence . . O
of . . O
serious . . B-Severity
gi . . B-AdverseReaction
events . . I-AdverseReaction
was . . O
1% . . O
in . . O
patients . . O
treated . . O
with . . O
tecfidera . . O
. . . O

invasive . . O
fungal . . O
infections . . O

the . . O
rates . . O
of . . O
adverse . . O
reactions . . O
below . . O
were . . O
derived . . O
from . . O
two . . O
randomized . . O
, . . O
multi . . O
- . . O
center . . O
, . . O
vehicle . . O
- . . O
controlled . . O
clinical . . O
trials . . O
and . . O
one . . O
open . . O
- . . O
label . . O
study . . O
in . . O
subjects . . O
with . . O
head . . O
lice . . O
infestation . . O
. . . O

in . . O
many . . O
cases . . O
, . . O
the . . O
occurrence . . O
of . . O
these . . O
adverse . . O
reactions . . O
led . . O
to . . O
discontinuation . . O
of . . O
therapy . . O
. . . O

in . . O
the . . O
cimzia . . O
ra . . O
clinical . . O
trials . . O
( . . O
placebo . . O
- . . O
controlled . . O
and . . O
open . . O
label . . O
) . . O
a . . O
total . . O
of . . O
three . . O
cases . . O
of . . O
lymphoma . . B-AdverseReaction
were . . O
observed . . O
among . . O
2,367 . . O
patients . . O
. . . O

during . . O
the . . O
initial . . O
phase . . O
of . . O
combination . . O
antiretroviral . . O
treatment . . O
, . . O
patients . . O
whose . . O
immune . . O
system . . O
responds . . O
may . . B-Factor
develop . . O
an . . O
inflammatory . . O
response . . O
to . . O
indolent . . O
or . . O
residual . . B-AdverseReaction
opportunistic . . I-AdverseReaction
infections . . I-AdverseReaction
[ . . O
such . . O
as . . O
mycobacterium . . B-AdverseReaction
avium . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
cytomegalovirus . . B-AdverseReaction
, . . O
pneumocystis . . B-AdverseReaction
jirovecii . . I-AdverseReaction
pneumonia . . I-AdverseReaction
( . . O
pcp . . B-AdverseReaction
) . . O
, . . O
or . . O
tuberculosis . . B-AdverseReaction
] . . O
, . . O
which . . O
may . . O
necessitate . . O
further . . O
evaluation . . O
and . . O
treatment . . O
. . . O

5.7 . . O
pancreatitis . . O

table . . O
5 . . O
. . . O

the . . O
following . . O
grade . . B-Severity
1-4 . . I-Severity
adverse . . O
reactions . . O
were . . O
reported . . O
at . . O
rates . . O
> . . O
= . . O
5% . . O
higher . . O
in . . O
patients . . O
65 . . O
years . . O
of . . O
age . . O
or . . O
greater . . O
compared . . O
to . . O
younger . . O
patients . . O
: . . O
fatigue . . B-AdverseReaction
( . . O
40% . . O
vs . . O
. . . O
30% . . O
) . . O
, . . O
neutropenia . . B-AdverseReaction
( . . O
97% . . O
vs . . O
. . . O
89% . . O
) . . O
, . . O
asthenia . . B-AdverseReaction
( . . O
24% . . O
vs . . O
. . . O
15% . . O
) . . O
, . . O
pyrexia . . B-AdverseReaction
( . . O
15% . . O
vs . . O
. . . O
8% . . O
) . . O
, . . O
dizziness . . B-AdverseReaction
( . . O
10% . . O
vs . . O
. . . O
5% . . O
) . . O
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
10% . . O
vs . . O
. . . O
3% . . O
) . . O
and . . O
dehydration . . B-AdverseReaction
( . . O
7% . . O
vs . . O
. . . O
2% . . O
) . . O
, . . O
respectively . . O
. . . O

the . . O
following . . O
additional . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
approval . . O
use . . O
of . . O
zytiga . . O
. . . O

with . . O
appropriate . . O
medical . . O
support . . O
to . . O
manage . . O
anaphylaxis . . O
and . . O
hereditary . . O

( . . O
5.2 . . O
) . . O
* . . O
hypoglycemia . . B-AdverseReaction
: . . O
can . . O
occur . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
insulin . . O
secretagogues . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
sulfonylureas . . O
) . . O
or . . O
insulin . . O
. . . O

arcapta . . O
neohaler . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
acutely . . O
deteriorating . . O
copd . . O
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
genital . . O
mycotic . . O
infections . . O
were . . O
more . . O
likely . . O
to . . O
develop . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

discontinue . . O
sirturo . . O
if . . O
: . . O

( . . O
5.1 . . O
) . . O

under . . O
conditions . . O
of . . O
metabolic . . O
inhibition . . O
for . . O
both . . O
2d6 . . O
and . . O
3a4 . . O
, . . O
fanapt . . O
12 . . O
mg . . O
twice . . O
daily . . O
was . . O
associated . . O
with . . O
a . . O
mean . . O
qtcf . . B-AdverseReaction
increase . . I-AdverseReaction
from . . O
baseline . . O
of . . O
about . . O
19 . . O
msec . . O
. . . O

advise . . O
pregnant . . O
women . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
( . . O
5.12 . . O
) . . O
. . . O

table . . O
2 . . O
: . . O
most . . O
commonly . . O
reported . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
adverse . . O
reactions . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
classical . . O
hl . . O
salcl . . O
total . . O
n . . O
= . . O
102% . . O
of . . O
patients . . O
total . . O
n . . O
= . . O
58% . . O
of . . O
patients . . O
adverse . . O
reaction . . O
anygrade . . O
grade3 . . O
grade4 . . O
anygrade . . O
grade3 . . O
grade4 . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
neutropenia . . B-AdverseReaction
54 . . O
15 . . O
6 . . O
55 . . O
12 . . O
9 . . O

myocardial . . B-AdverseReaction
ischemia . . I-AdverseReaction
or . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
led . . O
to . . O
death . . B-AdverseReaction
in . . O
3 . . O
patients . . O
in . . O
the . . O
placebo . . B-Factor
arms . . O
and . . O
2 . . O
deaths . . B-AdverseReaction
in . . O
the . . O
zytiga . . O
arms . . O
. . . O

in . . O
addition . . O
to . . O
diarrhea . . B-AdverseReaction
and . . O
nausea . . B-AdverseReaction
( . . O
see . . O
table . . O
1 . . O
) . . O
, . . O
the . . O
following . . O
gastrointestinal . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
also . . O
occurred . . O
more . . O
frequently . . O
in . . O
patients . . O
receiving . . O
tanzeum . . O
: . . O
vomiting . . B-AdverseReaction
( . . O
2.6% . . O
versus . . O
4.2% . . O
for . . O
placebo . . O
versus . . O
tanzeum . . O
) . . O
, . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
( . . O
1.9% . . O
versus . . O
3.5% . . O
for . . O
placebo . . O
versus . . O
tanzeum . . O
) . . O
, . . O
and . . O
dyspepsia . . B-AdverseReaction
( . . O
2.8% . . O
versus . . O
3.4% . . O
for . . O
placebo . . O
versus . . O
tanzeum . . O
) . . O
. . . O

* . . O
hepatotoxicity . . B-AdverseReaction
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

in . . O
a . . O
6 . . O
- . . O
month . . O
randomized . . O
, . . O
active . . O
controlled . . O
asthma . . O
safety . . O
trial . . O
, . . O
805 . . O
adult . . O
patients . . O
with . . O
moderate . . O
to . . O
severe . . O
persistent . . O
asthma . . O
were . . O
treated . . O
with . . O
arcapta . . O
neohaler . . O
300 . . O
mcg . . O
( . . O
n . . O
= . . O
268 . . O
) . . O
, . . O
arcapta . . O
neohaler . . O
600 . . O
mcg . . O
( . . O
n . . O
= . . O
268 . . O
) . . O
, . . O
and . . O
salmeterol . . O
( . . O
n . . O
= . . O
269 . . O
) . . O
, . . O
all . . O
concomitant . . O
with . . O
inhaled . . O
corticosteroids . . O
, . . O
which . . O
were . . O
not . . O
co . . O
- . . O
randomized . . O
. . . O

ecg . . O
analysis . . O
did . . B-Negation
not . . I-Negation
identify . . I-Negation
qtc . . B-AdverseReaction
prolongation . . I-AdverseReaction
. . . O

table . . O
1 . . O
lists . . O
adverse . . O
reactions . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
occurring . . O
in . . O
at . . O
least . . O
3% . . O
of . . O
patients . . O
with . . O
sle . . O
who . . O
received . . O
benlysta . . O
10 . . O
mg . . O
/ . . O
kg . . O
and . . O
at . . O
an . . O
incidence . . O
at . . O
least . . O
1% . . O
greater . . O
than . . O
that . . O
observed . . O
with . . O
placebo . . O
in . . O
the . . O
3 . . O
controlled . . O
studies . . O
. . . O

warning . . O
: . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction

the . . O
majority . . O
of . . O
elevations . . O
occurred . . O
within . . O
6 . . O
to . . O
9 . . O
months . . O
. . . O

excerpt . . O
: . . O
* . . O
hypotension . . B-AdverseReaction
: . . O
before . . O
initiating . . O
jardiance . . O
assess . . O
and . . O
correct . . O
volume . . O
status . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
, . . O
the . . O
elderly . . O
, . . O
in . . O
patients . . O
with . . O
low . . O
systolic . . O
blood . . O
pressure . . O
, . . O
and . . O
in . . O
patients . . O
on . . O
diuretics . . O
. . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
gastrointestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
was . . O
reported . . O
in . . O
1 . . O
/ . . O
359 . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
none . . O
of . . O
the . . O
patients . . O
receiving . . O
sorafenib . . O
. . . O

5.5 . . O
use . . O
in . . O
elderly . . O
patients . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O

severe . . O
and . . O
sometimes . . O
fatal . . B-AdverseReaction
sickle . . B-AdverseReaction
cell . . I-AdverseReaction
crises . . I-AdverseReaction
can . . B-Factor
occur . . O
in . . O
patients . . O
with . . O
sickle . . O
cell . . O
disease . . O
receiving . . O
human . . O
granulocyte . . O
colony . . O
- . . O
stimulating . . O
factors . . O
. . . O

no . . O
study . . O
adequate . . O
to . . O
determine . . O
whether . . O
the . . O
rate . . O
of . . O
asthma . . O
- . . O
related . . O
death . . O
is . . O
increased . . O
in . . O
patients . . O
treated . . O
with . . O
arcapta . . O
neohaler . . O
has . . O
been . . O
conducted . . O
. . . O

( . . O
6.1 . . O
) . . O

in . . O
such . . O
cases . . O
, . . O
topical . . O
treatments . . O
are . . O
recommended . . O
, . . O
but . . O
alcohol . . O
- . . O
, . . O
hydrogen . . O
peroxide . . O
- . . O
, . . O
iodine . . O
- . . O
, . . O
or . . O
thyme . . O
- . . O
containing . . O
mouthwashes . . O
should . . O
be . . O
avoided . . O
as . . O
they . . O
may . . O
exacerbate . . O
the . . O
condition . . O
. . . O

6 . . O
adverse . . O
reactions . . O

in . . O
individual . . O
clinical . . O
trials . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
, . . O
episodes . . O
of . . O
hypoglycemia . . B-AdverseReaction
occurred . . O
at . . O
a . . O
higher . . O
rate . . O
when . . O
invokana . . O
was . . O
co . . O
- . . O
administered . . O
with . . O
insulin . . O
or . . O
sulfonylureas . . O
( . . O
table . . O
4 . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O
evaluating . . O
jardiance . . O
10 . . O
and . . O
25 . . O
mg . . O
the . . O
data . . O
in . . O
table . . O
1 . . O
are . . O
derived . . O
from . . O
a . . O
pool . . O
of . . O
four . . O
24 . . O
- . . O
week . . O
placebo . . O
- . . O
controlled . . O
trials . . O
and . . O
18 . . O
- . . O
week . . O
data . . O
from . . O
a . . O
placebo . . O
- . . O
controlled . . O
trial . . O
with . . O
insulin . . O
. . . O

all . . O
patients . . O
who . . O
tested . . O
positive . . O
for . . O
binding . . O
antibodies . . O
also . . O
tested . . O
positive . . O
for . . O
neutralizing . . O
anti . . O
- . . O
blinatumomab . . O
antibodies . . O
. . . O

permanently . . O
discontinue . . O
for . . O
life . . O
- . . O
threatening . . O
bradycardia . . O
due . . O
to . . O
xalkori . . O
; . . O
however . . O
, . . O
if . . O
associated . . O
with . . O
concomitant . . O
medications . . O
known . . O
to . . O
cause . . O
bradycardia . . O
or . . O
hypotension . . O
, . . O
hold . . O
xalkori . . O
until . . O
recovery . . O
to . . O
asymptomatic . . O
bradycardia . . O
or . . O
to . . O
a . . O
heart . . O
rate . . O
of . . O
60 . . O
bpm . . O
or . . O
above . . O
, . . O
and . . O
if . . O
concomitant . . O
medications . . O
can . . O
be . . O
adjusted . . O
or . . O
discontinued . . O
, . . O
restart . . O
xalkori . . O
at . . O
250 . . O
mg . . O
once . . O
daily . . O
with . . O
frequent . . O
monitoring . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

warning . . O
: . . O
agranulocytosis . . B-AdverseReaction
/ . . O
neutropenia . . B-AdverseReaction

if . . O
a . . O
patient . . O
is . . O
exposed . . O
to . . O
chickenpox . . O
, . . O
prophylaxis . . O
with . . O
varicella . . O
zoster . . O
immune . . O
globulin . . O
( . . O
vzig . . O
) . . O
may . . O
be . . O
indicated . . O
. . . O

figure . . O
1 . . O
: . . O
major . . B-Severity
bleeding . . B-AdverseReaction
hazard . . O
ratios . . O
by . . O
baseline . . O
characteristics . . O
- . . O
aristotle . . O
study . . O

eye . . O
disorders . . O
: . . O
conjunctivitis . . B-AdverseReaction

table . . O
3 . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
mean . . O
heart . . O
rate . . O
in . . O
patients . . O
treated . . O
with . . O
tanzeum . . O
was . . O
higher . . O
by . . O
an . . O
average . . O
of . . O
1 . . O
to . . O
2 . . O
bpm . . O
compared . . O
with . . O
mean . . O
heart . . O
rate . . O
in . . O
patients . . O
treated . . O
with . . O
placebo . . O
across . . O
study . . O
visits . . O
. . . O

tudorza . . O
pressair . . O
was . . O
studied . . O
in . . O
three . . O
long . . O
term . . O
safety . . O
trials . . O
, . . O
two . . O
double . . O
blind . . O
and . . O
one . . O
open . . O
label . . O
, . . O
ranging . . O
from . . O
40 . . O
to . . O
52 . . O
weeks . . O
in . . O
patients . . O
with . . O
moderate . . O
to . . O
severe . . O
copd . . O
. . . O

resume . . O
tafinlar . . O
at . . O
the . . O
same . . O
dose . . O
level . . O
upon . . O
recovery . . O
of . . O
cardiac . . O
function . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

287 . . O
( . . O
72 . . O
) . . O
299 . . O
( . . O
74 . . O
) . . O
329 . . O
( . . O
82 . . O
) . . O
327 . . O
( . . O
81 . . O
) . . O
serious . . B-Severity
infectionss . . O
98 . . O
( . . O
24 . . O
) . . O
113 . . O
( . . O
28 . . O
) . . O
144 . . O
( . . O
36 . . O
) . . O
157 . . O
( . . O
39 . . O
) . . O
cmv . . O
44 . . O
( . . O
11 . . O
) . . O
52 . . O
( . . O
13 . . O
) . . O
53 . . O
( . . O
13 . . O
) . . O
56 . . O
( . . O
14 . . O
) . . O
polyoma . . O
virus . . O
10 . . O
( . . O
3 . . O
) . . O
23 . . O
( . . O
6 . . O
) . . O
17 . . O
( . . O
4 . . O
) . . O
27 . . O
( . . O
7 . . O
) . . O
herpes . . O
# . . O
27 . . O
( . . O
7 . . O
) . . O
26 . . O
( . . O
6 . . O
) . . O
55 . . O
( . . O
14 . . O
) . . O
46 . . O
( . . O
11 . . O
) . . O
tuberculosis . . B-AdverseReaction
2 . . O
( . . O
1 . . O
) . . O
1 . . O
( . . O
< . . O
1 . . O
) . . O
6 . . O
( . . O
2 . . O
) . . O
1 . . O
( . . O
< . . O
1 . . O
) . . O
infections . . O
reported . . O
in . . O
the . . O
cns . . O
following . . O
three . . O
years . . O
of . . O
treatment . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
, . . O
cryptococcal . . B-AdverseReaction
meningitis . . I-AdverseReaction
was . . O
reported . . O
in . . O
one . . O
patient . . O
out . . O
of . . O
401 . . O
patients . . O
treated . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
( . . O
0.2% . . O
) . . O
and . . O
one . . O
patient . . O
out . . O
of . . O
the . . O
405 . . O
treated . . O
with . . O
the . . O
cyclosporine . . O
control . . O
( . . O
0.2% . . O
) . . O
. . . O

no . . B-Negation
cases . . O
of . . O
torsade . . B-AdverseReaction
de . . I-AdverseReaction
pointes . . I-AdverseReaction
or . . O
other . . O
severe . . B-Severity
cardiac . . B-AdverseReaction
arrhythmias . . I-AdverseReaction
were . . O
observed . . O
during . . O
the . . O
pre . . O
- . . O
marketing . . O
clinical . . O
program . . O
. . . O

study . . O
3 . . O
was . . O
an . . O
open . . O
- . . O
label . . O
, . . O
noncomparative . . O
study . . O
with . . O
sirturo . . O
administered . . O
as . . O
part . . O
of . . O
an . . O
individualized . . O
pulmonary . . O
mdr . . O
- . . O
tb . . O
treatment . . O
regimen . . O
in . . O
previously . . O
treated . . O
patients . . O
. . . O

patients . . O
with . . O
major . . O
depressive . . O
disorder . . O
( . . O
mdd . . O
) . . O
, . . O
both . . O
adult . . O
and . . O
pediatric . . O
, . . O
may . . O
experience . . O
worsening . . O
of . . O
their . . O
depression . . O
and . . O
/ . . O
or . . O
the . . O
emergence . . O
of . . O
suicidal . . O
ideation . . O
and . . O
behavior . . O
( . . O
suicidality . . O
) . . O
or . . O
unusual . . O
changes . . O
in . . O
behavior . . O
, . . O
whether . . O
or . . O
not . . O
they . . O
are . . O
taking . . O
antidepressant . . O
medications . . O
, . . O
and . . O
this . . O
risk . . O
may . . O
persist . . O
until . . O
significant . . O
remission . . O
occurs . . O
. . . O

advise . . O
females . . O
of . . O
reproductive . . O
potential . . O
to . . O
use . . O
highly . . O
effective . . O
contraception . . O
during . . O
treatment . . O
, . . O
and . . O
for . . O
at . . O
least . . O
2 . . O
weeks . . O
after . . O
the . . O
last . . O
dose . . O
of . . O
gilotrif . . O
. . . O

in . . O
patients . . O
with . . O
an . . O
activated . . O
renin . . O
- . . O
angiotensin . . O
system . . O
, . . O
such . . O
as . . O
volume . . O
- . . O
and . . O
/ . . O
or . . O
salt . . O
- . . O
depleted . . O
patients . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
those . . O
being . . O
treated . . O
with . . O
high . . O
doses . . O
of . . O
diuretics . . O
) . . O
, . . O
symptomatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
may . . B-Factor
occur . . O
after . . O
initiation . . O
of . . O
treatment . . O
with . . O
edarbi . . O
. . . O

table . . O
3 . . O
identifies . . O
adverse . . O
reactions . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
10% . . O
for . . O
all . . O
grades . . O
and . . O
grades . . O
3 . . O
or . . O
4 . . O
for . . O
the . . O
phase . . O
1 . . O
/ . . O
2 . . O
cml . . O
safety . . O
population . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
in . . O
study . . O
1 . . O
and . . O
2 . . O
reported . . O
for . . O
tecfidera . . O
240 . . O
mg . . O
bid . . O
at . . O
> . . O
= . . O
2% . . O
higher . . O
incidence . . O
than . . O
placebo . . O
tecfidera . . O
n . . O
= . . O
769 . . O
% . . O
placebo . . O
n . . O
= . . O
771 . . O
% . . O
flushing . . B-AdverseReaction
40 . . O
6 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
18 . . O
10 . . O
diarrhea . . B-AdverseReaction
14 . . O
11 . . O
nausea . . B-AdverseReaction
12 . . O
9 . . O
vomiting . . B-AdverseReaction
9 . . O
5 . . O
pruritus . . B-AdverseReaction
8 . . O
4 . . O
rash . . B-AdverseReaction
8 . . O
3 . . O
albumin . . B-AdverseReaction
urine . . I-AdverseReaction
present . . I-AdverseReaction
6 . . O
4 . . O
erythema . . B-AdverseReaction
5 . . O
1 . . O
dyspepsia . . B-AdverseReaction
5 . . O
3 . . O
aspartate . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
4 . . O
2 . . O
lymphopenia . . B-AdverseReaction
2 . . O
< . . O
1 . . O
gastrointestinal . . O

atypical . . O
subtrochanteric . . O
and . . O
diaphyseal . . O
fractures . . O
in . . O
the . . O
osteoporosis . . O
clinical . . O
trial . . O
program . . O
, . . O
atypical . . B-AdverseReaction
femoral . . I-AdverseReaction
fractures . . I-AdverseReaction
were . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
prolia . . O
. . . O

there . . O
were . . O
808 . . O
subjects . . O
included . . O
in . . O
the . . O
efficacy . . O
and . . O
safety . . O
analyses . . O
. . . O

* . . O
immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
myositis . . B-AdverseReaction
, . . O
chondropathy . . B-AdverseReaction
, . . O
trismus . . B-AdverseReaction
. . . O

5.2 . . O
immune . . O
- . . O
mediated . . O
reactions . . O

* . . O
you . . O
and . . O
your . . O
healthcare . . O
provider . . O
should . . O
talk . . O
regularly . . O
about . . O
whether . . O
you . . O
still . . O
need . . O
treatment . . O
with . . O
duavee . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
agranulocytosis . . B-AdverseReaction
/ . . O
neutropenia . . B-AdverseReaction

qt . . O
prolongation . . O

these . . O
metabolic . . B-AdverseReaction
changes . . I-AdverseReaction
include . . O
hyperglycemia . . B-AdverseReaction
, . . O
dyslipidemia . . B-AdverseReaction
, . . O
and . . O
weight . . B-AdverseReaction
gain . . I-AdverseReaction
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

two . . O
patients . . O
continued . . O
treatment . . O
with . . O
potiga . . O
and . . O
were . . O
able . . O
to . . O
void . . O
spontaneously . . O
after . . O
catheter . . O
removal . . O
. . . O

gilenya . . O
should . . O
be . . O
discontinued . . O
if . . O
significant . . O
liver . . O
injury . . O
is . . O
confirmed . . O
. . . O

a . . O
total . . O
of . . O
2.2% . . O
of . . O
hiv . . O
- . . O
1 . . O
- . . O
infected . . O
subjects . . O
receiving . . O
intelence . . O
( . . O
r . . O
) . . O
discontinued . . O
from . . O
phase . . O
3 . . O
trials . . O
due . . O
to . . O
rash . . B-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

* . . O
cytokine . . O
release . . O
syndrome . . O
( . . O
crs . . O
) . . O
, . . O
which . . O
may . . B-Factor
be . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
or . . O
fatal . . B-AdverseReaction
, . . O
occurred . . O
in . . O
patients . . O
receiving . . O
blincyto . . O
. . . O

no . . B-Negation
severe . . B-Severity
injection . . B-AdverseReaction
- . . I-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
reported . . O
and . . O
none . . O
led . . O
to . . O
discontinuation . . O
of . . O
treatment . . O
. . . O

in . . O
virologically . . O
- . . O
suppressed . . O
hiv . . O
- . . O
1 . . O
- . . O
infected . . O
subjects . . O

an . . O
examination . . O
of . . O
population . . O
subgroups . . O
in . . O
the . . O
4 . . O
placebo . . O
- . . O
controlled . . O
, . . O
4 . . O
- . . O
or . . O
6 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
or . . O
flexible . . O
- . . O
dose . . O
studies . . O
did . . O
not . . O
reveal . . O
any . . O
evidence . . O
of . . O
differences . . O
in . . O
safety . . O
on . . O
the . . O
basis . . O
of . . O
age . . O
, . . O
gender . . O
or . . O
race . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

in . . O
the . . O
extension . . O
trial . . O
, . . O
cataracts . . B-AdverseReaction
developed . . O
or . . O
worsened . . O
in . . O
4% . . O
of . . O
patients . . O
who . . O
underwent . . O
ocular . . O
examination . . O
prior . . O
to . . O
therapy . . O
with . . O
promacta . . O
. . . O

alglucosidase . . O
alfa . . O
- . . O
treated . . O
patients . . O
who . . O
experience . . O
a . . O
decrease . . O
in . . O
motor . . O
function . . O
should . . O
be . . O
tested . . O
for . . O
the . . O
presence . . O
of . . O
inhibitory . . O
antibodies . . O
that . . O
neutralize . . O
enzyme . . O
uptake . . O
or . . O
activity . . O
. . . O

do . . O
not . . O
start . . O
in . . O
patients . . O
with . . O
active . . O
infections . . O
. . . O

* . . O
severe . . B-Severity
acute . . B-AdverseReaction
exacerbations . . I-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction
[ . . O
see . . O
boxed . . O
warning . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

the . . O
use . . O
of . . O
pradaxa . . O
for . . O
the . . O
prophylaxis . . O
of . . O
thromboembolic . . O
events . . O
in . . O
patients . . O
with . . O
atrial . . O
fibrillation . . O
in . . O
the . . O
setting . . O
of . . O
other . . O
forms . . O
of . . O
valvular . . O
heart . . O
disease . . O
, . . O
including . . O
the . . O
presence . . O
of . . O
a . . O
bioprosthetic . . O
heart . . O
valve . . O
, . . O
has . . O
not . . O
been . . O
studied . . O
and . . O
is . . O
not . . O
recommended . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
blinded . . O
study . . O
treatment . . O
was . . O
48 . . O
weeks . . O
( . . O
range . . O
2 . . O
to . . O
115 . . O
weeks . . O
) . . O
for . . O
patients . . O
receiving . . O
afinitor . . O
and . . O
45 . . O
weeks . . O
( . . O
range . . O
9 . . O
to . . O
115 . . O
weeks . . O
) . . O
for . . O
those . . O
receiving . . O
placebo . . O
. . . O

cognitive . . B-AdverseReaction
dysfunction . . I-AdverseReaction
events . . O
were . . O
also . . O
observed . . O
in . . O
monotherapy . . O
trials . . O
. . . O

elevated . . B-AdverseReaction
alt . . I-AdverseReaction
( . . O
5.3 . . O
) . . O
, . . O
decreased . . B-AdverseReaction
plasma . . I-AdverseReaction
zinc . . I-AdverseReaction
concentrations . . I-AdverseReaction
( . . O
5.3 . . O
) . . O
. . . O

cimzia . . O
has . . O
been . . O
studied . . O
in . . O
325 . . O
patients . . O
with . . O
axial . . O
spondyloarthritis . . O
of . . O
whom . . O
the . . O
majority . . O
had . . O
ankylosing . . O
spondylitis . . O
( . . O
as . . O
) . . O
in . . O
a . . O
placebo . . O
- . . O
controlled . . O
study . . O
( . . O
as . . O
- . . O
1 . . O
) . . O
. . . O

5.10 . . O
hyperprolactinemia . . O

withdrawal . . O
symptoms . . O
occurred . . O
following . . O
abrupt . . O
discontinuation . . O
of . . O
onfi . . O
; . . O
the . . O
risk . . O
of . . O
withdrawal . . O
symptoms . . O
is . . O
greater . . O
with . . O
higher . . O
doses . . O
. . . O

dose . . O
modifications . . O

in . . O
the . . O
emtp . . O
trial . . O
, . . O
the . . O
planned . . O
number . . O
of . . O
doses . . O
of . . O
erwinaze . . O
ranged . . O
from . . O
3 . . O
to . . O
48 . . O
doses . . O
. . . O

if . . O
toxicity . . O
recurs . . O
at . . O
grade . . O
3 . . O
, . . O
consider . . O
discontinuation . . O
of . . O
afinitor . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
albiglutide . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
of . . O
other . . O
products . . O
. . . O

cardiac . . O
disorders . . O
: . . O
angina . . B-AdverseReaction
pectoris . . I-AdverseReaction
, . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
/ . . O
flutter . . O
, . . O
cardiac . . B-AdverseReaction
murmur . . I-AdverseReaction
, . . O
ecg . . B-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
palpitations . . B-AdverseReaction
, . . O
sinus . . B-AdverseReaction
bradycardia . . I-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
* . . O
serious . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
may . . B-Factor
occur . . O
. . . O

prescribers . . O
and . . O
patients . . O
should . . O
be . . O
alert . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
prostatic . . O
hyperplasia . . O
or . . O
bladder . . O
- . . O
neck . . O
obstruction . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
difficulty . . O
passing . . O
urine . . O
, . . O
painful . . O
urination . . O
) . . O
. . . O

in . . O
a . . O
dose . . O
- . . O
finding . . O
trial . . O
, . . O
grade . . B-Severity
3 . . I-Severity
increases . . B-AdverseReaction
in . . I-AdverseReaction
transaminases . . I-AdverseReaction
with . . O
or . . O
without . . O
concomitant . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
total . . I-AdverseReaction
bilirubin . . I-AdverseReaction
occurred . . O
in . . O
6 . . O
of . . O
10 . . O
patients . . O
who . . O
received . . O
concurrent . . O
yervoy . . O
( . . O
3 . . O
mg . . O
/ . . O
kg . . O
) . . O
and . . O
vemurafenib . . O
( . . O
960 . . O
mg . . O
bid . . O
or . . O
720 . . O
mg . . O
bid . . O
) . . O
. . . O

advise . . O
the . . O
patient . . O
to . . O
rinse . . O
his . . O
/ . . O
her . . O
mouth . . O
with . . O
water . . O
without . . O
swallowing . . O
after . . O
inhalation . . O
to . . O
help . . O
reduce . . O
the . . O
risk . . O
. . . O

life . . B-Severity
- . . I-Severity
threatening . . I-Severity
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
occurred . . O
in . . O
some . . O
patients . . O
during . . O
vimizim . . O
infusions . . O
. . . O

dizziness . . O
and . . O
disturbance . . O
in . . O
gait . . O
and . . O
coordination . . O

do . . O
not . . O
restart . . O
multaq . . O
in . . O
patients . . O
without . . O
another . . O
explanation . . O
for . . O
the . . O
observed . . O
liver . . O
injury . . O
. . . O

conjugated . . O
estrogens . . O
are . . O
a . . O
mixture . . O
of . . O
sodium . . O
estrone . . O
sulfate . . O
and . . O
sodium . . O
equilin . . O
sulfate . . O
and . . O
other . . O
components . . O
, . . O
including . . O
sodium . . O
sulfate . . O
conjugates . . O
, . . O
17alpha . . O
- . . O
dihydroequilin . . O
, . . O
17alpha . . O
- . . O
estradiol . . O
, . . O
and . . O
17beta . . O
- . . O
dihydroequilin . . O
. . . O

in . . O
an . . O
oral . . O
carcinogenicity . . O
study . . O
, . . O
gabapentin . . O
enacarbil . . O
increased . . O
the . . O
incidence . . O
of . . O
pancreatic . . B-AdverseReaction
acinar . . I-AdverseReaction
cell . . I-AdverseReaction
adenoma . . I-AdverseReaction
and . . O
carcinoma . . O
in . . O
male . . O
and . . O
female . . O
rats . . B-Animal
[ . . O
see . . O
nonclinical . . O
toxicology . . O
( . . O
13.1 . . O
) . . O
] . . O
. . . O

* . . O
after . . O
opening . . O
the . . O
foil . . O
pouch . . O
the . . O
duavee . . O
blisters . . O
come . . O
in . . O
, . . O
duavee . . O
must . . O
be . . O
used . . O
within . . O
60 . . O
days . . O
. . . O

long . . O
- . . O
term . . O
cumulative . . O
radiation . . O
exposure . . O
is . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . B-Factor
for . . O
cancer . . B-AdverseReaction
. . . O

while . . O
all . . O
atypical . . O
antipsychotic . . O
drugs . . O
have . . O
been . . O
shown . . O
to . . O
produce . . O
some . . O
metabolic . . O
changes . . O
, . . O
each . . O
drug . . O
in . . O
the . . O
class . . O
has . . O
its . . O
own . . O
specific . . O
risk . . O
profile . . O
. . . O

upper . . O
limb . . O
spasticity . . O

it . . O
is . . O
possible . . O
that . . O
use . . O
of . . O
il . . O
- . . O
1 . . O
inhibitors . . O
such . . O
as . . O
ilaris . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
reactivation . . B-AdverseReaction
of . . I-AdverseReaction
tuberculosis . . I-AdverseReaction
or . . O
of . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
. . . O

5.5 . . O
risk . . O
of . . O
antibody . . O
development . . O

infections . . O
and . . O
infestations . . O
- . . O
clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
colitis . . I-AdverseReaction

monitoring . . O
of . . O
fasting . . O
serum . . O
glucose . . O
and . . O
lipid . . O
profile . . O
is . . O
recommended . . O
prior . . O
to . . O
the . . O
start . . O
of . . O
afinitor . . O
therapy . . O
and . . O
periodically . . O
thereafter . . O
as . . O
well . . O
as . . O
management . . O
with . . O
appropriate . . O
medical . . O
therapy . . O
. . . O

5.3 . . O
gastrointestinal . . O
adverse . . O
reactions . . O

consider . . O
other . . O
antidiabetic . . O
therapies . . O
in . . O
patients . . O
with . . O
history . . O
of . . O
pancreatitis . . O
( . . O
5.2 . . O
) . . O
. . . O

in . . O
trial . . O
2 . . O
, . . O
ophthalmologic . . O
examinations . . O
including . . O
retinal . . O
evaluation . . O
were . . O
performed . . O
pretreatment . . O
and . . O
at . . O
regular . . O
intervals . . O
during . . O
treatment . . O
. . . O

assess . . O
creatinine . . O
clearance . . O
( . . O
clcr . . O
) . . O
, . . O
urine . . O
glucose . . O
and . . O
urine . . O
protein . . O
before . . O
initiating . . O
treatment . . O
with . . O
stribild . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

* . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
* . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
anaphylactic . . B-AdverseReaction
shock . . I-AdverseReaction
, . . O
circulatory . . B-AdverseReaction
collapse . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
bronchospasm . . B-AdverseReaction
, . . O
cyanosis . . B-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
laryngeal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
conjunctivitis . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
sneezing . . B-AdverseReaction
, . . O
burning . . B-AdverseReaction
sensation . . I-AdverseReaction
, . . O
and . . O
pallor . . B-AdverseReaction
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O

( . . O
2.2 . . O
, . . O
5.4 . . O
) . . O
* . . O
hyperglycemia . . B-AdverseReaction
: . . O
zykadia . . O
can . . B-Factor
cause . . O
hyperglycemia . . B-AdverseReaction
. . . O

patients . . O
receiving . . O
more . . O
than . . O
3 . . O
doses . . O
of . . O
an . . O
opioid . . O
within . . O
the . . O
week . . O
prior . . O
to . . O
surgery . . O
were . . O
not . . O
studied . . O
in . . O
the . . O
postoperative . . O
ileus . . O
clinical . . O
trials . . O
. . . O

hold . . O
adcetris . . O
dosing . . O
for . . O
any . . O
suspected . . O
case . . O
of . . O
pml . . O
and . . O
discontinue . . O
adcetris . . O
dosing . . O
if . . O
a . . O
diagnosis . . O
of . . O
pml . . O
is . . O
confirmed . . O
. . . O

ctcae . . O
grade . . B-Severity
3-4 . . I-Severity
elevations . . B-AdverseReaction
of . . I-AdverseReaction
lipase . . I-AdverseReaction
and . . O
/ . . O
or . . O
amylase . . O
occurred . . O
in . . O
15% . . O
of . . O
patients . . O
receiving . . O
zykadia . . O
in . . O
study . . O
1 . . O
. . . O

perform . . O
an . . O
ophthalmological . . O
evaluation . . O
consisting . . O
of . . O
best . . O
corrected . . O
visual . . O
acuity . . O
, . . O
retinal . . O
photographs . . O
, . . O
visual . . O
fields . . O
, . . O
optical . . O
coherence . . O
tomography . . O
( . . O
oct . . O
) . . O
and . . O
other . . O
evaluations . . O
as . . O
appropriate . . O
for . . O
new . . O
onset . . O
of . . O
severe . . O
visual . . O
loss . . O
. . . O

volume . . O
depletion . . O
jardiance . . O
causes . . O
an . . O
osmotic . . B-AdverseReaction
diuresis . . I-AdverseReaction
, . . O
which . . O
may . . B-Factor
lead . . O
to . . O
intravascular . . B-AdverseReaction
volume . . I-AdverseReaction
contraction . . I-AdverseReaction
and . . O
adverse . . O
reactions . . O
related . . O
to . . O
volume . . B-AdverseReaction
depletion . . I-AdverseReaction
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
- . . O
anemia . . B-AdverseReaction
, . . O
eosinophilia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction

the . . O
risk . . O
did . . O
not . . O
vary . . O
substantially . . O
by . . O
age . . O
( . . O
5-100 . . O
years . . O
) . . O
in . . O
the . . O
clinical . . O
trials . . O
analyzed . . O
. . . O

among . . O
these . . O
202 . . O
patients . . O
, . . O
66 . . O
( . . O
33% . . O
) . . O
were . . O
exposed . . O
to . . O
tafinlar . . O
and . . O
68 . . O
( . . O
34% . . O
) . . O
were . . O
exposed . . O
to . . O
trametinib . . O
for . . O
greater . . O
than . . O
6 . . O
to . . O
12 . . O
months . . O
while . . O
40 . . O
( . . O
20% . . O
) . . O
were . . O
exposed . . O
to . . O
tafinlar . . O
and . . O
36 . . O
( . . O
18% . . O
) . . O
were . . O
exposed . . O
to . . O
trametinib . . O
for . . O
greater . . O
than . . O
one . . O
year . . O
. . . O

the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
including . . O
assay . . O
sensitivity . . O
and . . O
specificity . . O
, . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

one . . O
additional . . O
patient's . . O
death . . B-AdverseReaction
was . . O
attributed . . O
to . . O
neutropenia . . B-AdverseReaction
without . . B-Negation
a . . O
documented . . O
infection . . B-AdverseReaction
. . . O

merkel . . B-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
tnf . . O
- . . O
blocking . . O
agents . . O
. . . O

additional . . O
adrs . . O
of . . O
at . . O
least . . O
moderate . . O
intensity . . O
observed . . O
in . . O
other . . O
trials . . O
were . . O
acquired . . B-AdverseReaction
lipodystrophy . . I-AdverseReaction
, . . O
angioneurotic . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
erythema . . B-AdverseReaction
multiforme . . I-AdverseReaction
and . . O
haemorrhagic . . B-AdverseReaction
stroke . . I-AdverseReaction
, . . O
each . . O
reported . . O
in . . O
no . . O
more . . O
than . . O
0.5% . . O
of . . O
subjects . . O
. . . O

in . . O
addition . . O
, . . O
patients . . O
taking . . O
edarbi . . O
who . . O
had . . O
moderate . . O
to . . O
severe . . O
renal . . O
impairment . . O
at . . O
baseline . . O
or . . O
who . . O
were . . O
> . . O
75 . . O
years . . O
of . . O
age . . O
were . . O
more . . O
likely . . O
to . . O
report . . O
serum . . B-AdverseReaction
creatinine . . I-AdverseReaction
increases . . I-AdverseReaction
. . . O

during . . O
adult . . O
pre . . O
- . . O
marketing . . O
clinical . . O
trials . . O
with . . O
saphris . . O
, . . O
including . . O
long . . O
- . . O
term . . O
trials . . O
without . . O
comparison . . O
to . . O
placebo . . O
, . . O
syncope . . B-AdverseReaction
was . . O
reported . . O
in . . O
0.6% . . O
( . . O
11 . . O
/ . . O
1953 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
. . . O

monitor . . O
and . . O
treat . . O
as . . O
appropriate . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
described . . O
in . . O
more . . O
detail . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O
of . . O
the . . O
label . . O
: . . O
seizures . . B-AdverseReaction
, . . O
anaphylaxis . . B-AdverseReaction
, . . O
and . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

c . . O
. . . O
difficile . . O
produces . . O
toxins . . O
a . . O
and . . O
b . . O
which . . O
contribute . . O
to . . O
the . . O
development . . O
of . . O
cdad . . O
. . . O

clinically . . O
significant . . O
cardiovascular . . O
effects . . O
and . . O
fatalities . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
excessive . . O
use . . O
of . . O
inhaled . . B-DrugClass
sympathomimetic . . I-DrugClass
drugs . . I-DrugClass
. . . O

* . . O
patients . . O
with . . O
smaller . . O
neck . . O
muscle . . O
mass . . O
and . . O
patients . . O
who . . O
require . . O
bilateral . . O
injections . . O
into . . O
the . . O
sternocleidomastoid . . O
muscles . . O
are . . O
at . . O
greater . . O
risk . . B-Factor
of . . O
dysphagia . . B-AdverseReaction
. . . O

serious . . B-Severity
febrile . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
fever . . B-AdverseReaction
of . . O
any . . O
severity . . O
complicated . . O
by . . O
hypotension . . B-AdverseReaction
, . . O
rigors . . B-AdverseReaction
or . . O
chills . . B-AdverseReaction
, . . O
dehydration . . B-AdverseReaction
, . . O
or . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
administered . . O
as . . O
a . . O
single . . O
agent . . O
or . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

patients . . O
should . . O
be . . O
instructed . . O
to . . O
report . . O
any . . O
symptoms . . O
suggestive . . O
of . . O
endophthalmitis . . O
or . . O
retinal . . O
detachment . . O
without . . O
delay . . O
and . . O
should . . O
be . . O
managed . . O
appropriately . . O
[ . . O
seedosage . . O
and . . O
administration . . O
( . . O
2.7 . . O
) . . O
andpatient . . O
counseling . . O
information . . O
( . . O
17 . . O
) . . O
] . . O
. . . O

clinically . . O
significant . . O
hyponatremia . . B-AdverseReaction
( . . O
sodium . . O
< . . O
125 . . O
meq . . O
/ . . O
l . . O
) . . O
can . . O
develop . . O
in . . O
patients . . O
taking . . O
aptiom . . O
. . . O

one . . O
case . . O
of . . O
mtc . . B-AdverseReaction
was . . O
reported . . O
in . . O
a . . O
patient . . O
treated . . O
with . . O
trulicity . . O
. . . O

5.3 . . O
hypoglycemia . . O
with . . O
concomitant . . O
use . . O
with . . O
insulin . . O
and . . O
insulin . . O
secretagogues . . O

new . . O
onset . . O
or . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
has . . O
been . . O
reported . . O
during . . O
treatment . . O
with . . O
multaq . . O
in . . O
the . . O
postmarketing . . O
setting . . O
. . . O

use . . O
of . . O
duavee . . O
in . . O
patients . . O
with . . O
hepatic . . O
impairment . . O
is . . O
contraindicated . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

benlysta . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
combination . . O
with . . O
other . . O
biologic . . O
therapies . . O
, . . O
including . . O
b . . O
- . . O
cell . . O
targeted . . O
therapies . . O
, . . O
or . . O
intravenous . . O
cyclophosphamide . . O
. . . O

vascular . . O
disorders . . O
: . . O
hemorrhage . . B-AdverseReaction

elderly . . O
patients . . O
and . . O
patients . . O
with . . O
impaired . . O
renal . . O
function . . O
were . . O
more . . O
susceptible . . O
to . . O
these . . O
adverse . . O
reactions . . O
( . . O
see . . O
table . . O
4 . . O
) . . O
. . . O

adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
postapproval . . O
use . . O
of . . O
uloric . . O
. . . O

do . . O
not . . O
administer . . O
cometriq . . O
to . . O
patients . . O
with . . O
severe . . O
hemorrhage . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
hypoglycemia . . B-AdverseReaction
: . . O
in . . O
patients . . O
taking . . O
insulin . . O
or . . O
an . . O
insulin . . O
secretagogue . . O
with . . O
farxiga . . O
, . . O
consider . . O
a . . O
lower . . O
dose . . O
of . . O
insulin . . O
or . . O
the . . O
insulin . . O
secretagogue . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
. . . O

( . . O
5.14 . . O
) . . O
* . . O
see . . O
full . . O
prescribing . . O
information . . O
for . . O
additional . . O
warnings . . O
and . . O
precautions . . O
. . . O

long . . O
- . . O
acting . . O
beta2 . . O
- . . O
adrenergic . . O
agonists . . O
( . . O
laba . . B-DrugClass
) . . O
, . . O
such . . O
as . . O
vilanterol . . O
, . . O
one . . O
of . . O
the . . O
active . . O
ingredients . . O
in . . O
breo . . O
ellipta . . O
, . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
. . . O

in . . B-Factor
vitro . . I-Factor
studies . . I-Factor
with . . O
human . . O
platelets . . O
indicate . . O
that . . O
stendra . . O
potentiates . . B-AdverseReaction
the . . I-AdverseReaction
anti . . I-AdverseReaction
- . . I-AdverseReaction
aggregatory . . I-AdverseReaction
effect . . I-AdverseReaction
of . . I-AdverseReaction
sodium . . I-AdverseReaction
nitroprusside . . I-AdverseReaction
( . . O
a . . O
nitric . . O
oxide . . O
[ . . O
no . . O
] . . O
donor . . O
) . . O
. . . O

there . . O
were . . O
no . . B-Negation
reports . . O
of . . O
gynecomastia . . B-AdverseReaction
in . . O
this . . O
trial . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
supine . . B-AdverseReaction
hypertension . . I-AdverseReaction

to . . O
decrease . . O
thyroid . . O
accumulation . . O
of . . O
iodine . . O
123 . . O
, . . O
block . . O
the . . O
thyroid . . O
gland . . O
before . . O
administration . . O
of . . O
datscan . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

keep . . O
out . . O
of . . O
reach . . O
of . . O
children . . O
. . . O

table . . O
2 . . O
: . . O
adverse . . O
drug . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
642 . . O
ferriprox . . O
- . . O
treated . . O
patients . . O
body . . O
system . . O
% . . O
subjects . . O
preferred . . O
term . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
neutropenia . . B-AdverseReaction
6.2 . . O
agranulocytosis . . B-AdverseReaction
1.7 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
12.6 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
/ . . O
discomfort . . O
10.4 . . O
vomiting . . B-AdverseReaction
9.8 . . O
diarrhea . . B-AdverseReaction
3.0 . . O
dyspepsia . . B-AdverseReaction
2.0 . . O
investigations . . O
alanine . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
7.5 . . O
neutrophil . . B-AdverseReaction
count . . I-AdverseReaction
decreased . . I-AdverseReaction
7.3 . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
1.9 . . O
aspartate . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
1.2 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
increased . . B-AdverseReaction
appetite . . I-AdverseReaction
4.0 . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
1.1 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
arthralgia . . B-AdverseReaction
9.8 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
2.0 . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
1.9 . . O
arthropathy . . B-AdverseReaction
1.4 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
2.5 . . O
urinary . . O
disorders . . O
chromaturia . . B-AdverseReaction
14.6 . . O
gastrointestinal . . O
symptoms . . O
such . . O
as . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
and . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
were . . O
the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
reported . . O
by . . O
patients . . O
participating . . O
in . . O
clinical . . O
trials . . O
and . . O
led . . O
to . . O
the . . O
discontinuation . . O
of . . O
ferriprox . . O
therapy . . O
in . . O
1.6% . . O
of . . O
patients . . O
. . . O

serious . . B-Severity
infections . . B-AdverseReaction
occurred . . O
in . . O
6.0% . . O
of . . O
patients . . O
treated . . O
with . . O
benlysta . . O
and . . O
in . . O
5.2% . . O
of . . O
patients . . O
who . . O
received . . O
placebo . . O
. . . O

treatment . . O
- . . O
experienced . . O
, . . O
integrase . . O
strand . . O
transfer . . O
inhibitor . . O
- . . O
naive . . O
subjects . . O
: . . O
in . . O
an . . O
international . . O
, . . O
multicenter . . O
, . . O
double . . O
- . . O
blind . . O
trial . . O
( . . O
ing111762 . . O
, . . O
sailing . . O
) . . O
, . . O
719 . . O
hiv . . O
- . . O
1 . . O
- . . O
infected . . O
, . . O
antiretroviral . . O
treatment . . O
- . . O
experienced . . O
adults . . O
were . . O
randomized . . O
and . . O
received . . O
either . . O
tivicay . . O
50 . . O
mg . . O
once . . O
daily . . O
or . . O
raltegravir . . O
400 . . O
mg . . O
twice . . O
daily . . O
with . . O
investigator . . O
- . . O
selected . . O
background . . O
regimen . . O
consisting . . O
of . . O
up . . O
to . . O
2 . . O
agents . . O
, . . O
including . . O
at . . O
least . . O
one . . O
fully . . O
active . . O
agent . . O
. . . O

cyp3a4 . . O
inducers . . O
/ . . O
inhibitors . . O

common . . O
adverse . . O
events . . O
( . . O
> . . O
= . . O
10% . . O
) . . O

although . . O
the . . O
effect . . O
of . . O
supplementation . . O
with . . O
calcium . . O
and . . O
vitamin . . O
d . . O
was . . O
not . . O
studied . . O
, . . O
such . . O
supplementation . . O
may . . O
be . . O
beneficial . . O
in . . O
all . . O
patients . . O
. . . O

monitor . . O
blood . . O
pressure . . O
, . . O
serum . . O
potassium . . O
and . . O
symptoms . . O
of . . O
fluid . . O
retention . . O
at . . O
least . . O
monthly . . O
. . . O

nervous . . O
system . . O
disorders . . O
: . . O
infrequent . . O
- . . O
paresthesia . . B-AdverseReaction
, . . O
psychomotor . . B-AdverseReaction
hyperactivity . . I-AdverseReaction
, . . O
restlessness . . B-AdverseReaction
, . . O
amnesia . . B-AdverseReaction
, . . O
nystagmus . . B-AdverseReaction
; . . O
rare . . O
- . . O
restless . . B-AdverseReaction
legs . . I-AdverseReaction
syndrome . . I-AdverseReaction

the . . O
events . . O
were . . O
reported . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
subjects . . O
receiving . . O
tivicay . . O
in . . O
phase . . O
3 . . O
clinical . . O
trials . . O
. . . O

all . . O
other . . O
patients . . O
tested . . O
negative . . O
for . . O
inhibition . . O
of . . O
cellular . . O
uptake . . O
. . . O

* . . O
do . . O
not . . O
use . . O
estrogens . . O
to . . O
prevent . . O
heart . . O
disease . . O
, . . O
heart . . O
attacks . . O
, . . O
strokes . . O
or . . O
dementia . . O
( . . O
decline . . O
in . . O
brain . . O
function . . O
) . . O
. . . O

the . . O
radiation . . O
dose . . O
to . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
may . . O
be . . O
increased . . O
due . . O
to . . O
the . . O
delayed . . O
elimination . . O
of . . O
the . . O
drug . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
neuropsychiatric . . B-AdverseReaction
symptoms . . I-AdverseReaction
: . . O
monitor . . O
for . . O
confusional . . O
state . . O
, . . O
psychotic . . O
symptoms . . O
, . . O
and . . O
hallucinations . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
endometrial . . B-AdverseReaction
cancer . . I-AdverseReaction
, . . O
cardiovascular . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
and . . O
probable . . B-Factor
dementia . . B-AdverseReaction

monitor . . O
patients . . O
for . . O
pulmonary . . O
symptoms . . O
indicative . . O
of . . O
ild . . O
/ . . O
pneumonitis . . O
. . . O

prescriptions . . O
for . . O
saphris . . O
should . . O
be . . O
written . . O
for . . O
the . . O
smallest . . O
quantity . . O
of . . O
tablets . . O
consistent . . O
with . . O
good . . O
patient . . O
management . . O
in . . O
order . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
overdose . . O
. . . O

table . . O
2 . . O
. . . O

monitor . . O
patients . . O
for . . O
the . . O
development . . O
of . . O
signs . . O
and . . O
symptoms . . O
of . . O
tuberculosis . . O
including . . O
patients . . O
who . . O
tested . . O
negative . . O
for . . O
latent . . O
tuberculosis . . O
infection . . O
prior . . O
to . . O
initiating . . O
therapy . . O
, . . O
patients . . O
who . . O
are . . O
on . . O
treatment . . O
for . . O
latent . . O
tuberculosis . . O
, . . O
or . . O
patients . . O
who . . O
were . . O
previously . . O
treated . . O
for . . O
tuberculosis . . O
infection . . O
. . . O

* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
serious . . B-Severity
systemic . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
including . . O
anaphylaxis . . B-AdverseReaction
may . . B-Factor
occur . . O
( . . O
5.10 . . O
) . . O
. . . O

the . . O
overall . . O
incidence . . O
of . . O
bone . . B-AdverseReaction
pain . . I-AdverseReaction
in . . O
cycle . . O
1 . . O
of . . O
treatment . . O
was . . O
3.4% . . O
( . . O
3.4% . . O
granix . . O
, . . O
1.4% . . O
placebo . . O
, . . O
7.5% . . O
non . . O
- . . O
us . . O
- . . O
approved . . O
filgrastim . . O
product . . O
) . . O
. . . O

patients . . O
in . . O
the . . O
treatment . . O
studies . . O
who . . O
rolled . . O
over . . O
into . . O
the . . O
re . . O
- . . O
sonate . . O
study . . O
had . . O
combined . . O
treatment . . O
duration . . O
up . . O
to . . O
9 . . O
months . . O
, . . O
with . . O
mean . . O
exposure . . O
of . . O
165 . . O
days . . O
. . . O

these . . O
clinical . . O
trials . . O
excluded . . O
patients . . O
with . . O
diabetes . . O
mellitus . . O
, . . O
a . . O
known . . O
risk . . O
factor . . O
for . . O
macular . . O
edema . . O
( . . O
see . . O
below . . O
macular . . O
edema . . O
in . . O
patients . . O
with . . O
history . . O
of . . O
uveitis . . O
or . . O
diabetes . . O
mellitus . . O
) . . O
. . . O

in . . O
other . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
( . . O
9 . . O
of . . O
1044 . . O
; . . O
0.9% . . O
) . . O
, . . O
a . . O
combination . . O
of . . O
penile . . B-AdverseReaction
ecchymoses . . I-AdverseReaction
or . . O
hematoma . . O
, . . O
sudden . . O
penile . . B-AdverseReaction
detumescence . . I-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
a . . O
penile . . B-AdverseReaction
" . . I-AdverseReaction
popping . . I-AdverseReaction
" . . I-AdverseReaction
sound . . I-AdverseReaction
or . . O
sensation . . O
was . . O
reported . . O
, . . O
and . . O
in . . O
these . . O
cases . . O
, . . O
a . . O
diagnosis . . O
of . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
cannot . . B-Factor
be . . I-Factor
excluded . . I-Factor
. . . O

treatment . . O
discontinuation . . O
due . . O
to . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
35 . . O
/ . . O
1300 . . O
( . . O
2.7% . . O
) . . O
of . . O
patients . . O
receiving . . O
teflaro . . O
and . . O
48 . . O
/ . . O
1297 . . O
( . . O
3.7% . . O
) . . O
of . . O
patients . . O
receiving . . O
comparator . . O
drugs . . O
with . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
being . . O
hypersensitivity . . B-AdverseReaction
for . . O
both . . O
treatment . . O
groups . . O
at . . O
a . . O
rate . . O
of . . O
0.3% . . O
in . . O
the . . O
teflaro . . O
group . . O
and . . O
0.5% . . O
in . . O
comparator . . O
group . . O
. . . O

the . . O
other . . O
most . . O
common . . O
reactions . . O
were . . O
flushing . . B-AdverseReaction
( . . O
0.3% . . O
) . . O
and . . O
headache . . B-AdverseReaction
( . . O
0.4% . . O
) . . O
. . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
hemorrhagic . . B-AdverseReaction
events . . I-AdverseReaction
were . . O
reported . . O
in . . O
58 . . O
/ . . O
359 . . O
patients . . O
( . . O
16% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
64 . . O
/ . . O
355 . . O
patients . . O
( . . O
18% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

atypical . . B-AdverseReaction
femoral . . I-AdverseReaction
fractures . . I-AdverseReaction
most . . O
commonly . . O
occur . . O
with . . O
minimal . . O
or . . O
no . . O
trauma . . O
to . . O
the . . O
affected . . O
area . . O
. . . O

adverse . . O
reactions . . O
reported . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
subjects . . O
were . . O
: . . O
facial . . B-AdverseReaction
paresis . . I-AdverseReaction
( . . O
brow . . B-AdverseReaction
ptosis . . I-AdverseReaction
) . . O
, . . O
muscle . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
elevation . . B-AdverseReaction
of . . I-AdverseReaction
eyebrow . . I-AdverseReaction
) . . O
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
. . . O

half . . O
of . . O
the . . O
patients . . O
in . . O
the . . O
controlled . . O
trials . . O
who . . O
discontinued . . O
potiga . . O
due . . O
to . . O
hallucinations . . B-AdverseReaction
or . . O
psychosis . . B-AdverseReaction
required . . O
hospitalization . . O
. . . O

drugs . . O
that . . O
affect . . O
the . . O
immune . . O
system . . O
by . . O
blocking . . O
tnf . . O
have . . O
been . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . O
of . . O
new . . O
tuberculosis . . O
and . . O
reactivation . . O
of . . O
latent . . O
tuberculosis . . O
( . . O
tb . . O
) . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
there . . O
were . . O
uncommon . . O
reports . . O
of . . O
ischemic . . B-AdverseReaction
cardiac . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
myocardial . . B-AdverseReaction
ischemia . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
and . . O
coronary . . B-AdverseReaction
occlusion . . I-AdverseReaction
requiring . . O
revascularization . . O
; . . O
these . . O
patients . . O
had . . O
multiple . . O
underlying . . O
cardiac . . O
risk . . O
factors . . O
. . . O

on . . O
average . . O
, . . O
women . . O
with . . O
hepatic . . O
impairment . . O
treated . . O
with . . O
bazedoxifene . . O
alone . . O
showed . . O
a . . O
4.3 . . O
- . . O
fold . . O
increase . . O
in . . O
overall . . O
exposures . . O
compared . . O
with . . O
controls . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.7 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

two . . O
patients . . O
with . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
have . . O
had . . O
more . . O
extensive . . O
diagnostic . . O
retinal . . O
evaluations . . O
. . . O

no . . O
single . . O
cause . . O
of . . O
death . . B-AdverseReaction
predominated . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
entereg . . O
12 . . O
mg . . O
in . . O
1,793 . . O
patients . . O
in . . O
10 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
paradoxical . . B-AdverseReaction
bronchospasm . . I-AdverseReaction
: . . O
discontinue . . O
tudorza . . O
pressair . . O
and . . O
consider . . O
other . . O
treatments . . O
if . . O
paradoxical . . O
bronchospasm . . O
occurs . . O
. . . O

additional . . O
adverse . . O
reactions . . O

in . . O
treatment . . O
- . . O
naive . . O
subjects . . O
, . . O
a . . O
mean . . O
change . . O
from . . O
baseline . . O
of . . O
0.15 . . O
mg . . O
per . . O
dl . . O
( . . O
range . . O
: . . O
- . . O
0.32 . . O
mg . . O
per . . O
dl . . O
to . . O
0.65 . . O
mg . . O
per . . O
dl . . O
) . . O
was . . O
observed . . O
after . . O
96 . . O
weeks . . O
of . . O
treatment . . O
. . . O

* . . O
the . . O
risk . . B-Factor
for . . O
nsf . . B-AdverseReaction
appears . . O
highest . . O
among . . O
patients . . O
with . . O
: . . O
chronic . . O
, . . O
severe . . O
kidney . . O
disease . . O
( . . O
gfr . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m2 . . O
) . . O
, . . O
oracute . . O
kidney . . O
injury . . O
. . . O

use . . O
of . . O
tnf . . O
- . . O
blockers . . O
, . . O
of . . O
which . . O
simponi . . O
aria . . O
is . . O
a . . O
member . . O
, . . O
has . . O
been . . O
associated . . O
with . . O
rare . . O
cases . . O
of . . O
new . . O
onset . . O
or . . O
exacerbation . . O
of . . O
central . . O
nervous . . O
system . . O
( . . O
cns . . O
) . . O
demyelinating . . O
disorders . . O
, . . O
including . . O
multiple . . B-AdverseReaction
sclerosis . . I-AdverseReaction
( . . O
ms . . B-AdverseReaction
) . . O
and . . O
peripheral . . B-AdverseReaction
demyelinating . . I-AdverseReaction
disorders . . I-AdverseReaction
, . . O
including . . O
guillain . . B-AdverseReaction
- . . I-AdverseReaction
barre . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

the . . O
data . . O
in . . O
table . . O
5 . . O
are . . O
derived . . O
from . . O
343 . . O
patients . . O
with . . O
alk . . O
- . . O
positive . . O
metastatic . . O
nsclc . . O
enrolled . . O
in . . O
a . . O
randomized . . O
, . . O
multicenter . . O
, . . O
active . . O
- . . O
controlled . . O
, . . O
open . . O
- . . O
label . . O
trial . . O
( . . O
study . . O
2 . . O
) . . O
. . . O

manage . . O
with . . O
dose . . O
delay . . O
and . . O
adjustment . . O
( . . O
2.2 . . O
, . . O
5.2 . . O
, . . O
6 . . O
) . . O
* . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
can . . B-Factor
occur . . O
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
( . . O
5.3 . . O
) . . O
( . . O
8.1 . . O
) . . O
* . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
: . . O
monitor . . O
for . . O
prolonged . . O
qt . . O
intervals . . O
in . . O
patients . . O
with . . O
congestive . . O
heart . . O
failure . . O
, . . O
bradyarrhythmias . . O
, . . O
drugs . . O
known . . O
to . . O
prolong . . O
the . . O
qt . . O
interval . . O
, . . O
and . . O
electrolyte . . O
abnormalities . . O
. . . O

* . . O
malignancies . . B-AdverseReaction
- . . O
more . . O
cases . . O
of . . O
lymphoma . . B-AdverseReaction
have . . O
been . . O
observed . . O
among . . O
patients . . O
receiving . . O
tnf . . O
- . . O
blockers . . O
compared . . O
with . . O
patients . . O
in . . O
the . . O
control . . O
groups . . O
. . . O

stribild . . O
should . . O
be . . O
discontinued . . O
if . . O
estimated . . O
creatinine . . O
clearance . . O
declines . . O
below . . O
50 . . O
ml . . O
per . . O
minute . . O
as . . O
dose . . O
interval . . O
adjustment . . O
required . . O
for . . O
emtricitabine . . O
and . . O
tenofovir . . O
df . . O
cannot . . O
be . . O
achieved . . O
with . . O
the . . O
fixed . . O
- . . O
dose . . O
combination . . O
tablet . . O
. . . O

5.6 . . O
cardiovascular . . O
effects . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
following . . O
adreview . . O
administration . . O
. . . O

gilenya . . O
may . . O
therefore . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
infections . . O
, . . O
some . . O
serious . . B-Severity
in . . O
nature . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

* . . O
active . . B-AdverseReaction
tuberculosis . . I-AdverseReaction
, . . O
including . . O
reactivation . . B-AdverseReaction
of . . I-AdverseReaction
latent . . I-AdverseReaction
tuberculosis . . I-AdverseReaction
. . . O

immunogenicity . . O

the . . O
preservative . . O
in . . O
bepreve . . O
, . . O
benzalkonium . . O
chloride . . O
, . . O
may . . O
be . . O
absorbed . . O
by . . O
soft . . O
contact . . O
lenses . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
eye . . B-AdverseReaction
irritation . . I-AdverseReaction
: . . O
avoid . . O
eye . . O
exposure . . O
. . . O

hypertension . . B-AdverseReaction
led . . O
to . . O
study . . O
discontinuation . . O
in . . O
< . . O
1% . . O
of . . O
patients . . O
in . . O
each . . O
arm . . O
. . . O

table . . O
2 . . O
: . . O
incidence . . O
of . . O
hematology . . O
laboratory . . O
abnormalities . . O
in . . O
patients . . O
who . . O
received . . O
treanda . . O
or . . O
chlorambucil . . O
in . . O
the . . O
randomized . . O
cll . . O
clinical . . O
study . . O
treanda . . O
n . . O
= . . O
150 . . O
chlorambuciln . . O
= . . O
141 . . O
laboratory . . O
abnormality . . O
all . . O
gradesn . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4n . . O
( . . O
% . . O
) . . O
all . . O
gradesn . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4n . . O
( . . O
% . . O
) . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
134 . . O
( . . O
89 . . O
) . . O
20 . . O
( . . O
13 . . O
) . . O
115 . . O
( . . O
82 . . O
) . . O
12 . . O
( . . O
9 . . O
) . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
116 . . O
( . . O
77 . . O
) . . O
16 . . O
( . . O
11 . . O
) . . O
110 . . O
( . . O
78 . . O
) . . O
14 . . O
( . . O
10 . . O
) . . O
leukocytes . . B-AdverseReaction
decreased . . I-AdverseReaction
92 . . O
( . . O
61 . . O
) . . O
42 . . O
( . . O
28 . . O
) . . O
26 . . O
( . . O
18 . . O
) . . O
4 . . O
( . . O
3 . . O
) . . O
lymphocytes . . B-AdverseReaction
decreased . . I-AdverseReaction
102 . . O
( . . O
68 . . O
) . . O
70 . . O
( . . O
47 . . O
) . . O
27 . . O
( . . O
19 . . O
) . . O
6 . . O
( . . O
4 . . O
) . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
113 . . O
( . . O
75 . . O
) . . O
65 . . O
( . . O
43 . . O
) . . O
86 . . O
( . . O
61 . . O
) . . O
30 . . O
( . . O
21 . . O
) . . O
in . . O
the . . O
cll . . O
trial . . O
, . . O
34% . . O
of . . O
patients . . O
had . . O
bilirubin . . B-AdverseReaction
elevations . . I-AdverseReaction
, . . O
some . . O
without . . B-Negation
associated . . O
significant . . B-Severity
elevations . . O
in . . O
ast . . O
and . . O
alt . . O
. . . O

one . . O
of . . O
these . . O
forms . . O
of . . O
contraception . . O
can . . O
be . . O
a . . O
combined . . O
oral . . O
contraceptive . . O
product . . O
containing . . O
at . . O
least . . O
1 . . O
mg . . O
of . . O
norethindrone . . O
. . . O

prior . . O
to . . O
adreview . . O
administration . . O
, . . O
ensure . . O
emergency . . O
cardiac . . O
and . . O
anti . . O
- . . O
hypertensive . . O
treatments . . O
are . . O
readily . . O
available . . O
. . . O

invasive . . O
fungal . . O
infections . . O

complete . . O
treatment . . O
of . . O
pre . . O
- . . O
existing . . O
invasive . . O
fungal . . O
infections . . O
prior . . O
to . . O
starting . . O
treatment . . O
with . . O
afinitor . . O
. . . O

six . . O
of . . O
the . . O
9 . . O
patients . . O
were . . O
hospitalized . . O
for . . O
severe . . B-Severity
endocrinopathies . . B-AdverseReaction
. . . O

6 . . O
adverse . . O
reactions . . O

* . . O
cimzia . . O
should . . O
be . . O
discontinued . . O
if . . O
a . . O
patient . . O
develops . . O
a . . O
serious . . O
infection . . O
or . . O
sepsis . . O
( . . O
5.1 . . O
) . . O
. . . O

appropriate . . O
medical . . O
support . . O
, . . O
including . . O
cardiopulmonary . . O
resuscitation . . O
equipment . . O
, . . O
should . . O
be . . O
readily . . O
available . . O
when . . O
alglucosidase . . O
alfa . . O
is . . O
administered . . O
. . . O

* . . O
hypotension . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
impairment . . B-AdverseReaction
in . . I-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
hyperkalemia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
hypoglycemia . . B-AdverseReaction
with . . O
concomitant . . O
use . . O
with . . O
insulin . . O
and . . O
insulin . . O
secretagogues . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
bone . . B-AdverseReaction
fracture . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
low . . I-AdverseReaction
- . . I-AdverseReaction
density . . I-AdverseReaction
lipoprotein . . I-AdverseReaction
( . . O
ldl . . O
- . . O
c . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
* . . O
most . . O
common . . O
adverse . . O
reactions . . O
associated . . O
with . . O
invokana . . O
( . . O
5% . . O
or . . O
greater . . O
incidence . . O
) . . O
: . . O
female . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
and . . O
increased . . B-AdverseReaction
urination . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
excerpt . . O
: . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
janssen . . O
pharmaceuticals . . O
, . . O
inc . . O
. . . O
at . . O
1-800-526-7736 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

copd . . O
may . . O
deteriorate . . O
acutely . . O
over . . O
a . . O
period . . O
of . . O
hours . . O
or . . O
chronically . . O
over . . O
several . . O
days . . O
or . . O
longer . . O
. . . O

you . . O
may . . O
report . . O
side . . O
effects . . O
to . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
. . . O

in . . O
monotherapy . . O
trials . . O
in . . O
patients . . O
with . . O
partial . . O
- . . O
onset . . O
seizures . . O
[ . . O
study . . O
1 . . O
and . . O
study . . O
2 . . O
, . . O
see . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
, . . O
365 . . O
patients . . O
received . . O
aptiom . . O
, . . O
of . . O
whom . . O
225 . . O
were . . O
treated . . O
for . . O
longer . . O
than . . O
12 . . O
months . . O
and . . O
134 . . O
for . . O
longer . . O
than . . O
24 . . O
months . . O
. . . O

the . . O
placebo . . O
- . . O
controlled . . O
experience . . O
with . . O
cleviprex . . O
in . . O
the . . O
perioperative . . O
setting . . O
was . . O
both . . O
small . . O
and . . O
brief . . O
( . . O
about . . O
30 . . O
minutes . . O
) . . O
. . . O

at . . O
baseline . . O
, . . O
the . . O
population . . O
had . . O
diabetes . . O
for . . O
an . . O
average . . O
of . . O
8.2 . . O
years . . O
and . . O
had . . O
a . . O
mean . . O
hba1c . . O
of . . O
7.6-8.5% . . O
. . . O

data . . O
from . . O
a . . O
large . . O
placebo . . O
- . . O
controlled . . O
us . . O
trial . . O
that . . O
compared . . O
the . . O
safety . . O
of . . O
another . . O
laba . . B-DrugClass
( . . O
salmeterol . . O
) . . O
with . . O
placebo . . O
added . . O
to . . O
usual . . O
asthma . . O
therapy . . O
showed . . O
an . . O
increase . . O
in . . O
asthma . . O
- . . O
related . . O
deaths . . B-AdverseReaction
in . . O
subjects . . O
receiving . . O
salmeterol . . O
. . . O

malignancies . . B-AdverseReaction
, . . O
excluding . . B-Negation
non . . B-AdverseReaction
- . . I-AdverseReaction
melanoma . . I-AdverseReaction
skin . . I-AdverseReaction
cancer . . I-AdverseReaction
and . . O
ptld . . B-AdverseReaction
, . . O
were . . O
reported . . O
in . . O
study . . O
1 . . O
and . . O
study . . O
2 . . O
in . . O
3.5% . . O
( . . O
14 . . O
/ . . O
401 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
the . . O
recommended . . O
nulojix . . O
regimen . . O
and . . O
3.7% . . O
( . . O
15 . . O
/ . . O
405 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
the . . O
cyclosporine . . O
control . . O
regimen . . O
. . . O

* . . O
renal . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

patients . . O
without . . O
a . . O
healthcare . . O
professional . . O
confirmed . . O
history . . O
of . . O
chickenpox . . O
or . . O
without . . O
documentation . . O
of . . O
a . . O
full . . O
course . . O
of . . O
vaccination . . O
against . . O
varicella . . O
zoster . . O
virus . . O
( . . O
vzv . . O
) . . O
should . . O
be . . O
tested . . O
for . . O
antibodies . . O
to . . O
vzv . . O
before . . O
initiating . . O
gilenya . . O
. . . O

institute . . O
medical . . O
intervention . . O
as . . O
appropriate . . O
for . . O
management . . O
of . . O
severe . . O
neuropathy . . O
. . . O

given . . O
these . . O
confounders . . O
, . . O
the . . O
relationship . . O
between . . O
atypical . . B-DrugClass
antipsychotic . . I-DrugClass
use . . O
and . . O
hyperglycemia . . B-AdverseReaction
- . . O
related . . O
adverse . . O
reactions . . O
is . . O
not . . O
completely . . O
understood . . O
. . . O

based . . O
on . . O
the . . O
visual . . O
symptom . . O
assessment . . O
questionnaire . . O
( . . O
vsaq . . O
- . . O
alk . . O
) . . O
, . . O
patients . . O
treated . . O
with . . O
xalkori . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
reported . . O
a . . O
higher . . O
incidence . . O
of . . O
visual . . B-AdverseReaction
disturbances . . I-AdverseReaction
compared . . O
to . . O
patients . . O
treated . . O
with . . O
chemotherapy . . O
. . . O

bedaquiline . . O
is . . O
metabolized . . O
by . . O
cyp3a4 . . O
and . . O
its . . O
systemic . . O
exposure . . O
and . . O
therapeutic . . O
effect . . O
may . . O
therefore . . O
be . . O
reduced . . O
during . . O
co . . O
- . . O
administration . . O
with . . O
inducers . . O
of . . O
cyp3a4 . . O
. . . O

serious . . B-Severity
skin . . B-AdverseReaction
toxicity . . I-AdverseReaction
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
and . . O
with . . O
trametinib . . O
as . . O
a . . O
single . . O
agent . . O
[ . . O
refer . . O
to . . O
full . . O
prescribing . . O
information . . O
for . . O
trametinib . . O
] . . O
. . . O

women . . O
of . . O
childbearing . . O
potential . . O
should . . O
be . . O
advised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
and . . O
to . . O
avoid . . O
becoming . . O
pregnant . . O
while . . O
receiving . . O
inlyta . . O
. . . O

with . . O
the . . O
interventions . . O
used . . O
for . . O
anemia . . O
management . . O
in . . O
the . . O
clinical . . O
trials . . O
, . . O
the . . O
average . . O
additional . . O
decrease . . O
of . . O
hemoglobin . . O
was . . O
approximately . . O
1 . . O
g . . O
per . . O
dl . . O
. . . O

the . . O
incidence . . O
of . . O
adverse . . O
events . . O
resulting . . O
in . . O
permanent . . O
discontinuation . . O
of . . O
study . . O
medication . . O
in . . O
trial . . O
1 . . O
was . . O
3% . . O
for . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
and . . O
3% . . O
for . . O
patients . . O
treated . . O
with . . O
dacarbazine . . O
. . . O

most . . O
adverse . . O
reactions . . O
were . . O
local . . O
events . . O
of . . O
the . . O
penis . . O
and . . O
groin . . O
and . . O
the . . O
majority . . O
of . . O
these . . O
events . . O
were . . O
of . . O
mild . . B-Severity
or . . O
moderate . . B-Severity
severity . . O
, . . O
and . . O
most . . O
( . . O
79% . . O
) . . O
resolved . . O
within . . O
14 . . O
days . . O
of . . O
the . . O
injection . . O
. . . O

a . . O
placebo . . O
- . . O
controlled . . O
trial . . O
with . . O
another . . O
laba . . B-DrugClass
( . . O
salmeterol . . O
) . . O
showed . . O
an . . O
increase . . O
in . . O
asthma . . O
- . . O
related . . O
deaths . . B-AdverseReaction
. . . O

interrupt . . O
or . . O
discontinue . . O
zydelig . . O
. . . O

rash . . B-AdverseReaction
generally . . O
resolved . . O
within . . O
1 . . O
to . . O
2 . . O
weeks . . O
on . . O
continued . . O
therapy . . O
. . . O

vzv . . O
vaccination . . O
of . . O
antibody . . O
- . . O
negative . . O
patients . . O
is . . O
recommended . . O
prior . . O
to . . O
commencing . . O
treatment . . O
with . . O
gilenya . . O
, . . O
following . . O
which . . O
initiation . . O
of . . O
treatment . . O
with . . O
gilenya . . O
should . . O
be . . O
postponed . . O
for . . O
1 . . O
month . . O
to . . O
allow . . O
the . . O
full . . O
effect . . O
of . . O
vaccination . . O
to . . O
occur . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
safety . . O
profile . . O
for . . O
patients . . O
in . . O
study . . O
as . . O
- . . O
1 . . O
treated . . O
with . . O
cimzia . . O
was . . O
similar . . O
to . . O
the . . O
safety . . O
profile . . O
seen . . O
in . . O
patients . . O
with . . O
ra . . O
. . . O

a . . O
dose . . O
decrease . . O
is . . O
recommended . . O
when . . O
administering . . O
inlyta . . O
to . . O
patients . . O
with . . O
moderate . . O
hepatic . . O
impairment . . O
( . . O
child . . O
- . . O
pugh . . O
class . . O
b . . O
) . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O

5.7 . . O
coexisting . . O
conditions . . O

invokana . . O
is . . O
associated . . O
with . . O
a . . O
dose . . O
- . . O
dependent . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
a . . O
concomitant . . O
fall . . B-AdverseReaction
in . . I-AdverseReaction
estimated . . I-AdverseReaction
gfr . . I-AdverseReaction
( . . O
table . . O
3 . . O
) . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
compared . . O
directly . . O
to . . O
rates . . O
from . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
related . . O
to . . O
blincyto . . O
treatment . . O
were . . O
hypersensitivity . . B-AdverseReaction
( . . O
1% . . O
) . . O
and . . O
bronchospasm . . B-AdverseReaction
( . . O
< . . O
1% . . O
) . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

during . . O
prolia . . O
treatment . . O
, . . O
patients . . O
should . . O
be . . O
advised . . O
to . . O
report . . O
new . . O
or . . O
unusual . . O
thigh . . O
, . . O
hip . . O
, . . O
or . . O
groin . . O
pain . . O
. . . O

these . . O
patients . . O
should . . O
also . . O
be . . O
instructed . . O
to . . O
carry . . O
a . . O
warning . . O
card . . O
indicating . . O
that . . O
they . . O
may . . O
need . . O
supplementary . . O
systemic . . O
corticosteroids . . O
during . . O
periods . . O
of . . O
stress . . O
, . . O
a . . O
severe . . O
copd . . O
exacerbation . . O
, . . O
or . . O
a . . O
severe . . O
asthma . . O
attack . . O
. . . O

the . . O
overall . . O
safety . . O
profile . . O
of . . O
kalydeco . . O
is . . O
based . . O
on . . O
pooled . . O
data . . O
from . . O
three . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
conducted . . O
in . . O
353 . . O
patients . . O
6 . . O
years . . O
of . . O
age . . O
and . . O
older . . O
with . . O
cf . . O
who . . O
had . . O
a . . O
g551d . . O
mutation . . O
in . . O
the . . O
cftr . . O
gene . . O
( . . O
trials . . O
1 . . O
and . . O
2 . . O
) . . O
or . . O
were . . O
homozygous . . O
for . . O
the . . O
f508del . . O
mutation . . O
( . . O
trial . . O
3 . . O
) . . O
. . . O

a . . O
causal . . O
relationship . . O
between . . O
study . . O
drug . . O
and . . O
adverse . . O
reactions . . O
was . . O
not . . O
always . . O
established . . O
. . . O

} . . O
} . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
amgen . . O
inc . . O
. . . O
at . . O
1-800-77 . . O
- . . O
amgen . . O
( . . O
1-800-772-6436 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

the . . O
most . . O
common . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
> . . O
= . . O
3% . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
) . . O
were . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
. . . O

monitor . . O
blood . . O
pressure . . O
periodically . . O
during . . O
the . . O
treatment . . O
and . . O
provide . . O
adequate . . O
support . . O
for . . O
treatment . . O
related . . O
pain . . O
. . . O

* . . O
somnolence . . B-AdverseReaction
/ . . O
sedation . . B-AdverseReaction
and . . O
dizziness . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
rls . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
and . . O
at . . O
least . . O
2 . . O
times . . O
the . . O
rate . . O
of . . O
placebo . . O
) . . O
were . . O
somnolence . . B-AdverseReaction
/ . . O
sedation . . B-AdverseReaction
and . . O
dizziness . . B-AdverseReaction
. . . O

the . . O
incidence . . O
of . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

* . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
. . . O

two . . O
patients . . O
died . . B-AdverseReaction
of . . O
herpetic . . B-AdverseReaction
infections . . I-AdverseReaction
during . . O
controlled . . O
trials . . O
. . . O

( . . O
5.2 . . O
) . . O
nutritional . . O
management . . O
: . . O
in . . O
the . . O
initial . . O
treatment . . O
of . . O
nags . . O
deficiency . . O
, . . O
protein . . O
restriction . . O
is . . O
recommended . . O
. . . O

non . . B-AdverseReaction
- . . I-AdverseReaction
melanoma . . I-AdverseReaction
skin . . I-AdverseReaction
cancer . . I-AdverseReaction
was . . O
reported . . O
in . . O
1.5% . . O
( . . O
6 . . O
/ . . O
401 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
the . . O
recommended . . O
nulojix . . O
regimen . . O
and . . O
in . . O
3.7% . . O
( . . O
15 . . O
/ . . O
405 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
cyclosporine . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

the . . O
clinical . . O
significance . . O
of . . O
small . . O
changes . . O
in . . O
bmd . . O
with . . O
regard . . O
to . . O
long . . O
- . . O
term . . O
consequences . . O
such . . O
as . . O
fracture . . O
is . . O
unknown . . O
. . . O

keep . . O
a . . O
list . . O
of . . O
your . . O
medicines . . O
and . . O
show . . O
it . . O
to . . O
your . . O
healthcare . . O
provider . . O
and . . O
pharmacist . . O
when . . O
you . . O
get . . O
a . . O
new . . O
medicine . . O
. . . O

in . . O
the . . O
extension . . O
chronic . . O
itp . . O
trial . . O
, . . O
one . . O
additional . . O
patient . . O
had . . O
promacta . . O
discontinued . . O
due . . O
to . . O
liver . . O
test . . O
abnormalities . . O
( . . O
less . . O
than . . O
or . . O
equal . . O
to . . O
grade . . B-Severity
3 . . I-Severity
) . . O
. . . O

5.5 . . O
pulmonary . . O
hypertension . . O

the . . O
population . . O
was . . O
19 . . O
to . . O
97 . . O
years . . O
old . . O
, . . O
64% . . O
were . . O
female . . O
, . . O
and . . O
84% . . O
were . . O
caucasian . . O
; . . O
64% . . O
were . . O
undergoing . . O
a . . O
surgery . . O
that . . O
included . . O
bowel . . O
resection . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
a . . O
6 . . O
- . . O
dose . . O
regimen . . O
of . . O
coartem . . O
tablets . . O
in . . O
1,979 . . O
patients . . O
including . . O
647 . . O
adults . . O
( . . O
older . . O
than . . O
16 . . O
years . . O
) . . O
and . . O
1,332 . . O
children . . O
( . . O
16 . . O
years . . O
and . . O
younger . . O
) . . O
. . . O

5.3 . . O
progressive . . O
multifocal . . O
leukoencephalopathy . . O

monitor . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
pulmonary . . O
toxicity . . O
, . . O
including . . O
cough . . O
and . . O
dyspnea . . O
. . . O

5.7 . . O
intradermal . . O
immune . . O
reaction . . O

incidence . . O
of . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
at . . O
least . . O
3% . . O
of . . O
patients . . O
treated . . O
with . . O
benlysta . . O
10 . . O
mg . . O
/ . . O
kg . . O
plus . . O
standard . . O
of . . O
care . . O
and . . O
at . . O
least . . O
1% . . O
more . . O
frequently . . O
than . . O
in . . O
patients . . O
receiving . . O
placebo . . O
plus . . O
standard . . O
of . . O
care . . O
in . . O
3 . . O
controlled . . O
sle . . O
studies . . O
preferred . . O
term . . O
benlysta . . O
10 . . O
mg . . O
/ . . O
kg . . O
+ . . O
standard . . O
of . . O
care . . O
( . . O
n . . O
= . . O
674 . . O
) . . O
% . . O
placebo . . O
+ . . O
standard . . O
of . . O
care . . O
( . . O
n . . O
= . . O
675 . . O
) . . O
% . . O
nausea . . B-AdverseReaction
15 . . O
12 . . O
diarrhea . . B-AdverseReaction
12 . . O
9 . . O
pyrexia . . B-AdverseReaction
10 . . O
8 . . O
nasopharyngitis . . B-AdverseReaction
9 . . O
7 . . O
bronchitis . . B-AdverseReaction
9 . . O
5 . . O
insomnia . . B-AdverseReaction
7 . . O
5 . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
6 . . O
4 . . O
depression . . B-AdverseReaction
5 . . O
4 . . O
migraine . . B-AdverseReaction
5 . . O
4 . . O
pharyngitis . . B-AdverseReaction
5 . . O
3 . . O
cystitis . . B-AdverseReaction
4 . . O
3 . . O
leukopenia . . B-AdverseReaction
4 . . O
2 . . O
gastroenteritis . . B-AdverseReaction
viral . . I-AdverseReaction
3 . . O
1 . . O
6.2 . . O
immunogenicity . . O
in . . O
trials . . O
2 . . O
and . . O
3 . . O
, . . O
anti . . O
- . . O
belimumab . . O
antibodies . . O
were . . O
detected . . O
in . . O
4 . . O
of . . O
563 . . O
( . . O
0.7% . . O
) . . O
patients . . O
receiving . . O
benlysta . . O
10 . . O
mg . . O
/ . . O
kg . . O
and . . O
in . . O
27 . . O
of . . O
559 . . O
( . . O
4.8% . . O
) . . O
patients . . O
receiving . . O
benlysta . . O
1 . . O
mg . . O
/ . . O
kg . . O
. . . O
the . . O
reported . . O
frequency . . O
for . . O
the . . O
group . . O
receiving . . O
10 . . O
mg . . O
/ . . O
kg . . O
may . . O
underestimate . . O
the . . O
actual . . O
frequency . . O
due . . O
to . . O
lower . . O
assay . . O
sensitivity . . O
in . . O
the . . O
presence . . O
of . . O
high . . O
drug . . O
concentrations . . O
. . . O

5.8 . . O
proteinuria . . O

in . . O
this . . O
trial . . O
, . . O
the . . O
safety . . O
profile . . O
of . . O
firazyr . . O
in . . O
patients . . O
who . . O
self . . O
- . . O
administered . . O
firazyr . . O
was . . O
similar . . O
in . . O
nature . . O
and . . O
frequency . . O
to . . O
that . . O
of . . O
patients . . O
whose . . O
therapy . . O
was . . O
administered . . O
by . . O
healthcare . . O
professionals . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
ocular . . B-AdverseReaction
adverse . . I-AdverseReaction
reaction . . I-AdverseReaction
was . . O
conjunctival . . B-AdverseReaction
redness . . I-AdverseReaction
, . . O
reported . . O
in . . O
approximately . . O
2% . . O
of . . O
patients . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
enterocolitis . . B-AdverseReaction
, . . O
rectal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
gastric . . B-AdverseReaction
ulcer . . I-AdverseReaction
, . . O
pancreatitis . . B-AdverseReaction
, . . O
parotid . . B-AdverseReaction
gland . . I-AdverseReaction
enlargement . . I-AdverseReaction
. . . O

controlled . . O
studies . . O
with . . O
rheumatoid . . O
arthritis . . O

( . . O
see . . O
the . . O
respective . . O
package . . O
inserts . . O
for . . O
complete . . O
vzig . . O
and . . O
ig . . O
prescribing . . O
information . . O
. . . O
) . . O
if . . O
chickenpox . . O
develops . . O
, . . O
treatment . . O
with . . O
antiviral . . O
agents . . O
may . . O
be . . O
considered . . O
. . . O

discontinue . . O
use . . O
if . . O
severe . . O
symptoms . . O
develop . . O
( . . O
5.8 . . O
) . . O
* . . O
suppression . . B-AdverseReaction
of . . I-AdverseReaction
bone . . I-AdverseReaction
turnover . . I-AdverseReaction
: . . O
significant . . O
suppression . . O
has . . O
been . . O
demonstrated . . O
. . . O

therefore . . O
, . . O
the . . O
combination . . O
of . . O
tnf . . O
- . . O
blockers . . O
including . . O
simponi . . O
aria . . O
and . . O
abatacept . . O
is . . O
not . . O
recommended . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
] . . O
. . . O

in . . O
general . . O
, . . O
adverse . . O
events . . O
reported . . O
by . . O
intelence . . O
( . . O
r . . O
) . . O
- . . O
treated . . O
subjects . . O
with . . O
hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
hepatitis . . O
c . . O
virus . . O
co . . O
- . . O
infection . . O
were . . O
similar . . O
to . . O
intelence . . O
( . . O
r . . O
) . . O
- . . O
treated . . O
subjects . . O
without . . O
hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
hepatitis . . O
c . . O
virus . . O
co . . O
- . . O
infection . . O
. . . O

table . . O
3 . . O
presents . . O
the . . O
adverse . . O
reactions . . O
reported . . O
in . . O
this . . O
study . . O
. . . O

in . . O
randomized . . O
controlled . . O
studies . . O
, . . O
serum . . O
alanine . . O
aminotransferase . . O
( . . O
alt . . O
) . . O
elevations . . O
greater . . O
than . . O
three . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . I-Severity
uln . . I-Severity
) . . I-Severity
were . . O
observed . . O
: . . O
1.3% . . O
in . . O
alogliptin . . O
- . . O
treated . . O
patients . . O
and . . O
1.5% . . O
in . . O
all . . O
comparator . . O
- . . O
treated . . O
patients . . O
. . . O

nervousness . . B-AdverseReaction
. . . O

adverse . . O
reactions . . O
were . . O
all . . O
mild . . B-Severity
to . . O
moderate . . B-Severity
in . . O
severity . . O
and . . O
were . . O
predominantly . . O
isolated . . O
occurrences . . O
( . . O
< . . O
= . . O
2 . . O
patients . . O
) . . O
of . . O
one . . O
of . . O
the . . O
following . . O
reactions . . O
: . . O
dizziness . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
or . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
. . . O

for . . O
these . . O
events . . O
, . . O
the . . O
median . . O
time . . O
to . . O
onset . . O
was . . O
15 . . O
days . . O
. . . O

the . . O
majority . . O
of . . O
patients . . O
were . . O
able . . O
to . . O
be . . O
rechallenged . . O
with . . O
alglucosidase . . O
alfa . . O
using . . O
lower . . O
doses . . O
and . . O
/ . . O
or . . O
pretreatment . . O
with . . O
anti . . O
- . . O
inflammatory . . O
drugs . . O
and . . O
/ . . O
or . . O
corticosteroids . . O
and . . O
were . . O
able . . O
to . . O
continue . . O
treatment . . O
under . . O
close . . O
clinical . . O
supervision . . O
. . . O

in . . O
a . . O
study . . O
of . . O
55 . . O
subjects . . O
with . . O
varying . . O
degrees . . O
of . . O
renal . . O
function . . O
, . . O
serum . . O
calcium . . O
levels . . O
< . . O
7.5 . . O
mg . . O
/ . . O
dl . . O
or . . O
symptomatic . . B-AdverseReaction
hypocalcemia . . I-AdverseReaction
were . . O
observed . . O
in . . O
5 . . O
subjects . . O
. . . O

the . . O
treatment . . O
discontinuation . . O
rate . . O
due . . O
to . . O
anemia . . B-AdverseReaction
was . . O
similar . . O
in . . O
subjects . . O
randomized . . O
to . . O
receive . . O
ribavirin . . O
dose . . O
reduction . . O
compared . . O
to . . O
subjects . . O
randomized . . O
to . . O
receive . . O
esa . . O
( . . O
2% . . O
in . . O
each . . O
group . . O
) . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
canakinumab . . O
between . . O
the . . O
caps . . O
and . . O
sjia . . O
clinical . . O
studies . . O
or . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

grade . . B-Severity
3-4 . . I-Severity
lymphopenia . . B-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
hyperglycemia . . B-AdverseReaction
( . . O
7% . . O
) . . O
and . . O
high . . B-AdverseReaction
alanine . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
( . . O
6% . . O
) . . O
occurred . . O
at . . O
a . . O
greater . . O
than . . O
5% . . O
rate . . O
in . . O
the . . O
zytiga . . O
arm . . O
. . . O

among . . O
entereg . . O
- . . O
treated . . O
patients . . O
undergoing . . O
surgeries . . O
that . . O
included . . O
a . . O
bowel . . O
resection . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reaction . . O
( . . O
incidence . . O
> . . O
= . . O
1.5% . . O
) . . O
occurring . . O
with . . O
a . . O
higher . . O
frequency . . O
than . . O
placebo . . O
was . . O
dyspepsia . . B-AdverseReaction
( . . O
entereg . . O
, . . O
1.5% . . O
; . . O
placebo . . O
, . . O
0.8% . . O
) . . O
. . . O

adverse . . O
reaction . . O
xiaflexn . . O
= . . O
551 . . O
placebon . . O
= . . O
281 . . O
all . . O
adverse . . O
reactions . . O
84.2% . . O
36.3% . . O
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
a . . O
65.5% . . O
19.2% . . O
penile . . B-AdverseReaction
swelling . . I-AdverseReaction
b . . O
55.0% . . O
3.2% . . O
penile . . B-AdverseReaction
pain . . I-AdverseReaction
c . . O
45.4% . . O
9.3% . . O
penile . . B-AdverseReaction
ecchymoses . . I-AdverseReaction
d . . O
14.5% . . O
6.8% . . O
blood . . B-AdverseReaction
blister . . I-AdverseReaction
4.5% . . O
0 . . O
penile . . B-AdverseReaction
blister . . I-AdverseReaction
3.3% . . O
0 . . O
pruritus . . B-AdverseReaction
genital . . I-AdverseReaction
3.1% . . O
0 . . O
painful . . B-AdverseReaction
erection . . I-AdverseReaction
2.9% . . O
0 . . O
erectile . . B-AdverseReaction
dysfunction . . I-AdverseReaction
1.8% . . O
0.4% . . O
skin . . B-AdverseReaction
discoloration . . I-AdverseReaction
1.8% . . O
0 . . O
procedural . . B-AdverseReaction
pain . . I-AdverseReaction
1.6% . . O
0.7% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
vesicles . . I-AdverseReaction
1.3% . . O
0 . . O
localized . . B-AdverseReaction
edema . . I-AdverseReaction
1.3% . . O
0 . . O
dyspareunia . . B-AdverseReaction
1.1% . . O
0 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pruritus . . I-AdverseReaction
1.1% . . O
0 . . O
nodule . . B-AdverseReaction
1.1% . . O
0 . . O
suprapubic . . B-AdverseReaction
pain . . I-AdverseReaction
1.1% . . O
0 . . O
severe . . B-Severity
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
or . . O
severe . . B-Severity
injection . . B-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
were . . O
reported . . O
in . . O
33 . . O
/ . . O
551 . . O
( . . O
6.0% . . O
) . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
and . . O
0 . . O
/ . . O
281 . . O
( . . O
0% . . O
) . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
combined . . O
. . . O

an . . O
increased . . O
incidence . . O
of . . O
elevations . . B-AdverseReaction
of . . I-AdverseReaction
hepatic . . I-AdverseReaction
transaminases . . I-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
tecfidera . . O
was . . O
seen . . O
primarily . . O
during . . O
the . . O
first . . O
six . . O
months . . O
of . . O
treatment . . O
, . . O
and . . O
most . . O
patients . . O
with . . O
elevations . . O
had . . O
levels . . O
< . . O
3 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
( . . O
uln . . O
) . . O
. . . O

for . . O
more . . O
information . . O
, . . O
ask . . O
your . . O
healthcare . . O
provider . . O
or . . O
pharmacist . . O
. . . O

for . . O
patients . . O
taking . . O
concomitant . . O
strong . . O
cyp3a4 . . O
inhibitors . . O
( . . O
including . . O
ketoconazole . . O
, . . O
ritonavir . . O
, . . O
atazanavir . . O
, . . O
clarithromycin . . O
, . . O
indinavir . . O
, . . O
itraconazole . . O
, . . O
nefazodone . . O
, . . O
nelfinavir . . O
, . . O
saquinavir . . O
, . . O
and . . O
telithromycin . . O
) . . O
, . . O
do . . O
not . . O
use . . O
stendra . . O
[ . . O
seedrug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
] . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

they . . O
represent . . O
an . . O
evaluation . . O
of . . O
the . . O
adverse . . O
reaction . . O
data . . O
from . . O
870 . . O
patients . . O
with . . O
ph+ . . O
leukemia . . O
who . . O
received . . O
at . . O
least . . O
1 . . O
dose . . O
of . . O
single . . O
- . . O
agent . . O
bosulif . . O
. . . O

adverse . . O
reactions . . O
in . . O
study . . O
1 . . O
xtandi . . O
n . . O
= . . O
800 . . O
placebo . . O
n . . O
= . . O
399 . . O
grade . . O
1-4a . . O
( . . O
% . . O
) . . O
grade . . O
3-4 . . O
( . . O
% . . O
) . . O
grade . . O
1-4 . . O
( . . O
% . . O
) . . O
grade . . O
3-4 . . O
( . . O
% . . O
) . . O
general . . O
disorders . . O
asthenic . . B-AdverseReaction
conditionsb . . O
50.6 . . O
9.0 . . O
44.4 . . O
9.3 . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
15.4 . . O
1.0 . . O
13.3 . . O
0.8 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
26.4 . . O
5.3 . . O
24.3 . . O
4.0 . . O
arthralgia . . B-AdverseReaction
20.5 . . O
2.5 . . O
17.3 . . O
1.8 . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
15.0 . . O
1.3 . . O
11.5 . . O
0.3 . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
9.8 . . O
1.5 . . O
6.8 . . O
1.8 . . O
musculoskeletal . . B-AdverseReaction
stiffness . . I-AdverseReaction
2.6 . . O
0.3 . . O
0.3 . . O
0.0 . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
21.8 . . O
1.1 . . O
17.5 . . O
0.3 . . O
vascular . . O
disorders . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
20.3 . . O
0.0 . . O
10.3 . . O
0.0 . . O
hypertension . . B-AdverseReaction
6.4 . . O
2.1 . . O
2.8 . . O
1.3 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
12.1 . . O
0.9 . . O
5.5 . . O
0.0 . . O
dizzinessc . . O
9.5 . . O
0.5 . . O
7.5 . . O
0.5 . . O
spinal . . B-AdverseReaction
cord . . I-AdverseReaction
compression . . I-AdverseReaction
and . . O
cauda . . B-AdverseReaction
equina . . I-AdverseReaction
syndrome . . I-AdverseReaction
7.4 . . O
6.6 . . O
4.5 . . O
3.8 . . O
paresthesia . . B-AdverseReaction
6.6 . . O
0.0 . . O
4.5 . . O
0.0 . . O
mental . . B-AdverseReaction
impairment . . I-AdverseReaction
disordersd . . O
4.3 . . O
0.3 . . O
1.8 . . O
0.0 . . O
hypoesthesia . . B-AdverseReaction
4.0 . . O
0.3 . . O
1.8 . . O
0.0 . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infectione . . O
10.9 . . O
0.0 . . O
6.5 . . O
0.3 . . O
lower . . O
respiratory . . O
tract . . O
and . . O
lung . . B-AdverseReaction
infectionf . . O
8.5 . . O
2.4 . . O
4.8 . . O
1.3 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
8.8 . . O
0.0 . . O
6.0 . . O
0.5 . . O
anxiety . . B-AdverseReaction
6.5 . . O
0.3 . . O
4.0 . . O
0.0 . . O
renal . . O
and . . O
urinary . . O
disorders . . O
hematuria . . B-AdverseReaction
6.9 . . O
1.8 . . O
4.5 . . O
1.0 . . O
pollakiuria . . B-AdverseReaction
4.8 . . O
0.0 . . O
2.5 . . O
0.0 . . O
injury . . O
, . . O
poisoning . . O
and . . O
procedural . . O
complications . . O
fall . . B-AdverseReaction
4.6 . . O
0.3 . . O
1.3 . . O
0.0 . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
pathologic . . I-AdverseReaction
fractures . . I-AdverseReaction
4.0 . . O
1.4 . . O
0.8 . . O
0.3 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
pruritus . . B-AdverseReaction
3.8 . . O
0.0 . . O
1.3 . . O
0.0 . . O
dry . . B-AdverseReaction
skin . . I-AdverseReaction
3.5 . . O
0.0 . . O
1.3 . . O
0.0 . . O
respiratory . . O
disorders . . O
epistaxis . . B-AdverseReaction
3.3 . . O
0.1 . . O
1.3 . . O
0.3 . . O
a . . O
ctcae . . O
v4b . . O
includes . . O
asthenia . . B-AdverseReaction
and . . O
fatigue . . B-AdverseReaction
. . . O
c . . O
includes . . O
dizziness . . B-AdverseReaction
and . . O
vertigo . . B-AdverseReaction
. . . O
d . . O
includes . . O
amnesia . . B-AdverseReaction
, . . O
memory . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
cognitive . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
and . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
attention . . I-AdverseReaction
. . . O
e . . O
includes . . O
nasopharyngitis . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
rhinitis . . B-AdverseReaction
, . . O
pharyngitis . . B-AdverseReaction
, . . O
and . . O
laryngitis . . B-AdverseReaction
. . . O
f . . O
includes . . O
pneumonia . . B-AdverseReaction
, . . O
lower . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
and . . O
lung . . B-AdverseReaction
infection . . I-AdverseReaction
. . . O

among . . O
the . . O
290 . . O
patients . . O
included . . O
in . . O
the . . O
safety . . O
evaluation . . O
of . . O
voraxaze . . O
, . . O
there . . O
were . . O
8 . . O
deaths . . B-AdverseReaction
within . . O
30 . . O
days . . O
of . . O
voraxaze . . O
exposure . . O
that . . O
were . . O
not . . O
related . . O
to . . O
progressive . . O
disease . . O
. . . O

( . . O
5.1 . . O
, . . O
6 . . O
) . . O
* . . O
use . . O
with . . O
cyp3a . . O
inducers . . O
: . . O
concomitant . . O
use . . O
with . . O
strong . . O
cyp3a . . O
inducers . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
rifampin . . O
, . . O
st . . O
. . . O
john's . . O
wort . . O
) . . O
substantially . . O
decreases . . O
exposure . . O
of . . O
ivacaftor . . O
, . . O
which . . O
may . . O
diminish . . O
effectiveness . . O
. . . O

sixty . . O
- . . O
two . . O
percent . . O
of . . O
these . . O
patients . . O
had . . O
at . . O
least . . O
one . . O
sample . . O
that . . O
was . . O
positive . . O
for . . O
the . . O
presence . . O
of . . O
neutralizing . . O
antibodies . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
anaphylaxis . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
and . . O
severe . . B-Severity
cutaneous . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
hepatic . . B-AdverseReaction
enzyme . . I-AdverseReaction
elevations . . I-AdverseReaction
, . . O
fulminant . . B-AdverseReaction
hepatic . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
severe . . B-Severity
and . . O
disabling . . B-Severity
arthralgia . . B-AdverseReaction
and . . O
acute . . B-AdverseReaction
pancreatitis . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1,5.2,5.3,5.5 . . O
) . . O
] . . O
. . . O

these . . O
metabolic . . B-AdverseReaction
changes . . I-AdverseReaction
include . . O
hyperglycemia . . B-AdverseReaction
, . . O
dyslipidemia . . B-AdverseReaction
, . . O
and . . O
weight . . B-AdverseReaction
gain . . I-AdverseReaction
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

most . . O
adverse . . O
events . . O
were . . O
mild . . O
in . . O
severity . . O
and . . O
transient . . O
in . . O
nature . . O
, . . O
and . . O
all . . O
patients . . O
recovered . . O
without . . O
treatment . . O
. . . O

precise . . O
risk . . O
estimates . . O
for . . O
hyperglycemia . . B-AdverseReaction
- . . O
related . . O
adverse . . O
events . . O
in . . O
patients . . O
treated . . O
with . . O
atypical . . B-DrugClass
antipsychotics . . I-DrugClass
are . . O
not . . O
available . . O
. . . O

recurrence . . O
of . . O
liver . . B-AdverseReaction
transaminase . . I-AdverseReaction
elevations . . I-AdverseReaction
occurred . . O
with . . O
rechallenge . . O
in . . O
some . . O
patients . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

anemia . . B-AdverseReaction
33 . . O
8 . . O
2 . . O
52 . . O
2 . . O
- . . O

6.1 . . O
clinical . . O
studies . . O
experience . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
genzyme . . O
at . . O
1-800-745-4447 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

the . . O
size . . O
of . . O
the . . O
control . . O
group . . O
and . . O
limited . . O
duration . . O
of . . O
the . . O
controlled . . O
portions . . O
of . . O
the . . O
studies . . O
precludes . . O
the . . O
ability . . O
to . . O
draw . . O
firm . . O
conclusions . . O
. . . O

table . . O
3 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
subjects . . O
on . . O
otezla . . O
and . . O
with . . O
greater . . O
frequency . . O
than . . O
in . . O
subjects . . O
on . . O
placebo . . O
; . . O
up . . O
to . . O
day . . O
112 . . O
( . . O
week . . O
16 . . O
) . . O
* . . O
two . . O
subjects . . O
treated . . O
with . . O
otezla . . O
experienced . . O
serious . . B-Severity
adverse . . O
reaction . . O
of . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

( . . O
5.2 . . O
) . . O
* . . O
do . . O
not . . O
use . . O
in . . O
combination . . O
with . . O
an . . O
additional . . O
medicine . . O
containing . . O
a . . O
laba . . O
because . . O
of . . O
risk . . O
of . . O
overdose . . O
. . . O

the . . O
use . . O
of . . O
clinical . . O
information . . O
in . . O
the . . O
interpretation . . O
of . . O
vizamyl . . O
images . . O
has . . O
not . . O
been . . O
evaluated . . O
and . . O
may . . O
lead . . O
to . . O
errors . . O
. . . O

adverse . . O
drug . . O
reactions . . O
for . . O
sirturo . . O
were . . O
identified . . O
from . . O
the . . O
pooled . . O
safety . . O
data . . O
from . . O
335 . . O
sirturo . . O
- . . O
exposed . . O
patients . . O
who . . O
received . . O
8 . . O
weeks . . O
( . . O
study . . O
2 . . O
) . . O
and . . O
24 . . O
weeks . . O
( . . O
studies . . O
1 . . O
and . . O
3 . . O
) . . O
at . . O
the . . O
proposed . . O
dose . . O
. . . O

there . . O
was . . O
a . . O
greater . . O
incidence . . O
of . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
in . . O
alvimopan . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
placebo . . O
- . . O
treated . . O
patients . . O
in . . O
a . . O
12 . . O
- . . O
month . . O
clinical . . O
trial . . O
, . . O
although . . O
a . . O
causal . . O
relationship . . O
has . . O
not . . O
been . . O
established . . O
. . . O

because . . O
postmarketing . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

braf . . O
v600e . . O
or . . O
v600k . . O
unresectable . . O
or . . O
metastatic . . O
melanoma . . O
: . . O

consider . . O
an . . O
alternate . . O
contraceptive . . O
method . . O
for . . O
women . . O
with . . O
uncontrolled . . O
dyslipidemia . . O
. . . O

dizziness . . B-AdverseReaction
362014 . . O
31 . . O
< . . O
1 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
15 . . O
0 . . O
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
dyspneadyspnea . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
bronchial . . B-AdverseReaction
hyperactivity . . I-AdverseReaction
, . . O
bronchospasm . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
exertional . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
distress . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
and . . O
wheezing . . B-AdverseReaction
. . . O

in . . O
clinical . . O
trials . . O
, . . O
rapid . . O
corticosteroid . . O
tapering . . O
resulted . . O
in . . O
recurrence . . O
or . . O
worsening . . O
symptoms . . O
of . . O
enterocolitis . . O
in . . O
some . . O
patients . . O
. . . O

warning . . O
: . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O

5.3 . . O
risks . . O
for . . O
benzyl . . O
alcohol . . O
toxicity . . O
in . . O
infants . . O

patients . . O
treated . . O
with . . O
treanda . . O
may . . B-Factor
also . . O
have . . O
changes . . O
in . . O
their . . O
creatinine . . O
levels . . O
. . . O

cardiac . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
pericardial . . B-AdverseReaction
effusion . . I-AdverseReaction
; . . O
0.1% . . O
and . . O
less . . O
than . . O
1% . . O
- . . O
pericarditis . . B-AdverseReaction

patients . . O
with . . O
pre . . O
- . . O
existing . . O
swallowing . . O
or . . O
breathing . . O
difficulties . . O
may . . O
be . . O
more . . O
susceptible . . O
to . . O
these . . O
complications . . O
. . . O

patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
at . . O
baseline . . O
had . . O
larger . . O
mean . . O
changes . . O
. . . O

patients . . O
experienced . . O
relief . . O
of . . O
symptoms . . O
upon . . O
discontinuation . . O
of . . O
the . . O
medication . . O
. . . O

refer . . O
to . . O
the . . O
prescribing . . O
information . . O
for . . O
ribavirin . . O
for . . O
additional . . O
information . . O
. . . O

if . . O
ferriprox . . O
is . . O
used . . O
during . . O
pregnancy . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
ferriprox . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
. . . O

farxiga . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

overall . . O
discontinuation . . O
of . . O
therapy . . O
due . . O
to . . O
adverse . . O
events . . O
was . . O
4.7% . . O
with . . O
nesina . . O
25 . . O
mg . . O
compared . . O
to . . O
4.5% . . O
with . . O
placebo . . O
or . . O
6.2% . . O
with . . O
active . . O
comparator . . O
. . . O

in . . O
the . . O
relapsed . . O
classical . . O
hl . . O
and . . O
salcl . . O
clinical . . O
trials . . O
, . . O
54% . . O
of . . O
patients . . O
experienced . . O
any . . O
grade . . O
of . . O
neuropathy . . B-AdverseReaction
. . . O

adverse . . O
reactions . . O
( . . O
> . . O
= . . O
3% . . O
) . . O
with . . O
a . . O
higher . . O
incidence . . O
for . . O
promacta . . O
versus . . O
placebo . . O
from . . O
two . . O
placebo . . O
- . . O
controlled . . O
trials . . O
in . . O
pediatric . . O
patients . . O
6 . . O
years . . O
and . . O
older . . O
with . . O
chronic . . O
immune . . O
( . . O
idiopathic . . O
) . . O
thrombocytopenia . . O
promacta . . O
placebo . . O
n . . O
= . . O
82 . . O
n . . O
= . . O
40 . . O
adverse . . O
reaction . . O
( . . O
% . . O
) . . O
( . . O
% . . O
) . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
16 . . O
5 . . O
nasopharyngitis . . B-AdverseReaction
12 . . O
5 . . O
rhinitis . . B-AdverseReaction
11 . . O
8 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
9 . . O
5 . . O
cough . . B-AdverseReaction
9 . . O
0 . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
9 . . O
3 . . O
toothache . . B-AdverseReaction
6 . . O
0 . . O
ast . . B-AdverseReaction
increased . . I-AdverseReaction
5 . . O
0 . . O
diarrhea . . B-AdverseReaction
5 . . O
3 . . O
rash . . B-AdverseReaction
5 . . O
3 . . O
alt . . B-AdverseReaction
increaseda . . O
6 . . O
0 . . O
vitamin . . B-AdverseReaction
d . . I-AdverseReaction
deficiency . . I-AdverseReaction
4 . . O
0 . . O
* . . O
a . . O
includes . . O
adverse . . O
reactions . . O
or . . O
laboratory . . O
abnormalities . . O
> . . O
3 . . O
x . . O
uln . . O
. . . O

the . . O
concomitant . . O
use . . O
of . . O
a . . O
tnf . . O
- . . O
blocker . . O
and . . O
abatacept . . O
or . . O
anakinra . . O
was . . O
associated . . O
with . . O
a . . O
higher . . O
risk . . O
of . . O
serious . . O
infections . . O
; . . O
therefore . . O
, . . O
the . . O
concomitant . . O
use . . O
of . . O
simponi . . O
aria . . O
and . . O
these . . O
biologic . . O
products . . O
is . . O
not . . O
recommended . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
, . . O
5.6 . . O
) . . O
and . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
] . . O
. . . O

these . . O
data . . O
reflect . . O
exposure . . O
of . . O
923 . . O
patients . . O
to . . O
tanzeum . . O
and . . O
a . . O
mean . . O
duration . . O
of . . O
exposure . . O
to . . O
tanzeum . . O
of . . O
93 . . O
weeks . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction

the . . O
median . . O
age . . O
of . . O
patients . . O
was . . O
31 . . O
years . . O
( . . O
range . . O
18 . . O
to . . O
61 . . O
years . . O
) . . O
, . . O
89% . . O
were . . O
caucasian . . O
, . . O
and . . O
34% . . O
were . . O
male . . O
. . . O

excerpt . . O
: . . O
* . . O
severe . . O
or . . O
persistent . . O
gastrointestinal . . O
toxicity . . O
: . . O
dose . . O
modification . . O
due . . O
to . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
or . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
occurred . . O
in . . O
38% . . O
of . . O
patients . . O
. . . O

among . . O
patients . . O
in . . O
study . . O
3 . . O
who . . O
reported . . O
no . . O
prior . . O
exposure . . O
to . . O
xiaflex . . O
, . . O
97% . . O
of . . O
patients . . O
had . . O
antibodies . . O
against . . O
aux . . O
- . . O
i . . O
and . . O
aux . . O
- . . O
ii . . O
after . . O
two . . O
concurrent . . O
doses . . O
of . . O
xiaflex . . O
0.58 . . O
mg . . O
( . . O
total . . O
dose . . O
of . . O
1.16 . . O
mg . . O
) . . O
in . . O
the . . O
same . . O
hand . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
urticaria . . B-AdverseReaction
. . . O

warning . . O
: . . O
risk . . B-Factor
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction

avoid . . O
halaven . . O
in . . O
patients . . O
with . . O
congenital . . O
long . . O
qt . . O
syndrome . . O
. . . O

other . . O
uses . . O
of . . O
therapeutic . . O
infectious . . O
agents . . O
such . . O
as . . O
live . . O
attenuated . . O
bacteria . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
bcg . . O
bladder . . O
instillation . . O
for . . O
the . . O
treatment . . O
of . . O
cancer . . O
) . . O
could . . O
result . . O
in . . O
clinical . . O
infections . . O
, . . O
including . . O
disseminated . . O
infections . . O
. . . O

the . . O
type . . O
and . . O
frequency . . O
of . . O
adverse . . O
drug . . O
reactions . . O
appeared . . O
to . . O
be . . O
consistent . . O
over . . O
time . . O
. . . O

the . . O
most . . O
frequent . . O
second . . B-AdverseReaction
primary . . I-AdverseReaction
malignancy . . I-AdverseReaction
was . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
melanoma . . I-AdverseReaction
skin . . I-AdverseReaction
cancer . . I-AdverseReaction
( . . O
range . . O
, . . O
4 . . O
to . . O
11 . . O
% . . O
) . . O
. . . O

approximately . . O
half . . O
the . . O
cases . . O
were . . O
lymphomas . . B-AdverseReaction
, . . O
including . . O
hodgkin's . . O
and . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
hodgkin's . . I-AdverseReaction
lymphoma . . I-AdverseReaction
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction

in . . O
clinical . . O
trials . . O
with . . O
victrelis . . O
, . . O
dose . . O
modifications . . O
( . . O
generally . . O
of . . O
pegintron . . O
/ . . O
rebetol . . O
) . . O
due . . O
to . . O
anemia . . B-AdverseReaction
occurred . . O
twice . . O
as . . O
often . . O
in . . O
subjects . . O
treated . . O
with . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
( . . O
26% . . O
) . . O
compared . . O
to . . O
pegintron . . O
/ . . O
rebetol . . O
( . . O
13% . . O
) . . O
. . . O

table . . O
3 . . O
adverse . . O
events . . O
reported . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
and . . O
reported . . O
at . . O
a . . O
rate . . O
of . . O
> . . O
= . . O
5% . . O
than . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
adverse . . O
events . . O
previously . . O
untreated . . O
( . . O
sprint . . O
- . . O
1 . . O
and . . O
sprint . . O
- . . O
2 . . O
) . . O
previous . . O
treatment . . O
failures . . O
( . . O
respond . . O
- . . O
2 . . O
) . . O
percentage . . O
of . . O
subjects . . O
reporting . . O
adverse . . O
events . . O
percentage . . O
of . . O
subjects . . O
reporting . . O
adverse . . O
events . . O
body . . O
system . . O
organ . . O
class . . O
victrelis . . O
+ . . O
pegintron . . O
+ . . O
rebetol . . O
( . . O
n . . O
= . . O
1225 . . O
) . . O
pegintron . . O
+ . . O
rebetol . . O
( . . O
n . . O
= . . O
467 . . O
) . . O
victrelis . . O
+ . . O
pegintron . . O
+ . . O
rebetol . . O
( . . O
n . . O
= . . O
323 . . O
) . . O
pegintron . . O
+ . . O
rebetol . . O
( . . O
n . . O
= . . O
80 . . O
) . . O
median . . O
exposure . . O
( . . O
days . . O
) . . O
197 . . O
216 . . O
253 . . O
104 . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
anemia . . B-AdverseReaction
50 . . O
30 . . O
45 . . O
20 . . O
neutropenia . . B-AdverseReaction
25 . . O
19 . . O
14 . . O
10 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
46 . . O
42 . . O
43 . . O
38 . . O
dysgeusia . . B-AdverseReaction
35 . . O
16 . . O
44 . . O
11 . . O
diarrhea . . B-AdverseReaction
25 . . O
22 . . O
24 . . O
16 . . O
vomiting . . B-AdverseReaction
20 . . O
13 . . O
15 . . O
8 . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
11 . . O
10 . . O
15 . . O
9 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
58 . . O
59 . . O
55 . . O
50 . . O
chills . . B-AdverseReaction
34 . . O
29 . . O
33 . . O
30 . . O
asthenia . . B-AdverseReaction
15 . . O
18 . . O
21 . . O
16 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
25 . . O
24 . . O
26 . . O
16 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
arthralgia . . B-AdverseReaction
19 . . O
19 . . O
23 . . O
16 . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
19 . . O
16 . . O
16 . . O
10 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
34 . . O
34 . . O
30 . . O
24 . . O
irritability . . B-AdverseReaction
22 . . O
23 . . O
21 . . O
13 . . O
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
dyspnea . . B-AdverseReaction
exertional . . I-AdverseReaction
8 . . O
8 . . O
11 . . O
5 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
alopecia . . B-AdverseReaction
27 . . O
27 . . O
22 . . O
16 . . O
dry . . B-AdverseReaction
skin . . I-AdverseReaction
18 . . O
18 . . O
22 . . O
9 . . O
rash . . B-AdverseReaction
17 . . O
19 . . O
16 . . O
6 . . O
other . . O
important . . O
adverse . . O
reactions . . O
reported . . O
in . . O
clinical . . O
trials . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

eye . . O
disorders . . O
: . . O
diplopia . . B-AdverseReaction
, . . O
papilledema . . B-AdverseReaction
, . . O
retinal . . B-AdverseReaction
toxicity . . I-AdverseReaction
. . . O

eight . . O
of . . O
79 . . O
( . . O
10.1% . . O
) . . O
patients . . O
in . . O
the . . O
sirturo . . O
group . . O
and . . O
16 . . O
of . . O
81 . . O
( . . O
19.8% . . O
) . . O
patients . . O
in . . O
the . . O
placebo . . O
treatment . . O
group . . O
were . . O
hiv . . O
- . . O
infected . . O
. . . O

stepwise . . O
increase . . O
in . . O
alpha . . O
- . . O
blocker . . O
dose . . O
may . . O
be . . O
associated . . O
with . . O
further . . O
lowering . . O
of . . O
blood . . O
pressure . . O
when . . O
taking . . O
a . . O
pde5 . . O
inhibitor . . O
. . . O

long . . B-AdverseReaction
- . . I-AdverseReaction
term . . I-AdverseReaction
cumulative . . I-AdverseReaction
radiation . . I-AdverseReaction
exposure . . I-AdverseReaction
is . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
cancer . . B-AdverseReaction
. . . O

6.1 . . O
ocular . . O
surgery . . O

5 . . O
warnings . . O
and . . O
precautions . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
novartis . . O
pharmaceuticals . . O
corporation . . O
at . . O
1-888-669-6682 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

if . . O
a . . O
patient . . O
experiences . . O
anticholinergic . . O
cns . . O
effects . . O
, . . O
dose . . O
reduction . . O
or . . O
drug . . O
discontinuation . . O
should . . O
be . . O
considered . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
hemorrhage . . B-AdverseReaction
: . . O
severe . . B-Severity
, . . O
sometimes . . O
fatal . . B-AdverseReaction
, . . O
hemorrhage . . O
including . . O
hemoptysis . . B-AdverseReaction
and . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
occurred . . O
in . . O
3% . . O
of . . O
cometriq . . O
- . . O
treated . . O
patients . . O
. . . O

two . . O
cases . . O
of . . O
anaphylaxis . . B-AdverseReaction
were . . O
reported . . O
in . . O
the . . O
dose . . O
- . . O
finding . . O
trials . . O
. . . O

6 . . O
adverse . . O
reactions . . O

the . . O
clinical . . O
relevance . . O
of . . O
the . . O
presence . . O
of . . O
anti . . O
- . . O
belimumab . . O
antibodies . . O
is . . O
not . . O
known . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
1% . . O
) . . O
with . . O
voraxaze . . O
are . . O
paraesthesias . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
and . . O
/ . . O
or . . O
vomiting . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
five . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
, . . O
adverse . . O
reactions . . O
related . . O
to . . O
volume . . B-AdverseReaction
depletion . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
blood . . O
pressure . . O
( . . O
ambulatory . . O
) . . O
decreased . . O
, . . O
blood . . B-AdverseReaction
pressure . . I-AdverseReaction
systolic . . I-AdverseReaction
decreased . . I-AdverseReaction
, . . O
dehydration . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
hypovolemia . . B-AdverseReaction
, . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
and . . O
syncope . . B-AdverseReaction
) . . O
were . . O
reported . . O
by . . O
0.3% . . O
, . . O
0.5% . . O
, . . O
and . . O
0.3% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
, . . O
jardiance . . O
10 . . O
mg . . O
, . . O
and . . O
jardiance . . O
25 . . O
mg . . O
respectively . . O
. . . O

immediate . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
( . . O
including . . O
swelling . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
lips . . I-AdverseReaction
, . . O
tongue . . O
, . . O
or . . O
throat . . O
) . . O
, . . O
urticaria . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
bronchospasm . . B-AdverseReaction
, . . O
or . . O
itching . . B-AdverseReaction
, . . O
have . . O
occurred . . O
after . . O
administration . . O
of . . O
tudorza . . O
pressair . . O
. . . O

in . . O
addition . . O
, . . O
beta . . B-DrugClass
- . . I-DrugClass
agonists . . I-DrugClass
have . . O
been . . O
reported . . O
to . . O
produce . . O
electrocardiographic . . B-AdverseReaction
changes . . I-AdverseReaction
, . . O
such . . O
as . . O
flattening . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
t . . I-AdverseReaction
wave . . I-AdverseReaction
, . . O
prolongation . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
qtc . . I-AdverseReaction
interval . . I-AdverseReaction
, . . O
and . . O
st . . B-AdverseReaction
segment . . I-AdverseReaction
depression . . I-AdverseReaction
, . . O
although . . O
the . . O
clinical . . O
significance . . O
of . . O
these . . O
findings . . O
is . . O
unknown . . O
. . . O

if . . O
hypotension . . O
does . . O
occur . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
placed . . O
in . . O
the . . O
supine . . O
position . . O
and . . O
, . . O
if . . O
necessary . . O
, . . O
given . . O
an . . O
intravenous . . O
infusion . . O
of . . O
normal . . O
saline . . O
. . . O

laboratory . . O
parameter . . O
afinitor . . O
( . . O
10 . . O
mg . . O
/ . . O
day . . O
) . . O
+ . . O
exemestane . . O
a . . O
n . . O
= . . O
482 . . O
placebo . . O
+ . . O
exemestane . . O
a . . O
n . . O
= . . O
238 . . O
all . . O
grades . . O
grade . . O
3 . . O
grade . . O
4 . . O
all . . O
grades . . O
grade . . O
3 . . O
grade . . O
4 . . O
% . . O
% . . O
% . . O
% . . O
% . . O
% . . O
hematology . . O
b . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
68 . . O
6 . . O
0.6 . . O
40 . . O
0.8 . . O
0.4 . . O
wbc . . B-AdverseReaction
decreased . . I-AdverseReaction
58 . . O
1 . . O
0 . . O
28 . . O
5 . . O
0.8 . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
54 . . O
3 . . O
0.2 . . O
5 . . O
0 . . O
0.4 . . O
lymphocytes . . B-AdverseReaction
decreased . . I-AdverseReaction
54 . . O
11 . . O
0.6 . . O
37 . . O
5 . . O
0.8 . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
31 . . O
2 . . O
0 . . O
11 . . O
0.8 . . O
0.8 . . O
clinical . . O
chemistry . . O
glucose . . B-AdverseReaction
increased . . I-AdverseReaction
69 . . O
9 . . O
0.4 . . O
44 . . O
0.8 . . O
0.4 . . O
cholesterol . . B-AdverseReaction
increased . . I-AdverseReaction
70 . . O
0.6 . . O
0.2 . . O
38 . . O
0.8 . . O
0.8 . . O
aspartate . . O
transaminase . . O
( . . O
ast . . O
) . . O
increased . . O
69 . . O
4 . . O
0.2 . . O
45 . . O
3 . . O
0.4 . . O
alanine . . O
transaminase . . O
( . . O
alt . . O
) . . O
increased . . O
51 . . O
4 . . O
0.2 . . O
29 . . O
5 . . O
0 . . O
triglycerides . . B-AdverseReaction
increased . . I-AdverseReaction
50 . . O
0.8 . . O
0 . . O
26 . . O
0 . . O
0 . . O
albumin . . B-AdverseReaction
decreased . . I-AdverseReaction
33 . . O
0.8 . . O
0 . . O
16 . . O
0.8 . . O
0 . . O
potassium . . B-AdverseReaction
decreased . . I-AdverseReaction
29 . . O
4 . . O
0.2 . . O
7 . . O
1 . . O
0 . . O
creatinine . . B-AdverseReaction
increased . . I-AdverseReaction
24 . . O
2 . . O
0.2 . . O
13 . . O
0 . . O
0 . . O
6.2 . . O
clinical . . O
study . . O
experience . . O
in . . O
advanced . . O
pancreatic . . O
neuroendocrine . . O
tumors . . O
in . . O
a . . O
randomized . . O
, . . O
controlled . . O
trial . . O
of . . O
afinitor . . O
( . . O
n . . O
= . . O
204 . . O
) . . O
versus . . O
placebo . . O
( . . O
n . . O
= . . O
203 . . O
) . . O
in . . O
patients . . O
with . . O
advanced . . O
pnet . . O
the . . O
median . . O
age . . O
of . . O
patients . . O
was . . O
58 . . O
years . . O
( . . O
range . . O
20-87 . . O
) . . O
, . . O
79% . . O
were . . O
caucasian . . O
, . . O
and . . O
55% . . O
were . . O
male . . O
. . . O

fourteen . . O
( . . O
24% . . O
) . . O
patients . . O
stopped . . O
therapy . . O
prior . . O
to . . O
completion . . O
; . . O
seven . . O
due . . O
to . . O
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
five . . O
due . . O
to . . O
physician . . O
or . . O
patient . . O
choice . . O
, . . O
one . . O
due . . O
to . . O
disease . . O
progression . . O
, . . O
and . . O
one . . O
due . . O
to . . O
discontinuation . . O
during . . O
frontline . . O
protocol . . O
. . . O

table . . O
1 . . O
: . . O
select . . O
adverse . . O
reactions . . O
from . . O
study . . O
1 . . O
that . . O
occurred . . O
more . . O
frequently . . O
than . . O
placebo . . O
during . . O
treatment . . O
with . . O
sirturo . . O
adverse . . O
reactions . . O
sirturo . . O
treatment . . O
groupn . . O
= . . O
79n . . O
( . . O
% . . O
) . . O
placebo . . O
treatment . . O
groupn . . O
= . . O
81n . . O
( . . O
% . . O
) . . O
nausea . . B-AdverseReaction
30 . . O
( . . O
38 . . O
) . . O
26 . . O
( . . O
32 . . O
) . . O
arthralgia . . B-AdverseReaction
26 . . O
( . . O
33 . . O
) . . O
18 . . O
( . . O
22 . . O
) . . O
headache . . B-AdverseReaction
22 . . O
( . . O
28 . . O
) . . O
10 . . O
( . . O
12 . . O
) . . O
hemoptysis . . B-AdverseReaction
14 . . O
( . . O
18 . . O
) . . O
9 . . O
( . . O
11 . . O
) . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
9 . . O
( . . O
11 . . O
) . . O
6 . . O
( . . O
7 . . O
) . . O
anorexia . . B-AdverseReaction
7 . . O
( . . O
9 . . O
) . . O
3 . . O
( . . O
4 . . O
) . . O
transaminases . . B-AdverseReaction
increased . . I-AdverseReaction
7 . . O
( . . O
9 . . O
) . . O
1 . . O
( . . O
1 . . O
) . . O
rash . . B-AdverseReaction
6 . . O
( . . O
8 . . O
) . . O
3 . . O
( . . O
4 . . O
) . . O
blood . . B-AdverseReaction
amylase . . I-AdverseReaction
increased . . I-AdverseReaction
2 . . O
( . . O
3 . . O
) . . O
1 . . O
( . . O
1 . . O
) . . O
no . . O
additional . . O
unique . . O
adverse . . O
reactions . . O
were . . O
identified . . O
from . . O
the . . O
uncontrolled . . O
study . . O
3 . . O
. . . O

* . . O
take . . O
duavee . . O
with . . O
or . . O
without . . O
food . . O
. . . O

monitor . . O
complete . . O
blood . . O
counts . . O
prior . . O
to . . O
each . . O
dose . . O
; . . O
increase . . O
the . . O
frequency . . O
of . . O
monitoring . . O
in . . O
patients . . O
who . . O
develop . . O
grade . . O
3 . . O
or . . O
4 . . O
cytopenias . . O
. . . O

duavee . . O
is . . O
used . . O
after . . O
menopause . . O
for . . O
women . . O
with . . O
a . . O
uterus . . O
to . . O
: . . O

it . . O
is . . O
important . . O
to . . O
exclude . . O
cases . . O
where . . O
the . . O
clinical . . O
presentation . . O
includes . . O
both . . O
serious . . O
medical . . O
illness . . O
( . . O
e . . O
. . . O
g . . O
. . . O
pneumonia . . O
, . . O
systemic . . O
infection . . O
) . . O
and . . O
untreated . . O
or . . O
inadequately . . O
treated . . O
extrapyramidal . . O
signs . . O
and . . O
symptoms . . O
( . . O
eps . . O
) . . O
. . . O

grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
increased . . B-AdverseReaction
bilirubin . . I-AdverseReaction
occurred . . O
in . . O
3% . . O
of . . O
patients . . O
. . . O

5.7 . . O
hematological . . O
reactions . . O

one . . O
case . . O
of . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
( . . O
ten . . B-AdverseReaction
) . . O
occurred . . O
in . . O
a . . O
study . . O
of . . O
zydelig . . O
in . . O
combination . . O
with . . O
rituximab . . O
and . . O
bendamustine . . O
. . . O

when . . O
medically . . O
feasible . . O
, . . O
stop . . O
these . . O
drugs . . O
before . . O
adreview . . O
administration . . O
and . . O
monitor . . O
patients . . O
for . . O
the . . O
occurrence . . O
of . . O
clinically . . O
significant . . O
withdrawal . . O
symptoms . . O
, . . O
especially . . O
patients . . O
with . . O
elevated . . O
levels . . O
of . . O
circulating . . O
catecholamines . . O
and . . O
their . . O
metabolites . . O
. . . O

dystonic . . B-AdverseReaction
symptoms . . I-AdverseReaction
include . . O
: . . O
spasm . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
neck . . I-AdverseReaction
muscles . . I-AdverseReaction
, . . O
sometimes . . O
progressing . . O
to . . O
tightness . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
throat . . I-AdverseReaction
, . . O
swallowing . . B-AdverseReaction
difficulty . . I-AdverseReaction
, . . O
difficulty . . B-AdverseReaction
breathing . . I-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
protrusion . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
tongue . . I-AdverseReaction
. . . O

( . . O
5.1 . . O
) . . O
* . . O
some . . O
patients . . O
with . . O
retinal . . O
abnormalities . . O
have . . O
been . . O
found . . O
to . . O
have . . O
abnormal . . O
visual . . O
acuity . . O
. . . O

atrial . . B-AdverseReaction
flutter . . I-AdverseReaction
with . . I-AdverseReaction
1 . . I-AdverseReaction
: . . I-AdverseReaction
1 . . I-AdverseReaction
atrioventricular . . I-AdverseReaction
conduction . . I-AdverseReaction
has . . O
been . . O
reported . . O
very . . O
rarely . . O
. . . O

* . . O
possible . . O
clinically . . O
significant . . O
adverse . . O
reactions . . O
from . . O
greater . . O
exposures . . O
of . . O
concomitant . . O
drugs . . O
. . . O

adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
subjects . . O
treated . . O
with . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
and . . O
at . . O
a . . O
higher . . O
frequency . . O
than . . O
the . . O
vehicle . . O
are . . O
presented . . O
in . . O
table . . O
3 . . O
and . . O
table . . O
4 . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
2.2 . . O
) . . O
deaths . . B-AdverseReaction
have . . O
occurred . . O
due . . O
to . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
perforation . . O
and . . O
neutropenic . . B-AdverseReaction
enterocolitis . . I-AdverseReaction
. . . O

* . . O
flushing . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

the . . O
data . . O
described . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O
and . . O
below . . O
reflect . . O
exposure . . O
to . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
and . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

side . . O
- . . O
by . . O
- . . O
side . . O
tabulation . . O
is . . O
to . . O
simplify . . O
presentation . . O
; . . O
direct . . O
comparisons . . O
across . . O
trials . . O
should . . O
not . . O
be . . O
made . . O
due . . O
to . . O
differing . . O
trial . . O
designs . . O
. . . O

have . . O
resuscitation . . O
equipment . . O
and . . O
trained . . O
personnel . . O
immediately . . O
available . . O
at . . O
the . . O
time . . O
of . . O
vizamyl . . O
administration . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

pvan . . B-AdverseReaction
is . . O
associated . . O
with . . O
serious . . O
outcomes . . O
; . . O
including . . O
deteriorating . . B-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
and . . O
kidney . . B-AdverseReaction
graft . . I-AdverseReaction
loss . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

5.3 . . O
tumor . . O
lysis . . O
syndrome . . O

3.7 . . O
5.7 . . O
4.3 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
3.2 . . O
3.1 . . O
4.2 . . O
increased . . O
urinationincreased . . O
urination . . B-AdverseReaction
includes . . O
the . . O
following . . O
adverse . . O
reactions . . O
, . . O
listed . . O
in . . O
order . . O
of . . O
frequency . . O
reported . . O
: . . O
pollakiuria . . B-AdverseReaction
, . . O
polyuria . . B-AdverseReaction
, . . O
and . . O
urine . . B-AdverseReaction
output . . I-AdverseReaction
increased . . I-AdverseReaction
. . . O

the . . O
population . . O
studied . . O
had . . O
a . . O
mean . . O
age . . O
of . . O
49 . . O
years . . O
( . . O
3% . . O
of . . O
subjects . . O
were . . O
older . . O
than . . O
65 . . O
years . . O
of . . O
age . . O
) . . O
, . . O
39% . . O
were . . O
female . . O
, . . O
82% . . O
were . . O
white . . O
and . . O
15% . . O
were . . O
black . . O
. . . O

fanapt . . O
should . . O
be . . O
discontinued . . O
in . . O
patients . . O
who . . O
are . . O
found . . O
to . . O
have . . O
persistent . . O
qtc . . O
measurements . . O
> . . O
500 . . O
msec . . O
. . . O

* . . O
infections . . B-AdverseReaction
: . . O
monitor . . O
patients . . O
for . . O
fever . . O
and . . O
infections . . O
and . . O
evaluate . . O
promptly . . O
( . . O
5.2 . . O
) . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
increased . . O
risk . . B-Factor
of . . O
pneumonia . . B-AdverseReaction
in . . O
patients . . O
with . . O
copd . . O
. . . O

the . . O
extent . . O
to . . O
which . . O
the . . O
findings . . O
of . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
in . . O
observational . . O
studies . . O
may . . O
be . . O
attributed . . O
to . . O
the . . O
antipsychotic . . B-DrugClass
drug . . I-DrugClass
as . . O
opposed . . O
to . . O
some . . O
characteristic . . O
( . . O
s . . O
) . . O
of . . O
the . . O
patients . . O
is . . O
not . . O
clear . . O
. . . O

following . . O
is . . O
a . . O
list . . O
of . . O
adverse . . O
reactions . . O
reported . . O
by . . O
patients . . O
treated . . O
with . . O
potiga . . O
during . . O
all . . O
clinical . . O
trials . . O
: . . O
rash . . B-AdverseReaction
, . . O
nystagmus . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
, . . O
alopecia . . B-AdverseReaction
, . . O
nephrolithiasis . . B-AdverseReaction
, . . O
syncope . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
euphoric . . B-AdverseReaction
mood . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
colic . . I-AdverseReaction
, . . O
coma . . B-AdverseReaction
, . . O
encephalopathy . . B-AdverseReaction
. . . O

horizant . . O
in . . O
the . . O
treatment . . O
of . . O
rls . . O
was . . O
studied . . O
primarily . . O
in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
( . . O
n . . O
= . . O
642 . . O
) . . O
, . . O
and . . O
in . . O
long . . O
- . . O
term . . O
follow . . O
- . . O
up . . O
studies . . O
. . . O

* . . O
? . . O

monitor . . O
urine . . O
protein . . O
regularly . . O
during . . O
cometriq . . O
treatment . . O
. . . O

similar . . O
svr . . O
rates . . O
were . . O
reported . . O
in . . O
subjects . . O
who . . O
were . . O
randomized . . O
to . . O
receive . . O
ribavirin . . O
dose . . O
reduction . . O
compared . . O
to . . O
subjects . . O
who . . O
were . . O
randomized . . O
to . . O
receive . . O
an . . O
esa . . O
. . . O

food . . O
enhances . . O
absorption . . O
of . . O
artemether . . O
and . . O
lumefantrine . . O
following . . O
administration . . O
of . . O
coartem . . O
tablets . . O
. . . O

the . . O
most . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
with . . O
nulojix . . O
are . . O
: . . O

in . . O
study . . O
1 . . O
, . . O
the . . O
number . . O
of . . O
erwinaze . . O
courses . . O
ranged . . O
from . . O
1 . . O
to . . O
9 . . O
. . . O

monitor . . O
patients . . O
for . . O
new . . O
malignancies . . O
prior . . O
to . . O
initiation . . O
of . . O
therapy . . O
, . . O
while . . O
on . . O
therapy . . O
, . . O
and . . O
following . . O
discontinuation . . O
of . . O
tafinlar . . O
or . . O
the . . O
combination . . O
therapy . . O
. . . O

see . . O
full . . O
prescribing . . O

* . . O
clinically . . O
significant . . O
ventricular . . O
arrhythmia . . O
* . . O
a . . O
qtcf . . O
interval . . O
of . . O
greater . . O
than . . O
500 . . O
ms . . O
( . . O
confirmed . . O
by . . O
repeat . . O
ecg . . O
) . . O
if . . O
syncope . . O
occurs . . O
, . . O
obtain . . O
an . . O
ecg . . O
to . . O
detect . . O
qt . . O
prolongation . . O
. . . O

adverse . . O
reactions . . O
of . . O
venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
were . . O
reported . . O
in . . O
0.0% . . B-Negation
of . . O
patients . . O
treated . . O
with . . O
duavee . . O
and . . O
0.1% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

there . . O
are . . O
insufficient . . O
data . . O
to . . O
determine . . O
whether . . O
farxiga . . O
has . . O
an . . O
effect . . O
on . . O
pre . . O
- . . O
existing . . O
bladder . . O
tumors . . O
. . . O

patients . . O
with . . O
tuberculosis . . B-AdverseReaction
have . . O
frequently . . O
presented . . O
with . . O
disseminated . . O
or . . O
extrapulmonary . . O
disease . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
jaw . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
3% . . O
) . . O

signs . . O
and . . O
symptoms . . O
of . . O
hyponatremia . . B-AdverseReaction
include . . O
headache . . B-AdverseReaction
, . . O
difficulty . . B-AdverseReaction
concentrating . . I-AdverseReaction
, . . O
memory . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
confusion . . B-AdverseReaction
, . . O
weakness . . B-AdverseReaction
, . . O
and . . O
unsteadiness . . B-AdverseReaction
, . . O
which . . O
can . . B-Factor
lead . . O
to . . O
falls . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
advanced . . O
hr+ . . O
bc . . O
, . . O
advanced . . O
pnet . . O
, . . O
advanced . . O
rcc . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
30% . . O
) . . O
include . . O
stomatitis . . B-AdverseReaction
, . . O
infections . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
edema . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
fever . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
and . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
. . . O

some . . O
patients . . O
experienced . . O
circulatory . . B-AdverseReaction
collapse . . I-AdverseReaction
and . . O
died . . B-AdverseReaction
. . . O

some . . O
antimalarials . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
halofantrine . . O
, . . O
quinine . . O
, . . O
quinidine . . O
) . . O
including . . O
coartem . . O
tablets . . O
have . . O
been . . O
associated . . O
with . . O
prolongation . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
qt . . I-AdverseReaction
interval . . I-AdverseReaction
on . . O
the . . O
electrocardiogram . . O
. . . O

four . . O
( . . O
0.62% . . O
) . . O
ferriprox . . O
- . . O
treated . . O
subjects . . O
discontinued . . O
the . . O
drug . . O
due . . O
to . . O
increased . . B-AdverseReaction
serum . . I-AdverseReaction
alt . . I-AdverseReaction
levels . . O
and . . O
1 . . O
( . . O
0.16% . . O
) . . O
due . . O
to . . O
an . . O
increase . . O
in . . O
both . . O
alt . . O
and . . O
ast . . O
. . . O

patients . . O
with . . O
acute . . O
febrile . . O
or . . O
respiratory . . O
illness . . O
at . . O
the . . O
time . . O
of . . O
vimizim . . O
infusion . . O
may . . O
be . . O
at . . O
higher . . O
risk . . B-Factor
of . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
complications . . O
from . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
. . . O

treatment . . O
- . . O
experienced . . O
, . . O
integrase . . O
strand . . O
transfer . . O
inhibitor . . O
- . . O
experienced . . O
subjects . . O
: . . O
the . . O
most . . O
common . . O
treatment . . O
- . . O
emergent . . O
laboratory . . O
abnormalities . . O
( . . O
greater . . O
than . . O
5% . . O
for . . O
grades . . O
2 . . O
to . . O
4 . . O
combined . . O
) . . O
observed . . O
in . . O
viking . . O
- . . O
3 . . O
at . . O
week . . O
48 . . O
were . . O
elevated . . B-AdverseReaction
alt . . I-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
ast . . O
( . . O
8% . . O
) . . O
, . . O
cholesterol . . O
( . . O
10% . . O
) . . O
, . . O
creatine . . O
kinase . . O
( . . O
6% . . O
) . . O
, . . O
hyperglycemia . . B-AdverseReaction
( . . O
14% . . O
) . . O
, . . O
and . . O
lipase . . O
( . . O
10% . . O
) . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
alglucosidase . . O
alfa . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

5.3 . . O
lack . . O
of . . O
interchangeability . . O
with . . O
gabapentin . . O

6.2 . . O
clinical . . O
studies . . O
experience . . O
in . . O
patients . . O
with . . O
peyronie's . . O
disease . . O

5.7 . . O
discontinuation . . O
syndrome . . O

warning . . O
: . . O
neutropenia . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction

monitor . . O
patients . . O
receiving . . O
the . . O
combination . . O
closely . . O
for . . O
signs . . O
or . . O
symptoms . . O
of . . O
non . . O
- . . O
cutaneous . . O
malignancies . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

for . . O
cases . . O
of . . O
grade . . O
4 . . O
non . . O
- . . O
infectious . . O
pneumonitis . . O
, . . O
discontinue . . O
afinitor . . O
. . . O

table . . O
2 . . O
displays . . O
the . . O
frequency . . O
of . . O
adverse . . O
drug . . O
reactions . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
5% . . O
of . . O
subjects . . O
in . . O
any . . O
treatment . . O
arm . . O
. . . O

treatment . . O
- . . O
emergent . . O
adrs . . O
in . . O
viking . . O
- . . O
3 . . O
were . . O
generally . . O
similar . . O
compared . . O
with . . O
observations . . O
with . . O
the . . O
50 . . O
- . . O
mg . . O
once . . O
- . . O
daily . . O
dose . . O
in . . O
adult . . O
phase . . O
3 . . O
trials . . O
. . . O

adverse . . O
reactions . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
with . . O
> . . O
= . . O
3% . . O
incidence . . O
and . . O
more . . O
common . . O
than . . O
placebo . . O
in . . O
subjects . . O
with . . O
chronic . . O
obstructive . . O
pulmonary . . O
disease . . O

the . . O
following . . O
safety . . O
concerns . . O
are . . O
described . . O
elsewhere . . O
in . . O
the . . O
label . . O
: . . O

reactions . . O
already . . O
listed . . O
for . . O
either . . O
adults . . O
or . . O
pediatric . . O
patients . . O
in . . O
other . . O
parts . . O
of . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
, . . O
or . . O
those . . O
considered . . O
in . . O
contraindications . . O
( . . O
4 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5 . . O
) . . O
or . . O
overdosage . . O
( . . O
10 . . O
) . . O
are . . O
not . . O
included . . O
. . . O

hemodialysis . . O
can . . O
remove . . O
dabigatran . . O
; . . O
however . . O
the . . O
clinical . . O
experience . . O
supporting . . O
the . . O
use . . O
of . . O
hemodialysis . . O
as . . O
a . . O
treatment . . O
for . . O
bleeding . . O
is . . O
limited . . O
[ . . O
see . . O
overdosage . . O
( . . O
10 . . O
) . . O
] . . O
. . . O

confirm . . O
evidence . . O
of . . O
braf . . O
v600e . . O
or . . O
v600k . . O
mutation . . O
status . . O
prior . . O
to . . O
initiation . . O
of . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
or . . O
combination . . O
therapy . . O
[ . . O
see . . O
indications . . O
and . . O
usage . . O
( . . O
1 . . O
) . . O
, . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

cimzia . . O
has . . O
been . . O
studied . . O
in . . O
409 . . O
patients . . O
with . . O
psoriatic . . O
arthritis . . O
( . . O
psa . . O
) . . O
in . . O
a . . O
placebo . . O
- . . O
controlled . . O
trial . . O
. . . O

table . . O
4 . . O
. . . O

seventeen . . O
patients . . O
( . . O
1.0% . . O
) . . O
required . . O
permanent . . O
discontinuation . . O
due . . O
to . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
. . . O

there . . O
was . . O
an . . O
increased . . O
risk . . O
of . . O
these . . O
adverse . . O
reactions . . O
during . . O
the . . O
titration . . O
period . . O
( . . O
compared . . O
to . . O
the . . O
maintenance . . O
period . . O
) . . O
and . . O
there . . O
also . . O
may . . O
be . . O
an . . O
increased . . O
risk . . O
of . . O
these . . O
adverse . . O
reactions . . O
in . . O
patients . . O
60 . . O
years . . O
of . . O
age . . O
and . . O
older . . O
compared . . O
to . . O
younger . . O
adults . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
serious . . B-Severity
dermatologic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
drug . . B-AdverseReaction
reaction . . I-AdverseReaction
with . . I-AdverseReaction
eosinophilia . . I-AdverseReaction
and . . I-AdverseReaction
systemic . . I-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
dress . . B-AdverseReaction
) . . O
, . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
angioedema . . B-AdverseReaction
: . . O
monitor . . O
and . . O
discontinue . . O
if . . O
another . . O
cause . . O
cannot . . O
be . . O
established . . O
. . . O

avoid . . O
use . . O
of . . O
gbcas . . O
among . . O
these . . O
patients . . O
unless . . O
the . . O
diagnostic . . O
information . . O
is . . O
essential . . O
and . . O
not . . O
available . . O
with . . O
non . . O
- . . O
contrast . . O
mri . . O
or . . O
other . . O
modalities . . O
. . . O

genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
were . . O
reported . . O
in . . O
0.9% . . O
of . . O
patients . . O
on . . O
placebo . . O
, . . O
5.7% . . O
on . . O
farxiga . . O
5 . . O
mg . . O
, . . O
and . . O
4.8% . . O
on . . O
farxiga . . O
10 . . O
mg . . O
, . . O
in . . O
the . . O
12 . . O
- . . O
study . . O
placebo . . O
- . . O
controlled . . O
pool . . O
. . . O

use . . O
of . . O
trulicity . . O
may . . O
be . . O
associated . . O
with . . O
gastrointestinal . . O
adverse . . O
reactions . . O
, . . O
sometimes . . O
severe . . B-Severity
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
: . . O
perform . . O
an . . O
examination . . O
of . . O
the . . O
fundus . . O
including . . O
the . . O
macula . . O
before . . O
and . . O
3-4 . . O
months . . O
after . . O
treatment . . O
initiation . . O
. . . O

stroke . . O

no . . O
serious . . O
adverse . . O
reactions . . O
related . . O
to . . O
neuraceq . . O
administration . . O
have . . O
been . . O
reported . . O
. . . O

persistent . . O
or . . O
worsening . . O
bone . . O
pain . . O
, . . O
pain . . O
in . . O
extremities . . O
, . . O
fractures . . O
and . . O
/ . . O
or . . O
muscular . . O
pain . . O
or . . O
weakness . . O
may . . O
be . . O
manifestations . . O
of . . O
proximal . . O
renal . . O
tubulopathy . . O
and . . O
should . . O
prompt . . O
an . . O
evaluation . . O
of . . O
renal . . O
function . . O
in . . O
at . . O
- . . O
risk . . O
patients . . O
. . . O

withhold . . O
trametinib . . O
if . . O
rped . . O
is . . O
diagnosed . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
uloric . . O
- . . O
treated . . O
patients . . O
and . . O
at . . O
least . . O
0.5%greater . . O
than . . O
seen . . O
in . . O
patients . . O
receiving . . O
placebo . . O
in . . O
controlled . . O
studies . . O
adverse . . O
reactions . . O
placebo . . O
uloric . . O
allopurinolof . . O
the . . O
subjects . . O
who . . O
received . . O
allopurinol . . O
, . . O
10 . . O
received . . O
100 . . O
mg . . O
, . . O
145 . . O
received . . O
200 . . O
mg . . O
, . . O
and . . O
1122 . . O
received . . O
300 . . O
mg . . O
, . . O
based . . O
on . . O
level . . O
of . . O
renal . . O
impairment . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
: . . O
monitor . . O
renal . . O
function . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
reporting . . O
severe . . O
adverse . . O
gastrointestinal . . O
reactions . . O
. . . O

ear . . O
and . . O
labyrinth . . O
disorders . . O
: . . O
tinnitus . . B-AdverseReaction

in . . O
a . . O
study . . O
of . . O
697 . . O
patients . . O
with . . O
available . . O
24 . . O
- . . O
hour . . O
holter . . O
monitoring . . O
data . . O
after . . O
their . . O
first . . O
dose . . O
( . . O
n . . O
= . . O
351 . . O
receiving . . O
gilenya . . O
and . . O
n . . O
= . . O
346 . . O
on . . O
placebo . . O
) . . O
, . . O
second . . B-AdverseReaction
- . . I-AdverseReaction
degree . . I-AdverseReaction
av . . I-AdverseReaction
blocks . . I-AdverseReaction
( . . O
mobitz . . O
types . . O
i . . O
[ . . O
wenckebach . . O
] . . O
or . . O
2 . . B-AdverseReaction
: . . I-AdverseReaction
1 . . I-AdverseReaction
av . . I-AdverseReaction
blocks . . I-AdverseReaction
) . . O
occurred . . O
in . . O
4% . . O
( . . O
n . . O
= . . O
14 . . O
) . . O
of . . O
patients . . O
receiving . . O
gilenya . . O
and . . O
2% . . O
( . . O
n . . O
= . . O
7 . . O
) . . O
of . . O
patients . . O
on . . O
placebo . . O
. . . O

the . . O
acute . . O
reactions . . O
requiring . . O
intervention . . O
were . . O
managed . . O
by . . O
either . . O
temporarily . . O
interrupting . . O
or . . O
discontinuing . . O
infusion . . O
, . . O
and . . O
administering . . O
additional . . O
antihistamine . . O
, . . O
antipyretics . . O
, . . O
or . . O
corticosteroids . . O
. . . O

5.4 . . O
risk . . O
of . . O
cardiac . . O
arrhythmia . . O
and . . O
sudden . . O
cardiac . . O
death . . O
during . . O
general . . O
anesthesia . . O
for . . O
central . . O
venous . . O
catheter . . O
placement . . O

alanine . . O
aminotransferase . . O
( . . O
alt . . O
) . . O
elevations . . O

skin . . O
, . . O
scalp . . O
, . . O
and . . O
ocular . . O
irritation . . O
were . . O
monitored . . O
in . . O
the . . O
clinical . . O
trials . . O
. . . O

patients . . O
who . . O
have . . O
been . . O
previously . . O
maintained . . O
on . . O
20 . . O
mg . . O
or . . O
more . . O
of . . O
prednisone . . O
( . . O
or . . O
its . . O
equivalent . . O
) . . O
may . . O
be . . O
most . . O
susceptible . . O
, . . O
particularly . . O
when . . O
their . . O
systemic . . O
corticosteroids . . O
have . . O
been . . O
almost . . O
completely . . O
withdrawn . . O
. . . O

in . . O
the . . O
combined . . O
clinical . . O
trial . . O
experience . . O
with . . O
all . . O
doses . . O
of . . O
fingolimod . . O
, . . O
the . . O
rate . . O
of . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
was . . O
approximately . . O
20% . . O
in . . O
ms . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
uveitis . . O
versus . . O
0.6% . . O
in . . O
those . . O
without . . O
a . . O
history . . O
of . . O
uveitis . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
acute . . B-AdverseReaction
pancreatitis . . I-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
tanzeum . . O
. . . O

table . . O
7 . . O
presents . . O
the . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
( . . O
experienced . . O
by . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
10% . . O
of . . O
patients . . O
receiving . . O
promacta . . O
compared . . O
with . . O
placebo . . O
) . . O
. . . O

permanently . . O
discontinue . . O
tafinlar . . O
and . . O
trametinib . . O
for . . O
all . . O
grade . . O
4 . . O
hemorrhagic . . O
events . . O
and . . O
for . . O
any . . O
grade . . O
3 . . O
hemorrhagic . . O
events . . O
that . . O
do . . O
not . . O
improve . . O
. . . O

5.3 . . O
spinal . . O
or . . O
cervical . . O
cord . . O
compression . . O

inhaled . . O
fluticasone . . O
furoate . . O
is . . O
absorbed . . O
into . . O
the . . O
circulation . . O
and . . O
can . . O
be . . O
systemically . . O
active . . O
. . . O

patients . . O
treated . . O
with . . O
simponi . . O
aria . . O
are . . O
at . . O
increased . . O
risk . . B-Factor
for . . O
developing . . O
serious . . B-Severity
infections . . B-AdverseReaction
involving . . O
various . . O
organ . . O
systems . . O
and . . O
sites . . O
that . . O
may . . B-Factor
lead . . O
to . . O
hospitalization . . O
or . . O
death . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
10% . . O
and . . O
> . . O
= . . O
2% . . O
placebo . . O
) . . O
were . . O
flushing . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
. . . O

no . . O
clinically . . O
meaningful . . O
changes . . O
in . . O
hematology . . O
, . . O
serum . . O
chemistry . . O
or . . O
urinalysis . . O
were . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
nesina . . O
. . . O

decrease . . B-AdverseReaction
of . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
platelets . . O
, . . O
or . . O
neutrophils . . O
in . . O
patients . . O
with . . O
wm . . O
( . . O
n . . O
= . . O
63 . . O
) . . O
percent . . O
of . . O
patients . . O
( . . O
n . . O
= . . O
63 . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
43 . . O
13 . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
44 . . O
19 . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
13 . . O
8 . . O
6 . . O
. . . O

in . . O
aristotle . . O
, . . O
the . . O
mean . . O
duration . . O
of . . O
exposure . . O
was . . O
89 . . O
weeks . . O
( . . O
> . . O
15,000 . . O
patient . . O
- . . O
years . . O
) . . O
. . . O

* . . O
hypocalcemia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
serious . . B-Severity
infections . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
dermatologic . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
osteonecrosis . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
jaw . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
atypical . . O
subtrochanteric . . O
and . . O
diaphyseal . . O
femoral . . O
fractures . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
reported . . O
with . . O
prolia . . O
in . . O
patients . . O
with . . O
postmenopausal . . O
osteoporosis . . O
are . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
hypercholesterolemia . . B-AdverseReaction
, . . O
and . . O
cystitis . . B-AdverseReaction
. . . O

available . . O
data . . O
from . . O
controlled . . O
clinical . . O
trials . . O
suggest . . O
that . . O
laba . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
hospitalization . . O
in . . O
pediatric . . O
and . . O
adolescent . . O
patients . . O
. . . O

6.2 . . O
clinical . . O
laboratory . . O
findings . . O

premature . . O
discontinuation . . O
of . . O
any . . O
oral . . O
anticoagulant . . O
, . . O
including . . O
pradaxa . . O
, . . O
in . . O
the . . O
absence . . O
of . . O
adequate . . O
alternative . . O
anticoagulation . . O
increases . . O
the . . O
risk . . O
of . . O
thrombotic . . O
events . . O
. . . O

saphris . . O
( . . O
r . . O
) . . O

5.8 . . O
leukopenia . . O
, . . O
neutropenia . . O
and . . O
agranulocytosis . . O

the . . O
discontinuation . . O
rate . . O
due . . O
to . . O
bleeding . . B-AdverseReaction
events . . O
was . . O
approximately . . O
1% . . O
in . . O
the . . O
eliquis . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
0.4% . . O
in . . O
those . . O
patients . . O
in . . O
the . . O
placebo . . O
group . . O
in . . O
the . . O
amplify . . O
- . . O
ext . . O
study . . O
. . . O

withholding . . O
treatment . . O
should . . O
be . . O
considered . . O
in . . O
patients . . O
with . . O
serious . . O
infections . . O
until . . O
the . . O
infection . . O
( . . O
s . . O
) . . O
is . . O
resolved . . O
. . . O

it . . O
is . . O
unknown . . O
whether . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
pancreatitis . . O
are . . O
at . . O
increased . . O
risk . . O
for . . O
the . . O
development . . O
of . . O
pancreatitis . . O
while . . O
using . . O
nesina . . O
. . . O

diarrhea . . B-AdverseReaction
can . . B-Factor
occur . . O
at . . O
any . . O
time . . O
. . . O

of . . O
the . . O
329 . . O
enrolled . . O
patients . . O
, . . O
327 . . O
( . . O
167 . . O
brentuximab . . O
vedotin . . O
, . . O
160 . . O
placebo . . O
) . . O
received . . O
at . . O
least . . O
one . . O
dose . . O
of . . O
study . . O
treatment . . O
. . . O

to . . O
reduce . . O
the . . O
potential . . O
risk . . O
of . . O
bleeding . . O
associated . . O
with . . O
the . . O
concurrent . . O
use . . O
of . . O
dabigatran . . O
and . . O
epidural . . O
or . . O
spinal . . O
anesthesia . . O
/ . . O
analgesia . . O
or . . O
spinal . . O
puncture . . O
, . . O
consider . . O
the . . O
pharmacokinetic . . O
profile . . O
of . . O
dabigatran . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

these . . O
subjects . . O
did . . O
not . . O
receive . . O
calcium . . O
and . . O
vitamin . . O
d . . O
supplementation . . O
. . . O

obtain . . O
an . . O
ecg . . O
before . . O
initiation . . O
of . . O
treatment . . O
, . . O
and . . O
at . . O
least . . O
2 . . O
, . . O
12 . . O
, . . O
and . . O
24 . . O
weeks . . O
after . . O
starting . . O
treatment . . O
with . . O
sirturo . . O
. . . O

severe . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
require . . O
immediate . . O
discontinuation . . O
of . . O
the . . O
jevtana . . O
infusion . . O
and . . O
appropriate . . O
therapy . . O
. . . O

glaucoma . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
intraocular . . I-AdverseReaction
pressure . . I-AdverseReaction
, . . O
and . . O
cataracts . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
with . . O
copd . . O
or . . O
asthma . . O
following . . O
the . . O
long . . O
- . . O
term . . O
administration . . O
of . . O
inhaled . . O
corticosteroids . . B-DrugClass
. . . O

more . . O
gilotrif . . O
- . . O
treated . . O
patients . . O
( . . O
2.2% . . O
; . . O
n . . O
= . . O
5 . . O
) . . O
experienced . . O
ventricular . . B-AdverseReaction
dysfunction . . I-AdverseReaction
( . . O
defined . . O
as . . O
diastolic . . B-AdverseReaction
dysfunction . . I-AdverseReaction
, . . O
left . . B-AdverseReaction
ventricular . . I-AdverseReaction
dysfunction . . I-AdverseReaction
, . . O
or . . O
ventricular . . B-AdverseReaction
dilation . . I-AdverseReaction
; . . O
all . . O
< . . O
grade . . O
3 . . O
) . . O
compared . . O
to . . O
chemotherapy . . O
- . . O
treated . . O
patients . . O
( . . O
0.9% . . O
; . . O
n . . O
= . . O
1 . . O
) . . O
. . . O

consider . . O
the . . O
benefit . . O
- . . O
risk . . O
of . . O
withholding . . O
imbruvica . . O
for . . O
at . . O
least . . O
3 . . O
to . . O
7 . . O
days . . O
pre . . O
and . . O
post . . O
- . . O
surgery . . O
depending . . O
upon . . O
the . . O
type . . O
of . . O
surgery . . O
and . . O
the . . O
risk . . O
of . . O
bleeding . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

because . . O
of . . O
the . . O
nature . . O
of . . O
the . . O
adverse . . O
events . . O
seen . . O
with . . O
this . . O
combination . . O
therapy . . O
, . . O
similar . . O
toxicities . . O
may . . O
also . . O
result . . O
from . . O
the . . O
use . . O
of . . O
cimzia . . O
in . . O
this . . O
combination . . O
. . . O

5.3 . . O
hepatic . . O
effects . . O

excerpt . . O
: . . O
. . . O
anaphylaxis . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
anaphylaxis . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction
reactions . . O
have . . O
been . . O
observed . . O
in . . O
some . . O
patients . . O
during . . O
treatment . . O
with . . O
vimizim . . O
. . . O

this . . O
pool . . O
combined . . O
13 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
including . . O
3 . . O
monotherapy . . O
studies . . O
, . . O
9 . . O
add . . O
- . . O
on . . O
to . . O
background . . O
antidiabetic . . O
therapy . . O
studies . . O
, . . O
and . . O
an . . O
initial . . O
combination . . O
with . . O
metformin . . O
study . . O
. . . O

three . . O
of . . O
these . . O
patients . . O
had . . O
subsequent . . O
tests . . O
which . . O
were . . O
negative . . O
. . . O

cardiovert . . O
patients . . O
who . . O
are . . O
in . . O
atrial . . O
fibrillation . . O
( . . O
if . . O
clinically . . O
indicated . . O
) . . O
or . . O
discontinue . . O
multaq . . O
. . . O

6 . . O
adverse . . O
reactions . . O

5 . . O
warnings . . O
and . . O
precautions . . O

patients . . O
treated . . O
with . . O
concomitant . . O
immunosuppressant . . O
therapy . . O
( . . O
mtx . . O
) . . O
in . . O
ra . . O
- . . O
i . . O
, . . O
ra . . O
- . . O
ii . . O
, . . O
ra . . O
- . . O
iii . . O
had . . O
a . . O
lower . . O
rate . . O
of . . O
neutralizing . . O
antibody . . O
formation . . O
overall . . O
than . . O
patients . . O
treated . . O
with . . O
cimzia . . O
monotherapy . . O
in . . O
ra . . O
- . . O
iv . . O
( . . O
2% . . O
vs . . O
. . . O
8% . . O
) . . O
. . . O

it . . O
is . . O
possible . . O
that . . O
systemic . . O
corticosteroid . . O
effects . . O
such . . O
as . . O
hypercorticism . . B-AdverseReaction
and . . O
adrenal . . B-AdverseReaction
suppression . . I-AdverseReaction
( . . O
including . . O
adrenal . . B-AdverseReaction
crisis . . I-AdverseReaction
) . . O
may . . B-Factor
appear . . O
in . . O
a . . O
small . . O
number . . O
of . . O
patients . . O
who . . O
are . . O
sensitive . . O
to . . O
these . . O
effects . . O
. . . O

the . . O
treatment . . O
emergent . . O
adverse . . O
events . . O
leading . . O
to . . O
discontinuation . . O
of . . O
at . . O
least . . O
2 . . O
patients . . O
treated . . O
with . . O
ampyra . . O
and . . O
that . . O
led . . O
to . . O
discontinuation . . O
more . . O
frequently . . O
compared . . O
to . . O
placebo . . O
were . . O
headache . . B-AdverseReaction
( . . O
ampyra . . O
0.5% . . O
, . . O
placebo . . O
0% . . O
) . . O
, . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
ampyra . . O
0.5% . . O
, . . O
placebo . . O
0% . . O
) . . O
, . . O
dizziness . . B-AdverseReaction
( . . O
ampyra . . O
0.5% . . O
, . . O
placebo . . O
0% . . O
) . . O
, . . O
and . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
( . . O
ampyra . . O
0.3% . . O
, . . O
placebo . . O
0% . . O
) . . O
. . . O

because . . O
it . . O
takes . . O
approximately . . O
2 . . O
months . . O
to . . O
eliminate . . O
gilenya . . O
from . . O
the . . O
body . . O
, . . O
women . . O
of . . O
childbearing . . O
potential . . O
should . . O
use . . O
effective . . O
contraception . . O
to . . O
avoid . . O
pregnancy . . O
during . . O
and . . O
for . . O
2 . . O
months . . O
after . . O
stopping . . O
gilenya . . O
treatment . . O
. . . O

serious . . B-Severity
febrile . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
fever . . B-AdverseReaction
of . . O
any . . O
severity . . O
complicated . . O
by . . O
hypotension . . B-AdverseReaction
, . . O
rigors . . B-AdverseReaction
or . . O
chills . . B-AdverseReaction
occurred . . O
in . . O
25% . . O
( . . O
14 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
compared . . O
with . . O
2% . . O
( . . O
1 . . O
/ . . O
53 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

healthcare . . O
providers . . O
should . . O
be . . O
prepared . . O
to . . O
address . . O
severe . . O
allergic . . O
reactions . . O
following . . O
xiaflex . . O
injections . . O
. . . O

the . . O
increased . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
with . . O
aeds . . B-DrugClass
was . . O
observed . . O
as . . O
early . . O
as . . O
1 . . O
week . . O
after . . O
starting . . O
drug . . O
treatment . . O
with . . O
aeds . . O
and . . O
persisted . . O
for . . O
the . . O
duration . . O
of . . O
treatment . . O
assessed . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
hand . . B-AdverseReaction
- . . I-AdverseReaction
foot . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
reported . . O
as . . O
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
) . . O
( . . O
5% . . O
) . . O
, . . O
nail . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
erythema . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
onychoclasis . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
skin . . B-AdverseReaction
lesion . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
acneiform . . B-AdverseReaction
dermatitis . . I-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
angioedema . . B-AdverseReaction
( . . O
< . . O
1% . . O
) . . O

only . . O
use . . O
sirturo . . O
when . . O
an . . O
effective . . O
treatment . . O
regimen . . O
cannot . . O
otherwise . . O
be . . O
provided . . O
[ . . O
see . . O
indications . . O
and . . O
usage . . O
( . . O
1 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
2 . . O
patients . . O
in . . O
the . . O
retrospective . . O
case . . O
series . . O
treated . . O
with . . O
carbaglu . . O

* . . O
fatal . . B-AdverseReaction
and . . O
/ . . O
or . . O
serious . . B-Severity
hepatotoxicity . . B-AdverseReaction
occurred . . O
in . . O
14% . . O
of . . O
zydelig . . O
- . . O
treated . . O
patients . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
merz . . O
pharmaceuticals . . O
, . . O
llc . . O
at . . O
888-493-6646 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

adverse . . O
events . . O
leading . . O
to . . O
dose . . O
reduction . . O
occurred . . O
in . . O
approximately . . O
6% . . O
of . . O
patients . . O
. . . O

withhold . . O
then . . O
dose . . O
reduce . . O
, . . O
or . . O
permanently . . O
discontinue . . O
zykadia . . O
. . . O

table . . O
4 . . O
shows . . O
the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
that . . O
were . . O
reported . . O
in . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
5% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
after . . O
two . . O
concurrent . . O
injections . . O
of . . O
xiaflex . . O
in . . O
the . . O
same . . O
hand . . O
through . . O
day . . O
60 . . O
in . . O
study . . O
3 . . O
. . . O

5.17 . . O
effect . . O
on . . O
growth . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

the . . O
adverse . . O
events . . O
observed . . O
within . . O
one . . O
hour . . O
of . . O
the . . O
end . . O
of . . O
the . . O
infusion . . O
were . . O
similar . . O
in . . O
patients . . O
who . . O
received . . O
cleviprex . . O
and . . O
in . . O
those . . O
who . . O
received . . O
comparator . . O
agents . . O
. . . O

the . . O
adverse . . O
events . . O
reported . . O
in . . O
the . . O
long . . O
term . . O
safety . . O
trials . . O
were . . O
similar . . O
to . . O
those . . O
occurring . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
trials . . O
of . . O
3 . . O
to . . O
6 . . O
months . . O
. . . O

one . . O
case . . O
of . . O
anc . . B-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
0.5 . . I-AdverseReaction
x . . I-AdverseReaction
10 . . I-AdverseReaction
9 . . I-AdverseReaction
/ . . I-AdverseReaction
l . . I-AdverseReaction
was . . O
observed . . O
in . . O
the . . O
ilaris . . O
group . . O
and . . O
none . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

the . . O
following . . O
important . . O
adverse . . O
reactions . . O
are . . O
described . . O
below . . O
and . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

voraxaze . . O
was . . O
given . . O
at . . O
a . . O
dose . . O
of . . O
50 . . O
units . . O
/ . . O
kg . . O
as . . O
an . . O
intravenous . . O
injection . . O
over . . O
5 . . O
minutes . . O
. . . O

warning . . O
: . . O
risk . . B-Factor
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction

cardiac . . O
disorders . . O
- . . O
tachycardia . . B-AdverseReaction
. . . O

increasing . . O
inhaled . . O
beta2 . . O
- . . O
agonist . . O
use . . O
is . . O
a . . O
signal . . O
of . . O
deteriorating . . O
disease . . O
for . . O
which . . O
prompt . . O
medical . . O
attention . . O
is . . O
indicated . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
are . . O
: . . O
nasopharyngitis . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
. . . O

ask . . O
your . . O
healthcare . . O
provider . . O
for . . O
ways . . O
to . . O
lower . . O
your . . O
chances . . O
of . . O
getting . . O
heart . . O
disease . . O
. . . O

these . . O
adverse . . O
reactions . . O
were . . O
not . . O
present . . O
at . . O
baseline . . O
, . . O
occurred . . O
more . . O
commonly . . O
on . . O
farxiga . . O
than . . O
on . . O
placebo . . O
, . . O
and . . O
occurred . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
either . . O
farxiga . . O
5 . . O
mg . . O
or . . O
farxiga . . O
10 . . O
mg . . O
. . . O

the . . O
safety . . O
assessment . . O
is . . O
based . . O
on . . O
all . . O
data . . O
from . . O
1203 . . O
subjects . . O
in . . O
the . . O
phase . . O
3 . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
tmc125 . . O
- . . O
c206 . . O
and . . O
tmc125 . . O
- . . O
c216 . . O
, . . O
conducted . . O
in . . O
antiretroviral . . O
treatment . . O
- . . O
experienced . . O
hiv . . O
- . . O
1 . . O
- . . O
infected . . O
adult . . O
subjects . . O
, . . O
599 . . O
of . . O
whom . . O
received . . O
intelence . . O
( . . O
r . . O
) . . O
( . . O
200 . . O
mg . . O
twice . . O
daily . . O
) . . O
. . . O

the . . O
mean . . O
baseline . . O
hemoglobin . . O
value . . O
was . . O
approximately . . O
14.1 . . O
g . . O
/ . . O
dl . . O
across . . O
treatment . . O
groups . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

in . . O
patients . . O
with . . O
abnormally . . O
high . . O
( . . O
> . . O
3 . . O
mg . . O
/ . . O
dl . . O
) . . O
serum . . O
bilirubin . . O
, . . O
reduced . . O
hepatic . . O
contrast . . O
was . . O
observed . . O
. . . O

dress . . B-AdverseReaction
typically . . O
, . . O
although . . O
not . . O
exclusively . . O
, . . O
presents . . O
with . . O
fever . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
lymphadenopathy . . B-AdverseReaction
, . . O
in . . O
association . . O
with . . O
other . . O
organ . . O
system . . O
involvement . . O
, . . O
such . . O
as . . O
hepatitis . . B-AdverseReaction
, . . O
nephritis . . B-AdverseReaction
, . . O
hematological . . B-AdverseReaction
abnormalities . . I-AdverseReaction
, . . O
myocarditis . . B-AdverseReaction
, . . O
or . . O
myositis . . B-AdverseReaction
sometimes . . O
resembling . . O
an . . O
acute . . O
viral . . O
infection . . O
. . . O

the . . O
majority . . O
of . . O
cases . . O
occurred . . O
in . . O
countries . . O
with . . O
high . . O
endemic . . O
rates . . O
of . . O
tb . . B-AdverseReaction
. . . O

both . . O
patients . . O
had . . O
markedly . . O
elevated . . O
serum . . O
calcitonin . . O
levels . . O
at . . O
baseline . . O
. . . O

permanently . . O
discontinue . . O
yervoy . . O
and . . O
initiate . . O
systemic . . O
high . . O
- . . O
dose . . O
corticosteroid . . O
therapy . . O
for . . O
severe . . O
immune . . O
- . . O
mediated . . O
reactions . . O
. . . O

the . . O
absolute . . O
risk . . O
of . . O
probable . . O
dementia . . B-AdverseReaction
for . . O
ce . . B-DrugClass
- . . O
alone . . O
versus . . O
placebo . . O
was . . O
37 . . O
versus . . O
25 . . O
cases . . O
per . . O
10,000 . . O
women . . O
- . . O
years . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
) . . O
and . . O
clinical . . O
studies . . O
( . . O
14.6 . . O
) . . O
] . . O
. . . O

* . . O
serotonin . . B-AdverseReaction
syndrome . . I-AdverseReaction
: . . O
serotonin . . B-AdverseReaction
syndrome . . I-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
ssris . . O
and . . O
snris . . O
, . . O
including . . O
with . . O
pristiq . . O
, . . O
both . . O
when . . O
taken . . O
alone . . O
, . . O
but . . O
especially . . O
when . . O
co . . O
- . . O
administered . . O
with . . O
other . . O
serotonergic . . O
agents . . O
( . . O
including . . O
triptans . . O
, . . O
tricyclic . . O
antidepressants . . O
, . . O
fentanyl . . O
, . . O
lithium . . O
, . . O
tramadol . . O
, . . O
tryptophan . . O
, . . O
buspirone . . O
, . . O
and . . O
st . . O
. . . O
john's . . O
wort . . O
) . . O
. . . O

the . . O
most . . O
frequently . . O
observed . . O
adverse . . O
drug . . O
reactions . . O
in . . O
subjects . . O
receiving . . O
neuraceq . . O
were . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
consisting . . O
of . . O
erythema . . O
, . . O
irritation . . O
and . . O
pain . . O
. . . O

over . . O
the . . O
course . . O
of . . O
a . . O
typical . . O
10 . . O
- . . O
week . . O
controlled . . O
trial . . O
, . . O
the . . O
rate . . O
of . . O
death . . B-AdverseReaction
in . . O
drug . . O
- . . O
treated . . O
patients . . O
was . . O
about . . O
4.5% . . O
, . . O
compared . . O
to . . O
a . . O
rate . . O
of . . O
about . . O
2.6% . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

baseline . . O
renal . . O
function . . O
was . . O
normal . . O
or . . O
mildly . . O
impaired . . O
in . . O
88% . . O
of . . O
patients . . O
and . . O
moderately . . O
impaired . . O
in . . O
11% . . O
of . . O
patients . . O
( . . O
mean . . O
egfr . . O
82 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
. . . O

table . . O
5 . . O
reflects . . O
exposure . . O
to . . O
dysport . . O
( . . O
r . . O
) . . O
in . . O
398 . . O
patients . . O
19 . . O
to . . O
75 . . O
years . . O
of . . O
age . . O
who . . O
were . . O
evaluated . . O
in . . O
the . . O
randomized . . O
, . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
studies . . O
that . . O
assessed . . O
the . . O
use . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
for . . O
the . . O
temporary . . O
improvement . . O
in . . O
the . . O
appearance . . O
of . . O
glabellar . . O
lines . . O
[ . . O
seeclinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

other . . O
ocular . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
1-5% . . O
of . . O
subjects . . O
included . . O
reduced . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
, . . O
punctate . . B-AdverseReaction
keratitis . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
inflammation . . I-AdverseReaction
, . . O
and . . O
iritis . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
* . . O
intraocular . . O
pressure . . O
( . . O
iop . . O
) . . O
increase . . O
- . . O
prolonged . . O
use . . O
of . . O
corticosteroids . . B-DrugClass
may . . O
result . . O
in . . O
glaucoma . . B-AdverseReaction
with . . O
damage . . B-AdverseReaction
to . . I-AdverseReaction
the . . I-AdverseReaction
optic . . I-AdverseReaction
nerve . . I-AdverseReaction
, . . O
defects . . B-AdverseReaction
in . . I-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
and . . O
fields . . O
of . . O
vision . . O
. . . O

if . . O
a . . O
patient . . O
develops . . O
a . . O
dermatologic . . O
reaction . . O
while . . O
taking . . O
aptiom . . O
, . . O
discontinue . . O
aptiom . . O
use . . O
, . . O
unless . . O
the . . O
reaction . . O
is . . O
clearly . . O
not . . O
drug . . O
- . . O
related . . O
. . . O

cimzia . . O
is . . O
not . . O
indicated . . O
for . . O
use . . O
in . . O
pediatric . . O
patients . . O
. . . O

advise . . O
women . . O
of . . O
potential . . O
risk . . O
to . . O
a . . O
fetus . . O
and . . O
to . . O
avoid . . O
pregnancy . . O
while . . O
taking . . O
zydelig . . O
. . . O

mouth . . B-AdverseReaction
ulcers . . I-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
and . . O
oral . . B-AdverseReaction
mucositis . . I-AdverseReaction
have . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
afinitor . . O
at . . O
an . . O
incidence . . O
ranging . . O
from . . O
44% . . O
- . . O
78% . . O
across . . O
the . . O
clinical . . O
trial . . O
experience . . O
. . . O

* . . O
risk . . B-Factor
of . . O
acute . . B-AdverseReaction
cardiorespiratory . . I-AdverseReaction
failure . . I-AdverseReaction
: . . O
patients . . O
with . . O
compromised . . O
cardiac . . O
or . . O
respiratory . . O
function . . O
may . . B-Factor
be . . O
at . . O
risk . . O
of . . O
acute . . B-AdverseReaction
cardiorespiratory . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

grade . . B-Severity
2 . . I-Severity
adrs . . O
reported . . O
in . . O
at . . O
least . . O
1 . . O
subject . . O
were . . O
rash . . B-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
, . . O
and . . O
diarrhea . . B-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
. . . O

a . . O
total . . O
of . . O
171 . . O
patients . . O
in . . O
the . . O
chemotherapy . . O
arm . . O
received . . O
pemetrexed . . O
500 . . O
mg . . O
/ . . O
m . . O
2 . . O
( . . O
n . . O
= . . O
99 . . O
) . . O
or . . O
docetaxel . . O
75 . . O
mg . . O
/ . . O
m . . O
2 . . O
( . . O
n . . O
= . . O
72 . . O
) . . O
by . . O
intravenous . . O
infusion . . O
every . . O
three . . O
weeks . . O
until . . O
documented . . O
disease . . O
progression . . O
, . . O
intolerance . . O
to . . O
therapy . . O
, . . O
or . . O
the . . O
investigator . . O
determined . . O
that . . O
the . . O
patient . . O
was . . O
no . . O
longer . . O
experiencing . . O
clinical . . O
benefit . . O
. . . O

recipients . . O
without . . O
immunity . . O
to . . O
epstein . . O
- . . O
barr . . O
virus . . O
( . . O
ebv . . O
) . . O
are . . O
at . . O
a . . O
particularly . . O
increased . . O
risk . . O
; . . O
therefore . . O
, . . O
use . . O
in . . O
ebv . . O
seropositive . . O
patients . . O
only . . O
. . . O

comparison . . O
of . . O
gender . . O
, . . O
age . . O
, . . O
and . . O
race . . O

consider . . O
discontinuing . . O
prolia . . O
if . . O
severe . . O
symptoms . . O
develop . . O
. . . O

because . . O
of . . O
the . . O
risk . . O
of . . O
anaphylaxis . . O
, . . O
kalbitor . . O
should . . O
only . . O
be . . O
administered . . O

consider . . O
the . . O
diagnosis . . O
of . . O
pml . . O
in . . O
any . . O
patient . . O
presenting . . O
with . . O
new . . O
- . . O
onset . . O
signs . . O
and . . O
symptoms . . O
of . . O
central . . O
nervous . . O
system . . O
abnormalities . . O
. . . O

immune . . O
system . . O
disorders . . O
: . . O
cytokine . . B-AdverseReaction
storm . . I-AdverseReaction
( . . O
1% . . O
) . . O

investigations . . O
: . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
blood . . I-AdverseReaction
bicarbonate . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
hepatic . . I-AdverseReaction
enzymes . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
platelet . . I-AdverseReaction
count . . I-AdverseReaction

table . . O
2 . . O
presents . . O
the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
reported . . O
in . . O
> . . O
= . . O
10% . . O
patients . . O
who . . O
received . . O
inlyta . . O
or . . O
sorafenib . . O
. . . O

6 . . O
adverse . . O
reactions . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
uncommonly . . O
been . . O
reported . . O
during . . O
the . . O
postmarketing . . O
use . . O
of . . O
adreview . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
* . . O
? . . O

5.1 . . O
drugs . . O
containing . . O
progestins . . O
, . . O
estrogens . . O
or . . O
estrogen . . O
agonist . . O
/ . . O
antagonists . . O

the . . O
most . . O
frequent . . O
adverse . . O
drug . . O
reactions . . O
that . . O
led . . O
to . . O
discontinuation . . O
in . . O
1% . . O
or . . O
more . . O
of . . O
patients . . O
in . . O
study . . O
1 . . O
were . . O
pneumonia . . B-AdverseReaction
, . . O
ild . . B-AdverseReaction
/ . . O
pneumonitis . . B-AdverseReaction
, . . O
and . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
. . . O

common . . O
adverse . . O
reactions . . O
in . . O
all . . O
controlled . . O
clinical . . O
studies . . O

in . . O
the . . O
controlled . . O
portions . . O
of . . O
the . . O
clinical . . O
trials . . O
in . . O
dupuytren's . . O
contracture . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
, . . O
a . . O
greater . . O
proportion . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
( . . O
15% . . O
) . . O
compared . . O
to . . O
placebo . . O
- . . O
treated . . O
patients . . O
( . . O
1% . . O
) . . O
had . . O
mild . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
pruritus . . B-AdverseReaction
) . . O
after . . O
up . . O
to . . O
3 . . O
injections . . O
. . . O

keratitis . . O
was . . O
reported . . O
in . . O
5 . . O
( . . O
2.2% . . O
) . . O
patients . . O
in . . O
study . . O
1 . . O
, . . O
with . . O
grade . . B-Severity
3 . . I-Severity
in . . O
1 . . O
( . . O
0.4% . . O
) . . O
. . . O

antipsychotic . . O
treatment . . O
, . . O
itself . . O
, . . O
however . . O
, . . O
may . . O
suppress . . O
( . . O
or . . O
partially . . O
suppress . . O
) . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
the . . O
syndrome . . O
and . . O
thereby . . O
may . . O
possibly . . O
mask . . O
the . . O
underlying . . O
process . . O
. . . O

5.1 . . O
nephrogenic . . O
systemic . . O
fibrosis . . O

intravitreal . . O
injections . . O
, . . O
including . . O
those . . O
with . . O
eylea . . O
, . . O
have . . O
been . . O
associated . . O
with . . O
endophthalmitis . . B-AdverseReaction
and . . O
retinal . . B-AdverseReaction
detachments . . I-AdverseReaction
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

s . . O
on . . O
- . . O
treatment . . O
analysis . . O
based . . O
on . . O
the . . O
safety . . O
population . . O
, . . O
compared . . O
to . . O
itt . . O
analysis . . O
presented . . O
in . . O
section . . O
14 . . O
. . . O

* . . O
tissue . . O
inflammation . . O
as . . O
well . . O
as . . O
prostatic . . O
hyperplasia . . O
have . . O
been . . O
associated . . O
with . . O
false . . O
positive . . O
11 . . O
c . . O
- . . O
choline . . O
pet . . O
images . . O
. . . O

confusional . . B-AdverseReaction
state . . I-AdverseReaction
, . . O
psychotic . . B-AdverseReaction
symptoms . . I-AdverseReaction
, . . O
and . . O
hallucinations . . B-AdverseReaction
were . . O
reported . . O
more . . O
frequently . . O
as . . O
adverse . . O
reactions . . O
in . . O
patients . . O
treated . . O
with . . O
potiga . . O
than . . O
in . . O
those . . O
treated . . O
with . . O
placebo . . O
in . . O
placebo . . O
- . . O
controlled . . O
epilepsy . . O
trials . . O
( . . O
see . . O
table . . O
2 . . O
) . . O
. . . O

the . . O
overall . . O
percentage . . O
of . . O
antibody . . O
positive . . O
patients . . O
was . . O
8% . . O
in . . O
patients . . O
continuously . . O
exposed . . O
to . . O
cimzia . . O
, . . O
approximately . . O
6% . . O
were . . O
neutralizing . . O
in . . O
vitro . . O
. . . O

patients . . O
should . . O
be . . O
monitored . . O
for . . O
hypertension . . O
and . . O
treated . . O
as . . O
needed . . O
with . . O
standard . . O
anti . . O
- . . O
hypertensive . . O
therapy . . O
. . . O

excerpt . . O
: . . O
* . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
: . . O
see . . O
boxed . . O
warning . . O
. . . O

the . . O
majority . . O
of . . O
the . . O
events . . O
were . . O
mild . . B-Severity
to . . I-Severity
moderate . . I-Severity
although . . O
serious . . B-Severity
infections . . O
were . . O
observed . . O
. . . O

kyprolis . . O
causes . . O
thrombocytopenia . . B-AdverseReaction
with . . O
platelet . . B-AdverseReaction
nadirs . . I-AdverseReaction
observed . . O
between . . O
day . . O
8 . . O
and . . O
day . . O
15 . . O
of . . O
each . . O
28 . . O
- . . O
day . . O
cycle . . O
with . . O
recovery . . O
to . . O
baseline . . O
platelet . . O
count . . O
usually . . O
by . . O
the . . O
start . . O
of . . O
the . . O
next . . O
cycle . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

hepatic . . O
effects . . O
, . . O
ranging . . O
from . . O
mild . . B-Severity
to . . I-Severity
moderate . . I-Severity
elevations . . B-AdverseReaction
in . . I-AdverseReaction
transaminases . . I-AdverseReaction
( . . O
> . . O
3 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
) . . O
to . . O
rare . . O
cases . . O
with . . O
concomitant . . O
elevations . . B-AdverseReaction
of . . I-AdverseReaction
total . . I-AdverseReaction
bilirubin . . I-AdverseReaction
( . . O
> . . O
2 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
) . . O
have . . O
been . . O
reported . . O
with . . O
aptiom . . O
use . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

discontinue . . O
zydelig . . O
for . . O
recurrent . . O
hepatotoxicity . . O
. . . O

for . . O
moderate . . O
to . . O
severe . . O
proteinuria . . O
, . . O
reduce . . O
the . . O
dose . . O
or . . O
temporarily . . O
interrupt . . O
treatment . . O
with . . O
inlyta . . O
. . . O

monitor . . O
patients . . O
for . . O
pulmonary . . O
symptoms . . O
indicative . . O
of . . O
ild . . O
/ . . O
pneumonitis . . O
. . . O

* . . O
classical . . O
hl . . O
post . . O
- . . O
auto . . O
- . . O
hsct . . O
consolidation . . O
: . . O
neutropenia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
and . . O
diarrhea . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

pulmonary . . O
arterial . . O
hypertension . . O
( . . O
pah . . O
) . . O
was . . O
reported . . O
in . . O
approximately . . O
1% . . O
of . . O
patients . . O
treated . . O
with . . O
kyprolis . . O
and . . O
was . . O
grade . . B-Severity
3 . . I-Severity
or . . O
greater . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
patients . . O
. . . O

if . . O
traumatic . . O
puncture . . O
occurs . . O
, . . O
delay . . O
the . . O
administration . . O
of . . O
eliquis . . O
for . . O
48 . . O
hours . . O
. . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
a . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

discontinue . . O
promacta . . O
if . . O
alt . . O
levels . . O
increase . . O
to . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3 . . O
x . . O
uln . . O
in . . O
patients . . O
with . . O
normal . . O
liver . . O
function . . O
or . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3 . . O
x . . O
baseline . . O
in . . O
patients . . O
with . . O
pre . . O
- . . O
treatment . . O
elevations . . O
in . . O
transaminases . . O
and . . O
are . . O
: . . O

caution . . O
patients . . O
about . . O
risk . . O
of . . O
activation . . O
of . . O
mania . . O
/ . . O
hypomania . . O
( . . O
5.6 . . O
) . . O
. . . O

in . . O
the . . O
controlled . . O
clinical . . O
trials . . O
, . . O
malignancies . . B-AdverseReaction
, . . O
excluding . . O
non . . O
- . . O
melanoma . . O
skin . . O
cancers . . O
, . . O
were . . O
observed . . O
in . . O
0.2% . . O
( . . O
3 . . O
/ . . O
1,458 . . O
) . . O
and . . O
0.3% . . O
( . . O
2 . . O
/ . . O
675 . . O
) . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
and . . O
placebo . . O
, . . O
respectively . . O
. . . O

delayed . . O
- . . O
onset . . O
reactions . . O
, . . O
defined . . O
as . . O
adverse . . O
reactions . . O
occurring . . O
2 . . O
- . . O
48 . . O
hours . . O
after . . O
completion . . O
of . . O
alglucosidase . . O
alfa . . O
infusion . . O
, . . O
that . . O
were . . O
observed . . O
in . . O
> . . O
= . . O
3% . . O
more . . O
patients . . O
in . . O
the . . O
alglucosidase . . O
alfa . . O
- . . O
treated . . O
group . . O
compared . . O
to . . O
patients . . O
in . . O
the . . O
placebo . . O
- . . O
treated . . O
group . . O
in . . O
the . . O
controlled . . O
trial . . O
, . . O
included . . O
hyperhidrosis . . B-AdverseReaction
. . . O

1.5 . . O
8.4 . . O
6.9 . . O
nasopharyngitis . . B-AdverseReaction
6.2 . . O
6.6 . . O
6.3 . . O
urinary . . O
tract . . O
infectionsurinary . . O
tract . . B-AdverseReaction
infections . . I-AdverseReaction
include . . O
the . . O
following . . O
adverse . . O
reactions . . O
, . . O
listed . . O
in . . O
order . . O
of . . O
frequency . . O
reported . . O
: . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
cystitis . . B-AdverseReaction
, . . O
escherichia . . B-AdverseReaction
urinary . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
genitourinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
pyelonephritis . . B-AdverseReaction
, . . O
trigonitis . . B-AdverseReaction
, . . O
urethritis . . B-AdverseReaction
, . . O
kidney . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
and . . O
prostatitis . . B-AdverseReaction
. . . O

a . . O
routine . . O
oral . . O
exam . . O
should . . O
be . . O
performed . . O
by . . O
the . . O
prescriber . . O
prior . . O
to . . O
initiation . . O
of . . O
prolia . . O
treatment . . O
. . . O

antimalarials . . O
should . . O
not . . O
be . . O
given . . O
concomitantly . . O
with . . O
coartem . . O
tablets . . O
, . . O
unless . . O
there . . O
is . . O
no . . O
other . . O
treatment . . O
option . . O
, . . O
due . . O
to . . O
limited . . O
safety . . O
data . . O
. . . O

in . . O
the . . O
lung . . O
cancer . . O
study . . O
, . . O
80% . . O
of . . O
patients . . O
were . . O
male . . O
, . . O
the . . O
median . . O
age . . O
was . . O
58 . . O
years . . O
, . . O
and . . O
95% . . O
of . . O
patients . . O
were . . O
caucasian . . O
. . . O

all . . O
women . . O
should . . O
receive . . O
yearly . . O
breast . . O
examinations . . O
by . . O
a . . O
healthcare . . O
provider . . O
and . . O
perform . . O
monthly . . O
breast . . O
self . . O
- . . O
examinations . . O
. . . O

however . . O
, . . O
the . . O
attributable . . O
risk . . O
of . . O
liver . . B-AdverseReaction
cancers . . I-AdverseReaction
in . . O
coc . . B-DrugClass
users . . O
is . . O
less . . O
than . . O
one . . O
case . . O
per . . O
million . . O
users . . O
. . . O

cimzia . . O
should . . O
be . . O
discontinued . . O
if . . O
a . . O
patient . . O
develops . . O
a . . O
serious . . O
infection . . O
or . . O
sepsis . . O
. . . O

* . . O
increased . . B-AdverseReaction
toxicity . . I-AdverseReaction
in . . O
the . . O
presence . . O
of . . O
moderate . . O
or . . O
severe . . O
hepatic . . O
impairment . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O

if . . O
anaphylaxis . . O
occurs . . O
, . . O
immediately . . O
and . . O
permanently . . O
discontinue . . O
administration . . O
of . . O
adcetris . . O
and . . O
administer . . O
appropriate . . O
medical . . O
therapy . . O
. . . O

5.1 . . O
severe . . O
skin . . O
and . . O
hypersensitivity . . O
reactions . . O

the . . O
usefulness . . O
of . . O
hemodialysis . . O
in . . O
the . . O
prevention . . O
of . . O
nsf . . O
is . . O
unknown . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

in . . O
trial . . O
2 . . O
, . . O
treatment . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
resulted . . O
in . . O
an . . O
increased . . O
incidence . . O
and . . O
severity . . O
of . . O
any . . O
hemorrhagic . . B-AdverseReaction
event . . I-AdverseReaction
: . . O
16% . . O
( . . O
9 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
compared . . O
with . . O
2% . . O
( . . O
1 . . O
/ . . O
53 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

5.11 . . O
seizures . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
( . . O
a . . O
) . . O
premature . . O
discontinuation . . O

pheochromocytoma . . O
and . . O
neuroblastoma . . O

patients . . O
with . . O
a . . O
prior . . O
dress . . O
reaction . . O
with . . O
either . . O
oxcarbazepine . . O
or . . O
aptiom . . O
should . . O
not . . O
be . . O
treated . . O
with . . O
aptiom . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

monitor . . O
patients . . O
receiving . . O
blincyto . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
neurological . . O
toxicities . . O
, . . O
and . . O
interrupt . . O
or . . O
discontinue . . O
blincyto . . O
as . . O
recommended . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

anyone . . O
considering . . O
prescribing . . O
potiga . . O
or . . O
any . . O
other . . O
aed . . O
must . . O
balance . . O
this . . O
risk . . O
with . . O
the . . O
risk . . O
of . . O
untreated . . O
illness . . O
. . . O

treanda . . O
caused . . O
severe . . B-Severity
myelosuppression . . B-AdverseReaction
( . . O
grade . . B-Severity
3-4 . . I-Severity
) . . O
in . . O
98% . . O
of . . O
patients . . O
in . . O
the . . O
two . . O
nhl . . O
studies . . O
( . . O
see . . O
table . . O
4 . . O
) . . O
. . . O

dizziness . . B-AdverseReaction
was . . O
reported . . O
in . . O
13% . . O
of . . O
patients . . O
receiving . . O
600 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
compared . . O
with . . O
4% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

interrupt . . O
blincyto . . O
if . . O
prolonged . . O
neutropenia . . O
occurs . . O
. . . O

duavee . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
women . . O
with . . O
impaired . . O
liver . . O
function . . O
or . . O
past . . O
history . . O
of . . O
cholestatic . . O
jaundice . . O
. . . O

5.3 . . O
hypersensitivity . . O

* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
diarrhea . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
in . . O
either . . O
indication . . O
) . . O
are . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
and . . O
pyrexia . . B-AdverseReaction
. . . O

cases . . O
of . . O
syncope . . B-AdverseReaction
were . . O
also . . O
reported . . O
after . . O
the . . O
first . . O
dose . . O
of . . O
gilenya . . O
. . . O

in . . O
addition . . O
to . . O
adverse . . O
reactions . . O
reported . . O
from . . O
clinical . . O
trials . . O
, . . O
the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
postapproval . . O
use . . O
of . . O
breo . . O
ellipta . . O
. . . O

( . . O
2.3,5.4 . . O
) . . O
* . . O
keratitis . . B-AdverseReaction
: . . O
occurs . . O
in . . O
0.8% . . O
of . . O
patients . . O
. . . O

therefore . . O
, . . O
a . . O
rankl . . O
inhibitor . . O
such . . O
as . . O
prolia . . O
may . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
infection . . B-AdverseReaction
. . . O

there . . O
have . . O
been . . O
no . . O
clinical . . O
studies . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
trulicity . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
. . . O

the . . O
frequency . . O
of . . O
hypoglycemia . . B-AdverseReaction
by . . O
study . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
is . . O
shown . . O
in . . O
table . . O
5 . . O
. . . O

new . . O
malignancies . . O
the . . O
overall . . O
incidence . . O
of . . O
new . . O
malignancies . . B-AdverseReaction
was . . O
4.3% . . O
in . . O
the . . O
placebo . . O
and . . O
4.8% . . O
in . . O
the . . O
prolia . . O
groups . . O
. . . O

there . . O
was . . O
fatal . . B-AdverseReaction
pneumonia . . B-AdverseReaction
in . . O
1 . . O
subject . . O
receiving . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
and . . O
in . . O
7 . . O
subjects . . O
receiving . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
( . . O
less . . O
than . . O
1% . . O
for . . O
each . . O
treatment . . O
group . . O
) . . O
. . . O

in . . O
those . . O
patients . . O
treated . . O
with . . O
1,200 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
who . . O
reported . . O
somnolence . . B-AdverseReaction
( . . O
10% . . O
) . . O
, . . O
the . . O
somnolence . . B-AdverseReaction
persisted . . O
during . . O
treatment . . O
in . . O
about . . O
27% . . O
. . . O

in . . O
clinical . . O
trials . . O
with . . O
inlyta . . O
, . . O
venous . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
were . . O
reported . . O
in . . O
22 . . O
/ . . O
715 . . O
patients . . O
( . . O
3% . . O
) . . O
, . . O
with . . O
two . . O
deaths . . B-AdverseReaction
secondary . . O
to . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
. . . O

in . . O
a . . O
3 . . O
- . . O
week . . O
monotherapy . . O
trial . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
and . . O
at . . O
least . . O
twice . . O
the . . O
rate . . O
of . . O
placebo . . O
) . . O
reported . . O
in . . O
pediatric . . O
patients . . O
with . . O
bipolar . . O
i . . O
disorder . . O
treated . . O
with . . O
saphris . . O
were . . O
somnolence . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
dysgeusia . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
paresthesia . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
increased . . B-AdverseReaction
weight . . I-AdverseReaction
. . . O

breo . . O
ellipta . . O
should . . O
not . . O
be . . O
used . . O
for . . O
the . . O
relief . . O
of . . O
acute . . O
symptoms . . O
, . . O
i . . O
. . . O
e . . O
. . . O
, . . O
as . . O
rescue . . O
therapy . . O
for . . O
the . . O
treatment . . O
of . . O
acute . . O
episodes . . O
of . . O
bronchospasm . . O
. . . O

alt . . O
= . . O
alanine . . O
aminotransferase . . O
; . . O
ast . . O
= . . O
aspartate . . O
aminotransferase . . O
; . . O
ggt . . O
= . . O
gamma . . O
glutamyltransferase . . O
. . . O

the . . O
median . . O
time . . O
to . . O
death . . B-AdverseReaction
for . . O
the . . O
remaining . . O
eight . . O
subjects . . O
in . . O
the . . O
sirturo . . O
treatment . . O
group . . O
was . . O
329 . . O
days . . O
after . . O
last . . O
intake . . O
of . . O
sirturo . . O
. . . O

the . . O
average . . O
age . . O
of . . O
patients . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
in . . O
the . . O
nulojix . . O
recommended . . O
dose . . O
and . . O
cyclosporine . . O
control . . O
regimens . . O
was . . O
49 . . O
years . . O
, . . O
ranging . . O
from . . O
18 . . O
to . . O
79 . . O
years . . O
. . . O

it . . O
is . . O
unknown . . O
whether . . O
this . . O
finding . . O
applies . . O
to . . O
younger . . O
postmenopausal . . O
women . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
in . . O
the . . O
absence . . O
of . . O
comparable . . O
data . . O
, . . O
these . . O
risks . . O
should . . O
be . . O
assumed . . O
to . . O
be . . O
similar . . O
for . . O
other . . O
doses . . O
of . . O
conjugated . . O
estrogens . . O
and . . O
other . . O
dosage . . O
forms . . O
of . . O
estrogens . . O
. . . O

table . . O
5 . . O
. . . O

table . . O
1 . . O
summarizes . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
trial . . O
with . . O
an . . O
incidence . . O
of . . O
> . . O
= . . O
10% . . O
in . . O
patients . . O
treated . . O
with . . O
vimizim . . O
2 . . O
mg . . O
/ . . O
kg . . O
once . . O
per . . O
week . . O
and . . O
with . . O
a . . O
higher . . O
incidence . . O
than . . O
in . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

patients . . O
who . . O
are . . O
ebv . . O
seropositive . . O
and . . O
cmv . . O
seronegative . . O
may . . O
be . . O
at . . O
increased . . O
risk . . O
for . . O
ptld . . O
compared . . O
to . . O
patients . . O
who . . O
are . . O
ebv . . O
seropositive . . O
and . . O
cmv . . O
seropositive . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

baseline . . O
renal . . O
function . . O
was . . O
normal . . O
or . . O
mildly . . O
impaired . . O
in . . O
91% . . O
of . . O
patients . . O
and . . O
moderately . . O
impaired . . O
in . . O
9% . . O
of . . O
patients . . O
( . . O
mean . . O
egfr . . O
86.8 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
. . . O

due . . O
to . . O
the . . O
low . . O
rate . . O
of . . O
events . . O
in . . O
both . . O
groups . . O
, . . O
it . . O
is . . O
not . . O
possible . . O
to . . O
conclude . . O
that . . O
the . . O
risk . . B-Factor
of . . O
venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
with . . O
duavee . . O
is . . O
different . . O
from . . O
that . . O
seen . . O
with . . O
other . . O
estrogen . . O
therapies . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

pancreatitis . . B-AdverseReaction
, . . O
including . . O
one . . O
fatality . . B-AdverseReaction
, . . O
has . . O
been . . O
reported . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
patients . . O
receiving . . O
zykadia . . O
in . . O
clinical . . O
trials . . O
. . . O

perform . . O
an . . O
evaluation . . O
for . . O
rpls . . O
in . . O
any . . O
patient . . O
presenting . . O
with . . O
seizures . . O
, . . O
headache . . O
, . . O
visual . . O
disturbances . . O
, . . O
confusion . . O
or . . O
altered . . O
mental . . O
function . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
gastritis . . B-AdverseReaction
; . . O
0.1% . . O
and . . O
less . . O
than . . O
1% . . O
- . . O
acute . . B-AdverseReaction
pancreatitis . . I-AdverseReaction
, . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
( . . O
includes . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
gastric . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
gastrointestinal . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
) . . O

table . . O
8 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
undergoing . . O
extended . . O
treatment . . O
for . . O
dvt . . O
and . . O
pe . . O
in . . O
the . . O
amplify . . O
- . . O
ext . . O
study . . O
eliquis . . O
2.5 . . O
mg . . O
bidn . . O
= . . O
840n . . O
( . . O
% . . O
) . . O
eliquis . . O
5 . . O
mg . . O
bidn . . O
= . . O
811n . . O
( . . O
% . . O
) . . O
placebon . . O
= . . O
826n . . O
( . . O
% . . O
) . . O
epistaxis . . B-AdverseReaction
13 . . O
( . . O
1.5 . . O
) . . O
29 . . O
( . . O
3.6 . . O
) . . O
9 . . O
( . . O
1.1 . . O
) . . O
hematuria . . B-AdverseReaction
12 . . O
( . . O
1.4 . . O
) . . O
17 . . O
( . . O
2.1 . . O
) . . O
9 . . O
( . . O
1.1 . . O
) . . O
hematoma . . B-AdverseReaction
13 . . O
( . . O
1.5 . . O
) . . O
16 . . O
( . . O
2.0 . . O
) . . O
10 . . O
( . . O
1.2 . . O
) . . O
contusion . . B-AdverseReaction
18 . . O
( . . O
2.1 . . O
) . . O
18 . . O
( . . O
2.2 . . O
) . . O
18 . . O
( . . O
2.2 . . O
) . . O
gingival . . B-AdverseReaction
bleeding . . I-AdverseReaction
12 . . O
( . . O
1.4 . . O
) . . O
9 . . O
( . . O
1.1 . . O
) . . O
3 . . O
( . . O
0.4 . . O
) . . O
other . . O
adverse . . O
reactions . . O
less . . O
common . . O
adverse . . O
reactions . . O
in . . O
eliquis . . O
- . . O
treated . . O
patients . . O
in . . O
the . . O
amplify . . O
or . . O
amplify . . O
- . . O
ext . . O
studies . . O
occurring . . O
at . . O
a . . O
frequency . . O
of . . O
> . . O
= . . O
0.1% . . O
to . . O
< . . O
1% . . O
: . . O

interrupt . . O
or . . O
adjust . . O
dosage . . O
until . . O
recovery . . O
, . . O
or . . O
permanently . . O
discontinue . . O
beleodaq . . O
based . . O
on . . O
the . . O
severity . . O
of . . O
the . . O
hepatic . . O
toxicity . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
other . . O
clinical . . O
trials . . O
of . . O
the . . O
same . . O
or . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

routine . . O
monitoring . . O
of . . O
serum . . O
calcitonin . . O
or . . O
using . . O
thyroid . . O
ultrasound . . O
monitoring . . O
is . . O
of . . O
uncertain . . O
value . . O
for . . O
early . . O
detection . . O
of . . O
mtc . . O
in . . O
patients . . O
treated . . O
with . . O
tanzeum . . O
[ . . O
see . . O
contraindications . . O
( . . O
4.1 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

free . . O
t4 . . O
and . . O
free . . O
t3 . . O
concentrations . . O
are . . O
unaltered . . O
. . . O

( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . O
hematoma . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

the . . O
most . . O
frequent . . O
serious . . B-Severity
infections . . B-AdverseReaction
included . . O
pneumonia . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
cellulitis . . B-AdverseReaction
, . . O
and . . O
bronchitis . . B-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O
* . . O
asthma . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
2% . . O
) . . O
are . . O
nasopharyngitis . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
dysphonia . . B-AdverseReaction
, . . O
and . . O
cough . . B-AdverseReaction
. . . O

if . . O
an . . O
anaphylactic . . O
or . . O
other . . O
clinically . . O
significant . . O
allergic . . O
reaction . . O
occurs . . O
, . . O
initiate . . O
appropriate . . O
therapy . . O
and . . O
discontinue . . O
further . . O
use . . O
of . . O
prolia . . O
[ . . O
see . . O
contraindications . . O
( . . O
4.3 . . O
) . . O
, . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

approximately . . O
60% . . O
of . . O
the . . O
treated . . O
patients . . O
were . . O
male . . O
, . . O
with . . O
a . . O
mean . . O
age . . O
of . . O
55.1 . . O
years . . O
. . . O

additional . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
observed . . O
in . . O
infantile . . O
- . . O
onset . . O
pompe . . O
disease . . O
patients . . O
treated . . O
in . . O
other . . O
clinical . . O
trials . . O
and . . O
expanded . . O
access . . O
programs . . O
with . . O
alglucosidase . . O
alfa . . O
included . . O
livedo . . B-AdverseReaction
reticularis . . I-AdverseReaction
, . . O
irritability . . B-AdverseReaction
, . . O
retching . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
lacrimation . . I-AdverseReaction
, . . O
ventricular . . B-AdverseReaction
extrasystoles . . I-AdverseReaction
, . . O
nodal . . B-AdverseReaction
rhythm . . I-AdverseReaction
, . . O
rales . . B-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
irritation . . I-AdverseReaction
, . . O
and . . O
cold . . B-AdverseReaction
sweat . . I-AdverseReaction
. . . O

ferriprox . . O
can . . B-Factor
also . . O
cause . . O
neutropenia . . B-AdverseReaction
, . . O
which . . O
may . . B-Factor
foreshadow . . O
agranulocytosis . . B-AdverseReaction
. . . O

tecfidera . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
low . . O
lymphocyte . . O
counts . . O
. . . O

adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
of . . O
treatment . . O
: . . O
a . . O
total . . O
of . . O
6.7% . . O
( . . O
7 . . O
/ . . O
104 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
, . . O
5.1% . . O
( . . O
5 . . O
/ . . O
99 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
5 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
5.1% . . O
( . . O
5 . . O
/ . . O
99 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
10 . . O
mg . . O
twice . . O
daily . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
reactions . . O
compared . . O
to . . O
4% . . O
( . . O
4 . . O
/ . . O
101 . . O
) . . O
on . . O
placebo . . O
. . . O

in . . O
the . . O
pooled . . O
phase . . O
3 . . O
cabp . . O
trials . . O
, . . O
51 . . O
/ . . O
520 . . O
( . . O
9.8% . . O
) . . O
of . . O
teflaro . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
24 . . O
/ . . O
534 . . O
( . . O
4.5% . . O
) . . O
of . . O
ceftriaxone . . O
- . . O
treated . . O
patients . . O
seroconverted . . B-AdverseReaction
from . . I-AdverseReaction
a . . I-AdverseReaction
negative . . I-AdverseReaction
to . . I-AdverseReaction
a . . I-AdverseReaction
positive . . I-AdverseReaction
direct . . I-AdverseReaction
coombs' . . I-AdverseReaction
test . . I-AdverseReaction
result . . I-AdverseReaction
. . . O

table . . O
1shows . . O
all . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
with . . O
a . . O
frequency . . O
of . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
1% . . O
in . . O
the . . O
tudorza . . O
pressair . . O
group . . O
in . . O
the . . O
two . . O
3 . . O
- . . O
month . . O
and . . O
one . . O
6 . . O
- . . O
month . . O
placebo . . O
- . . O
controlled . . O
trials . . O
where . . O
the . . O
rates . . O
in . . O
the . . O
tudorza . . O
pressair . . O
group . . O
exceeded . . O
placebo . . O
. . . O

* . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
infectious . . I-AdverseReaction
pneumonitis . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

5.9 . . O
renal . . O
impairment . . O
and . . O
failure . . O

since . . O
hyperammonemia . . O
is . . O
the . . O
result . . O
of . . O
protein . . O
catabolism . . O
, . . O
complete . . O
protein . . O
restriction . . O
is . . O
recommended . . O
to . . O
be . . O
maintained . . O
for . . O
24 . . O
to . . O
48 . . O
hours . . O
and . . O
caloric . . O
supplementation . . O
should . . O
be . . O
maximized . . O
to . . O
reverse . . O
catabolism . . O
and . . O
nitrogen . . O
turnover . . O
. . . O

( . . O
6 . . O
) . . O

in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
types . . O
and . . O
frequency . . O
of . . O
common . . O
adverse . . O
reactions . . O
, . . O
excluding . . O
hypoglycemia . . B-AdverseReaction
, . . O
were . . O
similar . . O
to . . O
those . . O
listed . . O
in . . O
table . . O
1 . . O
. . . O

restart . . O
treatment . . O
based . . O
on . . O
anc . . O
and . . O
platelet . . O
count . . O
recovery . . O
. . . O

new . . O
malignancies . . O
related . . O
to . . O
the . . O
breast . . O
( . . O
0.7% . . O
placebo . . O
vs . . O
. . . O
0.9% . . O
prolia . . O
) . . O
, . . O
reproductive . . O
system . . O
( . . O
0.2% . . O
placebo . . O
vs . . O
. . . O
0.5% . . O
prolia . . O
) . . O
, . . O
and . . O
gastrointestinal . . O
system . . O
( . . O
0.6% . . O
placebo . . O
vs . . O
. . . O
0.9% . . O
prolia . . O
) . . O
were . . O
reported . . O
. . . O

among . . O
the . . O
712 . . O
patients . . O
who . . O
participated . . O
in . . O
this . . O
open . . O
- . . O
label . . O
extension . . O
study . . O
, . . O
the . . O
mean . . O
age . . O
of . . O
the . . O
population . . O
was . . O
56.4 . . O
years . . O
( . . O
range . . O
from . . O
23 . . O
to . . O
88 . . O
years . . O
) . . O
. . . O

treatment . . O
of . . O
cervical . . O
dystonia . . O
with . . O
botulinum . . B-DrugClass
toxins . . I-DrugClass
may . . O
weaken . . B-AdverseReaction
neck . . I-AdverseReaction
muscles . . I-AdverseReaction
that . . O
serve . . O
as . . O
accessory . . O
muscles . . O
of . . O
ventilation . . O
. . . O

all . . O
but . . O
one . . O
subject . . O
who . . O
died . . B-AdverseReaction
of . . O
tb . . O
had . . O
not . . O
converted . . O
or . . O
had . . O
relapsed . . O
. . . O

the . . O
mean . . O
change . . O
from . . O
baseline . . O
for . . O
the . . O
all . . O
- . . O
saphris . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
treated . . O
group . . O
was . . O
comparable . . O
to . . O
placebo . . O
in . . O
each . . O
of . . O
the . . O
rating . . O
scale . . O
scores . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
for . . O
48 . . O
hours . . O
after . . O
voraxaze . . O
administration . . O
, . . O
determine . . O
the . . O
leucovorin . . O
dose . . O
based . . O
on . . O
the . . O
patient's . . O
pre . . O
- . . O
voraxaze . . O
methotrexate . . O
concentration . . O
. . . O

primary . . O
prophylaxis . . O
with . . O
g . . O
- . . O
csf . . O
should . . O
be . . O
considered . . O
in . . O
patients . . O
with . . O
high . . O
- . . O
risk . . O
clinical . . O
features . . O
( . . O
age . . O
> . . O
65 . . O
years . . O
, . . O
poor . . O
performance . . O
status . . O
, . . O
previous . . O
episodes . . O
of . . O
febrile . . O
neutropenia . . O
, . . O
extensive . . O
prior . . O
radiation . . O
ports . . O
, . . O
poor . . O
nutritional . . O
status . . O
, . . O
or . . O
other . . O
serious . . O
comorbidities . . O
) . . O
that . . O
predispose . . O
them . . O
to . . O
increased . . O
complications . . O
from . . O
prolonged . . O
neutropenia . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

in . . O
caps . . O
study . . O
1 . . O
, . . O
subcutaneous . . B-AdverseReaction
injection . . I-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
observed . . O
in . . O
9% . . O
of . . O
patients . . O
in . . O
part . . O
1 . . O
with . . O
mild . . O
tolerability . . O
reactions . . O
; . . O
in . . O
part . . O
2 . . O
, . . O
one . . O
patient . . O
each . . O
( . . O
7% . . O
) . . O
had . . O
a . . O
mild . . O
or . . O
a . . O
moderate . . O
tolerability . . O
reaction . . O
and . . O
, . . O
in . . O
part . . O
3 . . O
, . . O
one . . O
patient . . O
had . . O
a . . O
mild . . B-Severity
local . . B-AdverseReaction
tolerability . . I-AdverseReaction
reaction . . I-AdverseReaction
. . . O

four . . O
weeks . . O
after . . O
stopping . . O
tecfidera . . O
, . . O
mean . . O
lymphocyte . . O
counts . . O
increased . . O
but . . O
did . . O
not . . O
return . . O
to . . O
baseline . . O
. . . O

counsel . . O
patients . . O
regarding . . O
the . . O
potential . . O
risk . . O
of . . O
mtc . . O
and . . O
symptoms . . O
of . . O
thyroid . . O
tumors . . O
( . . O
4.1 . . O
, . . O
5.1 . . O
) . . O
. . . O

( . . O
5.1 . . O
) . . O
therapeutic . . O
monitoring . . O
: . . O
plasma . . O
ammonia . . O
levels . . O
should . . O
be . . O
maintained . . O
within . . O
normal . . O
range . . O
for . . O
age . . O
via . . O
individual . . O
dose . . O
adjustment . . O
. . . O

these . . O
cases . . O
were . . O
reported . . O
post . . O
- . . O
marketing . . O
and . . O
are . . O
derived . . O
from . . O
a . . O
variety . . O
of . . O
sources . . O
, . . O
including . . O
registries . . O
and . . O
spontaneous . . O
post . . O
- . . O
marketing . . O
reports . . O
. . . O

higher . . O
than . . O
recommended . . O
dosing . . O
or . . O
repeated . . O
dosing . . O
appears . . O
to . . O
increase . . O
the . . O
risk . . O
( . . O
5.1 . . O
) . . O
* . . O
hypersensitivity . . O
: . . O
anaphylactoid . . O
/ . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
with . . O
cardiovascular . . O
, . . O
respiratory . . O
and . . O
cutaneous . . B-AdverseReaction
manifestations . . I-AdverseReaction
, . . O
ranging . . O
from . . O
mild . . B-Severity
to . . O
severe . . B-Severity
reactions . . O
including . . O
shock . . B-AdverseReaction
can . . B-Factor
occur . . O
. . . O

consider . . O
lowering . . O
sulfonylurea . . O
or . . O
insulin . . O
dosage . . O
when . . O
starting . . O
tanzeum . . O
. . . O

table . . O
10 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
afinitor . . O
- . . O
treated . . O
patients . . O
with . . O
sega . . O
in . . O
study . . O
1 . . O
grading . . O
according . . O
to . . O
ctcae . . O
version . . O
3.0 . . O
a . . O
includes . . O
mouth . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
and . . O
lip . . B-AdverseReaction
ulceration . . I-AdverseReaction
b . . O
includes . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
and . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
viral . . I-AdverseReaction
c . . O
includes . . O
gastroenteritis . . B-AdverseReaction
, . . O
gastroenteritis . . B-AdverseReaction
viral . . I-AdverseReaction
, . . O
and . . O
gastrointestinal . . B-AdverseReaction
infection . . I-AdverseReaction
d . . O
includes . . O
agitation . . B-AdverseReaction
, . . O
anxiety . . B-AdverseReaction
, . . O
panic . . B-AdverseReaction
attack . . I-AdverseReaction
, . . O
aggression . . B-AdverseReaction
, . . O
abnormal . . B-AdverseReaction
behavior . . I-AdverseReaction
, . . O
and . . O
obsessive . . B-AdverseReaction
compulsive . . I-AdverseReaction
disorder . . I-AdverseReaction
e . . O
includes . . O
rash . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
generalized . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
macular . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
maculo . . I-AdverseReaction
- . . I-AdverseReaction
papular . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
papular . . I-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
allergic . . I-AdverseReaction
, . . O
and . . O
urticaria . . B-AdverseReaction
afinitor . . O
n . . O
= . . O
78 . . O
placebo . . O
n . . O
= . . O
39 . . O
all . . O
grades . . O
% . . O
grade . . O
3 . . O
% . . O
grade . . O
4 . . O
% . . O
all . . O
grades . . O
% . . O
grade . . O
3 . . O
% . . O
grade . . O
4 . . O
% . . O
any . . O
adverse . . O
reaction . . O
97 . . O
36 . . O
3 . . O
92 . . O
23 . . O
3 . . O
gastrointestinal . . O
disorders . . O
stomatitis . . B-AdverseReaction
a . . O
62 . . O
9 . . O
0 . . O
26 . . O
3 . . O
0 . . O
vomiting . . B-AdverseReaction
22 . . O
1 . . O
0 . . O
13 . . O
0 . . O
0 . . O
diarrhea . . B-AdverseReaction
17 . . O
0 . . O
0 . . O
5 . . O
0 . . O
0 . . O
constipation . . B-AdverseReaction
10 . . O
0 . . O
0 . . O
3 . . O
0 . . O
0 . . O
infections . . O
and . . O
infestations . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
b . . O
31 . . O
1 . . O
1 . . O
23 . . O
0 . . O
0 . . O
gastroenteritis . . B-AdverseReaction
c . . O
10 . . O
4 . . O
1 . . O
3 . . O
0 . . O
0 . . O
pharyngitis . . O
streptococcal . . O
10 . . O
0 . . O
0 . . O
3 . . O
0 . . O
0 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
pyrexia . . B-AdverseReaction
23 . . O
6 . . O
0 . . O
18 . . O
3 . . O
0 . . O
fatigue . . B-AdverseReaction
14 . . O
0 . . O
0 . . O
3 . . O
0 . . O
0 . . O
psychiatric . . O
disorders . . O
anxiety . . B-AdverseReaction
, . . O
aggression . . B-AdverseReaction
or . . O
other . . O
behavioral . . B-AdverseReaction
disturbance . . I-AdverseReaction
d . . O
21 . . O
5 . . O
0 . . O
3 . . O
0 . . O
0 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
e . . O
21 . . O
0 . . O
0 . . O
8 . . O
0 . . O
0 . . O
acne . . B-AdverseReaction
10 . . O
0 . . O
0 . . O
5 . . O
0 . . O
0 . . O
amenorrhea . . B-AdverseReaction
occurred . . O
in . . O
17% . . O
of . . O
afinitor . . O
- . . O
treated . . O
females . . O
aged . . O
10 . . O
to . . O
55 . . O
years . . O
( . . O
3 . . O
of . . O
18 . . O
) . . O
and . . O
none . . O
of . . O
the . . O
females . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

asymptomatic . . O
and . . O
mild . . B-Severity
elevations . . B-AdverseReaction
of . . I-AdverseReaction
serum . . I-AdverseReaction
bilirubin . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
ilaris . . O
without . . B-Negation
concomitant . . O
elevations . . B-AdverseReaction
of . . I-AdverseReaction
transaminases . . I-AdverseReaction
. . . O

careful . . O
testing . . O
of . . O
corneal . . O
sensation . . O
in . . O
eyes . . O
previously . . O
operated . . O
upon . . O
, . . O
avoidance . . O
of . . O
injection . . O
into . . O
the . . O
lower . . O
lid . . O
area . . O
to . . O
avoid . . O
ectropion . . O
, . . O
and . . O
vigorous . . O
treatment . . O
of . . O
any . . O
epithelial . . O
defect . . O
should . . O
be . . O
employed . . O
. . . O

certain . . O
circumstances . . O
may . . O
increase . . O
the . . O
risk . . O
of . . O
torsade . . O
de . . O
pointes . . O
and . . O
/ . . O
or . . O
sudden . . O
death . . O
in . . O
association . . O
with . . O
the . . O
use . . O
of . . O
drugs . . O
that . . O
prolong . . O
the . . O
qtc . . O
interval . . O
, . . O
including . . O
( . . O
1 . . O
) . . O
bradycardia . . O
; . . O
( . . O
2 . . O
) . . O
hypokalemia . . O
or . . O
hypomagnesemia . . O
; . . O
( . . O
3 . . O
) . . O
concomitant . . O
use . . O
of . . O
other . . O
drugs . . O
that . . O
prolong . . O
the . . O
qtc . . O
interval . . O
; . . O
and . . O
( . . O
4 . . O
) . . O
presence . . O
of . . O
congenital . . O
prolongation . . O
of . . O
the . . O
qt . . O
interval . . O
; . . O
( . . O
5 . . O
) . . O
recent . . O
acute . . O
myocardial . . O
infarction . . O
; . . O
and . . O
/ . . O
or . . O
( . . O
6 . . O
) . . O
uncompensated . . O
heart . . O
failure . . O
. . . O

5.9 . . O
hepatic . . O
impairment . . O
and . . O
past . . O
history . . O
of . . O
cholestatic . . O
jaundice . . O

over . . O
95% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
had . . O
an . . O
adverse . . B-AdverseReaction
reaction . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
injected . . I-AdverseReaction
extremity . . I-AdverseReaction
after . . O
up . . O
to . . O
3 . . O
injections . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
7 . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
adverse . . O
reaction . . O
of . . O
pneumonia . . B-AdverseReaction
was . . O
reported . . O
more . . O
frequently . . O
in . . O
patients . . O
receiving . . O
tanzeum . . O
( . . O
1.8% . . O
) . . O
than . . O
in . . O
patients . . O
in . . O
the . . O
all . . O
- . . O
comparators . . O
group . . O
( . . O
0.8% . . O
) . . O
. . . O

through . . O
96 . . O
weeks . . O
, . . O
the . . O
rate . . O
of . . O
adverse . . O
events . . O
leading . . O
to . . O
discontinuation . . O
was . . O
2% . . O
in . . O
both . . O
treatment . . O
arms . . O
. . . O

complete . . O
blood . . O
counts . . O
( . . O
with . . O
white . . O
blood . . O
cell . . O
differential . . O
counts . . O
) . . O
should . . O
be . . O
obtained . . O
at . . O
pretreatment . . O
, . . O
and . . O
at . . O
treatment . . O
weeks . . O
2 . . O
, . . O
4 . . O
, . . O
8 . . O
, . . O
and . . O
12 . . O
, . . O
and . . O
should . . O
be . . O
monitored . . O
closely . . O
at . . O
other . . O
time . . O
points . . O
, . . O
as . . O
clinically . . O
appropriate . . O
. . . O

monitor . . O
for . . O
consequences . . O
of . . O
bone . . O
oversuppression . . O
( . . O
5.9 . . O
) . . O

* . . O
have . . O
a . . O
pelvic . . O
exam . . O
, . . O
breast . . O
exam . . O
and . . O
mammogram . . O
( . . O
breast . . O
x . . O
- . . O
ray . . O
) . . O
every . . O
year . . O
unless . . O
your . . O
healthcare . . O
provider . . O
tells . . O
you . . O
something . . O
else . . O
. . . O

* . . O
bone . . B-AdverseReaction
effects . . I-AdverseReaction
of . . O
tenofovir . . O
df . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
. . . O

the . . O
cobicistat . . O
component . . O
of . . O
stribild . . O
has . . O
been . . O
shown . . O
to . . O
increase . . B-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
decrease . . B-AdverseReaction
estimated . . I-AdverseReaction
creatinine . . I-AdverseReaction
clearance . . I-AdverseReaction
due . . O
to . . O
inhibition . . O
of . . O
tubular . . O
secretion . . O
of . . O
creatinine . . O
without . . B-Negation
affecting . . B-AdverseReaction
renal . . I-AdverseReaction
glomerular . . I-AdverseReaction
function . . I-AdverseReaction
. . . O

although . . O
the . . O
causes . . O
of . . O
death . . B-AdverseReaction
were . . O
varied . . O
, . . O
most . . O
of . . O
the . . O
deaths . . B-AdverseReaction
appeared . . O
to . . O
be . . O
either . . O
cardiovascular . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
sudden . . B-AdverseReaction
death . . I-AdverseReaction
) . . O
or . . O
infectious . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
pneumonia . . B-AdverseReaction
) . . O
in . . O
nature . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
salix . . O
pharmaceuticals . . O
at . . O
1-800-508-0024 . . O
or . . O
www . . O
. . . O
salix . . O
. . . O
com . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

one . . O
case . . O
consistent . . O
with . . O
drug . . B-AdverseReaction
induced . . I-AdverseReaction
liver . . I-AdverseReaction
injury . . I-AdverseReaction
( . . O
defined . . O
as . . O
concurrent . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
alt . . I-AdverseReaction
or . . O
ast . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3 . . B-Severity
* . . I-Severity
uln . . I-Severity
with . . O
total . . B-AdverseReaction
bilirubin . . I-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
2 . . I-AdverseReaction
* . . I-AdverseReaction
uln . . I-AdverseReaction
and . . O
alkaline . . B-AdverseReaction
phosphatase . . I-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
2 . . I-AdverseReaction
* . . I-AdverseReaction
uln . . I-AdverseReaction
) . . O
occurred . . O
in . . O
a . . O
trial . . O
of . . O
bosulif . . O
in . . O
combination . . O
with . . O
letrozole . . O
. . . O

( . . O
r . . O
) . . O
. . . O

in . . O
one . . O
trial . . O
invokana . . O
was . . O
used . . O
as . . O
monotherapy . . O
and . . O
in . . O
three . . O
trials . . O
invokana . . O
was . . O
used . . O
as . . O
add . . O
- . . O
on . . O
therapy . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
was . . O
the . . O
most . . O
common . . O
toxicity . . O
leading . . O
to . . O
discontinuation . . O
of . . O
halaven . . O
( . . O
5% . . O
of . . O
patients . . O
; . . O
24 . . O
/ . . O
503 . . O
) . . O
. . . O

* . . O
hypoglycemia . . B-AdverseReaction
: . . O
when . . O
trulicity . . O
is . . O
used . . O
with . . O
an . . O
insulin . . O
secretagogue . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
a . . O
sulfonylurea . . O
) . . O
or . . O
insulin . . O
, . . O
consider . . O
lowering . . O
the . . O
dose . . O
of . . O
the . . O
sulfonylurea . . O
or . . O
insulin . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
( . . O
5.3 . . O
) . . O
. . . O

febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
occurred . . O
in . . O
5% . . O
( . . O
23 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
; . . O
two . . O
patients . . O
( . . O
0.4% . . O
) . . O
died . . B-AdverseReaction
from . . O
complications . . O
of . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
. . . O

evaluate . . O
patients . . O
who . . O
develop . . O
fever . . O
and . . O
lung . . O
infiltrates . . O
or . . O
respiratory . . O
distress . . O
after . . O
receiving . . O
granix . . O
, . . O
for . . O
ards . . O
. . . O

since . . O
cmv . . O
seronegative . . O
patients . . O
are . . O
at . . O
increased . . O
risk . . O
for . . O
cmv . . O
disease . . O
( . . O
a . . O
known . . O
risk . . O
factor . . O
for . . O
ptld . . O
) . . O
, . . O
the . . O
clinical . . O
significance . . O
of . . O
cmv . . O
serology . . O
for . . O
ptld . . O
remains . . O
to . . O
be . . O
determined . . O
; . . O
however . . O
, . . O
these . . O
findings . . O
should . . O
be . . O
considered . . O
when . . O
prescribing . . O
nulojix . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reaction . . O
leading . . O
to . . O
treatment . . O
discontinuation . . O
was . . O
seizure . . B-AdverseReaction
, . . O
which . . O
occurred . . O
in . . O
0.9% . . O
of . . O
the . . O
xtandi . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
none . . O
( . . O
0% . . O
) . . O
of . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

live . . O
vaccines . . O
should . . O
not . . O
be . . O
given . . O
concurrently . . O
with . . O
ilaris . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
] . . O
. . . O

patients . . O
receiving . . O
benlysta . . O
should . . O
be . . O
instructed . . O
to . . O
contact . . O
their . . O
healthcare . . O
provider . . O
if . . O
they . . O
experience . . O
new . . O
or . . O
worsening . . O
depression . . O
, . . O
suicidal . . O
thoughts . . O
, . . O
or . . O
other . . O
mood . . O
changes . . O
. . . O

jc . . B-AdverseReaction
virus . . I-AdverseReaction
infection . . I-AdverseReaction
resulting . . O
in . . O
pml . . B-AdverseReaction
and . . O
death . . B-AdverseReaction
can . . B-Factor
occur . . O
in . . O
patients . . O
receiving . . O
adcetris . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
, . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O

infections . . O
and . . O
infestations . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
pneumonia . . B-AdverseReaction
( . . O
includes . . O
pneumonia . . B-AdverseReaction
, . . O
bronchopneumonia . . B-AdverseReaction
, . . O
lobar . . B-AdverseReaction
pneumonia . . I-AdverseReaction
, . . O
primary . . B-AdverseReaction
atypical . . I-AdverseReaction
pneumonia . . I-AdverseReaction
) . . O
, . . O
influenza . . B-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction

in . . O
all . . O
three . . O
studies . . O
a . . O
placebo . . O
( . . O
cycle . . O
1 . . O
of . . O
the . . O
breast . . O
cancer . . O
study . . O
only . . O
) . . O
or . . O
a . . O
non . . O
- . . O
us . . O
- . . O
approved . . O
filgrastim . . O
product . . O
were . . O
used . . O
as . . O
controls . . O
. . . O

if . . O
clinically . . O
indicated . . O
, . . O
perform . . O
appropriate . . O
tests . . O
to . . O
confirm . . O
the . . O
diagnosis . . O
of . . O
adrenocortical . . O
insufficiency . . O
. . . O

5.3 . . O
withdrawal . . O
symptoms . . O

safe . . O
handling . . O
should . . O
be . . O
ensured . . O
to . . O
minimize . . O
radiation . . O
exposure . . O
to . . O
the . . O
patient . . O
and . . O
health . . O
care . . O
workers . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reactions . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
safety . . O
of . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
was . . O
evaluated . . O
in . . O
586 . . O
patients . . O
with . . O
braf . . O
v600 . . O
mutation . . O
- . . O
positive . . O
unresectable . . O
or . . O
metastatic . . O
melanoma . . O
, . . O
previously . . O
treated . . O
or . . O
untreated . . O
, . . O
who . . O
received . . O
tafinlar . . O
150 . . O
mg . . O
orally . . O
twice . . O
daily . . O
until . . O
disease . . O
progression . . O
or . . O
unacceptable . . O
toxicity . . O
, . . O
including . . O
181 . . O
patients . . O
treated . . O
for . . O
at . . O
least . . O
6 . . O
months . . O
and . . O
86 . . O
additional . . O
patients . . O
treated . . O
for . . O
more . . O
than . . O
12 . . O
months . . O
. . . O

discontinuation . . O
of . . O
simponi . . O
aria . . O
should . . O
be . . O
considered . . O
if . . O
these . . O
disorders . . O
develop . . O
. . . O

atrioventricular . . O
blocks . . O

( . . O
5.1 . . O
) . . O
* . . O
all . . O
patients . . O
taking . . O
potiga . . O
should . . O
have . . O
baseline . . O
and . . O
periodic . . O
( . . O
every . . O
6 . . O
months . . O
) . . O
systematic . . O
visual . . O
monitoring . . O
by . . O
an . . O
ophthalmic . . O
professional . . O
. . . O

monitor . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
pneumonia . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
10% . . O
and . . O
> . . O
= . . O
2% . . O
more . . O
than . . O
placebo . . O
) . . O
for . . O
tecfidera . . O
were . . O
flushing . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
. . . O

the . . O
use . . O
of . . O
live . . O
vaccines . . O
should . . O
be . . O
avoided . . O
during . . O
treatment . . O
with . . O
nulojix . . O
, . . O
including . . O
but . . O
not . . O
limited . . O
to . . O
the . . O
following . . O
: . . O
intranasal . . O
influenza . . O
, . . O
measles . . O
, . . O
mumps . . O
, . . O
rubella . . O
, . . O
oral . . O
polio . . O
, . . O
bcg . . O
, . . O
yellow . . O
fever . . O
, . . O
varicella . . O
, . . O
and . . O
ty21a . . O
typhoid . . O
vaccines . . O
. . . O

psychiatric . . O
disorders . . O
: . . O
confusion . . B-AdverseReaction
( . . O
7% . . O
) . . O
, . . O
disorientation . . B-AdverseReaction
( . . O
3% . . O
) . . O

monitor . . O
heart . . O
rate . . O
and . . O
blood . . O
pressure . . O
regularly . . O
. . . O

the . . O
median . . O
dose . . O
intensity . . O
was . . O
483 . . O
mg . . O
/ . . O
day . . O
, . . O
and . . O
500 . . O
mg . . O
/ . . O
day . . O
, . . O
in . . O
the . . O
ap . . O
cml . . O
and . . O
bp . . O
cml . . O
cohorts . . O
, . . O
respectively . . O
. . . O

no . . B-Negation
adverse . . O
reactions . . O
representing . . O
hemolytic . . B-AdverseReaction
anemia . . I-AdverseReaction
were . . O
reported . . O
in . . O
any . . O
treatment . . O
group . . O
. . . O

routine . . O
ophthalmological . . O
examination . . O
detected . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
in . . O
some . . O
patients . . O
with . . O
no . . B-Negation
visual . . B-AdverseReaction
symptoms . . I-AdverseReaction
. . . O

promacta . . O
can . . B-Factor
cause . . O
liver . . B-AdverseReaction
enzyme . . I-AdverseReaction
elevations . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

5.2 . . O
bladder . . O
outlet . . O
obstruction . . O

withhold . . O
tafinlar . . O
, . . O
and . . O
trametinib . . O
if . . O
used . . O
in . . O
combination . . O
, . . O
for . . O
intolerable . . O
or . . O
severe . . O
skin . . O
toxicity . . O
. . . O

immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
combination . . O
antiretroviral . . B-DrugClass
therapy . . O
, . . O
including . . O
intelence . . O
( . . O
r . . O
) . . O
. . . O

the . . O
following . . O
changes . . O
were . . O
observed . . O
in . . O
pre . . O
- . . O
marketing . . O
placebo . . O
- . . O
controlled . . O
, . . O
short . . O
- . . O
term . . O
mdd . . O
studies . . O
with . . O
pristiq . . O
. . . O

these . . O
women . . O
should . . O
have . . O
their . . O
thyroid . . O
function . . O
monitored . . O
in . . O
order . . O
to . . O
maintain . . O
their . . O
free . . O
thyroid . . O
hormone . . O
levels . . O
in . . O
an . . O
acceptable . . O
range . . O
. . . O

exercise . . O
caution . . O
in . . O
the . . O
peri . . O
- . . O
surgical . . O
period . . O
. . . O

the . . O
percentage . . O
of . . O
patients . . O
who . . O
withdrew . . O
from . . O
the . . O
study . . O
due . . O
to . . O
adverse . . O
events . . O
was . . O
4.2% . . O
and . . O
0.8% . . O
for . . O
the . . O
placebo . . O
and . . O
prolia . . O
groups . . O
, . . O
respectively . . O
. . . O

* . . O
with . . O
chronic . . O
or . . O
recurrent . . O
infection . . O
; . . O
* . . O
who . . O
have . . O
been . . O
exposed . . O
to . . O
tuberculosis . . O
; . . O
* . . O
with . . O
a . . O
history . . O
of . . O
an . . O
opportunistic . . O
infection . . O
; . . O
* . . O
who . . O
have . . O
resided . . O
or . . O
traveled . . O
in . . O
areas . . O
of . . O
endemic . . O
tuberculosis . . O
or . . O
endemic . . O
mycoses . . O
, . . O
such . . O
as . . O
histoplasmosis . . O
, . . O
coccidioidomycosis . . O
, . . O
or . . O
blastomycosis . . O
; . . O
or . . O
* . . O
with . . O
underlying . . O
conditions . . O
that . . O
may . . O
predispose . . O
them . . O
to . . O
infection . . O
. . . O

[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

interruption . . O
of . . O
prolia . . O
therapy . . O
should . . O
be . . O
considered . . O
, . . O
pending . . O
a . . O
risk . . O
/ . . O
benefit . . O
assessment . . O
, . . O
on . . O
an . . O
individual . . O
basis . . O
. . . O

patients . . O
were . . O
treated . . O
with . . O
alglucosidase . . O
alfa . . O
20 . . O
or . . O
40 . . O
mg . . O
/ . . O
kg . . O
every . . O
other . . O
week . . O
for . . O
periods . . O
ranging . . O
from . . O
1 . . O
to . . O
106 . . O
weeks . . O
( . . O
mean . . O
: . . O
61 . . O
weeks . . O
) . . O
. . . O

6 . . O
adverse . . O
reactions . . O

in . . O
three . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
lasting . . O
up . . O
to . . O
3 . . O
months . . O
in . . O
duration . . O
, . . O
the . . O
mean . . O
age . . O
of . . O
patients . . O
was . . O
56.4 . . O
years . . O
( . . O
range . . O
from . . O
23 . . O
to . . O
88 . . O
years . . O
) . . O
. . . O

serious . . B-Severity
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
excluding . . B-Negation
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
) . . O
were . . O
reported . . O
in . . O
0.5% . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
and . . O
0.4% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
and . . O
included . . O
bradycardia . . B-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
and . . O
hypotension . . B-AdverseReaction
. . . O

table . . O
2 . . O
. . . O

hepatic . . B-AdverseReaction
adenomas . . I-AdverseReaction
are . . O
associated . . O
with . . O
coc . . B-DrugClass
use . . O
. . . O

advise . . O
patients . . O
to . . O
immediately . . O
seek . . O
medical . . O
care . . O
if . . O
they . . O
develop . . O
symptoms . . O
of . . O
dvt . . O
or . . O
pe . . O
, . . O
such . . O
as . . O
shortness . . O
of . . O
breath . . O
, . . O
chest . . O
pain . . O
, . . O
or . . O
arm . . O
or . . O
leg . . O
swelling . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
40% . . O
of . . O
tecfidera . . O
treated . . O
patients . . O
experienced . . O
flushing . . B-AdverseReaction
. . . O

however . . O
, . . O
the . . O
syndrome . . O
can . . O
develop . . O
, . . O
although . . O
much . . O
less . . O
commonly . . O
, . . O
after . . O
relatively . . O
brief . . O
treatment . . O
periods . . O
at . . O
low . . O
doses . . O
. . . O

the . . O
6 . . O
- . . O
dose . . O
coartem . . O
tablets . . O
population . . O
was . . O
patients . . O
with . . O
malaria . . O
between . . O
ages . . O
2 . . O
months . . O
and . . O
71 . . O
years . . O
: . . O
67% . . O
( . . O
1,332 . . O
) . . O
were . . O
16 . . O
years . . O
and . . O
younger . . O
and . . O
33% . . O
( . . O
647 . . O
) . . O
were . . O
older . . O
than . . O
16 . . O
years . . O
. . . O

table . . O
3 . . O
: . . O
adverse . . O
reactions . . O
in . . O
the . . O
postmarketing . . O
experience . . O
system . . O
organ . . O
class . . O
adverse . . O
reaction . . O
cardiac . . O
disorders . . O
bradycardia . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
arrhythmia . . B-AdverseReaction
immune . . O
system . . O
disorders . . O
hypersensitivity . . B-AdverseReaction
/ . . O
anaphylactoid . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
cyanosis . . B-AdverseReaction
pharyngeal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
laryngospasm . . B-AdverseReaction
, . . O
bronchospasm . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
conjunctivitis . . B-AdverseReaction
, . . O
ocular . . B-AdverseReaction
hyperemia . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
lacrimation . . B-AdverseReaction
increased . . I-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
nervous . . O
system . . O
disorders . . O
coma . . B-AdverseReaction
, . . O
convulsion . . B-AdverseReaction
, . . O
syncope . . B-AdverseReaction
, . . O
presyncope . . B-AdverseReaction
, . . O
parosmia . . B-AdverseReaction
, . . O
tremor . . B-AdverseReaction
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
muscle . . B-AdverseReaction
contracture . . I-AdverseReaction
, . . O
muscle . . B-AdverseReaction
weakness . . I-AdverseReaction
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
, . . O
salivary . . B-AdverseReaction
hypersecretion . . I-AdverseReaction
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
malaise . . B-AdverseReaction
, . . O
fever . . B-AdverseReaction
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
nsf . . B-AdverseReaction
, . . O
in . . O
patients . . O
whose . . O
reports . . O
were . . O
confounded . . O
by . . O
the . . O
receipt . . O
of . . O
other . . O
gbcas . . B-DrugClass
or . . O
in . . O
situations . . O
where . . O
receipt . . O
of . . O
other . . O
gbcas . . O
could . . O
not . . O
be . . O
ruled . . O
out . . O
. . . O

in . . O
studies . . O
1 . . O
and . . O
2 . . O
the . . O
nulojix . . O
regimen . . O
is . . O
identical . . O
to . . O
the . . O
recommended . . O
regimen . . O
, . . O
but . . O
is . . O
slightly . . O
different . . O
in . . O
study . . O
3 . . O
. . . O

overall . . O
, . . O
approximately . . O
4% . . O
of . . O
subjects . . O
reported . . O
one . . O
or . . O
more . . O
adverse . . O
reactions . . O
during . . O
a . . O
follow . . O
- . . O
up . . O
period . . O
that . . O
ranged . . O
from . . O
24 . . O
hours . . O
to . . O
7 . . O
days . . O
after . . O
gadavist . . O
administration . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

table . . O
1 . . O
shows . . O
common . . O
adverse . . O
reactions . . O
( . . O
excluding . . O
hypoglycemia . . B-AdverseReaction
) . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
jardiance . . O
. . . O

for . . O
this . . O
same . . O
group . . O
of . . O
afinitor . . O
- . . O
treated . . O
females . . O
, . . O
the . . O
following . . O
menstrual . . B-AdverseReaction
abnormalities . . I-AdverseReaction
were . . O
reported . . O
: . . O
dysmenorrhea . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
menorrhagia . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
metrorrhagia . . B-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
and . . O
unspecified . . B-AdverseReaction
menstrual . . I-AdverseReaction
irregularity . . I-AdverseReaction
( . . O
6% . . O
) . . O
. . . O

prior . . O
to . . O
initiation . . O
of . . O
therapy . . O
with . . O
ilaris . . O
, . . O
patients . . O
should . . O
receive . . O
all . . O
recommended . . O
vaccinations . . O
. . . O

treatment . . O
with . . O
antibacterial . . O
agents . . O
alters . . O
the . . O
normal . . O
flora . . O
of . . O
the . . O
colon . . O
and . . O
may . . O
permit . . O
overgrowth . . O
of . . O
c . . O
. . . O
difficile . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
blinded . . O
study . . O
treatment . . O
was . . O
141 . . O
days . . O
( . . O
range . . O
19-451 . . O
days . . O
) . . O
for . . O
patients . . O
receiving . . O
afinitor . . O
and . . O
60 . . O
days . . O
( . . O
range . . O
21-295 . . O
days . . O
) . . O
for . . O
those . . O
receiving . . O
placebo . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

some . . O
patients . . O
required . . O
hospitalization . . O
and . . O
renal . . O
replacement . . O
therapy . . O
. . . O

adverse . . O
reactions . . O
from . . O
the . . O
mcl . . O
trial . . O
( . . O
n . . O
= . . O
111 . . O
) . . O
using . . O
single . . O
agent . . O
imbruvica . . O
560 . . O
mg . . O
daily . . O
occurring . . O
at . . O
a . . O
rate . . O
of . . O
> . . O
= . . O
10% . . O
are . . O
presented . . O
in . . O
table . . O
1 . . O
. . . O

because . . O
immobilization . . O
increases . . O
the . . O
risk . . O
for . . O
venous . . O
thromboembolic . . O
events . . O
independent . . O
of . . O
therapy . . O
, . . O
duavee . . O
should . . O
be . . O
discontinued . . O
prior . . O
to . . O
and . . O
during . . O
prolonged . . O
immobilization . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
post . . O
- . . O
surgical . . O
recovery . . O
, . . O
prolonged . . O
bed . . O
rest . . O
) . . O
and . . O
duavee . . O
therapy . . O
should . . O
be . . O
resumed . . O
only . . O
after . . O
the . . O
patient . . O
is . . O
fully . . O
ambulatory . . O
. . . O

patients . . O
treated . . O
with . . O
dalvance . . O
were . . O
predominantly . . O
male . . O
( . . O
60% . . O
) . . O
and . . O
caucasian . . O
( . . O
78% . . O
) . . O
. . . O

7 . . O
15 . . O
13 . . O
13 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
13 . . O
16 . . O
15 . . O
15 . . O
vascular . . O
disorders . . O
hypertension . . B-AdverseReaction
2 . . O
2 . . O
3 . . O
2 . . O
dose . . O
- . . O
related . . O
adverse . . O
reactions . . O
: . . O
in . . O
the . . O
short . . O
term . . O
schizophrenia . . O
trials . . O
the . . O
incidence . . O
of . . O
akathisia . . B-AdverseReaction
appeared . . O
to . . O
be . . O
dose . . O
- . . O
related . . O
( . . O
seetable . . O
8 . . O
) . . O
. . . O

in . . O
study . . O
2 . . O
, . . O
1 . . O
patient . . O
in . . O
each . . O
treatment . . O
group . . O
( . . O
0.1% . . O
) . . O
had . . O
an . . O
infection . . B-AdverseReaction
resulting . . O
in . . O
death . . B-AdverseReaction
. . . O

warning . . O
: . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O

5.6 . . O
hepatic . . O
and . . O
renal . . O
impairment . . O

5 . . O
warnings . . O
and . . O
precautions . . O

anaphylaxis . . B-AdverseReaction

discontinue . . O
natazia . . O
if . . O
jaundice . . O
develops . . O
. . . O

acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
acute . . B-AdverseReaction
tubular . . I-AdverseReaction
necrosis . . I-AdverseReaction
, . . O
fanconi . . B-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
proximal . . B-AdverseReaction
renal . . I-AdverseReaction
tubulopathy . . I-AdverseReaction
, . . O
interstitial . . B-AdverseReaction
nephritis . . I-AdverseReaction
( . . O
including . . O
acute . . O
cases . . O
) . . O
, . . O
nephrogenic . . B-AdverseReaction
diabetes . . I-AdverseReaction
insipidus . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
insufficiency . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
creatinine . . I-AdverseReaction
, . . O
proteinuria . . B-AdverseReaction
, . . O
polyuria . . B-AdverseReaction

these . . O
reactions . . O
can . . O
occur . . O
within . . O
hours . . O
to . . O
weeks . . O
after . . O
injection . . O
with . . O
botulinum . . O
toxin . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
, . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
, . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
( . . O
3% . . O
) . . O

this . . O
product's . . O
label . . O
may . . O
have . . O
been . . O
updated . . O
. . . O

the . . O
following . . O
symptoms . . O
, . . O
anxiety . . B-AdverseReaction
, . . O
agitation . . B-AdverseReaction
, . . O
panic . . B-AdverseReaction
attacks . . I-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
irritability . . B-AdverseReaction
, . . O
hostility . . B-AdverseReaction
, . . O
aggressiveness . . B-AdverseReaction
, . . O
impulsivity . . B-AdverseReaction
, . . O
akathisia . . B-AdverseReaction
( . . O
psychomotor . . B-AdverseReaction
restlessness . . I-AdverseReaction
) . . O
, . . O
hypomania . . B-AdverseReaction
, . . O
and . . O
mania . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
adult . . O
and . . O
pediatric . . O
patients . . O
being . . O
treated . . O
with . . O
antidepressants . . B-DrugClass
for . . O
major . . O
depressive . . O
disorder . . O
as . . O
well . . O
as . . O
for . . O
other . . O
indications . . O
, . . O
both . . O
psychiatric . . O
and . . O
nonpsychiatric . . O
. . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
a . . O
potential . . O
for . . O
an . . O
immune . . O
response . . O
in . . O
patients . . O
treated . . O
with . . O
eylea . . O
. . . O

* . . O
progressively . . O
increasing . . O
, . . O
or . . O
* . . O
persistent . . O
for . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
4 . . O
weeks . . O
, . . O
or . . O
* . . O
accompanied . . O
by . . O
increased . . O
direct . . O
bilirubin . . O
, . . O
or . . O
* . . O
accompanied . . O
by . . O
clinical . . O
symptoms . . O
of . . O
liver . . O
injury . . O
or . . O
evidence . . O
for . . O
hepatic . . O
decompensation . . O
. . . O

* . . O
tanzeum . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
a . . O
personal . . O
or . . O
family . . O
history . . O
of . . O
mtc . . O
or . . O
in . . O
patients . . O
with . . O
multiple . . O
endocrine . . O
neoplasia . . O
syndrome . . O
type . . O
2 . . O
( . . O
men . . O
2 . . O
) . . O
. . . O

ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
may . . B-Factor
cause . . O
eye . . B-AdverseReaction
irritation . . I-AdverseReaction
. . . O

the . . O
majority . . O
of . . O
these . . O
reports . . O
have . . O
occurred . . O
in . . O
patients . . O
who . . O
received . . O
concomitant . . O
immunosuppressants . . O
. . . O

the . . O
significance . . O
of . . O
this . . O
finding . . O
is . . O
unknown . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

table . . O
3 . . O
: . . O
monitored . . O
adverse . . O
reactions . . O
- . . O
pruritus . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
pyoderma . . B-AdverseReaction
and . . O
ocular . . B-AdverseReaction
irritation . . I-AdverseReaction
with . . O
onset . . O
after . . O
treatment . . O
signs . . O
/ . . O
symptoms . . O
ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
vehicle . . O
pruritus . . B-AdverseReaction
12% . . O
( . . O
14 . . O
/ . . O
116 . . O
) . . O
4% . . O
( . . O
3 . . O
/ . . O
67 . . O
) . . O
erythema . . B-AdverseReaction
10% . . O
( . . O
32 . . O
/ . . O
309 . . O
) . . O
9% . . O
( . . O
19 . . O
/ . . O
217 . . O
) . . O
pyoderma . . B-AdverseReaction
7% . . O
( . . O
22 . . O
/ . . O
308 . . O
) . . O
4% . . O
( . . O
10 . . O
/ . . O
230 . . O
) . . O
ocular . . B-AdverseReaction
irritation . . I-AdverseReaction
6% . . O
( . . O
26 . . O
/ . . O
428 . . O
) . . O
1% . . O
( . . O
3 . . O
/ . . O
313 . . O
) . . O
other . . O
less . . O
common . . O
reactions . . O
( . . O
less . . O
than . . O
1% . . O
but . . O
more . . O
than . . O
0.1% . . O
) . . O
were . . O
, . . O
in . . O
decreasing . . O
order . . O
of . . O
incidence . . O
: . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
dryness . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
excoriation . . I-AdverseReaction
, . . O
paraesthesia . . B-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
dermatitis . . I-AdverseReaction
, . . O
excoriation . . B-AdverseReaction
, . . O
thermal . . B-AdverseReaction
burn . . I-AdverseReaction
, . . O
dandruff . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
skin . . B-AdverseReaction
exfoliation . . I-AdverseReaction
. . . O

aptiom . . O
causes . . O
dose . . O
- . . O
dependent . . O
increases . . O
in . . O
somnolence . . B-AdverseReaction
and . . O
fatigue . . B-AdverseReaction
- . . O
related . . O
adverse . . O
reactions . . O
( . . O
fatigue . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
malaise . . B-AdverseReaction
, . . O
hypersomnia . . B-AdverseReaction
, . . O
sedation . . B-AdverseReaction
, . . O
and . . O
lethargy . . B-AdverseReaction
) . . O
. . . O

hepatobiliary . . O
disorders . . O
: . . O
liver . . B-AdverseReaction
function . . I-AdverseReaction
test . . I-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
bilirubin . . I-AdverseReaction
increased . . I-AdverseReaction

5.1 . . O
hypersensitivity . . O
reactions . . O

table . . O
3 . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
1% . . O
) . . O
in . . O
dme . . O
studies . . O
adverse . . O
reactions . . O
baseline . . O
to . . O
week . . O
52 . . O
baseline . . O
to . . O
week . . O
100 . . O
eylea . . O
( . . O
n . . O
= . . O
578 . . O
) . . O
control . . O
( . . O
n . . O
= . . O
287 . . O
) . . O
eylea . . O
( . . O
n . . O
= . . O
578 . . O
) . . O
control . . O
( . . O
n . . O
= . . O
287 . . O
) . . O
conjunctival . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
28% . . O
17% . . O
31% . . O
21% . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
9% . . O
6% . . O
11% . . O
9% . . O
cataract . . B-AdverseReaction
8% . . O
9% . . O
19% . . O
17% . . O
vitreous . . B-AdverseReaction
floaters . . I-AdverseReaction
6% . . O
3% . . O
8% . . O
6% . . O
corneal . . B-AdverseReaction
epithelium . . I-AdverseReaction
defect . . I-AdverseReaction
5% . . O
3% . . O
7% . . O
5% . . O
intraocular . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
5% . . O
3% . . O
9% . . O
5% . . O
ocular . . B-AdverseReaction
hyperemia . . I-AdverseReaction
5% . . O
6% . . O
5% . . O
6% . . O
vitreous . . B-AdverseReaction
detachment . . I-AdverseReaction
3% . . O
3% . . O
8% . . O
6% . . O
foreign . . B-AdverseReaction
body . . I-AdverseReaction
sensation . . I-AdverseReaction
in . . I-AdverseReaction
eyes . . I-AdverseReaction
3% . . O
3% . . O
3% . . O
3% . . O
lacrimation . . B-AdverseReaction
increased . . I-AdverseReaction
3% . . O
2% . . O
4% . . O
2% . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
2% . . O
2% . . O
3% . . O
4% . . O
intraocular . . B-AdverseReaction
inflammation . . I-AdverseReaction
2% . . O
< . . O
1% . . O
3% . . O
1% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
2% . . O
< . . O
1% . . O
2% . . O
< . . O
1% . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
< . . O
1% . . O
1% . . O
2% . . O
1% . . O
less . . O
common . . O
adverse . . O
reactions . . O
reported . . O
in . . O
< . . O
1% . . O
of . . O
the . . O
patients . . O
treated . . O
with . . O
eylea . . O
were . . O
hypersensitivity . . B-AdverseReaction
, . . O
retinal . . B-AdverseReaction
detachment . . I-AdverseReaction
, . . O
retinal . . B-AdverseReaction
tear . . I-AdverseReaction
, . . O
corneal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
. . . O

in . . O
a . . O
randomized . . O
trial . . O
comparing . . O
kyprolis . . O
as . . O
a . . O
single . . O
agent . . O
versus . . O
corticosteroids . . O
with . . O
optional . . O
oral . . O
cyclophosphamide . . O
for . . O
patients . . O
with . . O
relapsed . . O
and . . O
refractory . . O
multiple . . O
myeloma . . O
, . . O
mortality . . B-AdverseReaction
was . . O
higher . . O
in . . O
the . . O
patients . . O
treated . . O
with . . O
kyprolis . . O
in . . O
comparison . . O
to . . O
the . . O
control . . O
arm . . O
in . . O
the . . O
subgroup . . O
of . . O
48 . . O
patients . . O
> . . O
= . . O
75 . . O
years . . O
of . . O
age . . O
. . . O

( . . O
5.11 . . O
, . . O
8.1 . . O
) . . O
excerpt . . O
: . . O

the . . O
safety . . O
of . . O
horizant . . O
in . . O
doses . . O
ranging . . O
from . . O
1,200 . . O
to . . O
3,600 . . O
mg . . O
has . . O
been . . O
evaluated . . O
in . . O
417 . . O
patients . . O
with . . O
phn . . O
in . . O
3 . . O
clinical . . O
studies . . O
. . . O

given . . O
the . . O
potential . . O
for . . O
delay . . O
in . . O
lymphocyte . . O
recovery . . O
after . . O
discontinuation . . O
of . . O
tecfidera . . O
, . . O
consider . . O
following . . O
lymphocyte . . O
counts . . O
until . . O
lymphopenia . . O
is . . O
resolved . . O
. . . O

table . . O
2 . . O
and . . O
table . . O
3 . . O
summarize . . O
common . . O
adverse . . O
reactions . . O
and . . O
laboratory . . O
abnormalities . . O
reported . . O
for . . O
zydelig . . O
+ . . O
rituximab . . O
and . . O
placebo . . O
+ . . O
rituximab . . O
arms . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
, . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

when . . O
coartem . . O
tablets . . O
are . . O
coadministered . . O
with . . O
substrates . . O
of . . O
cyp3a4 . . O
it . . O
may . . O
result . . O
in . . O
decreased . . O
concentrations . . O
of . . O
the . . O
substrate . . O
and . . O
potential . . O
loss . . O
of . . O
substrate . . O
efficacy . . O
. . . O

diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
were . . O
the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
. . . O

in . . O
clinical . . O
trial . . O
and . . O
postmarketing . . O
experience . . O
, . . O
events . . O
of . . O
leukopenia . . B-AdverseReaction
/ . . O
neutropenia . . B-AdverseReaction
have . . O
been . . O
reported . . O
temporally . . O
related . . O
to . . O
antipsychotic . . B-DrugClass
agents . . I-DrugClass
. . . O

the . . O
median . . O
duration . . O
of . . O
exposure . . O
was . . O
118 . . O
days . . O
for . . O
patients . . O
receiving . . O
halaven . . O
and . . O
63 . . O
days . . O
for . . O
patients . . O
receiving . . O
control . . O
therapy . . O
. . . O

studies . . O
suggest . . O
a . . O
small . . O
increased . . O
relative . . O
risk . . O
of . . O
developing . . O
gallbladder . . B-AdverseReaction
disease . . I-AdverseReaction
among . . O
coc . . B-DrugClass
users . . O
. . . O

currently . . O
available . . O
data . . O
are . . O
inadequate . . O
to . . O
determine . . O
whether . . O
concurrent . . O
use . . O
of . . O
inhaled . . O
corticosteroids . . O
or . . O
other . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
drugs . . O
mitigates . . O
the . . O
increased . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
from . . O
laba . . B-DrugClass
. . . O

the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
drug . . O
reactions . . O
( . . O
> . . O
= . . O
25% . . O
) . . O
in . . O
the . . O
xiaflex . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
peyronie's . . O
disease . . O
were . . O
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
, . . O
penile . . B-AdverseReaction
swelling . . I-AdverseReaction
, . . O
and . . O
penile . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

patients . . O
with . . O
active . . O
acute . . O
or . . O
chronic . . O
infections . . O
should . . O
not . . O
start . . O
treatment . . O
until . . O
the . . O
infection . . O
( . . O
s . . O
) . . O
is . . O
resolved . . O
. . . O

the . . O
extent . . O
to . . O
which . . O
the . . O
findings . . O
of . . O
increased . . O
mortality . . O
in . . O
observational . . O
studies . . O
may . . O
be . . O
attributed . . O
to . . O
the . . O
antipsychotic . . O
drug . . O
as . . O
opposed . . O
to . . O
some . . O
characteristic . . O
( . . O
s . . O
) . . O
of . . O
the . . O
patients . . O
is . . O
not . . O
clear . . O
. . . O

the . . O
following . . O
additional . . O
adverse . . O
reactions . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
ferriprox . . O
. . . O

flush . . O
eyes . . O
and . . O
mucous . . O
membranes . . O
with . . O
cool . . O
water . . O
. . . O

overall . . O
, . . O
67% . . O
were . . O
female . . O
and . . O
73% . . O
were . . O
white . . O
; . . O
the . . O
mean . . O
age . . O
was . . O
42 . . O
years . . O
( . . O
adolescents . . O
aged . . O
12 . . O
to . . O
17 . . O
years . . O
made . . O
up . . O
14% . . O
of . . O
the . . O
population . . O
) . . O
. . . O

hypoglycemia . . O

6 . . O
adverse . . O
reactions . . O

grade . . B-Severity
3-4 . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
occurred . . O
in . . O
six . . O
patients . . O
in . . O
the . . O
everolimus . . O
arm . . O
and . . O
three . . O
patients . . O
in . . O
the . . O
placebo . . O
arm . . O
. . . O

excerpt . . O
: . . O
* . . O
same . . O
active . . O
ingredient . . O
: . . O
patients . . O
receiving . . O
prolia . . O
should . . O
not . . O
receive . . O
xgeva . . O
( . . O
r . . O
) . . O
( . . O
5.1 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
including . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
may . . O
occur . . O
. . . O

data . . O
from . . O
a . . O
large . . O
, . . O
prospective . . O
cohort . . O
safety . . O
study . . O
of . . O
various . . O
cocs . . O
suggest . . O
that . . O
this . . O
increased . . O
risk . . O
, . . O
as . . O
compared . . O
to . . O
that . . O
in . . O
non . . O
- . . O
coc . . O
users . . O
, . . O
is . . O
greatest . . O
during . . O
the . . O
first . . O
6 . . O
months . . O
of . . O
coc . . O
use . . O
. . . O

consider . . O
follow . . O
- . . O
up . . O
renal . . O
function . . O
assessments . . O
for . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
renal . . O
dysfunction . . O
. . . O

5.8 . . O
combination . . O
with . . O
other . . O
pde5 . . O
inhibitors . . O
or . . O
erectile . . O
dysfunction . . O
therapies . . O

* . . O
cobicistat . . O
( . . O
tybost . . O
) . . O
; . . O
* . . O
elvitegravir . . O
( . . O
vitekta . . O
) . . O
; . . O
* . . O
products . . O
containing . . O
emtricitabine . . O
or . . O
tenofovir . . O
df . . O
( . . O
atripla . . O
, . . O
complera . . O
, . . O
emtriva . . O
, . . O
truvada . . O
, . . O
viread . . O
) . . O
; . . O
* . . O
products . . O
containing . . O
lamivudine . . O
( . . O
combivir . . O
, . . O
epivir . . O
, . . O
epivir . . O
- . . O
hbv . . O
, . . O
epzicom . . O
, . . O
triumeq . . O
, . . O
trizivir . . O
) . . O
; . . O
* . . O
adefovir . . O
dipivoxil . . O
( . . O
hepsera . . O
) . . O
; . . O
* . . O
products . . O
containing . . O
ritonavir . . O
( . . O
norvir . . O
, . . O
kaletra . . O
) . . O
5.5 . . O
risk . . O
of . . O
adverse . . O
reactions . . O
or . . O
loss . . O
of . . O
virologic . . O
response . . O
due . . O
to . . O
drug . . O
interactions . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
, . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
medical . . O
practice . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
risk . . O
of . . O
adverse . . O
reactions . . O
or . . O
loss . . O
of . . O
virologic . . O
response . . O
due . . O
to . . O
drug . . O
interactions . . O
: . . O
the . . O
concomitant . . O
use . . O
of . . O
stribild . . O
and . . O
other . . O
drugs . . O
may . . O
result . . O
in . . O
known . . O
or . . O
potentially . . O
significant . . O
drug . . O
interactions . . O
, . . O
some . . O
of . . O
which . . O
may . . O
lead . . O
to . . O
loss . . O
of . . O
therapeutic . . O
effect . . O
of . . O
stribild . . O
and . . O
possible . . O
development . . O
of . . O
resistance . . O
; . . O
and . . O
possible . . O
clinically . . O
significant . . O
adverse . . O
reactions . . O
from . . O
greater . . O
exposures . . O
of . . O
concomitant . . O
drugs . . O
. . . O

other . . O
than . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
most . . O
adverse . . O
reactions . . O
became . . O
noticeable . . O
about . . O
one . . O
week . . O
after . . O
treatment . . O
and . . O
lasted . . O
several . . O
weeks . . O
. . . O

the . . O
mean . . O
age . . O
of . . O
patients . . O
treated . . O
with . . O
tanzeum . . O
was . . O
55 . . O
years . . O
, . . O
1.5% . . O
of . . O
the . . O
population . . O
in . . O
these . . O
studies . . O
was . . O
75 . . O
years . . O
or . . O
older . . O
and . . O
51% . . O
of . . O
participants . . O
were . . O
male . . O
. . . O

therefore . . O
, . . O
arcapta . . O
neohaler . . O
, . . O
like . . O
other . . O
sympathomimetic . . O
amines . . O
, . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
cardiovascular . . O
disorders . . O
, . . O
especially . . O
coronary . . O
insufficiency . . O
, . . O
cardiac . . O
arrhythmias . . O
, . . O
and . . O
hypertension . . O
. . . O

skin . . B-AdverseReaction
discoloration . . I-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
higher . . O
frequency . . O
among . . O
emtricitabine . . O
- . . O
treated . . O
subjects . . O
; . . O
it . . O
was . . O
manifested . . O
by . . O
hyperpigmentation . . B-AdverseReaction
on . . I-AdverseReaction
the . . I-AdverseReaction
palms . . I-AdverseReaction
and . . O
/ . . O
or . . O
soles . . O
and . . O
was . . O
generally . . O
mild . . B-Severity
and . . O
asymptomatic . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

( . . O
5.3 . . O
) . . O

because . . O
these . . O
events . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

twenty . . O
- . . O
five . . O
of . . O
these . . O
121 . . O
patients . . O
( . . O
21% . . O
) . . O
had . . O
detectable . . O
anti . . O
- . . O
glucarpidase . . O
antibodies . . O
following . . O
voraxaze . . O
administration . . O
, . . O
of . . O
which . . O
19 . . O
received . . O
a . . O
single . . O
dose . . O
of . . O
voraxaze . . O
and . . O
6 . . O
received . . O
two . . O
doses . . O
of . . O
voraxaze . . O
. . . O

counsel . . O
patients . . O
regarding . . O
the . . O
potential . . O
risk . . O
of . . O
mtc . . O
with . . O
use . . O
of . . O
trulicity . . O
and . . O
inform . . O
them . . O
of . . O
symptoms . . O
of . . O
thyroid . . O
tumors . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
mass . . O
in . . O
the . . O
neck . . O
, . . O
dysphagia . . O
, . . O
dyspnea . . O
, . . O
persistent . . O
hoarseness . . O
) . . O
. . . O

cervical . . O
dystonia . . O

g . . O
- . . O
csf . . O
( . . O
granulocyte . . O
colony . . O
- . . O
stimulating . . O
factor . . O
) . . O
or . . O
gm . . O
- . . O
csf . . O
( . . O
granulocyte . . O
- . . O
macrophage . . O
colony . . O
- . . O
stimulating . . O
factor . . O
) . . O
was . . O
used . . O
in . . O
19% . . O
of . . O
patients . . O
who . . O
received . . O
halaven . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
controlled . . O
, . . O
but . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
clinical . . O
trials . . O
of . . O
erwinaze . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
other . . O
drugs . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
stop . . O
inlyta . . O
at . . O
least . . O
24 . . O
hours . . O
prior . . O
to . . O
scheduled . . O
surgery . . O
. . . O

table . . O
10 . . O
compares . . O
the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
reported . . O
with . . O
an . . O
incidence . . O
of . . O
> . . O
= . . O
10% . . O
for . . O
patients . . O
receiving . . O
afinitor . . O
and . . O
occurring . . O
more . . O
frequently . . O
with . . O
afinitor . . O
than . . O
with . . O
placebo . . O
. . . O

the . . O
data . . O
described . . O
below . . O
are . . O
based . . O
on . . O
two . . O
pooled . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
through . . O
day . . O
90 . . O
in . . O
patients . . O
with . . O
dupuytren's . . O
contracture . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
. . . O

if . . O
a . . O
patient . . O
develops . . O
any . . O
of . . O
these . . O
reactions . . O
after . . O
treatment . . O
with . . O
aptiom . . O
, . . O
the . . O
drug . . O
should . . O
be . . O
discontinued . . O
. . . O

therefore . . O
, . . O
when . . O
treating . . O
patients . . O
with . . O
asthma . . O
, . . O
physicians . . O
should . . O
only . . O
prescribe . . O
breo . . O
ellipta . . O
for . . O
patients . . O
not . . O
adequately . . O
controlled . . O
on . . O
a . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
medication . . O
, . . O
such . . O
as . . O
an . . O
inhaled . . O
corticosteroid . . O
, . . O
or . . O
whose . . O
disease . . O
severity . . O
clearly . . O
warrants . . O
initiation . . O
of . . O
treatment . . O
with . . O
both . . O
an . . O
inhaled . . O
corticosteroid . . O
and . . O
a . . O
laba . . O
. . . O

lenses . . O
may . . O
be . . O
reinserted . . O
after . . O
10 . . O
minutes . . O
following . . O
administration . . O
of . . O
durezol . . O
. . . O

in . . O
two . . O
clinical . . O
trials . . O
, . . O
1227 . . O
subjects . . O
were . . O
treated . . O
with . . O
jublia . . O
, . . O
1161 . . O
for . . O
at . . O
least . . O
24 . . O
weeks . . O
and . . O
780 . . O
for . . O
48 . . O
weeks . . O
. . . O

discontinue . . O
for . . O
life . . O
- . . O
threatening . . O
cutaneous . . O
reactions . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

* . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
primarily . . O
in . . O
the . . O
sublingual . . O
area . . O
, . . O
have . . O
been . . O
reported . . O
. . . O

the . . O
system . . O
organ . . O
class . . O
and . . O
individual . . O
adr . . O
terms . . O
are . . O
sorted . . O
in . . O
descending . . O
frequency . . O
order . . O
in . . O
the . . O
imbruvica . . O
arm . . O
. . . O

nervous . . O
system . . O
disorders . . O

( . . O
5.5 . . O
) . . O
* . . O
macrovascular . . O
outcomes . . O
: . . O
there . . O
have . . O
been . . O
no . . O
clinical . . O
studies . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
nesina . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
of . . O
these . . O
adverse . . O
reactions . . O
were . . O
headache . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
uri . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
bruising . . I-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
( . . O
numbness . . O
, . . O
discomfort . . O
, . . O
erythema . . O
, . . O
tenderness . . O
, . . O
tingling . . O
, . . O
itching . . O
, . . O
stinging . . O
, . . O
warmth . . O
, . . O
irritation . . O
, . . O
tightness . . O
, . . O
swelling . . O
) . . O
. . . O

because . . O
gilenya . . O
exposure . . O
is . . O
doubled . . O
in . . O
patients . . O
with . . O
severe . . O
hepatic . . O
impairment . . O
, . . O
these . . O
patients . . O
should . . O
be . . O
closely . . O
monitored . . O
, . . O
as . . O
the . . O
risk . . O
of . . O
adverse . . O
reactions . . O
is . . O
greater . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
, . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

* . . O
hemorrhage . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
infections . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
cytopenias . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
second . . B-AdverseReaction
primary . . I-AdverseReaction
malignancies . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
variable . . O
conditions . . O
, . . O
adverse . . O
event . . O
rates . . O
observed . . O
in . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
of . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

rpls . . B-AdverseReaction
is . . O
a . . O
neurological . . O
disorder . . O
which . . O
can . . B-Factor
present . . O
with . . O
headache . . B-AdverseReaction
, . . O
seizure . . B-AdverseReaction
, . . O
lethargy . . B-AdverseReaction
, . . O
confusion . . B-AdverseReaction
, . . O
blindness . . B-AdverseReaction
and . . O
other . . O
visual . . O
and . . O
neurologic . . B-AdverseReaction
disturbances . . I-AdverseReaction
. . . O

frequent . . O
symptoms . . O
of . . O
hypersensitivity . . B-AdverseReaction
reactions . . O
( . . O
occurring . . O
in . . O
more . . O
than . . O
2 . . O
patients . . O
) . . O
included . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
and . . O
flushing . . B-AdverseReaction
. . . O

study . . O
2 . . O
: . . O
chemotherapy . . O
- . . O
naive . . O
metastatic . . O
castration . . O
- . . O
resistant . . O
prostate . . O
cancer . . O
study . . O
2 . . O
enrolled . . O
1717 . . O
patients . . O
with . . O
metastatic . . O
crpc . . O
who . . O
had . . O
not . . O
received . . O
prior . . O
cytotoxic . . O
chemotherapy . . O
, . . O
of . . O
whom . . O
1715 . . O
received . . O
at . . O
least . . O
one . . O
dose . . O
of . . O
study . . O
drug . . O
. . . O

grade . . B-Severity
3 . . I-Severity
or . . O
higher . . O
( . . O
severe . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
or . . O
fatal . . B-AdverseReaction
) . . O
neurological . . B-AdverseReaction
toxicities . . I-AdverseReaction
following . . O
initiation . . O
of . . O
blincyto . . O
administration . . O
occurred . . O
in . . O
approximately . . O
15% . . O
of . . O
patients . . O
and . . O
included . . O
encephalopathy . . B-AdverseReaction
, . . O
convulsions . . B-AdverseReaction
, . . O
speech . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
disturbances . . B-AdverseReaction
in . . I-AdverseReaction
consciousness . . I-AdverseReaction
, . . O
confusion . . B-AdverseReaction
and . . O
disorientation . . B-AdverseReaction
, . . O
and . . O
coordination . . O
and . . O
balance . . B-AdverseReaction
disorders . . I-AdverseReaction
. . . O

subject . . O
- . . O
years . . O
is . . O
defined . . O
as . . O
cumulative . . O
number . . O
of . . O
days . . O
from . . O
first . . O
drug . . O
intake . . O
to . . O
event . . O
date . . O
, . . O
date . . O
of . . O
last . . O
drug . . O
intake . . O
+ . . O
2 . . O
, . . O
death . . O
date . . O
( . . O
whatever . . O
occurred . . O
first . . O
) . . O
across . . O
all . . O
treated . . O
subjects . . O
divided . . O
by . . O
365.25 . . O
. . . O

reduced . . B-AdverseReaction
blinking . . I-AdverseReaction
from . . O
injection . . O
of . . O
botulinum . . B-DrugClass
toxin . . I-DrugClass
products . . I-DrugClass
in . . O
the . . O
orbicularis . . O
muscle . . O
can . . O
lead . . O
to . . O
corneal . . B-AdverseReaction
exposure . . I-AdverseReaction
, . . O
persistent . . O
epithelial . . O
defect . . O
and . . O
corneal . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
especially . . O
in . . O
patients . . O
with . . O
vii . . O
nerve . . O
disorders . . O
. . . O

the . . O
risk . . B-Factor
of . . O
ptld . . B-AdverseReaction
was . . O
higher . . O
in . . O
ebv . . O
seronegative . . O
patients . . O
compared . . O
to . . O
ebv . . O
seropositive . . O
patients . . O
. . . O

in . . O
total . . O
, . . O
from . . O
the . . O
281 . . O
subjects . . O
treated . . O
in . . O
the . . O
long . . O
- . . O
term . . O
studies . . O
and . . O
tested . . O
for . . O
the . . O
presence . . O
of . . O
neutralizing . . O
antibodies . . O
, . . O
3.6% . . O
developed . . O
neutralizing . . O
antibodies . . O
after . . O
treatment . . O
. . . O

the . . O
mechanism . . O
of . . O
ferriprox . . O
- . . O
associated . . O
agranulocytosis . . B-AdverseReaction
is . . O
unknown . . O
. . . O

ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
should . . O
only . . O
be . . O
used . . O
on . . O
children . . O
( . . O
6 . . O
months . . O
of . . O
age . . O
and . . O
older . . O
) . . O
under . . O
the . . O
direct . . O
supervision . . O
of . . O
an . . O
adult . . O
. . . O

discontinue . . O
immediately . . O
. . . O

the . . O
adverse . . O
drug . . O
reactions . . O
associated . . O
with . . O
ilaris . . O
treatment . . O
in . . O
sjia . . O
patients . . O
were . . O
infections . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
. . . O

esophageal . . B-AdverseReaction
dysmotility . . I-AdverseReaction
and . . O
aspiration . . B-AdverseReaction
have . . O
been . . O
associated . . O
with . . O
antipsychotic . . B-DrugClass
drug . . I-DrugClass
use . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
this . . O
finding . . O
of . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
with . . O
salmeterol . . O
is . . O
considered . . O
a . . O
class . . O
effect . . O
of . . O
laba . . O
, . . O
including . . O
indacaterol . . O
, . . O
the . . O
active . . O
ingredient . . O
in . . O
arcapta . . O
neohaler . . O
. . . O

consider . . O
anti . . O
- . . O
tuberculosis . . O
therapy . . O
prior . . O
to . . O
initiation . . O
of . . O
simponi . . O
aria . . O
in . . O
patients . . O
with . . O
a . . O
past . . O
history . . O
of . . O
latent . . O
or . . O
active . . O
tuberculosis . . O
in . . O
whom . . O
an . . O
adequate . . O
course . . O
of . . O
treatment . . O
cannot . . O
be . . O
confirmed . . O
, . . O
and . . O
for . . O
patients . . O
with . . O
a . . O
negative . . O
test . . O
for . . O
latent . . O
tuberculosis . . O
but . . O
having . . O
risk . . O
factors . . O
for . . O
tuberculosis . . O
infection . . O
. . . O

cases . . O
of . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
have . . O
occurred . . O
in . . O
patients . . O
receiving . . O
kyprolis . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
pneumonitis . . B-AdverseReaction
was . . O
reported . . O
in . . O
4% . . O
of . . O
255 . . O
patients . . O
treated . . O
with . . O
zykadia . . O
. . . O

anyone . . O
considering . . O
prescribing . . O
aptiom . . O
or . . O
any . . O
other . . O
aed . . O
must . . O
balance . . O
this . . O
risk . . O
with . . O
the . . O
risk . . O
of . . O
untreated . . O
illness . . O
. . . O

serious . . B-Severity
depression . . B-AdverseReaction
was . . O
reported . . O
in . . O
0.4% . . O
( . . O
6 . . O
/ . . O
1,458 . . O
) . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
and . . O
0.1% . . O
( . . O
1 . . O
/ . . O
675 . . O
) . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

instruct . . O
patients . . O
to . . O
immediately . . O
report . . O
if . . O
they . . O
experience . . O
any . . O
of . . O
the . . O
above . . O
signs . . O
or . . O
symptoms . . O
. . . O

6 . . O
adverse . . O
reactions . . O

5.2 . . O
infections . . O

constipation . . B-AdverseReaction
also . . O
contributed . . O
to . . O
the . . O
frequently . . O
reported . . O
reactions . . O
. . . O

table . . O
4 . . O
: . . O
change . . O
in . . O
cholesterol . . O
mean . . O
change . . O
from . . O
baseline . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O

symptomatic . . B-AdverseReaction
bradycardia . . I-AdverseReaction
can . . O
occur . . O
in . . O
patients . . O
receiving . . O
xalkori . . O
. . . O

the . . O
safety . . O
and . . O
efficacy . . O
of . . O
pradaxa . . O
in . . O
patients . . O
with . . O
bileaflet . . O
mechanical . . O
prosthetic . . O
heart . . O
valves . . O
was . . O
evaluated . . O
in . . O
the . . O
re . . O
- . . O
align . . O
trial . . O
, . . O
in . . O
which . . O
patients . . O
with . . O
bileaflet . . O
mechanical . . O
prosthetic . . O
heart . . O
valves . . O
( . . O
recently . . O
implanted . . O
or . . O
implanted . . O
more . . O
than . . O
three . . O
months . . O
prior . . O
to . . O
enrollment . . O
) . . O
were . . O
randomized . . O
to . . O
dose . . O
adjusted . . O
warfarin . . O
or . . O
150 . . O
, . . O
220 . . O
, . . O
or . . O
300 . . O
mg . . O
of . . O
pradaxa . . O
twice . . O
a . . O
day . . O
. . . O

fifty . . O
percent . . O
( . . O
50% . . O
) . . O
of . . O
the . . O
population . . O
were . . O
male . . O
; . . O
81% . . O
were . . O
white . . O
, . . O
14% . . O
were . . O
asian . . O
, . . O
and . . O
3% . . O
were . . O
black . . O
or . . O
african . . O
american . . O
. . . O

provide . . O
patients . . O
with . . O
an . . O
anti . . O
- . . O
diarrheal . . O
agent . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
loperamide . . O
) . . O
for . . O
self . . O
- . . O
administration . . O
at . . O
the . . O
onset . . O
of . . O
diarrhea . . O
and . . O
instruct . . O
patients . . O
to . . O
continue . . O
anti . . O
- . . O
diarrheal . . O
therapy . . O
until . . O
loose . . O
bowel . . O
movements . . O
cease . . O
for . . O
12 . . O
hours . . O
. . . O

in . . O
most . . O
cases . . O
, . . O
these . . O
effects . . O
appear . . O
to . . O
be . . O
reversible . . O
upon . . O
drug . . O
discontinuation . . O
and . . O
with . . O
appropriate . . O
medical . . O
treatment . . O
. . . O

do . . O
not . . O
administer . . O
cometriq . . O
to . . O
patients . . O
with . . O
a . . O
recent . . O
history . . O
of . . O
hemorrhage . . O
or . . O
hemoptysis . . O
. . . O

( . . O
5.5 . . O
) . . O
metabolic . . B-AdverseReaction
changes . . I-AdverseReaction
: . . O
atypical . . B-DrugClass
antipsychotic . . I-DrugClass
drugs . . I-DrugClass
have . . O
been . . O
associated . . O
with . . O
metabolic . . O
changes . . O
that . . O
may . . O
increase . . O
cardiovascular . . O
/ . . O
cerebrovascular . . B-AdverseReaction
risk . . I-AdverseReaction
. . . O

advise . . O
patients . . O
to . . O
contact . . O
their . . O
healthcare . . O
provider . . O
if . . O
they . . O
become . . O
pregnant . . O
, . . O
or . . O
if . . O
pregnancy . . O
is . . O
suspected . . O
, . . O
while . . O
taking . . O
gilotrif . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1and8.6 . . O
) . . O
] . . O
. . . O

* . . O
lactic . . B-AdverseReaction
acidosis . . I-AdverseReaction
/ . . O
severe . . B-Severity
hepatomegaly . . B-AdverseReaction
with . . O
steatosis . . B-AdverseReaction
[ . . O
see . . O
boxed . . O
warning . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

other . . O
factors . . O
associated . . O
with . . O
hematuria . . B-AdverseReaction
were . . O
well . . O
- . . O
balanced . . O
between . . O
arms . . O
and . . O
do . . O
not . . O
account . . O
for . . O
the . . O
increased . . O
rate . . O
of . . O
hematuria . . B-AdverseReaction
on . . O
the . . O
jevtana . . O
arm . . O
. . . O

adverse . . O
reactions . . O
that . . O
occurred . . O
after . . O
repeated . . O
injections . . O
in . . O
2-3% . . O
of . . O
the . . O
population . . O
included . . O
bronchitis . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
pharyngolaryngeal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
contact . . B-AdverseReaction
dermatitis . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
swelling . . I-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
discomfort . . I-AdverseReaction
. . . O

when . . O
distant . . O
effects . . O
occur . . O
, . . O
additional . . O
respiratory . . O
muscles . . O
may . . O
be . . O
involved . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
hepatic . . B-AdverseReaction
effects . . I-AdverseReaction
: . . O
postmarketing . . O
reports . . O
of . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
sometimes . . O
fatal . . B-AdverseReaction
. . . O

neutralizing . . O
antibodies . . O
to . . O
ecallantide . . O
were . . O
determined . . O
in . . O
vitro . . O
to . . O
be . . O
present . . O
in . . O
8.8% . . O
of . . O
patients . . O
and . . O
were . . O
not . . O
associated . . O
with . . O
loss . . O
of . . O
efficacy . . O
. . . O

5.8 . . O
leukoencephalopathy . . O

5.3 . . O
increased . . O
risk . . O
of . . O
stroke . . O
in . . O
permanent . . O
af . . O

this . . O
trial . . O
did . . O
not . . O
have . . O
a . . O
placebo . . O
arm . . O
. . . O

prescriptions . . O
for . . O
fanapt . . O
should . . O
be . . O
written . . O
for . . O
the . . O
smallest . . O
quantity . . O
of . . O
tablets . . O
consistent . . O
with . . O
good . . O
patient . . O
management . . O
in . . O
order . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
overdose . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
the . . O
median . . O
time . . O
to . . O
onset . . O
of . . O
hemoglobin . . B-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
10 . . I-AdverseReaction
g . . I-AdverseReaction
per . . I-AdverseReaction
dl . . I-AdverseReaction
from . . O
the . . O
initiation . . O
of . . O
therapy . . O
was . . O
similar . . O
among . . O
subjects . . O
treated . . O
with . . O
the . . O
combination . . O
of . . O
victrelis . . O
and . . O
pegintron . . O
/ . . O
rebetol . . O
( . . O
71 . . O
days . . O
with . . O
a . . O
range . . O
of . . O
15-337 . . O
days . . O
) . . O
, . . O
compared . . O
to . . O
those . . O
who . . O
received . . O
pegintron . . O
/ . . O
rebetol . . O
( . . O
71 . . O
days . . O
with . . O
a . . O
range . . O
of . . O
8-337 . . O
days . . O
) . . O
. . . O

in . . O
most . . O
cases . . O
, . . O
this . . O
is . . O
a . . O
consequence . . O
of . . O
weakening . . O
of . . O
muscles . . O
in . . O
the . . O
area . . O
of . . O
injection . . O
that . . O
are . . O
involved . . O
in . . O
breathing . . O
or . . O
swallowing . . O
. . . O

multaq . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
symptomatic . . O
heart . . O
failure . . O
with . . O
recent . . O
decompensation . . O
requiring . . O
hospitalization . . O
or . . O
nyha . . O
class . . O
iv . . O
heart . . O
failure . . O
. . . O

the . . O
rate . . O
of . . O
progression . . O
of . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
and . . O
the . . O
reversibility . . O
after . . O
drug . . O
discontinuation . . O
are . . O
unknown . . O
. . . O

5.11 . . O
hepatic . . O
impairment . . O

there . . O
were . . O
no . . O
treatment . . O
discontinuations . . O
and . . O
one . . O
death . . B-AdverseReaction
due . . O
to . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
in . . O
the . . O
placebo . . B-Factor
group . . O
. . . O

the . . O
other . . O
patient . . O
developed . . O
probable . . B-Factor
pml . . B-AdverseReaction
after . . O
taking . . O
gilenya . . O
for . . O
approximately . . O
4 . . O
years . . O
. . . O

at . . O
the . . O
first . . O
sign . . O
or . . O
symptom . . O
suggestive . . O
of . . O
pml . . O
, . . O
withhold . . O
tecfidera . . O
and . . O
perform . . O
an . . O
appropriate . . O
diagnostic . . O
evaluation . . O
. . . O

( . . O
5.1 . . O
) . . O
. . . O

three . . O
percent . . O
( . . O
3% . . O
) . . O
of . . O
patients . . O
discontinued . . O
tecfidera . . O
for . . O
flushing . . B-AdverseReaction
and . . O
< . . O
1% . . O
had . . O
serious . . B-Severity
flushing . . B-AdverseReaction
symptoms . . O
that . . O
were . . O
not . . B-Severity
life . . I-Severity
- . . I-Severity
threatening . . I-Severity
but . . O
led . . O
to . . O
hospitalization . . O
. . . O

zytiga . . O
may . . B-Factor
cause . . O
hypertension . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
and . . O
fluid . . B-AdverseReaction
retention . . I-AdverseReaction
as . . O
a . . O
consequence . . O
of . . O
increased . . B-AdverseReaction
mineralocorticoid . . I-AdverseReaction
levels . . I-AdverseReaction
resulting . . O
from . . O
cyp17 . . O
inhibition . . O
[ . . O
seeclinical . . O
pharmacology . . O
( . . O
12.1 . . O
) . . O
] . . O
. . . O

the . . O
overall . . O
percentage . . O
of . . O
patients . . O
with . . O
antibodies . . O
to . . O
certolizumab . . O
pegol . . O
detectable . . O
on . . O
at . . O
least . . O
one . . O
occasion . . O
was . . O
7% . . O
( . . O
105 . . O
of . . O
1,509 . . O
) . . O
in . . O
the . . O
rheumatoid . . O
arthritis . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

monitor . . O
for . . O
pulmonary . . O
symptoms . . O
and . . O
bilateral . . O
interstitial . . O
infiltrates . . O
. . . O

patients . . O
with . . O
histoplasmosis . . O
or . . O
other . . O
invasive . . O
fungal . . O
infections . . O
may . . O
present . . O
with . . O
disseminated . . O
, . . O
rather . . O
than . . O
localized . . O
, . . O
disease . . O
. . . O

* . . O
hypersensitivity . . B-AdverseReaction
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
dysphagia . . B-AdverseReaction
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
in . . O
treatment . . O
of . . O
cervical . . O
dystonia . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
spread . . B-AdverseReaction
of . . I-AdverseReaction
effects . . I-AdverseReaction
from . . I-AdverseReaction
toxin . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
excerpt . . O
: . . O
cervical . . O
dystonia . . O
: . . O
the . . O
most . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
and . . O
> . . O
placebo . . O
) . . O
are . . O
dysphagia . . B-AdverseReaction
, . . O
neck . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
muscle . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
not . . O
recommended . . O
in . . O
patients . . O
with . . O
severe . . O
hepatic . . O
impairment . . O
. . . O

use . . O
aseptic . . O
technique . . O
and . . O
discard . . O
any . . O
unused . . O
product . . O
within . . O
12 . . O
hours . . O
of . . O
stopper . . O
puncture . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

at . . O
baseline . . O
, . . O
57% . . O
of . . O
the . . O
population . . O
had . . O
diabetes . . O
more . . O
than . . O
5 . . O
years . . O
and . . O
had . . O
a . . O
mean . . O
hemoglobin . . O
a1c . . O
( . . O
hba1c . . O
) . . O
of . . O
8% . . O
. . . O

carfilzomib . . O
caused . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
in . . O
pregnant . . O
rabbits . . B-Animal
at . . O
doses . . O
that . . O
were . . O
lower . . O
than . . O
in . . O
patients . . O
receiving . . O
the . . O
recommended . . O
dose . . O
. . . O

the . . O
two . . O
cases . . O
of . . O
ptld . . B-AdverseReaction
were . . O
reported . . O
among . . O
the . . O
140 . . O
ebv . . O
seropositive . . O
patients . . O
( . . O
1.4% . . O
) . . O
. . . O

cardiovascular . . O
safety . . O

monitor . . O
and . . O
manage . . O
patients . . O
using . . O
standards . . O
of . . O
care . . O
. . . O

bleeding . . B-AdverseReaction
into . . I-AdverseReaction
an . . I-AdverseReaction
operated . . I-AdverseReaction
joint . . I-AdverseReaction
requiring . . O
re . . O
- . . O
operation . . O
or . . O
intervention . . O
was . . O
present . . O
in . . O
all . . O
patients . . O
with . . O
this . . O
category . . O
of . . O
bleeding . . B-AdverseReaction
. . . O

red . . O
blood . . O
cell . . O
transfusions . . O
were . . O
administered . . O
to . . O
20% . . O
of . . O
patients . . O
receiving . . O
treanda . . O
compared . . O
with . . O
6% . . O
of . . O
patients . . O
receiving . . O
chlorambucil . . O
. . . O

one . . O
death . . B-AdverseReaction
was . . O
due . . O
to . . O
disseminated . . B-AdverseReaction
primary . . I-AdverseReaction
herpes . . I-AdverseReaction
zoster . . I-AdverseReaction
and . . O
the . . O
other . . O
to . . O
herpes . . B-AdverseReaction
simplex . . I-AdverseReaction
encephalitis . . I-AdverseReaction
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
were . . O
dose . . O
- . . O
related . . O
: . . O
somnolence . . B-AdverseReaction
/ . . O
sedation . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
feeling . . B-AdverseReaction
drunk . . I-AdverseReaction
, . . O
libido . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
depression . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
and . . O
vertigo . . B-AdverseReaction
. . . O

farxiga . . O
causes . . O
an . . O
osmotic . . B-AdverseReaction
diuresis . . I-AdverseReaction
, . . O
which . . O
may . . B-Factor
lead . . O
to . . O
reductions . . B-AdverseReaction
in . . I-AdverseReaction
intravascular . . I-AdverseReaction
volume . . I-AdverseReaction
. . . O

6.2 . . O
postmarketing . . O
experience . . O

in . . O
patients . . O
with . . O
baseline . . O
moderate . . O
hepatic . . O
impairment . . O
receiving . . O
a . . O
reduced . . O
zytiga . . O
dose . . O
of . . O
250 . . O
mg . . O
, . . O
measure . . O
alt . . O
, . . O
ast . . O
, . . O
and . . O
bilirubin . . O
prior . . O
to . . O
the . . O
start . . O
of . . O
treatment . . O
, . . O
every . . O
week . . O
for . . O
the . . O
first . . O
month . . O
, . . O
every . . O
two . . O
weeks . . O
for . . O
the . . O
following . . O
two . . O
months . . O
of . . O
treatment . . O
and . . O
monthly . . O
thereafter . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
were . . O
reported . . O
less . . O
frequently . . O
( . . O
< . . O
5% . . O
) . . O
. . . O

5.5 . . O
paradoxical . . O
bronchospasm . . O

in . . O
the . . O
event . . O
of . . O
an . . O
erection . . O
that . . O
persists . . O
longer . . O
than . . O
4 . . O
hours . . O
, . . O
the . . O
patient . . O
should . . O
seek . . O
immediate . . O
medical . . O
assistance . . O
. . . O

6.3 . . O
postmarketing . . O
experience . . O

fatalities . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
excessive . . O
use . . O
of . . O
inhaled . . O
sympathomimetic . . O
drugs . . O
. . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O

ldl . . B-AdverseReaction
- . . I-AdverseReaction
c . . I-AdverseReaction
increased . . I-AdverseReaction
by . . O
2.3% . . O
, . . O
4.6% . . O
, . . O
and . . O
6.5% . . O
in . . O
patients . . O
treated . . O
with . . O
placebo . . O
, . . O
jardiance . . O
10 . . O
mg . . O
, . . O
and . . O
jardiance . . O
25 . . O
mg . . O
, . . O
respectively . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
. . . O

patients . . O
treated . . O
with . . O
dysport . . O
( . . O
r . . O
) . . O
exhibited . . O
a . . O
small . . B-Severity
increase . . O
from . . O
baseline . . O
( . . O
0.23 . . O
mol . . O
/ . . O
l . . O
) . . O
in . . O
mean . . O
blood . . O
glucose . . O
relative . . O
to . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

adverse . . O
reactions . . O
occurring . . O
at . . O
a . . O
frequency . . O
of . . O
< . . O
10% . . O

11 . . O
c . . O
- . . O
choline . . O
uptake . . O
is . . O
not . . O
specific . . O
for . . O
prostate . . O
cancer . . O
and . . O
may . . O
occur . . O
with . . O
other . . O
types . . O
of . . O
cancer . . O
( . . O
such . . O
as . . O
lung . . O
carcinoma . . O
and . . O
brain . . O
tumors . . O
) . . O
. . . O

these . . O
reactions . . O
occurred . . O
several . . O
weeks . . O
to . . O
3 . . O
years . . O
after . . O
initiation . . O
of . . O
alglucosidase . . O
alfa . . O
infusions . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
thrombotic . . O
/ . . O
thromboembolic . . B-AdverseReaction
complications . . I-AdverseReaction
: . . O
portal . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
with . . O
chronic . . O
liver . . O
disease . . O
receiving . . O
promacta . . O
. . . O

the . . O
following . . O
selected . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
dalvance . . O
treated . . O
patients . . O
at . . O
a . . O
rate . . O
of . . O
less . . O
than . . O
2% . . O
in . . O
these . . O
clinical . . O
trials . . O
: . . O

if . . O
experiencing . . O
grade . . O
> . . O
= . . O
3 . . O
diarrhea . . O
, . . O
dosage . . O
should . . O
be . . O
modified . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

there . . O
have . . O
been . . O
rare . . O
cases . . O
of . . O
posterior . . B-AdverseReaction
reversible . . I-AdverseReaction
encephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
pres . . B-AdverseReaction
) . . O
reported . . O
in . . O
patients . . O
receiving . . O
gilenya . . O
. . . O

table . . O
1 . . O
shows . . O
common . . O
adverse . . O
reactions . . O
excluding . . O
hypoglycemia . . B-AdverseReaction
associated . . O
with . . O
the . . O
use . . O
of . . O
tanzeum . . O
in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

monitor . . O
patients . . O
closely . . O
for . . O
signs . . O
of . . O
peripheral . . O
motor . . O
and . . O
sensory . . O
neuropathy . . O
. . . O

5.3 . . O
fat . . O
redistribution . . O

excerpt . . O
: . . O
* . . O
anaphylaxis . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
anaphylaxis . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
some . . O
patients . . O
during . . O
and . . O
after . . O
treatment . . O
with . . O
alglucosidase . . O
alfa . . O
. . . O

* . . O
data . . O
from . . O
a . . O
large . . O
placebo . . O
- . . O
controlled . . O
study . . O
in . . O
asthma . . O
patients . . O
showed . . O
that . . O
long . . B-DrugClass
- . . I-DrugClass
acting . . I-DrugClass
beta . . I-DrugClass
2 . . I-DrugClass
- . . I-DrugClass
adrenergic . . I-DrugClass
agonists . . I-DrugClass
may . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
. . . O

farxiga . . O
can . . B-Factor
increase . . O
the . . O
risk . . O
of . . O
hypoglycemia . . B-AdverseReaction
when . . O
combined . . O
with . . O
insulin . . O
or . . O
an . . O
insulin . . O
secretagogue . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
* . . O
splenic . . B-AdverseReaction
rupture . . I-AdverseReaction
: . . O
discontinue . . O
granix . . O
if . . O
suspected . . O
( . . O
5.1 . . O
) . . O
* . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ards . . B-AdverseReaction
) . . O
: . . O
monitor . . O
for . . O
and . . O
manage . . O
immediately . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

autoimmune . . B-AdverseReaction
disorders . . I-AdverseReaction
( . . O
such . . O
as . . O
graves' . . B-AdverseReaction
disease . . I-AdverseReaction
, . . O
polymyositis . . B-AdverseReaction
, . . O
and . . O
guillain . . B-AdverseReaction
- . . I-AdverseReaction
barre . . I-AdverseReaction
syndrome . . I-AdverseReaction
) . . O
have . . O
also . . O
been . . O
reported . . O
to . . O
occur . . O
in . . O
the . . O
setting . . O
of . . O
immune . . O
reconstitution . . O
; . . O
however . . O
, . . O
the . . O
time . . O
to . . O
onset . . O
is . . O
more . . O
variable . . O
and . . O
can . . O
occur . . O
many . . O
months . . O
after . . O
initiation . . O
of . . O
treatment . . O
. . . O

5.1 . . O
cytokine . . O
release . . O
syndrome . . O

the . . O
most . . O
common . . O
cause . . O
of . . O
deaths . . B-AdverseReaction
occurring . . O
in . . O
patients . . O
( . . O
% . . O
) . . O
in . . O
the . . O
two . . O
arms . . O
( . . O
krd . . O
versus . . O
rd . . O
) . . O
included . . O
cardiac . . O
10 . . O
( . . O
3% . . O
) . . O
versus . . O
7 . . O
( . . O
2% . . O
) . . O
, . . O
infection . . O
9 . . O
( . . O
2% . . O
) . . O
versus . . O
10 . . O
( . . O
3% . . O
) . . O
, . . O
renal . . O
0 . . O
( . . O
0% . . O
) . . O
versus . . O
1 . . O
( . . O
< . . O
1% . . O
) . . O
, . . O
and . . O
other . . O
adverse . . O
events . . O
9 . . O
( . . O
2% . . O
) . . O
versus . . O
10 . . O
( . . O
3% . . O
) . . O
. . . O

do . . O
not . . O
discontinue . . O
therapy . . O
with . . O
leucovorin . . O
based . . O
on . . O
the . . O
determination . . O
of . . O
a . . O
single . . O
methotrexate . . O
concentration . . O
below . . O
the . . O
leucovorin . . O
treatment . . O
threshold . . O
. . . O

for . . O
invasive . . O
dental . . O
procedures . . O
, . . O
withhold . . O
cometriq . . O
treatment . . O
for . . O
at . . O
least . . O
28 . . O
days . . O
prior . . O
to . . O
scheduled . . O
surgery . . O
, . . O
if . . O
possible . . O
. . . O

table . . O
2 . . O
shows . . O
absolute . . O
and . . O
relative . . O
risk . . O
by . . O
indication . . O
for . . O
all . . O
evaluated . . O
aeds . . O
. . . O

there . . O
is . . O
evidence . . O
to . . O
suggest . . O
that . . O
some . . O
patients . . O
who . . O
develop . . O
high . . O
sustained . . O
titers . . O
of . . O
anti . . O
- . . O
alglucosidase . . O
alfa . . O
antibodies . . O
may . . O
experience . . O
reduced . . O
clinical . . O
efficacy . . O
to . . O
alglucosidase . . O
alfa . . O
treatment . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

6.2 . . O
clinical . . O
trials . . O
experience . . O
in . . O
asthma . . O

c . . O
. . . O
difficile . . O
produces . . O
toxins . . O
a . . O
and . . O
b . . O
which . . O
contribute . . O
to . . O
the . . O
development . . O
of . . O
cdad . . O
. . . O

use . . O
caution . . O
and . . O
monitor . . O
for . . O
symptoms . . O
and . . O
signs . . O
of . . O
adrenocortical . . O
insufficiency . . O
, . . O
particularly . . O
if . . O
patients . . O
are . . O
withdrawn . . O
from . . O
prednisone . . O
, . . O
have . . O
prednisone . . O
dose . . O
reductions . . O
, . . O
or . . O
experience . . O
unusual . . O
stress . . O
. . . O

potential . . B-Factor
for . . O
tumor . . B-AdverseReaction
growth . . I-AdverseReaction
stimulatory . . I-AdverseReaction
effects . . I-AdverseReaction
on . . I-AdverseReaction
malignant . . I-AdverseReaction
cells . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O

* . . O
before . . O
gadavist . . O
administration . . O
, . . O
assess . . O
all . . O
patients . . O
for . . O
any . . O
history . . O
of . . O
a . . O
reaction . . O
to . . O
contrast . . O
media . . O
, . . O
bronchial . . O
asthma . . O
and . . O
/ . . O
or . . O
allergic . . O
disorders . . O
. . . O

eosinophilia . . O

there . . O
were . . O
7 . . O
( . . O
0.5% . . O
) . . O
deaths . . B-AdverseReaction
due . . O
to . . O
cardiorespiratory . . B-AdverseReaction
arrest . . I-AdverseReaction
in . . O
the . . O
zytiga . . O
arms . . O
and . . O
3 . . O
( . . O
0.3% . . O
) . . O
deaths . . B-AdverseReaction
in . . O
the . . O
placebo . . B-Factor
arms . . O
. . . O

this . . O
is . . O
supplemented . . O
with . . O
information . . O
on . . O
adverse . . O
drug . . O
reactions . . O
in . . O
1326 . . O
patients . . O
with . . O
alk . . O
- . . O
positive . . O
metastatic . . O
nsclc . . O
who . . O
received . . O
xalkori . . O
250 . . O
mg . . O
twice . . O
daily . . O
across . . O
clinical . . O
trials . . O
, . . O
for . . O
a . . O
total . . O
of . . O
1669 . . O
patients . . O
across . . O
all . . O
clinical . . O
studies . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
hypotension . . O
after . . O
initiating . . O
therapy . . O
and . . O
increase . . O
monitoring . . O
in . . O
clinical . . O
situations . . O
where . . O
volume . . O
contraction . . O
is . . O
expected . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
) . . O
] . . O
. . . O

5.2 . . O
acute . . O
renal . . O
failure . . O

( . . O
5.1 . . O
, . . O
5.2 . . O
) . . O
* . . O
withdrawal . . O
: . . O
symptoms . . O
may . . O
occur . . O
with . . O
rapid . . O
dose . . O
reduction . . O
or . . O
discontinuation . . O
. . . O

avoid . . O
use . . O
of . . O
gbcas . . O
in . . O
these . . O
patients . . O
unless . . O
the . . O
diagnostic . . O
information . . O
is . . O
essential . . O
and . . O
not . . O
available . . O
with . . O
non . . O
- . . O
contrasted . . O
mri . . O
or . . O
other . . O
modalities . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
no . . O
serious . . O
adverse . . O
reactions . . O
were . . O
reported . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

other . . O
adverse . . O
reactions . . O
with . . O
incidences . . O
of . . O
less . . O
than . . O
5% . . O
in . . O
the . . O
dysport . . O
( . . O
r . . O
) . . O
500 . . O
units . . O
group . . O
in . . O
the . . O
double . . O
- . . O
blind . . O
phase . . O
of . . O
clinical . . O
trials . . O
included . . O
dizziness . . B-AdverseReaction
in . . O
3.5% . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
- . . O
treated . . O
patients . . O
and . . O
1% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
and . . O
muscle . . B-AdverseReaction
atrophy . . I-AdverseReaction
in . . O
1% . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
- . . O
treated . . O
patients . . O
and . . O
in . . O
none . . O
of . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

decreases . . O
in . . O
neutrophil . . O
counts . . O
may . . O
require . . O
dose . . O
reduction . . O
or . . O
discontinuation . . O
of . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
. . . O

these . . O
risk . . O
differences . . O
( . . O
drug . . O
- . . O
placebo . . O
difference . . O
in . . O
the . . O
number . . O
of . . O
cases . . O
of . . O
suicidality . . B-AdverseReaction
per . . O
1,000 . . O
patients . . O
treated . . O
) . . O
are . . O
provided . . O
in . . O
table . . O
1 . . O
. . . O

most . . O
of . . O
the . . O
patients . . O
were . . O
receiving . . O
concomitant . . O
immunosuppressants . . O
. . . O

controlled . . O
clinical . . O
studies . . O

interrupt . . O
and . . O
then . . O
reduce . . O
or . . O
discontinue . . O
zydelig . . O
as . . O
recommended . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

* . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
can . . B-Factor
occur . . O
with . . O
sirturo . . O
. . . O

when . . O
possible . . O
, . . O
avoid . . O
use . . O
of . . O
zykadia . . O
in . . O
patients . . O
with . . O
congenital . . O
long . . O
qt . . O
syndrome . . O
. . . O

5.2 . . O
hypersensitivity . . O
reactions . . O

( . . O
5.2 . . O
) . . O
* . . O
anaphylaxis . . B-AdverseReaction
and . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
severe . . O
and . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
occurred . . O
; . . O
monitor . . O
clinically . . O
and . . O
discontinue . . O
treanda . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
bronchospasm . . B-AdverseReaction

6 . . O
adverse . . O
reactions . . O

the . . O
increased . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
with . . O
aeds . . B-DrugClass
was . . O
observed . . O
as . . O
early . . O
as . . O
one . . O
week . . O
after . . O
starting . . O
drug . . O
treatment . . O
with . . O
aeds . . O
and . . O
persisted . . O
for . . O
the . . O
duration . . O
of . . O
treatment . . O
assessed . . O
. . . O

in . . O
phase . . O
2 . . O
and . . O
3 . . O
clinical . . O
trials . . O
, . . O
seven . . O
percent . . O
of . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
had . . O
neutrophil . . B-AdverseReaction
counts . . I-AdverseReaction
of . . I-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
0.5 . . I-AdverseReaction
* . . I-AdverseReaction
10 . . I-AdverseReaction
9 . . I-AdverseReaction
per . . I-AdverseReaction
l . . I-AdverseReaction
compared . . O
to . . O
4% . . O
of . . O
subjects . . O
receiving . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
( . . O
see . . O
table . . O
4 . . O
) . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
anemia . . B-AdverseReaction
- . . O
the . . O
addition . . O
of . . O
victrelis . . O
to . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
is . . O
associated . . O
with . . O
an . . O
additional . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
concentrations . . I-AdverseReaction
compared . . O
with . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
alone . . O
. . . O

the . . O
overall . . O
number . . O
of . . O
infections . . B-AdverseReaction
, . . O
serious . . B-Severity
infections . . B-AdverseReaction
, . . O
and . . O
select . . O
infections . . B-AdverseReaction
with . . O
identified . . O
etiology . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
or . . O
the . . O
cyclosporine . . O
control . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
are . . O
shown . . O
in . . O
table . . O
3 . . O
. . . O

some . . O
medicines . . O
may . . O
affect . . O
how . . O
duavee . . O
works . . O
. . . O

whether . . O
antipsychotic . . B-DrugClass
drug . . I-DrugClass
products . . O
differ . . O
in . . O
their . . O
potential . . O
to . . O
cause . . O
tardive . . B-AdverseReaction
dyskinesia . . I-AdverseReaction
( . . O
td . . B-AdverseReaction
) . . O
is . . O
unknown . . O
. . . O

excerpt . . O
: . . O
* . . O
angioedema . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
face . . I-AdverseReaction
, . . O
lips . . O
, . . O
tongue . . O
, . . O
and . . O
/ . . O
or . . O
larynx . . O
has . . O
been . . O
reported . . O
with . . O
fesoterodine . . O
. . . O

5.8 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

fatal . . B-AdverseReaction
adverse . . O
reactions . . O
occurred . . O
more . . O
frequently . . O
in . . O
patients . . O
who . . O
received . . O
afinitor . . O
plus . . O
exemestane . . O
( . . O
2% . . O
) . . O
compared . . O
to . . O
patients . . O
on . . O
the . . O
placebo . . O
plus . . O
exemestane . . O
arm . . O
( . . O
0.4% . . O
) . . O
. . . O

jc . . B-AdverseReaction
virus . . I-AdverseReaction
infection . . I-AdverseReaction
resulting . . O
in . . O
pml . . B-AdverseReaction
and . . O
death . . B-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
adcetris . . O
- . . O
treated . . O
patients . . O
. . . O

symptoms . . O
of . . O
taking . . O
too . . O
much . . O
duavee . . O
include . . O
: . . O
nauseavomitingbreast . . O
tendernessdizzinessabdominal . . O
painfeeling . . O
tiredvaginal . . O
bleeding . . O
what . . O
are . . O
the . . O
possible . . O
side . . O
effects . . O
of . . O
duavee . . O
? . . O

no . . O
new . . O
major . . O
safety . . O
findings . . O
were . . O
reported . . O
from . . O
a . . O
50 . . O
- . . O
week . . O
, . . O
open . . O
- . . O
label . . O
, . . O
uncontrolled . . O
safety . . O
trial . . O
. . . O

5.2 . . O
pancreatitis . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
across . . O
products . . O
in . . O
this . . O
class . . O
may . . O
be . . O
misleading . . O
. . . O

concurrent . . O
hypochloremia . . B-AdverseReaction
was . . O
also . . O
present . . O
in . . O
patients . . O
with . . O
hyponatremia . . B-AdverseReaction
. . . O

laboratory . . O
test . . O
abnormalities . . O
: . . O

tables . . O
1 . . O
and . . O
2 . . O
show . . O
the . . O
number . . O
of . . O
patients . . O
experiencing . . O
major . . B-Severity
bleeding . . B-AdverseReaction
during . . O
the . . O
treatment . . O
period . . O
and . . O
the . . O
bleeding . . B-AdverseReaction
rate . . O
( . . O
percentage . . O
of . . O
subjects . . O
with . . O
at . . O
least . . O
one . . O
bleeding . . B-AdverseReaction
event . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
) . . O
in . . O
aristotle . . O
and . . O
averroes . . O
. . . O

swallowing . . O
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
can . . B-Factor
be . . O
life . . B-Severity
threatening . . I-Severity
and . . O
there . . O
have . . O
been . . O
reports . . O
of . . O
death . . B-AdverseReaction
related . . O
to . . O
the . . O
spread . . B-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effects . . I-AdverseReaction
. . . O

* . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
and . . O
ideation . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
serious . . B-Severity
dermatologic . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
drug . . B-AdverseReaction
reaction . . I-AdverseReaction
with . . I-AdverseReaction
eosinophilia . . I-AdverseReaction
and . . I-AdverseReaction
systemic . . I-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
dress . . B-AdverseReaction
) . . O
/ . . O
multiorgan . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
angioedema . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
hyponatremia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
neurological . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
drug . . B-AdverseReaction
induced . . I-AdverseReaction
liver . . I-AdverseReaction
injury . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
* . . O
abnormal . . B-AdverseReaction
thyroid . . I-AdverseReaction
function . . I-AdverseReaction
tests . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
in . . O
patients . . O
receiving . . O
aptiom . . O
( . . O
> . . O
= . . O
4% . . O
and . . O
> . . O
= . . O
2% . . O
greater . . O
than . . O
placebo . . O
) . . O
: . . O
dizziness . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
diplopia . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
vertigo . . B-AdverseReaction
, . . O
ataxia . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
and . . O
tremor . . B-AdverseReaction
. . . O

this . . O
risk . . O
was . . O
greater . . O
in . . O
patients . . O
with . . O
a . . O
baseline . . O
reduced . . O
estimated . . O
creatinine . . O
clearance . . O
( . . O
calculated . . O
using . . O
cockcroft . . O
and . . O
gault . . O
equation . . O
) . . O
. . . O

of . . O
34 . . O
patients . . O
enrolled . . O
, . . O
32 . . O
had . . O
the . . O
g551d . . O
mutation . . O
and . . O
2 . . O
had . . O
the . . O
s549n . . O
mutation . . O
. . . O

consider . . O
the . . O
benefits . . O

after . . O
the . . O
first . . O
dose . . O
of . . O
gilenya . . O
, . . O
the . . O
heart . . B-AdverseReaction
rate . . I-AdverseReaction
decrease . . I-AdverseReaction
starts . . O
within . . O
an . . O
hour . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
endometrial . . B-AdverseReaction
cancer . . I-AdverseReaction
, . . O
cardiovascular . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
and . . O
probable . . B-Factor
dementia . . B-AdverseReaction

risk . . B-Factor
of . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
complications . . I-AdverseReaction
: . . O
patients . . O
with . . O
acute . . O
febrile . . O
or . . O
respiratory . . O
illness . . O
may . . O
be . . O
at . . O
higher . . O
risk . . O
of . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
complications . . O
from . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
. . . O

symptoms . . O
associated . . O
with . . O
these . . O
reactions . . O
have . . O
included . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
pharyngeal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
rhinorrhea . . B-AdverseReaction
, . . O
sneezing . . B-AdverseReaction
, . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
, . . O
throat . . B-AdverseReaction
irritation . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
wheezing . . B-AdverseReaction
, . . O
and . . O
hypotension . . B-AdverseReaction
. . . O

monitor . . O
complete . . O
blood . . O
counts . . O
monthly . . O
. . . O

in . . O
all . . O
controlled . . O
and . . O
uncontrolled . . O
trials . . O
across . . O
various . . O
patient . . O
populations . . O
, . . O
more . . O
than . . O
2,300 . . O
patients . . O
have . . O
received . . O
horizant . . O
orally . . O
in . . O
daily . . O
doses . . O
ranging . . O
from . . O
600 . . O
to . . O
3,600 . . O
mg . . O
. . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
clinical . . O
trials . . O
of . . O
vizamyl . . O
( . . O
n . . O
= . . O
761 . . O
subjects . . O
) . . O
adverse . . O
reaction . . O
n . . O
( . . O
percent . . O
of . . O
patients . . O
) . . O
flushing . . B-AdverseReaction
16 . . O
( . . O
2% . . O
) . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
13 . . O
( . . O
2% . . O
) . . O
headache . . B-AdverseReaction
10 . . O
( . . O
1% . . O
) . . O
nausea . . B-AdverseReaction
8 . . O
( . . O
1% . . O
) . . O
dizziness . . B-AdverseReaction
8 . . O
( . . O
1% . . O
) . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

therefore . . O
, . . O
use . . O
of . . O
eliquis . . O
is . . O
not . . O
recommended . . O
in . . O
these . . O
patients . . O
. . . O

5.7 . . O
serious . . O
febrile . . O
reactions . . O

use . . O
with . . O
caution . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
gastrointestinal . . O
perforation . . O
or . . O
fistula . . O
. . . O

in . . O
this . . O
study . . O
, . . O
the . . O
majority . . O
of . . O
myocardial . . B-AdverseReaction
infarctions . . I-AdverseReaction
occurred . . O
between . . O
1 . . O
and . . O
4 . . O
months . . O
after . . O
initiation . . O
of . . O
treatment . . O
. . . O

in . . O
some . . O
patients . . O
infected . . O
with . . O
hbv . . O
and . . O
treated . . O
with . . O
emtriva . . O
, . . O
the . . O
exacerbations . . B-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction
were . . O
associated . . O
with . . O
liver . . B-AdverseReaction
decompensation . . I-AdverseReaction
and . . O
liver . . B-AdverseReaction
failure . . I-AdverseReaction
. . . O

limited . . O
information . . O
is . . O
presented . . O
on . . O
the . . O
110 . . O
mg . . O
dosing . . O
arm . . O
because . . O
this . . O
dose . . O
is . . O
not . . O
approved . . O
. . . O

musculoskeletal . . O
- . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction

in . . O
the . . O
wet . . O
amd . . O
, . . O
rvo . . O
, . . O
and . . O
dme . . O
studies . . O
, . . O
the . . O
pre . . O
- . . O
treatment . . O
incidence . . O
of . . O
immunoreactivity . . O
to . . O
eylea . . O
was . . O
approximately . . O
1% . . O
to . . O
3% . . O
across . . O
treatment . . O
groups . . O
. . . O

if . . O
an . . O
anaphylactic . . O
or . . O
other . . O
serious . . O
allergic . . O
reaction . . O
occurs . . O
, . . O
administration . . O
of . . O
simponi . . O
aria . . O
should . . O
be . . O
discontinued . . O
immediately . . O
and . . O
appropriate . . O
therapy . . O
instituted . . O
. . . O

instruct . . O
patients . . O
to . . O
consult . . O
a . . O
physician . . O
immediately . . O
should . . O
any . . O
of . . O
these . . O
signs . . O
or . . O
symptoms . . O
develop . . O
. . . O

elevating . . O
the . . O
head . . O
of . . O
the . . O
bed . . O
lessens . . O
the . . O
risk . . O
of . . O
supine . . O
hypertension . . O
, . . O
and . . O
blood . . O
pressure . . O
should . . O
be . . O
measured . . O
in . . O
this . . O
position . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
bronchitis . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
epistaxis . . B-AdverseReaction
, . . O
nasal . . B-AdverseReaction
dryness . . I-AdverseReaction
, . . O
paranasal . . B-AdverseReaction
sinus . . I-AdverseReaction
hypersecretion . . I-AdverseReaction
, . . O
pharyngeal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
congestion . . I-AdverseReaction
, . . O
sneezing . . B-AdverseReaction
, . . O
throat . . B-AdverseReaction
irritation . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
. . . O

discontinue . . O
cometriq . . O
in . . O
patients . . O
who . . O
experience . . O
a . . O
perforation . . O
or . . O
a . . O
fistula . . O
. . . O

these . . O
hematomas . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
long . . O
- . . O
term . . O
or . . O
permanent . . B-AdverseReaction
paralysis . . I-AdverseReaction
. . . O

* . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
( . . O
penile . . B-AdverseReaction
fracture . . I-AdverseReaction
) . . O
was . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
in . . O
5 . . O
of . . O
1044 . . O
( . . O
0.5% . . O
) . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
in . . O
clinical . . O
studies . . O
. . . O

more . . O
frequent . . O
monitoring . . O
is . . O
recommended . . O
in . . O
patients . . O
with . . O
egfr . . O
below . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
( . . O
5.2 . . O
) . . O
* . . O
hyperkalemia . . B-AdverseReaction
: . . O
monitor . . O
potassium . . O
levels . . O
in . . O
patients . . O
with . . O
impaired . . O
renal . . O
function . . O
and . . O
in . . O
patients . . O
predisposed . . O
to . . O
hyperkalemia . . O
( . . O
2.2 . . O
, . . O
5.3 . . O
, . . O
6.1 . . O
, . . O
8.6 . . O
) . . O
* . . O
hypoglycemia . . B-AdverseReaction
: . . O
consider . . O
a . . O
lower . . O
dose . . O
of . . O
insulin . . O
or . . O
the . . O
insulin . . O
secretagogue . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
invokana . . O
( . . O
5.4 . . O
) . . O
* . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
: . . O
monitor . . O
and . . O
treat . . O
if . . O
indicated . . O
( . . O
5.5 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
discontinue . . O
invokana . . O
and . . O
monitor . . O
until . . O
signs . . O
and . . O
symptoms . . O
resolve . . O
( . . O
5.6 . . O
) . . O
* . . O
bone . . B-AdverseReaction
fracture . . I-AdverseReaction
: . . O
consider . . O
factors . . O
that . . O
contribute . . O
to . . O
fracture . . O
risk . . O
before . . O
initiating . . O
invokana . . O
( . . O
5.7 . . O
) . . O
* . . O
increased . . B-AdverseReaction
ldl . . I-AdverseReaction
- . . I-AdverseReaction
c . . I-AdverseReaction
: . . O
monitor . . O
ldl . . O
- . . O
c . . O
and . . O
treat . . O
if . . O
appropriate . . O
( . . O
5.8 . . O
) . . O

overall . . O
, . . O
patients . . O
had . . O
a . . O
mean . . O
pre . . O
- . . O
bronchodilator . . O
forced . . O
expiratory . . O
volume . . O
in . . O
one . . O
second . . O
( . . O
fev1 . . O
) . . O
percent . . O
predicted . . O
of . . O
54% . . O
. . . O

because . . O
cerdelga . . O
is . . O
predicted . . O
to . . O
cause . . O
increases . . O
in . . O
ecg . . O
intervals . . O
( . . O
pr . . O
, . . O
qtc . . O
, . . O
and . . O
qrs . . O
) . . O
at . . O
substantially . . O
elevated . . O
eliglustat . . O
plasma . . O
concentrations . . O
, . . O
use . . O
of . . O
cerdelga . . O
is . . O
not . . O
recommended . . O
in . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
cardiac . . O
disease . . O
( . . O
congestive . . O
heart . . O
failure . . O
, . . O
recent . . O
acute . . O
myocardial . . O
infarction . . O
, . . O
bradycardia . . O
, . . O
heart . . O
block . . O
, . . O
ventricular . . O
arrhythmia . . O
) . . O
, . . O
long . . O
qt . . O
syndrome . . O
, . . O
and . . O
in . . O
combination . . O
with . . O
class . . O
ia . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
quinidine . . O
, . . O
procainamide . . O
) . . O
and . . O
class . . O
iii . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
amiodarone . . O
, . . O
sotalol . . O
) . . O
antiarrhythmic . . O
medications . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
more . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
: . . O
closely . . O
monitor . . O
patients . . O
with . . O
rapidly . . O
proliferating . . O
tumor . . O
or . . O
high . . O
tumor . . O
burden . . O
( . . O
5.5 . . O
) . . O
. . . O

in . . O
single . . O
, . . O
833 . . O
subjects . . O
were . . O
randomized . . O
and . . O
received . . O
at . . O
least . . O
1 . . O
dose . . O
of . . O
either . . O
tivicay . . O
50 . . O
mg . . O
with . . O
fixed . . O
- . . O
dose . . O
abacavir . . O
sulfate . . O
and . . O
lamivudine . . O
( . . O
epzicom . . O
) . . O
once . . O
daily . . O
or . . O
fixed . . O
- . . O
dose . . O
efavirenz . . O
/ . . O
emtricitabine . . O
/ . . O
tenofovir . . O
( . . O
atripla . . O
( . . O
r . . O
) . . O
) . . O
once . . O
daily . . O
. . . O

hematologic . . O
disorders . . O
: . . O
hemorrhage . . B-AdverseReaction
( . . O
3% . . O
) . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
described . . O
in . . O
greater . . O
detail . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O

treatment . . O
- . . O
naive . . O
subjects . . O
: . . O
the . . O
safety . . O
assessment . . O
of . . O
tivicay . . O
in . . O
hiv . . O
- . . O
1 . . O
- . . O
infected . . O
treatment . . O
- . . O
naive . . O
subjects . . O
is . . O
based . . O
on . . O
the . . O
analyses . . O
of . . O
96 . . O
- . . O
week . . O
data . . O
from . . O
2 . . O
international . . O
, . . O
multicenter . . O
, . . O
double . . O
- . . O
blind . . O
trials . . O
, . . O
spring . . O
- . . O
2 . . O
( . . O
ing113086 . . O
) . . O
and . . O
single . . O
( . . O
ing114467 . . O
) . . O
and . . O
48 . . O
- . . O
week . . O
data . . O
from . . O
the . . O
international . . O
, . . O
multicenter . . O
, . . O
open . . O
- . . O
label . . O
flamingo . . O
( . . O
ing114915 . . O
) . . O
trial . . O
. . . O

adverse . . O
events . . O
leading . . O
to . . O
discontinuation . . O
of . . O
kyprolis . . O
occurred . . O
in . . O
12% . . O
of . . O
patients . . O
and . . O
the . . O
most . . O
common . . O
events . . O
included . . O
pneumonia . . B-AdverseReaction
( . . O
1% . . O
) . . O
, . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
( . . O
0.8% . . O
) . . O
, . . O
and . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
0.8% . . O
) . . O
. . . O

a . . O
syndrome . . O
of . . O
potentially . . B-Severity
irreversible . . I-Severity
, . . O
involuntary . . B-AdverseReaction
, . . I-AdverseReaction
dyskinetic . . I-AdverseReaction
movements . . I-AdverseReaction
can . . O
develop . . O
in . . O
patients . . O
treated . . O
with . . O
antipsychotic . . B-DrugClass
drugs . . I-DrugClass
. . . O

adverse . . O
reactions . . O
occurring . . O
at . . O
an . . O
incidence . . O
of . . O
2% . . O
or . . O
more . . O
among . . O
saphris . . O
- . . O
treated . . O
( . . O
adjunctive . . O
) . . O
bipolar . . O
patients . . O
: . . O
adverse . . O
reactions . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
saphris . . O
( . . O
incidence . . O
of . . O
2% . . O
or . . O
greater . . O
, . . O
rounded . . O
to . . O
the . . O
nearest . . O
percent . . O
, . . O
and . . O
saphris . . O
incidence . . O
greater . . O
than . . O
placebo . . O
) . . O
that . . O
occurred . . O
during . . O
acute . . O
adjunctive . . O
therapy . . O
at . . O
3 . . O
weeks . . O
, . . O
a . . O
time . . O
when . . O
most . . O
of . . O
the . . O
patients . . O
were . . O
still . . O
participating . . O
in . . O
the . . O
trial . . O
, . . O
are . . O
shown . . O
in . . O
table . . O
11 . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
pediatric . . O
patients . . O
are . . O
rash . . B-AdverseReaction
and . . O
diarrhea . . B-AdverseReaction
. . . O

glabellar . . O
lines . . O

rapid . . O
intravenous . . O
infusions . . O
of . . O
dalvance . . O
can . . B-Factor
cause . . O
reactions . . O
that . . O
resemble . . O
" . . O
red . . B-AdverseReaction
- . . I-AdverseReaction
man . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
" . . O
including . . O
flushing . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
upper . . I-AdverseReaction
body . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
rash . . B-AdverseReaction
. . . O

monitor . . O
closely . . O
. . . O

5.1 . . O
transaminase . . O
( . . O
alt . . O
or . . O
ast . . O
) . . O
elevations . . O

table . . O
3 . . O
compares . . O
the . . O
incidence . . O
of . . O
the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
from . . O
a . . O
single . . O
treatment . . O
cycle . . O
of . . O
500 . . O
units . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
compared . . O
to . . O
placebo . . O
[ . . O
seeclinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

in . . O
an . . O
open . . O
- . . O
label . . O
qtc . . O
study . . O
in . . O
patients . . O
with . . O
schizophrenia . . O
or . . O
schizoaffective . . O
disorder . . O
( . . O
n . . O
= . . O
160 . . O
) . . O
, . . O
fanapt . . O
was . . O
associated . . O
with . . O
qtc . . B-AdverseReaction
prolongation . . I-AdverseReaction
of . . O
9 . . O
msec . . O
at . . O
an . . O
iloperidone . . O
dose . . O
of . . O
12 . . O
mg . . O
twice . . O
daily . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reaction . . O
resulting . . O
in . . O
permanent . . O
discontinuation . . O
was . . O
pyrexia . . B-AdverseReaction
( . . O
4% . . O
) . . O
. . . O

a . . O
total . . O
of . . O
2,034 . . O
subjects . . O
with . . O
copd . . O
received . . O
at . . O
least . . O
1 . . O
dose . . O
of . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
, . . O
and . . O
1,087 . . O
subjects . . O
received . . O
a . . O
higher . . O
strength . . O
of . . O
fluticasone . . O
furoate . . O
/ . . O
vilanterol . . O
. . . O

before . . O
initiating . . O
jardiance . . O
, . . O
assess . . O
for . . O
volume . . O
contraction . . O
and . . O
correct . . O
volume . . O
status . . O
if . . O
indicated . . O
. . . O

* . . O
macrovascular . . O
outcomes . . O
: . . O
there . . O
have . . O
been . . O
no . . O
studies . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
trulicity . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
( . . O
5.7 . . O
) . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
direct . . B-AdverseReaction
coombs' . . I-AdverseReaction
test . . I-AdverseReaction
seroconversion . . I-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
teflaro . . O
. . . O

serious . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O

5.1 . . O
hypotension . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
- . . O
hyperglycemia . . B-AdverseReaction
, . . O
hyperkalemia . . B-AdverseReaction

5.11 . . O
dysphagia . . O

baseline . . O
renal . . O
function . . O
was . . O
normal . . O
or . . O
mildly . . O
impaired . . O
( . . O
mean . . O
egfr . . O
81 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
. . . O

there . . O
is . . O
insufficient . . O
information . . O
to . . O
characterize . . O
the . . O
risks . . O
of . . O
resumption . . O
of . . O
xalkori . . O
in . . O
patients . . O
with . . O
a . . O
severe . . O
visual . . O
loss . . O
; . . O
a . . O
decision . . O
to . . O
resume . . O
xalkori . . O
should . . O
consider . . O
the . . O
potential . . O
benefits . . O
to . . O
the . . O
patient . . O
. . . O

warning . . O
: . . O
fetal . . B-AdverseReaction
toxicity . . I-AdverseReaction

5.7 . . O
elevated . . O
liver . . O
enzymes . . O

autoimmune . . B-AdverseReaction
disorders . . I-AdverseReaction
( . . O
such . . O
as . . O
graves' . . B-AdverseReaction
disease . . I-AdverseReaction
, . . O
polymyositis . . B-AdverseReaction
, . . O
and . . O
guillain . . B-AdverseReaction
- . . I-AdverseReaction
barre . . I-AdverseReaction
syndrome . . I-AdverseReaction
) . . O
have . . O
also . . O
been . . O
reported . . O
to . . O
occur . . O
in . . O
the . . O
setting . . O
of . . O
immune . . O
reconstitution . . O
, . . O
however . . O
, . . O
the . . O
time . . O
to . . O
onset . . O
is . . O
more . . O
variable . . O
, . . O
and . . O
can . . O
occur . . O
many . . O
months . . O
after . . O
initiation . . O
of . . O
treatment . . O
. . . O

among . . O
the . . O
factors . . O
that . . O
may . . O
increase . . O
the . . O
risk . . B-Factor
for . . O
nsf . . B-AdverseReaction
are . . O
repeated . . O
or . . O
higher . . O
than . . O
recommended . . O
doses . . O
of . . O
a . . O
gbca . . O
and . . O
degree . . O
of . . O
renal . . O
impairment . . O
at . . O
the . . O
time . . O
of . . O
exposure . . O
. . . O

vascular . . O
disorder . . O
: . . O
systemic . . B-AdverseReaction
vasculitis . . I-AdverseReaction
has . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
. . . O

ensure . . O
safe . . O
handling . . O
to . . O
protect . . O
patients . . O
and . . O
health . . O
care . . O
workers . . O
from . . O
unintentional . . O
radiation . . O
exposure . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

across . . O
repeated . . O
treatment . . O
in . . O
the . . O
controlled . . O
trials . . O
, . . O
4 . . O
patients . . O
tested . . O
positive . . O
for . . O
anti . . O
- . . O
icatibant . . O
antibodies . . O
. . . O

6 . . O
adverse . . O
reactions . . O

do . . O
not . . O
use . . O
if . . O
the . . O
blister . . O
package . . O
has . . O
been . . O
open . . O
for . . O
more . . O
than . . O
60 . . O
days . . O
. . . O

generally . . O
milder . . O
withdrawal . . O
symptoms . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
dysphoria . . O
, . . O
anxiety . . O
, . . O
and . . O
insomnia . . O
) . . O
have . . O
been . . O
reported . . O
following . . O
abrupt . . O
discontinuance . . O
of . . O
benzodiazepines . . O
taken . . O
continuously . . O
at . . O
therapeutic . . O
doses . . O
for . . O
several . . O
months . . O
. . . O

grade . . B-Severity
3 . . I-Severity
/ . . O
4 . . O
venous . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
were . . O
reported . . O
in . . O
9 . . O
/ . . O
359 . . O
patients . . O
( . . O
3% . . O
) . . O
receiving . . O
inlyta . . O
( . . O
including . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
, . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
, . . O
retinal . . B-AdverseReaction
vein . . I-AdverseReaction
occlusion . . I-AdverseReaction
and . . O
retinal . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
) . . O
and . . O
2 . . O
/ . . O
355 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
four . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
mean . . O
changes . . O
( . . O
percent . . O
changes . . O
) . . O
from . . O
baseline . . O
in . . O
hemoglobin . . O
were . . O
- . . O
0.18 . . O
g . . O
/ . . O
dl . . O
( . . O
- . . O
1.1% . . O
) . . O
with . . O
placebo . . O
, . . O
0.47 . . B-Severity
g . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
3.5% . . O
) . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
0.51 . . B-Severity
g . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
3.8% . . O
) . . O
with . . O
invokana . . O
300 . . O
mg . . O
. . . O

study . . O
1 . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
bayer . . O
healthcare . . O
pharmaceuticals . . O
inc . . O
. . . O
at . . O
1-888-84 . . O
- . . O
bayer . . O
( . . O
1-888-842-2937 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

ask . . O
your . . O
healthcare . . O
provider . . O
if . . O
you . . O
do . . O
not . . O
know . . O
if . . O
you . . O
take . . O
any . . O
of . . O
these . . O
medicines . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
such . . O
as . . O
anaphylaxis . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
urticaria . . B-AdverseReaction
may . . B-Factor
occur . . O
after . . O
administration . . O
of . . O
breo . . O
ellipta . . O
. . . O

excerpt . . O
: . . O
seizure . . B-AdverseReaction
occurred . . O
in . . O
0.9% . . O
of . . O
patients . . O
receiving . . O
xtandi . . O
who . . O
previously . . O
received . . O
docetaxel . . O
and . . O
in . . O
0.1% . . O
of . . O
patients . . O
who . . O
were . . O
chemotherapy . . O
- . . O
naive . . O
. . . O

in . . O
most . . O
cases . . O
, . . O
initial . . O
symptoms . . O
occurred . . O
within . . O
minutes . . O
of . . O
dotarem . . O
administration . . O
and . . O
resolved . . O
with . . O
prompt . . O
emergency . . O
treatment . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
intestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
occurred . . O
in . . O
zydelig . . O
- . . O
treated . . O
patients . . O
. . . O

for . . O
patients . . O
who . . O
develop . . O
prolonged . . O
grade . . O
2 . . O
diarrhea . . O
lasting . . O
more . . O
than . . O
48 . . O
hours . . O
or . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
grade . . O
3 . . O
diarrhea . . O
, . . O
withhold . . O
gilotrif . . O
until . . O
diarrhea . . O
resolves . . O
to . . O
grade . . O
1 . . O
or . . O
less . . O
, . . O
and . . O
resume . . O
gilotrif . . O
with . . O
appropriate . . O
dose . . O
reduction . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

less . . O
common . . O
adverse . . O
reactions . . O

in . . O
patients . . O
anticoagulated . . O
or . . O
to . . O
be . . O
anticoagulated . . O
[ . . O
see . . O
warnings . . O

less . . O
common . . O
adverse . . O
reactions . . O
: . . O
the . . O
following . . O
additional . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
> . . O
= . . O
5% . . O
to . . O
< . . O
10% . . O
of . . O
the . . O
halaven . . O
- . . O
treated . . O
group . . O
: . . O

( . . O
5.4 . . O
) . . O
* . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
beleodaq . . O
may . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

b . . O
grade . . B-Severity
4 . . I-Severity
adverse . . O
reactions . . O
limited . . O
to . . O
hyperkeratosis . . B-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
and . . O
constipation . . B-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
. . . O

excessive . . O
use . . O
or . . O
use . . O
in . . O
conjunction . . O
with . . O
other . . O
medications . . O
containing . . O
laba . . B-DrugClass
can . . O
result . . O
in . . O
clinically . . O
significant . . B-Severity
cardiovascular . . B-AdverseReaction
effects . . I-AdverseReaction
and . . O
may . . O
be . . O
fatal . . B-AdverseReaction
( . . O
5.3 . . O
) . . O
* . . O
immediate . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
may . . B-Factor
occur . . O
. . . O

local . . B-AdverseReaction
skin . . I-AdverseReaction
reactions . . I-AdverseReaction
typically . . O
occurred . . O
within . . O
1 . . O
day . . O
of . . O
treatment . . O
initiation . . O
, . . O
peaked . . O
in . . O
intensity . . O
up . . O
to . . O
1 . . O
week . . O
following . . O
completion . . O
of . . O
treatment . . O
, . . O
and . . O
resolved . . O
within . . O
2 . . O
weeks . . O
for . . O
areas . . O
treated . . O
on . . O
the . . O
face . . O
and . . O
scalp . . O
, . . O
and . . O
within . . O
4 . . O
weeks . . O
for . . O
areas . . O
treated . . O
on . . O
the . . O
trunk . . O
and . . O
extremities . . O
. . . O

serious . . B-Severity
and . . O
sometimes . . O
fatal . . B-AdverseReaction
infections . . O
, . . O
including . . O
pneumonia . . B-AdverseReaction
and . . O
sepsis . . B-AdverseReaction
, . . O
have . . O
occurred . . O
with . . O
beleodaq . . O
. . . O

these . . O
metabolic . . B-AdverseReaction
changes . . I-AdverseReaction
include . . O
hyperglycemia . . B-AdverseReaction
, . . O
dyslipidemia . . B-AdverseReaction
, . . O
and . . O
body . . B-AdverseReaction
weight . . I-AdverseReaction
gain . . I-AdverseReaction
. . . O

cleviprex . . O
is . . O
not . . O
a . . O
beta . . O
- . . O
blocker . . O
, . . O
does . . O
not . . O
reduce . . O
heart . . O
rate . . O
, . . O
and . . O
gives . . O
no . . O
protection . . O
against . . O
the . . O
effects . . O
of . . O
abrupt . . O
beta . . O
- . . O
blocker . . O
withdrawal . . O
. . . O

inlyta . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
who . . O
had . . O
an . . O
arterial . . O
thromboembolic . . O
event . . O
within . . O
the . . O
previous . . O
12 . . O
months . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
chills . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
, . . O
multi . . B-AdverseReaction
- . . I-AdverseReaction
organ . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

median . . O
exposure . . O
in . . O
days . . O
for . . O
pooled . . O
studies . . O
: . . O
1203 . . O
for . . O
nulojix . . O
recommended . . O
regimen . . O
and . . O
1163 . . O
for . . O
cyclosporine . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
. . . O
? . . O

patients . . O
with . . O
hypovolemia . . O
may . . O
be . . O
more . . O
susceptible . . O
to . . O
these . . O
changes . . O
. . . O

therefore . . O
, . . O
use . . O
of . . O
benlysta . . O
is . . O
not . . O
recommended . . O
in . . O
combination . . O
with . . O
biologic . . O
therapies . . O
or . . O
intravenous . . O
cyclophosphamide . . O
. . . O

5.9 . . O
hyperglycemia . . O

before . . O
prescribing . . O
stendra . . O
, . . O
it . . O
is . . O
important . . O
to . . O
note . . O
the . . O
following . . O
: . . O

the . . O
median . . O
age . . O
of . . O
patients . . O
was . . O
61 . . O
years . . O
( . . O
range . . O
27-85 . . O
) . . O
, . . O
88% . . O
were . . O
caucasian . . O
, . . O
and . . O
78% . . O
were . . O
male . . O
. . . O

fatigue . . B-AdverseReaction
/ . . O
asthenia . . B-AdverseReaction
was . . O
reported . . O
in . . O
6% . . O
of . . O
patients . . O
treated . . O
with . . O
1,200 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
compared . . O
with . . O
1% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

5.7 . . O
laboratory . . O
tests . . O

discontinue . . O
jevtana . . O
immediately . . O
if . . O
severe . . O
reactions . . O
occur . . O
and . . O
administer . . O
appropriate . . O
therapy . . O
. . . O

gastrointestinal . . O
( . . O
gi . . O
) . . O
perforations . . O
and . . O
fistulas . . O
were . . O
reported . . O
in . . O
3% . . O
and . . O
1% . . O
of . . O
cometriq . . O
- . . O
treated . . O
patients . . O
, . . O
respectively . . O
. . . O

no . . O
fractures . . B-AdverseReaction
occurred . . O
in . . O
the . . O
placebo . . O
group . . O
, . . O
5 . . O
occurred . . O
in . . O
the . . O
farxiga . . O
5 . . O
mg . . O
group . . O
, . . O
and . . O
8 . . O
occurred . . O
in . . O
the . . O
farxiga . . O
10 . . O
mg . . O
group . . O
. . . O

individuals . . O
with . . O
peripheral . . O
motor . . O
neuropathic . . O
diseases . . O
, . . O
amyotrophic . . O
lateral . . O
sclerosis . . O
or . . O
neuromuscular . . O
junction . . O
disorders . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
myasthenia . . O
gravis . . O
or . . O
lambert . . O
- . . O
eaton . . O
syndrome . . O
) . . O
should . . O
be . . O
monitored . . O
particularly . . O
closely . . O
when . . O
given . . O
botulinum . . O
toxin . . O
. . . O

table . . O
3 . . O
per . . O
- . . O
patient . . O
incidence . . O
of . . O
hypertension . . B-AdverseReaction
in . . O
protocol . . O
xl184-301 . . O
hypertension . . B-AdverseReaction
, . . O
jncstage . . O
cometriqn . . O
= . . O
211 . . O
( . . O
% . . O
) . . O
placebon . . O
= . . O
107 . . O
( . . O
% . . O
) . . O
normal . . O
: . . O
grade . . O
0 . . O
: . . O
systolic . . O
< . . O
120 . . O
mmhg . . O
and . . O
diastolic . . O
< . . O
80 . . O
mmhg . . O
4 . . O
15 . . O
pre . . B-AdverseReaction
- . . I-AdverseReaction
hypertension . . I-AdverseReaction
: . . O
systolic . . O
> . . O
= . . O
120 . . O
mmhg . . O
or . . O
diastolic . . O
> . . O
= . . O
80 . . O
mmhg . . O
34 . . O
54 . . O
stage . . O
1 . . O
: . . O
systolic . . O
> . . O
= . . O
140 . . O
mmhg . . O
or . . O
diastolic . . O
> . . O
= . . O
90 . . O
mmhg . . O
46 . . O
25 . . O
stage . . O
2 . . O
: . . O
systolic . . O
> . . O
= . . O
160 . . O
mmhg . . O
or . . O
diastolic . . O
> . . O
= . . O
100 . . O
mmhg . . O
15 . . O
5 . . O
malignant . . O
: . . O
diastolic . . O
> . . O
= . . O
120 . . O
mmhg . . O
0 . . O
0 . . O

patients . . O
with . . O
these . . O
diagnoses . . O
were . . O
excluded . . O
from . . O
pre . . O
- . . O
marketing . . O
clinical . . O
trials . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
( . . O
penile . . B-AdverseReaction
fracture . . I-AdverseReaction
) . . O
or . . O
other . . O
serious . . B-Severity
injury . . B-AdverseReaction
to . . I-AdverseReaction
the . . I-AdverseReaction
penis . . I-AdverseReaction
: . . O
avoid . . O
injecting . . O
into . . O
the . . O
urethra . . O
, . . O
nerves . . O
, . . O
blood . . O
vessels . . O
, . . O
corpora . . O
cavernosa . . O
or . . O
other . . O
collagen . . O
- . . O
containing . . O
structures . . O
of . . O
the . . O
penis . . O
. . . O

aptiom . . O
should . . O
be . . O
discontinued . . O
and . . O
not . . O
be . . O
resumed . . O
if . . O
an . . O
alternative . . O
etiology . . O
for . . O
the . . O
signs . . O
or . . O
symptoms . . O
cannot . . O
be . . O
established . . O
. . . O

table . . O
7 . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
hemorrhage . . B-AdverseReaction
: . . O
major . . B-Severity
hemorrhagic . . B-AdverseReaction
events . . I-AdverseReaction
can . . B-Factor
occur . . O
in . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

consultation . . O
with . . O
a . . O
physician . . O
with . . O
expertise . . O
in . . O
the . . O
treatment . . O
of . . O
tuberculosis . . O
is . . O
recommended . . O
to . . O
aid . . O
in . . O
the . . O
decision . . O
whether . . O
initiating . . O
anti . . O
- . . O
tuberculosis . . O
therapy . . O
is . . O
appropriate . . O
for . . O
an . . O
individual . . O
patient . . O
. . . O

after . . O
adjusting . . O
for . . O
age . . O
and . . O
sex . . O
, . . O
the . . O
mean . . O
change . . O
from . . O
baseline . . O
to . . O
endpoint . . O
in . . O
weight . . O
z . . O
- . . O
score . . O
for . . O
saphrs . . O
2.5 . . O
mg . . O
, . . O
5 . . O
mg . . O
, . . O
and . . O
10 . . O
mg . . O
twice . . O
daily . . O
, . . O
was . . O
0.11 . . O
, . . O
0.08 . . O
and . . O
0.09 . . O
sd . . O
versus . . O
0.02 . . O
sd . . O
for . . O
placebo . . O
, . . O
respectively . . O
. . . O

the . . O
safety . . O
of . . O
beleodaq . . O
was . . O
evaluated . . O
in . . O
129 . . O
patients . . O
with . . O
relapsed . . O
or . . O
refractory . . O
ptcl . . O
in . . O
the . . O
single . . O
arm . . O
clinical . . O
trial . . O
in . . O
which . . O
patients . . O
were . . O
administered . . O
beleodaq . . O
at . . O
a . . O
dosage . . O
of . . O
1,000 . . O
mg . . O
/ . . O
m2 . . O
administered . . O
over . . O
30 . . O
minutes . . O
by . . O
iv . . O
infusion . . O
once . . O
daily . . O
on . . O
days . . O
1-5 . . O
of . . O
a . . O
21 . . O
- . . O
day . . O
cycle . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

kyprolis . . O
can . . B-Factor
cause . . O
increased . . B-AdverseReaction
serum . . I-AdverseReaction
transaminases . . I-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O

in . . O
premarketing . . O
controlled . . O
trials . . O
of . . O
all . . O
patient . . O
populations . . O
combined . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
8% . . O
) . . O
were . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
18% . . O
) . . O
, . . O
rash . . B-AdverseReaction
( . . O
9% . . O
) . . O
and . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
8% . . O
) . . O
. . . O

sirturo . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
ventricular . . O
arrhythmias . . O
or . . O
recent . . O
myocardial . . O
infarction . . O
. . . O

in . . O
the . . O
two . . O
well . . O
- . . O
controlled . . O
studies . . O
demonstrating . . O
effectiveness . . O
, . . O
1529 . . O
patients . . O
received . . O
tecfidera . . O
with . . O
an . . O
overall . . O
exposure . . O
of . . O
2244 . . O
person . . O
- . . O
years . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

consider . . O
dose . . O
adjustment . . O
in . . O
patients . . O
with . . O
baseline . . O
and . . O
treatment . . O
emergent . . O
renal . . O
impairment . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.7 . . O
) . . O
] . . O
. . . O

if . . O
symptoms . . O
are . . O
moderate . . O
, . . O
consider . . O
interrupting . . O
therapy . . O
until . . O
symptoms . . O
improve . . O
. . . O

teflaro . . O
was . . O
evaluated . . O
in . . O
four . . O
controlled . . O
comparative . . O
phase . . O
3 . . O
clinical . . O
trials . . O
( . . O
two . . O
in . . O
absssi . . O
and . . O
two . . O
in . . O
cabp . . O
) . . O
which . . O
included . . O
1300 . . O
adult . . O
patients . . O
treated . . O
with . . O
teflaro . . O
( . . O
600 . . O
mg . . O
administered . . O
by . . O
iv . . O
over . . O
1 . . O
hour . . O
every . . O
12h . . O
) . . O
and . . O
1297 . . O
patients . . O
treated . . O
with . . O
comparator . . O
( . . O
vancomycin . . O
plus . . O
aztreonam . . O
or . . O
ceftriaxone . . O
) . . O
for . . O
a . . O
treatment . . O
period . . O
up . . O
to . . O
21 . . O
days . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

therefore . . O
, . . O
patients . . O
using . . O
oral . . O
, . . O
transdermal . . O
patch . . O
, . . O
or . . O
other . . O
systemic . . O
hormonal . . O
contraceptives . . O
should . . O
be . . O
advised . . O
to . . O
use . . O
an . . O
additional . . O
non . . O
- . . O
hormonal . . O
method . . O
of . . O
birth . . O
control . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.5 . . O
) . . O
] . . O
. . . O

table . . O
1 . . O
shows . . O
common . . O
adverse . . O
reactions . . O
, . . O
excluding . . O
hypoglycemia . . B-AdverseReaction
, . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
trulicity . . O
in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

instruct . . O
the . . O
patient . . O
to . . O
immediately . . O
discontinue . . O
ferriprox . . O
and . . O
all . . O
other . . O
medications . . O
with . . O
a . . O
potential . . O
to . . O
cause . . O
neutropenia . . O
. . . O

approximately . . O
half . . O
the . . O
cases . . O
were . . O
lymphomas . . B-AdverseReaction
, . . O
including . . O
hodgkin's . . O
and . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
hodgkin's . . I-AdverseReaction
lymphoma . . I-AdverseReaction
. . . O

the . . O
safety . . O
of . . O
resuming . . O
tnf . . O
- . . O
blockers . . O
after . . O
hbv . . O
reactivation . . O
has . . O
been . . O
controlled . . O
is . . O
not . . O
known . . O
. . . O

excerpt . . O
: . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
followed . . O
adreview . . O
administration . . O
. . . O

the . . O
need . . O
for . . O
continued . . O
treatment . . O
should . . O
be . . O
reassessed . . O
periodically . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
hepatotoxicity . . B-AdverseReaction
may . . B-Factor
occur . . O
with . . O
use . . O
of . . O
sirturo . . O
. . . O

patients . . O
with . . O
thyroid . . O
nodules . . O
noted . . O
on . . O
physical . . O
examination . . O
or . . O
neck . . O
imaging . . O
should . . O
also . . O
be . . O
further . . O
evaluated . . O
. . . O

autoimmune . . O
disorders . . O
and . . O
autoantibodies . . O

acute . . O
symptoms . . O
should . . O
be . . O
treated . . O
with . . O
an . . O
inhaled . . O
, . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonist . . O
. . . O

somnolence . . B-AdverseReaction
/ . . O
sedation . . B-AdverseReaction
led . . O
to . . O
withdrawal . . O
in . . O
2% . . O
of . . O
patients . . O
receiving . . O
600 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
. . . O

adverse . . O
reactions . . O
that . . O
led . . O
to . . O
dose . . O
modifications . . O
of . . O
any . . O
drug . . O
( . . O
primarily . . O
pegintron . . O
and . . O
rebetol . . O
) . . O
occurred . . O
in . . O
39% . . O
of . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
compared . . O
to . . O
24% . . O
of . . O
subjects . . O
receiving . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
. . . O

nervous . . O
system . . O
disorders . . O
: . . O
dizziness . . B-AdverseReaction

there . . O
are . . O
no . . O
data . . O
on . . O
the . . O
risks . . O
of . . O
using . . O
cimzia . . O
in . . O
patients . . O
who . . O
have . . O
experienced . . O
a . . O
severe . . O
hypersensitivity . . O
reaction . . O
towards . . O
another . . O
tnf . . O
blocker . . O
; . . O
in . . O
these . . O
patients . . O
caution . . O
is . . O
needed . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

a . . O
total . . O
of . . O
725 . . O
men . . O
were . . O
exposed . . O
to . . O
placebo . . O
and . . O
731 . . O
men . . O
were . . O
exposed . . O
to . . O
prolia . . O
administered . . O
once . . O
every . . O
6 . . O
months . . O
as . . O
a . . O
single . . O
60 . . O
mg . . O
subcutaneous . . O
dose . . O
. . . O

the . . O
most . . O
common . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
grade . . B-Severity
3-4 . . I-Severity
adverse . . O
reactions . . O
in . . O
patients . . O
who . . O
received . . O
jevtana . . O
were . . O
neutropenia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
asthenia . . B-AdverseReaction
. . . O

prolia . . O
contains . . O
the . . O
same . . O
active . . O
ingredient . . O
( . . O
denosumab . . O
) . . O
found . . O
in . . O
xgeva . . O
. . . O

severe . . B-Severity
priapism . . B-AdverseReaction
may . . O
require . . O
surgical . . O
intervention . . O
. . . O

osteonecrosis . . O
of . . O
the . . O
jaw . . O
no . . B-Negation
cases . . O
of . . O
onj . . B-AdverseReaction
were . . O
reported . . O
. . . O

the . . O
following . . O
events . . O
occurred . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
patients . . O
in . . O
the . . O
three . . O
placebo . . O
- . . O
controlled . . O
3 . . O
- . . O
month . . O
clinical . . O
trials . . O
and . . O
/ . . O
or . . O
the . . O
open . . O
- . . O
label . . O
, . . O
long . . O
- . . O
term . . O
extension . . O
study . . O
lasting . . O
12 . . O
months . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
increased . . B-AdverseReaction
susceptibility . . I-AdverseReaction
to . . I-AdverseReaction
infection . . I-AdverseReaction
and . . O
the . . O
possible . . O
development . . O
of . . O
malignancies . . B-AdverseReaction
may . . B-Factor
result . . O
from . . O
immunosuppression . . O
. . . O

6.1 . . O
clinical . . O
trial . . O
experience . . O

* . . O
eye . . O
disorders . . O
: . . O
infrequent . . O
: . . O
diplopia . . B-AdverseReaction
, . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
* . . O
gastrointestinal . . O
disorders . . O
: . . O
infrequent . . O
: . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
* . . O
injury . . O
, . . O
poisoning . . O
, . . O
and . . O
procedural . . O
complications . . O
: . . O
infrequent . . O
: . . O
fall . . B-AdverseReaction
* . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
infrequent . . O
: . . O
photosensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
* . . O
renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
infrequent . . O
: . . O
enuresis . . B-AdverseReaction
6.2 . . O
postmarketing . . O
experience . . O
the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
saphris . . O
. . . O

approximately . . O
50% . . O
of . . O
the . . O
subjects . . O
were . . O
male . . O
and . . O
the . . O
ethnic . . O
distribution . . O
was . . O
60% . . O
caucasian . . O
, . . O
30% . . O
asian . . O
, . . O
6% . . O
hispanic . . O
, . . O
2% . . O
black . . O
, . . O
and . . O
3% . . O
patients . . O
of . . O
other . . O
ethnic . . O
groups . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
imbruvica . . O
in . . O
a . . O
clinical . . O
trial . . O
that . . O
included . . O
111 . . O
patients . . O
with . . O
previously . . O
treated . . O
mcl . . O
treated . . O
with . . O
560 . . O
mg . . O
daily . . O
with . . O
a . . O
median . . O
treatment . . O
duration . . O
of . . O
8.3 . . O
months . . O
. . . O

in . . O
patients . . O
with . . O
confirmed . . O
pml . . O
, . . O
consider . . O
stopping . . O
immunosuppressant . . O
therapy . . O
, . . O
including . . O
benlysta . . O
. . . O

monitor . . O
renal . . O
function . . O
periodically . . O
. . . O

reduction . . O
of . . O
risk . . O
of . . O
stroke . . O
and . . O
systemic . . O
embolism . . O
in . . O
patients . . O
with . . O
nonvalvular . . O
atrial . . O
fibrillation . . O

stop . . O
simponi . . O
aria . . O
if . . O
new . . O
or . . O
worsening . . O
symptoms . . O
occur . . O
( . . O
5.3 . . O
) . . O
. . . O

based . . O
on . . O
the . . O
clinical . . O
trial . . O
experience . . O
, . . O
ilaris . . O
does . . O
not . . O
appear . . O
to . . O
increase . . O
the . . O
incidence . . O
of . . O
mas . . B-AdverseReaction
in . . O
sjia . . O
patients . . O
, . . O
but . . O
no . . B-Factor
definitive . . I-Factor
conclusion . . I-Factor
can . . O
be . . O
made . . O
. . . O

* . . O
somnolence . . B-AdverseReaction
or . . O
sedation . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
potentiation . . B-AdverseReaction
of . . I-AdverseReaction
sedation . . I-AdverseReaction
from . . O
concomitant . . O
use . . O
with . . O
central . . O
nervous . . O
system . . O
depressants . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
withdrawal . . O
symptoms . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
serious . . B-Severity
dermatological . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
physical . . O
and . . O
psychological . . B-AdverseReaction
dependence . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
and . . O
ideation . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
excerpt . . O
: . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
at . . O
least . . O
10% . . O
more . . O
frequently . . O
than . . O
placebo . . O
in . . O
any . . O
onfi . . O
dose . . O
included . . O
constipation . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
or . . O
sedation . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
lethargy . . B-AdverseReaction
, . . O
and . . O
drooling . . B-AdverseReaction
( . . O
6.1 . . O
) . . O

cases . . O
of . . O
reactivation . . B-AdverseReaction
of . . I-AdverseReaction
tuberculosis . . I-AdverseReaction
or . . O
new . . B-AdverseReaction
tuberculosis . . I-AdverseReaction
infections . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
patients . . O
receiving . . O
tnf . . O
- . . O
blockers . . O
, . . O
including . . O
patients . . O
who . . O
have . . O
previously . . O
received . . O
treatment . . O
for . . O
latent . . O
or . . O
active . . O
tuberculosis . . O
. . . O

eye . . O
events . . O
were . . O
serious . . B-Severity
in . . O
0.7% . . O
of . . O
aptiom . . O
- . . O
treated . . O
patients . . O
( . . O
and . . O
0 . . O
placebo . . O
patients . . O
) . . O
and . . O
led . . O
to . . O
discontinuation . . O
in . . O
4% . . O
of . . O
aptiom . . O
- . . O
treated . . O
patients . . O
( . . O
and . . O
0.2% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
) . . O
. . . O

* . . O
risk . . B-Factor
of . . O
ptosis . . B-AdverseReaction
( . . O
5.7 . . O
) . . O
. . . O

if . . O
abnormalities . . O
are . . O
detected . . O
, . . O
monitoring . . O
of . . O
these . . O
parameters . . O
should . . O
be . . O
continued . . O
to . . O
ensure . . O
that . . O
further . . O
deterioration . . O
does . . O
not . . O
occur . . O
. . . O

to . . O
avoid . . O
transfer . . O
of . . O
the . . O
drug . . O
into . . O
the . . O
eyes . . O
and . . O
to . . O
the . . O
periocular . . O
area . . O
during . . O
and . . O
after . . O
application . . O
, . . O
patients . . O
should . . O
wash . . O
hands . . O
well . . O
after . . O
applying . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
. . . O

if . . O
drug . . O
- . . O
induced . . O
hemolytic . . O
anemia . . O
is . . O
suspected . . O
, . . O
discontinuation . . O
of . . O
teflaro . . O
should . . O
be . . O
considered . . O
and . . O
supportive . . O
care . . O
should . . O
be . . O
administered . . O
to . . O
the . . O
patient . . O
( . . O
i . . O
. . . O
e . . O
. . . O
transfusion . . O
) . . O
if . . O
clinically . . O
indicated . . O
. . . O

* . . O
d . . O
event . . O
requiring . . O
another . . O
person . . O
to . . O
administer . . O
a . . O
resuscitative . . O
action . . O
. . . O

5.5 . . O
urinary . . O
tract . . O
infections . . O

fungal . . B-AdverseReaction
infections . . I-AdverseReaction
were . . O
reported . . O
in . . O
18% . . O
of . . O
patients . . O
receiving . . O
nulojix . . O
compared . . O
to . . O
22% . . O
receiving . . O
cyclosporine . . O
, . . O
primarily . . O
due . . O
to . . O
skin . . O
and . . O
mucocutaneous . . B-AdverseReaction
fungal . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

use . . O
of . . O
cerdelga . . O
in . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
cardiac . . O
conditions . . O
has . . O
not . . O
been . . O
studied . . O
during . . O
clinical . . O
trials . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

there . . O
was . . O
no . . O
apparent . . O
pattern . . O
with . . O
respect . . O
to . . O
the . . O
anatomic . . O
site . . O
of . . O
fracture . . B-AdverseReaction
. . . O

hyperglycemia . . B-AdverseReaction
can . . B-Factor
occur . . O
in . . O
patients . . O
receiving . . O
zykadia . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
antibodies . . O
to . . O
denosumab . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

patients . . O
with . . O
pre . . O
- . . O
existing . . O
swallowing . . O
or . . O
breathing . . O
difficulties . . O
may . . O
be . . O
more . . O
susceptible . . O
to . . O
these . . O
complications . . O
. . . O

table . . O
2 . . O
. . . O

in . . O
order . . O
to . . O
reduce . . O
the . . O
complication . . O
of . . O
ptosis . . O
the . . O
following . . O
steps . . O
should . . O
be . . O
taken . . O
: . . O

5.1 . . O
hypersensitivity . . O
reactions . . O

additionally . . O
, . . O
placebo . . O
- . . O
adjusted . . O
bmd . . O
declines . . O
were . . O
0.1% . . B-Severity
at . . O
the . . O
femoral . . O
neck . . O
for . . O
both . . O
invokana . . O
doses . . O
and . . O
0.4% . . B-Severity
at . . O
the . . O
distal . . O
forearm . . O
for . . O
patients . . O
randomized . . O
to . . O
invokana . . O
300 . . O
mg . . O
. . . O

treatment . . O
discontinuations . . O
due . . O
to . . O
adverse . . O
drug . . O
reactions . . O
occurred . . O
in . . O
18% . . O
of . . O
patients . . O
who . . O
received . . O
jevtana . . O
and . . O
8% . . O
of . . O
patients . . O
who . . O
received . . O
mitoxantrone . . O
. . . O

the . . O
pooled . . O
analyses . . O
of . . O
placebo . . O
- . . O
controlled . . O
studies . . O
in . . O
adults . . O
with . . O
mdd . . O
or . . O
other . . O
psychiatric . . O
disorders . . O
included . . O
a . . O
total . . O
of . . O
295 . . O
short . . O
- . . O
term . . O
studies . . O
( . . O
median . . O
duration . . O
of . . O
2 . . O
months . . O
) . . O
of . . O
11 . . O
antidepressant . . O
drugs . . O
in . . O
over . . O
77,000 . . O
patients . . O
. . . O

severe . . B-Severity
diarrhea . . B-AdverseReaction
or . . O
colitis . . B-AdverseReaction
( . . O
grade . . B-Severity
3 . . I-Severity
or . . O
higher . . O
) . . O
occurred . . O
in . . O
14% . . O
of . . O
zydelig . . O
- . . O
treated . . O
patients . . O
across . . O
clinical . . O
trials . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reactions . . O
( . . O
occurring . . O
in . . O
greater . . O
than . . O
1% . . O
of . . O
patients . . O
and . . O
at . . O
a . . O
higher . . O
rate . . O
with . . O
firazyr . . O
versus . . O
placebo . . O
) . . O
are . . O
shown . . O
in . . O
table . . O
1 . . O
. . . O

prolonged . . O
use . . O
of . . O
corticosteroids . . B-DrugClass
may . . O
suppress . . B-AdverseReaction
the . . I-AdverseReaction
host . . I-AdverseReaction
response . . I-AdverseReaction
and . . O
thus . . O
increase . . O
the . . O
hazard . . O
of . . O
secondary . . B-AdverseReaction
ocular . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

prolonged . . O
exposure . . O
to . . O
elevated . . O
plasma . . O
ammonia . . O
levels . . O
can . . O
rapidly . . O
result . . O
in . . O
injury . . O
to . . O
the . . O
brain . . O
or . . O
death . . O
. . . O

in . . O
these . . O
trials . . O
6% . . O
of . . O
patients . . O
on . . O
potiga . . O
and . . O
1.2% . . O
on . . O
placebo . . O
discontinued . . O
treatment . . O
because . . O
of . . O
dizziness . . B-AdverseReaction
; . . O
3% . . O
of . . O
patients . . O
on . . O
potiga . . O
and . . O
< . . O
1.0% . . O
on . . O
placebo . . O
discontinued . . O
because . . O
of . . O
somnolence . . B-AdverseReaction
. . . O

musculoskeletal . . O
disorders . . O
: . . O
myositis . . B-AdverseReaction
. . . O

if . . O
appropriate . . O
, . . O
initiation . . O
of . . O
anti . . O
- . . O
hepatitis . . O
b . . O
therapy . . O
may . . O
be . . O
warranted . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

in . . O
the . . O
placebo . . O
- . . O
controlled . . O
epilepsy . . O
trials . . O
, . . O
" . . O
urinary . . B-AdverseReaction
retention . . I-AdverseReaction
, . . O
" . . O
" . . O
urinary . . B-AdverseReaction
hesitation . . I-AdverseReaction
, . . O
" . . O
and . . O
" . . O
dysuria . . B-AdverseReaction
" . . O
were . . O
reported . . O
in . . O
0.9% . . O
, . . O
2.2% . . O
, . . O
and . . O
2.3% . . O
of . . O
patients . . O
on . . O
potiga . . O
, . . O
respectively . . O
, . . O
and . . O
in . . O
0.5% . . O
, . . O
0.9% . . O
, . . O
and . . O
0.7% . . O
of . . O
patients . . O
on . . O
placebo . . O
, . . O
respectively . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction
: . . O
may . . O
necessitate . . O
further . . O
evaluation . . O
and . . O
treatment . . O
. . . O

5.11 . . O
immunosuppression . . O

test . . O
patients . . O
for . . O
hbv . . O
infection . . O
before . . O
initiating . . O
treatment . . O
with . . O
cimzia . . O
. . . O

these . . O
may . . B-Factor
include . . O
asthenia . . B-AdverseReaction
, . . O
generalized . . B-AdverseReaction
muscle . . I-AdverseReaction
weakness . . I-AdverseReaction
, . . O
diplopia . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
ptosis . . B-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
, . . O
dysphonia . . B-AdverseReaction
, . . O
dysarthria . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
incontinence . . I-AdverseReaction
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
. . . O

the . . O
following . . O
important . . O
adverse . . O
reactions . . O
are . . O
described . . O
below . . O
and . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

in . . O
the . . O
event . . O
of . . O
a . . O
serious . . O
reaction . . O
, . . O
administration . . O
of . . O
benlysta . . O
must . . O
be . . O
discontinued . . O
immediately . . O
and . . O
appropriate . . O
medical . . O
therapy . . O
administered . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
withdrawal . . O
of . . O
aptiom . . O
: . . O
withdraw . . O
aptiom . . O
gradually . . O
to . . O
minimize . . O
the . . O
risk . . O
of . . O
increased . . O
seizure . . O
frequency . . O
and . . O
status . . O
epilepticus . . O
. . . O

6.3 . . O
postmarketing . . O
experience . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
ttp . . O
/ . . O
hus . . O
. . . O

if . . O
grade . . O
3 . . O
or . . O
4 . . O
neutropenia . . O
develops . . O
, . . O
consider . . O
dose . . O
delays . . O
, . . O
reductions . . O
, . . O
discontinuation . . O
, . . O
or . . O
g . . O
- . . O
csf . . O
prophylaxis . . O
with . . O
subsequent . . O
doses . . O
( . . O
5.3 . . O
) . . O
. . . O

if . . O
the . . O
adreview . . O
imaging . . O
information . . O
is . . O
essential . . O
for . . O
clinical . . O
care . . O
, . . O
consider . . O
the . . O
withdrawal . . O
of . . O
the . . O
following . . O
categories . . O
of . . O
medications . . O
if . . O
the . . O
withdrawal . . O
can . . O
be . . O
accomplished . . O
safely . . O
: . . O
antihypertensives . . O
that . . O
deplete . . O
norepinephrine . . O
stores . . O
or . . O
inhibit . . O
reuptake . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
reserpine . . O
, . . O
labetalol . . O
) . . O
, . . O
antidepressants . . O
that . . O
inhibit . . O
norepinephrine . . O
transporter . . O
function . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
amitriptyline . . O
and . . O
derivatives . . O
, . . O
imipramine . . O
and . . O
derivatives . . O
, . . O
selective . . O
serotonin . . O
reuptake . . O
inhibitors . . O
) . . O
, . . O
and . . O
sympathomimetic . . O
amines . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
phenylephrine . . O
, . . O
phenylpropanolamine . . O
, . . O
pseudoephedrine . . O
and . . O
ephedrine . . O
) . . O
. . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
events . . O
reported . . O
in . . O
the . . O
krd . . O
arm . . O
as . . O
compared . . O
with . . O
the . . O
rd . . O
arm . . O
were . . O
pneumonia . . B-AdverseReaction
( . . O
14% . . O
versus . . O
11% . . O
) . . O
, . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
4% . . O
versus . . O
1.5% . . O
) . . O
, . . O
pyrexia . . B-AdverseReaction
( . . O
4% . . O
versus . . O
2% . . O
) . . O
, . . O
and . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
( . . O
3% . . O
versus . . O
2% . . O
) . . O
. . . O

5.6 . . O
pulmonary . . O
toxicity . . O

l . . B-DrugClass
ong . . I-DrugClass
- . . I-DrugClass
acting . . I-DrugClass
beta . . I-DrugClass
2 . . I-DrugClass
- . . I-DrugClass
adrenergic . . I-DrugClass
agonist . . I-DrugClass
s . . I-DrugClass
( . . O
laba . . B-DrugClass
) . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
. . . O

all . . O
5 . . O
patients . . O
had . . O
maximum . . O
alt . . O
or . . O
ast . . B-AdverseReaction
levels . . I-AdverseReaction
> . . I-AdverseReaction
8 . . I-AdverseReaction
* . . I-AdverseReaction
uln . . I-AdverseReaction
, . . O
which . . O
returned . . O
to . . O
baseline . . O
levels . . O
following . . O
interruption . . O
of . . O
kalydeco . . O
dosing . . O
. . . O

in . . O
a . . O
controlled . . O
clinical . . O
study . . O
with . . O
inlyta . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
rcc . . O
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
was . . O
reported . . O
in . . O
6 . . O
/ . . O
359 . . O
patients . . O
( . . O
2% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
3 . . O
/ . . O
355 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

withhold . . O
dose . . O
for . . O
moderate . . O
immune . . O
- . . O
mediated . . O
adverse . . O
reactions . . O
until . . O
return . . O
to . . O
baseline . . O
, . . O
improvement . . O
to . . O
mild . . O
severity . . O
, . . O
or . . O
complete . . O
resolution . . O
, . . O
and . . O
patient . . O
is . . O
receiving . . O
less . . O
than . . O
7.5 . . O
mg . . O
prednisone . . O
or . . O
equivalent . . O
per . . O
day . . O
. . . O

prescribe . . O
only . . O
for . . O
recommended . . O
patient . . O
populations . . O
. . . O

aptiom . . O
causes . . O
dose . . O
- . . O
related . . O
increases . . O
in . . O
adverse . . O
reactions . . O
related . . O
to . . O
dizziness . . B-AdverseReaction
and . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
gait . . I-AdverseReaction
and . . O
coordination . . O
( . . O
dizziness . . B-AdverseReaction
, . . O
ataxia . . B-AdverseReaction
, . . O
vertigo . . B-AdverseReaction
, . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
, . . O
nystagmus . . B-AdverseReaction
, . . O
and . . O
abnormal . . B-AdverseReaction
coordination . . I-AdverseReaction
) . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

when . . O
feasible . . O
, . . O
the . . O
decision . . O
to . . O
administer . . O
empiric . . O
antifungal . . O
therapy . . O
in . . O
these . . O
patients . . O
should . . O
be . . O
made . . O
in . . O
consultation . . O
with . . O
a . . O
physician . . O
with . . O
expertise . . O
in . . O
the . . O
diagnosis . . O
and . . O
treatment . . O
of . . O
invasive . . O
fungal . . O
infections . . O
and . . O
should . . O
take . . O
into . . O
account . . O
both . . O
the . . O
risk . . O
for . . O
severe . . O
fungal . . O
infection . . O
and . . O
risks . . O
of . . O
antifungal . . O
therapy . . O
. . . O

elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
treated . . O
with . . O
antipsychotic . . B-DrugClass
drugs . . I-DrugClass
are . . O
at . . O
an . . O
increased . . O
risk . . O
of . . O
death . . B-AdverseReaction
. . . O

at . . O
2 . . O
years . . O
, . . O
patients . . O
randomized . . O
to . . O
invokana . . O
100 . . O
mg . . O
and . . O
invokana . . O
300 . . O
mg . . O
had . . O
placebo . . O
- . . O
corrected . . O
declines . . B-AdverseReaction
in . . I-AdverseReaction
bmd . . I-AdverseReaction
at . . I-AdverseReaction
the . . I-AdverseReaction
total . . I-AdverseReaction
hip . . I-AdverseReaction
of . . O
0.9% . . B-Severity
and . . O
1.2% . . B-Severity
, . . O
respectively . . O
, . . O
and . . O
at . . O
the . . O
lumbar . . O
spine . . O
of . . O
0.3% . . B-Severity
and . . O
0.7% . . B-Severity
, . . O
respectively . . O
. . . O

drug . . O
- . . O
induced . . O
hepatotoxicity . . B-AdverseReaction
with . . O
fatal . . B-AdverseReaction
outcome . . O
occurred . . O
in . . O
2 . . O
( . . O
0.1% . . O
) . . O
of . . O
the . . O
1669 . . O
patients . . O
treated . . O
with . . O
xalkori . . O
across . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
nsclc . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
sanofi . . O
- . . O
aventis . . O
u . . O
. . . O
s . . O
. . . O
llc . . O
at . . O
1-800-633-1610 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

elevations . . B-AdverseReaction
of . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
proteinuria . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
afinitor . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
, . . O
6.2 . . O
, . . O
6.3 . . O
, . . O
6.4 . . O
, . . O
6.5 . . O
) . . O
] . . O
. . . O

the . . O
study . . O
2 . . O
population . . O
included . . O
patients . . O
with . . O
a . . O
median . . O
age . . O
of . . O
7 . . O
years . . O
( . . O
1 . . O
to . . O
17 . . O
years . . O
) . . O
; . . O
63% . . O
were . . O
male . . O
, . . O
27% . . O
were . . O
hispanic . . O
or . . O
latino . . O
, . . O
83% . . O
were . . O
white . . O
, . . O
3% . . O
were . . O
black . . O
/ . . O
african . . O
american . . O
, . . O
7% . . O
were . . O
asian . . O
, . . O
and . . O
7% . . O
were . . O
other . . O
( . . O
american . . O
indian . . O
, . . O
alaska . . O
native . . O
or . . O
indian . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

5.2 . . O
embryofetal . . O
toxicity . . O

reactions . . O
can . . O
occur . . O
on . . O
initial . . O
exposure . . O
. . . O

the . . O
qt . . B-AdverseReaction
- . . I-AdverseReaction
prolonging . . I-AdverseReaction
effect . . O
occurred . . O
within . . O
3 . . O
hours . . O
. . . O

hcv . . O
- . . O
rna . . O
result . . O
should . . O
not . . O
be . . O
considered . . O
equivalent . . O
to . . O
an . . O
" . . O
undetectable . . O
" . . O

yervoy . . O
can . . B-Factor
result . . O
in . . O
severe . . B-Severity
and . . O
fatal . . B-AdverseReaction
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
due . . O
to . . O
t . . O
- . . O
cell . . O
activation . . O
and . . O
proliferation . . O
. . . O

pre . . O
- . . O
existing . . O
hypocalcemia . . O
must . . O
be . . O
corrected . . O
prior . . O
to . . O
initiating . . O
therapy . . O
with . . O
prolia . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
were . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
. . . O

* . . O
when . . O
pregnancy . . O
is . . O
detected . . O
, . . O
discontinue . . O
edarbi . . O
as . . O
soon . . O
as . . O
possible . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

table . . O
4 . . O
: . . O
incidence . . O
of . . O
hematology . . O
laboratory . . O
abnormalities . . O
in . . O
patients . . O
who . . O
received . . O
treanda . . O
in . . O
the . . O
nhl . . O
studies . . O
percent . . O
of . . O
patients . . O
hematology . . O
variable . . O
all . . O
grades . . O
grades . . O
3 . . O
/ . . O
4 . . O
lymphocytes . . B-AdverseReaction
decreased . . I-AdverseReaction
99 . . O
94 . . O
leukocytes . . B-AdverseReaction
decreased . . I-AdverseReaction
94 . . O
56 . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
88 . . O
11 . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
86 . . O
60 . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
86 . . O
25 . . O
in . . O
both . . O
studies . . O
, . . O
serious . . O
adverse . . O
reactions . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
were . . O
reported . . O
in . . O
37% . . O
of . . O
patients . . O
receiving . . O
treanda . . O
. . . O

thromboprophylaxis . . O
is . . O
recommended . . O
and . . O
should . . O
be . . O
based . . O
on . . O
an . . O
assessment . . O
of . . O
the . . O
patient's . . O
underlying . . O
risks . . O
, . . O
treatment . . O
regimen . . O
, . . O
and . . O
clinical . . O
status . . O
. . . O

somnolence . . B-AdverseReaction
led . . O
to . . O
discontinuation . . O
in . . O
0% . . O
, . . O
3% . . O
, . . O
1% . . O
, . . O
and . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
, . . O
and . . O
saphris . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
, . . O
5 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
10 . . O
mg . . O
twice . . O
daily . . O
, . . O
respectively . . O
. . . O

individuals . . O
with . . O
" . . O
crowded . . O
" . . O
optic . . O
disc . . O
are . . O
also . . O
considered . . O
at . . O
greater . . O
risk . . O
for . . O
naion . . O
compared . . O
to . . O
the . . O
general . . O
population . . O
, . . O
however . . O
, . . O
evidence . . O
is . . O
insufficient . . O
to . . O
support . . O
screening . . O
of . . O
prospective . . O
users . . O
of . . O
pde5 . . O
inhibitors . . O
, . . O
including . . O
stendra . . O
, . . O
for . . O
this . . O
uncommon . . O
condition . . O
. . . O

5.3 . . O
acute . . O
kidney . . O
injury . . O

drug . . B-AdverseReaction
reaction . . I-AdverseReaction
with . . I-AdverseReaction
eosinophilia . . I-AdverseReaction
and . . I-AdverseReaction
systemic . . I-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
dress . . B-AdverseReaction
) . . O
, . . O
also . . O
known . . O
as . . O
multiorgan . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
, . . O
has . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
antiepileptic . . B-DrugClass
drugs . . I-DrugClass
, . . O
including . . O
gabapentin . . O
. . . O

5.2 . . O
imaging . . O
errors . . O
due . . O
to . . O
concomitant . . O
medications . . O
and . . O
risks . . O
associated . . O
with . . O
withdrawal . . O
of . . O
medications . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
dermatitis . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

interrupt . . O
ferriprox . . O
therapy . . O
if . . O
neutropenia . . O
develops . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
the . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
other . . O
trials . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

since . . O
many . . O
of . . O
the . . O
patients . . O
in . . O
the . . O
phase . . O
3 . . O
trial . . O
were . . O
also . . O
taking . . O
medications . . O
that . . O
cause . . O
liver . . O
enzyme . . O
elevations . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
nonsteroidal . . O
anti . . O
- . . O
inflammatory . . O
drugs . . O
[ . . O
nsaids . . O
] . . O
, . . O
methotrexate . . O
[ . . O
mtx . . O
] . . O
, . . O
or . . O
isoniazid . . O
prophylaxis . . O
) . . O
, . . O
the . . O
relationship . . O
between . . O
simponi . . O
aria . . O
and . . O
liver . . O
enzyme . . O
elevation . . O
is . . O
not . . O
clear . . O
. . . O

monitor . . O
patients . . O
during . . O
and . . O
for . . O
an . . O
appropriate . . O
period . . O
of . . O
time . . O
after . . O
administration . . O
of . . O
benlysta . . O
. . . O

ctcae . . O
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
ild . . B-AdverseReaction
/ . . O
pneumonitis . . B-AdverseReaction
was . . O
reported . . O
in . . O
3% . . O
of . . O
patients . . O
, . . O
and . . O
fatal . . B-AdverseReaction
ild . . B-AdverseReaction
/ . . O
pneumonitis . . B-AdverseReaction
was . . O
reported . . O
in . . O
1 . . O
patient . . O
( . . O
0.4% . . O
) . . O
in . . O
study . . O
1 . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
. . . O
] . . O

consider . . O
discontinuation . . O
of . . O
cimzia . . O
therapy . . O
in . . O
patients . . O
with . . O
confirmed . . O
significant . . O
hematologic . . O
abnormalities . . O
. . . O

cases . . O
of . . O
worsening . . B-AdverseReaction
congestive . . I-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
chf . . O
) . . O
and . . O
new . . B-AdverseReaction
onset . . I-AdverseReaction
chf . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
tnf . . O
- . . O
blockers . . O
, . . O
including . . O
simponi . . O
aria . . O
. . . O

* . . O
fluid . . B-AdverseReaction
retention . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

because . . O
clinical . . O
studies . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

use . . O
of . . O
ocular . . O
steroids . . B-DrugClass
may . . O
prolong . . O
the . . O
course . . O
and . . O
may . . O
exacerbate . . O
the . . O
severity . . O
of . . O
many . . O
viral . . O
infections . . O
of . . O
the . . O
eye . . O
( . . O
including . . O
herpes . . O
simplex . . O
) . . O
. . . O

serious . . O
infections . . O

patients . . O
must . . O
have . . O
a . . O
negative . . O
pregnancy . . O
test . . O
prior . . O
to . . O
therapy . . O
; . . O
use . . O
two . . O
or . . O
more . . O
forms . . O
of . . O
contraception . . O
, . . O
and . . O
have . . O
monthly . . O
pregnancy . . O
tests . . O
. . . O

appropriate . . O
screening . . O
tests . . O
should . . O
be . . O
performed . . O
in . . O
all . . O
patients . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

dysphagia . . B-AdverseReaction
may . . O
persist . . O
for . . O
several . . O
weeks . . O
, . . O
and . . O
require . . O
use . . O
of . . O
a . . O
feeding . . O
tube . . O
to . . O
maintain . . O
adequate . . O
nutrition . . O
and . . O
hydration . . O
. . . O

some . . O
igg . . O
- . . O
positive . . O
patients . . O
in . . O
clinical . . O
trials . . O
who . . O
were . . O
retrospectively . . O
evaluated . . O
for . . O
the . . O
presence . . O
of . . O
inhibitory . . O
antibodies . . O
tested . . O
positive . . O
for . . O
inhibition . . O
of . . O
enzyme . . O
activity . . O
and . . O
/ . . O
or . . O
uptake . . O
in . . O
in . . O
vitro . . O
assays . . O
. . . O

( . . O
5.6 . . O
) . . O

pristiq . . O
should . . O
also . . O
not . . O
be . . O
started . . O
in . . O
a . . O
patient . . O
who . . O
is . . O
being . . O
treated . . O
with . . O
maois . . O
such . . O
as . . O
linezolid . . O
or . . O
intravenous . . O
methylene . . O
blue . . O
. . . O

of . . O
the . . O
353 . . O
patients . . O
included . . O
in . . O
the . . O
pooled . . O
analyses . . O
of . . O
patients . . O
with . . O
cf . . O
who . . O
had . . O
either . . O
a . . O
g551d . . O
mutation . . O
or . . O
were . . O
homozygous . . O
for . . O
the . . O
f508del . . O
mutation . . O
in . . O
the . . O
cftr . . O
gene . . O
, . . O
50% . . O
of . . O
patients . . O
were . . O
female . . O
and . . O
97% . . O
were . . O
caucasian . . O
; . . O
221 . . O
received . . O
kalydeco . . O
, . . O
and . . O
132 . . O
received . . O
placebo . . O
from . . O
16 . . O
to . . O
48 . . O
weeks . . O
. . . O

before . . O
initiating . . O
farxiga . . O
in . . O
patients . . O
with . . O
one . . O
or . . O
more . . O
of . . O
these . . O
characteristics . . O
, . . O
volume . . O
status . . O
should . . O
be . . O
assessed . . O
and . . O
corrected . . O
. . . O

have . . O
anaphylactic . . O
and . . O
hypersensitivity . . O
treatment . . O
measures . . O
available . . O
prior . . O
to . . O
datscan . . O
administration . . O
. . . O

a . . O
total . . O
of . . O
696 . . O
hiv . . O
- . . O
positive . . O
patients . . O
in . . O
three . . O
placebo . . O
- . . O
controlled . . O
trials . . O
received . . O
fulyzaq . . O
for . . O
a . . O
mean . . O
duration . . O
of . . O
78 . . O
days . . O
. . . O

of . . O
a . . O
course . . O
of . . O
therapy . . O
, . . O
consider . . O
coverage . . O
with . . O
another . . O
anticoagulant . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
, . . O
2.5 . . O
, . . O
2.6 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

because . . O
trough . . O
levels . . O
of . . O
ipilimumab . . O
interfere . . O
with . . O
the . . O
ecl . . O
assay . . O
results . . O
, . . O
a . . O
subset . . O
analysis . . O
was . . O
performed . . O
in . . O
the . . O
dose . . O
cohort . . O
with . . O
the . . O
lowest . . O
trough . . O
levels . . O
. . . O

warning . . O
: . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O

cases . . O
of . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
sjs . . B-AdverseReaction
) . . O
and . . O
ten . . B-AdverseReaction
, . . O
some . . O
fatal . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
when . . O
treanda . . O
was . . O
administered . . O
concomitantly . . O
with . . O
allopurinol . . O
and . . O
other . . O
medications . . O
known . . O
to . . O
cause . . O
these . . O
syndromes . . O
. . . O

patients . . O
with . . O
mps . . O
iva . . O
should . . O
be . . O
monitored . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
scc . . O
( . . O
including . . O
back . . O
pain . . O
, . . O
paralysis . . O
of . . O
limbs . . O
below . . O
the . . O
level . . O
of . . O
compression . . O
, . . O
urinary . . O
and . . O
fecal . . O
incontinence . . O
) . . O
and . . O
given . . O
appropriate . . O
clinical . . O
care . . O
. . . O

advise . . O
patients . . O
not . . O
to . . O
drive . . O
or . . O
operate . . O
heavy . . O
machinery . . O
until . . O
they . . O
know . . O
how . . O
toviaz . . O
affects . . O
them . . O
( . . O
5.5 . . O
) . . O
* . . O
toviaz . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
myasthenia . . O
gravis . . O
, . . O
a . . O
disease . . O
characterized . . O
by . . O
decreased . . O
cholinergic . . O
activity . . O
at . . O
the . . O
neuromuscular . . O
junction . . O
. . . O

rates . . O
of . . O
serious . . B-Severity
infections . . B-AdverseReaction
in . . O
the . . O
200 . . O
mg . . O
every . . O
other . . O
week . . O
dose . . O
group . . O
were . . O
0.06 . . O
per . . O
patient . . O
- . . O
year . . O
and . . O
in . . O
the . . O
400 . . O
mg . . O
every . . O
4 . . O
weeks . . O
dose . . O
group . . O
were . . O
0.04 . . O
per . . O
patient . . O
- . . O
year . . O
. . . O

it . . O
is . . O
unknown . . O
whether . . O
the . . O
suicidality . . B-AdverseReaction
risk . . B-Factor
extends . . O
to . . O
longer . . O
- . . O
term . . O
use . . O
, . . O
i . . O
. . . O
e . . O
. . . O
, . . O
beyond . . O
several . . O
months . . O
. . . O

table . . O
1 . . O
. . . O

in . . O
study . . O
ra . . O
- . . O
iv . . O
( . . O
monotherapy . . O
) . . O
, . . O
the . . O
acr20 . . O
response . . O
was . . O
33% . . O
versus . . O
56% . . O
, . . O
antibody . . O
- . . O
positive . . O
versus . . O
antibody . . O
- . . O
negative . . O
status . . O
, . . O
respectively . . O
. . . O

pancreatitis . . B-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
clinical . . O
trials . . O
( . . O
6.1 . . O
) . . O
* . . O
male . . O
osteoporosis . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
5% . . O
and . . O
more . . O
common . . O
than . . O
placebo . . O
) . . O
were . . O
: . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
and . . O
nasopharyngitis . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
* . . O
bone . . O
loss . . O
due . . O
to . . O
hormone . . O
ablation . . O
for . . O
cancer . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
and . . O
more . . O
common . . O
than . . O
placebo . . O
) . . O
were . . O
: . . O
arthralgia . . B-AdverseReaction
and . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

multaq . . O
should . . O
only . . O
be . . O
initiated . . O
in . . O
patients . . O
in . . O
sinus . . O
rhythm . . O
who . . O
are . . O
receiving . . O
appropriate . . O
antithrombotic . . O
therapy . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.3 . . O
) . . O
] . . O
. . . O

advise . . O
patients . . O
to . . O
consult . . O
a . . O
physician . . O
if . . O
they . . O
develop . . O
signs . . O
or . . O
symptoms . . O
of . . O
heart . . O
failure . . O
, . . O
such . . O
as . . O
weight . . O
gain . . O
, . . O
dependent . . O
edema . . O
, . . O
or . . O
increasing . . O
shortness . . O
of . . O
breath . . O
. . . O

treatment . . O
delay . . O
or . . O
dosage . . O
reduction . . O
may . . O
be . . O
necessary . . O
if . . O
patients . . O
experience . . O
grade . . O
> . . O
= . . O
3 . . O
diarrhea . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

a . . O
total . . O
of . . O
120 . . O
men . . O
were . . O
exposed . . O
to . . O
placebo . . O
and . . O
120 . . O
men . . O
were . . O
exposed . . O
to . . O
prolia . . O
administered . . O
subcutaneously . . O
once . . O
every . . O
6 . . O
months . . O
as . . O
a . . O
single . . O
60 . . O
mg . . O
dose . . O
. . . O

( . . O
5.2 . . O
) . . O

the . . O
following . . O
groups . . O
of . . O
patients . . O
were . . O
not . . O
included . . O
in . . O
clinical . . O
safety . . O
and . . O
efficacy . . O
trials . . O
for . . O
stendra . . O
, . . O
and . . O
therefore . . O
until . . O
further . . O
information . . O
is . . O
available . . O
, . . O
stendra . . O
is . . O
not . . O
recommended . . O
for . . O
the . . O
following . . O
groups . . O
: . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

in . . O
a . . O
large . . O
, . . O
randomized . . O
, . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
study . . O
, . . O
a . . O
generalized . . O
effect . . O
of . . O
estrogens . . O
on . . O
blood . . O
pressure . . O
was . . O
not . . B-Negation
seen . . O
. . . O

binding . . O
to . . O
this . . O
receptor . . O
is . . O
required . . O
for . . O
vimizim . . O
to . . O
be . . O
taken . . O
into . . O
cells . . O
where . . O
it . . O
is . . O
active . . O
. . . O

other . . O
glp . . B-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
receptor . . I-DrugClass
agonists . . I-DrugClass
have . . O
caused . . O
dose . . O
- . . O
related . . O
and . . O
treatment . . O
- . . O
duration . . O
- . . O
dependent . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
( . . O
adenomas . . O
or . . O
carcinomas . . O
) . . O
in . . O
rodents . . B-Animal
. . . O

other . . O
important . . O
considerations . . O
in . . O
the . . O
differential . . O
diagnosis . . O
include . . O
central . . O
anticholinergic . . O
toxicity . . O
, . . O
heat . . O
stroke . . O
, . . O
drug . . O
fever . . O
, . . O
and . . O
primary . . O
central . . O
nervous . . O
system . . O
( . . O
cns . . O
) . . O
pathology . . O
. . . O

the . . O
principal . . O
efficacy . . O
study . . O
evaluating . . O
the . . O
efficacy . . O
and . . O
safety . . O
of . . O
horizant . . O
in . . O
the . . O
management . . O
of . . O
phn . . O
was . . O
a . . O
12 . . O
- . . O
week . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
multicenter . . O
study . . O
comparing . . O
1,200 . . O
mg . . O
/ . . O
day . . O
, . . O
2,400 . . O
mg . . O
/ . . O
day . . O
and . . O
3,600 . . O
mg . . O
/ . . O
day . . O
to . . O
placebo . . O
. . . O

about . . O
3% . . O
of . . O
subjects . . O
developed . . O
antibodies . . O
( . . O
binding . . O
or . . O
neutralizing . . O
) . . O
over . . O
time . . O
with . . O
dysport . . O
( . . O
r . . O
) . . O
treatment . . O
. . . O

* . . O
lower . . O
lid . . O
injections . . O
should . . O
not . . O
be . . O
repeated . . O
if . . O
diplopia . . O
occurred . . O
with . . O
previous . . O
botulinum . . O
toxin . . O
injections . . O
. . . O

table . . O
7 . . O
enumerates . . O
the . . O
pooled . . O
incidences . . O
of . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactions . . O
that . . O
were . . O
spontaneously . . O
reported . . O
in . . O
four . . O
placebo . . O
- . . O
controlled . . O
, . . O
4 . . O
- . . O
or . . O
6 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
or . . O
flexible . . O
- . . O
dose . . O
studies . . O
, . . O
listing . . O
those . . O
reactions . . O
that . . O
occurred . . O
in . . O
2% . . O
or . . O
more . . O
of . . O
patients . . O
treated . . O
with . . O
fanapt . . O
in . . O
any . . O
of . . O
the . . O
dose . . O
groups . . O
, . . O
and . . O
for . . O
which . . O
the . . O
incidence . . O
in . . O
fanapt . . O
- . . O
treated . . O
patients . . O
in . . O
any . . O
dose . . O
group . . O
was . . O
greater . . O
than . . O
the . . O
incidence . . O
in . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

* . . O
you . . O
should . . O
not . . O
remove . . O
duavee . . O
from . . O
the . . O
blister . . O
until . . O
right . . O
before . . O
you . . O
are . . O
ready . . O
to . . O
take . . O
it . . O
. . . O

monitor . . O
blood . . O
pressure . . O
regularly . . O
during . . O
treatment . . O
( . . O
5.3 . . O
) . . O
. . . O

trial . . O
2 . . O
was . . O
a . . O
12 . . O
- . . O
week . . O
trial . . O
that . . O
evaluated . . O
the . . O
efficacy . . O
of . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
, . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
, . . O
and . . O
fluticasone . . O
furoate . . O
100 . . O
mcg . . O
in . . O
adolescent . . O
and . . O
adult . . O
subjects . . O
with . . O
asthma . . O
. . . O

patients . . O
treated . . O
with . . O
concomitant . . O
immunosuppressants . . O
( . . O
mtx . . O
) . . O
had . . O
a . . O
lower . . O
rate . . O
of . . O
antibody . . O
development . . O
than . . O
patients . . O
not . . O
taking . . O
immunosuppressants . . O
at . . O
baseline . . O
. . . O

refer . . O
to . . O
the . . O
prescribing . . O
information . . O
for . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
for . . O
pre . . O
- . . O
treatment . . O
, . . O
on . . O
- . . O
treatment . . O
and . . O
post . . O
- . . O
treatment . . O
laboratory . . O
testing . . O
recommendations . . O
including . . O
hematology . . O
, . . O
biochemistry . . O
( . . O
including . . O
hepatic . . O
function . . O
tests . . O
) . . O
, . . O
and . . O
pregnancy . . O
testing . . O
requirements . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
majority . . O
of . . O
patients . . O
who . . O
reported . . O
serious . . B-Severity
depression . . B-AdverseReaction
or . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
had . . O
a . . O
history . . O
of . . O
depression . . O
or . . O
other . . O
serious . . O
psychiatric . . O
disorders . . O
and . . O
most . . O
were . . O
receiving . . O
psychoactive . . O
medications . . O
. . . O

in . . O
study . . O
3 . . O
, . . O
pulmonary . . B-AdverseReaction
toxicity . . I-AdverseReaction
was . . O
reported . . O
in . . O
8 . . O
patients . . O
( . . O
5% . . O
) . . O
in . . O
the . . O
adcetris . . O
- . . O
treated . . O
arm . . O
and . . O
5 . . O
patients . . O
( . . O
3% . . O
) . . O
in . . O
the . . O
placebo . . O
arm . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
myocardial . . O
infarction . . O
( . . O
mi . . O
) . . O
and . . O
stroke . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
cough . . B-AdverseReaction
, . . O
throat . . B-AdverseReaction
irritation . . I-AdverseReaction

( . . O
5.1 . . O
) . . O
* . . O
drugs . . O
which . . O
block . . O
norepinephrine . . O
uptake . . O
or . . O
deplete . . O
norepinephrine . . O
stores . . O
may . . O
decrease . . O
adreview . . O
uptake . . O
. . . O

table . . O
2 . . O
summarizes . . O
the . . O
adverse . . O
reactions . . O
regardless . . O
of . . O
causality . . O
from . . O
the . . O
trial . . O
in . . O
patients . . O
with . . O
relapsed . . O
or . . O
refractory . . O
ptcl . . O
. . . O

* . . O
hyponatremia . . B-AdverseReaction
: . . O
can . . O
occur . . O
in . . O
association . . O
with . . O
siadh . . O
( . . O
5.9 . . O
) . . O
. . . O

flush . . O
immediately . . O
with . . O
water . . O
if . . O
ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
comes . . O
into . . O
contact . . O
with . . O
eyes . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

because . . O
these . . O
events . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
unknown . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

* . . O
infections . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

no . . O
patient . . O
required . . O
dose . . O
reduction . . O
or . . O
permanent . . O
discontinuation . . O
of . . O
tafinlar . . O
or . . O
trametinib . . O
for . . O
skin . . O
toxicity . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
distant . . B-AdverseReaction
spread . . I-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effect . . I-AdverseReaction

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
anaphylaxis . . B-AdverseReaction

( . . O
5.7 . . O
) . . O

withhold . . O
zydelig . . O
if . . O
the . . O
alt . . O
or . . O
ast . . O
is . . O
greater . . O
than . . O
5 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
, . . O
and . . O
continue . . O
to . . O
monitor . . O
ast . . O
, . . O
alt . . O
and . . O
total . . O
bilirubin . . O
weekly . . O
until . . O
the . . O
abnormality . . O
is . . O
resolved . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

autoimmune . . B-AdverseReaction
disorders . . I-AdverseReaction
( . . O
such . . O
as . . O
graves' . . B-AdverseReaction
disease . . I-AdverseReaction
, . . O
polymyositis . . B-AdverseReaction
, . . O
and . . O
guillain . . B-AdverseReaction
- . . I-AdverseReaction
barre . . I-AdverseReaction
syndrome . . I-AdverseReaction
) . . O
have . . O
also . . O
been . . O
reported . . O
to . . O
occur . . O
in . . O
the . . O
setting . . O
of . . O
immune . . O
reconstitution . . O
; . . O
however . . O
, . . O
the . . O
time . . O
to . . O
onset . . O
is . . O
more . . O
variable . . O
, . . O
and . . O
can . . O
occur . . O
many . . O
months . . O
after . . O
initiation . . O
of . . O
treatment . . O
. . . O

5.6 . . O
use . . O
with . . O
anakinra . . O

5.1 . . O
cardiovascular . . O
death . . O
in . . O
nyha . . O
class . . O
iv . . O
or . . O
decompensated . . O
heart . . O
failure . . O

immunogenicity . . O

additional . . O
adverse . . O
reactions . . O
observed . . O
during . . O
all . . O
phase . . O
2 . . O
and . . O
3 . . O
clinical . . O
trials . . O

the . . O
proportion . . O
of . . O
subjects . . O
who . . O
received . . O
a . . O
transfusion . . O
for . . O
the . . O
management . . O
of . . O
anemia . . O
was . . O
3% . . O
of . . O
subjects . . O
treated . . O
with . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
compared . . O
to . . O
less . . O
than . . O
1% . . O
in . . O
subjects . . O
who . . O
received . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
subjects . . O
who . . O
received . . O
a . . O
higher . . O
dose . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
had . . O
an . . O
increased . . O
incidence . . O
of . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
glaxosmithkline . . O
at . . O
1-888-825-5249 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

5.4 . . O
local . . O
effects . . O
of . . O
inhaled . . O
corticosteroids . . O

nervous . . O
- . . O
depression . . B-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
vertigo . . B-AdverseReaction

hypophosphatemia . . O
and . . O
osteomalacia . . O
secondary . . O
to . . O
proximal . . O
renal . . O
tubulopathy . . O
should . . O
be . . O
considered . . O
in . . O
patients . . O
at . . O
risk . . O
of . . O
renal . . O
dysfunction . . O
who . . O
present . . O
with . . O
persistent . . O
or . . O
worsening . . O
bone . . O
or . . O
muscle . . O
symptoms . . O
while . . O
receiving . . O
products . . O
containing . . O
tenofovir . . O
df . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

dabrafenib . . O
was . . O
teratogenic . . B-AdverseReaction
and . . O
embryotoxic . . B-AdverseReaction
in . . O
rats . . B-Animal
at . . O
doses . . O
three . . O
times . . O
greater . . O
than . . O
the . . O
human . . O
exposure . . O
at . . O
the . . O
recommended . . O
clinical . . O
dose . . O
. . . O

the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
associated . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
and . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
is . . O
shown . . O
in . . O
table . . O
3 . . O
. . . O

adjunctive . . O
therapy . . O
controlled . . O
trials . . O

progressive . . O
multifocal . . O
leukoencephalopathy . . O
( . . O
pml . . O
) . . O

adverse . . O
events . . O
that . . O
led . . O
to . . O
treatment . . O
discontinuation . . O
and . . O
occurred . . O
in . . O
more . . O
than . . O
1% . . O
of . . O
patients . . O
taking . . O
gilenya . . O
0.5 . . O
mg . . O
were . . O
serum . . B-AdverseReaction
transaminase . . I-AdverseReaction
elevations . . I-AdverseReaction
( . . O
4.7% . . O
compared . . O
to . . O
1% . . O
on . . O
placebo . . O
) . . O
and . . O
basal . . B-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
( . . O
1% . . O
compared . . O
to . . O
0.5% . . O
on . . O
placebo . . O
) . . O
. . . O

when . . O
neuraxial . . O
anesthesia . . O
( . . O
spinal . . O
/ . . O
epidural . . O
anesthesia . . O
) . . O
or . . O
spinal . . O
puncture . . O
is . . O
employed . . O
, . . O
patients . . O
treated . . O
with . . O
anticoagulant . . B-DrugClass
agents . . I-DrugClass
are . . O
at . . O
risk . . O
of . . O
developing . . O
an . . O
epidural . . O
or . . O
spinal . . B-AdverseReaction
hematoma . . I-AdverseReaction
which . . O
can . . O
result . . O
in . . O
long . . O
- . . O
term . . O
or . . O
permanent . . B-AdverseReaction
paralysis . . I-AdverseReaction
[ . . O
see . . O
boxed . . O
warning . . O
] . . O
. . . O

antibody . . O
titers . . O
were . . O
determined . . O
using . . O
a . . O
bridging . . O
enzyme . . O
- . . O
linked . . O
immunosorbent . . O
assay . . O
( . . O
elisa . . O
) . . O
for . . O
anti . . O
- . . O
glucarpidase . . O
antibodies . . O
. . . O

most . . O
common . . O
adverse . . O
reactions . . O
in . . O
an . . O
lgs . . O
placebo . . O
controlled . . O
clinical . . O
trial . . O
( . . O
study . . O
1 . . O
) . . O
table . . O
3 . . O
lists . . O
the . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
onfi . . O
treated . . O
patients . . O
( . . O
at . . O
any . . O
dose . . O
) . . O
, . . O
and . . O
at . . O
a . . O
rate . . O
greater . . O
than . . O
placebo . . O
treated . . O
patients . . O
, . . O
in . . O
the . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
parallel . . O
group . . O
clinical . . O
study . . O
of . . O
adjunctive . . O
aed . . O
therapy . . O
for . . O
15 . . O
weeks . . O
( . . O
study . . O
1 . . O
) . . O
. . . O

premedication . . O
may . . O
include . . O
acetaminophen . . O
, . . O
an . . O
antihistamine . . O
, . . O
and . . O
a . . O
corticosteroid . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
bristol . . O
- . . O
myers . . O
squibb . . O
at . . O
1-800-721-5072 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

pool . . O
of . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O

the . . O
increased . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
with . . O
aeds . . O
was . . O
observed . . O
as . . O
early . . O
as . . O
one . . O
week . . O
after . . O
starting . . O
treatment . . O
with . . O
aeds . . O
and . . O
persisted . . O
for . . O
the . . O
duration . . O
of . . O
treatment . . O
assessed . . O
. . . O

( . . O
6.1 . . O
) . . O

( . . O
5.1 . . O
) . . O
* . . O
when . . O
treating . . O
patients . . O
with . . O
asthma . . O
, . . O
only . . O
prescribe . . O
breo . . O
ellipta . . O
for . . O
patients . . O
not . . O
adequately . . O
controlled . . O
on . . O
a . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
medication . . O
, . . O
such . . O
as . . O
an . . O
ics . . O
, . . O
or . . O
whose . . O
disease . . O
severity . . O
clearly . . O
warrants . . O
initiation . . O
of . . O
treatment . . O
with . . O
both . . O
an . . O
ics . . O
and . . O
a . . O
laba . . O
. . . O

it . . O
is . . O
unknown . . B-Factor
whether . . O
trulicity . . O
causes . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
, . . O
including . . O
medullary . . B-AdverseReaction
thyroid . . I-AdverseReaction
carcinoma . . I-AdverseReaction
( . . O
mtc . . B-AdverseReaction
) . . O
, . . O
in . . O
humans . . O
as . . O
human . . O
relevance . . O
of . . O
dulaglutide . . O
- . . O
induced . . O
rodent . . B-Animal
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
has . . O
not . . O
been . . O
determined . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
, . . O
and . . O
nonclinical . . O
toxicology . . O
( . . O
13.1 . . O
) . . O
] . . O
. . . O

durezol . . O
is . . O
not . . O
indicated . . O
for . . O
intraocular . . O
administration . . O
. . . O

spinal . . O
puncture . . O
. . . O

excerpt . . O
: . . O
* . . O
tendon . . B-AdverseReaction
rupture . . I-AdverseReaction
or . . O
serious . . B-Severity
injury . . B-AdverseReaction
to . . I-AdverseReaction
the . . I-AdverseReaction
injected . . I-AdverseReaction
finger . . I-AdverseReaction
/ . . O
hand . . O
: . . O
avoid . . O
injecting . . O
xiaflex . . O
into . . O
tendons . . O
, . . O
nerves . . O
, . . O
blood . . O
vessels . . O
, . . O
or . . O
other . . O
collagen . . O
- . . O
containing . . O
structure . . O
of . . O
the . . O
hand . . O
. . . O

acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
was . . O
reported . . O
more . . O
frequently . . O
in . . O
patients . . O
with . . O
advanced . . O
relapsed . . O
and . . O
refractory . . O
multiple . . O
myeloma . . O
who . . O
received . . O
kyprolis . . O
monotherapy . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
and . . O
behaviors . . O

table . . O
2 . . O
: . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
in . . O
any . . O
fixed . . O
- . . O
dose . . O
group . . O
and . . O
twice . . O
the . . O
rate . . O
of . . O
placebo . . O
) . . O
in . . O
pre . . O
- . . O
marketing . . O
pooled . . O
mdd . . O
8 . . O
- . . O
week . . O
placebo . . O
- . . O
controlled . . O
studies . . O
percentage . . O
of . . O
patients . . O
reporting . . O
reaction . . O
pristiq . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
placebo . . O
( . . O
n . . O
= . . O
636 . . O
) . . O
50 . . O
mg . . O
( . . O
n . . O
= . . O
317 . . O
) . . O
100 . . O
mg . . O
( . . O
n . . O
= . . O
424 . . O
) . . O
200 . . O
mg . . O
( . . O
n . . O
= . . O
307 . . O
) . . O
400 . . O
mg . . O
( . . O
n . . O
= . . O
317 . . O
) . . O
cardiac . . O
disorders . . O
blood . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
1 . . O
1 . . O
1 . . O
2 . . O
2 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
10 . . O
22 . . O
26 . . O
36 . . O
41 . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
9 . . O
11 . . O
17 . . O
21 . . O
25 . . O
constipation . . B-AdverseReaction
4 . . O
9 . . O
9 . . O
10 . . O
14 . . O
vomiting . . B-AdverseReaction
3 . . O
3 . . O
4 . . O
6 . . O
9 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
4 . . O
7 . . O
7 . . O
10 . . O
11 . . O
chills . . B-AdverseReaction
1 . . O
1 . . O
< . . O
1 . . O
3 . . O
4 . . O
feeling . . B-AdverseReaction
jittery . . I-AdverseReaction
1 . . O
1 . . O
2 . . O
3 . . O
3 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
2 . . O
5 . . O
8 . . O
10 . . O
10 . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
5 . . O
13 . . O
10 . . O
15 . . O
16 . . O
somnolence . . B-AdverseReaction
4 . . O
4 . . O
9 . . O
12 . . O
12 . . O
tremor . . B-AdverseReaction
2 . . O
2 . . O
3 . . O
9 . . O
9 . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
attention . . I-AdverseReaction
< . . O
1 . . O
< . . O
1 . . O
1 . . O
2 . . O
1 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
6 . . O
9 . . O
12 . . O
14 . . O
15 . . O
anxiety . . B-AdverseReaction
2 . . O
3 . . O
5 . . O
4 . . O
4 . . O
nervousness . . B-AdverseReaction
1 . . O
< . . O
1 . . O
1 . . O
2 . . O
2 . . O
abnormal . . B-AdverseReaction
dreams . . I-AdverseReaction
1 . . O
2 . . O
3 . . O
2 . . O
4 . . O
renal . . O
and . . O
urinary . . O
disorders . . O
urinary . . B-AdverseReaction
hesitation . . I-AdverseReaction
0 . . O
< . . O
1 . . O
1 . . O
2 . . O
2 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
yawning . . B-AdverseReaction
< . . O
1 . . O
1 . . O
1 . . O
4 . . O
3 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
hyperhidrosis . . B-AdverseReaction
4 . . O
10 . . O
11 . . O
18 . . O
21 . . O
special . . O
senses . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
1 . . O
3 . . O
4 . . O
4 . . O
4 . . O
mydriasis . . B-AdverseReaction
< . . O
1 . . O
2 . . O
2 . . O
6 . . O
6 . . O
vertigo . . B-AdverseReaction
1 . . O
2 . . O
1 . . O
5 . . O
3 . . O
tinnitus . . B-AdverseReaction
1 . . O
2 . . O
1 . . O
1 . . O
2 . . O
dysgeusia . . B-AdverseReaction
1 . . O
1 . . O
1 . . O
1 . . O
2 . . O
vascular . . O
disorders . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
< . . O
1 . . O
1 . . O
1 . . O
2 . . O
2 . . O
sexual . . O
function . . O
adverse . . O
reactions . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
exelixis . . O
, . . O
inc . . O
. . . O
at . . O
1-855-500-3935 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

administration . . O
of . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
is . . O
not . . O
recommended . . O
until . . O
skin . . O
is . . O
healed . . O
from . . O
any . . O
previous . . O
drug . . O
or . . O
surgical . . O
treatment . . O
. . . O

overall . . O
, . . O
the . . O
safety . . O
profile . . O
in . . O
subjects . . O
with . . O
hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
c . . O
virus . . O
co . . O
- . . O
infection . . O
was . . O
similar . . O
to . . O
that . . O
observed . . O
in . . O
subjects . . O
without . . O
hepatitis . . O
b . . O
or . . O
c . . O
co . . O
- . . O
infection . . O
, . . O
although . . O
the . . O
rates . . O
of . . O
ast . . O
and . . O
alt . . B-AdverseReaction
abnormalities . . I-AdverseReaction
were . . O
higher . . O
in . . O
the . . O
subgroup . . O
with . . O
hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
c . . O
virus . . O
co . . O
- . . O
infection . . O
for . . O
all . . O
treatment . . O
groups . . O
. . . O

no . . O
additional . . O
postmarketing . . O
adverse . . O
reactions . . O
specific . . O
for . . O
emtricitabine . . O
have . . O
been . . O
identified . . O
. . . O

however . . O
, . . O
the . . O
development . . O
of . . O
neutralizing . . O
antibodies . . O
may . . O
be . . O
underreported . . O
due . . O
to . . O
lack . . O
of . . O
assay . . O
sensitivity . . O
. . . O

( . . O
5.5 . . O
) . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
30% . . O
) . . O
were . . O
stomatitis . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
edema . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
fever . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

serious . . B-Severity
and . . O
sometimes . . O
fatal . . B-AdverseReaction
hemorrhage . . O
occurred . . O
with . . O
cometriq . . O
. . . O

consider . . O
obtaining . . O
periodic . . O
hepatic . . O
serum . . O
enzymes . . O
, . . O
especially . . O
during . . O
the . . O
first . . O
6 . . O
months . . O
of . . O
treatment . . O
, . . O
but . . O
it . . O
is . . O
not . . O
known . . O
whether . . O
routine . . O
periodic . . O
monitoring . . O
of . . O
serum . . O
enzymes . . O
will . . O
prevent . . O
the . . O
development . . O
of . . O
severe . . O
liver . . O
injury . . O
. . . O

there . . O
have . . O
been . . O
post . . O
- . . O
marketing . . O
reports . . O
of . . O
serious . . B-Severity
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
, . . O
including . . O
respiratory . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
in . . O
patients . . O
with . . O
cervical . . O
dystonia . . O
treated . . O
with . . O
botulinum . . B-DrugClass
toxin . . I-DrugClass
products . . I-DrugClass
. . . O

* . . O
140 . . O
patients . . O
with . . O
advanced . . O
phase . . O
cml . . O
including . . O
76 . . O
patients . . O
with . . O
ap . . O
cml . . O
and . . O
64 . . O
patients . . O
with . . O
bp . . O
cml . . O
. . . O

if . . O
skin . . O
reactions . . O
are . . O
severe . . O
or . . O
progressive . . O
, . . O
withhold . . O
or . . O
discontinue . . O
treanda . . O
. . . O

5.2 . . O
bullous . . O
and . . O
exfoliative . . O
skin . . O
disorders . . O

( . . O
5.1 . . O
) . . O
* . . O
entereg . . O
is . . O
available . . O
only . . O
through . . O
a . . O
restricted . . O
program . . O
for . . O
short . . O
- . . O
term . . O
use . . O
( . . O
15 . . O
doses . . O
) . . O
called . . O
the . . O
entereg . . O
access . . O
support . . O
and . . O
education . . O
( . . O
e . . O
. . . O
a . . O
. . . O
s . . O
. . . O
e . . O
. . . O
( . . O
r . . O
) . . O
) . . O
program . . O
. . . O

adverse . . O
reactions . . O
leading . . O
to . . O
permanent . . O
treatment . . O
discontinuation . . O
occurred . . O
in . . O
33% . . O
of . . O
patients . . O
> . . O
= . . O
65 . . O
years . . O
of . . O
age . . O
compared . . O
to . . O
17% . . O
in . . O
patients . . O
< . . O
65 . . O
years . . O
of . . O
age . . O
. . . O

onj . . B-AdverseReaction
can . . B-Factor
manifest . . O
as . . O
jaw . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
osteomyelitis . . B-AdverseReaction
, . . O
osteitis . . B-AdverseReaction
, . . O
bone . . B-AdverseReaction
erosion . . I-AdverseReaction
, . . O
tooth . . O
or . . O
periodontal . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
toothache . . B-AdverseReaction
, . . O
gingival . . B-AdverseReaction
ulceration . . I-AdverseReaction
or . . O
erosion . . O
, . . O
persistent . . B-AdverseReaction
jaw . . I-AdverseReaction
pain . . I-AdverseReaction
or . . O
slow . . O
healing . . O
of . . O
the . . O
mouth . . O
or . . O
jaw . . O
after . . O
dental . . O
surgery . . O
. . . O

the . . O
following . . O
symptoms . . O
that . . O
could . . B-Factor
be . . O
compatible . . O
with . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
rarely . . O
following . . O
cimzia . . O
administration . . O
to . . O
patients . . O
: . . O
angioedema . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
serum . . B-AdverseReaction
sickness . . I-AdverseReaction
, . . O
and . . O
urticaria . . B-AdverseReaction
. . . O

approximately . . O
10% . . O
of . . O
patients . . O
in . . O
long . . O
- . . O
term . . O
clinical . . O
trials . . O
developed . . O
skin . . B-AdverseReaction
discoloration . . I-AdverseReaction
, . . O
generally . . O
after . . O
2 . . O
or . . O
more . . O
years . . O
of . . O
treatment . . O
and . . O
at . . O
higher . . O
doses . . O
( . . O
900 . . O
mg . . O
or . . O
greater . . O
) . . O
of . . O
potiga . . O
. . . O

5.9 . . O
reversible . . O
posterior . . O
leukoencephalopathy . . O
syndrome . . O

6 . . O
adverse . . O
reactions . . O

nsf . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
fatal . . B-AdverseReaction
or . . O
debilitating . . B-Severity
fibrosis . . B-AdverseReaction
affecting . . O
the . . O
skin . . O
, . . O
muscle . . O
and . . O
internal . . O
organs . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
eli . . O
lilly . . O
and . . O
company . . O
at . . O
1-800 . . O
- . . O
lillyrx . . O
( . . O
1-800-545-5979 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
risk . . B-Factor
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
lundbeck . . O
at . . O
1-800-455-1141 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

assess . . O
lvef . . O
by . . O
echocardiogram . . O
or . . O
multigated . . O
acquisition . . O
( . . O
muga . . O
) . . O
scan . . O
before . . O
initiation . . O
of . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
, . . O
one . . O
month . . O
after . . O
initiation . . O
, . . O
and . . O
then . . O
at . . O
2 . . O
- . . O
to . . O
3 . . O
- . . O
month . . O
intervals . . O
while . . O
on . . O
treatment . . O
with . . O
the . . O
combination . . O
. . . O

available . . O
data . . O
from . . O
controlled . . O
clinical . . O
trials . . O
suggest . . O
that . . O
laba . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
hospitalization . . O
in . . O
pediatric . . O
and . . O
adolescent . . O
patients . . O
. . . O

serious . . O
adverse . . O
reactions . . O
: . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
( . . O
2 . . O
cases . . O
) . . O
, . . O
ruptured . . B-AdverseReaction
ovarian . . I-AdverseReaction
cyst . . I-AdverseReaction
( . . O
2 . . O
cases . . O
) . . O
, . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
, . . O
focal . . B-AdverseReaction
nodular . . I-AdverseReaction
hyperplasia . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
liver . . I-AdverseReaction
, . . O
uterine . . B-AdverseReaction
leiomyoma . . I-AdverseReaction
, . . O
acute . . B-AdverseReaction
cholecystitis . . I-AdverseReaction
, . . O
and . . O
chronic . . B-AdverseReaction
acalculous . . I-AdverseReaction
cholecystitis . . I-AdverseReaction
. . . O

one . . O
patient . . O
experienced . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
attention . . I-AdverseReaction
, . . O
eyelid . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
feeling . . B-AdverseReaction
abnormal . . I-AdverseReaction
and . . O
headache . . B-AdverseReaction
, . . O
and . . O
one . . O
patient . . O
experienced . . O
dysphagia . . B-AdverseReaction
. . . O

stendra . . O
200 . . O
mg . . O
resulted . . O
in . . O
transient . . B-AdverseReaction
decreases . . I-AdverseReaction
in . . I-AdverseReaction
sitting . . I-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
in . . O
healthy . . O
volunteers . . O
of . . O
8.0 . . B-Severity
mmhg . . I-Severity
systolic . . I-Severity
and . . I-Severity
3.3 . . I-Severity
mmhg . . I-Severity
diastolic . . I-Severity
[ . . O
seeclinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
, . . O
with . . O
the . . O
maximum . . O
decrease . . O
observed . . O
at . . O
1 . . O
hour . . O
after . . O
dosing . . O
. . . O

* . . O
tendon . . B-AdverseReaction
ruptures . . I-AdverseReaction
or . . O
other . . O
serious . . B-Severity
injury . . B-AdverseReaction
to . . I-AdverseReaction
the . . I-AdverseReaction
injected . . I-AdverseReaction
extremity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
in . . O
patients . . O
with . . O
peyronie's . . O
disease . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

* . . O
carcinogenicity . . O
of . . O
albiglutide . . O
could . . O
not . . O
be . . O
assessed . . O
in . . O
rodents . . O
, . . O
but . . O
other . . O
glucagon . . B-DrugClass
- . . I-DrugClass
like . . I-DrugClass
peptide . . I-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
( . . I-DrugClass
glp . . I-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
) . . I-DrugClass
receptor . . I-DrugClass
agonists . . I-DrugClass
have . . O
caused . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
in . . O
rodents . . B-Animal
at . . O
clinically . . O
relevant . . O
exposures . . O
. . . O

of . . O
these . . O
6 . . O
ada . . O
positive . . O
patients . . O
, . . O
one . . O
experienced . . O
a . . O
hypersensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
during . . O
study . . O
1 . . O
( . . O
2% . . O
, . . O
1 . . O
of . . O
56 . . O
) . . O
. . . O

fatal . . B-AdverseReaction
hemorrhage . . B-AdverseReaction
was . . O
reported . . O
in . . O
1 . . O
/ . . O
359 . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
( . . O
gastric . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
) . . O
and . . O
3 . . O
/ . . O
355 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O
in . . O
chronic . . O
obstructive . . O
pulmonary . . O
disease . . O

adverse . . O
reaction . . O
information . . O
for . . O
ferriprox . . O
represents . . O
the . . O
pooled . . O
data . . O
collected . . O
from . . O
642 . . O
patients . . O
who . . O
participated . . O
in . . O
single . . O
arm . . O
or . . O
active . . O
- . . O
controlled . . O
clinical . . O
studies . . O
. . . O

provide . . O
supportive . . O
medical . . O
care . . O
if . . O
shortness . . O
of . . O
breath . . O
develops . . O
. . . O

the . . O
changes . . O
in . . O
mean . . O
serum . . O
creatinine . . O
were . . O
similar . . O
to . . O
those . . O
observed . . O
in . . O
adults . . O
. . . O

monitor . . O
ecgs . . O
. . . O

antidepressants . . B-DrugClass
increased . . O
the . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
and . . O
behavior . . O
in . . O
children . . O
, . . O
adolescents . . O
, . . O
and . . O
young . . O
adults . . O
in . . O
short . . O
- . . O
term . . O
studies . . O
. . . O

monitor . . O
heart . . O
failure . . O
patients . . O
carefully . . O
. . . O

infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
, . . O
have . . O
occurred . . O
with . . O
adcetris . . O
. . . O

excerpt . . O
: . . O
for . . O
all . . O
indications . . O
: . . O

the . . O
risk . . O
of . . O
acute . . O
kidney . . O
injury . . O
may . . O
increase . . O
with . . O
increasing . . O
dose . . O
of . . O
the . . O
contrast . . O
agent . . O
; . . O
administer . . O
the . . O
lowest . . O
dose . . O
necessary . . O
for . . O
adequate . . O
imaging . . O
. . . O

* . . O
with . . O
chronic . . O
or . . O
recurrent . . O
infection . . O
* . . O
who . . O
have . . O
been . . O
exposed . . O
to . . O
tuberculosis . . O
* . . O
with . . O
a . . O
history . . O
of . . O
an . . O
opportunistic . . O
infection . . O
* . . O
who . . O
have . . O
resided . . O
or . . O
traveled . . O
in . . O
areas . . O
of . . O
endemic . . O
tuberculosis . . O
or . . O
endemic . . O
mycoses . . O
, . . O
such . . O
as . . O
histoplasmosis . . O
, . . O
coccidioidomycosis . . O
, . . O
or . . O
blastomycosis . . O
* . . O
with . . O
underlying . . O
conditions . . O
that . . O
may . . O
predispose . . O
them . . O
to . . O
infection . . O
tuberculosis . . O

creatinine . . B-AdverseReaction
increases . . I-AdverseReaction
were . . O
comparable . . O
by . . O
background . . O
nrtis . . O
and . . O
were . . O
similar . . O
in . . O
treatment . . O
- . . O
experienced . . O
subjects . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
avoid . . O
coadministration . . O
with . . O
other . . O
anti . . O
- . . O
retroviral . . O
products . . O
: . . O
do . . O
not . . O
use . . O
with . . O
products . . O
containing . . O
any . . O
of . . O
the . . O
components . . O
of . . O
stribild . . O
( . . O
cobicistat . . O
, . . O
elvitegravir . . O
, . . O
emtricitabine . . O
, . . O
and . . O
tenofovir . . O
disoproxil . . O
fumarate . . O
) . . O
, . . O
including . . O
atripla . . O
, . . O
complera . . O
, . . O
emtriva . . O
, . . O
truvada . . O
, . . O
tybost . . O
, . . O
viread . . O
, . . O
or . . O
vitekta . . O
; . . O
with . . O
drugs . . O
containing . . O
lamivudine . . O
; . . O
or . . O
with . . O
drugs . . O
or . . O
regimens . . O
containing . . O
ritonavir . . O
. . . O

excerpt . . O
: . . O
* . . O
ecg . . B-AdverseReaction
changes . . I-AdverseReaction
and . . O
potential . . B-Factor
for . . O
cardiac . . B-AdverseReaction
arrhythmias . . I-AdverseReaction
: . . O
not . . O
recommended . . O
in . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
cardiac . . O
disease . . O
, . . O
long . . O
qt . . O
syndrome . . O
, . . O
and . . O
concomitant . . O
use . . O
of . . O
class . . O
ia . . O
and . . O
class . . O
iii . . O
antiarrhythmics . . O
( . . O
5.2 . . O
) . . O

anesthesia . . O
or . . O
undergoing . . O
spinal . . O
puncture . . O
. . . O

posterior . . O
reversible . . O
encephalopathy . . O
syndrome . . O
( . . O
pres . . O
) . . O
, . . O
formerly . . O
termed . . O
reversible . . O
posterior . . O
leukoencephalopathy . . O
syndrome . . O
( . . O
rpls . . O
) . . O
, . . O
is . . O
a . . O
neurological . . O
disorder . . O
which . . O
can . . O
present . . O
with . . O
seizure . . O
, . . O
headache . . O
, . . O
lethargy . . O
, . . O
confusion . . O
, . . O
blindness . . O
, . . O
altered . . O
consciousness . . O
, . . O
and . . O
other . . O
visual . . O
and . . O
neurological . . O
disturbances . . O
, . . O
along . . O
with . . O
hypertension . . O
, . . O
and . . O
the . . O
diagnosis . . O
is . . O
confirmed . . O
by . . O
neuro . . O
- . . O
radiological . . O
imaging . . O
( . . O
mri . . O
) . . O
. . . O

the . . O
incidence . . O
of . . O
ild . . B-AdverseReaction
appeared . . O
to . . O
be . . O
higher . . O
in . . O
patients . . O
of . . O
asian . . O
ethnicity . . O
( . . O
2.1% . . O
) . . O
as . . O
compared . . O
to . . O
non . . O
- . . O
asians . . O
( . . O
1.2% . . O
) . . O
. . . O

patients . . O
who . . O
develop . . O
increased . . O
transaminase . . O
levels . . O
should . . O
be . . O
closely . . O
monitored . . O
until . . O
the . . O
abnormalities . . O
resolve . . O
. . . O

at . . O
baseline . . O
, . . O
2.5% . . O
of . . O
the . . O
population . . O
reported . . O
retinopathy . . O
. . . O

adreview . . O
imaging . . O
should . . O
not . . O
be . . O
performed . . O
if . . O
discontinuation . . O
of . . O
these . . O
medications . . O
would . . O
involve . . O
risks . . O
which . . O
outweigh . . O
the . . O
value . . O
of . . O
adreview . . O
imaging . . O
. . . O

6.2 . . O
post . . O
- . . O
marketing . . O
experience . . O

stribildn . . O
= . . O
701 . . O
atriplan . . O
= . . O
352 . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvadan . . O
= . . O
355 . . O
eye . . O
disorders . . O
ocular . . B-AdverseReaction
icterus . . I-AdverseReaction
< . . O
1% . . O
0% . . O
13% . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
12% . . O
11% . . O
17% . . O
flatulence . . B-AdverseReaction
2% . . O
< . . O
1% . . O
8% . . O
nausea . . B-AdverseReaction
16% . . O
9% . . O
14% . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
4% . . O
8% . . O
6% . . O
hepatobiliary . . O
disorders . . O
jaundice . . B-AdverseReaction
0% . . O
< . . O
1% . . O
9% . . O
nervous . . O
system . . O
disorders . . O
somnolence . . B-AdverseReaction
1% . . O
7% . . O
1% . . O
headache . . B-AdverseReaction
7% . . O
4% . . O
6% . . O
dizziness . . B-AdverseReaction
3% . . O
21% . . O
5% . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
3% . . O
9% . . O
1% . . O
abnormal . . B-AdverseReaction
dreams . . I-AdverseReaction
9% . . O
27% . . O
4% . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
4% . . O
15% . . O
6% . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
, . . O
for . . O
a . . O
discussion . . O
of . . O
renal . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
from . . O
clinical . . O
trials . . O
experience . . O
with . . O
stribild . . O
. . . O

concomitant . . O
use . . O
of . . O
drugs . . O
affecting . . O
hemostasis . . O
increases . . O
the . . O
risk . . B-Factor
of . . O
bleeding . . B-AdverseReaction
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O

the . . O
majority . . O
of . . O
injection . . O
site . . O
reactions . . O
were . . O
judged . . O
as . . O
" . . O
mild . . B-Severity
" . . O
by . . O
investigators . . O
in . . O
both . . O
groups . . O
( . . O
73% . . O
for . . O
tanzeum . . O
versus . . O
94% . . O
for . . O
placebo . . O
) . . O
. . . O

the . . O
skin . . B-AdverseReaction
discoloration . . I-AdverseReaction
is . . O
generally . . O
described . . O
as . . O
blue . . O
, . . O
but . . O
has . . O
also . . O
been . . O
described . . O
as . . O
grey . . O
- . . O
blue . . O
or . . O
brown . . O
. . . O

5.11 . . O
hypersensitivity . . O
reactions . . O
, . . O
including . . O
anaphylaxis . . O

( . . O
5.1 . . O
) . . O
* . . O
pancreatitis . . B-AdverseReaction
: . . O
discontinue . . O
promptly . . O
if . . O
suspected . . O
. . . O

( . . O
6.1 . . O
) . . O

if . . O
accidental . . O
exposure . . O
occurs . . O
, . . O
the . . O
area . . O
should . . O
be . . O
flushed . . O
with . . O
water . . O
and . . O
the . . O
patient . . O
should . . O
seek . . O
medical . . O
care . . O
as . . O
soon . . O
as . . O
possible . . O
. . . O

cocs . . B-DrugClass
have . . O
been . . O
shown . . O
to . . O
increase . . O
both . . O
the . . O
relative . . O
and . . O
attributable . . O
risks . . O
of . . O
cerebrovascular . . B-AdverseReaction
events . . I-AdverseReaction
( . . O
thrombotic . . O
and . . O
hemorrhagic . . B-AdverseReaction
strokes . . I-AdverseReaction
) . . O
, . . O
although . . O
, . . O
in . . O
general . . O
, . . O
the . . O
risk . . O
is . . O
greatest . . O
among . . O
older . . O
( . . O
> . . O
35 . . O
years . . O
of . . O
age . . O
) . . O
, . . O
hypertensive . . O
women . . O
who . . O
also . . O
smoke . . O
. . . O

arcapta . . O
neohaler . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
the . . O
relief . . O
of . . O
acute . . O
symptoms . . O
and . . O
extra . . O
doses . . O
should . . O
not . . O
be . . O
used . . O
for . . O
that . . O
purpose . . O
. . . O

5.1 . . O
hyperammonemia . . O

stribild . . O
is . . O
indicated . . O
for . . O
use . . O
as . . O
a . . O
complete . . O
regimen . . O
for . . O
the . . O
treatment . . O
of . . O
hiv . . O
- . . O
1 . . O
infection . . O
and . . O
coadministration . . O
with . . O
other . . O
antiretroviral . . O
products . . O
is . . O
not . . O
recommended . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

in . . O
the . . O
randomized . . O
, . . O
placebo . . O
- . . O
controlled . . O
portion . . O
of . . O
sjia . . O
study . . O
2 . . O
decreased . . B-AdverseReaction
white . . I-AdverseReaction
blood . . I-AdverseReaction
cell . . I-AdverseReaction
counts . . I-AdverseReaction
( . . O
wbc . . O
) . . O
less . . O
than . . O
or . . O
equal . . O
to . . O
0.8 . . B-Severity
times . . I-Severity
lower . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . O
lln . . O
) . . O
were . . O
reported . . O
in . . O
5 . . O
patients . . O
( . . O
10.4% . . O
) . . O
in . . O
the . . O
ilaris . . O
group . . O
compared . . O
to . . O
2 . . O
( . . O
4.0% . . O
) . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

the . . O
most . . O
common . . O
cause . . O
of . . O
death . . B-AdverseReaction
as . . O
reported . . O
by . . O
the . . O
investigator . . O
was . . O
tb . . O
( . . O
9 . . O
subjects . . O
) . . O
. . . O

everolimus . . O
caused . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicities . . I-AdverseReaction
in . . O
animals . . B-Animal
at . . O
maternal . . O
exposures . . O
that . . O
were . . O
lower . . O
than . . O
human . . O
exposures . . O
. . . O

patients . . O
with . . O
classical . . O
hl . . O
and . . O
salcl . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
were . . O
tested . . O
for . . O
antibodies . . O
to . . O
brentuximab . . O
vedotin . . O
every . . O
3 . . O
weeks . . O
using . . O
a . . O
sensitive . . O
electrochemiluminescent . . O
immunoassay . . O
. . . O

malignancy . . O

( . . O
5.2 . . O
) . . O

and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

because . . O
of . . O
physiological . . O
diurnal . . O
variation . . O
, . . O
there . . O
is . . O
a . . O
second . . O
period . . O
of . . O
heart . . B-AdverseReaction
rate . . I-AdverseReaction
decrease . . I-AdverseReaction
within . . O
24 . . O
hours . . O
after . . O
the . . O
first . . O
dose . . O
. . . O

* . . O
screen . . O
patients . . O
for . . O
acute . . O
kidney . . O
injury . . O
and . . O
other . . O
conditions . . O
that . . O
may . . O
reduce . . O
renal . . O
function . . O
. . . O

patients . . O
using . . O
breo . . O
ellipta . . O
should . . O
not . . O
use . . O
another . . O
medicine . . O
containing . . O
a . . O
laba . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
salmeterol . . O
, . . O
formoterol . . O
fumarate . . O
, . . O
arformoterol . . O
tartrate . . O
, . . O
indacaterol . . O
) . . O
for . . O
any . . O
reason . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
bleeding . . B-AdverseReaction
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
belatacept . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

consequently . . O
, . . O
farxiga . . O
should . . O
not . . O
be . . O
used . . O
in . . O
patients . . O
with . . O
active . . O
bladder . . O
cancer . . O
. . . O

patients . . O
treated . . O
with . . O
cimzia . . O
may . . O
receive . . O
vaccinations . . O
, . . O
except . . O
for . . O
live . . O
or . . O
live . . O
attenuated . . O
vaccines . . O
. . . O

in . . O
clinical . . O
trials . . O
( . . O
studies . . O
1 . . O
, . . O
2 . . O
, . . O
and . . O
3 . . O
) . . O
, . . O
a . . O
total . . O
of . . O
1212 . . O
patients . . O
with . . O
relapsing . . O
forms . . O
of . . O
multiple . . O
sclerosis . . O
received . . O
gilenya . . O
0.5 . . O
mg . . O
. . . O

causality . . O
cannot . . O
be . . O
excluded . . O
. . . O

in . . O
three . . O
randomized . . O
, . . O
controlled . . O
clinical . . O
studies . . O
( . . O
studies . . O
1 . . O
, . . O
2 . . O
and . . O
3 . . O
) . . O
, . . O
which . . O
were . . O
six . . O
to . . O
12 . . O
months . . O
in . . O
duration . . O
, . . O
the . . O
following . . O
adverse . . O
reactions . . O
were . . O
reported . . O
by . . O
the . . O
treating . . O
physician . . O
as . . O
related . . O
to . . O
study . . O
drug . . O
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
leukocytosis . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
lymphopenia . . B-AdverseReaction
( . . O
1% . . O
) . . O

no . . O
association . . O
was . . O
seen . . O
between . . O
antibody . . O
development . . O
and . . O
development . . O
of . . O
adverse . . O
events . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
premature . . O
discontinuation . . O
because . . O
of . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
11.8% . . O
of . . O
the . . O
dronedarone . . O
- . . O
treated . . O
patients . . O
and . . O
in . . O
7.7% . . O
of . . O
the . . O
placebo . . O
- . . O
treated . . O
group . . O
. . . O

urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
utis . . B-AdverseReaction
) . . O
were . . O
reported . . O
more . . O
frequently . . O
as . . O
adverse . . O
reactions . . O
in . . O
controlled . . O
studies . . O
in . . O
patients . . O
receiving . . O
ampyra . . O
10 . . O
mg . . O
twice . . O
daily . . O
( . . O
12% . . O
) . . O
as . . O
compared . . O
to . . O
placebo . . O
( . . O
8% . . O
) . . O
. . . O

( . . O
5.1 . . O
, . . O
5.4 . . O
, . . O
5.5 . . O
) . . O
* . . O
liver . . O
transplant . . O
: . . O
use . . O
is . . O
not . . O
recommended . . O
. . . O

as . . O
pml . . O
has . . O
been . . O
associated . . O
with . . O
high . . O
levels . . O
of . . O
overall . . O
immunosuppression . . O
, . . O
the . . O
recommended . . O
doses . . O
and . . O
frequency . . O
of . . O
nulojix . . O
and . . O
concomitant . . O
immunosuppressives . . O
, . . O
including . . O
mmf . . O
, . . O
should . . O
not . . O
be . . O
exceeded . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
requiring . . O
intervention . . O
in . . O
clinical . . O
trials . . O
were . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
occurring . . O
in . . O
20 . . O
of . . O
39 . . O
( . . O
51% . . O
) . . O
patients . . O
treated . . O
with . . O
alglucosidase . . O
alfa . . O
, . . O
and . . O
included . . O
rash . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
oxygen . . I-AdverseReaction
saturation . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
tachypnea . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
/ . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
, . . O
pallor . . B-AdverseReaction
, . . O
rigors . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
cyanosis . . B-AdverseReaction
, . . O
agitation . . B-AdverseReaction
, . . O
and . . O
tremor . . B-AdverseReaction
. . . O

the . . O
patient . . O
had . . O
no . . O
other . . O
identified . . O
systemic . . O
medical . . O
conditions . . O
resulting . . O
in . . O
compromised . . O
immune . . O
system . . O
function . . O
and . . O
had . . O
not . . O
previously . . O
been . . O
treated . . O
with . . O
natalizumab . . O
, . . O
which . . O
has . . O
a . . O
known . . O
association . . O
with . . O
pml . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
night . . B-AdverseReaction
sweats . . I-AdverseReaction
, . . O
lipohypertrophy . . B-AdverseReaction
, . . O
prurigo . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
skin . . I-AdverseReaction
, . . O
swelling . . B-AdverseReaction
face . . I-AdverseReaction

no . . O
serious . . O
adverse . . O
reactions . . O
to . . O
adreview . . O
were . . O
observed . . O
in . . O
clinical . . O
studies . . O
. . . O

nervous . . O
system . . O
disorders . . O
- . . O
syncope . . B-AdverseReaction
, . . O
convulsion . . B-AdverseReaction
, . . O
dystonia . . B-AdverseReaction
. . . O

5.16 . . O
laboratory . . O
tests . . O

avoid . . O
administration . . O
of . . O
cometriq . . O
with . . O
agents . . O
that . . O
are . . O
strong . . O
cyp3a4 . . O
inducers . . O
or . . O
inhibitors . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
and . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
, . . O
7.2 . . O
) . . O
] . . O
. . . O

oral . . O
contraceptive . . O
use . . O
should . . O
be . . O
discontinued . . O
if . . O
pregnancy . . O
is . . O
confirmed . . O
. . . O

the . . O
safety . . O
and . . O
efficacy . . O
of . . O
arcapta . . O
neohaler . . O
in . . O
patients . . O
with . . O
asthma . . O
have . . O
not . . O
been . . O
established . . O
. . . O

adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
postmenopausal . . O
women . . O
with . . O
osteoporosis . . O
and . . O
more . . O
frequently . . O
in . . O
the . . O
prolia . . O
- . . O
treated . . O
women . . O
than . . O
in . . O
the . . O
placebo . . O
- . . O
treated . . O
women . . O
are . . O
shown . . O
in . . O
the . . O
table . . O
below . . O
. . . O

deaths . . B-AdverseReaction
as . . O
a . . O
complication . . O
of . . O
severe . . B-Severity
dysphagia . . B-AdverseReaction
have . . O
been . . O
reported . . O
after . . O
treatment . . O
with . . O
botulinum . . B-DrugClass
toxin . . I-DrugClass
. . . O

5.1 . . O
risk . . O
of . . O
serious . . O
infections . . O

5.8 . . O
increases . . O
in . . O
low . . O
- . . O
density . . O
lipoprotein . . O
( . . O
ldl . . O
- . . O
c . . O
) . . O

multaq . . O
doubles . . O
the . . O
risk . . B-Factor
of . . O
cardiovascular . . B-AdverseReaction
death . . I-AdverseReaction
( . . O
largely . . O
arrhythmic . . O
) . . O
and . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
events . . I-AdverseReaction
in . . O
patients . . O
with . . O
permanent . . O
af . . O
. . . O

patients . . O
who . . O
experience . . O
anaphylactic . . O
or . . O
hypersensitivity . . O
reactions . . O
may . . O
also . . O
be . . O
tested . . O
for . . O
ige . . O
antibodies . . O
to . . O
alglucosidase . . O
alfa . . O
and . . O
other . . O
mediators . . O
of . . O
anaphylaxis . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

treatment . . O
to . . O
increase . . O
bone . . O
mass . . O
in . . O
men . . O
with . . O
osteoporosis . . O

5.1 . . O
neutropenia . . O

table . . O
4 . . O
displays . . O
the . . O
mean . . O
changes . . O
in . . O
serum . . O
creatinine . . O
and . . O
egfr . . O
levels . . O
at . . O
week . . O
144 . . O
and . . O
the . . O
percentage . . O
of . . O
subjects . . O
with . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
( . . O
all . . O
grades . . O
) . . O
. . . O

swallowing . . O
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
can . . B-Factor
be . . O
life . . B-Severity
threatening . . I-Severity
and . . O
there . . O
have . . O
been . . O
reports . . O
of . . O
death . . B-AdverseReaction
. . . O

reduce . . O
or . . O
withhold . . O
dose . . O
as . . O
appropriate . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

reduce . . O
or . . O
withhold . . O
dose . . O
as . . O
appropriate . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
infections . . B-AdverseReaction
: . . O
increased . . O
risk . . B-Factor
of . . O
infections . . B-AdverseReaction
, . . O
some . . O
fatal . . B-AdverseReaction
. . . O

the . . O
median . . O
time . . O
to . . O
onset . . O
of . . O
any . . O
neurological . . O
toxicity . . O
was . . O
7 . . O
days . . O
. . . O

hepatic . . O
transaminases . . O

if . . O
anaphylactic . . O
or . . O
other . . O
clinically . . O
significant . . O
hypersensitivity . . O
reactions . . O
occur . . O
, . . O
discontinue . . O
picato . . O
( . . O
r . . O
) . . O
immediately . . O
and . . O
institute . . O
appropriate . . O
medical . . O
therapy . . O
. . . O

hepatic . . B-AdverseReaction
steatosis . . I-AdverseReaction
, . . O
hepatitis . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
( . . O
most . . O
commonly . . O
ast . . O
, . . O
alt . . O
gamma . . O
gt . . O
) . . O

( . . O
5.12 . . O
) . . O
* . . O
assess . . O
for . . O
decrease . . O
in . . O
bone . . O
mineral . . O
density . . O
initially . . O
and . . O
periodically . . O
thereafter . . O
. . . O

other . . O
known . . O
risk . . O
factors . . O
for . . O
ptld . . O
include . . O
cytomegalovirus . . O
( . . O
cmv . . O
) . . O
infection . . O
and . . O
t . . O
- . . O
cell . . O
- . . O
depleting . . O
therapy . . O
. . . O

discontinue . . O
granix . . O
in . . O
patients . . O
undergoing . . O
a . . O
sickle . . O
cell . . O
crisis . . O
. . . O

5.2 . . O
fat . . O
redistribution . . O

steroid . . O
hormones . . O
may . . O
be . . O
poorly . . O
metabolized . . O
in . . O
patients . . O
with . . O
impaired . . O
liver . . O
function . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
redistribution . . O
/ . . O
accumulation . . B-AdverseReaction
of . . I-AdverseReaction
body . . I-AdverseReaction
fat . . I-AdverseReaction
: . . O
observed . . O
in . . O
patients . . O
receiving . . O
antiretroviral . . O
therapy . . O
. . . O

table . . O
3 . . O
: . . O
adverse . . O
reactions . . O
( . . O
10% . . O
or . . O
greater . . O
) . . O
in . . O
patients . . O
with . . O
cml . . O
in . . O
study . . O
1 . . O
chronic . . O
phase . . O
cmln . . O
= . . O
406 . . O
advanced . . O
phase . . O
cmln . . O
= . . O
140 . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4 . . O
( . . O
% . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4 . . O
( . . O
% . . O
) . . O
advanced . . O
phase . . O
cml . . O
includes . . O
patients . . O
with . . O
accelerated . . O
phase . . O
and . . O
blast . . O
phase . . O
cml . . O
diarrhea . . B-AdverseReaction
84 . . O
9 . . O
76 . . O
5 . . O
nausea . . B-AdverseReaction
46 . . O
1 . . O
47 . . O
2 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
40 . . O
1 . . O
29 . . O
5 . . O
thrombocytopenia . . B-AdverseReaction
40 . . O
26 . . O
42 . . O
37 . . O
vomiting . . B-AdverseReaction
37 . . O
3 . . O
42 . . O
4 . . O
rash . . B-AdverseReaction
34 . . O
8 . . O
35 . . O
4 . . O
fatigue . . B-AdverseReaction
26 . . O
1 . . O
20 . . O
4 . . O
anemia . . B-AdverseReaction
23 . . O
9 . . O
37 . . O
26 . . O
pyrexia . . B-AdverseReaction
22 . . O
< . . O
1 . . O
36 . . O
3 . . O
increased . . B-AdverseReaction
alanine . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
20 . . O
7 . . O
10 . . O
5 . . O
headache . . B-AdverseReaction
20 . . O
1 . . O
18 . . O
4 . . O
cough . . B-AdverseReaction
20 . . O
0 . . O
21 . . O
0 . . O
increased . . B-AdverseReaction
aspartate . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
16 . . O
4 . . O
11 . . O
3 . . O
neutropenia . . B-AdverseReaction
16 . . O
11 . . O
19 . . O
18 . . O
edema . . B-AdverseReaction
14 . . O
< . . O
1 . . O
14 . . O
1 . . O
arthralgia . . B-AdverseReaction
14 . . O
< . . O
1 . . O
13 . . O
0 . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
13 . . O
1 . . O
14 . . O
0 . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
12 . . O
< . . O
1 . . O
10 . . O
0 . . O
nasopharyngitis . . B-AdverseReaction
12 . . O
0 . . O
5 . . O
0 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
12 . . O
1 . . O
7 . . O
1 . . O
asthenia . . B-AdverseReaction
11 . . O
1 . . O
10 . . O
1 . . O
pruritus . . B-AdverseReaction
11 . . O
1 . . O
8 . . O
0 . . O
dizziness . . B-AdverseReaction
10 . . O
0 . . O
13 . . O
1 . . O
dyspnea . . B-AdverseReaction
10 . . O
1 . . O
19 . . O
6 . . O
in . . O
the . . O
single . . O
- . . O
arm . . O
phase . . O
1 . . O
/ . . O
2 . . O
clinical . . O
trial . . O
, . . O
one . . O
patient . . O
( . . O
0.2% . . O
) . . O
experienced . . O
qtcf . . B-AdverseReaction
interval . . I-AdverseReaction
of . . I-AdverseReaction
greater . . I-AdverseReaction
than . . I-AdverseReaction
500 . . I-AdverseReaction
milliseconds . . I-AdverseReaction
. . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
( . . O
incidence . . O
> . . O
= . . O
50% . . O
) . . O
were . . O
anemia . . B-AdverseReaction
, . . O
hypercholesterolemia . . B-AdverseReaction
, . . O
hypertriglyceridemia . . O
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
and . . O
increased . . B-AdverseReaction
creatinine . . I-AdverseReaction
. . . O

the . . O
rate . . O
of . . O
withdrawals . . O
due . . O
to . . O
adverse . . O
events . . O
in . . O
placebo . . O
- . . O
controlled . . O
monotherapy . . O
and . . O
combination . . O
therapy . . O
trials . . O
was . . O
2.4% . . O
( . . O
19 . . O
/ . . O
801 . . O
) . . O
for . . O
placebo . . O
, . . O
2.2% . . O
( . . O
24 . . O
/ . . O
1072 . . O
) . . O
for . . O
edarbi . . O
40 . . O
mg . . O
, . . O
and . . O
2.7% . . O
( . . O
29 . . O
/ . . O
1074 . . O
) . . O
for . . O
edarbi . . O
80 . . O
mg . . O
. . . O

1 . . O
neonatal . . O
toxicity . . O

discontinue . . O
pradaxa . . O
in . . O
patients . . O
with . . O
active . . O
pathological . . O
bleeding . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

antiepileptic . . O
drugs . . O
( . . O
aeds . . O
) . . O
, . . O
including . . O
potiga . . O
, . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
in . . O
patients . . O
taking . . O
these . . O
drugs . . O
for . . O
any . . O
indication . . O
. . . O

approximately . . O
86% . . O
of . . O
the . . O
population . . O
studied . . O
was . . O
caucasian . . O
, . . O
and . . O
0.8% . . O
of . . O
the . . O
population . . O
was . . O
aged . . O
65 . . O
years . . O
or . . O
older . . O
. . . O

boxed . . O
warning . . O
: . . O

5.1 . . O
non . . O
- . . O
infectious . . O
pneumonitis . . O

the . . O
incidence . . O
of . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
in . . O
female . . O
patients . . O
randomized . . O
to . . O
placebo . . O
, . . O
jardiance . . O
10 . . O
mg . . O
, . . O
and . . O
jardiance . . O
25 . . O
mg . . O
was . . O
16.6% . . O
, . . O
18.4% . . O
, . . O
and . . O
17.0% . . O
, . . O
respectively . . O
. . . O

preventive . . O
measures . . O
include . . O
vigorous . . O
hydration . . O
and . . O
close . . O
monitoring . . O
of . . O
blood . . O
chemistry . . O
, . . O
particularly . . O
potassium . . O
and . . O
uric . . O
acid . . O
levels . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
7.5% . . O
of . . O
642 . . O
subjects . . O
treated . . O
with . . O
ferriprox . . O
developed . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
values . . I-AdverseReaction
. . . O

renal . . O
disorders . . O
: . . O
glycosuria . . B-AdverseReaction
, . . O
hemoglobinuria . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
* . . O
endophthalmitis . . B-AdverseReaction
and . . O
retinal . . B-AdverseReaction
detachments . . I-AdverseReaction
may . . B-Factor
occur . . O
following . . O
intravitreal . . O
injections . . O
. . . O

fanapt . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
known . . O
cardiovascular . . O
disease . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
heart . . O
failure . . O
, . . O
history . . O
of . . O
myocardial . . O
infarction . . O
, . . O
ischemia . . O
, . . O
or . . O
conduction . . O
abnormalities . . O
) . . O
, . . O
cerebrovascular . . O
disease . . O
, . . O
or . . O
conditions . . O
that . . O
predispose . . O
the . . O
patient . . O
to . . O
hypotension . . O
( . . O
dehydration . . O
, . . O
hypovolemia . . O
, . . O
and . . O
treatment . . O
with . . O
antihypertensive . . O
medications . . O
) . . O
. . . O

treatment . . O
of . . O
hyperammonemia . . O
may . . O
require . . O
dialysis . . O
, . . O
preferably . . O
hemodialysis . . O
, . . O
to . . O
remove . . O
a . . O
large . . O
burden . . O
of . . O
ammonia . . O
. . . O

* . . O
infections . . O
and . . O
infestations . . O
: . . O
rhinitis . . B-AdverseReaction
* . . O
investigations . . O
: . . O
aspartate . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
bacteria . . B-AdverseReaction
in . . I-AdverseReaction
sputum . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
glucose . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
hepatic . . B-AdverseReaction
enzyme . . I-AdverseReaction
increased . . I-AdverseReaction
* . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
arthralgia . . B-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
chest . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
* . . O
nervous . . O
system . . O
disorders . . O
: . . O
sinus . . B-AdverseReaction
headache . . I-AdverseReaction
* . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
pharyngeal . . B-AdverseReaction
erythema . . I-AdverseReaction
, . . O
pleuritic . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
sinus . . B-AdverseReaction
congestion . . I-AdverseReaction
, . . O
wheezing . . B-AdverseReaction
* . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
acne . . B-AdverseReaction
the . . O
safety . . O
profile . . O
for . . O
the . . O
cf . . O
patients . . O
enrolled . . O
in . . O
the . . O
other . . O
clinical . . O
trials . . O
( . . O
trials . . O
3-6 . . O
) . . O
was . . O
similar . . O
to . . O
that . . O
observed . . O
in . . O
the . . O
48 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
( . . O
trials . . O
1 . . O
and . . O
2 . . O
) . . O
. . . O

patients . . O
using . . O
supplemental . . O
oxygen . . O
or . . O
continuous . . O
positive . . O
airway . . O
pressure . . O
( . . O
cpap . . O
) . . O
during . . O
sleep . . O
should . . O
have . . O
these . . O
treatments . . O
readily . . O
available . . O
during . . O
infusion . . O
in . . O
the . . O
event . . O
of . . O
an . . O
acute . . O
reaction . . O
, . . O
or . . O
extreme . . O
drowsiness . . O
/ . . O
sleep . . O
induced . . O
by . . O
antihistamine . . O
use . . O
. . . O

due . . O
to . . O
the . . O
potential . . B-Factor
for . . O
neurologic . . B-AdverseReaction
events . . I-AdverseReaction
, . . O
including . . O
seizures . . B-AdverseReaction
, . . O
patients . . O
receiving . . O
blincyto . . O
are . . O
at . . O
risk . . B-Factor
for . . O
loss . . B-AdverseReaction
of . . I-AdverseReaction
consciousness . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

adverse . . O
reactions . . O
related . . O
to . . O
renal . . O
function . . O
can . . B-Factor
occur . . O
after . . O
initiating . . O
farxiga . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

although . . O
some . . O
of . . O
the . . O
patients . . O
with . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
have . . O
been . . O
found . . O
to . . O
have . . O
abnormal . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
, . . O
it . . O
is . . O
not . . O
possible . . O
to . . O
assess . . O
whether . . B-Factor
potiga . . O
caused . . O
their . . O
decreased . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
, . . O
as . . O
baseline . . O
assessments . . O
are . . O
not . . O
available . . O
for . . O
these . . O
patients . . O
. . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
1% . . O
or . . O
greater . . O
) . . O
are . . O
: . . O
systemic . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
transaminases . . B-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
fever . . B-AdverseReaction
, . . O
pancreatitis . . B-AdverseReaction
, . . O
local . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
thrombosis . . B-AdverseReaction
, . . O
hyperbilirubinemia . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
/ . . O
discomfort . . O
, . . O
and . . O
diarrhea . . B-AdverseReaction
. . . O

6 . . O
adverse . . O
reactions . . O

two . . O
patients . . O
receiving . . O
alglucosidase . . O
alfa . . O
discontinued . . O
the . . O
trial . . O
due . . O
to . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
fatal . . B-AdverseReaction
and . . O
serious . . B-Severity
toxicities . . B-AdverseReaction
: . . O
hepatic . . O
, . . O
severe . . B-Severity
diarrhea . . B-AdverseReaction
, . . O
colitis . . B-AdverseReaction
, . . O
pneumonitis . . B-AdverseReaction
, . . O
and . . O
intestinal . . B-AdverseReaction
perforation . . I-AdverseReaction

* . . O
hepatitis . . B-AdverseReaction
b . . I-AdverseReaction
reactivation . . I-AdverseReaction
- . . O
monitor . . O
hbv . . O
carriers . . O
during . . O
and . . O
several . . O
months . . O
after . . O
therapy . . O
. . . O

e . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
brain . . B-AdverseReaction
stem . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
cerebral . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
gastric . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
epistaxis . . B-AdverseReaction
, . . O
gingival . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
hematuria . . B-AdverseReaction
, . . O
vaginal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
hemorrhage . . B-AdverseReaction
intracranial . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
and . . O
vitreous . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
. . . O

injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
has . . O
also . . O
been . . O
reported . . O
. . . O

inhaled . . O
corticosteroids . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
, . . O
if . . O
at . . O
all . . O
, . . O
in . . O
patients . . O
with . . O
active . . O
or . . O
quiescent . . O
tuberculosis . . O
infections . . O
of . . O
the . . O
respiratory . . O
tract . . O
; . . O
systemic . . O
fungal . . O
, . . O
bacterial . . O
, . . O
viral . . O
, . . O
or . . O
parasitic . . O
infections . . O
; . . O
or . . O
ocular . . O
herpes . . O
simplex . . O
. . . O

sustained . . O
decreases . . O
in . . O
egfr . . O
were . . O
seen . . O
in . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
( . . O
egfr . . O
30 . . O
to . . O
less . . O
than . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
. . . O

rash . . B-AdverseReaction
was . . O
reported . . O
more . . O
frequently . . O
in . . O
female . . O
subjects . . O
than . . O
in . . O
male . . O
subjects . . O
( . . O
rash . . B-AdverseReaction
> . . O
= . . O
grade . . B-Severity
2 . . I-Severity
was . . O
reported . . O
in . . O
13 . . O
/ . . O
64 . . O
[ . . O
20.3% . . O
] . . O
females . . O
versus . . O
2 . . O
/ . . O
37 . . O
[ . . O
5.4% . . O
] . . O
males . . O
; . . O
discontinuations . . O
due . . O
to . . O
rash . . B-AdverseReaction
were . . O
reported . . O
in . . O
4 . . O
/ . . O
64 . . O
[ . . O
6.3% . . O
] . . O
females . . O
versus . . O
0 . . O
/ . . O
37 . . O
[ . . O
0% . . O
] . . O
males . . O
) . . O
. . . O

5.7 . . O
topical . . O
ophthalmic . . O
use . . O
only . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

* . . O
schizophrenia . . O
adults . . O
: . . O
akathisia . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
. . . O

entereg . . O
is . . O
contraindicated . . O
in . . O
patients . . O
who . . O
have . . O
taken . . O
therapeutic . . O
doses . . O
of . . O
opioids . . O
for . . O
more . . O
than . . O
7 . . O
consecutive . . O
days . . O
immediately . . O
prior . . O
to . . O
taking . . O
entereg . . O
. . . O

( . . O
5.3 . . O
) . . O

pristiq . . O
should . . O
be . . O
discontinued . . O
before . . O
initiating . . O
treatment . . O
with . . O
the . . O
maoi . . O
[ . . O
see . . O
contraindications . . O
( . . O
4.2 . . O
) . . O
and . . O
dosage . . O
and . . O
administration . . O
( . . O
2.6 . . O
) . . O
] . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
rarely . . O
during . . O
the . . O
post . . O
- . . O
marketing . . O
use . . O
of . . O
bepreve . . O
. . . O

healthcare . . O
professionals . . O
should . . O
be . . O
aware . . O
of . . O
the . . O
similarity . . O

bleeding . . B-AdverseReaction
results . . O
during . . O
the . . O
treatment . . O
period . . O
in . . O
the . . O
phase . . O
iii . . O
studies . . O
are . . O
shown . . O
in . . O
table . . O
3 . . O
. . . O

a . . O
total . . O
of . . O
503 . . O
patients . . O
received . . O
halaven . . O
, . . O
and . . O
247 . . O
patients . . O
in . . O
the . . O
control . . O
group . . O
received . . O
therapy . . O
consisting . . O
of . . O
chemotherapy . . O
[ . . O
total . . O
97% . . O
( . . O
anthracyclines . . O
10% . . O
, . . O
capecitabine . . O
18% . . O
, . . O
gemcitabine . . O
19% . . O
, . . O
taxanes . . O
15% . . O
, . . O
vinorelbine . . O
25% . . O
, . . O
other . . O
chemotherapies . . O
10% . . O
) . . O
] . . O
or . . O
hormonal . . O
therapy . . O
( . . O
3% . . O
) . . O
. . . O

during . . O
the . . O
clinical . . O
studies . . O
, . . O
two . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
experienced . . O
adverse . . O
reactions . . O
leading . . O
to . . O
withdrawal . . O
. . . O

in . . O
such . . O
children . . O
or . . O
adults . . O
who . . O
have . . O
not . . O
had . . O
these . . O
diseases . . O
or . . O
been . . O
properly . . O
immunized . . O
, . . O
particular . . O
care . . O
should . . O
be . . O
taken . . O
to . . O
avoid . . O
exposure . . O
. . . O

there . . O
was . . O
no . . O
adverse . . O
reaction . . O
that . . O
was . . O
more . . O
than . . O
2% . . O
more . . O
common . . O
on . . O
cleviprex . . O
than . . O
on . . O
the . . O
average . . O
of . . O
all . . O
comparators . . O
. . . O

no . . O
significant . . O
gender . . O
differences . . O
were . . O
noted . . O
in . . O
the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
. . . O

5.2 . . O
urinary . . O
retention . . O

( . . O
5.1 . . O
) . . O
* . . O
measure . . O
the . . O
absolute . . O
neutrophil . . O
count . . O
( . . O
anc . . O
) . . O
before . . O
starting . . O
ferriprox . . O
and . . O
monitor . . O
the . . O
anc . . O
weekly . . O
on . . O
therapy . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
were . . O
neutropenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
and . . O
pain . . B-AdverseReaction
. . . O

5.7 . . O
elevated . . O
blood . . O
pressure . . O

elevations . . B-AdverseReaction
in . . I-AdverseReaction
fasting . . I-AdverseReaction
serum . . I-AdverseReaction
total . . I-AdverseReaction
cholesterol . . I-AdverseReaction
, . . O
ldl . . O
( . . O
low . . O
density . . O
lipoproteins . . O
) . . O
cholesterol . . O
, . . O
and . . O
triglycerides . . O
occurred . . O
in . . O
the . . O
controlled . . O
studies . . O
. . . O

5.8 . . O
musculoskeletal . . O
pain . . O

gastrointestinal . . O
disorders . . O
: . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
melena . . B-AdverseReaction
, . . O
hematochezia . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction

trunk . . O
and . . O
extremities . . O
( . . O
n . . O
= . . O
457 . . O
) . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
, . . O
0.05% . . O
once . . O
daily . . O
for . . O
2 . . O
days . . O
skin . . O
reactions . . O
any . . O
gradea . . O
> . . O
baseline . . O
grade . . O
4 . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
( . . O
n . . O
= . . O
225 . . O
) . . O
vehicle . . O
( . . O
n . . O
= . . O
232 . . O
) . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
( . . O
n . . O
= . . O
225 . . O
) . . O
vehicle . . O
( . . O
n . . O
= . . O
232 . . O
) . . O
erythema . . O
207 . . O
( . . O
92% . . O
) . . O
43 . . O
( . . O
19% . . O
) . . O
34 . . O
( . . O
15% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
flaking . . O
/ . . O
scaling . . O
203 . . O
( . . O
90% . . O
) . . O
44 . . O
( . . O
19% . . O
) . . O
18 . . O
( . . O
8% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
crusting . . O
167 . . O
( . . O
74% . . O
) . . O
23 . . O
( . . O
10% . . O
) . . O
8 . . O
( . . O
4% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
swelling . . O
143 . . O
( . . O
64% . . O
) . . O
13 . . O
( . . O
6% . . O
) . . O
7 . . O
( . . O
3% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
vesiculation . . O
/ . . O
pustulation . . O
98 . . O
( . . O
44% . . O
) . . O
2 . . O
( . . O
1% . . O
) . . O
3 . . O
( . . O
1% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
erosion . . O
/ . . O
ulceration . . O
58 . . O
( . . O
26% . . O
) . . O
6 . . O
( . . O
3% . . O
) . . O
2 . . O
( . . O
1% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
a . . O
mild . . O
( . . O
grade . . O
1 . . O
) . . O
, . . O
moderate . . O
( . . O
grade . . O
2-3 . . O
) . . O
or . . O
severe . . O
( . . O
grade . . O
4 . . O
) . . O
. . . O

patients . . O
received . . O
placebo . . O
( . . O
n . . O
= . . O
995 . . O
) . . O
, . . O
jardiance . . O
10 . . O
mg . . O
( . . O
n . . O
= . . O
999 . . O
) . . O
, . . O
or . . O
jardiance . . O
25 . . O
mg . . O
( . . O
n . . O
= . . O
977 . . O
) . . O
once . . O
daily . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

any . . O
episode . . O
of . . O
acute . . O
symptomatic . . O
hyperammonemia . . O
should . . O
be . . O
treated . . O
as . . O
a . . O
life . . O
- . . O
threatening . . O
emergency . . O
. . . O

( . . O
5.6 . . O
) . . O
* . . O
headache . . B-AdverseReaction
: . . O
evaluate . . O
significant . . O
change . . O
in . . O
headaches . . O
and . . O
discontinue . . O
natazia . . O
if . . O
indicated . . O
. . . O

six . . O
xeomin . . O
treated . . O
subjects . . O
experienced . . O
six . . O
serious . . O
adverse . . O
events . . O
. . . O

for . . O
agranulocytosis . . O
( . . O
anc . . O
< . . O
0.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
) . . O
: . . O

5.8 . . O
contact . . O
lens . . O
wear . . O

patients . . O
should . . O
be . . O
closely . . O
monitored . . O
for . . O
the . . O
development . . O
of . . O
signs . . O
and . . O
symptoms . . O
of . . O
infection . . O
during . . O
and . . O
after . . O
treatment . . O
with . . O
cimzia . . O
, . . O
including . . O
the . . O
development . . O
of . . O
tuberculosis . . O
in . . O
patients . . O
who . . O
tested . . O
negative . . O
for . . O
latent . . O
tuberculosis . . O
infection . . O
prior . . O
to . . O
initiating . . O
therapy . . O
. . . O

if . . O
such . . O
signs . . O
or . . O
symptoms . . O
are . . O
present . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
evaluated . . O
immediately . . O
. . . O

5.13 . . O
body . . O
temperature . . O
regulation . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

if . . O
sjs . . O
or . . O
ten . . O
occurs . . O
, . . O
discontinue . . O
adcetris . . O
and . . O
administer . . O
appropriate . . O
medical . . O
therapy . . O
. . . O

analyses . . O
of . . O
patients . . O
in . . O
pristiq . . O
pre . . O
- . . O
marketing . . O
short . . O
- . . O
term . . O
controlled . . O
studies . . O
who . . O
met . . O
criteria . . O
for . . O
sustained . . B-Severity
hypertension . . B-AdverseReaction
revealed . . O
a . . O
consistent . . O
increase . . O
in . . O
the . . O
proportion . . O
of . . O
patients . . O
who . . O
developed . . O
sustained . . B-Severity
hypertension . . B-AdverseReaction
. . . O

( . . O
5.2 . . O
) . . O
* . . O
monitor . . O
for . . O
worsening . . O
renal . . O
function . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
. . . O

in . . O
study . . O
3 . . O
, . . O
infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
reported . . O
in . . O
25 . . O
patients . . O
( . . O
15% . . O
) . . O
in . . O
the . . O
adcetris . . O
- . . O
treated . . O
arm . . O
and . . O
3 . . O
patients . . O
( . . O
2% . . O
) . . O
in . . O
the . . O
placebo . . O
arm . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
datscan . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

( . . O
5.4 . . O
) . . O

monitor . . O
and . . O
treat . . O
as . . O
appropriate . . O
. . . O

pancreatitis . . O
pancreatitis . . B-AdverseReaction
was . . O
reported . . O
in . . O
1 . . O
patient . . O
( . . O
0.8% . . O
) . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
1 . . O
patient . . O
( . . O
0.8% . . O
) . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

table . . O
2 . . O
: . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behaviors . . O
by . . O
indication . . O
for . . O
antiepileptic . . O
drugs . . O
in . . O
the . . O
pooled . . O
analysis . . O
indication . . O
placebo . . O
patients . . O
with . . O
events . . O
per . . O
1000 . . O
patients . . O
drug . . O
patients . . O
with . . O
events . . O
per . . O
1000 . . O
patients . . O
relative . . O
risk . . O
: . . O
incidence . . O
of . . O
events . . O
in . . O
drug . . O
patients . . O
/ . . O
incidence . . O
in . . O
placebo . . O
patients . . O
risk . . O
differences . . O
: . . O
additional . . O
drug . . O
patients . . O
with . . O
events . . O
per . . O
1000 . . O
patients . . O
epilepsy . . O
1.0 . . O
3.4 . . O
3.5 . . O
2.4 . . O
psychiatric . . O
5.7 . . O
8.5 . . O
1.5 . . O
2.9 . . O
other . . O
1.0 . . O
1.8 . . O
1.9 . . O
0.9 . . O
total . . O
2.4 . . O
4.3 . . O
1.8 . . O
1.9 . . O
the . . O
relative . . O
risk . . O
for . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
was . . O
higher . . O
in . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
epilepsy . . O
than . . O
in . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
psychiatric . . O
or . . O
other . . O
conditions . . O
, . . O
but . . O
the . . O
absolute . . O
risk . . O
differences . . O
were . . O
similar . . O
for . . O
epilepsy . . O
and . . O
psychiatric . . O
indications . . O
. . . O

the . . O
frequency . . O
of . . O
> . . O
= . . O
grade . . O
3 . . O
adverse . . O
reactions . . O
and . . O
deaths . . B-AdverseReaction
was . . O
greater . . O
in . . O
patients . . O
with . . O
moderate . . O
and . . O
severe . . O
hepatic . . O
impairment . . O
compared . . O
to . . O
patients . . O
with . . O
normal . . O
hepatic . . O
function . . O
. . . O

table . . O
1 . . O
presents . . O
the . . O
profile . . O
from . . O
the . . O
9 . . O
- . . O
month . . O
double . . O
- . . O
blind . . O
, . . O
randomized . . O
, . . O
placebo . . O
- . . O
controlled . . O
trial . . O
of . . O
40 . . O
treatment . . O
- . . O
naive . . O
patients . . O
( . . O
trial . . O
1 . . O
) . . O
. . . O

table . . O
3 . . O
bleeding . . B-AdverseReaction
events . . O
in . . O
re . . O
- . . O
cover . . O
and . . O
re . . O
- . . O
cover . . O
ii . . O
treated . . O
patients . . O
note . . O
: . . O
mbe . . B-AdverseReaction
can . . O
belong . . O
to . . O
more . . O
than . . O
one . . O
criterion . . O
. . . O
a . . O
patients . . O
with . . O
at . . O
least . . O
one . . O
mbe . . B-AdverseReaction
. . . O
b . . O
bleeding . . B-AdverseReaction
site . . O
based . . O
on . . O
investigator . . O
assessment . . O
. . . O

the . . O
possibility . . B-Factor
that . . O
granix . . O
acts . . O
as . . O
a . . O
growth . . O
factor . . O
for . . O
any . . O
tumor . . O
type . . O
, . . O
including . . O
myeloid . . B-AdverseReaction
malignancies . . I-AdverseReaction
and . . O
myelodysplasia . . B-AdverseReaction
, . . O
diseases . . O
for . . O
which . . O
granix . . O
is . . O
not . . O
approved . . O
, . . O
cannot . . O
be . . O
excluded . . O
. . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
hypoglycemia . . B-AdverseReaction

there . . O
is . . O
no . . O
post . . O
- . . O
marketing . . O
experience . . O
available . . O
for . . O
simponi . . O
aria . . O
. . . O

monitor . . O
closely . . O
and . . O
take . . O
appropriate . . O
measures . . O
. . . O

long . . O
- . . O
term . . O
safety . . O
trials . . O

excerpt . . O
: . . O
* . . O
anaphylaxis . . B-AdverseReaction
and . . O
angioedema . . B-AdverseReaction
: . . O
discontinue . . O
and . . O
do . . O
not . . O
restart . . O
tecfidera . . O
if . . O
these . . O
occur . . O
. . . O

other . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
ocular . . B-AdverseReaction
manifestations . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
. . . O

antibodies . . O
to . . O
simponi . . O
aria . . O
were . . O
detected . . O
in . . O
13 . . O
( . . O
3% . . O
) . . O
golimumab . . O
- . . O
treated . . O
patients . . O
following . . O
iv . . O
administration . . O
of . . O
simponi . . O
aria . . O
in . . O
combination . . O
with . . O
mtx . . O
through . . O
week . . O
24 . . O
of . . O
trial . . O
1 . . O
. . . O

table . . O
3 . . O
: . . O
bleeding . . B-AdverseReaction
during . . O
the . . O
treatment . . O
period . . O
in . . O
patients . . O
undergoing . . O
elective . . O
hip . . O
or . . O
knee . . O
replacement . . O
surgery . . O
bleeding . . O
endpoint . . O
* . . O
advance . . O
- . . O
3hip . . O
replacement . . O
surgery . . O
advance . . O
- . . O
2knee . . O
replacement . . O
surgery . . O
advance . . O
- . . O
1knee . . O
replacement . . O
surgery . . O
* . . O
all . . O
bleeding . . B-AdverseReaction
criteria . . O
included . . O
surgical . . B-AdverseReaction
site . . I-AdverseReaction
bleeding . . I-AdverseReaction
. . . O

6.1 . . O
clinical . . O
studies . . O
experience . . O

5.2 . . O
hypersensitivity . . O
reactions . . O

before . . O
initiating . . O
invokana . . O
in . . O
patients . . O
with . . O
one . . O
or . . O
more . . O
of . . O
these . . O
characteristics . . O
, . . O
volume . . O
status . . O
should . . O
be . . O
assessed . . O
and . . O
corrected . . O
. . . O

therefore . . O
, . . O
co . . O
- . . O
administration . . O
is . . O
not . . O
recommended . . O
. . . O

methotrexate . . O
concentrations . . O
within . . O
48 . . O
hours . . O
following . . O
administration . . O
of . . O
voraxaze . . O
can . . O
only . . O
be . . O
reliably . . O
measured . . O
by . . O
a . . O
chromatographic . . O
method . . O
. . . O

events . . O
resulting . . O
in . . O
discontinuation . . O
were . . O
similar . . O
to . . O
those . . O
seen . . O
in . . O
previous . . O
studies . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
. . . O

based . . O
on . . O
effective . . O
donor . . O
screening . . O
and . . O
product . . O
manufacturing . . O
processes . . O
, . . O
it . . O
carries . . O
an . . O
extremely . . O
remote . . O
risk . . B-Factor
for . . O
transmission . . B-AdverseReaction
of . . I-AdverseReaction
viral . . I-AdverseReaction
diseases . . I-AdverseReaction
. . . O

breast . . O
cancer . . O

discontinue . . O
granix . . O
in . . O
patients . . O
with . . O
ards . . O
. . . O

6includes . . O
the . . O
preferred . . O
terms . . O
somnolence . . B-AdverseReaction
, . . O
sedation . . B-AdverseReaction
, . . O
and . . O
hypersomnia . . B-AdverseReaction
. . . O

6.3 . . O
postmarketing . . O
experience . . O

antifungal . . O
agents . . O
should . . O
not . . O
be . . O
used . . O
unless . . O
fungal . . O
infection . . O
has . . O
been . . O
diagnosed . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

at . . O
baseline . . O
, . . O
21% . . O
of . . O
the . . O
population . . O
reported . . O
peripheral . . O
neuropathy . . O
and . . O
5% . . O
reported . . O
retinopathy . . O
. . . O

refer . . O
to . . O
the . . O
prescribing . . O
information . . O
for . . O
ribavirin . . O
and . . O
peginterferon . . O
alfa . . O
for . . O
guidelines . . O
for . . O
discontinuation . . O
of . . O
therapy . . O
based . . O
on . . O
laboratory . . O
parameters . . O
. . . O

mri . . O
signs . . O
may . . O
be . . O
apparent . . O
before . . O
clinical . . O
symptoms . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

5.3 . . O
thromboembolic . . O
events . . O

vizamyl . . O
scan . . O
results . . O
are . . O
indicative . . O
of . . O
the . . O
brain . . O
neuritic . . O
amyloid . . O
plaque . . O
content . . O
only . . O
at . . O
the . . O
time . . O
of . . O
image . . O
acquisition . . O
and . . O
a . . O
negative . . O
scan . . O
result . . O
does . . O
not . . O
preclude . . O
the . . O
development . . O
of . . O
brain . . O
amyloid . . O
in . . O
the . . O
future . . O
. . . O

monitor . . O
thyroid . . O
function . . O
before . . O
initiation . . O
of . . O
, . . O
and . . O
periodically . . O
throughout . . O
, . . O
treatment . . O
with . . O
inlyta . . O
. . . O

see . . O
the . . O
list . . O
of . . O
ingredients . . O
in . . O
duavee . . O
at . . O
the . . O
end . . O
of . . O
this . . O
leaflet . . O
. . . O

episodes . . O
vary . . O
in . . O
frequency . . O
, . . O
severity . . O
and . . O
may . . O
be . . O
life . . O
- . . O
threatening . . O
if . . O
treatment . . O
is . . O
delayed . . O
. . . O

the . . O
median . . O
time . . O
to . . O
onset . . O
of . . O
moderate . . B-Severity
to . . O
severe . . B-Severity
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
endocrinopathy . . I-AdverseReaction
was . . O
11 . . O
weeks . . O
and . . O
ranged . . O
up . . O
to . . O
19.3 . . O
weeks . . O
after . . O
the . . O
initiation . . O
of . . O
yervoy . . O
. . . O

the . . O
relative . . O
risk . . O
of . . O
probable . . O
dementia . . B-AdverseReaction
for . . O
ce . . B-DrugClass
- . . O
alone . . O
versus . . O
placebo . . O
was . . O
1.49 . . O
( . . O
95 . . O
percent . . O
ci . . O
, . . O
0.83-2.66 . . O
) . . O
. . . O

in . . O
two . . O
controlled . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
and . . O
thrombocytopenia . . O
, . . O
3% . . O
( . . O
31 . . O
/ . . O
955 . . O
) . . O
treated . . O
with . . O
promacta . . O
experienced . . O
a . . O
thrombotic . . B-AdverseReaction
event . . I-AdverseReaction
compared . . O
with . . O
1% . . O
( . . O
5 . . O
/ . . O
484 . . O
) . . O
on . . O
placebo . . O
. . . O

monitor . . O
for . . O
signs . . O
or . . O
symptoms . . O
of . . O
cardiac . . O
failure . . O
throughout . . O
treatment . . O
with . . O
inlyta . . O
. . . O

life . . B-Severity
- . . I-Severity
threatening . . I-Severity
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
occurred . . O
in . . O
some . . O
patients . . O
during . . O
vimizim . . O
infusions . . O
. . . O

prior . . O
to . . O
initiating . . O
simponi . . O
aria . . O
, . . O
assess . . O
if . . O
treatment . . O
for . . O
latent . . O
tuberculosis . . O
is . . O
needed . . O
; . . O
an . . O
induration . . O
of . . O
5 . . O
mm . . O
or . . O
greater . . O
is . . O
a . . O
positive . . O
tuberculin . . O
skin . . O
test . . O
, . . O
even . . O
for . . O
patients . . O
previously . . O
vaccinated . . O
with . . O
bacille . . O
calmette . . O
- . . O
guerin . . O
( . . O
bcg . . O
) . . O
. . . O

12 . . O
- . . O
week . . O
trials . . O

if . . O
pancreatitis . . O
is . . O
suspected . . O
, . . O
nesina . . O
should . . O
promptly . . O
be . . O
discontinued . . O
and . . O
appropriate . . O
management . . O
should . . O
be . . O
initiated . . O
. . . O

clinical . . O
status . . O
including . . O
liver . . O
transaminases . . O
should . . O
be . . O
monitored . . O
and . . O
appropriate . . O
therapy . . O
initiated . . O
. . . O

table . . O
3 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
at . . O
least . . O
3% . . O
of . . O
alglucosidase . . O
alfa . . O
- . . O
treated . . O
late . . O
- . . O
onset . . O
patients . . O
and . . O
with . . O
a . . O
higher . . O
incidence . . O
than . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
adverse . . O
reaction . . O
alglucosidase . . O
alfan . . O
= . . O
60n . . O
( . . O
% . . O
) . . O
placebon . . O
= . . O
30n . . O
( . . O
% . . O
) . . O
hyperhidrosis . . B-AdverseReaction
5 . . O
( . . O
8.3 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
urticaria . . B-AdverseReaction
5 . . O
( . . O
8.3 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
anaphylaxis . . B-AdverseReaction
4 . . O
( . . O
6.7 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
4 . . O
( . . O
6.7 . . O
) . . O
1 . . O
( . . O
3.3 . . O
) . . O
muscle . . B-AdverseReaction
twitching . . I-AdverseReaction
4 . . O
( . . O
6.7 . . O
) . . O
1 . . O
( . . O
3.3 . . O
) . . O
myalgia . . B-AdverseReaction
3 . . O
( . . O
5.0 . . O
) . . O
1 . . O
( . . O
3.3 . . O
) . . O
flushing . . B-AdverseReaction
/ . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
3 . . O
( . . O
5.0 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
3 . . O
( . . O
5.0 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
vomiting . . B-AdverseReaction
3 . . O
( . . O
5.0 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
edema . . B-AdverseReaction
, . . I-AdverseReaction
peripheral . . I-AdverseReaction
2 . . O
( . . O
3.3 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
pruritus . . B-AdverseReaction
2 . . O
( . . O
3.3 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
rash . . B-AdverseReaction
papular . . I-AdverseReaction
2 . . O
( . . O
3.3 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
throat . . B-AdverseReaction
tightness . . I-AdverseReaction
2 . . O
( . . O
3.3 . . O
) . . O
0 . . O
( . . O
0 . . O
) . . O
in . . O
clinical . . O
trials . . O
, . . O
anaphylaxis . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
were . . O
managed . . O
with . . O
infusion . . O
interruption . . O
, . . O
decreased . . O
infusion . . O
rate . . O
, . . O
administration . . O
of . . O
antihistamines . . O
, . . O
corticosteroids . . O
, . . O
intravenous . . O
fluids . . O
, . . O
and . . O
/ . . O
or . . O
oxygen . . O
, . . O
when . . O
clinically . . O
indicated . . O
. . . O

if . . O
such . . O
a . . O
reaction . . O
occurs . . O
, . . O
therapy . . O
with . . O
tudorza . . O
pressair . . O
should . . O
be . . O
stopped . . O
at . . O
once . . O
and . . O
alternative . . O
treatments . . O
should . . O
be . . O
considered . . O
. . . O

fanapt . . O
shares . . O
this . . O
pharmacologic . . O
activity . . O
. . . O

in . . O
these . . O
patients . . O
, . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
potassium . . I-AdverseReaction
were . . O
more . . O
commonly . . O
seen . . O
in . . O
those . . O
with . . O
elevated . . O
potassium . . O
at . . O
baseline . . O
. . . O

5.6 . . O
gastrointestinal . . O
perforation . . O
and . . O
fistula . . O
formation . . O

in . . O
the . . O
controlled . . O
and . . O
uncontrolled . . O
portions . . O
of . . O
trial . . O
1 . . O
, . . O
958 . . O
total . . O
patient . . O
- . . O
years . . O
of . . O
follow . . O
- . . O
up . . O
with . . O
a . . O
median . . O
follow . . O
- . . O
up . . O
of . . O
approximately . . O
92 . . O
weeks . . O
, . . O
the . . O
incidence . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
of . . O
all . . O
serious . . B-Severity
infections . . B-AdverseReaction
was . . O
4.07 . . O
( . . O
ci . . O
: . . O
2.90 . . O
, . . O
5.57 . . O
) . . O
in . . O
patients . . O
receiving . . O
simponi . . O
aria . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

glabellar . . O
lines . . O
( . . O
5.7 . . O
) . . O
: . . O

stendra . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
, . . O
and . . O
only . . O
when . . O
the . . O
anticipated . . O
benefits . . O
outweigh . . O
the . . O
risks . . O
, . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
naion . . O
. . . O

therefore . . O
, . . O
a . . O
lower . . O
dose . . O
of . . O
the . . O
insulin . . O
secretagogue . . O
or . . O
insulin . . O
may . . O
be . . O
required . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
jardiance . . O
. . . O

infusion . . O
reactions . . O
, . . O
including . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
reactions . . O
, . . O
have . . O
occurred . . O
in . . O
patients . . O
receiving . . O
kyprolis . . O
. . . O

breakthrough . . B-AdverseReaction
bleeding . . I-AdverseReaction
and . . O
spotting . . B-AdverseReaction
sometimes . . O
occur . . O
in . . O
patients . . O
on . . O
cocs . . B-DrugClass
, . . O
especially . . O
during . . O
the . . O
first . . O
three . . O
months . . O
of . . O
use . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

in . . O
clinical . . O
studies . . O
of . . O
cimzia . . O
, . . O
the . . O
overall . . O
incidence . . O
rate . . O
of . . O
malignancies . . B-AdverseReaction
was . . O
similar . . O
for . . O
cimzia . . O
- . . O
treated . . O
and . . O
control . . O
patients . . O
. . . O

excerpt . . O
: . . O
* . . O
myelosuppression . . B-AdverseReaction
: . . O
delay . . O
or . . O
reduce . . O
dose . . O
. . . O

because . . O
postmarketing . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

all . . O
patients . . O
treated . . O
with . . O
vimizim . . O
2 . . O
mg . . O
/ . . O
kg . . O
once . . O
per . . O
week . . O
tested . . O
positive . . O
for . . O
neutralizing . . O
antibodies . . O
capable . . O
of . . O
inhibiting . . O
the . . O
drug . . O
from . . O
binding . . O
to . . O
the . . O
mannose . . O
- . . O
6 . . O
- . . O
phosphate . . O
receptor . . O
at . . O
least . . O
once . . O
during . . O
the . . O
trial . . O
. . . O

uveitis . . B-AdverseReaction
and . . O
iritis . . B-AdverseReaction
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
administered . . O
as . . O
a . . O
single . . O
agent . . O
or . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

the . . O
mean . . O
age . . O
of . . O
patients . . O
was . . O
64 . . O
years . . O
, . . O
with . . O
47% . . O
of . . O
patients . . O
aged . . O
65 . . O
years . . O
or . . O
older . . O
, . . O
and . . O
the . . O
majority . . O
( . . O
88% . . O
) . . O
was . . O
caucasian . . O
. . . O

acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ards . . B-AdverseReaction
) . . O
can . . O
occur . . O
in . . O
patients . . O
receiving . . O
human . . B-DrugClass
granulocyte . . I-DrugClass
colony . . I-DrugClass
- . . I-DrugClass
stimulating . . I-DrugClass
factors . . I-DrugClass
. . . O

somnolence . . B-AdverseReaction
includes . . O
the . . O
following . . O
events . . O
: . . O
somnolence . . B-AdverseReaction
, . . O
sedation . . B-AdverseReaction
, . . O
and . . O
hypersomnia . . B-AdverseReaction
. . . O

in . . O
a . . O
longer . . O
- . . O
term . . O
study . . O
, . . O
up . . O
to . . O
9 . . O
months . . O
, . . O
the . . O
most . . O
common . . O
was . . O
vomiting . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

gastrointestinal . . O
adverse . . O
reactions . . O

the . . O
clinical . . O
relevance . . O
of . . O
this . . O
in . . O
vitro . . O
inhibition . . O
is . . O
not . . O
fully . . O
understood . . O
. . . O

the . . O
early . . O
diagnosis . . O
of . . O
this . . O
condition . . O
is . . O
important . . O
for . . O
the . . O
appropriate . . O
management . . O
of . . O
these . . O
patients . . O
. . . O

the . . O
frequency . . O
of . . O
laboratory . . O
abnormalities . . O
( . . O
grades . . O
3-4 . . O
) . . O
occurring . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
subjects . . O
receiving . . O
stribild . . O
in . . O
studies . . O
102 . . O
and . . O
103 . . O
are . . O
presented . . O
in . . O
table . . O
3 . . O
. . . O

patients . . O
received . . O
6 . . O
doses . . O
of . . O
erwinaze . . O
25,000 . . O
international . . O
units . . O
/ . . O
m . . O
2 . . O
intramuscularly . . O
on . . O
a . . O
monday . . O
, . . O
wednesday . . O
, . . O
and . . O
friday . . O
schedule . . O
as . . O
a . . O
replacement . . O
for . . O
each . . O
scheduled . . O
dose . . O
of . . O
pegaspargase . . O
remaining . . O
on . . O
their . . O
original . . O
treatment . . O
protocol . . O
. . . O

5.4 . . O
bradycardia . . O

in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
occurred . . O
more . . O
frequently . . O
on . . O
tanzeum . . O
( . . O
18% . . O
) . . O
than . . O
on . . O
placebo . . O
( . . O
8% . . O
) . . O
. . . O

while . . O
receiving . . O
study . . O
drug . . O
through . . O
week . . O
144 . . O
, . . O
an . . O
additional . . O
11% . . O
of . . O
stribild . . O
subjects . . O
were . . O
started . . O
on . . O
lipid . . O
lowering . . O
agents . . O
, . . O
compared . . O
to . . O
13% . . O
of . . O
atripla . . O
and . . O
12% . . O
of . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
subjects . . O
. . . O

the . . O
elisa . . O
assay . . O
is . . O
subject . . O
to . . O
interference . . O
by . . O
co . . O
- . . O
present . . O
golimumab . . O
and . . O
thus . . O
the . . O
results . . O
are . . O
an . . O
underestimate . . O
of . . O
the . . O
rate . . O
of . . O
product . . O
immunogenicity . . O
and . . O
are . . O
in . . O
addition . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

5.14 . . O
suicide . . O

in . . O
the . . O
breast . . O
cancer . . O
study . . O
, . . O
99% . . O
of . . O
patients . . O
were . . O
female . . O
, . . O
the . . O
median . . O
age . . O
was . . O
50 . . O
years . . O
, . . O
and . . O
86% . . O
of . . O
patients . . O
were . . O
caucasian . . O
. . . O

corticosteroids . . O
may . . O
be . . O
indicated . . O
until . . O
clinical . . O
symptoms . . O
resolve . . O
. . . O

table . . O
displays . . O
adverse . . O
reactions . . O
that . . O
were . . O
reported . . O
in . . O
greater . . O
than . . O
5% . . O
of . . O
patients . . O
in . . O
the . . O
northera . . O
group . . O
and . . O
with . . O
at . . O
least . . O
a . . O
3% . . O
greater . . O
incidence . . O
in . . O
the . . O
northera . . O
group . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

while . . O
subjects . . O
aged . . O
12 . . O
to . . O
17 . . O
years . . O
were . . O
included . . O
in . . O
this . . O
trial . . O
, . . O
breo . . O
ellipta . . O
is . . O
not . . O
approved . . O
for . . O
use . . O
in . . O
this . . O
age . . O
- . . O
group . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.4 . . O
) . . O
] . . O
. . . O

horizant . . O
causes . . O
somnolence . . B-AdverseReaction
/ . . O
sedation . . B-AdverseReaction
and . . O
dizziness . . B-AdverseReaction
( . . O
see . . O
tables . . O
4 . . O
and . . O
5 . . O
) . . O
. . . O

a . . O
total . . O
of . . O
1,867 . . O
subjects . . O
were . . O
included . . O
in . . O
two . . O
clinical . . O
phase . . O
3 . . O
studies . . O
with . . O
a . . O
treatment . . O
duration . . O
up . . O
to . . O
28 . . O
cycles . . O
with . . O
natazia . . O
as . . O
an . . O
oral . . O
contraceptive . . O
and . . O
264 . . O
subjects . . O
in . . O
the . . O
two . . O
phase . . O
3 . . O
clinical . . O
trials . . O
with . . O
a . . O
treatment . . O
duration . . O
of . . O
7 . . O
cycles . . O
evaluating . . O
natazia . . O
in . . O
the . . O
treatment . . O
of . . O
heavy . . O
, . . O
prolonged . . O
, . . O
and . . O
/ . . O
or . . O
frequent . . O
menstrual . . O
bleeding . . O
in . . O
women . . O
without . . O
organic . . O
pathology . . O
. . . O

duavee . . O
contains . . O
an . . O
estrogen . . O
agonist . . O
/ . . O
antagonist . . O
. . . O

treatment . . O
with . . O
medications . . B-DrugClass
that . . I-DrugClass
work . . I-DrugClass
through . . I-DrugClass
inhibition . . I-DrugClass
of . . I-DrugClass
il . . I-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
has . . O
been . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . O
of . . O
serious . . B-Severity
infections . . B-AdverseReaction
. . . O

adcetris . . O
was . . O
studied . . O
in . . O
102 . . O
patients . . O
with . . O
classical . . O
hl . . O
in . . O
a . . O
single . . O
arm . . O
clinical . . O
trial . . O
in . . O
which . . O
the . . O
recommended . . O
starting . . O
dose . . O
and . . O
schedule . . O
was . . O
1.8 . . O
mg . . O
/ . . O
kg . . O
intravenously . . O
every . . O
3 . . O
weeks . . O
. . . O

event . . O
pradaxa . . O
150 . . O
mgn . . O
= . . O
6059n . . O
( . . O
% . . O
/ . . O
year . . O
b . . O
) . . O
warfarinn . . O
= . . O
5998n . . O
( . . O
% . . O
/ . . O
year . . O
b . . O
) . . O
pradaxa . . O
150 . . O
mgvs . . O
. . . O

treatment . . O
- . . O
emergent . . O
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
cytopenias . . O
including . . O
neutropenia . . B-AdverseReaction
( . . O
range . . O
, . . O
19 . . O
to . . O
29% . . O
) . . O
, . . O
thrombocytopenia . . B-AdverseReaction
( . . O
range . . O
, . . O
5 . . O
to . . O
17% . . O
) . . O
, . . O
and . . O
anemia . . B-AdverseReaction
( . . O
range . . O
, . . O
0 . . O
to . . O
9% . . O
) . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
imbruvica . . O
. . . O

5.13 . . O
drug . . O
interactions . . O

cases . . O
of . . O
worsening . . B-AdverseReaction
congestive . . I-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
chf . . O
) . . O
and . . O
new . . B-AdverseReaction
onset . . I-AdverseReaction
chf . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
tnf . . O
blockers . . O
, . . O
including . . O
cimzia . . O
. . . O

consider . . O
administration . . O
of . . O
platelet . . O
concentrates . . O
in . . O
cases . . O
where . . O
thrombocytopenia . . O
is . . O
present . . O
or . . O
long . . O
- . . O
acting . . O
antiplatelet . . O
drugs . . O
have . . O
been . . O
used . . O
. . . O

redistribution . . O
/ . . O
accumulation . . B-AdverseReaction
of . . I-AdverseReaction
body . . I-AdverseReaction
fat . . I-AdverseReaction
, . . O
including . . O
central . . B-AdverseReaction
obesity . . I-AdverseReaction
, . . O
dorsocervical . . B-AdverseReaction
fat . . I-AdverseReaction
enlargement . . I-AdverseReaction
( . . O
buffalo . . B-AdverseReaction
hump . . I-AdverseReaction
) . . O
, . . O
peripheral . . O
wasting . . O
, . . O
facial . . B-AdverseReaction
wasting . . I-AdverseReaction
, . . O
breast . . B-AdverseReaction
enlargement . . I-AdverseReaction
, . . O
and . . O
" . . O
cushingoid . . B-AdverseReaction
appearance . . I-AdverseReaction
" . . O
have . . O
been . . O
observed . . O
in . . O
patients . . O
receiving . . O
antiretroviral . . B-DrugClass
therapy . . I-DrugClass
. . . O

( . . O
5.3 . . O
) . . O

do . . O
not . . O
exceed . . O
the . . O
recommended . . O
dosage . . O
and . . O
frequency . . O
of . . O
administration . . O
of . . O
xeomin . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
: . . O
anaphylaxis . . B-AdverseReaction
; . . O
and . . O
injection . . O
or . . O
infusion . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
including . . O
phlebitis . . O
, . . O
pruritus . . O
, . . O
irritation . . O
, . . O
pain . . O
, . . O
and . . O
swelling . . O
; . . O
pneumocystis . . B-AdverseReaction
jiroveci . . I-AdverseReaction
pneumonia . . I-AdverseReaction
and . . O
pneumonitis . . B-AdverseReaction
. . . O

horizant . . O
may . . B-Factor
cause . . O
significant . . B-Severity
driving . . B-AdverseReaction
impairment . . I-AdverseReaction
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.3 . . O
) . . O
] . . O
. . . O

warning . . O
: . . O
cigarette . . O
smoking . . O
and . . O
serious . . B-Severity
cardiovascular . . B-AdverseReaction
events . . I-AdverseReaction

discontinuation . . O
from . . O
study . . O
due . . O
to . . O
genital . . B-AdverseReaction
infection . . I-AdverseReaction
occurred . . O
in . . O
0% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
and . . O
0.2% . . O
of . . O
patients . . O
treated . . O
with . . O
either . . O
jardiance . . O
10 . . O
or . . O
25 . . O
mg . . O
. . . O

5.8 . . O
laboratory . . O
tests . . O
and . . O
monitoring . . O

the . . O
detection . . O
of . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

( . . O
6.2 . . O
) . . O
in . . O
clinical . . O
trials . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
, . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vertigo . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
or . . O
dizziness . . B-AdverseReaction
occurred . . O
in . . O
< . . O
1% . . O
of . . O
subjects . . O
. . . O

there . . O
is . . O
neither . . O
scientific . . O
rationale . . O
for . . O
reversal . . O
nor . . O
experience . . O
with . . O
systemic . . O
hemostatics . . O
( . . O
desmopressin . . O
and . . O
aprotinin . . O
) . . O
in . . O
individuals . . O
receiving . . O
apixaban . . O
. . . O

patients . . O
receiving . . O
cimzia . . O
400 . . O
mg . . O
as . . O
monotherapy . . O
every . . O
4 . . O
weeks . . O
in . . O
rheumatoid . . O
arthritis . . O
controlled . . O
clinical . . O
trials . . O
had . . O
similar . . O
adverse . . O
reactions . . O
to . . O
those . . O
patients . . O
receiving . . O
cimzia . . O
200 . . O
mg . . O
every . . O
other . . O
week . . O
. . . O

laboratory . . O
abnormalities . . O
observed . . O
in . . O
the . . O
flamingo . . O
trial . . O
were . . O
generally . . O
consistent . . O
with . . O
observations . . O
in . . O
spring . . O
- . . O
2 . . O
and . . O
single . . O
. . . O

the . . O
risk . . O
of . . O
symptoms . . O
is . . O
probably . . O
greatest . . O
in . . O
children . . O
treated . . O
for . . O
spasticity . . O
but . . O
symptoms . . O
can . . O
also . . O
occur . . O
in . . O
adults . . O
treated . . O
for . . O
spasticity . . O
and . . O
other . . O
conditions . . O
, . . O
particularly . . O
in . . O
those . . O
patients . . O
who . . O
have . . O
underlying . . O
conditions . . O
that . . O
would . . O
predispose . . O
them . . O
to . . O
these . . O
symptoms . . O
. . . O

in . . O
controlled . . O
and . . O
uncontrolled . . O
clinical . . O
trials . . O
, . . O
2% . . O
of . . O
patients . . O
experienced . . O
lymphocyte . . B-AdverseReaction
counts . . I-AdverseReaction
< . . I-AdverseReaction
0.5 . . I-AdverseReaction
x . . I-AdverseReaction
10 . . I-AdverseReaction
9 . . I-AdverseReaction
/ . . I-AdverseReaction
l . . I-AdverseReaction
for . . O
at . . O
least . . O
six . . O
months . . O
. . . O

autoantibodies . . O

do . . O
not . . O
exceed . . O
the . . O
recommended . . O
dosage . . O
and . . O
frequency . . O
of . . O
administration . . O
of . . O
dysport . . B-Factor
( . . O
r . . O
) . . O
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
genital . . O
mycotic . . O
infections . . O
were . . O
more . . O
likely . . O
to . . O
develop . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
on . . O
invokana . . O
. . . O

* . . O
no . . O
dosing . . O
adjustments . . O
are . . O
recommended . . O
in . . O
the . . O
presence . . O
of . . O
moderate . . O
cyp3a4 . . O
inhibitors . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
erythromycin . . O
, . . O
fluconazole . . O
, . . O
diltiazem . . O
, . . O
verapamil . . O
and . . O
grapefruit . . O
juice . . O
) . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

perform . . O
hepatic . . O
enzyme . . O
tests . . O
monthly . . O
for . . O
the . . O
first . . O
three . . O
months . . O
of . . O
bosulif . . O
treatment . . O
and . . O
as . . O
clinically . . O
indicated . . O
. . . O

in . . O
some . . O
cases . . O
, . . O
disseminated . . B-AdverseReaction
intravascular . . I-AdverseReaction
coagulation . . I-AdverseReaction
( . . O
dic . . B-AdverseReaction
) . . O
, . . O
capillary . . B-AdverseReaction
leak . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
cls . . B-AdverseReaction
) . . O
, . . O
and . . O
hemophagocytic . . B-AdverseReaction
lymphohistiocytosis . . I-AdverseReaction
/ . . O
macrophage . . B-AdverseReaction
activation . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
hlh . . B-AdverseReaction
/ . . O
mas . . B-AdverseReaction
) . . O
have . . O
been . . O
reported . . O
in . . O
the . . O
setting . . O
of . . O
crs . . B-AdverseReaction
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
approval . . O
use . . O
of . . O
pradaxa . . O
. . . O

in . . O
this . . O
pool . . O
, . . O
invokana . . O
was . . O
also . . O
associated . . O
with . . O
the . . O
adverse . . O
reactions . . O
of . . O
fatigue . . B-AdverseReaction
( . . O
1.7% . . O
with . . O
comparator . . O
, . . O
2.2% . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
2.0% . . O
with . . O
invokana . . O
300 . . O
mg . . O
) . . O
and . . O
loss . . B-AdverseReaction
of . . I-AdverseReaction
strength . . I-AdverseReaction
or . . O
energy . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
asthenia . . B-AdverseReaction
) . . O
( . . O
0.6% . . O
with . . O
comparator . . O
, . . O
0.7% . . O
with . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
1.1% . . O
with . . O
invokana . . O
300 . . O
mg . . O
) . . O
. . . O

sprint . . O
- . . O
2 . . O
( . . O
subjects . . O
who . . O
were . . O
previously . . O
untreated . . O
) . . O
and . . O
respond . . O
- . . O
2 . . O
( . . O
subjects . . O
who . . O
had . . O
failed . . O
previous . . O
therapy . . O
) . . O
evaluated . . O
the . . O
use . . O
of . . O
victrelis . . O
800 . . O
mg . . O
three . . O
times . . O
daily . . O
in . . O
combination . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
with . . O
a . . O
four . . O
- . . O
week . . O
lead . . O
- . . O
in . . O
period . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
compared . . O
to . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

many . . O
of . . O
the . . O
drugs . . O
metabolized . . O
by . . O
cyp2d6 . . O
can . . O
prolong . . O
the . . O
qt . . O
interval . . O
and . . O
should . . O
not . . O
be . . O
administered . . O
with . . O
coartem . . O
tablets . . O
due . . O
to . . O
the . . O
potential . . O
additive . . O
effect . . O
on . . O
the . . O
qt . . O
interval . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
flecainide . . O
, . . O
imipramine . . O
, . . O
amitriptyline . . O
, . . O
clomipramine . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
, . . O
drug . . O
interactions . . O
( . . O
7.6 . . O
) . . O
, . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

at . . O
the . . O
end . . O
of . . O
treatment . . O
, . . O
0.8% . . O
, . . O
4.0% . . O
, . . O
and . . O
2.7% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
, . . O
had . . O
hemoglobin . . B-AdverseReaction
above . . I-AdverseReaction
the . . I-AdverseReaction
upper . . I-AdverseReaction
limit . . I-AdverseReaction
of . . I-AdverseReaction
normal . . I-AdverseReaction
. . . O

aptiom . . O
causes . . O
dose . . O
- . . O
dependent . . O
increases . . O
in . . O
events . . O
related . . O
to . . O
visual . . B-AdverseReaction
changes . . I-AdverseReaction
including . . O
diplopia . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
and . . O
impaired . . B-AdverseReaction
vision . . I-AdverseReaction
. . . O

do . . O
not . . O
administer . . O
leucovorin . . O
within . . O
2 . . O
hours . . O
before . . O
or . . O
after . . O
a . . O
dose . . O
of . . O
voraxaze . . O
because . . O
leucovorin . . O
is . . O
a . . O
substrate . . O
for . . O
voraxaze . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
cigarette . . O
smoking . . O
and . . O
serious . . B-Severity
cardiovascular . . B-AdverseReaction
events . . I-AdverseReaction

summary . . O
of . . O
clinical . . O
trials . . O
in . . O
chronic . . O
lymphocytic . . O
leukemia . . O

in . . O
patients . . O
with . . O
mild . . O
renal . . O
impairment . . O
( . . O
crcl . . O
51-80 . . O
ml . . O
/ . . O
min . . O
) . . O
, . . O
ampyra . . O
plasma . . O
levels . . O
may . . O
approach . . O
those . . O
seen . . O
at . . O
a . . O
dose . . O
of . . O
15 . . O
mg . . O
twice . . O
daily . . O
, . . O
a . . O
dose . . O
that . . O
may . . B-Factor
be . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . O
of . . O
seizures . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

in . . O
male . . O
and . . O
female . . O
rats . . B-Animal
, . . O
dulaglutide . . O
causes . . O
a . . O
dose . . O
- . . O
related . . O
and . . O
treatment . . O
- . . O
duration . . O
- . . O
dependent . . O
increase . . O
in . . O
the . . O
incidence . . O
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
( . . O
adenomas . . O
and . . O
carcinomas . . O
) . . O
after . . O
lifetime . . O
exposure . . O
[ . . O
see . . O
nonclinical . . O
toxicology . . O
( . . O
13.1 . . O
) . . O
] . . O
. . . O

assure . . O
good . . O
venous . . O
access . . O
prior . . O
to . . O
starting . . O
treanda . . O
infusion . . O
and . . O
monitor . . O
the . . O
intravenous . . O
infusion . . O
site . . O
for . . O
redness . . O
, . . O
swelling . . O
, . . O
pain . . O
, . . O
infection . . O
, . . O
and . . O
necrosis . . O
during . . O
and . . O
after . . O
administration . . O
of . . O
treanda . . O
. . . O

however . . O
, . . O
some . . O
patients . . O
may . . O
require . . O
treatment . . O
with . . O
fanapt . . O
despite . . O
the . . O
presence . . O
of . . O
the . . O
syndrome . . O
. . . O

the . . O
data . . O
described . . O
herein . . O
reflect . . O
exposure . . O
to . . O
ilaris . . O
in . . O
104 . . O
adult . . O
and . . O
pediatric . . O
caps . . O
patients . . O
, . . O
including . . O
20 . . O
fcas . . O
, . . O
72 . . O
mws . . O
, . . O
10 . . O
mws . . O
/ . . O
nomid . . O
( . . O
neonatal . . O
onset . . O
multisystem . . O
inflammatory . . O
disorder . . O
) . . O
overlap . . O
, . . O
1 . . O
non . . O
- . . O
fcas . . O
non . . O
- . . O
mws . . O
, . . O
and . . O
1 . . O
misdiagnosed . . O
in . . O
placebo . . O
- . . O
controlled . . O
( . . O
35 . . O
patients . . O
) . . O
and . . O
uncontrolled . . O
trials . . O
. . . O

because . . O
of . . O
its . . O
anticholinergic . . O
effects . . O
, . . O
xeomin . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
at . . O
risk . . O
of . . O
developing . . O
narrow . . O
angle . . O
glaucoma . . O
. . . O

a . . O
total . . O
of . . O
200 . . O
subjects . . O
participated . . O
in . . O
the . . O
clinical . . O
trials . . O
for . . O
endogenous . . O
anterior . . O
uveitis . . O
, . . O
of . . O
which . . O
106 . . O
were . . O
exposed . . O
to . . O
durezol . . O
. . . O

cases . . O
have . . O
occurred . . O
after . . O
the . . O
first . . O
dose . . O
of . . O
adcetris . . O
or . . O
after . . O
adcetris . . O
rechallenge . . O
. . . O

serious . . B-Severity
and . . O
sometimes . . O
fatal . . B-AdverseReaction
dermatologic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
( . . O
ten . . B-AdverseReaction
) . . O
and . . O
sjs . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
using . . O
oxcarbazepine . . B-DrugClass
or . . O
carbamazepine . . O
which . . O
are . . O
chemically . . O
related . . O
to . . O
aptiom . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
: . . O
vertigo . . B-AdverseReaction
, . . O
photophobia . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
illness . . I-AdverseReaction
, . . O
amyotrophy . . B-AdverseReaction
, . . O
burning . . B-AdverseReaction
sensation . . I-AdverseReaction
, . . O
facial . . B-AdverseReaction
paresis . . I-AdverseReaction
, . . O
hypoesthesia . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
and . . O
excessive . . B-AdverseReaction
granulation . . I-AdverseReaction
tissue . . I-AdverseReaction
. . . O

in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
rate . . O
of . . O
herpetic . . B-AdverseReaction
infections . . I-AdverseReaction
was . . O
9% . . O
in . . O
patients . . O
receiving . . O
gilenya . . O
0.5 . . O
mg . . O
and . . O
7% . . O
on . . O
placebo . . O
. . . O

* . . O
monitor . . O
all . . O
patients . . O
for . . O
active . . O
tb . . O
during . . O
treatment . . O
, . . O
even . . O
if . . O
initial . . O
latent . . O
tb . . O
test . . O
is . . O
negative . . O
( . . O
5.1 . . O
) . . O
* . . O
lymphoma . . B-AdverseReaction
and . . O
other . . O
malignancies . . B-AdverseReaction
, . . O
some . . O
fatal . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
children . . O
and . . O
adolescent . . O
patients . . O
treated . . O
with . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
, . . O
of . . O
which . . O
cimzia . . O
is . . O
a . . O
member . . O
( . . O
5.2 . . O
) . . O
. . . O

reduce . . O
the . . O
dose . . O
of . . O
pradaxa . . O
to . . O
75 . . O
mg . . O
twice . . O
daily . . O
when . . O
dronedarone . . O
or . . O
systemic . . O
ketoconazole . . O
is . . O
coadministered . . O
with . . O
pradaxa . . O
in . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
( . . O
crcl . . O
30-50 . . O
ml . . O
/ . . O
min . . O
) . . O
. . . O

other . . O
adverse . . O
reactions . . O
observed . . O
during . . O
the . . O
premarketing . . O
evaluation . . O
of . . O
saphris . . O
: . . O
following . . O
is . . O
a . . O
list . . O
of . . O
meddra . . O
terms . . O
that . . O
reflect . . O
adverse . . O
reactions . . O
reported . . O
by . . O
patients . . O
treated . . O
with . . O
sublingual . . O
saphris . . O
at . . O
multiple . . O
doses . . O
of . . O
> . . O
= . . O
5 . . O
mg . . O
twice . . O
daily . . O
during . . O
any . . O
phase . . O
of . . O
a . . O
trial . . O
within . . O
the . . O
database . . O
of . . O
adult . . O
patients . . O
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
seizures . . O
were . . O
excluded . . O
from . . O
pre . . O
- . . O
marketing . . O
clinical . . O
studies . . O
. . . O

and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O
consider . . O
the . . O
benefits . . O
and . . O
risks . . O
before . . O
neuraxial . . O
intervention . . O

withhold . . O
tafinlar . . O
, . . O
and . . O
trametinib . . O
if . . O
used . . O
in . . O
combination . . O
, . . O
for . . O
any . . O
serious . . O
febrile . . O
reaction . . O
or . . O
fever . . O
complicated . . O
by . . O
hypotension . . O
, . . O
rigors . . O
or . . O
chills . . O
, . . O
dehydration . . O
, . . O
or . . O
renal . . O
failure . . O
and . . O
evaluate . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
infection . . O
. . . O

consider . . O
other . . O
antidiabetic . . O
therapies . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
pancreatitis . . O
. . . O

if . . O
supine . . O
hypertension . . O
cannot . . O
be . . O
managed . . O
by . . O
elevation . . O
of . . O
the . . O
head . . O
of . . O
the . . O
bed . . O
, . . O
reduce . . O
or . . O
discontinue . . O
northera . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

* . . O
fat . . B-AdverseReaction
redistribution . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

reductions . . O
in . . O
immunosuppression . . O
should . . O
be . . O
considered . . O
for . . O
patients . . O
who . . O
develop . . O
evidence . . O
of . . O
pvan . . O
. . . O

* . . O
during . . O
and . . O
following . . O
dotarem . . O
administration . . O
, . . O
observe . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
hypersensitivity . . O
reactions . . O
. . . O

if . . O
skin . . O
not . . O
intended . . O
to . . O
be . . O
treated . . O
comes . . O
in . . O
contact . . O
with . . O
qutenza . . O
, . . O
apply . . O
cleansing . . O
gel . . O
for . . O
one . . O
minute . . O
and . . O
wipe . . O
off . . O
with . . O
dry . . O
gauze . . O
. . . O

acute . . O
or . . O
chronic . . O
disturbances . . O
of . . O
liver . . O
function . . O
may . . O
necessitate . . O
the . . O
discontinuation . . O
of . . O
coc . . O
use . . O
until . . O
markers . . O
of . . O
liver . . O
function . . O
return . . O
to . . O
normal . . O
and . . O
coc . . O
causation . . O
has . . O
been . . O
excluded . . O
. . . O

vascular . . O
disorders . . O
superficial . . B-AdverseReaction
phlebitis . . I-AdverseReaction

hepatobiliary . . O
disorders . . O
: . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
( . . O
some . . O
fatal . . B-AdverseReaction
) . . O
, . . O
jaundice . . B-AdverseReaction
, . . O
serious . . B-Severity
cases . . O
of . . O
abnormal . . B-AdverseReaction
liver . . I-AdverseReaction
function . . I-AdverseReaction
test . . O
results . . O
, . . O
liver . . B-AdverseReaction
disorder . . I-AdverseReaction
. . . O

monitoring . . O
of . . O
complete . . O
blood . . O
counts . . O
is . . O
essential . . O
on . . O
a . . O
weekly . . O
basis . . O
during . . O
cycle . . O
1 . . O
and . . O
before . . O
each . . O
treatment . . O
cycle . . O
thereafter . . O
so . . O
that . . O
the . . O
dose . . O
can . . O
be . . O
adjusted . . O
, . . O
if . . O
needed . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

5.13 . . O
priapism . . O

in . . O
a . . O
pooled . . O
population . . O
of . . O
patients . . O
( . . O
n . . O
= . . O
723 . . O
) . . O
with . . O
moderate . . O
renal . . O
impairment . . O
( . . O
egfr . . O
45 . . O
to . . O
less . . O
than . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
, . . O
increases . . O
in . . O
serum . . O
potassium . . O
to . . O
greater . . O
than . . O
5.4 . . B-Severity
meq . . I-Severity
/ . . I-Severity
l . . I-Severity
and . . O
15% . . B-Severity
above . . I-Severity
baseline . . I-Severity
occurred . . O
in . . O
5.3% . . O
, . . O
5.0% . . O
, . . O
and . . O
8.8% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

( . . O
5.3 . . O
, . . O
5.4 . . O
) . . O

several . . O
patients . . O
had . . O
a . . O
prior . . O
history . . O
of . . O
pancreatitis . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
administer . . O
a . . O
thyroid . . O
- . . O
blocking . . O
agent . . O
before . . O
datscan . . O
administration . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

however . . O
, . . O
across . . O
clinical . . O
trials . . O
no . . B-Negation
renal . . B-AdverseReaction
abscesses . . I-AdverseReaction
were . . O
confirmed . . O
by . . O
microbiology . . O
tests . . O
. . . O

14 . . O
( . . O
0.93% . . O
) . . O
11 . . O
( . . O
0.69% . . O
) . . O
22 . . O
( . . O
1.39% . . O
) . . O
fatal . . B-AdverseReaction
0 . . O
0 . . O
0 . . O
0 . . O
0 . . O
1 . . O
( . . O
0.06% . . O
) . . O
hgb . . B-AdverseReaction
decrease . . I-AdverseReaction
> . . O
= . . O
2 . . B-Severity
g . . I-Severity
/ . . I-Severity
dl . . I-Severity
13 . . O
( . . O
0.49% . . O
) . . O
10 . . O
( . . O
0.38% . . O
) . . O
8 . . O
( . . O
0.53% . . O
) . . O
9 . . O
( . . O
0.60% . . O
) . . O
10 . . O
( . . O
0.63% . . O
) . . O
16 . . O
( . . O
1.01% . . O
) . . O
transfusion . . O
of . . O
> . . O
= . . O
2 . . O
units . . O
rbc . . O
16 . . O
( . . O
0.60% . . O
) . . O
14 . . O
( . . O
0.53% . . O
) . . O
5 . . O
( . . O
0.33% . . O
) . . O
9 . . O
( . . O
0.60% . . O
) . . O
9 . . O
( . . O
0.56% . . O
) . . O
18 . . O
( . . O
1.13% . . O
) . . O
bleed . . B-AdverseReaction
at . . I-AdverseReaction
critical . . I-AdverseReaction
sites . . O
1 . . O
( . . O
0.04% . . O
) . . O
1 . . O
( . . O
0.04% . . O
) . . O
1 . . O
( . . O
0.07% . . O
) . . O
2 . . O
( . . O
0.13% . . O
) . . O
1 . . O
( . . O
0.06% . . O
) . . O
4 . . O
( . . O
0.25% . . O
) . . O
major+ . . O
crnm . . O
129 . . O
( . . O
4.83% . . O
) . . O
134 . . O
( . . O
5.04% . . O
) . . O
53 . . O
( . . O
3.53% . . O
) . . O
72 . . O
( . . O
4.77% . . O
) . . O
46 . . O
( . . O
2.88% . . O
) . . O
68 . . O
( . . O
4.28% . . O
) . . O
all . . O
313 . . O
( . . O
11.71% . . O
) . . O
334 . . O
( . . O
12.56% . . O
) . . O
104 . . O
( . . O
6.93% . . O
) . . O
126 . . O
( . . O
8.36% . . O
) . . O
85 . . O
( . . O
5.33% . . O
) . . O
108 . . O
( . . O
6.80% . . O
) . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
undergoing . . O
hip . . O
or . . O
knee . . O
replacement . . O
surgery . . O
in . . O
the . . O
1 . . O
phase . . O
ii . . O
study . . O
and . . O
the . . O
3 . . O
phase . . O
iii . . O
studies . . O
are . . O
listed . . O
in . . O
table . . O
4 . . O
. . . O

for . . O
these . . O
reasons . . O
, . . O
comparison . . O
of . . O
incidence . . O
of . . O
antibodies . . O
to . . O
collagenase . . O
clostridium . . O
histolyticum . . O
with . . O
the . . O
incidence . . O
of . . O
antibodies . . O
to . . O
other . . O
products . . O
may . . O
be . . O
misleading . . O
. . . O

this . . O
risk . . O
has . . O
been . . O
shown . . O
to . . O
persist . . O
for . . O
at . . O
least . . O
8 . . O
to . . O
15 . . O
years . . O
after . . O
estrogen . . O
therapy . . O
is . . O
discontinued . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
nausea . . B-AdverseReaction

in . . O
the . . O
long . . O
- . . O
term . . O
extension . . O
studies . . O
, . . O
the . . O
incidences . . O
of . . O
adjudicated . . O
aptc . . O
events . . O
were . . O
: . . O
uloric . . O
80 . . O
mg . . O
0.97 . . O
( . . O
95% . . O
ci . . O
0.57-1.56 . . O
) . . O
, . . O
and . . O
allopurinol . . O
0.58 . . O
( . . O
95% . . O
ci . . O
0.02-3.24 . . O
) . . O
. . . O

table . . O
1 . . O
contains . . O
the . . O
treatment . . O
emergent . . O
adverse . . O
reactions . . O
, . . O
regardless . . O
of . . O
attribution . . O
, . . O
that . . O
were . . O
reported . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
in . . O
either . . O
treatment . . O
group . . O
in . . O
the . . O
randomized . . O
cll . . O
clinical . . O
study . . O
. . . O

severe . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
or . . O
fatal . . B-AdverseReaction
ild . . O
/ . . O
pneumonitis . . O
can . . B-Factor
occur . . O
in . . O
patients . . O
treated . . O
with . . O
zykadia . . O
. . . O

the . . O
duration . . O
of . . O
prolia . . O
exposure . . O
to . . O
time . . O
of . . O
atypical . . B-AdverseReaction
femoral . . I-AdverseReaction
fracture . . I-AdverseReaction
diagnosis . . O
was . . O
as . . O
early . . O
as . . O
21 . . O
/ . . O
2 . . O
years . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

for . . O
the . . O
6 . . O
- . . O
dose . . O
regimen . . O
, . . O
coartem . . O
tablets . . O
was . . O
studied . . O
in . . O
active . . O
- . . O
controlled . . O
( . . O
366 . . O
patients . . O
) . . O
and . . O
non . . O
- . . O
controlled . . O
, . . O
open . . O
- . . O
label . . O
trials . . O
( . . O
1,613 . . O
patients . . O
) . . O
. . . O

* . . O
avoid . . O
injection . . O
near . . O
the . . O
levator . . O
palpebrae . . O
superioris . . O
, . . O
particularly . . O
in . . O
patients . . O
with . . O
larger . . O
brow . . O
depressor . . O
complexes . . O
. . . O

excerpt . . O
: . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
5% . . O
and . . O
at . . O
least . . O
twice . . O
that . . O
for . . O
placebo . . O
) . . O
were . . O
( . . O
6.1 . . O
) . . O
: . . O

30.6% . . O
had . . O
diabetes . . O
mellitus . . O
. . . O

the . . O
most . . O
common . . O
cause . . O
of . . O
discontinuation . . O
due . . O
to . . O
an . . O
adverse . . O
event . . O
was . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

adverse . . O
reactions . . O
are . . O
events . . O
that . . O
occurred . . O
after . . O
the . . O
first . . O
dose . . O
of . . O
study . . O
medication . . O
treatment . . O
and . . O
within . . O
7 . . O
days . . O
of . . O
the . . O
last . . O
dose . . O
of . . O
study . . O
medication . . O
or . . O
events . . O
present . . O
at . . O
baseline . . O
that . . O
increased . . O
in . . O
severity . . O
after . . O
the . . O
start . . O
of . . O
study . . O
medication . . O
treatment . . O
. . . O

and . . O
patients . . O
should . . O
be . . O
monitored . . O
closely . . O
. . . O

major . . O
327 . . O
( . . O
2.13 . . O
) . . O
462 . . O
( . . O
3.09 . . O
) . . O
0.69 . . O
( . . O
0.60 . . O
, . . O
0.80 . . O
) . . O
< . . O
0.0001 . . O
intracranial . . O
( . . O
ich . . B-AdverseReaction
) . . O
? . . O

females . . O
of . . O
childbearing . . O
potential . . O
should . . O
be . . O
advised . . O
to . . O
avoid . . O
becoming . . O
pregnant . . O
during . . O
treatment . . O
with . . O
jevtana . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

controlled . . O
study . . O
the . . O
data . . O
in . . O
tables . . O
1 . . O
and . . O
2 . . O
below . . O
reflect . . O
exposure . . O
of . . O
229 . . O
egfr . . O
- . . O
tki . . O
naive . . O
gilotrif . . O
- . . O
treated . . O
patients . . O
with . . O
egfr . . O
mutation . . O
- . . O
positive . . O
, . . O
metastatic . . O
, . . O
non . . O
- . . O
squamous . . O
, . . O
nsclc . . O
enrolled . . O
in . . O
a . . O
randomized . . O
, . . O
multicenter . . O
, . . O
open . . O
- . . O
label . . O
trial . . O
( . . O
study . . O
1 . . O
) . . O
. . . O

if . . O
contraceptive . . O
methods . . O
are . . O
being . . O
considered . . O
, . . O
use . . O
effective . . O
contraception . . O
during . . O
treatment . . O
, . . O
and . . O
for . . O
at . . O
least . . O
1 . . O
month . . O
after . . O
the . . O
last . . O
dose . . O
of . . O
zydelig . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

dosing . . O
should . . O
be . . O
interrupted . . O
in . . O
patients . . O
with . . O
alt . . O
or . . O
ast . . O
of . . O
greater . . O
than . . O
5 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
( . . O
uln . . O
) . . O
. . . O

( . . O
5.7 . . O
) . . O
( . . O
8.1 . . O
) . . O

the . . O
safety . . O
of . . O
voraxaze . . O
is . . O
based . . O
on . . O
data . . O
from . . O
290 . . O
patients . . O
who . . O
were . . O
treated . . O
in . . O
2 . . O
single . . O
- . . O
arm . . O
, . . O
open . . O
- . . O
label . . O
, . . O
multicenter . . O
trials . . O
enrolling . . O
patients . . O
who . . O
had . . O
markedly . . O
delayed . . O
methotrexate . . O
clearance . . O
secondary . . O
to . . O
renal . . O
dysfunction . . O
. . . O

* . . O
report . . O
any . . O
unusual . . O
vaginal . . O
bleeding . . O
right . . O
away . . O
while . . O
you . . O
are . . O
taking . . O
duavee . . O
. . . O

table . . O
2 . . O
presents . . O
the . . O
adverse . . O
reactions . . O
reported . . O
when . . O
stendra . . O
was . . O
taken . . O
as . . O
recommended . . O
( . . O
on . . O
an . . O
as . . O
- . . O
needed . . O
basis . . O
) . . O
in . . O
this . . O
open . . O
- . . O
label . . O
extension . . O
trial . . O
. . . O

eye . . O
disorders . . O
: . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction

tanzeum . . O
was . . O
used . . O
as . . O
monotherapy . . O
in . . O
1 . . O
trial . . O
and . . O
as . . O
add . . O
- . . O
on . . O
therapy . . O
in . . O
3 . . O
trials . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

ilaris . . O
has . . O
been . . O
associated . . O
with . . O
an . . O
increased . . O
incidence . . O
of . . O
serious . . B-Severity
infections . . B-AdverseReaction
. . . O

( . . O
5.1 . . O
) . . O
* . . O
serious . . B-Severity
infections . . B-AdverseReaction
: . . O
serious . . B-Severity
and . . O
sometimes . . O
fatal . . B-AdverseReaction
infections . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
immunosuppressive . . O
agents . . O
, . . O
including . . O
benlysta . . O
. . . O

angioedema . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
face . . I-AdverseReaction
, . . O
lips . . O
, . . O
tongue . . O
, . . O
and . . O
/ . . O
or . . O
larynx . . O
has . . O
been . . O
reported . . O
with . . O
fesoterodine . . O
. . . O

exposure . . O
to . . O
excessive . . O
amounts . . O
of . . O
benzyl . . O
alcohol . . O
has . . O
been . . O
associated . . O
with . . O
toxicity . . O
( . . O
hypotension . . O
, . . O
metabolic . . O
acidosis . . O
) . . O
, . . O
particularly . . O
in . . O
neonates . . O
, . . O
and . . O
an . . O
increased . . O
incidence . . O
of . . O
kernicterus . . O
, . . O
particularly . . O
in . . O
small . . O
preterm . . O
infants . . O
. . . O

the . . O
clinical . . O
program . . O
for . . O
breo . . O
ellipta . . O
included . . O
7,700 . . O
subjects . . O
with . . O
copd . . O
in . . O
two . . O
6 . . O
- . . O
month . . O
lung . . O
function . . O
trials . . O
, . . O
two . . O
12 . . O
- . . O
month . . O
exacerbation . . O
trials . . O
, . . O
and . . O
6 . . O
other . . O
trials . . O
of . . O
shorter . . O
duration . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

pml . . O
is . . O
an . . O
opportunistic . . O
viral . . O
infection . . O
of . . O
the . . O
brain . . O
caused . . O
by . . O
the . . O
jc . . O
virus . . O
( . . O
jcv . . O
) . . O
that . . O
typically . . O
only . . O
occurs . . O
in . . O
patients . . O
who . . O
are . . O
immunocompromised . . O
, . . O
and . . O
that . . O
usually . . O
leads . . O
to . . O
death . . O
or . . O
severe . . O
disability . . O
. . . O

in . . O
both . . O
studies . . O
, . . O
patients . . O
received . . O
xtandi . . O
160 . . O
mg . . O
orally . . O
once . . O
daily . . O
in . . O
the . . O
active . . O
treatment . . O
arm . . O
or . . O
placebo . . O
in . . O
the . . O
control . . O
arm . . O
. . . O

the . . O
median . . O
time . . O
to . . O
onset . . O
of . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
and . . O
ast . . O
was . . O
30 . . O
and . . O
33 . . O
days . . O
, . . O
respectively . . O
, . . O
and . . O
the . . O
median . . O
duration . . O
for . . O
each . . O
was . . O
21 . . O
days . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
bausch . . O
& . . O
lomb . . O
incorporated . . O
. . . O
at . . O
1-800-323-0000 . . O
, . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

perform . . O
an . . O
examination . . O
of . . O
the . . O
fundus . . O
including . . O
the . . O
macula . . O
in . . O
all . . O
patients . . O
before . . O
starting . . O
treatment . . O
, . . O
again . . O
3-4 . . O
months . . O
after . . O
starting . . O
treatment . . O
, . . O
and . . O
again . . O
at . . O
any . . O
time . . O
after . . O
a . . O
patient . . O
reports . . O
visual . . O
disturbances . . O
while . . O
on . . O
gilenya . . O
therapy . . O
. . . O

hyperprolactinemia . . B-AdverseReaction
may . . B-Factor
suppress . . B-AdverseReaction
hypothalamic . . I-AdverseReaction
gnrh . . I-AdverseReaction
, . . O
resulting . . O
in . . O
reduced . . B-AdverseReaction
pituitary . . I-AdverseReaction
gonadotropin . . I-AdverseReaction
secretion . . I-AdverseReaction
. . . O

gilenya . . O
has . . O
not . . O
been . . O
tested . . O
in . . O
ms . . O
patients . . O
with . . O
diabetes . . O
mellitus . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
events . . O
occurring . . O
in . . O
at . . O
least . . O
20% . . O
of . . O
patients . . O
treated . . O
with . . O
kyprolis . . O
in . . O
the . . O
combination . . O
therapy . . O
trial . . O
: . . O
decreased . . B-AdverseReaction
lymphocytes . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
absolute . . I-AdverseReaction
neutrophil . . I-AdverseReaction
count . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
phosphorus . . I-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
total . . I-AdverseReaction
white . . I-AdverseReaction
blood . . I-AdverseReaction
cell . . I-AdverseReaction
count . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
platelets . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
spasm . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
25% . . O
) . . O
of . . O
xalkori . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
are . . O
vision . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
edema . . B-AdverseReaction
, . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
and . . O
dysgeusia . . B-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
bayer . . O
healthcare . . O
pharmaceuticals . . O
inc . . O
. . . O
at . . O
1-888-842-2937 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

monitor . . O
liver . . O
enzymes . . O
and . . O
bilirubin . . O
. . . O

the . . O
use . . O
of . . O
cocs . . O
may . . O
change . . O
the . . O
results . . O
of . . O
some . . O
laboratory . . O
tests . . O
, . . O
such . . O
as . . O
coagulation . . O
factors . . O
, . . O
lipids . . O
, . . O
glucose . . O
tolerance . . O
, . . O
and . . O
binding . . O
proteins . . O
. . . O

two . . O
patients . . O
treated . . O
with . . O
kalydeco . . O
were . . O
reported . . O
to . . O
have . . O
serious . . B-Severity
adverse . . O
reactions . . O
of . . O
elevated . . B-AdverseReaction
liver . . I-AdverseReaction
transaminases . . I-AdverseReaction
compared . . O
to . . O
none . . O
on . . O
placebo . . O
. . . O

adverse . . O
reactions . . O
most . . O
commonly . . O
leading . . O
to . . O
discontinuation . . O
of . . O
treatment . . O
in . . O
premarketing . . O
controlled . . O
trials . . O

prolonged . . O
( . . O
> . . O
= . . O
1 . . O
week . . O
) . . O
severe . . B-Severity
neutropenia . . B-AdverseReaction
and . . O
grade . . B-Severity
3 . . I-Severity
or . . O
grade . . B-Severity
4 . . I-Severity
thrombocytopenia . . B-AdverseReaction
or . . O
anemia . . B-AdverseReaction
can . . B-Factor
occur . . O
with . . O
adcetris . . O
. . . O

do . . O
not . . O
use . . O
breo . . O
ellipta . . O
for . . O
patients . . O
whose . . O
asthma . . O
is . . O
adequately . . O
controlled . . O
on . . O
low . . O
- . . O
or . . O
medium . . O
- . . O
dose . . O
ics . . O
. . . O
( . . O
1.2 . . O
, . . O
5.1 . . O
) . . O

consider . . O
the . . O
risks . . O
and . . O
benefits . . O
of . . O
treatment . . O
prior . . O
to . . O
initiating . . O
simponi . . O
aria . . O
in . . O
patients . . O
: . . O

abdominal . . O
pain . . O
and . . O
tenderness . . O
, . . O
fever . . O
, . . O
persistent . . O
constipation . . O
, . . O
diarrhea . . O
, . . O
with . . O
or . . O
without . . O
neutropenia . . O
, . . O
may . . O
be . . O
early . . O
manifestations . . O
of . . O
serious . . O
gastrointestinal . . O
toxicity . . O
and . . O
should . . O
be . . O
evaluated . . O
and . . O
treated . . O
promptly . . O
. . . O

ear . . O
and . . O
labyrinth . . O
disorders . . O
: . . O
vertigo . . B-AdverseReaction

extreme . . O
care . . O
should . . O
be . . O
exercised . . O
, . . O
with . . O
appropriate . . O
resuscitation . . O
measures . . O
available . . O
, . . O
if . . O
the . . O
decision . . O
is . . O
made . . O
to . . O
re . . O
- . . O
administer . . O
the . . O
product . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

5.2 . . O
acute . . O
pancreatitis . . O

5.5 . . O
renal . . O
toxicity . . O

of . . O
the . . O
patients . . O
who . . O
developed . . O
tuberculosis . . B-AdverseReaction
through . . O
3 . . O
years . . O
, . . O
all . . O
but . . O
one . . O
nulojix . . O
patient . . O
lived . . O
in . . O
countries . . O
with . . O
a . . O
high . . O
prevalence . . O
of . . O
tuberculosis . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

5.2 . . O
deterioration . . O
of . . O
disease . . O
and . . O
acute . . O
episodes . . O

* . . O
serious . . B-Severity
infections . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
malignancies . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
because . . O
clinical . . O
studies . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
and . . O
controlled . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
clinical . . O
studies . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
another . . O
drug . . O
, . . O
and . . O
may . . O
not . . O
predict . . O
the . . O
rates . . O
observed . . O
in . . O
a . . O
broader . . O
patient . . O
population . . O
in . . O
clinical . . O
practice . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
lactic . . B-AdverseReaction
acidosis . . I-AdverseReaction
/ . . O
severe . . B-Severity
hepatomegaly . . B-AdverseReaction
with . . O
steatosis . . B-AdverseReaction
and . . O
post . . O
treatment . . O
acute . . B-AdverseReaction
exacerbation . . I-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction

if . . O
neurological . . O
compromise . . O
is . . O
noted . . O
, . . O
urgent . . O
diagnosis . . O
and . . O
treatment . . O
is . . O
necessary . . O
. . . O

etiologies . . O
included . . O
infection . . B-AdverseReaction
, . . O
cardiovascular . . B-AdverseReaction
disease . . I-AdverseReaction
, . . O
and . . O
suicide . . B-AdverseReaction
. . . O

assessment . . O
of . . O
the . . O
relationship . . O
between . . O
atypical . . O
antipsychotic . . O
use . . O
and . . O
glucose . . O
abnormalities . . O
is . . O
complicated . . O
by . . O
the . . O
possibility . . O
of . . O
an . . O
increased . . O
background . . O
risk . . O
of . . O
diabetes . . O
mellitus . . O
in . . O
patients . . O
with . . O
schizophrenia . . O
and . . O
the . . O
increasing . . O
incidence . . O
of . . O
diabetes . . O
mellitus . . O
in . . O
the . . O
general . . O
population . . O
. . . O

grade . . B-Severity
3 . . I-Severity
peripheral . . O
neuropathy . . O
occurred . . O
in . . O
8% . . O
( . . O
40 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
, . . O
and . . O
grade . . B-Severity
4 . . I-Severity
in . . O
0.4% . . O
( . . O
2 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
in . . O
study . . O
1 . . O
. . . O

tuberculosis . . B-AdverseReaction
was . . O
more . . O
frequently . . O
observed . . O
in . . O
patients . . O
receiving . . O
nulojix . . O
than . . O
cyclosporine . . O
in . . O
clinical . . O
trials . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

* . . O
doses . . O
of . . O
toviaz . . O
greater . . O
than . . O
4 . . O
mg . . O
are . . O
not . . O
recommended . . O
in . . O
patients . . O
taking . . O
a . . O
potent . . O
cyp3a4 . . O
inhibitor . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
ketoconazole . . O
, . . O
itraconazole . . O
, . . O
clarithromycin . . O
) . . O
. . . O

adcetris . . O
- . . O
induced . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
is . . O
cumulative . . O
. . . O

the . . O
risk . . B-Factor
of . . O
acute . . B-AdverseReaction
kidney . . I-AdverseReaction
injury . . I-AdverseReaction
might . . O
be . . O
lower . . O
with . . O
eovist . . O
due . . O
to . . O
its . . O
dual . . O
excretory . . O
pathways . . O
. . . O

the . . O
mechanism . . O
and . . O
long . . O
- . . O
term . . O
consequences . . O
of . . O
these . . O
events . . O
are . . O
currently . . O
unknown . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
, . . O
serious . . B-Severity
events . . O
of . . O
appendicitis . . B-AdverseReaction
occurred . . O
in . . O
0.3% . . O
of . . O
patients . . O
treated . . O
with . . O
tanzeum . . O
compared . . O
with . . O
0% . . O
among . . O
all . . O
comparators . . O
. . . O

non . . O
- . . O
hodgkin . . O
lymphoma . . O

( . . O
5.2 . . O
) . . O
* . . O
clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
diarrhea . . I-AdverseReaction
( . . O
cdad . . B-AdverseReaction
) . . O
has . . O
been . . O
reported . . O
with . . O
nearly . . O
all . . O
systemic . . O
antibacterial . . O
agents . . O
, . . O
including . . O
zerbaxa . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
discontinue . . O
for . . O
severe . . O
skin . . O
reactions . . O
. . . O

the . . O
mean . . O
baseline . . O
non . . O
- . . O
hdl . . O
- . . O
c . . O
levels . . O
were . . O
140 . . O
to . . O
147 . . O
mg . . O
/ . . O
dl . . O
across . . O
treatment . . O
groups . . O
. . . O

5.3 . . O
interstitial . . O
lung . . O
disease . . O
( . . O
ild . . O
) . . O
/ . . O
pneumonitis . . O

data . . O
from . . O
a . . O
4 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
dose . . O
study . . O
in . . O
adult . . O
subjects . . O
with . . O
schizophrenia . . O
, . . O
in . . O
which . . O
fasting . . O
blood . . O
samples . . O
were . . O
drawn . . O
, . . O
are . . O
presented . . O
in . . O
table . . O
1 . . O
. . . O

( . . O
6.1 . . O
) . . O
* . . O
phn . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
were . . O
dizziness . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

kalbitor . . O
should . . O
not . . O
be . . O
administered . . O
to . . O
any . . O
patients . . O
with . . O
known . . O
clinical . . O
hypersensitivity . . O
to . . O
kalbitor . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

beyond . . O
48 . . O
hours . . O
after . . O
voraxaze . . O
, . . O
administer . . O
leucovorin . . O
based . . O
on . . O
the . . O
measured . . O
methotrexate . . O
concentration . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
5.3 . . O
) . . O
* . . O
tardive . . B-AdverseReaction
dyskinesia . . I-AdverseReaction
: . . O
discontinue . . O
if . . O
clinically . . O
appropriate . . O
. . . O

5.2 . . O
anaphylaxis . . O
and . . O
infusion . . O
reactions . . O

consultation . . O
with . . O
a . . O
specialist . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
neurologist . . O
and . . O
/ . . O
or . . O
infectious . . O
disease . . O
) . . O
should . . O
be . . O
considered . . O
for . . O
any . . O
suspected . . O
or . . O
confirmed . . O
cases . . O
of . . O
pml . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
hypertension . . B-AdverseReaction
: . . O
monitor . . O
blood . . O
pressure . . O
regularly . . O
. . . O

typical . . B-Factor
symptoms . . O
associated . . O
with . . O
pml . . B-AdverseReaction
are . . O
diverse . . O
, . . O
progress . . O
over . . O
days . . O
to . . O
weeks . . O
, . . O
and . . O
include . . O
progressive . . B-AdverseReaction
weakness . . I-AdverseReaction
on . . I-AdverseReaction
one . . I-AdverseReaction
side . . I-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
body . . I-AdverseReaction
or . . O
clumsiness . . B-AdverseReaction
of . . I-AdverseReaction
limbs . . I-AdverseReaction
, . . O
disturbance . . B-AdverseReaction
of . . I-AdverseReaction
vision . . I-AdverseReaction
, . . O
and . . O
changes . . B-AdverseReaction
in . . I-AdverseReaction
thinking . . I-AdverseReaction
, . . O
memory . . O
, . . O
and . . O
orientation . . O
leading . . O
to . . O
confusion . . B-AdverseReaction
and . . O
personality . . B-AdverseReaction
changes . . I-AdverseReaction
. . . O

( . . O
5.1 . . O
) . . O
* . . O
inhalation . . O
of . . O
airborne . . O
capsaicin . . O
can . . B-Factor
result . . O
in . . O
coughing . . B-AdverseReaction
or . . O
sneezing . . B-AdverseReaction
. . . O

the . . O
results . . O
suggest . . O
an . . O
approximate . . O
2 . . O
- . . O
fold . . O
increase . . O
in . . O
the . . O
risk . . O
of . . O
naion . . B-AdverseReaction
within . . O
5 . . O
half . . O
- . . O
lives . . O
of . . O
pde5 . . B-DrugClass
inhibitor . . I-DrugClass
use . . O
. . . O

if . . O
hepatic . . O
injury . . O
is . . O
suspected . . O
, . . O
promptly . . O
discontinue . . O
multaq . . O
and . . O
test . . O
serum . . O
enzymes . . O
, . . O
aspartate . . O
aminotransferase . . O
( . . O
ast . . O
) . . O
, . . O
alanine . . O
aminotransferase . . O
( . . O
alt . . O
) . . O
and . . O
alkaline . . O
phosphatase . . O
, . . O
as . . O
well . . O
as . . O
serum . . O
bilirubin . . O
, . . O
to . . O
establish . . O
whether . . O
there . . O
is . . O
liver . . O
injury . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
more . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

table . . O
2 . . O
tabulated . . O
summary . . O
of . . O
adverse . . O
drug . . O
reactions . . O
from . . O
pivotal . . O
sjia . . O
clinical . . O
trials . . O
n . . O
= . . O
number . . O
of . . O
patients^ . . O
ir . . O
= . . O
exposure . . O
adjusted . . O
incidence . . O
rate . . O
per . . O
100 . . O
patient . . O
- . . O
days . . O
* . . O
no . . O
injection . . O
site . . O
reaction . . O
led . . O
to . . O
study . . O
discontinuation . . O
sjia . . O
study . . O
2 . . O
sjia . . O
study . . O
1 . . O
part . . O
i . . O
part . . O
ii . . O
ilarisn . . O
= . . O
177n . . O
( . . O
% . . O
) . . O
( . . O
ir . . O
) . . O
^ . . O
ilarisn . . O
= . . O
50n . . O
( . . O
% . . O
) . . O
( . . O
ir . . O
) . . O
placebon . . O
= . . O
50n . . O
( . . O
% . . O
) . . O
( . . O
ir . . O
) . . O
ilarisn . . O
= . . O
43n . . O
( . . O
% . . O
) . . O
( . . O
ir . . O
) . . O
placebon . . O
= . . O
41n . . O
( . . O
% . . O
) . . O
( . . O
ir . . O
) . . O
infections . . O
and . . O
infestations . . O
all . . O
infections . . B-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
( . . O
viral . . O
) . . O
upper . . O
respiratory . . O
tract . . O
infection . . O
, . . O
pneumonia . . B-AdverseReaction
, . . O
rhinitis . . B-AdverseReaction
, . . O
pharyngitis . . B-AdverseReaction
, . . O
tonsillitis . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
gastroenteritis . . B-AdverseReaction
, . . O
viral . . B-AdverseReaction
infection . . I-AdverseReaction
) . . O
97 . . O
( . . O
54.8% . . O
) . . O
( . . O
0.91 . . O
) . . O
27 . . O
( . . O
54% . . O
) . . O
( . . O
0.59 . . O
) . . O
19 . . O
( . . O
38% . . O
) . . O
( . . O
0.63 . . O
) . . O
13 . . O
( . . O
30.2% . . O
) . . O
( . . O
1.26 . . O
) . . O
5 . . O
( . . O
12.2% . . O
) . . O
( . . O
1.37 . . O
) . . O
gastrointestinal . . O
disorders . . O
abdominal . . O
pain . . O
( . . O
upper . . O
) . . O
25 . . O
( . . O
14.1% . . O
) . . O
( . . O
0.16 . . O
) . . O
8 . . O
( . . O
16% . . O
) . . O
( . . O
0.15 . . O
) . . O
6 . . O
( . . O
12% . . O
) . . O
( . . O
0.08 . . O
) . . O
3 . . O
( . . O
7% . . O
) . . O
( . . O
0.25 . . O
) . . O
1 . . O
( . . O
2.4% . . O
) . . O
( . . O
0.23 . . O
) . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
* . . O
mild . . O
19 . . O
( . . O
10.7% . . O
) . . O
6 . . O
( . . O
12.0% . . O
) . . O
2 . . O
( . . O
4.0% . . O
) . . O
0 . . O
3 . . O
( . . O
7.3% . . O
) . . O
moderate . . O
2 . . O
( . . O
1.1% . . O
) . . O
1 . . O
( . . O
2.0% . . O
) . . O
0 . . O
0 . . O
0 . . O
6.2 . . O
hypersensitivity . . O
during . . O
clinical . . O
trials . . O
, . . O
no . . B-Negation
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

monitor . . O
crcl . . O
at . . O
least . . O
daily . . O
in . . O
patients . . O
with . . O
changing . . O
renal . . O
function . . O
and . . O
adjust . . O
the . . O
dosage . . O
of . . O
zerbaxa . . O
accordingly . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

therefore . . O
, . . O
xiaflex . . O
should . . O
be . . O
injected . . O
only . . O
into . . O
the . . O
peyronie's . . O
plaque . . O
and . . O
care . . O
should . . O
be . . O
taken . . O
to . . O
avoid . . O
injecting . . O
into . . O
the . . O
urethra . . O
, . . O
nerves . . O
, . . O
blood . . O
vessels . . O
, . . O
corpora . . O
cavernosa . . O
or . . O
other . . O
collagen . . O
- . . O
containing . . O
structures . . O
of . . O
the . . O
penis . . O
. . . O

proper . . O
aseptic . . O
injection . . O
technique . . O
must . . O
always . . O
be . . O
used . . O
when . . O
administering . . O
eylea . . O
. . . O

factors . . O
that . . O
can . . O
increase . . O
the . . O
risk . . O
of . . O
developing . . O
epidural . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
at . . O
least . . O
5% . . O
of . . O
infantile . . O
- . . O
onset . . O
patients . . O
treated . . O
with . . O
alglucosidase . . O
alfa . . O
in . . O
clinical . . O
trials . . O
number . . O
of . . O
patients . . O
( . . O
n . . O
= . . O
39 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
adverse . . O
reaction . . O
20 . . O
( . . O
51 . . O
) . . O
rash . . B-AdverseReaction
( . . O
including . . O
rash . . B-AdverseReaction
erythematous . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
macular . . I-AdverseReaction
and . . O
maculo . . O
- . . O
papular . . O
) . . O
7 . . O
( . . O
18 . . O
) . . O
pyrexia . . B-AdverseReaction
6 . . O
( . . O
15 . . O
) . . O
urticaria . . B-AdverseReaction
5 . . O
( . . O
13 . . O
) . . O
flushing . . B-AdverseReaction
5 . . O
( . . O
13 . . O
) . . O
hypertension . . B-AdverseReaction
/ . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
4 . . O
( . . O
10 . . O
) . . O
decreased . . B-AdverseReaction
oxygen . . I-AdverseReaction
saturation . . I-AdverseReaction
3 . . O
( . . O
8 . . O
) . . O
cough . . B-AdverseReaction
3 . . O
( . . O
8 . . O
) . . O
tachypnea . . B-AdverseReaction
3 . . O
( . . O
8 . . O
) . . O
tachycardia . . B-AdverseReaction
3 . . O
( . . O
8 . . O
) . . O
erythema . . B-AdverseReaction
2 . . O
( . . O
5 . . O
) . . O
vomiting . . B-AdverseReaction
2 . . O
( . . O
5 . . O
) . . O
rigors . . B-AdverseReaction
2 . . O
( . . O
5 . . O
) . . O
pallor . . B-AdverseReaction
2 . . O
( . . O
5 . . O
) . . O
cyanosis . . B-AdverseReaction
2 . . O
( . . O
5 . . O
) . . O
agitation . . B-AdverseReaction
2 . . O
( . . O
5 . . O
) . . O
tremor . . B-AdverseReaction
2 . . O
( . . O
5 . . O
) . . O
an . . O
open . . O
- . . O
label . . O
, . . O
single . . O
- . . O
center . . O
trial . . O
was . . O
conducted . . O
in . . O
18 . . O
treatment . . O
- . . O
naive . . O
infantile . . O
- . . O
onset . . O
pompe . . O
disease . . O
patients . . O
who . . O
were . . O
treated . . O
exclusively . . O
with . . O
alglucosidase . . O
alfa . . O
. . . O

depression . . B-AdverseReaction
was . . O
reported . . O
as . . O
serious . . B-Severity
in . . O
0.1% . . O
( . . O
1 . . O
/ . . O
1308 . . O
) . . O
of . . O
subjects . . O
exposed . . O
to . . O
otezla . . O
, . . O
compared . . O
to . . O
none . . O
in . . O
placebo . . O
- . . O
treated . . O
subjects . . O
( . . O
0 . . O
/ . . O
506 . . O
) . . O
. . . O

it . . O
is . . O
unknown . . B-Factor
whether . . O
tanzeum . . O
( . . O
r . . O
) . . O
causes . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
, . . O
including . . O
medullary . . B-AdverseReaction
thyroid . . I-AdverseReaction
carcinoma . . I-AdverseReaction
( . . O
mtc . . B-AdverseReaction
) . . O
, . . O
in . . O
humans . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
, . . O
nonclinical . . O
toxicology . . O
( . . O
13.1 . . O
) . . O
] . . O
. . . O

based . . O
on . . O
the . . O
severity . . O
of . . O
the . . O
adverse . . O
drug . . O
reaction . . O
, . . O
withhold . . O
zykadia . . O
with . . O
resumption . . O
at . . O
a . . O
reduced . . O
dose . . O
as . . O
described . . O
in . . O
table . . O
1 . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
ge . . O
healthcare . . O
at . . O
1-800-654-0118 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
patients . . O
were . . O
randomized . . O
( . . O
2 . . O
: . . O
1 . . O
) . . O
to . . O
receive . . O
either . . O
halaven . . O
( . . O
1.4 . . O
mg . . O
/ . . O
m . . O
2 . . O
on . . O
days . . O
1 . . O
and . . O
8 . . O
of . . O
a . . O
21 . . O
- . . O
day . . O
cycle . . O
) . . O
or . . O
single . . O
agent . . O
treatment . . O
chosen . . O
by . . O
their . . O
physician . . O
( . . O
control . . O
group . . O
) . . O
. . . O

adverse . . O
reactions . . O
that . . O
led . . O
to . . O
dose . . O
delays . . O
in . . O
more . . O
than . . O
5% . . O
of . . O
patients . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
were . . O
neutropenia . . B-AdverseReaction
( . . O
14% . . O
) . . O
and . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
11% . . O
) . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

serious . . O
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
complications . . O
were . . O
reported . . O
with . . O
aptiom . . O
- . . O
associated . . O
hyponatremia . . O
( . . O
as . . O
low . . O
as . . O
112 . . B-Severity
meq . . I-Severity
/ . . I-Severity
l . . I-Severity
) . . O
including . . O
seizures . . B-AdverseReaction
, . . O
severe . . B-Severity
nausea . . B-AdverseReaction
/ . . O
vomiting . . B-AdverseReaction
leading . . O
to . . O
dehydration . . B-AdverseReaction
, . . O
severe . . B-Severity
gait . . B-AdverseReaction
instability . . I-AdverseReaction
, . . O
and . . O
injury . . B-AdverseReaction
. . . O

in . . O
phase . . O
2 . . O
and . . O
3 . . O
clinical . . O
trials . . O
, . . O
more . . O
dalvance . . O
- . . O
than . . O
comparator . . O
- . . O
treated . . O
subjects . . O
with . . O
normal . . O
baseline . . O
transaminase . . O
levels . . O
had . . O
post . . O
- . . O
baseline . . O
alanine . . O
aminotransferase . . O
( . . O
alt . . O
) . . O
elevation . . O
greater . . O
than . . O
3 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . O
uln . . O
) . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

fatal . . B-AdverseReaction
agranulocytosis . . B-AdverseReaction
can . . B-Factor
occur . . O
with . . O
ferriprox . . O
use . . O
. . . O

table . . O
7 . . O
: . . O
proportion . . O
of . . O
patients . . O
with . . O
sustained . . B-Severity
elevation . . B-AdverseReaction
of . . I-AdverseReaction
supine . . I-AdverseReaction
diastolic . . I-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
treatment . . O
group . . O
proportion . . O
of . . O
patients . . O
with . . O
sustained . . O
hypertension . . O
placebo . . O
0.5% . . O
pristiq . . O
50 . . O
mg . . O
per . . O
day . . O
1.3% . . O
pristiq . . O
100 . . O
mg . . O
per . . O
day . . O
0.7% . . O
pristiq . . O
200 . . O
mg . . O
per . . O
day . . O
1.1% . . O
pristiq . . O
400 . . O
mg . . O
per . . O
day . . O
2.3% . . O
orthostatic . . O
hypotension . . O

no . . B-Negation
patients . . O
experienced . . O
hypertensive . . B-AdverseReaction
crisis . . I-AdverseReaction
. . . O

in . . O
the . . O
pre . . O
- . . O
marketing . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
studies . . O
with . . O
doses . . O
of . . O
50 . . O
to . . O
400 . . O
mg . . O
, . . O
systolic . . B-AdverseReaction
orthostatic . . I-AdverseReaction
hypotension . . I-AdverseReaction
( . . O
decrease . . O
> . . O
= . . O
30 . . O
mm . . O
hg . . O
from . . O
supine . . O
to . . O
standing . . O
position . . O
) . . O
occurred . . O
more . . O
frequently . . O
in . . O
patients . . O
> . . O
= . . O
65 . . O
years . . O
of . . O
age . . O
receiving . . O
pristiq . . O
( . . O
8% . . O
, . . O
7 . . O
/ . . O
87 . . O
) . . O
versus . . O
placebo . . O
( . . O
2.5% . . O
, . . O
1 . . O
/ . . O
40 . . O
) . . O
, . . O
compared . . O
to . . O
patients . . O
< . . O
65 . . O
years . . O
of . . O
age . . O
receiving . . O
pristiq . . O
( . . O
0.9% . . O
, . . O
18 . . O
/ . . O
1,937 . . O
) . . O
versus . . O
placebo . . O
( . . O
0.7% . . O
, . . O
8 . . O
/ . . O
1,218 . . O
) . . O
. . . O

in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
, . . O
the . . O
median . . O
time . . O
to . . O
initial . . O
onset . . O
of . . O
fever . . B-AdverseReaction
was . . O
30 . . O
days . . O
compared . . O
with . . O
19 . . O
days . . O
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
; . . O
the . . O
median . . O
duration . . O
of . . O
fever . . B-AdverseReaction
was . . O
6 . . O
days . . O
with . . O
the . . O
combination . . O
compared . . O
with . . O
4 . . O
days . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

five . . O
of . . O
the . . O
six . . O
patients . . O
in . . O
the . . O
group . . O
that . . O
received . . O
promacta . . O
experienced . . O
a . . O
thrombotic . . B-AdverseReaction
complication . . I-AdverseReaction
within . . O
30 . . O
days . . O
of . . O
completing . . O
treatment . . O
with . . O
promacta . . O
and . . O
at . . O
a . . O
platelet . . O
count . . O
above . . O
200 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
. . . O
the . . O
risk . . B-Factor
of . . O
portal . . B-AdverseReaction
venous . . I-AdverseReaction
thrombosis . . I-AdverseReaction
was . . O
increased . . O
in . . O
thrombocytopenic . . O
patients . . O
with . . O
chronic . . O
liver . . O
disease . . O
treated . . O
with . . O
75 . . O
mg . . O
of . . O
promacta . . O
once . . O
daily . . O
for . . O
2 . . O
weeks . . O
in . . O
preparation . . O
for . . O
invasive . . O
procedures . . O
. . . O

because . . O
adverse . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
estimate . . O
reliably . . O
their . . O
frequency . . O
or . . O
to . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

breo . . O
ellipta . . O
should . . O
not . . O
be . . O
initiated . . O
in . . O
patients . . O
during . . O
rapidly . . O
deteriorating . . O
or . . O
potentially . . O
life . . O
- . . O
threatening . . O
episodes . . O
of . . O
copd . . O
or . . O
asthma . . O
. . . O

the . . O
mean . . O
age . . O
of . . O
the . . O
population . . O
was . . O
56 . . O
years . . O
and . . O
3% . . O
were . . O
older . . O
than . . O
75 . . O
years . . O
of . . O
age . . O
. . . O

there . . O
were . . O
two . . O
additional . . O
reports . . O
of . . O
rpls . . B-AdverseReaction
in . . O
other . . O
clinical . . O
trials . . O
with . . O
inlyta . . O
. . . O

5.3 . . O
venous . . O
thromboembolic . . O
events . . O

7 . . O
) . . O
] . . O
excerpt . . O
: . . O
cervical . . O
dystonia . . O

( . . O
5.5 . . O
) . . O
( . . O
6 . . O
) . . O
( . . O
8.5 . . O
) . . O
* . . O
hepatic . . B-AdverseReaction
impairment . . I-AdverseReaction
: . . O
reduce . . O
the . . O
jevtana . . O
dose . . O
to . . O
20 . . O
mg . . O
/ . . O
m . . O
2 . . O
in . . O
patients . . O
with . . O
mild . . O
hepatic . . O
impairment . . O
and . . O
to . . O
15 . . O
mg . . O
/ . . O
m . . O
2 . . O
in . . O
patients . . O
with . . O
moderate . . O
hepatic . . O
impairment . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
treatment . . O
discontinuation . . O
in . . O
the . . O
jevtana . . O
group . . O
were . . O
neutropenia . . B-AdverseReaction
and . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
. . . O

after . . O
resumption . . O
of . . O
treatment . . O
at . . O
a . . O
lower . . O
dose . . O
, . . O
26% . . O
of . . O
patients . . O
had . . O
recurrence . . O
of . . O
alt . . O
and . . O
ast . . O
elevations . . O
. . . O

if . . O
a . . O
diagnosis . . O
of . . O
invasive . . O
systemic . . O
fungal . . O
infection . . O
is . . O
made . . O
, . . O
discontinue . . O
afinitor . . O
and . . O
treat . . O
with . . O
appropriate . . O
antifungal . . O
therapy . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
prescribing . . O
information . . O
. . . O

patients . . O
in . . O
the . . O
xalkori . . O
arm . . O
( . . O
n . . O
= . . O
171 . . O
) . . O
received . . O
xalkori . . O
250 . . O
mg . . O
orally . . O
twice . . O
daily . . O
until . . O
documented . . O
disease . . O
progression . . O
, . . O
intolerance . . O
to . . O
therapy . . O
, . . O
or . . O
the . . O
investigator . . O
determined . . O
that . . O
the . . O
patient . . O
was . . O
no . . O
longer . . O
experiencing . . O
clinical . . O
benefit . . O
. . . O

table . . O
2 . . O
shows . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
8% . . O
of . . O
kalydeco . . O
- . . O
treated . . O
patients . . O
with . . O
cf . . O
who . . O
have . . O
a . . O
g551d . . O
mutation . . O
in . . O
the . . O
cftr . . O
gene . . O
that . . O
also . . O
occurred . . O
at . . O
a . . O
higher . . O
rate . . O
than . . O
in . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
in . . O
the . . O
two . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

6.2 . . O
clinical . . O
trials . . O
experience . . O
: . . O
pediatric . . O
subjects . . O
( . . O
6 . . O
years . . O
to . . O
less . . O
than . . O
18 . . O
years . . O
of . . O
age . . O
) . . O

5.2 . . O
hypotension . . O
and . . O
reflex . . O
tachycardia . . O

the . . O
placebo . . O
- . . O
adjusted . . O
change . . O
at . . O
the . . O
distal . . O
forearm . . O
for . . O
patients . . O
randomized . . O
to . . O
invokana . . O
100 . . O
mg . . O
was . . O
0% . . O
. . . O

symptoms . . O
of . . O
pres . . B-AdverseReaction
are . . O
usually . . O
reversible . . O
but . . O
may . . B-Factor
evolve . . O
into . . O
ischemic . . B-AdverseReaction
stroke . . I-AdverseReaction
or . . O
cerebral . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
. . . O

funduscopic . . B-AdverseReaction
abnormalities . . I-AdverseReaction
have . . O
most . . O
commonly . . O
been . . O
described . . O
as . . O
perivascular . . O
pigmentation . . O
( . . O
bone . . O
spicule . . O
pattern . . O
) . . O
in . . O
the . . O
retinal . . O
periphery . . O
and . . O
/ . . O
or . . O
as . . O
areas . . O
of . . O
focal . . B-AdverseReaction
retinal . . I-AdverseReaction
pigment . . I-AdverseReaction
epithelium . . I-AdverseReaction
clumping . . I-AdverseReaction
. . . O

in . . O
clinical . . O
trials . . O
, . . O
761 . . O
adults . . O
( . . O
367 . . O
men . . O
and . . O
394 . . O
women . . O
, . . O
91% . . O
caucasian . . O
) . . O
with . . O
a . . O
mean . . O
age . . O
of . . O
62 . . O
years . . O
( . . O
range . . O
18-93 . . O
years . . O
) . . O
received . . O
vizamyl . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

5.3 . . O
laboratory . . O
tests . . O

infusion . . O
reactions . . O

common . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
2% . . O
of . . O
subjects . . O
switching . . O
to . . O
stribild . . O
were . . O
nausea . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
flatulence . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
and . . O
headache . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
rheumatoid . . O
arthritis . . O
who . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
reactions . . O
in . . O
the . . O
controlled . . O
clinical . . O
studies . . O
was . . O
5% . . O
for . . O
cimzia . . O
and . . O
2.5% . . O
for . . O
placebo . . O
. . . O

rare . . O
post . . O
- . . O
marketing . . O
cases . . O
of . . O
hepatosplenic . . B-AdverseReaction
t . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
lymphoma . . I-AdverseReaction
( . . O
hstcl . . B-AdverseReaction
) . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
tnf . . O
- . . O
blocking . . O
agents . . O
. . . O

there . . O
were . . O
no . . B-Negation
reported . . O
thromboembolic . . B-AdverseReaction
events . . I-AdverseReaction
in . . O
the . . O
patients . . O
treated . . O
with . . O
eylea . . O
in . . O
the . . O
first . . O
six . . O
months . . O
of . . O
the . . O
rvo . . O
studies . . O
. . . O

excerpt . . O
: . . O
* . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
: . . O
see . . O
boxed . . O
warning . . O
( . . O
5.1 . . O
) . . O
. . . O

the . . O
first . . O
dose . . O
of . . O
entereg . . O
was . . O
administered . . O
30 . . O
minutes . . O
to . . O
5 . . O
hours . . O
before . . O
the . . O
scheduled . . O
start . . O
of . . O
surgery . . O
and . . O
then . . O
twice . . O
daily . . O
until . . O
hospital . . O
discharge . . O
( . . O
or . . O
for . . O
a . . O
maximum . . O
of . . O
7 . . O
days . . O
of . . O
postoperative . . O
treatment . . O
) . . O
. . . O

( . . O
5.11 . . O
, . . O
8.1 . . O
) . . O

although . . O
cobicistat . . O
( . . O
a . . O
component . . O
of . . O
stribild . . O
) . . O
may . . B-Factor
cause . . O
modest . . B-Severity
increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
modest . . B-Severity
declines . . B-AdverseReaction
in . . I-AdverseReaction
estimated . . I-AdverseReaction
creatinine . . I-AdverseReaction
clearance . . I-AdverseReaction
without . . O
affecting . . O
renal . . O
glomerular . . O
function . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
, . . O
patients . . O
who . . O
experience . . O
a . . O
confirmed . . O
increase . . O
in . . O
serum . . O
creatinine . . O
of . . O
greater . . O
than . . O
0.4 . . O
mg . . O
per . . O
dl . . O
from . . O
baseline . . O
should . . O
be . . O
closely . . O
monitored . . O
for . . O
renal . . O
safety . . O
. . . O

l . . O
ong . . O
- . . O
acting . . O
beta . . O
2 . . O
- . . O
adrenergic . . O
agonists . . O
, . . O
such . . O
as . . O
a . . O
rcapta . . O
neohaler . . O
, . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
asthma . . B-AdverseReaction
- . . O
related . . O
death . . B-AdverseReaction
. . . O

in . . O
clinical . . O
trials . . O
in . . O
women . . O
with . . O
postmenopausal . . O
osteoporosis . . O
, . . O
treatment . . O
with . . O
prolia . . O
resulted . . O
in . . O
significant . . O
suppression . . B-AdverseReaction
of . . I-AdverseReaction
bone . . I-AdverseReaction
remodeling . . I-AdverseReaction
as . . O
evidenced . . O
by . . O
markers . . O
of . . O
bone . . O
turnover . . O
and . . O
bone . . O
histomorphometry . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
and . . O
clinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

5.3 . . O
immune . . O
reconstitution . . O
syndrome . . O

withhold . . O
gilotrif . . O
during . . O
evaluation . . O
of . . O
patients . . O
with . . O
suspected . . O
keratitis . . O
, . . O
and . . O
if . . O
diagnosis . . O
of . . O
ulcerative . . O
keratitis . . O
is . . O
confirmed . . O
, . . O
treatment . . O
with . . O
gilotrif . . O
should . . O
be . . O
interrupted . . O
or . . O
discontinued . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

* . . O
lymphoma . . B-AdverseReaction
and . . O
other . . O
malignancies . . B-AdverseReaction
, . . O
some . . O
fatal . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
children . . O
and . . O
adolescent . . O
patients . . O
treated . . O
with . . O
tnf . . O
blockers . . O
, . . O
of . . O
which . . O
simponi . . O
aria . . O
is . . O
a . . O
member . . O
( . . O
5.2 . . O
) . . O
. . . O

after . . O
initiation . . O
of . . O
uloric . . O
, . . O
an . . O
increase . . O
in . . O
gout . . B-AdverseReaction
flares . . I-AdverseReaction
is . . O
frequently . . O
observed . . O
. . . O

patients . . O
were . . O
randomized . . O
to . . O
three . . O
treatment . . O
groups . . O
: . . O
vimizim . . O
2 . . O
mg . . O
/ . . O
kg . . O
once . . O
per . . O
week . . O
( . . O
n . . O
= . . O
58 . . O
) . . O
, . . O
vimizim . . O
2 . . O
mg . . O
/ . . O
kg . . O
once . . O
every . . O
other . . O
week . . O
( . . O
n . . O
= . . O
59 . . O
) . . O
, . . O
or . . O
placebo . . O
( . . O
n . . O
= . . O
59 . . O
) . . O
. . . O

although . . O
the . . O
overall . . O
incidence . . O
of . . O
fd&c . . O
yellow . . O
no . . O
. . . O
5 . . O
( . . O
tartrazine . . O
) . . O
sensitivity . . O
in . . O
the . . O
general . . O
population . . O
is . . O
low . . O
, . . O
it . . O
is . . O
frequently . . O
seen . . O
in . . O
patients . . O
who . . O
also . . O
have . . O
aspirin . . O
hypersensitivity . . O
. . . O

patients . . O
with . . O
pre . . O
- . . O
voraxaze . . O
methotrexate . . O
concentrations . . O
> . . O
100 . . O
mumol . . O
/ . . O
l . . O
were . . O
to . . O
receive . . O
a . . O
second . . O
dose . . O
of . . O
voraxaze . . O
48 . . O
hours . . O
after . . O
the . . O
first . . O
dose . . O
. . . O

( . . O
5.2 . . O
, . . O
5.3 . . O
) . . O
* . . O
transient . . B-Severity
increases . . B-AdverseReaction
in . . I-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
may . . B-Factor
occur . . O
in . . O
patients . . O
during . . O
and . . O
shortly . . O
after . . O
the . . O
qutenza . . O
treatment . . O
. . . O

immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
combination . . O
antiretroviral . . O
therapy . . O
, . . O
including . . O
stribild . . O
. . . O

the . . O
mean . . O
duration . . O
of . . O
exposure . . O
to . . O
eliquis . . O
was . . O
154 . . O
days . . O
and . . O
to . . O
enoxaparin . . O
/ . . O
warfarin . . O
was . . O
152 . . O
days . . O
in . . O
the . . O
amplify . . O
study . . O
. . . O

this . . O
includes . . O
cases . . O
of . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
reaction . . I-AdverseReaction
, . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
and . . O
erythema . . B-AdverseReaction
multiforme . . I-AdverseReaction
. . . O

adverse . . O
drug . . O
reactions . . O
listed . . O
in . . O
table . . O
2 . . O
showed . . O
higher . . O
rates . . O
than . . O
placebo . . O
from . . O
both . . O
trials . . O
. . . O

tests . . O
for . . O
latent . . O
tuberculosis . . O
infection . . O
may . . O
also . . O
be . . O
falsely . . O
negative . . O
while . . O
on . . O
therapy . . O
with . . O
cimzia . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
are . . O
: . . O
fatigue . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremities . . I-AdverseReaction
, . . O
and . . O
upper . . B-AdverseReaction
abdominal . . I-AdverseReaction
pain . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
genzyme . . O
corporation . . O
at . . O
1-800-745-4447 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

( . . O
6 . . O
) . . O

keep . . O
bottle . . O
tightly . . O
closed . . O
when . . O
not . . O
in . . O
use . . O
. . . O

of . . O
the . . O
1,039 . . O
subjects . . O
, . . O
60% . . O
were . . O
female . . O
and . . O
88% . . O
were . . O
white . . O
; . . O
the . . O
mean . . O
age . . O
was . . O
46 . . O
years . . O
. . . O

for . . O
complete . . O
boxed . . O
warning . . O
( . . O
a . . O
) . . O

table . . O
1 . . O
summarizes . . O
adverse . . O
reactions . . O
reported . . O
at . . O
a . . O
rate . . O
of . . O
at . . O
least . . O
1% . . O
in . . O
uloric . . O
treatment . . O
groups . . O
and . . O
at . . O
least . . O
0.5% . . O
greater . . O
than . . O
placebo . . O
. . . O

if . . O
pancreatitis . . O
is . . O
suspected . . O
, . . O
promptly . . O
discontinue . . O
trulicity . . O
. . . O

5.3 . . O
hepatotoxicity . . O

rates . . O
of . . O
seroconversion . . O
increased . . O
with . . O
exposure . . O
to . . O
kalbitor . . O
over . . O
time . . O
. . . O

this . . O
patient . . O
information . . O
summarizes . . O
the . . O
most . . O
important . . O
information . . O
about . . O
duavee . . O
. . . O

c . . O
. . . O
difficile . . O
produces . . O
toxins . . O
a . . O
and . . O
b . . O
which . . O
contribute . . O
to . . O
the . . O
development . . O
of . . O
cdad . . O
. . . O

* . . O
hepatotoxicity . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
severe . . B-Severity
diarrhea . . B-AdverseReaction
or . . O
colitis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
pneumonitis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
intestinal . . B-AdverseReaction
perforation . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
severe . . B-Severity
cutaneous . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
anaphylaxis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
neutropenia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
20% . . O
) . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
chills . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

6.3 . . O
immunogenicity . . O

blood . . O
disorders . . O
: . . O
anemia . . B-AdverseReaction
, . . O
eosinophilia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
eye . . O
disorders . . O
: . . O
diplopia . . B-AdverseReaction
, . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
gastrointestinal . . O
disorders . . O
: . . O
abdominal . . B-AdverseReaction
distention . . I-AdverseReaction
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
hypothermia . . B-AdverseReaction
investigations . . O
: . . O
hepatic . . B-AdverseReaction
enzyme . . I-AdverseReaction
increased . . I-AdverseReaction
musculoskeletal . . O
: . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
psychiatric . . O
disorders . . O
: . . O
agitation . . B-AdverseReaction
, . . O
anxiety . . B-AdverseReaction
, . . O
apathy . . B-AdverseReaction
, . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
, . . O
depression . . B-AdverseReaction
, . . O
delirium . . B-AdverseReaction
, . . O
delusion . . B-AdverseReaction
, . . O
hallucination . . B-AdverseReaction
renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
urinary . . B-AdverseReaction
retention . . I-AdverseReaction
respiratory . . O
disorders . . O
: . . O
aspiration . . B-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
depression . . I-AdverseReaction
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
rash . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
and . . O
facial . . O
and . . O
lip . . B-AdverseReaction
edema . . I-AdverseReaction

dosing . . O
should . . O
be . . O
interrupted . . O
in . . O
patients . . O
with . . O
alt . . O
or . . O
ast . . O
of . . O
greater . . O
than . . O
5 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
( . . O
uln . . O
) . . O
. . . O

tafinlar . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
results . . O
in . . O
an . . O
increased . . O
incidence . . O
of . . O
basal . . B-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
. . . O

5.5 . . O
immediate . . O
hypersensitivity . . O
reactions . . O

the . . O
incidence . . O
of . . O
all . . O
- . . O
cause . . O
mortality . . B-AdverseReaction
was . . O
0.8% . . O
( . . O
n . . O
= . . O
1 . . O
) . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
0.8% . . O
( . . O
n . . O
= . . O
1 . . O
) . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

invokana . . O
results . . O
in . . O
an . . O
osmotic . . B-AdverseReaction
diuresis . . I-AdverseReaction
, . . O
which . . O
may . . B-Factor
lead . . O
to . . O
reductions . . B-AdverseReaction
in . . I-AdverseReaction
intravascular . . I-AdverseReaction
volume . . I-AdverseReaction
. . . O

a . . O
2 . . O
- . . O
to . . O
4 . . O
- . . O
fold . . O
increase . . O
in . . O
the . . O
risk . . B-Factor
of . . O
gallbladder . . B-AdverseReaction
disease . . I-AdverseReaction
requiring . . O
surgery . . O
in . . O
postmenopausal . . O
women . . O
receiving . . O
estrogens . . O
has . . O
been . . O
reported . . O
. . . O

tardive . . B-AdverseReaction
dyskinesia . . I-AdverseReaction
is . . O
a . . O
syndrome . . O
consisting . . O
of . . O
potentially . . O
irreversible . . O
, . . O
involuntary . . B-AdverseReaction
, . . I-AdverseReaction
dyskinetic . . I-AdverseReaction
movements . . I-AdverseReaction
, . . O
which . . O
may . . O
develop . . O
in . . O
patients . . O
treated . . O
with . . O
antipsychotic . . B-DrugClass
drugs . . I-DrugClass
. . . O

warning . . O
: . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
occurring . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
cimzia . . O
- . . O
treated . . O
patients . . O
, . . O
and . . O
with . . O
a . . O
higher . . O
incidence . . O
compared . . O
to . . O
placebo . . O
) . . O
in . . O
controlled . . O
clinical . . O
studies . . O
with . . O
cimzia . . O
were . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
nasopharyngitis . . B-AdverseReaction
, . . O
laryngitis . . B-AdverseReaction
, . . O
viral . . B-AdverseReaction
infection . . I-AdverseReaction
) . . O
in . . O
20% . . O
of . . O
cimzia . . O
- . . O
treated . . O
patients . . O
and . . O
13% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
bladder . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
bacteriuria . . B-AdverseReaction
, . . O
cystitis . . B-AdverseReaction
) . . O
in . . O
7% . . O
of . . O
cimzia . . O
- . . O
treated . . O
patients . . O
and . . O
in . . O
6% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
and . . O
arthralgia . . B-AdverseReaction
( . . O
6% . . O
cimzia . . O
, . . O
4% . . O
placebo . . O
) . . O
. . . O

lymphocyte . . O
counts . . O
generally . . O
return . . O
to . . O
the . . O
normal . . O
range . . O
within . . O
1-2 . . O
months . . O
of . . O
stopping . . O
therapy . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

in . . O
studies . . O
1 . . O
and . . O
2 . . O
, . . O
grade . . B-Severity
3 . . I-Severity
syncope . . B-AdverseReaction
occurred . . O
in . . O
2.0% . . O
of . . O
xalkori . . O
- . . O
treated . . O
patients . . O
and . . O
in . . O
0.6% . . O
of . . O
the . . O
chemotherapy . . O
- . . O
treated . . O
patients . . O
. . . O

overall . . O
, . . O
a . . O
higher . . O
rate . . O
of . . O
aptc . . O
events . . O
was . . O
observed . . O
in . . O
uloric . . O
than . . O
in . . O
allopurinol . . O
- . . O
treated . . O
patients . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
urticaria . . B-AdverseReaction

the . . O
usefulness . . O
of . . O
hemodialysis . . O
in . . O
the . . O
prevention . . O
of . . O
nsf . . O
is . . O
unknown . . O
. . . O

the . . O
physician . . O
responsible . . O
for . . O
maintenance . . O
therapy . . O
should . . O
have . . O
complete . . O
information . . O
requisite . . O
for . . O
the . . O
follow . . O
- . . O
up . . O
of . . O
the . . O
patient . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

the . . O
mean . . O
duration . . O
of . . O
exposure . . O
to . . O
invokana . . O
was . . O
38 . . O
weeks . . O
with . . O
1832 . . O
individuals . . O
exposed . . O
to . . O
invokana . . O
for . . O
greater . . O
than . . O
50 . . O
weeks . . O
. . . O

in . . O
the . . O
pool . . O
of . . O
7 . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
, . . O
116 . . O
( . . O
5.5% . . O
) . . O
of . . O
2,098 . . O
patients . . O
exposed . . O
to . . O
tanzeum . . O
tested . . O
positive . . O
for . . O
anti . . O
- . . O
albiglutide . . O
antibodies . . O
at . . O
any . . O
time . . O
during . . O
the . . O
trials . . O
. . . O

these . . O
data . . O
reflect . . O
exposure . . O
of . . O
1667 . . O
patients . . O
to . . O
invokana . . O
and . . O
a . . O
mean . . O
duration . . O
of . . O
exposure . . O
to . . O
invokana . . O
of . . O
24 . . O
weeks . . O
. . . O

due . . O
to . . O
the . . O
potential . . O
for . . O
anaphylaxis . . O
, . . O
appropriate . . O
medical . . O
support . . O
should . . O
be . . O
readily . . O
available . . O
when . . O
vimizim . . O
is . . O
administered . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
- . . O
rash . . B-AdverseReaction
, . . O
alopecia . . B-AdverseReaction
, . . O
photosensitivity . . B-AdverseReaction
reaction . . O
, . . O
angioedema . . B-AdverseReaction
. . . O

6.2 . . O
clinical . . O
trials . . O
experience . . O
in . . O
asthma . . O

arcapta . . O
neohaler . . O
is . . O
not . . O
indicated . . O
for . . O
the . . O
treatment . . O
of . . O
asthma . . O
. . . O

selected . . O
adverse . . O
reactions . . O
in . . O
phase . . O
2 . . O
/ . . O
3 . . O
trials . . O
( . . O
number . . O
( . . O
% . . O
) . . O
of . . O
patients . . O
) . . O
dalbavancin . . O
comparator . . O
* . . O
( . . O
n . . O
= . . O
1778 . . O
) . . O
( . . O
n . . O
= . . O
1224 . . O
) . . O
nausea . . B-AdverseReaction
98 . . O
( . . O
5.5 . . O
) . . O
78 . . O
( . . O
6.4 . . O
) . . O
vomiting . . B-AdverseReaction
50 . . O
( . . O
2.8 . . O
) . . O
37 . . O
( . . O
3 . . O
) . . O
diarrhea . . B-AdverseReaction
79 . . O
( . . O
4.4 . . O
) . . O
72 . . O
( . . O
5.9 . . O
) . . O
headache . . B-AdverseReaction
83 . . O
( . . O
4.7 . . O
) . . O
59 . . O
( . . O
4.8 . . O
) . . O
rash . . B-AdverseReaction
48 . . O
( . . O
2.7 . . O
) . . O
30 . . O
( . . O
2.4 . . O
) . . O
pruritus . . B-AdverseReaction
38 . . O
( . . O
2.1 . . O
) . . O
41 . . O
( . . O
3.3 . . O
) . . O
* . . O
comparators . . O
included . . O
linezolid . . O
, . . O
cefazolin . . O
, . . O
cephalexin . . O
, . . O
and . . O
vancomycin . . O
. . . O

( . . O
6.4 . . O
) . . O

remove . . O
1 . . O
tablet . . O
at . . O
a . . O
time . . O
from . . O
the . . O
blister . . O
package . . O
. . . O

6 . . O
adverse . . O
reactions . . O

in . . O
ms . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
the . . O
overall . . O
rate . . O
of . . O
infections . . B-AdverseReaction
( . . O
72% . . O
) . . O
with . . O
gilenya . . O
was . . O
similar . . O
to . . O
placebo . . O
. . . O

5.7 . . O
hypokalemia . . O
and . . O
hypomagnesemia . . O
with . . O
potassium . . O
- . . O
depleting . . O
diuretics . . O

you . . O
and . . O
your . . O
healthcare . . O
provider . . O
should . . O
talk . . O
regularly . . O
about . . O
whether . . O
you . . O
still . . O
need . . O
treatment . . O
with . . O
duavee . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
treanda . . O
in . . O
153 . . O
patients . . O
with . . O
cll . . O
studied . . O
in . . O
an . . O
active . . O
- . . O
controlled . . O
, . . O
randomized . . O
trial . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

selected . . O
laboratory . . O
abnormalities . . O
( . . O
grades . . O
2 . . O
to . . O
4 . . O
) . . O
in . . O
treatment . . O
- . . O
naive . . O
subjects . . O
in . . O
spring . . O
- . . O
2 . . O
and . . O
single . . O
trials . . O
( . . O
week . . O
96 . . O
analysis . . O
) . . O
laboratory . . O
parameter . . O
preferred . . O
term . . O
spring . . O
- . . O
2 . . O
single . . O
tivicay . . O
50 . . O
mg . . O
once . . O
daily . . O
+ . . O
2 . . O
nrtis . . O
( . . O
n . . O
= . . O
403 . . O
) . . O
raltegravir . . O
400 . . O
mg . . O
twice . . O
daily . . O
+ . . O
2 . . O
nrtis . . O
( . . O
n . . O
= . . O
405 . . O
) . . O
tivicay . . O
50 . . O
mg . . O
+ . . O
epzicom . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
414 . . O
) . . O
atripla . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
419 . . O
) . . O
alt . . O
4% . . O
4% . . O
2% . . O
5% . . O
2% . . O
2% . . O
< . . O
1% . . O
< . . O
1% . . O
ast . . O
5% . . O
3% . . O
3% . . O
3% . . O
3% . . O
2% . . O
< . . O
1% . . O
3% . . O
3% . . O
2% . . O
< . . O
1% . . O
0 . . O
< . . O
1% . . O
< . . O
1% . . O
< . . O
1% . . O
0 . . O
creatine . . O
kinase . . O
2% . . O
5% . . O
4% . . O
1% . . O
7% . . O
4% . . O
5% . . O
7% . . O
hyperglycemia . . B-AdverseReaction
6% . . O
6% . . O
7% . . O
5% . . O
< . . O
1% . . O
2% . . O
2% . . O
< . . O
1% . . O
lipase . . O
7% . . O
7% . . O
9% . . O
9% . . O
2% . . O
5% . . O
4% . . O
3% . . O
total . . O
neutrophils . . O
4% . . O
3% . . O
3% . . O
5% . . O
2% . . O
2% . . O
2% . . O
3% . . O
uln . . O
= . . O
upper . . O
limit . . O
of . . O
normal . . O
. . . O

follow . . O
instructions . . O
for . . O
preparation . . O
( . . O
including . . O
admixing . . O
) . . O
and . . O
administration . . O
strictly . . O
to . . O
minimize . . O
medication . . O
errors . . O
( . . O
including . . O
underdose . . O
and . . O
overdose . . O
) . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
( . . O
2.4 . . O
) . . O
] . . O
. . . O

neuropathy . . B-AdverseReaction
lasting . . O
more . . O
than . . O
one . . O
year . . O
occurred . . O
in . . O
5% . . O
( . . O
26 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
. . . O

manifestations . . O
included . . O
hypotension . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
or . . O
other . . O
rash . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
and . . O
dyspnea . . B-AdverseReaction
. . . O

withhold . . O
gilotrif . . O
for . . O
acute . . O
onset . . O
or . . O
worsening . . O
of . . O
pulmonary . . O
symptoms . . O
. . . O

* . . O
before . . O
eovist . . O
administration . . O
, . . O
assess . . O
all . . O
patients . . O
for . . O
any . . O
history . . O
of . . O
a . . O
reaction . . O
to . . O
contrast . . O
media . . O
, . . O
bronchial . . O
asthma . . O
and . . O
allergic . . O
disorders . . O
. . . O

the . . O
commonly . . O
reported . . O
adverse . . O
events . . O
were . . O
falls . . B-AdverseReaction
( . . O
24% . . O
) . . O
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
15% . . O
) . . O
, . . O
headache . . B-AdverseReaction
( . . O
13% . . O
) . . O
, . . O
syncope . . B-AdverseReaction
( . . O
13% . . O
) . . O
, . . O
and . . O
dizziness . . B-AdverseReaction
( . . O
10% . . O
) . . O
. . . O

5.10 . . O
hepatic . . O
impairment . . O

use . . O
inlyta . . O
with . . O
caution . . O
in . . O
patients . . O
who . . O
are . . O
at . . O
risk . . O
for . . O
, . . O
or . . O
who . . O
have . . O
a . . O
history . . O
of . . O
, . . O
these . . O
events . . O
. . . O

for . . O
a . . O
reason . . O
other . . O
than . . O
pathological . . O
bleeding . . O
or . . O
completion . . O
of . . O
a . . O
course . . O

5.3 . . O
infections . . O

in . . O
these . . O
studies . . O
, . . O
a . . O
total . . O
of . . O
6285 . . O
patients . . O
were . . O
randomized . . O
and . . O
treated . . O
, . . O
3282 . . O
patients . . O
with . . O
multaq . . O
400 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
2875 . . O
with . . O
placebo . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
drug . . O
reactions . . O
were . . O
infections . . B-AdverseReaction
predominantly . . O
of . . O
the . . O
upper . . O
respiratory . . O
tract . . O
. . . O

delay . . O
administration . . O
of . . O
halaven . . O
and . . O
reduce . . O
subsequent . . O
doses . . O
in . . O
patients . . O
who . . O
experience . . O
febrile . . O
neutropenia . . O
or . . O
grade . . O
4 . . O
neutropenia . . O
lasting . . O
longer . . O
than . . O
7 . . O
days . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
urticaria . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
acne . . B-AdverseReaction
; . . O
0.1% . . O
and . . O
less . . O
than . . O
1% . . O
- . . O
erythema . . B-AdverseReaction
multiforme . . I-AdverseReaction
, . . O
exfoliative . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
drug . . B-AdverseReaction
eruption . . I-AdverseReaction

through . . O
week . . O
24 . . O
, . . O
the . . O
incidence . . O
of . . O
serious . . B-Severity
infections . . B-AdverseReaction
per . . O
100 . . O
patient . . O
- . . O
years . . O
of . . O
follow . . O
- . . O
up . . O
was . . O
2.2 . . O
( . . O
95% . . O
ci . . O
0.61 . . O
, . . O
5.71 . . O
) . . O
for . . O
the . . O
simponi . . O
aria . . O
group . . O
, . . O
and . . O
0 . . O
( . . O
0.00 . . O
, . . O
3.79 . . O
) . . O
for . . O
the . . O
placebo . . O
group . . O
. . . O

a . . O
small . . O
proportion . . O
of . . O
women . . O
will . . O
have . . O
adverse . . B-AdverseReaction
lipid . . I-AdverseReaction
changes . . I-AdverseReaction
while . . O
on . . O
cocs . . B-DrugClass
. . . O

coadministration . . O
of . . O
ilaris . . O
with . . O
tnf . . O
inhibitors . . O
is . . O
not . . O
recommended . . O
because . . O
this . . O
may . . O
increase . . O
the . . O
risk . . O
of . . O
serious . . O
infections . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

monitor . . O
clcr . . O
, . . O
urine . . O
glucose . . O
, . . O
and . . O
urine . . O
protein . . O
in . . O
all . . O
patients . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
malignancy . . B-AdverseReaction

nervous . . O
system . . O
disorders . . O
: . . O
dizziness . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
postural . . I-AdverseReaction

( . . O
5.3,7.2,7.3 . . O
) . . O
5.1 . . O
prolongation . . O
of . . O
the . . O
qt . . O
interval . . O

in . . O
addition . . O
to . . O
the . . O
term . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
( . . O
see . . O
table . . O
1 . . O
) . . O
, . . O
the . . O
following . . O
other . . O
types . . O
of . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
also . . O
occurred . . O
more . . O
frequently . . O
on . . O
tanzeum . . O
: . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
( . . O
1.9% . . O
versus . . O
2.1% . . O
for . . O
placebo . . O
versus . . O
tanzeum . . O
) . . O
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
erythema . . I-AdverseReaction
( . . O
0.4% . . O
versus . . O
1.7% . . O
for . . O
placebo . . O
versus . . O
tanzeum . . O
) . . O
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
rash . . I-AdverseReaction
( . . O
0% . . O
versus . . O
1.4% . . O
for . . O
placebo . . O
versus . . O
tanzeum . . O
) . . O
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hypersensitivity . . I-AdverseReaction
( . . O
0% . . O
versus . . O
0.8% . . O
for . . O
placebo . . O
versus . . O
tanzeum . . O
) . . O
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
( . . O
0.6% . . O
versus . . O
0.7% . . O
for . . O
placebo . . O
versus . . O
tanzeum . . O
) . . O
. . . O

investigations . . O
: . . O
alanine . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
aspartate . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
hematocrit . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
lymphocyte . . B-AdverseReaction
morphology . . I-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
platelet . . B-AdverseReaction
count . . I-AdverseReaction
decreased . . I-AdverseReaction
, . . O
platelet . . B-AdverseReaction
count . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
white . . B-AdverseReaction
blood . . I-AdverseReaction
cell . . I-AdverseReaction
count . . I-AdverseReaction
decreased . . I-AdverseReaction
, . . O
white . . B-AdverseReaction
blood . . I-AdverseReaction
cell . . I-AdverseReaction
count . . I-AdverseReaction
increased . . I-AdverseReaction

5.3 . . O
hepatotoxicity . . O

( . . O
5.2 . . O
) . . O

5.2 . . O
hypersensitivity . . O
reactions . . O

injection . . O
of . . O
xiaflex . . O
into . . O
collagen . . O
- . . O
containing . . O
structures . . O
such . . O
as . . O
the . . O
corpora . . O
cavernosa . . O
of . . O
the . . O
penis . . O
may . . B-Factor
result . . O
in . . O
damage . . O
to . . O
those . . O
structures . . O
and . . O
possible . . B-Factor
injury . . O
such . . O
as . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
( . . O
penile . . B-AdverseReaction
fracture . . I-AdverseReaction
) . . O
. . . O

local . . B-AdverseReaction
cystic . . I-AdverseReaction
invasion . . I-AdverseReaction
beyond . . I-AdverseReaction
the . . I-AdverseReaction
kidney . . I-AdverseReaction
occurred . . O
, . . O
in . . O
some . . O
cases . . O
with . . O
imaging . . O
characteristics . . O
suggestive . . B-Factor
of . . O
abscess . . B-AdverseReaction
formation . . O
. . . O

immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
combination . . O
antiretroviral . . O
therapy . . O
, . . O
including . . O
tivicay . . O
. . . O

the . . O
rate . . O
of . . O
adverse . . O
reactions . . O
resulting . . O
in . . O
permanent . . O
discontinuation . . O
was . . O
3.8% . . O
in . . O
the . . O
afinitor . . O
- . . O
treated . . O
patients . . O
. . . O

use . . O
of . . O
live . . O
vaccines . . O
could . . O
result . . O
in . . O
clinical . . O
infections . . O
, . . O
including . . O
disseminated . . O
infections . . O
. . . O

[ . . O

5.1 . . O
drug . . O
products . . O
with . . O
same . . O
active . . O
ingredient . . O

in . . O
phase . . O
3 . . O
trials . . O
tmc125 . . O
- . . O
c206 . . O
and . . O
tmc125 . . O
- . . O
c216 . . O
, . . O
139 . . O
subjects . . O
( . . O
12.3% . . O
) . . O
with . . O
chronic . . O
hepatitis . . O
b . . O
and . . O
/ . . O
or . . O
hepatitis . . O
c . . O
virus . . O
co . . O
- . . O
infection . . O
out . . O
of . . O
1129 . . O
subjects . . O
were . . O
permitted . . O
to . . O
enroll . . O
. . . O

increased . . B-AdverseReaction
thyroid . . I-AdverseReaction
- . . I-AdverseReaction
binding . . I-AdverseReaction
globulin . . I-AdverseReaction
( . . O
tbg . . O
) . . O
leading . . O
to . . O
increased . . B-AdverseReaction
circulating . . I-AdverseReaction
total . . I-AdverseReaction
thyroid . . I-AdverseReaction
hormone . . I-AdverseReaction
, . . O
as . . O
measured . . O
by . . O
protein . . O
- . . O
bound . . O
iodine . . O
( . . O
pbi . . O
) . . O
, . . O
t4 . . O
levels . . O
( . . O
by . . O
column . . O
or . . O
by . . O
radioimmunoassay . . O
) . . O
, . . O
or . . O
t3 . . O
levels . . O
by . . O
radioimmunoassay . . O
. . . O

if . . O
appropriate . . O
, . . O
initiation . . O
of . . O
anti . . O
- . . O
hepatitis . . O
b . . O
therapy . . O
may . . O
be . . O
warranted . . O
. . . O

( . . O
2.4 . . O
, . . O
5.10 . . O
) . . O
* . . O
hepatic . . B-AdverseReaction
toxicity . . I-AdverseReaction
and . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
: . . O
monitor . . O
liver . . O
enzymes . . O
. . . O

because . . O
adverse . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

before . . O
administering . . O
vizamyl . . O
, . . O
ask . . O
patients . . O
about . . O
prior . . O
reactions . . O
to . . O
drugs . . O
, . . O
especially . . O
those . . O
containing . . O
polysorbate . . O
80 . . O
. . . O

because . . O
the . . O
elimination . . O
of . . O
fingolimod . . O
after . . O
discontinuation . . O
may . . O
take . . O
up . . O
to . . O
2 . . O
months . . O
, . . O
continue . . O
monitoring . . O
for . . O
infections . . O
throughout . . O
this . . O
period . . O
. . . O

all . . O
patients . . O
were . . O
treated . . O
with . . O
antihistamines . . O
prior . . O
to . . O
each . . O
infusion . . O
. . . O

hematology . . O

in . . O
short . . O
- . . O
term . . O
schizophrenia . . O
adult . . O
trials . . O
, . . O
syncope . . B-AdverseReaction
was . . O
reported . . O
in . . O
0.2% . . O
( . . O
1 . . O
/ . . O
572 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
therapeutic . . O
doses . . O
( . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
) . . O
of . . O
saphris . . O
, . . O
compared . . O
to . . O
0.3% . . O
( . . O
1 . . O
/ . . O
378 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

it . . O
is . . O
unknown . . B-Factor
whether . . O
tanzeum . . O
causes . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
, . . O
including . . O
mtc . . B-AdverseReaction
, . . O
in . . O
humans . . O
[ . . O
see . . O
boxed . . O
warning . . O
, . . O
contraindications . . O
( . . O
4.1 . . O
) . . O
] . . O
. . . O

trial . . O
1 . . O
included . . O
197 . . O
control . . O
- . . O
treated . . O
patients . . O
and . . O
463 . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
( . . O
which . . O
includes . . O
control . . O
- . . O
treated . . O
patients . . O
who . . O
switched . . O
to . . O
simponi . . O
aria . . O
at . . O
week . . O
16 . . O
) . . O
. . . O

5.4 . . O
worsening . . O
of . . O
urinary . . O
retention . . O

5.9 . . O
autoimmunity . . O

patients . . O
who . . O
fail . . O
to . . O
show . . O
substantial . . O
clinical . . O
benefit . . O
after . . O
adequate . . O
titration . . O
should . . O
be . . O
discontinued . . O
from . . O
potiga . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
acute . . B-AdverseReaction
kidney . . I-AdverseReaction
injury . . I-AdverseReaction
are . . O
described . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
and . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

an . . O
accelerated . . O
vaccination . . O
schedule . . O
may . . O
be . . O
appropriate . . O
. . . O

the . . O
most . . O
common . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
adverse . . O
reactions . . O
observed . . O
following . . O
treatment . . O
with . . O
inlyta . . O
were . . O
diarrhea . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
dysphonia . . B-AdverseReaction
, . . O
palmar . . O
- . . O
plantar . . O
erythrodysesthesia . . O
( . . O
hand . . O
- . . O
foot . . O
) . . O
syndrome . . O
, . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
and . . O
constipation . . B-AdverseReaction
. . . O

table . . O
8 . . O
describes . . O
grade . . O
3-4 . . O
laboratory . . O
abnormalities . . O
reported . . O
at . . O
a . . O
rate . . O
of . . O
> . . O
10% . . O
for . . O
patients . . O
who . . O
received . . O
kyprolis . . O
monotherapy . . O
. . . O

symptoms . . O
and . . O
signs . . O
of . . O
adrenocortical . . B-AdverseReaction
insufficiency . . I-AdverseReaction
may . . O
be . . O
masked . . O
by . . O
adverse . . O
reactions . . O
associated . . O
with . . O
mineralocorticoid . . B-AdverseReaction
excess . . I-AdverseReaction
seen . . O
in . . O
patients . . O
treated . . O
with . . O
zytiga . . O
. . . O

excerpt . . O
: . . O
* . . O
mortality . . B-AdverseReaction
: . . O
there . . O
were . . O
more . . O
deaths . . B-AdverseReaction
reported . . O
with . . O
benlysta . . O
than . . O
with . . O
placebo . . O
during . . O
the . . O
controlled . . O
period . . O
of . . O
clinical . . O
trials . . O
. . . O

5.9 . . O
abnormal . . O
thyroid . . O
function . . O
tests . . O

intravenous . . O
administration . . O
of . . O
products . . O
containing . . O
benzyl . . O
alcohol . . O
has . . O
been . . O
associated . . O
with . . O
neonatal . . B-AdverseReaction
gasping . . I-AdverseReaction
syndrome . . I-AdverseReaction
consisting . . O
of . . O
severe . . B-Severity
metabolic . . B-AdverseReaction
acidosis . . I-AdverseReaction
, . . O
gasping . . B-AdverseReaction
respirations . . I-AdverseReaction
, . . O
progressive . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
seizures . . B-AdverseReaction
, . . O
central . . B-AdverseReaction
nervous . . I-AdverseReaction
system . . I-AdverseReaction
depression . . I-AdverseReaction
, . . O
intraventricular . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
and . . O
death . . B-AdverseReaction
in . . O
preterm . . O
, . . O
low . . O
birth . . O
weight . . O
infants . . O
. . . O

* . . O
bipolar . . O
disorder . . O
pediatric . . O
patients . . O
( . . O
monotherapy . . O
) . . O
: . . O
somnolence . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
dysgeusia . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
paresthesia . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
weight . . I-AdverseReaction
. . . O

in . . O
addition . . O
, . . O
it . . O
is . . O
recommended . . O
to . . O
avoid . . O
use . . O
of . . O
xiaflex . . O
in . . O
patients . . O
with . . O
coagulation . . O
disorders . . O
, . . O
including . . O
patients . . O
receiving . . O
concomitant . . O
anticoagulants . . O
( . . O
except . . O
for . . O
low . . O
- . . O
dose . . O
aspirin . . O
) . . O
. . . O

in . . O
addition . . O
, . . O
beta . . B-DrugClass
- . . I-DrugClass
agonists . . I-DrugClass
have . . O
been . . O
reported . . O
to . . O
produce . . O
ecg . . B-AdverseReaction
changes . . I-AdverseReaction
, . . O
such . . O
as . . O
flattening . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
t . . I-AdverseReaction
wave . . I-AdverseReaction
, . . O
prolongation . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
qtc . . I-AdverseReaction
interval . . I-AdverseReaction
, . . O
and . . O
st . . B-AdverseReaction
segment . . I-AdverseReaction
depression . . I-AdverseReaction
, . . O
although . . O
the . . O
clinical . . O
significance . . O
of . . O
these . . O
findings . . O
is . . O
unknown . . O
. . . O

patients . . O
should . . O
be . . O
tested . . O
for . . O
latent . . O
tuberculosis . . O
before . . O
cimzia . . O
use . . O
and . . O
during . . O
therapy . . O
. . . O

obesity . . O
and . . O
prolonged . . O
nucleoside . . O
exposure . . O
may . . O
be . . O
risk . . O
factors . . O
. . . O

the . . O
safety . . O
of . . O
reinitiating . . O
kyprolis . . O
therapy . . O
in . . O
patients . . O
previously . . O
experiencing . . O
ttp . . O
/ . . O
hus . . O
is . . O
not . . O
known . . O
. . . O

after . . O
dosing . . O
with . . O
eylea . . O
for . . O
24-100 . . O
weeks . . O
, . . O
antibodies . . O
to . . O
eylea . . O
were . . O
detected . . O
in . . O
a . . O
similar . . O
percentage . . O
range . . O
of . . O
patients . . O
. . . O

table . . O
1 . . O
: . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reaction . . O
incidence . . O
( . . O
% . . O
) . . O
in . . O
controlled . . O
trials . . O
in . . O
postherpetic . . O
neuralgia . . O
( . . O
events . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
qutenza . . O
- . . O
treated . . O
patients . . O
and . . O
at . . O
least . . O
1% . . O
greater . . O
in . . O
the . . O
qutenza . . O
group . . O
than . . O
in . . O
the . . O
control . . O
group . . O
) . . O
body . . O
systempreferred . . O
term . . O
qutenza60 . . O
minutes . . O
( . . O
n . . O
= . . O
622 . . O
) . . O
% . . O
control60 . . O
minutes . . O
( . . O
n . . O
= . . O
495 . . O
) . . O
% . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
erythema . . I-AdverseReaction
63 . . O
54 . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
42 . . O
21 . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pruritus . . I-AdverseReaction
6 . . O
4 . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
papules . . I-AdverseReaction
6 . . O
3 . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
edema . . I-AdverseReaction
4 . . O
1 . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
swelling . . I-AdverseReaction
2 . . O
1 . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
dryness . . I-AdverseReaction
2 . . O
1 . . O
infections . . O
and . . O
infestations . . O
nasopharyngitis . . B-AdverseReaction
4 . . O
2 . . O
bronchitis . . B-AdverseReaction
2 . . O
1 . . O
sinusitis . . B-AdverseReaction
3 . . O
1 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
5 . . O
2 . . O
vomiting . . B-AdverseReaction
3 . . O
1 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorder . . O
pruritus . . B-AdverseReaction
2 . . O
< . . O
1 . . O
vascular . . O
disorders . . O
hypertension . . B-AdverseReaction
2 . . O
1 . . O
other . . O
adverse . . O
reactions . . O
observed . . O
during . . O
the . . O
clinical . . O
studies . . O
of . . O
qutenza . . O

if . . O
anaphylaxis . . O
or . . O
severe . . O
hypersensitivity . . O
reactions . . O
occur . . O
, . . O
immediately . . O
stop . . O
the . . O
infusion . . O
and . . O
initiate . . O
appropriate . . O
medical . . O
treatment . . O
. . . O

impairment . . O
in . . O
renal . . O
function . . O

table . . O
4 . . O
change . . O
from . . O
baseline . . O
in . . O
serum . . O
creatinine . . O
and . . O
egfr . . O
and . . O
incidence . . O
of . . O
elevated . . B-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
( . . O
all . . O
grades . . O
) . . O
in . . O
studies . . O
102 . . O
and . . O
103 . . O
at . . O
week . . O
144 . . O
stribild . . O
( . . O
n . . O
= . . O
701 . . O
) . . O
atripla . . O
( . . O
n . . O
= . . O
352 . . O
) . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
( . . O
n . . O
= . . O
355 . . O
) . . O
serum . . O
creatinine . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
0.14 . . O
( . . O
+ . . O
/ . . O
- . . O
0.14 . . O
) . . O
0.01 . . O
( . . O
+ . . O
/ . . O
- . . O
0.12 . . O
) . . O
0.09 . . O
( . . O
+ . . O
/ . . O
- . . O
0.15 . . O
) . . O
egfr . . O
by . . O
cockcroft . . O
- . . O
gault . . O
( . . O
ml . . O
/ . . O
minute . . O
) . . O
- . . O
14.0 . . O
( . . O
+ . . O
/ . . O
- . . O
16.6 . . O
) . . O
- . . O
1.9 . . O
( . . O
+ . . O
/ . . O
- . . O
17.9 . . O
) . . O
- . . O
9.8 . . O
( . . O
+ . . O
/ . . O
- . . O
19.4 . . O
) . . O
subjects . . O
with . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
( . . O
all . . O
grades . . O
) . . O
( . . O
% . . O
) . . O
12 . . O
2 . . O
6 . . O
emtricitabine . . O
or . . O
tenofovir . . O
df . . O
: . . O
in . . O
addition . . O
to . . O
the . . O
laboratory . . O
abnormalities . . O
observed . . O
with . . O
stribild . . O
, . . O
the . . O
following . . O
laboratory . . O
abnormalities . . O
have . . O
been . . O
previously . . O
reported . . O
in . . O
subjects . . O
treated . . O
with . . O
emtricitabine . . O
or . . O
tenofovir . . O
df . . O
with . . O
other . . O
antiretroviral . . O
agents . . O
in . . O
other . . O
clinical . . O
trials . . O
: . . O
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
laboratory . . O
abnormalities . . B-AdverseReaction
of . . I-AdverseReaction
alt . . I-AdverseReaction
( . . O
m . . O
: . . O
greater . . O
than . . O
215 . . B-Severity
u . . I-Severity
per . . I-Severity
l . . I-Severity
; . . O
f . . O
: . . O
greater . . O
than . . O
170 . . B-Severity
u . . I-Severity
per . . I-Severity
l . . I-Severity
) . . O
, . . O
alkaline . . O
phosphatase . . O
( . . O
greater . . O
than . . O
550 . . B-Severity
u . . I-Severity
per . . I-Severity
l . . I-Severity
) . . O
, . . O
bilirubin . . O
( . . O
greater . . O
than . . O
2.5 . . B-Severity
* . . I-Severity
uln . . I-Severity
) . . O
, . . O
serum . . O
glucose . . O
( . . O
less . . O
than . . O
40 . . O
or . . O
greater . . O
than . . O
250 . . B-Severity
mg . . I-Severity
per . . I-Severity
dl . . I-Severity
) . . O
, . . O
glycosuria . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3+ . . B-Severity
) . . O
, . . O
neutrophils . . O
( . . O
less . . O
than . . O
750 . . B-Severity
per . . I-Severity
mm . . I-Severity
3 . . I-Severity
) . . O
, . . O
fasting . . O
cholesterol . . O
( . . O
greater . . O
than . . O
240 . . B-Severity
mg . . I-Severity
per . . I-Severity
dl . . I-Severity
) . . O
, . . O
and . . O
fasting . . O
triglycerides . . O
( . . O
greater . . O
than . . O
750 . . B-Severity
mg . . I-Severity
per . . I-Severity
dl . . I-Severity
) . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

6 . . O
adverse . . O
reactions . . O

warning . . O
: . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
malignancy . . B-AdverseReaction

using . . O
an . . O
electrochemiluminescent . . O
bridging . . O
immunoassay . . O
, . . O
less . . O
than . . O
1% . . O
( . . O
55 . . O
out . . O
of . . O
8113 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
prolia . . O
for . . O
up . . O
to . . O
5 . . O
years . . O
tested . . O
positive . . O
for . . O
binding . . O
antibodies . . O
( . . O
including . . O
pre . . O
- . . O
existing . . O
, . . O
transient . . O
, . . O
and . . O
developing . . O
antibodies . . O
) . . O
. . . O

6 . . O
adverse . . O
reactions . . O

six . . O
out . . O
of . . O
107 . . O
( . . O
6% . . O
) . . O
patients . . O
treated . . O
with . . O
1,200 . . O
mg . . O
of . . O
horizant . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
events . . O
compared . . O
with . . O
12 . . O
of . . O
the . . O
95 . . O
( . . O
13% . . O
) . . O
patients . . O
who . . O
received . . O
placebo . . O
. . . O

5.2 . . O
serious . . O
dermatologic . . O
reactions . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
to . . O
cerdelga . . O
( . . O
occurring . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
the . . O
126 . . O
gd1 . . O
patients . . O
treated . . O
with . . O
cerdelga . . O
across . . O
trials . . O
1 . . O
and . . O
2 . . O
) . . O
were . . O
fatigue . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremities . . I-AdverseReaction
, . . O
and . . O
upper . . B-AdverseReaction
abdominal . . I-AdverseReaction
pain . . I-AdverseReaction
. . . O

( . . O
5.3 . . O
) . . O
* . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O
: . . O
increased . . O
risk . . B-Factor
; . . O
consider . . O
in . . O
the . . O
diagnosis . . O
of . . O
patients . . O
reporting . . O
new . . O
or . . O
worsening . . O
neurological . . O
, . . O
cognitive . . O
, . . O
or . . O
behavioral . . O
signs . . O
and . . O
symptoms . . O
. . . O

among . . O
those . . O
, . . O
2110 . . O
patients . . O
were . . O
treated . . O
with . . O
the . . O
recommended . . O
dose . . O
of . . O
2 . . O
mg . . O
. . . O

table . . O
6 . . O
: . . O
grade . . O
3-4 . . O
laboratory . . O
abnormalities . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
in . . O
cycles . . O
1-12 . . O
( . . O
combination . . O
therapy . . O
) . . O
krd . . O
= . . O
kyprolis . . O
, . . O
lenalidomide . . O
, . . O
and . . O
low . . O
- . . O
dose . . O
dexamethasone . . O
; . . O
rd . . O
= . . O
lenalidomide . . O
and . . O
low . . O
- . . O
dose . . O
dexamethasone . . O
laboratory . . O
abnormality . . O
krd . . O
( . . O
n . . O
= . . O
392 . . O
) . . O
rd . . O
( . . O
n . . O
= . . O
389 . . O
) . . O
decreased . . B-AdverseReaction
lymphocytes . . I-AdverseReaction
182 . . O
( . . O
46% . . O
) . . O
119 . . O
( . . O
31% . . O
) . . O
decreased . . B-AdverseReaction
absolute . . I-AdverseReaction
neutrophil . . I-AdverseReaction
count . . I-AdverseReaction
152 . . O
( . . O
39% . . O
) . . O
140 . . O
( . . O
36% . . O
) . . O
decreased . . B-AdverseReaction
phosphorus . . I-AdverseReaction
122 . . O
( . . O
31% . . O
) . . O
106 . . O
( . . O
27% . . O
) . . O
decreased . . B-AdverseReaction
platelets . . I-AdverseReaction
101 . . O
( . . O
26% . . O
) . . O
59 . . O
( . . O
15% . . O
) . . O
decreased . . B-AdverseReaction
total . . I-AdverseReaction
white . . I-AdverseReaction
blood . . I-AdverseReaction
cell . . I-AdverseReaction
count . . I-AdverseReaction
97 . . O
( . . O
25% . . O
) . . O
71 . . O
( . . O
18% . . O
) . . O
decreased . . B-AdverseReaction
hemoglobin . . I-AdverseReaction
58 . . O
( . . O
15% . . O
) . . O
68 . . O
( . . O
18% . . O
) . . O
decreased . . B-AdverseReaction
potassium . . I-AdverseReaction
41 . . O
( . . O
11% . . O
) . . O
23 . . O
( . . O
6% . . O
) . . O
6.1.2 . . O
safety . . O
experience . . O
with . . O
kyprolis . . O
in . . O
patients . . O
with . . O
multiple . . O
myeloma . . O
who . . O
received . . O
monotherapy . . O
the . . O
safety . . O
of . . O
kyprolis . . O
was . . O
evaluated . . O
in . . O
clinical . . O
trials . . O
in . . O
which . . O
598 . . O
patients . . O
with . . O
relapsed . . O
and . . O
/ . . O
or . . O
refractory . . O
myeloma . . O
received . . O
kyprolis . . O
monotherapy . . O
starting . . O
with . . O
the . . O
20 . . O
mg . . O
/ . . O
m . . O
2 . . O
dose . . O
in . . O
cycle . . O
1 . . O
day . . O
1 . . O
and . . O
escalating . . O
to . . O
27 . . O
mg . . O
/ . . O
m . . O
2 . . O
on . . O
cycle . . O
1 . . O
day . . O
8 . . O
or . . O
cycle . . O
2 . . O
day . . O
1 . . O
. . . O

three . . O
percent . . O
of . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
had . . O
platelet . . B-AdverseReaction
counts . . I-AdverseReaction
of . . I-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
50 . . I-AdverseReaction
* . . I-AdverseReaction
10 . . I-AdverseReaction
9 . . I-AdverseReaction
per . . I-AdverseReaction
l . . I-AdverseReaction
compared . . O
to . . O
1% . . O
of . . O
subjects . . O
receiving . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
cimzia . . O
at . . O
400 . . O
mg . . O
subcutaneous . . O
dosing . . O
in . . O
studies . . O
of . . O
patients . . O
with . . O
crohn's . . O
disease . . O
. . . O

* . . O
using . . O
estrogens . . O
may . . O
increase . . O
your . . O
chances . . O
of . . O
getting . . O
strokes . . O
or . . O
blood . . O
clots . . O
. . . O

adverse . . O
reactions . . O
based . . O
on . . O
gender . . O
and . . O
race . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
were . . O
pyrexia . . B-AdverseReaction
( . . O
62% . . O
) . . O
, . . O
headache . . B-AdverseReaction
( . . O
36% . . O
) . . O
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
( . . O
25% . . O
) . . O
, . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
( . . O
25% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
25% . . O
) . . O
, . . O
hypokalemia . . B-AdverseReaction
( . . O
23% . . O
) . . O
, . . O
and . . O
constipation . . B-AdverseReaction
( . . O
20% . . O
) . . O
. . . O

tables . . O
3 . . O
and . . O
4 . . O
summarize . . O
common . . O
adverse . . O
reactions . . O
and . . O
laboratory . . O
abnormalities . . O
in . . O
xalkori . . O
- . . O
treated . . O
patients . . O
. . . O

in . . O
the . . O
non . . O
- . . O
hodgkin's . . O
lymphoma . . O
study . . O
, . . O
52% . . O
of . . O
patients . . O
were . . O
male . . O
, . . O
the . . O
median . . O
age . . O
was . . O
55 . . O
years . . O
, . . O
and . . O
88% . . O
of . . O
patients . . O
were . . O
caucasian . . O
. . . O

in . . O
study . . O
2 . . O
all . . O
adverse . . O
events . . O
of . . O
all . . O
grades . . O
were . . O
prospectively . . O
collected . . O
. . . O

* . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
: . . O
monitor . . O
patients . . O
for . . O
atrial . . O
fibrillation . . O
( . . O
5.4 . . O
) . . O
. . . O

transaminases . . O
: . . O
transient . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
transaminases . . I-AdverseReaction
( . . O
primarily . . O
alt . . O
) . . O
in . . O
the . . O
short . . O
- . . O
term . . O
schizophrenia . . O
and . . O
bipolar . . O
mania . . O
adult . . O
trials . . O
were . . O
more . . O
common . . O
in . . O
treated . . O
patients . . O
. . . O

other . . O
adverse . . O
reactions . . O

the . . O
significance . . O
of . . O
these . . O
findings . . O
and . . O
the . . O
effect . . O
of . . O
long . . O
- . . O
term . . O
treatment . . O
with . . O
prolia . . O
are . . O
unknown . . O
. . . O

during . . O
the . . O
trial . . O
, . . O
48% . . O
of . . O
patients . . O
on . . O
the . . O
xtandi . . O
arm . . O
and . . O
46% . . O
of . . O
patients . . O
on . . O
the . . O
placebo . . O
arm . . O
received . . O
glucocorticoids . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
urticaria . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
paresthesia . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
dermatitis . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
hyperesthesia . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
excoriation . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
warmth . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
anesthesia . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
bruising . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
inflammation . . I-AdverseReaction
, . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
exfoliation . . I-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction

most . . O
of . . O
these . . O
adverse . . O
reactions . . O
were . . O
mild . . O
to . . O
moderate . . O
in . . O
intensity . . O
and . . O
occurred . . O
during . . O
the . . O
titration . . O
phase . . O
. . . O

patients . . O
who . . O
develop . . O
increased . . O
transaminase . . O
levels . . O
should . . O
be . . O
closely . . O
monitored . . O
until . . O
the . . O
abnormalities . . O
resolve . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

because . . O
of . . O
the . . O
risks . . B-Factor
of . . O
corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
or . . O
other . . O
serious . . B-Severity
penile . . B-AdverseReaction
injury . . I-AdverseReaction
, . . O
xiaflex . . O
is . . O
available . . O
for . . O
the . . O
treatment . . O
of . . O
peyronie's . . O
disease . . O
only . . O
through . . O
a . . O
restricted . . O
program . . O
under . . O
a . . O
risk . . O
evaluation . . O
and . . O
mitigation . . O
strategy . . O
( . . O
rems . . O
) . . O
called . . O
the . . O
xiaflex . . O
rems . . O
program . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

5.5 . . O
recrudescence . . O

6 . . O
adverse . . O
reactions . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

heart . . O
rate . . O
increase . . O
and . . O
tachycardia . . O
related . . O
adverse . . O
reactions . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
median . . O
age . . O
of . . O
patients . . O
treated . . O
with . . O
teflaro . . O
was . . O
54 . . O
years . . O
, . . O
ranging . . O
between . . O
18 . . O
and . . O
99 . . O
years . . O
old . . O
. . . O

* . . O
perform . . O
test . . O
for . . O
latent . . O
tb . . O
; . . O
if . . O
positive . . O
, . . O
start . . O
treatment . . O
for . . O
tb . . O
prior . . O
to . . O
starting . . O
simponi . . O
aria . . O
( . . O
5.1 . . O
) . . O
. . . O

discontinue . . O
simponi . . O
aria . . O
if . . O
a . . O
patient . . O
develops . . O
a . . O
serious . . O
infection . . O
, . . O
an . . O
opportunistic . . O
infection . . O
, . . O
or . . O
sepsis . . O
. . . O

patients . . O
with . . O
new . . O
york . . O
heart . . O
association . . O
class . . O
iii . . O
and . . O
iv . . O
heart . . O
failure . . O
, . . O
recent . . O
myocardial . . O
infarction . . O
, . . O
and . . O
conduction . . O
abnormalities . . O
uncontrolled . . O
by . . O
medications . . O
were . . O
not . . O
eligible . . O
for . . O
the . . O
clinical . . O
trials . . O
. . . O

serum . . O
creatinine . . O
levels . . O
and . . O
estimated . . O
gfr . . O
may . . O
not . . O
reliably . . O
assess . . O
renal . . O
function . . O
in . . O
the . . O
setting . . O
of . . O
acute . . O
kidney . . O
injury . . O
. . . O

5.4 . . O
immune . . O
reconstitution . . O
syndrome . . O

excerpt . . O
: . . O
the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
were . . O
: . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
consisting . . O
of . . O
erythema . . O
( . . O
1.7 . . O
% . . O
) . . O
, . . O
irritation . . O
( . . O
1.2 . . O
% . . O
) . . O
, . . O
and . . O
pain . . O
( . . O
3.9 . . O
% . . O
) . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
osteonecrosis . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
jaw . . I-AdverseReaction
: . . O
discontinue . . O
cometriq . . O
. . . O

2 . . O
postmarketing . . O
experience . . O
the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
imbruvica . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
( . . O
5 . . O
) . . O
section . . O
of . . O
the . . O
labeling . . O
: . . O

if . . O
hypertension . . O
cannot . . O
be . . O
adequately . . O
controlled . . O
, . . O
withhold . . O
kyprolis . . O
and . . O
evaluate . . O
. . . O

a . . O
total . . O
of . . O
741 . . O
patients . . O
have . . O
been . . O
treated . . O
with . . O
ampyra . . O
for . . O
over . . O
six . . O
months . . O
, . . O
501 . . O
for . . O
over . . O
one . . O
year . . O
and . . O
352 . . O
for . . O
over . . O
two . . O
years . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O

dizziness . . B-AdverseReaction
and . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
gait . . I-AdverseReaction
and . . O
coordination . . O
were . . O
also . . O
observed . . O
in . . O
monotherapy . . O
trials . . O
. . . O

gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
37 . . O
0 . . O
nausea . . B-AdverseReaction
21 . . O
0 . . O
stomatitis . . B-AdverseReaction
16 . . O
0 . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
13 . . O
0 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
22 . . O
0 . . O
bruising . . B-AdverseReaction
16 . . O
0 . . O
pruritus . . B-AdverseReaction
11 . . O
0 . . O
general . . O
disorders . . O
and . . O
administrative . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
21 . . O
0 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
21 . . O
0 . . O
arthropathy . . B-AdverseReaction
13 . . O
0 . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
19 . . O
0 . . O
sinusitis . . B-AdverseReaction
19 . . O
0 . . O
pneumonia . . B-AdverseReaction
14 . . O
6 . . O
skin . . B-AdverseReaction
infection . . I-AdverseReaction
14 . . O
2 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
epistaxis . . B-AdverseReaction
19 . . O
0 . . O
cough . . B-AdverseReaction
13 . . O
0 . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
14 . . O
0 . . O
headache . . B-AdverseReaction
13 . . O
0 . . O
neoplasms . . O
benign . . O
, . . O
malignant . . O
, . . O
and . . O
unspecified . . O
( . . O
including . . O
cysts . . O
and . . O
polyps . . O
) . . O
skin . . B-AdverseReaction
cancer . . I-AdverseReaction
11 . . O
0 . . O
table . . O
8 . . O
: . . O
treatment . . O
- . . O
emergentbased . . O
on . . O
laboratory . . O
measurements . . O
. . . O

some . . O
patients . . O
required . . O
hospitalization . . O
and . . O
discontinuation . . O
of . . O
aptiom . . O
. . . O

inform . . O
patients . . O
of . . O
the . . O
risk . . O
and . . O
of . . O
symptoms . . O
and . . O
to . . O
contact . . O
a . . O
physician . . O
immediately . . O
if . . O
symptoms . . O
of . . O
an . . O
infusion . . O
reaction . . O
occur . . O
[ . . O
see . . O
patient . . O
counseling . . O
information . . O
( . . O
17 . . O
) . . O
] . . O
. . . O

the . . O
adverse . . O
reactions . . O
were . . O
predominantly . . O
of . . O
mild . . O
to . . O
moderate . . O
intensity . . O
. . . O

hypoglycemia . . O

patients . . O
recently . . O
exposed . . O
to . . O
opioids . . O
are . . O
expected . . O
to . . O
be . . O
more . . O
sensitive . . O
to . . O
the . . O
effects . . O
of . . O
mu . . O
- . . O
opioid . . O
receptor . . O
antagonists . . O
, . . O
such . . O
as . . O
entereg . . O
. . . O

cases . . O
of . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O
have . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
imbruvica . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
treatment . . O
was . . O
10.9 . . O
months . . O
for . . O
both . . O
tafinlar . . O
and . . O
trametinib . . O
( . . O
2 . . O
- . . O
mg . . O
orally . . O
once . . O
- . . O
daily . . O
treatment . . O
group . . O
) . . O
when . . O
used . . O
in . . O
combination . . O
, . . O
10.6 . . O
months . . O
for . . O
both . . O
tafinlar . . O
and . . O
trametinib . . O
( . . O
1 . . O
- . . O
mg . . O
orally . . O
once . . O
- . . O
daily . . O
treatment . . O
group . . O
) . . O
when . . O
used . . O
in . . O
combination . . O
, . . O
and . . O
6.1 . . O
months . . O
for . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

* . . O
duavee . . O
should . . O
be . . O
swallowed . . O
whole . . O
. . . O

the . . O
proportion . . O
of . . O
subjects . . O
who . . O
discontinued . . O
treatment . . O
with . . O
stribild . . O
( . . O
elvitegravir . . O
150 . . O
mg . . O
/ . . O
cobicistat . . O
150 . . O
mg . . O
/ . . O
emtricitabine . . O
200 . . O
mg . . O
/ . . O
tenofovir . . O
df . . O
300 . . O
mg . . O
) . . O
; . . O
atripla . . O
( . . O
efavirenz . . O
600 . . O
mg . . O
/ . . O
emtricitabine . . O
200 . . O
mg . . O
/ . . O
tenofovir . . O
df . . O
300 . . O
mg . . O
) . . O
; . . O
or . . O
atazanavir . . O
( . . O
atv . . O
) . . O
+ . . O
ritonavir . . O
( . . O
rtv . . O
) . . O
+ . . O
truvada . . O
( . . O
emtricitabine . . O
200 . . O
mg . . O
/ . . O
tenofovir . . O
df . . O
300 . . O
mg . . O
) . . O
due . . O
to . . O
adverse . . O
events . . O
, . . O
regardless . . O
of . . O
severity . . O
, . . O
was . . O
6.0% . . O
, . . O
7.4% . . O
and . . O
8.5% . . O
, . . O
respectively . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
: . . O
healthcare . . O
providers . . O
should . . O
be . . O
prepared . . O
to . . O
address . . O
hypersensitivity . . O
reactions . . O
, . . O
including . . O
anaphylaxis . . O
, . . O
following . . O
xiaflex . . O
injections . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

initiate . . O
treatment . . O
for . . O
latent . . O
tuberculosis . . O
prior . . O
to . . O
simponi . . O
aria . . O
use . . O
. . . O

the . . O
data . . O
described . . O
below . . O
are . . O
based . . O
on . . O
two . . O
identical . . O
, . . O
pooled . . O
, . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
multi . . O
- . . O
center . . O
trials . . O
through . . O
day . . O
365 . . O
in . . O
patients . . O
with . . O
peyronie's . . O
disease . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

aptiom . . O
should . . O
be . . O
discontinued . . O
in . . O
patients . . O
with . . O
jaundice . . O
or . . O
other . . O
evidence . . O
of . . O
significant . . O
liver . . O
injury . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
laboratory . . O
evidence . . O
) . . O
. . . O

some . . O
patients . . O
had . . O
residual . . O
visual . . B-AdverseReaction
acuity . . I-AdverseReaction
loss . . I-AdverseReaction
even . . O
after . . O
resolution . . O
of . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
. . . O

potiga . . O
was . . O
associated . . O
with . . O
dose . . O
- . . O
related . . O
weight . . B-AdverseReaction
gain . . I-AdverseReaction
, . . O
with . . O
mean . . O
weight . . B-AdverseReaction
increasing . . I-AdverseReaction
by . . O
0.2 . . O
kg . . O
, . . O
1.2 . . O
kg . . O
, . . O
1.6 . . O
kg . . O
, . . O
and . . O
2.7 . . O
kg . . O
in . . O
the . . O
placebo . . O
, . . O
600 . . O
mg . . O
per . . O
day . . O
, . . O
900 . . O
mg . . O
per . . O
day . . O
, . . O
and . . O
1,200 . . O
mg . . O
per . . O
day . . O
groups . . O
, . . O
respectively . . O
. . . O

monitor . . O
ecgs . . O
and . . O
discontinue . . O
sirturo . . O
if . . O
significant . . O
ventricular . . O
arrhythmia . . O
or . . O
qtcf . . O
interval . . O
> . . O
500 . . O
ms . . O
develops . . O
. . . O

( . . O
4 . . O
, . . O
5.1 . . O
) . . O

excerpt . . O
: . . O
* . . O
laryngeal . . O
attacks . . O
: . . O
following . . O
treatment . . O
of . . O
laryngeal . . O
attacks . . O
with . . O
firazyr . . O
, . . O
advise . . O
patients . . O
to . . O
seek . . O
immediate . . O
medical . . O
attention . . O
. . . O

table . . O
3 . . O
shows . . O
adverse . . O
reactions . . O
on . . O
the . . O
zytiga . . O
arm . . O
in . . O
study . . O
2 . . O
that . . O
occurred . . O
with . . O
a . . O
> . . O
= . . O
2% . . O
absolute . . O
increase . . O
in . . O
frequency . . O
compared . . O
to . . O
placebo . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
venous . . B-AdverseReaction
thrombosis . . I-AdverseReaction
: . . O
thromboprophylaxis . . O
is . . O
recommended . . O
. . . O

symptoms . . O
of . . O
pvt . . B-AdverseReaction
included . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
and . . O
diarrhea . . B-AdverseReaction
. . . O

promptly . . O
measure . . O
serum . . O
total . . O
bilirubin . . O
, . . O
ast . . O
, . . O
and . . O
alt . . O
if . . O
clinical . . O
symptoms . . O
or . . O
signs . . O
suggestive . . O
of . . O
hepatotoxicity . . O
develop . . O
. . . O

other . . O
serious . . O
adverse . . O
reactions . . O
included . . O
thrombotic . . O
/ . . O
thromboembolic . . B-AdverseReaction
complications . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

1 . . O
risks . . O
of . . O
treatment . . O
in . . O
patients . . O
with . . O
infectious . . O
diarrhea . . O

monitor . . O
patients . . O
closely . . O
for . . O
need . . O
of . . O
emergency . . O
cardiorespiratory . . O
support . . O
. . . O

the . . O
adverse . . O
reaction . . O
profile . . O
was . . O
similar . . O
for . . O
each . . O
injection . . O
, . . O
regardless . . O
of . . O
the . . O
number . . O
of . . O
injections . . O
administered . . O
. . . O

6 . . O
adverse . . O
reactions . . O

( . . O
6.1 . . O
) . . O

infections . . O
and . . O
infestations . . O
: . . O
abscess . . B-AdverseReaction
, . . O
acrodermatitis . . B-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
ear . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
gastroenteritis . . B-AdverseReaction
, . . O
helminthic . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
hookworm . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
impetigo . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
lower . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
malaria . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
herpes . . I-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
subcutaneous . . B-AdverseReaction
abscess . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
( . . O
a . . O
) . . O
premature . . O
discontinuation . . O
of . . O
pradaxa . . O
increases . . O
the . . O
risk . . O

the . . O
median . . O
duration . . O
of . . O
exposure . . O
to . . O
zydelig . . O
was . . O
5 . . O
months . . O
. . . O

( . . O
5.10 . . O
) . . O
* . . O
embryofetal . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

c . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
rash . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
generalized . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
pruritic . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
erythematous . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
papular . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
vesicular . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
macular . . I-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
maculo . . I-AdverseReaction
- . . I-AdverseReaction
papular . . I-AdverseReaction
. . . O

5.4 . . O
tardive . . O
dyskinesia . . O

failure . . O
to . . O
block . . O
thyroid . . O
uptake . . O
of . . O
iodine . . O
123 . . O
may . . O
result . . O
in . . O
an . . O
increased . . O
long . . O
term . . O
risk . . O
for . . O
thyroid . . O
neoplasia . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

5.1 . . O
drug . . O
- . . O
drug . . O
interactions . . O

the . . O
following . . O
additional . . O
adverse . . O
reactions . . O
have . . O
been . . O
reported . . O
during . . O
postmarketing . . O
use . . O
of . . O
gadavist . . O
. . . O

non . . O
- . . O
hematologic . . O
adverse . . O
reactions . . O
( . . O
any . . O
grade . . O
) . . O
in . . O
the . . O
treanda . . O
group . . O
that . . O
occurred . . O
with . . O
a . . O
frequency . . O
greater . . O
than . . O
15% . . O
were . . O
pyrexia . . B-AdverseReaction
( . . O
24% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
20% . . O
) . . O
, . . O
and . . O
vomiting . . B-AdverseReaction
( . . O
16% . . O
) . . O
. . . O

in . . O
a . . O
clinical . . O
trial . . O
of . . O
liver . . O
transplant . . O
patients . . O
, . . O
use . . O
of . . O
nulojix . . O
regimens . . O
with . . O
more . . O
frequent . . O
administration . . O
of . . O
belatacept . . O
than . . O
any . . O
of . . O
those . . O
studied . . O
in . . O
kidney . . O
transplant . . O
, . . O
along . . O
with . . O
mycophenolate . . O
mofetil . . O
( . . O
mmf . . O
) . . O
and . . O
corticosteroids . . O
, . . O
was . . O
associated . . O
with . . O
a . . O
higher . . O
rate . . O
of . . O
graft . . B-AdverseReaction
loss . . I-AdverseReaction
and . . O
death . . B-AdverseReaction
compared . . O
to . . O
the . . O
tacrolimus . . O
control . . O
arms . . O
. . . O

in . . O
these . . O
trials . . O
, . . O
891 . . O
patients . . O
were . . O
treated . . O
with . . O
tudorza . . O
pressair . . O
at . . O
the . . O
recommended . . O
dose . . O
of . . O
400 . . O
mcg . . O
twice . . O
daily . . O
. . . O

thrombocytopenia . . B-AdverseReaction
was . . O
reported . . O
in . . O
approximately . . O
40% . . O
of . . O
patients . . O
in . . O
clinical . . O
trials . . O
with . . O
kyprolis . . O
. . . O

* . . O
distant . . B-AdverseReaction
spread . . I-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effect . . I-AdverseReaction
[ . . O
seeboxed . . O
warning . . O
] . . O
* . . O
lack . . O
of . . O
interchangeability . . O
between . . O
botulinum . . O
toxin . . O
products . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
spread . . B-AdverseReaction
of . . I-AdverseReaction
effects . . I-AdverseReaction
from . . I-AdverseReaction
toxin . . I-AdverseReaction
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
dysphagia . . B-AdverseReaction
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
facial . . O
anatomy . . O
in . . O
the . . O
treatment . . O
of . . O
glabellar . . O
lines . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
pre . . O
- . . O
existing . . O
neuromuscular . . O
disorders . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
human . . O
albumin . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
intradermal . . B-AdverseReaction
immune . . I-AdverseReaction
reaction . . I-AdverseReaction
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5 . . O
. . . O

monitor . . O
liver . . O
function . . O
and . . O
modify . . O
, . . O
interrupt . . O
, . . O
or . . O
discontinue . . O
zytiga . . O
dosing . . O
as . . O
recommended . . O
. . . O

6 . . O
adverse . . O
reactions . . O

adverse . . O
reactions . . O
associated . . O
with . . O
the . . O
use . . O
of . . O
gadavist . . O
were . . O
usually . . O
mild . . O
to . . O
moderate . . O
in . . O
severity . . O
and . . O
transient . . O
in . . O
nature . . O
. . . O

there . . O
have . . O
been . . O
no . . O
clinical . . O
studies . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
farxiga . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
has . . O
been . . O
observed . . O
and . . O
can . . B-Factor
be . . O
fatal . . B-AdverseReaction
. . . O

administer . . O
kalbitor . . O
in . . O
a . . O
setting . . O
equipped . . O
to . . O
manage . . O
anaphylaxis . . O
and . . O
hereditary . . O
angioedema . . O
. . . O

this . . O
increase . . O
is . . O
due . . O
to . . O
reduction . . O
in . . O
serum . . O
uric . . O
acid . . O
levels . . O
, . . O
resulting . . O
in . . O
mobilization . . O
of . . O
urate . . O
from . . O
tissue . . O
deposits . . O
. . . O

email . . O
: . . O
medicalsafety . . O
@ . . O
apopharma . . O
. . . O
com . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

patients . . O
, . . O
their . . O
caregivers . . O
, . . O
and . . O
families . . O
should . . O
be . . O
informed . . O
that . . O
aeds . . O
increase . . O
the . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
and . . O
should . . O
be . . O
advised . . O
of . . O
the . . O
need . . O
to . . O
be . . O
alert . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
depression . . O
, . . O
any . . O
unusual . . O
changes . . O
in . . O
mood . . O
or . . O
behavior . . O
, . . O
or . . O
the . . O
emergence . . O
of . . O
suicidal . . O
thoughts . . O
, . . O
behavior . . O
, . . O
or . . O
thoughts . . O
about . . O
self . . O
- . . O
harm . . O
. . . O

excerpt . . O
: . . O
* . . O
to . . O
minimize . . O
the . . O
risk . . O
of . . O
contamination . . O
, . . O
do . . O
not . . O
touch . . O
dropper . . O
tip . . O
to . . O
any . . O
surface . . O
. . . O

for . . O
patients . . O
receiving . . O
cleviprex . . O
and . . O
all . . O
active . . O
comparators . . O
the . . O
incidence . . O
of . . O
serious . . O
adverse . . O
events . . O
within . . O
one . . O
hour . . O
of . . O
drug . . O
infusion . . O
discontinuation . . O
was . . O
similar . . O
. . . O

the . . O
mechanism . . O
of . . O
action . . O
of . . O
benlysta . . O
could . . O
increase . . O
the . . O
risk . . B-Factor
for . . O
the . . O
development . . O
of . . O
malignancies . . B-AdverseReaction
. . . O

glabellar . . O
lines . . O

beta . . O
- . . O
blockers . . O
should . . O
be . . O
withdrawn . . O
only . . O
after . . O
a . . O
gradual . . O
reduction . . O
in . . O
dose . . O
. . . O

in . . O
postmarketing . . O
experience . . O
with . . O
tudorza . . O
pressair . . O
, . . O
immediate . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
( . . O
including . . O
swelling . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
lips . . I-AdverseReaction
, . . O
tongue . . O
, . . O
or . . O
throat . . O
) . . O
, . . O
urticaria . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
bronchospasm . . B-AdverseReaction
, . . O
or . . O
itching . . B-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O
; . . O
withhold . . O
gilenya . . O
at . . O
the . . O
first . . O
sign . . O
or . . O
symptom . . O
suggestive . . O
of . . O
pml . . O
. . . O

in . . O
the . . O
whi . . O
estrogen . . O
- . . O
alone . . O
substudy . . O
, . . O
after . . O
an . . O
average . . O
follow . . O
- . . O
up . . O
of . . O
7.1 . . O
years . . O
, . . O
daily . . O
conjugated . . B-DrugClass
estrogen . . I-DrugClass
( . . O
0.625 . . O
mg . . O
) . . O
- . . O
alone . . O
was . . O
not . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . O
of . . O
invasive . . B-AdverseReaction
breast . . I-AdverseReaction
cancer . . I-AdverseReaction
( . . O
relative . . O
risk . . O
[ . . O
rr . . O
] . . O
0.80 . . O
) . . O
. . . O

withhold . . O
yervoy . . O
dosing . . O
in . . O
symptomatic . . O
patients . . O
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
anemia . . B-AdverseReaction
, . . O
idiopathic . . B-AdverseReaction
thrombocytopenic . . I-AdverseReaction
purpura . . I-AdverseReaction
, . . O
leukocytosis . . B-AdverseReaction
/ . . O
leukopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
pancytopenia . . B-AdverseReaction
, . . O
splenomegaly . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
. . . O

respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
cough . . B-AdverseReaction

in . . O
a . . O
combined . . O
analysis . . O
of . . O
studies . . O
115 . . O
and . . O
121 . . O
, . . O
the . . O
frequency . . O
of . . O
adverse . . O
reactions . . O
( . . O
all . . O
grades . . O
) . . O
was . . O
24% . . O
in . . O
subjects . . O
switching . . O
to . . O
stribild . . O
compared . . O
to . . O
6% . . O
of . . O
subjects . . O
in . . O
either . . O
group . . O
who . . O
stayed . . O
on . . O
their . . O
baseline . . O
antiretroviral . . O
regimen . . O
, . . O
rtv . . O
- . . O
boosted . . O
pi . . O
+ . . O
truvada . . O
or . . O
nnrti . . O
+ . . O
truvada . . O
. . . O

there . . O
have . . O
been . . O
no . . O
clinical . . O
studies . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
nesina . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
. . . O

permanently . . O
discontinue . . O
yervoy . . O
and . . O
initiate . . O
systemic . . O
high . . O
- . . O
dose . . O
corticosteroid . . O
therapy . . O
for . . O
severe . . O
immune . . O
- . . O
mediated . . O
reactions . . O
. . . O

5.6 . . O
severe . . O
gastrointestinal . . O
disease . . O

excerpt . . O
: . . O
* . . O
post . . B-AdverseReaction
- . . I-AdverseReaction
transplant . . I-AdverseReaction
lymphoproliferative . . I-AdverseReaction
disorder . . I-AdverseReaction
( . . O
ptld . . B-AdverseReaction
) . . O
: . . O
increased . . O
risk . . B-Factor
, . . O
predominantly . . O
involving . . O
the . . O
cns . . O
; . . O
monitor . . O
for . . O
new . . O
or . . O
worsening . . O
neurological . . O
, . . O
cognitive . . O
, . . O
or . . O
behavioral . . O
signs . . O
and . . O
symptoms . . O
. . . O

for . . O
patients . . O
requiring . . O
invasive . . O
dental . . O
procedures . . O
, . . O
clinical . . O
judgment . . O
of . . O
the . . O
treating . . O
physician . . O
and . . O
/ . . O
or . . O
oral . . O
surgeon . . O
should . . O
guide . . O
the . . O
management . . O
plan . . O
of . . O
each . . O
patient . . O
based . . O
on . . O
individual . . O
benefit . . O
- . . O
risk . . O
assessment . . O
. . . O

all . . O
other . . O
chemotherapy . . O
was . . O
continued . . O
according . . O
to . . O
the . . O
patient's . . O
prescribed . . O
treatment . . O
regimen . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O
study . . O
2 . . O
enrolled . . O
30 . . O
patients . . O
[ . . O
29 . . O
were . . O
being . . O
treated . . O
for . . O
all . . O
and . . O
one . . O
for . . O
lymphoblastic . . O
lymphoma . . O
( . . O
lbl . . O
) . . O
] . . O
following . . O
allergy . . O
to . . O
native . . O
e . . O
. . . O
coli . . O
asparaginase . . O
or . . O
pegaspargase . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
proteinuria . . B-AdverseReaction
: . . O
monitor . . O
urine . . O
protein . . O
. . . O

in . . O
a . . O
pooled . . O
analysis . . O
of . . O
these . . O
14 . . O
controlled . . O
clinical . . O
trials . . O
, . . O
the . . O
overall . . O
incidence . . O
of . . O
adverse . . O
events . . O
was . . O
66% . . O
in . . O
patients . . O
treated . . O
with . . O
nesina . . O
25 . . O
mg . . O
compared . . O
to . . O
62% . . O
with . . O
placebo . . O
and . . O
70% . . O
with . . O
active . . O
comparator . . O
. . . O

other . . O
serious . . O
or . . O
significant . . O
adverse . . O
reactions . . O
reported . . O
in . . O
controlled . . O
and . . O
uncontrolled . . O
studies . . O
in . . O
crohn's . . O
disease . . O
and . . O
other . . O
diseases . . O
, . . O
occurring . . O
in . . O
patients . . O
receiving . . O
cimzia . . O
at . . O
doses . . O
of . . O
400 . . O
mg . . O
or . . O
other . . O
doses . . O
include . . O
: . . O

reported . . O
thrombotic . . O
/ . . O
thromboembolic . . B-AdverseReaction
complications . . I-AdverseReaction
included . . O
both . . O
venous . . O
and . . O
arterial . . O
events . . O
and . . O
were . . O
observed . . O
at . . O
low . . O
and . . O
at . . O
normal . . O
platelet . . O
counts . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

forty . . O
percent . . O
of . . O
patients . . O
had . . O
elevated . . O
uric . . O
acid . . O
levels . . O
on . . O
study . . O
including . . O
13% . . O
with . . O
values . . O
above . . B-Severity
10 . . I-Severity
mg . . I-Severity
/ . . I-Severity
dl . . I-Severity
. . . O
adverse . . O
reaction . . O
of . . O
hyperuricemia . . B-AdverseReaction
was . . O
reported . . O
for . . O
15% . . O
of . . O
patients . . O
. . . O

to . . O
adjust . . O
for . . O
normal . . O
growth . . O
, . . O
z . . O
- . . O
scores . . O
were . . O
derived . . O
( . . O
measured . . O
in . . O
standard . . O
deviations . . O
[ . . O
sd . . O
] . . O
) . . O
, . . O
which . . O
normalize . . O
for . . O
the . . O
natural . . O
growth . . O
of . . O
pediatric . . O
patients . . O
by . . O
comparisons . . O
to . . O
age . . O
- . . O
and . . O
sex . . O
- . . O
matched . . O
population . . O
standards . . O
. . . O

* . . O
severe . . B-Severity
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
was . . O
also . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
in . . O
39 . . O
of . . O
1044 . . O
patients . . O
( . . O
3.7% . . O
) . . O
in . . O
the . . O
controlled . . O
and . . O
uncontrolled . . O
clinical . . O
trials . . O
in . . O
peyronie's . . O
disease . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

if . . O
retinal . . O
pigmentary . . O
abnormalities . . O
or . . O
vision . . O
changes . . O
are . . O
detected . . O
, . . O
potiga . . O
should . . O
be . . O
discontinued . . O
unless . . O
no . . O
other . . O
suitable . . O
treatment . . O
options . . O
are . . O
available . . O
and . . O
the . . O
benefits . . O
of . . O
treatment . . O
outweigh . . O
the . . O
potential . . O
risk . . O
of . . O
vision . . O
loss . . O
. . . O

careful . . O
consideration . . O
should . . O
be . . O
given . . O
to . . O
the . . O
patient's . . O
clinical . . O
status . . O
prior . . O
to . . O
administration . . O
of . . O
vimizim . . O
and . . O
consider . . O
delaying . . O
the . . O
vimizim . . O
infusion . . O
( . . O
5.2 . . O
) . . O
. . . O

6 . . O
adverse . . O
reactions . . O

in . . O
the . . O
combination . . O
study . . O
, . . O
the . . O
incidence . . O
of . . O
venous . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
in . . O
the . . O
first . . O
12 . . O
cycles . . O
was . . O
13% . . O
in . . O
the . . O
kyprolis . . O
combination . . O
arm . . O
versus . . O
6% . . O
in . . O
the . . O
control . . O
arm . . O
. . . O

the . . O
safety . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
for . . O
the . . O
treatment . . O
of . . O
hyperhidrosis . . O
has . . O
not . . O
been . . O
established . . O
. . . O

please . . O
refer . . O
to . . O
table . . O
5 . . O
for . . O
established . . O
and . . O
other . . O
potentially . . O
significant . . O
drug . . O
interactions . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.3 . . O
) . . O
] . . O
. . . O

* . . O
paradoxical . . B-AdverseReaction
bronchospasm . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
narrow . . I-AdverseReaction
- . . I-AdverseReaction
angle . . I-AdverseReaction
glaucoma . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
urinary . . I-AdverseReaction
retention . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
immediate . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
3% . . O
incidence . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
are . . O
headache . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
and . . O
cough . . B-AdverseReaction
. . . O

( . . O
5.2 . . O
) . . O

5 . . O
. . . O

therefore . . O
, . . O
a . . O
lower . . O
dose . . O
of . . O
insulin . . O
or . . O
insulin . . O
secretagogue . . O
may . . O
be . . O
required . . O
to . . O
minimize . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
invokana . . O
. . . O

cases . . O
of . . O
pres . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
kyprolis . . O
. . . O

most . . O
adverse . . O
reactions . . O
were . . O
mild . . O
or . . O
moderate . . O
in . . O
severity . . O
and . . O
transient . . O
in . . O
nature . . O
. . . O

farxiga . . O
should . . O
not . . O
be . . O
used . . O
in . . O
patients . . O
with . . O
active . . O
bladder . . O
cancer . . O
and . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
a . . O
prior . . O
history . . O
of . . O
bladder . . O
cancer . . O
. . . O

adverse . . O
reactions . . O
that . . O
occurred . . O
with . . O
a . . O
frequency . . O
of . . O
< . . O
0.1% . . O
in . . O
subjects . . O
who . . O
received . . O
gadavist . . O
include . . O
: . . O
loss . . B-AdverseReaction
of . . I-AdverseReaction
consciousness . . I-AdverseReaction
, . . O
convulsion . . B-AdverseReaction
, . . O
parosmia . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
palpitation . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
malaise . . B-AdverseReaction
and . . O
feeling . . B-AdverseReaction
cold . . I-AdverseReaction
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
coartem . . O
tablets . . O
. . . O

entereg . . O
is . . O
not . . O
recommended . . O
for . . O
use . . O
in . . O
these . . O
patients . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
rapid . . O
intravenous . . O
infusion . . O
of . . O
glycopeptide . . O
antibacterial . . O
agents . . O
can . . B-Factor
cause . . O
reactions . . O
. . . O

in . . O
patients . . O
with . . O
transaminase . . O
elevations . . O
, . . O
monitor . . O
liver . . O
enzymes . . O
more . . O
frequently . . O
. . . O

this . . O
study . . O
showed . . O
a . . O
statistically . . O
significant . . O
reduction . . B-AdverseReaction
in . . I-AdverseReaction
heart . . I-AdverseReaction
rate . . I-AdverseReaction
compared . . O
to . . O
baseline . . O
, . . O
averaging . . O
about . . O
three . . O
beats . . O
per . . O
minute . . O
, . . O
observed . . O
thirty . . O
minutes . . O
after . . O
injection . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
fatal . . B-AdverseReaction
cases . . O
of . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
have . . O
been . . O
reported . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

discontinue . . O
onfi . . O
gradually . . O
. . . O

5.2 . . O
qt . . O
prolongation . . O

* . . O
concomitant . . O
colchicine . . O
or . . O
androgen . . O
- . . O
deprivation . . O
therapeutic . . O
drugs . . O
( . . O
such . . O
as . . O
luteinizing . . O
hormone . . O
- . . O
releasing . . O
analogs . . O
and . . O
anti . . O
- . . O
androgen . . O
drugs . . O
) . . O
may . . O
interfere . . O
with . . O
11 . . O
c . . O
- . . O
choline . . O
pet . . O
imaging . . O
. . . O

table . . O
2 . . O
includes . . O
adverse . . O
reactions . . O
reported . . O
in . . O
study . . O
2 . . O
that . . O
occurred . . O
at . . O
a . . O
> . . O
= . . O
2% . . O
higher . . O
frequency . . O
in . . O
the . . O
xtandi . . O
arm . . O
compared . . O
to . . O
the . . O
placebo . . O
arm . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
jazz . . O
pharmaceuticals . . O
, . . O
inc . . O
. . . O
at . . O
1-800-520-5568 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

reproductive . . O
system . . O
and . . O
breast . . O
disorders . . O
: . . O
vaginal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
metrorrhagia . . B-AdverseReaction
, . . O
menometrorrhagia . . B-AdverseReaction
, . . O
genital . . B-AdverseReaction
hemorrhage . . I-AdverseReaction

warning . . O
: . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction

control . . O
hypertension . . O
and . . O
correct . . O
hypokalemia . . O
before . . O
and . . O
during . . O
treatment . . O
with . . O
zytiga . . O
. . . O

( . . O
6.1 . . O
) . . O

[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
common . . O
grade . . B-Severity
3 . . I-Severity
/ . . I-Severity
4 . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
2% . . O
) . . O
were . . O
stomatitis . . B-AdverseReaction
, . . O
infections . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
pneumonitis . . B-AdverseReaction
, . . O
and . . O
diarrhea . . B-AdverseReaction
. . . O

( . . O
5.11 . . O
) . . O
* . . O
thrombotic . . B-AdverseReaction
thrombocytopenic . . I-AdverseReaction
purpura . . I-AdverseReaction
/ . . O
hemolytic . . B-AdverseReaction
uremic . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ttp . . B-AdverseReaction
/ . . O
hus . . B-AdverseReaction
) . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
reported . . O
adverse . . O
reaction . . O
was . . O
headache . . B-AdverseReaction
, . . O
occurring . . O
in . . O
2% . . O
of . . O
patients . . O
, . . O
followed . . O
by . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
all . . O
occurring . . O
in . . O
< . . O
1% . . O
of . . O
patients . . O
( . . O
6 . . O
) . . O
. . . O

5.5 . . O
gallbladder . . O
disease . . O

( . . O
5.2 . . O
) . . O
* . . O
alt . . B-AdverseReaction
elevations . . I-AdverseReaction
with . . O
dalvance . . O
treatment . . O
were . . O
reported . . O
in . . O
clinical . . O
trials . . O
. . . O

pool . . O
of . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O

excerpt . . O
: . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
ask . . O
patients . . O
about . . O
prior . . O
reactions . . O
to . . O
vizamyl . . O
. . . O

eliquis2.5 . . O
mg . . O
po . . O
bid35+ . . O
/ . . O
- . . O
3 . . O
days . . O
enoxaparin . . O
40 . . O
mg . . O
sc . . O
qd . . O
35+ . . O
/ . . O
- . . O
3 . . O
days . . O
eliquis . . O
2.5 . . O
mg . . O
po . . O
bid . . O
12+ . . O
/ . . O
- . . O
2 . . O
days . . O
enoxaparin . . O
40 . . O
mg . . O
sc . . O
qd . . O
12+ . . O
/ . . O
- . . O
2 . . O
days . . O
eliquis . . O
2.5 . . O
mg . . O
po . . O
bid . . O
12+ . . O
/ . . O
- . . O
2 . . O
days . . O
enoxaparin . . O
30 . . O
mg . . O
sc . . O
q12h . . O
12+ . . O
/ . . O
- . . O
2 . . O
days . . O
first . . O
dose . . O
12 . . O
to . . O
24 . . O
hours . . O
post . . O
surgery . . O
first . . O
dose . . O
9 . . O
to . . O
15 . . O
hours . . O
prior . . O
to . . O
surgery . . O
first . . O
dose . . O
12 . . O
to . . O
24 . . O
hours . . O
post . . O
surgery . . O
first . . O
dose . . O
9 . . O
to . . O
15 . . O
hours . . O
prior . . O
to . . O
surgery . . O
first . . O
dose . . O
12 . . O
to . . O
24 . . O
hours . . O
post . . O
surgery . . O
first . . O
dose . . O
12 . . O
to . . O
24 . . O
hours . . O
post . . O
surgery . . O
all . . O
treated . . O
n . . O
= . . O
2673 . . O
n . . O
= . . O
2659 . . O
n . . O
= . . O
1501 . . O
n . . O
= . . O
1508 . . O
n . . O
= . . O
1596 . . O
n . . O
= . . O
1588 . . O
major . . O
( . . O
including . . O
surgical . . O
site . . O
) . . O
22 . . O
( . . O
0.82% . . O
) . . O
18 . . O
( . . O
0.68% . . O
) . . O
9 . . O
( . . O
0.60% . . O
) . . O
? . . O

treatment . . O
of . . O
latent . . O
tuberculosis . . O
infection . . O
prior . . O
to . . O
therapy . . O
with . . O
tnf . . O
- . . O
blocking . . O
agents . . O
has . . O
been . . O
shown . . O
to . . O
reduce . . O
the . . O
risk . . O
of . . O
tuberculosis . . O
reactivation . . O
during . . O
therapy . . O
. . . O

when . . O
injecting . . O
a . . O
cord . . O
affecting . . O
a . . O
pip . . O
joint . . O
of . . O
the . . O
fifth . . O
finger . . O
, . . O
the . . O
needle . . O
insertion . . O
should . . O
not . . O
be . . O
more . . O
than . . O
2 . . O
to . . O
3 . . O
mm . . O
in . . O
depth . . O
and . . O
avoid . . O
injecting . . O
more . . O
than . . O
4 . . O
mm . . O
distal . . O
to . . O
the . . O
palmar . . O
digital . . O
crease . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction

table . . O
4 . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
of . . O
subjects . . O
) . . O
in . . O
patients . . O
with . . O
indolent . . O
non . . O
- . . O
hodgkin . . O
lymphoma . . O
treated . . O
with . . O
zydelig . . O
150 . . O
mg . . O
bid . . O
zydelig . . O
monotherapyn . . O
= . . O
146 . . O
( . . O
% . . O
) . . O
adverse . . O
reaction . . O
any . . O
grade . . O
grade . . O
> . . O
= . . O
3 . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
68 . . O
( . . O
47 . . O
) . . O
20 . . O
( . . O
14 . . O
) . . O
nausea . . B-AdverseReaction
42 . . O
( . . O
29 . . O
) . . O
2 . . O
( . . O
1 . . O
) . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
38 . . O
( . . O
26 . . O
) . . O
3 . . O
( . . O
2 . . O
) . . O
vomiting . . B-AdverseReaction
22 . . O
( . . O
15 . . O
) . . O
2 . . O
( . . O
1 . . O
) . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
44 . . O
( . . O
30 . . O
) . . O
2 . . O
( . . O
1 . . O
) . . O
pyrexia . . B-AdverseReaction
41 . . O
( . . O
28 . . O
) . . O
3 . . O
( . . O
2 . . O
) . . O
asthenia . . B-AdverseReaction
17 . . O
( . . O
12 . . O
) . . O
3 . . O
( . . O
2 . . O
) . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
15 . . O
( . . O
10 . . O
) . . O
3 . . O
( . . O
2 . . O
) . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
18 . . O
( . . O
12 . . O
) . . O
0 . . O
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
pneumonia . . B-AdverseReaction
37 . . O
( . . O
25 . . O
) . . O
23 . . O
( . . O
16 . . O
) . . O
cough . . B-AdverseReaction
42 . . O
( . . O
29 . . O
) . . O
1 . . O
( . . O
1 . . O
) . . O
dyspnea . . B-AdverseReaction
25 . . O
( . . O
17 . . O
) . . O
6 . . O
( . . O
4 . . O
) . . O
skin . . O
and . . O
subcutaneous . . O
disorders . . O
rash . . B-AdverseReaction
31 . . O
( . . O
21 . . O
) . . O
4 . . O
( . . O
3 . . O
) . . O
night . . B-AdverseReaction
sweats . . I-AdverseReaction
18 . . O
( . . O
12 . . O
) . . O
0 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
16 . . O
( . . O
11 . . O
) . . O
1 . . O
( . . O
1 . . O
) . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
24 . . O
( . . O
16 . . O
) . . O
1 . . O
( . . O
1 . . O
) . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
17 . . O
( . . O
12 . . O
) . . O
0 . . O
table . . O
5 . . O
treatment . . O
- . . O
emergent . . O
laboratory . . O
abnormalities . . O
in . . O
patients . . O
with . . O
indolent . . O
non . . O
- . . O
hodgkin . . O
lymphoma . . O
treated . . O
with . . O
zydelig . . O
150 . . O
mg . . O
bid . . O
zydelig . . O
monotherapyn . . O
= . . O
146 . . O
( . . O
% . . O
) . . O
laboratory . . O
abnormality . . O
any . . O
grade . . O
grade . . O
3 . . O
grade . . O
4 . . O
grades . . O
were . . O
obtained . . O
per . . O
ctcae . . O
version . . O
4.03 . . O
. . . O

table . . O
6 . . O
presents . . O
the . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
( . . O
experienced . . O
by . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3% . . O
of . . O
pediatric . . O
patients . . O
6 . . O
years . . O
and . . O
older . . O
receiving . . O
promacta . . O
) . . O
across . . O
the . . O
two . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
with . . O
a . . O
higher . . O
incidence . . O
for . . O
promacta . . O
versus . . O
placebo . . O
. . . O

fanapt . . O
should . . O
be . . O
avoided . . O
in . . O
patients . . O
with . . O
histories . . O
of . . O
significant . . O
cardiovascular . . O
illness . . O
, . . O
e . . O
. . . O
g . . O
. . . O
, . . O
qt . . O
prolongation . . O
, . . O
recent . . O
acute . . O
myocardial . . O
infarction . . O
, . . O
uncompensated . . O
heart . . O
failure . . O
, . . O
or . . O
cardiac . . O
arrhythmia . . O
. . . O

monitor . . O
serum . . O
alt . . O
values . . O
monthly . . O
during . . O
therapy . . O
with . . O
ferriprox . . O
, . . O
and . . O
consider . . O
interruption . . O
of . . O
therapy . . O
if . . O
there . . O
is . . O
a . . O
persistent . . O
increase . . O
in . . O
the . . O
serum . . O
transaminase . . O
levels . . O
. . . O

gbcas . . B-DrugClass
have . . O
been . . O
associated . . O
with . . O
a . . O
risk . . O
for . . O
nsf . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

in . . O
these . . O
trials . . O
, . . O
patients . . O
were . . O
given . . O
up . . O
to . . O
4 . . O
treatment . . O
cycles . . O
of . . O
xiaflex . . O
or . . O
placebo . . O
. . . O

respiratory . . O
- . . O
cough . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
exertional . . I-AdverseReaction
, . . O
epistaxis . . B-AdverseReaction
, . . O
wheezing . . B-AdverseReaction

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
the . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
a . . O
potential . . O
for . . O
immunogenicity . . O
with . . O
the . . O
use . . O
of . . O
kalbitor . . O
. . . O

five . . O
of . . O
the . . O
9 . . O
sirturo . . O
deaths . . B-AdverseReaction
and . . O
the . . O
2 . . O
placebo . . B-Factor
deaths . . B-AdverseReaction
were . . O
tuberculosis . . O
- . . O
related . . O
. . . O

saphris . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
with . . O
flexible . . O
dosing . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

5 . . O
warnings . . O
and . . O
precautions . . O

* . . O
lactic . . B-AdverseReaction
acidosis . . I-AdverseReaction
and . . O
severe . . B-Severity
hepatomegaly . . B-AdverseReaction
with . . O
steatosis . . B-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
cases . . O
, . . O
have . . O
been . . O
reported . . O
with . . O
the . . O
use . . O
of . . O
nucleoside . . O
analogs . . O
, . . O
including . . O
tenofovir . . O
disoproxil . . O
fumarate . . O
( . . O
df . . O
) . . O
, . . O
a . . O
component . . O
of . . O
stribild . . O
. . . O

summary . . O
of . . O
clinical . . O
trial . . O
experience . . O
in . . O
classical . . O
hl . . O
post . . O
- . . O
auto . . O
- . . O
hsct . . O
consolidation . . O
( . . O
study . . O
3 . . O
) . . O

therefore . . O
, . . O
units . . O
of . . O
biological . . O
activity . . O
of . . O
xeomin . . O
cannot . . O
be . . O
compared . . O
to . . O
or . . O
converted . . O
into . . O
units . . O
of . . O
any . . O
other . . O
botulinum . . O
toxin . . O
products . . O
( . . O
5.2 . . O
) . . O
. . . O

clinical . . O
adrs . . O
of . . O
moderate . . O
intensity . . O
or . . O
greater . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
grade . . O
2 . . O
) . . O
and . . O
reported . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
subjects . . O
treated . . O
with . . O
intelence . . O
( . . O
r . . O
) . . O
and . . O
occurring . . O
at . . O
a . . O
higher . . O
rate . . O
compared . . O
to . . O
placebo . . O
( . . O
excess . . O
of . . O
1% . . O
) . . O
are . . O
presented . . O
in . . O
table . . O
1 . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
after . . O
initiating . . O
therapy . . O
. . . O

adult . . O
patients . . O
with . . O
schizophrenia . . O
: . . O
the . . O
following . . O
findings . . O
are . . O
based . . O
on . . O
the . . O
short . . O
- . . O
term . . O
placebo . . O
- . . O
controlled . . O
pre . . O
- . . O
marketing . . O
trials . . O
for . . O
schizophrenia . . O
( . . O
a . . O
pool . . O
of . . O
three . . O
6 . . O
- . . O
week . . O
fixed . . O
- . . O
dose . . O
trials . . O
and . . O
one . . O
6 . . O
- . . O
week . . O
flexible . . O
- . . O
dose . . O
trial . . O
) . . O
in . . O
which . . O
sublingual . . O
saphris . . O
was . . O
administered . . O
in . . O
doses . . O
ranging . . O
from . . O
5 . . O
to . . O
10 . . O
mg . . O
twice . . O
daily . . O
. . . O

* . . O
currently . . O
have . . O
or . . O
have . . O
had . . O
liver . . O
problems . . O
* . . O
have . . O
been . . O
diagnosed . . O
with . . O
a . . O
bleeding . . O
disorder . . O
* . . O
think . . O
you . . O
may . . O
be . . O
pregnant . . O
. . . O

( . . O
5.3 . . O
) . . O

potiga . . O
causes . . O
skin . . O
, . . O
scleral . . O
, . . O
nail . . O
, . . O
and . . O
mucous . . B-AdverseReaction
membrane . . I-AdverseReaction
discoloration . . I-AdverseReaction
and . . O
it . . O
is . . O
not . . O
clear . . O
whether . . O
this . . O
discoloration . . B-AdverseReaction
is . . O
related . . O
to . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

because . . O
most . . O
trials . . O
included . . O
in . . O
the . . O
analysis . . O
did . . O
not . . O
extend . . O
beyond . . O
24 . . O
weeks . . O
, . . O
the . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
beyond . . O
24 . . O
weeks . . O
could . . O
not . . O
be . . O
assessed . . O
. . . O

* . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

the . . O
safety . . O
of . . O
saphris . . O
was . . O
evaluated . . O
in . . O
403 . . O
pediatric . . O
patients . . O
with . . O
bipolar . . O
i . . O
disorder . . O
who . . O
participated . . O
in . . O
a . . O
3 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
double . . O
- . . O
blind . . O
trial . . O
, . . O
of . . O
whom . . O
302 . . O
patients . . O
received . . O
saphris . . O
at . . O
fixed . . O
doses . . O
ranging . . O
from . . O
2.5 . . O
mg . . O
to . . O
10 . . O
mg . . O
twice . . O
daily . . O
. . . O

in . . O
pooled . . O
analysis . . O
from . . O
clinical . . O
studies . . O
including . . O
longer . . O
term . . O
trials . . O
, . . O
in . . O
3210 . . O
adults . . O
treated . . O
with . . O
iloperidone . . O
, . . O
gynecomastia . . B-AdverseReaction
was . . O
reported . . O
in . . O
2 . . O
male . . O
subjects . . O
( . . O
0.1% . . O
) . . O
compared . . O
to . . O
0% . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
and . . O
galactorrhea . . B-AdverseReaction
was . . O
reported . . O
in . . O
8 . . O
female . . O
subjects . . O
( . . O
0.2% . . O
) . . O
compared . . O
to . . O
3 . . O
female . . O
subjects . . O
( . . O
0.5% . . O
) . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

tanzeum . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
a . . O
personal . . O
or . . O
family . . O
history . . O
of . . O
mtc . . O
or . . O
in . . O
patients . . O
with . . O
men . . O
2 . . O
. . . O

the . . O
arcapta . . O
neohaler . . O
safety . . O
database . . O
reflects . . O
exposure . . O
of . . O
2516 . . O
patients . . O
to . . O
arcapta . . O
neohaler . . O
at . . O
doses . . O
of . . O
75 . . O
mcg . . O
or . . O
greater . . O
for . . O
at . . O
least . . O
12 . . O
weeks . . O
in . . O
six . . O
confirmatory . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
and . . O
active . . O
- . . O
controlled . . O
clinical . . O
trials . . O
( . . O
see . . O
section . . O
14 . . O
) . . O
. . . O

at . . O
three . . O
years . . O
after . . O
transplantation . . O
, . . O
the . . O
total . . O
cholesterol . . O
, . . O
hdl . . O
, . . O
ldl . . O
, . . O
and . . O
triglycerides . . O
were . . O
176 . . O
mg . . O
/ . . O
dl . . O
, . . O
49 . . O
mg . . O
/ . . O
dl . . O
, . . O
100 . . O
mg . . O
/ . . O
dl . . O
, . . O
and . . O
141 . . O
mg . . O
/ . . O
dl . . O
, . . O
respectively . . O
, . . O
in . . O
nulojix . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
193 . . O
mg . . O
/ . . O
dl . . O
, . . O
48 . . O
mg . . O
/ . . O
dl . . O
, . . O
106 . . O
mg . . O
/ . . O
dl . . O
, . . O
and . . O
180 . . O
mg . . O
/ . . O
dl . . O
in . . O
cyclosporine . . O
- . . O
treated . . O
patients . . O
. . . O

jardiance . . O
was . . O
used . . O
as . . O
monotherapy . . O
in . . O
one . . O
trial . . O
and . . O
as . . O
add . . O
- . . O
on . . O
therapy . . O
in . . O
four . . O
trials . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

the . . O
demographic . . O
and . . O
baseline . . O
characteristics . . O
of . . O
the . . O
long . . O
term . . O
safety . . O
trials . . O
were . . O
similar . . O
to . . O
those . . O
of . . O
the . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
physical . . O
and . . O
psychological . . B-AdverseReaction
dependence . . I-AdverseReaction
: . . O
monitor . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
substance . . O
abuse . . O
for . . O
signs . . O
of . . O
habituation . . O
and . . O
dependence . . O
( . . O
5.5 . . O
, . . O
9 . . O
) . . O
* . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
and . . O
ideation . . O
: . . O
monitor . . O
for . . O
suicidal . . O
thoughts . . O
or . . O
behaviors . . O
( . . O
5.6 . . O
) . . O

* . . O
if . . O
you . . O
have . . O
high . . O
blood . . O
pressure . . O
, . . O
high . . O
cholesterol . . O
( . . O
fat . . O
in . . O
the . . O
blood . . O
) . . O
, . . O
diabetes . . O
, . . O
are . . O
overweight . . O
, . . O
or . . O
if . . O
you . . O
use . . O
tobacco . . O
, . . O
you . . O
may . . O
have . . O
higher . . O
chances . . O
of . . O
getting . . O
heart . . O
disease . . O
. . . O

consider . . O
the . . O
risks . . O
and . . O
benefits . . O
of . . O
treatment . . O
with . . O
simponi . . O
aria . . O
prior . . O
to . . O
initiating . . O
therapy . . O
in . . O
patients . . O
with . . O
chronic . . O
or . . O
recurrent . . O
infection . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
who . . O
discontinued . . O
treatment . . O
due . . O
to . . O
any . . O
adverse . . O
reaction . . O
during . . O
the . . O
controlled . . O
clinical . . O
trials . . O
was . . O
6.2% . . O
for . . O
patients . . O
receiving . . O
benlysta . . O
and . . O
7.1% . . O
for . . O
patients . . O
receiving . . O
placebo . . O
. . . O

when . . O
dermatitis . . O
is . . O
controlled . . O
, . . O
corticosteroid . . O
tapering . . O
should . . O
occur . . O
over . . O
a . . O
period . . O
of . . O
at . . O
least . . O
1 . . O
month . . O
. . . O

because . . O
all . . O
patients . . O
developed . . O
anti . . O
- . . O
drug . . O
antibodies . . O
, . . O
associations . . O
between . . O
antibody . . O
titers . . O
and . . O
reductions . . O
in . . O
treatment . . O
effect . . O
or . . O
the . . O
occurrence . . O
of . . O
anaphylaxis . . O
or . . O
other . . O
hypersensitivity . . O
reactions . . O
could . . O
not . . O
be . . O
determined . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
glaxosmithkline . . O
at . . O
1-888-825-5249 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

discontinue . . O
immediately . . O
. . . O

although . . O
the . . O
majority . . O
of . . O
these . . O
events . . O
were . . O
observed . . O
in . . O
the . . O
setting . . O
of . . O
crs . . B-AdverseReaction
, . . O
some . . O
were . . O
observed . . O
outside . . O
of . . O
this . . O
setting . . O
. . . O

* . . O
neutropenic . . B-AdverseReaction
deaths . . B-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

ninety . . O
- . . O
two . . O
percent . . O
( . . O
92% . . O
) . . O
of . . O
patients . . O
on . . O
the . . O
cometriq . . O
arm . . O
had . . O
a . . O
prior . . O
thyroidectomy . . O
, . . O
and . . O
89% . . O
were . . O
taking . . O
thyroid . . O
hormone . . O
replacement . . O
prior . . O
to . . O
the . . O
first . . O
dose . . O
. . . O

6.1 . . O
clinical . . O
studies . . O
experience . . O
in . . O
patients . . O
with . . O
dupuytren's . . O
contracture . . O

in . . O
phase . . O
2 . . O
and . . O
3 . . O
clinical . . O
studies . . O
the . . O
following . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
subjects . . O
and . . O
in . . O
more . . O
than . . O
one . . O
subject . . O
treated . . O
with . . O
doses . . O
ranging . . O
from . . O
40 . . O
mg . . O
to . . O
240 . . O
mg . . O
of . . O
uloric . . O
. . . O

5.2 . . O
cataracts . . O

the . . O
rates . . O
of . . O
adverse . . O
reactions . . O
leading . . O
to . . O
treatment . . O
discontinuation . . O
were . . O
21% . . O
for . . O
pradaxa . . O
150 . . O
mg . . O
and . . O
16% . . O
for . . O
warfarin . . O
. . . O

* . . O
angle . . B-AdverseReaction
closure . . I-AdverseReaction
glaucoma . . I-AdverseReaction
: . . O
angle . . B-AdverseReaction
closure . . I-AdverseReaction
glaucoma . . I-AdverseReaction
has . . O
occurred . . O
in . . O
patients . . O
with . . O
untreated . . O
anatomically . . O
narrow . . O
angles . . O
treated . . O
with . . O
antidepressants . . B-DrugClass
. . . O

( . . O
5.4 . . O
) . . O
* . . O
* . . O
hyperglycemia . . B-AdverseReaction
and . . O
diabetes . . B-AdverseReaction
mellitus . . I-AdverseReaction
: . . O
monitor . . O
patients . . O
for . . O
symptoms . . O
of . . O
hyperglycemia . . O
including . . O
polydipsia . . O
, . . O
polyuria . . O
, . . O
polyphagia . . O
, . . O
and . . O
weakness . . O
. . . O

discard . . O
unused . . O
portion . . O
12 . . O
hours . . O
after . . O
stopper . . O
puncture . . O
. . . O

to . . O
patients . . O
with . . O
known . . O
clinical . . O
hypersensitivity . . O
to . . O
kalbitor . . O
. . . O

table . . O
5 . . O
. . . O

jevtana . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
severe . . O
hypersensitivity . . O
reactions . . O
to . . O
cabazitaxel . . O
or . . O
to . . O
other . . O
drugs . . O
formulated . . O
with . . O
polysorbate . . O
80 . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

( . . O
boxed . . O
warning . . O
, . . O
4 . . O
, . . O
5.1 . . O
, . . O
5.6 . . O
) . . O
* . . O
other . . O
malignancies . . B-AdverseReaction
: . . O
increased . . O
risk . . O
with . . O
all . . O
immunosuppressants . . B-DrugClass
; . . O
appears . . O
related . . O
to . . O
intensity . . O
and . . O
duration . . O
of . . O
use . . O
. . . O

for . . O
patients . . O
at . . O
risk . . O
for . . O
chronically . . O
reduced . . O
renal . . O
function . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
age . . O
> . . O
60 . . O
years . . O
, . . O
diabetes . . O
mellitus . . O
or . . O
chronic . . O
hypertension . . O
) . . O
, . . O
estimate . . O
the . . O
gfr . . O
through . . O
laboratory . . O
testing . . O
. . . O

reversible . . B-AdverseReaction
posterior . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
rpls . . B-AdverseReaction
) . . O
, . . O
a . . O
syndrome . . O
of . . O
subcortical . . B-AdverseReaction
vasogenic . . I-AdverseReaction
edema . . I-AdverseReaction
diagnosed . . O
by . . O
characteristic . . O
finding . . O
on . . O
mri . . O
, . . O
occurred . . O
in . . O
one . . O
( . . O
< . . O
1% . . O
) . . O
patient . . O
. . . O

spinal . . O
or . . O
cervical . . O
cord . . O
compression . . O
( . . O
scc . . O
) . . O
is . . O
a . . O
known . . O
and . . O
serious . . O
complication . . O
of . . O
mps . . O
iva . . O
and . . O
may . . O
occur . . O
as . . O
part . . O
of . . O
the . . O
natural . . O
history . . O
of . . O
the . . O
disease . . O
. . . O

a . . O
theoretical . . O
risk . . B-Factor
for . . O
transmission . . O
of . . O
creutzfeldt . . B-AdverseReaction
- . . I-AdverseReaction
jakob . . I-AdverseReaction
disease . . I-AdverseReaction
( . . O
cjd . . B-AdverseReaction
) . . O
is . . O
also . . O
considered . . O
extremely . . O
remote . . O
. . . O

5.3 . . O
development . . O
of . . O
drug . . O
- . . O
resistant . . O
bacteria . . O

4includes . . O
the . . O
preferred . . O
terms . . O
fatigue . . B-AdverseReaction
and . . O
lethargy . . B-AdverseReaction
. . . O

( . . O
5.9 . . O
) . . O
* . . O
seizures . . B-AdverseReaction
: . . O
use . . O
cautiously . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
seizures . . O
or . . O
with . . O
conditions . . O
that . . O
lower . . O
the . . O
seizure . . O
threshold . . O
. . . O

endometrial . . O
cancer . . O

5.2 . . O
hepatotoxicity . . O

in . . O
study . . O
1 . . O
and . . O
study . . O
2 . . O
, . . O
nulojix . . O
was . . O
studied . . O
at . . O
the . . O
recommended . . O
dose . . O
and . . O
frequency . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
in . . O
a . . O
total . . O
of . . O
401 . . O
patients . . O
compared . . O
to . . O
a . . O
cyclosporine . . O
control . . O
regimen . . O
in . . O
a . . O
total . . O
of . . O
405 . . O
patients . . O
. . . O

because . . O
clinical . . O
studies . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

risk . . O
factors . . O
for . . O
pml . . O
include . . O
treatment . . O
with . . O
immunosuppressant . . O
therapies . . O
and . . O
impairment . . O
of . . O
immune . . O
function . . O
. . . O

other . . O
accompanying . . O
reactions . . O
included . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
/ . . O
pain . . O
, . . O
wheezing . . B-AdverseReaction
, . . O
tachypnea . . B-AdverseReaction
, . . O
cyanosis . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
oxygen . . I-AdverseReaction
saturation . . I-AdverseReaction
, . . O
convulsions . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
/ . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
, . . O
flushing . . B-AdverseReaction
/ . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
pallor . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
coldness . . I-AdverseReaction
, . . O
restlessness . . B-AdverseReaction
, . . O
nervousness . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
paresthesia . . B-AdverseReaction
. . . O

in . . O
addition . . O
to . . O
the . . O
examination . . O
of . . O
the . . O
fundus . . O
including . . O
the . . O
macula . . O
prior . . O
to . . O
treatment . . O
and . . O
at . . O
3-4 . . O
months . . O
after . . O
starting . . O
treatment . . O
, . . O
ms . . O
patients . . O
with . . O
diabetes . . O
mellitus . . O
or . . O
a . . O
history . . O
of . . O
uveitis . . O
should . . O
have . . O
regular . . O
follow . . O
- . . O
up . . O
examinations . . O
. . . O

physicians . . O
should . . O
be . . O
attentive . . O
to . . O
symptoms . . O
of . . O
infection . . O
or . . O
worsening . . O
of . . O
sjia . . O
, . . O
as . . O
these . . O
are . . O
known . . O
triggers . . O
for . . O
mas . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behaviors . . O
: . . O
horizant . . O
is . . O
a . . O
prodrug . . O
of . . O
gabapentin . . O
, . . O
an . . O
antiepileptic . . O
drug . . O
( . . O
aed . . O
) . . O
. . . O

consider . . O
whether . . O
to . . O
restart . . O
kyprolis . . O
based . . O
on . . O
a . . O
benefit . . O
/ . . O
risk . . O
assessment . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

if . . O
neurological . . O
compromise . . O
is . . O
noted . . O
, . . O
urgent . . O
treatment . . O
is . . O
necessary . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

the . . O
mean . . O
age . . O
of . . O
the . . O
population . . O
was . . O
60 . . O
years . . O
and . . O
5% . . O
were . . O
older . . O
than . . O
75 . . O
years . . O
of . . O
age . . O
. . . O

healthcare . . O
providers . . O
should . . O
be . . O
aware . . O
of . . O
the . . O
risk . . O
of . . O
hypersensitivity . . O
reactions . . O
, . . O
which . . O
may . . O
present . . O
as . . O
infusion . . O
reactions . . O
, . . O
and . . O
monitor . . O
patients . . O
closely . . O
. . . O

patients . . O
should . . O
be . . O
cautioned . . O
about . . O
the . . O
risk . . O
of . . O
bleeding . . O
associated . . O
with . . O
the . . O
concomitant . . O
use . . O
of . . O
pristiq . . O
and . . O
nsaids . . O
, . . O
aspirin . . O
, . . O
or . . O
other . . O
drugs . . O
that . . O
affect . . O
coagulation . . O
or . . O
bleeding . . O
. . . O

6.3 . . O
postmarketing . . O
experience . . O

apprise . . O
women . . O
of . . O
reproductive . . O
potential . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
a . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

if . . O
appropriate . . O
, . . O
initiation . . O
of . . O
anti . . O
- . . O
hepatitis . . O
b . . O
therapy . . O
may . . O
be . . O
warranted . . O
. . . O

in . . O
patients . . O
treated . . O
with . . O
glp . . B-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
receptor . . I-DrugClass
agonists . . I-DrugClass
, . . O
there . . O
have . . O
been . . O
postmarketing . . O
reports . . O
of . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
and . . O
worsening . . O
of . . O
chronic . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
which . . O
may . . O
sometimes . . O
require . . O
hemodialysis . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
novartis . . O
pharmaceuticals . . O
corporation . . O
at . . O
1-888-669-6682 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

these . . O
adverse . . O
reactions . . O
are . . O
: . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
paradoxical . . B-AdverseReaction
bronchospasm . . I-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
/ . . O
heart . . B-AdverseReaction
rate . . I-AdverseReaction
increase . . I-AdverseReaction
/ . . O
palpitations . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
/ . . O
rash . . B-AdverseReaction
and . . O
dizziness . . B-AdverseReaction
. . . O

increases . . B-AdverseReaction
in . . I-AdverseReaction
ldl . . I-AdverseReaction
- . . I-AdverseReaction
c . . I-AdverseReaction
can . . B-Factor
occur . . O
with . . O
jardiance . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
* . . O
acute . . B-AdverseReaction
pancreatitis . . I-AdverseReaction
: . . O
there . . O
have . . O
been . . O
postmarketing . . O
reports . . O
of . . O
acute . . B-AdverseReaction
pancreatitis . . I-AdverseReaction
. . . O

hepatobiliary . . O
disorders . . O
: . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
hepatomegaly . . B-AdverseReaction
, . . O
cytolytic . . B-AdverseReaction
hepatitis . . I-AdverseReaction
, . . O
hepatic . . B-AdverseReaction
steatosis . . I-AdverseReaction
, . . O
hepatitis . . B-AdverseReaction

patients . . O
treated . . O
with . . O
teflaro . . O
were . . O
predominantly . . O
male . . O
( . . O
63% . . O
) . . O
and . . O
caucasian . . O
( . . O
82% . . O
) . . O
. . . O

data . . O
are . . O
not . . O
available . . O
to . . O
determine . . O
whether . . O
the . . O
rate . . O
of . . O
death . . O
in . . O
patients . . O
with . . O
copd . . O
is . . O
increased . . O
by . . O
long . . O
- . . O
acting . . O
beta . . O
2 . . O
- . . O
adrenergic . . O
agonists . . O
. . . O

in . . O
clinical . . O
trial . . O
and . . O
postmarketing . . O
experience . . O
, . . O
leukopenia . . B-AdverseReaction
and . . O
neutropenia . . B-AdverseReaction
have . . O
been . . O
reported . . O
temporally . . O
related . . O
to . . O
antipsychotic . . O
agents . . O
, . . O
including . . O
saphris . . O
. . . O

as . . O
with . . O
any . . O
injectable . . O
drug . . O
product . . O
, . . O
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
anaphylaxis . . B-AdverseReaction
may . . B-Factor
occur . . O
. . . O

after . . O
an . . O
average . . O
follow . . O
- . . O
up . . O
of . . O
5.2 . . O
years . . O
, . . O
28 . . O
women . . O
in . . O
the . . O
estrogen . . B-DrugClass
- . . O
alone . . O
group . . O
and . . O
19 . . O
women . . O
in . . O
the . . O
placebo . . O
group . . O
were . . O
diagnosed . . O
with . . O
probable . . O
dementia . . B-AdverseReaction
. . . O

monitor . . O
patients . . O

consideration . . O
should . . O
be . . O
given . . O
to . . O
changing . . O
the . . O
therapeutic . . O
regimen . . O
, . . O
including . . O
possibly . . O
discontinuing . . O
the . . O
medication . . O
, . . O
in . . O
patients . . O
whose . . O
depression . . O
is . . O
persistently . . O
worse . . O
, . . O
or . . O
who . . O
are . . O
experiencing . . O
emergent . . O
suicidality . . O
or . . O
symptoms . . O
that . . O
might . . O
be . . O
precursors . . O
to . . O
worsening . . O
depression . . O
or . . O
suicidality . . O
, . . O
especially . . O
if . . O
these . . O
symptoms . . O
are . . O
severe . . O
, . . O
abrupt . . O
in . . O
onset . . O
, . . O
or . . O
were . . O
not . . O
part . . O
of . . O
the . . O
patient's . . O
presenting . . O
symptoms . . O
. . . O

a . . O
total . . O
of . . O
201 . . O
sjia . . O
patients . . O
aged . . O
2 . . O
to . . O
less . . O
than . . O
20 . . O
years . . O
have . . O
received . . O
ilaris . . O
in . . O
clinical . . O
trials . . O
. . . O

dampa . . O
( . . O
4 . . O
- . . O
deoxy . . O
- . . O
4 . . O
- . . O
amino . . O
- . . O
n . . O
10 . . O
- . . O
methylpteroic . . O
acid . . O
) . . O
is . . O
an . . O
inactive . . O
metabolite . . O
of . . O
methotrexate . . O
resulting . . O
from . . O
treatment . . O
with . . O
voraxaze . . O
. . . O

any . . O
patient . . O
treated . . O
with . . O
atypical . . O
antipsychotics . . O
should . . O
be . . O
monitored . . O
for . . O
symptoms . . O
of . . O
hyperglycemia . . O
including . . O
polydipsia . . O
, . . O
polyuria . . O
, . . O
polyphagia . . O
, . . O
and . . O
weakness . . O
. . . O

table . . O
1 . . O
. . . O

the . . O
numbers . . O
of . . O
patients . . O
and . . O
their . . O
exposures . . O
are . . O
described . . O
in . . O
table . . O
1 . . O
. . . O

should . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
emerge . . O
during . . O
treatment . . O
, . . O
the . . O
prescriber . . O
needs . . O
to . . O
consider . . O
whether . . O
the . . O
emergence . . O
of . . O
these . . O
symptoms . . O
in . . O
any . . O
given . . O
patient . . O
may . . O
be . . O
related . . O
to . . O
the . . O
illness . . O
being . . O
treated . . O
. . . O

consider . . O
discontinuing . . O
use . . O
if . . O
severe . . O
symptoms . . O
develop . . O
[ . . O
see . . O
patient . . O
counseling . . O
information . . O
( . . O
17.8 . . O
) . . O
] . . O
. . . O

* . . O
mortality . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
serious . . B-Severity
infections . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
malignancy . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
depression . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
excerpt . . O
: . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
in . . O
clinical . . O
trials . . O
were . . O
: . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
, . . O
depression . . B-AdverseReaction
, . . O
migraine . . B-AdverseReaction
, . . O
and . . O
pharyngitis . . B-AdverseReaction
. . . O

in . . O
the . . O
dupuytren's . . O
contracture . . O
clinical . . O
studies . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
, . . O
at . . O
30 . . O
days . . O
post . . O
the . . O
first . . O
injection . . O
of . . O
xiaflex . . O
0.58 . . O
mg . . O
, . . O
92% . . O
of . . O
patients . . O
had . . O
antibodies . . O
against . . O
aux . . O
- . . O
i . . O
detected . . O
and . . O
86% . . O
of . . O
patients . . O
had . . O
antibodies . . O
against . . O
aux . . O
- . . O
ii . . O
detected . . O
. . . O

the . . O
majority . . O
of . . O
these . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
initially . . O
manifested . . O
during . . O
treatment . . O
; . . O
however . . O
, . . O
a . . O
minority . . O
occurred . . O
weeks . . O
to . . O
months . . O
after . . O
discontinuation . . O
of . . O
yervoy . . O
. . . O

5.7 . . O
risk . . O
of . . O
ptosis . . O
in . . O
patients . . O
treated . . O
with . . O
xeomin . . O
for . . O
glabellar . . O
lines . . O

the . . O
median . . O
duration . . O
of . . O
exposure . . O
to . . O
zykadia . . O
was . . O
6 . . O
months . . O
. . . O

( . . O
6 . . O
) . . O

by . . O
week . . O
24 . . O
, . . O
hematocrit . . B-AdverseReaction
values . . I-AdverseReaction
> . . I-AdverseReaction
55% . . I-AdverseReaction
were . . O
reported . . O
in . . O
0.4% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
and . . O
1.3% . . O
of . . O
farxiga . . O
10 . . O
mg . . O
- . . O
treated . . O
patients . . O
. . . O

there . . O
are . . O
no . . O
adequate . . O
and . . O
well . . O
- . . O
controlled . . O
studies . . O
in . . O
pregnant . . O
women . . O
using . . O
kyprolis . . O
. . . O

psychiatric . . O
disorders . . O
: . . O
insomnia . . B-AdverseReaction
( . . O
9% . . O
) . . O

in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
with . . O
risperidone . . O
, . . O
aripiprazole . . O
, . . O
and . . O
olanzapine . . O
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
, . . O
there . . O
was . . O
a . . O
higher . . O
incidence . . O
of . . O
cerebrovascular . . B-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
cerebrovascular . . B-AdverseReaction
accidents . . I-AdverseReaction
and . . O
transient . . B-AdverseReaction
ischemic . . I-AdverseReaction
attacks . . I-AdverseReaction
) . . O
including . . O
fatalities . . B-AdverseReaction
compared . . O
to . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

monotherapy . . O
in . . O
adult . . O
patients . . O
with . . O
bipolar . . O
mania . . O
: . . O
the . . O
following . . O
findings . . O
are . . O
based . . O
on . . O
the . . O
short . . O
- . . O
term . . O
placebo . . O
- . . O
controlled . . O
trials . . O
for . . O
bipolar . . O
mania . . O
( . . O
a . . O
pool . . O
of . . O
two . . O
3 . . O
- . . O
week . . O
flexible . . O
- . . O
dose . . O
trials . . O
) . . O
in . . O
which . . O
sublingual . . O
saphris . . O
was . . O
administered . . O
in . . O
doses . . O
of . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
. . . O

5.4 . . O
tardive . . O
dyskinesia . . O

psoriatic . . O
arthritis . . O
: . . O
during . . O
the . . O
0 . . O
to . . O
16 . . O
week . . O
placebo . . O
- . . O
controlled . . O
period . . O
of . . O
the . . O
3 . . O
controlled . . O
clinical . . O
trials . . O
, . . O
1.0% . . O
( . . O
10 . . O
/ . . O
998 . . O
) . . O
of . . O
subjects . . O
treated . . O
with . . O
otezla . . O
reported . . O
depression . . B-AdverseReaction
or . . O
depressed . . B-AdverseReaction
mood . . I-AdverseReaction
compared . . O
to . . O
0.8% . . O
( . . O
4 . . O
/ . . O
495 . . O
) . . O
treated . . O
with . . O
placebo . . O
. . . O

5.7 . . O
immunization . . O

many . . O
commonly . . O
used . . O
cardiovascular . . O
, . . O
pulmonary . . O
, . . O
and . . O
neuropsychiatric . . O
medications . . O
interfere . . O
with . . O
adreview . . O
imaging . . O
( . . O
see . . O
above . . O
) . . O
. . . O

across . . O
clinical . . O
trials . . O
of . . O
tafinlar . . O
administered . . O
in . . O
combination . . O
with . . O
trametinib . . O
( . . O
n . . O
= . . O
202 . . O
) . . O
, . . O
the . . O
incidence . . O
of . . O
pyrexia . . B-AdverseReaction
was . . O
57% . . O
( . . O
116 . . O
/ . . O
202 . . O
) . . O
. . . O

the . . O
risk . . O
of . . O
seizures . . O
in . . O
patients . . O
with . . O
epileptiform . . O
activity . . O
on . . O
an . . O
eeg . . O
is . . O
unknown . . O
, . . O
and . . O
could . . O
be . . O
substantially . . O
higher . . O
than . . O
that . . O
observed . . O
in . . O
ampyra . . O
clinical . . O
studies . . O
. . . O

twenty . . O
- . . O
nine . . O
patients . . O
( . . O
85% . . O
) . . O
with . . O
grade . . B-Severity
3-5 . . I-Severity
enterocolitis . . B-AdverseReaction
were . . O
treated . . O
with . . O
high . . O
- . . O
dose . . O
( . . O
> . . O
= . . O
40 . . O
mg . . O
prednisone . . O
equivalent . . O
per . . O
day . . O
) . . O
corticosteroids . . O
, . . O
with . . O
a . . O
median . . O
dose . . O
of . . O
80 . . O
mg . . O
/ . . O
day . . O
of . . O
prednisone . . O
or . . O
equivalent . . O
; . . O
the . . O
median . . O
duration . . O
of . . O
treatment . . O
was . . O
2.3 . . O
weeks . . O
( . . O
ranging . . O
up . . O
to . . O
13.9 . . O
weeks . . O
) . . O
followed . . O
by . . O
corticosteroid . . O
taper . . O
. . . O

subjects . . O
received . . O
1 . . O
inhalation . . O
once . . O
daily . . O
of . . O
the . . O
following . . O
: . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
, . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
, . . O
fluticasone . . O
furoate . . O
/ . . O
vilanterol . . O
50 . . O
mcg . . O
/ . . O
25 . . O
mcg . . O
, . . O
fluticasone . . O
furoate . . O
100 . . O
mcg . . O
, . . O
fluticasone . . O
furoate . . O
200 . . O
mcg . . O
, . . O
vilanterol . . O
25 . . O
mcg . . O
, . . O
or . . O
placebo . . O
. . . O

two . . O
multicenter . . O
, . . O
open . . O
- . . O
label . . O
clinical . . O
trials . . O
were . . O
conducted . . O
in . . O
39 . . O
infantile . . O
- . . O
onset . . O
pompe . . O
disease . . O
patients . . O
, . . O
ages . . O
1 . . O
month . . O
to . . O
3.5 . . O
years . . O
old . . O
. . . O

a . . O
total . . O
of . . O
108 . . O
subjects . . O
treated . . O
with . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
on . . O
the . . O
face . . O
/ . . O
scalp . . O
and . . O
38 . . O
subjects . . O
treated . . O
on . . O
the . . O
trunk . . O
/ . . O
extremities . . O
were . . O
followed . . O
for . . O
12 . . O
months . . O
. . . O

5.4 . . O
controlled . . O
narrow . . O
- . . O
angle . . O
glaucoma . . O

severe . . O
hypoglycemia . . O
was . . O
defined . . O
as . . O
an . . O
event . . O
consistent . . O
with . . O
hypoglycemia . . O
where . . O
the . . O
patient . . O
required . . O
the . . O
assistance . . O
of . . O
another . . O
person . . O
to . . O
recover . . O
, . . O
lost . . O
consciousness . . O
, . . O
or . . O
experienced . . O
a . . O
seizure . . O
( . . O
regardless . . O
of . . O
whether . . O
biochemical . . O
documentation . . O
of . . O
a . . O
low . . O
glucose . . O
value . . O
was . . O
obtained . . O
) . . O
. . . O

( . . O
6 . . O
) . . O

other . . O
adverse . . O
reactions . . O
indicative . . O
of . . O
hypersensitivity . . B-AdverseReaction
reactions . . O
included . . O
the . . O
following . . O
: . . O
pruritus . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
rash . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
and . . O
urticaria . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

monitor . . O
with . . O
liver . . O
function . . O
tests . . O
including . . O
alt . . O
and . . O
total . . O
bilirubin . . O
every . . O
2 . . O
weeks . . O
during . . O
the . . O
first . . O
2 . . O
months . . O
of . . O
treatment . . O
, . . O
then . . O
once . . O
a . . O
month . . O
and . . O
as . . O
clinically . . O
indicated . . O
, . . O
with . . O
more . . O
frequent . . O
repeat . . O
testing . . O
for . . O
increased . . O
liver . . O
transaminases . . O
, . . O
alkaline . . O
phosphatase . . O
, . . O
or . . O
total . . O
bilirubin . . O
in . . O
patients . . O
who . . O
develop . . O
transaminase . . O
elevations . . O
. . . O

pristiq . . O
should . . O
be . . O
prescribed . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
a . . O
seizure . . O
disorder . . O
. . . O

5.9 . . O
vaccinations . . O
/ . . O
therapeutic . . O
infectious . . O
agents . . O

the . . O
most . . O
common . . O
adverse . . O
drug . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
reported . . O
in . . O
the . . O
two . . O
randomized . . O
clinical . . O
trials . . O
that . . O
occurred . . O
more . . O
commonly . . O
( . . O
> . . O
2% . . O
) . . O
in . . O
the . . O
abiraterone . . O
acetate . . O
arm . . O
were . . O
fatigue . . B-AdverseReaction
, . . O
joint . . B-AdverseReaction
swelling . . I-AdverseReaction
or . . O
discomfort . . O
, . . O
edema . . B-AdverseReaction
, . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
and . . O
contusion . . B-AdverseReaction
. . . O

( . . O
5.4 . . O
) . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
other . . O
drugs . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

alt . . B-AdverseReaction
elevations . . I-AdverseReaction
were . . O
reversible . . O
in . . O
all . . O
subjects . . O
. . . O

5.2 . . O
spread . . O
of . . O
toxin . . O
effect . . O

death . . B-AdverseReaction
due . . O
to . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
has . . O
occurred . . O
within . . O
a . . O
day . . O
of . . O
kyprolis . . O
administration . . O
. . . O

( . . O
2.3 . . O
) . . O
, . . O
( . . O
5.1 . . O
) . . O
* . . O
neurological . . O
toxicities . . O
, . . O
which . . O
may . . B-Factor
be . . O
severe . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
or . . O
fatal . . B-AdverseReaction
, . . O
occurred . . O
in . . O
patients . . O
receiving . . O
blincyto . . O
. . . O

excerpt . . O
: . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
anaphylaxis . . B-AdverseReaction
: . . O
anaphylaxis . . B-AdverseReaction
has . . O
occurred . . O
in . . O
4% . . O
of . . O
treated . . O
patients . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

* . . O
blood . . O
and . . O
lymphatic . . O
disorders . . O
: . . O
infrequent . . O
: . . O
anemia . . B-AdverseReaction
; . . O
rare . . O
: . . O
thrombocytopenia . . B-AdverseReaction
* . . O
cardiac . . O
disorders . . O
: . . O
infrequent . . O
: . . O
temporary . . B-AdverseReaction
bundle . . I-AdverseReaction
branch . . I-AdverseReaction
block . . I-AdverseReaction
* . . O
eye . . O
disorders . . O
: . . O
infrequent . . O
: . . O
accommodation . . B-AdverseReaction
disorder . . I-AdverseReaction
* . . O
gastrointestinal . . O
disorders . . O
: . . O
infrequent . . O
: . . O
swollen . . B-AdverseReaction
tongue . . I-AdverseReaction
* . . O
general . . O
disorders . . O
: . . O
rare . . O
: . . O
idiosyncratic . . B-AdverseReaction
drug . . I-AdverseReaction
reaction . . I-AdverseReaction
* . . O
investigations . . O
: . . O
infrequent . . O
: . . O
hyponatremia . . B-AdverseReaction
* . . O
nervous . . O
system . . O
disorders . . O
: . . O
infrequent . . O
: . . O
dysarthria . . B-AdverseReaction
following . . O
is . . O
a . . O
list . . O
of . . O
meddra . . O
terms . . O
not . . O
already . . O
listed . . O
either . . O
for . . O
adults . . O
or . . O
pediatric . . O
patients . . O
in . . O
other . . O
parts . . O
of . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
, . . O
or . . O
those . . O
considered . . O
in . . O
contraindications . . O
( . . O
4 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5 . . O
) . . O
or . . O
overdosage . . O
( . . O
10 . . O
) . . O
that . . O
reflect . . O
adverse . . O
reactions . . O
reported . . O
by . . O
pediatric . . O
patients . . O
( . . O
ages . . O
10 . . O
to . . O
17 . . O
years . . O
) . . O
treated . . O
with . . O
sublingual . . O
saphris . . O
at . . O
doses . . O
of . . O
2.5 . . O
mg . . O
, . . O
5 . . O
mg . . O
, . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
during . . O
any . . O
phase . . O
of . . O
a . . O
trial . . O
within . . O
the . . O
database . . O
of . . O
pediatric . . O
patients . . O
. . . O

although . . O
some . . O
past . . O
studies . . O
have . . O
suggested . . O
that . . O
cocs . . O
might . . O
increase . . O
the . . O
incidence . . O
of . . O
breast . . B-AdverseReaction
cancer . . I-AdverseReaction
, . . O
more . . O
recent . . O
studies . . O
have . . O
not . . B-Negation
confirmed . . I-Negation
such . . O
findings . . O
. . . O

if . . O
anaphylaxis . . O
occurs . . O
, . . O
immediately . . O
discontinue . . O
the . . O
infusion . . O
( . . O
5.2 . . O
) . . O
. . . O

in . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
somnolence . . B-AdverseReaction
( . . O
including . . O
sedation . . B-AdverseReaction
) . . O
was . . O
reported . . O
in . . O
11.9% . . O
( . . O
104 . . O
/ . . O
874 . . O
) . . O
of . . O
adult . . O
patients . . O
treated . . O
with . . O
fanapt . . O
at . . O
doses . . O
of . . O
10 . . O
mg . . O
/ . . O
day . . O
or . . O
greater . . O
versus . . O
5.3% . . O
( . . O
31 . . O
/ . . O
587 . . O
) . . O
treated . . O
with . . O
placebo . . O
. . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
3% . . O
) . . O
are . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
flatulence . . B-AdverseReaction
and . . O
increased . . B-AdverseReaction
bilirubin . . I-AdverseReaction
. . . O

the . . O
mechanism . . O
and . . O
long . . O
- . . O
term . . O
consequences . . O
of . . O
these . . O
events . . O
are . . O
currently . . O
unknown . . O
. . . O

adverse . . O
reactions . . O
with . . O
gilenya . . O
0.5 . . O
mg . . O
in . . O
study . . O
2 . . O
, . . O
the . . O
1 . . O
- . . O
year . . O
active . . O
- . . O
controlled . . O
( . . O
versus . . O
interferon . . O
beta . . O
- . . O
1a . . O
) . . O
study . . O
were . . O
generally . . O
similar . . O
to . . O
those . . O
in . . O
studies . . O
1 . . O
and . . O
3 . . O
. . . O

idelalisib . . O
is . . O
teratogenic . . B-AdverseReaction
in . . O
rats . . B-Animal
, . . O
at . . O
systemic . . O
exposures . . O
12 . . O
times . . O
those . . O
reported . . O
in . . O
patients . . O
at . . O
the . . O
recommended . . O
dose . . O
of . . O
150 . . O
mg . . O
twice . . O
daily . . O
. . . O

initiation . . O
of . . O
stribild . . O
in . . O
patients . . O
with . . O
estimated . . O
creatinine . . O
clearance . . O
below . . O
70 . . O
ml . . O
per . . O
minute . . O
is . . O
not . . O
recommended . . O
. . . O

the . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
was . . O
generally . . O
consistent . . O
among . . O
drugs . . O
in . . O
the . . O
data . . O
analyzed . . O
. . . O

monitor . . O
patients . . O
with . . O
clinically . . O
significant . . O
neutropenia . . O
for . . O
fever . . O
or . . O
other . . O
symptoms . . O
or . . O
signs . . O
of . . O
infection . . O
and . . O
treat . . O
promptly . . O
if . . O
such . . O
symptoms . . O
or . . O
signs . . O
occur . . O
. . . O

fungal . . O
culture . . O
should . . O
be . . O
taken . . O
when . . O
appropriate . . O
. . . O

the . . O
incidence . . O
of . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
was . . O
similar . . O
to . . O
that . . O
reported . . O
with . . O
placebo . . O
. . . O

live . . O
vaccines . . O

these . . O
reactions . . O
were . . O
more . . O
likely . . O
to . . O
occur . . O
with . . O
higher . . O
infusion . . O
rates . . O
. . . O

pre . . O
- . . O
treatment . . O
with . . O
antihistamines . . O
with . . O
or . . O
without . . O
antipyretics . . O
is . . O
recommended . . O
prior . . O
to . . O
the . . O
start . . O
of . . O
infusion . . O
( . . O
5.1 . . O
) . . O
. . . O

mean . . O
change . . O
from . . O
baseline . . O
in . . O
fasted . . O
lipid . . O
values . . O
in . . O
treatment . . O
- . . O
naive . . O
subjects . . O
in . . O
spring . . O
- . . O
2 . . O
and . . O
single . . O
trials . . O
( . . O
week . . O
96 . . O
analysisa . . O
) . . O
laboratory . . O
parameter . . O
preferred . . O
term . . O
spring . . O
- . . O
2 . . O
single . . O
tivicay . . O
50 . . O
mg . . O
once . . O
daily . . O
+ . . O
2 . . O
nrtis . . O
( . . O
n . . O
= . . O
403 . . O
) . . O
raltegravir . . O
400 . . O
mg . . O
twice . . O
daily . . O
+ . . O
2 . . O
nrtis . . O
( . . O
n . . O
= . . O
405 . . O
) . . O
tivicay . . O
50 . . O
mg . . O
+ . . O
epzicom . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
414 . . O
) . . O
atripla . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
419 . . O
) . . O
cholesterol . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
8.1 . . O
10.1 . . O
23.2 . . O
28.0 . . O
hdl . . O
cholesterol . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
2.0 . . O
2.3 . . O
5.2 . . O
7.4 . . O
ldl . . O
cholesterol . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
5.1 . . O
6.1 . . O
14.5 . . O
18.0 . . O
triglycerides . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
6.7 . . O
6.6 . . O
17.2 . . O
17.4 . . O
a . . O
subjects . . O
on . . O
lipid . . O
- . . O
lowering . . O
agents . . O
at . . O
baseline . . O
were . . O
excluded . . O
from . . O
these . . O
analyses . . O
( . . O
19 . . O
subjects . . O
in . . O
each . . O
arm . . O
in . . O
spring . . O
- . . O
2 . . O
, . . O
and . . O
in . . O
single . . O
: . . O
tivicay . . O
n . . O
= . . O
30 . . O
and . . O
atripla . . O
n . . O
= . . O
27 . . O
) . . O
. . . O

the . . O
risks . . O
and . . O
benefits . . O
of . . O
re . . O
- . . O
administering . . O
alglucosidase . . O
alfa . . O
following . . O
an . . O
anaphylactic . . O
or . . O
hypersensitivity . . O
reaction . . O
should . . O
be . . O
considered . . O
. . . O

across . . O
clinical . . O
trials . . O
, . . O
bradycardia . . B-AdverseReaction
occurred . . O
in . . O
205 . . O
( . . O
12.3% . . O
) . . O
of . . O
1669 . . O
patients . . O
treated . . O
with . . O
xalkori . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

( . . O
5.13 . . O
) . . O
* . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
kyprolis . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

patients . . O
should . . O
be . . O
instructed . . O
to . . O
report . . O
any . . O
symptoms . . O
suggestive . . O
of . . O
endophthalmitis . . O
or . . O
retinal . . O
detachment . . O
without . . O
delay . . O
and . . O
should . . O
be . . O
managed . . O
appropriately . . O
. . . O

avoid . . O
the . . O
use . . O
of . . O
adcetris . . O
in . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
[ . . O
creatinine . . O
clearance . . O
( . . O
clcr . . O
) . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
] . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

some . . O
patients . . O
in . . O
the . . O
clinical . . O
studies . . O
or . . O
in . . O
the . . O
postmarketing . . O
setting . . O
have . . O
undergone . . O
testing . . O
for . . O
alglucosidase . . O
alfa . . O
- . . O
specific . . O
ige . . O
antibodies . . O
. . . O

warning . . O
: . . O
( . . O
a . . O
) . . O
premature . . O
discontinuation . . O
of . . O
pradaxa . . O
increases . . O
the . . O
risk . . O

( . . O
5.9 . . O
) . . O
* . . O
embryofetal . . B-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

5.5 . . O
pre . . O
- . . O
existing . . O
neuromuscular . . O
disorders . . O
and . . O
other . . O
special . . O
populations . . O

6.3 . . O
immunogenicity . . O
denosumab . . O
is . . O
a . . O
human . . O
monoclonal . . O
antibody . . O
. . . O

in . . O
the . . O
controlled . . O
clinical . . O
trials . . O
, . . O
the . . O
overall . . O
incidence . . O
of . . O
infections . . B-AdverseReaction
was . . O
71% . . O
in . . O
patients . . O
treated . . O
with . . O
benlysta . . O
compared . . O
with . . O
67% . . O
in . . O
patients . . O
who . . O
received . . O
placebo . . O
. . . O

( . . O
5.14 . . O
, . . O
8.1 . . O
) . . O

if . . O
immune . . O
- . . O
mediated . . O
reactions . . O
occur . . O
, . . O
consider . . O
discontinuation . . O
of . . O
the . . O
administration . . O
of . . O
alglucosidase . . O
alfa . . O
, . . O
and . . O
initiate . . O
appropriate . . O
medical . . O
treatment . . O
. . . O

at . . O
baseline . . O
, . . O
the . . O
population . . O
had . . O
diabetes . . O
for . . O
an . . O
average . . O
of . . O
6 . . O
years . . O
, . . O
had . . O
a . . O
mean . . O
hemoglobin . . O
a1c . . O
( . . O
hba1c . . O
) . . O
of . . O
8.3% . . O
, . . O
and . . O
21% . . O
had . . O
established . . O
microvascular . . O
complications . . O
of . . O
diabetes . . O
. . . O

. . . O
anaphylaxis . . B-AdverseReaction
and . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

bepreve . . O
should . . O
not . . O
be . . O
instilled . . O
while . . O
wearing . . O
contact . . O
lenses . . O
. . . O

evaluate . . O
if . . O
diarrhea . . O
occurs . . O
. . . O

without . . O
knowledge . . O
of . . O
the . . O
background . . O
incidence . . O
and . . O
recurrence . . O
in . . O
a . . O
similar . . O
population . . O
not . . O
treated . . O
with . . O
gabapentin . . O
, . . O
it . . O
is . . O
impossible . . O
to . . O
know . . O
whether . . O
the . . O
incidence . . O
reported . . O
in . . O
this . . O
cohort . . O
is . . O
or . . O
is . . O
not . . O
affected . . O
by . . O
treatment . . O
. . . O

excerpt . . O
: . . O
* . . O
avoid . . O
use . . O
in . . O
patients . . O
with . . O
known . . O
qt . . O
prolongation . . O
, . . O
those . . O
with . . O
hypokalemia . . O
or . . O
hypomagnesemia . . O
, . . O
and . . O
those . . O
taking . . O
other . . O
drugs . . O
that . . O
prolong . . O
the . . O
qt . . O
interval . . O
. . . O

saphris . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
. . . O

ild . . B-AdverseReaction
or . . O
ild . . B-AdverseReaction
- . . I-AdverseReaction
like . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
lung . . B-AdverseReaction
infiltration . . I-AdverseReaction
, . . O
pneumonitis . . B-AdverseReaction
, . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
or . . O
alveolitis . . B-AdverseReaction
allergic . . I-AdverseReaction
) . . O
occurred . . O
in . . O
1.5% . . O
of . . O
the . . O
3865 . . O
patients . . O
who . . O
received . . O
gilotrif . . O
across . . O
clinical . . O
trials . . O
; . . O
of . . O
these . . O
, . . O
0.4% . . O
were . . O
fatal . . B-AdverseReaction
. . . O

it . . O
is . . O
not . . O
known . . O
if . . O
duavee . . O
passes . . O
into . . O
your . . O
breast . . O
milk . . O
. . . O

excerpt . . O
: . . O
* . . O
dificid . . O
should . . O
not . . O
be . . O
used . . O
for . . O
systemic . . O
infections . . O
. . . O

fatal . . B-AdverseReaction
and . . O
non . . B-Severity
- . . I-Severity
fatal . . I-Severity
infections . . B-AdverseReaction
have . . O
occurred . . O
with . . O
imbruvica . . O
therapy . . O
. . . O

yervoy . . O
can . . B-Factor
result . . O
in . . O
severe . . B-Severity
and . . O
fatal . . B-AdverseReaction
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
due . . O
to . . O
t . . O
- . . O
cell . . O
activation . . O
and . . O
proliferation . . O
. . . O

in . . O
other . . O
women . . O
, . . O
symptoms . . O
can . . O
be . . O
more . . O
severe . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
hepatotoxicity . . B-AdverseReaction
: . . O
beleodaq . . O
may . . B-Factor
cause . . O
hepatic . . B-AdverseReaction
toxicity . . I-AdverseReaction
and . . O
liver . . B-AdverseReaction
function . . I-AdverseReaction
test . . I-AdverseReaction
abnormalities . . I-AdverseReaction
. . . O

percentages . . O
calculated . . O
with . . O
the . . O
number . . O
of . . O
female . . O
subjects . . O
in . . O
each . . O
group . . O
as . . O
denominator . . O
: . . O
placebo . . O
( . . O
n . . O
= . . O
481 . . O
) . . O
, . . O
jardiance . . O
10 . . O
mg . . O
( . . O
n . . O
= . . O
443 . . O
) . . O
, . . O
jardiance . . O
25 . . O
mg . . O
( . . O
n . . O
= . . O
420 . . O
) . . O
. . . O
c . . O
predefined . . O
adverse . . O
event . . O
grouping . . O
, . . O
including . . O
, . . O
but . . O
not . . O
limited . . O
to . . O
, . . O
polyuria . . B-AdverseReaction
, . . O
pollakiuria . . B-AdverseReaction
, . . O
and . . O
nocturia . . B-AdverseReaction
d . . O
male . . O
genital . . O
mycotic . . O
infections . . O
include . . O
the . . O
following . . O
adverse . . O
reactions . . O
: . . O
balanoposthitis . . B-AdverseReaction
, . . O
balanitis . . B-AdverseReaction
, . . O
genital . . B-AdverseReaction
infections . . I-AdverseReaction
fungal . . I-AdverseReaction
, . . O
genitourinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
balanitis . . B-AdverseReaction
candida . . I-AdverseReaction
, . . O
scrotal . . B-AdverseReaction
abscess . . I-AdverseReaction
, . . O
penile . . B-AdverseReaction
infection . . I-AdverseReaction
. . . O

some . . O
of . . O
these . . O
reactions . . O
were . . O
ige . . O
- . . O
mediated . . O
. . . O

temporarily . . O
suspend . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
permanently . . O
discontinue . . O
xalkori . . O
as . . O
described . . O
in . . O
table . . O
2 . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

treatment . . O
and . . O
reduction . . O
in . . O
the . . O
risk . . O
of . . O
recurrence . . O
of . . O
deep . . O
venous . . O
thrombosis . . O
and . . O
pulmonary . . O
embolism . . O

in . . O
a . . O
controlled . . O
trial . . O
in . . O
patients . . O
with . . O
chronic . . O
liver . . O
disease . . O
and . . O
thrombocytopenia . . O
not . . O
related . . O
to . . O
itp . . O
undergoing . . O
elective . . O
invasive . . O
procedures . . O
( . . O
n . . O
= . . O
292 . . O
) . . O
, . . O
the . . O
risk . . B-Factor
of . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
was . . O
increased . . O
in . . O
patients . . O
treated . . O
with . . O
75 . . O
mg . . O
of . . O
promacta . . O
once . . O
daily . . O
. . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
patients . . O
by . . O
preferred . . O
term . . O
and . . O
severity . . O
in . . O
patients . . O
with . . O
relapsed . . O
or . . O
refractory . . O
ptcl . . O
( . . O
nci . . O
- . . O
ctc . . O
grade . . O
1-4 . . O
) . . O
meddra . . O
preferred . . O
term . . O
percentage . . O
of . . O
patients . . O
( . . O
% . . O
) . . O
( . . O
n . . O
= . . O
129 . . O
) . . O
all . . O
grades . . O
grade . . O
3 . . O
or . . O
4 . . O
all . . O
adverse . . O
reactions . . O
97 . . O
61 . . O
nausea . . B-AdverseReaction
42 . . O
1 . . O
fatigue . . B-AdverseReaction
37 . . O
5 . . O
pyrexia . . B-AdverseReaction
35 . . O
2 . . O
anemia . . B-AdverseReaction
32 . . O
11 . . O
vomiting . . B-AdverseReaction
29 . . O
1 . . O
constipation . . B-AdverseReaction
23 . . O
1 . . O
diarrhea . . B-AdverseReaction
23 . . O
2 . . O
dyspnea . . B-AdverseReaction
22 . . O
6 . . O
rash . . B-AdverseReaction
20 . . O
1 . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
20 . . O
0 . . O
cough . . B-AdverseReaction
19 . . O
0 . . O
thrombocytopenia . . B-AdverseReaction
16 . . O
7 . . O
pruritus . . B-AdverseReaction
16 . . O
3 . . O
chills . . B-AdverseReaction
16 . . O
1 . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
lactate . . I-AdverseReaction
dehydrogenase . . I-AdverseReaction
16 . . O
2 . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
15 . . O
2 . . O
headache . . B-AdverseReaction
15 . . O
0 . . O
infusion . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
14 . . O
0 . . O
hypokalemia . . B-AdverseReaction
12 . . O
4 . . O
prolonged . . B-AdverseReaction
qt . . I-AdverseReaction
11 . . O
4 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
11 . . O
1 . . O
hypotension . . B-AdverseReaction
10 . . O
3 . . O
phlebitis . . B-AdverseReaction
10 . . O
1 . . O
dizziness . . B-AdverseReaction
10 . . O
0 . . O
note . . O
: . . O
adverse . . O
reactions . . O
are . . O
listed . . O
by . . O
order . . O
of . . O
incidence . . O
in . . O
the . . O
" . . O
all . . O
grades . . O
" . . O
category . . O
first . . O
, . . O
then . . O
by . . O
incidence . . O
in . . O
" . . O
the . . O
grade . . O
3 . . O
or . . O
4 . . O
" . . O
category . . O
; . . O
meddra . . O
= . . O
medical . . O
dictionary . . O
for . . O
regulatory . . O
activities . . O
; . . O
severity . . O
measured . . O
by . . O
national . . O
cancer . . O
institute . . O
common . . O
terminology . . O
criteria . . O
for . . O
adverse . . O
events . . O
( . . O
nci . . O
- . . O
ctcae . . O
) . . O
version . . O
3.0 . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
enterocolitis . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

one . . O
( . . O
n . . O
= . . O
106 . . O
) . . O
or . . O
2 . . O
( . . O
n . . O
= . . O
30 . . O
) . . O
doses . . O
of . . O
voraxaze . . O
were . . O
administered . . O
intravenously . . O
; . . O
the . . O
number . . O
of . . O
doses . . O
was . . O
not . . O
specified . . O
in . . O
13 . . O
patients . . O
. . . O

treated . . O
with . . O
pradaxa . . O
who . . O
are . . O
receiving . . O
neuraxial . . O
anesthesia . . O
or . . O
undergoing . . O

in . . O
study . . O
1 . . O
, . . O
diarrhea . . O
occurred . . O
in . . O
96% . . O
of . . O
patients . . O
treated . . O
with . . O
gilotrif . . O
( . . O
n . . O
= . . O
229 . . O
) . . O
, . . O
of . . O
which . . O
15% . . O
was . . O
grade . . B-Severity
3 . . I-Severity
in . . O
severity . . O
and . . O
occurred . . O
within . . O
the . . O
first . . O
6 . . O
weeks . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

adverse . . O
reactions . . O
similar . . O
in . . O
nature . . O
and . . O
frequency . . O
were . . O
observed . . O
to . . O
those . . O
seen . . O
in . . O
the . . O
controlled . . O
phase . . O
of . . O
the . . O
trials . . O
. . . O

fatal . . B-AdverseReaction
cerebrovascular . . B-AdverseReaction
accident . . I-AdverseReaction
was . . O
reported . . O
in . . O
1 . . O
/ . . O
359 . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
none . . O
of . . O
the . . O
patients . . O
receiving . . O
sorafenib . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

a . . O
woman . . O
who . . O
is . . O
taking . . O
cocs . . O
should . . O
have . . O
a . . O
yearly . . O
visit . . O
with . . O
her . . O
healthcare . . O
provider . . O
for . . O
a . . O
blood . . O
pressure . . O
check . . O
and . . O
for . . O
other . . O
indicated . . O
healthcare . . O
. . . O

in . . O
all . . O
open . . O
- . . O
label . . O
trials . . O
combined . . O
, . . O
857 . . O
, . . O
701 . . O
, . . O
529 . . O
, . . O
and . . O
105 . . O
patients . . O
received . . O
toviaz . . O
for . . O
at . . O
least . . O
6 . . O
months . . O
, . . O
1 . . O
year . . O
, . . O
2 . . O
years . . O
, . . O
and . . O
3 . . O
years . . O
, . . O
respectively . . O
. . . O

ribavirin . . O
therapy . . O
should . . O
not . . O
be . . O
started . . O
unless . . O
a . . O
report . . O
of . . O
a . . O
negative . . O
pregnancy . . O
test . . O
has . . O
been . . O
obtained . . O
immediately . . O
prior . . O
to . . O
initiation . . O
of . . O
therapy . . O
. . . O

in . . O
the . . O
remaining . . O
patients . . O
, . . O
symptoms . . O
resolved . . O
within . . O
4 . . O
to . . O
5 . . O
weeks . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
halaven . . O
has . . O
been . . O
administered . . O
to . . O
1,222 . . O
patients . . O
with . . O
multiple . . O
tumor . . O
types . . O
, . . O
including . . O
240 . . O
patients . . O
exposed . . O
to . . O
halaven . . O
for . . O
6 . . O
months . . O
or . . O
longer . . O
. . . O

because . . O
they . . O
are . . O
reported . . O
from . . O
a . . O
population . . O
of . . O
unknown . . O
size . . O
, . . O
precise . . O
estimates . . O
of . . O
frequency . . O
cannot . . O
be . . O
made . . O
. . . O

5.7 . . O
macrovascular . . O
outcomes . . O

the . . O
effects . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
and . . O
all . . O
botulinum . . O
toxin . . O
products . . O
may . . B-Factor
spread . . O
from . . O
the . . O
area . . O
of . . O
injection . . O
to . . O
produce . . O
symptoms . . O
consistent . . O
with . . O
botulinum . . O
toxin . . O
effects . . O
. . . O

} . . O
} . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
alcon . . O
laboratories . . O
, . . O
inc . . O
. . . O
at . . O
1-800-757-9195 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

5.14 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

varicella . . O
zoster . . O
virus . . O
antibody . . O
testing . . O
/ . . O
vaccination . . O

monitor . . O
with . . O
periodic . . O
liver . . O
testing . . O
. . . O

5.5 . . O
gallbladder . . O
disease . . O

infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
occurred . . O
with . . O
the . . O
blincyto . . O
infusion . . O
and . . O
may . . O
be . . O
clinically . . O
indistinguishable . . O
from . . O
manifestations . . O
of . . O
crs . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
chloasma . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
nodosum . . I-AdverseReaction
, . . O
erythema . . B-AdverseReaction
multiforme . . I-AdverseReaction

6 . . O
adverse . . O
reactions . . O

monitor . . O
liver . . O
function . . O
tests . . O
( . . O
hepatic . . O
transaminase . . O
and . . O
bilirubin . . O
levels . . O
) . . O
and . . O
assess . . O
patients . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
hepatotoxicity . . O
before . . O
each . . O
dose . . O
of . . O
yervoy . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
risk . . B-Factor
of . . O
anaphylaxis . . B-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
and . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
and . . O
risk . . B-Factor
of . . O
cardiorespiratory . . B-AdverseReaction
failure . . I-AdverseReaction

additionally . . O
, . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
alt . . I-AdverseReaction
or . . O
ast . . O
greater . . O
than . . O
five . . B-Severity
times . . I-Severity
the . . I-Severity
uln . . I-Severity
occurred . . O
in . . O
184 . . O
( . . O
11% . . O
) . . O
and . . O
93 . . O
( . . O
5.7% . . O
) . . O
patients . . O
, . . O
respectively . . O
. . . O

fungus . . O
invasion . . O
must . . O
be . . O
considered . . O
in . . O
any . . O
persistent . . O
corneal . . O
ulceration . . O
where . . O
a . . O
steroid . . O
has . . O
been . . O
used . . O
or . . O
is . . O
in . . O
use . . O
. . . O

avoid . . O
in . . O
patients . . O
with . . O
congenital . . O
long . . O
qt . . O
syndrome . . O
( . . O
5.4 . . O
) . . O

consider . . B-Factor
a . . O
diagnosis . . O
of . . O
non . . O
- . . O
infectious . . O
pneumonitis . . O
in . . O
patients . . O
presenting . . O
with . . O
non . . O
- . . O
specific . . O
respiratory . . O
signs . . O
and . . O
symptoms . . O
such . . O
as . . O
hypoxia . . O
, . . O
pleural . . O
effusion . . O
, . . O
cough . . O
, . . O
or . . O
dyspnea . . O
, . . O
and . . O
in . . O
whom . . O
infectious . . O
, . . O
neoplastic . . O
, . . O
and . . O
other . . O
causes . . O
have . . O
been . . O
excluded . . O
by . . O
means . . O
of . . O
appropriate . . O
investigations . . O
. . . O

discontinue . . O
if . . O
significant . . O
liver . . O
injury . . O
occurs . . O
. . . O

monitor . . O
lipase . . O
and . . O
amylase . . O
prior . . O
to . . O
treatment . . O
and . . O
periodically . . O
thereafter . . O
as . . O
clinically . . O
indicated . . O
. . . O

for . . O
patients . . O
who . . O
develop . . O
a . . O
new . . O
infection . . O
during . . O
treatment . . O
with . . O
simponi . . O
aria . . O
, . . O
perform . . O
a . . O
prompt . . O
and . . O
complete . . O
diagnostic . . O
workup . . O
appropriate . . O
for . . O
an . . O
immunocompromised . . O
patient . . O
and . . O
initiate . . O
appropriate . . O
antimicrobial . . O
therapy . . O
and . . O
closely . . O
monitor . . O
them . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
are . . O
nausea . . B-AdverseReaction
( . . O
11% . . O
) . . O
, . . O
vomiting . . B-AdverseReaction
( . . O
7% . . O
) . . O
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
anemia . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
and . . O
neutropenia . . B-AdverseReaction
( . . O
2% . . O
) . . O
( . . O
6 . . O
) . . O
. . . O

in . . O
2 . . O
- . . O
year . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
studies . . O
in . . O
patients . . O
with . . O
multiple . . O
sclerosis . . O
, . . O
macular . . B-AdverseReaction
edema . . I-AdverseReaction
with . . O
or . . O
without . . O
visual . . B-AdverseReaction
symptoms . . I-AdverseReaction
occurred . . O
in . . O
1.5% . . O
of . . O
patients . . O
( . . O
11 . . O
/ . . O
799 . . O
) . . O
treated . . O
with . . O
fingolimod . . O
1.25 . . O
mg . . O
, . . O
0.5% . . O
of . . O
patients . . O
( . . O
4 . . O
/ . . O
783 . . O
) . . O
treated . . O
with . . O
gilenya . . O
0.5 . . O
mg . . O
and . . O
0.4% . . O
of . . O
patients . . O
( . . O
3 . . O
/ . . O
773 . . O
) . . O
treated . . O
with . . O
placebo . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
ge . . O
healthcare . . O
at . . O
1-800-654-0118 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

in . . O
a . . O
trial . . O
in . . O
patients . . O
with . . O
classical . . O
hl . . O
that . . O
studied . . O
adcetris . . O
with . . O
bleomycin . . O
as . . O
part . . O
of . . O
a . . O
combination . . O
regimen . . O
, . . O
the . . O
rate . . O
of . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
infectious . . I-AdverseReaction
pulmonary . . I-AdverseReaction
toxicity . . I-AdverseReaction
was . . O
higher . . O
than . . O
the . . O
historical . . O
incidence . . O
reported . . O
with . . O
abvd . . O
( . . O
adriamycin . . O
, . . O
bleomycin . . O
, . . O
vinblastine . . O
, . . O
dacarbazine . . O
) . . O
. . . O

the . . O
detection . . O
of . . O
anti . . O
- . . O
blinatumomab . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

report . . O
any . . O
diagnosis . . O
of . . O
nsf . . O
following . . O
dotarem . . O
administration . . O
to . . O
guerbet . . O
llc . . O
( . . O
1-877-729-6679 . . O
) . . O
or . . O
fda . . O
( . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
) . . O
. . . O

hypersensitivity . . O
reactions . . O

the . . O
granulocyte . . O
colony . . O
- . . O
stimulating . . O
factor . . O
( . . O
g . . O
- . . O
csf . . O
) . . O
receptor . . O
through . . O
which . . O
granix . . O
acts . . O
has . . O
been . . O
found . . O
on . . O
tumor . . O
cell . . O
lines . . O
. . . O

postmarketing . . O
reports . . O
indicate . . O
that . . O
the . . O
effects . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
and . . O
all . . O
botulinum . . O
toxin . . O
products . . O
may . . B-Factor
spread . . O
from . . O
the . . O
area . . O
of . . O
injection . . O
to . . O
produce . . O
symptoms . . O
consistent . . O
with . . O
botulinum . . O
toxin . . O
effects . . O
. . . O

dronedarone . . O
caused . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
in . . O
animal . . B-Animal
studies . . O
at . . O
doses . . O
equivalent . . O
to . . O
recommended . . O
human . . O
doses . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
anaphylaxis . . B-AdverseReaction
: . . O
monitor . . O
patients . . O
for . . O
anaphylaxis . . O
and . . O
discontinue . . O
zydelig . . O
. . . O

cases . . O
of . . O
elevated . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
requiring . . O
immediate . . O
treatment . . O
have . . O
been . . O
reported . . O
with . . O
pristiq . . O
. . . O

excerpt . . O
: . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
characterized . . O
by . . O
rash . . B-AdverseReaction
, . . O
constitutional . . O
findings . . O
, . . O
and . . O
sometimes . . O
organ . . B-AdverseReaction
dysfunction . . I-AdverseReaction
, . . O
including . . O
liver . . B-AdverseReaction
injury . . I-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
. . . O

what . . O
is . . O
duavee . . O
used . . O
for . . O
? . . O

6 . . O
adverse . . O
reactions . . O

the . . O
following . . O
events . . O
have . . O
been . . O
reported . . O
in . . O
association . . O
with . . O
fesoterodine . . O
use . . O
in . . O
worldwide . . O
post . . O
- . . O
marketing . . O
experience . . O
: . . O
eye . . O
disorders . . O
: . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
; . . O
cardiac . . O
disorders . . O
: . . O
palpitations . . B-AdverseReaction
; . . O
general . . O
disorders . . O
and . . O
administrative . . O
site . . O
conditions . . O
: . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
angioedema . . B-AdverseReaction
with . . O
airway . . B-AdverseReaction
obstruction . . I-AdverseReaction
, . . O
face . . B-AdverseReaction
edema . . I-AdverseReaction
; . . O
central . . O
nervous . . O
system . . O
disorders . . O
: . . O
dizziness . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
; . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
urticaria . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction

during . . O
randomized . . O
controlled . . O
studies . . O
, . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
greater . . O
than . . O
three . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . O
uln . . O
) . . O
were . . O
observed . . O
( . . O
ast . . O
: . . O
2% . . O
, . . O
2% . . O
, . . O
and . . O
alt . . O
: . . O
3% . . O
, . . O
2% . . O
in . . O
uloric . . O
and . . O
allopurinol . . O
- . . O
treated . . O
patients . . O
, . . O
respectively . . O
) . . O
. . . O

of . . O
the . . O
176 . . O
patients . . O
, . . O
65% . . O
were . . O
white . . O
, . . O
23% . . O
asian . . O
, . . O
3% . . O
black . . O
, . . O
and . . O
10% . . O
other . . O
race . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
patients . . O
who . . O
received . . O
gilenya . . O
did . . O
not . . O
receive . . O
concomitant . . O
treatment . . O
with . . O
antineoplastic . . O
, . . O
non . . O
- . . O
corticosteroid . . O
immunosuppressive . . O
, . . O
or . . O
immune . . O
- . . O
modulating . . O
therapies . . O
used . . O
for . . O
treatment . . O
of . . O
ms . . O
. . . O
concomitant . . O
use . . O
of . . O
gilenya . . O
with . . O
any . . O
of . . O
these . . O
therapies . . O
, . . O
and . . O
also . . O
with . . O
corticosteroids . . O
, . . O
would . . O
be . . O
expected . . O
to . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
immunosuppression . . B-AdverseReaction
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7 . . O
) . . O
] . . O
. . . O

two . . O
randomized . . O
placebo . . O
- . . O
controlled . . O
, . . O
multicenter . . O
clinical . . O
trials . . O
enrolled . . O
patients . . O
who . . O
had . . O
metastatic . . O
castration . . O
- . . O
resistant . . O
prostate . . O
cancer . . O
who . . O
were . . O
using . . O
a . . O
gonadotropin . . O
- . . O
releasing . . O
hormone . . O
( . . O
gnrh . . O
) . . O
agonist . . O
or . . O
were . . O
previously . . O
treated . . O
with . . O
orchiectomy . . O
. . . O

neutropenia . . O
and . . O
febrile . . O
neutropenia . . O
, . . O
including . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
cases . . O
, . . O
have . . O
been . . O
observed . . O
in . . O
patients . . O
receiving . . O
blincyto . . O
. . . O

in . . O
most . . O
cases . . O
, . . O
this . . O
is . . O
a . . O
consequence . . O
of . . O
weakening . . O
of . . O
muscles . . O
in . . O
the . . O
area . . O
of . . O
injection . . O
that . . O
are . . O
involved . . O
in . . O
breathing . . O
or . . O
swallowing . . O
. . . O

discontinue . . O
sirturo . . O
if . . O
significant . . O
ventricular . . O
arrhythmia . . O
or . . O
if . . O
qtcf . . O
interval . . O
prolongation . . O
of . . O
greater . . O
than . . O
500 . . O
ms . . O
develops . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

use . . O
caution . . O
in . . O
a . . O
patient . . O
with . . O
a . . O
history . . O
of . . O
angioedema . . O
with . . O
another . . O
dpp . . O
- . . O
4 . . O
inhibitor . . O
because . . O
it . . O
is . . O
unknown . . O
whether . . O
such . . O
patients . . O
will . . O
be . . O
predisposed . . O
to . . O
angioedema . . O
with . . O
nesina . . O
. . . O

adverse . . O
reactions . . O
of . . O
grade . . O
3 . . O
or . . O
higher . . O
were . . O
reported . . O
in . . O
80% . . O
of . . O
patients . . O
. . . O

renal . . B-AdverseReaction
function . . I-AdverseReaction
abnormalities . . I-AdverseReaction
can . . B-Factor
occur . . O
after . . O
initiating . . O
invokana . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

the . . O
majority . . O
of . . O
peyronie's . . O
patients . . O
experienced . . O
at . . O
least . . O
one . . O
adverse . . O
reaction . . O
( . . O
92% . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
, . . O
61% . . O
placebo . . O
- . . O
treated . . O
) . . O
. . . O

all . . O
women . . O
were . . O
instructed . . O
to . . O
take . . O
at . . O
least . . O
1000 . . O
mg . . O
of . . O
calcium . . O
and . . O
400 . . O
iu . . O
of . . O
vitamin . . O
d . . O
supplementation . . O
per . . O
day . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
treanda . . O
in . . O
176 . . O
patients . . O
with . . O
indolent . . O
b . . O
- . . O
cell . . O
nhl . . O
treated . . O
in . . O
two . . O
single . . O
- . . O
arm . . O
studies . . O
. . . O

the . . O
effect . . O
of . . O
anti . . O
- . . O
brentuximab . . O
vedotin . . O
antibodies . . O
on . . O
safety . . O
and . . O
efficacy . . O
is . . O
not . . O
known . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
: . . O
there . . O
have . . O
been . . O
postmarketing . . O
reports . . O
of . . O
serious . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
nesina . . O
such . . O
as . . O
anaphylaxis . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
and . . O
severe . . B-Severity
cutaneous . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
events . . O
( . . O
incidence . . O
> . . O
= . . O
2% . . O
and . . O
at . . O
a . . O
rate . . O
greater . . O
than . . O
the . . O
placebo . . O
rate . . O
) . . O
for . . O
ampyra . . O
were . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
multiple . . B-AdverseReaction
sclerosis . . I-AdverseReaction
relapse . . I-AdverseReaction
, . . O
paresthesia . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
and . . O
pharyngolaryngeal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

5.9 . . O
suppression . . O
of . . O
bone . . O
turnover . . O

( . . O
5.11 . . O
) . . O
* . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
can . . B-Factor
occur . . O
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

monitor . . O
for . . O
signs . . O
or . . O
symptoms . . O
of . . O
tls . . O
. . . O

5.10 . . O
immune . . O
system . . O
effects . . O
following . . O
gilenya . . O
discontinuation . . O

ates . . O
are . . O
defined . . O
as . . O
nonfatal . . O
stroke . . O
, . . O
nonfatal . . O
myocardial . . O
infarction . . O
, . . O
or . . O
vascular . . O
death . . O
( . . O
including . . O
deaths . . O
of . . O
unknown . . O
cause . . O
) . . O
. . . O

non . . O
- . . O
cutaneous . . O
malignancies . . O
: . . O

( . . O
6 . . O
) . . O

blepharospasm . . O
: . . O
the . . O
most . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
and . . O
> . . O
placebo . . O
) . . O
are . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
, . . O
dry . . B-AdverseReaction
eye . . I-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
visual . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
and . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

other . . O
malignancies . . O

other . . O
binding . . O
proteins . . O
may . . B-Factor
be . . O
elevated . . O
in . . O
serum . . O
, . . O
for . . O
example . . O
, . . O
corticosteroid . . O
binding . . O
globulin . . O
( . . O
cbg . . O
) . . O
, . . O
sex . . O
hormone . . O
- . . O
binding . . O
globulin . . O
( . . O
shbg . . O
) . . O
, . . O
leading . . O
to . . O
increased . . B-AdverseReaction
total . . I-AdverseReaction
circulating . . I-AdverseReaction
corticosteroids . . I-AdverseReaction
and . . O
sex . . O
steroids . . O
, . . O
respectively . . O
. . . O

increases . . B-AdverseReaction
in . . I-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
were . . O
unrelated . . O
to . . O
the . . O
pretreatment . . O
blood . . O
pressure . . O
but . . O
were . . O
related . . O
to . . O
treatment . . O
- . . O
related . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
pain . . I-AdverseReaction
. . . O

( . . O
5.1 . . O
) . . O
, . . O
and . . O
adverse . . O
reactions . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
approval . . O
use . . O
of . . O
promacta . . O
. . . O

across . . O
the . . O
clinical . . O
program . . O
, . . O
serious . . B-Severity
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
severe . . B-Severity
cutaneous . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
and . . O
angioedema . . B-AdverseReaction
were . . O
reported . . O
in . . O
0.2% . . O
of . . O
comparator . . O
- . . O
treated . . O
patients . . O
and . . O
0.3% . . O
of . . O
farxiga . . O
- . . O
treated . . O
patients . . O
. . . O

discontinuation . . O
of . . O
inlyta . . O
treatment . . O
due . . O
to . . O
hypertension . . B-AdverseReaction
occurred . . O
in . . O
1 . . O
/ . . O
359 . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
none . . O
of . . O
the . . O
patients . . O
receiving . . O
sorafenib . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

* . . O
blood . . O
clots . . O
* . . O
stroke . . O
* . . O
heart . . O
attack . . O
* . . O
cancer . . O
of . . O
the . . O
lining . . O
of . . O
the . . O
uterus . . O
* . . O
breast . . O
cancer . . O
* . . O
cancer . . O
of . . O
the . . O
ovary . . O
* . . O
dementia . . O
* . . O
gallbladder . . O
problems . . O
* . . O
loss . . O
of . . O
vision . . O
* . . O
high . . O
blood . . O
pressure . . O
* . . O
increased . . O
fats . . O
in . . O
your . . O
blood . . O
* . . O
liver . . O
problems . . O
* . . O
thyroid . . O
problems . . O
* . . O
fluid . . O
retention . . O
* . . O
low . . O
calcium . . O
* . . O
swelling . . O
of . . O
your . . O
mouth . . O
or . . O
tongue . . O
* . . O
worsening . . O
of . . O
other . . O
medical . . O
problems . . O
such . . O
as . . O
asthma . . O
, . . O
diabetes . . O
, . . O
epilepsy . . O
, . . O
migraines . . O
, . . O
a . . O
genetic . . O
problem . . O
called . . O
porphyria . . O
, . . O
lupus . . O
and . . O
liver . . O
problems . . O
call . . O
your . . O
healthcare . . O
provider . . O
right . . O
away . . O
if . . O
you . . O
get . . O
any . . O
of . . O
the . . O
following . . O
warning . . O
signs . . O
, . . O
or . . O
any . . O
other . . O
unusual . . O
symptoms . . O
that . . O
concern . . O
you . . O
: . . O

serious . . O
adverse . . O
reactions . . O
were . . O
not . . O
observed . . O
in . . O
the . . O
adreview . . O
clinical . . O
study . . O
. . . O

prescribers . . O
should . . O
carefully . . O
evaluate . . O
the . . O
risks . . O
and . . O
benefits . . O
of . . O
continuing . . O
treatment . . O
with . . O
otezla . . O
if . . O
such . . O
events . . O
occur . . O
. . . O

in . . O
controlled . . O
adjunctive . . O
epilepsy . . O
trials . . O
, . . O
these . . O
events . . O
were . . O
reported . . O
in . . O
26% . . O
and . . O
38% . . O
of . . O
patients . . O
randomized . . O
to . . O
receive . . O
aptiom . . O
at . . O
doses . . O
of . . O
800 . . O
mg . . O
and . . O
1200 . . O
mg . . O
/ . . O
day . . O
, . . O
respectively . . O
, . . O
compared . . O
to . . O
12% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
most . . O
common . . O
medical . . O
interventions . . O
required . . O
during . . O
afinitor . . O
treatment . . O
were . . O
for . . O
infections . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
and . . O
stomatitis . . B-AdverseReaction
. . . O

an . . O
increased . . O
incidence . . O
was . . O
observed . . O
in . . O
patients . . O
on . . O
the . . O
300 . . O
mg . . O
dose . . O
. . . O

the . . O
race . . O
distribution . . O
was . . O
89% . . O
white . . O
, . . O
7% . . O
black . . O
, . . O
3% . . O
hispanic . . O
, . . O
1% . . O
other . . O
, . . O
and . . O
< . . O
1% . . O
asian . . O
. . . O

excerpt . . O
: . . O
* . . O
decreased . . O
efficacy . . O
in . . O
patients . . O
with . . O
baseline . . O
crcl . . O
of . . O
30 . . O
to . . O
< . . O
= . . O
50 . . O
ml . . O
/ . . O
min . . O
. . . O

pancreatitis . . O
pancreatitis . . B-AdverseReaction
was . . O
reported . . O
in . . O
4 . . O
patients . . O
( . . O
0.1% . . O
) . . O
in . . O
the . . O
placebo . . O
and . . O
8 . . O
patients . . O
( . . O
0.2% . . O
) . . O
in . . O
the . . O
prolia . . O
groups . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
flatulence . . B-AdverseReaction
, . . O
gastritis . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
distension . . I-AdverseReaction
, . . O
pancreatitis . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
hematemesis . . B-AdverseReaction
, . . O
retching . . B-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction

psoriasis . . O
clinical . . O
trials . . O
the . . O
safety . . O
of . . O
otezla . . O
( . . O
r . . O
) . . O
was . . O
assessed . . O
in . . O
1426 . . O
subjects . . O
in . . O
3 . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
in . . O
adult . . O
subjects . . O
with . . O
moderate . . O
to . . O
severe . . O
plaque . . O
psoriasis . . O
who . . O
were . . O
candidates . . O
for . . O
phototherapy . . O
or . . O
systemic . . O
therapy . . O
. . . O

the . . O
most . . O
commonly . . O
- . . O
reported . . O
adverse . . O
reactions . . O
, . . O
occurring . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
in . . O
clinical . . O
trials . . O
were . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
, . . O
depression . . B-AdverseReaction
, . . O
migraine . . B-AdverseReaction
, . . O
and . . O
pharyngitis . . B-AdverseReaction
. . . O

monitor . . O
for . . O
hypertension . . O
and . . O
treat . . O
as . . O
needed . . O
. . . O

in . . O
the . . O
whi . . O
estrogen . . O
- . . O
alone . . O
substudy . . O
, . . O
a . . O
statistically . . O
significant . . O
increased . . O
risk . . O
of . . O
stroke . . B-AdverseReaction
was . . O
reported . . O
in . . O
women . . O
50 . . O
to . . O
79 . . O
years . . O
of . . O
age . . O
receiving . . O
daily . . O
conjugated . . B-DrugClass
estrogens . . I-DrugClass
( . . O
ce . . O
) . . O
( . . O
0.625 . . O
mg . . O
) . . O
- . . O
alone . . O
compared . . O
to . . O
women . . O
in . . O
the . . O
same . . O
age . . O
group . . O
receiving . . O
placebo . . O
( . . O
45 . . O
versus . . O
33 . . O
per . . O
10,000 . . O
women . . O
- . . O
years . . O
) . . O
. . . O

if . . O
examination . . O
reveals . . O
papilledema . . O
or . . O
retinal . . O
vascular . . O
lesions . . O
, . . O
duavee . . O
should . . O
be . . O
permanently . . O
discontinued . . O
. . . O

the . . O
safety . . O
of . . O
two . . O
concurrent . . O
injections . . O
of . . O
xiaflex . . O
0.58 . . O
mg . . O
into . . O
dupuytren's . . O
cords . . O
in . . O
the . . O
same . . O
hand . . O
was . . O
evaluated . . O
in . . O
a . . O
historically . . O
- . . O
controlled . . O
, . . O
open . . O
- . . O
label . . O
multi . . O
- . . O
center . . O
trial . . O
in . . O
715 . . O
adult . . O
subjects . . O
with . . O
dupuytren's . . O
contracture . . O
( . . O
study . . O
3 . . O
) . . O
. . . O

5.3 . . O
concurrent . . O
treatment . . O
with . . O
other . . O
forms . . O
of . . O
4 . . O
- . . O
aminopyridine . . O

patients . . O
taking . . O
horizant . . O
should . . O
not . . O
drive . . O
until . . O
they . . O
have . . O
gained . . O
sufficient . . O
experience . . O
to . . O
assess . . O
whether . . O
horizant . . O
impairs . . O
their . . O
ability . . O
to . . O
drive . . O
. . . O

table . . O
8 . . O
: . . O
percentage . . O
of . . O
eps . . B-AdverseReaction
compared . . O
to . . O
placebo . . O
placebo . . O
( . . O
% . . O
) . . O
fanapt . . O
10-16 . . O
mg . . O
/ . . O
day . . O
( . . O
% . . O
) . . O
fanapt . . O
20-24 . . O
mg . . O
/ . . O
day . . O
( . . O
% . . O
) . . O
adverse . . O
event . . O
term . . O
( . . O
n . . O
= . . O
587 . . O
) . . O
( . . O
n . . O
= . . O
483 . . O
) . . O
( . . O
n . . O
= . . O
391 . . O
) . . O
all . . O
eps . . O
events . . O
11.6 . . O
13.5 . . O
15.1 . . O
akathisia . . B-AdverseReaction
2.7 . . O
1.7 . . O
2.3 . . O
bradykinesia . . B-AdverseReaction
0 . . O
0.6 . . O
0.5 . . O
dyskinesia . . B-AdverseReaction
1.5 . . O
1.7 . . O
1.0 . . O
dystonia . . B-AdverseReaction
0.7 . . O
1.0 . . O
0.8 . . O
parkinsonism . . B-AdverseReaction
0 . . O
0.2 . . O
0.3 . . O
tremor . . B-AdverseReaction
1.9 . . O
2.5 . . O
3.1 . . O
adverse . . O
reactions . . O
associated . . O
with . . O
discontinuation . . O
of . . O
treatment . . O
in . . O
clinical . . O
trials . . O

cases . . O
of . . O
active . . O
tuberculosis . . O
have . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
the . . O
subcutaneous . . O
formulation . . O
of . . O
golimumab . . O
during . . O
and . . O
after . . O
treatment . . O
for . . O
latent . . O
tuberculosis . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

* . . O
new . . O
primary . . B-AdverseReaction
malignancies . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
tumor . . B-AdverseReaction
promotion . . I-AdverseReaction
in . . I-AdverseReaction
braf . . I-AdverseReaction
wild . . I-AdverseReaction
- . . I-AdverseReaction
type . . I-AdverseReaction
melanoma . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
hemorrhage . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
venous . . B-AdverseReaction
thromboembolism . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
cardiomyopathy . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
ocular . . B-AdverseReaction
toxicities . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
serious . . B-Severity
febrile . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
serious . . B-Severity
skin . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
* . . O
hyperglycemia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O
* . . O
glucose . . B-AdverseReaction
- . . I-AdverseReaction
6 . . I-AdverseReaction
- . . I-AdverseReaction
phosphate . . I-AdverseReaction
dehydrogenase . . I-AdverseReaction
deficiency . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.10 . . O
) . . O
] . . O
* . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
for . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
are . . O
hyperkeratosis . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
papilloma . . B-AdverseReaction
, . . O
alopecia . . B-AdverseReaction
, . . O
and . . O
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

thromboembolic . . B-AdverseReaction
events . . I-AdverseReaction
were . . O
reported . . O
in . . O
clinical . . O
trials . . O
with . . O
victrelis . . O
among . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
, . . O
and . . O
among . . O
those . . O
receiving . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
, . . O
regardless . . O
of . . O
esa . . O
use . . O
. . . O

investigations . . O
: . . O
hepatic . . B-AdverseReaction
transaminases . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
international . . B-AdverseReaction
normalized . . I-AdverseReaction
ratio . . I-AdverseReaction
increased . . I-AdverseReaction

6 . . O
adverse . . O
reactions . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
reactions . . O
experienced . . O
by . . O
patients . . O
with . . O
classical . . O
hl . . O
include . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
pneumonitis . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
pneumothorax . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
pyelonephritis . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
and . . O
pyrexia . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
novartis . . O
pharmaceuticals . . O
corporation . . O
at . . O
1-888-669-6682 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

across . . O
8 . . O
phase . . O
iii . . O
clinical . . O
trials . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
, . . O
pancreatitis . . B-AdverseReaction
adjudicated . . O
as . . O
likely . . O
related . . O
to . . O
therapy . . O
occurred . . O
more . . O
frequently . . O
in . . O
patients . . O
receiving . . O
tanzeum . . O
( . . O
6 . . O
of . . O
2,365 . . O
[ . . O
0.3% . . O
] . . O
) . . O
than . . O
in . . O
patients . . O
receiving . . O
placebo . . O
( . . O
0 . . O
of . . O
468 . . O
[ . . O
0% . . O
] . . O
) . . O
or . . O
active . . O
comparators . . O
( . . O
2 . . O
of . . O
2,065 . . O
[ . . O
0.1% . . O
] . . O
) . . O
. . . O

the . . O
conditions . . O
and . . O
duration . . O
of . . O
treatment . . O
with . . O
fanapt . . O
varied . . O
greatly . . O
and . . O
included . . O
( . . O
in . . O
overlapping . . O
categories . . O
) . . O
, . . O
open . . O
- . . O
label . . O
and . . O
double . . O
- . . O
blind . . O
phases . . O
of . . O
studies . . O
, . . O
inpatients . . O
and . . O
outpatients . . O
, . . O
fixed . . O
- . . O
dose . . O
and . . O
flexible . . O
- . . O
dose . . O
studies . . O
, . . O
and . . O
short . . O
- . . O
term . . O
and . . O
longer . . O
- . . O
term . . O
exposure . . O
. . . O

in . . O
the . . O
randomized . . O
, . . O
placebo . . O
- . . O
controlled . . O
portion . . O
of . . O
sjia . . O
study . . O
2 . . O
, . . O
high . . B-AdverseReaction
alt . . I-AdverseReaction
and . . O
/ . . O
or . . O
ast . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
3 . . B-Severity
times . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . O
uln . . O
) . . O
were . . O
reported . . O
in . . O
2 . . O
( . . O
4.1% . . O
) . . O
ilaris . . O
- . . O
treated . . O
patients . . O
and . . O
1 . . O
( . . O
2.0% . . O
) . . O
placebo . . O
patient . . O
. . . O

patients . . O
receiving . . O
the . . O
drug . . O
should . . O
be . . O
managed . . O
in . . O
facilities . . O
equipped . . O
and . . O
staffed . . O
with . . O
adequate . . O
laboratory . . O
and . . O
supportive . . O
medical . . O
resources . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
pleural . . B-AdverseReaction
effusion . . I-AdverseReaction
( . . O
7% . . O
) . . O
, . . O
pharyngolaryngeal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
rhinorrhea . . B-AdverseReaction
( . . O
3% . . O
) . . O

the . . O
data . . O
described . . O
below . . O
represent . . O
adverse . . O
reactions . . O
observed . . O
from . . O
the . . O
two . . O
placebo . . O
- . . O
controlled . . O
trials . . O
, . . O
consisting . . O
of . . O
77 . . O
patients . . O
who . . O
received . . O
firazyr . . O
at . . O
a . . O
dose . . O
of . . O
30 . . O
mg . . O
sc . . O
, . . O
and . . O
75 . . O
who . . O
received . . O
placebo . . O
. . . O

5.6 . . O
osteonecrosis . . O
of . . O
the . . O
jaw . . O

( . . O
5.8 . . O
) . . O
* . . O
cyp3a4 . . O
induction . . O
: . . O
women . . O
taking . . O
strong . . O
cyp3a4 . . O
inducers . . O
( . . O
for . . O
example . . O
, . . O
carbamazepine . . O
, . . O
phenytoin . . O
, . . O
rifampicin . . O
, . . O
and . . O
st . . O
. . . O
john's . . O
wort . . O
) . . O
should . . O
not . . O
choose . . O
natazia . . O
as . . O
their . . O
oral . . O
contraceptive . . O
due . . O
to . . O
the . . O
possibility . . O
of . . O
decreased . . O
contraceptive . . O
efficacy . . O
. . . O

the . . O
mean . . O
age . . O
of . . O
patients . . O
was . . O
56 . . O
years . . O
, . . O
2% . . O
were . . O
75 . . O
years . . O
or . . O
older . . O
and . . O
51% . . O
were . . O
male . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
. . . O
] . . O

among . . O
the . . O
32 . . O
patients . . O
with . . O
evaluable . . O
pharmacokinetic . . O
( . . O
pk . . O
) . . O
samples . . O
, . . O
5 . . O
patients . . O
tested . . O
positive . . O
for . . O
uptake . . O
inhibition . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
approval . . O
use . . O
of . . O
pradaxa . . O
: . . O
angioedema . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
esophageal . . B-AdverseReaction
ulcer . . I-AdverseReaction
. . . O

new . . O
primary . . B-AdverseReaction
melanoma . . I-AdverseReaction
occurred . . O
in . . O
2% . . O
( . . O
1 . . O
/ . . O
53 . . O
) . . O
of . . O
patients . . O
receiving . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
and . . O
in . . O
none . . O
of . . O
the . . O
55 . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

for . . O
patients . . O
at . . O
highest . . O
risk . . O
for . . O
nsf . . O
, . . O
do . . O
not . . O
exceed . . O
the . . O
recommended . . O
eovist . . O
dose . . O
and . . O
allow . . O
a . . O
sufficient . . O
period . . O
of . . O
time . . O
for . . O
elimination . . O
of . . O
the . . O
drug . . O
from . . O
the . . O
body . . O
prior . . O
to . . O
any . . O
re . . O
- . . O
administration . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
hematuria . . B-AdverseReaction
, . . O
nephrolithiasis . . B-AdverseReaction
, . . O
pollakiuria . . B-AdverseReaction
, . . O
proteinuria . . B-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
insufficiency . . I-AdverseReaction
, . . O
urgency . . O
, . . O
incontinence . . O
. . . O

reduce . . O
or . . O
discontinue . . O
northera . . O
if . . O
supine . . O
hypertension . . O
persists . . O
. . . O

5.7 . . O
risk . . O
of . . O
serious . . O
adverse . . O
reactions . . O
in . . O
pancreatic . . O
and . . O
gastric . . O
anastomoses . . O

* . . O
talk . . O
with . . O
your . . O
healthcare . . O
provider . . O
regularly . . O
about . . O
whether . . O
you . . O
should . . O
continue . . O
taking . . O
duavee . . O
. . . O

in . . O
total . . O
, . . O
11% . . O
of . . O
the . . O
patients . . O
treated . . O
with . . O
eliquis . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
experienced . . O
adverse . . O
reactions . . O
. . . O

if . . O
eliquis . . O
is . . O
discontinued . . O
for . . O
a . . O
reason . . O
other . . O
than . . O
pathological . . O
bleeding . . O
or . . O
completion . . O
of . . O
a . . O
course . . O
of . . O
therapy . . O
, . . O
consider . . O
coverage . . O
with . . O
another . . O
anticoagulant . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
) . . O
andclinical . . O
studies . . O
( . . O
14.1 . . O
) . . O
] . . O
. . . O

6 . . O
adverse . . O
reactions . . O

obtain . . O
periodic . . O
liver . . O
testing . . O
in . . O
patients . . O
during . . O
treatment . . O
with . . O
gilotrif . . O
. . . O

particular . . O
care . . O
is . . O
needed . . O
for . . O
patients . . O
who . . O
have . . O
been . . O
transferred . . O
from . . O
systemically . . O
active . . O
corticosteroids . . O
to . . O
inhaled . . O
corticosteroids . . O
because . . O
deaths . . O
due . . O
to . . O
adrenal . . O
insufficiency . . O
have . . O
occurred . . O
in . . O
patients . . O
with . . O
asthma . . O
during . . O
and . . O
after . . O
transfer . . O
from . . O
systemic . . O
corticosteroids . . O
to . . O
less . . O
systemically . . O
available . . O
inhaled . . O
corticosteroids . . O
. . . O

overall . . O
, . . O
a . . O
higher . . O
incidence . . O
of . . O
infusion . . B-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction
was . . O
observed . . O
in . . O
patients . . O
who . . O
developed . . O
persistently . . O
positive . . O
antibodies . . O
. . . O

table . . O
5 . . O
presents . . O
adverse . . O
reactions . . O
from . . O
trial . . O
2 . . O
, . . O
a . . O
multicenter . . O
, . . O
open . . O
- . . O
label . . O
, . . O
randomized . . O
trial . . O
of . . O
162 . . O
patients . . O
with . . O
braf . . O
v600e . . O
or . . O
v600k . . O
mutation . . O
- . . O
positive . . O
melanoma . . O
receiving . . O
tafinlar . . O
150 . . O
mg . . O
twice . . O
daily . . O
in . . O
combination . . O
with . . O
trametinib . . O
2 . . O
mg . . O
orally . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
55 . . O
) . . O
, . . O
tafinlar . . O
150 . . O
mg . . O
orally . . O
twice . . O
daily . . O
in . . O
combination . . O
with . . O
trametinib . . O
1 . . O
mg . . O
once . . O
daily . . O
( . . O
n . . O
= . . O
54 . . O
) . . O
, . . O
and . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
150 . . O
mg . . O
orally . . O
twice . . O
daily . . O
( . . O
n . . O
= . . O
53 . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
] . . O
. . . O

fatal . . B-AdverseReaction
adverse . . O
reactions . . O
in . . O
patients . . O
treated . . O
with . . O
zykadia . . O
occurred . . O
in . . O
5% . . O
of . . O
patients . . O
, . . O
consisting . . O
of . . O
: . . O
pneumonia . . B-AdverseReaction
( . . O
4 . . O
patients . . O
) . . O
, . . O
respiratory . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
ild . . B-AdverseReaction
/ . . O
pneumonitis . . B-AdverseReaction
, . . O
pneumothorax . . B-AdverseReaction
, . . O
gastric . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
general . . B-AdverseReaction
physical . . I-AdverseReaction
health . . I-AdverseReaction
deterioration . . I-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
tuberculosis . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
tamponade . . I-AdverseReaction
, . . O
and . . O
sepsis . . B-AdverseReaction
( . . O
1 . . O
patient . . O
each . . O
) . . O
. . . O

note . . O
: . . O
percentages . . O
reflect . . O
the . . O
number . . O
of . . O
patients . . O
that . . O
reported . . O
at . . O
least . . O
1 . . O
treatment . . O
- . . O
emergent . . O
occurrence . . O
of . . O
the . . O
adverse . . O
reaction . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
hypercorticism . . B-AdverseReaction
and . . O
adrenal . . B-AdverseReaction
suppression . . I-AdverseReaction
may . . B-Factor
occur . . O
with . . O
very . . O
high . . O
dosages . . O
or . . O
at . . O
the . . O
regular . . O
dosage . . O
in . . O
susceptible . . O
individuals . . O
. . . O

advise . . O
patients . . O
to . . O
report . . O
symptoms . . O
of . . O
severe . . O
hyperglycemia . . O
such . . O
as . . O
excessive . . O
thirst . . O
or . . O
any . . O
increase . . O
in . . O
the . . O
volume . . O
or . . O
frequency . . O
of . . O
urination . . O
. . . O

before . . O
you . . O
take . . O
duavee . . O
, . . O
tell . . O
your . . O
healthcare . . O
provider . . O
if . . O
you . . O
: . . O

another . . O
patient . . O
developed . . O
severe . . B-Severity
inflammatory . . B-AdverseReaction
arthropathy . . I-AdverseReaction
in . . O
association . . O
with . . O
pyrexia . . B-AdverseReaction
and . . O
elevated . . B-AdverseReaction
erythrocyte . . I-AdverseReaction
sedimentation . . I-AdverseReaction
rate . . I-AdverseReaction
. . . O

nearly . . O
all . . O
of . . O
the . . O
reported . . O
tnf . . O
- . . O
blocker . . O
associated . . O
cases . . O
have . . O
occurred . . O
in . . O
patients . . O
with . . O
crohn's . . O
disease . . O
or . . O
ulcerative . . O
colitis . . O
. . . O

* . . O
the . . O
risk . . B-Factor
for . . O
nsf . . B-AdverseReaction
appears . . O
highest . . O
among . . O
patients . . O
with . . O
: . . O
ochronic . . O
, . . O
severe . . O
kidney . . O
disease . . O
( . . O
gfr . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m2 . . O
) . . O
, . . O
oroacute . . O
kidney . . O
injury . . O
. . . O

in . . O
patients . . O
receiving . . O
the . . O
recommended . . O
cimzia . . O
dosage . . O
of . . O
200 . . O
mg . . O
every . . O
other . . O
week . . O
with . . O
concomitant . . O
mtx . . O
, . . O
the . . O
acr20 . . O
response . . O
was . . O
lower . . O
among . . O
antibody . . O
positive . . O
patients . . O
than . . O
among . . O
antibody . . O
- . . O
negative . . O
patients . . O
( . . O
study . . O
ra . . O
- . . O
i . . O
, . . O
48% . . O
versus . . O
60% . . O
; . . O
study . . O
ra . . O
- . . O
ii . . O
35% . . O
versus . . O
59% . . O
, . . O
respectively . . O
) . . O
. . . O

5.2 . . O
aerosolization . . O
of . . O
capsaicin . . O

angioedema . . O
associated . . O
with . . O
upper . . B-AdverseReaction
airway . . I-AdverseReaction
swelling . . I-AdverseReaction
may . . B-Factor
be . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
. . . O

all . . O
men . . O
were . . O
instructed . . O
to . . O
take . . O
at . . O
least . . O
1000 . . O
mg . . O
of . . O
calcium . . O
and . . O
400 . . O
iu . . O
of . . O
vitamin . . O
d . . O
supplementation . . O
per . . O
day . . O
. . . O

reports . . O
include . . O
cases . . O
of . . O
miliary . . O
, . . O
lymphatic . . O
, . . O
peritoneal . . O
, . . O
as . . O
well . . O
as . . O
pulmonary . . B-AdverseReaction
tb . . I-AdverseReaction
. . . O

herpes . . O
viral . . O
infections . . O

more . . O
rapid . . O
titration . . O
would . . O
be . . O
expected . . O
to . . O
increase . . O
the . . O
rate . . O
of . . O
orthostatic . . O
hypotension . . O
and . . O
syncope . . O
. . . O

( . . O
6.1 . . O
) . . O
excerpt . . O
: . . O

the . . O
re . . O
- . . O
medy . . O
and . . O
re . . O
- . . O
sonate . . O
studies . . O
provided . . O
safety . . O
information . . O
on . . O
the . . O
use . . O
of . . O
pradaxa . . O
for . . O
the . . O
reduction . . O
in . . O
the . . O
risk . . O
of . . O
recurrence . . O
of . . O
deep . . O
vein . . O
thrombosis . . O
and . . O
pulmonary . . O
embolism . . O
. . . O

if . . O
bone . . O
abnormalities . . O
are . . O
suspected . . O
, . . O
then . . O
appropriate . . O
consultation . . O
should . . O
be . . O
obtained . . O
. . . O

patients . . O
with . . O
an . . O
established . . O
diagnosis . . O
of . . O
diabetes . . O
mellitus . . O
who . . O
are . . O
started . . O
on . . O
atypical . . O
antipsychotics . . O
should . . O
be . . O
monitored . . O
regularly . . O
for . . O
worsening . . O
of . . O
glucose . . O
control . . O
. . . O

invokana . . O
causes . . O
intravascular . . B-AdverseReaction
volume . . I-AdverseReaction
contraction . . I-AdverseReaction
. . . O

permanent . . O
discontinuation . . O
of . . O
xalkori . . O
treatment . . O
for . . O
adverse . . O
reactions . . O
was . . O
8.2% . . O
. . . O

patients . . O
with . . O
unstable . . O
or . . O
poorly . . O
controlled . . O
hypertension . . O
, . . O
a . . O
recent . . O
history . . O
of . . O
cardiovascular . . O
or . . O
cerebrovascular . . O
events . . O
may . . O
be . . O
at . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
adverse . . B-AdverseReaction
cardiovascular . . I-AdverseReaction
effects . . I-AdverseReaction
. . . O

adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
men . . O
with . . O
osteoporosis . . O
and . . O
more . . O
frequently . . O
with . . O
prolia . . O
than . . O
in . . O
the . . O
placebo . . O
- . . O
treated . . O
patients . . O
were . . O
: . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
6.7% . . O
placebo . . O
vs . . O
. . . O
8.3% . . O
prolia . . O
) . . O
, . . O
arthralgia . . B-AdverseReaction
( . . O
5.8% . . O
placebo . . O
vs . . O
. . . O
6.7% . . O
prolia . . O
) . . O
, . . O
and . . O
nasopharyngitis . . B-AdverseReaction
( . . O
5.8% . . O
placebo . . O
vs . . O
. . . O
6.7% . . O
prolia . . O
) . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
edema . . B-AdverseReaction
( . . O
5% . . O
) . . O

most . . O
, . . O
but . . O
not . . O
all . . O
, . . O
of . . O
these . . O
patients . . O
had . . O
underlying . . O
anatomic . . O
or . . O
vascular . . O
risk . . O
factors . . O
for . . O
developing . . O
naion . . O
, . . O
including . . O
but . . O
not . . O
necessarily . . O
limited . . O
to . . O
: . . O
low . . O
cup . . O
to . . O
disc . . O
ratio . . O
( . . O
" . . O
crowded . . O
disc . . O
" . . O
) . . O
, . . O
age . . O
over . . O
50 . . O
, . . O
diabetes . . O
, . . O
hypertension . . O
, . . O
coronary . . O
artery . . O
disease . . O
, . . O
hyperlipidemia . . O
, . . O
and . . O
smoking . . O
. . . O

the . . O
conditions . . O
and . . O
duration . . O
of . . O
exposure . . O
varied . . O
greatly . . O
and . . O
included . . O
single . . O
- . . O
and . . O
multiple . . O
- . . O
dose . . O
clinical . . O
pharmacology . . O
studies . . O
in . . O
healthy . . O
volunteers . . O
and . . O
two . . O
double . . O
- . . O
blind . . O
studies . . O
in . . O
patients . . O
with . . O
lgs . . O
( . . O
study . . O
1 . . O
and . . O
2 . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

mammary . . B-AdverseReaction
gland . . I-AdverseReaction
proliferative . . I-AdverseReaction
changes . . I-AdverseReaction
and . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
prolactin . . I-AdverseReaction
were . . O
seen . . O
in . . O
mice . . B-Animal
and . . O
rats . . B-Animal
treated . . O
with . . O
fanapt . . O
[ . . O
see . . O
nonclinical . . O
toxicology . . O
( . . O
13.1 . . O
) . . O
] . . O
. . . O

the . . O
risk . . O
of . . O
thrombotic . . O
events . . O
. . . O

monitor . . O
alt . . O
and . . O
ast . . O
in . . O
all . . O
patients . . O
every . . O
2 . . O
weeks . . O
for . . O
the . . O
first . . O
3 . . O
months . . O
of . . O
treatment . . O
, . . O
every . . O
4 . . O
weeks . . O
for . . O
the . . O
next . . O
3 . . O
months . . O
, . . O
then . . O
every . . O
1 . . O
to . . O
3 . . O
months . . O
thereafter . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
noninfectious . . B-AdverseReaction
pulmonary . . I-AdverseReaction
toxicity . . I-AdverseReaction
including . . O
pneumonitis . . B-AdverseReaction
, . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
and . . O
ards . . B-AdverseReaction
( . . O
some . . O
with . . O
fatal . . B-AdverseReaction
outcomes . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.10 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

( . . O
6.1 . . O
) . . O

6 . . O
adverse . . O
reactions . . O

excerpt . . O
: . . O
warning . . O
: . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction

the . . O
majority . . O
of . . O
patients . . O
( . . O
78% . . O
) . . O
were . . O
non . . O
- . . O
hispanic . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
unknown . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
casual . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

these . . O
adverse . . O
reactions . . O
were . . O
not . . O
present . . O
at . . O
baseline . . O
, . . O
occurred . . O
more . . O
commonly . . O
on . . O
trulicity . . O
than . . O
on . . O
placebo . . O
, . . O
and . . O
occurred . . O
in . . O
at . . O
least . . O
5% . . O
of . . O
patients . . O
treated . . O
with . . O
trulicity . . O
. . . O

5.4 . . O
oral . . O
ulceration . . O

5.2 . . O
allergic . . O
reactions . . O

of . . O
these . . O
, . . O
two . . O
studies . . O
were . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
single . . O
treatment . . O
, . . O
placebo . . O
controlled . . O
studies . . O
with . . O
subsequent . . O
optional . . O
open . . O
label . . O
treatment . . O
in . . O
which . . O
dose . . O
optimization . . O
( . . O
250 . . O
to . . O
1000 . . O
units . . O
per . . O
treatment . . O
) . . O
over . . O
the . . O
course . . O
of . . O
5 . . O
treatment . . O
cycles . . O
was . . O
allowed . . O
. . . O

transaminase . . O
elevations . . O
were . . O
more . . O
common . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
transaminase . . O
elevations . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

hypoglycemia . . O

the . . O
median . . O
exposure . . O
was . . O
11.0 . . O
months . . O
for . . O
patients . . O
treated . . O
with . . O
gilotrif . . O
and . . O
3.4 . . O
months . . O
for . . O
patients . . O
treated . . O
with . . O
pemetrexed . . O
/ . . O
cisplatin . . O
. . . O

do . . O
not . . O
administer . . O
kalbitor . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
the . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
other . . O
trials . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
. . . O
] . . O
the . . O
data . . O
described . . O
below . . O
reflect . . O
a . . O
median . . O
exposure . . O
to . . O
cometriq . . O
for . . O
204 . . O
days . . O
. . . O

if . . O
an . . O
infusion . . O
- . . O
related . . O
reaction . . O
occurs . . O
, . . O
the . . O
infusion . . O
should . . O
be . . O
interrupted . . O
and . . O
appropriate . . O
medical . . O
management . . O
instituted . . O
. . . O

delayed . . O
reactions . . O
can . . O
occur . . O
up . . O
to . . O
several . . O
days . . O
after . . O
administration . . O
. . . O

monitoring . . O
of . . O
orthostatic . . O
vital . . O
signs . . O
should . . O
be . . O
considered . . O
in . . O
all . . O
such . . O
patients . . O
, . . O
and . . O
a . . O
dose . . O
reduction . . O
should . . O
be . . O
considered . . O
if . . O
hypotension . . O
occurs . . O
. . . O

gadolinium . . B-DrugClass
- . . I-DrugClass
based . . I-DrugClass
contrast . . I-DrugClass
agents . . I-DrugClass
( . . O
gbcas . . O
) . . O
increase . . O
the . . O
risk . . O
for . . O
nsf . . B-AdverseReaction
among . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
the . . O
drugs . . O
. . . O

6 . . O
adverse . . O
reactions . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
worldwide . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
indacaterol . . O
, . . O
the . . O
active . . O
ingredient . . O
in . . O
arcapta . . O
neohaler . . O
. . . O

6.2 . . O
immunogenicity . . O

a . . O
mean . . O
increase . . O
from . . O
baseline . . O
in . . O
pr . . O
interval . . O
of . . O
2-3 . . O
milliseconds . . O
was . . O
observed . . O
in . . O
trulicity . . O
- . . O
treated . . O
patients . . O
in . . O
contrast . . O
to . . O
a . . O
mean . . O
decrease . . O
of . . O
0.9 . . O
millisecond . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

one . . O
( . . O
0.3% . . O
) . . O
subject . . O
who . . O
received . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
developed . . O
laboratory . . O
findings . . O
consistent . . O
with . . O
proximal . . B-AdverseReaction
renal . . I-AdverseReaction
tubular . . I-AdverseReaction
dysfunction . . I-AdverseReaction
leading . . O
to . . O
discontinuation . . O
of . . O
atv . . O
+ . . O
rtv . . O
+ . . O
truvada . . O
after . . O
week . . O
96 . . O
. . . O

( . . O
6.1 . . O
) . . O

ventricular . . B-AdverseReaction
arrhythmias . . I-AdverseReaction
and . . O
bradycardia . . B-AdverseReaction
, . . O
resulting . . O
in . . O
cardiac . . B-AdverseReaction
arrest . . I-AdverseReaction
or . . O
death . . B-AdverseReaction
, . . O
or . . O
requiring . . O
cardiac . . O
resuscitation . . O
or . . O
defibrillation . . O
have . . O
been . . O
observed . . O
in . . O
infantile . . O
- . . O
onset . . O
pompe . . O
disease . . O
patients . . O
with . . O
cardiac . . O
hypertrophy . . O
during . . O
general . . O
anesthesia . . O
for . . O
central . . O
venous . . O
catheter . . O
placement . . O
. . . O

inhalation . . O
of . . O
airborne . . O
capsaicin . . O
can . . B-Factor
result . . O
in . . O
coughing . . B-AdverseReaction
or . . O
sneezing . . B-AdverseReaction
. . . O

* . . O
cytokine . . B-AdverseReaction
release . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
neurological . . B-AdverseReaction
toxicities . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
infections . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
neutropenia . . B-AdverseReaction
and . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
effects . . B-AdverseReaction
on . . I-AdverseReaction
ability . . I-AdverseReaction
to . . I-AdverseReaction
drive . . I-AdverseReaction
and . . O
use . . O
machines . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
elevated . . B-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
leukoencephalopathy . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
* . . O
preparation . . O
and . . O
administration . . O
errors . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O
* . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
were . . O
pyrexia . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
tremor . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
constipation . . B-AdverseReaction
. . . O

afatinib . . O
was . . O
embryotoxic . . B-AdverseReaction
and . . O
, . . O
in . . O
animals . . O
with . . O
maternal . . O
toxicity . . O
, . . O
led . . O
to . . O
abortions . . B-AdverseReaction
at . . I-AdverseReaction
late . . I-AdverseReaction
gestational . . I-AdverseReaction
stages . . I-AdverseReaction
in . . O
rabbits . . B-Animal
at . . O
doses . . O
of . . O
5 . . O
mg . . O
/ . . O
kg . . O
( . . O
approximately . . O
0.2 . . O
times . . O
the . . O
human . . O
exposure . . O
at . . O
the . . O
recommended . . O
dose . . O
of . . O
40 . . O
mg . . O
daily . . O
) . . O
or . . O
greater . . O
. . . O

the . . O
majority . . O
were . . O
in . . O
adolescent . . O
and . . O
young . . O
adult . . O
males . . O
. . . O

5.8 . . O
fetal . . O
risk . . O

inactive . . O
ingredients . . O
: . . O
calcium . . O
phosphate . . O
tribasic . . O
, . . O
hydroxypropyl . . O
cellulose . . O
, . . O
microcrystalline . . O
cellulose . . O
, . . O
powdered . . O
cellulose . . O
, . . O
hypromellose . . O
, . . O
lactose . . O
monohydrate . . O
, . . O
magnesium . . O
stearate . . O
, . . O
polyethylene . . O
glycol . . O
, . . O
sucrose . . O
, . . O
ascorbic . . O
acid . . O
, . . O
sucrose . . O
palmitic . . O
acid . . O
ester . . O
, . . O
hydroxyethylcellulose . . O
, . . O
titanium . . O
dioxide . . O
, . . O
red . . O
iron . . O
oxide . . O
, . . O
yellow . . O
iron . . O
oxide . . O
, . . O
black . . O
iron . . O
oxide . . O
, . . O
povidone . . O
, . . O
polydextrose . . O
, . . O
maltitol . . O
, . . O
poloxamer . . O
188 . . O
, . . O
propylene . . O
glycol . . O
, . . O
isopropyl . . O
alcohol . . O
. . . O

with . . O
kyprolis . . O
monotherapy . . O
, . . O
the . . O
incidence . . O
of . . O
venous . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
was . . O
2% . . O
. . . O

counsel . . O
patients . . O
regarding . . O
the . . O
potential . . O
risk . . O
for . . O
mtc . . O
with . . O
the . . O
use . . O
of . . O
tanzeum . . O
and . . O
inform . . O
them . . O
of . . O
symptoms . . O
of . . O
thyroid . . O
tumors . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
a . . O
mass . . O
in . . O
the . . O
neck . . O
, . . O
dysphagia . . O
, . . O
dyspnea . . O
, . . O
or . . O
persistent . . O
hoarseness . . O
) . . O
. . . O

table . . O
1 . . O
lists . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
ampyra . . O
10 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
more . . O
frequently . . O
than . . O
in . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
in . . O
controlled . . O
clinical . . O
trials . . O
. . . O

table . . O
1 . . O
adverse . . O
reactions . . O
reported . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
gilotrif . . O
- . . O
treated . . O
patients . . O
in . . O
study . . O
1 . . O

excerpt . . O
: . . O
the . . O
most . . O
frequent . . O
( . . O
> . . O
= . . O
0.2% . . O
) . . O
adverse . . O
reactions . . O
in . . O
clinical . . O
studies . . O
were . . O
nausea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
coldness . . I-AdverseReaction
, . . O
and . . O
burning . . B-AdverseReaction
sensation . . I-AdverseReaction
. . . O

however . . O
, . . O
prior . . O
to . . O
initiating . . O
treatment . . O
with . . O
an . . O
antidepressant . . O
, . . O
patients . . O
with . . O
depressive . . O
symptoms . . O
should . . O
be . . O
adequately . . O
screened . . O
to . . O
determine . . O
if . . O
they . . O
are . . O
at . . O
risk . . O
for . . O
bipolar . . O
disorder . . O
; . . O
such . . O
screening . . O
should . . O
include . . O
a . . O
detailed . . O
psychiatric . . O
history . . O
, . . O
including . . O
a . . O
family . . O
history . . O
of . . O
suicide . . O
, . . O
bipolar . . O
disorder . . O
, . . O
and . . O
depression . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
angioedema . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
; . . O
drug . . O
rash . . O
with . . O
eosinophilia . . O
and . . O
systemic . . O
symptoms . . O
( . . O
dress . . O
) . . O
syndrome . . O
, . . O
exfoliative . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
exfoliative . . B-AdverseReaction
dermatitis . . I-AdverseReaction
, . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
toxic . . B-AdverseReaction
skin . . I-AdverseReaction
eruption . . I-AdverseReaction
, . . O
toxicoderma . . B-AdverseReaction

5.7 . . O
acute . . O
rejection . . O
and . . O
graft . . O
loss . . O
with . . O
corticosteroid . . O
minimization . . O

the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
associated . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
in . . O
table . . O
1 . . O
is . . O
based . . O
on . . O
2 . . O
placebo . . O
- . . O
controlled . . O
, . . O
6 . . O
- . . O
month . . O
clinical . . O
trials . . O
( . . O
trials . . O
1 . . O
and . . O
2 . . O
; . . O
n . . O
= . . O
1,224 . . O
and . . O
n . . O
= . . O
1,030 . . O
, . . O
respectively . . O
) . . O
. . . O

nephrotic . . B-AdverseReaction
syndrome . . I-AdverseReaction
secondary . . O
to . . O
membranous . . B-AdverseReaction
glomerulonephritis . . I-AdverseReaction
was . . O
observed . . O
in . . O
some . . O
pompe . . O
disease . . O
patients . . O
treated . . O
with . . O
alglucosidase . . O
alfa . . O
who . . O
had . . O
persistently . . O
positive . . B-AdverseReaction
anti . . I-AdverseReaction
- . . I-AdverseReaction
rhgaa . . I-AdverseReaction
igg . . I-AdverseReaction
antibody . . I-AdverseReaction
titers . . I-AdverseReaction
. . . O

arcapta . . O
neohaler . . O
should . . O
not . . O
be . . O
initiated . . O
in . . O
patients . . O
with . . O
acutely . . O
deteriorating . . O
copd . . O
, . . O
which . . O
may . . O
be . . O
a . . O
life . . O
- . . O
threatening . . O
condition . . O
. . . O

* . . O
muscle . . O
spasms . . O
* . . O
nausea . . O
* . . O
diarrhea . . O
* . . O
upset . . O
stomach . . O
* . . O
abdominal . . O
pain . . O
* . . O
throat . . O
pain . . O
* . . O
dizziness . . O
* . . O
neck . . O
pain . . O
these . . O
are . . O
not . . O
all . . O
the . . O
possible . . O
side . . O
effects . . O
of . . O
duavee . . O
. . . O

a . . O
total . . O
of . . O
2757 . . O
subjects . . O
with . . O
hyperuricemia . . O
and . . O
gout . . O
were . . O
treated . . O
with . . O
uloric . . O
40 . . O
mg . . O
or . . O
80 . . O
mg . . O
daily . . O
in . . O
clinical . . O
studies . . O
. . . O

abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
vomiting . . B-AdverseReaction
2520201513 . . O
0 . . O
< . . O
1120 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
pyrexia . . B-AdverseReaction
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
fatigue . . B-AdverseReaction
chills . . B-AdverseReaction
chest . . B-AdverseReaction
pain . . I-AdverseReaction
6225171511 . . O
7 . . O
< . . O
1101 . . O
immune . . O
system . . O
disorders . . O
cytokine . . B-AdverseReaction
release . . I-AdverseReaction
syndrome . . I-AdverseReaction
11 . . O
1 . . O
infections . . O
and . . O
infestations . . O
other . . O
pathogen . . O
infections . . B-AdverseReaction
bacterial . . B-AdverseReaction
infections . . I-AdverseReaction
fungal . . B-AdverseReaction
infections . . I-AdverseReaction
viral . . B-AdverseReaction
infections . . I-AdverseReaction
pneumonia . . B-AdverseReaction
sepsis . . B-AdverseReaction
4419151397 . . O
25127486 . . O
investigations . . O
increased . . B-AdverseReaction
alanine . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . B-AdverseReaction
aspartate . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . B-AdverseReaction
weight . . I-AdverseReaction
121111 . . O
640 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
hypokalemia . . B-AdverseReaction
hypomagnesemia . . B-AdverseReaction
hyperglycemia . . B-AdverseReaction
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
hypophosphatemia . . B-AdverseReaction
231211106 . . O
60735 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
bone . . B-AdverseReaction
pain . . I-AdverseReaction
arthralgia . . B-AdverseReaction
14121110 . . O
2132 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
tremortremor . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
resting . . B-AdverseReaction
tremor . . I-AdverseReaction
and . . O
tremor . . B-AdverseReaction
. . . O

the . . O
use . . O
of . . O
clinical . . O
information . . O
in . . O
the . . O
interpretation . . O
of . . O
neuraceq . . O
images . . O
has . . O
not . . O
been . . O
evaluated . . O
and . . O
may . . O
lead . . O
to . . O
errors . . O
. . . O

conduct . . O
periodic . . O
monitoring . . O
with . . O
electrocardiograms . . O
( . . O
ecgs . . O
) . . O
and . . O
electrolytes . . O
in . . O
patients . . O
with . . O
congestive . . O
heart . . O
failure . . O
, . . O
bradyarrhythmias . . O
, . . O
electrolyte . . O
abnormalities . . O
, . . O
or . . O
those . . O
who . . O
are . . O
taking . . O
medications . . O
that . . O
are . . O
known . . O
to . . O
prolong . . O
the . . O
qtc . . O
interval . . O
. . . O

in . . O
a . . O
pooled . . O
population . . O
of . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
( . . O
n . . O
= . . O
1085 . . O
) . . O
with . . O
baseline . . O
egfr . . O
of . . O
30 . . O
to . . O
less . . O
than . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
( . . O
mean . . O
baseline . . O
egfr . . O
48 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
, . . O
the . . O
overall . . O
incidence . . O
of . . O
these . . O
events . . O
was . . O
lower . . O
than . . O
in . . O
the . . O
dedicated . . O
trial . . O
but . . O
a . . O
dose . . O
- . . O
dependent . . O
increase . . O
in . . O
incident . . O
episodes . . O
of . . O
significant . . B-Severity
renal . . B-AdverseReaction
function . . I-AdverseReaction
decline . . I-AdverseReaction
compared . . O
to . . O
placebo . . O
was . . O
still . . O
observed . . O
. . . O

neoplasms . . O
benign . . O
, . . O
malignant . . O
, . . O
and . . O
unspecified . . O
( . . O
including . . O
cysts . . O
and . . O
polyps . . O
) . . O
: . . O
skin . . B-AdverseReaction
papilloma . . I-AdverseReaction
. . . O

nervous . . O
system . . O
disorders . . O
: . . O
altered . . B-AdverseReaction
taste . . I-AdverseReaction
, . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
cerebrovascular . . B-AdverseReaction
accident . . I-AdverseReaction
, . . O
guillain . . B-AdverseReaction
- . . I-AdverseReaction
barre . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
hemiparesis . . B-AdverseReaction
, . . O
hypoesthesia . . B-AdverseReaction
, . . O
hyposmia . . B-AdverseReaction
, . . O
lacunar . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
lethargy . . B-AdverseReaction
, . . O
mental . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
migraine . . B-AdverseReaction
, . . O
paresthesia . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
transient . . B-AdverseReaction
ischemic . . I-AdverseReaction
attack . . I-AdverseReaction
, . . O
tremor . . B-AdverseReaction
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
cimzia . . O
. . . O

acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ards . . B-AdverseReaction
) . . O
, . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
and . . O
acute . . B-AdverseReaction
diffuse . . I-AdverseReaction
infiltrative . . I-AdverseReaction
pulmonary . . I-AdverseReaction
disease . . I-AdverseReaction
such . . O
as . . O
pneumonitis . . B-AdverseReaction
and . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
have . . O
occurred . . O
in . . O
less . . O
than . . O
1% . . O
of . . O
patients . . O
receiving . . O
kyprolis . . O
. . . O

5.6 . . O
drug . . O
interactions . . O

excerpt . . O
: . . O
* . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
are . . O
( . . O
incidence . . O
> . . O
= . . O
5% . . O
) . . O
chromaturia . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
and . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
alanine . . B-AdverseReaction
aminotransferase . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
and . . O
neutropenia . . B-AdverseReaction
. . . O

5.1 . . O
embryofetal . . O
toxicity . . O
( . . O
use . . O
with . . O
ribavirin . . O
and . . O
peginterferon . . O
alfa . . O
) . . O

( . . O
2.1 . . O
, . . O
5.7 . . O
, . . O
14.1 . . O
) . . O
* . . O
immunizations . . O
: . . O
avoid . . O
use . . O
of . . O
live . . O
vaccines . . O
during . . O
treatment . . O
. . . O

a . . O
total . . O
of . . O
2.2% . . O
of . . O
hiv . . O
- . . O
1 . . O
- . . O
infected . . O
subjects . . O
in . . O
phase . . O
3 . . O
trials . . O
receiving . . O
intelence . . O
( . . O
r . . O
) . . O
discontinued . . O
due . . O
to . . O
rash . . B-AdverseReaction
. . . O

emtricitabine . . O
and . . O
tenofovir . . O
disoproxil . . O
fumarate . . O
: . . O
in . . O
addition . . O
to . . O
the . . O
adverse . . O
reactions . . O
observed . . O
with . . O
stribild . . O
, . . O
the . . O
following . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
at . . O
least . . O
5% . . O
of . . O
treatment . . O
- . . O
experienced . . O
or . . O
treatment . . O
- . . O
naive . . O
subjects . . O
receiving . . O
emtricitabine . . O
or . . O
tenofovir . . O
df . . O
with . . O
other . . O
antiretroviral . . O
agents . . O
in . . O
other . . O
clinical . . O
trials . . O
: . . O
depression . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
fever . . B-AdverseReaction
, . . O
pain . . B-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
, . . O
paresthesia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
including . . O
peripheral . . B-AdverseReaction
neuritis . . I-AdverseReaction
and . . O
neuropathy . . O
) . . O
, . . O
anxiety . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
cough . . I-AdverseReaction
, . . O
and . . O
rhinitis . . B-AdverseReaction
. . . O

cases . . O
of . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
cases . . O
, . . O
have . . O
been . . O
reported . . O
( . . O
< . . O
1% . . O
) . . O
during . . O
treatment . . O
with . . O
kyprolis . . O
. . . O

because . . O
of . . O
the . . O
risk . . O
of . . O
anaphylaxis . . O
, . . O

appropriate . . O
fluid . . O
and . . O
electrolyte . . O
management . . O
, . . O
protein . . O
supplementation . . O
, . . O
antibiotic . . O
treatment . . O
of . . O
c . . O
. . . O
difficile . . O
, . . O
and . . O
surgical . . O
evaluation . . O
should . . O
be . . O
instituted . . O
as . . O
clinically . . O
indicated . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

consider . . O
hospitalization . . O
and . . O
other . . O
management . . O
as . . O
clinically . . O
appropriate . . O
. . . O

or . . O
spinal . . O
surgery . . O
optimal . . O
timing . . O
between . . O
the . . O
administration . . O

advise . . O
patients . . O
to . . O
report . . O
promptly . . O
any . . O
new . . O
or . . O
worsening . . O
respiratory . . O
symptoms . . O
. . . O

use . . O
of . . O
duavee . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
is . . O
not . . O
recommended . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
important . . O
randomized . . O
clinical . . O
study . . O
providing . . O
information . . O
about . . O
breast . . O
cancer . . O
in . . O
estrogen . . O
- . . O
alone . . O
users . . O
is . . O
the . . O
whi . . O
substudy . . O
of . . O
daily . . O
conjugated . . O
estrogens . . O
( . . O
0.625 . . O
mg . . O
) . . O
- . . O
alone . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction

warning . . O
: . . O
post . . B-AdverseReaction
- . . I-AdverseReaction
transplant . . I-AdverseReaction
lymphoproliferative . . I-AdverseReaction
disorder . . I-AdverseReaction
, . . O
other . . O
malignancies . . B-AdverseReaction
, . . O
and . . O
serious . . B-Severity
infections . . B-AdverseReaction

increased . . O
dosage . . O
of . . O
corticosteroids . . O
may . . O
be . . O
indicated . . O
before . . O
, . . O
during . . O
and . . O
after . . O
stressful . . O
situations . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

increase . . B-AdverseReaction
in . . I-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O

the . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
include . . O
itching . . B-AdverseReaction
, . . O
body . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
and . . O
swelling . . B-AdverseReaction
of . . I-AdverseReaction
lips . . I-AdverseReaction
, . . O
tongue . . O
and . . O
/ . . O
or . . O
throat . . O
. . . O

( . . O
2.2 . . O
, . . O
5.5 . . O
) . . O
* . . O
bradycardia . . B-AdverseReaction
: . . O
zykadia . . O
can . . B-Factor
cause . . O
bradycardia . . B-AdverseReaction
. . . O

elevations . . O
5 . . O
- . . O
fold . . O
the . . O
uln . . O
or . . O
greater . . O
occurred . . O
in . . O
4.5% . . O
of . . O
patients . . O
on . . O
gilenya . . O
and . . O
1% . . O
of . . O
patients . . O
on . . O
placebo . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
risk . . B-Factor
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction

cardiovascular . . B-AdverseReaction
events . . I-AdverseReaction
and . . O
deaths . . B-AdverseReaction
were . . O
adjudicated . . O
to . . O
one . . O
of . . O
the . . O
pre . . O
- . . O
defined . . O
endpoints . . O
from . . O
the . . O
anti . . O
- . . O
platelet . . O
trialists' . . O
collaborations . . O
( . . O
aptc . . O
) . . O
( . . O
cardiovascular . . B-AdverseReaction
death . . I-AdverseReaction
, . . O
non . . B-Severity
- . . I-Severity
fatal . . I-Severity
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
and . . O
non . . B-Severity
- . . I-Severity
fatal . . I-Severity
stroke . . B-AdverseReaction
) . . O
in . . O
the . . O
randomized . . O
controlled . . O
and . . O
long . . O
- . . O
term . . O
extension . . O
studies . . O
. . . O

schizophrenia . . O
( . . O
6 . . O
- . . O
weeks . . O
) . . O
bipolar . . O
( . . O
3 . . O
- . . O
weeks . . O
) . . O
placebo . . O
saphris . . O
placebo . . O
saphris5 . . O
or . . O
10 . . O
mgtwice . . O
daily . . O
5 . . O
mgtwice . . O
daily . . O
10 . . O
mgtwice . . O
daily . . O
5 . . O
or . . O
10 . . O
mgtwice . . O
daily . . O
s . . O
mean . . O
change . . O
from . . O
baseline . . O
in . . O
fasting . . O
glucose . . O
at . . O
endpoint . . O
change . . O
from . . O
baseline . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
n . . O
* . . O
) . . O
- . . O
0.2(232 . . O
) . . O
3.8(158 . . O
) . . O
1.1(153 . . O
) . . O
3.2(377 . . O
) . . O
- . . O
0.6(89 . . O
) . . O
- . . O
0.6(156 . . O
) . . O
proportion . . O
of . . O
patients . . O
with . . O
shifts . . O
from . . O
baseline . . O
to . . O
endpoint . . O
normal . . O
to . . O
high . . O
< . . O
100 . . O
to . . O
> . . O
= . . O
126 . . O
mg . . O
/ . . O
dl . . O
4.1% . . O
4.5% . . O
4.5% . . O
5.0% . . O
3.3% . . O
2.7% . . O
( . . O
n . . O
/ . . O
n . . O
* . . O
* . . O
) . . O
( . . O
7 . . O
/ . . O
170 . . O
) . . O
( . . O
5 . . O
/ . . O
111 . . O
) . . O
( . . O
5 . . O
/ . . O
111 . . O
) . . O
( . . O
13 . . O
/ . . O
262 . . O
) . . O
( . . O
2 . . O
/ . . O
61 . . O
) . . O
( . . O
3 . . O
/ . . O
111 . . O
) . . O
borderline . . O
to . . O
high . . O
> . . O
= . . O
100 . . O
and . . O
< . . O
126to . . O
> . . O
= . . O
126 . . O
mg . . O
/ . . O
dl . . O
5.9% . . O
6.8% . . O
6.3% . . O
10.5% . . O
0.0% . . O
11.4% . . O
( . . O
n . . O
/ . . O
n . . O
* . . O
* . . O
) . . O
( . . O
3 . . O
/ . . O
51 . . O
) . . O
( . . O
3 . . O
/ . . O
44 . . O
) . . O
( . . O
2 . . O
/ . . O
32 . . O
) . . O
( . . O
10 . . O
/ . . O
95 . . O
) . . O
( . . O
0 . . O
/ . . O
23 . . O
) . . O
( . . O
4 . . O
/ . . O
35 . . O
) . . O
in . . O
a . . O
52 . . O
- . . O
week . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
comparator . . O
- . . O
controlled . . O
trial . . O
that . . O
included . . O
primarily . . O
patients . . O
with . . O
schizophrenia . . O
, . . O
the . . O
mean . . O
increase . . O
from . . O
baseline . . O
of . . O
fasting . . O
glucose . . O
was . . O
2.4 . . O
mg . . O
/ . . O
dl . . O
. . . O

compared . . O
to . . O
placebo . . O
, . . O
aptiom . . O
use . . O
was . . O
associated . . O
with . . O
slightly . . O
higher . . O
frequencies . . O
of . . O
decreases . . O
in . . O
hemoglobin . . O
and . . O
hematocrit . . O
, . . O
increases . . O
in . . O
total . . O
cholesterol . . O
, . . O
triglycerides . . O
, . . O
and . . O
ldl . . O
, . . O
and . . O
increases . . O
in . . O
creatine . . O
phosphokinase . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
leo . . O
pharma . . O
inc . . O
. . . O
at . . O
1-877-494-4536 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

6 . . O
adverse . . O
reactions . . O

in . . O
children . . O
, . . O
the . . O
adverse . . O
reactions . . O
were . . O
pyrexia . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
anorexia . . B-AdverseReaction
, . . O
and . . O
headache . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
* . . O
interleukin . . O
- . . O
1 . . O
blockade . . O
may . . O
interfere . . O
with . . O
immune . . O
response . . O
to . . O
infections . . O
. . . O

additional . . O
testing . . O
may . . O
include . . O
fluorescein . . O
angiograms . . O
( . . O
fa . . O
) . . O
, . . O
optical . . O
coherence . . O
tomography . . O
( . . O
oct . . O
) . . O
, . . O
perimetry . . O
, . . O
and . . O
electroretinograms . . O
( . . O
erg . . O
) . . O
. . . O

administer . . O
systemic . . O
high . . O
- . . O
dose . . O
corticosteroids . . O
for . . O
severe . . O
, . . O
persistent . . O
, . . O
or . . O
recurring . . O
immune . . O
- . . O
mediated . . O
reactions . . O
. . . O

lymphoma . . B-AdverseReaction
and . . O
other . . O
malignancies . . B-AdverseReaction
, . . O
some . . O
fatal . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
in . . O
children . . O
and . . O
adolescent . . O
patients . . O
treated . . O
with . . O
tnf . . B-DrugClass
blockers . . I-DrugClass
, . . O
of . . O
which . . O
cimzia . . O
is . . O
a . . O
member . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

changes . . O
in . . O
body . . O
weight . . O
( . . O
kg . . O
) . . O
and . . O
the . . O
proportion . . O
of . . O
subjects . . O
with . . O
> . . O
= . . O
7% . . O
gain . . B-AdverseReaction
in . . I-AdverseReaction
body . . I-AdverseReaction
weight . . I-AdverseReaction
from . . O
4 . . O
placebo . . O
- . . O
controlled . . O
, . . O
4 . . O
- . . O
or . . O
6 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
or . . O
flexible . . O
- . . O
dose . . O
studies . . O
in . . O
adult . . O
subjects . . O
are . . O
presented . . O
in . . O
table . . O
6 . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
label . . O
. . . O

patients . . O
should . . O
not . . O
use . . O
more . . O
than . . O
1 . . O
inhalation . . O
once . . O
daily . . O
of . . O
breo . . O
ellipta . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
associated . . O
with . . O
discontinuation . . O
in . . O
patients . . O
treated . . O
with . . O
saphris . . O
( . . O
rates . . O
at . . O
least . . O
1% . . O
and . . O
at . . O
least . . O
twice . . O
the . . O
placebo . . O
rate . . O
) . . O
were . . O
anxiety . . B-AdverseReaction
( . . O
1.1% . . O
) . . O
and . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
( . . O
1.1% . . O
) . . O
compared . . O
to . . O
placebo . . O
( . . O
0% . . O
) . . O
. . . O

prescribers . . O
and . . O
patients . . O
should . . O
be . . O
alert . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
acute . . O
narrow . . O
- . . O
angle . . O
glaucoma . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
eye . . O
pain . . O
or . . O
discomfort . . O
, . . O
blurred . . O
vision . . O
, . . O
visual . . O
halos . . O
or . . O
colored . . O
images . . O
in . . O
association . . O
with . . O
red . . O
eyes . . O
from . . O
conjunctival . . O
congestion . . O
and . . O
corneal . . O
edema . . O
) . . O
. . . O

the . . O
following . . O
serious . . O
and . . O
otherwise . . O
important . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
labeling . . O
: . . O

the . . O
symptoms . . O
are . . O
consistent . . O
with . . O
the . . O
mechanism . . O
of . . O
action . . O
of . . O
botulinum . . O
toxin . . O
and . . O
may . . B-Factor
include . . O
asthenia . . B-AdverseReaction
, . . O
generalized . . B-AdverseReaction
muscle . . I-AdverseReaction
weakness . . I-AdverseReaction
, . . O
diplopia . . B-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
ptosis . . B-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
, . . O
dysphonia . . B-AdverseReaction
, . . O
dysarthria . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
incontinence . . I-AdverseReaction
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
. . . O

discontinue . . O
zydelig . . O
if . . O
intestinal . . O
perforation . . O
is . . O
suspected . . O
. . . O

5.15 . . O
premenopausal . . O
women . . O

the . . O
proportion . . O
of . . O
patients . . O
who . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
reaction . . O
was . . O
5% . . O
for . . O
arcapta . . O
neohaler . . O
- . . O
treated . . O
patients . . O
and . . O
5% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

withhold . . O
trametinib . . O
for . . O
up . . O
to . . O
3 . . O
weeks . . O
for . . O
grade . . O
3 . . O
hemorrhagic . . O
events . . O
; . . O
if . . O
improved . . O
, . . O
resume . . O
at . . O
a . . O
lower . . O
dose . . O
level . . O
. . . O

for . . O
patients . . O
who . . O
require . . O
use . . O
of . . O
corticosteroids . . O
for . . O
treatment . . O
of . . O
non . . O
- . . O
infectious . . O
pneumonitis . . O
, . . O
prophylaxis . . O
for . . O
pjp . . O
may . . O
be . . O
considered . . O
. . . O

among . . O
these . . O
patients . . O
, . . O
63% . . O
had . . O
a . . O
history . . O
of . . O
hypertension . . O
, . . O
51% . . O
had . . O
a . . O
history . . O
of . . O
dyslipidemia . . O
, . . O
25% . . O
had . . O
a . . O
history . . O
of . . O
myocardial . . O
infarction . . O
, . . O
8% . . O
had . . O
a . . O
history . . O
of . . O
unstable . . O
angina . . O
and . . O
7% . . O
had . . O
a . . O
history . . O
of . . O
congestive . . O
heart . . O
failure . . O
. . . O

if . . O
ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
comes . . O
in . . O
contact . . O
with . . O
the . . O
eyes . . O
, . . O
flush . . O
them . . O
immediately . . O
with . . O
water . . O
. . . O

in . . O
unapproved . . O
uses . . O
, . . O
including . . O
spasticity . . O
in . . O
children . . O
and . . O
adults . . O
, . . O
and . . O
in . . O
approved . . O
indications . . O
, . . O
cases . . O
of . . O
spread . . B-AdverseReaction
of . . I-AdverseReaction
effect . . I-AdverseReaction
have . . O
been . . O
reported . . O
at . . O
doses . . O
comparable . . O
to . . O
those . . O
used . . O
to . . O
treat . . O
cervical . . O
dystonia . . O
and . . O
at . . O
lower . . O
doses . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
who . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
reactions . . O
in . . O
the . . O
controlled . . O
phase . . O
of . . O
trial . . O
1 . . O
through . . O
week . . O
24 . . O
was . . O
3.5% . . O
for . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
and . . O
0.5% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

bradycardia . . B-AdverseReaction
can . . B-Factor
occur . . O
in . . O
patients . . O
receiving . . O
zykadia . . O
. . . O

table . . O
6 . . O
. . . O

the . . O
most . . O
common . . O
reason . . O
for . . O
treatment . . O
discontinuation . . O
in . . O
both . . O
studies . . O
was . . O
for . . O
bleeding . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
; . . O
in . . O
aristotle . . O
this . . O
occurred . . O
in . . O
1.7% . . O
and . . O
2.5% . . O
of . . O
patients . . O
treated . . O
with . . O
eliquis . . O
and . . O
warfarin . . O
, . . O
respectively . . O
, . . O
and . . O
in . . O
averroes . . O
, . . O
in . . O
1.5% . . O
and . . O
1.3% . . O
on . . O
eliquis . . O
and . . O
aspirin . . O
, . . O
respectively . . O
. . . O

serious . . O
adverse . . O
reactions . . O
, . . O
whether . . O
considered . . O
drug . . O
- . . O
related . . O
or . . O
not . . O
by . . O
the . . O
investigators . . O
, . . O
that . . O
occurred . . O
more . . O
frequently . . O
in . . O
kalydeco . . O
- . . O
treated . . O
patients . . O
included . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
hepatic . . I-AdverseReaction
enzymes . . I-AdverseReaction
, . . O
and . . O
hypoglycemia . . B-AdverseReaction
. . . O

cases . . O
of . . O
tb . . B-AdverseReaction
included . . O
pulmonary . . O
and . . O
extrapulmonary . . B-AdverseReaction
tb . . I-AdverseReaction
. . . O

symptoms . . O
include . . O
fever . . B-AdverseReaction
, . . O
chills . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
and . . O
rash . . B-AdverseReaction
. . . O

monitor . . O
plasma . . O
zinc . . O
, . . O
and . . O
supplement . . O
in . . O
the . . O
event . . O
of . . O
a . . O
deficiency . . O
. . . O

the . . O
forms . . B-Factor
specifically . . I-Factor
requested . . I-Factor
information . . I-Factor
on . . O
occurrence . . O
of . . O
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
, . . O
hemorrhagic . . B-AdverseReaction
events . . I-AdverseReaction
, . . O
hepatobiliary . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
pancreatic . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
and . . O
hyperglycemia . . B-AdverseReaction
. . . O

cytomegalovirus . . O
and . . O
pneumocystis . . O
prophylaxis . . O
are . . O
recommended . . O
after . . O
transplantation . . O
. . . O

advise . . O
pregnant . . O
women . . O
of . . O
the . . O
potential . . O
risk . . O
to . . O
a . . O
fetus . . O
. . . O

ampyra . . O
is . . O
eliminated . . O
through . . O
the . . O
kidneys . . O
primarily . . O
as . . O
unchanged . . O
drug . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.4 . . O
) . . O
] . . O
. . . O

dyslipidemia . . O

if . . O
anticoagulation . . O
with . . O
eliquis . . O
is . . O
discontinued . . O
for . . O
a . . O
reason . . O
other . . O
than . . O
pathological . . O
bleeding . . O
or . . O
completion . . O
of . . O
a . . O
course . . O
of . . O
therapy . . O
, . . O
consider . . O
coverage . . O
with . . O
another . . O
anticoagulant . . O

there . . O
were . . O
differences . . O
in . . O
absolute . . O
risk . . O
of . . O
suicidality . . B-AdverseReaction
across . . O
the . . O
different . . O
indications . . O
, . . O
with . . O
the . . O
highest . . O
incidence . . O
in . . O
mdd . . O
. . . O

careful . . O
medical . . O
history . . O
is . . O
necessary . . O
because . . O
cdad . . O
has . . O
been . . O
reported . . O
to . . O
occur . . O
more . . O
than . . O
2 . . O
months . . O
after . . O
the . . O
administration . . O
of . . O
antibacterial . . O
agents . . O
. . . O

monitor . . O
ldl . . O
- . . O
c . . O
and . . O
treat . . O
per . . O
standard . . O
of . . O
care . . O
after . . O
initiating . . O
farxiga . . O
. . . O

no . . O
data . . O
are . . O
available . . O
on . . O
the . . O
effectiveness . . O
of . . O
vaccinations . . O
with . . O
inactivated . . O
( . . O
killed . . O
) . . O
antigens . . O
in . . O
patients . . O
receiving . . O
ilaris . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
] . . O
. . . O

somnolence . . B-AdverseReaction
and . . O
fatigue . . B-AdverseReaction
were . . O
also . . O
observed . . O
in . . O
monotherapy . . O
trials . . O
. . . O

( . . O
5.13 . . O
) . . O
* . . O
close . . O
monitoring . . O
for . . O
glaucoma . . O
and . . O
cataracts . . O
is . . O
warranted . . O
. . . O

neither . . O
clinical . . O
studies . . O
nor . . O
epidemiologic . . O
studies . . O
conducted . . O
to . . O
date . . O
have . . O
shown . . O
an . . O
association . . O
between . . O
chronic . . O
administration . . O
of . . O
this . . O
class . . O
of . . O
drugs . . O
and . . O
tumorigenesis . . B-AdverseReaction
in . . O
humans . . O
, . . O
but . . O
the . . O
available . . O
evidence . . O
is . . O
too . . O
limited . . O
to . . O
be . . O
conclusive . . O
. . . O

in . . O
this . . O
trial . . O
, . . O
elevated . . B-AdverseReaction
plasma . . I-AdverseReaction
prolactin . . I-AdverseReaction
levels . . I-AdverseReaction
were . . O
observed . . O
in . . O
26% . . O
of . . O
adults . . O
treated . . O
with . . O
fanapt . . O
compared . . O
to . . O
12% . . O
in . . O
the . . O
placebo . . O
- . . O
group . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
dihydropyridine . . B-DrugClass
calcium . . I-DrugClass
channel . . I-DrugClass
blockers . . I-DrugClass
can . . O
produce . . O
negative . . B-AdverseReaction
inotropic . . I-AdverseReaction
effects . . I-AdverseReaction
and . . O
exacerbate . . B-AdverseReaction
heart . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

an . . O
increase . . O
in . . O
the . . O
incidence . . O
of . . O
pneumonia . . B-AdverseReaction
has . . O
been . . O
observed . . O
in . . O
subjects . . O
with . . O
copd . . O
receiving . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
in . . O
clinical . . O
trials . . O
. . . O

therefore . . O
, . . O
a . . O
lower . . O
dose . . O
of . . O
insulin . . O
or . . O
insulin . . O
secretagogue . . O
may . . O
be . . O
required . . O
to . . O
minimize . . O
the . . O
risk . . O
of . . O
hypoglycemia . . O
when . . O
these . . O
agents . . O
are . . O
used . . O
in . . O
combination . . O
with . . O
farxiga . . O
. . . O

n . . O
* . . O
* . . O
= . . O
number . . O
of . . O
patients . . O
at . . O
risk . . O
at . . O
baseline . . O
with . . O
assessments . . O
at . . O
both . . O
baseline . . O
and . . O
endpoint . . O
. . . O

the . . O
majority . . O
of . . O
the . . O
1,222 . . O
patients . . O
were . . O
women . . O
( . . O
82% . . O
) . . O
with . . O
a . . O
median . . O
age . . O
of . . O
58 . . O
years . . O
( . . O
range . . O
: . . O
26 . . O
to . . O
91 . . O
years . . O
) . . O
. . . O

neutralizing . . O
antibodies . . O
to . . O
aux . . O
- . . O
i . . O
or . . O
aux . . O
- . . O
ii . . O
, . . O
were . . O
detected . . O
in . . O
10% . . O
and . . O
21% . . O
, . . O
respectively . . O
, . . O
of . . O
patients . . O
treated . . O
with . . O
xiaflex . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
with . . O
the . . O
use . . O
of . . O
cocs . . O
are . . O
discussed . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

monitor . . O
and . . O
treat . . O
appropriately . . O
. . . O

5.4 . . O
new . . O
onset . . O
or . . O
worsening . . O
heart . . O
failure . . O

no . . O
studies . . O
have . . O
been . . O
conducted . . O
in . . O
patients . . O
with . . O
end . . O
- . . O
stage . . O
renal . . O
disease . . O
. . . O

perform . . O
ophthalmological . . O
evaluation . . O
at . . O
any . . O
time . . O
a . . O
patient . . O
reports . . O
visual . . O
disturbances . . O
and . . O
compare . . O
with . . O
baseline . . O
, . . O
if . . O
available . . O
. . . O

the . . O
majority . . O
of . . O
events . . O
resolved . . O
following . . O
interruption . . O
of . . O
blincyto . . O
, . . O
but . . O
some . . O
resulted . . O
in . . O
treatment . . O
discontinuation . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
sunovion . . O
at . . O
1-877-737-7226 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

if . . O
such . . O
an . . O
acute . . O
reaction . . O
occurs . . O
, . . O
combination . . O
therapy . . O
should . . O
be . . O
discontinued . . O
and . . O
appropriate . . O
medical . . O
therapy . . O
immediately . . O
instituted . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

screening . . O
patients . . O
for . . O
bipolar . . O
disorder . . O

( . . O
5.1 . . O
) . . O
* . . O
liver . . B-AdverseReaction
disease . . I-AdverseReaction
: . . O
discontinue . . O
natazia . . O
if . . O
jaundice . . O
occurs . . O
. . . O

less . . O
common . . O
adverse . . O
reactions . . O
in . . O
apixaban . . O
- . . O
treated . . O
patients . . O
undergoing . . O
hip . . O
or . . O
knee . . O
replacement . . O
surgery . . O
occurring . . O
at . . O
a . . O
frequency . . O
of . . O
< . . O
0.1% . . O
: . . O

the . . O
qtcf . . B-AdverseReaction
was . . I-AdverseReaction
increased . . I-AdverseReaction
more . . O
than . . O
60 . . B-Severity
msec . . I-Severity
from . . I-Severity
baseline . . I-Severity
in . . O
13% . . O
( . . O
7 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
and . . O
2% . . O
( . . O
1 . . O
/ . . O
53 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

investigations . . O
: . . O
blood . . B-AdverseReaction
bilirubin . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
blood . . B-AdverseReaction
creatinine . . I-AdverseReaction
phosphokinase . . I-AdverseReaction
increased . . I-AdverseReaction
. . . O

( . . O
6.1 . . O
) . . O
excerpt . . O
: . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
teva . . O
pharmaceuticals . . O
at . . O
1-800-896-5855 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

the . . O
immunogenicity . . O
data . . O
reflect . . O
the . . O
percentage . . O
of . . O
patients . . O
whose . . O
test . . O
results . . O
were . . O
considered . . O
positive . . O
for . . O
antibodies . . O
to . . O
eylea . . O
in . . O
immunoassays . . O
. . . O

wound . . B-AdverseReaction
complications . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
cometriq . . O
. . . O

and . . O
risks . . O
before . . O
neuraxial . . O
intervention . . O
in . . O
patients . . O
who . . O
are . . O
or . . O
who . . O

table . . O
3 . . O
: . . O
change . . O
in . . O
fasting . . O
lipids . . O
fanapt . . O
placebo . . O
24 . . O
mg . . O
/ . . O
day . . O
mean . . O
change . . O
from . . O
baseline . . O
( . . O
mg . . O
/ . . O
dl . . O
) . . O
cholesterol . . O
n . . O
= . . O
114 . . O
n . . O
= . . O
228 . . O
change . . O
from . . O
baseline . . O
- . . O
2.17 . . O
8.18 . . O
ldl . . O
n . . O
= . . O
109 . . O
n . . O
= . . O
217 . . O
change . . O
from . . O
baseline . . O
- . . O
1.41 . . O
9.03 . . O
hdl . . O
n . . O
= . . O
114 . . O
n . . O
= . . O
228 . . O
change . . O
from . . O
baseline . . O
- . . O
3.35 . . O
0.55 . . O
triglycerides . . O
n . . O
= . . O
114 . . O
n . . O
= . . O
228 . . O
change . . O
from . . O
baseline . . O
16.47 . . O
- . . O
0.83 . . O
proportion . . O
of . . O
patients . . O
with . . O
shifts . . O
cholesterol . . O
normal . . O
to . . O
high . . O
1.4% . . O
3.6% . . O
( . . O
< . . O
200 . . O
mg . . O
/ . . O
dl . . O
to . . O
> . . O
= . . O
240 . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
1 . . O
/ . . O
72 . . O
) . . O
( . . O
5 . . O
/ . . O
141 . . O
) . . O
ldl . . O
normal . . O
to . . O
high . . O
2.4% . . O
1.1% . . O
( . . O
< . . O
100 . . O
mg . . O
/ . . O
dl . . O
to . . O
> . . O
= . . O
160 . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
1 . . O
/ . . O
42 . . O
) . . O
( . . O
1 . . O
/ . . O
90 . . O
) . . O
hdl . . O
normal . . O
to . . O
low . . O
23.8% . . O
12.1% . . O
( . . O
> . . O
= . . O
40 . . O
mg . . O
/ . . O
dl . . O
to . . O
< . . O
40 . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
19 . . O
/ . . O
80 . . O
) . . O
( . . O
20 . . O
/ . . O
166 . . O
) . . O
triglycerides . . O
normal . . O
to . . O
high . . O
8.3% . . O
10.1% . . O
( . . O
< . . O
150 . . O
mg . . O
/ . . O
dl . . O
to . . O
> . . O
= . . O
200 . . O
mg . . O
/ . . O
dl . . O
) . . O
( . . O
6 . . O
/ . . O
72 . . O
) . . O
( . . O
15 . . O
/ . . O
148 . . O
) . . O
pooled . . O
analyses . . O
of . . O
cholesterol . . O
and . . O
triglyceride . . O
data . . O
from . . O
clinical . . O
studies . . O
including . . O
longer . . O
term . . O
trials . . O
are . . O
shown . . O
in . . O
tables . . O
4 . . O
and . . O
5 . . O
. . . O

in . . O
placebo . . O
- . . O
controlled . . O
trials . . O
in . . O
patients . . O
with . . O
epilepsy . . O
, . . O
dizziness . . B-AdverseReaction
was . . O
reported . . O
in . . O
23% . . O
of . . O
patients . . O
treated . . O
with . . O
potiga . . O
and . . O
9% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

on . . O
average . . O
, . . O
pain . . O
scores . . O
returned . . O
to . . O
baseline . . O
by . . O
the . . O
end . . O
of . . O
the . . O
treatment . . O
day . . O
and . . O
then . . O
remained . . O
at . . O
or . . O
below . . O
baseline . . O
levels . . O
. . . O

because . . O
patients . . O
with . . O
moderate . . O
to . . O
severe . . O
renal . . O
impairment . . O
( . . O
crcl . . O
< . . O
= . . O
50ml . . O
/ . . O
min . . O
) . . O
would . . O
require . . O
a . . O
dose . . O
lower . . O
than . . O
10 . . O
mg . . O
twice . . O
daily . . O
and . . O
no . . O
strength . . O
smaller . . O
than . . O
10 . . O
mg . . O
is . . O
available . . O
, . . O
ampyra . . O
is . . O
contraindicated . . O
in . . O
these . . O
patients . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

patients . . O
who . . O
have . . O
experienced . . O
a . . O
prior . . O
infusion . . O
- . . O
related . . O
reaction . . O
should . . O
be . . O
premedicated . . O
for . . O
subsequent . . O
infusions . . O
. . . O

in . . O
a . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trial . . O
of . . O
patients . . O
with . . O
rheumatoid . . O
arthritis . . O
, . . O
no . . O
difference . . O
was . . O
detected . . O
in . . O
antibody . . O
response . . O
to . . O
vaccine . . O
between . . O
cimzia . . O
and . . O
placebo . . O
treatment . . O
groups . . O
when . . O
the . . O
pneumococcal . . O
polysaccharide . . O
vaccine . . O
and . . O
influenza . . O
vaccine . . O
were . . O
administered . . O
concurrently . . O
with . . O
cimzia . . O
. . . O

6 . . O
adverse . . O
reactions . . O

galactorrhea . . B-AdverseReaction
or . . O
dysmenorrhea . . B-AdverseReaction
were . . O
reported . . O
in . . O
0% . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
, . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
5 . . O
mg . . O
twice . . O
daily . . O
, . . O
and . . O
1% . . O
of . . O
patients . . O
treated . . O
with . . O
saphris . . O
10 . . O
mg . . O
twice . . O
daily . . O
compared . . O
to . . O
1% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

adult . . O
patients . . O
: . . O
pooled . . O
data . . O
on . . O
mean . . O
changes . . O
in . . O
body . . O
weight . . O
and . . O
the . . O
proportion . . O
of . . O
subjects . . O
meeting . . O
a . . O
weight . . B-AdverseReaction
gain . . I-AdverseReaction
criterion . . O
of . . O
> . . O
= . . O
7% . . B-Severity
of . . O
body . . O
weight . . O
from . . O
the . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
schizophrenia . . O
and . . O
bipolar . . O
mania . . O
trials . . O
are . . O
presented . . O
in . . O
table . . O
5 . . O
. . . O

the . . O
population . . O
in . . O
these . . O
studies . . O
was . . O
71% . . O
white . . O
, . . O
7% . . O
black . . O
or . . O
african . . O
american . . O
, . . O
11% . . O
asian . . O
; . . O
32% . . O
were . . O
of . . O
hispanic . . O
or . . O
latino . . O
ethnicity . . O
. . . O

patients . . O
were . . O
treated . . O
with . . O
pemetrexed . . O
500 . . O
mg . . O
/ . . O
m2 . . O
followed . . O
after . . O
30 . . O
minutes . . O
by . . O
cisplatin . . O
75 . . O
mg . . O
/ . . O
m2 . . O
every . . O
three . . O
weeks . . O
for . . O
a . . O
maximum . . O
of . . O
six . . O
treatment . . O
courses . . O
. . . O

decreased . . B-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
lymphocytes . . O
, . . O
neutrophils . . O
, . . O
and . . O
platelets . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
afinitor . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
, . . O
6.2 . . O
, . . O
6.3 . . O
, . . O
6.4 . . O
, . . O
6.5 . . O
) . . O
] . . O
. . . O

in . . O
unapproved . . O
uses . . O
, . . O
including . . O
spasticity . . O
in . . O
children . . O
, . . O
and . . O
in . . O
approved . . O
indications . . O
, . . O
cases . . O
of . . O
spread . . O
of . . O
effect . . O
have . . O
been . . O
reported . . O
at . . O
doses . . O
comparable . . O
to . . O
or . . O
lower . . O
than . . O
the . . O
maximum . . O
recommended . . O
total . . O
dose . . O
. . . O

gastrointestinal . . O
disorders . . O
- . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction

a . . O
fatal . . B-AdverseReaction
case . . O
of . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O
occurred . . O
in . . O
a . . O
patient . . O
with . . O
ms . . O
who . . O
received . . O
tecfidera . . O
for . . O
4 . . O
years . . O
while . . O
enrolled . . O
in . . O
a . . O
clinical . . O
trial . . O
. . . O

all . . O
second . . O
degree . . O
av . . O
blocks . . O
on . . O
placebo . . B-Factor
were . . O
mobitz . . O
type . . O
i . . O
and . . O
occurred . . O
after . . O
the . . O
first . . O
12 . . O
hours . . O
postdose . . O
. . . O

pool . . O
of . . O
12 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
for . . O
farxiga . . O
5 . . O
and . . O
10 . . O
mg . . O

interstitial . . O
infiltration . . O
and . . O
/ . . O
or . . O
inflammation . . O
were . . O
observed . . O
on . . O
radiographs . . O
and . . O
computed . . O
tomographic . . O
imaging . . O
of . . O
the . . O
chest . . O
. . . O

increased . . O
incidence . . O
of . . O
seizures . . B-AdverseReaction
has . . O
been . . O
observed . . O
at . . O
20 . . O
mg . . O
twice . . O
daily . . O
in . . O
controlled . . O
clinical . . O
studies . . O
of . . O
9-14 . . O
weeks . . O
duration . . O
with . . O
dalfampridine . . O
in . . O
patients . . O
with . . O
ms . . O
. . . O
in . . O
open . . O
label . . O
extension . . O
trials . . O
in . . O
ms . . O
patients . . O
, . . O
the . . O
incidence . . O
of . . O
seizures . . B-AdverseReaction
during . . O
treatment . . O
with . . O
dalfampridine . . O
15 . . O
mg . . O
twice . . O
daily . . O
( . . O
1.7 . . O
/ . . O
100py . . O
) . . O
was . . O
over . . O
4 . . O
times . . O
higher . . O
than . . O
the . . O
incidence . . O
during . . O
treatment . . O
with . . O
10 . . O
mg . . O
twice . . O
daily . . O
( . . O
0.4 . . O
/ . . O
100py . . O
) . . O
. . . O

treatment . . O
- . . O
emergent . . O
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
neutropenia . . B-AdverseReaction
occurred . . O
in . . O
31% . . O
of . . O
zydelig . . O
- . . O
treated . . O
patients . . O
across . . O
clinical . . O
trials . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

peyronie's . . O
disease . . O
( . . O
6.2 . . O
) . . O

in . . O
females . . O
, . . O
discontinuation . . O
due . . O
to . . O
genital . . O
mycotic . . O
infections . . O
occurred . . O
in . . O
0% . . O
and . . O
0.7% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
and . . O
invokana . . O
, . . O
respectively . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

5.15 . . O
dysphagia . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

and . . O
adverse . . O
reactions . . O

in . . O
the . . O
group . . O
treated . . O
with . . O
tanzeum . . O
, . . O
investigators . . O
graded . . O
the . . O
severity . . O
of . . O
gi . . B-AdverseReaction
reactions . . I-AdverseReaction
as . . O
" . . O
mild . . B-Severity
" . . O
in . . O
56% . . O
of . . O
cases . . O
, . . O
" . . O
moderate . . B-Severity
" . . O
in . . O
37% . . O
of . . O
cases . . O
, . . O
and . . O
" . . O
severe . . B-Severity
" . . O
in . . O
7% . . O
of . . O
cases . . O
. . . O

one . . O
of . . O
these . . O
events . . O
was . . O
fatal . . B-AdverseReaction
. . . O

adverse . . O
reactions . . O
associated . . O
with . . O
discontinuation . . O
of . . O
treatment . . O
: . . O
a . . O
total . . O
of . . O
9% . . O
of . . O
saphris . . O
- . . O
treated . . O
patients . . O
and . . O
10% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
discontinued . . O
due . . O
to . . O
adverse . . O
reactions . . O
. . . O

monitor . . O
patients . . O
during . . O
infusion . . O
. . . O

while . . O
these . . O
symptoms . . O
can . . O
occur . . O
at . . O
low . . O
doses . . O
, . . O
they . . O
occur . . O
more . . O
frequently . . O
and . . O
with . . O
greater . . O
severity . . O
with . . O
high . . O
potency . . O
and . . O
at . . O
higher . . O
doses . . O
of . . O
first . . O
generation . . O
antipsychotic . . O
drugs . . O
. . . O

table . . O
2 . . O
reports . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
at . . O
least . . O
10% . . O
of . . O
patients . . O
in . . O
either . . O
group . . O
. . . O

continue . . O
hydration . . O
and . . O
alkalinization . . O
of . . O
the . . O
urine . . O
as . . O
indicated . . O
. . . O

adverse . . O
reactions . . O
in . . O
study . . O
2 . . O
xtandi . . O
n . . O
= . . O
871 . . O
placebo . . O
n . . O
= . . O
844 . . O
grade . . O
1-4 . . O
a . . O
( . . O
% . . O
) . . O
grade . . O
3-4 . . O
( . . O
% . . O
) . . O
grade . . O
1-4 . . O
( . . O
% . . O
) . . O
grade . . O
3-4 . . O
( . . O
% . . O
) . . O
general . . O
disorders . . O
asthenic . . B-AdverseReaction
conditionsb . . O
46.9 . . O
3.4 . . O
33.0 . . O
2.8 . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
11.5 . . O
0.2 . . O
8.2 . . O
0.4 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
28.6 . . O
2.5 . . O
22.4 . . O
3.0 . . O
arthralgia . . B-AdverseReaction
21.4 . . O
1.6 . . O
16.1 . . O
1.1 . . O
gastrointestinal . . O
disorders . . O
constipation . . B-AdverseReaction
23.2 . . O
0.7 . . O
17.3 . . O
0.4 . . O
diarrhea . . B-AdverseReaction
16.8 . . O
0.3 . . O
14.3 . . O
0.4 . . O
vascular . . O
disorders . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
18.0 . . O
0.1 . . O
7.8 . . O
0.0 . . O
hypertension . . B-AdverseReaction
14.2 . . O
7.2 . . O
4.1 . . O
2.3 . . O
nervous . . O
system . . O
disorders . . O
dizzinessc . . O
11.3 . . O
0.3 . . O
7.1 . . O
0.0 . . O
headache . . B-AdverseReaction
11.0 . . O
0.2 . . O
7.0 . . O
0.4 . . O
dysgeusia . . B-AdverseReaction
7.6 . . O
0.1 . . O
3.7 . . O
0.0 . . O
mental . . B-AdverseReaction
impairment . . I-AdverseReaction
disordersd . . O
5.7 . . O
0.0 . . O
1.3 . . O
0.1 . . O
restless . . B-AdverseReaction
legs . . I-AdverseReaction
syndrome . . I-AdverseReaction
2.1 . . O
0.1 . . O
0.4 . . O
0.0 . . O
respiratory . . O
disorders . . O
dyspneae . . B-AdverseReaction
11.0 . . O
0.6 . . O
8.5 . . O
0.6 . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infectionf . . O
16.4 . . O
0.0 . . O
10.5 . . O
0.0 . . O
lower . . O
respiratory . . O
tract . . O
and . . O
lung . . B-AdverseReaction
infectiong . . O
7.9 . . O
1.5 . . O
4.7 . . O
1.1 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
8.2 . . O
0.1 . . O
5.7 . . O
0.0 . . O
renal . . O
and . . O
urinary . . O
disorders . . O
hematuria . . B-AdverseReaction
8.8 . . O
1.3 . . O
5.8 . . O
1.3 . . O
injury . . O
, . . O
poisoning . . O
and . . O
procedural . . O
complications . . O
fall . . B-AdverseReaction
12.7 . . O
1.6 . . O
5.3 . . O
0.7 . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
pathological . . I-AdverseReaction
fracture . . I-AdverseReaction
8.8 . . O
2.1 . . O
3.0 . . O
1.1 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
18.9 . . O
0.3 . . O
16.4 . . O
0.7 . . O
investigations . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
12.4 . . O
0.8 . . O
8.5 . . O
0.2 . . O
reproductive . . O
system . . O
and . . O
breast . . O
disorders . . O
gynecomastia . . B-AdverseReaction
3.4 . . O
0.0 . . O
1.4 . . O
0.0 . . O
a . . O
ctcae . . O
v4b . . O
includes . . O
asthenia . . B-AdverseReaction
and . . O
fatigue . . B-AdverseReaction
. . . O
c . . O
includes . . O
dizziness . . B-AdverseReaction
and . . O
vertigo . . B-AdverseReaction
. . . O
d . . O
includes . . O
amnesia . . B-AdverseReaction
, . . O
memory . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
cognitive . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
and . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
attention . . I-AdverseReaction
. . . O
e . . O
includes . . O
dyspnea . . B-AdverseReaction
, . . O
exertional . . B-AdverseReaction
dyspnea . . I-AdverseReaction
, . . O
and . . O
dyspnea . . B-AdverseReaction
at . . I-AdverseReaction
rest . . I-AdverseReaction
. . . O
f . . O
includes . . O
nasopharyngitis . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
rhinitis . . B-AdverseReaction
, . . O
pharyngitis . . B-AdverseReaction
, . . O
and . . O
laryngitis . . B-AdverseReaction
. . . O
g . . O
includes . . O
pneumonia . . B-AdverseReaction
, . . O
lower . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
and . . O
lung . . B-AdverseReaction
infection . . I-AdverseReaction
. . . O

while . . O
all . . O
of . . O
the . . O
drugs . . B-DrugClass
in . . I-DrugClass
the . . I-DrugClass
class . . I-DrugClass
have . . O
been . . O
shown . . O
to . . O
produce . . O
some . . O
metabolic . . B-AdverseReaction
changes . . I-AdverseReaction
, . . O
each . . O
drug . . O
has . . O
its . . O
own . . O
specific . . O
risk . . O
profile . . O
. . . O

baseline . . O
and . . O
follow . . O
- . . O
up . . O
examinations . . O
are . . O
recommended . . O
in . . O
pediatric . . O
patients . . O
initiating . . O
kalydeco . . O
treatment . . O
. . . O

table . . O
1 . . O
. . . O

( . . O
5.4 . . O
, . . O
5.5 . . O
) . . O

if . . O
signs . . O
or . . O
symptoms . . O
of . . O
spinal . . O
hematoma . . O
are . . O
suspected . . O
, . . O
initiate . . O
urgent . . O
diagnosis . . O
and . . O
treatment . . O
including . . O
consideration . . O
for . . O
spinal . . O
cord . . O
decompression . . O
even . . O
though . . O
such . . O
treatment . . O
may . . O
not . . O
prevent . . O
or . . O
reverse . . O
neurological . . O
sequelae . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

when . . O
possible . . O
, . . O
optimal . . O
glucose . . O
and . . O
lipid . . O
control . . O
should . . O
be . . O
achieved . . O
before . . O
starting . . O
a . . O
patient . . O
on . . O
afinitor . . O
. . . O

monitor . . O
hepatic . . O
function . . O
prior . . O
to . . O
and . . O
during . . O
treatment . . O
. . . O

studies . . O
also . . O
do . . O
not . . B-Negation
suggest . . O
a . . O
teratogenic . . B-AdverseReaction
effect . . I-AdverseReaction
, . . O
particularly . . O
in . . O
so . . O
far . . O
as . . O
cardiac . . B-AdverseReaction
anomalies . . I-AdverseReaction
and . . O
limb . . B-AdverseReaction
- . . I-AdverseReaction
reduction . . I-AdverseReaction
defects . . I-AdverseReaction
are . . O
concerned . . O
, . . O
when . . O
taken . . O
inadvertently . . O
during . . O
early . . O
pregnancy . . O
. . . O

the . . O
possibility . . O
of . . O
a . . O
suicide . . O
attempt . . O
is . . O
inherent . . O
in . . O
psychotic . . O
illness . . O
, . . O
and . . O
close . . O
supervision . . O
of . . O
high . . O
- . . O
risk . . O
patients . . O
should . . O
accompany . . O
drug . . O
therapy . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
, . . O
5.2 . . O
, . . O
5.3 . . O
, . . O
5.4 . . O
, . . O
5.5 . . O
) . . O
. . . O
] . . O

5.1 . . O
cardiac . . O
toxicities . . O

the . . O
same . . O
dose . . O
of . . O
horizant . . O
results . . O
in . . O
different . . O
plasma . . O
concentrations . . O
of . . O
gabapentin . . O
relative . . O
to . . O
other . . O
gabapentin . . O
products . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
ctcae . . O
grade . . B-Severity
3-4 . . I-Severity
hyperglycemia . . B-AdverseReaction
, . . O
based . . O
on . . O
laboratory . . O
values . . O
, . . O
occurred . . O
in . . O
13% . . O
of . . O
255 . . O
patients . . O
. . . O

tafinlar . . O
and . . O
trametinib . . O
may . . O
be . . O
resumed . . O
at . . O
lower . . O
dose . . O
levels . . O
in . . O
patients . . O
with . . O
improvement . . O
or . . O
recovery . . O
from . . O
skin . . O
toxicity . . O
within . . O
3 . . O
weeks . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

tivicay . . O
is . . O
contraindicated . . O
in . . O
patients . . O
who . . O
have . . O
experienced . . O
a . . O
previous . . O
hypersensitivity . . O
reaction . . O
to . . O
dolutegravir . . O
. . . O

patients . . O
typically . . O
reported . . O
cough . . B-AdverseReaction
and . . O
dyspnea . . B-AdverseReaction
. . . O

upon . . O
improvement . . O
to . . O
grade . . O
1 . . O
or . . O
less . . O
, . . O
initiate . . O
corticosteroid . . O
taper . . O
and . . O
continue . . O
to . . O
taper . . O
over . . O
at . . O
least . . O
1 . . O
month . . O
. . . O

four . . O
percent . . O
( . . O
4% . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tecfidera . . O
and . . O
less . . O
than . . O
1% . . O
of . . O
placebo . . O
patients . . O
discontinued . . O
due . . O
to . . O
gastrointestinal . . B-AdverseReaction
events . . I-AdverseReaction
. . . O

the . . O
mean . . O
age . . O
of . . O
the . . O
population . . O
was . . O
59 . . O
years . . O
and . . O
4% . . O
were . . O
older . . O
than . . O
75 . . O
years . . O
. . . O

in . . O
long . . O
- . . O
term . . O
or . . O
permanent . . B-AdverseReaction
paralysis . . I-AdverseReaction
( . . O
5.3 . . O
) . . O
. . . O

common . . O
and . . O
drug . . O
- . . O
related . . O
adverse . . O
reactions . . O
in . . O
clinical . . O
trials . . O

for . . O
additional . . O
information . . O
, . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
and . . O
consult . . O
the . . O
viread . . O
prescribing . . O
information . . O
. . . O

xeomin . . O
- . . O
treated . . O
patients . . O
were . . O
22 . . O
to . . O
79 . . O
years . . O
of . . O
age . . O
( . . O
mean . . O
62 . . O
years . . O
) . . O
, . . O
predominantly . . O
female . . O
( . . O
65% . . O
) . . O
, . . O
caucasian . . O
( . . O
79% . . O
) . . O
, . . O
and . . O
had . . O
a . . O
mean . . O
time . . O
since . . O
diagnosis . . O
of . . O
approximately . . O
5 . . O
years . . O
. . . O

fanapt . . O
, . . O
like . . O
other . . O
antipsychotics . . O
, . . O
has . . O
the . . O
potential . . B-Factor
to . . O
impair . . B-AdverseReaction
judgment . . I-AdverseReaction
, . . O
thinking . . O
or . . O
motor . . O
skills . . O
. . . O

skin . . O
biopsy . . O
in . . O
one . . O
patient . . O
demonstrated . . O
deposition . . B-AdverseReaction
of . . I-AdverseReaction
anti . . I-AdverseReaction
- . . I-AdverseReaction
rhgaa . . I-AdverseReaction
antibodies . . I-AdverseReaction
in . . O
the . . O
lesion . . O
. . . O

the . . O
diagnosis . . O
of . . O
probable . . B-Factor
pml . . B-AdverseReaction
was . . O
based . . O
on . . O
mri . . O
findings . . O
and . . O
the . . O
detection . . O
of . . O
jcv . . O
dna . . O
in . . O
the . . O
csf . . O
in . . O
the . . O
absence . . B-Negation
of . . O
clinical . . O
signs . . O
or . . O
symptoms . . O
specific . . O
to . . O
pml . . B-AdverseReaction
. . . O

table . . O
1 . . O
adverse . . O
reactions . . O
observed . . O
in . . O
> . . O
1% . . O
of . . O
patients . . O
with . . O
acute . . O
attacks . . O
of . . O
hae . . O
and . . O
at . . O
a . . O
higher . . O
rate . . O
with . . O
firazyr . . O
versus . . O
placebo . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
trialsevents . . O
occurring . . O
within . . O
14 . . O
days . . O
of . . O
study . . O
drug . . O
administration . . O
firazyr . . O
( . . O
n . . O
= . . O
77 . . O
) . . O
placebo . . O
( . . O
n . . O
= . . O
75 . . O
) . . O
system . . O
organ . . O
classpreferred . . O
term . . O
subjects . . O
( . . O
% . . O
) . . O
subjects . . O
( . . O
% . . O
) . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
75 . . O
( . . O
97 . . O
) . . O
25 . . O
( . . O
33 . . O
) . . O
pyrexia . . B-AdverseReaction
3 . . O
( . . O
4 . . O
) . . O
0 . . O
investigations . . O
transaminase . . B-AdverseReaction
increased . . I-AdverseReaction
3 . . O
( . . O
4 . . O
) . . O
0 . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
2 . . O
( . . O
3 . . O
) . . O
1 . . O
( . . O
1 . . O
) . . O
the . . O
third . . O
trial . . O
was . . O
active . . O
- . . O
controlled . . O
and . . O
was . . O
comprised . . O
of . . O
35 . . O
patients . . O
who . . O
received . . O
firazyr . . O
30 . . O
mg . . O
and . . O
38 . . O
patients . . O
who . . O
received . . O
the . . O
comparator . . O
. . . O

5.11 . . O
serious . . O
dermatologic . . O
reactions . . O

systemic . . B-AdverseReaction
immune . . I-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
possible . . B-Factor
type . . B-AdverseReaction
iii . . I-AdverseReaction
immune . . I-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
observed . . O
with . . O
alglucosidase . . O
alfa . . O
. . . O

safety . . O
was . . O
also . . O
evaluated . . O
in . . O
99 . . O
patients . . O
( . . O
51 . . O
male . . O
, . . O
48 . . O
females . . O
) . . O
with . . O
pompe . . O
disease . . O
in . . O
an . . O
ongoing . . O
, . . O
open . . O
- . . O
label . . O
, . . O
prospective . . O
study . . O
in . . O
patients . . O
12 . . O
months . . O
of . . O
age . . O
and . . O
older . . O
who . . O
were . . O
previously . . O
treated . . O
with . . O
the . . O
160 . . O
l . . O
scale . . O
of . . O
alglucosidase . . O
alfa . . O
and . . O
switched . . O
to . . O
the . . O
4000 . . O
l . . O
scale . . O
of . . O
alglucosidase . . O
alfa . . O
. . . O

6 . . O
adverse . . O
reactions . . O

on . . O
day . . O
1 . . O
, . . O
the . . O
maximum . . O
decline . . B-AdverseReaction
in . . I-AdverseReaction
heart . . I-AdverseReaction
rate . . I-AdverseReaction
generally . . O
occurs . . O
within . . O
6 . . O
hours . . O
and . . O
recovers . . O
, . . O
although . . O
not . . O
to . . O
baseline . . O
levels . . O
, . . O
by . . O
8 . . O
to . . O
10 . . O
hours . . O
postdose . . O
. . . O

( . . O
5.5 . . O
, . . O
2.3 . . O
) . . O
* . . O
ocular . . B-AdverseReaction
toxicities . . I-AdverseReaction
: . . O
perform . . O
ophthalmologic . . O
evaluation . . O
for . . O
any . . O
visual . . O
disturbances . . O
. . . O

baseline . . O
and . . O
follow . . O
- . . O
up . . O
ophthalmological . . O
examinations . . O
are . . O
recommended . . O
in . . O
pediatric . . O
patients . . O
initiating . . O
kalydeco . . O
treatment . . O
. . . O

consider . . O
the . . O
diagnosis . . O
of . . O
pancreatitis . . O
for . . O
patients . . O
presenting . . O
with . . O
severe . . O
abdominal . . O
pain . . O
. . . O

dose . . O
modifications . . O
or . . O
temporary . . O
delay . . O
of . . O
treatment . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
occurred . . O
in . . O
199 . . O
/ . . O
359 . . O
patients . . O
( . . O
55% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
220 . . O
/ . . O
355 . . O
patients . . O
( . . O
62% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

an . . O
on . . O
- . . O
treatment . . O
decline . . B-AdverseReaction
in . . I-AdverseReaction
estimated . . I-AdverseReaction
glomerular . . I-AdverseReaction
filtration . . I-AdverseReaction
rate . . I-AdverseReaction
( . . O
egfr . . O
) . . O
has . . O
occurred . . O
in . . O
patients . . O
treated . . O
with . . O
bosulif . . O
. . . O

0 . . O
1 . . O
( . . O
1 . . O
) . . O
add . . O
- . . O
on . . O
to . . O
insulin . . O
( . . O
+ . . O
/ . . O
- . . O
metformin . . O
) . . O
( . . O
26 . . O
weeks . . O
) . . O
nesina . . O
25 . . O
mg+ . . O
insulin . . O
( . . O
+ . . O
/ . . O
- . . O
metformin . . O
) . . O
placebo+ . . O
insulin . . O
( . . O
+ . . O
/ . . O
- . . O
metformin . . O
) . . O
n . . O
= . . O
129 . . O
n . . O
= . . O
129 . . O
overall . . O
( . . O
% . . O
) . . O
35 . . O
( . . O
27 . . O
) . . O
31 . . O
( . . O
24 . . O
) . . O
severe . . O
( . . O
% . . O
) . . O
1 . . O
( . . O
0.8 . . O
) . . O
2 . . O
( . . O
1.6 . . O
) . . O
add . . O
- . . O
on . . O
to . . O
metformin . . O
( . . O
26 . . O
weeks . . O
) . . O
nesina . . O
25 . . O
mg+ . . O
metformin . . O
placebo+ . . O
metformin . . O
n . . O
= . . O
207 . . O
n . . O
= . . O
104 . . O
overall . . O
( . . O
% . . O
) . . O
0 . . O
3 . . O
( . . O
2.9 . . O
) . . O
severe . . O
( . . O
% . . O
) . . O
0 . . O
0 . . O
add . . O
- . . O
on . . O
to . . O
pioglitazone . . O
( . . O
+ . . O
/ . . O
- . . O
metformin . . O
or . . O
sulfonylurea . . O
) . . O
( . . O
26 . . O
weeks . . O
) . . O
nesina . . O
25 . . O
mg+ . . O
pioglitazone . . O
placebo+ . . O
pioglitazone . . O
n . . O
= . . O
199 . . O
n . . O
= . . O
97 . . O
overall . . O
( . . O
% . . O
) . . O
14 . . O
( . . O
7.0 . . O
) . . O
5 . . O
( . . O
5.2 . . O
) . . O
severe . . O
( . . O
% . . O
) . . O
0 . . O
1 . . O
( . . O
1 . . O
) . . O
compared . . O
to . . O
glipizide . . O
( . . O
52 . . O
weeks . . O
) . . O
nesina . . O
25 . . O
mg . . O
glipizide . . O
n . . O
= . . O
222 . . O
n . . O
= . . O
219 . . O
overall . . O
( . . O
% . . O
) . . O
12 . . O
( . . O
5.4 . . O
) . . O
57 . . O
( . . O
26 . . O
) . . O
severe . . O
( . . O
% . . O
) . . O
0 . . O
3 . . O
( . . O
1.4 . . O
) . . O
add . . O
- . . O
on . . O
to . . O
metformin . . O
( . . O
26 . . O
weeks . . O
) . . O
nesina . . O
25 . . O
mg . . O
metformin . . O
500 . . O
mg . . O
twice . . O
daily . . O
n . . O
= . . O
112 . . O
n . . O
= . . O
109 . . O
overall . . O
( . . O
% . . O
) . . O
2 . . O
( . . O
1.8 . . O
) . . O
2 . . O
( . . O
1.8 . . O
) . . O
severe . . O
( . . O
% . . O
) . . O
0 . . O
0 . . O
add . . O
- . . O
on . . O
to . . O
metformin . . O
compared . . O
to . . O
glipizide . . O
( . . O
52 . . O
weeks . . O
) . . O
nesina . . O
25 . . O
mg+ . . O
metformin . . O
glipizide . . O
+ . . O
metformin . . O
n . . O
= . . O
877 . . O
n . . O
= . . O
869 . . O
overall . . O
( . . O
% . . O
) . . O
12 . . O
( . . O
1.4 . . O
) . . O
207 . . O
( . . O
23.8 . . O
) . . O
severe . . O
( . . O
% . . O
) . . O
0 . . O
4 . . O
( . . O
0.5 . . O
) . . O
vital . . O
signs . . O

3 . . O
contact . . O
dermatitis . . O

if . . O
an . . O
anaphylactic . . O
reaction . . O
to . . O
zerbaxa . . O
occurs . . O
, . . O
discontinue . . O
the . . O
drug . . O
and . . O
institute . . O
appropriate . . O
therapy . . O
. . . O

patients . . O
were . . O
allowed . . O
, . . O
but . . O
not . . O
required . . O
, . . O
to . . O
take . . O
glucocorticoids . . O
. . . O

following . . O
resolution . . O
of . . O
transaminase . . O
elevations . . O
, . . O
consider . . O
the . . O
benefits . . O
and . . O
risks . . O
of . . O
resuming . . O
kalydeco . . O
dosing . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

duavee . . O
is . . O
not . . O
for . . O
pregnant . . O
women . . O
. . . O

* . . O
bacterial . . O
, . . O
viral . . O
and . . O
other . . O
infections . . O
due . . O
to . . O
opportunistic . . O
pathogens . . O
, . . O
including . . O
legionella . . O
and . . O
listeria . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
carbohydrate . . O
and . . O
lipid . . B-AdverseReaction
metabolic . . I-AdverseReaction
effects . . I-AdverseReaction
: . . O
monitor . . O
prediabetic . . O
and . . O
diabetic . . O
women . . O
taking . . O
natazia . . O
. . . O

5.6 . . O
embryofetal . . O
toxicity . . O

the . . O
stated . . O
frequencies . . O
of . . O
adverse . . O
reactions . . O
represent . . O
the . . O
proportion . . O
of . . O
individuals . . O
who . . O
experienced . . O
a . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
event . . O
of . . O
the . . O
type . . O
listed . . O
. . . O

face . . O
and . . O
scalp . . O
( . . O
n . . O
= . . O
545 . . O
) . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
, . . O
0.015% . . O
once . . O
daily . . O
for . . O
3 . . O
days . . O

( . . O
5.3 . . O
) . . O
* . . O
clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
diarrhea . . I-AdverseReaction
( . . O
cdad . . B-AdverseReaction
) . . O
has . . O
been . . O
reported . . O
with . . O
nearly . . O
all . . O
systemic . . O
antibacterial . . O
agents . . O
, . . O
including . . O
dalvance . . O
. . . O

the . . O
protocol . . O
specified . . O
that . . O
patients . . O
continue . . O
receiving . . O
intravenous . . O
hydration . . O
, . . O
urinary . . O
alkalinization . . O
and . . O
leucovorin . . O
, . . O
and . . O
that . . O
leucovorin . . O
administration . . O
be . . O
adjusted . . O
to . . O
ensure . . O
that . . O
it . . O
was . . O
not . . O
administered . . O
within . . O
two . . O
hours . . O
before . . O
or . . O
after . . O
voraxaze . . O
. . . O

excerpt . . O
: . . O
* . . O
thrombotic . . B-AdverseReaction
events . . I-AdverseReaction
: . . O
discontinue . . O
cometriq . . O
for . . O
myocardial . . O
infarction . . O
, . . O
cerebral . . O
infarction . . O
, . . O
or . . O
other . . O
serious . . O
arterial . . O
thromboembolic . . O
events . . O
. . . O

the . . O
incidence . . O
of . . O
the . . O
following . . O
grade . . B-Severity
3-4 . . I-Severity
adverse . . O
reactions . . O
were . . O
higher . . O
in . . O
patients . . O
> . . O
= . . O
65 . . O
years . . O
of . . O
age . . O
compared . . O
to . . O
younger . . O
patients . . O
; . . O
neutropenia . . B-AdverseReaction
( . . O
87% . . O
vs . . O
. . . O
74% . . O
) . . O
, . . O
and . . O
febrile . . B-AdverseReaction
neutropenia . . I-AdverseReaction
( . . O
8% . . O
vs . . O
. . . O
6% . . O
) . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
) . . O
] . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
. . . O

adverse . . O
reaction . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
( . . O
n . . O
= . . O
201 . . O
) . . O
% . . O
fluticasone . . O
furoate . . O
100 . . O
mcg . . O
( . . O
n . . O
= . . O
205 . . O
) . . O
% . . O
placebo . . O
( . . O
n . . O
= . . O
203 . . O
) . . O
% . . O
infections . . O
and . . O
infestations . . O
nasopharyngitis . . B-AdverseReaction
10 . . O
7 . . O
7 . . O
oral . . B-AdverseReaction
candidiasis . . I-AdverseReaction
a . . O
2 . . O
2 . . O
0 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
5 . . O
4 . . O
4 . . O
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
2 . . O
2 . . O
1 . . O
dysphonia . . B-AdverseReaction
2 . . O
1 . . O
0 . . O
a . . O
includes . . O
oral . . B-AdverseReaction
candidiasis . . I-AdverseReaction
and . . O
oropharyngeal . . B-AdverseReaction
candidiasis . . I-AdverseReaction
. . . O

clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
diarrhea . . I-AdverseReaction
( . . O
cdad . . B-AdverseReaction
) . . O
has . . O
been . . O
reported . . O
for . . O
nearly . . O
all . . O
systemic . . O
antibacterial . . O
agents . . O
, . . O
including . . O
zerbaxa . . O
, . . O
and . . O
may . . O
range . . O
in . . O
severity . . O
from . . O
mild . . B-Severity
diarrhea . . B-AdverseReaction
to . . O
fatal . . B-AdverseReaction
colitis . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
commonly . . O
observed . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
5% . . O
and . . O
2 . . O
- . . O
fold . . O
greater . . O
than . . O
placebo . . O
) . . O
were . . O
: . . O
dizziness . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
, . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
and . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

patients . . O
with . . O
risk . . O
factors . . O
for . . O
diabetes . . O
mellitus . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
obesity . . O
, . . O
family . . O
history . . O
of . . O
diabetes . . O
) . . O
who . . O
are . . O
starting . . O
treatment . . O
with . . O
atypical . . O
antipsychotics . . O
should . . O
undergo . . O
fasting . . O
blood . . O
glucose . . O
testing . . O
at . . O
the . . O
beginning . . O
of . . O
treatment . . O
and . . O
periodically . . O
during . . O
treatment . . O
. . . O

fungus . . O
invasion . . O
must . . O
be . . O
considered . . O
in . . O
any . . O
persistent . . O
corneal . . O
ulceration . . O
where . . O
a . . O
steroid . . O
has . . O
been . . O
used . . O
or . . O
is . . O
in . . O
use . . O
. . . O

who . . O
should . . O
not . . O
take . . O
duavee . . O
? . . O

the . . O
possibility . . O
of . . O
these . . O
adverse . . O
events . . O
should . . O
be . . O
considered . . O
in . . O
patients . . O
treated . . O
with . . O
pristiq . . O
who . . O
present . . O
with . . O
progressive . . O
dyspnea . . O
, . . O
cough . . O
, . . O
or . . O
chest . . O
discomfort . . O
. . . O

table . . O
5 . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
with . . O
> . . O
1% . . O
incidence . . O
in . . O
pooled . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
for . . O
glabellar . . O
lines . . O
adverse . . O
reactions . . O
by . . O
body . . O
system . . O
dysport . . O
( . . O
r . . O
) . . O
n . . O
= . . O
398 . . O
( . . O
% . . O
) . . O
placebon . . O
= . . O
496 . . O
( . . O
% . . O
) . . O
any . . O
adverse . . O
reaction . . O
48 . . O
33 . . O
eye . . O
disorders . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
2 . . O
0 . . O
eyelid . . B-AdverseReaction
ptosis . . I-AdverseReaction
2 . . O
< . . O
1 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
2 . . O
1 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
3 . . O
2 . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
3 . . O
< . . O
1 . . O
infections . . O
and . . O
infestations . . O
nasopharyngitis . . B-AdverseReaction
10 . . O
4 . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
3 . . O
2 . . O
sinusitis . . B-AdverseReaction
2 . . O
1 . . O
investigations . . O
blood . . B-AdverseReaction
present . . I-AdverseReaction
in . . I-AdverseReaction
urine . . I-AdverseReaction
2 . . O
< . . O
1 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
9 . . O
5 . . O
in . . O
the . . O
overall . . O
safety . . O
database . . O
, . . O
where . . O
some . . O
patients . . O
received . . O
up . . O
to . . O
twelve . . O
treatments . . O
with . . O
dysport . . O
( . . O
r . . O
) . . O
, . . O
adverse . . O
reactions . . O
were . . O
reported . . O
for . . O
57% . . O
( . . O
1425 . . O
/ . . O
2491 . . O
) . . O
of . . O
patients . . O
. . . O

human . . O
relevance . . O
of . . O
glp . . B-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
receptor . . I-DrugClass
agonist . . I-DrugClass
induced . . O
c . . B-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
in . . O
rodents . . B-Animal
has . . O
not . . O
been . . O
determined . . O
. . . O

table . . O
8 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
2% . . O
or . . O
more . . O
of . . O
adult . . O
patients . . O
in . . O
any . . O
saphris . . O
dose . . O
group . . O
and . . O
which . . O
occurred . . O
at . . O
greater . . O
incidence . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
in . . O
6 . . O
- . . O
week . . O
schizophrenia . . O
trials . . O
* . . O
akathisia . . B-AdverseReaction
includes . . O
: . . O
akathisia . . B-AdverseReaction
and . . O
hyperkinesia . . B-AdverseReaction
. . . O

adverse . . O
reaction . . O
n . . O
= . . O
290n . . O
( . . O
% . . O
) . . O
paresthesias . . B-AdverseReaction
7 . . O
( . . O
2% . . O
) . . O
flushing . . B-AdverseReaction
1,2 . . O
5 . . O
( . . O
2% . . O
) . . O
nausea . . B-AdverseReaction
/ . . O
vomiting . . B-AdverseReaction
5 . . O
( . . O
2% . . O
) . . O
headache . . B-AdverseReaction
2 . . O
( . . O
1% . . O
) . . O
hypotension . . B-AdverseReaction
2 . . O
( . . O
1% . . O
) . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
1 . . O
( . . O
< . . O
1% . . O
) . . O
diarrhea . . B-AdverseReaction
1 . . O
( . . O
< . . O
1% . . O
) . . O
hypersensitivity . . B-AdverseReaction
1 . . O
( . . O
< . . O
1% . . O
) . . O
hypertension . . B-AdverseReaction
1 . . O
( . . O
< . . O
1% . . O
) . . O
rash . . B-AdverseReaction
1 . . O
( . . O
< . . O
1% . . O
) . . O
throat . . B-AdverseReaction
irritation . . I-AdverseReaction
/ . . O
throat . . B-AdverseReaction
tightness . . I-AdverseReaction
1 . . O
( . . O
< . . O
1% . . O
) . . O
tremor . . B-AdverseReaction
1 . . O
( . . O
< . . O
1% . . O
) . . O
6.2 . . O
immunogenicity . . O
as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
potential . . O
for . . O
immunogenicity . . O
. . . O

adverse . . O
reactions . . O
which . . O
occurred . . O
in . . O
> . . O
= . . O
25% . . O
of . . O
cometriq . . O
- . . O
treated . . O
patients . . O
occurring . . O
more . . O
frequently . . O
in . . O
the . . O
cometriq . . O
arm . . O
with . . O
a . . O
between . . O
- . . O
arm . . O
difference . . O
of . . O
> . . O
= . . O
5% . . O
included . . O
, . . O
in . . O
order . . O
of . . O
decreasing . . O
frequency . . O
: . . O
diarrhea . . B-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ppes . . B-AdverseReaction
) . . O
, . . O
decreased . . B-AdverseReaction
weight . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
hair . . B-AdverseReaction
color . . I-AdverseReaction
changes . . I-AdverseReaction
, . . O
dysgeusia . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
constipation . . B-AdverseReaction
. . . O

seroconversion . . B-AdverseReaction
from . . I-AdverseReaction
a . . I-AdverseReaction
negative . . I-AdverseReaction
to . . I-AdverseReaction
a . . I-AdverseReaction
positive . . I-AdverseReaction
direct . . I-AdverseReaction
coombs' . . I-AdverseReaction
test . . I-AdverseReaction
result . . I-AdverseReaction
occurred . . O
in . . O
120 . . O
/ . . O
1114 . . O
( . . O
10.8% . . O
) . . O
of . . O
patients . . O
receiving . . O
teflaro . . O
and . . O
49 . . O
/ . . O
1116 . . O
( . . O
4.4% . . O
) . . O
of . . O
patients . . O
receiving . . O
comparator . . O
drugs . . O
in . . O
the . . O
four . . O
pooled . . O
phase . . O
3 . . O
trials . . O
. . . O

serum . . O
iron . . O
determination . . O
using . . O
complexometric . . O
methods . . O
( . . O
for . . O
example . . O
, . . O
ferrocene . . O
complexation . . O
method . . O
) . . O
may . . O
result . . O
in . . O
falsely . . O
high . . O
or . . O
low . . O
values . . O
for . . O
up . . O
to . . O
24 . . O
hours . . O
after . . O
the . . O
examination . . O
with . . O
eovist . . O
because . . O
of . . O
the . . O
caloxetate . . O
trisodium . . O
excipients . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

for . . O
patients . . O
at . . O
highest . . O
risk . . O
for . . O
nsf . . O
, . . O
do . . O
not . . O
exceed . . O
the . . O
recommended . . O
gadavist . . O
dose . . O
and . . O
allow . . O
a . . O
sufficient . . O
period . . O
of . . O
time . . O
for . . O
elimination . . O
of . . O
the . . O
drug . . O
prior . . O
to . . O
re . . O
- . . O
administration . . O
. . . O

5.1 . . O
iop . . O
increase . . O

( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
high . . O
- . . O
dose . . O
or . . O
multiple . . O
non . . O
- . . O
steroidal . . O
anti . . O
- . . O
inflammatory . . O
drugs . . O
( . . O
nsaids . . O
) . . O
) . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.4 . . O
) . . O
] . . O
. . . O

limited . . O
safety . . O
data . . O
are . . O
available . . O
in . . O
patients . . O
with . . O
predisposing . . O
factors . . O
for . . O
seizure . . O
because . . O
these . . O
patients . . O
were . . O
generally . . O
excluded . . O
from . . O
the . . O
trials . . O
. . . O

the . . O
long . . O
- . . O
term . . O
clinical . . O
effects . . O
of . . O
the . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
hr . . I-AdverseReaction
have . . O
not . . O
been . . O
established . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
. . . O

5.6 . . O
rebound . . O
hypertension . . O

eleven . . O
of . . O
the . . O
13 . . O
fractures . . B-AdverseReaction
were . . O
reported . . O
within . . O
the . . O
first . . O
52 . . O
weeks . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
progressive . . B-AdverseReaction
multifocal . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
( . . O
pml . . B-AdverseReaction
) . . O
: . . O
withhold . . O
tecfidera . . O
at . . O
the . . O
first . . O
sign . . O
or . . O
symptom . . O
suggestive . . O
of . . O
pml . . O
. . . O

reduce . . O
or . . O
withhold . . O
dose . . O
as . . O
appropriate . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
that . . O
led . . O
to . . O
permanent . . O
discontinuation . . O
in . . O
xalkori . . O
- . . O
treated . . O
patients . . O
were . . O
elevated . . B-AdverseReaction
transaminases . . I-AdverseReaction
( . . O
1.2% . . O
) . . O
, . . O
hepatotoxicity . . B-AdverseReaction
( . . O
1.2% . . O
) . . O
, . . O
and . . O
ild . . B-AdverseReaction
( . . O
1.2% . . O
) . . O
. . . O

new . . O
malignancies . . O
new . . O
malignancies . . B-AdverseReaction
were . . O
reported . . O
in . . O
no . . O
patients . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
4 . . O
( . . O
3.3% . . O
) . . O
patients . . O
( . . O
3 . . O
prostate . . B-AdverseReaction
cancers . . I-AdverseReaction
, . . O
1 . . O
basal . . B-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
) . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

( . . O
5.5 . . O
) . . O

the . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
observed . . O
with . . O
potiga . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
who . . O
were . . O
originally . . O
enrolled . . O
in . . O
clinical . . O
trials . . O
with . . O
potiga . . O
and . . O
who . . O
have . . O
generally . . O
taken . . O
the . . O
drug . . O
for . . O
a . . O
long . . O
period . . O
of . . O
time . . O
in . . O
2 . . O
ongoing . . O
extension . . O
trials . . O
. . . O

patients . . O
with . . O
neuromuscular . . O
disorders . . O
may . . O
be . . O
at . . O
increased . . O
risk . . B-Factor
of . . O
clinically . . O
significant . . O
effects . . O
including . . O
severe . . B-Severity
dysphagia . . B-AdverseReaction
and . . O
respiratory . . B-AdverseReaction
compromise . . I-AdverseReaction
from . . O
typical . . O
doses . . O
of . . O
xeomin . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

among . . O
patients . . O
in . . O
whom . . O
the . . O
status . . O
of . . O
both . . O
skin . . O
, . . O
nail . . O
, . . O
lip . . O
, . . O
or . . O
mucous . . B-AdverseReaction
membrane . . I-AdverseReaction
discoloration . . I-AdverseReaction
and . . O
retinal . . B-AdverseReaction
pigmentary . . I-AdverseReaction
abnormalities . . I-AdverseReaction
are . . O
reported . . O
, . . O
approximately . . O
a . . O
quarter . . O
of . . O
those . . O
with . . O
skin . . O
, . . O
nail . . O
, . . O
lip . . O
, . . O
or . . O
mucous . . B-AdverseReaction
membrane . . I-AdverseReaction
discoloration . . I-AdverseReaction
had . . O
concurrent . . O
retinal . . B-AdverseReaction
pigmentary . . I-AdverseReaction
abnormalities . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

some . . O
of . . O
these . . O
abnormalities . . O
were . . O
considered . . O
potentially . . O
clinically . . O
significant . . O
. . . O

remove . . O
contact . . O
lenses . . O
prior . . O
to . . O
instillation . . O
of . . O
durezol . . O
. . . O

excerpt . . O
: . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
were . . O
flushing . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
headache . . B-AdverseReaction
( . . O
1% . . O
) . . O
, . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
1% . . O
) . . O
, . . O
and . . O
dizziness . . B-AdverseReaction
( . . O
1% . . O
) . . O
. . . O

intensive . . O
measures . . O
may . . O
be . . O
required . . O
for . . O
severe . . O
diarrhea . . O
and . . O
electrolyte . . O
imbalance . . O
. . . O

some . . O
patients . . O
who . . O
were . . O
pre . . O
- . . O
treated . . O
with . . O
antihistamines . . O
, . . O
antipyretics . . O
and . . O
/ . . O
or . . O
corticosteroids . . O
still . . O
experienced . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
. . . O

do . . O
not . . O
restart . . O
if . . O
confirmed . . O
. . . O

table . . O
3 . . O
: . . O
key . . O
laboratory . . O
abnormalities . . O
reported . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
patients . . O
with . . O
advanced . . O
hr+ . . O
bc . . O
grading . . O
according . . O
to . . O
ctcae . . O
version . . O
3.0 . . O
a . . O
exemestane . . O
( . . O
25 . . O
mg . . O
/ . . O
day . . O
) . . O
b . . O
reflects . . O
corresponding . . O
adverse . . O
drug . . O
reaction . . O
reports . . O
of . . O
anemia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
and . . O
thrombocytopenia . . B-AdverseReaction
( . . O
collectively . . O
as . . O
pancytopenia . . B-AdverseReaction
) . . O
, . . O
which . . O
occurred . . O
at . . O
lower . . O
frequency . . O
. . . O

excerpt . . O
: . . O
rule . . O
out . . O
infectious . . O
etiologies . . O
of . . O
diarrhea . . O
before . . O
starting . . O
crofelemer . . O
. . . O

concurrent . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
alanine . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
( . . O
alt . . O
) . . O
or . . O
aspartate . . O
aminotransferase . . O
( . . O
ast . . O
) . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
three . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . I-Severity
uln . . I-Severity
) . . I-Severity
and . . O
total . . O
bilirubin . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
two . . O
times . . O
the . . O
uln . . O
, . . O
with . . O
normal . . O
alkaline . . O
phosphatase . . O
, . . O
occurred . . O
in . . O
10 . . O
patients . . O
( . . O
0.6% . . O
) . . O
treated . . O
with . . O
xalkori . . O
. . . O

( . . O
6.1 . . O
) . . O
* . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
for . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
are . . O
pyrexia . . B-AdverseReaction
, . . O
chills . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
night . . B-AdverseReaction
sweats . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
and . . O
myalgia . . B-AdverseReaction
. . . O

in . . O
the . . O
pooled . . O
analysis . . O
of . . O
8 . . O
controlled . . O
trials . . O
, . . O
phimosis . . B-AdverseReaction
was . . O
reported . . O
in . . O
0.3% . . O
of . . O
uncircumcised . . O
male . . O
patients . . O
treated . . O
with . . O
invokana . . O
and . . O
0.2% . . O
required . . O
circumcision . . O
to . . O
treat . . O
the . . O
phimosis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
. . . O

appropriate . . O
medical . . O
support . . O
and . . O
monitoring . . O
measures . . O
should . . O
be . . O
readily . . O
available . . O
during . . O
alglucosidase . . O
alfa . . O
infusion . . O
, . . O
and . . O
some . . O
patients . . O
may . . O
require . . O
prolonged . . O
observation . . O
times . . O
that . . O
should . . O
be . . O
individualized . . O
based . . O
on . . O
the . . O
needs . . O
of . . O
the . . O
patient . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reaction . . O
occurring . . O
in . . O
approximately . . O
25% . . O
of . . O
patients . . O
was . . O
a . . O
mild . . B-Severity
taste . . B-AdverseReaction
following . . I-AdverseReaction
instillation . . I-AdverseReaction
. . . O

impairment . . O
and . . O
if . . O
observed . . O
, . . O
treat . . O
urgently . . O
. . . O

in . . O
patients . . O
with . . O
normal . . O
or . . O
mildly . . O
impaired . . O
renal . . O
function . . O
at . . O
baseline . . O
, . . O
serum . . O
creatinine . . O
and . . O
egfr . . O
returned . . O
to . . O
baseline . . O
values . . O
at . . O
week . . O
24 . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
- . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction

laboratory . . O
abnormalities . . O
occurring . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
patients . . O
who . . O
received . . O
inlyta . . O
or . . O
sorafenib . . O
laboratory . . O
abnormality . . O
n . . O
inlyta . . O
n . . O
sorafenib . . O
all . . O
grades . . O
grade . . O
3 . . O
/ . . O
4 . . O
all . . O
grades . . O
grade . . O
3 . . O
/ . . O
4 . . O
% . . O
% . . O
% . . O
% . . O
alp . . O
: . . O
alkaline . . O
phosphatase . . O
; . . O
alt . . O
: . . O
alanine . . O
aminotransferase . . O
; . . O
ast . . O
: . . O
aspartate . . O
aminotransferase . . O
hematology . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
320 . . O
35 . . O
< . . O
1 . . O
316 . . O
52 . . O
4 . . O
lymphocytes . . B-AdverseReaction
( . . I-AdverseReaction
absolute . . I-AdverseReaction
) . . I-AdverseReaction
decreased . . I-AdverseReaction
317 . . O
33 . . O
3 . . O
309 . . O
36 . . O
4 . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
312 . . O
15 . . O
< . . O
1 . . O
310 . . O
14 . . O
0 . . O
white . . B-AdverseReaction
blood . . I-AdverseReaction
cells . . I-AdverseReaction
decreased . . I-AdverseReaction
320 . . O
11 . . O
0 . . O
315 . . O
16 . . O
< . . O
1 . . O
chemistry . . O
creatinine . . B-AdverseReaction
increased . . I-AdverseReaction
336 . . O
55 . . O
0 . . O
318 . . O
41 . . O
< . . O
1 . . O
bicarbonate . . B-AdverseReaction
decreased . . I-AdverseReaction
314 . . O
44 . . O
< . . O
1 . . O
291 . . O
43 . . O
0 . . O
hypocalcemia . . B-AdverseReaction
336 . . O
39 . . O
1 . . O
319 . . O
59 . . O
2 . . O
alp . . B-AdverseReaction
increased . . I-AdverseReaction
336 . . O
30 . . O
1 . . O
319 . . O
34 . . O
1 . . O
hyperglycemia . . B-AdverseReaction
336 . . O
28 . . O
2 . . O
319 . . O
23 . . O
2 . . O
lipase . . B-AdverseReaction
increased . . I-AdverseReaction
338 . . O
27 . . O
5 . . O
319 . . O
46 . . O
15 . . O
amylase . . B-AdverseReaction
increased . . I-AdverseReaction
338 . . O
25 . . O
2 . . O
319 . . O
33 . . O
2 . . O
alt . . B-AdverseReaction
increased . . I-AdverseReaction
331 . . O
22 . . O
< . . O
1 . . O
313 . . O
22 . . O
2 . . O
ast . . B-AdverseReaction
increased . . I-AdverseReaction
331 . . O
20 . . O
< . . O
1 . . O
311 . . O
25 . . O
1 . . O
hypernatremia . . B-AdverseReaction
338 . . O
17 . . O
1 . . O
319 . . O
13 . . O
1 . . O
hypoalbuminemia . . B-AdverseReaction
337 . . O
15 . . O
< . . O
1 . . O
319 . . O
18 . . O
1 . . O
hyperkalemia . . B-AdverseReaction
333 . . O
15 . . O
3 . . O
314 . . O
10 . . O
3 . . O
hypoglycemia . . B-AdverseReaction
336 . . O
11 . . O
< . . O
1 . . O
319 . . O
8 . . O
< . . O
1 . . O
hyponatremia . . B-AdverseReaction
338 . . O
13 . . O
4 . . O
319 . . O
11 . . O
2 . . O
hypophosphatemia . . B-AdverseReaction
336 . . O
13 . . O
2 . . O
318 . . O
49 . . O
16 . . O
selected . . O
laboratory . . O
abnormalities . . O
( . . O
all . . O
grades . . O
) . . O
that . . O
were . . O
reported . . O
in . . O
< . . O
10% . . O
of . . O
patients . . O
treated . . O
with . . O
inlyta . . O
included . . O
hemoglobin . . B-AdverseReaction
increased . . I-AdverseReaction
( . . O
above . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
) . . O
( . . O
9% . . O
for . . O
inlyta . . O
versus . . O
1% . . O
for . . O
sorafenib . . O
) . . O
and . . O
hypercalcemia . . B-AdverseReaction
( . . O
6% . . O
for . . O
inlyta . . O
versus . . O
2% . . O
for . . O
sorafenib . . O
) . . O
. . . O

the . . O
rates . . O
of . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
events . . O
resulting . . O
in . . O
permanent . . O
discontinuation . . O
were . . O
24% . . O
and . . O
5% . . O
for . . O
the . . O
afinitor . . O
plus . . O
exemestane . . O
and . . O
placebo . . O
plus . . O
exemestane . . O
treatment . . O
groups . . O
, . . O
respectively . . O
. . . O

the . . O
adverse . . O
reactions . . O
below . . O
reflect . . O
exposure . . O
to . . O
xeomin . . O
with . . O
glabellar . . O
lines . . O
in . . O
placebo . . O
- . . O
controlled . . O
studies . . O
. . . O

serum . . O
creatinine . . O

hcv . . O
- . . O
rna . . O
result . . O
( . . O
reported . . O
as . . O
" . . O
target . . O
not . . O
detected . . O
" . . O
or . . O
" . . O
hcv . . O
- . . O
rna . . O
not . . O
detected . . O
" . . O
) . . O
. . . O

tables . . O
5 . . O
and . . O
6 . . O
summarize . . O
common . . O
adverse . . O
reactions . . O
and . . O
laboratory . . O
abnormalities . . O
in . . O
xalkori . . O
- . . O
treated . . O
patients . . O
. . . O

blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
: . . O
agranulocytosis . . B-AdverseReaction
, . . O
pancytopenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O

5 . . O
warnings . . O
and . . O
precautions . . O

record . . O
the . . O
specific . . O
gbca . . O
and . . O
the . . O
dose . . O
administrated . . O
to . . O
a . . O
patient . . O
. . . O

adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
in . . O
an . . O
lgs . . O
placebo . . O
controlled . . O
clinical . . O
trial . . O
( . . O
study . . O
1 . . O
) . . O
the . . O
adverse . . O
reactions . . O
associated . . O
with . . O
onfi . . O
treatment . . O
discontinuation . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
in . . O
decreasing . . O
order . . O
of . . O
frequency . . O
included . . O
lethargy . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
ataxia . . B-AdverseReaction
, . . O
aggression . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
insomnia . . B-AdverseReaction
. . . O

monitor . . O
patients . . O
for . . O
fever . . O
and . . O
infections . . O
and . . O
evaluate . . O
promptly . . O
. . . O

patients . . O
should . . O
discontinue . . O
use . . O
of . . O
any . . O
product . . O
containing . . O
4 . . O
- . . O
aminopyridine . . O
prior . . O
to . . O
initiating . . O
treatment . . O
with . . O
ampyra . . O
in . . O
order . . O
to . . O
reduce . . O
the . . O
potential . . O
for . . O
dose . . O
- . . O
related . . O
adverse . . O
reactions . . O
. . . O

mild . . B-Severity
( . . O
less . . O
than . . O
lln . . B-Severity
and . . O
greater . . O
than . . O
75 . . B-Severity
x . . I-Severity
10 . . I-Severity
9 . . I-Severity
/ . . I-Severity
l . . I-Severity
) . . O
and . . O
transient . . B-Severity
decreases . . B-AdverseReaction
in . . I-AdverseReaction
platelet . . I-AdverseReaction
counts . . I-AdverseReaction
were . . O
observed . . O
in . . O
3 . . O
( . . O
6.3% . . O
) . . O
ilaris . . O
treated . . O
patients . . O
versus . . O
1 . . O
( . . O
2.0% . . O
) . . O
placebo . . O
- . . O
treated . . O
patient . . O
. . . O

neuropathy . . O

ensure . . O
safe . . O
handling . . O
to . . O
protect . . O
patients . . O
and . . O
health . . O
care . . O
workers . . O
from . . O
unintentional . . O
radiation . . O
exposure . . O
( . . O
2.1 . . O
, . . O
5.3 . . O
) . . O

consider . . O
the . . O
risks . . O
and . . O
benefits . . O
of . . O
re . . O
- . . O
administering . . O
vimizim . . O
following . . O
a . . O
severe . . O
reaction . . O
. . . O

the . . O
median . . O
time . . O
to . . O
first . . O
onset . . O
of . . O
any . . O
grade . . O
was . . O
14 . . O
weeks . . O
( . . O
range . . O
, . . O
0.1-47 . . O
) . . O
, . . O
of . . O
grade . . O
2 . . O
was . . O
27 . . O
weeks . . O
( . . O
range . . O
, . . O
0.4-52 . . O
) . . O
and . . O
of . . O
grade . . O
3 . . O
was . . O
34 . . O
weeks . . O
( . . O
range . . O
, . . O
7-106 . . O
) . . O
. . . O

manage . . O
fluid . . O
and . . O
electrolyte . . O
levels . . O
as . . O
appropriate . . O
, . . O
supplement . . O
protein . . O
intake . . O
, . . O
monitor . . O
antibacterial . . O
treatment . . O
of . . O
c . . O
. . . O
difficile . . O
, . . O
and . . O
institute . . O
surgical . . O
evaluation . . O
as . . O
clinically . . O
indicated . . O
. . . O

adverse . . O
reactions . . O
with . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
with . . O
> . . O
= . . O
2% . . O
incidence . . O
and . . O
more . . O
common . . O
than . . O
placebo . . O
in . . O
subjects . . O
with . . O
asthma . . O
( . . O
trial . . O
1 . . O
) . . O

excerpt . . O
: . . O
exclusive . . O
of . . O
an . . O
uncommon . . O
, . . O
mild . . B-Severity
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
no . . O
other . . O
adverse . . O
reactions . . O
have . . O
been . . O
reported . . O
( . . O
6 . . O
) . . O
. . . O

* . . O
increased . . O
risk . . B-Factor
of . . O
serious . . B-Severity
infections . . B-AdverseReaction
leading . . O
to . . O
hospitalization . . O
or . . O
death . . B-AdverseReaction
including . . O
tuberculosis . . B-AdverseReaction
( . . O
tb . . B-AdverseReaction
) . . O
, . . O
bacterial . . B-AdverseReaction
sepsis . . I-AdverseReaction
, . . O
invasive . . B-AdverseReaction
fungal . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
such . . O
as . . O
histoplasmosis . . B-AdverseReaction
) . . O
, . . O
and . . O
infections . . B-AdverseReaction
due . . I-AdverseReaction
to . . I-AdverseReaction
other . . I-AdverseReaction
opportunistic . . I-AdverseReaction
pathogens . . I-AdverseReaction
( . . O
5.1 . . O
) . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

5.3 . . O
neuroleptic . . O
malignant . . O
syndrome . . O
( . . O
nms . . O
) . . O

in . . O
the . . O
pool . . O
of . . O
13 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
increases . . O
from . . O
baseline . . O
in . . O
mean . . O
hematocrit . . O
values . . O
were . . O
observed . . O
in . . O
farxiga . . O
- . . O
treated . . O
patients . . O
starting . . O
at . . O
week . . O
1 . . O
and . . O
continuing . . O
up . . O
to . . O
week . . O
16 . . O
, . . O
when . . O
the . . O
maximum . . O
mean . . O
difference . . O
from . . O
baseline . . O
was . . O
observed . . O
. . . O

table . . O
6 . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
observed . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
patients . . O
treated . . O
in . . O
pooled . . O
, . . O
double . . O
- . . O
blind . . O
trials . . O
of . . O
patients . . O
with . . O
upper . . O
limb . . O
spasticity . . O
reported . . O
more . . O
frequently . . O
than . . O
with . . O
placebo . . O
adverse . . O
reaction . . O
preferred . . O
term . . O
dysport . . O
( . . O
r . . O
) . . O
placebo . . O
500 . . O
units . . O
( . . O
n . . O
= . . O
197 . . O
) . . O
% . . O
1000 . . O
units . . O
( . . O
n . . O
= . . O
194 . . O
) . . O
% . . O
( . . O
n . . O
= . . O
279 . . O
) . . O
% . . O
infections . . O
and . . O
infestations . . O
nasopharyngitis . . B-AdverseReaction
4 . . O
1 . . O
1 . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
3 . . O
1 . . O
2 . . O
influenza . . B-AdverseReaction
1 . . O
2 . . O
1 . . O
infection . . B-AdverseReaction
1 . . O
2 . . O
1 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
2 . . O
4 . . O
1 . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
0 . . O
2 . . O
1 . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
3 . . O
2 . . O
2 . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
1 . . O
2 . . O
1 . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
1 . . O
2 . . O
1 . . O
dizziness . . B-AdverseReaction
3 . . O
1 . . O
1 . . O
convulsion . . B-AdverseReaction
2 . . O
2 . . O
1 . . O
syncope . . B-AdverseReaction
1 . . O
2 . . O
0 . . O
hypoaesthesia . . B-AdverseReaction
0 . . O
2 . . O
< . . O
1 . . O
partial . . B-AdverseReaction
seizures . . I-AdverseReaction
0 . . O
2 . . O
0 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
2 . . O
2 . . O
0 . . O
asthenia . . B-AdverseReaction
2 . . O
1 . . O
< . . O
1 . . O
injury . . O
, . . O
poisoning . . O
and . . O
procedural . . O
complications . . O
fall . . B-AdverseReaction
2 . . O
3 . . O
2 . . O
injury . . B-AdverseReaction
2 . . O
2 . . O
1 . . O
contusion . . B-AdverseReaction
1 . . O
2 . . O
< . . O
1 . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
1 . . O
2 . . O
< . . O
1 . . O
nausea . . B-AdverseReaction
2 . . O
1 . . O
1 . . O
constipation . . B-AdverseReaction
0 . . O
2 . . O
1 . . O
investigation . . O
blood . . B-AdverseReaction
triglycerides . . I-AdverseReaction
increased . . I-AdverseReaction
2 . . O
1 . . O
0 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
1 . . O
2 . . O
1 . . O
vascular . . O
disorders . . O
hypertension . . B-AdverseReaction
1 . . O
2 . . O
< . . O
1 . . O
psychiatric . . O
disorders . . O
depression . . B-AdverseReaction
2 . . O
3 . . O
1 . . O
injection . . O
site . . O
reactions . . O

5.1 . . O
asthma . . O
- . . O
related . . O
death . . O
[ . . O
see . . O
boxed . . O
warning . . O
] . . O

jardiance . . O
increases . . O
the . . O
risk . . B-Factor
for . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

rare . . O
cases . . O
of . . O
anaphylaxis . . B-AdverseReaction
and . . O
angioedema . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
aptiom . . O
. . . O

advise . . O
patients . . O
treated . . O
with . . O
multaq . . O
to . . O
report . . O
immediately . . O
symptoms . . O
suggesting . . O
hepatic . . O
injury . . O
( . . O
such . . O
as . . O
anorexia . . O
, . . O
nausea . . O
, . . O
vomiting . . O
, . . O
fever . . O
, . . O
malaise . . O
, . . O
fatigue . . O
, . . O
right . . O
upper . . O
quadrant . . O
pain . . O
, . . O
jaundice . . O
, . . O
dark . . O
urine . . O
, . . O
or . . O
itching . . O
) . . O
. . . O

no . . O
cases . . O
of . . O
transmission . . O
of . . O
viral . . B-AdverseReaction
diseases . . I-AdverseReaction
or . . O
cjd . . B-AdverseReaction
have . . O
ever . . O
been . . O
reported . . O
for . . O
albumin . . O
. . . O

the . . O
safety . . O
of . . O
stendra . . O
is . . O
unknown . . O
in . . O
patients . . O
with . . O
bleeding . . O
disorders . . O
and . . O
patients . . O
with . . O
active . . O
peptic . . O
ulceration . . O
. . . O

in . . O
the . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
portions . . O
of . . O
the . . O
clinical . . O
trials . . O
in . . O
peyronie's . . O
disease . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
, . . O
a . . O
greater . . O
proportion . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
( . . O
4% . . O
) . . O
compared . . O
to . . O
placebo . . O
- . . O
treated . . O
patients . . O
( . . O
1% . . O
) . . O
had . . O
localized . . B-AdverseReaction
pruritus . . I-AdverseReaction
after . . O
up . . O
to . . O
4 . . O
treatment . . O
cycles . . O
( . . O
involving . . O
up . . O
to . . O
8 . . O
xiaflex . . O
injection . . O
procedures . . O
) . . O
. . . O

* . . O
a . . O
placebo . . O
- . . O
controlled . . O
study . . O
with . . O
another . . O
long . . B-DrugClass
- . . I-DrugClass
acting . . I-DrugClass
beta2 . . I-DrugClass
- . . I-DrugClass
adrenergic . . I-DrugClass
agonist . . I-DrugClass
( . . O
salmeterol . . O
) . . O
showed . . O
an . . O
increase . . O
in . . O
asthma . . O
- . . O
related . . O
deaths . . B-AdverseReaction
in . . O
patients . . O
receiving . . O
salmeterol . . O
. . . O

macular . . B-AdverseReaction
edema . . I-AdverseReaction
generally . . O
partially . . O
or . . O
completely . . O
resolved . . O
with . . O
or . . O
without . . O
treatment . . O
after . . O
drug . . O
discontinuation . . O
. . . O

a . . O
total . . O
of . . O
1,224 . . O
patients . . O
were . . O
treated . . O
with . . O
duavee . . O
and . . O
1,069 . . O
patients . . O
received . . O
placebo . . O
. . . O

tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
associated . . O
with . . O
treanda . . O
treatment . . O
has . . O
occurred . . O
in . . O
patients . . O
in . . O
clinical . . O
trials . . O
and . . O
in . . O
postmarketing . . O
reports . . O
. . . O

if . . O
intolerable . . O
symptoms . . O
occur . . O
following . . O
a . . O
decrease . . O
in . . O
the . . O
dose . . O
or . . O
upon . . O
discontinuation . . O
of . . O
treatment . . O
, . . O
then . . O
resuming . . O
the . . O
previously . . O
prescribed . . O
dose . . O
may . . O
be . . O
considered . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

cases . . O
of . . O
acute . . O
and . . O
chronic . . B-AdverseReaction
leukemia . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
post . . O
- . . O
marketing . . O
tnf . . O
- . . O
blocker . . O
use . . O
in . . O
rheumatoid . . O
arthritis . . O
and . . O
other . . O
indications . . O
. . . O

* . . O
do . . O
not . . O
place . . O
duavee . . O
in . . O
pill . . O
boxes . . O
or . . O
pill . . O
organizers . . O
. . . O

if . . O
feasible . . O
, . . O
duavee . . O
should . . O
be . . O
discontinued . . O
at . . O
least . . O
4 . . O
to . . O
6 . . O
weeks . . O
before . . O
surgery . . O
of . . O
the . . O
type . . O
associated . . O
with . . O
an . . O
increased . . O
risk . . O
of . . O
thromboembolism . . O
, . . O
or . . O
during . . O
periods . . O
of . . O
prolonged . . O
immobilization . . O
. . . O

therefore . . O
, . . O
co . . O
- . . O
administration . . O
of . . O
kalydeco . . O
with . . O
strong . . O
cyp3a . . O
inducers . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
rifampin . . O
, . . O
st . . O
. . . O
john's . . O
wort . . O
) . . O
is . . O
not . . O
recommended . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.2 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

osteonecrosis . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
jaw . . I-AdverseReaction
( . . O
onj . . B-AdverseReaction
) . . O
occurred . . O
in . . O
1% . . O
of . . O
cometriq . . O
- . . O
treated . . O
patients . . O
. . . O

monitor . . O
for . . O
evidence . . O
of . . O
tls . . O
during . . O
treatment . . O
and . . O
manage . . O
promptly . . O
including . . O
interruption . . O
of . . O
kyprolis . . O
until . . O
tls . . O
is . . O
resolved . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

( . . O
6.1 . . O
) . . O

patients . . O
who . . O
receive . . O
prolonged . . O
cleviprex . . O
infusions . . O
and . . O
are . . O
not . . O
transitioned . . O
to . . O
other . . O
antihypertensive . . O
therapies . . O
should . . O
be . . O
monitored . . O
for . . O
the . . O
possibility . . O
of . . O
rebound . . O
hypertension . . O
for . . O
at . . O
least . . O
8 . . O
hours . . O
after . . O
the . . O
infusion . . O
is . . O
stopped . . O
. . . O

infections . . O
and . . O
infestations . . O
: . . O
clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
colitis . . I-AdverseReaction
, . . O
oral . . B-AdverseReaction
candidiasis . . I-AdverseReaction
, . . O
vulvovaginal . . B-AdverseReaction
mycotic . . I-AdverseReaction
infection . . I-AdverseReaction

the . . O
mean . . O
age . . O
was . . O
63 . . O
years . . O
, . . O
80% . . O
were . . O
male . . O
and . . O
20% . . O
were . . O
female . . O
, . . O
and . . O
100% . . O
were . . O
white . . O
. . . O

vaginal . . O
bleeding . . O
after . . O
menopause . . O
may . . O
be . . O
a . . O
warning . . O
sign . . O
of . . O
cancer . . O
of . . O
the . . O
uterus . . O
( . . O
womb . . O
) . . O
. . . O

fall . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
injuries . . I-AdverseReaction
were . . O
more . . O
severe . . O
in . . O
patients . . O
treated . . O
with . . O
xtandi . . O
and . . O
included . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
pathologic . . I-AdverseReaction
fractures . . I-AdverseReaction
, . . O
joint . . B-AdverseReaction
injuries . . I-AdverseReaction
, . . O
and . . O
hematomas . . B-AdverseReaction
. . . O

in . . O
a . . O
monotherapy . . O
study . . O
comparing . . O
nesina . . O
to . . O
a . . O
sulfonylurea . . O
in . . O
elderly . . O
patients . . O
, . . O
the . . O
incidence . . O
of . . O
hypoglycemia . . B-AdverseReaction
was . . O
5.4% . . O
with . . O
nesina . . O
compared . . O
to . . O
26% . . O
with . . O
glipizide . . O
( . . O
table . . O
2 . . O
) . . O
. . . O

hepatic . . O
function . . O
should . . O
be . . O
monitored . . O
closely . . O
in . . O
these . . O
patients . . O
. . . O

t . . O
- . . O
cell . . O
- . . O
depleting . . O
therapies . . O
to . . O
treat . . O
acute . . O
rejection . . O
should . . O
be . . O
used . . O
cautiously . . O
. . . O

* . . O
take . . O
1 . . O
duavee . . O
tablet . . O
at . . O
the . . O
same . . O
time . . O
each . . O
day . . O
. . . O

the . . O
infections . . B-AdverseReaction
consisted . . O
primarily . . O
of . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
, . . O
herpes . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
, . . O
and . . O
lower . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

vomiting . . B-AdverseReaction
was . . O
the . . O
primary . . O
adverse . . O
reaction . . O
leading . . O
to . . O
discontinuation . . O
of . . O
dosing . . O
; . . O
this . . O
occurred . . O
at . . O
an . . O
incidence . . O
of . . O
0.5% . . O
in . . O
both . . O
the . . O
fidaxomicin . . O
and . . O
vancomycin . . O
patients . . O
in . . O
phase . . O
3 . . O
studies . . O
. . . O

item{ . . O
cataracts . . O
- . . O
use . . O
of . . O
corticosteroids . . B-DrugClass
may . . O
result . . O
in . . O
posterior . . B-AdverseReaction
subcapsular . . I-AdverseReaction
cataract . . I-AdverseReaction
formation . . O
. . . O

5.3 . . O
spinal . . O
/ . . O
epidural . . O
anesthesia . . O
or . . O
puncture . . O

5.1 . . O
suicidal . . O
behavior . . O
and . . O
ideation . . O

table . . O
1 . . O
: . . O
selected . . O
adverse . . O
reactions . . O
in . . O
study . . O
1 . . O
a . . O
incidences . . O
presented . . O
in . . O
this . . O
table . . O
are . . O
based . . O
on . . O
reports . . O
of . . O
adverse . . O
events . . O
regardless . . O
of . . O
causality . . O
. . . O

corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
( . . O
penile . . B-AdverseReaction
fracture . . I-AdverseReaction
) . . O
or . . O

estrogens . . O
may . . O
be . . O
poorly . . O
metabolized . . O
in . . O
women . . O
with . . O
impaired . . O
liver . . O
function . . O
. . . O

perform . . O
an . . O
ophthalmological . . O
evaluation . . O
. . . O

in . . O
a . . O
trial . . O
of . . O
patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.3 . . O
) . . O
] . . O
, . . O
the . . O
mean . . O
serum . . B-AdverseReaction
phosphate . . I-AdverseReaction
levels . . I-AdverseReaction
increased . . I-AdverseReaction
by . . O
1.2% . . O
, . . O
5.0% . . O
, . . O
and . . O
9.3% . . O
with . . O
placebo . . O
, . . O
invokana . . O
100 . . O
mg . . O
, . . O
and . . O
invokana . . O
300 . . O
mg . . O
, . . O
respectively . . O
. . . O

all . . O
patients . . O
being . . O
treated . . O
with . . O
antidepressants . . O
for . . O
any . . O
indication . . O
should . . O
be . . O
monitored . . O
appropriately . . O
and . . O
observed . . O
closely . . O
for . . O
clinical . . O
worsening . . O
, . . O
suicidality . . O
, . . O
and . . O
unusual . . O
changes . . O
in . . O
behavior . . O
, . . O
especially . . O
during . . O
the . . O
initial . . O
few . . O
months . . O
of . . O
a . . O
course . . O
of . . O
drug . . O
therapy . . O
, . . O
or . . O
at . . O
times . . O
of . . O
dose . . O
changes . . O
, . . O
either . . O
increases . . O
or . . O
decreases . . O
. . . O

approximately . . O
80% . . O
of . . O
these . . O
patients . . O
had . . O
> . . O
10 . . O
weeks . . O
exposure . . O
to . . O
toviaz . . O
in . . O
these . . O
trials . . O
. . . O

if . . O
bleeding . . O
persists . . O
or . . O
occurs . . O
after . . O
previously . . O
regular . . O
cycles . . O
, . . O
check . . O
for . . O
causes . . O
such . . O
as . . O
pregnancy . . O
or . . O
malignancy . . O
. . . O

avoid . . O
use . . O
of . . O
fanapt . . O
in . . O
combination . . O
with . . O
other . . O
drugs . . O
that . . O
are . . O
known . . O
to . . O
prolong . . O
qtc . . O
; . . O
use . . O
caution . . O
and . . O
consider . . O
dose . . O
modification . . O
when . . O
prescribing . . O
fanapt . . O
with . . O
other . . O
drugs . . O
that . . O
inhibit . . O
fanapt . . O
metabolism . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
reported . . O
in . . O
patients . . O
receiving . . O
eylea . . O
were . . O
conjunctival . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
cataract . . B-AdverseReaction
, . . O
vitreous . . B-AdverseReaction
floaters . . I-AdverseReaction
, . . O
intraocular . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
, . . O
and . . O
vitreous . . B-AdverseReaction
detachment . . I-AdverseReaction
. . . O

evaluate . . O
abnormal . . O
serum . . O
liver . . O
tests . . O
with . . O
repeat . . O
testing . . O
within . . O
3 . . O
to . . O
5 . . O
days . . O
. . . O

lactic . . B-AdverseReaction
acidosis . . I-AdverseReaction
and . . O
severe . . B-Severity
hepatomegaly . . B-AdverseReaction
with . . O
steatosis . . B-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
cases . . O
, . . O
have . . O
been . . O
reported . . O
with . . O
the . . O
use . . O
of . . O
nucleoside . . O
analogs . . O
, . . O
including . . O
tenofovir . . O
disoproxil . . O
fumarate . . O
, . . O
a . . O
component . . O
of . . O
stribild . . O
, . . O
in . . O
combination . . O
with . . O
other . . O
antiretrovirals . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

this . . O
finding . . O
with . . O
salmeterol . . O
is . . O
considered . . O
a . . O
class . . O
effect . . O
of . . O
all . . O
laba . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
- . . O
serious . . B-Severity
acute . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
urticaria . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
) . . O
have . . O
been . . O
observed . . O
during . . O
combination . . O
therapy . . O
with . . O
victrelis . . O
, . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
. . . O

if . . O
a . . O
decision . . O
is . . O
made . . O
to . . O
administer . . O
simponi . . O
aria . . O
to . . O
ra . . O
patients . . O
with . . O
chf . . O
, . . O
these . . O
patients . . O
should . . O
be . . O
closely . . O
monitored . . O
during . . O
therapy . . O
, . . O
and . . O
simponi . . O
aria . . O
should . . O
be . . O
discontinued . . O
if . . O
new . . O
or . . O
worsening . . O
symptoms . . O
of . . O
chf . . O
appear . . O
. . . O

there . . O
was . . O
no . . B-Negation
increased . . O
incidence . . O
of . . O
serious . . B-Severity
infections . . O
observed . . O
in . . O
patients . . O
with . . O
lymphocyte . . O
counts . . O
< . . O
0.8 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
or . . O
0.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
in . . O
controlled . . O
trials . . O
, . . O
although . . O
one . . O
patient . . O
in . . O
an . . O
extension . . O
study . . O
developed . . O
pml . . B-AdverseReaction
in . . O
the . . O
setting . . O
of . . O
prolonged . . B-AdverseReaction
lymphopenia . . I-AdverseReaction
( . . O
lymphocyte . . O
counts . . O
predominantly . . O
< . . O
0.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
for . . O
3.5 . . O
years . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

* . . O
e . . O
rate . . O
of . . O
documented . . O
symptomatic . . B-Severity
hypoglycemia . . B-AdverseReaction
for . . O
active . . O
controls . . O
18% . . O
( . . O
glimepiride . . O
) . . O
and . . O
2% . . O
( . . O
sitagliptin . . O
) . . O
. . . O

anaphylaxis . . B-AdverseReaction
was . . O
observed . . O
in . . O
0.6% . . O
( . . O
9 . . O
/ . . O
1,458 . . O
) . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
and . . O
0.4% . . O
( . . O
3 . . O
/ . . O
675 . . O
) . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

in . . O
addition . . O
, . . O
one . . O
case . . O
of . . O
hyperparathyroidism . . B-AdverseReaction
has . . O
been . . O
reported . . O
. . . O

the . . O
range . . O
of . . O
time . . O
to . . O
diagnosis . . O
of . . O
basal . . B-AdverseReaction
cell . . I-AdverseReaction
carcinoma . . I-AdverseReaction
was . . O
28 . . O
to . . O
249 . . O
days . . O
in . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
and . . O
was . . O
197 . . O
days . . O
for . . O
the . . O
patient . . O
receiving . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

withhold . . O
yervoy . . O
in . . O
patients . . O
with . . O
grade . . O
2 . . O
hepatotoxicity . . O
. . . O

all . . O
subjects . . O
were . . O
queried . . O
about . . O
the . . O
presence . . O
of . . O
skin . . O
and . . O
scalp . . O
symptoms . . O
; . . O
the . . O
results . . O
are . . O
presented . . O
in . . O
table . . O
2 . . O
. . . O

these . . O
fractures . . O
can . . O
occur . . O
anywhere . . O
in . . O
the . . O
femoral . . O
shaft . . O
from . . O
just . . O
below . . O
the . . O
lesser . . O
trochanter . . O
to . . O
above . . O
the . . O
supracondylar . . O
flare . . O
and . . O
are . . O
transverse . . O
or . . O
short . . O
oblique . . O
in . . O
orientation . . O
without . . O
evidence . . O
of . . O
comminution . . O
. . . O

however . . O
, . . O
there . . O
is . . O
substantial . . O
evidence . . O
from . . O
placebo . . O
- . . O
controlled . . O
maintenance . . O
studies . . O
in . . O
adults . . O
with . . O
depression . . O
that . . O
the . . O
use . . O
of . . O
antidepressants . . O
can . . O
delay . . O
the . . O
recurrence . . O
of . . O
depression . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

three . . O
subjects . . O
experienced . . O
severe . . B-Severity
or . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
infections . . B-AdverseReaction
associated . . O
with . . O
neutropenia . . B-AdverseReaction
, . . O
and . . O
two . . O
subjects . . O
experienced . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
neutropenia . . B-AdverseReaction
while . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
that . . O
occurred . . O
more . . O
commonly . . O
( . . O
> . . O
= . . O
2% . . O
over . . O
placebo . . O
) . . O
in . . O
the . . O
xtandi . . O
- . . O
treated . . O
patients . . O
from . . O
the . . O
two . . O
randomized . . O
clinical . . O
trials . . O
were . . O
asthenia . . B-AdverseReaction
/ . . O
fatigue . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
and . . O
dizziness . . B-AdverseReaction
/ . . O
vertigo . . B-AdverseReaction
. . . O

fifty . . O
- . . O
eight . . O
percent . . O
( . . O
58% . . O
) . . O
of . . O
the . . O
population . . O
were . . O
male . . O
; . . O
84% . . O
were . . O
white . . O
, . . O
9% . . O
were . . O
asian . . O
, . . O
and . . O
3% . . O
were . . O
black . . O
or . . O
african . . O
american . . O
. . . O

table . . O
2 . . O
: . . O
adverse . . O
reactions . . O
( . . O
> . . O
10% . . O
for . . O
all . . O
nci . . O
ctcae . . O
* . . O
grades . . O
or . . O
> . . O
= . . O
2% . . O
for . . O
grades . . O
3-4 . . O
) . . O
in . . O
alk . . O
- . . O
positive . . O
patients . . O
treated . . O
with . . O
zykadia . . O
in . . O
study . . O
1 . . O
* . . O
national . . O
cancer . . O
institute . . O
common . . O
terminology . . O
criteria . . O
for . . O
adverse . . O
events . . O
( . . O
version . . O
4.03 . . O
) . . O
a . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
upper . . B-AdverseReaction
abdominal . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
epigastric . . B-AdverseReaction
discomfort . . I-AdverseReaction
) . . O
b . . O
esophageal . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
dyspepsia . . B-AdverseReaction
, . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
) . . O
c . . O
fatigue . . B-AdverseReaction
( . . O
fatigue . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
) . . O
d . . O
rash . . B-AdverseReaction
( . . O
rash . . B-AdverseReaction
, . . O
maculopapular . . B-AdverseReaction
rash . . I-AdverseReaction
, . . O
acneiform . . B-AdverseReaction
dermatitis . . I-AdverseReaction
) . . O
zykadian . . O
= . . O
255 . . O
all . . O
grades . . O
grade . . O
3-4 . . O
% . . O
% . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
86 . . O
6 . . O
nausea . . B-AdverseReaction
80 . . O
4 . . O
vomiting . . B-AdverseReaction
60 . . O
4 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
a . . O
54 . . O
2 . . O
constipation . . B-AdverseReaction
29 . . O
0 . . O
esophageal . . B-AdverseReaction
disorder . . I-AdverseReaction
b . . O
16 . . O
1 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
c . . O
52 . . O
5 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
34 . . O
1 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
d . . O
16 . . O
0 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
/ . . O
pneumonitis . . B-AdverseReaction
4 . . O
3 . . O
additional . . O
clinically . . O
significant . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
2% . . O
or . . O
more . . O
of . . O
patients . . O
treated . . O
with . . O
zykadia . . O
included . . O
neuropathy . . B-AdverseReaction
( . . O
17% . . O
; . . O
comprised . . O
of . . O
paresthesia . . B-AdverseReaction
, . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
gait . . B-AdverseReaction
disturbance . . I-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
hypoesthesia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
dysesthesia . . B-AdverseReaction
, . . O
neuralgia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
hypotonia . . B-AdverseReaction
, . . O
or . . O
polyneuropathy . . B-AdverseReaction
) . . O
, . . O
vision . . B-AdverseReaction
disorder . . I-AdverseReaction
( . . O
9% . . O
; . . O
comprised . . O
of . . O
vision . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
photopsia . . B-AdverseReaction
, . . O
accommodation . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
presbyopia . . B-AdverseReaction
, . . O
or . . O
reduced . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
) . . O
, . . O
prolonged . . B-AdverseReaction
qt . . I-AdverseReaction
interval . . I-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
and . . O
bradycardia . . B-AdverseReaction
( . . O
3% . . O
) . . O
. . . O

psychiatric . . O
disorders . . O
: . . O
anxiety . . B-AdverseReaction
, . . O
sleep . . B-AdverseReaction
disorders . . I-AdverseReaction
, . . O
abnormal . . B-AdverseReaction
dreams . . I-AdverseReaction
, . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
, . . O
disorientation . . B-AdverseReaction
, . . O
nervousness . . B-AdverseReaction
, . . O
nightmares . . B-AdverseReaction

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
of . . O
promacta . . O
to . . O
446 . . O
patients . . O
with . . O
chronic . . O
itp . . O
aged . . O
18 . . O
to . . O
85 . . O
years . . O
, . . O
of . . O
whom . . O
65% . . O
were . . O
female . . O
, . . O
across . . O
the . . O
itp . . O
clinical . . O
development . . O
program . . O
including . . O
three . . O
placebo . . O
- . . O
controlled . . O
trials . . O
. . . O

because . . O
clinical . . O
studies . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
studies . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

5.3 . . O
drug . . O
interactions . . O

monitor . . O
laboratory . . O
parameters . . O
( . . O
including . . O
, . . O
but . . O
not . . O
limited . . O
to . . O
, . . O
white . . O
blood . . O
cell . . O
count . . O
and . . O
absolute . . O
neutrophil . . O
count . . O
) . . O
during . . O
blincyto . . O
infusion . . O
. . . O

neither . . O
clinical . . O
studies . . O
nor . . O
epidemiologic . . O
studies . . O
conducted . . O
to . . O
date . . O
have . . O
shown . . O
an . . O
association . . O
between . . O
chronic . . O
administration . . O
of . . O
this . . O
class . . O
of . . O
drugs . . O
and . . O
tumorigenesis . . O
in . . O
humans . . O
; . . O
the . . O
available . . O
evidence . . O
is . . O
considered . . O
too . . O
limited . . O
to . . O
be . . O
conclusive . . O
at . . O
this . . O
time . . O
. . . O

investigations . . O
: . . O
decreased . . B-AdverseReaction
immunoglobulins . . I-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
bilirubin . . I-AdverseReaction
( . . O
8% . . O
) . . O
, . . O
increased . . B-AdverseReaction
gamma . . I-AdverseReaction
- . . I-AdverseReaction
glutamyl . . I-AdverseReaction
- . . I-AdverseReaction
transferase . . I-AdverseReaction
( . . O
6% . . O
) . . O
, . . O
increased . . B-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
( . . O
1% . . O
) . . O

because . . O
of . . O
the . . O
potential . . O
for . . O
hypersensitivity . . O
reactions . . O
, . . O
administer . . O
antihistamines . . O
with . . O
or . . O
without . . O
antipyretics . . O
prior . . O
to . . O
infusion . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

a . . O
24 . . O
- . . O
week . . O
, . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trial . . O
of . . O
vimizim . . O
was . . O
conducted . . O
in . . O
176 . . O
patients . . O
with . . O
mps . . O
iva . . O
, . . O
ages . . O
5 . . O
to . . O
57 . . O
years . . O
old . . O
. . . O

in . . O
the . . O
presence . . O
of . . O
binding . . O
and . . O
neutralizing . . O
antibodies . . O
to . . O
dysport . . O
( . . O
r . . O
) . . O
some . . O
patients . . O
continue . . O
to . . O
experience . . O
clinical . . O
benefit . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
with . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

evaluate . . O
at . . O
each . . O
visit . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
endocrinopathy . . O
. . . O

good . . O
oral . . O
hygiene . . O
practices . . O
should . . O
be . . O
maintained . . O
during . . O
treatment . . O
with . . O
prolia . . O
. . . O

treatment . . O
- . . O
related . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
3% . . O
) . . O
from . . O
extension . . O
trial . . O
in . . O
adults . . O
with . . O
chronic . . O
immune . . O
( . . O
idiopathic . . O
) . . O
thrombocytopenia . . O
adverse . . O
reaction . . O
promacta . . O
50 . . O
mg . . O
n . . O
= . . O
299 . . O
( . . O
% . . O
) . . O
headache . . B-AdverseReaction
10 . . O
hyperbilirubinemia . . B-AdverseReaction
6 . . O
alt . . B-AdverseReaction
increased . . I-AdverseReaction
6 . . O
cataract . . B-AdverseReaction
5 . . O
ast . . B-AdverseReaction
increased . . I-AdverseReaction
4 . . O
fatigue . . B-AdverseReaction
4 . . O
nausea . . B-AdverseReaction
4 . . O
in . . O
the . . O
three . . O
controlled . . O
chronic . . O
itp . . O
trials . . O
, . . O
serum . . O
liver . . O
test . . O
abnormalities . . O
( . . O
predominantly . . O
grade . . B-Severity
2 . . I-Severity
or . . O
less . . O
in . . O
severity . . O
) . . O
were . . O
reported . . O
in . . O
11% . . O
and . . O
7% . . O
of . . O
patients . . O
for . . O
promacta . . O
and . . O
placebo . . O
, . . O
respectively . . O
. . . O

the . . O
adverse . . O
reactions . . O
described . . O
in . . O
table . . O
2 . . O
were . . O
identified . . O
in . . O
750 . . O
patients . . O
treated . . O
in . . O
study . . O
1 . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

* . . O
hyperpyrexia . . B-AdverseReaction
and . . O
confusion . . B-AdverseReaction
( . . O
5.2 . . O
) . . O
* . . O
may . . B-Factor
exacerbate . . O
symptoms . . O
in . . O
patients . . O
with . . O
existing . . O
ischemic . . O
heart . . O
disease . . O
, . . O
arrhythmias . . O
, . . O
and . . O
congestive . . O
heart . . O
failure . . O
( . . O
5.3 . . O
) . . O
* . . O
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
5.4 . . O
) . . O

with . . O
continued . . O
dosing . . O
, . . O
the . . O
heart . . O
rate . . O
returns . . O
to . . O
baseline . . O
within . . O
1 . . O
month . . O
of . . O
chronic . . O
treatment . . O
. . . O

* . . O
seizure . . B-AdverseReaction
: . . O
can . . O
occur . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
: . . O
acute . . B-AdverseReaction
pancreatitis . . I-AdverseReaction
, . . O
cholecystitis . . B-AdverseReaction
, . . O
cholelithiasis . . B-AdverseReaction
, . . O
arterial . . B-AdverseReaction
thrombotic . . I-AdverseReaction
events . . I-AdverseReaction
and . . O
reflex . . B-AdverseReaction
sympathetic . . I-AdverseReaction
dystrophy . . I-AdverseReaction
. . . O

* . . O
women . . O
over . . O
35 . . O
years . . O
old . . O
who . . O
smoke . . O
should . . O
not . . O
use . . O
natazia . . O
. . . O

prior . . O
to . . O
initiating . . O
immunomodulatory . . O
therapies . . O
, . . O
including . . O
ilaris . . O
, . . O
patients . . O
should . . O
be . . O
evaluated . . O
for . . O
active . . O
and . . O
latent . . O
tuberculosis . . O
infection . . O
. . . O

* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
clostridium . . B-AdverseReaction
difficile . . I-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
diarrhea . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
direct . . B-AdverseReaction
coombs' . . I-AdverseReaction
test . . I-AdverseReaction
seroconversion . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
2 . . O
% . . O
of . . O
patients . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
. . . O

the . . O
datscan . . O
injection . . O
may . . O
contain . . O
up . . O
to . . O
6% . . O
of . . O
free . . O
iodide . . O
( . . O
iodine . . O
123 . . O
) . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
? . . O

table . . O
2 . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
1% . . O
) . . O
in . . O
rvo . . O
studies . . O
adverse . . O
reactions . . O
crvo . . O
brvo . . O
eylea . . O
( . . O
n . . O
= . . O
218 . . O
) . . O
control . . O
( . . O
n . . O
= . . O
142 . . O
) . . O
eylea . . O
( . . O
n . . O
= . . O
91 . . O
) . . O
control . . O
( . . O
n . . O
= . . O
92 . . O
) . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
13% . . O
5% . . O
4% . . O
5% . . O
conjunctival . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
12% . . O
11% . . O
20% . . O
4% . . O
intraocular . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
8% . . O
6% . . O
2% . . O
0% . . O
corneal . . B-AdverseReaction
epithelium . . I-AdverseReaction
defect . . I-AdverseReaction
5% . . O
4% . . O
2% . . O
0% . . O
vitreous . . B-AdverseReaction
floaters . . I-AdverseReaction
5% . . O
1% . . O
1% . . O
0% . . O
ocular . . B-AdverseReaction
hyperemia . . I-AdverseReaction
5% . . O
3% . . O
2% . . O
2% . . O
foreign . . B-AdverseReaction
body . . I-AdverseReaction
sensation . . I-AdverseReaction
in . . I-AdverseReaction
eyes . . I-AdverseReaction
3% . . O
5% . . O
3% . . O
0% . . O
vitreous . . B-AdverseReaction
detachment . . I-AdverseReaction
3% . . O
4% . . O
2% . . O
0% . . O
lacrimation . . B-AdverseReaction
increased . . I-AdverseReaction
3% . . O
4% . . O
3% . . O
0% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
3% . . O
1% . . O
1% . . O
0% . . O
vision . . B-AdverseReaction
blurred . . I-AdverseReaction
1% . . O
< . . O
1% . . O
1% . . O
1% . . O
intraocular . . B-AdverseReaction
inflammation . . I-AdverseReaction
1% . . O
1% . . O
0% . . O
0% . . O
cataract . . B-AdverseReaction
< . . O
1% . . O
1% . . O
5% . . O
0% . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
< . . O
1% . . O
1% . . O
1% . . O
0% . . O
less . . O
common . . O
adverse . . O
reactions . . O
reported . . O
in . . O
< . . O
1% . . O
of . . O
the . . O
patients . . O
treated . . O
with . . O
eylea . . O
in . . O
the . . O
crvo . . O
studies . . O
were . . O
corneal . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
retinal . . B-AdverseReaction
tear . . I-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
, . . O
and . . O
endophthalmitis . . B-AdverseReaction
. . . O

less . . O
common . . O
adverse . . O
reactions . . O
in . . O
patients . . O
with . . O
severe . . O
or . . O
essential . . O
hypertension . . O

most . . O
patients . . O
who . . O
developed . . O
these . . O
infections . . B-AdverseReaction
were . . O
taking . . O
concomitant . . O
immunosuppressants . . O
such . . O
as . . O
methotrexate . . O
or . . O
corticosteroids . . O
. . . O

( . . O
5.8 . . O
) . . O
* . . O
suicide . . B-AdverseReaction
: . . O
close . . O
supervision . . O
of . . O
high . . O
risk . . O
patients . . O
. . . O

table . . O
2 . . O
shows . . O
absolute . . O
and . . O
relative . . O
risk . . O
by . . O
indication . . O
for . . O
all . . O
evaluated . . O
aeds . . O
. . . O

hyperglycemia . . B-AdverseReaction
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
administered . . O
as . . O
a . . O
single . . O
agent . . O
or . . O
when . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

5.1 . . O
not . . O
for . . O
systemic . . O
infections . . O

withhold . . O
cometriq . . O
for . . O
hypertension . . O
that . . O
is . . O
not . . O
adequately . . O
controlled . . O
with . . O
medical . . O
management . . O
; . . O
when . . O
controlled . . O
, . . O
resume . . O
cometriq . . O
at . . O
a . . O
reduced . . O
dose . . O
. . . O

no . . B-Negation
patients . . O
treated . . O
with . . O
saphris . . O
experienced . . O
qtc . . B-AdverseReaction
increases . . I-AdverseReaction
> . . O
= . . O
60 . . B-Severity
msec . . I-Severity
from . . O
baseline . . O
measurements . . O
, . . O
nor . . B-Negation
did . . O
any . . O
patient . . O
experience . . O
a . . O
qtc . . B-AdverseReaction
of . . I-AdverseReaction
> . . I-AdverseReaction
= . . I-AdverseReaction
500 . . I-AdverseReaction
msec . . I-AdverseReaction
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
at . . O
least . . O
10% . . O
of . . O
patients . . O
in . . O
either . . O
study . . O
1 . . O
or . . O
2 . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
using . . O
the . . O
nci . . O
common . . O
toxicity . . O
criteria . . O
( . . O
ctc . . O
) . . O
version . . O
3.0 . . O
, . . O
are . . O
shown . . O
in . . O
table . . O
2 . . O
. . . O

dose . . O
- . . O
related . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
non . . I-AdverseReaction
- . . I-AdverseReaction
hdl . . I-AdverseReaction
- . . I-AdverseReaction
c . . I-AdverseReaction
with . . O
invokana . . O
were . . O
observed . . O
. . . O

5.3 . . O
hepatic . . O
effects . . O

the . . O
population . . O
exposed . . O
to . . O
tafinlar . . O
was . . O
60% . . O
male . . O
, . . O
99% . . O
white . . O
, . . O
and . . O
had . . O
a . . O
median . . O
age . . O
of . . O
53 . . O
years . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O

grade . . B-Severity
3 . . I-Severity
proteinuria . . B-AdverseReaction
was . . O
reported . . O
in . . O
11 . . O
/ . . O
359 . . O
patients . . O
( . . O
3% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
6 . . O
/ . . O
355 . . O
patients . . O
( . . O
2% . . O
) . . O
receiving . . O
sorafenib . . O
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

when . . O
coartem . . O
tablets . . O
are . . O
coadministered . . O
with . . O
an . . O
inhibitor . . O
of . . O
cyp3a4 . . O
, . . O
including . . O
grapefruit . . O
juice . . O
it . . O
may . . B-Factor
result . . O
in . . O
increased . . O
concentrations . . O
of . . O
artemether . . O
and . . O
/ . . O
or . . O
lumefantrine . . O
and . . O
potentiate . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
that . . O
led . . O
to . . O
discontinuation . . O
in . . O
pediatric . . O
patients . . O
treated . . O
with . . O
saphris . . O
( . . O
rates . . O
at . . O
least . . O
2% . . O
in . . O
any . . O
saphris . . O
arm . . O
and . . O
at . . O
least . . O
twice . . O
the . . O
placebo . . O
rate . . O
) . . O
were . . O
somnolence . . B-AdverseReaction
( . . O
3% . . O
in . . O
the . . O
2.5mg . . O
twice . . O
daily . . O
group . . O
, . . O
1% . . O
in . . O
the . . O
5mg . . O
twice . . O
daily . . O
group . . O
, . . O
and . . O
2% . . O
in . . O
the . . O
10mg . . O
twice . . O
daily . . O
group . . O
) . . O
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
2% . . O
in . . O
the . . O
10mg . . O
twice . . O
daily . . O
group . . O
) . . O
, . . O
and . . O
nausea . . B-AdverseReaction
( . . O
2% . . O
in . . O
the . . O
10mg . . O
twice . . O
daily . . O
group . . O
) . . O
no . . O
placebo . . O
- . . O
treated . . O
patients . . O
dropped . . O
out . . O
for . . O
these . . O
events . . O
. . . O

when . . O
prescribing . . O
arcapta . . O
neohaler . . O
, . . O
the . . O
healthcare . . O
provider . . O
should . . O
also . . O
prescribe . . O
an . . O
inhaled . . O
, . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonist . . O
and . . O
instruct . . O
the . . O
patient . . O
on . . O
how . . O
it . . O
should . . O
be . . O
used . . O
. . . O

5.4 . . O
pancytopenia . . O
( . . O
use . . O
with . . O
ribavirin . . O
and . . O
peginterferon . . O
alfa . . O
) . . O

the . . O
gbca . . B-DrugClass
- . . O
associated . . O
nsf . . B-AdverseReaction
risk . . O
appears . . O
highest . . O
for . . O
patients . . O
with . . O
chronic . . O
, . . O
severe . . O
kidney . . O
disease . . O
( . . O
gfr . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m . . O
2 . . O
) . . O
as . . O
well . . O
as . . O
patients . . O
with . . O
acute . . O
kidney . . O
injury . . O
. . . O

the . . O
contribution . . O
of . . O
the . . O
underlying . . O
disease . . O
and . . O
/ . . O
or . . O
prior . . O
corticosteroid . . O
treatment . . O
to . . O
the . . O
risk . . O
is . . O
also . . O
not . . O
known . . O
. . . O

5.3 . . O
new . . O
onset . . O
or . . O
worsening . . O
renal . . O
impairment . . O

nervous . . O
system . . O
disorders . . O
: . . O
dizziness . . B-AdverseReaction
, . . O
paresthesia . . B-AdverseReaction

table . . O
3 . . O
: . . O
changes . . O
in . . O
lipids . . O
in . . O
adult . . O
patients . . O
n . . O
* . . O
= . . O
number . . O
of . . O
subjects . . O
who . . O
had . . O
assessments . . O
at . . O
both . . O
baseline . . O
and . . O
endpoint . . O
. . . O

figures . . O
rounded . . O
to . . O
the . . O
nearest . . O
integer . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

kalydeco . . O
was . . O
permanently . . O
discontinued . . O
in . . O
one . . O
patient . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

* . . O
hepatic . . B-AdverseReaction
decompensation . . I-AdverseReaction
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
hepatotoxicity . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
thrombotic . . O
/ . . O
thromboembolic . . B-AdverseReaction
complications . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
cataracts . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
in . . O
adult . . O
patients . . O
with . . O
itp . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
5% . . O
and . . O
greater . . O
than . . O
placebo . . O
) . . O
were . . O
: . . O
nausea . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
, . . O
myalgia . . B-AdverseReaction
, . . O
and . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
. . . O

careful . . O
medical . . O
history . . O
is . . O
necessary . . O
because . . O
cdad . . O
has . . O
been . . O
reported . . O
to . . O
occur . . O
more . . O
than . . O
2 . . O
months . . O
after . . O
the . . O
administration . . O
of . . O
antibacterial . . O
agents . . O
. . . O

incidence . . O
of . . O
laboratory . . O
abnormalities . . O
increased . . O
from . . O
baseline . . O
occurring . . O
at . . O
a . . O
higher . . O
incidence . . O
in . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
trial . . O
1 . . O
[ . . O
between . . O
- . . O
arm . . O
difference . . O
of . . O
> . . O
= . . O
5% . . O
( . . O
all . . O
grades . . O
) . . O
or . . O
> . . O
= . . O
2% . . O
( . . O
grades . . O
3 . . O
or . . O
4 . . O
) . . O
] . . O
test . . O
tafinlar . . O
n . . O
= . . O
187 . . O
dtic . . O
n . . O
= . . O
59 . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grades . . O
3 . . O
and . . O
4 . . O
( . . O
% . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grades . . O
3 . . O
and . . O
4 . . O
( . . O
% . . O
) . . O
hyperglycemia . . B-AdverseReaction
50 . . O
6 . . O
43 . . O
0 . . O
hypophosphatemia . . B-AdverseReaction
37 . . O
6a . . O
14 . . O
2 . . O
increased . . B-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
19 . . O
0 . . O
14 . . O
2 . . O
hyponatremia . . B-AdverseReaction
8 . . O
2 . . O
3 . . O
0 . . O
a . . O
grade . . B-Severity
4 . . I-Severity
laboratory . . O
abnormality . . O
limited . . O
to . . O
hypophosphatemia . . B-AdverseReaction
( . . O
n . . O
= . . O
1 . . O
) . . O
. . . O

the . . O
overall . . O
safety . . O
profile . . O
of . . O
neuraceq . . O
is . . O
based . . O
on . . O
data . . O
from . . O
978 . . O
administrations . . O
of . . O
neuraceq . . O
to . . O
872 . . O
subjects . . O
and . . O
12 . . O
subjects . . O
who . . O
received . . O
vehicle . . O
only . . O
. . . O

in . . O
the . . O
ms . . O
placebo . . O
controlled . . O
trials . . O
, . . O
mean . . O
lymphocyte . . B-AdverseReaction
counts . . I-AdverseReaction
decreased . . I-AdverseReaction
by . . O
approximately . . O
30% . . O
during . . O
the . . O
first . . O
year . . O
of . . O
treatment . . O
with . . O
tecfidera . . O
and . . O
then . . O
remained . . O
stable . . O
. . . O

if . . O
pulmonary . . O
toxicity . . O
is . . O
confirmed . . O
, . . O
multaq . . O
should . . O
be . . O
discontinued . . O
. . . O

( . . O
5.8 . . O
) . . O
* . . O
blood . . O
pressure . . O
( . . O
bp . . O
) . . O
: . . O
monitor . . O
bp . . O
during . . O
treatment . . O
. . . O

about . . O
25% . . O
of . . O
patients . . O
were . . O
from . . O
the . . O
united . . O
states . . O
and . . O
75% . . O
from . . O
other . . O
countries . . O
. . . O

follow . . O
the . . O
dose . . O
adjustment . . O
guidelines . . O
to . . O
achieve . . O
and . . O
maintain . . O
target . . O
platelet . . O
counts . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
, . . O
2.2 . . O
, . . O
2.3 . . O
) . . O
] . . O
. . . O

if . . O
inlyta . . O
is . . O
interrupted . . O
, . . O
patients . . O
receiving . . O
antihypertensive . . O
medications . . O
should . . O
be . . O
monitored . . O
for . . O
hypotension . . O
[ . . O
seedosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

immune . . O
system . . O
disorders . . O
: . . O
anaphylactic . . B-AdverseReaction
shock . . I-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
. . . O

if . . O
signs . . O
or . . O
symptoms . . O
suggest . . O
sjs . . O
/ . . O
ten . . O
, . . O
use . . O
of . . O
this . . O
drug . . O
should . . O
not . . O
be . . O
resumed . . O
and . . O
alternative . . O
therapy . . O
should . . O
be . . O
considered . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

refer . . O
to . . O
the . . O
prescribing . . O
information . . O
for . . O
ribavirin . . O
for . . O
additional . . O
information . . O
regarding . . O
dose . . O
reduction . . O
and . . O
/ . . O
or . . O
discontinuation . . O
. . . O

5.10 . . O
glucose . . O
- . . O
6 . . O
- . . O
phosphate . . O
dehydrogenase . . O
deficiency . . O

in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O
, . . O
promacta . . O
in . . O
combination . . O
with . . O
interferon . . O
and . . O
ribavirin . . O
may . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
hepatic . . B-AdverseReaction
decompensation . . I-AdverseReaction
. . . O

for . . O
advanced . . O
hr+ . . O
bc . . O
, . . O
advanced . . O
pnet . . O
, . . O
advanced . . O
rcc . . O
, . . O
and . . O
renal . . O
angiomyolipoma . . O
with . . O
tsc . . O
patients . . O
with . . O
severe . . B-Severity
hepatic . . B-AdverseReaction
impairment . . I-AdverseReaction
( . . O
child . . O
- . . O
pugh . . O
class . . O
c . . O
) . . O
, . . O
afinitor . . O
may . . O
be . . O
used . . O
at . . O
a . . O
reduced . . O
dose . . O
if . . O
the . . O
desired . . O
benefit . . O
outweighs . . O
the . . O
risk . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
30% . . O
) . . O
were . . O
stomatitis . . B-AdverseReaction
, . . O
infections . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
and . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
. . . O

of . . O
the . . O
609 . . O
subjects . . O
, . . O
58% . . O
were . . O
female . . O
and . . O
84% . . O
were . . O
white . . O
; . . O
the . . O
mean . . O
age . . O
was . . O
40 . . O
years . . O
. . . O

the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
( . . O
incidence . . O
> . . O
= . . O
50% . . O
) . . O
were . . O
hypercholesterolemia . . B-AdverseReaction
, . . O
hypertriglyceridemia . . B-AdverseReaction
, . . O
and . . O
anemia . . B-AdverseReaction
. . . O

( . . O
n . . O
for . . O
males . . O
: . . O
placebo . . O
= . . O
716 . . O
, . . O
farxiga . . O
5 . . O
mg . . O
= . . O
564 . . O
, . . O
farxiga . . O
10 . . O
mg . . O
= . . O
595 . . O
) . . O
. . . O

closely . . O
observe . . O
patients . . O
during . . O
and . . O
after . . O
vimizim . . O
administration . . O
and . . O
be . . O
prepared . . O
to . . O
manage . . O
anaphylaxis . . O
. . . O

none . . O
of . . O
these . . O
4 . . O
patients . . O
had . . O
neutralizing . . O
antibodies . . O
. . . O
the . . O
presence . . O
of . . O
ada . . O
to . . O
erwinaze . . O
is . . O
associated . . O
with . . O
a . . O
higher . . O
risk . . B-Factor
of . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
in . . O
patients . . O
who . . O
received . . O
erwinaze . . O
through . . O
intravenous . . O
infusion . . O
compared . . O
to . . O
intramuscular . . O
administration . . O
of . . O
erwinaze . . O
. . . O
immunogenicity . . O
assay . . O
are . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
and . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
such . . O
as . . O
: . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

ensure . . O
safe . . O
handling . . O
to . . O
protect . . O
patients . . O
and . . O
health . . O
care . . O
workers . . O
from . . O
unintentional . . O
radiation . . O
exposure . . O
( . . O
2.1 . . O
, . . O
5.2 . . O
) . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

routine . . O
monitoring . . O
of . . O
estimated . . O
creatinine . . O
clearance . . O
, . . O
urine . . O
glucose . . O
, . . O
and . . O
urine . . O
protein . . O
should . . O
be . . O
performed . . O
during . . O
stribild . . O
therapy . . O
in . . O
all . . O
patients . . O
. . . O

grade . . B-Severity
3-4 . . I-Severity
low . . B-AdverseReaction
serum . . I-AdverseReaction
phosphorus . . I-AdverseReaction
( . . O
7% . . O
) . . O
and . . O
low . . B-AdverseReaction
potassium . . I-AdverseReaction
( . . O
5% . . O
) . . O
occurred . . O
at . . O
a . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
5% . . O
rate . . O
in . . O
the . . O
zytiga . . O
arm . . O
. . . O

if . . O
such . . O
effects . . O
occur . . O
, . . O
breo . . O
ellipta . . O
should . . O
be . . O
reduced . . O
slowly . . O
, . . O
consistent . . O
with . . O
accepted . . O
procedures . . O
for . . O
reducing . . O
systemic . . O
corticosteroids . . O
, . . O
and . . O
other . . O
treatments . . O
for . . O
management . . O
of . . O
copd . . O
or . . O
asthma . . O
symptoms . . O
should . . O
be . . O
considered . . O
. . . O

hyperglycemia . . B-AdverseReaction
, . . O
hyperlipidemia . . B-AdverseReaction
, . . O
and . . O
hypertriglyceridemia . . B-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
afinitor . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
, . . O
6.2 . . O
, . . O
6.3 . . O
, . . O
6.4 . . O
, . . O
6.5 . . O
) . . O
] . . O
. . . O

in . . O
2 . . O
- . . O
year . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
, . . O
elevation . . B-AdverseReaction
of . . I-AdverseReaction
liver . . I-AdverseReaction
transaminases . . I-AdverseReaction
to . . O
3 . . B-Severity
- . . I-Severity
fold . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
( . . I-Severity
uln . . I-Severity
) . . I-Severity
or . . O
greater . . O
occurred . . O
in . . O
14% . . O
of . . O
patients . . O
treated . . O
with . . O
gilenya . . O
0.5 . . O
mg . . O
and . . O
3% . . O
of . . O
patients . . O
on . . O
placebo . . O
. . . O

5.5 . . O
pre . . O
- . . O
existing . . O
neuromuscular . . O
disorders . . O

counseling . . O
patients . . O
about . . O
the . . O
protective . . O
measures . . O
necessary . . O
to . . O
guard . . O
against . . O
sexually . . O
transmitted . . O
diseases . . O
, . . O
including . . O
human . . O
immunodeficiency . . O
virus . . O
( . . O
hiv . . O
) . . O
, . . O
should . . O
be . . O
considered . . O
. . . O

in . . O
acute . . O
purulent . . O
conditions . . O
, . . O
steroids . . O
may . . O
mask . . O
infection . . O
or . . O
enhance . . O
existing . . O
infection . . O
. . . O

* . . O
administer . . O
gadavist . . O
only . . O
in . . O
situations . . O
where . . O
trained . . O
personnel . . O
and . . O
therapies . . O
are . . O
promptly . . O
available . . O
for . . O
the . . O
treatment . . O
of . . O
hypersensitivity . . O
reactions . . O
, . . O
including . . O
personnel . . O
trained . . O
in . . O
resuscitation . . O
. . . O

amplify . . O
study . . O

excerpt . . O
: . . O
* . . O
clinical . . B-AdverseReaction
worsening . . I-AdverseReaction
/ . . O
suicide . . B-AdverseReaction
risk . . I-AdverseReaction
: . . O
monitor . . O
for . . O
clinical . . O
worsening . . O
and . . O
suicide . . O
risk . . O
( . . O
5.1 . . O
) . . O
. . . O

withhold . . O
treatment . . O
with . . O
trametinib . . O
and . . O
continue . . O
tafinlar . . O
at . . O
the . . O
same . . O
dose . . O
if . . O
absolute . . O
lvef . . O
value . . O
decreases . . O
by . . O
10% . . O
from . . O
pretreatment . . O
values . . O
and . . O
is . . O
less . . O
than . . O
the . . O
lower . . O
limit . . O
of . . O
normal . . O
. . . O

clinical . . O
trials . . O
in . . O
infantile . . O
- . . O
onset . . O
and . . O
juvenile . . O
- . . O
onset . . O
pompe . . O
disease . . O

advise . . O
patients . . O
with . . O
myelosuppression . . O
following . . O
treanda . . O
treatment . . O
to . . O
contact . . O
a . . O
physician . . O
if . . O
they . . O
have . . O
symptoms . . O
or . . O
signs . . O
of . . O
infection . . O
. . . O

( . . O
5.8 . . O
) . . O
* . . O
vaccinations . . O
: . . O
avoid . . O
live . . O
vaccines . . O
and . . O
close . . O
contact . . O
with . . O
those . . O
who . . O
have . . O
received . . O
live . . O
vaccines . . O
. . . O

cimzia . . O
should . . O
be . . O
discontinued . . O
if . . O
a . . O
patient . . O
develops . . O
a . . O
serious . . O
infection . . O
or . . O
sepsis . . O
. . . O

5.1 . . O
hepatotoxicity . . O

patients . . O
with . . O
an . . O
established . . O
diagnosis . . O
of . . O
diabetes . . O
mellitus . . O
who . . O
are . . O
started . . O
on . . O
atypical . . O
antipsychotics . . O
should . . O
be . . O
monitored . . O
regularly . . O
for . . O
worsening . . O
of . . O
glucose . . O
control . . O
. . . O

the . . O
addition . . O
of . . O
victrelis . . O
to . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
is . . O
associated . . O
with . . O
an . . O
additional . . B-AdverseReaction
decrease . . I-AdverseReaction
in . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
concentrations . . I-AdverseReaction
. . . O

macular . . O
edema . . O
following . . O
retinal . . O
vein . . O
occlusion . . O
( . . O
rvo . . O
) . . O

renal . . O
function . . O
of . . O
patients . . O
should . . O
be . . O
monitored . . O
particularly . . O
where . . O
patients . . O
have . . O
additional . . O
risk . . O
factors . . O
that . . O
may . . O
further . . O
impair . . O
renal . . O
function . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
. . . O
] . . O

entereg . . O
is . . O
available . . O
only . . O
through . . O
a . . O
program . . O
called . . O
the . . O
entereg . . O
access . . O
support . . O
and . . O
education . . O
( . . O
e . . O
. . . O
a . . O
. . . O
s . . O
. . . O
e . . O
. . . O
) . . O
entereg . . O
rems . . O
program . . O
that . . O
restricts . . O
use . . O
to . . O
enrolled . . O
hospitals . . O
because . . O
of . . O
the . . O
potential . . O
risk . . O
of . . O
myocardial . . O
infarction . . O
with . . O
long . . O
- . . O
term . . O
use . . O
of . . O
entereg . . O
[ . . O
seewarnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

duavee . . O
may . . O
also . . O
affect . . O
how . . O
your . . O
other . . O
medicines . . O
work . . O
. . . O

the . . O
safety . . O
of . . O
xalkori . . O
is . . O
based . . O
primarily . . O
on . . O
343 . . O
patients . . O
with . . O
alk . . O
- . . O
positive . . O
metastatic . . O
nsclc . . O
who . . O
received . . O
xalkori . . O
250 . . O
mg . . O
twice . . O
daily . . O
in . . O
two . . O
open . . O
- . . O
label . . O
, . . O
randomized . . O
, . . O
active . . O
- . . O
controlled . . O
trials . . O
( . . O
studies . . O
1 . . O
and . . O
2 . . O
) . . O
. . . O

do . . O
not . . O
resume . . O
ferriprox . . O
in . . O
patients . . O
who . . O
have . . O
developed . . O
agranulocytosis . . O
unless . . O
potential . . O
benefits . . O
outweigh . . O
potential . . O
risks . . O
. . . O

tecfidera . . O
may . . O
cause . . O
flushing . . B-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
warmth . . B-AdverseReaction
, . . O
redness . . B-AdverseReaction
, . . O
itching . . B-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
burning . . B-AdverseReaction
sensation . . I-AdverseReaction
) . . O
. . . O

the . . O
causes . . O
of . . O
death . . B-AdverseReaction
varied . . O
and . . O
included . . O
worsening . . O
and . . O
/ . . O
or . . O
complications . . B-AdverseReaction
of . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
surgery . . O
and . . O
underlying . . O
conditions . . O
. . . O

kalbitor . . O
should . . O
only . . O
be . . O
administered . . O
by . . O
a . . O
healthcare . . O
professional . . O

in . . O
study . . O
1 . . O
, . . O
severe . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
or . . O
fatal . . B-AdverseReaction
hepatotoxicity . . B-AdverseReaction
( . . O
ast . . O
or . . O
alt . . B-AdverseReaction
elevations . . I-AdverseReaction
of . . O
more . . O
than . . O
5 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
or . . O
total . . B-AdverseReaction
bilirubin . . I-AdverseReaction
elevations . . I-AdverseReaction
more . . O
than . . O
3 . . B-Severity
times . . I-Severity
the . . I-Severity
upper . . I-Severity
limit . . I-Severity
of . . I-Severity
normal . . I-Severity
; . . O
grade . . B-Severity
3-5 . . I-Severity
) . . O
occurred . . O
in . . O
8 . . O
( . . O
2% . . O
) . . O
yervoy . . O
- . . O
treated . . O
patients . . O
, . . O
with . . O
fatal . . B-AdverseReaction
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
in . . O
0.2% . . O
and . . O
hospitalization . . O
in . . O
0.4% . . O
of . . O
yervoy . . O
- . . O
treated . . O
patients . . O
. . . O

[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
. . . O
] . . O

* . . O
hypersensitivity . . O
reactions . . O
: . . O
anaphylaxis . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
, . . O
and . . O
serious . . B-Severity
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
bullous . . B-AdverseReaction
eruption . . I-AdverseReaction
) . . O
have . . O
been . . O
reported . . O
. . . O

5.2 . . O
hypersensitivity . . O
reactions . . O

implement . . O
a . . O
plan . . O
to . . O
monitor . . O
for . . O
and . . O
to . . O
manage . . O
agranulocytosis . . O
/ . . O
neutropenia . . O
prior . . O
to . . O
initiating . . O
ferriprox . . O
treatment . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

* . . O
hematologic . . B-AdverseReaction
toxicities . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O

5.3 . . O
pneumonitis . . O

the . . O
three . . O
factors . . O
associated . . O
with . . O
the . . O
largest . . O
increase . . O
in . . O
volume . . B-AdverseReaction
depletion . . I-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
were . . O
the . . O
use . . O
of . . O
loop . . O
diuretics . . O
, . . O
moderate . . O
renal . . O
impairment . . O
( . . O
egfr . . O
30 . . O
to . . O
less . . O
than . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
, . . O
and . . O
age . . O
75 . . O
years . . O
and . . O
older . . O
( . . O
table . . O
2 . . O
) . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
, . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.5 . . O
and . . O
8.6 . . O
) . . O
] . . O
. . . O

approximately . . O
8500 . . O
patients . . O
with . . O
type . . O
2 . . O
diabetes . . O
have . . O
been . . O
treated . . O
with . . O
nesina . . O
in . . O
14 . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
, . . O
controlled . . O
clinical . . O
trials . . O
with . . O
approximately . . O
2900 . . O
subjects . . O
randomized . . O
to . . O
placebo . . O
and . . O
approximately . . O
2200 . . O
to . . O
an . . O
active . . O
comparator . . O
. . . O

the . . O
clinical . . O
significance . . O
of . . O
this . . O
finding . . O
is . . O
unknown . . O
. . . O

appropriate . . O
empiric . . O
antifungal . . O
therapy . . O
should . . O
be . . O
considered . . O
while . . O
a . . O
diagnostic . . O
workup . . O
is . . O
being . . O
performed . . O
. . . O

in . . O
study . . O
3 . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
in . . O
the . . O
adcetris . . O
- . . O
treatment . . O
arm . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
were . . O
neutropenia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
and . . O
diarrhea . . B-AdverseReaction
. . . O

patients . . O
treated . . O
with . . O
cimzia . . O
are . . O
at . . O
increased . . O
risk . . B-Factor
for . . O
developing . . O
serious . . B-Severity
infections . . B-AdverseReaction
that . . O
may . . B-Factor
lead . . O
to . . O
hospitalization . . O
or . . O
death . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

more . . O
than . . O
half . . O
( . . O
55% . . O
) . . O
of . . O
the . . O
population . . O
was . . O
male . . O
; . . O
46% . . O
were . . O
white . . O
, . . O
50% . . O
were . . O
asian . . O
, . . O
and . . O
3% . . O
were . . O
black . . O
or . . O
african . . O
american . . O
. . . O

there . . O
is . . O
no . . O
information . . O
to . . O
guide . . O
use . . O
of . . O
cleviprex . . O
in . . O
treating . . O
hypertension . . O
associated . . O
with . . O
pheochromocytoma . . O
. . . O

previously . . O
untreated . . O
alk . . O
- . . O
positive . . O
metastatic . . O
nsclc . . O
- . . O
study . . O
1 . . O

the . . O
safety . . O
data . . O
described . . O
below . . O
are . . O
based . . O
on . . O
two . . O
12 . . O
- . . O
week . . O
efficacy . . O
trials . . O
, . . O
one . . O
24 . . O
- . . O
week . . O
efficacy . . O
trial . . O
, . . O
and . . O
two . . O
long . . O
- . . O
term . . O
trials . . O
. . . O

5.2 . . O
somnolence . . O
/ . . O
sedation . . O
and . . O
dizziness . . O

( . . O
5.1 . . O
) . . O
* . . O
impairment . . B-AdverseReaction
in . . I-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
: . . O
monitor . . O
renal . . O
function . . O
during . . O
therapy . . O
. . . O

5.7 . . O
hypertension . . O

patients . . O
, . . O
their . . O
caregivers . . O
, . . O
and . . O
families . . O
should . . O
be . . O
informed . . O
that . . O
horizant . . O
increases . . O
the . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
and . . O
should . . O
be . . O
advised . . O
of . . O
the . . O
need . . O
to . . O
be . . O
alert . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
the . . O
signs . . O
and . . O
symptoms . . O
of . . O
depression . . O
, . . O
any . . O
unusual . . O
changes . . O
in . . O
mood . . O
or . . O
behavior . . O
, . . O
or . . O
the . . O
emergence . . O
of . . O
suicidal . . O
thoughts . . O
, . . O
behavior . . O
, . . O
or . . O
thoughts . . O
about . . O
self . . O
- . . O
harm . . O
. . . O

5.4 . . O
osteonecrosis . . O
of . . O
the . . O
jaw . . O

( . . O
5.4 . . O
) . . O
* . . O
monitor . . O
for . . O
dizziness . . O
and . . O
somnolence . . O
. . . O

the . . O
mean . . O
age . . O
of . . O
treated . . O
patients . . O
was . . O
48 . . O
to . . O
50 . . O
years . . O
( . . O
range . . O
18 . . O
to . . O
92 . . O
years . . O
) . . O
, . . O
across . . O
treatment . . O
arms . . O
and . . O
indications . . O
. . . O

administer . . O
dexamethasone . . O
prior . . O
to . . O
kyprolis . . O
to . . O
reduce . . O
the . . O
incidence . . O
and . . O
severity . . O
of . . O
infusion . . O
reactions . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

* . . O
screen . . O
patients . . O
for . . O
acute . . O
kidney . . O
injury . . O
and . . O
other . . O
conditions . . O
that . . O
may . . O
reduce . . O
renal . . O
function . . O
. . . O

tuberculosis . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
forest . . O
laboratories . . O
, . . O
llc . . O
. . . O
at . . O
1-800-678-1605 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

5.7 . . O
liver . . O
injury . . O

infections . . O
and . . O
infestations . . O
: . . O
cellulitis . . B-AdverseReaction
, . . O
folliculitis . . B-AdverseReaction
, . . O
paronychia . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
pustular . . I-AdverseReaction
. . . O

at . . O
screening . . O
, . . O
the . . O
mean . . O
postbronchodilator . . O
percent . . O
predicted . . O
fev1was . . O
45% . . O
( . . O
range . . O
: . . O
12% . . O
to . . O
91% . . O
) . . O
, . . O
and . . O
the . . O
mean . . O
postbronchodilator . . O
fev1 . . O
/ . . O
fvc . . O
ratio . . O
was . . O
46% . . O
( . . O
range . . O
: . . O
17% . . O
to . . O
81% . . O
) . . O
, . . O
indicating . . O
that . . O
the . . O
subject . . O
population . . O
had . . O
moderate . . O
to . . O
very . . O
severely . . O
impaired . . O
airflow . . O
obstruction . . O
. . . O

discontinuation . . O
of . . O
pristiq . . O
should . . O
be . . O
considered . . O
in . . O
patients . . O
with . . O
symptomatic . . O
hyponatremia . . O
and . . O
appropriate . . O
medical . . O
intervention . . O
should . . O
be . . O
instituted . . O
. . . O

the . . O
safety . . O
and . . O
efficacy . . O
of . . O
arcapta . . O
neohaler . . O
in . . O
patients . . O
with . . O
asthma . . O
have . . O
not . . O
been . . O
established . . O
. . . O

obtain . . O
serum . . O
potassium . . O
, . . O
calcium . . O
, . . O
and . . O
magnesium . . O
at . . O
baseline . . O
and . . O
correct . . O
if . . O
abnormal . . O
. . . O

more . . O
patients . . O
on . . O
tanzeum . . O
than . . O
on . . O
placebo . . O
: . . O
discontinued . . O
due . . O
to . . O
an . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
( . . O
2% . . O
versus . . O
0.2% . . O
) . . O
, . . O
experienced . . O
more . . O
than . . O
2 . . O
reactions . . O
( . . O
38% . . O
versus . . O
20% . . O
) . . O
, . . O
had . . O
a . . O
reaction . . O
judged . . O
by . . O
investigators . . O
to . . O
be . . O
" . . O
moderate . . O
" . . O
or . . O
" . . O
severe . . O
" . . O

adverse . . O
reaction . . O
crofelemer . . O
125 . . O
mg . . O
bid . . O
* . . O
n . . O
= . . O
229n . . O
( . . O
% . . O
) . . O
placebon . . O
= . . O
274n . . O
( . . O
% . . O
) . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
13 . . O
( . . O
5.7 . . O
) . . O
4 . . O
( . . O
1.5 . . O
) . . O
bronchitis . . B-AdverseReaction
9 . . O
( . . O
3.9 . . O
) . . O
0 . . O
cough . . B-AdverseReaction
8 . . O
( . . O
3.5 . . O
) . . O
3 . . O
( . . O
1.1 . . O
) . . O
flatulence . . B-AdverseReaction
7 . . O
( . . O
3.1 . . O
) . . O
3 . . O
( . . O
1.1 . . O
) . . O
increased . . B-AdverseReaction
bilirubin . . I-AdverseReaction
7 . . O
( . . O
3.1 . . O
) . . O
3 . . O
( . . O
1.1 . . O
) . . O
nausea . . B-AdverseReaction
6 . . O
( . . O
2.6 . . O
) . . O
4 . . O
( . . O
1.5 . . O
) . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
6 . . O
( . . O
2.6 . . O
) . . O
4 . . O
( . . O
1.5 . . O
) . . O
arthralgia . . B-AdverseReaction
6 . . O
( . . O
2.6 . . O
) . . O
0 . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
5 . . O
( . . O
2.2 . . O
) . . O
2 . . O
( . . O
0.7 . . O
) . . O
nasopharyngitis . . B-AdverseReaction
5 . . O
( . . O
2.2 . . O
) . . O
2 . . O
( . . O
0.7 . . O
) . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
5 . . O
( . . O
2.2 . . O
) . . O
1 . . O
( . . O
0.4 . . O
) . . O
hemorrhoids . . B-AdverseReaction
5 . . O
( . . O
2.2 . . O
) . . O
0 . . O
giardiasis . . B-AdverseReaction
5 . . O
( . . O
2.2 . . O
) . . O
0 . . O
anxiety . . B-AdverseReaction
5 . . O
( . . O
2.2 . . O
) . . O
1 . . O
( . . O
0.4 . . O
) . . O
increased . . B-AdverseReaction
alanine . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
5 . . O
( . . O
2.2 . . O
) . . O
3 . . O
( . . O
1.1 . . O
) . . O
abdominal . . B-AdverseReaction
distension . . I-AdverseReaction
5 . . O
( . . O
2.2 . . O
) . . O
1 . . O
( . . O
0.4 . . O
) . . O
* . . O
twice . . O
daily . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
between . . O
1% . . O
and . . O
2% . . O
of . . O
patients . . O
taking . . O
a . . O
250 . . O
mg . . O
daily . . O
dose . . O
of . . O
fulyzaq . . O
were . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
acne . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
aspartate . . I-AdverseReaction
aminotransferase . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
conjugated . . I-AdverseReaction
bilirubin . . I-AdverseReaction
, . . O
increased . . B-AdverseReaction
unconjugated . . I-AdverseReaction
blood . . I-AdverseReaction
bilirubin . . I-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
depression . . B-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
gastroenteritis . . B-AdverseReaction
, . . O
herpes . . B-AdverseReaction
zoster . . I-AdverseReaction
, . . O
nephrolithiasis . . B-AdverseReaction
, . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
, . . O
pollakiuria . . B-AdverseReaction
, . . O
procedural . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
seasonal . . B-AdverseReaction
allergy . . I-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
and . . O
decreased . . B-AdverseReaction
white . . I-AdverseReaction
blood . . I-AdverseReaction
cell . . I-AdverseReaction
count . . I-AdverseReaction
. . . O

safety . . O
of . . O
combined . . O
use . . O
of . . O
pde5 . . O
inhibitors . . O
and . . O
alpha . . O
- . . O
blockers . . O
may . . O
be . . O
affected . . O
by . . O
other . . O
variables . . O
, . . O
including . . O
intravascular . . O
volume . . O
depletion . . O
and . . O
other . . O
anti . . O
- . . O
hypertensive . . O
drugs . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
and . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

the . . O
assay . . O
should . . O
have . . O
a . . O
lower . . O
limit . . O
of . . O
hcv . . O
- . . O
rna . . O
quantification . . O
of . . O
equal . . O
to . . O
or . . O
less . . O
than . . O
25 . . O
iu . . O
per . . O
ml . . O
, . . O
and . . O
a . . O
limit . . O
of . . O
hcv . . O
- . . O
rna . . O
detection . . O
of . . O
approximately . . O
10 . . O
to . . O
15 . . O
iu . . O
per . . O
ml . . O
. . . O
for . . O
the . . O
purposes . . O
of . . O
assessing . . O
response . . O
- . . O
guided . . O
therapy . . O
milestones . . O
, . . O
a . . O
confirmed . . O
" . . O
detectable . . O
but . . O
below . . O
limit . . O
of . . O
quantification . . O
" . . O

progressive . . O
multifocal . . O
leukoencephalopathy . . O

the . . O
mean . . O
age . . O
at . . O
study . . O
entry . . O
was . . O
38 . . O
years . . O
( . . O
range . . O
18 . . O
to . . O
83 . . O
years . . O
) . . O
, . . O
64% . . O
were . . O
female . . O
, . . O
and . . O
95% . . O
were . . O
white . . O
. . . O

in . . O
the . . O
placebo . . O
- . . O
controlled . . O
portions . . O
of . . O
studies . . O
1 . . O
and . . O
2 . . O
through . . O
day . . O
90 . . O
, . . O
98% . . O
and . . O
51% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
and . . O
placebo . . O
- . . O
treated . . O
patients . . O
had . . O
an . . O
adverse . . O
reaction . . O
after . . O
up . . O
to . . O
3 . . O
injections . . O
, . . O
respectively . . O
. . . O

decreases . . O
in . . O
bone . . O
mineral . . O
density . . O

hepatic . . O
function . . O
should . . O
be . . O
monitored . . O
closely . . O
with . . O
both . . O
clinical . . O
and . . O
laboratory . . O
follow . . O
- . . O
up . . O
for . . O
at . . O
least . . O
several . . O
months . . O
in . . O
patients . . O
who . . O
are . . O
coinfected . . O
with . . O
hiv . . O
- . . O
1 . . O
and . . O
hbv . . O
and . . O
discontinue . . O
stribild . . O
. . . O

male . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
occurred . . O
more . . O
commonly . . O
in . . O
uncircumcised . . O
males . . O
and . . O
in . . O
males . . O
with . . O
a . . O
prior . . O
history . . O
of . . O
balanitis . . O
or . . O
balanoposthitis . . O
. . . O

perform . . O
complete . . O
blood . . O
counts . . O
weekly . . O
for . . O
the . . O
first . . O
month . . O
of . . O
therapy . . O
and . . O
then . . O
monthly . . O
thereafter . . O
, . . O
or . . O
as . . O
clinically . . O
indicated . . O
. . . O

caution . . O
should . . O
be . . O
exercised . . O
in . . O
treating . . O
patients . . O
with . . O
pre . . O
- . . O
existing . . O
hypertension . . O
, . . O
cardiovascular . . O
, . . O
or . . O
cerebrovascular . . O
conditions . . O
that . . O
might . . O
be . . O
compromised . . O
by . . O
increases . . O
in . . O
blood . . O
pressure . . O
. . . O

serious . . O
adverse . . O
events . . O
and . . O
discontinuation . . O
- . . O
perioperative . . O
hypertension . . O
studies . . O
the . . O
incidence . . O
of . . O
adverse . . O
events . . O
leading . . O
to . . O
study . . O
drug . . O
discontinuation . . O
in . . O
patients . . O
with . . O
perioperative . . O
hypertension . . O
receiving . . O
cleviprex . . O
was . . O
5.9% . . O
versus . . O
3.2% . . O
for . . O
all . . O
active . . O
comparators . . O
. . . O

standard . . O
international . . O
guidelines . . O
were . . O
followed . . O
for . . O
infection . . O
prophylaxis . . O
for . . O
herpes . . O
simplex . . O
virus . . O
( . . O
hsv . . O
) . . O
, . . O
varicella . . O
- . . O
zoster . . O
virus . . O
( . . O
vzv . . O
) . . O
, . . O
and . . O
pneumocystis . . O
jiroveci . . O
pneumonia . . O
( . . O
pcp . . O
) . . O
post . . O
- . . O
auto . . O
- . . O
hsct . . O
. . . O

increases . . B-AdverseReaction
in . . I-AdverseReaction
ldl . . I-AdverseReaction
- . . I-AdverseReaction
c . . I-AdverseReaction
occur . . O
with . . O
farxiga . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

nervous . . O
system . . O
disorders . . O
: . . O
1% . . O
and . . O
less . . O
than . . O
10% . . O
- . . O
dysgeusia . . B-AdverseReaction

pediatric . . O
patients . . O
: . . O
data . . O
from . . O
the . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
bipolar . . O
mania . . O
trial . . O
are . . O
presented . . O
in . . O
table . . O
4 . . O
. . . O

dizziness . . B-AdverseReaction
led . . O
to . . O
withdrawal . . O
in . . O
2% . . O
of . . O
patients . . O
receiving . . O
1,200 . . O
mg . . O
of . . O
horizant . . O
per . . O
day . . O
compared . . O
with . . O
3% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

( . . O
5.2 . . O
, . . O
5.3 . . O
, . . O
5.4 . . O
) . . O
* . . O
hyponatremia . . B-AdverseReaction
: . . O
monitor . . O
sodium . . O
levels . . O
in . . O
patients . . O
at . . O
risk . . O
or . . O
patients . . O
experiencing . . O
hyponatremia . . O
symptoms . . O
. . . O

dose . . O
- . . O
dependent . . O
decreases . . O
in . . O
serum . . O
t3 . . O
and . . O
t4 . . O
( . . O
free . . O
and . . O
total . . O
) . . O
values . . O
have . . O
been . . O
observed . . O
in . . O
patients . . O
taking . . O
aptiom . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
and . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
. . . O
] . . O

dose . . O
reductions . . O
due . . O
to . . O
adverse . . O
reactions . . O
were . . O
required . . O
in . . O
16% . . O
of . . O
xalkori . . O
- . . O
treated . . O
patients . . O
. . . O

appropriate . . O
measures . . O
such . . O
as . . O
fluid . . O
and . . O
electrolyte . . O
management . . O
, . . O
protein . . O
supplementation . . O
, . . O
antibacterial . . O
treatment . . O
of . . O
c . . O
. . . O
difficile . . O
, . . O
and . . O
surgical . . O
evaluation . . O
should . . O
be . . O
instituted . . O
as . . O
clinically . . O
indicated . . O
. . . O

heart . . O
rate . . O
increase . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

( . . O
6 . . O
) . . O

epilepsy . . O
and . . O
many . . O
other . . O
illnesses . . O
for . . O
which . . O
aeds . . O
are . . O
prescribed . . O
are . . O
themselves . . O
associated . . O
with . . O
morbidity . . O
and . . O
mortality . . O
and . . O
an . . O
increased . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
. . . O

gadolinium . . B-DrugClass
- . . I-DrugClass
based . . I-DrugClass
contrast . . I-DrugClass
agents . . I-DrugClass
( . . O
gbcas . . O
) . . O
increase . . O
the . . O
risk . . O
for . . O
nephrogenic . . B-AdverseReaction
systemic . . I-AdverseReaction
fibrosis . . I-AdverseReaction
( . . O
nsf . . B-AdverseReaction
) . . O
among . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
the . . O
drugs . . O
. . . O

an . . O
increased . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
was . . O
seen . . O
in . . O
the . . O
sirturo . . O
treatment . . O
group . . O
( . . O
9 . . O
/ . . O
79 . . O
, . . O
11.4% . . O
) . . O
compared . . O
to . . O
the . . O
placebo . . O
treatment . . O
group . . O
( . . O
2 . . O
/ . . O
81 . . O
, . . O
2.5% . . O
) . . O
in . . O
one . . O
placebo . . O
- . . O
controlled . . O
trial . . O
( . . O
based . . O
on . . O
the . . O
120 . . O
- . . O
week . . O
visit . . O
window . . O
) . . O
. . . O

no . . O
grade . . O
3 . . O
or . . O
4 . . O
adrs . . O
were . . O
reported . . O
. . . O

patients . . O
who . . O
are . . O
coinfected . . O
with . . O
hiv . . O
- . . O
1 . . O
and . . O
hbv . . O
should . . O
be . . O
closely . . O
monitored . . O
with . . O
both . . O
clinical . . O
and . . O
laboratory . . O
follow . . O
- . . O
up . . O
for . . O
at . . O
least . . O
several . . O
months . . O
after . . O
stopping . . O
treatment . . O
with . . O
stribild . . O
. . . O

infections . . O
: . . O
pml . . B-AdverseReaction
[ . . O
see . . O
boxed . . O
warning . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O
, . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
opportunistic . . B-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

zerbaxa . . O
was . . O
evaluated . . O
in . . O
phase . . O
3 . . O
comparator . . O
- . . O
controlled . . O
clinical . . O
trials . . O
of . . O
ciai . . O
and . . O
cuti . . O
, . . O
which . . O
included . . O
a . . O
total . . O
of . . O
1015 . . O
patients . . O
treated . . O
with . . O
zerbaxa . . O
and . . O
1032 . . O
patients . . O
treated . . O
with . . O
comparator . . O
( . . O
levofloxacin . . O
750 . . O
mg . . O
daily . . O
in . . O
cuti . . O
or . . O
meropenem . . O
1 . . O
g . . O
every . . O
8 . . O
hours . . O
in . . O
ciai . . O
) . . O
for . . O
up . . O
to . . O
14 . . O
days . . O
. . . O

the . . O
sudden . . O
drop . . O
in . . O
estrogen . . O
levels . . O
causes . . O
" . . O
surgical . . O
menopause . . O
. . . O
"when . . O
the . . O
estrogen . . O
levels . . O
begin . . O
dropping . . O
, . . O
some . . O
women . . O
get . . O
very . . O
uncomfortable . . O
symptoms . . O
, . . O
such . . O
as . . O
feelings . . O
of . . O
warmth . . O
in . . O
the . . O
face . . O
, . . O
neck . . O
, . . O
and . . O
chest . . O
, . . O
or . . O
sudden . . O
intense . . O
episodes . . O
of . . O
heat . . O
and . . O
sweating . . O
( . . O
" . . O
hot . . O
flashes . . O
" . . O
or . . O
" . . O
hot . . O
flushes . . O
" . . O
) . . O
. . . O

this . . O
was . . O
seen . . O
at . . O
all . . O
doses . . O
with . . O
a . . O
suggestion . . O
of . . O
a . . O
higher . . O
rate . . O
at . . O
400 . . O
mg . . O
per . . O
day . . O
. . . O

adverse . . O
events . . O
leading . . O
to . . O
dose . . O
reduction . . O
occurred . . O
in . . O
11% . . O
of . . O
patients . . O
. . . O

appropriate . . O
laboratory . . O
testing . . O
prior . . O
to . . O
initiating . . O
therapy . . O
and . . O
monitoring . . O
for . . O
hepatotoxicity . . O
during . . O
therapy . . O
with . . O
tivicay . . O
is . . O
recommended . . O
in . . O
patients . . O
with . . O
underlying . . O
hepatic . . O
disease . . O
such . . O
as . . O
hepatitis . . O
b . . O
or . . O
c . . O
. . . O
( . . O
5.2 . . O
) . . O
* . . O
redistribution . . O
/ . . O
accumulation . . B-AdverseReaction
of . . I-AdverseReaction
body . . I-AdverseReaction
fat . . I-AdverseReaction
and . . O
immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
combination . . B-DrugClass
antiretroviral . . I-DrugClass
therapy . . I-DrugClass
. . . O

for . . O
women . . O
with . . O
well . . O
- . . O
controlled . . O
hypertension . . O
, . . O
monitor . . O
blood . . O
pressure . . O
and . . O
stop . . O
natazia . . O
if . . O
blood . . O
pressure . . O
rises . . O
significantly . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
increased . . O
mortality . . B-AdverseReaction
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
hyperglycemia . . B-AdverseReaction
. . . O

5.2 . . O
qt . . O
prolongation . . O

swallowing . . O
and . . O
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
can . . O
be . . O
life . . O
threatening . . O
and . . O
there . . O
have . . O
been . . O
reports . . O
of . . O
death . . B-AdverseReaction
related . . O
to . . O
spread . . B-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effects . . I-AdverseReaction
. . . O

because . . O
of . . O
this . . O
, . . O
patients . . O
who . . O
have . . O
conditions . . O
that . . O
might . . O
be . . O
influenced . . O
by . . O
this . . O
factor . . O
, . . O
such . . O
as . . O
cardiac . . O
dysfunction . . O
or . . O
renal . . O
impairment . . O
, . . O
warrant . . O
careful . . O
observation . . O
when . . O
estrogens . . O
are . . O
prescribed . . O
. . . O

adverse . . O
reactions . . O
that . . O
led . . O
to . . O
treatment . . O
discontinuation . . O
in . . O
2 . . O
or . . O
more . . O
patients . . O
with . . O
classical . . O
hl . . O
or . . O
salcl . . O
were . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
8% . . O
) . . O
and . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
3% . . O
) . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

there . . O
have . . O
been . . O
post . . O
- . . O
marketing . . O
reports . . O
of . . O
serious . . B-Severity
breathing . . B-AdverseReaction
difficulties . . I-AdverseReaction
, . . O
including . . O
respiratory . . B-AdverseReaction
failure . . I-AdverseReaction
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
by . . O
at . . O
least . . O
1% . . O
of . . O
subjects . . O
treated . . O
for . . O
up . . O
to . . O
48 . . O
weeks . . O
adverse . . O
event . . O
, . . O
n . . O
( . . O
% . . O
) . . O
jublian . . O
= . . O
1227 . . O
vehiclen . . O
= . . O
413 . . O
ingrown . . B-AdverseReaction
toenail . . I-AdverseReaction
28 . . O
( . . O
2.3% . . O
) . . O
3 . . O
( . . O
0.7% . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
dermatitis . . I-AdverseReaction
27 . . O
( . . O
2.2% . . O
) . . O
1 . . O
( . . O
0.2% . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
vesicles . . I-AdverseReaction
20 . . O
( . . O
1.6% . . O
) . . O
0 . . O
( . . O
0.0% . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
13 . . O
( . . O
1.1% . . O
) . . O
1 . . O
( . . O
0.2% . . O
) . . O

excerpt . . O
: . . O
* . . O
non . . B-AdverseReaction
- . . I-AdverseReaction
infectious . . I-AdverseReaction
pneumonitis . . I-AdverseReaction
: . . O
monitor . . O
for . . O
clinical . . O
symptoms . . O
or . . O
radiological . . O
changes . . O
; . . O
fatal . . B-AdverseReaction
cases . . O
have . . O
occurred . . O
. . . O

severe . . B-Severity
acute . . B-AdverseReaction
exacerbations . . I-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
who . . O
are . . O
coinfected . . O
with . . O
hbv . . O
and . . O
human . . O
immunodeficiency . . O
virus . . O
- . . O
1 . . O
( . . O
hiv . . O
- . . O
1 . . O
) . . O
and . . O
have . . O
discontinued . . O
emtriva . . O
or . . O
viread . . O
, . . O
which . . O
are . . O
components . . O
of . . O
stribild . . O
. . . O

fanapt . . O
can . . B-Factor
induce . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
associated . . O
with . . O
dizziness . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
and . . O
syncope . . B-AdverseReaction
. . . O

adequately . . O
supplement . . O
all . . O
patients . . O
with . . O
calcium . . O
and . . O
vitamin . . O
d . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
, . . O
contraindications . . O
( . . O
4.1 . . O
) . . O
, . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
, . . O
and . . O
patient . . O
counseling . . O
information . . O
( . . O
17.3 . . O
) . . O
] . . O
. . . O

clinical . . O
myocardial . . O
infarction . . O
events . . O
in . . O
the . . O
active . . O
- . . O
controlled . . O
vte . . O
studies . . O
, . . O
a . . O
higher . . O
rate . . O
of . . O
clinical . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
was . . O
reported . . O
in . . O
patients . . O
who . . O
received . . O
pradaxa . . O
[ . . O
20 . . O
( . . O
0.66 . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
) . . O
] . . O
than . . O
in . . O
those . . O
who . . O
received . . O
warfarin . . O
[ . . O
5 . . O
( . . O
0.17 . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
) . . O
] . . O
. . . O

a . . O
total . . O
of . . O
64% . . O
of . . O
patients . . O
on . . O
gilotrif . . O
and . . O
67% . . O
of . . O
pemetrexed . . O
/ . . O
cisplatin . . O
patients . . O
were . . O
female . . O
. . . O

5.5 . . O
cardiac . . O
failure . . O

may . . B-Factor
occur . . O
in . . O
patients . . O
treated . . O
with . . O
pradaxa . . O
who . . O
are . . O
receiving . . O
neuraxial . . O

grade . . B-Severity
3 . . I-Severity
/ . . O
4 . . O
hemorrhagic . . B-AdverseReaction
events . . I-AdverseReaction
were . . O
reported . . O
in . . O
5 . . O
/ . . O
359 . . O
( . . O
1% . . O
) . . O
patients . . O
receiving . . O
inlyta . . O
( . . O
including . . O
cerebral . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
hematuria . . B-AdverseReaction
, . . O
hemoptysis . . B-AdverseReaction
, . . O
lower . . B-AdverseReaction
gastrointestinal . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
and . . O
melena . . B-AdverseReaction
) . . O
and . . O
11 . . O
/ . . O
355 . . O
( . . O
3% . . O
) . . O
patients . . O
receiving . . O
sorafenib . . O
. . . O

application . . B-AdverseReaction
- . . I-AdverseReaction
associated . . I-AdverseReaction
pain . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O

if . . O
cdad . . O
is . . O
suspected . . O
or . . O
confirmed . . O
, . . O
ongoing . . O
antibacterial . . O
use . . O
not . . O
directed . . O
against . . O
c . . O
. . . O
difficile . . O
should . . O
be . . O
discontinued . . O
, . . O
if . . O
possible . . O
. . . O

tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
imbruvica . . O
therapy . . O
. . . O

some . . O
of . . O
these . . O
events . . O
have . . O
been . . O
fatal . . B-AdverseReaction
. . . O

among . . O
patients . . O
treated . . O
with . . O
qutenza . . O
, . . O
1% . . O
discontinued . . O
prematurely . . O
due . . O
to . . O
an . . O
adverse . . O
event . . O
. . . O

5.13 . . O
posterior . . O
reversible . . O
encephalopathy . . O
syndrome . . O
( . . O
pres . . O
) . . O

( . . O
14.4 . . O
) . . O
. . . O

( . . O
5.9 . . O
) . . O

patients . . O
with . . O
uncontrolled . . O
or . . O
significant . . O
cardiovascular . . O
disease . . O
including . . O
qt . . O
interval . . O
prolongation . . O
were . . O
excluded . . O
by . . O
protocol . . O
. . . O

5.6 . . O
neurologic . . O
reactions . . O

* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.3 . . O
) . . O
] . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

adverse . . O
reactions . . O
were . . O
evaluated . . O
for . . O
1778 . . O
patients . . O
treated . . O
with . . O
dalvance . . O
and . . O
1224 . . O
patients . . O
treated . . O
with . . O
comparator . . O
antibacterial . . O
drugs . . O
in . . O
seven . . O
phase . . O
2 . . O
and . . O
phase . . O
3 . . O
clinical . . O
trials . . O
. . . O

details . . O
of . . O
the . . O
study . . O
treatment . . O
are . . O
described . . O
in . . O
section . . O
14.1 . . O
. . . O

adverse . . O
reactions . . O
n . . O
( . . O
percent . . O
of . . O
patients . . O
) . . O
headache . . B-AdverseReaction
10 . . O
( . . O
1.8% . . O
) . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
4 . . O
( . . O
0.7% . . O
) . . O
blood . . B-AdverseReaction
pressure . . I-AdverseReaction
increased . . I-AdverseReaction
a . . O
4 . . O
( . . O
0.7% . . O
) . . O
nausea . . B-AdverseReaction
4 . . O
( . . O
0.7% . . O
) . . O
fatigue . . B-AdverseReaction
3 . . O
( . . O
0.5% . . O
) . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
b . . O
3 . . O
( . . O
0.5% . . O
) . . O
anxiety . . B-AdverseReaction
2 . . O
( . . O
0.4% . . O
) . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
2 . . O
( . . O
0.4% . . O
) . . O
claustrophobia . . B-AdverseReaction
2 . . O
( . . O
0.4% . . O
) . . O
dizziness . . B-AdverseReaction
2 . . O
( . . O
0.4% . . O
) . . O
feeling . . B-AdverseReaction
cold . . I-AdverseReaction
c . . O
2 . . O
( . . O
0.4% . . O
) . . O
insomnia . . B-AdverseReaction
2 . . O
( . . O
0.4% . . O
) . . O
neck . . B-AdverseReaction
pain . . I-AdverseReaction
2 . . O
( . . O
0.4% . . O
) . . O
other . . O
adverse . . O
reactions . . O
occurred . . O
at . . O
lower . . O
frequencies . . O
and . . O
included . . O
infusion . . B-AdverseReaction
site . . I-AdverseReaction
rash . . I-AdverseReaction
, . . O
dysgeusia . . B-AdverseReaction
, . . O
pruritis . . B-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
and . . O
flushing . . B-AdverseReaction
. . . O

mild . . B-Severity
to . . I-Severity
severe . . I-Severity
hypertension . . B-AdverseReaction
may . . B-Factor
be . . O
present . . O
. . . O

5.3 . . O
dysphagia . . O
and . . O
breathing . . O
difficulties . . O

bone . . O
mineral . . O
density . . O
( . . O
bmd . . O
) . . O
was . . O
measured . . O
by . . O
dual . . O
- . . O
energy . . O
x . . O
- . . O
ray . . O
absorptiometry . . O
in . . O
a . . O
clinical . . O
trial . . O
of . . O
714 . . O
older . . O
adults . . O
( . . O
mean . . O
age . . O
64 . . O
years . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.3 . . O
) . . O
] . . O
. . . O

[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
. . . O
] . . O

testing . . O
should . . O
include . . O
visual . . O
acuity . . O
and . . O
dilated . . O
fundus . . O
photography . . O
. . . O

the . . O
adverse . . O
reactions . . O
presented . . O
in . . O
the . . O
table . . O
below . . O
are . . O
based . . O
on . . O
safety . . O
information . . O
from . . O
769 . . O
patients . . O
treated . . O
with . . O
tecfidera . . O
240 . . O
mg . . O
twice . . O
a . . O
day . . O
and . . O
771 . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

hematologic . . O
disorders . . O
: . . O
hemolytic . . B-AdverseReaction
anemia . . I-AdverseReaction

( . . O
5.4 . . O
, . . O
2.3 . . O
) . . O
* . . O
cardiomyopathy . . B-AdverseReaction
: . . O
assess . . O
lvef . . O
before . . O
treatment . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
, . . O
after . . O
one . . O
month . . O
of . . O
treatment . . O
, . . O
then . . O
every . . O
2 . . O
to . . O
3 . . O
months . . O
thereafter . . O
. . . O

at . . O
the . . O
first . . O
sign . . O
or . . O
symptom . . O
suggestive . . O
of . . O
pml . . O
, . . O
withhold . . O
gilenya . . O
and . . O
perform . . O
an . . O
appropriate . . O
diagnostic . . O
evaluation . . O
. . . O

( . . O
6.1 . . O
) . . O
* . . O
most . . O
common . . O
non . . O
- . . O
hematologic . . O
adverse . . O
reactions . . O
for . . O
nhl . . O
( . . O
frequency . . O
> . . O
= . . O
15% . . O
) . . O
are . . O
nausea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
anorexia . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
stomatitis . . B-AdverseReaction
. . . O

if . . O
hypersensitivity . . O
reactions . . O
occur . . O
, . . O
discontinue . . O
use . . O
of . . O
invokana . . O
; . . O
treat . . O
and . . O
monitor . . O
until . . O
signs . . O
and . . O
symptoms . . O
resolve . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

table . . O
4 . . O
provides . . O
the . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
at . . O
least . . O
10% . . O
of . . O
subjects . . O
receiving . . O
zydelig . . O
monotherapy . . O
, . . O
and . . O
table . . O
5 . . O
provides . . O
the . . O
treatment . . O
- . . O
emergent . . O
laboratory . . O
abnormalities . . O
. . . O

acute . . B-AdverseReaction
cardiorespiratory . . I-AdverseReaction
failure . . I-AdverseReaction
has . . O
been . . O
observed . . O
in . . O
infantile . . O
- . . O
onset . . O
pompe . . O
disease . . O
patients . . O
with . . O
underlying . . O
cardiac . . O
hypertrophy . . O
, . . O
possibly . . O
associated . . O
with . . O
fluid . . B-AdverseReaction
overload . . I-AdverseReaction
with . . O
intravenous . . O
administration . . O
of . . O
alglucosidase . . O
alfa . . O
[ . . O
seedosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

in . . O
this . . O
study . . O
, . . O
159 . . O
patients . . O
received . . O
xeomin . . O
( . . O
78 . . O
were . . O
randomized . . O
to . . O
receive . . O
a . . O
total . . O
dose . . O
of . . O
120 . . O
units . . O
, . . O
and . . O
81 . . O
were . . O
randomized . . O
to . . O
receive . . O
a . . O
total . . O
dose . . O
of . . O
240 . . O
units . . O
) . . O
. . . O

no . . B-Negation
hypersensitivity . . B-AdverseReaction
or . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
were . . O
reported . . O
with . . O
firazyr . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

epilepsy . . O
and . . O
many . . O
other . . O
illnesses . . O
for . . O
which . . O
aeds . . O
are . . O
prescribed . . O
are . . O
themselves . . O
associated . . O
with . . O
morbidity . . O
and . . O
mortality . . O
and . . O
an . . O
increased . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
and . . O
behavior . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . O
have . . O
occurred . . O
as . . O
early . . O
as . . O
30 . . O
minutes . . O
from . . O
the . . O
start . . O
of . . O
infusion . . O
but . . O
as . . O
late . . O
as . . O
six . . O
days . . O
after . . O
infusion . . O
. . . O

no . . B-Negation
patients . . O
developed . . O
malignant . . B-AdverseReaction
hypertension . . I-AdverseReaction
. . . O

6 . . O
adverse . . O
reactions . . O

muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
. . . O

renal . . O
function . . O
should . . O
be . . O
evaluated . . O
prior . . O
to . . O
initiation . . O
of . . O
farxiga . . O
and . . O
monitored . . O
periodically . . O
thereafter . . O
. . . O

5.3 . . O
cataracts . . O

instances . . O
of . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
0.1% . . O
( . . O
1 . . O
/ . . O
1308 . . O
) . . O
of . . O
subjects . . O
while . . O
receiving . . O
otezla . . O
, . . O
compared . . O
to . . O
0.2% . . O
( . . O
1 . . O
/ . . O
506 . . O
) . . O
in . . O
placebo . . O
- . . O
treated . . O
subjects . . O
. . . O

at . . O
week . . O
20 . . O
in . . O
trial . . O
1 . . O
, . . O
17% . . O
of . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
and . . O
13% . . O
of . . O
control . . O
patients . . O
were . . O
newly . . B-AdverseReaction
ana . . I-AdverseReaction
- . . I-AdverseReaction
positive . . I-AdverseReaction
( . . O
at . . B-Severity
titers . . I-Severity
of . . I-Severity
1 . . I-Severity
: . . I-Severity
160 . . I-Severity
or . . O
greater . . O
) . . O
. . . O

hepatobiliary . . O
disorders . . O
: . . O
jaundice . . B-AdverseReaction
, . . O
hepatomegaly . . B-AdverseReaction
. . . O

5.11 . . O
embryofetal . . O
toxicity . . O

table . . O
5 . . O
lists . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
with . . O
phn . . O
treated . . O
with . . O
horizant . . O
1,200 . . O
mg . . O
/ . . O
day . . O
and . . O
numerically . . O
greater . . O
than . . O
placebo . . O
. . . O

obtain . . O
frequent . . O
blood . . O
counts . . O
to . . O
monitor . . O
for . . O
neutropenia . . O
. . . O

mineralization . . O
defects . . O
: . . O

the . . O
proportion . . O
of . . O
patients . . O
who . . O
prematurely . . O
discontinued . . O
study . . O
drug . . O
due . . O
to . . O
adverse . . O
reactions . . O
was . . O
2% . . O
for . . O
kalydeco . . O
- . . O
treated . . O
patients . . O
and . . O
5% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

nesina . . O
should . . O
not . . O
be . . O
restarted . . O
in . . O
these . . O
patients . . O
without . . O
another . . O
explanation . . O
for . . O
the . . O
liver . . O
test . . O
abnormalities . . O
. . . O

experience . . O
in . . O
classical . . O
hodgkin . . O
lymphoma . . O

discontinuation . . O
of . . O
therapy . . O
due . . O
to . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
18% . . O
of . . O
patients . . O
treated . . O
with . . O
blincyto . . O
. . . O

prednisone . . O
reduction . . O
can . . O
be . . O
accomplished . . O
by . . O
reducing . . O
the . . O
daily . . O
prednisone . . O
dose . . O
by . . O
2.5 . . O
mg . . O
on . . O
a . . O
weekly . . O
basis . . O
during . . O
therapy . . O
with . . O
breo . . O
ellipta . . O
. . . O

no . . B-Negation
serious . . B-Severity
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
were . . O
reported . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
hematuria . . B-AdverseReaction
, . . O
proteinuria . . B-AdverseReaction

for . . O
pediatric . . O
patients . . O
with . . O
sega . . O
that . . O
do . . O
not . . O
require . . O
immediate . . O
treatment . . O
, . . O
complete . . O
the . . O
recommended . . O
childhood . . O
series . . O
of . . O
live . . O
virus . . O
vaccinations . . O
according . . O
to . . O
american . . O
council . . O
on . . O
immunization . . O
practices . . O
( . . O
acip . . O
) . . O
guidelines . . O
prior . . O
to . . O
the . . O
start . . O
of . . O
therapy . . O
. . . O

5.2 . . O
pancreatitis . . O

you . . O
should . . O
not . . O
do . . O
both . . O
. . . O

serum . . O
liver . . O
enzyme . . O
activities . . O

b . . O
includes . . O
the . . O
following . . O
terms . . O
: . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
edema . . B-AdverseReaction
, . . O
and . . O
lymphedema . . B-AdverseReaction
. . . O

retinal . . B-AdverseReaction
vascular . . I-AdverseReaction
thrombosis . . I-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
receiving . . O
estrogens . . O
. . . O

a . . O
total . . O
of . . O
701 . . O
subjects . . O
received . . O
stribild . . O
once . . O
daily . . O
in . . O
these . . O
two . . O
studies . . O
. . . O

diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
and . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
occur . . O
with . . O
bosulif . . O
treatment . . O
. . . O

5.1 . . O
splenic . . O
rupture . . O

laboratory . . O
test . . O
abnormalities . . O
in . . O
clinical . . O
trials . . O

83.9% . . O
of . . O
patients . . O
were . . O
white . . O
, . . O
13.8% . . O
were . . O
black . . O
, . . O
1.4% . . O
asian . . O
, . . O
and . . O
< . . O
1% . . O
hispanic . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
bristol . . O
- . . O
myers . . O
squibb . . O
at . . O
1-800-721-5072 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

most . . O
patients . . O
( . . O
87% . . O
) . . O
were . . O
less . . O
than . . O
65 . . O
years . . O
of . . O
age . . O
; . . O
58.4% . . O
were . . O
women . . O
. . . O

in . . O
the . . O
combined . . O
data . . O
for . . O
studies . . O
1 . . O
and . . O
2 . . O
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
occurred . . O
more . . O
commonly . . O
in . . O
patients . . O
treated . . O
with . . O
zytiga . . O
compared . . O
to . . O
patients . . O
on . . O
the . . O
placebo . . O
arm . . O
( . . O
2.1% . . O
versus . . O
0.7% . . O
) . . O
. . . O

have . . O
anaphylactic . . O
and . . O
hypersensitivity . . O
treatment . . O
measures . . O
available . . O
prior . . O
to . . O
adreview . . O
administration . . O
. . . O

do . . O
not . . O
use . . O
to . . O
treat . . O
acute . . O
symptoms . . O
. . . O

discontinue . . O
medication . . O
pending . . O
examination . . O
if . . O
there . . O
is . . O
sudden . . O
partial . . O
or . . O
complete . . O
loss . . O
of . . O
vision . . O
, . . O
or . . O
a . . O
sudden . . O
onset . . O
of . . O
proptosis . . O
, . . O
diplopia . . O
, . . O
or . . O
migraine . . O
. . . O

patients . . O
should . . O
be . . O
advised . . O
not . . O
to . . O
wear . . O
a . . O
contact . . O
lens . . O
if . . O
their . . O
eye . . O
is . . O
red . . O
. . . O

complete . . O
blood . . O
count . . O
( . . O
with . . O
white . . O
blood . . O
cell . . O
differential . . O
counts . . O
) . . O
should . . O
be . . O
obtained . . O
at . . O
pretreatment . . O
, . . O
and . . O
at . . O
treatment . . O
weeks . . O
2 . . O
, . . O
4 . . O
, . . O
8 . . O
, . . O
and . . O
12 . . O
, . . O
and . . O
should . . O
be . . O
monitored . . O
closely . . O
at . . O
other . . O
time . . O
points . . O
, . . O
as . . O
clinically . . O
appropriate . . O
. . . O

to . . O
aid . . O
in . . O
the . . O
management . . O
of . . O
such . . O
patients . . O
, . . O
consider . . O
consultation . . O
with . . O
a . . O
physician . . O
with . . O
expertise . . O
in . . O
the . . O
diagnosis . . O
and . . O
treatment . . O
of . . O
invasive . . O
fungal . . O
infections . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
the . . O
rate . . O
of . . O
progression . . O
of . . O
retinal . . O
abnormalities . . O
and . . O
their . . O
reversibility . . O
are . . O
unknown . . O
. . . O

the . . O
majority . . O
of . . O
renal . . B-AdverseReaction
cysts . . I-AdverseReaction
in . . O
xalkori . . O
- . . O
treated . . O
patients . . O
were . . O
complex . . O
. . . O

5.1 . . O
risk . . O
for . . O
image . . O
misinterpretation . . O
and . . O
other . . O
errors . . O

adverse . . O
reactions . . O
reported . . O
in . . O
the . . O
post . . O
marketing . . O
setting . . O
arise . . O
from . . O
a . . O
population . . O
of . . O
unknown . . O
size . . O
and . . O
are . . O
voluntary . . O
in . . O
nature . . O
. . . O

hemorrhage . . B-AdverseReaction
: . . O
severe . . B-Severity
, . . O
sometimes . . O
fatal . . B-AdverseReaction
, . . O
hemorrhage . . O
including . . O
hemoptysis . . B-AdverseReaction
and . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
occurred . . O
in . . O
3% . . O
of . . O
cometriq . . O
- . . O
treated . . O
patients . . O
. . . O

the . . O
data . . O
reflect . . O
the . . O
percentage . . O
of . . O
patients . . O
whose . . O
test . . O
results . . O
were . . O
positive . . O
for . . O
antibodies . . O
to . . O
belimumab . . O
in . . O
specific . . O
assays . . O
. . . O

bipolar . . O
i . . O
disorder . . O
( . . O
3 . . O
- . . O
weeks . . O
) . . O
placebo . . O
saphris2.5 . . O
mgtwice . . O
daily . . O
saphris5 . . O
mgtwice . . O
daily . . O
saphris10 . . O
mgtwice . . O
daily . . O
change . . O
from . . O
baseline . . O
( . . O
kg . . O
) . . O
( . . O
n . . O
* . . O
) . . O
0.5(89 . . O
) . . O
1.7(92 . . O
) . . O
1.6(90 . . O
) . . O
1.4(87 . . O
) . . O
proportion . . O
of . . O
subjects . . O
with . . O
a . . O
> . . O
= . . O
7% . . B-Severity
increase . . B-AdverseReaction
in . . I-AdverseReaction
body . . I-AdverseReaction
weight . . I-AdverseReaction
% . . O
with . . O
> . . O
= . . O
7% . . B-Severity
increase . . B-AdverseReaction
in . . I-AdverseReaction
body . . I-AdverseReaction
weight . . I-AdverseReaction
1.1% . . O
12.0% . . O
8.9% . . O
8.0% . . O
5.6 . . O
hypersensitivity . . O
reactions . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
saphris . . O
. . . O

in . . O
addition . . O
, . . O
women . . O
taking . . O
duavee . . O
should . . O
be . . O
advised . . O
to . . O
move . . O
about . . O
periodically . . O
during . . O
travel . . O
involving . . O
prolonged . . O
immobilization . . O
. . . O

titration . . O
was . . O
used . . O
over . . O
the . . O
first . . O
5 . . O
days . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

extreme . . O
care . . O
must . . O
be . . O
taken . . O
to . . O
avoid . . O
pregnancy . . O
in . . O
female . . O
patients . . O
and . . O
in . . O
female . . O
partners . . O
of . . O
male . . O
patients . . O
. . . O

* . . O
new . . O
onset . . O
or . . O
worsening . . B-AdverseReaction
renal . . I-AdverseReaction
impairment . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

cervical . . O
dystonia . . O

nulojix . . O
- . . O
treated . . O
patients . . O
have . . O
an . . O
increased . . O
risk . . B-Factor
for . . O
developing . . O
post . . B-AdverseReaction
- . . I-AdverseReaction
transplant . . I-AdverseReaction
lymphoproliferative . . I-AdverseReaction
disorder . . I-AdverseReaction
( . . O
ptld . . B-AdverseReaction
) . . O
, . . O
predominantly . . O
involving . . O
the . . O
cns . . O
, . . O
compared . . O
to . . O
patients . . O
on . . O
a . . O
cyclosporine . . O
- . . O
based . . O
regimen . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
and . . O
table . . O
2 . . O
] . . O
. . . O

warning . . O
: . . O
lactic . . B-AdverseReaction
acidosis . . I-AdverseReaction
/ . . O
severe . . B-Severity
hepatomegaly . . B-AdverseReaction
with . . O
steatosis . . B-AdverseReaction
and . . O
post . . O
treatment . . O
acute . . B-AdverseReaction
exacerbation . . I-AdverseReaction
of . . I-AdverseReaction
hepatitis . . I-AdverseReaction
b . . I-AdverseReaction

discontinue . . O
intelence . . O
( . . O
r . . O
) . . O
immediately . . O
if . . O
signs . . O
or . . O
symptoms . . O
of . . O
severe . . O
skin . . O
reactions . . O
or . . O
hypersensitivity . . O
reactions . . O
develop . . O
( . . O
including . . O
, . . O
but . . O
not . . O
limited . . O
to . . O
, . . O
severe . . O
rash . . O
or . . O
rash . . O
accompanied . . O
by . . O
fever . . O
, . . O
general . . O
malaise . . O
, . . O
fatigue . . O
, . . O
muscle . . O
or . . O
joint . . O
aches . . O
, . . O
blisters . . O
, . . O
oral . . O
lesions . . O
, . . O
conjunctivitis . . O
, . . O
facial . . O
edema . . O
, . . O
hepatitis . . O
, . . O
eosinophilia . . O
, . . O
angioedema . . O
) . . O
. . . O

malignancies . . O
in . . O
adult . . O
patients . . O

patients . . O
should . . O
be . . O
advised . . O
not . . O
to . . O
drive . . O
a . . O
car . . O
or . . O
operate . . O
other . . O
complex . . O
machinery . . O
until . . O
they . . O
have . . O
gained . . O
sufficient . . O
experience . . O
on . . O
horizant . . O
to . . O
assess . . O
whether . . O
horizant . . O
impairs . . O
their . . O
ability . . O
to . . O
perform . . O
these . . O
tasks . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
macrovascular . . O
outcomes . . O
: . . O
there . . O
have . . O
been . . O
no . . O
clinical . . O
trials . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
tanzeum . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
. . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
epistaxis . . B-AdverseReaction
, . . O
hemoptysis . . B-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
. . . O

refer . . O
to . . O
the . . O
prescribing . . O
information . . O
for . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
for . . O
additional . . O
information . . O
regarding . . O
dose . . O
reduction . . O
or . . O
discontinuation . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
may . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
. . . O

errors . . O
may . . O
occur . . O
in . . O
the . . O
amyvid . . O
estimation . . O
of . . O
brain . . O
neuritic . . O
plaque . . O
density . . O
during . . O
image . . O
interpretation . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

the . . O
mechanism . . O
for . . O
the . . O
bleeding . . O
events . . O
is . . O
not . . O
well . . O
understood . . O
. . . O

5.10 . . O
paradoxical . . O
bronchospasm . . O

infections . . O
, . . O
predominantly . . O
of . . O
the . . O
upper . . O
respiratory . . O
tract . . O
, . . O
in . . O
some . . O
instances . . O
serious . . B-Severity
, . . O
have . . O
been . . O
reported . . O
with . . O
ilaris . . O
. . . O

the . . O
most . . O
commonly . . O
occurring . . O
adverse . . O
reactions . . O
in . . O
the . . O
wm . . O
trial . . O
( . . O
> . . O
= . . O
20% . . O
) . . O
were . . O
neutropenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
, . . O
and . . O
fatigue . . B-AdverseReaction
. . . O

when . . O
vasodilators . . O
are . . O
used . . O
in . . O
combination . . O
, . . O
an . . O
additive . . O
effect . . O
on . . O
blood . . O
pressure . . O
may . . O
be . . O
anticipated . . O
. . . O

laboratory . . O
abnormalities . . O

macular . . B-AdverseReaction
edema . . I-AdverseReaction
occurred . . O
predominantly . . O
during . . O
the . . O
first . . O
3 . . O
to . . O
4 . . O
months . . O
of . . O
therapy . . O
. . . O

5.4 . . O
immunizations . . O

( . . O
5.1 . . O
) . . O
* . . O
measurement . . O
of . . O
methotrexate . . O
using . . O
immunoassays . . O
is . . O
unreliable . . O
for . . O
samples . . O
collected . . O
within . . O
48 . . O
hours . . O
following . . O
voraxaze . . O
administration . . O
. . . O

ampyra . . O
has . . O
not . . O
been . . O
evaluated . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
seizures . . O
or . . O
with . . O
evidence . . O
of . . O
epileptiform . . O
activity . . O
on . . O
an . . O
eeg . . O
, . . O
as . . O
these . . O
patients . . O
were . . O
excluded . . O
from . . O
clinical . . O
trials . . O
. . . O

5.4 . . O
tumor . . O
lysis . . O
syndrome . . O

an . . O
observational . . O
, . . O
open . . O
label . . O
study . . O
was . . O
conducted . . O
in . . O
subjects . . O
who . . O
had . . O
participated . . O
in . . O
xiaflex . . O
clinical . . O
trials . . O
for . . O
dupuytren's . . O
contracture . . O
( . . O
study . . O
4 . . O
) . . O
. . . O

blood . . O
pressure . . O
and . . O
use . . O
of . . O
antihypertensive . . O
medications . . O
were . . O
reported . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
. . . O

5.4 . . O
anaphylaxis . . O

the . . O
clearance . . O
values . . O
for . . O
4 . . O
of . . O
these . . O
5 . . O
patients . . O
were . . O
approximately . . O
1.2 . . O
- . . O
to . . O
1.8 . . O
- . . O
fold . . O
greater . . O
in . . O
the . . O
presence . . O
of . . O
inhibitory . . O
antibodies . . O
( . . O
week . . O
52 . . O
) . . O
as . . O
compared . . O
to . . O
in . . O
the . . O
absence . . O
of . . O
inhibitory . . O
antibodies . . O
( . . O
week . . O
0 . . O
) . . O
[ . . O
seeclinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

the . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
serum . . I-AdverseReaction
potassium . . I-AdverseReaction
is . . O
usually . . O
transient . . O
, . . O
not . . O
requiring . . O
supplementation . . O
. . . O

the . . O
majority . . O
of . . O
adult . . O
patients . . O
were . . O
enrolled . . O
in . . O
studies . . O
in . . O
thailand . . O
, . . O
while . . O
the . . O
majority . . O
of . . O
pediatric . . O
patients . . O
were . . O
enrolled . . O
in . . O
africa . . O
. . . O

5.4 . . O
hypersensitivity . . O
reactions . . O
, . . O
including . . O
anaphylaxis . . O

5.3 . . O
neuroleptic . . O
malignant . . O
syndrome . . O

if . . O
tafinlar . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
, . . O
do . . O
not . . O
modify . . O
the . . O
dose . . O
of . . O
trametinib . . O
. . . O

the . . O
diagnostic . . O
evaluation . . O
of . . O
patients . . O
with . . O
this . . O
syndrome . . O
is . . O
complicated . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
prolactin . . B-AdverseReaction
elevations . . I-AdverseReaction
> . . O
= . . O
4 . . B-Severity
times . . I-Severity
uln . . I-Severity
( . . O
at . . O
endpoint . . O
) . . O
were . . O
2.6% . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
versus . . O
0.6% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

read . . O
this . . O
patient . . O
information . . O
before . . O
you . . O
start . . O
taking . . O
duavee . . O
and . . O
each . . O
time . . O
you . . O
get . . O
a . . O
refill . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
drug . . B-AdverseReaction
rash . . I-AdverseReaction
with . . I-AdverseReaction
eosinophilia . . I-AdverseReaction
and . . I-AdverseReaction
systemic . . I-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
dress . . B-AdverseReaction
) . . O
have . . O
also . . O
been . . O
reported . . O
and . . O
were . . O
characterized . . O
by . . O
rash . . B-AdverseReaction
, . . O
constitutional . . O
findings . . O
, . . O
and . . O
sometimes . . O
organ . . B-AdverseReaction
dysfunction . . I-AdverseReaction
, . . O
including . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
. . . O

severe . . O
acute . . O
exacerbations . . O
of . . O
hepatitis . . O
b . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
who . . O
are . . O
coinfected . . O
with . . O
hbv . . O
and . . O
hiv . . O
- . . O
1 . . O
and . . O
have . . O
discontinued . . O
emtricitabine . . O
or . . O
tenofovir . . O
df . . O
, . . O
two . . O
of . . O
the . . O
components . . O
of . . O
stribild . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
high . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
: . . O
do . . O
not . . O
prescribe . . O
natazia . . O
for . . O
women . . O
with . . O
uncontrolled . . O
hypertension . . O
or . . O
hypertension . . O
with . . O
vascular . . O
disease . . O
. . . O

the . . O
incidence . . O
of . . O
antibody . . O
formation . . O
is . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
. . . O

5.2 . . O
growth . . O
of . . O
resistant . . O
organisms . . O
with . . O
prolonged . . O
use . . O

5.4 . . O
use . . O
in . . O
patients . . O
with . . O
sickle . . O
cell . . O
disease . . O

summary . . O
of . . O
treatment . . O
- . . O
emergent . . O
laboratory . . O
abnormalities . . O
with . . O
grade . . O
3 . . O
or . . O
4 . . O
incidence . . O
of . . O
> . . O
= . . O
4% . . O
in . . O
xalkori . . O
- . . O
treated . . O
patients . . O
in . . O
study . . O
2 . . O
laboratory . . O
abnormality . . O
xalkori . . O
chemotherapy . . O
any . . O
grade . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4 . . O
( . . O
% . . O
) . . O
any . . O
grade . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
/ . . O
4 . . O
( . . O
% . . O
) . . O
hematology . . O
neutropenia . . B-AdverseReaction
49 . . O
12 . . O
28 . . O
12 . . O
lymphopenia . . B-AdverseReaction
51 . . O
9 . . O
60 . . O
25 . . O
chemistry . . O
alt . . B-AdverseReaction
elevation . . I-AdverseReaction
76 . . O
17 . . O
38 . . O
4 . . O
ast . . B-AdverseReaction
elevation . . I-AdverseReaction
61 . . O
9 . . O
33 . . O
0 . . O
hypokalemia . . B-AdverseReaction
18 . . O
4 . . O
10 . . O
1 . . O
hypophosphatemia . . B-AdverseReaction
28 . . O
5 . . O
25 . . O
6 . . O
description . . O
of . . O
selected . . O
adverse . . O
drug . . O
reactions . . O

psychiatric . . O
disorders . . O
: . . O
suicidal . . B-AdverseReaction
ideation . . I-AdverseReaction
, . . O
attempt . . O
, . . O
behavior . . O
, . . O
or . . O
completion . . O
. . . O

to . . O
reduce . . O
this . . O
risk . . O
, . . O
consider . . O
coverage . . O
with . . O
another . . O
anticoagulant . . O
if . . O
eliquis . . O
is . . O
discontinued . . O
for . . O
a . . O
reason . . O
other . . O
than . . O
pathological . . O
bleeding . . O
or . . O
completion . . O
of . . O
a . . O
course . . O
of . . O
therapy . . O
. . . O

reversal . . O
of . . O
anticoagulant . . O
effect . . O
: . . O
a . . O
specific . . O
reversal . . O
agent . . O
for . . O
dabigatran . . O
is . . O
not . . O
available . . O
. . . O

table . . O
2 . . O
investigator . . O
assessment . . O
of . . O
maximal . . O
local . . B-AdverseReaction
skin . . I-AdverseReaction
reactions . . I-AdverseReaction
in . . O
the . . O
treatment . . O
area . . O
during . . O
the . . O
57 . . O
days . . O
post . . O
treatment . . O
period . . O
( . . O
trunk . . O
/ . . O
extremities . . O
trials . . O
) . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

in . . O
clinical . . O
trials . . O
of . . O
tnf . . O
blockers . . O
, . . O
including . . O
cimzia . . O
, . . O
in . . O
patients . . O
with . . O
ra . . O
, . . O
some . . O
patients . . O
have . . O
developed . . O
ana . . B-AdverseReaction
. . . O

due . . O
to . . O
higher . . O
mmae . . O
exposure . . O
, . . O
> . . O
= . . O
grade . . O
3 . . O
adverse . . O
reactions . . O
may . . O
be . . O
more . . O
frequent . . O
in . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
compared . . O
to . . O
patients . . O
with . . O
normal . . O
renal . . O
function . . O
. . . O

from . . O
230 . . O
subjects . . O
treated . . O
with . . O
dysport . . O
( . . O
r . . O
) . . O
and . . O
tested . . O
for . . O
the . . O
presence . . O
of . . O
binding . . O
antibodies . . O
, . . O
5 . . O
subjects . . O
were . . O
positive . . O
at . . O
baseline . . O
and . . O
17 . . O
developed . . O
antibodies . . O
after . . O
treatment . . O
. . . O

if . . O
involvement . . O
of . . O
the . . O
tongue . . O
, . . O
hypopharynx . . O
, . . O
or . . O
larynx . . O
occurs . . O
, . . O
fesoterodine . . O
should . . O
be . . O
promptly . . O
discontinued . . O
and . . O
appropriate . . O
therapy . . O
and . . O
/ . . O
or . . O
measures . . O
to . . O
ensure . . O
a . . O
patent . . O
airway . . O
should . . O
be . . O
promptly . . O
provided . . O
. . . O

most . . O
of . . O
these . . O
events . . O
were . . O
not . . O
specific . . O
to . . O
the . . O
injection . . O
site . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
. . . O

avoid . . O
treatment . . O
in . . O
the . . O
periocular . . O
area . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

see . . O
table . . O
3 . . O
and . . O
table . . O
4 . . O
for . . O
other . . O
potentially . . O
significant . . O
drug . . O
interactions . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
] . . O
. . . O

the . . O
data . . O
described . . O
below . . O
reflect . . O
exposure . . O
to . . O
imbruvica . . O
in . . O
an . . O
open . . O
label . . O
clinical . . O
trial . . O
that . . O
included . . O
63 . . O
patients . . O
with . . O
previously . . O
treated . . O
wm . . O
. . . O

6 . . O
adverse . . O
reactions . . O

besivance . . O
is . . O
for . . O
topical . . O
ophthalmic . . O
use . . O
only . . O
, . . O
and . . O
should . . O
not . . O
be . . O
injected . . O
subconjunctivally . . O
, . . O
nor . . O
should . . O
it . . O
be . . O
introduced . . O
directly . . O
into . . O
the . . O
anterior . . O
chamber . . O
of . . O
the . . O
eye . . O
. . . O

table . . O
2 . . O
adverse . . O
reactions . . O
with . . O
a . . O
frequency . . O
> . . O
= . . O
0.5% . . O
reported . . O
in . . O
clinical . . O
trials . . O
( . . O
n . . O
= . . O
978 . . O
administrations . . O
in . . O
872 . . O
subjects . . O
) . . O
adverse . . O
drug . . O
reaction . . O
n . . O
( . . O
% . . O
) . . O
injection . . O
/ . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
erythema . . I-AdverseReaction
17 . . O
( . . O
1.7 . . O
) . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
irritation . . I-AdverseReaction
12 . . O
( . . O
1.2 . . O
) . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
38 . . O
( . . O
3.9 . . O
) . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O

6 . . O
adverse . . O
reactions . . O

if . . O
unexplained . . O
or . . O
clinically . . O
significant . . O
weight . . O
loss . . O
occurs . . O
, . . O
weight . . O
loss . . O
should . . O
be . . O
evaluated . . O
, . . O
and . . O
discontinuation . . O
of . . O
otezla . . O
should . . O
be . . O
considered . . O
. . . O

5.3 . . O
direct . . O
coombs' . . O
test . . O
seroconversion . . O

stribild . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
chronic . . O
hepatitis . . O
b . . O
virus . . O
( . . O
hbv . . O
) . . O
infection . . O
and . . O
the . . O
safety . . O
and . . O
efficacy . . O
of . . O
stribild . . O
have . . O
not . . O
been . . O
established . . O
in . . O
patients . . O
coinfected . . O
with . . O
hbv . . O
and . . O
hiv . . O
- . . O
1 . . O
. . . O

there . . O
were . . O
suicides . . B-AdverseReaction
in . . O
the . . O
adult . . O
studies . . O
, . . O
but . . O
the . . O
number . . O
was . . O
not . . O
sufficient . . O
to . . O
reach . . O
any . . O
conclusion . . O
about . . O
drug . . O
effect . . O
on . . O
suicide . . O
. . . O

subjects . . O
participating . . O
in . . O
this . . O
trial . . O
had . . O
a . . O
history . . O
of . . O
one . . O
or . . O
more . . O
asthma . . O
exacerbations . . O
that . . O
required . . O
treatment . . O
with . . O
oral . . O
/ . . O
systemic . . O
corticosteroids . . O
or . . O
emergency . . O
department . . O
visit . . O
or . . O
in . . O
- . . O
patient . . O
hospitalization . . O
for . . O
the . . O
treatment . . O
of . . O
asthma . . O
in . . O
the . . O
year . . O
prior . . O
to . . O
trial . . O
entry . . O
. . . O

6.1 . . O
clinical . . O
trial . . O
experience . . O

excerpt . . O
: . . O
* . . O
most . . O
common . . O
adverse . . O
reaction . . O
to . . O
granix . . O
is . . O
bone . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
6 . . O
) . . O
to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
teva . . O
at . . O
1-866-832-8537 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
abdominal . . B-AdverseReaction
distention . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
flatulence . . B-AdverseReaction
, . . O
frequent . . B-AdverseReaction
stools . . I-AdverseReaction
, . . O
gastritis . . B-AdverseReaction
, . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
gastrointestinal . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
gingival . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
haematemesis . . B-AdverseReaction
, . . O
hyperchlorhydria . . B-AdverseReaction
, . . O
hematochezia . . B-AdverseReaction
, . . O
mouth . . B-AdverseReaction
ulceration . . I-AdverseReaction
, . . O
pancreatitis . . B-AdverseReaction
, . . O
peptic . . B-AdverseReaction
ulcer . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
. . . O

excerpt . . O
: . . O
* . . O
bradycardia . . B-AdverseReaction
and . . O
/ . . O
or . . O
atrioventricular . . B-AdverseReaction
conduction . . I-AdverseReaction
after . . O
first . . O
dose . . O
: . . O
monitor . . O
patients . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
( . . O
8% . . O
) . . O
, . . O
hemorrhoids . . B-AdverseReaction
( . . O
5% . . O
) . . O
, . . O
dysphagia . . B-AdverseReaction
( . . O
4% . . O
) . . O

low . . B-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
hematocrit . . O
, . . O
and . . O
rbc . . O
counts . . O
were . . O
observed . . O
in . . O
0.2% . . O
, . . O
0.4% . . O
, . . O
and . . O
0.3% . . O
of . . O
edarbi . . O
- . . O
treated . . O
subjects . . O
, . . O
respectively . . O
. . . O

table . . O
5 . . O
: . . O
incidence . . O
( . . O
% . . O
) . . O
of . . O
patients . . O
with . . O
proteinuria . . B-AdverseReaction
in . . O
the . . O
fixed . . O
- . . O
dose . . O
clinical . . O
studies . . O
pristiq . . O
placebo . . O
50 . . O
mg . . O
100 . . O
mg . . O
200 . . O
mg . . O
400 . . O
mg . . O
proteinuria . . B-AdverseReaction
4 . . O
6 . . O
8 . . O
5 . . O
7 . . O
vital . . O
sign . . O
changes . . O

6.2 . . O
postmarketing . . O
experience . . O

the . . O
following . . O
adverse . . O
reactions . . O
with . . O
northera . . O
are . . O
included . . O
in . . O
more . . O
detail . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O
of . . O
the . . O
label . . O
: . . O

concomitant . . O
use . . O
of . . O
p . . O
- . . O
gp . . O
inhibitors . . O
in . . O
patients . . O
with . . O
renal . . O
impairment . . O
is . . O
expected . . O
to . . O
produce . . O
increased . . O
exposure . . O
of . . O
dabigatran . . O
compared . . O
to . . O
that . . O
seen . . O
with . . O
either . . O
factor . . O
alone . . O
. . . O

table . . O
3 . . O
: . . O
adverse . . O
reactions . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
on . . O
the . . O
zytiga . . O
arm . . O
in . . O
study . . O
2 . . O
zytiga . . O
with . . O
prednisone . . O
( . . O
n . . O
= . . O
542 . . O
) . . O
placebo . . O
with . . O
prednisone . . O
( . . O
n . . O
= . . O
540 . . O
) . . O
system . . O
/ . . O
organ . . O
class . . O
adverse . . O
reaction . . O
all . . O
grades% . . O
grade . . O
3-4% . . O
all . . O
grades% . . O
grade . . O
3-4% . . O
general . . O
disorders . . O
fatigue . . B-AdverseReaction
39.1 . . O
2.2 . . O
34.3 . . O
1.7 . . O
edema . . B-AdverseReaction
25.1 . . O
0.4 . . O
20.7 . . O
1.1 . . O
pyrexia . . B-AdverseReaction
8.7 . . O
0.6 . . O
5.9 . . O
0.2 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
joint . . B-AdverseReaction
swelling . . I-AdverseReaction
/ . . O
discomfort . . O
30.3 . . O
2.0 . . O
25.2 . . O
2.0 . . O
groin . . B-AdverseReaction
pain . . I-AdverseReaction
6.6 . . O
0.4 . . O
4.1 . . O
0.7 . . O
gastrointestinal . . O
disorders . . O
constipation . . B-AdverseReaction
23.1 . . O
0.4 . . O
19.1 . . O
0.6 . . O
diarrhea . . B-AdverseReaction
21.6 . . O
0.9 . . O
17.8 . . O
0.9 . . O
dyspepsia . . B-AdverseReaction
11.1 . . O
0.0 . . O
5.0 . . O
0.2 . . O
vascular . . O
disorders . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
22.3 . . O
0.2 . . O
18.1 . . O
0.0 . . O
hypertension . . B-AdverseReaction
21.6 . . O
3.9 . . O
13.1 . . O
3.0 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
17.3 . . O
0.0 . . O
13.5 . . O
0.2 . . O
dyspnea . . B-AdverseReaction
11.8 . . O
2.4 . . O
9.6 . . O
0.9 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
13.5 . . O
0.2 . . O
11.3 . . O
0.0 . . O
injury . . O
, . . O
poisoning . . O
and . . O
procedural . . O
complications . . O
contusion . . B-AdverseReaction
13.3 . . O
0.0 . . O
9.1 . . O
0.0 . . O
falls . . B-AdverseReaction
5.9 . . O
0.0 . . O
3.3 . . O
0.0 . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
12.7 . . O
0.0 . . O
8.0 . . O
0.0 . . O
nasopharyngitis . . B-AdverseReaction
10.7 . . O
0.0 . . O
8.1 . . O
0.0 . . O
renal . . O
and . . O
urinary . . O
disorders . . O
hematuria . . B-AdverseReaction
10.3 . . O
1.3 . . O
5.6 . . O
0.6 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
8.1 . . O
0.0 . . O
3.7 . . O
0.0 . . O
table . . O
4 . . O
shows . . O
laboratory . . O
abnormalities . . O
that . . O
occurred . . O
in . . O
greater . . O
than . . O
15% . . O
of . . O
patients . . O
, . . O
and . . O
more . . O
frequently . . O
( . . O
> . . O
5% . . O
) . . O
in . . O
the . . O
zytiga . . O
arm . . O
compared . . O
to . . O
placebo . . O
in . . O
study . . O
2 . . O
. . . O

advise . . O
women . . O
of . . O
the . . O
potential . . O
risk . . O
to . . O
a . . O
fetus . . O
and . . O
to . . O
avoid . . O
pregnancy . . O
while . . O
taking . . O
the . . O
drug . . O
( . . O
5.7 . . O
) . . O
. . . O

peripheral . . O
neuropathy . . O

fanapt . . O
and . . O
other . . O
antipsychotic . . O
drugs . . O
should . . O
be . . O
used . . O
cautiously . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
aspiration . . O
pneumonia . . O
[ . . O
see . . O
boxed . . O
warning . . O
] . . O
. . . O

( . . O
5.1 . . O
) . . O

corporal . . O
rupture . . O
and . . O
other . . O
serious . . O
penile . . O
injury . . O

in . . O
addition . . O
, . . O
tudorza . . O
pressair . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
severe . . O
hypersensitivity . . O
to . . O
milk . . O
proteins . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
are . . O
described . . O
in . . O
more . . O
detail . . O
in . . O
the . . O
warnings . . O
and . . O
precautions . . O
section . . O
of . . O
the . . O
label . . O
: . . O

6 . . O
adverse . . O
reactions . . O

5.4 . . O
thromboembolic . . O
and . . O
bleeding . . O
events . . O
in . . O
patients . . O
with . . O
prosthetic . . O
heart . . O
valves . . O

5.5 . . O
end . . O
- . . O
stage . . O
renal . . O
disease . . O

assessment . . O
of . . O
the . . O
relationship . . O
between . . O
atypical . . O
antipsychotic . . O
use . . O
and . . O
glucose . . O
abnormalities . . O
is . . O
complicated . . O
by . . O
the . . O
possibility . . O
of . . O
an . . O
increased . . O
background . . O
risk . . O
of . . O
diabetes . . O
mellitus . . O
in . . O
patients . . O
with . . O
schizophrenia . . O
and . . O
the . . O
increasing . . O
incidence . . O
of . . O
diabetes . . O
mellitus . . O
in . . O
the . . O
general . . O
population . . O
. . . O

in . . O
patients . . O
who . . O
develop . . O
serious . . O
infections . . O
while . . O
on . . O
prolia . . O
, . . O
prescribers . . O
should . . O
assess . . O
the . . O
need . . O
for . . O
continued . . O
prolia . . O
therapy . . O
. . . O

the . . O
most . . O
common . . O
grade . . B-Severity
3 . . I-Severity
or . . O
4 . . O
non . . O
- . . O
hematological . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
were . . O
pneumonia . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
skin . . B-AdverseReaction
infections . . I-AdverseReaction
. . . O

the . . O
reactions . . O
generally . . O
related . . O
to . . O
rash . . B-AdverseReaction
and . . O
pruritis . . B-AdverseReaction
within . . O
minutes . . O
of . . O
datscan . . O
administration . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
constipation . . B-AdverseReaction

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

discontinuation . . O
symptoms . . O
have . . O
been . . O
systematically . . O
and . . O
prospectively . . O
evaluated . . O
in . . O
patients . . O
treated . . O
with . . O
pristiq . . O
during . . O
clinical . . O
studies . . O
in . . O
major . . O
depressive . . O
disorder . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
voraxaze . . O
- . . O
related . . O
adverse . . O
reactions . . O
were . . O
collected . . O
on . . O
a . . O
flow . . O
sheet . . O
with . . O
a . . O
daily . . O
log . . O
of . . O
adverse . . O
reactions . . O
characterized . . O
as . . O
" . . O
glucarpidase . . O
toxicity . . O
. . . O
" . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

( . . O
5.12 . . O
) . . O
* . . O
suicide . . B-AdverseReaction
: . . O
the . . O
possibility . . O
of . . O
a . . O
suicide . . O
attempt . . O
is . . O
inherent . . O
in . . O
schizophrenia . . O
and . . O
bipolar . . O
disorder . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
with . . O
elevations . . B-AdverseReaction
in . . I-AdverseReaction
triglycerides . . I-AdverseReaction
> . . O
= . . O
200 . . B-Severity
mg . . I-Severity
/ . . I-Severity
dl . . I-Severity
( . . O
at . . O
endpoint . . O
) . . O
was . . O
13.2% . . O
for . . O
saphris . . O
- . . O
treated . . O
patients . . O
versus . . O
10.5% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
treated . . O
with . . O
antipsychotic . . B-DrugClass
drugs . . I-DrugClass
are . . O
at . . O
an . . O
increased . . O
risk . . O
of . . O
death . . B-AdverseReaction
. . . O

seizures . . B-AdverseReaction
were . . O
reported . . O
in . . O
0% . . O
and . . O
0.3% . . O
( . . O
0 . . O
/ . . O
572 . . O
, . . O
1 . . O
/ . . O
379 . . O
) . . O
of . . O
adult . . O
patients . . O
treated . . O
with . . O
doses . . O
of . . O
5 . . O
mg . . O
and . . O
10 . . O
mg . . O
twice . . O
daily . . O
of . . O
saphris . . O
, . . O
respectively . . O
, . . O
compared . . O
to . . O
0% . . O
( . . O
0 . . O
/ . . O
503 . . O
, . . O
0 . . O
/ . . O
203 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
in . . O
short . . O
- . . O
term . . O
schizophrenia . . O
and . . O
bipolar . . O
mania . . O
trials . . O
, . . O
respectively . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
zylera . . O
pharmaceuticals . . O
, . . O
llc . . O
. . . O
at . . O
1-866-416-9637 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

abrupt . . O
discontinuation . . O
or . . O
dose . . O
reduction . . O
has . . O
been . . O
associated . . O
with . . O
the . . O
appearance . . O
of . . O
new . . O
symptoms . . O
that . . O
include . . O
dizziness . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
irritability . . B-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
anxiety . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
abnormal . . B-AdverseReaction
dreams . . I-AdverseReaction
, . . O
and . . O
hyperhidrosis . . B-AdverseReaction
. . . O

pooled . . O
analyses . . O
of . . O
199 . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
( . . O
mono . . O
- . . O
and . . O
adjunctive . . O
therapy . . O
) . . O
of . . O
11 . . O
different . . O
aeds . . B-DrugClass
showed . . O
that . . O
patients . . O
randomized . . O
to . . O
one . . O
of . . O
the . . O
aeds . . O
had . . O
approximately . . O
twice . . O
the . . O
risk . . O
( . . O
adjusted . . O
relative . . O
risk . . O
1.8 . . O
, . . O
95% . . O
confidence . . O
interval . . O
[ . . O
ci . . O
] . . O
: . . O
1.2 . . O
, . . O
2.7 . . O
) . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
or . . O
behavior . . O
compared . . O
to . . O
patients . . O
randomized . . O
to . . O
placebo . . O
. . . O

in . . O
the . . O
controlled . . O
rheumatoid . . O
arthritis . . O
studies . . O
, . . O
there . . O
were . . O
more . . O
new . . O
cases . . O
of . . O
serious . . B-Severity
infection . . B-AdverseReaction
adverse . . O
reactions . . O
in . . O
the . . O
cimzia . . O
treatment . . O
groups . . O
, . . O
compared . . O
to . . O
the . . O
placebo . . O
groups . . O
( . . O
0.06 . . O
per . . O
patient . . O
- . . O
year . . O
for . . O
all . . O
cimzia . . O
doses . . O
vs . . O
. . . O
0.02 . . O
per . . O
patient . . O
- . . O
year . . O
for . . O
placebo . . O
) . . O
. . . O

monitor . . O
liver . . O
function . . O
tests . . O
and . . O
omit . . O
or . . O
modify . . O
dosage . . O
for . . O
hepatic . . O
toxicities . . O
. . . O

of . . O
the . . O
255 . . O
patients . . O
, . . O
66% . . O
of . . O
patients . . O
were . . O
female . . O
and . . O
86% . . O
were . . O
caucasian . . O
. . . O

* . . O
a . . O
24 . . O
- . . O
week . . O
placebo . . O
- . . O
controlled . . O
trial . . O
( . . O
trial . . O
5 . . O
) . . O
involving . . O
69 . . O
patients . . O
between . . O
the . . O
ages . . O
of . . O
6 . . O
and . . O
68 . . O
years . . O
with . . O
an . . O
r117h . . O
mutation . . O
in . . O
the . . O
cftr . . O
gene . . O
. . . O

there . . O
was . . O
considerable . . O
variation . . O
in . . O
risk . . O
of . . O
suicidality . . B-AdverseReaction
among . . O
drugs . . B-DrugClass
, . . O
but . . O
a . . O
tendency . . O
toward . . O
an . . O
increase . . O
in . . O
the . . O
younger . . O
patients . . O
for . . O
almost . . O
all . . O
drugs . . O
studied . . O
. . . O

warning . . O
: . . O
distant . . B-AdverseReaction
spread . . I-AdverseReaction
of . . I-AdverseReaction
toxin . . I-AdverseReaction
effect . . I-AdverseReaction

5.10 . . O
proteinuria . . O

* . . O
serious . . B-Severity
infections . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
malignancies . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
3% . . O
) . . O
are . . O
: . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
viral . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
bronchitis . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

if . . O
unexplained . . O
or . . O
clinically . . O
significant . . O
weight . . O
loss . . O
occurs . . O
, . . O
evaluate . . O
weight . . O
loss . . O
and . . O
consider . . O
discontinuation . . O
of . . O
otezla . . O
( . . O
5.2 . . O
) . . O
* . . O
drug . . O
interactions . . O
: . . O
use . . O
with . . O
strong . . O
cytochrome . . O
p450 . . O
enzyme . . O
inducers . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
rifampin . . O
, . . O
phenobarbital . . O
, . . O
carbamazepine . . O
, . . O
phenytoin . . O
) . . O
is . . O
not . . O
recommended . . O
because . . O
loss . . O
of . . O
efficacy . . O
may . . O
occur . . O
( . . O
5.3,7.1 . . O
) . . O
5.1 . . O
depression . . O

cometriq . . O
is . . O
not . . O
recommended . . O
for . . O
use . . O
in . . O
patients . . O
with . . O
moderate . . O
or . . O
severe . . O
hepatic . . O
impairment . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

5.14 . . O
exacerbation . . O
of . . O
other . . O
conditions . . O

through . . O
96 . . O
weeks . . O
, . . O
the . . O
rates . . O
of . . O
adverse . . O
events . . O
leading . . O
to . . O
discontinuation . . O
were . . O
3% . . O
in . . O
subjects . . O
receiving . . O
tivicay . . O
50 . . O
mg . . O
once . . O
daily . . O
+ . . O
epzicom . . O
and . . O
12% . . O
in . . O
subjects . . O
receiving . . O
atripla . . O
once . . O
daily . . O
. . . O

doses . . O
ranged . . O
from . . O
6 . . O
to . . O
189 . . O
units . . O
/ . . O
kg . . O
, . . O
with . . O
a . . O
median . . O
dose . . O
of . . O
50 . . O
units . . O
/ . . O
kg . . O
. . . O

if . . O
keratitis . . O
is . . O
diagnosed . . O
, . . O
the . . O
benefits . . O
and . . O
risks . . O
of . . O
continuing . . O
treatment . . O
should . . O
be . . O
carefully . . O
considered . . O
. . . O

the . . O
data . . O
above . . O
reflect . . O
the . . O
percentage . . O
of . . O
patients . . O
whose . . O
test . . O
results . . O
were . . O
considered . . O
positive . . O
for . . O
antibodies . . O
to . . O
simponi . . O
aria . . O
in . . O
an . . O
elisa . . O
assay . . O
. . . O

patients . . O
with . . O
moderate . . O
renal . . O
impairment . . O
who . . O
are . . O
taking . . O
medications . . O
that . . O
interfere . . O
with . . O
potassium . . O
excretion . . O
, . . O
such . . O
as . . O
potassium . . O
- . . O
sparing . . O
diuretics . . O
, . . O
or . . O
medications . . O
that . . O
interfere . . O
with . . O
the . . O
renin . . O
- . . O
angiotensin . . O
- . . O
aldosterone . . O
system . . O
are . . O
at . . O
an . . O
increased . . O
risk . . B-Factor
of . . O
developing . . O
hyperkalemia . . B-AdverseReaction
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

features . . O
of . . O
acute . . O
kidney . . O
injury . . O
consist . . O
of . . O
rapid . . O
( . . O
over . . O
hours . . O
to . . O
days . . O
) . . O
and . . O
usually . . O
reversible . . O
decrease . . O
in . . O
kidney . . O
function . . O
, . . O
commonly . . O
in . . O
the . . O
setting . . O
of . . O
surgery . . O
, . . O
severe . . O
infection . . O
, . . O
injury . . O
or . . O
drug . . O
- . . O
induced . . O
kidney . . O
toxicity . . O
. . . O

currently . . O
available . . O
data . . O
are . . O
inadequate . . O
to . . O
determine . . O
whether . . O
concurrent . . O
use . . O
of . . O
inhaled . . O
corticosteroids . . O
( . . O
ics . . O
) . . O
or . . O
other . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
drugs . . O
mitigates . . O
the . . O
increased . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
from . . O
laba . . B-DrugClass
. . . O

when . . O
beginning . . O
arcapta . . O
neohaler . . O
, . . O
patients . . O
who . . O
have . . O
been . . O
taking . . O
inhaled . . O
, . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonists . . O
on . . O
a . . O
regular . . O
basis . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
four . . O
times . . O
a . . O
day . . O
) . . O
should . . O
be . . O
instructed . . O
to . . O
discontinue . . O
the . . O
regular . . O
use . . O
of . . O
these . . O
drugs . . O
and . . O
use . . O
them . . O
only . . O
for . . O
symptomatic . . O
relief . . O
of . . O
acute . . O
respiratory . . O
symptoms . . O
. . . O

a . . O
total . . O
of . . O
1314 . . O
saphris . . O
- . . O
treated . . O
patients . . O
were . . O
treated . . O
for . . O
at . . O
least . . O
24 . . O
weeks . . O
and . . O
785 . . O
saphris . . O
- . . O
treated . . O
patients . . O
had . . O
at . . O
least . . O
52 . . O
weeks . . O
of . . O
exposure . . O
at . . O
therapeutic . . O
doses . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
with . . O
an . . O
incidence . . O
> . . O
= . . O
2% . . O
of . . O
ampyra . . O
treated . . O
ms . . O
patients . . O
, . . O
and . . O
more . . O
frequent . . O
with . . O
ampyra . . O
compared . . O
to . . O
placebo . . O
in . . O
controlled . . O
clinical . . O
trials . . O
adverse . . O
reaction . . O
placebo . . O
( . . O
n . . O
= . . O
238 . . O
) . . O
ampyra10 . . O
mg . . O
twice . . O
daily . . O
( . . O
n . . O
= . . O
400 . . O
) . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
8% . . O
12% . . O
insomnia . . B-AdverseReaction
4% . . O
9% . . O
dizziness . . B-AdverseReaction
4% . . O
7% . . O
headache . . B-AdverseReaction
4% . . O
7% . . O
nausea . . B-AdverseReaction
3% . . O
7% . . O
asthenia . . B-AdverseReaction
4% . . O
7% . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
2% . . O
5% . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
1% . . O
5% . . O
multiple . . B-AdverseReaction
sclerosis . . I-AdverseReaction
relapse . . I-AdverseReaction
3% . . O
4% . . O
paresthesia . . B-AdverseReaction
3% . . O
4% . . O
nasopharyngitis . . B-AdverseReaction
2% . . O
4% . . O
constipation . . B-AdverseReaction
2% . . O
3% . . O
dyspepsia . . B-AdverseReaction
1% . . O
2% . . O
pharyngolaryngeal . . B-AdverseReaction
pain . . I-AdverseReaction
1% . . O
2% . . O
6.2 . . O
other . . O
adverse . . O
reactions . . O
ampyra . . O
has . . O
been . . O
evaluated . . O
in . . O
a . . O
total . . O
of . . O
1,952 . . O
subjects . . O
, . . O
including . . O
917 . . O
ms . . O
patients . . O
. . . O

if . . O
anaphylaxis . . O
or . . O
severe . . O
hypersensitivity . . O
reactions . . O
occur . . O
, . . O
immediately . . O
discontinue . . O
infusion . . O
and . . O
initiate . . O
appropriate . . O
medical . . O
treatment . . O
( . . O
5.1 . . O
) . . O
. . . O

six . . O
weeks . . O
after . . O
the . . O
eighth . . O
injection . . O
( . . O
fourth . . O
treatment . . O
cycle . . O
) . . O
of . . O
xiaflex . . O
, . . O
> . . O
99% . . O
of . . O
xiaflex . . O
- . . O
treated . . O
patients . . O
developed . . O
high . . O
titers . . O
of . . O
antibodies . . O
to . . O
both . . O
aux . . O
- . . O
i . . O
and . . O
aux . . O
- . . O
ii . . O
. . . O

other . . O
adverse . . O
reactions . . O
reported . . O
in . . O
patients . . O
receiving . . O
besivance . . O
occurring . . O
in . . O
approximately . . O
1-2% . . O
of . . O
patients . . O
included . . O
: . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
irritation . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
pruritus . . I-AdverseReaction
and . . O
headache . . B-AdverseReaction
. . . O

if . . O
a . . O
severe . . O
hypersensitivity . . O
reaction . . O
occurs . . O
, . . O
dificid . . O
( . . O
r . . O
) . . O
should . . O
be . . O
discontinued . . O
and . . O
appropriate . . O
therapy . . O
should . . O
be . . O
instituted . . O
. . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
endocrinopathies . . I-AdverseReaction
: . . O
monitor . . O
thyroid . . O
function . . O
tests . . O
and . . O
clinical . . O
chemistries . . O
prior . . O
to . . O
each . . O
dose . . O
. . . O

stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
drug . . O
hypersensitivity . . B-AdverseReaction
reaction . . O
and . . O
erythema . . B-AdverseReaction
multiforme . . I-AdverseReaction
were . . O
reported . . O
in . . O
less . . O
than . . O
0.1% . . O
of . . O
subjects . . O
during . . O
clinical . . O
development . . O
with . . O
intelence . . O
( . . O
r . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

cases . . O
of . . O
other . . O
malignancies . . B-AdverseReaction
have . . O
been . . O
observed . . O
among . . O
patients . . O
receiving . . O
tnf . . O
- . . O
blockers . . O
( . . O
5.2 . . O
) . . O
. . . O

significantly . . O
elevated . . O
serum . . O
calcitonin . . O
may . . O
indicate . . O
mtc . . O
and . . O
patients . . O
with . . O
mtc . . O
usually . . O
have . . O
calcitonin . . O
values . . O
> . . O
50 . . O
ng . . O
/ . . O
l . . O
. . . O
if . . O
serum . . O
calcitonin . . O
is . . O
measured . . O
and . . O
found . . O
to . . O
be . . O
elevated . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
further . . O
evaluated . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

6.3 . . O
immunogenicity . . O

( . . O
5.7 . . O
) . . O
5.1 . . O
potential . . O
risk . . O
of . . O
myocardial . . O
infarction . . O
with . . O
long . . O
- . . O
term . . O
use . . O

some . . O
of . . O
the . . O
patients . . O
who . . O
tested . . O
positive . . O
for . . O
alglucosidase . . O
alfa . . O
- . . O
specific . . O
ige . . O
antibodies . . O
experienced . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
seeboxed . . O
warningandwarnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

trial . . O
3 . . O
was . . O
a . . O
24 . . O
- . . O
week . . O
trial . . O
that . . O
evaluated . . O
the . . O
efficacy . . O
of . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
once . . O
daily . . O
, . . O
fluticasone . . O
furoate . . O
200 . . O
mcg . . O
once . . O
daily . . O
, . . O
and . . O
fluticasone . . O
propionate . . O
500 . . O
mcg . . O
twice . . O
daily . . O
in . . O
adolescent . . O
and . . O
adult . . O
subjects . . O
with . . O
asthma . . O
. . . O

6 . . O
adverse . . O
reactions . . O

all . . O
events . . O
resolved . . O
with . . O
continued . . O
treatment . . O
with . . O
ilaris . . O
. . . O

dosage . . O
modifications . . O
due . . O
to . . O
adverse . . O
reactions . . O

renal . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
and . . O
blood . . B-AdverseReaction
creatinine . . I-AdverseReaction
increase . . I-AdverseReaction
, . . O
were . . O
more . . O
frequent . . O
in . . O
patients . . O
treated . . O
with . . O
farxiga . . O
( . . O
see . . O
table . . O
4 . . O
) . . O
. . . O

sega . . O
with . . O
tsc . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
30% . . O
) . . O
are . . O
stomatitis . . B-AdverseReaction
and . . O
respiratory . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
. . . O

of . . O
the . . O
patients . . O
in . . O
those . . O
trials . . O
, . . O
95% . . O
were . . O
between . . O
18 . . O
and . . O
65 . . O
years . . O
old . . O
; . . O
48% . . O
were . . O
male . . O
, . . O
and . . O
84% . . O
were . . O
caucasian . . O
. . . O

5.3 . . O
excessive . . O
use . . O
of . . O
breo . . O
ellipta . . O
and . . O
use . . O
with . . O
other . . O
long . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonists . . O

the . . O
patient . . O
should . . O
be . . O
carefully . . O
monitored . . O
, . . O
since . . O
recurrences . . O
of . . O
nms . . O
have . . O
been . . O
reported . . O
. . . O

increased . . B-AdverseReaction
urination . . I-AdverseReaction
in . . O
the . . O
pool . . O
of . . O
five . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
, . . O
adverse . . O
reactions . . O
of . . O
increased . . B-AdverseReaction
urination . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
polyuria . . B-AdverseReaction
, . . O
pollakiuria . . B-AdverseReaction
, . . O
and . . O
nocturia . . B-AdverseReaction
) . . O
occurred . . O
more . . O
frequently . . O
on . . O
jardiance . . O
than . . O
on . . O
placebo . . O
( . . O
see . . O
table . . O
1 . . O
) . . O
. . . O

patients . . O
with . . O
liver . . O
metastases . . O
were . . O
excluded . . O
if . . O
ast . . O
and . . O
/ . . O
or . . O
alt . . O
> . . O
5 . . O
* . . O
uln . . O
. . . O

sometimes . . O
both . . O
ovaries . . O
are . . O
removed . . O
during . . O
an . . O
operation . . O
before . . O
natural . . O
menopause . . O
takes . . O
place . . O
. . . O

notable . . O
requirements . . O
of . . O
the . . O
e . . O
. . . O
a . . O
. . . O
s . . O
. . . O
e . . O
. . . O
program . . O
include . . O
the . . O
following . . O
: . . O

vascular . . O
disorders . . O
: . . O
flushing . . B-AdverseReaction
, . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
. . . O

warning . . O
: . . O
risk . . B-Factor
of . . O
anaphylaxis . . B-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
and . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
and . . O
risk . . B-Factor
of . . O
cardiorespiratory . . B-AdverseReaction
failure . . I-AdverseReaction

the . . O
long . . O
- . . O
term . . O
clinical . . O
effects . . O
of . . O
the . . O
increase . . B-AdverseReaction
in . . I-AdverseReaction
heart . . I-AdverseReaction
rate . . I-AdverseReaction
have . . O
not . . O
been . . O
established . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
. . . O

( . . O
5.3 . . O
) . . O
5.1 . . O
hypertension . . O
, . . O
hypokalemia . . O
and . . O
fluid . . O
retention . . O
due . . O
to . . O
mineralocorticoid . . O
excess . . O

( . . O
5.9 . . O
) . . O
* . . O
glucose . . B-AdverseReaction
- . . I-AdverseReaction
6 . . I-AdverseReaction
- . . I-AdverseReaction
phosphate . . I-AdverseReaction
dehydrogenase . . I-AdverseReaction
deficiency . . I-AdverseReaction
: . . O
closely . . O
monitor . . O
for . . O
hemolytic . . O
anemia . . O
. . . O

5.4 . . O
serious . . O
infections . . O
and . . O
opportunistic . . O
infections . . O

if . . O
at . . O
any . . O
time . . O
ast . . O
or . . O
alt . . O
rise . . O
above . . O
five . . O
times . . O
the . . O
uln . . O
, . . O
or . . O
the . . O
bilirubin . . O
rises . . O
above . . O
three . . O
times . . O
the . . O
uln . . O
, . . O
interrupt . . O
zytiga . . O
treatment . . O
and . . O
closely . . O
monitor . . O
liver . . O
function . . O
. . . O

the . . O
types . . O
and . . O
frequency . . O
of . . O
common . . O
adverse . . O
reactions . . O
observed . . O
in . . O
the . . O
pool . . O
of . . O
eight . . O
clinical . . O
trials . . O
were . . O
consistent . . O
with . . O
those . . O
listed . . O
in . . O
table . . O
1 . . O
. . . O

the . . O
safety . . O
profile . . O
for . . O
patients . . O
with . . O
psa . . O
treated . . O
with . . O
cimzia . . O
was . . O
similar . . O
to . . O
the . . O
safety . . O
profile . . O
seen . . O
in . . O
patients . . O
with . . O
ra . . O
and . . O
previous . . O
experience . . O
with . . O
cimzia . . O
. . . O

if . . O
pml . . O
is . . O
diagnosed . . O
, . . O
consideration . . O
should . . O
be . . O
given . . O
to . . O
reduction . . O
or . . O
withdrawal . . O
of . . O
immunosuppression . . O
taking . . O
into . . O
account . . O
the . . O
risk . . O
to . . O
the . . O
allograft . . O
. . . O

adverse . . O
laboratory . . O
and . . O
ecg . . O
effects . . O
are . . O
presented . . O
separately . . O
in . . O
table . . O
2 . . O
. . . O

6 . . O
adverse . . O
reactions . . O

advise . . O
families . . O
and . . O
caregivers . . O
of . . O
the . . O
need . . O
for . . O
close . . O
observation . . O
and . . O
communication . . O
with . . O
the . . O
prescriber . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

chronic . . O
lymphocytic . . O
leukemia . . O

dose . . O
reductions . . O
were . . O
reported . . O
in . . O
12% . . O
of . . O
jevtana . . O
- . . O
treated . . O
patients . . O
and . . O
4% . . O
of . . O
mitoxantrone . . O
- . . O
treated . . O
patients . . O
. . . O

tafinlar . . O
may . . O
render . . O
hormonal . . O
contraceptives . . O
less . . O
effective . . O
and . . O
an . . O
alternative . . O
method . . O
of . . O
contraception . . O
should . . O
be . . O
used . . O
. . . O

no . . B-Negation
deaths . . B-AdverseReaction
, . . O
intubations . . O
, . . O
or . . O
serious . . O
adverse . . O
reactions . . O
related . . O
to . . O
asthma . . B-AdverseReaction
exacerbation . . I-AdverseReaction
were . . O
reported . . O
in . . O
this . . O
trial . . O
. . . O

during . . O
the . . O
entire . . O
course . . O
of . . O
treatment . . O
, . . O
the . . O
proportion . . O
of . . O
subjects . . O
who . . O
discontinued . . O
treatment . . O
due . . O
to . . O
adverse . . O
reactions . . O
was . . O
13% . . O
for . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
and . . O
12% . . O
for . . O
subjects . . O
receiving . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
. . . O

each . . O
eclipse . . O
study . . O
compared . . O
cleviprex . . O
( . . O
n . . O
= . . O
752 . . O
) . . O
to . . O
an . . O
active . . O
comparator . . O
: . . O
nitroglycerin . . O
( . . O
ntg . . O
, . . O
n . . O
= . . O
278 . . O
) . . O
, . . O
sodium . . O
nitroprusside . . O
( . . O
snp . . O
, . . O
n . . O
= . . O
283 . . O
) . . O
, . . O
or . . O
nicardipine . . O
( . . O
nic . . O
, . . O
n . . O
= . . O
193 . . O
) . . O
. . . O

6.1 . . O
serious . . O
adverse . . O
reactions . . O

death . . B-AdverseReaction
related . . O
to . . O
diarrhea . . B-AdverseReaction
and . . O
electrolyte . . B-AdverseReaction
imbalance . . I-AdverseReaction
occurred . . O
in . . O
the . . O
randomized . . O
clinical . . O
trial . . O
. . . O

* . . O
anaphylaxis . . B-AdverseReaction
and . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
if . . O
an . . O
infusion . . O
reaction . . O
occurs . . O
, . . O
interrupt . . O
the . . O
infusion . . O
. . . O

5.2 . . O
concomitant . . O
use . . O
with . . O
cyp3a . . O
inducers . . O

5.5 . . O
hepatitis . . O
b . . O
virus . . O
reactivation . . O

if . . O
a . . O
patient . . O
requires . . O
antipsychotic . . O
drug . . O
treatment . . O
after . . O
recovery . . O
from . . O
nms . . O
, . . O
the . . O
potential . . O
reintroduction . . O
of . . O
drug . . O
therapy . . O
should . . O
be . . O
carefully . . O
considered . . O
. . . O

other . . O
clinically . . O
important . . O
adverse . . O
reactions . . O
observed . . O
in . . O
< . . O
10% . . O
of . . O
patients . . O
( . . O
n . . O
= . . O
586 . . O
) . . O
treated . . O
with . . O
tafinlar . . O
were . . O
: . . O

none . . O
of . . O
these . . O
antibodies . . O
were . . O
shown . . O
to . . O
neutralize . . O
the . . O
activity . . O
of . . O
albiglutide . . O
in . . O
an . . O
in . . O
vitro . . O
bioassay . . O
. . . O

of . . O
the . . O
586 . . O
subjects . . O
, . . O
59% . . O
were . . O
female . . O
and . . O
84% . . O
were . . O
white . . O
; . . O
the . . O
mean . . O
age . . O
was . . O
46 . . O
years . . O
. . . O

among . . O
those . . O
17 . . O
subjects . . O
, . . O
10 . . O
subjects . . O
developed . . O
neutralizing . . O
antibodies . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
are . . O
fatigue . . B-AdverseReaction
, . . O
joint . . B-AdverseReaction
swelling . . I-AdverseReaction
or . . O
discomfort . . O
, . . O
edema . . B-AdverseReaction
, . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
and . . O
contusion . . B-AdverseReaction
. . . O

pre . . O
- . . O
existing . . O
hypertension . . O
should . . O
be . . O
controlled . . O
before . . O
initiating . . O
treatment . . O
with . . O
pristiq . . O
. . . O

monitor . . O
heart . . O
failure . . O
patients . . O
carefully . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
takeda . . O
pharmaceuticals . . O
at . . O
1-877 . . O
- . . O
takeda . . O
- . . O
7 . . O
( . . O
1-877-825-3327 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

approximately . . O
70% . . O
of . . O
patients . . O
were . . O
male . . O
; . . O
67% . . O
were . . O
white . . O
, . . O
11% . . O
were . . O
black . . O
, . . O
and . . O
22% . . O
other . . O
races . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
: . . O

5.5 . . O
metabolic . . O
changes . . O

( . . O
5.3 . . O
) . . O
* . . O
use . . O
in . . O
children . . O
: . . O
ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
should . . O
only . . O
be . . O
used . . O
on . . O
children . . O
under . . O
the . . O
direct . . O
supervision . . O
of . . O
an . . O
adult . . O
. . . O

esophageal . . B-AdverseReaction
dysmotility . . I-AdverseReaction
and . . O
aspiration . . B-AdverseReaction
have . . O
been . . O
associated . . O
with . . O
antipsychotic . . B-DrugClass
drug . . I-DrugClass
use . . O
. . . O

5.5 . . O
hypertension . . O

serious . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
events . . O
of . . O
disseminated . . O
varicella . . O
zoster . . O
and . . O
herpes . . B-AdverseReaction
simplex . . I-AdverseReaction
infections . . I-AdverseReaction
, . . O
including . . O
cases . . O
of . . O
encephalitis . . B-AdverseReaction
and . . O
multiorgan . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
have . . O
occurred . . O
with . . O
gilenya . . O
0.5 . . O
mg . . O
in . . O
the . . O
postmarketing . . O
setting . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
25% . . O
) . . O
reported . . O
in . . O
patients . . O
receiving . . O
halaven . . O
were . . O
neutropenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
/ . . O
fatigue . . B-AdverseReaction
, . . O
alopecia . . B-AdverseReaction
, . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
constipation . . B-AdverseReaction
. . . O

( . . O
5.1 . . O
) . . O
, . . O

the . . O
efficacy . . O
and . . O
safety . . O
of . . O
duavee . . O
in . . O
premenopausal . . O
women . . O
have . . O
not . . O
been . . O
established . . O
, . . O
and . . O
its . . O
use . . O
is . . O
not . . O
recommended . . O
. . . O

warning . . O
: . . O
risk . . B-Factor
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction

5.10 . . O
hypothyroidism . . O

cases . . O
were . . O
consistent . . O
with . . O
hepatocellular . . B-AdverseReaction
injury . . I-AdverseReaction
, . . O
including . . O
elevations . . B-AdverseReaction
of . . I-AdverseReaction
transaminases . . I-AdverseReaction
and . . O
/ . . O
or . . O
bilirubin . . O
. . . O

severe . . B-Severity
neutropenia . . B-AdverseReaction
( . . O
anc . . O
< . . O
500 . . O
/ . . O
mm . . O
3 . . O
) . . O
lasting . . O
more . . O
than . . O
one . . O
week . . O
occurred . . O
in . . O
12% . . O
( . . O
62 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
in . . O
study . . O
1 . . O
, . . O
leading . . O
to . . O
discontinuation . . O
in . . O
< . . O
1% . . O
of . . O
patients . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

patients . . B-Factor
treated . . O
with . . O
botulinum . . O
toxin . . O
may . . O
require . . O
immediate . . O
medical . . O
attention . . O
should . . O
they . . O
develop . . O
problems . . O
with . . O
swallowing . . O
, . . O
speech . . O
or . . O
respiratory . . O
disorders . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
( . . O
ild . . B-AdverseReaction
) . . O
/ . . O
pneumonitis . . B-AdverseReaction
: . . O
occurred . . O
in . . O
2.9% . . O
of . . O
patients . . O
. . . O

in . . O
addition . . O
, . . O
grade . . B-Severity
1 . . I-Severity
insomnia . . B-AdverseReaction
was . . O
reported . . O
by . . O
1% . . O
and . . O
less . . O
than . . O
1% . . O
of . . O
subjects . . O
receiving . . O
tivicay . . O
and . . O
raltegravir . . O
, . . O
respectively . . O
, . . O
in . . O
spring . . O
- . . O
2 . . O
; . . O
whereas . . O
in . . O
single . . O
the . . O
rates . . O
were . . O
7% . . O
and . . O
4% . . O
for . . O
tivicay . . O
and . . O
atripla . . O
, . . O
respectively . . O
. . . O

these . . O
data . . O
reflect . . O
exposure . . O
of . . O
1976 . . O
patients . . O
to . . O
jardiance . . O
with . . O
a . . O
mean . . O
exposure . . O
duration . . O
of . . O
approximately . . O
23 . . O
weeks . . O
. . . O

these . . O
studies . . O
did . . O
not . . B-Negation
show . . O
an . . O
increase . . O
in . . O
the . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
and . . O
behavior . . O
with . . O
antidepressant . . O
use . . O
in . . O
patients . . O
over . . O
age . . O
24 . . O
; . . O
there . . O
was . . O
a . . O
reduction . . O
in . . O
risk . . O
with . . O
antidepressant . . O
use . . O
in . . O
patients . . O
aged . . O
65 . . O
and . . O
older . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

falls . . B-AdverseReaction
were . . O
not . . B-Negation
associated . . O
with . . O
loss . . B-AdverseReaction
of . . I-AdverseReaction
consciousness . . I-AdverseReaction
or . . O
seizure . . B-AdverseReaction
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
discontinuation . . O
for . . O
patients . . O
taking . . O
otezla . . O
were . . O
nausea . . B-AdverseReaction
( . . O
1.8% . . O
) . . O
, . . O
diarrhea . . B-AdverseReaction
( . . O
1.8% . . O
) . . O
, . . O
and . . O
headache . . B-AdverseReaction
( . . O
1.2% . . O
) . . O
. . . O

5.4 . . O
facial . . O
anatomy . . O
in . . O
the . . O
treatment . . O
of . . O
glabellar . . O
lines . . O

boxed . . O
warning . . O
: . . O
warnings . . O
: . . O
increased . . B-AdverseReaction
mortality . . I-AdverseReaction
; . . O
qt . . B-AdverseReaction
prolongation . . I-AdverseReaction

( . . O
5.1 . . O
) . . O
* . . O
hypotension . . B-AdverseReaction
and . . O
reflex . . B-AdverseReaction
tachycardia . . I-AdverseReaction
are . . O
potential . . B-Factor
consequences . . O
of . . O
rapid . . O
upward . . O
titration . . O
of . . O
cleviprex . . O
. . . O

consider . . O
the . . O
potential . . O
for . . O
drug . . O
interactions . . O
prior . . O
to . . O
and . . O
during . . O
stribild . . O
therapy . . O
; . . O
review . . O
concomitant . . O
medications . . O
during . . O
stribild . . O
therapy . . O
; . . O
and . . O
monitor . . O
for . . O
the . . O
adverse . . O
reactions . . O
associated . . O
with . . O
the . . O
concomitant . . O
drugs . . O
. . . O

trial . . O
1 . . O
was . . O
a . . O
12 . . O
- . . O
week . . O
trial . . O
that . . O
evaluated . . O
the . . O
efficacy . . O
of . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
in . . O
adolescent . . O
and . . O
adult . . O
subjects . . O
with . . O
asthma . . O
compared . . O
with . . O
fluticasone . . O
furoate . . O
100 . . O
mcg . . O
and . . O
placebo . . O
. . . O

dry . . B-AdverseReaction
mouth . . I-AdverseReaction
led . . O
to . . O
discontinuation . . O
in . . O
0.4% . . O
, . . O
0.4% . . O
, . . O
and . . O
0.8% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
, . . O
toviaz . . O
4 . . O
mg . . O
, . . O
and . . O
toviaz . . O
8 . . O
mg . . O
, . . O
respectively . . O
. . . O

5.1 . . O
anaphylaxis . . O
and . . O
hypersensitivity . . O
reactions . . O

estrogens . . O
should . . O
be . . O
prescribed . . O
at . . O
the . . O
lowest . . O
effective . . O
doses . . O
and . . O
for . . O
the . . O
shortest . . O
duration . . O
consistent . . O
with . . O
treatment . . O
goals . . O
and . . O
risks . . O
for . . O
the . . O
individual . . O
woman . . O
. . . O

out . . O
of . . O
1082 . . O
patients . . O
who . . O
received . . O
0.58 . . O
mg . . O
of . . O
xiaflex . . O
in . . O
the . . O
controlled . . O
and . . O
uncontrolled . . O
portions . . O
of . . O
the . . O
xiaflex . . O
studies . . O
( . . O
2630 . . O
xiaflex . . O
injections . . O
) . . O
, . . O
3 . . O
( . . O
0.3% . . O
) . . O
patients . . O
had . . O
a . . O
flexor . . O
tendon . . O
rupture . . O
of . . O
the . . O
treated . . O
finger . . O
within . . O
7 . . O
days . . O
of . . O
the . . O
injection . . O
. . . O

monitor . . O
serum . . O
phosphorus . . O
in . . O
patients . . O
at . . O
risk . . O
for . . O
renal . . O
impairment . . O
. . . O

hepatobiliary . . O
disorders . . O

patients . . O
should . . O
be . . O
counseled . . O
about . . O
the . . O
possibility . . O
of . . O
delayed . . O
- . . O
onset . . O
hypersensitivity . . O
reactions . . O
and . . O
given . . O
proper . . O
follow . . O
- . . O
up . . O
instructions . . O
. . . O

have . . O
anaphylactic . . O
and . . O
hypersensitivity . . O
treatment . . O
measures . . O
available . . O
prior . . O
to . . O
datscan . . O
administration . . O
and . . O
, . . O
following . . O
administration . . O
, . . O
observe . . O
patients . . O
for . . O
symptoms . . O
or . . O
signs . . O
of . . O
a . . O
hypersensitivity . . O
reaction . . O
. . . O

therefore . . O
, . . O
the . . O
use . . O
of . . O
such . . O
combinations . . O
is . . O
not . . O
recommended . . O
. . . O

grade . . B-Severity
3 . . I-Severity
and . . O
4 . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
after . . O
the . . O
use . . O
of . . O
erwinaze . . O
have . . O
occurred . . O
in . . O
5% . . O
of . . O
patients . . O
in . . O
clinical . . O
trials . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
during . . O
therapy . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
increased . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
, . . O
stroke . . B-AdverseReaction
and . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
in . . O
patients . . O
with . . O
decompensated . . O
heart . . O
failure . . O
or . . O
permanent . . O
atrial . . O
fibrillation . . O

the . . O
long . . O
- . . O
term . . O
consequences . . O
of . . O
the . . O
degree . . O
of . . O
suppression . . B-AdverseReaction
of . . I-AdverseReaction
bone . . I-AdverseReaction
remodeling . . I-AdverseReaction
observed . . O
with . . O
prolia . . O
may . . B-Factor
contribute . . O
to . . O
adverse . . O
outcomes . . O
such . . O
as . . O
osteonecrosis . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
jaw . . I-AdverseReaction
, . . O
atypical . . B-AdverseReaction
fractures . . I-AdverseReaction
, . . O
and . . O
delayed . . B-AdverseReaction
fracture . . I-AdverseReaction
healing . . I-AdverseReaction
. . . O

this . . O
included . . O
783 . . O
patients . . O
who . . O
received . . O
gilenya . . O
0.5 . . O
mg . . O
in . . O
the . . O
2 . . O
- . . O
year . . O
placebo . . O
- . . O
controlled . . O
trials . . O
( . . O
studies . . O
1 . . O
and . . O
3 . . O
) . . O
and . . O
429 . . O
patients . . O
who . . O
received . . O
gilenya . . O
0.5 . . O
mg . . O
in . . O
the . . O
1 . . O
year . . O
active . . O
- . . O
controlled . . O
trial . . O
( . . O
study . . O
2 . . O
) . . O
. . . O

tuberculosis . . O
and . . O
opportunistic . . O
infections . . O

additionally . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
( . . O
including . . O
neutralizing . . O
antibody . . O
) . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

these . . O
immune . . O
- . . O
mediated . . O
reactions . . O
may . . B-Factor
involve . . O
any . . O
organ . . O
system . . O
; . . O
however . . O
, . . O
the . . O
most . . O
common . . O
severe . . B-Severity
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
are . . O
enterocolitis . . B-AdverseReaction
, . . O
hepatitis . . B-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
( . . O
including . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
) . . O
, . . O
neuropathy . . B-AdverseReaction
, . . O
and . . O
endocrinopathy . . B-AdverseReaction
. . . O

cardiomyopathy . . B-AdverseReaction
was . . O
identified . . O
within . . O
the . . O
first . . O
month . . O
of . . O
treatment . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
in . . O
two . . O
of . . O
five . . O
patients . . O
. . . O

the . . O
occurrence . . O
of . . O
adverse . . O
reactions . . O
for . . O
canagliflozin . . O
was . . O
evaluated . . O
in . . O
a . . O
larger . . O
pool . . O
of . . O
patients . . O
participating . . O
in . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O
. . . O

table . . O
9 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
in . . O
2% . . O
or . . O
more . . O
of . . O
adult . . O
patients . . O
in . . O
any . . O
saphris . . O
dose . . O
group . . O
and . . O
which . . O
occurred . . O
at . . O
greater . . O
incidence . . O
than . . O
in . . O
the . . O
placebo . . O
group . . O
in . . O
3 . . O
- . . O
week . . O
bipolar . . O
mania . . O
trials . . O
* . . O
saphris . . O
5 . . O
mg . . O
to . . O
10 . . O
mg . . O
twice . . O
daily . . O
with . . O
flexible . . O
dosing . . O
. . . O

the . . O
grade . . B-Severity
3 . . I-Severity
laboratory . . O
abnormalities . . O
were . . O
elevated . . B-AdverseReaction
total . . I-AdverseReaction
bilirubin . . I-AdverseReaction
and . . O
lipase . . O
reported . . O
in . . O
1 . . O
subject . . O
each . . O
. . . O

the . . O
adverse . . O
reactions . . O
with . . O
> . . O
= . . O
10% . . O
incidence . . O
for . . O
any . . O
grade . . O
or . . O
> . . O
= . . O
5% . . O
incidence . . O
for . . O
grade . . O
3 . . O
or . . O
higher . . O
are . . O
summarized . . O
in . . O
table . . O
2 . . O
. . . O

ampyra . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
seizures . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

pulmonary . . O
toxicity . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
a . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

the . . O
systemic . . O
exposure . . O
to . . O
axitinib . . O
was . . O
higher . . O
in . . O
subjects . . O
with . . O
moderate . . O
hepatic . . O
impairment . . O
( . . O
child . . O
- . . O
pugh . . O
class . . O
b . . O
) . . O
compared . . O
to . . O
subjects . . O
with . . O
normal . . O
hepatic . . O
function . . O
. . . O

table . . O
2 . . O
. . . O

for . . O
mild . . O
to . . O
moderate . . O
dermatitis . . O
, . . O
such . . O
as . . O
localized . . O
rash . . O
and . . O
pruritus . . O
, . . O
treat . . O
symptomatically . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
auxilium . . O
pharmaceuticals . . O
, . . O
inc . . O
. . . O
at . . O
1-877-663-0412 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

events . . O
of . . O
noninfectious . . B-AdverseReaction
pulmonary . . I-AdverseReaction
toxicity . . I-AdverseReaction
including . . O
pneumonitis . . B-AdverseReaction
, . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
and . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ards . . B-AdverseReaction
) . . O
, . . O
some . . O
with . . O
fatal . . B-AdverseReaction
outcomes . . O
, . . O
have . . O
been . . O
reported . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
interstitial . . B-AdverseReaction
nephritis . . I-AdverseReaction
. . . O

sleep . . O
apnea . . O
is . . O
common . . O
in . . O
mps . . O
iva . . O
patients . . O
. . . O

the . . O
incidence . . O
of . . O
serious . . O
adverse . . O
reactions . . O
was . . O
3.5% . . O
in . . O
the . . O
duavee . . O
group . . O
and . . O
4.8% . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

of . . O
pradaxa . . O
increases . . O
the . . O
risk . . O
of . . O
thrombotic . . O
events . . O
, . . O
and . . O
( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . B-AdverseReaction
hematoma . . I-AdverseReaction
see . . O
full . . O
prescribing . . O
information . . O

pradaxa . . O
was . . O
studied . . O
in . . O
4387 . . O
patients . . O
in . . O
4 . . O
pivotal . . O
, . . O
parallel . . O
, . . O
randomized . . O
, . . O
double . . O
- . . O
blind . . O
trials . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
immediate . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
discontinue . . O
tudorza . . O
pressair . . O
at . . O
once . . O
and . . O
consider . . O
alternatives . . O
if . . O
immediate . . O
hypersensitivity . . O
reactions . . O
, . . O
including . . O
angioedema . . O
, . . O
bronchospasm . . O
, . . O
or . . O
anaphylaxis . . O
, . . O
occur . . O
. . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
a . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . O
hematoma . . O
: . . O
epidural . . O
or . . O
spinal . . B-AdverseReaction
hematomas . . I-AdverseReaction

the . . O
95% . . O
confidence . . O
limits . . O
that . . O
are . . O
shown . . O
do . . O
not . . O
take . . O
into . . O
account . . O
how . . O
many . . O
comparisons . . O
were . . O
made . . O
, . . O
nor . . O
do . . O
they . . O
reflect . . O
the . . O
effect . . O
of . . O
a . . O
particular . . O
factor . . O
after . . O
adjustment . . O
for . . O
all . . O
other . . O
factors . . O
. . . O

( . . O
5.1 . . O
) . . O

( . . O
5.5 . . O
) . . O
* . . O
potential . . B-Factor
worsening . . B-AdverseReaction
of . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
existing . . O
tuberculosis . . O
; . . O
fungal . . O
, . . O
bacterial . . O
, . . O
viral . . O
, . . O
or . . O
parasitic . . O
infections . . O
; . . O
ocular . . O
herpes . . O
simplex . . O
) . . O
. . . O

* . . O
screen . . O
patients . . O
for . . O
acute . . O
kidney . . O
injury . . O
and . . O
other . . O
conditions . . O
that . . O
may . . O
reduce . . O
renal . . O
function . . O
. . . O

a . . O
reaction . . O
was . . O
considered . . O
treatment . . O
- . . O
emergent . . O
if . . O
it . . O
occurred . . O
for . . O
the . . O
first . . O
time . . O
or . . O
worsened . . O
while . . O
receiving . . O
therapy . . O
following . . O
baseline . . O
evaluation . . O
. . . O

* . . O
invasive . . B-AdverseReaction
fungal . . I-AdverseReaction
infections . . I-AdverseReaction
, . . O
including . . O
histoplasmosis . . B-AdverseReaction
, . . O
coccidioidomycosis . . B-AdverseReaction
, . . O
candidiasis . . B-AdverseReaction
, . . O
aspergillosis . . B-AdverseReaction
, . . O
blastomycosis . . B-AdverseReaction
, . . O
and . . O
pneumocystosis . . B-AdverseReaction
. . . O

based . . O
on . . O
the . . O
pooled . . O
data . . O
from . . O
4 . . O
placebo . . O
- . . O
controlled . . O
, . . O
4 . . O
- . . O
or . . O
6 . . O
- . . O
week . . O
, . . O
fixed . . O
- . . O
or . . O
flexible . . O
- . . O
dose . . O
studies . . O
, . . O
the . . O
following . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
> . . O
= . . O
5% . . O
incidence . . O
in . . O
the . . O
patients . . O
treated . . O
with . . O
fanapt . . O
and . . O
at . . O
least . . O
twice . . O
the . . O
placebo . . O
rate . . O
for . . O
at . . O
least . . O
1 . . O
dose . . O
: . . O
dizziness . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
orthostatic . . B-AdverseReaction
hypotension . . I-AdverseReaction
, . . O
and . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
. . . O

( . . O
5.2 . . O
) . . O
* . . O
contact . . B-AdverseReaction
dermatitis . . I-AdverseReaction
: . . O
may . . B-Factor
occur . . O
with . . O
ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
. . . O

in . . O
patients . . O
with . . O
phn . . O
receiving . . O
horizant . . O
twice . . O
daily . . O
, . . O
the . . O
dose . . O
should . . O
be . . O
reduced . . O
to . . O
once . . O
daily . . O
for . . O
1 . . O
week . . O
prior . . O
to . . O
discontinuation . . O
to . . O
minimize . . O
the . . O
potential . . O
of . . O
withdrawal . . O
seizure . . O
, . . O
see . . O
table . . O
2 . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

dermatologic . . O
reactions . . O
a . . O
significantly . . O
higher . . O
number . . O
of . . O
patients . . O
treated . . O
with . . O
prolia . . O
developed . . O
epidermal . . O
and . . O
dermal . . B-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
such . . O
as . . O
dermatitis . . B-AdverseReaction
, . . O
eczema . . B-AdverseReaction
, . . O
and . . O
rashes . . B-AdverseReaction
) . . O
, . . O
with . . O
these . . O
events . . O
reported . . O
in . . O
8.2% . . O
of . . O
the . . O
placebo . . O
and . . O
10.8% . . O
of . . O
the . . O
prolia . . O
groups . . O
( . . O
p . . O
< . . O
0.0001 . . O
) . . O
. . . O

adverse . . O
reactions . . O
of . . O
any . . O
toxicity . . O
grade . . O
reported . . O
for . . O
greater . . O
than . . O
20% . . O
of . . O
patients . . O
in . . O
the . . O
phase . . O
1 . . O
/ . . O
2 . . O
safety . . O
population . . O
( . . O
n . . O
= . . O
546 . . O
) . . O
were . . O
diarrhea . . B-AdverseReaction
( . . O
82% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
46% . . O
) . . O
, . . O
thrombocytopenia . . B-AdverseReaction
( . . O
41% . . O
) . . O
, . . O
vomiting . . B-AdverseReaction
( . . O
39% . . O
) . . O
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
37% . . O
) . . O
, . . O
rash . . B-AdverseReaction
( . . O
35% . . O
) . . O
, . . O
anemia . . B-AdverseReaction
( . . O
27% . . O
) . . O
, . . O
pyrexia . . B-AdverseReaction
( . . O
26% . . O
) . . O
, . . O
and . . O
fatigue . . B-AdverseReaction
( . . O
24% . . O
) . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

causality . . O
cannot . . O
be . . O
excluded . . O
. . . O

monitoring . . O
of . . O
renal . . O
function . . O
, . . O
including . . O
measurement . . O
of . . O
blood . . O
urea . . O
nitrogen . . O
( . . O
bun . . O
) . . O
, . . O
urinary . . O
protein . . O
, . . O
or . . O
serum . . O
creatinine . . O
, . . O
is . . O
recommended . . O
prior . . O
to . . O
the . . O
start . . O
of . . O
afinitor . . O
therapy . . O
and . . O
periodically . . O
thereafter . . O
. . . O

5.4 . . O
hypersensitivity . . O
reactions . . O
, . . O
including . . O
anaphylaxis . . O

the . . O
infections . . B-AdverseReaction
consisted . . O
primarily . . O
of . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
infections . . I-AdverseReaction
( . . O
20% . . O
for . . O
cimzia . . O
, . . O
13% . . O
for . . O
placebo . . O
) . . O
. . . O

* . . O
risk . . B-Factor
of . . O
thyroid . . B-AdverseReaction
c . . I-AdverseReaction
- . . I-AdverseReaction
cell . . I-AdverseReaction
tumors . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
acute . . B-AdverseReaction
pancreatitis . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
hypoglycemia . . B-AdverseReaction
with . . O
concomitant . . O
use . . O
of . . O
insulin . . O
secretagogues . . O
or . . O
insulin . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
excerpt . . O
: . . O
adverse . . O
reactions . . O
, . . O
reported . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
patients . . O
treated . . O
with . . O
tanzeum . . O
and . . O
more . . O
frequently . . O
than . . O
in . . O
patients . . O
on . . O
placebo . . O
, . . O
were . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
back . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
and . . O
influenza . . B-AdverseReaction
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
substance . . O
abuse . . O
should . . O
be . . O
under . . O
careful . . O
surveillance . . O
when . . O
receiving . . O
onfi . . O
or . . O
other . . O
psychotropic . . O
agents . . O
because . . O
of . . O
the . . O
predisposition . . O
of . . O
such . . O
patients . . O
to . . O
habituation . . O
and . . O
dependence . . O
[ . . O
see . . O
drug . . O
abuse . . O
and . . O
dependence . . O
( . . O
9 . . O
) . . O
] . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reaction . . O
leading . . O
to . . O
afinitor . . O
dose . . O
adjustment . . O
was . . O
stomatitis . . B-AdverseReaction
. . . O

6 . . O
adverse . . O
reactions . . O

therefore . . O
, . . O
the . . O
use . . O
of . . O
pradaxa . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
mechanical . . O
prosthetic . . O
valves . . O
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
. . . O

overall . . O
, . . O
63% . . O
were . . O
female . . O
and . . O
67% . . O
were . . O
white . . O
. . . O

* . . O
long . . B-DrugClass
- . . I-DrugClass
acting . . I-DrugClass
beta2 . . I-DrugClass
- . . I-DrugClass
adrenergic . . I-DrugClass
agonists . . I-DrugClass
( . . O
laba . . B-DrugClass
) . . O
increase . . O
the . . O
risk . . O
of . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction
( . . O
5.1 . . O
) . . O
. . . O

permanently . . O
discontinue . . O
zykadia . . O
in . . O
patients . . O
who . . O
develop . . O
qtc . . O
interval . . O
prolongation . . O
in . . O
combination . . O
with . . O
torsade . . O
de . . O
pointes . . O
or . . O
polymorphic . . O
ventricular . . O
tachycardia . . O
or . . O
signs . . O
/ . . O
symptoms . . O
of . . O
serious . . O
arrhythmia . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.2 . . O
) . . O
] . . O
. . . O

the . . O
major . . B-Severity
hemorrhagic . . B-AdverseReaction
events . . I-AdverseReaction
of . . O
intracranial . . O
or . . O
gastric . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
occurred . . O
in . . O
5% . . O
( . . O
3 . . O
/ . . O
55 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
compared . . O
with . . O
none . . O
of . . O
the . . O
53 . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

serious . . O
side . . O
effects . . O
include . . O
: . . O

discontinue . . O
cometriq . . O
in . . O
patients . . O
who . . O
develop . . O
rpls . . O
. . . O

elevations . . O
of . . O
ast . . O
, . . O
alt . . O
, . . O
or . . O
bilirubin . . O
from . . O
the . . O
patient's . . O
baseline . . O
should . . O
prompt . . O
more . . O
frequent . . O
monitoring . . O
. . . O

table . . O
6 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
treated . . O
for . . O
dvt . . O
and . . O
pe . . O
in . . O
the . . O
amplify . . O
study . . O
eliquisn . . O
= . . O
2676n . . O
( . . O
% . . O
) . . O
enoxaparin . . O
/ . . O
warfarinn . . O
= . . O
2689n . . O
( . . O
% . . O
) . . O
epistaxis . . B-AdverseReaction
77 . . O
( . . O
2.9 . . O
) . . O
146 . . O
( . . O
5.4 . . O
) . . O
contusion . . B-AdverseReaction
49 . . O
( . . O
1.8 . . O
) . . O
97 . . O
( . . O
3.6 . . O
) . . O
hematuria . . B-AdverseReaction
46 . . O
( . . O
1.7 . . O
) . . O
102 . . O
( . . O
3.8 . . O
) . . O
menorrhagia . . B-AdverseReaction
38 . . O
( . . O
1.4 . . O
) . . O
30 . . O
( . . O
1.1 . . O
) . . O
hematoma . . B-AdverseReaction
35 . . O
( . . O
1.3 . . O
) . . O
76 . . O
( . . O
2.8 . . O
) . . O
hemoptysis . . B-AdverseReaction
32 . . O
( . . O
1.2 . . O
) . . O
31 . . O
( . . O
1.2 . . O
) . . O
rectal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
26 . . O
( . . O
1.0 . . O
) . . O
39 . . O
( . . O
1.5 . . O
) . . O
gingival . . B-AdverseReaction
bleeding . . I-AdverseReaction
26 . . O
( . . O
1.0 . . O
) . . O
50 . . O
( . . O
1.9 . . O
) . . O
amplify . . O
- . . O
ext . . O
study . . O
the . . O
mean . . O
duration . . O
of . . O
exposure . . O
to . . O
eliquis . . O
was . . O
approximately . . O
330 . . O
days . . O
and . . O
to . . O
placebo . . O
was . . O
312 . . O
days . . O
in . . O
the . . O
amplify . . O
- . . O
ext . . O
study . . O
. . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
potential . . O
for . . O
immunogenicity . . O
. . . O

excerpt . . O
: . . O
* . . O
a . . O
higher . . O
number . . O
of . . O
myocardial . . B-AdverseReaction
infarctions . . I-AdverseReaction
was . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
alvimopan . . O
0.5 . . O
mg . . O
twice . . O
daily . . O
compared . . O
with . . O
placebo . . O
in . . O
a . . O
12 . . O
- . . O
month . . O
study . . O
in . . O
patients . . O
treated . . O
with . . O
opioids . . O
for . . O
chronic . . O
non . . O
- . . O
cancer . . O
pain . . O
, . . O
although . . O
a . . O
causal . . O
relationship . . O
with . . O
long . . O
- . . O
term . . O
use . . O
has . . O
not . . O
been . . O
established . . O
. . . O

* . . O
increased . . O
incidence . . O
of . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
was . . O
seen . . O
in . . O
a . . O
clinical . . O
trial . . O
of . . O
patients . . O
taking . . O
alvimopan . . O
for . . O
long . . O
- . . O
term . . O
use . . O
. . . O

these . . O
reactions . . O
can . . O
occur . . O
immediately . . O
following . . O
or . . O
up . . O
to . . O
24 . . O
hours . . O
after . . O
administration . . O
of . . O
kyprolis . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
do . . O
not . . O
administer . . O
leucovorin . . O
within . . O
2 . . O
hours . . O
before . . O
or . . O
after . . O
a . . O
dose . . O
of . . O
voraxaze . . O
. . . O

counsel . . O
women . . O
of . . O
childbearing . . O
potential . . O
regarding . . O
appropriate . . O
contraceptive . . O
choices . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

even . . O
following . . O
use . . O
of . . O
a . . O
local . . O
anesthetic . . O
prior . . O
to . . O
administration . . O
of . . O
qutenza . . O
, . . O
patients . . O
may . . B-Factor
experience . . O
substantial . . B-Severity
procedural . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

in . . O
phase . . O
3 . . O
clinical . . O
trials . . O
, . . O
grade . . B-Severity
3 . . I-Severity
and . . O
4 . . O
rashes . . B-AdverseReaction
were . . O
reported . . O
in . . O
1.3% . . O
of . . O
subjects . . O
receiving . . O
intelence . . O
( . . O
r . . O
) . . O
compared . . O
to . . O
0.2% . . O
of . . O
placebo . . O
subjects . . O
. . . O

patients . . O
were . . O
tested . . O
at . . O
multiple . . O
time . . O
points . . O
for . . O
antibodies . . O
to . . O
certolizumab . . O
pegol . . O
during . . O
studies . . O
cd1 . . O
and . . O
cd2 . . O
. . . O

hypocalcemia . . B-AdverseReaction
( . . O
serum . . O
calcium . . O
< . . O
8.4 . . O
mg . . O
/ . . O
dl . . O
) . . O
was . . O
reported . . O
only . . O
in . . O
prolia . . O
- . . O
treated . . O
patients . . O
( . . O
2.4% . . O
vs . . O
. . . O
0% . . O
) . . O
at . . O
the . . O
month . . O
1 . . O
visit . . O
. . . O

the . . O
study . . O
population . . O
included . . O
34 . . O
males . . O
and . . O
26 . . O
females . . O
( . . O
n . . O
= . . O
60 . . O
) . . O
in . . O
the . . O
alglucosidase . . O
alfa . . O
group . . O
and . . O
11 . . O
males . . O
and . . O
19 . . O
females . . O
( . . O
n . . O
= . . O
30 . . O
) . . O
in . . O
the . . O
placebo . . O
group . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
development . . O
of . . O
drug . . O
- . . O
resistant . . O
bacteria . . O
: . . O
only . . O
use . . O
dificid . . O
for . . O
infection . . O
proven . . O
or . . O
strongly . . O
suspected . . O
to . . O
be . . O
caused . . O
by . . O
c . . O
. . . O
difficile . . O
. . . O

the . . O
efficacy . . O
and . . O
safety . . O
of . . O
afinitor . . O
( . . O
10 . . O
mg . . O
/ . . O
day . . O
) . . O
plus . . O
exemestane . . O
( . . O
25 . . O
mg . . O
/ . . O
day . . O
) . . O
( . . O
n . . O
= . . O
485 . . O
) . . O
versus . . O
placebo . . O
plus . . O
exemestane . . O
( . . O
25 . . O
mg . . O
/ . . O
day . . O
) . . O
( . . O
n . . O
= . . O
239 . . O
) . . O
was . . O
evaluated . . O
in . . O
a . . O
randomized . . O
, . . O
controlled . . O
trial . . O
in . . O
patients . . O
with . . O
advanced . . O
or . . O
metastatic . . O
hormone . . O
receptor . . O
- . . O
positive . . O
, . . O
her2 . . O
- . . O
negative . . O
breast . . O
cancer . . O
. . . O

lung . . O
function . . O
( . . O
fev1or . . O
peak . . O
expiratory . . O
flow . . O
) . . O
, . . O
beta . . O
- . . O
agonist . . O
use . . O
, . . O
and . . O
copd . . O
or . . O
asthma . . O
symptoms . . O
should . . O
be . . O
carefully . . O
monitored . . O
during . . O
withdrawal . . O
of . . O
oral . . O
corticosteroids . . O
. . . O

the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
associated . . O
with . . O
ilaris . . O
treatment . . O
in . . O
the . . O
caps . . O
patients . . O
were . . O
nasopharyngitis . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
. . . O

since . . O
patients . . O
with . . O
copd . . O
often . . O
have . . O
multiple . . O
risk . . O
factors . . O
for . . O
reduced . . O
bmd . . O
, . . O
assessment . . O
of . . O
bmd . . O
is . . O
recommended . . O
prior . . O
to . . O
initiating . . O
breo . . O
ellipta . . O
and . . O
periodically . . O
thereafter . . O
. . . O

invokana . . O
can . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
hypoglycemia . . B-AdverseReaction
when . . O
combined . . O
with . . O
insulin . . O
or . . O
an . . O
insulin . . O
secretagogue . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

in . . O
some . . O
patients . . O
, . . O
heart . . B-AdverseReaction
rate . . I-AdverseReaction
decrease . . I-AdverseReaction
during . . O
the . . O
second . . O
period . . O
is . . O
more . . O
pronounced . . O
than . . O
the . . O
decrease . . O
observed . . O
in . . O
the . . O
first . . O
6 . . O
hours . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
live . . O
vaccines . . O
should . . O
not . . O
be . . O
given . . O
concurrently . . O
with . . O
ilaris . . O
. . . O

benlysta . . O
should . . O
be . . O
administered . . O
by . . O
healthcare . . O
providers . . O
prepared . . O
to . . O
manage . . O
infusion . . O
reactions . . O
. . . O

increases . . O
in . . O
hemoglobin . . O

deaths . . B-AdverseReaction
due . . O
to . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
0.7% . . O
) . . O
, . . O
infection . . B-AdverseReaction
( . . O
0.7% . . O
) . . O
, . . O
and . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
( . . O
0.4% . . O
) . . O
were . . O
observed . . O
on . . O
the . . O
afinitor . . O
arm . . O
but . . O
none . . O
on . . O
the . . O
placebo . . O
arm . . O
. . . O

as . . O
with . . O
most . . O
therapeutic . . O
proteins . . O
, . . O
patients . . O
may . . O
develop . . O
anti . . O
- . . O
drug . . O
antibodies . . O
( . . O
ada . . O
) . . O
to . . O
erwinaze . . O
. . . O
in . . O
a . . O
study . . O
with . . O
erwinaze . . O
treatment . . O
by . . O
intramuscular . . O
administration . . O
( . . O
study . . O
1 . . O
) . . O
, . . O
6 . . O
of . . O
56 . . O
( . . O
11% . . O
) . . O
patients . . O
treated . . O
with . . O
erwinaze . . O
developed . . O
antibodies . . O
to . . O
erwinaze . . O
. . . O

adverse . . O
reactions . . O
observed . . O
in . . O
the . . O
other . . O
trials . . O
were . . O
similar . . O
to . . O
those . . O
observed . . O
in . . O
the . . O
confirmatory . . O
trials . . O
. . . O

in . . O
these . . O
trials . . O
, . . O
which . . O
had . . O
a . . O
median . . O
treatment . . O
duration . . O
of . . O
12 . . O
weeks . . O
, . . O
the . . O
estimated . . O
incidence . . O
rate . . O
of . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
or . . O
ideation . . O
among . . O
27,863 . . O
aed . . O
- . . O
treated . . O
patients . . O
was . . O
0.43% . . O
, . . O
compared . . O
with . . O
0.24% . . O
among . . O
16,029 . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
representing . . O
an . . O
increase . . O
of . . O
approximately . . O
1 . . O
case . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
or . . O
behavior . . O
for . . O
every . . O
530 . . O
patients . . O
treated . . O
. . . O

5.3 . . O
hyperkalemia . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
controlled . . O
but . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
clinical . . O
trials . . O
of . . O
voraxaze . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
other . . O
drugs . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

the . . O
adverse . . O
events . . O
observed . . O
during . . O
long . . O
- . . O
term . . O
, . . O
open . . O
- . . O
label . . O
studies . . O
were . . O
similar . . O
to . . O
those . . O
observed . . O
in . . O
the . . O
12 . . O
- . . O
week . . O
, . . O
placebo . . O
- . . O
controlled . . O
studies . . O
, . . O
and . . O
included . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
eyes . . I-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
, . . O
and . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
from . . O
clinical . . O
trials . . O
and . . O
/ . . O
or . . O
post . . O
- . . O
marketing . . O
surveillance . . O
. . . O

discontinue . . O
granix . . O
if . . O
suspected . . O
( . . O
5.2 . . O
) . . O
* . . O
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
angioneurotic . . B-AdverseReaction
edema . . I-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
allergic . . I-AdverseReaction
, . . O
drug . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
, . . O
hypersensitivity . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
pruritic . . B-AdverseReaction
rash . . I-AdverseReaction
and . . O
urticaria . . B-AdverseReaction
) . . O
( . . O
5.3 . . O
) . . O
* . . O
sickle . . B-AdverseReaction
cell . . I-AdverseReaction
crisis . . I-AdverseReaction
: . . O
severe . . B-Severity
and . . O
sometimes . . O
fatal . . B-AdverseReaction
crisis . . O
can . . B-Factor
occur . . O
. . . O

5.1 . . O
gastrointestinal . . O
toxicity . . O

skin . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
sjs . . B-AdverseReaction
and . . O
ten . . B-AdverseReaction
have . . O
occurred . . O
when . . O
treanda . . O
was . . O
administered . . O
concomitantly . . O
with . . O
allopurinol . . O
and . . O
other . . O
medications . . O
known . . O
to . . O
cause . . O
these . . O
syndromes . . O
. . . O

5.13 . . O
hereditary . . O
angioedema . . O

note . . O
: . . O
the . . O
figure . . O
above . . O
presents . . O
effects . . O
in . . O
various . . O
subgroups . . O
all . . O
of . . O
which . . O
are . . O
baseline . . O
characteristics . . O
and . . O
all . . O
of . . O
which . . O
were . . O
pre . . O
- . . O
specified . . O
. . . O

the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
( . . O
occurring . . O
in . . O
more . . O
than . . O
5% . . O
of . . O
patients . . O
who . . O
received . . O
500 . . O
units . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
in . . O
the . . O
placebo . . O
controlled . . O
clinical . . O
trials . . O
) . . O
in . . O
cervical . . O
dystonia . . O
patients . . O
were . . O
: . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
dysphagia . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
neck . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
dysphonia . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
eye . . B-AdverseReaction
disorders . . I-AdverseReaction
( . . O
consisting . . O
of . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
diplopia . . B-AdverseReaction
, . . O
and . . O
reduced . . B-AdverseReaction
visual . . I-AdverseReaction
acuity . . I-AdverseReaction
and . . O
accommodation . . O
) . . O
. . . O

use . . O
in . . O
patients . . O
with . . O
sickle . . O
cell . . O
disease . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O

adverse . . O
reactions . . O
related . . O
to . . O
bleeding . . B-AdverseReaction
occurred . . O
in . . O
417 . . O
( . . O
15.6% . . O
) . . O
eliquis . . O
- . . O
treated . . O
patients . . O
compared . . O
to . . O
661 . . O
( . . O
24.6% . . O
) . . O
enoxaparin . . O
/ . . O
warfarin . . O
- . . O
treated . . O
patients . . O
. . . O

following . . O
resolution . . O
of . . O
transaminase . . O
elevations . . O
, . . O
consider . . O
the . . O
benefits . . O
and . . O
risks . . O
of . . O
resuming . . O
kalydeco . . O
dosing . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
- . . O
pyrexia . . B-AdverseReaction

do . . O
not . . O
give . . O
jevtana . . O
if . . O
neutrophil . . O
counts . . O
are . . O
< . . O
= . . O
1,500 . . O
cells . . O
/ . . O
mm3 . . O
. . . O

gadolinium . . B-DrugClass
- . . I-DrugClass
based . . I-DrugClass
contrast . . I-DrugClass
agents . . I-DrugClass
( . . O
gbcas . . O
) . . O
increase . . O
the . . O
risk . . O
for . . O
nsf . . B-AdverseReaction
among . . O
patients . . O
with . . O
impaired . . O
elimination . . O
of . . O
the . . O
drugs . . O
. . . O

* . . O
hypersensitivity . . B-AdverseReaction
[ . . O
see . . O
contraindications . . O
( . . O
4 . . O
) . . O
] . . O
* . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
and . . O
behaviors . . O
in . . O
adolescents . . O
and . . O
young . . O
adults . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
serotonin . . B-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
elevated . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
abnormal . . B-AdverseReaction
bleeding . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
angle . . B-AdverseReaction
closure . . I-AdverseReaction
glaucoma . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
activation . . O
of . . O
mania . . B-AdverseReaction
/ . . O
hypomania . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
discontinuation . . B-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
seizure . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
* . . O
hyponatremia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O
* . . O
interstitial . . B-AdverseReaction
lung . . I-AdverseReaction
disease . . I-AdverseReaction
and . . O
eosinophilic . . B-AdverseReaction
pneumonia . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.10 . . O
) . . O
] . . O
excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
5% . . O
and . . O
twice . . O
the . . O
rate . . O
of . . O
placebo . . O
in . . O
the . . O
50 . . O
or . . O
100 . . O
mg . . O
dose . . O
groups . . O
) . . O
were . . O
: . . O
nausea . . B-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
insomnia . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
constipation . . B-AdverseReaction
, . . O
somnolence . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
anxiety . . B-AdverseReaction
, . . O
and . . O
specific . . O
male . . B-AdverseReaction
sexual . . I-AdverseReaction
function . . I-AdverseReaction
disorders . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

because . . O
these . . O
spontaneously . . O
reported . . O
events . . O
are . . O
from . . O
the . . O
worldwide . . O
post . . O
- . . O
marketing . . O
experience . . O
, . . O
the . . O
frequency . . O
of . . O
events . . O
and . . O
the . . O
role . . O
of . . O
fesoterodine . . O
in . . O
their . . O
causation . . O
cannot . . O
be . . O
reliably . . O
determined . . O
. . . O

results . . O
from . . O
these . . O
studies . . O
did . . O
not . . O
change . . O
the . . O
safety . . O
profile . . O
of . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
. . . O

serum . . O
creatinine . . O
levels . . O
and . . O
estimated . . O
gfr . . O
may . . O
not . . O
reliably . . O
assess . . O
renal . . O
function . . O
in . . O
the . . O
setting . . O
of . . O
acute . . O
kidney . . O
injury . . O
. . . O

table . . O
4 . . O
: . . O
common . . O
adverse . . O
reactions . . O
by . . O
dose . . O
in . . O
fixed . . O
- . . O
dose . . O
study . . O
in . . O
patients . . O
with . . O
cervical . . O
dystonia . . O
adverse . . O
reaction . . O
preferred . . O
term . . O
dysport . . O
( . . O
r . . O
) . . O
dose . . O
placebo . . O
250 . . O
units . . O
500 . . O
units . . O
1000 . . O
units . . O
any . . O
adverse . . O
event . . O
30% . . O
37% . . O
65% . . O
83% . . O
dysphagia . . B-AdverseReaction
5% . . O
21% . . O
29% . . O
39% . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
10% . . O
21% . . O
18% . . O
39% . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
0% . . O
11% . . O
12% . . O
56% . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
discomfort . . I-AdverseReaction
10% . . O
5% . . O
18% . . O
22% . . O
dysphonia . . B-AdverseReaction
0% . . O
0% . . O
18% . . O
28% . . O
facial . . B-AdverseReaction
paresis . . I-AdverseReaction
0% . . O
5% . . O
0% . . O
11% . . O
eye . . O
disorders . . O
0% . . O
0% . . O
6% . . O
17% . . O
injection . . O
site . . O
reactions . . O

( . . O
5.2 . . O
) . . O

in . . O
clinical . . O
trials . . O
, . . O
the . . O
development . . O
of . . O
localized . . O
infections . . O
of . . O
the . . O
mouth . . O
and . . O
pharynx . . O
with . . O
candida . . O
albicans . . O
has . . O
occurred . . O
in . . O
subjects . . O
treated . . O
with . . O
breo . . O
ellipta . . O
. . . O

permanently . . O
discontinue . . O
yervoy . . O
for . . O
clinically . . O
significant . . O
or . . O
severe . . O
immune . . O
- . . O
mediated . . O
adverse . . O
reactions . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
muscle . . B-AdverseReaction
spasm . . I-AdverseReaction

appropriate . . O
laboratory . . O
testing . . O
prior . . O
to . . O
initiating . . O
therapy . . O
and . . O
monitoring . . O
for . . O
hepatotoxicity . . O
during . . O
therapy . . O
with . . O
tivicay . . O
are . . O
recommended . . O
in . . O
patients . . O
with . . O
underlying . . O
hepatic . . O
disease . . O
such . . O
as . . O
hepatitis . . O
b . . O
or . . O
c . . O
. . . O

baseline . . O
estimated . . O
renal . . O
function . . O
was . . O
normal . . O
or . . O
mildly . . O
impaired . . O
( . . O
egfr . . O
> . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
in . . O
91% . . O
of . . O
the . . O
study . . O
population . . O
and . . O
moderately . . O
impaired . . O
( . . O
egfr . . O
30 . . O
to . . O
60 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
) . . O
in . . O
9% . . O
. . . O

three . . O
additional . . O
subjects . . O
tested . . O
positive . . O
for . . O
binding . . O
antibodies . . O
after . . O
receiving . . O
dysport . . O
( . . O
r . . O
) . . O
treatment . . O
. . . O

ear . . O
and . . O
labyrinth . . O
disorders . . O
: . . O
infrequent . . O
- . . O
vertigo . . B-AdverseReaction
, . . O
tinnitus . . B-AdverseReaction

in . . O
patients . . O
with . . O
prior . . O
history . . O
of . . O
bladder . . O
cancer . . O
, . . O
the . . O
benefits . . O
of . . O
glycemic . . O
control . . O
versus . . O
unknown . . O
risks . . O
for . . O
cancer . . O
recurrence . . O
with . . O
farxiga . . O
should . . O
be . . O
considered . . O
. . . O

however . . O
, . . O
an . . O
earlier . . O
onset . . O
cannot . . O
be . . O
ruled . . O
out . . O
, . . O
and . . O
it . . O
is . . O
possible . . O
that . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
were . . O
present . . O
earlier . . O
in . . O
the . . O
course . . O
of . . O
exposure . . O
to . . O
potiga . . O
. . . O

* . . O
help . . O
reduce . . O
your . . O
chances . . O
of . . O
developing . . O
osteoporosis . . O
( . . O
thin . . O
, . . O
weak . . O
bones . . O
) . . O
if . . O
you . . O
use . . O
duavee . . O
only . . O
to . . O
prevent . . O
osteoporosis . . O
due . . O
to . . O
menopause . . O
, . . O
talk . . O
with . . O
your . . O
healthcare . . O
provider . . O
about . . O
whether . . O
a . . O
different . . O
treatment . . O
or . . O
medicine . . O
without . . O
estrogens . . O
might . . O
be . . O
better . . O
for . . O
you . . O
. . . O
duavee . . O
should . . O
be . . O
taken . . O
for . . O
the . . O
shortest . . O
time . . O
possible . . O
and . . O
only . . O
for . . O
as . . O
long . . O
as . . O
treatment . . O
is . . O
needed . . O
. . . O

at . . O
baseline . . O
the . . O
population . . O
had . . O
diabetes . . O
for . . O
an . . O
average . . O
of . . O
7.3 . . O
years . . O
, . . O
had . . O
a . . O
mean . . O
hba1c . . O
of . . O
8.0% . . O
and . . O
20% . . O
had . . O
established . . O
microvascular . . O
complications . . O
of . . O
diabetes . . O
. . . O

approximately . . O
61% . . O
of . . O
xeomin . . O
- . . O
treated . . O
patients . . O
had . . O
previously . . O
received . . O
another . . O
botulinum . . O
toxin . . O
type . . O
a . . O
product . . O
. . . O

the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
( . . O
incidence . . O
> . . O
= . . O
30% . . O
) . . O
are . . O
neutropenia . . B-AdverseReaction
, . . O
hypertriglyceridemia . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
alt . . B-AdverseReaction
elevations . . I-AdverseReaction
, . . O
and . . O
ast . . B-AdverseReaction
elevations . . I-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
pain . . O
, . . O
bruising . . O
, . . O
haemorrhage . . O
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
erythema . . I-AdverseReaction
/ . . O
haematoma . . O
etc . . O
. . . O
) . . O
have . . O
occurred . . O
following . . O
administration . . O
of . . O
dysport . . O
( . . O
r . . O
) . . O
. . . O

hazardous . . O
activities . . O

treatment . . O
with . . O
simponi . . O
aria . . O
should . . O
not . . O
be . . O
initiated . . O
in . . O
patients . . O
with . . O
an . . O
active . . O
infection . . O
, . . O
including . . O
clinically . . O
important . . O
localized . . O
infections . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
eisai . . O
inc . . O
. . . O
at . . O
( . . O
1-877-873-4724 . . O
) . . O
or . . O
contact . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O

avoid . . O
prolonged . . O
exposure . . O
to . . O
uv . . O
light . . O
and . . O
sunlight . . O
. . . O

item{ . . O
delayed . . O
healing . . O
- . . O
the . . O
use . . O
of . . O
steroids . . B-DrugClass
after . . O
cataract . . O
surgery . . O
may . . O
delay . . B-AdverseReaction
healing . . I-AdverseReaction
and . . O
increase . . O
the . . O
incidence . . O
of . . O
bleb . . O
formation . . O
. . . O

it . . O
is . . O
predominantly . . O
on . . O
or . . O
around . . O
the . . O
lips . . O
or . . O
in . . O
the . . O
nail . . O
beds . . O
of . . O
the . . O
fingers . . O
or . . O
toes . . O
, . . O
but . . O
more . . O
widespread . . O
involvement . . O
of . . O
the . . O
face . . O
and . . O
legs . . O
has . . O
also . . O
been . . O
reported . . O
. . . O

serious . . B-Severity
infections . . B-AdverseReaction
were . . O
seen . . O
in . . O
clinical . . O
studies . . O
with . . O
concurrent . . O
use . . O
of . . O
anakinra . . O
( . . O
an . . O
interleukin . . O
- . . O
1 . . O
antagonist . . O
) . . O
and . . O
another . . O
tnf . . O
blocker . . O
, . . O
etanercept . . B-DrugClass
, . . O
with . . O
no . . O
added . . O
benefit . . O
compared . . O
to . . O
etanercept . . O
alone . . O
. . . O

ilaris . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
a . . O
positive . . O
tuberculosis . . O
screen . . O
, . . O
and . . O
the . . O
safety . . O
of . . O
ilaris . . O
in . . O
individuals . . O
with . . O
latent . . O
tuberculosis . . O
infection . . O
is . . O
unknown . . O
. . . O

beleodaq . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

in . . O
some . . O
cases . . O
, . . O
hyperglycemia . . O
has . . O
resolved . . O
when . . O
the . . O
atypical . . O
antipsychotic . . O
was . . O
discontinued . . O
; . . O
however . . O
, . . O
some . . O
patients . . O
required . . O
continuation . . O
of . . O
antidiabetic . . O
treatment . . O
despite . . O
discontinuation . . O
of . . O
the . . O
suspect . . O
drug . . O
. . . O

hemorrhages . . B-AdverseReaction
, . . O
including . . O
major . . B-Severity
hemorrhages . . B-AdverseReaction
defined . . O
as . . O
symptomatic . . B-AdverseReaction
bleeding . . I-AdverseReaction
in . . O
a . . O
critical . . O
area . . O
or . . O
organ . . O
, . . O
can . . B-Factor
occur . . O
when . . O
tafinlar . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
and . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
vizamyl . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

for . . O
current . . O
full . . O
prescribing . . O
information . . O
, . . O
please . . O
visit . . O
www . . O
. . . O
pfizer . . O
. . . O
com . . O
. . . O

this . . O
may . . B-Factor
result . . O
in . . O
a . . O
critical . . B-Severity
loss . . B-AdverseReaction
of . . I-AdverseReaction
breathing . . I-AdverseReaction
capacity . . I-AdverseReaction
in . . O
patients . . O
with . . O
respiratory . . O
disorders . . O
who . . O
may . . O
have . . O
become . . O
dependent . . O
upon . . O
these . . O
accessory . . O
muscles . . O
. . . O

( . . O
4 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O

dysgeusia . . B-AdverseReaction
( . . O
alteration . . B-AdverseReaction
of . . I-AdverseReaction
taste . . I-AdverseReaction
) . . O
was . . O
an . . O
adverse . . O
event . . O
reported . . O
at . . O
an . . O
increased . . O
frequency . . O
in . . O
subjects . . O
receiving . . O
victrelis . . O
in . . O
combination . . O
with . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
compared . . O
with . . O
subjects . . O
receiving . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
alone . . O
( . . O
table . . O
3 . . O
) . . O
. . . O

adequate . . O
diagnostic . . O
measures . . O
, . . O
including . . O
directed . . O
or . . O
random . . O
endometrial . . O
sampling . . O
when . . O
indicated . . O
, . . O
should . . O
be . . O
undertaken . . O
to . . O
rule . . O
out . . O
malignancy . . O
in . . O
postmenopausal . . O
women . . O
with . . O
undiagnosed . . O
persistent . . O
or . . O
recurring . . O
abnormal . . O
genital . . O
bleeding . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
estrogen . . O
therapy . . O
should . . O
not . . O
be . . O
used . . O
for . . O
the . . O
prevention . . O
of . . O
cardiovascular . . O
disease . . O
or . . O
dementia . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
, . . O
5.4 . . O
) . . O
] . . O
* . . O
the . . O
women's . . O
health . . O
initiative . . O
( . . O
whi . . O
) . . O
estrogen . . O
- . . O
alone . . O
substudy . . O
reported . . O
increased . . O
risks . . O
of . . O
stroke . . B-AdverseReaction
and . . O
deep . . B-AdverseReaction
vein . . I-AdverseReaction
thrombosis . . I-AdverseReaction
( . . O
dvt . . B-AdverseReaction
) . . O
in . . O
postmenopausal . . O
women . . O
( . . O
50 . . O
to . . O
79 . . O
years . . O
of . . O
age . . O
) . . O
during . . O
7.1 . . O
years . . O
of . . O
treatment . . O
with . . O
daily . . O
oral . . B-DrugClass
conjugated . . I-DrugClass
estrogens . . I-DrugClass
( . . O
0.625 . . O
mg . . O
) . . O
- . . O
alone . . O
, . . O
relative . . O
to . . O
placebo . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
the . . O
whi . . O
memory . . O
study . . O
( . . O
whims . . O
) . . O
estrogen . . O
- . . O
alone . . O
ancillary . . O
study . . O
of . . O
whi . . O
reported . . O
an . . O
increased . . O
risk . . O
of . . O
probable . . O
dementia . . B-AdverseReaction
in . . O
postmenopausal . . O
women . . O
65 . . O
years . . O
of . . O
age . . O
and . . O
older . . O
during . . O
5.2 . . O
years . . O
of . . O
treatment . . O
with . . O
daily . . O
conjugated . . B-DrugClass
estrogens . . I-DrugClass
( . . O
0.625 . . O
mg . . O
) . . O
- . . O
alone . . O
, . . O
relative . . O
to . . O
placebo . . O
. . . O

( . . O
14.3 . . O
) . . O
multaq . . O
is . . O
contraindicated . . O
in . . O
patients . . O
with . . O
symptomatic . . O
heart . . O
failure . . O
with . . O
recent . . O
decompensation . . O
requiring . . O
hospitalization . . O
or . . O
nyha . . O
class . . O
iv . . O
heart . . O
failure . . O
. . . O

the . . O
relationship . . O
to . . O
treanda . . O
cannot . . O
be . . O
determined . . O
. . . O

in . . O
general . . O
, . . O
in . . O
clinical . . O
trials . . O
, . . O
rash . . B-AdverseReaction
was . . O
mild . . B-Severity
to . . I-Severity
moderate . . I-Severity
, . . O
occurred . . O
primarily . . O
in . . O
the . . O
second . . O
week . . O
of . . O
therapy . . O
, . . O
and . . O
was . . O
infrequent . . O
after . . O
week . . O
4 . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
sluggishness . . B-AdverseReaction

swallowing . . O
and . . O
breathing . . O
difficulties . . O
can . . O
be . . O
life . . B-Severity
threatening . . I-Severity
and . . O
there . . O
have . . O
been . . O
reports . . O
of . . O
death . . B-AdverseReaction
. . . O

have . . O
anaphylactic . . O
and . . O
hypersensitivity . . O
treatment . . O
measures . . O
available . . O
prior . . O
to . . O
adreview . . O
administration . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

* . . O
hypotension . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
impairment . . B-AdverseReaction
in . . I-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
hypoglycemia . . B-AdverseReaction
with . . O
concomitant . . O
use . . O
with . . O
insulin . . O
and . . O
insulin . . O
secretagogues . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
genital . . B-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
increases . . B-AdverseReaction
in . . I-AdverseReaction
low . . I-AdverseReaction
- . . I-AdverseReaction
density . . I-AdverseReaction
lipoprotein . . I-AdverseReaction
cholesterol . . I-AdverseReaction
( . . O
ldl . . O
- . . O
c . . O
) . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
bladder . . B-AdverseReaction
cancer . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
associated . . O
with . . O
farxiga . . O
( . . O
5% . . O
or . . O
greater . . O
incidence . . O
) . . O
were . . O
female . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
, . . O
nasopharyngitis . . B-AdverseReaction
, . . O
and . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

serious . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
including . . O
anaphylaxis . . B-AdverseReaction
can . . O
occur . . O
in . . O
patients . . O
receiving . . O
human . . B-DrugClass
granulocyte . . I-DrugClass
colony . . I-DrugClass
- . . I-DrugClass
stimulating . . I-DrugClass
factors . . I-DrugClass
. . . O

decreased . . B-AdverseReaction
plasma . . I-AdverseReaction
zinc . . I-AdverseReaction
concentrations . . I-AdverseReaction
have . . O
been . . O
observed . . O
on . . O
ferriprox . . O
therapy . . O
. . . O

caution . . O
is . . O
warranted . . O
when . . O
prescribing . . O
fanapt . . O
with . . O
drugs . . O
that . . O
inhibit . . O
fanapt . . O
metabolism . . O
[ . . O
see . . O
drug . . O
interaction . . O
s . . O
( . . O
7.1 . . O
) . . O
] . . O
, . . O
and . . O
in . . O
patients . . O
with . . O
reduced . . O
activity . . O
of . . O
cyp2d6 . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

the . . O
protocol . . O
specified . . O
that . . O
patients . . O
continue . . O
receiving . . O
intravenous . . O
hydration . . O
, . . O
urinary . . O
alkalinization . . O
and . . O
leucovorin . . O
, . . O
and . . O
that . . O
leucovorin . . O
administration . . O
be . . O
adjusted . . O
to . . O
ensure . . O
that . . O
it . . O
was . . O
not . . O
administered . . O
within . . O
two . . O
hours . . O
before . . O
or . . O
after . . O
voraxaze . . O
. . . O

excerpt . . O
: . . O
* . . O
urinary . . B-AdverseReaction
retention . . I-AdverseReaction
: . . O
patients . . O
should . . O
be . . O
carefully . . O
monitored . . O
for . . O
urologic . . O
symptoms . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
stomatitis . . B-AdverseReaction
, . . O
including . . O
aphthous . . B-AdverseReaction
stomatitis . . I-AdverseReaction

moderate . . B-Severity
endocrinopathy . . B-AdverseReaction
( . . O
requiring . . O
hormone . . O
replacement . . O
or . . O
medical . . O
intervention . . O
; . . O
grade . . B-Severity
2 . . I-Severity
) . . O
occurred . . O
in . . O
12 . . O
( . . O
2.3% . . O
) . . O
patients . . O
and . . O
consisted . . O
of . . O
hypothyroidism . . B-AdverseReaction
, . . O
adrenal . . B-AdverseReaction
insufficiency . . I-AdverseReaction
, . . O
hypopituitarism . . B-AdverseReaction
, . . O
and . . O
1 . . O
case . . O
each . . O
of . . O
hyperthyroidism . . B-AdverseReaction
and . . O
cushing's . . B-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

table . . O
2 . . O
: . . O
monitored . . O
adverse . . O
reactions . . O
- . . O
application . . O
site . . O
symptoms . . O
event . . O
ulesfia . . O
( . . O
r . . O
) . . O
lotion . . O
vehicle . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
irritation . . I-AdverseReaction
2% . . O
( . . O
11 . . O
/ . . O
478 . . O
) . . O
1% . . O
( . . O
2 . . O
/ . . O
336 . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
anesthesia . . I-AdverseReaction
&hypoesthesia . . O
2% . . O
( . . O
10 . . O
/ . . O
478 . . O
) . . O
0% . . O
( . . O
0 . . O
/ . . O
336 . . O
) . . O
pain . . B-AdverseReaction
1% . . O
( . . O
5 . . O
/ . . O
478 . . O
) . . O
0% . . O
( . . O
1 . . O
/ . . O
336 . . O
) . . O
the . . O
subset . . O
of . . O
subjects . . O
who . . O
did . . O
not . . O
have . . O
pruritus . . O
, . . O
erythema . . O
, . . O
edema . . O
or . . O
pyoderma . . O
of . . O
skin . . O
and . . O
scalp . . O
, . . O
or . . O
ocular . . O
irritation . . O
prior . . O
to . . O
treatment . . O
were . . O
assessed . . O
for . . O
these . . O
signs . . O
and . . O
symptoms . . O
after . . O
treatment . . O
; . . O
the . . O
results . . O
are . . O
presented . . O
in . . O
table . . O
3 . . O
. . . O

women . . O
of . . O
childbearing . . O
potential . . O
and . . O
men . . O
must . . O
use . . O
at . . O
least . . O
two . . O
forms . . O
of . . O
effective . . O
contraception . . O
during . . O
treatment . . O
and . . O
for . . O
at . . O
least . . O
6 . . O
months . . O
after . . O
treatment . . O
has . . O
concluded . . O
. . . O

patients . . O
in . . O
the . . O
chemotherapy . . O
arm . . O
received . . O
pemetrexed . . O
unless . . O
they . . O
had . . O
received . . O
pemetrexed . . O
as . . O
part . . O
of . . O
first . . O
- . . O
line . . O
or . . O
maintenance . . O
treatment . . O
. . . O

women . . O
on . . O
thyroid . . O
hormone . . O
replacement . . O
therapy . . O
may . . O
need . . O
increased . . O
doses . . O
of . . O
thyroid . . O
hormone . . O
because . . O
serum . . O
concentrations . . O
of . . O
thyroid . . B-AdverseReaction
- . . I-AdverseReaction
binding . . I-AdverseReaction
globulin . . I-AdverseReaction
increase . . I-AdverseReaction
with . . O
use . . O
of . . O
cocs . . B-DrugClass
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
: . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
can . . B-Factor
occur . . O
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

5.2 . . O
impairment . . O
in . . O
renal . . O
function . . O

withhold . . O
kyprolis . . O
for . . O
grade . . O
3 . . O
or . . O
4 . . O
cardiac . . O
adverse . . O
events . . O
until . . O
recovery . . O
, . . O
and . . O
consider . . O
whether . . O
to . . O
restart . . O
kyprolis . . O
at . . O
1 . . O
dose . . O
level . . O
reduction . . O
based . . O
on . . O
a . . O
benefit . . O
/ . . O
risk . . O
assessment . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

5.1 . . O
seizures . . O

macular . . O
edema . . O
in . . O
patients . . O
with . . O
history . . O
of . . O
uveitis . . O
or . . O
diabetes . . O
mellitus . . O

adequate . . O
data . . O
are . . O
not . . O
available . . O
on . . O
the . . O
safety . . O
or . . O
efficacy . . O
of . . O
treating . . O
patients . . O
who . . O
are . . O
carriers . . O
of . . O
hbv . . O
with . . O
anti . . O
- . . O
viral . . O
therapy . . O
in . . O
conjunction . . O
with . . O
tnf . . O
blocker . . O
therapy . . O
to . . O
prevent . . O
hbv . . O
reactivation . . O
. . . O

5.2 . . O
immunosuppression . . O

patients . . O
taking . . O
zydelig . . O
who . . O
present . . O
with . . O
pulmonary . . O
symptoms . . O
such . . O
as . . O
cough . . O
, . . O
dyspnea . . O
, . . O
hypoxia . . O
, . . O
interstitial . . O
infiltrates . . O
on . . O
a . . O
radiologic . . O
exam . . O
, . . O
or . . O
a . . O
decline . . O
by . . O
more . . O
than . . O
5% . . O
in . . O
oxygen . . O
saturation . . O
should . . O
be . . O
evaluated . . O
for . . O
pneumonitis . . O
. . . O

patients . . O
received . . O
placebo . . O
( . . O
n . . O
= . . O
1393 . . O
) . . O
, . . O
farxiga . . O
5 . . O
mg . . O
( . . O
n . . O
= . . O
1145 . . O
) . . O
, . . O
or . . O
farxiga . . O
10 . . O
mg . . O
( . . O
n . . O
= . . O
1193 . . O
) . . O
once . . O
daily . . O
. . . O

thromboembolic . . O
events . . O
have . . O
been . . O
associated . . O
with . . O
esa . . O
use . . O
in . . O
other . . O
disease . . O
states . . O
; . . O
and . . O
have . . O
also . . O
been . . O
reported . . O
with . . O
peginterferon . . O
alfa . . O
use . . O
in . . O
hepatitis . . O
c . . O
patients . . O
. . . O

consider . . O
discontinuing . . O
prolia . . O
if . . O
severe . . O
symptoms . . O
develop . . O
( . . O
5.7 . . O
) . . O
* . . O
severe . . B-Severity
bone . . O
, . . O
joint . . O
, . . O
muscle . . B-AdverseReaction
pain . . I-AdverseReaction
may . . O
occur . . O
. . . O

5.2 . . O
interstitial . . O
lung . . O
disease . . O
( . . O
pneumonitis . . O
) . . O

5.15 . . O
coexisting . . O
conditions . . O

monitor . . O
patients . . O
frequently . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
neurological . . O

5 . . O
warnings . . O
and . . O
precautions . . O

the . . O
proportion . . O
of . . O
subjects . . O
who . . O
received . . O
an . . O
esa . . O
was . . O
43% . . O
in . . O
those . . O
treated . . O
with . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
compared . . O
to . . O
24% . . O
in . . O
those . . O
treated . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
: . . O
serious . . B-Severity
and . . O
fatal . . B-AdverseReaction
reactions . . O
have . . O
been . . O
reported . . O
. . . O

prophylaxis . . O
for . . O
cytomegalovirus . . O
is . . O
recommended . . O
for . . O
at . . O
least . . O
3 . . O
months . . O
after . . O
transplantation . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
( . . O
% . . O
patients . . O
) . . O
in . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trials . . O
treatment . . O
adverse . . O
reactions . . O
tudorza . . O
pressair . . O
placebo . . O
preferred . . O
term . . O
( . . O
n . . O
= . . O
636 . . O
) . . O
( . . O
n . . O
= . . O
640 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
n . . O
( . . O
% . . O
) . . O
headache . . B-AdverseReaction
42 . . O
( . . O
6.6 . . O
) . . O
32 . . O
( . . O
5.0 . . O
) . . O
nasopharyngitis . . B-AdverseReaction
35 . . O
( . . O
5.5 . . O
) . . O
25 . . O
( . . O
3.9 . . O
) . . O
cough . . B-AdverseReaction
19 . . O
( . . O
3.0 . . O
) . . O
14 . . O
( . . O
2.2 . . O
) . . O
diarrhea . . B-AdverseReaction
17 . . O
( . . O
2.7 . . O
) . . O
9 . . O
( . . O
1.4 . . O
) . . O
sinusitis . . B-AdverseReaction
11 . . O
( . . O
1.7 . . O
) . . O
5 . . O
( . . O
0.8 . . O
) . . O
rhinitis . . B-AdverseReaction
10 . . O
( . . O
1.6 . . O
) . . O
8 . . O
( . . O
1.2 . . O
) . . O
toothache . . B-AdverseReaction
7 . . O
( . . O
1.1 . . O
) . . O
5 . . O
( . . O
0.8 . . O
) . . O
fall . . B-AdverseReaction
7 . . O
( . . O
1.1 . . O
) . . O
3 . . O
( . . O
0.5 . . O
) . . O
vomiting . . B-AdverseReaction
7 . . O
( . . O
1.1 . . O
) . . O
3 . . O
( . . O
0.5 . . O
) . . O
in . . O
addition . . O
, . . O
among . . O
the . . O
adverse . . O
reactions . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
with . . O
an . . O
incidence . . O
of . . O
less . . O
than . . O
1% . . O
were . . O
diabetes . . B-AdverseReaction
mellitus . . I-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
1st . . B-Severity
degree . . I-Severity
av . . B-AdverseReaction
block . . I-AdverseReaction
, . . O
osteoarthritis . . B-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
and . . O
cardio . . B-AdverseReaction
- . . I-AdverseReaction
respiratory . . I-AdverseReaction
arrest . . I-AdverseReaction
. . . O

based . . O
on . . O
the . . O
severity . . O
of . . O
the . . O
adverse . . O
drug . . O
reaction . . O
, . . O
withhold . . O
zykadia . . O
with . . O
resumption . . O
at . . O
a . . O
reduced . . O
dose . . O
, . . O
or . . O
permanently . . O
discontinue . . O
zykadia . . O
as . . O
described . . O
in . . O
table . . O
1 . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

( . . O
5.7 . . O
) . . O
* . . O
leukopenia . . B-AdverseReaction
, . . O
neutropenia . . B-AdverseReaction
, . . O
and . . O
agranulocytosis . . B-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
antipsychotics . . B-DrugClass
. . . O

in . . O
the . . O
controlled . . O
phase . . O
of . . O
trial . . O
1 . . O
through . . O
week . . O
24 . . O
, . . O
1.1% . . O
of . . O
simponi . . O
aria . . O
infusions . . O
were . . O
associated . . O
with . . O
an . . O
infusion . . B-AdverseReaction
reaction . . I-AdverseReaction
compared . . O
with . . O
0.2% . . O
of . . O
infusions . . O
in . . O
the . . O
control . . O
group . . O
. . . O

in . . O
the . . O
majority . . O
of . . O
patients . . O
who . . O
experienced . . O
flushing . . B-AdverseReaction
, . . O
it . . O
was . . O
mild . . B-Severity
or . . O
moderate . . B-Severity
in . . O
severity . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
drug . . O
reactions . . O
reported . . O
with . . O
> . . O
= . . O
25% . . O
of . . O
patients . . O
treated . . O
with . . O
xiaflex . . O
and . . O
at . . O
an . . O
incidence . . O
greater . . O
than . . O
placebo . . O
were . . O
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
, . . O
penile . . B-AdverseReaction
swelling . . I-AdverseReaction
and . . O
penile . . B-AdverseReaction
pain . . I-AdverseReaction
. . . O

subgroup . . O
analyses . . O
of . . O
women . . O
50 . . O
to . . O
59 . . O
years . . O
of . . O
age . . O
suggest . . O
a . . O
statistically . . O
non . . O
- . . O
significant . . O
reduction . . B-Negation
in . . O
chd . . B-AdverseReaction
events . . O
( . . O
ce . . O
[ . . O
0.625 . . O
mg] . . O
- . . O
alone . . O
compared . . O
to . . O
placebo . . O
) . . O
in . . O
women . . O
with . . O
less . . O
than . . O
10 . . O
years . . O
since . . O
menopause . . O
( . . O
8 . . O
versus . . O
16 . . O
per . . O
10,000 . . O
women . . O
- . . O
years . . O
) . . O
. . . O

the . . O
possibility . . O
of . . O
an . . O
immune . . O
reaction . . O
when . . O
injected . . O
intradermally . . O
is . . O
unknown . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
cleviprex . . O
gives . . O
no . . O
protection . . O
against . . O
the . . O
effects . . O
of . . O
abrupt . . O
beta . . O
- . . O
blocker . . O
withdrawal . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
at . . O
least . . O
10% . . O
of . . O
patients . . O
, . . O
using . . O
the . . O
nci . . O
ctc . . O
version . . O
4 . . O
, . . O
are . . O
shown . . O
in . . O
table . . O
3 . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
arthralgia . . B-AdverseReaction
: . . O
severe . . B-Severity
and . . O
disabling . . B-Severity
arthralgia . . B-AdverseReaction
has . . O
been . . O
reported . . O
in . . O
patients . . O
taking . . O
dpp . . B-DrugClass
- . . I-DrugClass
4 . . I-DrugClass
inhibitors . . I-DrugClass
. . . O

if . . O
supine . . O
hypertension . . O
cannot . . O
be . . O
managed . . O
by . . O
elevation . . O
of . . O
the . . O
head . . O
of . . O
the . . O
bed . . O
, . . O
reduce . . O
or . . O
discontinue . . O
northera . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

two . . O
randomized . . O
clinical . . O
trials . . O
enrolled . . O
patients . . O
with . . O
metastatic . . O
prostate . . O
cancer . . O
that . . O
has . . O
progressed . . O
on . . O
androgen . . O
deprivation . . O
therapy . . O
( . . O
gnrh . . O
therapy . . O
or . . O
bilateral . . O
orchiectomy . . O
) . . O
, . . O
a . . O
disease . . O
setting . . O
that . . O
is . . O
also . . O
defined . . O
as . . O
metastatic . . O
crpc . . O
. . . O

in . . O
the . . O
placebo . . B-Factor
group . . O
, . . O
no . . O
serious . . B-Severity
infection . . B-AdverseReaction
occurred . . O
in . . O
more . . O
than . . O
one . . O
subject . . O
. . . O

some . . O
of . . O
the . . O
reactions . . O
were . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
and . . O
included . . O
anaphylactic . . O
shock . . O
, . . O
cardiac . . O
arrest . . O
, . . O
respiratory . . O
arrest . . O
, . . O
respiratory . . O
distress . . O
, . . O
hypoxia . . O
, . . O
apnea . . O
, . . O
dyspnea . . O
, . . O
bradycardia . . O
, . . O
tachycardia . . O
, . . O
bronchospasm . . O
, . . O
throat . . O
tightness . . O
, . . O
hypotension . . O
, . . O
angioedema . . O
( . . O
including . . O
tongue . . O
or . . O
lip . . O
swelling . . O
, . . O
periorbital . . O
edema . . O
, . . O
and . . O
face . . O
edema . . O
) . . O
, . . O
and . . O
urticaria . . O
. . . O

tudorza . . O
pressair . . O
is . . O
intended . . O
as . . O
a . . O
twice . . O
- . . O
daily . . O
maintenance . . O
treatment . . O
for . . O
copd . . O
and . . O
is . . O
not . . O
indicated . . O
for . . O
the . . O
initial . . O
treatment . . O
of . . O
acute . . O
episodes . . O
of . . O
bronchospasm . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
rescue . . O
therapy . . O
) . . O
. . . O

aptiom . . O
causes . . O
dose . . O
- . . O
dependent . . O
increases . . O
in . . O
cognitive . . B-AdverseReaction
dysfunction . . I-AdverseReaction
- . . O
related . . O
events . . O
( . . O
memory . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
disturbance . . B-AdverseReaction
in . . I-AdverseReaction
attention . . I-AdverseReaction
, . . O
amnesia . . B-AdverseReaction
, . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
, . . O
aphasia . . B-AdverseReaction
, . . O
speech . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
slowness . . B-AdverseReaction
of . . I-AdverseReaction
thought . . I-AdverseReaction
, . . O
disorientation . . B-AdverseReaction
, . . O
and . . O
psychomotor . . B-AdverseReaction
retardation . . I-AdverseReaction
) . . O
. . . O

consider . . O
discontinuation . . O
for . . O
grade . . O
3 . . O
infusions . . O
reactions . . O
as . . O
clinically . . O
appropriate . . O
considering . . O
individual . . O
benefits . . O
, . . O
risks . . O
, . . O
and . . O
supportive . . O
care . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
that . . O
lead . . O
to . . O
discontinuation . . O
of . . O
arcapta . . O
neohaler . . O
were . . O
copd . . B-AdverseReaction
and . . O
dyspnea . . B-AdverseReaction
. . . O

in . . O
these . . O
six . . O
clinical . . O
trials . . O
, . . O
48% . . O
of . . O
patients . . O
treated . . O
with . . O
any . . O
dose . . O
of . . O
arcapta . . O
neohaler . . O
reported . . O
an . . O
adverse . . O
reaction . . O
compared . . O
with . . O
43% . . O
of . . O
patients . . O
treated . . O
with . . O
placebo . . O
. . . O

immune . . O
system . . O
disorders . . O
: . . O
drug . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
, . . O
immune . . B-AdverseReaction
reconstitution . . I-AdverseReaction
syndrome . . I-AdverseReaction

monitor . . O
glucose . . O
levels . . O
in . . O
patients . . O
at . . O
baseline . . O
and . . O
periodically . . O
during . . O
treatment . . O
. . . O

most . . O
were . . O
grade . . O
1 . . O
or . . O
2 . . O
events . . O
. . . O

malignancies . . B-AdverseReaction
, . . O
some . . O
fatal . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
among . . O
children . . O
, . . O
adolescents . . O
, . . O
and . . O
young . . O
adults . . O
who . . O
received . . O
treatment . . O
with . . O
tnf . . B-DrugClass
- . . I-DrugClass
blocking . . I-DrugClass
agents . . I-DrugClass
( . . O
initiation . . O
of . . O
therapy . . O
< . . O
= . . O
18 . . O
years . . O
of . . O
age . . O
) . . O
, . . O
of . . O
which . . O
cimzia . . O
is . . O
a . . O
member . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
, . . O
5.2 . . O
) . . O
] . . O
. . . O

includes . . O
5 . . O
subjects . . O
with . . O
major . . B-Severity
bleeding . . B-AdverseReaction
events . . O
that . . O
occurred . . O
before . . B-Negation
the . . I-Negation
first . . I-Negation
dose . . I-Negation
of . . O
apixaban . . O
( . . O
administered . . O
12 . . O
to . . O
24 . . O
hours . . O
post . . O
surgery . . O
) . . O
. . . O

in . . O
trial . . O
2 . . O
, . . O
13% . . O
of . . O
patients . . O
receiving . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
experienced . . O
adverse . . O
reactions . . O
resulting . . O
in . . O
permanent . . O
discontinuation . . O
of . . O
trial . . O
medication . . O
( . . O
s . . O
) . . O
. . . O

benlysta . . O
should . . O
be . . O
administered . . O
by . . O
healthcare . . O
providers . . O
prepared . . O
to . . O
manage . . O
anaphylaxis . . O
. . . O

5.10 . . O
thrombocytopenia . . O

non . . B-AdverseReaction
- . . I-AdverseReaction
arteritic . . I-AdverseReaction
anterior . . I-AdverseReaction
ischemic . . I-AdverseReaction
optic . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
naion . . B-AdverseReaction
) . . O
, . . O
a . . O
cause . . O
of . . O
decreased . . B-AdverseReaction
vision . . I-AdverseReaction
including . . O
permanent . . B-AdverseReaction
loss . . I-AdverseReaction
of . . I-AdverseReaction
vision . . I-AdverseReaction
, . . O
has . . O
been . . O
reported . . O
rarely . . O
post . . O
- . . O
marketing . . O
in . . O
temporal . . O
association . . O
with . . O
the . . O
use . . O
of . . O
phosphodiesterase . . B-DrugClass
type . . I-DrugClass
5 . . I-DrugClass
( . . I-DrugClass
pde5 . . I-DrugClass
) . . I-DrugClass
inhibitors . . I-DrugClass
. . . O

these . . O
cases . . O
of . . O
anaphylaxis . . B-AdverseReaction
occurred . . O
as . . O
early . . O
as . . O
30 . . O
minutes . . O
from . . O
the . . O
start . . O
of . . O
infusion . . O
and . . O
up . . O
to . . O
three . . O
hours . . O
after . . O
infusion . . O
. . . O

signs . . O
and . . O
symptoms . . O
associated . . O
with . . O
more . . O
severe . . O
and . . O
/ . . O
or . . O
acute . . O
cases . . O
have . . O
included . . O
hallucination . . B-AdverseReaction
, . . O
syncope . . B-AdverseReaction
, . . O
seizure . . B-AdverseReaction
, . . O
coma . . B-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
arrest . . I-AdverseReaction
, . . O
and . . O
death . . B-AdverseReaction
. . . O

jevtana . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

* . . O
lymphopenia . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

* . . O
ferriprox . . O
can . . B-Factor
cause . . O
agranulocytosis . . B-AdverseReaction
that . . O
can . . B-Factor
lead . . O
to . . O
serious . . B-Severity
infections . . B-AdverseReaction
and . . O
death . . B-AdverseReaction
. . . O

table . . O
3 . . O
. . . O

patients . . O
received . . O
erwinaze . . O
25,000 . . O
international . . O
unit . . O
/ . . O
m . . O
2 . . O
/ . . O
dose . . O
, . . O
administered . . O
by . . O
intravenous . . O
infusion . . O
on . . O
a . . O
monday . . O
, . . O
wednesday . . O
, . . O
and . . O
friday . . O
schedule . . O
( . . O
6 . . O
doses . . O
) . . O
as . . O
a . . O
replacement . . O
for . . O
doses . . O
remaining . . O
on . . O
their . . O
original . . O
treatment . . O
plan . . O
. . . O

adverse . . O
reactions . . O
associated . . O
with . . O
discontinuation . . O
of . . O
treatment . . O
: . . O
approximately . . O
10% . . O
( . . O
38 . . O
/ . . O
379 . . O
) . . O
of . . O
saphris . . O
- . . O
treated . . O
patients . . O
in . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
trials . . O
discontinued . . O
treatment . . O
due . . O
to . . O
an . . O
adverse . . O
reaction . . O
, . . O
compared . . O
with . . O
about . . O
6% . . O
( . . O
12 . . O
/ . . O
203 . . O
) . . O
on . . O
placebo . . O
. . . O

laboratory . . O
tests . . O

table . . O
4 . . O
compares . . O
the . . O
incidence . . O
of . . O
treatment . . O
- . . O
emergent . . O
adverse . . O
reactions . . O
reported . . O
with . . O
an . . O
incidence . . O
of . . O
> . . O
= . . O
10% . . O
for . . O
patients . . O
receiving . . O
afinitor . . O
10 . . O
mg . . O
daily . . O
versus . . O
placebo . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
agranulocytosis . . B-AdverseReaction
/ . . O
neutropenia . . B-AdverseReaction

at . . O
48 . . O
weeks . . O
, . . O
the . . O
rates . . O
of . . O
adverse . . O
events . . O
leading . . O
to . . O
discontinuation . . O
were . . O
3% . . O
in . . O
subjects . . O
receiving . . O
tivicay . . O
50 . . O
mg . . O
once . . O
daily . . O
+ . . O
background . . O
regimen . . O
and . . O
4% . . O
in . . O
subjects . . O
receiving . . O
raltegravir . . O
400 . . O
mg . . O
twice . . O
daily . . O
+ . . O
background . . O
regimen . . O
. . . O

patients . . O
with . . O
major . . O
risk . . O
factors . . O
for . . O
decreased . . O
bone . . O
mineral . . O
content . . O
, . . O
such . . O
as . . O
prolonged . . O
immobilization . . O
, . . O
family . . O
history . . O
of . . O
osteoporosis . . O
, . . O
postmenopausal . . O
status . . O
, . . O
tobacco . . O
use . . O
, . . O
advanced . . O
age . . O
, . . O
poor . . O
nutrition . . O
, . . O
or . . O
chronic . . O
use . . O
of . . O
drugs . . O
that . . O
can . . O
reduce . . O
bone . . O
mass . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
anticonvulsants . . O
, . . O
oral . . O
corticosteroids . . O
) . . O
should . . O
be . . O
monitored . . O
and . . O
treated . . O
with . . O
established . . O
standards . . O
of . . O
care . . O
. . . O

the . . O
safety . . O
of . . O
ilaris . . O
compared . . O
to . . O
placebo . . O
was . . O
investigated . . O
in . . O
two . . O
phase . . O
3 . . O
studies . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14.2 . . O
) . . O
] . . O
. . . O

monitor . . O
blood . . O
pressure . . O
prior . . O
to . . O
initiation . . O
and . . O
regularly . . O
during . . O
cometriq . . O
treatment . . O
. . . O

no . . B-Negation
evidence . . O
of . . O
altered . . O
pharmacokinetic . . O
profile . . O
, . . O
toxicity . . B-AdverseReaction
profile . . O
, . . O
or . . O
clinical . . O
response . . O
was . . O
associated . . O
with . . O
binding . . O
antibody . . O
development . . O
. . . O

if . . O
accidental . . O
exposure . . O
occurs . . O
, . . O
flush . . O
eyes . . O
with . . O
water . . O
and . . O
seek . . O
medical . . O
care . . O
. . . O

the . . O
incidence . . O
of . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
was . . O
higher . . O
in . . O
those . . O
taking . . O
8 . . O
mg . . O
/ . . O
day . . O
( . . O
35% . . O
) . . O
and . . O
in . . O
those . . O
taking . . O
4 . . O
mg . . O
/ . . O
day . . O
( . . O
19% . . O
) . . O
, . . O
as . . O
compared . . O
to . . O
placebo . . O
( . . O
7% . . O
) . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
gilead . . O
sciences . . O
, . . O
inc . . O
. . . O
at . . O
1-800 . . O
- . . O
gilead . . O
- . . O
5 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

dose . . O
- . . O
related . . O
adverse . . O
reactions . . O
in . . O
clinical . . O
trials . . O

5.6 . . O
bone . . O
effects . . O
of . . O
tenofovir . . O
df . . O

these . . O
reactions . . O
occurred . . O
within . . O
the . . O
first . . O
hour . . O
after . . O
dosing . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
the . . O
subcutaneous . . O
formulation . . O
of . . O
golimumab . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
hyperkeratosis . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
. . . O

in . . O
the . . O
peyronie's . . O
disease . . O
clinical . . O
studies . . O
, . . O
at . . O
6 . . O
weeks . . O
after . . O
the . . O
first . . O
treatment . . O
cycle . . O
of . . O
xiaflex . . O
0.58 . . O
mg . . O
, . . O
approximately . . O
75% . . O
of . . O
patients . . O
had . . O
antibodies . . O
against . . O
aux . . O
- . . O
i . . O
and . . O
approximately . . O
55% . . O
of . . O
patients . . O
had . . O
antibodies . . O
against . . O
aux . . O
- . . O
ii . . O
. . . O

5.1 . . O
need . . O
for . . O
aseptic . . O
technique . . O

the . . O
data . . O
reflect . . O
the . . O
percentage . . O
of . . O
patients . . O
whose . . O
test . . O
results . . O
were . . O
considered . . O
positive . . O
for . . O
antibodies . . O
to . . O
alglucosidase . . O
alfa . . O
using . . O
an . . O
enzyme . . O
- . . O
linked . . O
immunosorbent . . O
assay . . O
( . . O
elisa . . O
) . . O
and . . O
confirmed . . O
by . . O
a . . O
radioimmunoprecipitation . . O
( . . O
rip . . O
) . . O
assay . . O
for . . O
alglucosidase . . O
alfa . . O
- . . O
specific . . O
igg . . O
antibodies . . O
. . . O

5.1 . . O
bradyarrhythmia . . O
and . . O
atrioventricular . . O
blocks . . O

the . . O
data . . O
from . . O
clinical . . O
studies . . O
reflect . . O
exposure . . O
to . . O
datscan . . O
in . . O
942 . . O
subjects . . O
with . . O
a . . O
mean . . O
age . . O
of . . O
66 . . O
years . . O
( . . O
range . . O
25 . . O
to . . O
90 . . O
years . . O
) . . O
. . . O

if . . O
af . . O
is . . O
detected . . O
discontinue . . O
multaq . . O
or . . O
cardiovert . . O
( . . O
5.2 . . O
) . . O
* . . O
ensure . . O
appropriate . . O
antithrombotic . . O
therapy . . O
prior . . O
to . . O
and . . O
throughout . . O
multaq . . O
use . . O
( . . O
5.3 . . O
) . . O
* . . O
liver . . B-AdverseReaction
injury . . I-AdverseReaction
: . . O
if . . O
hepatic . . O
injury . . O
is . . O
suspected . . O
, . . O
discontinue . . O
multaq . . O
( . . O
5.5 . . O
) . . O
* . . O
if . . O
pulmonary . . O
toxicity . . O
is . . O
confirmed . . O
, . . O
discontinue . . O
treatment . . O
( . . O
5.6 . . O
) . . O
* . . O
hypokalemia . . B-AdverseReaction
and . . O
hypomagnesemia . . B-AdverseReaction
: . . O
maintain . . O
potassium . . O
and . . O
magnesium . . O
levels . . O
within . . O
the . . O
normal . . O
range . . O
( . . O
5.7 . . O
) . . O
* . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
: . . O
monitor . . O
renal . . O
function . . O
periodically . . O
( . . O
5.9 . . O
) . . O
* . . O
teratogen . . B-AdverseReaction
: . . O
women . . O
of . . O
childbearing . . O
potential . . O
should . . O
use . . O
effective . . O
contraception . . O
while . . O
using . . O
multaq . . O
( . . O
5.10 . . O
) . . O

two . . O
( . . O
1% . . O
) . . O
of . . O
these . . O
were . . O
fatal . . B-AdverseReaction
. . . O

patients . . O
received . . O
invokana . . O
100 . . O
mg . . O
( . . O
n . . O
= . . O
833 . . O
) . . O
, . . O
invokana . . O
300 . . O
mg . . O
( . . O
n . . O
= . . O
834 . . O
) . . O
or . . O
placebo . . O
( . . O
n . . O
= . . O
646 . . O
) . . O
once . . O
daily . . O
. . . O

( . . O
5.14 . . O
) . . O
5.1 . . O
increased . . O
mortality . . O
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

cardiac . . O
disorders . . O
: . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
. . . O

similar . . O
results . . O
may . . O
be . . O
anticipated . . O
in . . O
patients . . O
treated . . O
with . . O
edarbi . . O
[ . . O
seedrug . . O
interactions . . O
( . . O
7 . . O
) . . O
, . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
, . . O
andclinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
1 . . O
case . . O
of . . O
fatal . . B-AdverseReaction
guillain . . B-AdverseReaction
- . . I-AdverseReaction
barre . . I-AdverseReaction
syndrome . . I-AdverseReaction
and . . O
1 . . O
case . . O
of . . O
severe . . B-Severity
( . . O
grade . . B-Severity
3 . . I-Severity
) . . O
peripheral . . B-AdverseReaction
motor . . I-AdverseReaction
neuropathy . . I-AdverseReaction
were . . O
reported . . O
. . . O

* . . O
b . . O
see . . O
below . . O
for . . O
other . . O
events . . O
of . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
reported . . O
. . . O

local . . B-AdverseReaction
skin . . I-AdverseReaction
reactions . . I-AdverseReaction
can . . B-Factor
occur . . O
including . . O
severe . . B-Severity
reactions . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
vesiculation . . O
/ . . O
pustulation . . O
, . . O
erosion . . O
/ . . O
ulceration . . O
) . . O
. . . O

further . . O
information . . O
is . . O
available . . O
at . . O
www . . O
. . . O
enteregrems . . O
. . . O
com . . O
or . . O
1-800-278-0340 . . O
. . . O

all . . O
patients . . O
continued . . O
androgen . . O
deprivation . . O
therapy . . O
. . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
that . . O
led . . O
to . . O
discontinuation . . O
of . . O
xalkori . . O
were . . O
ild . . B-AdverseReaction
( . . O
1.7% . . O
) . . O
, . . O
alt . . O
and . . O
ast . . B-AdverseReaction
elevation . . I-AdverseReaction
( . . O
1.2% . . O
) . . O
, . . O
dyspnea . . B-AdverseReaction
( . . O
1.2% . . O
) . . O
, . . O
and . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
( . . O
1.2% . . O
) . . O
. . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
are . . O
fatigue . . B-AdverseReaction
, . . O
diarrhea . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
and . . O
colitis . . B-AdverseReaction
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

most . . O
hypersensitivity . . O
reactions . . O
to . . O
gadavist . . O
have . . O
occurred . . O
within . . O
half . . O
an . . O
hour . . O
after . . O
administration . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

avoid . . O
use . . O
of . . O
pradaxa . . O
and . . O
p . . O
- . . O
gp . . O
inhibitors . . O
in . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
( . . O
crcl . . O
15-30 . . O
ml . . O
/ . . O
min . . O
) . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7.1 . . O
) . . O
and . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.6 . . O
) . . O
] . . O
. . . O

inlyta . . O
has . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
who . . O
had . . O
a . . O
venous . . O
thromboembolic . . O
event . . O
within . . O
the . . O
previous . . O
6 . . O
months . . O
. . . O

5.5 . . O
second . . O
primary . . O
malignancies . . O

( . . O
6.1 . . O
) . . O

immune . . O
system . . O
disorders . . O
: . . O
severe . . B-Severity
hypersensitivity . . B-AdverseReaction
reactions . . O
including . . O
dress . . B-AdverseReaction
and . . O
cases . . O
of . . O
hepatic . . B-AdverseReaction
failure . . I-AdverseReaction
have . . O
been . . O
reported . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

the . . O
pooled . . O
analyses . . O
of . . O
placebo . . O
- . . O
controlled . . O
studies . . O
in . . O
children . . O
and . . O
adolescents . . O
with . . O
mdd . . O
, . . O
obsessive . . O
compulsive . . O
disorder . . O
( . . O
ocd . . O
) . . O
, . . O
or . . O
other . . O
psychiatric . . O
disorders . . O
included . . O
a . . O
total . . O
of . . O
24 . . O
short . . O
- . . O
term . . O
studies . . O
of . . O
9 . . O
antidepressant . . O
drugs . . O
in . . O
over . . O
4,400 . . O
patients . . O
. . . O

( . . O
2 . . O
, . . O
5.1 . . O
) . . O
* . . O
infections . . B-AdverseReaction
: . . O
gilenya . . O
may . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
infections . . B-AdverseReaction
. . . O

the . . O
risk . . O
of . . O
the . . O
symptoms . . O
is . . O
probably . . O
greatest . . O
in . . O
children . . O
treated . . O
for . . O
spasticity . . O
but . . O
symptoms . . O
can . . O
also . . O
occur . . O
in . . O
adults . . O
treated . . O
for . . O
spasticity . . O
and . . O
other . . O
conditions . . O
, . . O
and . . O
particularly . . O
in . . O
those . . O
patients . . O
who . . O
have . . O
underlying . . O
conditions . . O
that . . O
would . . O
predispose . . O
them . . O
to . . O
these . . O
symptoms . . O
. . . O

patients . . O
who . . O
seroconvert . . O
may . . O
be . . O
at . . O
a . . O
higher . . O
risk . . O
of . . O
a . . O
hypersensitivity . . O
reaction . . O
. . . O

coartem . . O
tablets . . O
should . . O
be . . O
avoided . . O
in . . O
patients . . O
: . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

image . . O
interpretation . . O
is . . O
performed . . O
independently . . O
of . . O
the . . O
patient's . . O
clinical . . O
information . . O
. . . O

amylase . . O
and . . O
lipase . . O
increase . . O

5.2 . . O
infusion . . O
- . . O
related . . O
reactions . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

whether . . O
the . . O
impairment . . O
is . . O
related . . O
to . . O
somnolence . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
or . . O
other . . O
effects . . O
of . . O
horizant . . O
is . . O
unknown . . O
. . . O

discontinue . . O
granix . . O
if . . O
suspected . . O
( . . O
5.4 . . O
) . . O
* . . O
capillary . . B-AdverseReaction
leak . . I-AdverseReaction
syndrome . . I-AdverseReaction
: . . O
monitor . . O
if . . O
symptoms . . O
develop . . O
and . . O
administer . . O
standard . . O
symptomatic . . O
treatment . . O
( . . O
5.5 . . O
) . . O

5.8 . . O
hypertriglyceridemia . . O

( . . O
6 . . O
) . . O

( . . O
5.1,12.6 . . O
) . . O
* . . O
halofantrine . . O
and . . O
coartem . . O
tablets . . O
should . . O
not . . O
be . . O
administered . . O
within . . O
one . . O
month . . O
of . . O
each . . O
other . . O
due . . O
to . . O
potential . . O
additive . . O
effects . . O
on . . O
the . . O
qt . . O
interval . . O
. . . O

the . . O
safety . . O
of . . O
eliquis . . O
has . . O
been . . O
evaluated . . O
in . . O
1 . . O
phase . . O
ii . . O
and . . O
3 . . O
phase . . O
iii . . O
studies . . O
including . . O
5924 . . O
patients . . O
exposed . . O
to . . O
eliquis . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
undergoing . . O
major . . O
orthopedic . . O
surgery . . O
of . . O
the . . O
lower . . O
limbs . . O
( . . O
elective . . O
hip . . O
replacement . . O
or . . O
elective . . O
knee . . O
replacement . . O
) . . O
treated . . O
for . . O
up . . O
to . . O
38 . . O
days . . O
. . . O

administration . . O
of . . O
cabazitaxel . . O
to . . O
patients . . O
with . . O
mild . . O
and . . O
moderate . . O
hepatic . . O
impairment . . O
should . . O
be . . O
undertaken . . O
with . . O
caution . . O
and . . O
close . . O
monitoring . . O
of . . O
safety . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

6 . . O
adverse . . O
reactions . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
boehringer . . O
ingelheim . . O
pharmaceuticals . . O
, . . O
inc . . O
. . . O
at . . O
( . . O
800 . . O
) . . O
542-6257 . . O
or . . O
( . . O
800 . . O
) . . O
459-9906 . . O
tty . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
orwww . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

fifty . . O
- . . O
eight . . O
percent . . O
( . . O
58% . . O
) . . O
of . . O
the . . O
population . . O
was . . O
male . . O
and . . O
73% . . O
were . . O
caucasian . . O
, . . O
16% . . O
were . . O
asian . . O
, . . O
and . . O
4% . . O
were . . O
black . . O
or . . O
african . . O
american . . O
. . . O

keep . . O
bottle . . O
tightly . . O
closed . . O
when . . O
not . . O
in . . O
use . . O
. . . O

* . . O
nausea . . B-AdverseReaction
* . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
* . . O
rash . . B-AdverseReaction
* . . O
pruritus . . B-AdverseReaction
* . . O
angioedema . . B-AdverseReaction

although . . O
no . . O
high . . O
risk . . O
group . . O
has . . O
been . . O
identified . . O
, . . O
exercise . . O
caution . . O
in . . O
patients . . O
being . . O
treated . . O
with . . O
cimzia . . O
who . . O
have . . O
ongoing . . O
, . . O
or . . O
a . . O
history . . O
of . . O
, . . O
significant . . O
hematologic . . O
abnormalities . . O
. . . O

although . . O
the . . O
prevalence . . O
of . . O
the . . O
syndrome . . O
appears . . O
to . . O
be . . O
highest . . O
among . . O
the . . O
elderly . . O
, . . O
especially . . O
elderly . . O
women . . O
, . . O
it . . O
is . . O
impossible . . O
to . . O
rely . . O
upon . . O
prevalence . . O
estimates . . O
to . . O
predict . . O
, . . O
at . . O
the . . O
inception . . O
of . . O
antipsychotic . . O
treatment . . O
, . . O
which . . O
patients . . O
are . . O
likely . . O
to . . O
develop . . O
the . . O
syndrome . . O
. . . O

because . . O
postmarketing . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

closely . . O
observe . . O
patients . . O
during . . O
and . . O
after . . O
alglucosidase . . O
alfa . . O
administration . . O
and . . O
be . . O
prepared . . O
to . . O
manage . . O
anaphylaxis . . O
and . . O
hypersensitivity . . O
reactions . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
in . . O
patients . . O
with . . O
dupuytren's . . O
contracture . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
elsewhere . . O
in . . O
the . . O
labeling . . O
: . . O

the . . O
anti . . O
- . . O
brentuximab . . O
antibodies . . O
were . . O
directed . . O
against . . O
the . . O
antibody . . O
component . . O
of . . O
brentuximab . . O
vedotin . . O
in . . O
all . . O
patients . . O
with . . O
transiently . . O
or . . O
persistently . . O
positive . . O
antibodies . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
continue . . O
hydration . . O
and . . O
alkalinization . . O
of . . O
the . . O
urine . . O
as . . O
indicated . . O
. . . O

once . . O
asthma . . O
control . . O
is . . O
achieved . . O
and . . O
maintained . . O
, . . O
assess . . O
the . . O
patient . . O
at . . O
regular . . O
intervals . . O
and . . O
step . . O
down . . O
therapy . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
discontinue . . O
breo . . O
ellipta . . O
) . . O
if . . O
possible . . O
without . . O
loss . . O
of . . O
asthma . . O
control . . O
and . . O
maintain . . O
the . . O
patient . . O
on . . O
a . . O
long . . O
- . . O
term . . O
asthma . . O
control . . O
medication . . O
, . . O
such . . O
as . . O
an . . O
inhaled . . O
corticosteroid . . O
. . . O

warnings . . O
and . . O
precautions . . O

in . . O
a . . O
3 . . O
- . . O
week . . O
, . . O
bipolar . . O
mania . . O
pediatric . . O
trial . . O
, . . O
the . . O
incidence . . O
of . . O
adverse . . O
events . . O
related . . O
to . . O
abnormal . . B-AdverseReaction
prolactin . . I-AdverseReaction
levels . . I-AdverseReaction
were . . O
0% . . O
in . . O
the . . O
saphris . . O
2.5 . . O
mg . . O
twice . . O
daily . . O
treatment . . O
group . . O
, . . O
2% . . O
in . . O
the . . O
saphris . . O
5 . . O
mg . . O
twice . . O
daily . . O
treatment . . O
group . . O
, . . O
and . . O
1% . . O
in . . O
the . . O
saphris . . O
10 . . O
mg . . O
twice . . O
daily . . O
treatment . . O
group . . O
versus . . O
to . . O
1% . . O
for . . O
patients . . O
treated . . O
with . . O
placebo . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

in . . O
addition . . O
, . . O
the . . O
observed . . O
incidence . . O
of . . O
antibody . . O
positivity . . O
in . . O
an . . O
assay . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
including . . O
assay . . O
methodology . . O
, . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

5.9 . . O
reversible . . O
posterior . . O
leukoencephalopathy . . O
syndrome . . O

in . . O
replicate . . O
12 . . O
- . . O
month . . O
trials . . O
in . . O
3,255 . . O
subjects . . O
with . . O
copd . . O
who . . O
had . . O
experienced . . O
a . . O
copd . . O
exacerbation . . O
in . . O
the . . O
previous . . O
year . . O
, . . O
there . . O
was . . O
a . . O
higher . . O
incidence . . O
of . . O
pneumonia . . B-AdverseReaction
reported . . O
in . . O
subjects . . O
receiving . . O
fluticasone . . O
furoate . . O
/ . . O
vilanterol . . O
50 . . O
mcg . . O
/ . . O
25 . . O
mcg . . O
: . . O
6% . . O
( . . O
48 . . O
of . . O
820 . . O
subjects . . O
) . . O
; . . O
breo . . O
ellipta . . O
100 . . O
/ . . O
25 . . O
: . . O
6% . . O
( . . O
51 . . O
of . . O
806 . . O
subjects . . O
) . . O
; . . O
or . . O
breo . . O
ellipta . . O
200 . . O
/ . . O
25 . . O
: . . O
7% . . O
( . . O
55 . . O
of . . O
811 . . O
subjects . . O
) . . O
than . . O
in . . O
subjects . . O
receiving . . O
vilanterol . . O
25 . . O
mcg . . O
: . . O
3% . . O
( . . O
27 . . O
of . . O
818 . . O
subjects . . O
) . . O
. . . O

in . . O
study . . O
1 . . O
, . . O
severe . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
or . . O
fatal . . B-AdverseReaction
( . . O
diarrhea . . B-AdverseReaction
of . . O
7 . . B-Severity
or . . I-Severity
more . . I-Severity
stools . . I-Severity
above . . I-Severity
baseline . . I-Severity
, . . O
fever . . B-AdverseReaction
, . . O
ileus . . B-AdverseReaction
, . . O
peritoneal . . B-AdverseReaction
signs . . I-AdverseReaction
; . . O
grade . . B-Severity
3-5 . . I-Severity
) . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
enterocolitis . . I-AdverseReaction
occurred . . O
in . . O
34 . . O
( . . O
7% . . O
) . . O
yervoy . . O
- . . O
treated . . O
patients . . O
, . . O
and . . O
moderate . . B-Severity
( . . O
diarrhea . . B-AdverseReaction
with . . O
up . . B-Severity
to . . I-Severity
6 . . I-Severity
stools . . I-Severity
above . . I-Severity
baseline . . I-Severity
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
mucus . . O
or . . O
blood . . B-AdverseReaction
in . . I-AdverseReaction
stool . . I-AdverseReaction
; . . O
grade . . B-Severity
2 . . I-Severity
) . . O
enterocolitis . . B-AdverseReaction
occurred . . O
in . . O
28 . . O
( . . O
5% . . O
) . . O
yervoy . . O
- . . O
treated . . O
patients . . O
. . . O

adverse . . O
reaction . . O
vimizim . . O
2 . . O
mg . . O
/ . . O
kg . . O
once . . O
per . . O
week . . O
placebo . . O
n . . O
= . . O
58n . . O
( . . O
% . . O
) . . O
n . . O
= . . O
59 . . O
n . . O
( . . O
% . . O
) . . O
pyrexia . . B-AdverseReaction
19 . . O
( . . O
33% . . O
) . . O
8 . . O
( . . O
14% . . O
) . . O
vomiting . . B-AdverseReaction
18 . . O
( . . O
31% . . O
) . . O
4 . . O
( . . O
7% . . O
) . . O
headache . . B-AdverseReaction
15 . . O
( . . O
26% . . O
) . . O
9 . . O
( . . O
15% . . O
) . . O
nausea . . B-AdverseReaction
14 . . O
( . . O
24% . . O
) . . O
4 . . O
( . . O
7% . . O
) . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
12 . . O
( . . O
21% . . O
) . . O
1 . . O
( . . O
1.7% . . O
) . . O
chills . . B-AdverseReaction
6 . . O
( . . O
10.3% . . O
) . . O
1 . . O
( . . O
1.7% . . O
) . . O
fatigue . . B-AdverseReaction
6 . . O
( . . O
10.3% . . O
) . . O
2 . . O
( . . O
3.4% . . O
) . . O
extension . . O
trial . . O

* . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

heart . . O
failure . . O

* . . O
monitor . . O
for . . O
worsening . . O
and . . O
emergence . . O
of . . O
suicidal . . O
thoughts . . O
and . . O
behaviors . . O
( . . O
5.1 . . O
) . . O
. . . O

dose . . O
reductions . . O
due . . O
to . . O
adverse . . O
reactions . . O
were . . O
required . . O
in . . O
6.4% . . O
of . . O
xalkori . . O
- . . O
treated . . O
patients . . O
. . . O

no . . O
new . . O
safety . . O
findings . . O
were . . O
observed . . O
following . . O
the . . O
switch . . O
to . . O
4000 . . O
l . . O
scale . . O
of . . O
alglucosidase . . O
alfa . . O
. . . O

in . . O
a . . O
large . . O
clinical . . O
trial . . O
of . . O
over . . O
7800 . . O
women . . O
with . . O
postmenopausal . . O
osteoporosis . . O
, . . O
epidermal . . O
and . . O
dermal . . B-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
such . . O
as . . O
dermatitis . . B-AdverseReaction
, . . O
eczema . . B-AdverseReaction
, . . O
and . . O
rashes . . B-AdverseReaction
occurred . . O
at . . O
a . . O
significantly . . O
higher . . O
rate . . O
in . . O
the . . O
prolia . . O
group . . O
compared . . O
to . . O
the . . O
placebo . . O
group . . O
. . . O

corporal . . B-AdverseReaction
rupture . . I-AdverseReaction
was . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
after . . O
xiaflex . . O
injections . . O
in . . O
5 . . O
of . . O
1044 . . O
( . . O
0.5% . . O
) . . O
xiaflex . . O
treated . . O
patients . . O
in . . O
the . . O
controlled . . O
and . . O
uncontrolled . . O
clinical . . O
trials . . O
in . . O
peyronie's . . O
disease . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
the . . O
medicines . . O
company . . O
at . . O
1-888-977 . . O
- . . O
mdco . . O
( . . O
6326 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
pfizer . . O
inc . . O
. . . O
at . . O
1-800-438-1985 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

for . . O
infectious . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
the . . O
causative . . O
organism . . O
is . . O
reported . . O
if . . O
specified . . O
by . . O
the . . O
physician . . O
in . . O
the . . O
clinical . . O
trials . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
neutropenia . . B-AdverseReaction
- . . O
the . . O
addition . . O
of . . O
victrelis . . O
to . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
may . . B-Factor
result . . O
in . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
neutropenia . . I-AdverseReaction
associated . . O
with . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
therapy . . O
alone . . O
. . . O

the . . O
most . . O
common . . O
serious . . O
adverse . . O
reactions . . O
were . . O
pneumonia . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
pyrexia . . B-AdverseReaction
( . . O
4% . . O
) . . O
, . . O
vomiting . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
hepatotoxicity . . B-AdverseReaction
( . . O
2% . . O
) . . O
and . . O
peripheral . . B-AdverseReaction
sensory . . I-AdverseReaction
neuropathy . . I-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

adverse . . O
event . . O
data . . O
collected . . O
from . . O
those . . O
trials . . O
showed . . O
the . . O
following . . O
rates . . O
of . . O
eps . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
as . . O
shown . . O
in . . O
table . . O
8 . . O
. . . O

serious . . B-Severity
febrile . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
fever . . B-AdverseReaction
of . . O
any . . O
severity . . O
complicated . . O
by . . O
hypotension . . B-AdverseReaction
, . . O
rigors . . B-AdverseReaction
or . . O
chills . . B-AdverseReaction
occurred . . O
in . . O
3.7% . . O
( . . O
7 . . O
/ . . O
187 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
and . . O
in . . O
none . . O
of . . O
the . . O
59 . . O
patients . . O
treated . . O
with . . O
dacarbazine . . O
. . . O

adverse . . O
reactions . . O
were . . O
predominantly . . O
of . . O
mild . . O
to . . O
moderate . . O
severity . . O
. . . O

as . . O
with . . O
all . . O
antidepressants . . O
, . . O
pristiq . . O
should . . O
be . . O
used . . O
cautiously . . O
in . . O
patients . . O
with . . O
a . . O
history . . O
or . . O
family . . O
history . . O
of . . O
mania . . O
or . . O
hypomania . . O
. . . O

* . . O
use . . O
in . . O
patients . . O
with . . O
hepatic . . O
impairment . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
. . . O

monitor . . O
fasting . . O
glucose . . O
prior . . O
to . . O
treatment . . O
and . . O
periodically . . O
thereafter . . O
as . . O
clinically . . O
indicated . . O
. . . O

adverse . . O
reactions . . O
led . . O
to . . O
study . . O
treatment . . O
discontinuation . . O
in . . O
16% . . O
of . . O
patients . . O
receiving . . O
cometriq . . O
and . . O
in . . O
8% . . O
of . . O
patients . . O
receiving . . O
placebo . . O
. . . O

in . . O
both . . O
study . . O
1 . . O
and . . O
study . . O
2 . . O
zytiga . . O
was . . O
administered . . O
at . . O
a . . O
dose . . O
of . . O
1,000 . . O
mg . . O
daily . . O
in . . O
combination . . O
with . . O
prednisone . . O
5 . . O
mg . . O
twice . . O
daily . . O
in . . O
the . . O
active . . O
treatment . . O
arms . . O
. . . O

peripheral . . O
neuropathy . . O
: . . O
in . . O
study . . O
1 . . O
, . . O
17 . . O
% . . O
of . . O
enrolled . . O
patients . . O
had . . O
grade . . B-Severity
1 . . I-Severity
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
and . . O
3% . . O
of . . O
patients . . O
had . . O
grade . . B-Severity
2 . . I-Severity
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
at . . O
baseline . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
toviaz . . O
, . . O
like . . O
other . . O
antimuscarinic . . O
drugs . . O
, . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
decreased . . O
gastrointestinal . . O
motility . . O
, . . O
such . . O
as . . O
those . . O
with . . O
severe . . O
constipation . . O
. . . O

the . . O
incidence . . O
of . . O
these . . O
adverse . . O
reactions . . O
was . . O
greater . . O
in . . O
the . . O
patients . . O
receiving . . O
1,200 . . O
mg . . O
per . . O
day . . O
. . . O

only . . O
physicians . . O
experienced . . O
in . . O
management . . O
of . . O
systemic . . O
immunosuppressant . . O
therapy . . O
in . . O
transplantation . . O
should . . O
prescribe . . O
nulojix . . O
. . . O

keratitis . . B-AdverseReaction
, . . O
characterized . . O
as . . O
acute . . O
or . . O
worsening . . B-AdverseReaction
eye . . I-AdverseReaction
inflammation . . I-AdverseReaction
, . . O
lacrimation . . B-AdverseReaction
, . . O
light . . B-AdverseReaction
sensitivity . . I-AdverseReaction
, . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
, . . O
eye . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
/ . . O
or . . O
red . . B-AdverseReaction
eye . . I-AdverseReaction
occurred . . O
in . . O
0.8% . . O
of . . O
patients . . O
treated . . O
with . . O
gilotrif . . O
among . . O
3865 . . O
patients . . O
across . . O
clinical . . O
trials . . O
. . . O

a . . O
biosensor . . O
binding . . O
assay . . O
or . . O
a . . O
bridging . . O
immunoassay . . O
was . . O
used . . O
to . . O
detect . . O
antibodies . . O
directed . . O
against . . O
canakinumab . . O
in . . O
patients . . O
who . . O
received . . O
ilaris . . O
. . . O

vascular . . O
disorders . . O
: . . O
flushing . . B-AdverseReaction
, . . O
phlebitis . . B-AdverseReaction
, . . O
wound . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
spontaneous . . B-AdverseReaction
hematoma . . I-AdverseReaction

6 . . O
adverse . . O
reactions . . O

warning . . O
: . . O
supine . . B-AdverseReaction
hypertension . . I-AdverseReaction

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O

gastrointestinal . . O
disorders . . O
: . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
flatulence . . B-AdverseReaction
, . . O
upper . . B-AdverseReaction
abdominal . . I-AdverseReaction
pain . . I-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
eli . . O
lilly . . O
and . . O
company . . O
at . . O
1-800 . . O
- . . O
lillyrx . . O
( . . O
1-800-545-5979 . . O
) . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

adverse . . O
reactions . . O
in . . O
patients . . O
with . . O
peripheral . . O
t . . O
- . . O
cell . . O
lymphoma . . O

table . . O
2 . . O
. . . O

careful . . O
medical . . O
history . . O
is . . O
necessary . . O
because . . O
cdad . . O
has . . O
been . . O
reported . . O
to . . O
occur . . O
more . . O
than . . O
2 . . O
months . . O
after . . O
the . . O
administration . . O
of . . O
antibacterial . . O
agents . . O
. . . O

hypokalemia . . B-AdverseReaction
or . . O
hypomagnesemia . . B-AdverseReaction
may . . B-Factor
occur . . O
with . . O
concomitant . . O
administration . . O
of . . O
potassium . . O
- . . O
depleting . . O
diuretics . . O
. . . O

to . . O
report . . O
suspected . . O
adverse . . O
reactions . . O
, . . O
contact . . O
astellas . . O
pharma . . O
us . . O
, . . O
inc . . O
. . . O
at . . O
1-800-727-7003 . . O
or . . O
fda . . O
at . . O
1-800 . . O
- . . O
fda . . O
- . . O
1088 . . O
or . . O
www . . O
. . . O
fda . . O
. . . O
gov . . O
/ . . O
medwatch . . O
. . . O

after . . O
the . . O
cleansing . . O
gel . . O
has . . O
been . . O
wiped . . O
off . . O
, . . O
wash . . O
the . . O
area . . O
with . . O
soap . . O
and . . O
water . . O
. . . O

( . . O
2.4 . . O
, . . O
5.1 . . O
, . . O
14.1 . . O
) . . O

s . . O
includes . . O
patients . . O
treated . . O
with . . O
flexible . . O
dose . . O
of . . O
saphris . . O
5 . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
( . . O
n . . O
= . . O
90 . . O
) . . O
. . . O

patients . . O
may . . O
present . . O
with . . O
fatigue . . O
, . . O
headache . . O
, . . O
mental . . O
status . . O
changes . . O
, . . O
abdominal . . O
pain . . O
, . . O
unusual . . O
bowel . . O
habits . . O
, . . O
and . . O
hypotension . . O
, . . O
or . . O
nonspecific . . O
symptoms . . O
which . . O
may . . O
resemble . . O
other . . O
causes . . O
such . . O
as . . O
brain . . O
metastasis . . O
or . . O
underlying . . O
disease . . O
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

5.2 . . O
myelosuppression . . O

5.3 . . O
hepatic . . O
toxicity . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylaxis . . B-AdverseReaction
and . . O
allergic . . B-AdverseReaction
contact . . I-AdverseReaction
dermatitis . . I-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
post . . O
- . . O
marketing . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

changes . . O
from . . O
baseline . . O
in . . O
total . . O
cholesterol . . O
, . . O
hdl . . O
- . . O
cholesterol . . O
, . . O
ldl . . O
- . . O
cholesterol . . O
, . . O
and . . O
triglycerides . . O
are . . O
presented . . O
in . . O
table . . O
5 . . O
. . . O

excerpt . . O
: . . O
* . . O
hepatotoxicity . . B-AdverseReaction
: . . O
monitor . . O
liver . . O
function . . O
before . . O
and . . O
during . . O
therapy . . O
. . . O

beta . . O
- . . O
blocker . . O
use . . O
for . . O
this . . O
purpose . . O
is . . O
not . . O
recommended . . O
. . . O

the . . O
potential . . O
role . . O
of . . O
tnf . . O
blocker . . O
therapy . . O
in . . O
the . . O
development . . O
of . . O
malignancies . . O
in . . O
adults . . O
is . . O
not . . O
known . . O
. . . O

in . . O
the . . O
monotherapy . . O
study . . O
, . . O
the . . O
incidence . . O
of . . O
hypoglycemia . . B-AdverseReaction
was . . O
1.5% . . O
in . . O
patients . . O
treated . . O
with . . O
nesina . . O
compared . . O
to . . O
1.6% . . O
with . . O
placebo . . O
. . . O

* . . O
second . . B-AdverseReaction
primary . . I-AdverseReaction
malignancies . . I-AdverseReaction
: . . O
other . . O
malignancies . . B-AdverseReaction
have . . O
occurred . . O
in . . O
patients . . O
, . . O
including . . O
skin . . B-AdverseReaction
cancers . . I-AdverseReaction
, . . O
and . . O
other . . O
carcinomas . . B-AdverseReaction
( . . O
5.5 . . O
) . . O
. . . O

most . . O
common . . O
adverse . . O
reactions . . O

the . . O
risks . . O
and . . O
benefits . . O
of . . O
re . . O
- . . O
administering . . O
alglucosidase . . O
alfa . . O
following . . O
an . . O
immune . . O
- . . O
mediated . . O
reaction . . O
should . . O
be . . O
considered . . O
. . . O

* . . O
hepatotoxicity . . B-AdverseReaction
: . . O
monitor . . O
liver . . O
enzymes . . O
and . . O
bilirubin . . O
( . . O
5.8 . . O
) . . O
. . . O

the . . O
following . . O
serious . . O
adverse . . O
reactions . . O
are . . O
described . . O
in . . O
more . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
prescribing . . O
information . . O
. . . O

in . . O
saphris . . O
adult . . O
clinical . . O
trials . . O
, . . O
the . . O
incidences . . O
of . . O
adverse . . O
events . . O
related . . O
to . . O
abnormal . . B-AdverseReaction
prolactin . . I-AdverseReaction
levels . . I-AdverseReaction
were . . O
0.4% . . O
versus . . O
0% . . O
for . . O
placebo . . O
. . . O

table . . O
3 . . O
: . . O
sexual . . B-AdverseReaction
function . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
( . . O
> . . O
= . . O
2% . . O
in . . O
men . . O
or . . O
women . . O
in . . O
any . . O
pristiq . . O
group . . O
) . . O
during . . O
the . . O
on . . O
- . . O
therapy . . O
period . . O
pristiq . . O
placebo . . O
( . . O
n . . O
= . . O
239 . . O
) . . O
50 . . O
mg . . O
( . . O
n . . O
= . . O
108 . . O
) . . O
100 . . O
mg . . O
( . . O
n . . O
= . . O
157 . . O
) . . O
200 . . O
mg . . O
( . . O
n . . O
= . . O
131 . . O
) . . O
400 . . O
mg . . O
( . . O
n . . O
= . . O
154 . . O
) . . O
men . . O
only . . O
anorgasmia . . B-AdverseReaction
0 . . O
0 . . O
3 . . O
5 . . O
8 . . O
libido . . B-AdverseReaction
decreased . . I-AdverseReaction
1 . . O
4 . . O
5 . . O
6 . . O
3 . . O
orgasm . . B-AdverseReaction
abnormal . . I-AdverseReaction
0 . . O
0 . . O
1 . . O
2 . . O
3 . . O
ejaculation . . B-AdverseReaction
delayed . . I-AdverseReaction
< . . O
1 . . O
1 . . O
5 . . O
7 . . O
6 . . O
erectile . . B-AdverseReaction
dysfunction . . I-AdverseReaction
1 . . O
3 . . O
6 . . O
8 . . O
11 . . O
ejaculation . . B-AdverseReaction
disorder . . I-AdverseReaction
0 . . O
0 . . O
1 . . O
2 . . O
5 . . O
ejaculation . . B-AdverseReaction
failure . . I-AdverseReaction
0 . . O
1 . . O
0 . . O
2 . . O
2 . . O
sexual . . B-AdverseReaction
dysfunction . . I-AdverseReaction
0 . . O
1 . . O
0 . . O
0 . . O
2 . . O
pristiq . . O
placebo . . O
( . . O
n . . O
= . . O
397 . . O
) . . O
50 . . O
mg . . O
( . . O
n . . O
= . . O
209 . . O
) . . O
100 . . O
mg . . O
( . . O
n . . O
= . . O
267 . . O
) . . O
200 . . O
mg . . O
( . . O
n . . O
= . . O
176 . . O
) . . O
400 . . O
mg . . O
( . . O
n . . O
= . . O
163 . . O
) . . O
women . . O
only . . O
anorgasmia . . B-AdverseReaction
0 . . O
1 . . O
1 . . O
0 . . O
3 . . O
other . . O
adverse . . O
reactions . . O
observed . . O
in . . O
premarketing . . O
and . . O
postmarketing . . O
clinical . . O
studies . . O

the . . O
following . . O
additional . . O
adverse . . O
reactions . . O
have . . O
been . . O
reported . . O
during . . O
the . . O
postmarketing . . O
use . . O
of . . O
eovist . . O
. . . O

the . . O
time . . O
to . . O
onset . . O
of . . O
symptoms . . O
varied . . O
from . . O
one . . O
day . . O
to . . O
several . . O
months . . O
after . . O
starting . . O
prolia . . O
. . . O

cytopenias . . O
: . . O
grade . . B-Severity
3 . . I-Severity
neutropenia . . B-AdverseReaction
occurred . . O
in . . O
28% . . O
( . . O
143 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
who . . O
received . . O
halaven . . O
in . . O
study . . O
1 . . O
, . . O
and . . O
29% . . O
( . . O
144 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
experienced . . O
grade . . B-Severity
4 . . I-Severity
neutropenia . . B-AdverseReaction
. . . O

the . . O
rate . . O
of . . O
treatment . . O
discontinuation . . O
due . . O
to . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
was . . O
0.1% . . O
, . . O
0.2% . . O
, . . O
and . . O
0.1% . . O
for . . O
placebo . . O
, . . O
jardiance . . O
10 . . O
mg . . O
, . . O
and . . O
jardiance . . O
25 . . O
mg . . O
, . . O
respectively . . O
. . . O

for . . O
those . . O
patients . . O
who . . O
require . . O
the . . O
use . . O
of . . O
opioids . . O
to . . O
treat . . O
pain . . O
during . . O
or . . O
following . . O
the . . O
procedure . . O
, . . O
their . . O
ability . . O
to . . O
perform . . O
potentially . . O
hazardous . . O
activities . . O
such . . O
as . . O
driving . . O
or . . O
operating . . O
machinery . . O
may . . O
be . . O
affected . . O
. . . O

6.2 . . O
postmarketing . . O
experience . . O

the . . O
range . . O
of . . O
time . . O
to . . O
diagnosis . . O
of . . O
cuscc . . B-AdverseReaction
was . . O
136 . . O
to197 . . O
days . . O
in . . O
the . . O
combination . . O
arm . . O
and . . O
was . . O
9 . . O
to . . O
197 . . O
days . . O
in . . O
the . . O
arm . . O
receiving . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
. . . O

the . . O
duration . . O
of . . O
eliquis . . O
exposure . . O
was . . O
> . . O
= . . O
12 . . O
months . . O
for . . O
9375 . . O
patients . . O
and . . O
> . . O
= . . O
24 . . O
months . . O
for . . O
3369 . . O
patients . . O
in . . O
the . . O
two . . O
studies . . O
. . . O

fatal . . B-AdverseReaction
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
was . . O
reported . . O
in . . O
1 . . O
/ . . O
359 . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
none . . O
of . . O
the . . O
patients . . O
receiving . . O
sorafenib . . O
. . . O

6 . . O
. . . O

6.1 . . O
controlled . . O
clinical . . O
trials . . O
experience . . O

documented . . O
symptomatic . . B-AdverseReaction
hypoglycemia . . I-AdverseReaction
occurred . . O
in . . O
39% . . O
and . . O
40% . . O
of . . O
patients . . O
when . . O
trulicity . . O
0.75 . . O
mg . . O
and . . O
1.5 . . O
mg . . O
, . . O
respectively . . O
, . . O
was . . O
co . . O
- . . O
administered . . O
with . . O
a . . O
sulfonylurea . . O
. . . O

2 . . O
postmarketing . . O
experience . . O
the . . O
following . . O
adverse . . O
drug . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
of . . O
halaven . . O
. . . O

intracranial . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
included . . O
intracerebral . . O
( . . O
hemorrhagic . . B-AdverseReaction
stroke . . I-AdverseReaction
) . . O
, . . O
subarachnoid . . O
, . . O
and . . O
subdural . . B-AdverseReaction
bleeds . . I-AdverseReaction
. . . O

saphris . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
with . . O
flexible . . O
dosing . . O
. . . O

onfi . . O
causes . . O
somnolence . . B-AdverseReaction
and . . O
sedation . . B-AdverseReaction
. . . O

some . . O
infections . . B-AdverseReaction
were . . O
fatal . . B-AdverseReaction
. . . O

the . . O
safety . . O
and . . O
efficacy . . O
of . . O
cimzia . . O
in . . O
patients . . O
with . . O
immunosuppression . . O
has . . O
not . . O
been . . O
formally . . O
evaluated . . O
. . . O

discontinuation . . O
of . . O
therapy . . O
due . . O
to . . O
adverse . . O
reactions . . O
occurred . . O
in . . O
10% . . O
of . . O
patients . . O
treated . . O
with . . O
zykadia . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
also . . O
may . . O
not . . O
reflect . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

excerpt . . O
: . . O
* . . O
the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
in . . O
clinical . . O
trials . . O
were . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
and . . O
included . . O
: . . O
anaphylaxis . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
/ . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
oxygen . . I-AdverseReaction
saturation . . I-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
tachypnea . . B-AdverseReaction
, . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
twitching . . I-AdverseReaction
, . . O
agitation . . B-AdverseReaction
, . . O
cyanosis . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
/ . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
, . . O
pallor . . B-AdverseReaction
, . . O
rigors . . B-AdverseReaction
, . . O
tremor . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
myalgia . . B-AdverseReaction
( . . O
6.1 . . O
) . . O
. . . O

recent . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
within . . O
last . . O
6 . . O
months . . O
) . . O
transaminase . . O
and . . O
bilirubin . . O
levels . . O
should . . O
be . . O
available . . O
before . . O
initiation . . O
of . . O
gilenya . . O
therapy . . O
. . . O

clinically . . O
important . . O
chemistry . . O
laboratory . . O
values . . O
that . . O
were . . O
new . . O
or . . O
worsened . . O
from . . O
baseline . . O
and . . O
occurred . . O
in . . O
> . . O
1% . . O
of . . O
patients . . O
at . . O
grade . . O
3 . . O
or . . O
4 . . O
, . . O
in . . O
nhl . . O
patients . . O
treated . . O
in . . O
both . . O
single . . O
arm . . O
studies . . O
combined . . O
were . . O
hyperglycemia . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
elevated . . B-AdverseReaction
creatinine . . I-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
hyponatremia . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
and . . O
hypocalcemia . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

monitor . . O
patients . . O
with . . O
skin . . O
reactions . . O
closely . . O
. . . O

5.1 . . O
hepatic . . O
decompensation . . O
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O

vascular . . O
events . . O

patients . . O
received . . O
invokana . . O
100 . . O
mg . . O
( . . O
n . . O
= . . O
3092 . . O
) . . O
, . . O
invokana . . O
300 . . O
mg . . O
( . . O
n . . O
= . . O
3085 . . O
) . . O
or . . O
comparator . . O
( . . O
n . . O
= . . O
3262 . . O
) . . O
once . . O
daily . . O
. . . O

among . . O
these . . O
patients . . O
, . . O
2 . . O
patients . . O
discontinued . . O
invokana . . O
. . . O

for . . O
patients . . O
with . . O
sega . . O
and . . O
mild . . O
or . . O
moderate . . O
hepatic . . O
impairment . . O
, . . O
adjust . . O
the . . O
dose . . O
of . . O
afinitor . . O
tablets . . O
or . . O
afinitor . . O
disperz . . O
based . . O
on . . O
therapeutic . . O
drug . . O
monitoring . . O
. . . O

6 . . O
adverse . . O
reactions . . O

if . . O
pml . . O
is . . O
confirmed . . O
, . . O
consider . . O
discontinuation . . O
of . . O
immunosuppressant . . O
therapy . . O
, . . O
including . . O
benlysta . . O
. . . O

6 . . O
adverse . . O
reactions . . O

pooled . . O
analyses . . O
of . . O
short . . O
- . . O
term . . O
placebo . . O
- . . O
controlled . . O
studies . . O
of . . O
antidepressant . . B-DrugClass
drugs . . I-DrugClass
( . . O
ssris . . O
and . . O
others . . O
) . . O
showed . . O
that . . O
these . . O
drugs . . O
increase . . O
the . . O
risk . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
and . . O
behavior . . O
( . . O
suicidality . . B-AdverseReaction
) . . O
in . . O
children . . O
, . . O
adolescents . . O
, . . O
and . . O
young . . O
adults . . O
( . . O
ages . . O
18 . . O
to . . O
24 . . O
) . . O
with . . O
major . . O
depressive . . O
disorder . . O
( . . O
mdd . . O
) . . O
and . . O
other . . O
psychiatric . . O
disorders . . O
. . . O

5.6 . . O
corneal . . O
exposure . . O
, . . O
corneal . . O
ulceration . . O
, . . O
and . . O
ectropion . . O
in . . O
patients . . O
treated . . O
with . . O
xeomin . . O
for . . O
blepharospasm . . O

5 . . O
warnings . . O
and . . O
precautions . . O

serious . . B-Severity
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
sjs . . B-AdverseReaction
) . . O
and . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
( . . O
ten . . B-AdverseReaction
) . . O
, . . O
have . . O
been . . O
reported . . O
with . . O
onfi . . O
in . . O
both . . O
children . . O
and . . O
adults . . O
during . . O
the . . O
post . . O
- . . O
marketing . . O
period . . O
. . . O

jardiance . . O
increases . . B-AdverseReaction
serum . . I-AdverseReaction
creatinine . . I-AdverseReaction
and . . O
decreases . . B-AdverseReaction
egfr . . I-AdverseReaction
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

drugs . . B-DrugClass
with . . I-DrugClass
alpha . . I-DrugClass
- . . I-DrugClass
adrenergic . . I-DrugClass
blocking . . I-DrugClass
effects . . I-DrugClass
have . . O
been . . O
reported . . O
to . . O
induce . . O
priapism . . B-AdverseReaction
. . . O

cutaneous . . O
malignancies . . O
: . . O

during . . O
withdrawal . . O
from . . O
oral . . O
corticosteroids . . O
, . . O
some . . O
patients . . O
may . . O
experience . . O
symptoms . . O
of . . O
systemically . . O
active . . O
corticosteroid . . O
withdrawal . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
joint . . O
and . . O
/ . . O
or . . O
muscular . . O
pain . . O
, . . O
lassitude . . O
, . . O
depression . . O
) . . O
despite . . O
maintenance . . O
or . . O
even . . O
improvement . . O
of . . O
respiratory . . O
function . . O
. . . O

in . . O
both . . O
groups . . O
, . . O
patients . . O
with . . O
events . . O
were . . O
generally . . O
male . . O
, . . O
older . . O
, . . O
and . . O
had . . O
underlying . . O
renal . . O
impairment . . O
or . . O
cardiac . . O
disease . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
history . . O
of . . O
arrhythmia . . O
, . . O
palpitations . . O
, . . O
congestive . . O
heart . . O
failure . . O
, . . O
cardiomyopathy . . O
, . . O
etc . . O
. . . O
) . . O
. . . O

initiate . . O
systemic . . O
corticosteroids . . O
at . . O
a . . O
dose . . O
of . . O
1 . . O
to . . O
2 . . O
mg . . O
/ . . O
kg . . O
/ . . O
day . . O
of . . O
prednisone . . O
or . . O
equivalent . . O
, . . O
and . . O
initiate . . O
appropriate . . O
hormone . . O
replacement . . O
therapy . . O
. . . O

embryo . . B-AdverseReaction
- . . I-AdverseReaction
fetal . . I-AdverseReaction
toxicity . . I-AdverseReaction
and . . O
teratogenicity . . B-AdverseReaction
occurred . . O
in . . O
rats . . B-Animal
that . . O
received . . O
eribulin . . O
mesylate . . O
at . . O
approximately . . O
half . . O
of . . O
the . . O
recommended . . O
human . . O
dose . . O
based . . O
on . . O
body . . O
surface . . O
area . . O
. . . O

grade . . B-Severity
3 . . I-Severity
or . . O
greater . . O
thrombocytopenia . . B-AdverseReaction
occurred . . O
in . . O
1% . . O
( . . O
7 . . O
/ . . O
503 . . O
) . . O
of . . O
patients . . O
. . . O

anti . . O
- . . O
drug . . O
antibody . . O
titers . . O
were . . O
sustained . . O
or . . O
increased . . O
for . . O
the . . O
duration . . O
of . . O
vimizim . . O
treatment . . O
. . . O

in . . O
patients . . O
receiving . . O
blincyto . . O
in . . O
clinical . . O
trials . . O
, . . O
neurological . . B-AdverseReaction
toxicities . . I-AdverseReaction
have . . O
occurred . . O
in . . O
approximately . . O
50% . . O
of . . O
patients . . O
. . . O

aspiration . . B-AdverseReaction
may . . B-Factor
result . . O
from . . O
severe . . B-Severity
dysphagia . . B-AdverseReaction
and . . O
is . . O
a . . O
particular . . O
risk . . O
when . . O
treating . . O
patients . . O
in . . O
whom . . O
swallowing . . O
or . . O
respiratory . . O
function . . O
is . . O
already . . O
compromised . . O
. . . O

the . . O
median . . O
age . . O
of . . O
patients . . O
was . . O
9.5 . . O
years . . O
( . . O
range . . O
0.8 . . O
to . . O
26 . . O
years . . O
) . . O
, . . O
93% . . O
were . . O
caucasian . . O
, . . O
and . . O
57% . . O
were . . O
male . . O
. . . O

anaphylaxis . . B-AdverseReaction
was . . O
reported . . O
in . . O
a . . O
post . . O
- . . O
marketing . . O
clinical . . O
trial . . O
( . . O
study . . O
3 . . O
) . . O
in . . O
one . . O
patient . . O
who . . O
had . . O
previous . . O
exposure . . O
to . . O
xiaflex . . O
for . . O
the . . O
treatment . . O
of . . O
dupuytren's . . O
contracture . . O
. . . O

[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

immune . . O
system . . O
disorders . . O

patients . . O
with . . O
rapidly . . O
proliferating . . O
tumor . . O
and . . O
high . . O
tumor . . O
burden . . O
may . . B-Factor
be . . O
at . . O
increased . . O
risk . . O
of . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
patients . . O
in . . O
clinical . . O
trials . . O
with . . O
bosulif . . O
( . . O
less . . O
than . . O
10% . . O
of . . O
bosulif . . O
- . . O
treated . . O
patients . . O
) . . O
. . . O

the . . O
most . . O
serious . . O
adverse . . O
reaction . . O
reported . . O
in . . O
clinical . . O
trials . . O
with . . O
ferriprox . . O
was . . O
agranulocytosis . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

grade . . B-Severity
3-4 . . I-Severity
adverse . . O
reactions . . O
and . . O
laboratory . . O
abnormalities . . O
which . . O
occurred . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
cometriq . . O
- . . O
treated . . O
patients . . O
occurring . . O
more . . O
frequently . . O
in . . O
the . . O
cometriq . . O
arm . . O
with . . O
a . . O
between . . O
- . . O
arm . . O
difference . . O
of . . O
> . . O
= . . O
2% . . O
included . . O
, . . O
in . . O
order . . O
of . . O
decreasing . . O
frequency . . O
; . . O
diarrhea . . B-AdverseReaction
, . . O
ppes . . B-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
hypocalcemia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
asthenia . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
alt . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
weight . . I-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
and . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
( . . O
see . . O
table . . O
1 . . O
, . . O
table . . O
2 . . O
) . . O
. . . O

increases . . B-AdverseReaction
in . . I-AdverseReaction
weight . . I-AdverseReaction
have . . O
been . . O
observed . . O
in . . O
pre . . O
- . . O
marketing . . O
clinical . . O
trials . . O
with . . O
saphris . . O
. . . O

coartem . . O
tablets . . O
may . . O
reduce . . O
the . . O
effectiveness . . O
of . . O
hormonal . . O
contraceptives . . O
. . . O

prophylactic . . O
therapy . . O
( . . O
i . . O
. . . O
e . . O
. . . O
, . . O
non . . O
- . . O
steroidal . . O
anti . . O
- . . O
inflammatory . . O
drug . . O
[ . . O
nsaid . . O
] . . O
or . . O
colchicine . . O
upon . . O
initiation . . O
of . . O
treatment . . O
) . . O
may . . O
be . . O
beneficial . . O
for . . O
up . . O
to . . O
six . . O
months . . O
. . . O

cases . . O
of . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
tls . . B-AdverseReaction
) . . O
, . . O
including . . O
fatal . . B-AdverseReaction
outcomes . . O
, . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
who . . O
received . . O
kyprolis . . O
. . . O

the . . O
most . . O
frequently . . O
reported . . O
adverse . . O
drug . . O
reactions . . O
( . . O
> . . O
= . . O
25% . . O
) . . O
in . . O
the . . O
xiaflex . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
dupuytren's . . O
contracture . . O
included . . O
edema . . B-AdverseReaction
peripheral . . I-AdverseReaction
( . . O
mostly . . O
swelling . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
injected . . I-AdverseReaction
hand . . I-AdverseReaction
) . . O
, . . O
contusion . . B-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reaction . . I-AdverseReaction
, . . O
and . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
the . . I-AdverseReaction
treated . . I-AdverseReaction
extremity . . I-AdverseReaction
. . . O

adverse . . O
reactions . . O
for . . O
firazyr . . O
were . . O
similar . . O
in . . O
nature . . O
and . . O
frequency . . O
to . . O
those . . O
reported . . O
in . . O
table . . O
1 . . O
. . . O

in . . O
limited . . O
comparative . . O
studies . . O
, . . O
the . . O
adverse . . O
reaction . . O
profile . . O
of . . O
coartem . . O
tablets . . O
appeared . . O
similar . . O
to . . O
that . . O
of . . O
another . . O
antimalarial . . O
regimen . . O
. . . O

( . . O
5.3 . . O
) . . O
* . . O
tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
: . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
and . . O
death . . B-AdverseReaction
; . . O
anticipate . . O
and . . O
use . . O
supportive . . O
measures . . O
. . . O

since . . O
tnf . . O
mediates . . O
inflammation . . O
and . . O
modulates . . O
cellular . . O
immune . . O
responses . . O
, . . O
the . . O
possibility . . O
exists . . O
for . . O
tnf . . O
blockers . . O
, . . O
including . . O
cimzia . . O
, . . O
to . . O
affect . . O
host . . O
defenses . . O
against . . O
infections . . O
and . . O
malignancies . . O
. . . O

immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
cutaneous . . I-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
alglucosidase . . O
alfa . . O
including . . O
necrotizing . . B-AdverseReaction
skin . . I-AdverseReaction
lesions . . I-AdverseReaction
[ . . O
seeadverse . . O
reactions . . O
( . . O
6.3 . . O
) . . O
] . . O
. . . O

( . . O
5.16 . . O
) . . O

* . . O
qt . . B-AdverseReaction
interval . . I-AdverseReaction
prolongation . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
. . . O

some . . O
patients . . O
with . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
also . . O
reported . . O
a . . O
history . . O
of . . O
allergy . . O
to . . O
other . . O
macrolides . . O
. . . O

interrupt . . O
and . . O
then . . O
reduce . . O
or . . O
discontinue . . O
zydelig . . O
. . . O

if . . O
a . . O
hypersensitivity . . O
reaction . . O
occurs . . O
, . . O
discontinue . . O
teflaro . . O
. . . O

none . . O
of . . O
the . . O
subjects . . O
tested . . O
positive . . O
. . . O

5.11 . . O
hepatic . . O
toxicity . . O
and . . O
hepatic . . O
failure . . O

consider . . O
these . . O
risks . . O
when . . O
scheduling . . O
patients . . O
for . . O
spinal . . O
procedures . . O
. . . O

cases . . O
with . . O
serum . . B-AdverseReaction
sodium . . I-AdverseReaction
lower . . I-AdverseReaction
than . . I-AdverseReaction
110 . . I-AdverseReaction
mmol . . I-AdverseReaction
/ . . I-AdverseReaction
l . . I-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

serious . . B-Severity
allergic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
anaphylactic . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
may . . B-Factor
occur . . O
. . . O

withhold . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
discontinue . . O
bosulif . . O
as . . O
necessary . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

because . . O
of . . O
its . . O
mechanism . . O
of . . O
action . . O
, . . O
benlysta . . O
may . . O
interfere . . O
with . . O
the . . O
response . . O
to . . O
immunizations . . O
. . . O

renal . . O
and . . O
urinary . . O
disorders . . O
: . . O
frequent . . O
- . . O
urinary . . B-AdverseReaction
incontinence . . I-AdverseReaction
; . . O
infrequent . . O
- . . O
dysuria . . B-AdverseReaction
, . . O
pollakiuria . . B-AdverseReaction
, . . O
enuresis . . B-AdverseReaction
, . . O
nephrolithiasis . . B-AdverseReaction
; . . O
rare . . O
- . . O
urinary . . B-AdverseReaction
retention . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
acute . . I-AdverseReaction

physicians . . O
should . . O
consider . . O
ptld . . O
in . . O
patients . . O
reporting . . O
new . . O
or . . O
worsening . . O
neurological . . O
, . . O
cognitive . . O
, . . O
or . . O
behavioral . . O
signs . . O
or . . O
symptoms . . O
. . . O

* . . O
if . . O
you . . O
take . . O
too . . O
much . . O
duavee . . O
, . . O
call . . O
your . . O
healthcare . . O
provider . . O
. . . O

table . . O
3 . . O
shows . . O
the . . O
number . . O
of . . O
patients . . O
experiencing . . O
bleeding . . B-AdverseReaction
events . . O
in . . O
the . . O
pooled . . O
analysis . . O
of . . O
re . . O
- . . O
cover . . O
and . . O
re . . O
- . . O
cover . . O
ii . . O
studies . . O
during . . O
the . . O
full . . O
treatment . . O
including . . O
parenteral . . O
and . . O
oral . . O
only . . O
treatment . . O
periods . . O
after . . O
randomization . . O
. . . O

excerpt . . O
: . . O
warning . . O
: . . O
risk . . B-Factor
for . . O
hepatic . . B-AdverseReaction
decompensation . . I-AdverseReaction
in . . O
patients . . O
with . . O
chronic . . O
hepatitis . . O
c . . O

( . . O
5.6 . . O
, . . O
2.3 . . O
) . . O
* . . O
serious . . B-Severity
febrile . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
incidence . . O
and . . O
severity . . O
of . . O
pyrexia . . B-AdverseReaction
are . . O
increased . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

onfi . . O
should . . O
be . . O
discontinued . . O
at . . O
the . . O
first . . O
sign . . O
of . . O
rash . . O
, . . O
unless . . O
the . . O
rash . . O
is . . O
clearly . . O
not . . O
drug . . O
- . . O
related . . O
. . . O

exercise . . O
caution . . O
in . . O
patients . . O
with . . O
known . . O
hypersensitivity . . O
to . . O
beta . . O
- . . O
lactam . . O
antibacterial . . O
drugs . . O
. . . O

fatal . . B-AdverseReaction
adverse . . O
reactions . . O
in . . O
xalkori . . O
- . . O
treated . . O
patients . . O
in . . O
study . . O
2 . . O
occurred . . O
in . . O
9 . . O
( . . O
5% . . O
) . . O
patients . . O
, . . O
consisting . . O
of . . O
: . . O
acute . . B-AdverseReaction
respiratory . . I-AdverseReaction
distress . . I-AdverseReaction
syndrome . . I-AdverseReaction
, . . O
arrhythmia . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
pneumonitis . . B-AdverseReaction
, . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
, . . O
ild . . B-AdverseReaction
, . . O
respiratory . . B-AdverseReaction
failure . . I-AdverseReaction
and . . O
sepsis . . B-AdverseReaction
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
golimumab . . O
exposure . . O
. . . O

because . . O
these . . O
reactions . . O
are . . O
reported . . O
voluntarily . . O
from . . O
a . . O
population . . O
of . . O
uncertain . . O
size . . O
, . . O
it . . O
is . . O
not . . O
always . . O
possible . . O
to . . O
reliably . . O
estimate . . O
their . . O
frequency . . O
or . . O
establish . . O
a . . O
causal . . O
relationship . . O
to . . O
drug . . O
exposure . . O
. . . O

placebo . . O
patients . . O
whose . . O
tender . . O
and . . O
swollen . . O
joint . . O
counts . . O
had . . O
not . . O
improved . . O
by . . O
at . . O
least . . O
20% . . O
were . . O
re . . O
- . . O
randomized . . O
1 . . O
: . . O
1 . . O
in . . O
a . . O
blinded . . O
fashion . . O
to . . O
either . . O
otezla . . O
20 . . O
mg . . O
twice . . O
daily . . O
or . . O
30 . . O
mg . . O
twice . . O
daily . . O
at . . O
week . . O
16 . . O
while . . O
otezla . . O
patients . . O
remained . . O
on . . O
their . . O
initial . . O
treatment . . O
. . . O

both . . O
the . . O
loading . . O
dose . . O
of . . O
400 . . O
mg . . O
every . . O
other . . O
week . . O
at . . O
weeks . . O
0 . . O
, . . O
2 . . O
and . . O
4 . . O
and . . O
concomitant . . O
use . . O
of . . O
mtx . . O
were . . O
associated . . O
with . . O
reduced . . O
immunogenicity . . O
. . . O

the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
below . . O
is . . O
based . . O
upon . . O
2 . . O
placebo . . O
- . . O
controlled . . O
, . . O
clinical . . O
trials . . O
( . . O
edema3 . . O
( . . O
r . . O
) . . O
and . . O
edema4 . . O
( . . O
r . . O
) . . O
) . . O
in . . O
a . . O
total . . O
of . . O
143 . . O
unique . . O
patients . . O
with . . O
hae . . O
. . . O

table . . O
1 . . O
number . . O
( . . O
% . . O
) . . O
of . . O
patients . . O
with . . O
aes . . O
by . . O
preferred . . O
terms . . O
, . . O
in . . O
> . . O
10% . . O
of . . O
patients . . O
in . . O
parts . . O
1 . . O
to . . O
3 . . O
of . . O
the . . O
phase . . O
3 . . O
trial . . O
for . . O
caps . . O
patients . . O
preferred . . O
term . . O
ilarisn . . O
= . . O
35n . . O
( . . O
% . . O
) . . O
n . . O
% . . O
of . . O
patients . . O
with . . O
adverse . . O
events . . O
35 . . O
( . . O
100 . . O
) . . O
nasopharyngitis . . B-AdverseReaction
12 . . O
( . . O
34 . . O
) . . O
diarrhea . . B-AdverseReaction
7 . . O
( . . O
20 . . O
) . . O
influenza . . B-AdverseReaction
6 . . O
( . . O
17 . . O
) . . O
rhinitis . . B-AdverseReaction
6 . . O
( . . O
17 . . O
) . . O
nausea . . B-AdverseReaction
5 . . O
( . . O
14 . . O
) . . O
headache . . B-AdverseReaction
5 . . O
( . . O
14 . . O
) . . O
bronchitis . . B-AdverseReaction
4 . . O
( . . O
11 . . O
) . . O
gastroenteritis . . B-AdverseReaction
4 . . O
( . . O
11 . . O
) . . O
pharyngitis . . B-AdverseReaction
4 . . O
( . . O
11 . . O
) . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
4 . . O
( . . O
11 . . O
) . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
4 . . O
( . . O
11 . . O
) . . O
vertigo . . B-AdverseReaction
4 . . O
( . . O
11 . . O
) . . O
vertigo . . O

the . . O
potency . . O
units . . O
of . . O
xeomin . . O
are . . O
specific . . O
to . . O
the . . O
preparation . . O
and . . O
assay . . O
method . . O
utilized . . O
. . . O

the . . O
safety . . O
evaluation . . O
of . . O
northera . . O
is . . O
based . . O
on . . O
two . . O
placebo . . O
- . . O
controlled . . O
studies . . O
1 . . O
to . . O
2 . . O
weeks . . O
in . . O
duration . . O
( . . O
studies . . O
301 . . O
and . . O
302 . . O
) . . O
, . . O
one . . O
8 . . O
- . . O
week . . O
placebo . . O
- . . O
controlled . . O
study . . O
( . . O
study . . O
306 . . O
) . . O
, . . O
and . . O
two . . O
long . . O
- . . O
term . . O
, . . O
open . . O
- . . O
label . . O
extension . . O
studies . . O
( . . O
studies . . O
303 . . O
and . . O
304 . . O
) . . O
. . . O

5.1 . . O
lactic . . O
acidosis . . O
/ . . O
severe . . O
hepatomegaly . . O
with . . O
steatosis . . O

long . . O
- . . O
term . . O
, . . O
open . . O
- . . O
label . . O
trials . . O
with . . O
northera . . O
in . . O
the . . O
long . . O
- . . O
term . . O
, . . O
open . . O
- . . O
label . . O
extension . . O
studies . . O
, . . O
a . . O
total . . O
of . . O
422 . . O
patients . . O
, . . O
mean . . O
age . . O
65 . . O
years . . O
, . . O
were . . O
treated . . O
with . . O
northera . . O
for . . O
a . . O
mean . . O
total . . O
exposure . . O
of . . O
approximately . . O
one . . O
year . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
10% . . O
) . . O
observed . . O
across . . O
pre . . O
- . . O
marketing . . O
clinical . . O
trials . . O
were . . O
similar . . O
in . . O
type . . O
and . . O
frequency . . O
as . . O
those . . O
observed . . O
in . . O
the . . O
placebo . . O
- . . O
controlled . . O
trial . . O
( . . O
see . . O
table1 . . O
) . . O
. . . O

the . . O
median . . O
number . . O
of . . O
dosing . . O
delays . . O
was . . O
one . . O
in . . O
patients . . O
receiving . . O
cometriq . . O
compared . . O
to . . O
none . . O
in . . O
patients . . O
receiving . . O
placebo . . O
. . . O

reported . . O
infections . . O
include . . O
: . . O

* . . O
perforations . . B-AdverseReaction
and . . O
fistula . . B-AdverseReaction
[ . . O
see . . O
boxed . . O
warning . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
hemorrhage . . B-AdverseReaction
[ . . O
see . . O
boxed . . O
warning . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
* . . O
thromboembolic . . B-AdverseReaction
events . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
* . . O
wound . . B-AdverseReaction
complications . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.4 . . O
) . . O
] . . O
* . . O
hypertension . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.5 . . O
) . . O
] . . O
* . . O
osteonecrosis . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
jaw . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
* . . O
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
* . . O
proteinuria . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O
* . . O
reversible . . B-AdverseReaction
posterior . . I-AdverseReaction
leukoencephalopathy . . I-AdverseReaction
syndrome . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.9 . . O
) . . O
] . . O
excerpt . . O
: . . O
the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
drug . . O
reactions . . O
( . . O
> . . O
= . . O
25% . . O
) . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
stomatitis . . B-AdverseReaction
, . . O
palmar . . B-AdverseReaction
- . . I-AdverseReaction
plantar . . I-AdverseReaction
erythrodysesthesia . . I-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
ppes . . B-AdverseReaction
) . . O
, . . O
decreased . . B-AdverseReaction
weight . . I-AdverseReaction
, . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
oral . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
hair . . B-AdverseReaction
color . . I-AdverseReaction
changes . . I-AdverseReaction
, . . O
dysgeusia . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
and . . O
constipation . . B-AdverseReaction
. . . O

5.8 . . O
hepatotoxicity . . O

counsel . . O
patients . . O
regarding . . O
the . . O
potential . . O
risk . . O
of . . O
mtc . . O
with . . O
the . . O
use . . O
of . . O
tanzeum . . O
and . . O
inform . . O
them . . O
of . . O
the . . O
symptoms . . O
of . . O
thyroid . . O
tumors . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
mass . . O
in . . O
the . . O
neck . . O
, . . O
dysphagia . . O
, . . O
dyspnea . . O
, . . O
persistent . . O
hoarseness . . O
) . . O
. . . O

uveitis . . B-AdverseReaction
( . . O
including . . O
iritis . . B-AdverseReaction
) . . O
occurred . . O
in . . O
1% . . O
( . . O
6 . . O
/ . . O
586 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
as . . O
a . . O
single . . O
agent . . O
and . . O
uveitis . . B-AdverseReaction
occurred . . O
in . . O
1% . . O
( . . O
2 . . O
/ . . O
202 . . O
) . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

monitor . . O
serum . . O
potassium . . O
levels . . O
periodically . . O
after . . O
initiating . . O
invokana . . O
in . . O
patients . . O
with . . O
impaired . . O
renal . . O
function . . O
and . . O
in . . O
patients . . O
predisposed . . O
to . . O
hyperkalemia . . O
due . . O
to . . O
medications . . O
or . . O
other . . O
medical . . O
conditions . . O
. . . O

the . . O
adverse . . O
reaction . . O
of . . O
first . . B-AdverseReaction
degree . . I-AdverseReaction
av . . I-AdverseReaction
block . . I-AdverseReaction
occurred . . O
more . . O
frequently . . O
in . . O
patients . . O
treated . . O
with . . O
trulicity . . O
than . . O
placebo . . O
( . . O
0.9% . . O
, . . O
1.7% . . O
and . . O
2.3% . . O
for . . O
placebo . . O
, . . O
trulicity . . O
0.75 . . O
mg . . O
and . . O
trulicity . . O
1.5 . . O
mg . . O
, . . O
respectively . . O
) . . O
. . . O

in . . O
the . . O
event . . O
of . . O
treatment . . O
- . . O
related . . O
myelosuppression . . O
, . . O
monitor . . O
leukocytes . . O
, . . O
platelets . . O
, . . O
hemoglobin . . O
( . . O
hgb . . O
) . . O
, . . O
and . . O
neutrophils . . O
frequently . . O
. . . O

complete . . O
blood . . O
counts . . O
should . . O
be . . O
monitored . . O
prior . . O
to . . O
each . . O
dose . . O
of . . O
adcetris . . O
and . . O
more . . O
frequent . . O
monitoring . . O
should . . O
be . . O
considered . . O
for . . O
patients . . O
with . . O
grade . . O
3 . . O
or . . O
4 . . O
neutropenia . . O
. . . O

advise . . O
females . . O
of . . O
reproductive . . O
potential . . O
of . . O
the . . O
potential . . O
risk . . O
to . . O
a . . O
fetus . . O
. . . O

across . . O
these . . O
13 . . O
studies . . O
, . . O
2360 . . O
patients . . O
were . . O
treated . . O
once . . O
daily . . O
with . . O
farxiga . . O
10 . . O
mg . . O
for . . O
a . . O
mean . . O
duration . . O
of . . O
exposure . . O
of . . O
22 . . O
weeks . . O
. . . O

females . . O
of . . O
reproductive . . O
potential . . O
should . . O
avoid . . O
becoming . . O
pregnant . . O
while . . O
being . . O
treated . . O
with . . O
bosulif . . O
. . . O

other . . O
anticoagulants . . O
a . . O
history . . O
of . . O
traumatic . . O
or . . O
repeated . . O

for . . O
uloric . . O
40 . . O
mg . . O
, . . O
559 . . O
patients . . O
were . . O
treated . . O
for . . O
> . . O
= . . O
6 . . O
months . . O
. . . O

of . . O
these . . O
4 . . O
patients . . O
who . . O
developed . . O
anti . . O
- . . O
erwinaze . . O
antibodies . . O
, . . O
3 . . O
experienced . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
10% . . O
, . . O
3 . . O
of . . O
30 . . O
) . . O
during . . O
the . . O
study . . O
. . . O

monitoring . . O
of . . O
orthostatic . . O
vital . . O
signs . . O
should . . O
be . . O
considered . . O
in . . O
patients . . O
who . . O
are . . O
vulnerable . . O
to . . O
hypotension . . O
. . . O

these . . O
hematomas . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
long . . O
- . . O
term . . O
or . . O
permanent . . B-AdverseReaction
paralysis . . I-AdverseReaction
. . . O

there . . O
were . . O
no . . O
clinically . . O
meaningful . . O
differences . . O
in . . O
the . . O
incidence . . O
of . . O
adverse . . O
events . . O
following . . O
treatment . . O
with . . O
xiaflex . . O
based . . O
on . . O
the . . O
severity . . O
of . . O
baseline . . O
erectile . . O
dysfunction . . O
or . . O
concomitant . . O
phosphodiesterase . . O
type . . O
5 . . O
( . . O
pde5 . . O
) . . O
inhibitor . . O
use . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
due . . O
to . . O
zytiga . . O
in . . O
study . . O
1 . . O
zytiga . . O
with . . O
prednisone . . O
( . . O
n . . O
= . . O
791 . . O
) . . O
placebo . . O
with . . O
prednisone . . O
( . . O
n . . O
= . . O
394 . . O
) . . O
system . . O
/ . . O
organ . . O
class . . O
adverse . . O
reaction . . O
all . . O
grades% . . O
grade . . O
3-4% . . O
all . . O
grades% . . O
grade . . O
3-4% . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
joint . . B-AdverseReaction
swelling . . I-AdverseReaction
/ . . O
discomfort . . O
29.5 . . O
4.2 . . O
23.4 . . O
4.1 . . O
muscle . . B-AdverseReaction
discomfort . . I-AdverseReaction
26.2 . . O
3.0 . . O
23.1 . . O
2.3 . . O
general . . O
disorders . . O
edema . . B-AdverseReaction
26.7 . . O
1.9 . . O
18.3 . . O
0.8 . . O
vascular . . O
disorders . . O
hot . . B-AdverseReaction
flush . . I-AdverseReaction
19.0 . . O
0.3 . . O
16.8 . . O
0.3 . . O
hypertension . . B-AdverseReaction
8.5 . . O
1.3 . . O
6.9 . . O
0.3 . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
17.6 . . O
0.6 . . O
13.5 . . O
1.3 . . O
dyspepsia . . B-AdverseReaction
6.1 . . O
0 . . O
3.3 . . O
0 . . O
infections . . O
and . . O
infestations . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
11.5 . . O
2.1 . . O
7.1 . . O
0.5 . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
5.4 . . O
0 . . O
2.5 . . O
0 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
10.6 . . O
0 . . O
7.6 . . O
0 . . O
renal . . O
and . . O
urinary . . O
disorders . . O
urinary . . B-AdverseReaction
frequency . . I-AdverseReaction
7.2 . . O
0.3 . . O
5.1 . . O
0.3 . . O
nocturia . . B-AdverseReaction
6.2 . . O
0 . . O
4.1 . . O
0 . . O
injury . . O
, . . O
poisoning . . O
and . . O
procedural . . O
complications . . O
fractures . . B-AdverseReaction
5.9 . . O
1.4 . . O
2.3 . . O
0 . . O
cardiac . . O
disorders . . O
arrhythmia . . B-AdverseReaction
7.2 . . O
1.1 . . O
4.6 . . O
1.0 . . O
chest . . B-AdverseReaction
pain . . I-AdverseReaction
or . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
3.8 . . O
0.5 . . O
2.8 . . O
0 . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
2.3 . . O
1.9 . . O
1.0 . . O
0.3 . . O
table . . O
2 . . O
shows . . O
laboratory . . O
abnormalities . . O
of . . O
interest . . O
from . . O
study . . O
1 . . O
. . . O

contact . . O
lens . . O
use . . O
is . . O
also . . O
a . . O
risk . . O
factor . . O
for . . O
keratitis . . O
and . . O
ulceration . . O
. . . O

5 . . O
. . . O

( . . O
5.1 . . O
, . . O
5.2 . . O
) . . O

elevations . . B-AdverseReaction
of . . I-AdverseReaction
liver . . I-AdverseReaction
enzymes . . I-AdverseReaction
may . . B-Factor
occur . . O
in . . O
patients . . O
receiving . . O
gilenya . . O
. . . O

serious . . O
adverse . . O
reactions . . O
were . . O
reported . . O
in . . O
65% . . O
of . . O
patients . . O
. . . O

percentage . . O
( . . O
% . . O
) . . O
of . . O
patientsa . . O
yervoy3 . . O
mg . . O
/ . . O
kgn . . O
= . . O
131 . . O
yervoy3 . . O
mg . . O
/ . . O
kg . . O
+ . . O
gp100n . . O
= . . O
380 . . O
gp100n . . O
= . . O
132 . . O
system . . O
organ . . O
class . . O
/ . . O
preferred . . O
term . . O
anygrade . . O
grade3-5 . . O
anygrade . . O
grade3-5 . . O
anygrade . . O
grade3-5 . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
32 . . O
5 . . O
37 . . O
4 . . O
20 . . O
1 . . O
colitis . . B-AdverseReaction
8 . . O
5 . . O
5 . . O
3 . . O
2 . . O
0 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
pruritus . . B-AdverseReaction
31 . . O
0 . . O
21 . . O
< . . O
1 . . O
11 . . O
0 . . O
rash . . B-AdverseReaction
29 . . O
2 . . O
25 . . O
2 . . O
8 . . O
0 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
41 . . O
7 . . O
34 . . O
5 . . O
31 . . O
3 . . O
table . . O
2 . . O
presents . . O
the . . O
per . . O
- . . O
patient . . O
incidence . . O
of . . O
severe . . B-Severity
, . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
, . . O
or . . O
fatal . . B-AdverseReaction
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
from . . O
study . . O
1 . . O
. . . O

venous . . B-AdverseReaction
thromboembolic . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
including . . O
deep . . B-AdverseReaction
venous . . I-AdverseReaction
thrombosis . . I-AdverseReaction
and . . O
pulmonary . . B-AdverseReaction
embolism . . I-AdverseReaction
) . . O
have . . O
been . . O
observed . . O
with . . O
kyprolis . . O
. . . O

when . . O
prescribing . . O
breo . . O
ellipta . . O
, . . O
the . . O
healthcare . . O
provider . . O
should . . O
also . . O
prescribe . . O
an . . O
inhaled . . O
, . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonist . . O
and . . O
instruct . . O
the . . O
patient . . O
on . . O
how . . O
it . . O
should . . O
be . . O
used . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
skin . . B-AdverseReaction
exfoliation . . I-AdverseReaction
, . . O
bullous . . B-AdverseReaction
skin . . I-AdverseReaction
reactions . . I-AdverseReaction

the . . O
reported . . O
endometrial . . B-AdverseReaction
cancer . . I-AdverseReaction
risk . . O
among . . O
unopposed . . O
estrogen . . B-DrugClass
users . . O
is . . O
about . . O
2 . . O
to . . O
12 . . O
times . . O
greater . . O
than . . O
in . . O
non . . O
- . . O
users . . O
, . . O
and . . O
appears . . O
dependent . . O
on . . O
duration . . O
of . . O
treatment . . O
and . . O
on . . O
estrogen . . O
dose . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
during . . O
therapy . . O
( . . O
5.1 . . O
) . . O
* . . O
impairment . . B-AdverseReaction
in . . I-AdverseReaction
renal . . I-AdverseReaction
function . . I-AdverseReaction
: . . O
monitor . . O
renal . . O
function . . O
during . . O
therapy . . O
. . . O

adverse . . O
reactions . . O
led . . O
to . . O
dose . . O
reductions . . O
in . . O
49% . . O
and . . O
dose . . O
interruptions . . O
in . . O
67% . . O
of . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
in . . O
combination . . O
with . . O
trametinib . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

permanently . . O
discontinue . . O
granix . . O
in . . O
patients . . O
with . . O
serious . . O
allergic . . O
reactions . . O
. . . O

use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
narrow . . O
- . . O
angle . . O
glaucoma . . O
and . . O
instruct . . O
patients . . O
to . . O
consult . . O
a . . O
physician . . O
immediately . . O
if . . O
this . . O
occurs . . O
. . . O

in . . O
the . . O
event . . O
of . . O
drug . . O
- . . O
induced . . O
pulmonary . . O
toxicity . . O
, . . O
discontinue . . O
kyprolis . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2 . . O
) . . O
] . . O
. . . O

interrupt . . O
ferriprox . . O
therapy . . O
if . . O
neutropenia . . O
develops . . O
( . . O
anc . . O
< . . O
1.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
) . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

adverse . . O
reactions . . O

in . . O
study . . O
3 . . O
, . . O
serious . . O
adverse . . O
reactions . . O
, . . O
regardless . . O
of . . O
causality . . O
, . . O
were . . O
reported . . O
in . . O
25% . . O
of . . O
adcetris . . O
- . . O
treated . . O
patients . . O
. . . O

( . . O
5.11 . . O
) . . O
* . . O
potential . . B-Factor
for . . O
cognitive . . O
and . . O
motor . . B-AdverseReaction
impairment . . I-AdverseReaction
: . . O
use . . O
caution . . O
when . . O
operating . . O
machinery . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction

the . . O
median . . O
duration . . O
of . . O
study . . O
treatment . . O
was . . O
7.1 . . O
months . . O
for . . O
patients . . O
who . . O
received . . O
xalkori . . O
and . . O
2.8 . . O
months . . O
for . . O
patients . . O
who . . O
received . . O
chemotherapy . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
postapproval . . O
use . . O
of . . O
drug . . O
tudorza . . O
pressair . . O
. . . O

5.3 . . O
hepatotoxicity . . O

system . . O
organ . . O
class . . O
preferred . . O
term . . O
number . . O
of . . O
patients . . O
( . . O
n . . O
) . . O
( . . O
% . . O
) . . O
total . . O
23 . . O
( . . O
100 . . O
) . . O
blood . . O
and . . O
lymphatic . . O
system . . O
disorders . . O
anemia . . B-AdverseReaction
3 . . O
( . . O
13 . . O
) . . O
ear . . O
and . . O
labyrinth . . O
disorders . . O
ear . . B-AdverseReaction
infection . . I-AdverseReaction
3 . . O
( . . O
13 . . O
) . . O
gastrointestinal . . O
disorders . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
4 . . O
( . . O
17 . . O
) . . O
diarrhea . . B-AdverseReaction
3 . . O
( . . O
13 . . O
) . . O
vomiting . . B-AdverseReaction
6 . . O
( . . O
26 . . O
) . . O
dysgeusia . . B-AdverseReaction
2 . . O
( . . O
9 . . O
) . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
asthenia . . B-AdverseReaction
2 . . O
( . . O
9 . . O
) . . O
hyperhidrosis . . B-AdverseReaction
2 . . O
( . . O
9 . . O
) . . O
pyrexia . . B-AdverseReaction
4 . . O
( . . O
17 . . O
) . . O
infections . . O
and . . O
infestations . . O
infection . . B-AdverseReaction
3 . . O
( . . O
13 . . O
) . . O
influenza . . B-AdverseReaction
2 . . O
( . . O
9 . . O
) . . O
nasopharyngitis . . B-AdverseReaction
3 . . O
( . . O
13 . . O
) . . O
pneumonia . . B-AdverseReaction
2 . . O
( . . O
9 . . O
) . . O
tonsillitis . . B-AdverseReaction
4 . . O
( . . O
17 . . O
) . . O
investigations . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
3 . . O
( . . O
13 . . O
) . . O
weight . . B-AdverseReaction
decreased . . I-AdverseReaction
2 . . O
( . . O
9 . . O
) . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
anorexia . . B-AdverseReaction
2 . . O
( . . O
9 . . O
) . . O
nervous . . O
system . . O
disorders . . O
headache . . B-AdverseReaction
3 . . O
( . . O
13 . . O
) . . O
somnolence . . B-AdverseReaction
2 . . O
( . . O
9 . . O
) . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
rash . . B-AdverseReaction
2 . . O
( . . O
9 . . O
) . . O

there . . O
were . . O
four . . O
suicides . . B-AdverseReaction
in . . O
drug . . O
treated . . O
patients . . O
in . . O
the . . O
trials . . O
and . . O
none . . O
in . . O
placebo . . O
treated . . O
patients . . O
, . . O
but . . O
the . . O
number . . O
is . . O
too . . O
small . . O
to . . O
allow . . O
any . . O
conclusion . . O
about . . O
drug . . O
effect . . O
on . . O
suicide . . B-AdverseReaction
. . . O

the . . O
possibility . . O
of . . O
more . . O
extensive . . O
systemic . . O
involvement . . O
has . . O
not . . O
been . . O
excluded . . O
. . . O

the . . O
adverse . . O
reaction . . O
most . . O
commonly . . O
( . . O
> . . O
= . . O
1% . . O
on . . O
aptiom . . O
) . . O
leading . . O
to . . O
discontinuation . . O
was . . O
hyponatremia . . B-AdverseReaction
. . . O

s . . O
intracranial . . O
, . . O
intraspinal . . O
, . . O
intraocular . . O
, . . O
pericardial . . O
, . . O
an . . O
operated . . O
joint . . O
requiring . . O
re . . O
- . . O
operation . . O
or . . O
intervention . . O
, . . O
intramuscular . . O
with . . O
compartment . . O
syndrome . . O
, . . O
or . . O
retroperitoneal . . O
. . . O

the . . O
proportion . . O
of . . O
subjects . . O
who . . O
discontinued . . O
treatment . . O
with . . O
stribild . . O
, . . O
the . . O
rtv . . O
- . . O
boosted . . O
pi . . O
, . . O
or . . O
the . . O
nnrti . . O
due . . O
to . . O
adverse . . O
events . . O
, . . O
was . . O
2% . . O
, . . O
3% . . O
and . . O
1% . . O
, . . O
respectively . . O
. . . O

in . . O
most . . O
cases . . O
the . . O
reactions . . O
were . . O
of . . O
mild . . O
or . . O
moderate . . O
intensity . . O
. . . O

physicians . . O
and . . O
patients . . O
should . . O
be . . O
aware . . O
of . . O
the . . O
increased . . O
risk . . O
of . . O
infection . . O
with . . O
afinitor . . O
. . . O

given . . O
the . . O
potential . . O
for . . O
airway . . O
obstruction . . O
during . . O
acute . . O
laryngeal . . O
hae . . O
attacks . . O
, . . O
patients . . O
should . . O
be . . O
advised . . O
to . . O
seek . . O
medical . . O
attention . . O
in . . O
an . . O
appropriate . . O
healthcare . . O
facility . . O
immediately . . O
in . . O
addition . . O
to . . O
treatment . . O
with . . O
firazyr . . O
. . . O

the . . O
following . . O
adverse . . O
reactions . . O
to . . O
xeomin . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

( . . O
5.2 . . O
) . . O
* . . O
qt . . O
prolonging . . O
drugs . . O
, . . O
including . . O
quinine . . O
and . . O
quinidine . . O
, . . O
should . . O
be . . O
used . . O
cautiously . . O
following . . O
coartem . . O
tablets . . O
. . . O

* . . O
see . . O
you . . O
healthcare . . O
provider . . O
right . . O
away . . O
if . . O
you . . O
get . . O
vaginal . . O
bleeding . . O
while . . O
taking . . O
duavee . . O
. . . O

the . . O
population . . O
with . . O
rls . . O
ranged . . O
from . . O
18 . . O
to . . O
82 . . O
years . . O
of . . O
age . . O
, . . O
with . . O
60% . . O
being . . O
female . . O
and . . O
95% . . O
being . . O
caucasian . . O
. . . O

before . . O
therapy . . O
with . . O
teflaro . . O
is . . O
instituted . . O
, . . O
careful . . O
inquiry . . O
about . . O
previous . . O
hypersensitivity . . O
reactions . . O
to . . O
other . . O
cephalosporins . . O
, . . O
penicillins . . O
, . . O
or . . O
carbapenems . . O
should . . O
be . . O
made . . O
. . . O

table . . O
1 . . O
lists . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
in . . O
> . . O
= . . O
0.1% . . O
of . . O
subjects . . O
treated . . O
with . . O
eovist . . O
. . . O

monitor . . O
thyroid . . O
function . . O
tests . . O
and . . O
clinical . . O
chemistries . . O
at . . O
the . . O
start . . O
of . . O
treatment . . O
, . . O
before . . O
each . . O
dose . . O
, . . O
and . . O
as . . O
clinically . . O
indicated . . O
based . . O
on . . O
symptoms . . O
. . . O

( . . O
b . . O
) . . O
spinal . . O
/ . . O
epidural . . O

in . . O
addition . . O
, . . O
the . . O
following . . O
clinical . . O
trials . . O
have . . O
also . . O
been . . O
conducted . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12 . . O
) . . O
and . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
: . . O

antiepileptic . . O
drugs . . O
( . . O
aeds . . O
) . . O
, . . O
including . . O
onfi . . O
, . . O
increase . . O
the . . O
risk . . B-Factor
of . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
in . . O
patients . . O
taking . . O
these . . O
drugs . . O
for . . O
any . . O
indication . . O
. . . O

pyrexia . . B-AdverseReaction
, . . O
chills . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
were . . O
the . . O
most . . O
common . . O
reasons . . O
cited . . O
for . . O
dose . . O
reductions . . O
and . . O
pyrexia . . B-AdverseReaction
, . . O
chills . . B-AdverseReaction
, . . O
and . . O
decreased . . B-AdverseReaction
ejection . . I-AdverseReaction
fraction . . I-AdverseReaction
were . . O
the . . O
most . . O
common . . O
reasons . . O
cited . . O
for . . O
dose . . O
interruptions . . O
of . . O
tafinlar . . O
and . . O
trametinib . . O
when . . O
used . . O
in . . O
combination . . O
. . . O

table . . O
1 . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
at . . O
> . . O
= . . O
3% . . O
and . . O
higher . . O
than . . O
placebo . . O
in . . O
2 . . O
placebo . . O
controlled . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
hae . . O
treated . . O
with . . O
kalbitor . . O
a . . O
patients . . O
experiencing . . O
more . . O
than . . O
1 . . O
event . . O
with . . O
the . . O
same . . O
preferred . . O
term . . O
are . . O
counted . . O
only . . O
once . . O
for . . O
that . . O
preferred . . O
term . . O
. . . O

the . . O
effect . . O
that . . O
symptomatic . . O
suppression . . O
has . . O
upon . . O
the . . O
long . . O
- . . O
term . . O
course . . O
of . . O
the . . O
syndrome . . O
is . . O
unknown . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O

eight . . O
of . . O
12 . . O
patients . . O
treated . . O
with . . O
dalvance . . O
and . . O
one . . O
comparator . . O
patient . . O
had . . O
underlying . . O
conditions . . O
which . . O
could . . O
affect . . O
liver . . O
enzymes . . O
, . . O
including . . O
chronic . . O
viral . . O
hepatitis . . O
and . . O
a . . O
history . . O
of . . O
alcohol . . O
abuse . . O
. . . O

more . . O
than . . O
two . . O
- . . O
thirds . . O
of . . O
patients . . O
were . . O
from . . O
asia . . O
( . . O
gilotrif . . O
70% . . O
; . . O
pemetrexed . . O
/ . . O
cisplatin . . O
72% . . O
) . . O
. . . O

venous . . O
thromboembolism . . O
( . . O
vte . . O
) . . O

table . . O
1 . . O
: . . O
bleeding . . B-AdverseReaction
events . . O
in . . O
patients . . O
with . . O
nonvalvular . . O
atrial . . O
fibrillation . . O
in . . O
aristotle . . O
* . . O
eliquisn . . O
= . . O
9088n . . O
( . . O
per . . O
100 . . O
pt . . O
- . . O
year . . O
) . . O
warfarinn . . O
= . . O
9052n . . O
( . . O
per . . O
100 . . O
pt . . O
- . . O
year . . O
) . . O
hazard . . O
ratio . . O
( . . O
95% . . O
ci . . O
) . . O
p . . O
- . . O
value . . O
* . . O
bleeding . . B-AdverseReaction
events . . O
within . . O
each . . O
subcategory . . O
were . . O
counted . . O
once . . O
per . . O
subject . . O
, . . O
but . . O
subjects . . O
may . . O
have . . O
contributed . . O
events . . O
to . . O
multiple . . O
endpoints . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
patients . . O
were . . O
not . . O
eligible . . O
for . . O
adreview . . O
imaging . . O
if . . O
they . . O
were . . O
receiving . . O
medications . . O
in . . O
the . . O
above . . O
categories . . O
and . . O
the . . O
risks . . O
for . . O
medication . . O
withdrawal . . O
were . . O
unacceptable . . O
or . . O
if . . O
they . . O
were . . O
not . . O
clinically . . O
stable . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
experiencing . . O
continuing . . O
chest . . O
pain . . O
, . . O
hemodynamic . . O
instability . . O
, . . O
or . . O
clinically . . O
significant . . O
arrhythmia . . O
) . . O
. . . O

the . . O
time . . O
from . . O
product . . O
administration . . O
to . . O
event . . O
occurrence . . O
was . . O
variable . . O
. . . O

in . . O
the . . O
majority . . O
of . . O
cases . . O
, . . O
rash . . B-AdverseReaction
was . . O
mild . . B-Severity
to . . I-Severity
moderate . . I-Severity
, . . O
of . . O
macular . . O
/ . . O
papular . . O
type . . O
, . . O
and . . O
occurred . . O
in . . O
the . . O
second . . O
week . . O
of . . O
therapy . . O
. . . O

patients . . O
with . . O
a . . O
" . . O
crowded . . O
" . . O
optic . . O
disc . . O
may . . O
also . . O
be . . O
at . . O
an . . O
increased . . O
risk . . O
of . . O
naion . . O
( . . O
5.4,6.2 . . O
) . . O
* . . O
patients . . O
should . . O
stop . . O
taking . . O
stendra . . O
and . . O
seek . . O
prompt . . O
medical . . O
attention . . O
in . . O
the . . O
event . . O
of . . O
sudden . . O
decrease . . O
or . . O
loss . . O
of . . O
hearing . . O
( . . O
5.5 . . O
) . . O
5.1 . . O
cardiovascular . . O
risks . . O

everolimus . . O
delays . . B-AdverseReaction
wound . . I-AdverseReaction
healing . . I-AdverseReaction
and . . O
increases . . O
the . . O
occurrence . . O
of . . O
wound . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
complications . . I-AdverseReaction
like . . O
wound . . B-AdverseReaction
dehiscence . . I-AdverseReaction
, . . O
wound . . B-AdverseReaction
infection . . I-AdverseReaction
, . . O
incisional . . B-AdverseReaction
hernia . . I-AdverseReaction
, . . O
lymphocele . . B-AdverseReaction
, . . O
and . . O
seroma . . B-AdverseReaction
. . . O

females . . O
of . . O
reproductive . . O
potential . . O
should . . O
be . . O
advised . . O
to . . O
avoid . . O
pregnancy . . O
while . . O
being . . O
treated . . O
with . . O
bosulif . . O
. . . O

leukocytosis . . O

after . . O
initiation . . O
of . . O
nesina . . O
, . . O
patients . . O
should . . O
be . . O
observed . . O
carefully . . O
for . . O
signs . . O
and . . O
symptoms . . O
of . . O
pancreatitis . . O
. . . O

less . . O
common . . O
adverse . . O
reactions . . O

image . . O
interpretation . . O
should . . O
be . . O
performed . . O
independently . . O
of . . O
the . . O
patient's . . O
clinical . . O
information . . O
. . . O

patients . . O
treated . . O
with . . O
botulinum . . O
toxin . . O
may . . O
require . . O
immediate . . O
medical . . O
attention . . O
should . . O
they . . O
develop . . O
problems . . O
with . . O
swallowing . . O
, . . O
speech . . O
or . . O
respiratory . . O
disorders . . O
. . . O

horizant . . O
is . . O
a . . O
prodrug . . O
of . . O
gabapentin . . O
. . . O

among . . O
these . . O
were . . O
vertigo . . B-AdverseReaction
( . . O
2 . . O
patients . . O
) . . O
, . . O
infections . . B-AdverseReaction
( . . O
3 . . O
patients . . O
) . . O
, . . O
including . . O
intra . . B-AdverseReaction
- . . I-AdverseReaction
abdominal . . I-AdverseReaction
abscess . . I-AdverseReaction
following . . O
appendectomy . . O
( . . O
1 . . O
patient . . O
) . . O
. . . O

permanently . . O
discontinue . . O
zykadia . . O
in . . O
patients . . O
diagnosed . . O
with . . O
treatment . . O
- . . O
related . . O
ild . . O
/ . . O
pneumonitis . . O
. . . O

* . . O
pulmonary . . B-AdverseReaction
toxicity . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.10 . . O
) . . O
] . . O

vaginal . . O
bleeding . . O
after . . O
menopause . . O
may . . O
be . . O
a . . O
warning . . O
sign . . O
of . . O
cancer . . O
of . . O
the . . O
uterus . . O
( . . O
womb . . O
) . . O
. . . O

in . . O
short . . O
- . . O
term . . O
, . . O
placebo . . O
- . . O
controlled . . O
bipolar . . O
mania . . O
adult . . O
trials . . O
of . . O
therapeutic . . O
doses . . O
( . . O
5-10 . . O
mg . . O
twice . . O
daily . . O
) . . O
, . . O
somnolence . . B-AdverseReaction
was . . O
reported . . O
in . . O
24% . . O
( . . O
90 . . O
/ . . O
379 . . O
) . . O
of . . O
patients . . O
on . . O
saphris . . O
compared . . O
to . . O
6% . . O
( . . O
13 . . O
/ . . O
203 . . O
) . . O
of . . O
placebo . . O
patients . . O
. . . O

a . . O
causal . . O
relationship . . O
with . . O
alvimopan . . O
with . . O
long . . O
- . . O
term . . O
use . . O
has . . O
not . . O
been . . O
established . . O
. . . O

extrapyramidal . . B-AdverseReaction
symptoms . . I-AdverseReaction
included . . O
: . . O
dystonia . . B-AdverseReaction
, . . O
parkinsonism . . B-AdverseReaction
, . . O
oculogyration . . B-AdverseReaction
, . . O
and . . O
tremor . . B-AdverseReaction
( . . O
excluding . . B-Negation
akathisia . . B-AdverseReaction
) . . O
. . . O
? . . O

dress . . O
may . . O
be . . O
fatal . . B-AdverseReaction
or . . O
life . . B-Severity
- . . I-Severity
threatening . . I-Severity
. . . O

of . . O
the . . O
patients . . O
treated . . O
with . . O
the . . O
nulojix . . O
recommended . . O
regimen . . O
, . . O
5% . . O
( . . O
14 . . O
/ . . O
304 . . O
) . . O
developed . . O
nodat . . B-AdverseReaction
by . . O
the . . O
end . . O
of . . O
one . . O
year . . O
compared . . O
to . . O
10% . . O
( . . O
27 . . O
/ . . O
280 . . O
) . . O
of . . O
patients . . O
on . . O
the . . O
cyclosporine . . O
control . . O
regimen . . O
. . . O

grade . . O
3 . . O
and . . O
higher . . O
adverse . . O
reactions . . O
were . . O
reported . . O
among . . O
47% . . O
of . . O
xtandi . . O
- . . O
treated . . O
patients . . O
and . . O
53% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

based . . O
on . . O
its . . O
mechanism . . O
of . . O
action . . O
, . . O
zykadia . . O
may . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

in . . O
both . . O
treatment . . O
arms . . O
, . . O
patients . . O
received . . O
sirturo . . O
or . . O
placebo . . O
in . . O
combination . . O
with . . O
other . . O
drugs . . O
used . . O
to . . O
treat . . O
mdr . . O
- . . O
tb . . O
. . . O

use . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
prostatic . . O
hyperplasia . . O
or . . O
bladder . . O
- . . O
neck . . O
obstruction . . O
and . . O
instruct . . O
patients . . O
to . . O
consult . . O
a . . O
physician . . O
immediately . . O
if . . O
this . . O
occurs . . O
. . . O

tables . . O
2 . . O
and . . O
3 . . O
summarize . . O
the . . O
common . . O
adverse . . O
reactions . . O
and . . O
laboratory . . O
abnormalities . . O
observed . . O
in . . O
zykadia . . O
- . . O
treated . . O
patients . . O
. . . O

exercise . . O
caution . . O
in . . O
patients . . O
with . . O
heart . . O
failure . . O
and . . O
monitor . . O
them . . O
carefully . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

ensure . . O
safe . . O
handling . . O
to . . O
protect . . O
patients . . O
and . . O
health . . O
care . . O
workers . . O
from . . O
unintentional . . O
radiation . . O
exposure . . O
( . . O
5.2 . . O
) . . O
. . . O

monitor . . O
heart . . O
rate . . O
and . . O
blood . . O
pressure . . O
regularly . . O
. . . O

less . . O
common . . O
adverse . . O
reactions . . O

opioids . . O
may . . O
affect . . O
the . . O
ability . . O
to . . O
perform . . O
potentially . . O
hazardous . . O
activities . . O
such . . O
as . . O
driving . . O
or . . O
operating . . O
machinery . . O
. . . O

psychiatric . . O
disorders . . O
- . . O
depersonalization . . B-AdverseReaction
, . . O
bruxism . . B-AdverseReaction
. . . O

indication . . O
placebo . . O
patients . . O
with . . O
events . . O
per . . O
1,000 . . O
patients . . O
drug . . O
patients . . O
with . . O
events . . O
per . . O
1,000 . . O
patients . . O
relative . . O
risk . . O
: . . O
incidence . . O
of . . O
events . . O
in . . O
drug . . O
patients . . O
/ . . O
incidence . . O
in . . O
placebo . . O
patients . . O
risk . . O
difference . . O
: . . O
additional . . O
drug . . O
patients . . O
with . . O
events . . O
per . . O
1,000 . . O
patients . . O
epilepsy . . O
1.0 . . O
3.4 . . O
3.5 . . O
2.4 . . O
psychiatric . . O
5.7 . . O
8.5 . . O
1.5 . . O
2.9 . . O
other . . O
1.0 . . O
1.8 . . O
1.9 . . O
0.9 . . O
total . . O
2.4 . . O
4.3 . . O
1.8 . . O
1.9 . . O
the . . O
relative . . O
risk . . B-Factor
for . . O
suicidal . . B-AdverseReaction
thoughts . . I-AdverseReaction
or . . O
behavior . . O
was . . O
higher . . O
in . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
epilepsy . . O
than . . O
in . . O
clinical . . O
trials . . O
in . . O
patients . . O
with . . O
psychiatric . . O
or . . O
other . . O
conditions . . O
, . . O
but . . O
the . . O
absolute . . O
risk . . O
differences . . O
were . . O
similar . . O
for . . O
epilepsy . . O
and . . O
psychiatric . . O
indications . . O
. . . O

a . . O
patient . . O
who . . O
develops . . O
a . . O
new . . O
infection . . O
during . . O
treatment . . O
with . . O
cimzia . . O
should . . O
be . . O
closely . . O
monitored . . O
, . . O
undergo . . O
a . . O
prompt . . O
and . . O
complete . . O
diagnostic . . O
workup . . O
appropriate . . O
for . . O
an . . O
immunocompromised . . O
patient . . O
, . . O
and . . O
appropriate . . O
antimicrobial . . O
therapy . . O
should . . O
be . . O
initiated . . O
. . . O

anaphylaxis . . B-AdverseReaction
, . . O
presenting . . O
as . . O
cough . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
throat . . B-AdverseReaction
tightness . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
cyanosis . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
and . . O
gastrointestinal . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
nausea . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
retching . . B-AdverseReaction
, . . O
and . . O
vomiting . . B-AdverseReaction
) . . O
in . . O
conjunction . . O
with . . O
urticaria . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
to . . O
occur . . O
during . . O
vimizim . . O
infusions . . O
, . . O
regardless . . O
of . . O
duration . . O
of . . O
the . . O
course . . O
of . . O
treatment . . O
. . . O

cardiac . . O
disorders . . O
: . . O
angina . . B-AdverseReaction
pectoris . . I-AdverseReaction
, . . O
arrhythmias . . B-AdverseReaction
, . . O
atrial . . B-AdverseReaction
fibrillation . . I-AdverseReaction
, . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
, . . O
hypertensive . . B-AdverseReaction
heart . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
, . . O
myocardial . . B-AdverseReaction
ischemia . . I-AdverseReaction
, . . O
pericardial . . B-AdverseReaction
effusion . . I-AdverseReaction
, . . O
pericarditis . . B-AdverseReaction
, . . O
stroke . . B-AdverseReaction
and . . O
transient . . B-AdverseReaction
ischemic . . I-AdverseReaction
attack . . I-AdverseReaction
. . . O

there . . O
were . . O
no . . B-Negation
deaths . . B-AdverseReaction
in . . O
the . . O
arcapta . . O
neohaler . . O
600 . . O
mcg . . O
dose . . O
group . . O
or . . O
in . . O
the . . O
salmeterol . . O
active . . O
control . . O
group . . O
. . . O

monitor . . O
for . . O
symptoms . . O
of . . O
motor . . O
or . . O
sensory . . O
neuropathy . . O
such . . O
as . . O
unilateral . . O
or . . O
bilateral . . O
weakness . . O
, . . O
sensory . . O
alterations . . O
, . . O
or . . O
paresthesia . . O
. . . O

the . . O
most . . O
common . . O
grade . . B-Severity
3-4 . . I-Severity
adverse . . O
reactions . . O
( . . O
incidence . . O
> . . O
= . . O
2% . . O
) . . O
were . . O
stomatitis . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
pneumonia . . B-AdverseReaction
, . . O
gastroenteritis . . B-AdverseReaction
, . . O
aggression . . B-AdverseReaction
, . . O
agitation . . B-AdverseReaction
, . . O
and . . O
amenorrhea . . B-AdverseReaction
. . . O

in . . O
all . . O
three . . O
controlled . . O
trials . . O
, . . O
patients . . O
were . . O
eligible . . O
for . . O
treatment . . O
of . . O
subsequent . . O
attacks . . O
in . . O
an . . O
open . . O
- . . O
label . . O
extension . . O
. . . O

discontinuations . . O
due . . O
to . . O
adverse . . O
events . . O
were . . O
reported . . O
for . . O
16% . . O
of . . O
xtandi . . O
- . . O
treated . . O
patients . . O
and . . O
18% . . O
of . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
: . . O
headache . . B-AdverseReaction
( . . O
including . . O
migraines . . B-AdverseReaction
) . . O
( . . O
12.7% . . O
) . . O
, . . O
breast . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
discomfort . . O
or . . O
tenderness . . O
( . . O
7.0% . . O
) . . O
, . . O
menstrual . . B-AdverseReaction
disorders . . I-AdverseReaction
( . . O
metrorrhagia . . B-AdverseReaction
, . . O
menstruation . . B-AdverseReaction
irregular . . I-AdverseReaction
, . . O
menorrhagia . . B-AdverseReaction
, . . O
vaginal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
dysfunctional . . B-AdverseReaction
uterine . . I-AdverseReaction
bleeding . . I-AdverseReaction
, . . O
genital . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
abnormal . . B-AdverseReaction
withdrawal . . I-AdverseReaction
bleeding . . I-AdverseReaction
, . . O
uterine . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
) . . O
( . . O
6.9% . . O
) . . O
, . . O
nausea . . B-AdverseReaction
or . . O
vomiting . . B-AdverseReaction
( . . O
6.0% . . O
) . . O
, . . O
acne . . B-AdverseReaction
( . . O
3.9% . . O
) . . O
, . . O
mood . . B-AdverseReaction
changes . . I-AdverseReaction
( . . O
depression . . B-AdverseReaction
, . . O
mood . . B-AdverseReaction
swings . . I-AdverseReaction
, . . O
depressed . . B-AdverseReaction
mood . . I-AdverseReaction
, . . O
mood . . B-AdverseReaction
altered . . I-AdverseReaction
, . . O
affect . . B-AdverseReaction
lability . . I-AdverseReaction
, . . O
dysthymic . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
crying . . B-AdverseReaction
) . . O
( . . O
3.0% . . O
) . . O
and . . O
increased . . B-AdverseReaction
weight . . I-AdverseReaction
( . . O
2.9% . . O
) . . O
. . . O

consider . . O
interruption . . O
of . . O
tecfidera . . O
in . . O
patients . . O
with . . O
lymphocyte . . O
counts . . O
< . . O
0.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
persisting . . O
for . . O
more . . O
than . . O
six . . O
months . . O
. . . O

* . . O
use . . O
with . . O
other . . O
qt . . O
prolonging . . O
drugs . . O
including . . O
fluoroquinolones . . O
and . . O
macrolide . . O
antibacterial . . O
drugs . . O
and . . O
the . . O
antimycobacterial . . O
drug . . O
, . . O
clofazimine . . O
* . . O
a . . O
history . . O
of . . O
torsade . . O
de . . O
pointes . . O
* . . O
a . . O
history . . O
of . . O
congenital . . O
long . . O
qt . . O
syndrome . . O
* . . O
a . . O
history . . O
of . . O
or . . O
ongoing . . O
hypothyroidism . . O
* . . O
a . . O
history . . O
of . . O
or . . O
ongoing . . O
bradyarrhythmias . . O
* . . O
a . . O
history . . O
of . . O
uncompensated . . O
heart . . O
failure . . O
* . . O
serum . . O
calcium . . O
, . . O
magnesium . . O
, . . O
or . . O
potassium . . O
levels . . O
below . . O
the . . O
lower . . O
limits . . O
of . . O
normal . . O
if . . O
necessary . . O
, . . O
bedaquiline . . O
treatment . . O
initiation . . O
could . . O
be . . O
considered . . O
in . . O
these . . O
patients . . O
after . . O
a . . O
favorable . . O
benefit . . O
risk . . O
assessment . . O
and . . O
with . . O
frequent . . O
ecg . . O
monitoring . . O
. . . O

hepatic . . O
transaminases . . O

( . . O
5.8 . . O
) . . O
* . . O
if . . O
paradoxical . . O
bronchospasm . . O
occurs . . O
, . . O
discontinue . . O
breo . . O
ellipta . . O
and . . O
institute . . O
alternative . . O
therapy . . O
. . . O

evaluate . . O
with . . O
cardiac . . O
imaging . . O
and . . O
/ . . O
or . . O
other . . O
tests . . O
as . . O
indicated . . O
. . . O

approximately . . O
81% . . O
of . . O
these . . O
local . . O
reactions . . O
resolved . . O
without . . O
intervention . . O
within . . O
4 . . O
weeks . . O
of . . O
xiaflex . . O
injections . . O
. . . O

in . . O
these . . O
patients . . O
, . . O
the . . O
majority . . O
of . . O
lymphocyte . . O
counts . . O
remained . . O
< . . O
0.5 . . O
x . . O
10 . . O
9 . . O
/ . . O
l . . O
with . . O
continued . . O
therapy . . O
. . . O

ampyra . . O
should . . O
be . . O
discontinued . . O
and . . O
not . . O
restarted . . O
in . . O
patients . . O
who . . O
experience . . O
a . . O
seizure . . O
while . . O
on . . O
treatment . . O
. . . O

in . . O
short . . O
- . . O
term . . O
trials . . O
with . . O
entereg . . O
( . . O
r . . O
) . . O
, . . O
no . . B-Negation
increased . . O
risk . . O
of . . O
myocardial . . B-AdverseReaction
infarction . . I-AdverseReaction
was . . O
observed . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

a . . O
total . . O
of . . O
2,131 . . O
women . . O
, . . O
18 . . O
to . . O
54 . . O
years . . O
of . . O
age . . O
, . . O
who . . O
took . . O
at . . O
least . . O
one . . O
dose . . O
of . . O
natazia . . O
were . . O
enrolled . . O
in . . O
four . . O
clinical . . O
phase . . O
3 . . O
trials . . O
. . . O

adverse . . O
reaction . . O
placebon . . O
= . . O
646 . . O
invokana . . O
100 . . O
mgn . . O
= . . O
833 . . O
invokana . . O
300 . . O
mgn . . O
= . . O
834 . . O
female . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
3.2% . . O
10.4% . . O
11.4% . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infections . . I-AdverseReaction
4.0% . . O
5.9% . . O
4.3% . . O
increased . . B-AdverseReaction
urination . . I-AdverseReaction
0.8% . . O
5.3% . . O
4.6% . . O
male . . B-AdverseReaction
genital . . I-AdverseReaction
mycotic . . I-AdverseReaction
infections . . I-AdverseReaction
0.6% . . O
4.2% . . O
3.7% . . O
vulvovaginal . . B-AdverseReaction
pruritus . . I-AdverseReaction
0.0% . . O
1.6% . . O
3.0% . . O
thirst . . B-AdverseReaction
0.2% . . O
2.8% . . O
2.3% . . O
constipation . . B-AdverseReaction
0.9% . . O
1.8% . . O
2.3% . . O
nausea . . B-AdverseReaction
1.5% . . O
2.2% . . O
2.3% . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
was . . O
also . . O
more . . O
commonly . . O
reported . . O
in . . O
patients . . O
taking . . O
invokana . . O
100 . . O
mg . . O
( . . O
1.8% . . O
) . . O
, . . O
300 . . O
mg . . O
( . . O
1.7% . . O
) . . O
than . . O
in . . O
patients . . O
taking . . O
placebo . . O
( . . O
0.8% . . O
) . . O
. . . O

seven . . O
( . . O
8.9% . . O
) . . O
sirturo . . O
- . . O
treated . . O
patients . . O
and . . O
six . . O
( . . O
7.4% . . O
) . . O
placebo . . O
- . . O
treated . . O
patients . . O
discontinued . . O
study . . O
1 . . O
because . . O
of . . O
an . . O
adverse . . O
reaction . . O
. . . O

in . . O
the . . O
pre . . O
- . . O
marketing . . O
pooled . . O
8 . . O
- . . O
week . . O
placebo . . O
- . . O
controlled . . O
studies . . O
in . . O
patients . . O
with . . O
mdd . . O
, . . O
1,834 . . O
patients . . O
were . . O
exposed . . O
to . . O
pristiq . . O
( . . O
50 . . O
to . . O
400 . . O
mg . . O
) . . O
. . . O

in . . O
clinical . . O
trials . . O
, . . O
the . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
> . . O
= . . O
5% . . O
) . . O
following . . O
alglucosidase . . O
alfa . . O
treatment . . O
were . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
, . . O
and . . O
included . . O
anaphylaxis . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
/ . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
cough . . B-AdverseReaction
, . . O
decreased . . B-AdverseReaction
oxygen . . I-AdverseReaction
saturation . . I-AdverseReaction
, . . O
tachycardia . . B-AdverseReaction
, . . O
tachypnea . . B-AdverseReaction
, . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
dizziness . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
twitching . . I-AdverseReaction
, . . O
agitation . . B-AdverseReaction
, . . O
cyanosis . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
hypertension . . B-AdverseReaction
/ . . O
increased . . B-AdverseReaction
blood . . I-AdverseReaction
pressure . . I-AdverseReaction
, . . O
pallor . . B-AdverseReaction
, . . O
rigors . . B-AdverseReaction
, . . O
tremor . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
and . . O
myalgia . . B-AdverseReaction
. . . O

5 . . O
warnings . . O
and . . O
precautions . . O

consider . . O
initiation . . O
of . . O
systemic . . O
corticosteroids . . O
at . . O
a . . O
dose . . O
of . . O
1 . . O
to . . O
2 . . O
mg . . O
/ . . O
kg . . O
/ . . O
day . . O
prednisone . . O
or . . O
equivalent . . O
for . . O
severe . . O
neuropathies . . O
. . . O

as . . O
with . . O
all . . O
therapeutic . . O
proteins . . O
, . . O
there . . O
is . . O
potential . . O
for . . O
immunogenicity . . O
. . . O

patients . . O
who . . O
have . . O
serum . . O
alt . . O
greater . . O
than . . O
three . . O
times . . O
the . . O
reference . . O
range . . O
with . . O
serum . . O
total . . O
bilirubin . . O
greater . . O
than . . O
two . . O
times . . O
the . . O
reference . . O
range . . O
without . . O
alternative . . O
etiologies . . O
are . . O
at . . O
risk . . O
for . . O
severe . . O
drug . . O
- . . O
induced . . O
liver . . O
injury . . O
and . . O
should . . O
not . . O
be . . O
restarted . . O
on . . O
uloric . . O
. . . O

the . . O
safety . . O
evaluation . . O
of . . O
gilotrif . . O
is . . O
based . . O
on . . O
the . . O
data . . O
from . . O
more . . O
than . . O
3800 . . O
patients . . O
, . . O
including . . O
2135 . . O
nsclc . . O
patients . . O
receiving . . O
gilotrif . . O
monotherapy . . O
at . . O
or . . O
above . . O
the . . O
recommended . . O
dose . . O
. . . O

patients . . O
should . . O
be . . O
monitored . . O
for . . O
these . . O
symptoms . . O
when . . O
discontinuing . . O
treatment . . O
with . . O
pristiq . . O
. . . O

5.11 . . O
fluid . . O
retention . . O

conditions . . O
that . . O
lower . . O
the . . O
seizure . . O
threshold . . O
may . . O
be . . O
more . . O
prevalent . . O
in . . O
patients . . O
65 . . O
years . . O
or . . O
older . . O
. . . O

hemodialysis . . O
does . . O
not . . O
appear . . O
to . . O
have . . O
a . . O
substantial . . O
impact . . O
on . . O
apixaban . . O
exposure . . O
[ . . O
seeclinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

limited . . O
data . . O
suggest . . O
that . . O
patients . . O
with . . O
a . . O
history . . O
of . . O
multiple . . O
drug . . O
allergies . . O
or . . O
significant . . O
hypersensitivity . . O
may . . O
be . . O
at . . O
increased . . O
risk . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

5.8 . . O
embryo . . O
- . . O
fetal . . O
toxicity . . O

renal . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
including . . O
cases . . O
of . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
and . . O
fanconi . . B-AdverseReaction
syndrome . . I-AdverseReaction
( . . O
renal . . B-AdverseReaction
tubular . . I-AdverseReaction
injury . . I-AdverseReaction
with . . O
severe . . B-Severity
hypophosphatemia . . B-AdverseReaction
) . . O
, . . O
has . . O
been . . O
reported . . O
with . . O
the . . O
use . . O
of . . O
tenofovir . . O
df . . O
, . . O
a . . O
component . . O
of . . O
stribild . . O
, . . O
and . . O
with . . O
the . . O
use . . O
of . . O
stribild . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

the . . O
period . . O
of . . O
time . . O
necessary . . O
to . . O
discontinue . . O
any . . O
specific . . O
medication . . O
prior . . O
to . . O
adreview . . O
dosing . . O
has . . O
not . . O
been . . O
established . . O
[ . . O
see . . O
drug . . O
interactions . . O
( . . O
7 . . O
) . . O
] . . O
. . . O

hospitalizations . . O
due . . O
to . . O
serious . . B-Severity
infections . . B-AdverseReaction
in . . I-AdverseReaction
the . . I-AdverseReaction
abdomen . . I-AdverseReaction
( . . O
0.7% . . O
placebo . . O
vs . . O
. . . O
0.9% . . O
prolia . . O
) . . O
, . . O
urinary . . O
tract . . O
( . . O
0.5% . . O
placebo . . O
vs . . O
. . . O
0.7% . . O
prolia . . O
) . . O
, . . O
and . . O
ear . . O
( . . O
0.0% . . O
placebo . . O
vs . . O
. . . O
0.1% . . O
prolia . . O
) . . O
were . . O
reported . . O
. . . O

* . . O
hepatotoxicity . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.8 . . O
) . . O
] . . O

the . . O
most . . O
common . . O
laboratory . . O
abnormalities . . O
( . . O
> . . O
20% . . O
) . . O
are . . O
anemia . . B-AdverseReaction
, . . O
elevated . . B-AdverseReaction
alkaline . . I-AdverseReaction
phosphatase . . I-AdverseReaction
, . . O
hypertriglyceridemia . . B-AdverseReaction
, . . O
lymphopenia . . B-AdverseReaction
, . . O
hypercholesterolemia . . B-AdverseReaction
, . . O
hyperglycemia . . B-AdverseReaction
, . . O
elevated . . B-AdverseReaction
ast . . I-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
, . . O
elevated . . B-AdverseReaction
alt . . I-AdverseReaction
and . . O
hypokalemia . . B-AdverseReaction
. . . O

other . . O
adverse . . O
reactions . . O
seen . . O
frequently . . O
in . . O
one . . O
or . . O
more . . O
studies . . O
included . . O
asthenia . . B-AdverseReaction
, . . O
fatigue . . B-AdverseReaction
, . . O
malaise . . B-AdverseReaction
, . . O
and . . O
weakness . . B-AdverseReaction
; . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
; . . O
somnolence . . B-AdverseReaction
; . . O
cough . . B-AdverseReaction
; . . O
constipation . . B-AdverseReaction
; . . O
headache . . B-AdverseReaction
; . . O
mucosal . . B-AdverseReaction
inflammation . . I-AdverseReaction
and . . O
stomatitis . . B-AdverseReaction
. . . O

even . . O
in . . O
the . . O
absence . . O
of . . O
tnf . . O
- . . O
blocker . . O
therapy . . O
, . . O
patients . . O
with . . O
rheumatoid . . O
arthritis . . O
may . . O
be . . O
at . . O
a . . O
higher . . O
risk . . O
( . . O
approximately . . O
2 . . O
- . . O
fold . . O
) . . O
than . . O
the . . O
general . . O
population . . O
for . . O
the . . O
development . . O
of . . O
leukemia . . O
. . . O

table . . O
1 . . O
summarizes . . O
the . . O
adverse . . O
drug . . O
reactions . . O
that . . O
occurred . . O
at . . O
a . . O
rate . . O
of . . O
at . . O
least . . O
1% . . O
in . . O
the . . O
simponi . . O
aria . . O
+ . . O
mtx . . O
group . . O
with . . O
a . . O
higher . . O
incidence . . O
than . . O
in . . O
the . . O
placebo . . O
+ . . O
mtx . . O
group . . O
during . . O
the . . O
controlled . . O
period . . O
of . . O
trial . . O
1 . . O
through . . O
week . . O
24 . . O
. . . O

possible . . O
risk . . O
factors . . O
for . . O
leukopenia . . O
/ . . O
neutropenia . . O
include . . O
pre . . O
- . . O
existing . . O
low . . O
white . . O
blood . . O
cell . . O
count . . O
( . . O
wbc . . O
) . . O
/ . . O
absolute . . O
neutrophil . . O
count . . O
( . . O
anc . . O
) . . O
and . . O
history . . O
of . . O
drug . . O
induced . . O
leukopenia . . O
/ . . O
neutropenia . . O
. . . O

potential . . B-Factor
neonatal . . B-AdverseReaction
adverse . . I-AdverseReaction
effects . . I-AdverseReaction
include . . O
skull . . O
hypoplasia . . O
, . . O
anuria . . O
, . . O
hypotension . . O
, . . O
renal . . O
failure . . O
, . . O
and . . O
death . . O
. . . O

the . . O
risk . . B-Factor
of . . O
hypoglycemia . . B-AdverseReaction
is . . O
increased . . O
when . . O
jardiance . . O
is . . O
used . . O
in . . O
combination . . O
with . . O
insulin . . O
secretagogues . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
sulfonylurea . . O
) . . O
or . . O
insulin . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
: . . O
rhabdomyolysis . . B-AdverseReaction

the . . O
following . . O
adverse . . O
reactions . . O
, . . O
listed . . O
under . . O
the . . O
body . . O
system . . O
headings . . O
above . . O
, . . O
may . . O
occur . . O
as . . O
a . . O
consequence . . O
of . . O
proximal . . B-AdverseReaction
renal . . I-AdverseReaction
tubulopathy . . I-AdverseReaction
: . . O
rhabdomyolysis . . B-AdverseReaction
, . . O
osteomalacia . . B-AdverseReaction
, . . O
hypokalemia . . B-AdverseReaction
, . . O
muscular . . B-AdverseReaction
weakness . . I-AdverseReaction
, . . O
myopathy . . B-AdverseReaction
, . . O
hypophosphatemia . . B-AdverseReaction
. . . O

this . . O
finding . . O
with . . O
salmeterol . . O
is . . O
considered . . O
a . . O
class . . O
effect . . O
of . . O
laba . . O
, . . O
including . . O
indacaterol . . O
, . . O
the . . O
active . . O
ingredient . . O
in . . O
arcapta . . O
neohaler . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
pancreatitis . . B-AdverseReaction
( . . O
including . . O
fatal . . B-AdverseReaction
outcomes . . O
) . . O
. . . O

( . . O
4 . . O
, . . O
5.1 . . O
) . . O
* . . O
only . . O
physicians . . O
experienced . . O
in . . O
immunosuppressive . . O
therapy . . O
and . . O
management . . O
of . . O
kidney . . O
transplant . . O
patients . . O
should . . O
prescribe . . O
nulojix . . O
. . . O

skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
alopecia . . B-AdverseReaction
, . . O
angio . . B-AdverseReaction
- . . I-AdverseReaction
edema . . I-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
, . . O
dermographism . . B-AdverseReaction
, . . O
ecchymosis . . B-AdverseReaction
, . . O
eczema . . B-AdverseReaction
, . . O
hair . . B-AdverseReaction
color . . I-AdverseReaction
changes . . I-AdverseReaction
, . . O
hair . . B-AdverseReaction
growth . . I-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
hyperhidrosis . . B-AdverseReaction
, . . O
peeling . . B-AdverseReaction
skin . . I-AdverseReaction
, . . O
petechiae . . B-AdverseReaction
, . . O
photosensitivity . . B-AdverseReaction
, . . O
pruritus . . B-AdverseReaction
, . . O
purpura . . B-AdverseReaction
, . . O
skin . . B-AdverseReaction
discoloration . . I-AdverseReaction
/ . . O
altered . . O
pigmentation . . O
, . . O
skin . . B-AdverseReaction
lesion . . I-AdverseReaction
, . . O
skin . . B-AdverseReaction
odor . . I-AdverseReaction
abnormal . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
. . . O

more . . O
frequent . . O
monitoring . . O
is . . O
recommended . . O
when . . O
afinitor . . O
is . . O
co . . O
- . . O
administered . . O
with . . O
other . . O
drugs . . O
that . . O
may . . O
induce . . O
hyperglycemia . . O
. . . O

major . . B-Severity
bleeding . . B-AdverseReaction
is . . O
defined . . O
as . . O
bleeding . . B-AdverseReaction
accompanied . . O
by . . O
one . . O
or . . O
more . . O
of . . O
the . . O
following . . O
: . . O
a . . O
decrease . . B-AdverseReaction
in . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
of . . O
> . . O
= . . O
2 . . B-Severity
g . . I-Severity
/ . . I-Severity
dl . . I-Severity
, . . O
a . . O
transfusion . . O
of . . O
> . . O
= . . O
2 . . O
units . . O
of . . O
packed . . O
red . . O
blood . . O
cells . . O
, . . O
bleeding . . B-AdverseReaction
at . . I-AdverseReaction
a . . I-AdverseReaction
critical . . I-AdverseReaction
site . . I-AdverseReaction
or . . O
with . . O
a . . O
fatal . . B-AdverseReaction
outcome . . O
. . . O

the . . O
types . . O
of . . O
ar . . O
resulting . . O
in . . O
withdrawal . . O
from . . O
the . . O
study . . O
varied . . O
considerably . . O
. . . O

there . . O
were . . O
63 . . O
( . . O
12% . . O
) . . O
patients . . O
with . . O
moderate . . B-Severity
( . . O
grade . . B-Severity
2 . . I-Severity
) . . O
dermatitis . . B-AdverseReaction
. . . O

withhold . . O
cometriq . . O
in . . O
patients . . O
who . . O
develop . . O
intolerable . . O
grade . . O
2 . . O
ppes . . O
or . . O
grade . . O
3-4 . . O
ppes . . O
until . . O
improvement . . O
to . . O
grade . . O
1 . . O
; . . O
resume . . O
cometriq . . O
at . . O
a . . O
reduced . . O
dose . . O
. . . O

exclude . . O
other . . O
potential . . O
causes . . O
of . . O
ild . . O
/ . . O
pneumonitis . . O
, . . O
and . . O
permanently . . O
discontinue . . O
zykadia . . O
in . . O
patients . . O
diagnosed . . O
with . . O
treatment . . O
- . . O
related . . O
ild . . O
/ . . O
pneumonitis . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

patients . . O
treated . . O
with . . O
cimzia . . O
are . . O
at . . O
an . . O
increased . . O
risk . . B-Factor
for . . O
developing . . O
serious . . B-Severity
infections . . B-AdverseReaction
involving . . O
various . . O
organ . . O
systems . . O
and . . O
sites . . O
that . . O
may . . B-Factor
lead . . O
to . . O
hospitalization . . O
or . . O
death . . B-AdverseReaction
. . . O

alternatively . . O
, . . O
administration . . O
of . . O
non . . O
- . . O
enteric . . O
coated . . O
aspirin . . O
( . . O
up . . O
to . . O
a . . O
dose . . O
of . . O
325 . . O
mg . . O
) . . O
30 . . O
minutes . . O
prior . . O
to . . O
tecfidera . . O
dosing . . O
may . . O
reduce . . O
the . . O
incidence . . O
or . . O
severity . . O
of . . O
flushing . . B-AdverseReaction
[ . . O
see . . O
dosing . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
and . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

warning . . O
: . . O
perforations . . B-AdverseReaction
and . . O
fistulas . . B-AdverseReaction
, . . O
and . . O
hemorrhage . . B-AdverseReaction

( . . O
all . . O
grades . . O
) . . O
reported . . O
in . . O
> . . O
= . . O
5% . . O
of . . O
subjects . . O
in . . O
any . . O
treatment . . O
arm . . O
in . . O
studies . . O
102 . . O
and . . O
103 . . O
( . . O
week . . O
144 . . O
analysis . . O
) . . O
. . . O

women . . O
dependent . . O
on . . O
thyroid . . O
hormone . . O
replacement . . O
therapy . . O
who . . O
are . . O
also . . O
receiving . . O
estrogens . . O
may . . O
require . . O
increased . . O
doses . . O
of . . O
their . . O
thyroid . . O
replacement . . O
therapy . . O
. . . O

( . . O
5.8 . . O
) . . O
* . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
: . . O
pre . . O
- . . O
medicate . . O
with . . O
dexamethasone . . O
. . . O

gastrointestinal . . O
( . . O
gi . . O
) . . O
hemorrhage . . O
and . . O
perforation . . O
, . . O
ileus . . B-AdverseReaction
, . . O
enterocolitis . . B-AdverseReaction
, . . O
neutropenic . . B-AdverseReaction
enterocolitis . . I-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
outcome . . O
, . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
jevtana . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6.2 . . O
) . . O
] . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
fetal . . B-AdverseReaction
toxicity . . I-AdverseReaction

primary . . O
prophylaxis . . O
with . . O
g . . O
- . . O
csf . . O
should . . O
be . . O
considered . . O
in . . O
patients . . O
with . . O
high . . O
- . . O
risk . . O
clinical . . O
features . . O
. . . O

5.9 . . O
drug . . O
interactions . . O
with . . O
strong . . O
cytochrome . . O
p450 . . O
3a4 . . O
inhibitors . . O

there . . O
have . . O
been . . O
no . . O
clinical . . O
trials . . O
establishing . . O
conclusive . . O
evidence . . O
of . . O
macrovascular . . O
risk . . O
reduction . . O
with . . O
tanzeum . . O
or . . O
any . . O
other . . O
antidiabetic . . O
drug . . O
. . . O

in . . O
controlled . . O
clinical . . O
trials . . O
, . . O
first . . B-AdverseReaction
- . . I-AdverseReaction
degree . . I-AdverseReaction
av . . I-AdverseReaction
block . . I-AdverseReaction
after . . O
the . . O
first . . O
dose . . O
occurred . . O
in . . O
4.7% . . O
of . . O
patients . . O
receiving . . O
gilenya . . O
and . . O
1.6% . . O
of . . O
patients . . O
on . . O
placebo . . O
. . . O

( . . O
5.4 . . O
) . . O
* . . O
dispatch . . O
: . . O
unexpected . . O
key . . O
: . . O
list . . O
in . . O
dispatch . . O
table . . O
: . . O
{ . . O
' . . O
caption . . O
' . . O
: . . O
< . . O
function . . O
print_caption . . O
at . . O
0 . . O
x . . O
1c6c8c0 . . O
> . . O
, . . O
' . . O
text . . O
' . . O
: . . O
< . . O
function . . O
print_text . . O
at . . O
0 . . O
x . . O
1c6c500 . . O
> . . O
} . . O
metabolic . . B-AdverseReaction
changes . . I-AdverseReaction
: . . O
atypical . . B-DrugClass
antipsychotic . . I-DrugClass
drugs . . I-DrugClass
have . . O
been . . O
associated . . O
with . . O
metabolic . . B-AdverseReaction
changes . . I-AdverseReaction
that . . O
may . . O
increase . . O
cardiovascular . . O
/ . . O
cerebrovascular . . B-AdverseReaction
risk . . I-AdverseReaction
. . . O

the . . O
data . . O
in . . O
table . . O
1 . . O
is . . O
derived . . O
from . . O
12 . . O
placebo . . O
- . . O
controlled . . O
studies . . O
ranging . . O
from . . O
12 . . O
to . . O
24 . . O
weeks . . O
. . . O

5.9 . . O
hyponatremia . . O

adverse . . O
reactions . . O
from . . O
clinical . . O
trials . . O
of . . O
the . . O
components . . O
of . . O
stribild . . O

6 . . O
adverse . . O
reactions . . O

hypertoxin . . O
- . . O
producing . . O
strains . . O
of . . O
c . . O
. . . O
difficile . . O
cause . . O
increased . . O
morbidity . . O
and . . O
mortality . . O
, . . O
as . . O
these . . O
infections . . O
can . . O
be . . O
refractory . . O
to . . O
antibacterial . . O
therapy . . O
and . . O
may . . O
require . . O
colectomy . . O
. . . O

patients . . O
should . . O
be . . O
cautioned . . O
about . . O
performing . . O
activities . . O
requiring . . O
mental . . O
alertness . . O
, . . O
such . . O
as . . O
operating . . O
hazardous . . O
machinery . . O
or . . O
operating . . O
a . . O
motor . . O
vehicle . . O
, . . O
until . . O
they . . O
are . . O
reasonably . . O
certain . . O
that . . O
saphris . . O
therapy . . O
does . . O
not . . O
affect . . O
them . . O
adversely . . O
. . . O

other . . O
fatal . . B-AdverseReaction
adverse . . O
reactions . . O
in . . O
jevtana . . O
- . . O
treated . . O
patients . . O
included . . O
ventricular . . B-AdverseReaction
fibrillation . . I-AdverseReaction
, . . O
cerebral . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
and . . O
dyspnea . . B-AdverseReaction
. . . O

( . . O
see . . O
current . . O
recommended . . O
immunization . . O
schedules . . O
at . . O
the . . O
website . . O
of . . O
the . . O
centers . . O
for . . O
disease . . O
control . . O
, . . O
http . . O
: . . O
/ . . O
/ . . O
www . . O
. . . O
cdc . . O
. . . O
gov . . O
/ . . O
vaccines . . O
/ . . O
schedules . . O
/ . . O
index . . O
. . . O
html . . O
) . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
therapy . . O
with . . O
bosulif . . O
was . . O
approximately . . O
17 . . O
months . . O
( . . O
range . . O
, . . O
0.03 . . O
to . . O
95 . . O
) . . O
for . . O
patients . . O
in . . O
these . . O
studies . . O
. . . O

these . . O
reactions . . O
include . . O
anaphylaxis . . B-AdverseReaction
, . . O
angioedema . . B-AdverseReaction
and . . O
severe . . B-Severity
cutaneous . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
, . . O
including . . O
stevens . . B-AdverseReaction
- . . I-AdverseReaction
johnson . . I-AdverseReaction
syndrome . . I-AdverseReaction
. . . O

5.7 . . O
bone . . O
fracture . . O

the . . O
median . . O
duration . . O
on . . O
treatment . . O
was . . O
4.9 . . O
months . . O
for . . O
patients . . O
treated . . O
with . . O
tafinlar . . O
and . . O
2.8 . . O
months . . O
for . . O
dacarbazine . . O
- . . O
treated . . O
patients . . O
. . . O

excerpt . . O
: . . O
* . . O
diarrhea . . O
: . . O
diarrhea . . B-AdverseReaction
may . . B-Factor
result . . O
in . . O
dehydration . . B-AdverseReaction
and . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
. . . O

amyvid . . O
caused . . O
no . . O
serious . . O
adverse . . O
reactions . . O
in . . O
the . . O
studies . . O
and . . O
the . . O
reported . . O
adverse . . O
reactions . . O
were . . O
predominantly . . O
mild . . O
to . . O
moderate . . O
in . . O
severity . . O
. . . O

patients . . O
experiencing . . O
new . . O
, . . O
worsening . . O
, . . O
or . . O
recurrent . . O
hepatotoxicity . . O
may . . O
require . . O
a . . O
delay . . O
, . . O
change . . O
in . . O
dose . . O
, . . O
or . . O
discontinuation . . O
of . . O
adcetris . . O
. . . O

5.7 . . O
plasmodium . . O
vivax . . O
infection . . O

excerpt . . O
: . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
at . . O
least . . O
1% . . O
of . . O
uloric . . O
- . . O
treated . . O
patients . . O
, . . O
and . . O
at . . O
least . . O
0.5% . . O
greater . . O
than . . O
placebo . . O
, . . O
are . . O
liver . . B-AdverseReaction
function . . I-AdverseReaction
abnormalities . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
arthralgia . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
. . . O

5.3 . . O
hemorrhage . . O

the . . O
following . . O
adverse . . O
reactions . . O
have . . O
been . . O
identified . . O
during . . O
post . . O
- . . O
approval . . O
use . . O
of . . O
adcetris . . O
. . . O

if . . O
liver . . O
injury . . O
is . . O
detected . . O
, . . O
promptly . . O
interrupt . . O
nesina . . O
and . . O
assess . . O
patient . . O
for . . O
probable . . O
cause . . O
, . . O
then . . O
treat . . O
cause . . O
if . . O
possible . . O
, . . O
to . . O
resolution . . O
or . . O
stabilization . . O
. . . O

patients . . O
should . . O
be . . O
evaluated . . O
for . . O
tuberculosis . . O
risk . . O
factors . . O
and . . O
tested . . O
for . . O
latent . . O
infection . . O
prior . . O
to . . O
initiating . . O
cimzia . . O
and . . O
periodically . . O
during . . O
therapy . . O
. . . O

in . . O
clinical . . O
trials . . O
with . . O
nulojix . . O
, . . O
two . . O
cases . . O
of . . O
pml . . B-AdverseReaction
were . . O
reported . . O
in . . O
patients . . O
receiving . . O
nulojix . . O
at . . O
higher . . O
cumulative . . O
doses . . O
and . . O
more . . O
frequently . . O
than . . O
the . . O
recommended . . O
regimen . . O
, . . O
along . . O
with . . O
mycophenolate . . O
mofetil . . O
( . . O
mmf . . O
) . . O
and . . O
corticosteroids . . O
; . . O
one . . O
case . . O
occurred . . O
in . . O
a . . O
kidney . . O
transplant . . O
recipient . . O
and . . O
the . . O
second . . O
case . . O
occurred . . O
in . . O
a . . O
liver . . O
transplant . . O
recipient . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.6 . . O
) . . O
] . . O
. . . O

serious . . B-Severity
skin . . B-AdverseReaction
infections . . I-AdverseReaction
, . . O
as . . O
well . . O
as . . O
infections . . B-AdverseReaction
of . . I-AdverseReaction
the . . I-AdverseReaction
abdomen . . I-AdverseReaction
, . . O
urinary . . O
tract . . O
, . . O
and . . O
ear . . O
, . . O
were . . O
more . . O
frequent . . O
in . . O
patients . . O
treated . . O
with . . O
prolia . . O
. . . O

patients . . O
can . . O
have . . O
more . . O
than . . O
one . . O
site . . O
of . . O
bleeding . . B-AdverseReaction
. . . O
c . . O
confidence . . O
interval . . O
patients . . O
major . . B-Severity
bleeding . . B-AdverseReaction
event . . O
a . . O
clinically . . O
relevant . . O
non . . B-Severity
- . . I-Severity
major . . I-Severity
bleeding . . B-AdverseReaction
any . . O
bleeding . . B-AdverseReaction
in . . O
the . . O
re . . O
- . . O
sonate . . O
study . . O
, . . O
the . . O
rate . . O
of . . O
any . . O
gastrointestinal . . B-AdverseReaction
bleeds . . I-AdverseReaction
in . . O
patients . . O
receiving . . O
pradaxa . . O
150 . . O
mg . . O
was . . O
0.7% . . O
( . . O
0.3% . . O
on . . O
placebo . . O
) . . O
. . . O

during . . O
clinical . . O
trials . . O
with . . O
ilaris . . O
, . . O
mean . . O
values . . O
decreased . . O
for . . O
white . . O
blood . . O
cells . . O
, . . O
neutrophils . . O
and . . O
platelets . . O
. . . O

three . . O
of . . O
these . . O
6 . . O
patients . . O
tested . . O
positive . . O
for . . O
neutralizing . . O
antibodies . . O
. . . O

patients . . O
should . . O
be . . O
instructed . . O
to . . O
contact . . O
their . . O
healthcare . . O
provider . . O
if . . O
they . . O
experience . . O
new . . O
or . . O
worsening . . O
depression . . O
, . . O
suicidal . . O
thoughts . . O
or . . O
other . . O
mood . . O
changes . . O
. . . O

immunogenicity . . O
assay . . O
results . . O
are . . O
highly . . O
dependent . . O
on . . O
the . . O
sensitivity . . O
and . . O
specificity . . O
of . . O
the . . O
assay . . O
used . . O
in . . O
detection . . O
and . . O
may . . O
be . . O
influenced . . O
by . . O
several . . O
factors . . O
, . . O
including . . O
sample . . O
handling . . O
, . . O
timing . . O
of . . O
sample . . O
collection . . O
, . . O
concomitant . . O
medications . . O
, . . O
and . . O
underlying . . O
disease . . O
. . . O

across . . O
8 . . O
phase . . O
iii . . O
clinical . . O
trials . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
, . . O
mtc . . B-AdverseReaction
was . . O
diagnosed . . O
in . . O
1 . . O
patient . . O
receiving . . O
tanzeum . . O
and . . O
1 . . O
patient . . O
receiving . . O
placebo . . O
. . . O

there . . O
were . . O
more . . O
deaths . . B-AdverseReaction
reported . . O
with . . O
benlysta . . O
than . . O
with . . O
placebo . . O
during . . O
the . . O
controlled . . O
period . . O
of . . O
the . . O
clinical . . O
trials . . O
. . . O

5.6 . . O
carbohydrate . . O
and . . O
lipid . . O
metabolic . . O
effects . . O

the . . O
possibility . . O
of . . O
a . . O
suicide . . O
attempt . . O
is . . O
inherent . . O
in . . O
psychotic . . O
illnesses . . O
and . . O
bipolar . . O
disorder . . O
, . . O
and . . O
close . . O
supervision . . O
of . . O
high . . O
- . . O
risk . . O
patients . . O
should . . O
accompany . . O
drug . . O
therapy . . O
. . . O

treatment . . O
of . . O
dvt . . O
and . . O
pe . . O
and . . O
reduction . . O
in . . O
the . . O
risk . . O
of . . O
recurrence . . O
of . . O
dvt . . O
or . . O
pe . . O

warning . . O
: . . O
retinal . . B-AdverseReaction
abnormalities . . I-AdverseReaction
and . . O
potential . . B-Factor
vision . . B-AdverseReaction
loss . . I-AdverseReaction

in . . O
clinical . . O
trials . . O
, . . O
scc . . O
was . . O
observed . . O
both . . O
in . . O
patients . . O
receiving . . O
vimizim . . O
and . . O
patients . . O
receiving . . O
placebo . . O
. . . O

in . . O
clinical . . O
studies . . O
, . . O
555 . . O
patients . . O
were . . O
exposed . . O
to . . O
amyvid . . O
. . . O

discontinue . . O
promacta . . O
if . . O
antiviral . . O
therapy . . O
is . . O
discontinued . . O
. . . O

adverse . . O
reactions . . O
of . . O
infectious . . B-AdverseReaction
etiology . . I-AdverseReaction
were . . O
reported . . O
based . . O
on . . O
clinical . . O
assessment . . O
by . . O
physicians . . O
. . . O

pristiq . . O
is . . O
not . . O
approved . . O
for . . O
use . . O
in . . O
pediatric . . O
patients . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.4 . . O
) . . O
] . . O
. . . O

adverse . . O
events . . O
( . . O
regardless . . O
of . . O
investigator's . . O
causality . . O
assessment . . O
) . . O
reported . . O
in . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
10% . . O
of . . O
subjects . . O
receiving . . O
the . . O
combination . . O
of . . O
victrelis . . O
with . . O
pegintron . . O
/ . . O
rebetol . . O
and . . O
reported . . O
at . . O
a . . O
rate . . O
of . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
5% . . O
than . . O
pegintron . . O
/ . . O
rebetol . . O
alone . . O
in . . O
sprint . . O
- . . O
1 . . O
, . . O
sprint . . O
- . . O
2 . . O
, . . O
and . . O
respond . . O
- . . O
2 . . O
are . . O
presented . . O
in . . O
table . . O
3 . . O
. . . O

table . . O
4 . . O
bleeding . . B-AdverseReaction
events . . O
in . . O
re . . O
- . . O
medy . . O
treated . . O
patients . . O
note . . O
: . . O
mbe . . B-AdverseReaction
can . . O
belong . . O
to . . O
more . . O
than . . O
one . . O
criterion . . O
. . . O
a . . O
patients . . O
with . . O
at . . O
least . . O
one . . O
mbe . . B-AdverseReaction
. . . O
b . . O
bleeding . . B-AdverseReaction
site . . O
based . . O
on . . O
investigator . . O
assessment . . O
. . . O

a . . O
causal . . O
relationship . . O
with . . O
uloric . . O
has . . O
not . . O
been . . O
established . . O
. . . O

see . . O
full . . O
prescribing . . O
information . . O
for . . O
complete . . O
boxed . . O
warning . . O
. . . O

graft . . B-AdverseReaction
loss . . I-AdverseReaction
was . . O
a . . O
consequence . . O
of . . O
grade . . B-Severity
iii . . I-Severity
rejection . . O
in . . O
some . . O
patients . . O
. . . O

it . . O
is . . O
recommended . . O
that . . O
therapeutic . . O
infectious . . O
agents . . O
not . . O
be . . O
given . . O
concurrently . . O
with . . O
simponi . . O
aria . . O
. . . O

in . . O
patients . . O
treated . . O
with . . O
glp . . B-DrugClass
- . . I-DrugClass
1 . . I-DrugClass
receptor . . I-DrugClass
agonists . . I-DrugClass
, . . O
there . . O
have . . O
been . . O
postmarketing . . O
reports . . O
of . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
and . . O
worsening . . B-AdverseReaction
of . . I-AdverseReaction
chronic . . I-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
which . . O
may . . O
sometimes . . O
require . . O
hemodialysis . . O
. . . O

the . . O
most . . O
frequent . . O
adverse . . O
reactions . . O
in . . O
xeomin . . O
treated . . O
subjects . . O
were . . O
: . . O
headache . . B-AdverseReaction
29 . . O
( . . O
5.4% . . O
) . . O
, . . O
facial . . B-AdverseReaction
paresis . . I-AdverseReaction
4 . . O
( . . O
0.7% . . O
) . . O
, . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
hematoma . . I-AdverseReaction
3 . . O
( . . O
0.6% . . O
) . . O
and . . O
eyelid . . B-AdverseReaction
edema . . I-AdverseReaction
2 . . O
( . . O
0.4% . . O
) . . O
. . . O

the . . O
majority . . O
of . . O
patients . . O
on . . O
the . . O
xalkori . . O
arms . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
( . . O
> . . O
50% . . O
) . . O
reported . . O
visual . . B-AdverseReaction
disturbances . . I-AdverseReaction
which . . O
occurred . . O
at . . O
a . . O
frequency . . O
of . . O
4-7 . . O
days . . O
each . . O
week . . O
, . . O
lasted . . O
up . . O
to . . O
1 . . O
minute . . O
, . . O
and . . O
had . . O
mild . . O
or . . O
no . . O
impact . . O
( . . O
scores . . O
0 . . O
to . . O
3 . . O
out . . O
of . . O
a . . O
maximum . . O
score . . O
of . . O
10 . . O
) . . O
on . . O
daily . . O
activities . . O
as . . O
captured . . O
in . . O
the . . O
vsaq . . O
- . . O
alk . . O
questionnaire . . O
. . . O

when . . O
pregnancy . . O
is . . O
detected . . O
, . . O
discontinue . . O
edarbi . . O
as . . O
soon . . O
as . . O
possible . . O
[ . . O
seeuse . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

( . . O
5.4 . . O
) . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
in . . O
patients . . O
treated . . O
with . . O
dalvance . . O
were . . O
nausea . . B-AdverseReaction
( . . O
5.5% . . O
) . . O
, . . O
headache . . B-AdverseReaction
( . . O
4.7% . . O
) . . O
, . . O
and . . O
diarrhea . . B-AdverseReaction
( . . O
4.4% . . O
) . . O
. . . O

for . . O
these . . O
patients . . O
, . . O
a . . O
reduction . . O
in . . O
the . . O
quantity . . O
of . . O
concurrently . . O
administered . . O
lipids . . O
may . . O
be . . O
necessary . . O
to . . O
compensate . . O
for . . O
the . . O
amount . . O
of . . O
lipid . . O
infused . . O
as . . O
part . . O
of . . O
the . . O
cleviprex . . O
formulation . . O
. . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
botulinum . . B-DrugClass
toxin . . I-DrugClass
products . . I-DrugClass
( . . O
anaphylaxis . . B-AdverseReaction
, . . O
serum . . B-AdverseReaction
sickness . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
soft . . B-AdverseReaction
tissue . . I-AdverseReaction
edema . . I-AdverseReaction
, . . O
and . . O
dyspnea . . B-AdverseReaction
) . . O
. . . O

adverse . . O
events . . O
such . . O
as . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
and . . O
diarrhea . . B-AdverseReaction
were . . O
also . . O
reported . . O
at . . O
an . . O
increased . . O
frequency . . O
in . . O
subjects . . O
receiving . . O
victrelis . . O
in . . O
combination . . O
with . . O
peginterferon . . O
alfa . . O
and . . O
ribavirin . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
the . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
clinical . . O
practice . . O
. . . O

the . . O
data . . O
described . . O
below . . O
primarily . . O
derive . . O
from . . O
two . . O
randomized . . O
, . . O
active . . O
- . . O
controlled . . O
three . . O
- . . O
year . . O
trials . . O
of . . O
nulojix . . O
in . . O
de . . O
novo . . O
kidney . . O
transplant . . O
patients . . O
. . . O

baseline . . O
follow . . O
up . . O
renal . . O
function . . O
status . . O
n . . O
normaln . . O
( . . O
% . . O
) . . O
mildn . . O
( . . O
% . . O
) . . O
mild . . O
to . . O
moderaten . . O
( . . O
% . . O
) . . O
moderate . . O
to . . O
severen . . O
( . . O
% . . O
) . . O
severen . . O
( . . O
% . . O
) . . O
kidney . . B-AdverseReaction
failuren . . O
( . . O
% . . O
) . . O
notes . . O
: . . O
grading . . O
is . . O
based . . O
on . . O
modification . . O
in . . O
diet . . O
in . . O
renal . . O
disease . . O
method . . O
( . . O
mdrd . . O
) . . O
. . . O
kdigo . . O
classification . . O
by . . O
egfr . . O
: . . O
normal . . O
: . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
90 . . O
, . . O
mild . . O
: . . O
60 . . O
to . . O
less . . O
than . . O
90 . . O
, . . O
mild . . O
to . . O
moderate . . O
: . . O
45 . . O
to . . O
less . . O
than . . O
60 . . O
, . . O
moderate . . O
to . . O
severe . . O
: . . O
30 . . O
to . . O
less . . O
than . . O
45 . . O
, . . O
severe . . O
: . . O
15 . . O
to . . O
less . . O
than . . O
30 . . O
, . . O
kidney . . O
failure . . O
: . . O
less . . O
than . . O
15 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73 . . O
m . . O
2 . . O
. . . O

discontinue . . O
kyprolis . . O
if . . O
suspected . . O
. . . O

of . . O
therapy . . O
( . . O
2.4 . . O
, . . O
2.5 . . O
, . . O
2.6 . . O
, . . O
5.1 . . O
) . . O
. . . O

even . . O
in . . O
the . . O
absence . . O
of . . O
tnf . . O
- . . O
blocker . . O
therapy . . O
, . . O
patients . . O
with . . O
ra . . O
may . . O
be . . O
at . . O
a . . O
higher . . O
risk . . O
( . . O
approximately . . O
2 . . O
- . . O
fold . . O
) . . O
than . . O
the . . O
general . . O
population . . O
for . . O
the . . O
development . . O
of . . O
leukemia . . O
. . . O

approximately . . O
one . . O
third . . O
of . . O
the . . O
patients . . O
who . . O
had . . O
eye . . O
examinations . . O
performed . . O
after . . O
approximately . . O
4 . . O
years . . O
of . . O
treatment . . O
were . . O
found . . O
to . . O
have . . O
retinal . . B-AdverseReaction
pigmentary . . I-AdverseReaction
abnormalities . . I-AdverseReaction
. . . O

grade . . B-Severity
3 . . I-Severity
/ . . O
4 . . O
hypertension . . B-AdverseReaction
was . . O
observed . . O
in . . O
56 . . O
/ . . O
359 . . O
patients . . O
( . . O
16% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
39 . . O
/ . . O
355 . . O
patients . . O
( . . O
11% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

in . . O
study . . O
1 . . O
and . . O
2 . . O
, . . O
the . . O
majority . . O
of . . O
arrhythmias . . O
were . . O
grade . . B-Severity
1 . . I-Severity
or . . O
2 . . O
. . . O

two . . O
percent . . O
( . . O
4 . . O
of . . O
183 . . O
) . . O
of . . O
subjects . . O
had . . O
a . . O
grade . . O
3 . . O
to . . O
4 . . O
treatment . . O
- . . O
emergent . . O
hematology . . O
laboratory . . O
abnormality . . O
, . . O
with . . O
neutropenia . . B-AdverseReaction
( . . O
2% . . O
[ . . O
3 . . O
of . . O
183 . . O
] . . O
) . . O
being . . O
the . . O
most . . O
frequently . . O
reported . . O
. . . O

excerpt . . O
: . . O
most . . O
common . . O
adverse . . O
reactions . . O
( . . O
incidence . . O
greater . . O
than . . O
20% . . O
) . . O
are . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
vomiting . . B-AdverseReaction
, . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
pyrexia . . B-AdverseReaction
, . . O
and . . O
fatigue . . B-AdverseReaction
. . . O

diarrhea . . B-AdverseReaction
has . . O
resulted . . O
in . . O
dehydration . . B-AdverseReaction
with . . O
or . . O
without . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
; . . O
some . . O
of . . O
these . . O
cases . . O
were . . O
fatal . . B-AdverseReaction
. . . O

please . . O
see . . O
www . . O
. . . O
proliasafety . . O
. . . O
com . . O
or . . O
call . . O
1-800-772-6436 . . O
for . . O
more . . O
information . . O
about . . O
this . . O
program . . O
. . . O

premedicate . . O
with . . O
corticosteroids . . O
and . . O
h2 . . O
antagonists . . O
. . . O

5.2 . . O
bleeding . . O

after . . O
6 . . O
cycles . . O
, . . O
patients . . O
remained . . O
on . . O
study . . O
with . . O
no . . O
additional . . O
anticancer . . O
treatment . . O
, . . O
and . . O
tumor . . O
assessments . . O
continued . . O
until . . O
documented . . O
disease . . O
progression . . O
. . . O

( . . O
4 . . O
) . . O

5.4 . . O
wound . . O
complications . . O

[ . . O
seedosage . . O
and . . O
administration . . O
( . . O
2.3 . . O
) . . O
] . . O
. . . O

5.5 . . O
cardiomyopathy . . O

* . . O
b . . O
in . . O
this . . O
trial . . O
, . . O
no . . B-Negation
documented . . O
symptomatic . . B-Severity
or . . O
severe . . B-Severity
hypoglycemia . . B-AdverseReaction
were . . O
reported . . O
for . . O
tanzeum . . O
50 . . O
mg . . O
and . . O
these . . O
data . . O
are . . O
omitted . . O
from . . O
the . . O
table . . O
. . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
leading . . O
to . . O
the . . O
discontinuation . . O
of . . O
cimzia . . O
( . . O
for . . O
at . . O
least . . O
2 . . O
patients . . O
and . . O
with . . O
a . . O
higher . . O
incidence . . O
than . . O
placebo . . O
) . . O
were . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
( . . O
0.4% . . O
cimzia . . O
, . . O
0.2% . . O
placebo . . O
) . . O
, . . O
diarrhea . . B-AdverseReaction
( . . O
0.4% . . O
cimzia . . O
, . . O
0% . . O
placebo . . O
) . . O
, . . O
and . . O
intestinal . . B-AdverseReaction
obstruction . . I-AdverseReaction
( . . O
0.4% . . O
cimzia . . O
, . . O
0% . . O
placebo . . O
) . . O
. . . O

psoriatic . . O
arthritis . . O
clinical . . O
study . . O

renal . . B-AdverseReaction
insufficiency . . I-AdverseReaction
adverse . . I-AdverseReaction
events . . I-AdverseReaction
( . . O
renal . . B-AdverseReaction
impairment . . I-AdverseReaction
, . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
, . . O
renal . . B-AdverseReaction
failure . . I-AdverseReaction
) . . O
have . . O
occurred . . O
with . . O
an . . O
incidence . . O
of . . O
approximately . . O
8% . . O
in . . O
a . . O
randomized . . O
controlled . . O
trial . . O
. . . O

the . . O
youngest . . O
alglucosidase . . O
alfa . . O
- . . O
treated . . O
patient . . O
was . . O
16 . . O
years . . O
of . . O
age . . O
, . . O
and . . O
the . . O
youngest . . O
placebo . . O
- . . O
treated . . O
patient . . O
was . . O
10 . . O
years . . O
of . . O
age . . O
. . . O

monitor . . O
for . . O
signs . . O
and . . O
symptoms . . O
during . . O
therapy . . O
. . . O

aerosolization . . O
of . . O
capsaicin . . O
can . . O
occur . . O
upon . . O
rapid . . O
removal . . O
of . . O
qutenza . . O
patches . . O
. . . O

in . . O
the . . O
clinical . . O
trial . . O
program . . O
, . . O
pancreatitis . . B-AdverseReaction
was . . O
reported . . O
in . . O
11 . . O
of . . O
5902 . . O
( . . O
0.2% . . O
) . . O
patients . . O
receiving . . O
nesina . . O
25 . . O
mg . . O
daily . . O
compared . . O
to . . O
five . . O
of . . O
5183 . . O
( . . O
< . . O
0.1% . . O
) . . O
patients . . O
receiving . . O
all . . O
comparators . . O
. . . O

monitor . . O
hbv . . O
carriers . . O
during . . O
and . . O
several . . O
months . . O
after . . O
therapy . . O
. . . O

interrupt . . O
or . . O
discontinue . . O
blincyto . . O
as . . O
recommended . . O
. . . O

do . . O
not . . O
place . . O
duavee . . O
in . . O
pill . . O
boxes . . O
or . . O
pill . . O
organizers . . O
. . . O

p . . O
- . . O
gp . . O
inhibition . . O
and . . O
impaired . . O
renal . . O
function . . O
are . . O
the . . O
major . . O
independent . . O
factors . . O
that . . O
result . . O
in . . O
increased . . O
exposure . . O
to . . O
dabigatran . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

redistribution . . O
/ . . O
accumulation . . B-AdverseReaction
of . . I-AdverseReaction
body . . I-AdverseReaction
fat . . I-AdverseReaction
including . . O
central . . B-AdverseReaction
obesity . . I-AdverseReaction
, . . O
dorsocervical . . B-AdverseReaction
fat . . I-AdverseReaction
enlargement . . I-AdverseReaction
( . . O
buffalo . . B-AdverseReaction
hump . . I-AdverseReaction
) . . O
, . . O
peripheral . . O
wasting . . O
, . . O
facial . . B-AdverseReaction
wasting . . I-AdverseReaction
, . . O
breast . . B-AdverseReaction
enlargement . . I-AdverseReaction
, . . O
and . . O
" . . O
cushingoid . . B-AdverseReaction
appearance . . I-AdverseReaction
" . . O
have . . O
been . . O
observed . . O
in . . O
patients . . O
receiving . . O
antiretroviral . . O
therapy . . O
. . . O

5.3 . . O
heart . . O
failure . . O

discontinuation . . O
due . . O
to . . O
gi . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
occurred . . O
in . . O
2% . . O
of . . O
individuals . . O
on . . O
tanzeum . . O
or . . O
placebo . . O
. . . O

for . . O
patients . . O
who . . O
develop . . O
moderate . . O
to . . O
severe . . O
proteinuria . . O
, . . O
reduce . . O
the . . O
dose . . O
or . . O
temporarily . . O
interrupt . . O
inlyta . . O
treatment . . O
. . . O

case . . O
reports . . O
and . . O
epidemiological . . O
studies . . O
( . . O
case . . O
- . . O
control . . O
and . . O
cohort . . O
design . . O
) . . O
have . . O
demonstrated . . O
an . . O
association . . O
between . . O
use . . O
of . . O
drugs . . B-DrugClass
that . . I-DrugClass
interfere . . I-DrugClass
with . . I-DrugClass
serotonin . . I-DrugClass
reuptake . . I-DrugClass
and . . O
the . . O
occurrence . . O
of . . O
gastrointestinal . . B-AdverseReaction
bleeding . . I-AdverseReaction
. . . O

the . . O
management . . O
of . . O
nms . . O
should . . O
include . . O
: . . O
1 . . O
) . . O
immediate . . O
discontinuation . . O
of . . O
antipsychotic . . O
drugs . . O
and . . O
other . . O
drugs . . O
not . . O
essential . . O
to . . O
concurrent . . O
therapy . . O
; . . O
2 . . O
) . . O
intensive . . O
symptomatic . . O
treatment . . O
and . . O
medical . . O
monitoring . . O
; . . O
and . . O
3 . . O
) . . O
treatment . . O
of . . O
any . . O
concomitant . . O
serious . . O
medical . . O
problems . . O
for . . O
which . . O
specific . . O
treatments . . O
are . . O
available . . O
. . . O

* . . O
the . . O
risk . . B-Factor
for . . O
nsf . . B-AdverseReaction
appears . . O
highest . . O
among . . O
patients . . O
with . . O
: . . O
chronic . . O
, . . O
severe . . O
kidney . . O
disease . . O
( . . O
gfr . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
/ . . O
1.73m2 . . O
) . . O
, . . O
oracute . . O
kidney . . O
injury . . O
. . . O

5.5 . . O
tumor . . O
lysis . . O
syndrome . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
2% . . O
of . . O
patients . . O
receiving . . O
teflaro . . O
in . . O
the . . O
pooled . . O
phase . . O
3 . . O
clinical . . O
trials . . O
were . . O
diarrhea . . B-AdverseReaction
, . . O
nausea . . B-AdverseReaction
, . . O
and . . O
rash . . B-AdverseReaction
. . . O

the . . O
incidence . . O
of . . O
infections . . B-AdverseReaction
in . . O
controlled . . O
studies . . O
in . . O
crohn's . . O
disease . . O
was . . O
38% . . O
for . . O
cimzia . . O
- . . O
treated . . O
patients . . O
and . . O
30% . . O
for . . O
placebo . . O
- . . O
treated . . O
patients . . O
. . . O

ampyra . . O
should . . O
not . . O
be . . O
taken . . O
with . . O
other . . O
forms . . O
of . . O
4 . . O
- . . O
aminopyridine . . O
( . . O
4 . . O
- . . O
ap . . O
, . . O
fampridine . . O
) . . O
since . . O
the . . O
active . . O
ingredient . . O
is . . O
the . . O
same . . O
. . . O

patients . . O
received . . O
gilotrif . . O
40 . . O
mg . . O
daily . . O
until . . O
documented . . O
disease . . O
progression . . O
or . . O
intolerance . . O
to . . O
the . . O
therapy . . O
. . . O

to . . O
manage . . O
myelosuppression . . O
, . . O
withhold . . O
, . . O
dose . . O
reduce . . O
, . . O
or . . O
discontinue . . O
bosulif . . O
as . . O
necessary . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

the . . O
risks . . O
and . . O
benefits . . O
of . . O
treatment . . O
should . . O
be . . O
considered . . O
prior . . O
to . . O
prescribing . . O
tnf . . O
- . . O
blockers . . O
, . . O
including . . O
simponi . . O
aria . . O
, . . O
to . . O
patients . . O
who . . O
are . . O
carriers . . O
of . . O
hbv . . O
. . . O

( . . O
6.1 . . O
) . . O
* . . O
most . . O
common . . O
hematologic . . B-AdverseReaction
abnormalities . . I-AdverseReaction
for . . O
both . . O
indications . . O
( . . O
frequency . . O
> . . O
= . . O
15% . . O
) . . O
are . . O
lymphopenia . . B-AdverseReaction
, . . O
anemia . . B-AdverseReaction
, . . O
leukopenia . . B-AdverseReaction
, . . O
thrombocytopenia . . B-AdverseReaction
, . . O
and . . O
neutropenia . . B-AdverseReaction
. . . O

( . . O
5.13,8.1 . . O
) . . O
5.1 . . O
hypertension . . O
and . . O
hypertensive . . O
crisis . . O

5 . . O
warnings . . O
and . . O
precautions . . O

because . . O
most . . O
trials . . O
included . . O
in . . O
the . . O
analysis . . O
did . . O
not . . O
extend . . O
beyond . . O
24 . . O
weeks . . O
, . . O
the . . O
risk . . O
of . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
beyond . . O
24 . . O
weeks . . O
could . . O
not . . O
be . . O
assessed . . O
. . . O

incidence . . O
of . . O
adverse . . O
reactions . . O
( . . O
in . . O
at . . O
least . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
1,200 . . O
mg . . O
/ . . O
day . . O
of . . O
horizant . . O
and . . O
numerically . . O
greater . . O
than . . O
the . . O
placebo . . O
rate . . O
) . . O
reported . . O
in . . O
all . . O
patients . . O
in . . O
the . . O
12 . . O
- . . O
week . . O
phn . . O
study . . O
body . . O
system . . O
/ . . O
adverse . . O
reaction . . O
placebo . . O
( . . O
n . . O
= . . O
95 . . O
) . . O
% . . O
horizant1,200 . . O
mg . . O
/ . . O
day . . O
( . . O
n . . O
= . . O
107 . . O
) . . O
% . . O
horizant2,400 . . O
mg . . O
/ . . O
day . . O
( . . O
n . . O
= . . O
82 . . O
) . . O
% . . O
horizant3,600 . . O
mg . . O
/ . . O
day . . O
( . . O
n . . O
= . . O
87 . . O
) . . O
% . . O
nervous . . O
system . . O
dizziness . . B-AdverseReaction
15 . . O
17 . . O
26 . . O
30 . . O
somnolence . . B-AdverseReaction
8 . . O
10 . . O
11 . . O
14 . . O
headache . . B-AdverseReaction
9 . . O
10 . . O
10 . . O
7 . . O
gastrointestinal . . O
disorders . . O
nausea . . B-AdverseReaction
5 . . O
8 . . O
4 . . O
9 . . O
general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
/ . . O
asthenia . . B-AdverseReaction
1 . . O
6 . . O
4 . . O
10 . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
0 . . O
6 . . O
7 . . O
6 . . O
psychiatric . . O
disorders . . O
insomnia . . B-AdverseReaction
2 . . O
3 . . O
5 . . O
7 . . O
metabolism . . O
and . . O
nutritional . . O
disorders . . O
weight . . B-AdverseReaction
increased . . I-AdverseReaction
1 . . O
3 . . O
5 . . O
5 . . O
eye . . O
disorders . . O
blurred . . B-AdverseReaction
vision . . I-AdverseReaction
0 . . O
2 . . O
5 . . O
2 . . O
the . . O
following . . O
adverse . . O
reactions . . O
were . . O
also . . O
reported . . O
as . . O
> . . O
= . . O
2% . . O
at . . O
2,400 . . O
mg . . O
/ . . O
day . . O
and . . O
/ . . O
or . . O
3,600 . . O
mg . . O
/ . . O
day . . O
and . . O
appeared . . O
to . . O
be . . O
dose . . O
- . . O
related . . O
but . . O
were . . O
< . . O
2% . . O
at . . O
1,200 . . O
mg . . O
/ . . O
day . . O
: . . O
balance . . B-AdverseReaction
disorder . . I-AdverseReaction
, . . O
confusional . . B-AdverseReaction
state . . I-AdverseReaction
, . . O
depression . . B-AdverseReaction
, . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
, . . O
flatulence . . B-AdverseReaction
, . . O
increased . . B-AdverseReaction
appetite . . I-AdverseReaction
, . . O
irritability . . B-AdverseReaction
, . . O
and . . O
vertigo . . B-AdverseReaction
. . . O

no . . B-Negation
fatal . . B-AdverseReaction
adverse . . O
events . . O
occurred . . O
on . . O
treatment . . O
among . . O
patients . . O
in . . O
remission . . O
. . . O

the . . O
initial . . O
prescription . . O
and . . O
renewal . . O
of . . O
the . . O
medication . . O
order . . O
beyond . . O
28 . . O
days . . O
should . . O
be . . O
made . . O
by . . O
a . . O
physician . . O
only . . O
after . . O
examination . . O
of . . O
the . . O
patient . . O
with . . O
the . . O
aid . . O
of . . O
magnification . . O
such . . O
as . . O
slit . . O
lamp . . O
biomicroscopy . . O
and . . O
, . . O
where . . O
appropriate . . O
, . . O
fluorescein . . O
staining . . O
. . . O

psychiatric . . O
disorders . . O
: . . O
agitation . . B-AdverseReaction
, . . O
mood . . B-AdverseReaction
swings . . I-AdverseReaction

thirty . . O
- . . O
three . . O
patients . . O
receiving . . O
dificid . . O
( . . O
5.9% . . O
) . . O
withdrew . . O
from . . O
trials . . O
as . . O
a . . O
result . . O
of . . O
adverse . . O
reactions . . O
( . . O
ar . . O
) . . O
. . . O

a . . O
subset . . O
of . . O
patients . . O
who . . O
had . . O
recurrence . . O
of . . O
contracture . . O
in . . O
a . . O
joint . . O
that . . O
was . . O
previously . . O
successfully . . O
treated . . O
with . . O
xiaflex . . O
in . . O
study . . O
4 . . O
were . . O
retreated . . O
( . . O
study . . O
5 . . O
) . . O
. . . O

observe . . O
infants . . O
for . . O
signs . . O
or . . O
symptoms . . O
of . . O
benzyl . . O
alcohol . . O
toxicity . . O
following . . O
adreview . . O
administration . . O
. . . O

tafinlar . . O
was . . O
studied . . O
in . . O
open . . O
- . . O
label . . O
, . . O
single . . O
- . . O
arm . . O
trials . . O
and . . O
in . . O
an . . O
open . . O
- . . O
label . . O
, . . O
randomized . . O
, . . O
active . . O
- . . O
controlled . . O
trial . . O
. . . O

if . . O
a . . O
serious . . O
hypersensitivity . . O
reaction . . O
occurs . . O
, . . O
discontinue . . O
erwinaze . . O
and . . O
initiate . . O
appropriate . . O
therapy . . O
. . . O

12 . . O
- . . O
month . . O
trials . . O

the . . O
ovaries . . O
normally . . O
stop . . O
making . . O
estrogens . . O
when . . O
a . . O
woman . . O
is . . O
between . . O
45 . . O
and . . O
55 . . O
years . . O
old . . O
. . . O

cases . . O
of . . O
sjs . . B-AdverseReaction
and . . O
ten . . B-AdverseReaction
, . . O
some . . O
fatal . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
when . . O
treanda . . O
was . . O
administered . . O
concomitantly . . O
with . . O
allopurinol . . O
and . . O
other . . O
medications . . O
known . . O
to . . O
cause . . O
these . . O
syndromes . . O
. . . O

if . . O
hypersensitivity . . O
reactions . . O
occur . . O
, . . O
discontinue . . O
use . . O
of . . O
tanzeum . . O
; . . O
treat . . O
promptly . . O
per . . O
standard . . O
of . . O
care . . O
and . . O
monitor . . O
until . . O
signs . . O
and . . O
symptoms . . O
resolve . . O
[ . . O
see . . O
contraindications . . O
( . . O
4.2 . . O
) . . O
] . . O
. . . O

discontinuation . . O
of . . O
therapy . . O
in . . O
gilotrif . . O
- . . O
treated . . O
patients . . O
for . . O
adverse . . O
reactions . . O
was . . O
14.0% . . O
. . . O

boxed . . O
warning . . O
: . . O
warning . . O
: . . O
asthma . . O
- . . O
related . . O
death . . B-AdverseReaction

a . . O
total . . O
of . . O
35% . . O
were . . O
hispanic . . O
or . . O
latino . . O
. . . O

5.2 . . O
deterioration . . O
of . . O
disease . . O
and . . O
acute . . O
episodes . . O

the . . O
imbalance . . O
in . . O
deaths . . B-AdverseReaction
is . . O
unexplained . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
( . . O
including . . O
hematemesis . . B-AdverseReaction
and . . O
melena . . B-AdverseReaction
) . . O
, . . O
hematochezia . . B-AdverseReaction

excerpt . . O
: . . O
* . . O
maintain . . O
aseptic . . O
technique . . O
. . . O

the . . O
combination . . O
of . . O
transaminase . . B-AdverseReaction
elevations . . I-AdverseReaction
and . . O
elevated . . B-AdverseReaction
bilirubin . . I-AdverseReaction
without . . O
evidence . . O
of . . O
obstruction . . O
is . . O
generally . . O
recognized . . O
as . . O
an . . O
important . . O
predictor . . O
of . . O
severe . . B-Severity
liver . . B-AdverseReaction
injury . . I-AdverseReaction
. . . O

one . . O
patient . . O
experienced . . O
related . . O
grade . . B-Severity
3 . . I-Severity
flushing . . B-AdverseReaction
. . . O

mortality . . B-AdverseReaction
related . . O
to . . O
diarrhea . . B-AdverseReaction
has . . O
been . . O
reported . . O
. . . O

the . . O
safety . . O
of . . O
jevtana . . O
in . . O
combination . . O
with . . O
prednisone . . O
was . . O
evaluated . . O
in . . O
371 . . O
patients . . O
with . . O
hormone . . O
- . . O
refractory . . O
metastatic . . O
prostate . . O
cancer . . O
treated . . O
in . . O
a . . O
single . . O
randomized . . O
trial . . O
, . . O
compared . . O
to . . O
mitoxantrone . . O
plus . . O
prednisone . . O
. . . O

table . . O
4 . . O
: . . O
adverse . . O
reactions . . O
reported . . O
by . . O
> . . O
= . . O
2% . . O
of . . O
patients . . O
treated . . O
with . . O
stendra . . O
in . . O
a . . O
placebo . . O
- . . O
controlled . . O
clinical . . O
trial . . O
lasting . . O
2 . . O
months . . O
to . . O
determine . . O
the . . O
time . . O
to . . O
onset . . O
of . . O
effect . . O
( . . O
study . . O
3 . . O
) . . O
adverse . . O
reaction . . O
placebon . . O
= . . O
143 . . O
stendra . . O
100 . . O
mgn . . O
= . . O
146 . . O
stendra . . O
200 . . O
mgn . . O
= . . O
146 . . O
headache . . B-AdverseReaction
0.7% . . O
1.4% . . O
8.9% . . O
nasal . . B-AdverseReaction
congestion . . I-AdverseReaction
0.0% . . O
0.7% . . O
4.1% . . O
gastroenteritis . . B-AdverseReaction
viral . . I-AdverseReaction
0.0% . . O
0.0% . . O
2.1% . . O
across . . O
all . . O
trials . . O
with . . O
any . . O
stendra . . O
dose . . O
, . . O
1 . . O
subject . . O
reported . . O
a . . O
change . . B-AdverseReaction
in . . I-AdverseReaction
color . . I-AdverseReaction
vision . . I-AdverseReaction
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

there . . O
were . . O
no . . B-Negation
reports . . O
of . . O
anaphylaxis . . B-AdverseReaction
or . . O
drug . . B-AdverseReaction
hypersensitivity . . I-AdverseReaction
in . . O
patients . . O
treated . . O
with . . O
nulojix . . O
in . . O
studies . . O
1 . . O
and . . O
2 . . O
through . . O
three . . O
years . . O
. . . O

upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
was . . O
the . . O
most . . O
common . . O
adverse . . O
reaction . . O
reported . . O
in . . O
the . . O
trial . . O
through . . O
week . . O
24 . . O
occurring . . O
in . . O
6.5% . . O
of . . O
simponi . . O
aria . . O
- . . O
treated . . O
patients . . O
as . . O
compared . . O
with . . O
7.6% . . O
of . . O
control . . O
- . . O
treated . . O
patients . . O
, . . O
respectively . . O
. . . O

monitor . . O
weekly . . O
for . . O
liver . . O
toxicity . . O
if . . O
the . . O
alt . . O
or . . O
ast . . O
rises . . O
above . . O
3 . . O
times . . O
the . . O
upper . . O
limit . . O
of . . O
normal . . O
until . . O
resolved . . O
. . . O

there . . O
is . . O
no . . O
known . . O
treatment . . O
for . . O
established . . O
cases . . O
of . . O
tardive . . O
dyskinesia . . O
, . . O
although . . O
the . . O
syndrome . . O
may . . O
remit . . O
, . . O
partially . . O
or . . O
completely . . O
, . . O
if . . O
antipsychotic . . O
treatment . . O
is . . O
withdrawn . . O
. . . O

approximately . . O
15% . . O
of . . O
patients . . O
with . . O
retinal . . B-AdverseReaction
pigmentary . . I-AdverseReaction
abnormalities . . I-AdverseReaction
had . . O
no . . B-Negation
such . . O
discoloration . . B-AdverseReaction
. . . O

the . . O
most . . O
common . . O
grade . . B-Severity
3-4 . . I-Severity
laboratory . . O
abnormality . . O
( . . O
incidence . . O
> . . O
= . . O
3% . . O
) . . O
was . . O
neutropenia . . B-AdverseReaction
. . . O

there . . O
is . . O
no . . O
established . . O
way . . O
to . . O
reverse . . O
the . . O
anticoagulant . . O
effect . . O
of . . O
apixaban . . O
, . . O
which . . O
can . . O
be . . O
expected . . O
to . . O
persist . . O
for . . O
at . . O
least . . O
24 . . O
hours . . O
after . . O
the . . O
last . . O
dose . . O
, . . O
i . . O
. . . O
e . . O
. . . O
, . . O
for . . O
about . . O
two . . O
drug . . O
half . . O
- . . O
lives . . O
. . . O

the . . O
need . . O
for . . O
continued . . O
treatment . . O
should . . O
be . . O
reassessed . . O
periodically . . O
. . . O

the . . O
frequency . . O
of . . O
> . . O
= . . O
grade . . O
3 . . O
adverse . . O
reactions . . O
and . . O
deaths . . B-AdverseReaction
was . . O
greater . . O
in . . O
patients . . O
with . . O
severe . . O
renal . . O
impairment . . O
compared . . O
to . . O
patients . . O
with . . O
normal . . O
renal . . O
function . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
bladder . . B-AdverseReaction
cancer . . I-AdverseReaction
: . . O
an . . O
imbalance . . O
in . . O
bladder . . B-AdverseReaction
cancers . . I-AdverseReaction
was . . O
observed . . O
in . . O
clinical . . O
trials . . O
. . . O

tuberculosis . . B-AdverseReaction
and . . O
herpes . . B-AdverseReaction
infections . . I-AdverseReaction
were . . O
reported . . O
more . . O
frequently . . O
in . . O
patients . . O
receiving . . O
nulojix . . O
than . . O
cyclosporine . . O
. . . O

excerpt . . O
: . . O
* . . O
hemorrhage . . B-AdverseReaction
: . . O
monitor . . O
for . . O
bleeding . . O
( . . O
5.1 . . O
) . . O
. . . O

cases . . O
of . . O
jc . . B-AdverseReaction
virus . . I-AdverseReaction
- . . O
associated . . O
pml . . B-AdverseReaction
resulting . . O
in . . O
neurological . . B-AdverseReaction
deficits . . I-AdverseReaction
, . . O
including . . O
fatal . . B-AdverseReaction
cases . . O
, . . O
have . . O
been . . O
reported . . O
in . . O
patients . . O
with . . O
sle . . O
receiving . . O
immunosuppressants . . O
, . . O
including . . O
benlysta . . O
. . . O

anaphylactic . . O
and . . O
other . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
with . . O
cardiovascular . . O
, . . O
respiratory . . O
and . . O
cutaneous . . B-AdverseReaction
manifestations . . I-AdverseReaction
, . . O
ranging . . O
from . . O
mild . . B-Severity
to . . O
severe . . B-Severity
, . . O
including . . O
shock . . B-AdverseReaction
have . . O
uncommonly . . O
occurred . . O
following . . O
eovist . . O
administration . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
below . . O
is . . O
based . . O
upon . . O
two . . O
double . . O
- . . O
blind . . O
, . . O
placebo . . O
- . . O
controlled . . O
, . . O
48 . . O
- . . O
week . . O
clinical . . O
trials . . O
( . . O
trials . . O
1 . . O
and . . O
2 . . O
) . . O
in . . O
a . . O
total . . O
of . . O
213 . . O
patients . . O
with . . O
cf . . O
ages . . O
6 . . O
to . . O
53 . . O
who . . O
have . . O
a . . O
g551d . . O
mutation . . O
in . . O
the . . O
cftr . . O
gene . . O
and . . O
who . . O
were . . O
treated . . O
with . . O
kalydeco . . O
150 . . O
mg . . O
orally . . O
or . . O
placebo . . O
twice . . O
daily . . O
. . . O

monitor . . O
patients . . O
closely . . O
during . . O
and . . O
after . . O
administration . . O
of . . O
gadavist . . O
( . . O
5.2 . . O
) . . O

co . . O
- . . O
administration . . O
of . . O
a . . O
corticosteroid . . O
suppresses . . O
adrenocorticotropic . . O
hormone . . O
( . . O
acth . . O
) . . O
drive . . O
, . . O
resulting . . O
in . . O
a . . O
reduction . . O
in . . O
the . . O
incidence . . O
and . . O
severity . . O
of . . O
these . . O
adverse . . O
reactions . . O
. . . O

these . . O
reactions . . O
can . . O
occur . . O
within . . O
hours . . O
to . . O
weeks . . O
after . . O
injection . . O
with . . O
botulinum . . O
toxin . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
and . . O
adverse . . O
reactions . . O
( . . O
6.1 . . O
) . . O
] . . O
. . . O

fingolimod . . O
remains . . O
in . . O
the . . O
blood . . O
and . . O
has . . O
pharmacodynamic . . O
effects . . O
, . . O
including . . O
decreased . . B-AdverseReaction
lymphocyte . . I-AdverseReaction
counts . . I-AdverseReaction
, . . O
for . . O
up . . O
to . . O
2 . . O
months . . O
following . . O
the . . O
last . . O
dose . . O
of . . O
gilenya . . O
. . . O

prior . . O
and . . O
concomitant . . O
treatment . . O
with . . O
antineoplastic . . O
, . . O
immunosuppressive . . O
, . . O
or . . O
immune . . O
- . . O
modulating . . O
therapies . . O

if . . O
arcapta . . O
neohaler . . O
no . . O
longer . . O
controls . . O
the . . O
symptoms . . O
of . . O
bronchoconstriction . . O
, . . O
or . . O
the . . O
patient's . . O
inhaled . . O
, . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonist . . O
becomes . . O
less . . O
effective . . O
or . . O
the . . O
patient . . O
needs . . O
more . . O
inhalation . . O
of . . O
short . . O
- . . O
acting . . O
beta2 . . O
- . . O
agonist . . O
than . . O
usual . . O
, . . O
these . . O
may . . O
be . . O
markers . . O
of . . O
deterioration . . O
of . . O
disease . . O
. . . O

gastrointestinal . . O
disorders . . O
: . . O
hematochezia . . B-AdverseReaction
, . . O
hemorrhoidal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
gastrointestinal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction
, . . O
hematemesis . . B-AdverseReaction
, . . O
melena . . B-AdverseReaction
, . . O
anal . . B-AdverseReaction
hemorrhage . . I-AdverseReaction

do . . O
not . . O
restart . . O
nesina . . O
if . . O
liver . . O
injury . . O
is . . O
confirmed . . O
and . . O
no . . O
alternative . . O
etiology . . O
can . . O
be . . O
found . . O
. . . O

somnolence . . B-AdverseReaction
was . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
saphris . . O
. . . O

monitor . . O
renal . . O
function . . O
with . . O
regular . . O
measurement . . O
of . . O
the . . O
serum . . O
creatinine . . O
and . . O
/ . . O
or . . O
estimated . . O
creatinine . . O
clearance . . O
. . . O

during . . O
clinical . . O
trials . . O
with . . O
saphris . . O
, . . O
including . . O
long . . O
- . . O
term . . O
trials . . O
without . . O
comparison . . O
to . . O
placebo . . O
, . . O
the . . O
incidence . . O
of . . O
adverse . . O
reactions . . O
suggestive . . O
of . . O
body . . B-AdverseReaction
temperature . . I-AdverseReaction
increases . . I-AdverseReaction
( . . O
pyrexia . . B-AdverseReaction
and . . O
feeling . . B-AdverseReaction
hot . . I-AdverseReaction
) . . O
was . . O
< . . O
= . . O
1% . . O
. . . O

anaphylaxis . . B-AdverseReaction
, . . O
presenting . . O
as . . O
cough . . B-AdverseReaction
, . . O
erythema . . B-AdverseReaction
, . . O
throat . . B-AdverseReaction
tightness . . I-AdverseReaction
, . . O
urticaria . . B-AdverseReaction
, . . O
flushing . . B-AdverseReaction
, . . O
cyanosis . . B-AdverseReaction
, . . O
hypotension . . B-AdverseReaction
, . . O
rash . . B-AdverseReaction
, . . O
dyspnea . . B-AdverseReaction
, . . O
chest . . B-AdverseReaction
discomfort . . I-AdverseReaction
, . . O
and . . O
gastrointestinal . . B-AdverseReaction
symptoms . . I-AdverseReaction
in . . O
conjunction . . O
with . . O
urticaria . . B-AdverseReaction
, . . O
have . . O
been . . O
reported . . O
to . . O
occur . . O
during . . O
infusions . . O
, . . O
regardless . . O
of . . O
duration . . O
of . . O
the . . O
course . . O
of . . O
treatment . . O
. . . O

plasma . . O
ammonia . . O
levels . . O
should . . O
be . . O
maintained . . O
within . . O
normal . . O
range . . O
for . . O
age . . O
via . . O
individual . . O
dose . . O
adjustment . . O
. . . O

6 . . O
adverse . . O
reactions . . O

extensive . . O
brain . . O
atrophy . . O
may . . O
limit . . O
the . . O
ability . . O
to . . O
distinguish . . O
grey . . O
and . . O
white . . O
matter . . O
on . . O
a . . O
vizamyl . . O
scan . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.5 . . O
) . . O
] . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

therefore . . O
, . . O
entereg . . O
is . . O
not . . O
recommended . . O
for . . O
use . . O
in . . O
these . . O
patients . . O
. . . O

advise . . O
patients . . O
not . . O
to . . O
drive . . O
or . . O
operate . . O
heavy . . O
machinery . . O
until . . O
they . . O
know . . O
how . . O
toviaz . . O
affects . . O
them . . O
. . . O

vascular . . O
disorders . . O
: . . O
thrombotic . . B-AdverseReaction
microangiopathy . . I-AdverseReaction
with . . O
acute . . B-AdverseReaction
renal . . I-AdverseReaction
failure . . I-AdverseReaction
. . . O

in . . O
women . . O
with . . O
hereditary . . O
angioedema . . O
, . . O
exogenous . . O
estrogens . . O
may . . B-Factor
induce . . O
or . . O
exacerbate . . O
symptoms . . O
of . . O
angioedema . . B-AdverseReaction
. . . O

no . . O
apparent . . O
correlation . . O
of . . O
antibody . . O
development . . O
to . . O
adverse . . O
events . . O
or . . O
efficacy . . O
was . . O
observed . . O
. . . O

the . . O
study . . O
population . . O
characteristics . . O
were . . O
: . . O
median . . O
age . . O
53 . . O
years . . O
, . . O
age . . O
less . . O
than . . O
65 . . O
( . . O
84% . . O
) . . O
, . . O
female . . O
( . . O
53% . . O
) . . O
, . . O
caucasian . . O
( . . O
63% . . O
) . . O
, . . O
asian . . O
( . . O
34% . . O
) . . O
, . . O
nsclc . . O
adenocarcinoma . . O
histology . . O
( . . O
90% . . O
) . . O
, . . O
never . . O
or . . O
former . . O
smoker . . O
( . . O
97% . . O
) . . O
, . . O
ecog . . O
ps . . O
0 . . O
or . . O
1 . . O
( . . O
89% . . O
) . . O
, . . O
brain . . O
metastasis . . O
( . . O
49% . . O
) . . O
, . . O
and . . O
number . . O
of . . O
prior . . O
therapies . . O
2 . . O
or . . O
more . . O
( . . O
67% . . O
) . . O
. . . O

patients . . O
who . . O
remain . . O
averse . . O
to . . O
food . . O
during . . O
treatment . . O
should . . O
be . . O
closely . . O
monitored . . O
as . . O
the . . O
risk . . O
of . . O
recrudescence . . O
may . . O
be . . O
greater . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

patients . . O
treated . . O
with . . O
any . . O
aed . . O
for . . O
any . . O
indication . . O
should . . O
be . . O
monitored . . O
for . . O
the . . O
emergence . . O
or . . O
worsening . . O
of . . O
depression . . O
, . . O
suicidal . . O
thoughts . . O
or . . O
behavior . . O
, . . O
and . . O
/ . . O
or . . O
any . . O
unusual . . O
changes . . O
in . . O
mood . . O
or . . O
behavior . . O
. . . O

cns . . B-AdverseReaction
ptld . . I-AdverseReaction
, . . O
pml . . B-AdverseReaction
, . . O
and . . O
other . . O
cns . . B-AdverseReaction
infections . . I-AdverseReaction
were . . O
more . . O
frequently . . O
observed . . O
in . . O
association . . O
with . . O
a . . O
nulojix . . O
regimen . . O
of . . O
higher . . O
cumulative . . O
dose . . O
and . . O
more . . O
frequent . . O
dosing . . O
compared . . O
to . . O
the . . O
recommended . . O
regimen . . O
; . . O
therefore . . O
, . . O
administration . . O
of . . O
higher . . O
than . . O
the . . O
recommended . . O
doses . . O
and . . O
/ . . O
or . . O
more . . O
frequent . . O
dosing . . O
of . . O
nulojix . . O
is . . O
not . . O
recommended . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.1 . . O
) . . O
] . . O
. . . O

the . . O
safety . . O
and . . O
efficacy . . O
of . . O
eliquis . . O
have . . O
not . . O
been . . O
studied . . O
in . . O
patients . . O
with . . O
prosthetic . . O
heart . . O
valves . . O
. . . O

there . . O
were . . O
no . . O
differences . . O
between . . O
fanapt . . O
and . . O
placebo . . O
in . . O
the . . O
incidence . . O
of . . O
discontinuation . . O
due . . O
to . . O
changes . . O
in . . O
hematology . . O
, . . O
urinalysis . . O
, . . O
or . . O
serum . . O
chemistry . . O
. . . O

during . . O
the . . O
clinical . . O
trials . . O
, . . O
0.1% . . O
( . . O
1 . . O
/ . . O
1308 . . O
) . . O
of . . O
subjects . . O
treated . . O
with . . O
otezla . . O
discontinued . . O
treatment . . O
due . . O
to . . O
depression . . B-AdverseReaction
compared . . O
with . . O
none . . O
in . . O
placebo . . O
- . . O
treated . . O
subjects . . O
( . . O
0 . . O
/ . . O
506 . . O
) . . O
. . . O

warning . . O
: . . O
increased . . O
mortality . . B-AdverseReaction
in . . O
elderly . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O

( . . O
5.1 . . O
) . . O

halaven . . O
is . . O
a . . O
microtubule . . B-DrugClass
inhibitor . . I-DrugClass
; . . O
therefore . . O
, . . O
it . . O
is . . O
expected . . O
to . . O
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

table . . O
3 . . O
: . . O
non . . O
- . . O
hematologic . . O
adverse . . O
reactions . . O
in . . O
> . . O
= . . O
10% . . O
of . . O
patients . . O
with . . O
cll . . O
( . . O
n . . O
= . . O
48 . . O
) . . O
in . . O
study . . O
1 . . O
system . . O
organ . . O
class . . O
preferred . . O
term . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
gastrointestinal . . O
disorders . . O
diarrhea . . B-AdverseReaction
63 . . O
4 . . O
constipation . . B-AdverseReaction
23 . . O
2 . . O
nausea . . B-AdverseReaction
21 . . O
2 . . O
stomatitis . . B-AdverseReaction
21 . . O
0 . . O
vomiting . . B-AdverseReaction
19 . . O
2 . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
15 . . O
0 . . O
dyspepsia . . B-AdverseReaction
13 . . O
0 . . O
infections . . O
and . . O
infestations . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
48 . . O
2 . . O
sinusitis . . B-AdverseReaction
21 . . O
6 . . O
skin . . B-AdverseReaction
infection . . I-AdverseReaction
17 . . O
6 . . O
pneumonia . . B-AdverseReaction
10 . . O
8 . . O
urinary . . B-AdverseReaction
tract . . I-AdverseReaction
infection . . I-AdverseReaction
10 . . O
0 . . O
general . . O
disorders . . O
and . . O
administrative . . O
site . . O
conditions . . O
fatigue . . B-AdverseReaction
31 . . O
4 . . O
pyrexia . . B-AdverseReaction
25 . . O
2 . . O
peripheral . . B-AdverseReaction
edema . . I-AdverseReaction
23 . . O
0 . . O
asthenia . . B-AdverseReaction
13 . . O
4 . . O
chills . . B-AdverseReaction
13 . . O
0 . . O
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
bruising . . B-AdverseReaction
54 . . O
2 . . O
rash . . B-AdverseReaction
27 . . O
0 . . O
petechiae . . B-AdverseReaction
17 . . O
0 . . O
respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
cough . . B-AdverseReaction
19 . . O
0 . . O
oropharyngeal . . B-AdverseReaction
pain . . I-AdverseReaction
15 . . O
0 . . O
dyspnea . . B-AdverseReaction
10 . . O
0 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
musculoskeletal . . B-AdverseReaction
pain . . I-AdverseReaction
27 . . O
6 . . O
arthralgia . . B-AdverseReaction
23 . . O
0 . . O
muscle . . B-AdverseReaction
spasms . . I-AdverseReaction
19 . . O
2 . . O
nervous . . O
system . . O
disorders . . O
dizziness . . B-AdverseReaction
21 . . O
0 . . O
headache . . B-AdverseReaction
19 . . O
2 . . O
peripheral . . B-AdverseReaction
neuropathy . . I-AdverseReaction
10 . . O
0 . . O
metabolism . . O
and . . O
nutrition . . O
disorders . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
17 . . O
2 . . O
neoplasms . . O
benign . . O
, . . O
malignant . . O
, . . O
unspecified . . O
second . . B-AdverseReaction
malignancies . . I-AdverseReaction
10 . . O
0 . . O
injury . . O
, . . O
poisoning . . O
and . . O
procedural . . O
complications . . O
laceration . . B-AdverseReaction
10 . . O
2 . . O
psychiatric . . O
disorders . . O
anxiety . . B-AdverseReaction
10 . . O
0 . . O
insomnia . . B-AdverseReaction
10 . . O
0 . . O
vascular . . O
disorders . . O
hypertension . . B-AdverseReaction
17 . . O
8 . . O
table . . O
4 . . O
: . . O
treatment . . O
- . . O
emergentbased . . O
on . . O
laboratory . . O
measurements . . O
per . . O
iwcll . . O
criteria . . O
and . . O
adverse . . O
reactions . . O
decrease . . B-AdverseReaction
of . . I-AdverseReaction
hemoglobin . . I-AdverseReaction
, . . O
platelets . . O
, . . O
or . . O
neutrophils . . O
in . . O
patients . . O
with . . O
cll . . O
( . . O
n . . O
= . . O
48 . . O
) . . O
in . . O
study . . O
1 . . O
percent . . O
of . . O
patients . . O
( . . O
n . . O
= . . O
48 . . O
) . . O
all . . O
grades . . O
( . . O
% . . O
) . . O
grade . . O
3 . . O
or . . O
4 . . O
( . . O
% . . O
) . . O
platelets . . B-AdverseReaction
decreased . . I-AdverseReaction
71 . . O
10 . . O
neutrophils . . B-AdverseReaction
decreased . . I-AdverseReaction
54 . . O
27 . . O
hemoglobin . . B-AdverseReaction
decreased . . I-AdverseReaction
44 . . O
0 . . O
study . . O
2 . . O

fractures . . O
were . . O
observed . . O
as . . O
early . . O
as . . O
12 . . O
weeks . . O
after . . O
treatment . . O
initiation . . O
and . . O
were . . O
more . . O
likely . . O
to . . O
be . . O
low . . B-Severity
trauma . . I-Severity
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
fall . . O
from . . O
no . . O
more . . O
than . . O
standing . . O
height . . O
) . . O
, . . O
and . . O
affect . . O
the . . O
upper . . O
extremities . . O
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.7 . . O
) . . O
] . . O
. . . O

because . . O
clinical . . O
trials . . O
are . . O
conducted . . O
under . . O
widely . . O
varying . . O
conditions . . O
, . . O
adverse . . O
reaction . . O
rates . . O
observed . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
a . . O
drug . . O
cannot . . O
be . . O
directly . . O
compared . . O
to . . O
rates . . O
in . . O
the . . O
clinical . . O
trials . . O
of . . O
another . . O
drug . . O
and . . O
may . . O
not . . O
reflect . . O
the . . O
rates . . O
observed . . O
in . . O
practice . . O
. . . O

these . . O
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
reactions . . I-AdverseReaction
may . . B-Factor
involve . . O
any . . O
organ . . O
system . . O
; . . O
however . . O
, . . O
the . . O
most . . O
common . . O
severe . . B-Severity
immune . . B-AdverseReaction
- . . I-AdverseReaction
mediated . . I-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
are . . O
enterocolitis . . B-AdverseReaction
, . . O
hepatitis . . B-AdverseReaction
, . . O
dermatitis . . B-AdverseReaction
( . . O
including . . O
toxic . . B-AdverseReaction
epidermal . . I-AdverseReaction
necrolysis . . I-AdverseReaction
) . . O
, . . O
neuropathy . . B-AdverseReaction
, . . O
and . . O
endocrinopathy . . B-AdverseReaction
. . . O

therefore . . O
, . . O
caution . . O
should . . O
be . . O
used . . O
when . . O
administering . . O
general . . O
anesthesia . . O
. . . O

in . . O
completed . . O
and . . O
ongoing . . O
global . . O
clinical . . O
studies . . O
in . . O
all . . O
indications . . O
including . . O
5,118 . . O
cimzia . . O
- . . O
treated . . O
patients . . O
, . . O
the . . O
overall . . O
rate . . O
of . . O
tuberculosis . . B-AdverseReaction
is . . O
approximately . . O
0.61 . . O
per . . O
100 . . O
patient . . O
- . . O
years . . O
across . . O
all . . O
indications . . O
. . . O

5.7 . . O
macrovascular . . O
outcomes . . O

no . . B-Negation
unconfounded . . O
cases . . O
of . . O
nsf . . B-AdverseReaction
have . . O
been . . O
reported . . O
with . . O
dotarem . . O
. . . O

patients . . O
experiencing . . O
these . . O
symptoms . . O
should . . O
be . . O
advised . . O
to . . O
stop . . O
taking . . O
stendra . . O
and . . O
seek . . O
prompt . . O
medical . . O
attention . . O
. . . O

the . . O
immunogenicity . . O
of . . O
eylea . . O
was . . O
evaluated . . O
in . . O
serum . . O
samples . . O
. . . O

tumor . . B-AdverseReaction
lysis . . I-AdverseReaction
syndrome . . I-AdverseReaction
has . . O
occurred . . O
in . . O
beleodaq . . O
- . . O
treated . . O
patients . . O
in . . O
the . . O
clinical . . O
trial . . O
of . . O
patients . . O
with . . O
relapsed . . O
or . . O
refractory . . O
ptcl . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

the . . O
following . . O
potential . . O
serious . . O
adverse . . O
reactions . . O
are . . O
discussed . . O
in . . O
greater . . O
detail . . O
in . . O
other . . O
sections . . O
of . . O
the . . O
labeling . . O
: . . O

a . . O
total . . O
of . . O
2711 . . O
patients . . O
treated . . O
with . . O
eylea . . O
constituted . . O
the . . O
safety . . O
population . . O
in . . O
seven . . O
phase . . O
3 . . O
studies . . O
. . . O

if . . O
liver . . O
test . . O
abnormalities . . O
persist . . O
, . . O
worsen . . O
or . . O
recur . . O
, . . O
then . . O
permanently . . O
discontinue . . O
promacta . . O
. . . O

trunk . . O
/ . . O
extremities . . O
adverse . . O
reactions . . O
picato . . O
( . . O
r . . O
) . . O
gel . . O
, . . O
0.05% . . O
( . . O
n . . O
= . . O
225 . . O
) . . O
vehicle . . O
( . . O
n . . O
= . . O
232 . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pruritus . . I-AdverseReaction
18 . . O
( . . O
8% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
irritation . . I-AdverseReaction
8 . . O
( . . O
4% . . O
) . . O
1 . . O
( . . O
0% . . O
) . . O
nasopharyngitis . . B-AdverseReaction
4 . . O
( . . O
2% . . O
) . . O
2 . . O
( . . O
1% . . O
) . . O
application . . B-AdverseReaction
site . . I-AdverseReaction
pain . . I-AdverseReaction
5 . . O
( . . O
2% . . O
) . . O
0 . . O
( . . O
0% . . O
) . . O

5.1 . . O
tendon . . O
rupture . . O
or . . O
other . . O
serious . . O
injury . . O
to . . O
the . . O
injected . . O
finger . . O
/ . . O
hand . . O
in . . O
the . . O
treatment . . O
of . . O
dupuytren's . . O
contracture . . O

in . . O
post . . O
- . . O
marketing . . O
experience . . O
, . . O
serious . . B-Severity
systemic . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
including . . O
anaphylactic . . B-AdverseReaction
reaction . . I-AdverseReaction
) . . O
have . . O
been . . O
reported . . O
following . . O
administration . . O
of . . O
the . . O
subcutaneous . . O
formulation . . O
of . . O
golimumab . . O
. . . O

5.16 . . O
hypokalemia . . O
and . . O
hyperglycemia . . O

in . . O
patients . . O
with . . O
permanent . . O
af . . O
, . . O
multaq . . O
doubles . . O
the . . O
risk . . B-Factor
of . . O
death . . B-AdverseReaction
, . . O
stroke . . B-AdverseReaction
, . . O
and . . O
hospitalization . . O
for . . O
heart . . B-AdverseReaction
failure . . I-AdverseReaction
. . . O

discontinuations . . O
due . . O
to . . O
adverse . . O
drug . . O
reactions . . O
( . . O
adrs . . O
) . . O
were . . O
5.2% . . O
in . . O
the . . O
intelence . . O
( . . O
r . . O
) . . O
arm . . O
and . . O
2.6% . . O
in . . O
the . . O
placebo . . O
arm . . O
. . . O

excerpt . . O
: . . O
hypersensitivity . . B-AdverseReaction
and . . O
injection . . B-AdverseReaction
site . . I-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
following . . O
datscan . . O
administration . . O
. . . O

treatment . . O
of . . O
sjia . . O

monitor . . O
liver . . O
- . . O
related . . O
laboratory . . O
tests . . O
. . . O

although . . O
other . . O
risk . . O
factors . . O
were . . O
present . . O
in . . O
some . . O
cases . . O
( . . O
such . . O
as . . O
corticosteroid . . O
use . . O
and . . O
/ . . O
or . . O
exposure . . O
to . . O
radiation . . O
) . . O
, . . O
a . . O
possible . . O
risk . . O
attributable . . O
to . . O
kalydeco . . O
cannot . . O
be . . O
excluded . . O
. . . O

* . . O
infantile . . O
- . . O
onset . . O
pompe . . O
disease . . O
patients . . O
with . . O
compromised . . O
cardiac . . O
or . . O
respiratory . . O
function . . O
may . . B-Factor
be . . O
at . . O
risk . . O
of . . O
serious . . B-Severity
acute . . O
exacerbation . . O
of . . O
their . . O
cardiac . . O
or . . O
respiratory . . O
compromise . . O
due . . O
to . . O
fluid . . B-AdverseReaction
overload . . I-AdverseReaction
, . . O
and . . O
require . . O
additional . . O
monitoring . . O
( . . O
5.3 . . O
) . . O
. . . O

dose . . O
- . . O
dependent . . O
reductions . . B-AdverseReaction
in . . I-AdverseReaction
forced . . I-AdverseReaction
expiratory . . I-AdverseReaction
volume . . I-AdverseReaction
over . . I-AdverseReaction
1 . . I-AdverseReaction
second . . I-AdverseReaction
( . . O
fev1 . . O
) . . O
and . . O
diffusion . . O
lung . . O
capacity . . O
for . . O
carbon . . O
monoxide . . O
( . . O
dlco . . O
) . . O
were . . O
observed . . O
in . . O
patients . . O
treated . . O
with . . O
gilenya . . O
as . . O
early . . O
as . . O
1 . . O
month . . O
after . . O
treatment . . O
initiation . . O
. . . O

( . . O
5.2 . . O
) . . O

excerpt . . O
: . . O
* . . O
infections . . B-AdverseReaction
: . . O
monitor . . O
patients . . O
for . . O
signs . . O
or . . O
symptoms . . O
and . . O
treat . . O
appropriately . . O
. . . O

the . . O
most . . O
frequent . . O
serious . . O
adverse . . O
reactions . . O
that . . O
occurred . . O
were . . O
pneumonia . . B-AdverseReaction
( . . O
15% . . O
) . . O
, . . O
diarrhea . . B-AdverseReaction
( . . O
11% . . O
) . . O
, . . O
and . . O
pyrexia . . B-AdverseReaction
( . . O
9% . . O
) . . O
. . . O

there . . O
were . . O
no . . O
differences . . O
in . . O
the . . O
occurrence . . O
of . . O
3+ . . O
proteinuria . . B-AdverseReaction
( . . O
< . . O
4% . . O
in . . O
both . . O
studies . . O
) . . O
at . . O
any . . O
time . . O
point . . O
, . . O
and . . O
no . . B-Negation
patients . . O
experienced . . O
4+ . . O
proteinuria . . B-AdverseReaction
. . . O

neutropenia . . O
: . . O
neutropenic . . B-AdverseReaction
deaths . . B-AdverseReaction
have . . O
been . . O
reported . . O
. . . O

in . . O
women . . O
with . . O
pre . . O
- . . O
existing . . O
hypertriglyceridemia . . O
, . . O
treatment . . O
with . . O
estrogens . . O
may . . B-Factor
be . . O
associated . . O
with . . O
elevations . . B-AdverseReaction
of . . I-AdverseReaction
plasma . . I-AdverseReaction
triglycerides . . I-AdverseReaction
leading . . O
to . . O
pancreatitis . . B-AdverseReaction
. . . O

some . . O
women . . O
may . . B-Factor
encounter . . O
amenorrhea . . B-AdverseReaction
or . . O
oligomenorrhea . . B-AdverseReaction
after . . O
stopping . . O
cocs . . O
, . . O
especially . . O
when . . O
such . . O
a . . O
condition . . O
was . . O
pre . . O
- . . O
existent . . O
. . . O

clinical . . O
manifestations . . O
include . . O
hyperpyrexia . . B-AdverseReaction
, . . O
muscle . . B-AdverseReaction
rigidity . . I-AdverseReaction
, . . O
altered . . B-AdverseReaction
mental . . I-AdverseReaction
status . . I-AdverseReaction
( . . O
including . . O
catatonic . . B-AdverseReaction
signs . . I-AdverseReaction
) . . O
and . . O
evidence . . O
of . . O
autonomic . . B-AdverseReaction
instability . . I-AdverseReaction
( . . O
irregular . . B-AdverseReaction
pulse . . I-AdverseReaction
or . . O
blood . . O
pressure . . O
, . . O
tachycardia . . B-AdverseReaction
, . . O
diaphoresis . . B-AdverseReaction
, . . O
and . . O
cardiac . . B-AdverseReaction
dysrhythmia . . I-AdverseReaction
) . . O
. . . O

5.8 . . O
withdrawal . . O
seizures . . O

the . . O
most . . O
common . . O
adverse . . O
reactions . . O
resulting . . O
in . . O
discontinuation . . O
of . . O
treatment . . O
( . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
receiving . . O
benlysta . . O
or . . O
placebo . . O
) . . O
were . . O
infusion . . B-AdverseReaction
reactions . . I-AdverseReaction
( . . O
1.6% . . O
benlysta . . O
and . . O
0.9% . . O
placebo . . O
) . . O
, . . O
lupus . . B-AdverseReaction
nephritis . . I-AdverseReaction
( . . O
0.7% . . O
benlysta . . O
and . . O
1.2% . . O
placebo . . O
) . . O
, . . O
and . . O
infections . . B-AdverseReaction
( . . O
0.7% . . O
benlysta . . O
and . . O
1.0% . . O
placebo . . O
) . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

interrupt . . O
or . . O
discontinue . . O
zydelig . . O
as . . O
recommended . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
, . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.3 . . O
) . . O
] . . O
. . . O

the . . O
racial . . O
and . . O
ethnic . . O
distribution . . O
was . . O
caucasian . . O
( . . O
83% . . O
) . . O
, . . O
black . . O
( . . O
5% . . O
) . . O
, . . O
asian . . O
( . . O
2% . . O
) . . O
, . . O
and . . O
other . . O
( . . O
5% . . O
) . . O
. . . O

overall . . O
, . . O
6 . . O
pediatric . . O
patients . . O
( . . O
4.3% . . O
) . . O
reported . . O
at . . O
least . . O
one . . O
adverse . . O
reaction . . O
following . . O
dotarem . . O
administration . . O
. . . O

pool . . O
of . . O
placebo . . O
- . . O
and . . O
active . . O
- . . O
controlled . . O
trials . . O

overall . . O
, . . O
312 . . O
patients . . O
( . . O
95% . . O
) . . O
received . . O
hsv . . O
and . . O
vzv . . O
prophylaxis . . O
with . . O
a . . O
median . . O
duration . . O
of . . O
11.1 . . O
months . . O
( . . O
range . . O
, . . O
0-20 . . O
) . . O
and . . O
319 . . O
patients . . O
( . . O
98% . . O
) . . O
received . . O
pcp . . O
prophylaxis . . O
with . . O
a . . O
median . . O
duration . . O
of . . O
6.5 . . O
months . . O
( . . O
range . . O
, . . O
0-20 . . O
) . . O
. . . O

general . . O
disorders . . O
and . . O
administration . . O
site . . O
conditions . . O
: . . O
infusion . . B-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
reactions . . I-AdverseReaction

6 . . O
adverse . . O
reactions . . O

placebo . . O
otezla . . O
30 . . O
mg . . O
bid . . O
preferred . . O
term . . O
day . . O
1 . . O
to . . O
5 . . O
( . . O
n . . O
= . . O
495 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
c . . O
day . . O
6 . . O
to . . O
day . . O
112 . . O
( . . O
n . . O
= . . O
490 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
day . . O
1 . . O
to . . O
5 . . O
( . . O
n . . O
= . . O
497 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
day . . O
6 . . O
to . . O
day . . O
112 . . O
( . . O
n . . O
= . . O
493 . . O
) . . O
n . . O
( . . O
% . . O
) . . O
diarrhea . . B-AdverseReaction
a . . O
6 . . O
( . . O
1.2 . . O
) . . O
8 . . O
( . . O
1.6 . . O
) . . O
46 . . O
( . . O
9.3 . . O
) . . O
38 . . O
( . . O
7.7 . . O
) . . O
nausea . . B-AdverseReaction
a . . O
7 . . O
( . . O
1.4 . . O
) . . O
15 . . O
( . . O
3.1 . . O
) . . O
37 . . O
( . . O
7.4 . . O
) . . O
44 . . O
( . . O
8.9 . . O
) . . O
headache . . B-AdverseReaction
a . . O
9 . . O
( . . O
1.8 . . O
) . . O
11 . . O
( . . O
2.2 . . O
) . . O
24 . . O
( . . O
4.8 . . O
) . . O
29 . . O
( . . O
5.9 . . O
) . . O
upper . . B-AdverseReaction
respiratory . . I-AdverseReaction
tractinfection . . I-AdverseReaction
b . . O
3 . . O
( . . O
0.6 . . O
) . . O
9 . . O
( . . O
1.8 . . O
) . . O
3 . . O
( . . O
0.6 . . O
) . . O
19 . . O
( . . O
3.9 . . O
) . . O
vomiting . . B-AdverseReaction
a . . O
2 . . O
( . . O
0.4 . . O
) . . O
2 . . O
( . . O
0.4 . . O
) . . O
4 . . O
( . . O
0.8 . . O
) . . O
16 . . O
( . . O
3.2 . . O
) . . O
nasopharyngitis . . B-AdverseReaction
b . . O
1 . . O
( . . O
0.2 . . O
) . . O
8 . . O
( . . O
1.6 . . O
) . . O
1 . . O
( . . O
0.2 . . O
) . . O
13 . . O
( . . O
2.6 . . O
) . . O
abdominal . . B-AdverseReaction
pain . . I-AdverseReaction
upper . . I-AdverseReaction
b . . O
0 . . O
( . . O
0.0 . . O
) . . O
1 . . O
( . . O
0.2 . . O
) . . O
3 . . O
( . . O
0.6 . . O
) . . O
10 . . O
( . . O
2.0 . . O
) . . O
other . . O
adverse . . O
reactions . . O
reported . . O
in . . O
patients . . O
on . . O
otezla . . O
in . . O
clinical . . O
studies . . O
including . . O
extension . . O
studies . . O
: . . O
immune . . O
system . . O
disorders . . O
: . . O
hypersensitivity . . B-AdverseReaction
investigations . . O
: . . O
weight . . B-AdverseReaction
decrease . . I-AdverseReaction
gastrointestinal . . O
disorders . . O
: . . O
frequent . . B-AdverseReaction
bowel . . I-AdverseReaction
movement . . I-AdverseReaction
, . . O
gastroesophageal . . B-AdverseReaction
reflux . . I-AdverseReaction
disease . . I-AdverseReaction
, . . O
dyspepsia . . B-AdverseReaction
metabolism . . O
and . . O
nutrition . . O
disorders . . O
: . . O
decreased . . B-AdverseReaction
appetite . . I-AdverseReaction
* . . O
nervous . . O
system . . O
disorders . . O
: . . O
migraine . . B-AdverseReaction
respiratory . . O
, . . O
thoracic . . O
, . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
cough . . B-AdverseReaction
skin . . O
and . . O
subcutaneous . . O
tissue . . O
disorders . . O
: . . O
rash . . B-AdverseReaction
* . . O
1 . . O
patient . . O
treated . . O
with . . O
otezla . . O
30 . . O
mg . . O
twice . . O
daily . . O
experienced . . O
a . . O
serious . . O
adverse . . O
reaction . . O
. . . O

6 . . O
adverse . . O
reactions . . O

the . . O
median . . O
age . . O
of . . O
patients . . O
treated . . O
with . . O
dalvance . . O
was . . O
47 . . O
years . . O
, . . O
ranging . . O
between . . O
16 . . O
and . . O
93 . . O
years . . O
old . . O
. . . O

however . . O
, . . O
bronchitis . . B-AdverseReaction
, . . O
herpes . . B-AdverseReaction
zoster . . I-AdverseReaction
, . . O
influenza . . B-AdverseReaction
, . . O
sinusitis . . B-AdverseReaction
, . . O
and . . O
pneumonia . . B-AdverseReaction
were . . O
more . . O
common . . O
in . . O
gilenya . . O
- . . O
treated . . O
patients . . O
. . . O

6 . . O
adverse . . O
reactions . . O

after . . O
the . . O
fourth . . O
injection . . O
of . . O
xiaflex . . O
, . . O
every . . O
xiaflex . . O
- . . O
treated . . O
patient . . O
developed . . O
high . . O
titers . . O
of . . O
antibodies . . O
to . . O
both . . O
aux . . O
- . . O
i . . O
and . . O
aux . . O
- . . O
ii . . O
. . . O

clinically . . O
significant . . O
hypersensitivity . . B-AdverseReaction
including . . O
anaphylaxis . . B-AdverseReaction
has . . O
been . . O
reported . . O
with . . O
prolia . . O
. . . O

5.7 . . O
geriatric . . O
patients . . O

major . . O
15 . . O
( . . O
0.6 . . O
) . . O
49 . . O
( . . O
1.8 . . O
) . . O
0.31 . . O
( . . O
0.17 . . O
, . . O
0.55 . . O
) . . O
p . . O
< . . O
0.0001 . . O
crnm . . B-AdverseReaction
* . . O
103 . . O
( . . O
3.9 . . O
) . . O
215 . . O
( . . O
8.0 . . O
) . . O
major . . O
+ . . O
crnm . . B-AdverseReaction
115 . . O
( . . O
4.3 . . O
) . . O
261 . . O
( . . O
9.7 . . O
) . . O
minor . . O
313 . . O
( . . O
11.7 . . O
) . . O
505 . . O
( . . O
18.8 . . O
) . . O
all . . O
402 . . O
( . . O
15.0 . . O
) . . O
676 . . O
( . . O
25.1 . . O
) . . O
adverse . . O
reactions . . O
occurring . . O
in . . O
> . . O
= . . O
1% . . O
of . . O
patients . . O
in . . O
the . . O
amplify . . O
study . . O
are . . O
listed . . O
in . . O
table . . O
6 . . O
. . . O

table . . O
6 . . O
summarizes . . O
the . . O
changes . . O
that . . O
were . . O
observed . . O
in . . O
placebo . . O
- . . O
controlled . . O
, . . O
short . . O
- . . O
term . . O
, . . O
pre . . O
- . . O
marketing . . O
studies . . O
with . . O
pristiq . . O
in . . O
patients . . O
with . . O
mdd . . O
( . . O
doses . . O
50 . . O
to . . O
400 . . O
mg . . O
) . . O
. . . O

median . . O
time . . O
to . . O
resolution . . O
ranged . . O
between . . O
1 . . O
week . . O
and . . O
1 . . O
month . . O
across . . O
trials . . O
, . . O
following . . O
interruption . . O
of . . O
zydelig . . O
therapy . . O
and . . O
in . . O
some . . O
instances . . O
, . . O
use . . O
of . . O
corticosteroids . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.2 . . O
) . . O
] . . O
. . . O

system . . O
organ . . O
class . . O
/ . . O
preferred . . O
term . . O
placebo . . O
n . . O
= . . O
203 . . O
% . . O
saphris . . O
5 . . O
mg . . O
or . . O
10 . . O
mg . . O
twice . . O
daily . . O
* . . O
n . . O
= . . O
379 . . O
% . . O
gastrointestinal . . O
disorders . . O
dry . . B-AdverseReaction
mouth . . I-AdverseReaction
1 . . O
3 . . O
dyspepsia . . B-AdverseReaction
2 . . O
4 . . O
oral . . B-AdverseReaction
hypoesthesia . . I-AdverseReaction
< . . O
1 . . O
4 . . O
toothache . . B-AdverseReaction
2 . . O
3 . . O
general . . O
disorders . . O
fatigue . . B-AdverseReaction
2 . . O
4 . . O
investigations . . O
increased . . B-AdverseReaction
weight . . I-AdverseReaction
< . . O
1 . . O
5 . . O
metabolism . . O
disorders . . O
increased . . B-AdverseReaction
appetite . . I-AdverseReaction
1 . . O
4 . . O
musculoskeletal . . O
and . . O
connective . . O
tissue . . O
disorders . . O
arthralgia . . B-AdverseReaction
1 . . O
3 . . O
pain . . B-AdverseReaction
in . . I-AdverseReaction
extremity . . I-AdverseReaction
< . . O
1 . . O
2 . . O
nervous . . O
system . . O
disorders . . O
akathisia . . B-AdverseReaction
2 . . O
4 . . O
dizziness . . B-AdverseReaction
3 . . O
11 . . O
dysgeusia . . B-AdverseReaction
< . . O
1 . . O
3 . . O
headache . . B-AdverseReaction
11 . . O
12 . . O
other . . O
extrapyramidal . . B-AdverseReaction
symptoms . . I-AdverseReaction
( . . O
excluding . . B-Negation
akathisia . . B-AdverseReaction
) . . O
2 . . O
7 . . O
somnolence . . B-AdverseReaction
? . . O

table . . O
1 . . O
summary . . O
of . . O
treatment . . O
exposure . . O
in . . O
re . . O
- . . O
ly . . O
pradaxa . . O
110 . . O
mg . . O
twice . . O
daily . . O
pradaxa . . O
150 . . O
mg . . O
twice . . O
daily . . O
warfarin . . O
total . . O
number . . O
treated . . O
5983 . . O
6059 . . O
5998 . . O
exposure . . O
> . . O
12 . . O
months . . O
4936 . . O
4939 . . O
5193 . . O
> . . O
24 . . O
months . . O
2387 . . O
2405 . . O
2470 . . O
mean . . O
exposure . . O
( . . O
months . . O
) . . O
20.5 . . O
20.3 . . O
21.3 . . O
total . . O
patient . . O
- . . O
years . . O
10,242 . . O
10,261 . . O
10,659 . . O
drug . . O
discontinuation . . O
in . . O
re . . O
- . . O
ly . . O

these . . O
trials . . O
evaluated . . O
the . . O
use . . O
of . . O
tanzeum . . O
as . . O
monotherapy . . O
, . . O
and . . O
as . . O
add . . O
- . . O
on . . O
therapy . . O
to . . O
oral . . O
antidiabetic . . O
agents . . O
, . . O
and . . O
as . . O
add . . O
- . . O
on . . O
therapy . . O
to . . O
basal . . O
insulin . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
. . . O

across . . O
the . . O
treatment . . O
arms . . O
, . . O
the . . O
mean . . O
age . . O
of . . O
patients . . O
was . . O
56 . . O
years . . O
, . . O
1% . . O
were . . O
75 . . O
years . . O
or . . O
older . . O
and . . O
53% . . O
were . . O
male . . O
. . . O

table . . O
2 . . O
: . . O
bleeding . . B-AdverseReaction
events . . O
in . . O
patients . . O
with . . O
nonvalvular . . O
atrial . . O
fibrillation . . O
in . . O
averroes . . O
eliquisn . . O
= . . O
2798n . . O
( . . O
% . . O
/ . . O
year . . O
) . . O
aspirinn . . O
= . . O
2780n . . O
( . . O
% . . O
/ . . O
year . . O
) . . O
hazard . . O
ratio . . O
( . . O
95% . . O
ci . . O
) . . O
p . . O
- . . O
value . . O
events . . O
associated . . O
with . . O
each . . O
endpoint . . O
were . . O
counted . . O
once . . O
per . . O
subject . . O
, . . O
but . . O
subjects . . O
may . . O
have . . O
contributed . . O
events . . O
to . . O
multiple . . O
endpoints . . O
. . . O

therefore . . O
, . . O
close . . O
monitoring . . O
is . . O
warranted . . O
in . . O
patients . . O
with . . O
a . . O
change . . O
in . . O
vision . . O
or . . O
with . . O
a . . O
history . . O
of . . O
increased . . O
intraocular . . O
pressure . . O
, . . O
glaucoma . . O
, . . O
and . . O
/ . . O
or . . O
cataracts . . O
. . . O

patients . . O
with . . O
a . . O
history . . O
of . . O
chronic . . O
or . . O
recurrent . . O
genital . . O
mycotic . . O
infections . . O
were . . O
more . . O
likely . . O
to . . O
develop . . O
mycotic . . B-AdverseReaction
genital . . I-AdverseReaction
infections . . I-AdverseReaction
. . . O

the . . O
adverse . . O
reaction . . O
profile . . O
was . . O
similar . . O
after . . O
each . . O
injection . . O
, . . O
regardless . . O
of . . O
the . . O
number . . O
of . . O
injections . . O
administered . . O
. . . O

[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
interrupt . . O
ferriprox . . O
if . . O
infection . . O
develops . . O
, . . O
and . . O
monitor . . O
the . . O
anc . . O
more . . O
frequently . . O
. . . O

risk . . O
may . . O
be . . O
increased . . O
with . . O
concomitant . . O
use . . O
of . . O
other . . O
cns . . O
depressants . . O
. . . O

fanapt . . O
is . . O
not . . O
approved . . O
for . . O
the . . O
treatment . . O
of . . O
patients . . O
with . . O
dementia . . O
- . . O
related . . O
psychosis . . O
[ . . O
s . . O
ee . . O
boxed . . O
warning . . O
] . . O
. . . O

reduction . . O
of . . O
risk . . O
of . . O
stroke . . O
and . . O
systemic . . O
embolism . . O
in . . O
non . . O
- . . O
valvular . . O
atrial . . O
fibrillation . . O

your . . O
healthcare . . O
provider . . O
should . . O
check . . O
any . . O
unusual . . O
vaginal . . O
bleeding . . O
to . . O
find . . O
out . . O
the . . O
cause . . O
. . . O

( . . O
5.8 . . O
) . . O

( . . O
5.3 . . O
) . . O
5.1 . . O
endophthalmitis . . O
and . . O
retinal . . O
detachments . . O

patients . . O
received . . O
5-10 . . O
days . . O
of . . O
an . . O
approved . . O
parenteral . . O
anticoagulant . . O
therapy . . O
followed . . O
by . . O
6 . . O
months . . O
, . . O
with . . O
mean . . O
exposure . . O
of . . O
164 . . O
days . . O
, . . O
of . . O
oral . . O
only . . O
treatment . . O
; . . O
warfarin . . O
was . . O
overlapped . . O
with . . O
parenteral . . O
therapy . . O
. . . O

( . . O
5.1 . . O
) . . O
* . . O
weight . . B-AdverseReaction
decrease . . I-AdverseReaction
: . . O
monitor . . O
weight . . O
regularly . . O
. . . O

in . . O
these . . O
trials . . O
, . . O
93% . . O
of . . O
patients . . O
treated . . O
with . . O
benlysta . . O
reported . . O
an . . O
adverse . . O
reaction . . O
compared . . O
with . . O
92% . . O
treated . . O
with . . O
placebo . . O
. . . O

the . . O
incidence . . O
of . . O
nonfatal . . O
serious . . O
adverse . . O
events . . O
was . . O
7.5% . . O
in . . O
the . . O
placebo . . O
group . . O
and . . O
8.3% . . O
in . . O
the . . O
prolia . . O
group . . O
. . . O

in . . O
patients . . O
treated . . O
with . . O
kyprolis . . O
, . . O
the . . O
incidence . . O
of . . O
serious . . O
adverse . . O
events . . O
was . . O
higher . . O
in . . O
those . . O
> . . O
= . . O
65 . . O
years . . O
old . . O
and . . O
in . . O
those . . O
> . . O
= . . O
75 . . O
years . . O
old . . O
[ . . O
see . . O
geriatric . . O
use . . O
( . . O
8.5 . . O
) . . O
] . . O
. . . O

grade . . B-Severity
3 . . I-Severity
/ . . O
4 . . O
cardiac . . B-AdverseReaction
failure . . I-AdverseReaction
was . . O
observed . . O
in . . O
2 . . O
/ . . O
359 . . O
patients . . O
( . . O
1% . . O
) . . O
receiving . . O
inlyta . . O
and . . O
1 . . O
/ . . O
355 . . O
patients . . O
( . . O
< . . O
1% . . O
) . . O
receiving . . O
sorafenib . . O
. . . O

two . . O
of . . O
the . . O
5 . . O
cases . . O
presented . . O
with . . O
cns . . O
involvement . . O
. . . O

it . . O
is . . O
recommended . . O
that . . O
alt . . O
and . . O
ast . . O
be . . O
assessed . . O
prior . . O
to . . O
initiating . . O
kalydeco . . O
, . . O
every . . O
3 . . O
months . . O
during . . O
the . . O
first . . O
year . . O
of . . O
treatment . . O
, . . O
and . . O
annually . . O
thereafter . . O
. . . O

an . . O
increase . . O
in . . O
frequency . . O
or . . O
severity . . O
of . . O
migraine . . B-AdverseReaction
during . . O
coc . . B-DrugClass
use . . O
( . . O
which . . O
may . . B-Factor
be . . O
prodromal . . O
of . . O
a . . O
cerebrovascular . . B-AdverseReaction
event . . I-AdverseReaction
) . . O
may . . O
be . . O
a . . O
reason . . O
for . . O
immediate . . O
discontinuation . . O
of . . O
the . . O
coc . . O
. . . O

( . . O
5.2 . . O
) . . O
* . . O
lymphopenia . . B-AdverseReaction
: . . O
obtain . . O
a . . O
cbc . . O
including . . O
lymphocyte . . O
count . . O
before . . O
initiating . . O
tecfidera . . O
, . . O
after . . O
6 . . O
months . . O
, . . O
and . . O
every . . O
6 . . O
to . . O
12 . . O
months . . O
thereafter . . O
. . . O

5.7 . . O
increased . . O
toxicity . . O
in . . O
the . . O
presence . . O
of . . O
moderate . . O
or . . O
severe . . O
hepatic . . O
impairment . . O

the . . O
use . . O
of . . O
estrogen . . O
- . . O
alone . . O
has . . O
been . . O
reported . . O
to . . O
result . . O
in . . O
an . . O
increase . . O
in . . O
abnormal . . O
mammograms . . O
requiring . . O
further . . O
evaluation . . O
. . . O

for . . O
patients . . O
with . . O
sega . . O
and . . O
severe . . O
hepatic . . O
impairment . . O
, . . O
reduce . . O
the . . O
starting . . O
dose . . O
of . . O
afinitor . . O
tablets . . O
or . . O
afinitor . . O
disperz . . O
by . . O
approximately . . O
50% . . O
and . . O
adjust . . O
subsequent . . O
doses . . O
based . . O
on . . O
therapeutic . . O
drug . . O
monitoring . . O
[ . . O
see . . O
dosage . . O
and . . O
administration . . O
( . . O
2.4 . . O
, . . O
2.5 . . O
) . . O
] . . O
. . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

do . . O
not . . O
exceed . . O
the . . O
recommended . . O
dose . . O
; . . O
the . . O
risk . . O
of . . O
acute . . O
kidney . . O
injury . . O
may . . O
increase . . O
with . . O
higher . . O
than . . O
recommended . . O
doses . . O
. . . O

these . . O
symptoms . . O
have . . O
been . . O
reported . . O
hours . . O
to . . O
weeks . . O
after . . O
injection . . O
. . . O

toviaz . . O
, . . O
like . . O
other . . O
antimuscarinic . . O
drugs . . O
, . . O
should . . O
be . . O
used . . O
with . . O
caution . . O
in . . O
patients . . O
with . . O
decreased . . O
gastrointestinal . . O
motility . . O
, . . O
such . . O
as . . O
those . . O
with . . O
severe . . O
constipation . . O
. . . O

adverse . . O
reactions . . O
resulted . . O
in . . O
interruption . . O
or . . O
discontinuation . . O
for . . O
78 . . O
( . . O
53% . . O
) . . O
subjects . . O
. . . O

neurological . . B-AdverseReaction
toxicities . . I-AdverseReaction

severe . . B-Severity
penile . . B-AdverseReaction
hematoma . . I-AdverseReaction
was . . O
also . . O
reported . . O
as . . O
an . . O
adverse . . O
reaction . . O
in . . O
39 . . O
of . . O
1044 . . O
patients . . O
( . . O
3.7% . . O
) . . O
in . . O
the . . O
controlled . . O
and . . O
uncontrolled . . O
clinical . . O
trials . . O
in . . O
peyronie's . . O
disease . . O
[ . . O
see . . O
adverse . . O
reactions . . O
( . . O
6 . . O
) . . O
] . . O
. . . O

excerpt . . O
: . . O
the . . O
most . . O
common . . O
adverse . . O
reaction . . O
in . . O
adults . . O
was . . O
diarrhea . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

* . . O
ophthalmic . . B-AdverseReaction
adverse . . I-AdverseReaction
reaction . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.1 . . O
) . . O
] . . O
* . . O
hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O

hypersensitivity . . B-AdverseReaction
reactions . . I-AdverseReaction
such . . O
as . . O
flushing . . B-AdverseReaction
and . . O
dyspnea . . B-AdverseReaction
have . . O
been . . O
observed . . O
within . . O
minutes . . O
following . . O
vizamyl . . O
administration . . O
. . . O

5.6 . . O
bradycardia . . O

seizure . . B-AdverseReaction
occurred . . O
from . . O
31 . . O
to . . O
603 . . O
days . . O
after . . O
initiation . . O
of . . O
xtandi . . O
. . . O

diarrhea . . B-AdverseReaction
, . . O
headache . . B-AdverseReaction
, . . O
and . . O
nausea . . B-AdverseReaction
were . . O
the . . O
most . . O
commonly . . O
reported . . O
adverse . . O
reactions . . O
. . . O

5.3 . . O
delayed . . O
healing . . O

respiratory . . O
, . . O
thoracic . . O
and . . O
mediastinal . . O
disorders . . O
: . . O
exertional . . B-AdverseReaction
dyspnea . . I-AdverseReaction
, . . O
bronchospasm . . B-AdverseReaction

typical . . O
symptoms . . O
associated . . O
with . . O
pml . . O
are . . O
diverse . . O
, . . O
progress . . O
over . . O
days . . O
to . . O
weeks . . O
, . . O
and . . O
include . . O
progressive . . O
weakness . . O
on . . O
one . . O
side . . O
of . . O
the . . O
body . . O
or . . O
clumsiness . . O
of . . O
limbs . . O
, . . O
disturbance . . O
of . . O
vision . . O
, . . O
and . . O
changes . . O
in . . O
thinking . . O
, . . O
memory . . O
, . . O
and . . O
orientation . . O
leading . . O
to . . O
confusion . . O
and . . O
personality . . O
changes . . O
. . . O

5.1 . . O
spread . . O
of . . O
toxin . . O
effect . . O

table . . O
2 . . O
: . . O
proportion . . O
of . . O
patients . . O
with . . O
at . . O
least . . O
one . . O
volume . . B-AdverseReaction
depletion . . I-AdverseReaction
- . . I-AdverseReaction
related . . I-AdverseReaction
adverse . . I-AdverseReaction
reaction . . I-AdverseReaction
( . . O
pooled . . O
results . . O
from . . O
8 . . O
clinical . . O
trials . . O
) . . O
baseline . . O
characteristic . . O
comparator . . O
group% . . O
invokana . . O
100 . . O
mg% . . O
invokana . . O
300 . . O
mg% . . O
overall . . O
population . . O
1.5% . . O
2.3% . . O
3.4% . . O
75 . . O
years . . O
of . . O
age . . O
and . . O
older . . O
2.6% . . O
4.9% . . O
8.7% . . O
egfr . . B-AdverseReaction
less . . I-AdverseReaction
than . . I-AdverseReaction
60 . . I-AdverseReaction
ml . . I-AdverseReaction
/ . . I-AdverseReaction
min . . I-AdverseReaction
/ . . I-AdverseReaction
1.73 . . I-AdverseReaction
m . . I-AdverseReaction
2 . . I-AdverseReaction
2.5% . . O
4.7% . . O
8.1% . . O
use . . O
of . . O
loop . . O
diuretic . . O
4.7% . . O
3.2% . . O
8.8% . . O
falls . . O

patients . . O
with . . O
a . . O
pre . . O
- . . O
existing . . O
low . . O
white . . O
blood . . O
cell . . O
count . . O
( . . O
wbc . . O
) . . O
or . . O
a . . O
history . . O
of . . O
leukopenia . . O
/ . . O
neutropenia . . O
should . . O
have . . O
their . . O
complete . . O
blood . . O
count . . O
( . . O
cbc . . O
) . . O
monitored . . O
frequently . . O
during . . O
the . . O
first . . O
few . . O
months . . O
of . . O
therapy . . O
and . . O
saphris . . O
should . . O
be . . O
discontinued . . O
at . . O
the . . O
first . . O
sign . . O
of . . O
a . . O
decline . . O
in . . O
wbc . . O
in . . O
the . . O
absence . . O
of . . O
other . . O
causative . . O
factors . . O
. . . O

5.9 . . O
coc . . O
use . . O
before . . O
or . . O
during . . O
early . . O
pregnancy . . O

in . . O
a . . O
study . . O
of . . O
4550 . . O
postmenopausal . . O
women . . O
with . . O
osteoporosis . . O
, . . O
the . . O
mean . . O
change . . O
from . . O
baseline . . O
in . . O
serum . . O
calcium . . O
level . . O
10 . . O
days . . O
after . . O
prolia . . O
dosing . . O
was . . O
- . . O
5.5% . . O
in . . O
subjects . . O
with . . O
creatinine . . O
clearance . . O
< . . O
30 . . O
ml . . O
/ . . O
min . . O
vs . . O
. . . O
- . . O
3.1% . . O
in . . O
subjects . . O
with . . O
creatinine . . O
clearance . . O
> . . O
= . . O
30 . . O
ml . . O
/ . . O
min . . O
. . . O

based . . O
on . . O
evidence . . O
of . . O
genotoxicity . . B-AdverseReaction
and . . O
developmental . . O
toxicity . . O
in . . O
animal . . B-Animal
studies . . O
, . . O
ferriprox . . O
can . . B-Factor
cause . . O
fetal . . B-AdverseReaction
harm . . I-AdverseReaction
when . . O
administered . . O
to . . O
a . . O
pregnant . . O
woman . . O
. . . O

the . . O
most . . O
frequent . . O
( . . O
> . . O
= . . O
2% . . O
) . . O
adverse . . O
reactions . . O
leading . . O
to . . O
dose . . O
reduction . . O
of . . O
tafinlar . . O
were . . O
pyrexia . . B-AdverseReaction
( . . O
9% . . O
) . . O
, . . O
ppes . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
chills . . B-AdverseReaction
( . . O
3% . . O
) . . O
, . . O
fatigue . . B-AdverseReaction
( . . O
2% . . O
) . . O
, . . O
and . . O
headache . . B-AdverseReaction
( . . O
2% . . O
) . . O
. . . O

antigen . . O
and . . O
antibody . . O
testing . . O
for . . O
histoplasmosis . . O
may . . O
be . . O
negative . . O
in . . O
some . . O
patients . . O
with . . O
active . . O
infection . . O
. . . O

volume . . O
depletion . . O
- . . O
related . . O
adverse . . O
reactions . . O

patients . . O
should . . O
be . . O
instructed . . O
about . . O
non . . O
- . . O
pharmacologic . . O
interventions . . O
that . . O
help . . O
to . . O
reduce . . O
the . . O
occurrence . . O
of . . O
orthostatic . . O
hypotension . . O
( . . O
e . . O
. . . O
g . . O
. . . O
, . . O
sitting . . O
on . . O
the . . O
edge . . O
of . . O
the . . O
bed . . O
for . . O
several . . O
minutes . . O
before . . O
attempting . . O
to . . O
stand . . O
in . . O
the . . O
morning . . O
and . . O
slowly . . O
rising . . O
from . . O
a . . O
seated . . O
position . . O
) . . O
. . . O

of . . O
those . . O
patients . . O
who . . O
developed . . O
new . . O
cuscc . . B-AdverseReaction
, . . O
approximately . . O
33% . . O
developed . . O
one . . O
or . . O
more . . O
cuscc . . B-AdverseReaction
with . . O
continued . . O
administration . . O
of . . O
tafinlar . . O
. . . O

all . . O
infections . . B-AdverseReaction
include . . O
bacterial . . O
, . . O
viral . . O
, . . O
fungal . . O
, . . O
and . . O
other . . O
organisms . . O
. . . O

generally . . O
, . . O
adverse . . O
reactions . . O
were . . O
mild . . O
, . . O
not . . O
dose . . O
related . . O
, . . O
and . . O
similar . . O
regardless . . O
of . . O
age . . O
, . . O
gender . . O
, . . O
and . . O
race . . O
. . . O

5.4 . . O
atrial . . O
fibrillation . . O

6.2 . . O
postmarketing . . O
experience . . O

these . . O
events . . O
were . . O
confounded . . O
by . . O
concomitant . . O
medications . . O
and . . O
/ . . O
or . . O
preexisting . . O
disease . . O
, . . O
and . . O
the . . O
relationship . . O
to . . O
gilenya . . O
is . . O
uncertain . . O
. . . O

the . . O
median . . O
time . . O
between . . O
diagnosis . . O
of . . O
the . . O
first . . O
cuscc . . B-AdverseReaction
and . . O
the . . O
second . . O
cuscc . . B-AdverseReaction
was . . O
6 . . O
weeks . . O
. . . O

5.8 . . O
embryofetal . . O
toxicity . . O

5 . . O
warnings . . O
and . . O
precautions . . O

5 . . O
warnings . . O
and . . O
precautions . . O

only . . O
use . . O
sirturo . . O
when . . O
an . . O
effective . . O
treatment . . O
regimen . . O
cannot . . O
otherwise . . O
be . . O
provided . . O
. . . O

( . . O
5.5 . . O
) . . O
* . . O
weight . . B-AdverseReaction
gain . . I-AdverseReaction
: . . O
weight . . O
gain . . O
has . . O
been . . O
reported . . O
. . . O

malignancies . . O
in . . O
pediatric . . O
patients . . O

6.1 . . O
clinical . . O
trials . . O
experience . . O

6.2 . . O
postmarketing . . O
experience . . O

serious . . B-Severity
hypersensitivity . . O
( . . O
anaphylactic . . O
) . . O
and . . O
skin . . B-AdverseReaction
reactions . . I-AdverseReaction
have . . O
been . . O
reported . . O
in . . O
patients . . O
treated . . O
with . . O
dalvance . . O
. . . O

( . . O
6.1 . . O
) . . O

in . . O
these . . O
trials . . O
, . . O
which . . O
had . . O
a . . O
median . . O
treatment . . O
duration . . O
of . . O
12 . . O
weeks . . O
, . . O
the . . O
estimated . . O
incidence . . O
of . . O
suicidal . . B-AdverseReaction
behavior . . I-AdverseReaction
or . . O
ideation . . O
among . . O
27,863 . . O
aed . . O
- . . O
treated . . O
patients . . O
was . . O
0.43% . . O
, . . O
compared . . O
to . . O
0.24% . . O
among . . O
16,029 . . O
placebo . . O
- . . O
treated . . O
patients . . O
, . . O
representing . . O
an . . O
increase . . O
of . . O
approximately . . O
one . . O
case . . O
of . . O
suicidal . . B-AdverseReaction
thinking . . I-AdverseReaction
or . . O
behavior . . O
for . . O
every . . O
530 . . O
patients . . O
treated . . O
. . . O

the . . O
safety . . O
of . . O
zytiga . . O
re . . O
- . . O
treatment . . O
of . . O
patients . . O
who . . O
develop . . O
ast . . O
or . . O
alt . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
20 . . O
* . . O
uln . . O
and . . O
/ . . O
or . . O
bilirubin . . O
greater . . O
than . . O
or . . O
equal . . O
to . . O
10 . . O
* . . O
uln . . O
is . . O
unknown . . O
. . . O

6 . . O
adverse . . O
reactions . . O

monitoring . . O

in . . O
the . . O
safety . . O
population . . O
in . . O
controlled . . O
studies . . O
, . . O
a . . O
total . . O
of . . O
620 . . O
patients . . O
with . . O
crohn's . . O
disease . . O
received . . O
cimzia . . O
at . . O
a . . O
dose . . O
of . . O
400 . . O
mg . . O
, . . O
and . . O
614 . . O
subjects . . O
received . . O
placebo . . O
( . . O
including . . O
subjects . . O
randomized . . O
to . . O
placebo . . O
in . . O
study . . O
cd2 . . O
following . . O
open . . O
label . . O
dosing . . O
of . . O
cimzia . . O
at . . O
weeks . . O
0 . . O
, . . O
2 . . O
, . . O
4 . . O
) . . O
. . . O

the . . O
average . . O
age . . O
was . . O
53 . . O
years . . O
( . . O
range . . O
from . . O
0.1 . . O
to . . O
97 . . O
years . . O
) . . O
. . . O

the . . O
proportion . . O
of . . O
patients . . O
experiencing . . O
at . . O
least . . O
one . . O
documented . . O
symptomatic . . B-Severity
hypoglycemic . . B-AdverseReaction
episode . . I-AdverseReaction
on . . O
tanzeum . . O
and . . O
the . . O
proportion . . O
of . . O
patients . . O
experiencing . . O
at . . O
least . . O
one . . O
severe . . B-Severity
hypoglycemic . . B-AdverseReaction
episode . . I-AdverseReaction
on . . O
tanzeum . . O
in . . O
clinical . . O
trials . . O
[ . . O
see . . O
clinical . . O
studies . . O
( . . O
14 . . O
) . . O
] . . O
is . . O
shown . . O
in . . O
table . . O
2 . . O
. . . O

the . . O
most . . O
serious . . O
adverse . . O
reactions . . O
reported . . O
with . . O
pradaxa . . O
were . . O
related . . O
to . . O
bleeding . . B-AdverseReaction
[ . . O
see . . O
warnings . . O
and . . O
precautions . . O
( . . O
5.2 . . O
) . . O
] . . O
. . . O

if . . O
this . . O
drug . . O
is . . O
used . . O
during . . O
pregnancy . . O
, . . O
or . . O
if . . O
the . . O
patient . . O
becomes . . O
pregnant . . O
while . . O
taking . . O
this . . O
drug . . O
, . . O
the . . O
patient . . O
should . . O
be . . O
apprised . . O
of . . O
the . . O
potential . . O
hazard . . O
to . . O
the . . O
fetus . . O
[ . . O
see . . O
use . . O
in . . O
specific . . O
populations . . O
( . . O
8.1 . . O
) . . O
] . . O
. . . O

more . . O
patients . . O
receiving . . O
trulicity . . O
0.75 . . O
mg . . O
( . . O
1.3% . . O
) . . O
and . . O
trulicity . . O
1.5 . . O
mg . . O
( . . O
3.5% . . O
) . . O
discontinued . . O
treatment . . O
due . . O
to . . O
gastrointestinal . . B-AdverseReaction
adverse . . I-AdverseReaction
reactions . . I-AdverseReaction
than . . O
patients . . O
receiving . . O
placebo . . O
( . . O
0.2% . . O
) . . O
. . . O

the . . O
median . . O
duration . . O
of . . O
treatment . . O
was . . O
6.4 . . O
months . . O
( . . O
range . . O
0.03 . . O
to . . O
22.0 . . O
) . . O
for . . O
patients . . O
who . . O
received . . O
inlyta . . O
and . . O
5.0 . . O
months . . O
( . . O
range . . O
0.03 . . O
to . . O
20.1 . . O
) . . O
for . . O
patients . . O
who . . O
received . . O
sorafenib . . O
. . . O

patients . . O
receiving . . O
the . . O
drug . . O
should . . O
be . . O
managed . . O
in . . O
facilities . . O
equipped . . O
and . . O
staffed . . O
with . . O
adequate . . O
laboratory . . O
and . . O
supportive . . O
medical . . O
resources . . O
. . . O

antigen . . O
and . . O
antibody . . O
testing . . O
for . . O
histoplasmosis . . O
may . . O
be . . O
negative . . O
in . . O
some . . O
patients . . O
with . . O
active . . O
infection . . O
. . . O

data . . O
are . . O
not . . B-Factor
available . . I-Factor
to . . O
determine . . O
whether . . O
the . . O
rate . . O
of . . O
death . . B-AdverseReaction
in . . O
patients . . O
with . . O
copd . . O
is . . O
increased . . O
by . . O
laba . . O
. . . O

three . . O
percent . . O
( . . O
3% . . O
) . . O
of . . O
255 . . O
patients . . O
experienced . . O
a . . O
qtc . . B-AdverseReaction
interval . . I-AdverseReaction
increase . . I-AdverseReaction
over . . O
baseline . . O
greater . . O
than . . O
60 . . B-Severity
msec . . I-Severity
in . . O
study . . O
1 . . O
. . . O

no . . O
dose . . O
- . . O
effect . . O
relationship . . O
for . . O
these . . O
transaminase . . O
elevations . . O
was . . O
noted . . O
[ . . O
see . . O
clinical . . O
pharmacology . . O
( . . O
12.3 . . O
) . . O
] . . O
. . . O

